PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, ZM; Janes, K; Chen, C; Doyle, T; Bryant, L; Tosh, DK; Jacobson, KA; Salvemini, D				Chen, Zhoumou; Janes, Kali; Chen, Collin; Doyle, Tim; Bryant, Leesa; Tosh, Dilip K.; Jacobson, Kenneth A.; Salvemini, Daniela			Controlling murine and rat chronic pain through A(3) adenosine receptor activation	FASEB JOURNAL			English	Article						IB-MECA; MRS1898; paclitaxel; oxaliplatin; bortezomib	ISCHEMIC BRAIN-INJURY; SYNAPTIC-TRANSMISSION; RHEUMATOID-ARTHRITIS; INTERNATIONAL UNION; TARGET; CLASSIFICATION; A(3)-RECEPTORS; PHARMACOLOGY; NOMENCLATURE; OXALIPLATIN	Clinical management of chronic neuropathic pain is limited by marginal effectiveness and unacceptable side effects of current drugs. We demonstrate A(3) adenosine receptor (A(3)AR) agonism as a new target-based therapeutic strategy. The development of mechanoallodynia in a well-characterized mouse model of neuropathic pain following chronic constriction injury of the sciatic nerve was rapidly and dose-dependently reversed by the A(3)AR agonists: IB-MECA, its 2-chlorinated analog (Cl-IB-MECA), and the structurally distinct MRS1898. These effects were naloxone insensitive and thus are not opioid receptor mediated. IB-MECA was >= 1.6-fold more efficacious than morphine and >5-fold more potent. In addition, IB-MECA was equally efficacious as gabapentin (Neurontin) or amitriptyline, but respectively >350- and >75-fold more potent. Besides its potent standalone ability to reverse established mechanoallodynia, IB-MECA significantly increased the antiallodynic effects of all 3 analgesics. Moreover, neuropathic pain development in rats caused by widely used chemotherapeutics in the taxane (paclitaxel), platinum-complex (oxaliplatin), and proteasome-inhibitor (bortezomib) classes was blocked by IB-MECA without antagonizing their antitumor effect. A(3)AR agonist effects were blocked with A(3)AR antagonist MRS1523, but not with A(1)AR (DPCPX) or A(2)AAR (SCH-442416) antagonists. Our findings provide the scientific rationale and pharmacological basis for therapeutic development of A(3)AR agonists for chronic pain.-Chen, Z., Janes, K., Chen, C., Doyle, T., Bryant, L., Tosh, D. K., Jacobson, K. A., Salvemini, D. Controlling murine and rat chronic pain through A(3) adenosine receptor activation. FASEB J. 26, 1855-1865 (2012). www.fasebj.org	[Chen, Zhoumou; Janes, Kali; Chen, Collin; Doyle, Tim; Bryant, Leesa; Salvemini, Daniela] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; [Tosh, Dilip K.; Jacobson, Kenneth A.] NIDDK, NIH, Bethesda, MD USA	Saint Louis University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Salvemini, D (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	salvemd@slu.edu	Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	U.S. National Institutes of Health (NIH) [R01 DA024074]; St. Louis University; NIH National Institute of Diabetes and Digestive and Kidney Diseases; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK031117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA024074] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St. Louis University; NIH National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors are grateful to Dr. Gary Bennett, (McGill University, Montreal, QC, Canada) for critically reviewing our work. This work was supported by U.S. National Institutes of Health (NIH) grant R01 DA024074 (D. S.), St. Louis University President Research Funds (D. S.), and the NIH National Institute of Diabetes and Digestive and Kidney Diseases Intramural Program (K.A.J.). The authors report no conflicts of interest.	Abbracchio MP, 1997, BIOCHEM BIOPH RES CO, V241, P297, DOI 10.1006/bbrc.1997.7705; Bennett GJ, 2010, ONCOLOGIST, V15, P9, DOI 10.1634/theoncologist.2009-S503; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Cata JP, 2006, MINERVA ANESTESIOL, V72, P151; Chen GJ, 2006, J NEUROSCI RES, V84, P1848, DOI 10.1002/jnr.21071; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Farquhar-Smith Paul, 2011, Curr Opin Support Palliat Care, V5, P1, DOI 10.1097/SPC.0b013e328342f9cc; Fedorova IM, 2003, CELL MOL NEUROBIOL, V23, P431, DOI 10.1023/A:1023601007518; Finnerup NB, 2010, PAIN, V150, P573, DOI 10.1016/j.pain.2010.06.019; Fishman P, 2003, CURR TOP MED CHEM, V3, P463, DOI 10.2174/1568026033392147; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Fishman P, 2012, DRUG DISCOV TODAY, V17, P359, DOI 10.1016/j.drudis.2011.10.007; FOLEY KM, 1995, ANTI-CANCER DRUG, V6, P4, DOI 10.1097/00001813-199504003-00002; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285; Gao ZG, 2009, PURINERG SIGNAL, V5, P31, DOI 10.1007/s11302-008-9107-1; Ge ZD, 2006, J PHARMACOL EXP THER, V319, P1200, DOI 10.1124/jpet.106.111351; Giannaccini G, 2008, NEUROCHEM RES, V33, P852, DOI 10.1007/s11064-007-9525-4; Hentschel S, 2003, RESTOR NEUROL NEUROS, V21, P55; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; Jacobson KA, 1998, TRENDS PHARMACOL SCI, V19, P184, DOI 10.1016/S0165-6147(98)01203-6; Jacobson KA, 2011, ADV PHARMACOL, V61, P187, DOI 10.1016/B978-0-12-385526-8.00007-2; Joseph EK, 2004, EUR J NEUROSCI, V20, P2896, DOI 10.1111/j.1460-9568.2004.03750.x; Kiesman William F, 2009, Handb Exp Pharmacol, P25, DOI 10.1007/978-3-540-89615-9_2; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; Kreckler LM, 2006, J PHARMACOL EXP THER, V317, P172, DOI 10.1124/jpet.105.096016; Kriedt Christopher L, 2010, J Exp Ther Oncol, V8, P287; Kumar V, 2009, EUR J PHARMACOL, V616, P7, DOI 10.1016/j.ejphar.2009.05.005; Li AH, 1998, J MED CHEM, V41, P3186, DOI 10.1021/jm980093j; Lopes LV, 2003, NEUROREPORT, V14, P1645, DOI 10.1097/00001756-200308260-00021; Loram LC, 2009, J NEUROSCI, V29, P14015, DOI 10.1523/JNEUROSCI.3447-09.2009; Ndengele MM, 2009, J PHARMACOL EXP THER, V329, P64, DOI 10.1124/jpet.108.146290; Ochaion A, 2009, CELL IMMUNOL, V258, P115, DOI 10.1016/j.cellimm.2009.03.020; PELLATDECEUNYNK C, 1995, BLOOD, V86, P4001, DOI 10.1182/blood.V86.10.4001.bloodjournal86104001; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Ru F, 2011, AM J PHYSIOL-GASTR L, V300, pG485, DOI 10.1152/ajpgi.00361.2010; Rubaj A, 2003, BEHAV BRAIN RES, V141, P11, DOI 10.1016/S0166-4328(02)00314-5; Shah MR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-84; Shen H, 2005, STROKE, V36, P654, DOI 10.1161/01.STR.0000155747.15679.04; Silverman MH, 2008, J RHEUMATOL, V35, P41; Taliani S, 2010, CURR TOP MED CHEM, V10, P942, DOI 10.2174/156802610791293109; Tchilibon S, 2005, J MED CHEM, V48, P1745, DOI 10.1021/jm049580r; Torrance N, 2006, J PAIN, V7, P281, DOI 10.1016/j.jpain.2005.11.008; Von Lubitz DKJE, 1999, EUR J PHARMACOL, V367, P157, DOI 10.1016/S0014-2999(98)00977-7; Wang ZQ, 2004, J PHARMACOL EXP THER, V309, P869, DOI 10.1124/jpet.103.064154; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wunderlich JE, 2008, AM J PHYSIOL-GASTR L, V294, pG554, DOI 10.1152/ajpgi.00500.2007; Yi DH, 1997, ARCH BIOCHEM BIOPHYS, V344, P253, DOI 10.1006/abbi.1997.0218; Yoon MH, 2005, ANESTH ANALG, V101, P1417, DOI 10.1213/01.ANE.0000180994.10087.6F; Zhang M, 2010, NEUROCHEM INT, V56, P35, DOI 10.1016/j.neuint.2009.08.011; Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016; Zheng J, 2007, AM J PHYSIOL-HEART C, V293, pH3685, DOI 10.1152/ajpheart.00819.2007; Zylka MJ, 2011, TRENDS MOL MED, V17, P188, DOI 10.1016/j.molmed.2010.12.006	58	83	83	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1855	1865		10.1096/fj.11-201541	http://dx.doi.org/10.1096/fj.11-201541			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22345405	Green Published			2023-01-03	WOS:000303680800014
J	Ledermann, J; Harter, P; Gourley, C; Friedlander, M; Vergote, I; Rustin, G; Scott, C; Meier, W; Shapira-Frommer, R; Safra, T; Matei, D; Macpherson, E; Watkins, C; Carmichael, J; Matulonis, U				Ledermann, Jonathan; Harter, Philipp; Gourley, Charlie; Friedlander, Michael; Vergote, Ignace; Rustin, Gordon; Scott, Clare; Meier, Werner; Shapira-Frommer, Ronnie; Safra, Tamar; Matei, Daniela; Macpherson, Euan; Watkins, Claire; Carmichael, James; Matulonis, Ursula			Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLY(ADP-RIBOSE) POLYMERASE; BRCA1; CHEMOTHERAPY; INHIBITION; REPAIR; DEFICIENT; AZD2281; TUMORS; TRIAL	BACKGROUND Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. METHODS We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. RESULTS Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). CONCLUSIONS Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.)	[Ledermann, Jonathan] UCL, Inst Canc, UCL & UCL Hosp Comprehens Biomed Res Ctr, London W1T 4TJ, England; [Harter, Philipp] Kliniken Essen Mitte, Essen, Germany; [Meier, Werner] Evangel Krankenhaus, Dusseldorf, Germany; [Gourley, Charlie] Univ Edinburgh, Canc Res UK Ctr, Edinburgh, Midlothian, Scotland; [Friedlander, Michael] Prince Wales Hosp, Randwick, NSW 2031, Australia; [Scott, Clare] Royal Melbourne Hosp, Parkville, Vic 3050, Australia; [Vergote, Ignace] Katholieke Univ Leuven, Louvain, Belgium; [Rustin, Gordon] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England; [Macpherson, Euan; Watkins, Claire; Carmichael, James] AstraZeneca, Macclesfield, Cheshire, England; [Shapira-Frommer, Ronnie] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; [Safra, Tamar] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; [Matei, Daniela] Indiana Univ Sch Med, Indianapolis, IN USA; [Matulonis, Ursula] Dana Farber Canc Inst, Boston, MA 02115 USA	University of London; University College London; Kliniken Essen-Mitte; University of Edinburgh; Royal Melbourne Hospital; KU Leuven; AstraZeneca; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Indiana University System; Indiana University Bloomington; Harvard University; Dana-Farber Cancer Institute	Ledermann, J (corresponding author), UCL, Inst Canc, UCL & UCL Hosp Comprehens Biomed Res Ctr, 90 Tottenham Court Rd, London W1T 4TJ, England.	j.ledermann@ctc.ucl.ac.uk	Rustin, Gordon J. S./J-9763-2019; friedlander, michael l/G-3490-2013	friedlander, michael l/0000-0002-6488-0604; friedlander, michael/0000-0003-3090-795X; Matei, Daniela/0000-0003-2169-5035	AstraZeneca; Chief Scientist Office [SCD/11] Funding Source: researchfish	AstraZeneca(AstraZeneca); Chief Scientist Office	Supported by AstraZeneca.	Aghajanian C, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.18_suppl.lba5007; Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaye SB, 2010, ANN ONCOL S, V21, pLBA25; Konstantinopoulos, 2010, J CLIN ONCOL, V28, P4868, DOI 10.1200/JCO.2010.33.2205; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Ledermann JA, 2011, J CLIN ONCOL, V29, P3798, DOI 10.1200/JCO.2010.33.5208; Markman Maurie, 2009, Gynecol Oncol, V114, P195, DOI 10.1016/j.ygyno.2009.04.012; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758; Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024; Parmar MKB, 2003, LANCET, V361, P2099; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Perren TJ, 2012, NEW ENGL J MED, V366, P284; Pfisterer J, 2006, SEMIN ONCOL, V33, pS12, DOI 10.1053/j.seminoncol.2006.03.012; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Pujade-Lauraine E, 2010, J CLIN ONCOL, V28, P3323, DOI 10.1200/JCO.2009.25.7519; Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Rustin GJS, 2011, INT J GYNECOL CANCER, V21, P419, DOI 10.1097/IGC.0b013e3182070f17; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Weberpals JI, 2008, J CLIN ONCOL, V26, P3259, DOI 10.1200/JCO.2007.11.3902	34	1266	1320	1	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1382	1392		10.1056/NEJMoa1105535	http://dx.doi.org/10.1056/NEJMoa1105535			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923GV	22452356	Bronze			2023-01-03	WOS:000302608600002
J	Milicic, A; Kaur, R; Reyes-Sandoval, A; Tang, CK; Honeycutt, J; Perrie, Y; Hill, AVS				Milicic, Anita; Kaur, Randip; Reyes-Sandoval, Arturo; Tang, Choon-Kit; Honeycutt, Jared; Perrie, Yvonne; Hill, Adrian V. S.			Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses	PLOS ONE			English	Article							EXOGENOUS SOLUBLE-ANTIGEN; DENDRITIC CELLS; IMMUNE-RESPONSE; CORD FACTOR; CPG-DNA; MACROPINOCYTOSIS; IMMUNIZATION; TUBERCULOSIS; ACTIVATION; INDUCTION	Most subunit vaccines require adjuvants in order to induce protective immune responses to the targeted pathogen. However, many of the potent immunogenic adjuvants display unacceptable local or systemic reactogenicity. Liposomes are spherical vesicles consisting of single (unilamellar) or multiple (multilamellar) phospholipid bi-layers. The lipid membranes are interleaved with an aqueous buffer, which can be utilised to deliver hydrophilic vaccine components, such as protein antigens or ligands for immune receptors. Liposomes, in particular cationic DDA:TDB vesicles, have been shown in animal models to induce strong humoral responses to the associated antigen without increased reactogenicity, and are currently being tested in Phase I human clinical trials. We explored several modifications of DDA:TDB liposomes - including size, antigen association and addition of TLR agonists - to assess their immunogenic capacity as vaccine adjuvants, using Ovalbumin (OVA) protein as a model protein vaccine. Following triple homologous immunisation, small unilamellar vesicles (SUVs) with no TLR agonists showed a significantly higher capacity for inducing spleen CD8 IFN gamma responses against OVA in comparison with the larger multilamellar vesicles (MLVs). Antigen-specific antibody reponses were also higher with SUVs. Addition of the TLR3 and TLR9 agonists significantly increased the adjuvanting capacity of MLVs and OVA-encapsulating dehydration-rehydration vesicles (DRVs), but not of SUVs. Our findings lend further support to the use of liposomes as protein vaccine adjuvants. Importantly, the ability of DDA: TDB SUVs to induce potent CD8 T cell responses without the need for adding immunostimulators would avoid the potential safety risks associated with the clinical use of TLR agonists in vaccines adjuvanted with liposomes.	[Milicic, Anita; Reyes-Sandoval, Arturo; Tang, Choon-Kit; Honeycutt, Jared; Hill, Adrian V. S.] Univ Oxford, Jenner Inst, Oxford, England; [Kaur, Randip; Perrie, Yvonne] Aston Univ, Aston Pharm Sch, Birmingham B4 7ET, W Midlands, England	University of Oxford; Jenner Institute; Aston University	Milicic, A (corresponding author), Univ Oxford, Jenner Inst, Oxford, England.	anita.milicic@ndm.ox.ac.uk	Reyes-Sandoval, Arturo/B-4264-2011	Reyes-Sandoval, Arturo/0000-0002-2648-1696; Perrie, Yvonne/0000-0001-8497-2541	Wellcome Trust [EF113/Z/07/Z]; Singapore Agency for Science, Technology and Research (A*STAR); TB Vaccine Initiative (NewTBVAC) [HEALTH-F3-2009-241745]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007290] Funding Source: NIH RePORTER	Wellcome Trust(Wellcome Trust); Singapore Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); TB Vaccine Initiative (NewTBVAC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by a Wellcome Trust Strategic grant (grant no. EF113/Z/07/Z; www.wellcome.ac.uk), the Singapore Agency for Science, Technology and Research (A*STAR) personal fellowship to CKT (www.a-star.edu.sg), and the TB Vaccine Initiative (NewTBVAC) (grant no. HEALTH-F3-2009-241745; http://www.tbvi.eu/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; ALVING CR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P307, DOI 10.1016/0304-4157(92)90004-T; ALVING CR, 1995, IMMUNOL REV, V145, P5, DOI 10.1111/j.1600-065X.1995.tb00075.x; Amstutz B, 2008, EMBO J, V27, P956, DOI 10.1038/emboj.2008.38; Bagchi A, 2007, J IMMUNOL, V178, P1164, DOI 10.4049/jimmunol.178.2.1164; Bal SM, 2011, VACCINE, V29, P1045, DOI 10.1016/j.vaccine.2010.11.061; Blander JM, 2006, NAT IMMUNOL, V7, P1029, DOI 10.1038/ni1006-1029; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; Brunel F, 1999, VACCINE, V17, P2192, DOI 10.1016/S0264-410X(98)00492-7; Christensen D, 2011, EXPERT REV VACCINES, V10, P513, DOI [10.1586/ERV.11.17, 10.1586/erv.11.17]; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; DAVIS D, 1987, IMMUNOLOGY, V61, P229; de Cassan SC, 2011, J IMMUNOL, V187, P2602, DOI 10.4049/jimmunol.1101004; Dow SW, 1999, J IMMUNOL, V163, P1552; Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850; Edwards AD, 2002, J IMMUNOL, V169, P3652, DOI 10.4049/jimmunol.169.7.3652; Gluck R, 1995, VACCINE DESIGN SUBUN, P347; GREGORIADIS G, 1974, LANCET, V1, P1313, DOI 10.1016/S0140-6736(74)90682-5; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; GREGORIADIS G, 1994, J DRUG TARGET, V2, P351, DOI 10.3109/10611869408996809; Gregoriadis G, 1971, BIOCHEM J, V124, P58; Gregoriadis G, VACCINE ADJUVANTS PR, P137; Gursel I, 2001, J IMMUNOL, V167, P3324, DOI 10.4049/jimmunol.167.6.3324; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Henriksen-Lacey M, 2011, J CONTROL RELEASE, V154, P131, DOI 10.1016/j.jconrel.2011.05.019; Holten-Andersen L, 2004, INFECT IMMUN, V72, P1608, DOI 10.1128/IAI.72.3.1608-1617.2004; Jain AK, 2007, J DRUG TARGET, V15, P417, DOI 10.1080/10611860701453653; KAHL LP, 1989, J IMMUNOL, V142, P4441; Kaur R, 2011, J CONTROL RELEASE; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KIRBY C, 1984, BIO-TECHNOL, V2, P979, DOI 10.1038/nbt1184-979; Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x; Larsen KC, 2009, VACCINE, V27, P5589, DOI 10.1016/j.vaccine.2009.07.025; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; NAIR S, 1992, J EXP MED, V175, P609, DOI 10.1084/jem.175.2.609; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; RAHMAN YE, 1974, J LAB CLIN MED, V83, P640; SELTZER SE, 1988, INVEST RADIOL, V23, P131, DOI 10.1097/00004424-198802000-00009; SHEK PN, 1982, IMMUNOLOGY, V47, P627; Tanaka Y, 2004, BIOCONJUGATE CHEM, V15, P35, DOI 10.1021/bc034134o; Taneichi M, 2006, BIOCONJUGATE CHEM, V17, P899, DOI 10.1021/bc060024g; Wells JW, 2008, J IMMUNOL, V181, P3422, DOI 10.4049/jimmunol.181.5.3422; Zaks K, 2006, J IMMUNOL, V176, P7335, DOI 10.4049/jimmunol.176.12.7335	46	39	41	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2012	7	3							e34255	10.1371/journal.pone.0034255	http://dx.doi.org/10.1371/journal.pone.0034255			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948FM	22470545	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000304489000084
J	Chanumolu, SK; Rout, C; Chauhan, RS				Chanumolu, Sree Krishna; Rout, Chittaranjan; Chauhan, Rajinder S.			UniDrug-Target: A Computational Tool to Identify Unique Drug Targets in Pathogenic Bacteria	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ESSENTIAL GENES; PROTEIN; DISCOVERY; SUSCEPTIBILITY; DRUGGABILITY; DATABASE	Background: Targeting conserved proteins of bacteria through antibacterial medications has resulted in both the development of resistant strains and changes to human health by destroying beneficial microbes which eventually become breeding grounds for the evolution of resistances. Despite the availability of more than 800 genomes sequences, 430 pathways, 4743 enzymes, 9257 metabolic reactions and protein (three-dimensional) 3D structures in bacteria, no pathogen-specific computational drug target identification tool has been developed. Methods: A web server, UniDrug-Target, which combines bacterial biological information and computational methods to stringently identify pathogen-specific proteins as drug targets, has been designed. Besides predicting pathogen-specific proteins essentiality, chokepoint property, etc., three new algorithms were developed and implemented by using protein sequences, domains, structures, and metabolic reactions for construction of partial metabolic networks (PMNs), determination of conservation in critical residues, and variation analysis of residues forming similar cavities in proteins sequences. First, PMNs are constructed to determine the extent of disturbances in metabolite production by targeting a protein as drug target. Conservation of pathogen-specific protein's critical residues involved in cavity formation and biological function determined at domain-level with low-matching sequences. Last, variation analysis of residues forming similar cavities in proteins sequences from pathogenic versus non-pathogenic bacteria and humans is performed. Results: The server is capable of predicting drug targets for any sequenced pathogenic bacteria having fasta sequences and annotated information. The utility of UniDrug-Target server was demonstrated for Mycobacterium tuberculosis (H37Rv). The UniDrug-Target identified 265 mycobacteria pathogen-specific proteins, including 17 essential proteins which can be potential drug targets. Conclusions/Significance: UniDrug-Target is expected to accelerate pathogen-specific drug targets identification which will increase their success and durability as drugs developed against them have less chance to develop resistances and adverse impact on environment. The server is freely available at http://117.211.115.67/UDT/main.html. The standalone application (source codes) is available at http://www.bioinformatics.org/ftp/pub/bioinfojuit/UDT.rar.	[Chanumolu, Sree Krishna; Rout, Chittaranjan; Chauhan, Rajinder S.] Jaypee Univ Informat Technol, Dept Biotechnol & Bioinformat, Solan, Himachal Prades, India	Jaypee University of Information Technology	Chanumolu, SK (corresponding author), Jaypee Univ Informat Technol, Dept Biotechnol & Bioinformat, Solan, Himachal Prades, India.	rajinder.chauhan@juit.ac.in	chanumolu, sree/AAC-9600-2021; Chauhan, Rajinder Singh/HGB-5642-2022					Albrich WC, 2004, EMERG INFECT DIS, V10, P514, DOI 10.3201/eid1003.030252; Austen M, 2005, DRUG DISCOV TODAY, V10, P275, DOI 10.1016/S1359-6446(05)03368-4; Boyle-Vavra S, 2007, LAB INVEST, V87, P3, DOI 10.1038/labinvest.3700501; Bozdogan B, 2003, J ANTIMICROB CHEMOTH, V52, P864, DOI 10.1093/jac/dkg457; Brain RA, 2008, REV ENVIRON CONTAM T, V192, P67, DOI 10.1007/978-0-387-71724-1_3; Chan JNY, 2010, TRENDS PHARMACOL SCI, V31, P82, DOI 10.1016/j.tips.2009.11.002; Devasia RA, 2009, AM J RESP CRIT CARE, V180, P365, DOI 10.1164/rccm.200901-0146OC; Drews J, 1997, DRUG DISCOV TODAY, V2, P72, DOI 10.1016/S1359-6446(96)10051-9; Gao ZT, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-104; Gerdes S, 2006, CURR OPIN BIOTECH, V17, P448, DOI 10.1016/j.copbio.2006.08.006; Ghoshal Ujjala, 2006, Indian J Pathol Microbiol, V49, P620; Hajduk PJ, 2005, J MED CHEM, V48, P2518, DOI 10.1021/jm049131r; Hambly K, 2006, MOL DIVERS, V10, P273, DOI 10.1007/s11030-006-9035-3; Han LY, 2007, DRUG DISCOV TODAY, V12, P304, DOI 10.1016/j.drudis.2007.02.015; Hasan S, 2006, PLOS COMPUT BIOL, V2, P539, DOI 10.1371/journal.pcbi.0020061; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Ilag LL, 2002, DRUG DISCOV TODAY, V7, pS136, DOI 10.1016/S1359-6446(02)02429-7; Jackson RD, 2005, DRUG DISCOV TODAY, V10, P53, DOI 10.1016/S1359-6446(04)03303-3; Janowski Robert, 2009, Journal of Structural and Functional Genomics, V10, P137, DOI 10.1007/s10969-009-9060-4; Kim TY, 2010, METAB ENG, V12, P105, DOI 10.1016/j.ymben.2009.05.004; Kramer R, 2004, NAT REV DRUG DISCOV, V3, P965, DOI 10.1038/nrd1552; Li HL, 2006, NUCLEIC ACIDS RES, V34, pW219, DOI 10.1093/nar/gkl114; Li QL, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-353; Ohlstein EH, 2000, ANNU REV PHARMACOL, V40, P177, DOI 10.1146/annurev.pharmtox.40.1.177; Rahman SA, 2005, BIOINFORMATICS, V21, P1189, DOI 10.1093/bioinformatics/bti116; Rahman SA, 2006, BIOINFORMATICS, V22, P1767, DOI 10.1093/bioinformatics/btl181; Ryan TE, 2002, TRENDS BIOTECHNOL, V20, pS45, DOI 10.1016/S1471-1931(02)00199-4; Schmidtke P, 2010, NUCLEIC ACIDS RES, V38, pW582, DOI 10.1093/nar/gkq383; Sekirov I, 2008, INFECT IMMUN, V76, P4726, DOI 10.1128/IAI.00319-08; Shi R, 2007, MINI-REV MED CHEM, V7, P1177, DOI 10.2174/138955707782331740; Storteboom H, 2010, ENVIRON SCI TECHNOL, V44, P7397, DOI 10.1021/es101657s; Sugaya N, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-263; Vetting MW, 2008, ACTA CRYSTALLOGR F, V64, P978, DOI 10.1107/S1744309108031679; Walke DW, 2001, CURR OPIN BIOTECH, V12, P626, DOI 10.1016/S0958-1669(01)00271-3; Weiss K, 2009, INT J ANTIMICROB AG, V33, pS29, DOI 10.1016/S0924-8579(09)70013-5; Yeh W, 2004, GENOME RES, V14, P917, DOI 10.1101/gr.2050304; Zhang R, 2009, NUCLEIC ACIDS RES, V37, pD455, DOI 10.1093/nar/gkn858; Zhu F, 2010, NUCLEIC ACIDS RES, V38, pD787, DOI 10.1093/nar/gkp1014	38	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2012	7	3							e32833	10.1371/journal.pone.0032833	http://dx.doi.org/10.1371/journal.pone.0032833			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931EO	22431985	Green Published, gold, Green Submitted			2023-01-03	WOS:000303198600028
J	Kamel, H; Navi, BB; Fahimi, J				Kamel, Hooman; Navi, Babak B.; Fahimi, Jahan			National Trends in Ambulance Use by Patients With Stroke, 1997-2008	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							OUTCOMES; REGISTRY; DELAY; TIME		[Kamel, Hooman; Navi, Babak B.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA; [Fahimi, Jahan] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA	Cornell University; University of California System; University of California San Francisco	Kamel, H (corresponding author), Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA.	hok9010@med.cornell.edu	Kamel, Hooman/AGG-9071-2022	Navi, Babak/0000-0001-8424-6128; Kamel, Hooman/0000-0002-5745-0307				Centers for Disease Control and Prevention, NAT AMB MED CAR SURV; Concannon TW, 2009, CIRC-CARDIOVASC QUAL, V2, P9, DOI 10.1161/CIRCOUTCOMES.108.813741; Deng YZ, 2006, NEUROLOGY, V66, P306, DOI 10.1212/01.wnl.0000196478.77152.fc; Lacy CR, 2001, STROKE, V32, P63, DOI 10.1161/01.STR.32.1.63; Ovbiagele B, 2010, STROKE, V41, P1748, DOI 10.1161/STROKEAHA.110.585455; Wojner-Alexandrov AW, 2005, STROKE, V36, P1512, DOI 10.1161/01.STR.0000170700.45340.39	6	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1026	1028		10.1001/jama.2012.285	http://dx.doi.org/10.1001/jama.2012.285			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GU	22416095	Bronze			2023-01-03	WOS:000301479700017
J	Mathew, A; Fukuda, T; Nagaoka, Y; Hasumura, T; Morimoto, H; Yoshida, Y; Maekawa, T; Venugopal, K; Kumar, DS				Mathew, Anila; Fukuda, Takahiro; Nagaoka, Yutaka; Hasumura, Takashi; Morimoto, Hisao; Yoshida, Yasuhiko; Maekawa, Toru; Venugopal, Kizhikkilot; Kumar, D. Sakthi			Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; AMYLOID PATHOLOGY; OXIDATIVE DAMAGE; CANCER-THERAPY; FORMULATION; DELIVERY; VITRO; BIOAVAILABILITY	Alzheimer's disease is a growing concern in the modern world. As the currently available medications are not very promising, there is an increased need for the fabrication of newer drugs. Curcumin is a plant derived compound which has potential activities beneficial for the treatment of Alzheimer's disease. Anti-amyloid activity and anti-oxidant activity of curcumin is highly beneficial for the treatment of Alzheimer's disease. The insolubility of curcumin in water restricts its use to a great extend, which can be overcome by the synthesis of curcumin nanoparticles. In our work, we have successfully synthesized water-soluble PLGA coated-curcumin nanoparticles and characterized it using different techniques. As drug targeting to diseases of cerebral origin are difficult due to the stringency of blood-brain barrier, we have coupled the nanoparticle with Tet-1 peptide, which has the affinity to neurons and possess retrograde transportation properties. Our results suggest that curcumin encapsulated-PLGA nanoparticles are able to destroy amyloid aggregates, exhibit anti-oxidative property and are non-cytotoxic. The encapsulation of the curcumin in PLGA does not destroy its inherent properties and so, the PLGA-curcumin nanoparticles can be used as a drug with multiple functions in treating Alzheimer's disease proving it to be a potential therapeutic tool against this dreaded disease.	[Mathew, Anila; Fukuda, Takahiro; Nagaoka, Yutaka; Hasumura, Takashi; Morimoto, Hisao; Yoshida, Yasuhiko; Maekawa, Toru; Kumar, D. Sakthi] Toyo Univ, Grad Sch Interdisciplinary New Sci, Bio Nano Elect Res Ctr, Kawagoe, Saitama, Japan; [Venugopal, Kizhikkilot] Sooriya Hosp, Dept Resp Med, Madras, Tamil Nadu, India	Toyo University	Mathew, A (corresponding author), Toyo Univ, Grad Sch Interdisciplinary New Sci, Bio Nano Elect Res Ctr, Kawagoe, Saitama, Japan.	sakthi@toyo.jp		Kumar, Sakthi/0000-0003-4624-7327	Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [22560209] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Anila Mathew sincerely acknowledges her receipt of the Monbukagakusho Scholarship from the Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott A, 2011, NATURE, V475, pS2, DOI 10.1038/475S2a; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Anand P, 2010, BIOCHEM PHARMACOL, V79, P330, DOI 10.1016/j.bcp.2009.09.003; Balasubramanian K, 2006, J AGR FOOD CHEM, V54, P3512, DOI 10.1021/jf0603533; Bartczak D, 2011, LANGMUIR, V27, P10119, DOI 10.1021/la2022177; Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3; Cartiera MS, 2010, MOL PHARMACEUT, V7, P86, DOI 10.1021/mp900138a; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Fujisawa S, 2004, ANTICANCER RES, V24, P563; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x; Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016; Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5; Hanz S, 2004, NEUROSCIENTIST, V10, P404, DOI 10.1177/1073858404267884; Iqbal K, 2007, CELL MOL LIFE SCI, V64, P2234, DOI 10.1007/s00018-007-7221-9; Li JW, 2011, BIOMATERIALS, V32, P4943, DOI 10.1016/j.biomaterials.2011.03.031; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Liu JK, 2005, NEUROBIOL DIS, V19, P407, DOI 10.1016/j.nbd.2005.01.022; Lockman PR, 2004, J DRUG TARGET, V12, P635, DOI 10.1080/10611860400015936; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972-2327.40220; Mohorko N, 2010, J NEUROPATH EXP NEUR, V69, P405, DOI 10.1097/NEN.0b013e3181d709eb; Mondalek Fadee G., 2010, Journal of Nanobiotechnology, V8, P17, DOI 10.1186/1477-3155-8-17; Mourtas S, 2011, BIOMATERIALS, V32, P1635, DOI 10.1016/j.biomaterials.2010.10.027; Mukerjee A, 2009, ANTICANCER RES, V29, P3867; Noga DE, 2008, BIOMACROMOLECULES, V9, P2056, DOI 10.1021/bm800292Z; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Park IK, 2007, J GENE MED, V9, P691, DOI 10.1002/jgm.1062; Park SY, 2008, FOOD CHEM TOXICOL, V46, P2881, DOI 10.1016/j.fct.2008.05.030; Rafii MS, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-7; Ringman John M., 2005, Current Alzheimer Research, V2, P131, DOI 10.2174/1567205053585882; Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036; Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Shive MS, 1997, ADV DRUG DELIV REV, V28, P5; Taylor M, 2011, NANOMED-NANOTECHNOL, V7, P541, DOI 10.1016/j.nano.2011.06.015; Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022; Tsai YM, 2011, INT J PHARMACEUT, V416, P331, DOI 10.1016/j.ijpharm.2011.06.030; Vergoni AV, 2009, NANOMED-NANOTECHNOL, V5, P369, DOI 10.1016/j.nano.2009.02.005; Yanagisawa D, 2010, BIOMATERIALS, V31, P4179, DOI 10.1016/j.biomaterials.2010.01.142; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Youdim MBH, 2005, J NEURAL TRANSM, V112, P519, DOI 10.1007/s00702-004-0214-z	43	260	265	3	117	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2012	7	3							e32616	10.1371/journal.pone.0032616	http://dx.doi.org/10.1371/journal.pone.0032616			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928WA	22403681	Green Submitted, gold, Green Published			2023-01-03	WOS:000303017700078
J	Spence, D				Spence, Des			Continuity is never out of fashion	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 8	2012	344								e957	10.1136/bmj.e957	http://dx.doi.org/10.1136/bmj.e957			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	892IE	22318444				2023-01-03	WOS:000300279100013
J	Mack, JW; Cronin, A; Taback, N; Huskamp, HA; Keating, NL; Malin, JL; Earle, CC; Weeks, JC				Mack, Jennifer W.; Cronin, Angel; Taback, Nathan; Huskamp, Haiden A.; Keating, Nancy L.; Malin, Jennifer L.; Earle, Craig C.; Weeks, Jane C.			End-of-Life Care Discussions Among Patients With Advanced Cancer A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							METASTATIC COLORECTAL-CANCER; OUTCOMES RESEARCH; ILL PATIENTS; DEATH; SURVEILLANCE; SURVIVAL; PROGNOSTICATION; CHEMOTHERAPY; PREDICTORS; CARCINOMA	Background: National guidelines recommend that physicians discuss end-of-life (EOL) care planning with patients with cancer whose life expectancy is less than 1 year. Objective: To evaluate the incidence of EOL care discussions for patients with stage IV lung or colorectal cancer and where, when, and with whom these discussions take place. Design: Prospective cohort study of patients diagnosed with lung or colorectal cancer from 2003 to 2005. Setting: Participants lived in Northern California, Los Angeles County, North Carolina, Iowa, or Alabama or received care in 1 of 5 large HMOs or 1 of 15 Veterans Health Administration sites. Patients: 2155 patients with stage IV lung or colorectal cancer. Measurements: End-of-life care discussions reported in patient and surrogate interviews or documented in medical records through 15 months after diagnosis. Results: 73% of patients had EOL care discussions identified by at least 1 source. Among the 1470 patients who died during follow-up, 87% had EOL care discussions, compared with 41% of the 685 patients who were alive at the end of follow-up. Of the 1081 first EOL care discussions documented in records, 55% occurred in the hospital. Oncologists documented EOL care discussions with only 27% of their patients. Among 959 patients with documented EOL care discussions who died during follow-up, discussions took place a median of 33 days before death. Limitations: The depth and quality of EOL care discussions was not evaluated. Much of the information about discussions came from surrogates of patients who died before baseline interviews could be obtained. Conclusion: Although most patients with stage IV lung or colorectal cancer discuss EOL care planning with physicians before death, many discussions occur during acute hospital care, with providers other than oncologists, and late in the course of illness.	[Mack, Jennifer W.] Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA; Ontario Inst Canc Res, Toronto, ON, Canada	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Mack, JW (corresponding author), Harvard Univ, Dana Farber Canc Inst, Childrens Hosp, Sch Med, 450 Brookline Ave, Boston, MA 02215 USA.	jennifer_mack@dfci.harvard.edu	Keating, Nancy L/I-9968-2019	Keating, Nancy L/0000-0002-8274-4681; Taback, Nathan/0000-0001-9497-3951	National Cancer Institute (NCI) [U01 CA093344, U01 CA093332, U01 CA093324, U01 CA093348, U01 CA093329, U01 CA093339, U01 CA093326]; Department of Veterans Affairs [CRS 02-164]; American Cancer Society; National Palliative Care Research Center; NATIONAL CANCER INSTITUTE [U01CA093332, K05CA166208, U01CA093344, U01CA093339, U01CA093326, U01CA093324, U01CA093329] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs(US Department of Veterans Affairs); American Cancer Society(American Cancer Society); National Palliative Care Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work of the CanCORS Consortium was supported by grants from the National Cancer Institute (NCI) to the Statistical Coordinating Center (U01 CA093344) and the NCI-supported Primary Data Collection and Research Centers (grant U01 CA093332 to the Dana-Farber Cancer Institute/Cancer Research Network, grant U01 CA093324 to Harvard Medical School/Northern California Cancer Center, grant U01 CA093348 to RAND/University of California, Los Angeles, grant U01 CA093329 to the University of Alabama at Birmingham, grant U01 CA093339 to the University of Iowa, grant U01 CA093326 to University of North Carolina) and by grant CRS 02-164 from the Department of Veterans Affairs to the Durham Veterans Affairs Medical Center. Dr. Mack was funded by an American Cancer Society Mentored Research Scholar Grant and by the National Palliative Care Research Center.	[Anonymous], STAND DEF FIN DISP C; Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020; Blackstock AW, 2002, JNCI-J NATL CANCER I, V94, P284, DOI 10.1093/jnci/94.4.284; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Catalano P, 2012, MED CARE IN PRESS; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Earle CC, 2000, CHEST, V117, P1239, DOI 10.1378/chest.117.5.1239; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Jenkins V, 2011, J CLIN ONCOL, V29, P61, DOI 10.1200/JCO.2010.30.0814; Kato I, 2001, CANCER, V92, P2211, DOI 10.1002/1097-0142(20011015)92:8<2211::AID-CNCR1565>3.0.CO;2-W; Keating NL, 2010, J CLIN ONCOL, V28, P4364, DOI 10.1200/JCO.2009.26.8870; Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278; Lamont EB, 2003, JAMA-J AM MED ASSOC, V290, P98, DOI 10.1001/jama.290.1.98; Lehmann L, 2007, J CLIN ONCOL, V25; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Malin JL, 2006, SUPPORT CARE CANCER, V14, P837, DOI 10.1007/s00520-005-0902-8; MIYAJI NT, 1993, SOC SCI MED, V36, P249, DOI 10.1016/0277-9536(93)90008-R; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; National Comprehensive Cancer Network, PRACT GUID ONC PALL; National Consensus Project for Quality Palliative Care, CLIN PRACT GUID QUAL; Prigerson H G, 1991, Home Health Care Serv Q, V12, P81; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Ruddick W, 1999, BIOETHICS, V13, P343, DOI 10.1111/1467-8519.00162; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; WALLSTON KA, 1988, MED CARE, V26, P177, DOI 10.1097/00005650-198802000-00008; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	32	276	278	2	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					204	U65		10.7326/0003-4819-156-3-201202070-00008	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312140				2023-01-03	WOS:000299964200004
J	Bajaj, G; Van Alstine, WG; Yeo, Y				Bajaj, Gaurav; Van Alstine, William G.; Yeo, Yoon			Zwitterionic Chitosan Derivative, a New Biocompatible Pharmaceutical Excipient, Prevents Endotoxin-Mediated Cytokine Release	PLOS ONE			English	Article							POLYVINYL PYRROLIDONE HYDROGEL; WATER-SOLUBLE CHITOSAN; PHOTOCROSSLINKABLE CHITOSAN; GLYCOL CHITOSAN; MOLECULAR-WEIGHT; CHITIN; NANOPARTICLES; DELIVERY; DRUG; PEPTIDE	Chitosan is a cationic polymer of natural origin and has been widely explored as a pharmaceutical excipient for a broad range of biomedical applications. While generally considered safe and biocompatible, chitosan has the ability to induce inflammatory reactions, which varies with the physical and chemical properties. We hypothesized that the previously reported zwitterionic chitosan (ZWC) derivative had relatively low pro-inflammatory potential because of the aqueous solubility and reduced amine content. To test this, we compared various chitosans with different aqueous solubilities or primary amine contents with respect to the intraperitoneal (IP) biocompatibility and the propensity to induce proinflammatory cytokine production from macrophages. ZWC was relatively well tolerated in ICR mice after IP administration and had no pro-inflammatory effect on naive macrophages. Comparison with other chitosans indicates that these properties are mainly due to the aqueous solubility at neutral pH and relatively low molecular weight of ZWC. Interestingly, ZWC had a unique ability to suppress cytokine/chemokine production in macrophages challenged with lipopolysaccharide (LPS). This effect is likely due to the strong affinity of ZWC to LPS, which inactivates the pro-inflammatory function of LPS, and appears to be related to the reduced amine content. Our finding warrants further investigation of ZWC as a functional biomaterial.	[Bajaj, Gaurav; Yeo, Yoon] Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA; [Van Alstine, William G.] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Yeo, Yoon] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Yeo, Y (corresponding author), Purdue Univ, Dept Ind & Phys Pharm, W Lafayette, IN 47907 USA.	yyeo@purdue.edu	Yeo, Y/GWV-3316-2022		National Institutes of Health [R21 CA135130]; Lilly Endowment, Inc.; Direct For Mathematical & Physical Scien [1056997] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [R21CA135130] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lilly Endowment, Inc.; Direct For Mathematical & Physical Scien(National Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health R21 CA135130 and a grant from the Lilly Endowment, Inc., to the College of Pharmacy, Purdue University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amsden BG, 2007, BIOMACROMOLECULES, V8, P3758, DOI 10.1021/bm700691e; Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; [Anonymous], 2010, USP33NF28 US PHARM C; Azab AK, 2007, J BIOMED MATER RES A, V83A, P414, DOI 10.1002/jbm.a.31256; Baldrick P, 2009, REGUL TOXICOL PHARM; Bowman K, 2006, INT J NANOMED, V1, P117, DOI 10.2147/nano.2006.1.2.117; Canali MM, 2010, VACCINE, V28, P5718, DOI 10.1016/j.vaccine.2010.06.027; Chellat F, 2000, J BIOMED MATER RES, V51, P107, DOI 10.1002/(SICI)1097-4636(200007)51:1<107::AID-JBM14>3.0.CO;2-F; Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006; Chen CL, 2008, BIOMATERIALS, V29, P2173, DOI 10.1016/j.biomaterials.2008.01.023; Dobrovolskaia MA, 2008, MOL PHARMACEUT, V5, P487, DOI 10.1021/mp800032f; Dufrane D, 2006, BIOMATERIALS, V27, P3201, DOI 10.1016/j.biomaterials.2006.01.028; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hall JC, 1998, GASTROENTEROLOGY, V114, P185, DOI 10.1016/S0016-5085(98)70646-8; HIRANO S, 1994, ABSTR PAP AM CHEM S, V207, P118; Hirano S, 1996, Biotechnol Annu Rev, V2, P237, DOI 10.1016/S1387-2656(08)70012-7; Illum L, 1998, PHARM RES-DORDR, V15, P1326; Ishihara M, 2002, BIOMATERIALS, V23, P833, DOI 10.1016/S0142-9612(01)00189-2; Kawashima Y, 2000, PHARM DEV TECHNOL, V5, P77, DOI 10.1081/PDT-100100522; Kim MS, 2002, NEUROSCI LETT, V321, P105, DOI 10.1016/S0304-3940(02)00066-6; Kohane DS, 2006, J BIOMED MATER RES A, V77A, P351, DOI 10.1002/jbm.a.30654; LEE J, 1995, J IMMUNOL, V155, P2158; Liu HT, 2010, BASIC CLIN PHARMACOL, V106, P362, DOI 10.1111/j.1742-7843.2009.00493.x; Mathews S, 2006, J BIOMED MATER RES A, V79A, P147, DOI 10.1002/jbm.a.30710; Min KH, 2008, J CONTROL RELEASE, V127, P208, DOI 10.1016/j.jconrel.2008.01.013; Minami S, 1998, CARBOHYD POLYM, V36, P151, DOI 10.1016/S0144-8617(98)00015-0; Mori T, 1997, BIOMATERIALS, V18, P947, DOI 10.1016/S0142-9612(97)00017-3; Mori T, 1998, J BIOMED MATER RES, V43, P469; Muzzarelli RAA, 2010, MAR DRUGS, V8, P292, DOI 10.3390/md8020292; Nam KS, 2007, J MICROBIOL BIOTECHN, V17, P2042; Nettles DL, 2002, TISSUE ENG, V8, P1009, DOI 10.1089/107632702320934100; NISHIMURA K, 1986, VACCINE, V4, P151, DOI 10.1016/0264-410X(86)90002-2; Obara K, 2003, BIOMATERIALS, V24, P3437, DOI 10.1016/S0142-9612(03)00220-5; Ono K, 2000, J BIOMED MATER RES, V49, P289; Ono K, 2001, SURGERY, V130, P844, DOI 10.1067/msy.2001.117197; Park JH, 2004, J CONTROL RELEASE, V95, P579, DOI 10.1016/j.jconrel.2003.12.020; Park K, 2007, J CONTROL RELEASE, V122, P305, DOI 10.1016/j.jconrel.2007.04.009; PELUSO G, 1994, BIOMATERIALS, V15, P1215, DOI 10.1016/0142-9612(94)90272-0; Qin CQ, 2006, FOOD CHEM TOXICOL, V44, P855, DOI 10.1016/j.fct.2005.11.009; RAGHOEBAR M, 1987, AGENTS ACTIONS, V22, P314, DOI 10.1007/BF02009062; Risbud M, 2001, CELL TRANSPLANT, V10, P195; Risbud MV, 2001, J BIOMED MATER RES, V57, P300, DOI 10.1002/1097-4636(200111)57:2<300::AID-JBM1171>3.0.CO;2-Q; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Ryu JH, 2011, BIOMACROMOLECULES, V12, P2653, DOI 10.1021/bm200464x; Sagnella S, 2005, COLLOID SURFACE B, V42, P147, DOI 10.1016/j.colsurfb.2004.07.001; Tanaka Y, 1997, BIOMATERIALS, V18, P591, DOI 10.1016/S0142-9612(96)00182-2; USAMI Y, 1994, J VET MED SCI, V56, P1215, DOI 10.1292/jvms.56.1215; van der Merwe SM, 2004, EUR J PHARM BIOPHARM, V58, P225, DOI 10.1016/j.ejpb.2004.03.023; VandeVord PJ, 2002, J BIOMED MATER RES, V59, P585, DOI 10.1002/jbm.1270; Wiegand C, 2010, SKIN PHARMACOL PHYS, V23, P164, DOI 10.1159/000276996; Xu P, 2010, BIOMACROMOLECULES; Yeo Y, 2006, J BIOMED MATER RES A, V78A, P668, DOI 10.1002/jbm.a.30740; Yoon HJ, 2007, BIOCHEM BIOPH RES CO, V358, P954, DOI 10.1016/j.bbrc.2007.05.042	53	39	50	0	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2012	7	1							e30899	10.1371/journal.pone.0030899	http://dx.doi.org/10.1371/journal.pone.0030899			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910LV	22292072	gold, Green Published, Green Submitted			2023-01-03	WOS:000301639600065
J	Isaakidis, P; Cox, HS; Varghese, B; Montaldo, C; Da Silva, E; Mansoor, H; Ladomirska, J; Sotgiu, G; Migliori, GB; Pontali, E; Saranchuk, P; Rodrigues, C; Reid, T				Isaakidis, Petros; Cox, Helen S.; Varghese, Bhanumati; Montaldo, Chiara; Da Silva, Esdras; Mansoor, Homa; Ladomirska, Joanna; Sotgiu, Giovanni; Migliori, Giovanni B.; Pontali, Emanuele; Saranchuk, Peter; Rodrigues, Camilla; Reid, Tony			Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; COMMUNITY-BASED TREATMENT; MDR-TB TREATMENT; METAANALYSIS; MORTALITY; CAMBODIA; CHILDREN; THERAPY; PROGRAM; AFRICA	Background: India carries one quarter of the global burden of multi-drug resistant TB (MDR-TB) and has an estimated 2.5 million people living with HIV. Despite this reality, provision of treatment for MDR-TB is extremely limited, particularly for HIV-infected individuals. Medecins Sans Frontieres (MSF) has been treating HIV-infected MDR-TB patients in Mumbai since May 2007. This is the first report of treatment outcomes among HIV-infected MDR-TB patients in India. Methods: HIV-infected patients with suspected MDR-TB were referred to the MSF-clinic by public Antiretroviral Therapy (ART) Centers or by a network of community non-governmental organizations. Patients were initiated on either empiric or individualized second-line TB-treatment as per WHO recommendations. MDR-TB treatment was given on an ambulatory basis and under directly observed therapy using a decentralized network of providers. Patients not already receiving ART were started on treatment within two months of initiating MDR-TB treatment. Results: Between May 2007 and May 2011, 71 HIV-infected patients were suspected to have MDR-TB, and 58 were initiated on treatment. MDR-TB was confirmed in 45 (78%), of which 18 (40%) were resistant to ofloxacin. Final treatment outcomes were available for 23 patients; 11 (48%) were successfully treated, 4 (17%) died, 6 (26%) defaulted, and 2 (9%) failed treatment. Overall, among 58 patients on treatment, 13 (22%) were successfully treated, 13 (22%) died, 7 (12%) defaulted, two (3%) failed treatment, and 23 (40%) were alive and still on treatment at the end of the observation period. Twenty-six patients (45%) experienced moderate to severe adverse events, requiring modification of the regimen in 12 (20%). Overall, 20 (28%) of the 71 patients with MDR-TB died, including 7 not initiated on treatment. Conclusions: Despite high fluoroquinolone resistance and extensive prior second-line treatment, encouraging results are being achieved in an ambulatory MDR-T-program in a slum setting in India. Rapid scale-up of both ART and second-line treatment for MDR-TB is needed to ensure survival of co-infected patients and mitigate this growing epidemic.	[Isaakidis, Petros; Varghese, Bhanumati; Montaldo, Chiara; Da Silva, Esdras; Mansoor, Homa; Ladomirska, Joanna] Med San Frontieres, Bombay, Maharashtra, India; [Cox, Helen S.; Saranchuk, Peter] Med San Frontieres, Cape Town, South Africa; [Cox, Helen S.] Monash Univ, Melbourne, Vic 3004, Australia; [Sotgiu, Giovanni] Univ Sassari, Hyg & Prevent Med Inst, I-07100 Sassari, Italy; [Migliori, Giovanni B.] World Hlth Org Collaborating Ctr TB & Lung Dis, S Maugeri Fdn, Tradate, Italy; [Pontali, Emanuele] Galliera Hosp, Dept Infect Dis, Genoa, Italy; [Rodrigues, Camilla] PD Hinduja Natl Hosp & Med Res Ctr Hinduja, Bombay, Maharashtra, India; [Reid, Tony] Med San Frontieres, Operat Res Unit, Brussels, Belgium	Monash University; University of Sassari; Istituti Clinici Scientifici Maugeri IRCCS; World Health Organization; Ente Ospedaliero Ospedali Galliera; University of Genoa	Isaakidis, P (corresponding author), Med San Frontieres, Bombay, Maharashtra, India.	msfocb-asia-epidemio@brussels.msf.org	Sotgiu, Giovanni/N-1032-2017; Migliori, Giovanni Battista/AAB-8589-2020; Montaldo, Chiara/AAE-3265-2020	Sotgiu, Giovanni/0000-0002-1600-4474; Migliori, Giovanni Battista/0000-0002-2597-574X; Isaakidis, Petros/0000-0002-7881-1554; Pontali, Emanuele/0000-0002-1085-0442; Cox, Helen/0000-0002-6538-7192	M�decins Sans Fronti�res [OCG_pilot_00_Montaldo] Funding Source: researchfish	M�decins Sans Fronti�res		Agrawal D, 2009, INT J TUBERC LUNG D, V13, P79; [Anonymous], 2008, GUID PROGR MAN DRUG; [Anonymous], 2010, MULTIDRUG EXTENSIVEL; [Anonymous], 2010, ROADM ROLL OUT XPERT; Bhargava A, 2011, HYPOTHESIS, V9, pe7; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Brust J, 2010, PLOS ONE, V6; Chadha VK, 2005, INT J TUBERC LUNG D, V9, P1072; Cox HS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001126; D'souza DTB, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-211; Deivanayagam C N, 2002, Indian J Chest Dis Allied Sci, V44, P237; Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC; Heller T, 2010, INT J TUBERC LUNG D, V14, P420; Isaakidis P, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-11; Johnston JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006914; Joseph P, 2011, INDIAN J MED RES, V133, P529; Karim SSA, 2010, NEW ENGL J MED, V362, P697, DOI 10.1056/NEJMoa0905848; Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Mahadev B, 2004, INDIAN J TUBERC, V52, P5; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Murray J, 1999, AM J RESP CRIT CARE, V159, P733, DOI 10.1164/ajrccm.159.3.9804147; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; Orenstein EW, 2009, LANCET INFECT DIS, V9, P153, DOI 10.1016/S1473-3099(09)70041-6; Paramasivan CN, 2004, INDIAN J MED RES, V120, P377; Raguenaud ME, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-54; Seung KJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007186; Shin S, 2004, SOC SCI MED, V59, P1529, DOI 10.1016/j.socscimed.2004.01.027; Shin SS, 2006, INT J TUBERC LUNG D, V10, P402; Singla R, 2009, INT J TUBERC LUNG D, V13, P976; Tupasi TE, 2006, PLOS MED, V3, P1587, DOI 10.1371/journal.pmed.0030352; Udwadia ZF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012023; Vadwai V, 2011, J CLIN MICROBIOL, V49, P2540, DOI 10.1128/JCM.02319-10; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2009, MAN MDR TB FIELD GUI	35	62	63	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2011	6	12							e28066	10.1371/journal.pone.0028066	http://dx.doi.org/10.1371/journal.pone.0028066			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863MQ	22145022	Green Submitted, Green Published, gold			2023-01-03	WOS:000298168900005
J	Qaseem, A; Chou, R; Humphrey, LL; Starkey, M; Shekelle, P				Qaseem, Amir; Chou, Roger; Humphrey, Linda L.; Starkey, Melissa; Shekelle, Paul		Amer Coll Phys	Venous Thromboembolism Prophylaxis in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; ACUTE ISCHEMIC-STROKE; LOW-DOSE HEPARIN; FATAL PULMONARY-EMBOLISM; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; UNFRACTIONATED HEPARIN; MEDICAL PATIENTS; ACUTELY ILL	Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on prophylaxis of venous thromboembolism for hospitalized nonsurgical patients (medical patients and patients with acute stroke). Methods: This guideline is based on published literature on the topic from 1950 through April 2011 that was identified by using MEDLINE, the Cochrane Library, and reference lists of pertinent randomized trials and systematic reviews to identify additional reports. Searches were limited to randomized trials and English-language publications. The primary outcome for this guideline was total mortality up to 120 days after randomization. Secondary outcomes included symptomatic deep venous thrombosis; all pulmonary embolisms; fatal pulmonary embolism; all bleeding events; major bleeding events; and, for mechanical prophylaxis, effects on skin. This guideline grades the evidence and recommendations by using the ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends assessment of the risk for thromboembolism and bleeding in medical (including stroke) patients prior to initiation of prophylaxis of venous thromboembolism (Grade: strong recommendation, moderate-quality evidence). Recommendation 2: ACP recommends pharmacologic prophylaxis with heparin or a related drug for venous thromboembolism in medical (including stroke) patients unless the assessed risk for bleeding outweighs the likely benefits (Grade: strong recommendation, moderate-quality evidence). Recommendation 3: ACP recommends against the use of mechanical prophylaxis with graduated compression stockings for prevention of venous thromboembolism (Grade: strong recommendation, moderate-quality evidence). Policy Implication: ACP does not support the application of performance measures in medical (including stroke) patients that promotes universal venous thromboembolism prophylaxis regardless of risk.	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	American College of Physicians; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Chou, Roger/0000-0001-9889-8610; Starkey, Melissa/0000-0002-5818-0265	ACP	ACP	Financial support for the development of this guideline comes exclusively from the ACP operating budget.	Alikhan R, 2004, J CLIN PATHOL, V57, P1254, DOI 10.1136/jcp.2003.013581; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Aquino JP, 1991, FRAXIPARINE; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; Cook D, 2011, NEW ENGL J MED, V364, P1305; DAHAN R, 1986, HAEMOSTASIS, V16, P159; Dennis M, 2010, ANN INTERN MED, V153, P553, DOI 10.7326/0003-4819-153-9-201011020-00280; Dennis M, 2009, LANCET, V373, P1958, DOI 10.1016/S0140-6736(09)60941-7; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; Diener HC, 2006, STROKE, V37, P139, DOI 10.1161/01.STR.0000195182.67656.ee; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025; Gardlund B, 1996, LANCET, V347, P1357; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Green D., 1998, TOP STROKE REHABIL, V5, P68; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; Hillbom M, 2002, ACTA NEUROL SCAND, V106, P84, DOI 10.1034/j.1600-0404.2002.01215.x; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Kucher N, 2005, ARCH INTERN MED, V165, P341, DOI 10.1001/archinte.165.3.341; Lacut K, 2005, NEUROLOGY, V65, P865, DOI 10.1212/01.wnl.0000176073.80532.a2; Lechler E, 1996, HAEMOSTASIS, V26, P49; Lederle FA, 2006, AM J MED, V119, P54, DOI 10.1016/j.amjmed.2005.03.049; Lederle FA, 2011, ANN INTERN MED, V155, P602, DOI 10.7326/0003-4819-155-9-201111010-00008; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; LINDBLAD B, 1991, BRIT MED J, V302, P709, DOI 10.1136/bmj.302.6778.709; Luba Maria, 2007, Pol Arch Med Wewn, V117, P31; Mahe I, 2005, EUR J CLIN PHARMACOL, V61, P347, DOI 10.1007/s00228-005-0944-3; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; Muir KW, 2000, QJM-INT J MED, V93, P359, DOI 10.1093/qjmed/93.6.359; PRASAD BK, 1982, AGE AGEING, V11, P42, DOI 10.1093/ageing/11.1.42; PRINS MH, 1989, HAEMOSTASIS, V19, P245; Qaseem A, 2007, ANN INTERN MED, V146, P454, DOI 10.7326/0003-4819-146-6-200703200-00013; Qaseem A, 2010, ANN INTERN MED, V153, P194, DOI 10.7326/0003-4819-153-3-201008030-00010; Riess H, 2010, J THROMB HAEMOST, V8, P1209, DOI 10.1111/j.1538-7836.2010.03848.x; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Sandercock P, 1997, LANCET, V349, P1569; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Schellong SM, 2010, EXPERT OPIN PHARMACO, V11, P2953, DOI 10.1517/14656566.2010.521498; Sherman DG, 2007, LANCET, V369, P1347, DOI 10.1016/S0140-6736(07)60633-3; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; TURPIE AGG, 1987, LANCET, V1, P523; Weber C, 2008, SUPPORT CARE CANCER, V16, P847, DOI 10.1007/s00520-007-0339-3	50	182	187	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					625	U118		10.7326/0003-4819-155-9-201111010-00011	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041951				2023-01-03	WOS:000296612400007
J	Lee, N; Wong, CK; Chan, PKS; Chan, MCW; Wong, RYK; Lun, SWM; Ngai, KLK; Lui, GCY; Wong, BCK; Lee, SKW; Choi, KW; Hui, DSC				Lee, Nelson; Wong, Chun Kwok; Chan, Paul K. S.; Chan, Martin C. W.; Wong, Rity Y. K.; Lun, Samantha W. M.; Ngai, Karry L. K.; Lui, Grace C. Y.; Wong, Bonnie C. K.; Lee, Sharon K. W.; Choi, Kin Wing; Hui, David S. C.			Cytokine Response Patterns in Severe Pandemic 2009 H1N1 and Seasonal Influenza among Hospitalized Adults	PLOS ONE			English	Article							CLINICAL-ASPECTS; HOST RESPONSES; WHOLE-BLOOD; VIRUS; CELLS; FERRETS; HYPERCYTOKINEMIA; INTERFERON; ACTIVATION; INFECTION	Background: Studying cytokine/chemokine responses in severe influenza infections caused by different virus subtypes may improve understanding on pathogenesis. Methods: Adults hospitalized for laboratory-confirmed seasonal and pandemic 2009 A/H1N1 (pH1N1) influenza were studied. Plasma concentrations of 13 cytokines/chemokines were measured at presentation and then serially, using cytometric-bead-array with flow-cytometry and ELISA. PBMCs from influenza patients were studied for cytokine/chemokine expression using ex-vivo culture (Whole Blood Assay,+/- PHA/LPS stimulation). Clinical variables were prospectively recorded and analyzed. Results: 63 pH1N1 and 53 seasonal influenza patients were studied. pH1N1 patients were younger (mean +/- S.D. 42.8 +/- 19.2 vs 70.5 +/- 16.7 years), and fewer had comorbidities. Respiratory/cardiovascular complications were common in both groups (71.4% vs 81.1%), although severe pneumonia with hypoxemia (54.0% vs 28.3%) and ICU admissions (25.4% vs 1.9%) were more frequent with pH1N1. Hyperactivation of the proinflammatory cytokines IL-6, CXCL8/IL-8, CCL2/MCP-1 and sTNFR-1 was found in pH1N1 pneumonia (2-15 times normal) and in complicated seasonal influenza, but not in milder pH1N1 infections. The adaptive-immunity (Th1/Th17)-related CXCL10/IP-10, CXCL9/MIG and IL-17A however, were markedly suppressed in severe pH1N1 pneumonia (2-27 times lower than seasonal influenza; P-values<0.01). This pattern was further confirmed with serial measurements. Hypercytokinemia tended to be sustained in pH1N1 pneumonia, associated with a slower viral clearance [PCR-negativity: day 3-4, 55% vs 85%; day 6-7, 67% vs 100%]. Elevated proinflammatory cytokines, particularly IL-6, predicted ICU admission (adjusted OR 12.6, 95% CI 2.6-61.5, per log(10)unit increase; P = 0.002), and correlated with fever, tachypnoea, deoxygenation, and length-of-stay (Spearman's rho, P-values<0.01) in influenza infections. PBMCs in seasonal influenza patients were activated and expressed cytokines ex vivo (e.g. IL-6, CXCL8/IL-8, CCL2/MCP-1, CXCL10/IP-10, CXCL9/MIG); their 'responsiveness' to stimuli was shown to change dynamically during the illness course. Conclusions: A hyperactivated proinflammatory, but suppressed adaptive-immunity (Th1/Th17)-related cytokine response pattern was found in severe pH1N1 pneumonia, different from seasonal influenza. Cytokine/immune-dysregulation may be important in its pathogenesis.	[Lee, Nelson; Chan, Martin C. W.; Wong, Rity Y. K.; Lui, Grace C. Y.; Wong, Bonnie C. K.; Lee, Sharon K. W.; Choi, Kin Wing; Hui, David S. C.] Chinese Univ Hong Kong, Dept Med & Therapeut, Fac Med, Hong Kong, Hong Kong, Peoples R China; [Lee, Nelson; Chan, Paul K. S.; Hui, David S. C.] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Fac Med, Hong Kong, Hong Kong, Peoples R China; [Wong, Chun Kwok; Lun, Samantha W. M.; Lee, Sharon K. W.] Chinese Univ Hong Kong, Dept Chem Pathol, Fac Med, Hong Kong, Hong Kong, Peoples R China; [Chan, Paul K. S.; Ngai, Karry L. K.] Chinese Univ Hong Kong, Dept Microbiol, Fac Med, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Lee, N (corresponding author), Chinese Univ Hong Kong, Dept Med & Therapeut, Fac Med, Hong Kong, Hong Kong, Peoples R China.	leelsn@cuhk.edu.hk	Hui, David Shu-Cheong/O-2754-2015; Lui, Grace/N-4498-2019; Chan, Martin/B-3588-2009; Wong, CK/H-3256-2016; Chan, Paul KS/J-9360-2013; Lee, Nelson/B-6418-2008; Lui, Chung Yan Grace/N-5178-2016	Hui, David Shu-Cheong/0000-0003-4382-2445; Chan, Martin/0000-0002-1568-1596; Wong, CK/0000-0002-5637-8331; Chan, Paul KS/0000-0002-6360-4608; Lee, Nelson/0000-0002-0783-6607; Lui, Chung Yan Grace/0000-0001-5242-2967	Stanley Ho Centre for Emerging Infectious Diseases (The Chinese University of Hong Kong); Department of Medicine and Therapeutics, Faculty of Medicine (The Chinese University of Hong Kong); F. Hoffmann-La Roche Ltd.	Stanley Ho Centre for Emerging Infectious Diseases (The Chinese University of Hong Kong)(Chinese University of Hong Kong); Department of Medicine and Therapeutics, Faculty of Medicine (The Chinese University of Hong Kong)(Chinese University of Hong Kong); F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	This study was jointly supported by a research fund from the Stanley Ho Centre for Emerging Infectious Diseases and a research fund from the Department of Medicine and Therapeutics, Faculty of Medicine; both are internal funding sources (The Chinese University of Hong Kong). The third source was an unrestricted, educational grant from F. Hoffmann-La Roche Ltd for this principle investigator-initiated study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrati C, 2010, J INFECT DIS, V202, P681, DOI 10.1086/655469; [Anonymous], INFL; Arankalle V.A., 2010, PLOS ONE, V5; Baskin CR, 2009, P NATL ACAD SCI USA, V106, P3455, DOI 10.1073/pnas.0813234106; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Bermejo-Martin JF, 2010, CRIT CARE, V14, DOI 10.1186/cc9259; Bermejo-Martin JF, 2009, CRIT CARE, V13, DOI 10.1186/cc8208; Brun-Buisson C, 2011, AM J RESP CRIT CARE, V183, P1200, DOI 10.1164/rccm.201101-0135OC; Chan MCW, 2010, AM J PATHOL, V176, P1828, DOI 10.2353/ajpath.2010.091087; Crowe CR, 2009, J IMMUNOL, V183, P5301, DOI 10.4049/jimmunol.0900995; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Geiler J, 2011, MED MICROBIOL IMMUN, V200, P53, DOI 10.1007/s00430-010-0173-y; Giamarellos-Bourboulis EJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008393; Hagau N, 2010, CRIT CARE, V14, DOI 10.1186/cc9324; Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814; Han K, 2011, CLIN INFECT DIS, V53, P326, DOI 10.1093/cid/cir398; Hui DS, 2010, CHEST, V137, P916, DOI 10.1378/chest.09-2344; Hussain R, 2002, J IMMUNOL METHODS, V264, P95, DOI 10.1016/S0022-1759(02)00092-3; Ison MG, 2010, CLEV CLIN J MED, V77, P812, DOI 10.3949/ccjm.77a.10135; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jiang TJ, 2010, CLIN IMMUNOL, V137, P303, DOI 10.1016/j.clim.2010.07.010; Kudva A, 2011, J IMMUNOL, V186, P1666, DOI 10.4049/jimmunol.1002194; Lee N, 2007, CLIN INFECT DIS, V45, P723, DOI 10.1086/520981; LEE N, 2011, LANCET IN PRESS; Lee N, 2011, J INFECT DIS, V203, P1739, DOI 10.1093/infdis/jir187; Lee N, 2011, ANTIVIR THER, V16, P237, DOI 10.3851/IMP1722; Lee N, 2009, J INFECT DIS, V200, P492, DOI 10.1086/600383; Lee SMY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-147; Lit LCW, 2006, ANN RHEUM DIS, V65, P209, DOI 10.1136/ard.2005.038315; Longhi MP, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000006; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; McGill J, 2009, J LEUKOCYTE BIOL, V86, P803, DOI 10.1189/jlb.0509368; Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449; Osterlund P, 2010, J VIROL, V84, P1414, DOI 10.1128/JVI.01619-09; Peiris JSM, 2009, TRENDS IMMUNOL, V30, P574, DOI 10.1016/j.it.2009.09.004; Rigato O, 2003, SHOCK, V19, P113, DOI 10.1097/00024382-200302000-00004; Rowe T, 2010, VIROLOGY, V401, P257, DOI 10.1016/j.virol.2010.02.020; Sato M, 2009, CYTOKINE, V47, P65, DOI 10.1016/j.cyto.2009.05.003; Simmons C, 2008, NEW ENGL J MED, V359, P1621, DOI 10.1056/NEJMcibr0805865; Svitek N, 2008, VIROLOGY, V376, P53, DOI 10.1016/j.virol.2008.02.035; To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581; van den Brand JMA, 2010, J INFECT DIS, V201, P993, DOI 10.1086/651132; Walsh KB, 2011, P NATL ACAD SCI USA, V108, P12018, DOI 10.1073/pnas.1107024108; Wu WX, 2010, VIROLOGY, V396, P178, DOI 10.1016/j.virol.2009.10.016	44	104	108	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2011	6	10							e26050	10.1371/journal.pone.0026050	http://dx.doi.org/10.1371/journal.pone.0026050			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834QT	22022504	gold, Green Published, Green Submitted			2023-01-03	WOS:000295978600037
J	Ku, SW; Lee, U; Noh, GJ; Jun, IG; Mashour, GA				Ku, Seung-Woo; Lee, UnCheol; Noh, Gyu-Jeong; Jun, In-Gu; Mashour, George A.			Preferential Inhibition of Frontal-to-Parietal Feedback Connectivity Is a Neurophysiologic Correlate of General Anesthesia in Surgical Patients	PLOS ONE			English	Article							PROPOFOL-INDUCED LOSS; CONSCIOUSNESS; AWARENESS; DIRECTIONALITY; FEEDFORWARD; BREAKDOWN; FLASH; MODEL	Background: The precise mechanism and optimal measure of anesthetic-induced unconsciousness has yet to be elucidated. Preferential inhibition of feedback connectivity from frontal to parietal brain networks is one potential neurophysiologic correlate, but has only been demonstrated in animals or under limited conditions in healthy volunteers. Methods and Findings: We recruited eighteen patients presenting for surgery under general anesthesia; electroencephalography of the frontal and parietal regions was acquired during (i) baseline consciousness, (ii) anesthetic induction with propofol or sevoflurane, (iii) general anesthesia, (iv) recovery of consciousness, and (v) post-recovery states. We used two measures of effective connectivity, evolutional map approach and symbolic transfer entropy, to analyze causal interactions of the frontal and parietal regions. The dominant feedback connectivity of the baseline conscious state was inhibited after anesthetic induction and during general anesthesia, resulting in reduced asymmetry of feedback and feedforward connections in the frontoparietal network. Dominant feedback connectivity returned when patients recovered from anesthesia. Both analytic techniques and both classes of anesthetics demonstrated similar results in this heterogeneous population of surgical patients. Conclusions: The disruption of dominant feedback connectivity in the frontoparietal network is a common neurophysiologic correlate of general anesthesia across two anesthetic classes and two analytic measures. This study represents a key translational step from the underlying cognitive neuroscience of consciousness to more sophisticated monitoring of anesthetic effects in human surgical patients.	[Ku, Seung-Woo; Noh, Gyu-Jeong; Jun, In-Gu] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Ku, Seung-Woo; Lee, UnCheol; Mashour, George A.] Univ Michigan, Sch Med, Dept Anesthesiol, Ann Arbor, MI USA	University of Ulsan; Asan Medical Center; University of Michigan System; University of Michigan	Ku, SW (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea.	gmashour@umich.edu						[Anonymous], 1956, MODERN MATH ENG; Boehler CN, 2008, P NATL ACAD SCI USA, V105, P8742, DOI 10.1073/pnas.0801999105; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Chicharro D, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.026217; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; Del Cul A, 2007, PLOS BIOL, V5, P2408, DOI 10.1371/journal.pbio.0050260; Fahrenfort JJ, 2007, J COGNITIVE NEUROSCI, V19, P1488, DOI 10.1162/jocn.2007.19.9.1488; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Florin E, 2010, NEUROIMAGE, V50, P577, DOI 10.1016/j.neuroimage.2009.12.050; Goncharova II, 2003, CLIN NEUROPHYSIOL, V114, P1580, DOI 10.1016/S1388-2457(03)00093-2; Hudetz A., 2006, SEMIN ANESTH PERIO M, V25, P196, DOI [DOI 10.1053/j.sane.2006.09.003, 10.1053/j.sane.2006.09.003]; Hudetz AG, 2009, CONSCIOUS COGN, V18, P1079, DOI 10.1016/j.concog.2009.08.004; Hudetz AG, 2009, ANESTHESIOLOGY, V111, P231, DOI 10.1097/ALN.0b013e3181ab671e; Imas OA, 2005, NEUROSCI LETT, V387, P145, DOI 10.1016/j.neulet.2005.06.018; Imas OA, 2006, NEUROSCI LETT, V402, P216, DOI 10.1016/j.neulet.2006.04.003; Lamme VAF, 2000, TRENDS NEUROSCI, V23, P571, DOI 10.1016/S0166-2236(00)01657-X; Lee U, 2011, ANESTHESIOLOGY, V114, P872, DOI 10.1097/ALN.0b013e31821102c9; Lee U, 2009, CONSCIOUS COGN, V18, P1069, DOI 10.1016/j.concog.2009.04.004; Martuzzi R, 2010, NEUROIMAGE, V49, P823, DOI 10.1016/j.neuroimage.2009.07.028; Mhuircheartaigh RN, 2010, J NEUROSCI, V30, P9095, DOI 10.1523/JNEUROSCI.5516-09.2010; Mrowka R, 2003, AM J PHYSIOL-REG I, V285, pR1395, DOI 10.1152/ajpregu.00373.2003; Naghavi HR, 2005, CONSCIOUS COGN, V14, P390, DOI 10.1016/j.concog.2004.10.003; Nalatore H, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.031123; Orser BA, 2008, CAN MED ASSOC J, V178, P185, DOI 10.1503/cmaj.071761; Palanca BA, 2009, CURR OPIN ANESTHESIO, V22, P553, DOI 10.1097/ACO.0b013e3283304032; Pascual-Leone A, 2001, SCIENCE, V292, P510, DOI 10.1126/science.1057099; Plourde G, 2006, ANESTHESIOLOGY, V104, P448, DOI 10.1097/00000542-200603000-00011; Quan MN, 2011, BRAIN RES BULL, V85, P109, DOI 10.1016/j.brainresbull.2011.03.002; Ro T, 2003, CURR BIOL, V13, P1038, DOI 10.1016/S0960-9822(03)00337-3; Rosenblum MG, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041909; Rosenblum MG, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.045202; Schreiber T, 2000, PHYS REV LETT, V85, P461, DOI 10.1103/PhysRevLett.85.461; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Schrouff J, 2011, NEUROIMAGE, V57, P198, DOI 10.1016/j.neuroimage.2011.04.020; Shao ZW, 1996, J NEUROSCI, V16, P7353; Stamatakis EA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014224; Staniek M, 2009, BIOMED TECH, V54, P323, DOI 10.1515/BMT.2009.040; Staniek M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.158101; Tononi G, 2008, ANN NY ACAD SCI, V1124, P239, DOI 10.1196/annals.1440.004; Vicente R, 2011, J COMPUT NEUROSCI, V30, P45, DOI 10.1007/s10827-010-0262-3; Zheng CG, 2011, NEUROSCI LETT, V490, P52, DOI 10.1016/j.neulet.2010.12.024	43	154	158	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2011	6	10							e25155	10.1371/journal.pone.0025155	http://dx.doi.org/10.1371/journal.pone.0025155			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834NA	21998638	gold, Green Published, Green Submitted			2023-01-03	WOS:000295966900011
J	Yan, J; Wang, ZY; Yang, HZ; Liu, HZ; Mi, S; Lv, XX; Fu, XM; Yan, HM; Zhang, XW; Zhan, QM; Hu, ZW				Yan, Jun; Wang, Zi-Yan; Yang, Hong-Zhen; Liu, Han-Zhi; Mi, Su; Lv, Xiao-Xi; Fu, Xiao-Ming; Yan, Hui-Min; Zhang, Xiao-Wei; Zhan, Qi-Min; Hu, Zhuo-Wei			Timing Is Critical for an Effective Anti-Metastatic Immunotherapy: The Decisive Role of IFN gamma/STAT1-Mediated Activation of Autophagy	PLOS ONE			English	Article							CANCER-IMMUNOTHERAPY; INNATE IMMUNITY; SUPPRESSION; RECEPTORS; AGONISTS; STAT3; TLR4; GENE	Background: Immunotherapy is often recommended as an adjuvant treatment to reduce the chance of cancer recurrence or metastasis. Interestingly, timing is very important for a successful immunotherapy against metastasis, although the precise mechanism is still unknown. Methods and Findings: Using a mouse model of melanoma metastasis induced by intravenous injection of B16-F10 cells, we investigated the mechanism responsible for the diverse efficacy of the prophylactic or therapeutic TLR4 and TLR9 agonist complex against metastasis. We found that the activation of TLR4 and TLR9 prevented, but did not reverse, metastasis because the potency of this combination was neither sufficient to overcome the tumor cell-educated immune tolerance nor to induce efficacious autophagy in tumor cells. The prophylactic application of the complex promoted antimetastatic immunity, leading to the autophagy-associated death of melanoma cells via IFN gamma/STAT1 activation and attenuated tumor metastasis. IFN gamma neutralization reversed the prophylactic benefit induced by the complex by suppressing STAT1 activation and attenuating autophagy in mice. However, the therapeutic application of the complex did not suppress metastasis because the complex could not reverse tumor cell-induced STAT3 activation and neither activate IFN gamma/STAT1 signaling and autophagy. Suppressing STAT3 activation with the JAK/STAT antagonist AG490 restored the antimetastatic effect of the TLR4/9 agonist complex. Activation of autophagy after tumor inoculation by using rapamycin, with or without the TLR4/9 agonist complex, could suppress metastasis. Conclusion and Significance: Our studies suggest that activation of IFN gamma/STAT1 signaling and induction of autophagy are critical for an efficacious anti-metastatic immunotherapy and that autophagy activators may overcome the timing barrier for immunotherapy against metastasis.	[Yan, Jun; Wang, Zi-Yan; Yang, Hong-Zhen; Liu, Han-Zhi; Mi, Su; Lv, Xiao-Xi; Fu, Xiao-Ming; Yan, Hui-Min; Zhang, Xiao-Wei; Hu, Zhuo-Wei] Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Mol Immunol & Pharmacol Lab, Beijing 100050, Peoples R China; [Yan, Jun; Wang, Zi-Yan; Yang, Hong-Zhen; Liu, Han-Zhi; Mi, Su; Lv, Xiao-Xi; Fu, Xiao-Ming; Yan, Hui-Min; Zhang, Xiao-Wei; Zhan, Qi-Min; Hu, Zhuo-Wei] Peking Union Med Coll, Beijing 100021, Peoples R China; [Zhan, Qi-Min] Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100050, Peoples R China; [Zhan, Qi-Min] Chinese Acad Med Sci, Canc Hosp, Beijing 100050, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Materia Medica - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS	Yan, J (corresponding author), Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Mol Immunol & Pharmacol Lab, Beijing 100050, Peoples R China.	huzhuowei@imm.ac.cn	Wang, Ziyan/HII-8458-2022	Yan, Jun/0000-0002-3261-0749	National Major Basic Research Program of China [2006CB503808]; Creation of Major New Drugs [2009ZX09301-003-13, 2009ZX09301-003-9-1]; National Nature Scientific Foundation [30973557]; Ph.D. Programs Foundation of Ministry of Education of China [20070023035]	National Major Basic Research Program of China(National Basic Research Program of China); Creation of Major New Drugs; National Nature Scientific Foundation; Ph.D. Programs Foundation of Ministry of Education of China(Ministry of Education, China)	This study was supported by grants from the National Major Basic Research Program of China (2006CB503808, http://www.973.gov.cn/English/Index.aspx), Creation of Major New Drugs (2009ZX09301-003-13; 2009ZX09301-003-9-1, http://program.most.gov.cn/), National Nature Scientific Foundation (30973557, http://www.nsfc.gov.cn), and Ph.D. Programs Foundation of Ministry of Education of China (20070023035, http://www.cutech.edu.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avraham R, 2010, BRAIN BEHAV IMMUN, V24, P952, DOI 10.1016/j.bbi.2010.03.010; Bafica A, 2007, J IMMUNOL, V179, P5514, DOI 10.4049/jimmunol.179.8.5514; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Burdelya L, 2002, MOL CANCER THER, V1, P893; Chang YP, 2010, J BIOL CHEM, V285, P28715, DOI 10.1074/jbc.M110.133355; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Curiel TJ, 2007, J CLIN INVEST, V117, P1167, DOI 10.1172/JCI31202; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Delgado MA, 2009, CELL DEATH DIFFER, V16, P976, DOI 10.1038/cdd.2009.40; Deretic V, 2009, CURR OPIN IMMUNOL, V21, P53, DOI 10.1016/j.coi.2009.02.002; Fournier P, 2009, EXPERT REV VACCINES, V8, P51, DOI 10.1586/14760584.8.1.51; Haehnel PS, 2008, CANCER RES, V68, P3899, DOI 10.1158/0008-5472.CAN-07-6286; Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008; Kim HS, 2007, CELL SIGNAL, V19, P454, DOI 10.1016/j.cellsig.2006.09.003; Klinman D, 2008, J LEUKOCYTE BIOL, V84, P958, DOI 10.1189/jlb.1107775; Kopfstein L, 2006, CELL MOL LIFE SCI, V63, P449, DOI 10.1007/s00018-005-5296-8; Kortylewski M, 2009, CANCER RES, V69, P2497, DOI 10.1158/0008-5472.CAN-08-3031; Lasaro MO, 2010, CURR OPIN IMMUNOL, V22, P385, DOI 10.1016/j.coi.2010.04.005; Li JCB, 2011, AIDS, V25, P15, DOI 10.1097/QAD.0b013e328340fd61; Liu YY, 2008, J IMMUNOL, V180, P7349, DOI 10.4049/jimmunol.180.11.7349; Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Molavi O, 2008, IMMUNOL CELL BIOL, V86, P506, DOI 10.1038/icb.2008.27; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Noguchi M, 2001, CANCER GENE THER, V8, P421, DOI 10.1038/sj.cgt.7700320; Park HJ, 2011, MOL IMMUNOL, V48, P720, DOI 10.1016/j.molimm.2010.10.020; Raman VS, 2010, J IMMUNOL, V185, P1701, DOI 10.4049/jimmunol.1000238; Romagne F, 2007, DRUG DISCOV TODAY, V12, P80, DOI 10.1016/j.drudis.2006.11.007; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Ruttinger D, 2010, ONCOLOGIST, V15, P112, DOI 10.1634/theoncologist.2009-0213; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Sinnberg T, 2009, J INVEST DERMATOL, V129, P1500, DOI 10.1038/jid.2008.379; Theiner G, 2008, MOL IMMUNOL, V45, P244, DOI 10.1016/j.molimm.2007.02.021; Umansky V, 2009, FUTURE ONCOL, V5, P941, DOI [10.2217/fon.09.62, 10.2217/FON.09.62]; Van Grol J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011733; Yang HZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006520; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	44	26	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2011	6	9							e24705	10.1371/journal.pone.0024705	http://dx.doi.org/10.1371/journal.pone.0024705			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825ZV	21931823	Green Published, Green Submitted, gold			2023-01-03	WOS:000295321800051
J	Haywood-Watson, RJ; Holcomb, JB; Gonzalez, EA; Peng, ZL; Pati, S; Park, PW; Wang, WW; Zaske, AM; Menge, T; Kozar, RA				Haywood-Watson, Ricky J.; Holcomb, John B.; Gonzalez, Ernest A.; Peng, Zhanglong; Pati, Shibani; Park, Pyong Woo; Wang, WeiWei; Zaske, Ana Maria; Menge, Tyler; Kozar, Rosemary A.			Modulation of Syndecan-1 Shedding after Hemorrhagic Shock and Resuscitation	PLOS ONE			English	Article							FRESH-FROZEN PLASMA; HEPARAN-SULFATE PROTEOGLYCAN; ENDOTHELIAL GLYCOCALYX; INFLAMMATORY RESPONSE; BLOOD; TRAUMA; MODEL; TRANSFUSIONS; COAGULATION; FRACTALKINE	The early use of fresh frozen plasma as a resuscitative agent after hemorrhagic shock has been associated with improved survival, but the mechanism of protection is unknown. Hemorrhagic shock causes endothelial cell dysfunction and we hypothesized that fresh frozen plasma would restore endothelial integrity and reduce syndecan-1 shedding after hemorrhagic shock. A prospective, observational study in severely injured patients in hemorrhagic shock demonstrated significantly elevated levels of syndecan-1 (554+/-93 ng/ml) after injury, which decreased with resuscitation (187+/-36 ng/ml) but was elevated compared to normal donors (27+/-1 ng/ml). Three pro-inflammatory cytokines, interferon-gamma, fractalkine, and interleukin-1 beta, negatively correlated while one anti-inflammatory cytokine, IL-10, positively correlated with shed syndecan-1. These cytokines all play an important role in maintaining endothelial integrity. An in vitro model of endothelial injury then specifically examined endothelial permeability after treatment with fresh frozen plasma orlactated Ringers. Shock or endothelial injury disrupted junctional integrity and increased permeability, which was improved with fresh frozen plasma, but not lactated Ringers. Changes in endothelial cell permeability correlated with syndecan-1 shedding. These data suggest that plasma based resuscitation preserved endothelial syndecan-1 and maintained endothelial integrity, and may help to explain the protective effects of fresh frozen plasma after hemorrhagic shock.	[Haywood-Watson, Ricky J.; Holcomb, John B.; Peng, Zhanglong; Pati, Shibani; Menge, Tyler; Kozar, Rosemary A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA; [Holcomb, John B.; Pati, Shibani; Zaske, Ana Maria] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury & Res CeTIR, Houston, TX USA; [Gonzalez, Ernest A.] Univ Texas SW Austin, Dept Surg, Austin, TX USA; [Park, Pyong Woo] Harvard Univ, Childrens Hosp, Sch Med, Div Resp Dis, Boston, MA 02115 USA; [Wang, WeiWei] Univ Texas Hlth Sci Ctr Houston, Ctr Clin & Translat Sci, Houston, TX USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Texas System; University of Texas Health Science Center Houston	Haywood-Watson, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX USA.	Rosemary.A.Kozar@uth.tmc.edu		Park, Pyong Woo/0000-0002-7979-4979; holcomb, john/0000-0001-8312-9157	National Institutes of Health [T-32 GM008792, P-50 GM38529]; Department of Defense [W81XWH-08-C-0712]; NIH CTSA [UL1 RR024148]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM107482, T32GM008792, P50GM038529] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NIH CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The study was supported by the National Institutes of Health T-32 GM008792 and P-50 GM38529 and the Department of Defense W81XWH-08-C-0712. Statistical support was provided by the Biostatistics/Epidemiology/Research Design (BERD) component of the Center for Clinical and Translational Sciences (CCTS) for this project. CCTS is mainly funded by NIH CTSA grant (UL1 RR024148). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Childs EW, 2010, SHOCK, V34, P229, DOI 10.1097/SHK.0b013e3181d75b50; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Fux L, 2009, TRENDS BIOCHEM SCI, V34, P511, DOI 10.1016/j.tibs.2009.06.005; GONZALEZ EA, 2009, SHOCK, V31, P56; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hayashida K, 2009, BLOOD, V114, P3033, DOI 10.1182/blood-2009-02-204966; HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jastrow KM, 2009, J AM COLL SURGEONS, V209, P320, DOI 10.1016/j.jamcollsurg.2009.05.002; Kadl A, 2005, ANTIOXID REDOX SIGN, V7, P1744, DOI 10.1089/ars.2005.7.1744; KELLUM JA, 2009, ARCH INTERN MED, V167, P1655; Kliment CR, 2009, J BIOL CHEM, V284, P3537, DOI 10.1074/jbc.M807001200; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lee WL, 2010, NEW ENGL J MED, V363, P689, DOI 10.1056/NEJMcibr1007320; London NR, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000678; London NR, 2009, ANGIOGENESIS, V12, P149, DOI 10.1007/s10456-009-9130-z; Lozano FS, 2005, WORLD J SURG, V29, P1248, DOI 10.1007/s00268-005-7877-y; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Makley AT, 2010, J TRAUMA, V68, P305, DOI 10.1097/TA.0b013e3181cb4472; Maroszynska I, 2000, Ann Transplant, V5, P5; Matheson PJ, 2009, ARCH SURG-CHICAGO, V144, P625, DOI 10.1001/archsurg.2009.125; Matsuo Mitsunori, 2008, Kurume Medical Journal, V55, P19, DOI 10.2739/kurumemedj.55.19; Mees ST, 2007, LANGENBECK ARCH SURG, V392, P629, DOI 10.1007/s00423-007-0152-y; Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023; Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng Z, 2010, SHOCK, V33, P61; Rehm M, 2007, CIRCULATION, V116, P1896, DOI 10.1161/CIRCULATIONAHA.106.684852; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Robinson EK, 2008, JPEN-PARENTER ENTER, V32, P433, DOI 10.1177/0148607108319806; Sadir R, 1998, J BIOL CHEM, V273, P10919, DOI 10.1074/jbc.273.18.10919; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Steigemann P, 2004, CURR BIOL, V14, P225, DOI 10.1016/j.cub.2004.01.006; Steppan J, 2011, J SURG RES, V165, P136, DOI 10.1016/j.jss.2009.04.034; Takahashi T, 2001, CIRC RES, V88, P422; Tedgui A, 2001, CIRC RES, V88, P877, DOI 10.1161/hh0901.090440; Tharakan B, 2010, CLIN EXP PHARMACOL P, V37, P939, DOI 10.1111/j.1440-1681.2010.05414.x; Umehara H, 2004, ARTERIOSCL THROM VAS, V24, P34, DOI 10.1161/01.ATV.0000095360.62479.1F	46	129	136	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2011	6	8							e23530	10.1371/journal.pone.0023530	http://dx.doi.org/10.1371/journal.pone.0023530			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810LZ	21886795	Green Submitted, gold, Green Published			2023-01-03	WOS:000294128100017
J	Poiroux, G; Pitie, M; Culerrier, R; Lafont, E; Segui, B; Van Damme, EJM; Peumans, WJ; Bernadou, J; Levade, T; Rouge, P; Barre, A; Benoist, H				Poiroux, Guillaume; Pitie, Marguerite; Culerrier, Raphael; Lafont, Elodie; Segui, Bruno; Van Damme, Els J. M.; Peumans, Willy J.; Bernadou, Jean; Levade, Thierry; Rouge, Pierre; Barre, Annick; Benoist, Herve			Targeting of T/Tn Antigens with a Plant Lectin to Kill Human Leukemia Cells by Photochemotherapy	PLOS ONE			English	Article							JACALIN-RELATED LECTINS; GROWTH-FACTOR RECEPTOR; HUMAN-COLON-CANCER; PHOTODYNAMIC THERAPY; OXIDATIVE STRESS; LYMPHOCYTIC-LEUKEMIA; FLUORESCENT-PROBES; ANTIOXIDANT STATUS; INDUCED APOPTOSIS; SIALOSYL-TN	Photochemotherapy is used both for solid tumors and in extracorporeal treatment of various hematologic disorders. Nevertheless, its development in oncology remains limited, because of the low selectivity of photosensitizers (PS) towards human tumor cells. To enhance PS efficiency, we recently covalently linked a porphyrin (TrMPyP) to a plant lectin (Morniga G), known to recognize with high affinity tumor-associated T and Tn antigens. The conjugation allowed a quick uptake of PS by Tn-positive Jurkat leukemia cells and efficient PS-induced phototoxicity. The present study was performed: (i) to evaluate the targeting potential of the conjugate towards tumor and normal cells and its phototoxicity on various leukemia cells, (ii) to investigate the mechanism of conjugate-mediated cell death. The conjugate: (i) strongly increased (x1000) the PS phototoxicity towards leukemic Jurkat T cells through an O-glycan-dependent process; (ii) specifically purged tumor cells from a 1:1 mixture of Jurkat leukemia (Tn-positive) and healthy (Tn-negative) lymphocytes, preserving the activation potential of healthy lymphocytes; (iii) was effective against various leukemic cell lines with distinct phenotypes, as well as fresh human primary acute and chronic lymphoid leukemia cells; (iv) induced mostly a caspase-independent cell death, which might be an advantage as tumor cells often resist caspase-dependent cell death. Altogether, the present observations suggest that conjugation with plant lectins can allow targeting of photosensitizers towards aberrant glycosylation of tumor cells, e. g. to purge leukemia cells from blood and to preserve the normal leukocytes in extracorporeal photochemotherapy.	[Poiroux, Guillaume; Lafont, Elodie; Segui, Bruno; Levade, Thierry; Benoist, Herve] CHU Rangueil, Ctr Rech Cancerol Toulouse, INSERM, UMR 1037,Equipe 4, F-31432 Toulouse, France; [Lafont, Elodie; Segui, Bruno; Bernadou, Jean; Barre, Annick; Benoist, Herve] Univ Toulouse, Fac Pharmaceut Sci, F-31062 Toulouse, France; [Poiroux, Guillaume; Culerrier, Raphael; Rouge, Pierre; Barre, Annick] Univ Toulouse, UMR UPS CNRS 5546, F-31326 Castanet Tolosan, France; [Pitie, Marguerite; Bernadou, Jean] CNRS, Chim Coordinat Lab, F-31077 Toulouse, France; [Van Damme, Els J. M.; Peumans, Willy J.] Univ Ghent, Dept Mol Biotechnol, Lab Biochem & Glycobiol, B-9000 Ghent, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Ghent University	Poiroux, G (corresponding author), CHU Rangueil, Ctr Rech Cancerol Toulouse, INSERM, UMR 1037,Equipe 4, BP84225, F-31432 Toulouse, France.	herve.benoist@inserm.fr	Lafont, Elodie/L-3288-2019; Van Damme, Els J/B-4410-2015; Levade, Thierry/O-8948-2014; Ségui, Bruno/O-8957-2014; Guillaume, Poiroux/M-2854-2015; Lafont, Elodie/GPS-9642-2022; Van Damme, Els/U-3904-2019; Benoist, Hervé/P-2927-2014; Rouge, Pierre/T-2059-2019	Lafont, Elodie/0000-0003-1978-7491; Ségui, Bruno/0000-0002-6119-1889; Guillaume, Poiroux/0000-0002-6769-3716; Lafont, Elodie/0000-0003-1978-7491; Van Damme, Els/0000-0001-9848-766X; Barre, annick/0000-0002-1360-8491	Universite Paul Sabatier; Institut National de la Sante et de la Recherche Medicale [U858, I2MR]; Centre National de la Recherhce Scientifique [UMR5546]; Scientific Research Flanders	Universite Paul Sabatier; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherhce Scientifique; Scientific Research Flanders(FWO)	Funding provided by: Universite Paul Sabatier; Institut National de la Sante et de la Recherche Medicale U858, I2MR; Centre National de la Recherhce Scientifique UMR5546; and Scientific Research Flanders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcouffe J, 2004, FASEB J, V18, P122, DOI 10.1096/fj.02-0808fje; Battisti V, 2008, CLIN BIOCHEM, V41, P511, DOI 10.1016/j.clinbiochem.2008.01.027; Benoist H, 2009, J LEUKOCYTE BIOL, V86, P103, DOI [10.1189/JLB.0708434, 10.1189/jlb.0708434]; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Brooks CL, 2010, P NATL ACAD SCI USA, V107, P10056, DOI 10.1073/pnas.0915176107; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Cao Y, 2008, INT J CANCER, V123, P89, DOI 10.1002/ijc.23493; CASAS C, 1993, J ORG CHEM, V58, P2913, DOI 10.1021/jo00062a045; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Chen BJ, 2002, BLOOD, V99, P3083, DOI 10.1182/blood.V99.9.3083; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010; Copley L, 2008, INT J BIOCHEM CELL B, V40, P227, DOI 10.1016/j.biocel.2007.07.014; del Carmen MG, 2005, JNCI-J NATL CANCER I, V97, P1516, DOI 10.1093/jnci/dji314; Del Governatore M, 2000, BRIT J CANCER, V82, P56; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Fadeel B, 2008, CELL DEATH DIFFER, V15, P443, DOI 10.1038/sj.cdd.4402265; Giusti C, 2009, EXP CELL RES, V315, P26, DOI 10.1016/j.yexcr.2008.09.028; Hamblin MR, 2000, BRIT J CANCER, V83, P1544, DOI 10.1054/bjoc.2000.1486; Heimburg-Molinaro J, 2009, NEOPLASIA, V11, P780, DOI 10.1593/neo.09504; Hong SJ, 2004, TRENDS PHARMACOL SCI, V25, P259, DOI 10.1016/j.tips.2004.03.005; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Korbelik M, 2007, BRIT J CANCER, V97, P1381, DOI 10.1038/sj.bjc.6604059; Lafont E, 2010, CELL DEATH DIFFER, V17, P642, DOI 10.1038/cdd.2009.130; Liu B, 2010, CANCER LETT, V287, P1, DOI 10.1016/j.canlet.2009.05.013; Marchal S, 2005, BIOCHEM PHARMACOL, V69, P1167, DOI 10.1016/j.bcp.2005.01.021; Mazor D, 2008, PEDIATR BLOOD CANCER, V51, P613, DOI 10.1002/pbc.21665; Milhas D, 2005, J BIOL CHEM, V280, P19836, DOI 10.1074/jbc.M414358200; Moran EC, 2002, BRIT J HAEMATOL, V116, P316, DOI 10.1046/j.1365-2141.2002.03280.x; Negre-Salvayre A, 2002, METHOD ENZYMOL, V352, P62; Nyman ES, 2004, J PHOTOCH PHOTOBIO B, V73, P1, DOI 10.1016/j.jphotobiol.2003.10.002; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Oliven A, 2001, BLOOD REV, V15, P103, DOI 10.1054/blre.2001.0155; PILLER V, 1990, J BIOL CHEM, V265, P9264; Poiroux G, 2011, PHOTOCHEM PHOTOBIOL, V87, P370, DOI 10.1111/j.1751-1097.2010.00858.x; Price M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1177, DOI 10.1111/j.1751-1097.2009.00555.x; Savellano MD, 2005, CANCER RES, V65, P6371, DOI 10.1158/0008-5472.CAN-05-0426; Savellano MD, 2005, CLIN CANCER RES, V11, P1658, DOI 10.1158/1078-0432.CCR-04-1902; Separovic D, 2009, BRIT J CANCER, V100, P626, DOI 10.1038/sj.bjc.6604896; Serebrovskaya EO, 2009, P NATL ACAD SCI USA, V106, P9221, DOI 10.1073/pnas.0904140106; Shan L, 2004, MOL IMAGING CONTRAST; Shanafelt TD, 2005, BLOOD, V105, P2099, DOI 10.1182/blood-2004-06-2205; Singh T, 2007, MOL IMMUNOL, V44, P451, DOI 10.1016/j.molimm.2006.02.017; Smith MT, 2001, BLOOD, V97, P1422, DOI 10.1182/blood.V97.5.1422; Sze KL, 2011, APPL MICROBIOL BIOT, V89, P45, DOI 10.1007/s00253-010-2892-9; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; Toscano MA, 2007, NAT IMMUNOL, V8, P825, DOI 10.1038/ni1482; Van Damme EJM, 2002, PLANT PHYSIOL, V130, P757, DOI 10.1104/pp.005892; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Vittar NBR, 2010, INT J BIOCHEM CELL B, V42, P1123, DOI 10.1016/j.biocel.2010.03.019; Wu AM, 2009, GLYCOCONJUGATE J, V26, P899, DOI 10.1007/s10719-008-9119-7; Yamashima T, 2009, PROG NEUROBIOL, V89, P343, DOI 10.1016/j.pneurobio.2009.09.003	54	16	16	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2011	6	8							e23315	10.1371/journal.pone.0023315	http://dx.doi.org/10.1371/journal.pone.0023315			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810JJ	21858067	Green Published, gold, Green Submitted			2023-01-03	WOS:000294121300033
J	Su, FY; Alam, R; Mei, Q; Tian, YQ; Youngbull, C; Johnson, RH; Meldrum, DR				Su, Fengyu; Alam, Ruhaniyah; Mei, Qian; Tian, Yanqing; Youngbull, Cody; Johnson, Roger H.; Meldrum, Deirdre R.			Nanostructured Oxygen Sensor - Using Micelles to Incorporate a Hydrophobic Platinum Porphyrin	PLOS ONE			English	Article							DISSOLVED-OXYGEN; SENSING MATERIALS; PROBES; COMPLEXES; CELLS; LIFETIME; FILMS	Hydrophobic platinum(II)-5,10,15,20-tetrakis-(2,3,4,5,6-pentafluorophenyl)-porphyrin (PtTFPP) was physically incorporated into micelles formed from poly(epsilon-caprolactone)-block-poly(ethylene glycol) to enable the application of PtTFPP in aqueous solution. Micelles were characterized using dynamic light scattering (DLS) and atomic force microscopy (AFM) to show an average diameter of about 140 nm. PtTFPP showed higher quantum efficiency in micellar solution than in tetrahydrofuran (THF) and dichloromethane (CH2Cl2). PtTFPP in micelles also exhibited higher photostability than that of PtTFPP suspended in water. PtTFPP in micelles exhibited good oxygen sensitivity and response time. This study provided an efficient approach to enable the application of hydrophobic oxygen sensors in a biological environment.	[Su, Fengyu; Alam, Ruhaniyah; Mei, Qian; Tian, Yanqing; Youngbull, Cody; Johnson, Roger H.; Meldrum, Deirdre R.] Arizona State Univ, Ctr Biosignatures Discovery Automat, Biodesign Inst, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Su, FY (corresponding author), Arizona State Univ, Ctr Biosignatures Discovery Automat, Biodesign Inst, Tempe, AZ 85287 USA.	yanqing.tian@asu.edu	Su, Fengyu/ABE-2523-2021; Su, Fengyu/V-1014-2018; MLSC, Colletion/B-3912-2013; Tian, Yanqing/C-1423-2013; Tian, Yanqing/N-1506-2019	Su, Fengyu/0000-0003-1922-9182; Tian, Yanqing/0000-0002-1441-2431; Tian, Yanqing/0000-0002-1441-2431	NIH [5P50 HG002360]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002360] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	The work was supported by NIH, 5P50 HG002360. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amao Y, 2003, MICROCHIM ACTA, V143, P1, DOI 10.1007/s00604-003-0037-x; Amao Y, 2003, SENSOR ACTUAT B-CHEM, V88, P162, DOI 10.1016/S0925-4005(02)00320-9; Borisov SM, 2008, ANAL CHEM, V80, P573, DOI 10.1021/ac071374e; Borisov SM, 2007, ANAL CHEM, V79, P7501, DOI 10.1021/ac0710836; Borisov SM, 2006, ADV FUNCT MATER, V16, P1536, DOI [10.1002/adfm.200500778, 10.1002/adfm.20050U778]; Chen CY, 2007, J AM CHEM SOC, V129, P7220, DOI 10.1021/ja071057p; CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41; DeRosa MC, 2003, INORG CHEM, V42, P4864, DOI 10.1021/ic026230r; EVANS NTS, 1967, RESP PHYSIOL, V3, P38, DOI 10.1016/0034-5687(67)90021-7; Garcia-Fresnadillo D, 1999, LANGMUIR, V15, P6451, DOI 10.1021/la981689c; Han BH, 2005, ANAL CHEM, V77, P8075, DOI 10.1021/ac0511703; Hirohara S, 2009, BIOCONJUGATE CHEM, V20, P944, DOI 10.1021/bc800522y; HUCH R, 1974, ARCH DIS CHILD, V49, P213, DOI 10.1136/adc.49.3.213; Ji J, 2002, J BIOMED OPT, V7, P404, DOI 10.1117/1.1483082; Joshi HS, 1999, ANGEW CHEM INT EDIT, V38, P2722; Kimura F, 2006, MEAS SCI TECHNOL, V17, P1254, DOI 10.1088/0957-0233/17/6/S04; Koo YEL, 2004, ANAL CHEM, V76, P2498, DOI 10.1021/ac035493f; Kose ME, 2005, LANGMUIR, V21, P9121, DOI 10.1021/la050997p; Lai SW, 2004, INORG CHEM, V43, P3724, DOI 10.1021/ic049902h; Lee J, 2008, PHYS CHEM CHEM PHYS, V10, P1739, DOI 10.1039/b801317a; Lee SK, 1997, ANAL COMMUN, V34, P185, DOI 10.1039/a701130j; Lidstrom ME, 2003, NAT REV MICROBIOL, V1, P158, DOI 10.1038/nrmicro755; McDonagh C, 2008, CHEM REV, V108, P400, DOI 10.1021/cr068102g; Mcevoy AK, 1997, J SOL-GEL SCI TECHN, V8, P1121, DOI 10.1007/BF02436994; McNamara KP, 1998, ANAL CHEM, V70, P4853, DOI 10.1021/ac9803232; Mitsubayashi K, 2003, SENSOR ACTUAT B-CHEM, V95, P373, DOI 10.1016/S0925-4005(03)00441-6; Molter TW, 2009, SENSOR ACTUAT B-CHEM, V135, P678, DOI 10.1016/j.snb.2008.10.036; Nagl S, 2007, ANALYST, V132, P507, DOI 10.1039/b702753b; O'Donovan C, 2005, J MATER CHEM, V15, P2946, DOI 10.1039/b501748c; O'Riordan TC, 2007, AM J PHYSIOL-REG I, V292, pR1613, DOI 10.1152/ajpregu.00707.2006; Pang HL, 2007, SENSOR ACTUAT B-CHEM, V123, P120, DOI 10.1016/j.snb.2006.07.035; Pauly S, 1989, POLYM HDB, P435; Roche P, 2006, ANAL BIOANAL CHEM, V386, P1245, DOI 10.1007/s00216-006-0787-5; Saito T, 2007, J PORPHYR PHTHALOCYA, V11, P160, DOI 10.1142/S1088424607000205; Song HT, 2005, J AM CHEM SOC, V127, P9992, DOI 10.1021/ja051833y; Sud D, 2005, P SOC PHOTO-OPT INS, V5859; Thomas PC, 2009, ANAL CHEM, V81, P9239, DOI 10.1021/ac9013379; Tian Y, 2007, ADV FUNCT MATER, V17, P1691, DOI 10.1002/adfm.200600916; Tian YQ, 2010, SENSOR ACTUAT B-CHEM, V150, P579, DOI 10.1016/j.snb.2010.08.036; Tian YQ, 2010, SENSOR ACTUAT B-CHEM, V147, P714, DOI 10.1016/j.snb.2010.03.029; Tian YQ, 2010, J BIOMED MATER RES A, V93A, P1068, DOI 10.1002/jbm.a.32607; Tian YQ, 2010, CHEM MATER, V22, P2069, DOI 10.1021/cm903361y; Valeur B., 2002, MOL FLUORESCENCE PRI; VanderDonckt E, 1996, SENSOR ACTUAT B-CHEM, V32, P121, DOI 10.1016/0925-4005(96)80120-1; Xu H, 2001, ANAL CHEM, V73, P4124, DOI 10.1021/ac0102718; Zhang GQ, 2009, NAT MATER, V8, P747, DOI [10.1038/nmat2509, 10.1038/NMAT2509]	46	45	45	5	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2012	7	3							e33390	10.1371/journal.pone.0033390	http://dx.doi.org/10.1371/journal.pone.0033390			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940QX	22457758	gold, Green Published, Green Submitted			2023-01-03	WOS:000303909200028
J	Sharif, T; Alhosin, M; Auger, C; Minker, C; Kim, JH; Etienne-Selloum, N; Bories, P; Gronemeyer, H; Lobstein, A; Bronner, C; Fuhrmann, G; Schini-Kerth, VB				Sharif, Tanveer; Alhosin, Mahmoud; Auger, Cyril; Minker, Carole; Kim, Jong-Hun; Etienne-Selloum, Nelly; Bories, Pierre; Gronemeyer, Hinrich; Lobstein, Annelise; Bronner, Christian; Fuhrmann, Guy; Schini-Kerth, Valerie B.			Aronia melanocarpa Juice Induces a Redox-Sensitive p73-Related Caspase 3-Dependent Apoptosis in Human Leukemia Cells	PLOS ONE			English	Article							TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; COLON-CANCER; LYMPHOBLASTIC-LEUKEMIA; SRA DOMAIN; IN-VITRO; INDUCTION; EXTRACTS; PATHWAY; PROTEIN	Polyphenols are natural compounds widely present in fruits and vegetables, which have antimutagenic and anticancer properties. The aim of the present study was to determine the anticancer effect of a polyphenol-rich Aronia melanocarpa juice (AMJ) containing 7.15 g/L of polyphenols in the acute lymphoblastic leukemia Jurkat cell line, and, if so, to clarify the underlying mechanism and to identify the active polyphenols involved. AMJ inhibited cell proliferation, which was associated with cell cycle arrest in G(2)/M phase, and caused the induction of apoptosis. These effects were associated with an upregulation of the expression of tumor suppressor p73 and active caspase 3, and a downregulation of the expression of cyclin B1 and the epigenetic integrator UHRF1. AMJ significantly increased the formation of reactive oxygen species (ROS), decreased the mitochondrial membrane potential and caused the release of cytochrome c into the cytoplasm. Treatment with intracellular ROS scavengers prevented the AMJ-induced apoptosis and upregulation of the expression of p73 and active caspase 3. The fractionation of the AMJ and the use of identified isolated compounds indicated that the anticancer activity was associated predominantly with chlorogenic acids, some cyanidin glycosides, and derivatives of quercetin. AMJ treatment also induced apoptosis of different human lymphoblastic leukemia cells (HSB-2, Molt-4 and CCRF-CEM). In addition, AMJ exerted a strong pro-apoptotic effect in human primary lymphoblastic leukemia cells but not in human normal primary T-lymphocytes. Thus, the present findings indicate that AMJ exhibits strong anticancer activity through a redox-sensitive mechanism in the p53-deficient Jurkat cells and that this effect involves several types of polyphenols. They further suggest that AMJ has chemotherapeutic properties against acute lymphoblastic leukemia by selectively targeting lymphoblast-derived tumor cells.	[Sharif, Tanveer; Alhosin, Mahmoud; Auger, Cyril; Kim, Jong-Hun; Etienne-Selloum, Nelly; Bronner, Christian; Fuhrmann, Guy; Schini-Kerth, Valerie B.] Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, Illkirch Graffenstaden, France; [Minker, Carole; Lobstein, Annelise] Univ Strasbourg, CNRS, UMR 7200, Lab Innovat Therapeut,Fac Pharm, Illkirch Graffenstaden, France; [Bories, Pierre; Gronemeyer, Hinrich] Univ Strasbourg, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire,UMR 7104,U964, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Sharif, T (corresponding author), Univ Strasbourg, CNRS, UMR 7213, Lab Biophoton & Pharmacol,Fac Pharm, Illkirch Graffenstaden, France.	valerie.schini-kerth@unistra.fr	Bronner, Christian/R-8488-2016; Alhosin, Mahmoud/H-8101-2017; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016; Alhosin, Mahmoud/AAD-5782-2020; Gronemeyer, Hinrich/G-6240-2011; Auger, Cyril/N-4702-2016	Bronner, Christian/0000-0002-3101-9279; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Alhosin, Mahmoud/0000-0003-2147-1445; Gronemeyer, Hinrich/0000-0001-9454-2449; Bories, Pierre/0000-0002-2252-0395; Sharif, Tanveer/0000-0003-3269-8100	Higher Education Commission of Pakistan; Association pour la Recherche sur le Cancer (ARC); Syrian Higher Education Ministry	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Syrian Higher Education Ministry	TS is supported by a fellowship from the Higher Education Commission of Pakistan and from the Association pour la Recherche sur le Cancer (ARC). MA is supported by a fellowship from the Syrian Higher Education Ministry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855; Aiyer HS, 2010, CANCER PREV RES, V3, P727, DOI 10.1158/1940-6207.CAPR-09-0260; Alhosin M, 2010, BIOCHEM PHARMACOL, V79, P1251, DOI 10.1016/j.bcp.2009.12.015; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012; Bermudez-Soto MJ, 2004, EUR FOOD RES TECHNOL, V219, P133, DOI 10.1007/s00217-004-0940-3; Bermundez-Soto MJ, 2007, J NUTR BIOCHEM, V18, P259, DOI 10.1016/j.jnutbio.2006.05.003; Boominathan L, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-27; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Chen W, 2008, FREE RADICAL BIO MED, V45, P60, DOI 10.1016/j.freeradbiomed.2008.03.013; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Chung FL, 2003, J NUTR, V133, p3268S, DOI 10.1093/jn/133.10.3268S; Das A, 2010, CANCER-AM CANCER SOC, V116, P164, DOI 10.1002/cncr.24699; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041; Juan ME, 2008, J AGR FOOD CHEM, V56, P4813, DOI 10.1021/jf800175a; Feng RT, 2007, J BIOL CHEM, V282, P13468, DOI 10.1074/jbc.M610616200; Fuhrmann G, 1999, CELL MOL BIOL, V45, P717; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; Hakimuddin F, 2006, J AGR FOOD CHEM, V54, P7912, DOI 10.1021/jf060834m; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Jeong JC, 2010, NUTR CANCER, V62, P402, DOI 10.1080/01635580903441287; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kulling SE, 2008, PLANTA MED, V74, P1625, DOI 10.1055/s-0028-1088306; Kwan ML, 2004, AM J EPIDEMIOL, V160, P1098, DOI 10.1093/aje/kwh317; Lala G, 2006, NUTR CANCER, V54, P84, DOI 10.1207/s15327914nc5401_10; Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039; Liu CY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-15; Malik M, 2003, NUTR CANCER, V46, P186, DOI 10.1207/S15327914NC4602_12; Miller PE, 2010, NUTR CANCER, V62, P413, DOI 10.1080/01635580903407114; Misikangas M, 2007, J NUTR, V137, P2285, DOI 10.1093/jn/137.10.2285; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Murias M, 2008, TOXICOL IN VITRO, V22, P1361, DOI 10.1016/j.tiv.2008.03.002; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; Rigas B, 2008, BRIT J CANCER, V98, P1157, DOI 10.1038/sj.bjc.6604225; Sanchez-Duffhues G, 2009, BIOCHEM PHARMACOL, V77, P1401, DOI 10.1016/j.bcp.2009.01.004; Sharif T, 2011, INVEST NEW DRUG, V29, P239, DOI 10.1007/s10637-009-9352-3; Sharif T, 2010, EUR J CANCER, V46, P983, DOI 10.1016/j.ejca.2009.12.029; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Skupien K, 2008, PHYTOTHER RES, V22, P689, DOI 10.1002/ptr.2411; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840; Walter A, 2010, FASEB J, V24, P3360, DOI 10.1096/fj.09-149419; Warburg O., 1925, KLIN WOCHENSCHR, V4, P534, DOI DOI 10.1007/BF01726151	48	41	43	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2012	7	3							e32526	10.1371/journal.pone.0032526	http://dx.doi.org/10.1371/journal.pone.0032526			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KT	22412883	Green Published, Green Submitted, gold			2023-01-03	WOS:000303062000012
J	Phan, V; Thai, S; Choun, K; Lynen, L; van Griensven, J				Phan, Vichet; Thai, Sopheak; Choun, Kimcheng; Lynen, Lutgarde; van Griensven, Johan			Incidence of Treatment-Limiting Toxicity with Stavudine-Based Antiretroviral Therapy in Cambodia: A Retrospective Cohort Study	PLOS ONE			English	Article							HIV-INFECTED PERSONS; QUALITY-OF-LIFE; BODY CHANGES; LIPODYSTROPHY; PREVALENCE; ADULTS; RISK; SUBSTITUTION; ADHERENCE; SYMPTOMS	Background: Although stavudine (D4T) remains frequently used in low-income countries in Asia, associated long-term toxicity data are scarce. The aim of this study was to determine the long-term incidence of severe D4T-toxicity (requiring drug substitution) and associated risk factors in HIV-infected Cambodians up to six years on antiretroviral treatment (ART). Methodology/Principal Findings: This is a retrospective analysis of an observational cohort, using data from an ART program with systematic monitoring for D4T-toxicity. Probabilities of time to D4T substitution due to suspected D4T toxicity (treatment-limiting D4T toxicity) were calculated, a risk factor analysis was performed using multivariate Cox regression modelling. Out of 2581 adults initiating a D4T-containing regimen, D4T was replaced in 276 (10.7%) patients for neuropathy, 14 (0.5%) for lactic acidosis and 957 (37.1%) for lipoatrophy. The main early side effect was peripheral neuropathy (7.0% by 1 year). After the first year, lipoatrophy became predominant, with a cumulative incidence of 56.1% and 72.4% by 3 and 6 years respectively. Older age (aHR 1.8; 95%CI: 1.4-2.3) and lower baseline haemoglobin (aHR 1.7; 95%CI: 1.4-2.2) were associated with the occurrence of neuropathy. Being female (aHR 3.8; 95%CI: 1.1-12.5), a higher baseline BMI (aHR 12.6; 95%CI: 3.7-43.1), and TB treatment at ART initiation (aHR 8.6; 95%CI: 2.7-27.5) increased the likelihood of lactic acidosis. Lipoatrophy was positively associated with female gender (aHR 2.3; 95%CI: 2.0-2.6), an older age (aHR 1.3; 95%CI: 1.1-1.4), and a CD4 count <200 cells/mu L (aHR 1.3; 95%CI: 1.1-1.5). Conclusions: Stavudine-based treatment regimens in low-income countries are associated with significant long-term toxicities, predominantly lipoatrophy. Close clinical monitoring for toxicity with timely D4T substitution is recommended. Phasing-out of stavudine should be implemented, as costs allows.	[Phan, Vichet; Thai, Sopheak; Choun, Kimcheng; van Griensven, Johan] Sihanouk Hosp Ctr HOPE, Phnom Penh, Cambodia; [Lynen, Lutgarde; van Griensven, Johan] Inst Trop Med, B-2000 Antwerp, Belgium	Institute of Tropical Medicine (ITM)	Phan, V (corresponding author), Sihanouk Hosp Ctr HOPE, Phnom Penh, Cambodia.	phanvichet@yahoo.com	Lynen, Lutgarde/AAT-9180-2020; Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895; Lynen, Lutgarde/0000-0001-7183-4895	Belgian Directorate General of Development Cooperation; Institute of Tropical Medicine, Antwerp; Global Fund; InBev-Baillet Latour Fund	Belgian Directorate General of Development Cooperation; Institute of Tropical Medicine, Antwerp; Global Fund; InBev-Baillet Latour Fund	The HIV program was supported by the Belgian Directorate General of Development Cooperation through the framework agreement with the Institute of Tropical Medicine, Antwerp, the Global Fund to fight AIDS, Tuberculosis and Malaria, and Hope World Wide. JvG is supported by the InBev-Baillet Latour Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boulle A, 2007, ANTIVIR THER, V12, P753; Burgoyne R, 2005, QUAL LIFE RES, V14, P981, DOI 10.1007/s11136-004-2580-2; Clucas C, 2011, HIV MED, V12, P87, DOI 10.1111/j.1468-1293.2010.00851.x; Cooper V, 2009, AIDS CARE, V21, P520, DOI 10.1080/09540120802301824; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Glass TR, 2010, JAIDS-J ACQ IMM DEF, V54, P197, DOI 10.1097/QAI.0b013e3181ca48bf; Guaraldi G, 2008, AIDS REV, V10, P152; Hawkins C, 2007, JAIDS-J ACQ IMM DEF, V45, P304; Imhof A, 2005, CLIN INFECT DIS, V41, P721, DOI 10.1086/432471; Isaakidis P, 2008, JAIDS-J ACQ IMM DEF, V49, P48, DOI 10.1097/QAI.0b013e31817bec19; Justice AC, 2001, MED CARE, V39, P397, DOI 10.1097/00005650-200104000-00010; Kowalska JD, 2007, AIDS RES HUM RETROV, V23, P1183, DOI 10.1089/aid.2006.0292; Lampe FC, 2010, JAIDS-J ACQ IMM DEF, V54, P500, DOI 10.1097/QAI.0b013e3181ce6afe; Lynen L, 2009, JAIDS-J ACQ IMM DEF, V52, P40, DOI 10.1097/QAI.0b013e3181af6705; Mercier S, 2009, JAIDS-J ACQ IMM DEF, V51, P224, DOI 10.1097/QAI.0b013e31819c16f4; Mutimura E, 2007, JAIDS-J ACQ IMM DEF, V46, P451, DOI 10.1097/QAI.0b013e318158c0a6; Nachega Jean B, 2009, Curr HIV/AIDS Rep, V6, P121, DOI 10.1007/s11904-009-0017-9; Santos CP, 2005, AIDS, V19, pS14, DOI 10.1097/01.aids.0000191485.92285.c7; Thai S, 2009, TROP MED INT HEALTH, V14, P1048, DOI 10.1111/j.1365-3156.2009.02334.x; van Griensven J, 2007, T ROY SOC TROP MED H, V101, P793, DOI 10.1016/j.trstmh.2007.02.020; van Griensven J, 2010, T ROY SOC TROP MED H, V104, P148, DOI 10.1016/j.trstmh.2009.07.009; Westreich DJ, 2009, CLIN INFECT DIS, V48, P1617, DOI 10.1086/598977; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; WHO, 2010, ANT THER HIV INF AD; WHO, 2004, SCAL ANT THER RES LI; Womack J, 2009, AIDS READ, V19, P131; World Health Organization, 2006, ANT THER HIV INF AD	27	30	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2012	7	1							e30647	10.1371/journal.pone.0030647	http://dx.doi.org/10.1371/journal.pone.0030647			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911GB	22303447	gold, Green Submitted, Green Published			2023-01-03	WOS:000301704200026
J	Monti, DA; Mitchell, E; Bazzan, AJ; Littman, S; Zabrecky, G; Yeo, CJ; Pillai, MV; Newberg, AB; Deshmukh, S; Levine, M				Monti, Daniel A.; Mitchell, Edith; Bazzan, Anthony J.; Littman, Susan; Zabrecky, George; Yeo, Charles J.; Pillai, Madhaven V.; Newberg, Andrew B.; Deshmukh, Sandeep; Levine, Mark			Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer	PLOS ONE			English	Article							RECOMMENDED DIETARY ALLOWANCE; VITAMIN-C PHARMACOKINETICS; TERMINAL HUMAN CANCER; III TRIAL; SUPPLEMENTAL ASCORBATE; SUPPORTIVE TREATMENT; HYDROGEN-PEROXIDE; SURVIVAL TIMES; ANTIOXIDANTS; THERAPY	Background: Preclinical data support further investigation of ascorbic acid in pancreatic cancer. There are currently insufficient safety data in human subjects, particularly when ascorbic acid is combined with chemotherapy. Methods and Findings: 14 subjects with metastatic stage IV pancreatic cancer were recruited to receive an eight week cycle of intravenous ascorbic acid (three infusions per week), using a dose escalation design, along with standard treatment of gemcitabine and erlotinib. Of 14 recruited subjects enrolled, nine completed the study (three in each dosage tier). There were fifteen non-serious adverse events and eight serious adverse events, all likely related to progression of disease or treatment with gemcitabine or erlotinib. Applying RECIST 1.0 criteria, seven of the nine subjects had stable disease while the other two had progressive disease. Conclusions: These initial safety data do not reveal increased toxicity with the addition of ascorbic acid to gemcitabine and erlotinib in pancreatic cancer patients. This, combined with the observed response to treatment, suggests the need for a phase II study of longer duration.	[Monti, Daniel A.; Bazzan, Anthony J.; Zabrecky, George; Newberg, Andrew B.] Thomas Jefferson Univ, Myrna Brind Ctr Integrat Med, Philadelphia, PA 19107 USA; [Mitchell, Edith; Littman, Susan; Pillai, Madhaven V.] Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA; [Yeo, Charles J.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA; [Yeo, Charles J.] Thomas Jefferson Univ, Jefferson Pancreas Biliary & Related Canc Ctr, Philadelphia, PA 19107 USA; [Deshmukh, Sandeep] Thomas Jefferson Univ, Dept Radiol, Philadelphia, PA 19107 USA; [Levine, Mark] NIDDK, Mol & Clin Nutr Sect, NIH, Bethesda, MD USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Monti, DA (corresponding author), Thomas Jefferson Univ, Myrna Brind Ctr Integrat Med, Philadelphia, PA 19107 USA.	MarkL@mail.nih.gov	Levine, Mark/HIZ-8652-2022	Levine, Mark/0000-0001-6297-4650; Newberg, Andrew/0000-0001-8230-1752	NIDDK, NIH [ZIA DK053212-05]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK053211, ZIDDK070013, ZIADK053212] Funding Source: NIH RePORTER	NIDDK, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by a gift from the Marcus Foundation. M. L. was supported by the Intramural Research Program, NIDDK, NIH (ZIA DK053212-05). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ardavanis A, 2009, ANTICANCER RES, V29, P5211; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; Chen Q, 2007, P NATL ACAD SCI USA, V104, P8749, DOI 10.1073/pnas.0702854104; Coulter ID, 2006, J GEN INTERN MED, V21, P735, DOI 10.1111/j.1525-1497.2006.00483.x; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Drisko JA, 2003, J AM COLL NUTR, V22, P118, DOI 10.1080/07315724.2003.10719284; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Espey MG, 2011, FREE RADICAL BIO MED, V50, P1610, DOI 10.1016/j.freeradbiomed.2011.03.007; Feliu J, 2011, CANCER CHEMOTH PHARM, V67, P215, DOI 10.1007/s00280-010-1472-0; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377; JACKSON P, 1995, CLIN CHEM, V41, P1135; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Padayatty SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011414, 10.1371/journal.pone.0015288]; Padayatty SJ, 2000, J AM COLL NUTR, V19, P423, DOI 10.1080/07315724.2000.10718941; Padayatty SJ, 2006, CAN MED ASSOC J, V174, P937, DOI 10.1503/cmaj.050346; Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010; Reni M, 2005, LANCET ONCOL, V6, P369, DOI 10.1016/S1470-2045(05)70175-3; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Shaib W, 2010, ANTICANCER RES, V30, P4261; Stathopoulos GP, 2006, BRIT J CANCER, V95, P587, DOI 10.1038/sj.bjc.6603301; Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112; WITTES RE, 1985, NEW ENGL J MED, V312, P178, DOI 10.1056/NEJM198501173120310; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004	33	166	171	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2012	7	1							e29794	10.1371/journal.pone.0029794	http://dx.doi.org/10.1371/journal.pone.0029794			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	907XU	22272248	Green Published, Green Submitted, gold			2023-01-03	WOS:000301454400027
J	Spence, D				Spence, Des			FROM THE FRONTLINE Out of hours care: a call for continuity	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 11	2012	344								e279	10.1136/bmj.e279	http://dx.doi.org/10.1136/bmj.e279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877SI	22236600				2023-01-03	WOS:000299202500007
J	Reimer, D; Pos, KM; Thines, M; Grun, P; Bode, HB				Reimer, Daniela; Pos, Klaas M.; Thines, Marco; Gruen, Peter; Bode, Helge B.			A natural prodrug activation mechanism in nonribosomal peptide synthesis	NATURE CHEMICAL BIOLOGY			English	Article							XENORHABDUS-NEMATOPHILA; GENE-CLUSTER; ESCHERICHIA-COLI; CYCLIC-PEPTIDES; BIOSYNTHESIS; ALIGNMENT; TOOL	We have identified a new mechanism for the cleavage and activation of nonribosomally made peptides and peptidepolyketide hybrids that are apparently operational in several different bacteria. This process includes the cleavage of a precursor molecule by a membrane-bound and d-asparagine-specific peptidase, as shown here in the biosynthesis of the antibiotic xenocoumacin from Xenorhabdus nematophila.	[Reimer, Daniela; Gruen, Peter; Bode, Helge B.] Goethe Univ Frankfurt, Inst Mol Biosci, Frankfurt, Germany; [Pos, Klaas M.] Goethe Univ Frankfurt, Inst Biochem, Frankfurt, Germany; [Pos, Klaas M.] Goethe Univ Frankfurt, Cluster Excellence Frankfurt Macromol Complexes, Frankfurt, Germany; [Thines, Marco] Biodivers & Climate Res Ctr BiK F, Frankfurt, Germany; [Thines, Marco] Goethe Univ Frankfurt, Inst Ecol, Dept Biol Sci, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt; Senckenberg Biodiversitat & Klima- Forschungszentrum (BiK-F); Senckenberg Gesellschaft fur Naturforschung (SGN); Goethe University Frankfurt	Bode, HB (corresponding author), Goethe Univ Frankfurt, Inst Mol Biosci, Frankfurt, Germany.	h.bode@bio.uni-frankfurt.de	Reimer, Daniela/P-9070-2014; Thines, Marco/H-1685-2011; Bode, Helge B/F-7022-2014	Bode, Helge B/0000-0001-6048-5909	Deutsche Forschungsgemeinschaft (DFG); Frankfurt Initiative for Microbial Sciences (FIMS); European Community [223328 (GameXP)]; Hessen's Ministry of Higher Education, Research, and the Arts	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Frankfurt Initiative for Microbial Sciences (FIMS); European Community(European Commission); Hessen's Ministry of Higher Education, Research, and the Arts	The authors thank A. Venneri for technical assistance. D. R., P. G. and H. B. B. are grateful to the Deutsche Forschungsgemeinschaft (DFG) for financial support. Work in H. B. B.'s lab is additionally supported by the Frankfurt Initiative for Microbial Sciences (FIMS), the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 223328 (GameXP), and by the research funding program "LOEWE - Landes-Offensive zur Entwicklung Wissenschaftlich-"konomischer Exzellenz" of Hessen's Ministry of Higher Education, Research, and the Arts. Support by the DFG-EXC115 (Cluster of Excellence Macromolecular Complexes at the Goethe-University Frankfurt), DFG-SFB807 (Transport and Communication across Biological Membranes) and FIMS is gratefully acknowledged by K. M. P. M. T. is financially supported by the LOEWE program of Hessen's Ministry of Higher Education, Research, and the Arts.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Dubois D, 2011, J BIOL CHEM, V286, P35562, DOI 10.1074/jbc.M111.221960; Finking R, 2004, ANNU REV MICROBIOL, V58, P453, DOI 10.1146/annurev.micro.58.030603.123615; Fujii K, 1997, ANAL CHEM, V69, P3346, DOI 10.1021/ac9701795; Goodrich-Blair H, 2007, CURR OPIN MICROBIOL, V10, P225, DOI 10.1016/j.mib.2007.05.006; Green David, 2006, Hemodial Int, V10 Suppl 2, pS2, DOI 10.1111/j.1542-4758.2006.00119.x; Hashimoto M, 2007, J ANTIBIOT, V60, P752, DOI 10.1038/ja.2007.99; Herbert EE, 2007, NAT REV MICROBIOL, V5, P634, DOI 10.1038/nrmicro1706; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Homburg S, 2007, FEMS MICROBIOL LETT, V275, P255, DOI 10.1111/j.1574-6968.2007.00889.x; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Kevany BM, 2009, APPL ENVIRON MICROB, V75, P1144, DOI 10.1128/AEM.02518-08; Koketsu K, 2010, NAT CHEM BIOL, V6, P408, DOI 10.1038/nchembio.365; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lang G, 2008, J NAT PROD, V71, P1074, DOI 10.1021/np800053n; Mylne JS, 2011, NAT CHEM BIOL, V7, P257, DOI 10.1038/nchembio.542; Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059; Park D, 2009, MOL MICROBIOL, V73, P938, DOI 10.1111/j.1365-2958.2009.06817.x; Reimer D, 2009, CHEMBIOCHEM, V10, P1997, DOI 10.1002/cbic.200900187; Silakowski B, 1999, J BIOL CHEM, V274, P37391, DOI 10.1074/jbc.274.52.37391; Tuteja R, 2005, ARCH BIOCHEM BIOPHYS, V441, P107, DOI 10.1016/j.abb.2005.07.013; Willey JM, 2007, ANNU REV MICROBIOL, V61, P477, DOI 10.1146/annurev.micro.61.080706.093501	22	100	104	3	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2011	7	12					888	890		10.1038/NCHEMBIO.688	http://dx.doi.org/10.1038/NCHEMBIO.688			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	850AG	21926994				2023-01-03	WOS:000297166200010
J	Czarny, MJ; Arthurs, E; Coffie, DF; Smith, C; Steele, RJ; Ziegelstein, RC; Thombs, BD				Czarny, Matthew J.; Arthurs, Erin; Coffie, Diana-Frances; Smith, Cheri; Steele, Russell J.; Ziegelstein, Roy C.; Thombs, Brett D.			Prevalence of Antidepressant Prescription or Use in Patients with Acute Coronary Syndrome: A Systematic Review	PLOS ONE			English	Review							ACUTE MYOCARDIAL-INFARCTION; SEROTONIN REUPTAKE INHIBITORS; HEART-RATE-VARIABILITY; DEPRESSIVE SYMPTOMS; ARTERY-DISEASE; MAJOR DEPRESSION; MEDICATION USE; UNSTABLE ANGINA; CARDIAC EVENTS; YOUNGER WOMEN	Background and Objectives: Depression is common among acute coronary syndrome (ACS) patients and is associated with poor prognosis. Cardiac side effects of older antidepressants were well-known, but newer antidepressants are generally thought of as safe to use in patients with heart disease. The objective was to assess rates of antidepressant use or prescription to patients within a year of an ACS. Methods: PubMed, PsycINFO, and CINAHL databases searched through May 29, 2009; manual searching of 33 journals from May 2009 to September 2010. Articles in any language were included if they reported point or period prevalence of antidepressant use or prescription in the 12 months prior or subsequent to an ACS for >= 100 patients. Two investigators independently selected studies for inclusion/exclusion and extracted methodological characteristics and outcomes from included studies (study setting, inclusion/exclusion criteria, sample size, prevalence of antidepressant prescription/use, method of assessing antidepressant prescription/use, time period of assessment). Results: A total of 24 articles were included. The majority were from North America and Europe, and most utilized chart review or self-report to assess antidepressant use or prescription. Although there was substantial heterogeneity in results, overall, rates of antidepressant use or prescription increased from less than 5% prior to 1995 to 10-15% after 2000. In general, studies from North America reported substantially higher rates than studies from Europe, approximately 5% higher among studies that used chart or self-report data. Conclusions: Antidepressant use or prescription has increased considerably, and by 2005 approximately 10% to 15% of ACS patients were prescribed or using one of these drugs.	[Czarny, Matthew J.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Czarny, Matthew J.] Harvard Univ, Sch Med, Boston, MA USA; [Arthurs, Erin; Steele, Russell J.; Thombs, Brett D.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; [Coffie, Diana-Frances] Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; [Coffie, Diana-Frances] Brown Alpert Med Sch, Providence, RI USA; [Smith, Cheri] Johns Hopkins Bayview Med Ctr, Harold E Harrison Med Lib, Baltimore, MD USA; [Steele, Russell J.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Thombs, Brett D.] McGill Univ, Sch Nursing, Montreal, PQ, Canada; [Ziegelstein, Roy C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Lady Davis Institute; McGill University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Johns Hopkins University; Johns Hopkins Medicine; McGill University; McGill University; McGill University; McGill University; McGill University; Johns Hopkins University	Czarny, MJ (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	brett.thombs@mcgill.ca	Steele, Russell J/G-6926-2017	Thombs, Brett D./0000-0002-5644-8432	National Center for Complementary & Alternative Medicine [R24AT004641]; Miller Family Scholar Program; Canadian Institutes of Health Research; Fonds de la Recherche en Sante Quebec; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R24AT004641] Funding Source: NIH RePORTER	National Center for Complementary & Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Miller Family Scholar Program; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante Quebec(Fonds de la Recherche en Sante du Quebec); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Dr. Ziegelstein was supported by grant number R24AT004641 from the National Center for Complementary & Alternative Medicine and by the Miller Family Scholar Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary & Alternative Medicine or the National Institutes of Health. Dr. Thombs was supported by a New Investigator Award from the Canadian Institutes of Health Research and an Etablissement de Jeunes Chercheurs award from the Fonds de la Recherche en Sante Quebec. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso J, 2004, ACTA PSYCHIAT SCAND, V109, P55; Andrade C, 2010, J CLIN PSYCHIAT, V71, P1565, DOI 10.4088/JCP.09r05786blu; Benazon NR, 2005, PSYCHOSOM MED, V67, P916, DOI 10.1097/01.psy.0000188399.80167.aa; Bhattacharyya MR, 2007, EUR HEART J, V28, P160, DOI 10.1093/eurheartj/ehl440; BLACKWELL B, 1967, BRIT J PSYCHIAT, V113, P349, DOI 10.1192/bjp.113.497.349; Boudreau DM, 2004, AM J EPIDEMIOL, V159, P308, DOI 10.1093/aje/kwh038; Corser William, 2006, JOURNAL OF PHARMACY TECHNOLOGY, V22, P319; DELISLE VC, J PSYCHOPHARMACOL; Dias Carla Costa, 2005, Rev Port Cardiol, V24, P507; Dickens C, 2007, J AM COLL CARDIOL, V49, P1834, DOI 10.1016/j.jacc.2007.01.075; Dowlati Y, 2010, CAN J PSYCHIAT, V55, P91, DOI 10.1177/070674371005500205; Fosbol EL, 2009, CIRC-HEART FAIL, V2, P582, DOI 10.1161/CIRCHEARTFAILURE.109.851246; Frasure-Smith N, 2008, ARCH GEN PSYCHIAT, V65, P62, DOI 10.1001/archgenpsychiatry.2007.4; Gill JM, 2010, J AM BOARD FAM MED, V23, P499, DOI 10.3122/jabfm.2010.04.090299; GLASSMAN AH, 1993, JAMA-J AM MED ASSOC, V269, P2673, DOI 10.1001/jama.269.20.2673; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Grace SL, 2008, PSYCHOSOMATICS, V49, P199, DOI 10.1176/appi.psy.49.3.199; Grace SL, 2005, PSYCHOSOM MED, V67, P52, DOI 10.1097/01.psy.0000151486.28349.70; Grunau GL, 2006, CAN J CARDIOL, V22, P473, DOI 10.1016/S0828-282X(06)70263-X; Haapea M, 2010, INT J METH PSYCH RES, V19, P88, DOI 10.1002/mpr.304; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huffman JC, 2006, HEART, V92, P1656, DOI 10.1136/hrt.2005.087213; Jureidini J, 2006, CNS DRUGS, V20, P623, DOI 10.2165/00023210-200620080-00002; Kaptein KI, 2006, PSYCHOSOM MED, V68, P662, DOI 10.1097/01.psy.0000233237.79085.57; Krantz DS, 2009, HEART, V95, P1901, DOI 10.1136/hrt.2009.176040; Kwon A, 2003, MED CARE, V41, P368, DOI 10.1097/00005650-200303000-00005; Lauzon C, 2003, CAN MED ASSOC J, V168, P547; Lesperance F, 2000, ARCH INTERN MED, V160, P1354, DOI 10.1001/archinte.160.9.1354; Lesperance F, 2007, JAMA-J AM MED ASSOC, V297, P367, DOI 10.1001/jama.297.4.367; Licht CMM, 2008, ARCH GEN PSYCHIAT, V65, P1358, DOI 10.1001/archpsyc.65.12.1358; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Mallik S, 2006, ARCH INTERN MED, V166, P876, DOI 10.1001/archinte.166.8.876; Mazza M, 2010, J PSYCHOPHARMACOL, V24, P1785, DOI 10.1177/0269881109348176; Mojtabai R, 2011, HEALTH AFFAIR, V30, P1434, DOI 10.1377/hlthaff.2010.1024; Monster TBM, 2004, AM J MED, V117, P732, DOI 10.1016/j.amjmed.2004.06.027; Murray JB, 2000, J PSYCHOL, V134, P162, DOI 10.1080/00223980009600859; Nakatani D, 2005, AM HEART J, V150, P652, DOI 10.1016/j.ahj.2005.03.062; O'Connor CM, 2010, J AM COLL CARDIOL, V56, P692, DOI 10.1016/j.jacc.2010.03.068; Olfson M, 2009, ARCH GEN PSYCHIAT, V66, P848, DOI 10.1001/archgenpsychiatry.2009.81; Pacher P, 2004, CURR PHARM DESIGN, V10, P2463, DOI 10.2174/1381612043383872; Parakh K, 2008, AM J CARDIOL, V101, P602, DOI 10.1016/j.amjcard.2007.10.021; Parker GB, 2008, BIOL PSYCHIAT, V64, P660, DOI 10.1016/j.biopsych.2008.05.021; Pitzalis MV, 2001, AM HEART J, V141, P765, DOI 10.1067/mhj.2001.114806; Pizzi C, 2009, CLIN PHARMACOL THER, V86, P527, DOI 10.1038/clpt.2009.121; R Development Core Team, 2011, R LAND ENV STAT COMP; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Rumsfeld JS, 2005, CIRCULATION, V111, P250, DOI 10.1161/01.CIR.0000154573.62822.89; Rumsfeld JS, 2003, AM HEART J, V145, P493, DOI 10.1067/mhj.2003.177; Sauer WH, 2001, CIRCULATION, V104, P1894, DOI 10.1161/hc4101.097519; Smoller JW, 2009, ARCH INTERN MED, V169, P2128, DOI 10.1001/archinternmed.2009.436; Sorensen C, 2005, ACTA PSYCHIAT SCAND, V111, P116, DOI 10.1111/j.1600-0447.2004.00430.x; Spina E, 2008, CLIN THER, V30, P1206, DOI 10.1016/S0149-2918(08)80047-1; Stahl SM, 2005, CNS SPECTRUMS, V10, P732, DOI 10.1017/S1092852900019726; Strik JTMH, 2000, PSYCHOSOM MED, V62, P783, DOI 10.1097/00006842-200011000-00007; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Taylor CB, 2005, ARCH GEN PSYCHIAT, V62, P792, DOI 10.1001/archpsyc.62.7.792; Taylor D, 2008, ACTA PSYCHIAT SCAND, V118, P434, DOI 10.1111/j.1600-0447.2008.01260.x; Thombs BD, 2006, J GEN INTERN MED, V21, P30, DOI 10.1111/j.1525-1497.2005.00269.x; Thombs BD, 2008, JAMA-J AM MED ASSOC, V300, P2161, DOI 10.1001/jama.2008.667; Tibold A, 2007, AM J CARDIOL, V99, P1025, DOI 10.1016/j.amjcard.2006.11.030; U.S. Food and Drug Administration, CEL CIT HYDR DRUG SA; US Preventive Serv Task Force, 2009, ANN INTERN MED, V151, P784, DOI 10.7326/0003-4819-151-11-200912010-00006; van Melle JP, 2004, PSYCHOSOM MED, V66, P814, DOI 10.1097/01.psy.0000146294.82810.9c; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Whang W, 2009, J AM COLL CARDIOL, V53, P950, DOI 10.1016/j.jacc.2008.10.060; Wong CK, 2008, QJM-INT J MED, V101, P137, DOI 10.1093/qjmed/hcm153; Xiong GL, 2006, AM J CARDIOL, V98, P42, DOI 10.1016/j.amjcard.2006.01.051; Ziegelstein RC, 2007, AM J MED, V120, P525, DOI 10.1016/j.amjmed.2006.10.026; Zimmermann-Viehoff F, 2010, EUR J CARDIOV PREV R, V17, P509, DOI 10.1097/HJR.0b013e328337b57b	69	22	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2011	6	11							e27671	10.1371/journal.pone.0027671	http://dx.doi.org/10.1371/journal.pone.0027671			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	858JH	22132126	gold, Green Published, Green Submitted			2023-01-03	WOS:000297792400012
J	Hawkes, N				Hawkes, Nigel			DRUG MISUSE Highs and lows of drug decriminalisation	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com						CAMPBELL D, 2011, GUARDIAN        0127; COELHO MFP, 2010, BMJ; NHS Information Centre, 2010, SMOK DRINK DRUG US Y; Pacula RL, 2011, INT J DRUG POLICY, V22, P326, DOI 10.1016/j.drugpo.2011.07.008	4	5	5	1	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2011	343								d6881	10.1136/bmj.d6881	http://dx.doi.org/10.1136/bmj.d6881			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	840CY	22031913				2023-01-03	WOS:000296417100015
J	Milane, L; Duan, ZF; Amiji, M				Milane, Lara; Duan, Zhenfeng; Amiji, Mansoor			Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer	PLOS ONE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; PEPTIDE LIGAND; CELLS; GLYCOLYSIS; APOPTOSIS; GROWTH; DELIVERY; WARBURG; OXYGEN	The treatment of multi-drug resistant (MDR) cancer is a clinical challenge. Many MDR cells over-express epidermal growth factor receptor (EGFR). We exploit this expression through the development of EGFR-targeted, polymer blend nanocarriers for the treatment of MDR cancer using paclitaxel (a common chemotherapeutic agent) and lonidamine (an experimental drug; mitochondrial hexokinase 2 inhibitor). An orthotopic model of MDR human breast cancer was developed in nude mice and used to evaluate the safety and efficacy of nanoparticle treatment. The efficacy parameters included tumor volume measurements from day 0 through 28 days post-treatment, terminal tumor weight measurements, tumor density and morphology assessment through hematoxylin and eosin staining of excised tumors, and immunohistochemistry of tumor sections for MDR protein markers (P-glycoprotein, Hypoxia Inducible Factor, EGFR, Hexokinase 2, and Stem Cell Factor). Toxicity was assessed by tracking changes in animal body weight from day 0 through 28 days post-treatment, by measuring plasma levels of the liver enzymes ALT (Alanine Aminotransferase) and LDH (lactate dehydrogenase), and by white blood cell and platelet counts. In these studies, this nanocarrier system demonstrated superior efficacy relative to combination (paclitaxel/lonidamine) drug solution and single agent treatments in nanoparticle and solution form. The combination nanoparticles were the only treatment group that decreased tumor volume, sustaining this decrease until the 28 day time point. In addition, treatment with the EGFR-targeted lonidamine/paclitaxel nanoparticles decreased tumor density and altered the MDR phenotype of the tumor xenografts. These EGFR-targeted combination nanoparticles were considerably less toxic than solution treatments. Due to the flexible design and simple conjugation chemistry, this nanocarrier system could be used as a platform for the development of other MDR cancer therapies; the use of this system for EGFR-targeted, combination paclitaxel/lonidamine therapy is an advance in personalized medicine.	[Milane, Lara; Amiji, Mansoor] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA; [Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA; [Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA 02114 USA	Northeastern University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Milane, L (corresponding author), Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.	m.amiji@neu.edu	Amiji, Mansoor M/AAK-1531-2020; Amiji, Mansoor M/A-4365-2014	Amiji, Mansoor M/0000-0001-6170-881X; 	National Cancer Institute, National Institutes of Health [R01 CA-119617, R01 CA-119617S1, R21 CA-135594]; NATIONAL CANCER INSTITUTE [R21CA135594, R01CA119617] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute, National Institutes of Health through grants R01 CA-119617 and R01 CA-119617S1 (ARRA Supplement), and R21 CA-135594. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brawer Michael K, 2005, Rev Urol, V7 Suppl 7, pS21; Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0; Cosse JP, 2008, ANTI-CANCER AGENT ME, V8, P790, DOI 10.2174/187152008785914798; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Ditonno Pasquale, 2005, Rev Urol, V7 Suppl 7, pS27; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Han ZB, 2008, CARCINOGENESIS, V29, P1853, DOI 10.1093/carcin/bgn066; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARRIS AL, 1992, ACTA ONCOL, V31, P205, DOI 10.3109/02841869209088904; Li YC, 2002, LIFE SCI, V71, P2729, DOI 10.1016/S0024-3205(02)02103-3; Li ZH, 2005, FASEB J, V19, P1978, DOI 10.1096/fj.05-4058com; Lopez-Lazaro M, 2008, ANTI-CANCER AGENT ME, V8, P305, DOI 10.2174/187152008783961932; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; MILANE L, 2010, MOL PHARM; MILANE L, 2011, NANOMEDICINE; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2008, IUBMB LIFE, V60, P591, DOI 10.1002/iub.93; Song SX, 2008, INT J PHARMACEUT, V363, P155, DOI 10.1016/j.ijpharm.2008.07.012; Yague E, 2007, CANCER RES, V67, P1130, DOI 10.1158/0008-5472.CAN-06-2574	23	76	78	1	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2011	6	9							e24075	10.1371/journal.pone.0024075	http://dx.doi.org/10.1371/journal.pone.0024075			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CK	21931642	Green Published, Green Submitted, gold			2023-01-03	WOS:000294802800020
J	Breitbach, CJ; Burke, J; Jonker, D; Stephenson, J; Haas, AR; Chow, LQM; Nieva, J; Hwang, TH; Moon, A; Patt, R; Pelusio, A; Le Boeuf, F; Burns, J; Evgin, L; De Silva, N; Cvancic, S; Robertson, T; Je, JE; Lee, YS; Parato, K; Diallo, JS; Fenster, A; Daneshmand, M; Bell, JC; Kirn, DH				Breitbach, Caroline J.; Burke, James; Jonker, Derek; Stephenson, Joe; Haas, Andrew R.; Chow, Laura Q. M.; Nieva, Jorge; Hwang, Tae-Ho; Moon, Anne; Patt, Richard; Pelusio, Adina; Le Boeuf, Fabrice; Burns, Joe; Evgin, Laura; De Silva, Naomi; Cvancic, Sara; Robertson, Terri; Je, Ji-Eun; Lee, Yeon-Sook; Parato, Kelley; Diallo, Jean-Simon; Fenster, Aaron; Daneshmand, Manijeh; Bell, John C.; Kirn, David H.			Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans	NATURE			English	Article							VACCINIA VIRUS; GM-CSF; IMATINIB MESYLATE; THYMIDINE KINASE; MEASLES-VIRUS; GROWTH-FACTOR; THERAPY; TUMORS; CRITERIA; PROGRESS	The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal tissues after intravenous administration. This has not been achievable so far in humans. We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery and expression of transgenes in tumours. JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity(1). Here we show in a clinical trial that JX-594 selectively infects, replicates and expresses transgene products in cancer tissue after intravenous infusion, in a dose-related fashion. Normal tissues were not affected clinically. This platform technology opens up the possibility of multifunctional products that selectively express high concentrations of several complementary therapeutic and imaging molecules in metastatic solid tumours in humans.	[Breitbach, Caroline J.; Moon, Anne; Pelusio, Adina; Robertson, Terri; Kirn, David H.] Jennerex Inc, San Francisco, CA 94111 USA; [Burke, James; Nieva, Jorge] Billings Clin, Dept Hematol Oncol, Billings, MT 59101 USA; [Jonker, Derek; Chow, Laura Q. M.; Le Boeuf, Fabrice; Burns, Joe; Evgin, Laura; De Silva, Naomi; Cvancic, Sara; Parato, Kelley; Diallo, Jean-Simon; Daneshmand, Manijeh; Bell, John C.] Ottawa Hosp Res Inst, Ottawa, ON K1H 8L6, Canada; [Jonker, Derek; Chow, Laura Q. M.; Burns, Joe; Evgin, Laura; De Silva, Naomi; Cvancic, Sara; Daneshmand, Manijeh; Bell, John C.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Stephenson, Joe] Canc Ctr Carolinas, Greenville, SC 29605 USA; [Haas, Andrew R.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; [Hwang, Tae-Ho; Je, Ji-Eun; Lee, Yeon-Sook] Pusan Natl Univ, Pusan 609735, South Korea; [Patt, Richard] RadMD, Doylestown, PA 18901 USA; [Fenster, Aaron] Robarts Res Inst, London, ON N6A 5K8, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Pennsylvania; Pusan National University; Western University (University of Western Ontario)	Kirn, DH (corresponding author), Jennerex Inc, 450 Sansome St,16th Floor, San Francisco, CA 94111 USA.	dkirn@jennerex.com	Nieva, Jorge/AAE-3634-2022; FENSTER, Aaron/K-4337-2013; Diallo, Jean-Simon/G-4465-2017	Nieva, Jorge/0000-0003-1605-4719; Burns, Joseph/0000-0002-6926-232X; Diallo, Jean-Simon/0000-0002-4862-2795; Evgin, Laura/0000-0002-0913-5038	Terry Fox Foundation; Canadian Institute for Health Research (CIHR); Ministry for Health, Welfare and Family Affairs, Republic of Korea [A091047]; Vanier Scholarship; Natural Sciences and Engineering Research Council of Canada (NSERC); Ontario Graduate Scholarships in Science and Technology (OGSST); Canadian Institutes of Health Research/Small and Medium Enterprises (CIHR/SME); Ontario Institute for Cancer Research	Terry Fox Foundation; Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ministry for Health, Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Vanier Scholarship; Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Ontario Graduate Scholarships in Science and Technology (OGSST); Canadian Institutes of Health Research/Small and Medium Enterprises (CIHR/SME)(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research	Jennerex Inc. was involved in the study design, data monitoring, analysis and interpretation, and in writing and submission of the report for publication. Jennerex Inc. funded the clinical study. Translational work was supported by grants to J.B. from the Terry Fox Foundation and the Canadian Institute for Health Research (CIHR) and by grants to T.-H.H. from the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A091047). N.D.S. is supported by a Vanier Scholarship. C.J.B. was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) studentship. L.E. is supported by Ontario Graduate Scholarships in Science and Technology (OGSST). F.L.B. is supported by a Canadian Institutes of Health Research/Small and Medium Enterprises (CIHR/SME) Collaborative Research Program Fellowship. A.F. and J.C.B. are supported by Ontario Institute for Cancer Research.	BULLER RML, 1985, NATURE, V317, P813, DOI 10.1038/317813a0; Byrne MJ, 2004, ANN ONCOL, V15, P257, DOI 10.1093/annonc/mdh059; Choi H, 2004, AM J ROENTGENOL, V183, P1619, DOI 10.2214/ajr.183.6.01831619; Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOVGAARD D, 1992, EUR J CLIN INVEST, V22, P45, DOI 10.1111/j.1365-2362.1992.tb01934.x; Katsafanas GC, 2004, J BIOL CHEM, V279, P52210, DOI 10.1074/jbc.M411033200; Kim JH, 2006, MOL THER, V14, P361, DOI 10.1016/j.ymthe.2006.05.008; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Kulesh DA, 2004, J CLIN MICROBIOL, V42, P601, DOI 10.1128/JCM.42.2.601-609.2004; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Mastrangelo MJ, 1999, CANCER GENE THER, V6, P409, DOI 10.1038/sj.cgt.7700066; McCart JA, 2001, CANCER RES, V61, P8751; McCart JA, 2004, MOL THER, V10, P553, DOI 10.1016/j.ymthe.2004.06.158; MOSS B, 1991, SCIENCE, V252, P1662, DOI 10.1126/science.2047875; Msaouel P, 2009, MOL THER, V17, P2041, DOI 10.1038/mt.2009.218; MYERS JLW, 2003, RES DESIGN STAT ANAL, P505; Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Peng KW, 2002, CANCER RES, V62, P4656; Rozen S, 2000, Methods Mol Biol, V132, P365; Smith GL, 2003, ANNU REV MICROBIOL, V57, P323, DOI 10.1146/annurev.micro.57.030502.091037; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Thorne SH, 2010, MOL THER, V18, P1698, DOI 10.1038/mt.2010.140; Thorne SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JCI32727; Vanderplasschen A, 1997, J GEN VIROL, V78, P2041, DOI 10.1099/0022-1317-78-8-2041; Vanderplasschen A, 1998, P NATL ACAD SCI USA, V95, P7544, DOI 10.1073/pnas.95.13.7544; Wein LM, 2003, CANCER RES, V63, P1317; Yang HL, 2005, J CLIN INVEST, V115, P379, DOI 10.1172/jc1200523200	30	383	411	2	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 1	2011	477	7362					99	U102		10.1038/nature10358	http://dx.doi.org/10.1038/nature10358			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	813XT	21886163				2023-01-03	WOS:000294404300039
J	Reynolds, EE; Trivedi, NS				Reynolds, Eileen E.; Trivedi, Neha S.			Update: A 37-Year-Old Man Trying to Choose a High-Quality Hospital Review of Hospital Quality Indicators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Trivedi, Neha/0000-0003-1006-1408				Howell MD, 2009, JAMA-J AM MED ASSOC, V302, P2353, DOI 10.1001/jama.2009.1684	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					965	965		10.1001/jama.2012.210	http://dx.doi.org/10.1001/jama.2012.210			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396518				2023-01-03	WOS:000301172100025
J	Cao, SH; Xu, WT; Zhang, N; Wang, Y; Luo, YB; He, XY; Huang, KL				Cao, Sishuo; Xu, Wentao; Zhang, Nan; Wang, Yan; Luo, Yunbo; He, Xiaoyun; Huang, Kunlun			A Mitochondria-Dependent Pathway Mediates the Apoptosis of GSE-Induced Yeast	PLOS ONE			English	Article							GRAPEFRUIT-SEED-EXTRACT; ANTIBACTERIAL AGENT; PROTEOME ANALYSIS; REACTIVE OXYGEN; ACID; PHOSPHORYLATION; ACTIVATION; CARCINOMA; DEATH; CELLS	Grapefruit seed extract (GSE), which has powerful anti-fungal activity, can induce apoptosis in S. cerevisiae. The yeast cells underwent apoptosis as determined by testing for apoptotic markers of DNA cleavage and typical chromatin condensation by Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick End Labeling (TUNEL) and 4,69-diaminidino-2-phenylindole (DAPI) staining and electron microscopy. The changes of Delta Psi mt (mitochondrial transmembrane potential) and ROS (reactive oxygen species) indicated that the mitochondria took part in the apoptotic process. Changes in this process detected by metabonomics and proteomics revealed that the yeast cells tenaciously resisted adversity. Proteins related to redox, cellular structure, membrane, energy and DNA repair were significantly increased. In this study, the relative changes in the levels of proteins and metabolites showed the tenacious resistance of yeast cells. However, GSE induced apoptosis in the yeast cells by destruction of the mitochondrial 60 S ribosomal protein, L14-A, and prevented the conversion of pantothenic acid to coenzyme A (CoA). The relationship between the proteins and metabolites was analyzed by orthogonal projections to latent structures (OPLS). We found that the changes of the metabolites and the protein changes had relevant consistency.	[Cao, Sishuo; Xu, Wentao; Wang, Yan; Luo, Yunbo; He, Xiaoyun; Huang, Kunlun] China Agr Univ, Coll Food Sci & Nutr Engn, Lab Food Safety & Mol Biol, Beijing 100094, Peoples R China; [Xu, Wentao; Zhang, Nan; Luo, Yunbo; Huang, Kunlun] Minist Agr, Supervis Inspect & Testing Ctr Genetically Modifi, Beijing, Peoples R China	China Agricultural University; Ministry of Agriculture & Rural Affairs	Cao, SH (corresponding author), China Agr Univ, Coll Food Sci & Nutr Engn, Lab Food Safety & Mol Biol, Beijing 100094, Peoples R China.	xuwentaoboy@sina.com; hkl009@163.com		Kunlun, Huang/0000-0002-2350-5859	Ministry of Science and Technology of China	Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by the Fundamental Research Funds for the Central Universities of the Ministry of Science and Technology of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal C, 2006, MOL CANCER THER, V5, P3294, DOI 10.1158/1535-7163.MCT-06-0483; Almeida B, 2009, PROTEOMICS, V9, P720, DOI 10.1002/pmic.200700816; Altmann Katrin, 2007, Methods Mol Biol, V372, P81, DOI 10.1007/978-1-59745-365-3_6; Andersen G, 2007, FEBS J, V274, P1804, DOI 10.1111/j.1742-4658.2007.05729.x; Ashkenazi A, 2007, SCIENCE, V281, P1303; Bach B, 2009, APPL ENVIRON MICROB, V75, P4231, DOI 10.1128/AEM.00051-09; Bundy JG, 2007, GENOME RES, V17, P510, DOI 10.1101/gr.5662207; BYERS B, 1991, METHOD ENZYMOL, V194, P602; Cvetnic Zdenka, 2004, Acta Pharmaceutica (Zagreb), V54, P243; Eisenberg T, 2007, APOPTOSIS, V12, P1011, DOI 10.1007/s10495-007-0758-0; Heggers JP, 2002, J ALTERN COMPLEM MED, V8, P333, DOI 10.1089/10755530260128023; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu Y, 2003, ELECTROPHORESIS, V24, P1458, DOI 10.1002/elps.200390188; Ignacio C, 2005, COMP ANAL ANTIFUNGAL; Ionescu G, 1990, J ORTHOMOLECULAR MED, V5, P155; Kaur M, 2009, PHARM RES-DORDR, V26, P2133, DOI 10.1007/s11095-009-9926-y; Keun HC, 2003, ANAL CHIM ACTA, V490, P265, DOI 10.1016/S0003-2670(03)00094-1; Kissova I, 2000, FEBS LETT, V471, P113, DOI 10.1016/S0014-5793(00)01379-X; Kitagaki H, 2007, FEBS LETT, V581, P2935, DOI 10.1016/j.febslet.2007.05.048; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Krajewska-Kulak E, 2003, J EUR ACAD DERMATOL, V17, P486, DOI 10.1046/j.1468-3083.2003.00614_12.x; Laun P, 2005, FEMS YEAST RES, V5, P1261, DOI 10.1016/j.femsyr.2005.07.006; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Lutz NW, 2005, METABOLOMICS, V1, P251, DOI 10.1007/s11306-005-0005-z; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mazzoni C, 2007, FEBS LETT, V581, P4836, DOI 10.1016/j.febslet.2007.09.009; Perrone GG, 2008, BBA-MOL CELL RES, V1783, P1354, DOI 10.1016/j.bbamcr.2008.01.023; Pham NA, 2000, CYTOMETRY, V41, P245, DOI 10.1002/1097-0320(20001201)41:4<245::AID-CYTO2>3.0.CO;2-#; Pozniakovsky AI, 2005, J CELL BIOL, V168, P257, DOI 10.1083/jcb.200408145; Raina K, 2008, MOL CANCER THER, V7, P1258, DOI 10.1158/1535-7163.MCT-07-2220; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; Reagor L, 2002, J ALTERN COMPLEM MED, V8, P325, DOI 10.1089/10755530260128014; Roe S, 2004, United States Patent Application Publication, Patent No. [2004/0247714A1, 20040247714]; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saito M, 1998, J AGR FOOD CHEM, V46, P1460, DOI 10.1021/jf9709156; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Singh LR, 2007, MOL GENET METAB, V91, P335, DOI 10.1016/j.ymgme.2007.04.011; SODA T, 1953, J BIOCHEM-TOKYO, V40, P421, DOI 10.1093/oxfordjournals.jbchem.a126383; Sun W, 2007, MOL CELL PROTEOMICS, V6, P1798, DOI 10.1074/mcp.M600449-MCP200; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P446, DOI 10.1016/S0753-3322(02)00285-8; Tirillini B, 2000, FITOTERAPIA, V71, pS29, DOI 10.1016/S0367-326X(00)00176-3; Wei L, 2008, TOXICOL APPL PHARM, V227, P417, DOI 10.1016/j.taap.2007.11.015; Weinberger M, 2005, J CELL SCI, V118, P3543, DOI 10.1242/jcs.02477; Westman E, 2007, NEUROBIOL DIS, V26, P221, DOI 10.1016/j.nbd.2006.12.012; Wilk S, 2005, SCIENCE, ptr16; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P131, DOI 10.1016/S0169-7439(01)00156-3; Xu WT, 2007, POSTHARVEST BIOL TEC, V46, P86, DOI 10.1016/j.postharvbio.2007.03.019; Xu WT, 2007, POSTHARVEST BIOL TEC, V45, P126, DOI 10.1016/j.postharvbio.2006.11.019; Zhang XQ, 2006, PROTEOMICS, V6, P5260, DOI 10.1002/pmic.200600006	53	11	11	2	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2012	7	3							e32943	10.1371/journal.pone.0032943	http://dx.doi.org/10.1371/journal.pone.0032943			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928WA	22403727	Green Published, gold, Green Submitted			2023-01-03	WOS:000303017700124
J	Jilek, BL; Zarr, M; Sampah, ME; Rabi, SA; Bullen, CK; Lai, J; Shen, L; Siliciano, RF				Jilek, Benjamin L.; Zarr, Melissa; Sampah, Maame E.; Rabi, S. Alireza; Bullen, Cynthia K.; Lai, Jun; Shen, Lin; Siliciano, Robert F.			A quantitative basis for antiretroviral therapy for HIV-1 infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; TREATMENT-NAIVE PATIENTS; RESPONSE CURVE SLOPE; DYNAMICS IN-VIVO; COMBINATION THERAPY; CONTROLLED-TRIAL; VIRAL DYNAMICS; ZIDOVUDINE; LAMIVUDINE; INHIBITOR	Highly active antiretroviral therapy (HAART)(1-3) has dramatically decreased mortality from HIV-1 infection(4) and is a major achievement of modern medicine. However, there is no fundamental theory of HAART. Elegant models describe the dynamics of viral replication(3,5-9), but a metric for the antiviral activity of drug combinations relative to a target value needed for control of replication is lacking. Treatment guidelines(10,11) are based on empirical results of clinical trials in which other factors such as regimen tolerability also affect outcome. Why only certain drug combinations control viral replication remains unclear. Here we quantify the intrinsic antiviral activity of antiretroviral drug combinations. We show that most single antiretroviral drugs show previously unappreciated complex nonlinear pharmacodynamics that determine their inhibitory potential at clinical concentrations. We demonstrate that neither of the major theories for drug combinations accurately predicts the combined effects of multiple antiretrovirals. However, the combined effects can be understood with a new approach that considers the degree of independence of drug effects. This analysis allows a direct comparison of the inhibitory potential of different drug combinations under clinical concentrations, reconciles the results of clinical trials, defines a target level of inhibition associated with treatment success and provides a rational basis for treatment simplification and optimization.	[Jilek, Benjamin L.; Sampah, Maame E.; Rabi, S. Alireza; Bullen, Cynthia K.; Lai, Jun; Shen, Lin; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Zarr, Melissa; Shen, Lin; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu			US National Institutes of Health [AI081600]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081600] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank J. Blankson, A. Spivak, C. Durand, J. Gallant, J. Cofrancesco and W. Greco for helpful discussions. This work was supported by US National Institutes of Health grant AI081600 and by the Howard Hughes Medical Institute.	[Anonymous], 2009, GUID US ANT AG HIV 1; Bierman WFW, 2009, AIDS, V23, P279, DOI 10.1097/QAD.0b013e32831c54e5; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cooper DA, 2010, J INFECT DIS, V201, P803, DOI 10.1086/650697; Ferguson NM, 2001, TRENDS PHARMACOL SCI, V22, P97, DOI 10.1016/S0165-6147(00)01615-1; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gallant JE, 2005, J INFECT DIS, V192, P1921, DOI 10.1086/498069; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 2000, J INFECT DIS, V182, P321, DOI 10.1086/315683; Hill A.V, 1910, J PHYSL, V40, P4, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hoggard PG, 1997, ANTIMICROB AGENTS CH, V41, P1231, DOI 10.1128/AAC.41.6.1231; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; Katlama C, 2010, AIDS, V24, P2365, DOI 10.1097/QAD.0b013e32833dec20; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1; Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313; Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c; Muller B, 2009, J BIOL CHEM, V284, P29692, DOI 10.1074/jbc.M109.027144; Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Perez-Valero I, 2011, CURR OPIN INFECT DIS, V24, P7, DOI 10.1097/QCO.0b013e3283422cdf; Sampah MES, 2011, P NATL ACAD SCI USA, V108, P7613, DOI 10.1073/pnas.1018360108; Shen L, 2008, NAT MED, V14, P762, DOI 10.1038/nm1777; Shen L, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002304; Siliciano JD, 2010, CURR OPIN HIV AIDS, V5, P491, DOI 10.1097/COH.0b013e32833f206f; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wodarz D, 2002, BIOESSAYS, V24, P1178, DOI 10.1002/bies.10196; Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004	40	112	115	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2012	18	3					446	U211		10.1038/nm.2649	http://dx.doi.org/10.1038/nm.2649			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	905IF	22344296	Green Accepted, Green Published			2023-01-03	WOS:000301264800048
J	Hawkes, N				Hawkes, Nigel			BODY POLITIC Seeing through the alcohol statistics haze	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes1@btinternet.com						2011, BRIT MED J, V343, pD5869, DOI DOI 10.1136/BMJ.D5869; 2011, BRIT MED J, V342, DOI DOI 10.1136/BMJ.D4166; 2010, BRIT MED J, V341, DOI DOI 10.1136/BMJ.C4790; 2010, BRIT MED J, V340, DOI DOI 10.1136/BMJ.C2153	4	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 22	2012	344								e1273	10.1136/bmj.e1273	http://dx.doi.org/10.1136/bmj.e1273			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	900JQ	22362248				2023-01-03	WOS:000300883600010
J	Gamber, KM; Huo, LH; Ha, S; Hairston, JE; Greeley, S; Bjorbaek, C				Gamber, Kevin M.; Huo, Lihong; Ha, Sangdeuk; Hairston, Joyce E.; Greeley, Sarah; Bjorbaek, Christian			Over-Expression of Leptin Receptors in Hypothalamic POMC Neurons Increases Susceptibility to Diet-Induced Obesity	PLOS ONE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MESSENGER-RNA EXPRESSION; MICE OVEREXPRESSING LEPTIN; AGOUTI-RELATED PROTEIN; ARCUATE NUCLEUS; IN-VIVO; GLUCOSE-HOMEOSTASIS; LOCOMOTOR-ACTIVITY; GENE-EXPRESSION; MOUSE-BRAIN	Diet-induced obesity (DIO) in rodents is characterized by impaired activation of (s) under bar ignal-(t) under bar ransducer and (a) under bar ctivator of (t) under bar ranscription 3 (STAT3) by leptin receptors (LepRb) within the hypothalamic arcuate nucleus. This signaling defect likely plays an important role in development of DIO. However, the neuro-chemical identity of the leptin-STAT3 resistant arcuate neurons has not been determined and the underlying mechanisms responsible for development of cellular leptin resistance remain unclear. To investigate this, we first measured arcuate gene expression of known key signaling components of the LepRb signaling pathway and tested whether specifically the critical arcuate pro-opiomelanocortin (POMC) neurons are resistant to LepRb-STAT3 signaling in mice given a high-fat-diet (HFD) compared to mice provided a low-fat control diet (LFD). We found that leptin-dependent STAT3 phosphorylation was decreased within POMC neurons of HFD mice. In addition, Leprb mRNA and suppressor of cytokine signaling 3 (Socs3) mRNA were elevated in the arcuate of HFD mice. To investigate whether increased LepRb expression per se in POMC neurons can influence development of DIO and Socs3 expression, we created mice that over-express LepRb selectively in POMC neurons (POMC-LepRb). No differences in body weight, fat mass or food intake were found between LFD POMC-LepRb mice and LFD controls. Surprisingly, body weight, fat mass and caloric intake of HFD POMC-LepRb mice was markedly higher than HFD control mice. In addition, arcuate Socs3 mRNA was increased in HFD POMC-LepRb mice compared to HFD controls. These data show that specifically POMC neurons of DIO mice are resistant to STAT3 activation by leptin, indicating that those cells might play a role in development of DIO. Furthermore, over-expression of LepRb selectively in POMC neurons increases susceptibility to the development of DIO. We propose a model where over-reactivity of the leptin-LepRb signaling system in arcuate neurons may play causal a role in development of diet-induced obesity.	[Gamber, Kevin M.] Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Gamber, KM (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.	cbjorbae@bidmc.harvard.edu	Bjorbaek, Christian/S-4727-2019	Gamber, Kevin/0000-0002-0694-7639	American Diabetes Association [7-09-BS-17]; The Richard and Susan Smith Family Foundation [7-05-PPG-02]; National Institutes of Health [DK60673, DK65743]; Endocrine Society; Boston Obesity Nutrition Research Center [DK46200]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065743, P30DK046200, R01DK060673] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); The Richard and Susan Smith Family Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Endocrine Society; Boston Obesity Nutrition Research Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the American Diabetes Association (7-09-BS-17) and The Richard and Susan Smith Family Foundation Pinnacle Program Project (7-05-PPG-02), the National Institutes of Health (DK60673 and DK65743 and ARRA funds), the Endocrine Society (all to C.B.), and by the Boston Obesity Nutrition Research Center (DK46200). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Banno R, 2010, J CLIN INVEST, V120, P720, DOI 10.1172/JCI39620; Baskin DG, 2000, REGUL PEPTIDES, V92, P9, DOI 10.1016/S0167-0115(00)00143-9; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bjorbaek C, 2009, J INVEST MED, V57, P789, DOI 10.2310/JIM.0b013e3181bb0d49; Bouret SG, 2008, CELL METAB, V7, P179, DOI 10.1016/j.cmet.2007.12.001; Bradley RL, 2008, OBESITY, V16, P938, DOI 10.1038/oby.2008.39; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; de Wall EV, 2008, ENDOCRINOLOGY, V149, P1773, DOI 10.1210/en.2007-1132; El-Haschimi K, 2000, J CLIN INVEST, V105, P1827, DOI 10.1172/JCI9842; Enriori PJ, 2007, CELL METAB, V5, P181, DOI 10.1016/j.cmet.2007.02.004; Ernst MB, 2009, J NEUROSCI, V29, P11582, DOI 10.1523/JNEUROSCI.5712-08.2009; Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Guo FF, 2004, ENDOCRINOLOGY, V145, P2221, DOI 10.1210/en.2003-1312; Halaas JL, 1997, P NATL ACAD SCI USA, V94, P8878, DOI 10.1073/pnas.94.16.8878; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Huang XF, 2004, DIABETES OBES METAB, V6, P35, DOI 10.1111/j.1463-1326.2004.00312.x; Huang XF, 2003, MOL BRAIN RES, V115, P21, DOI 10.1016/S0169-328X(03)00174-8; Huo L, 2009, CELL METAB, V9, P537, DOI 10.1016/j.cmet.2009.05.003; Isobe A, 2006, PLACENTA, V27, P912, DOI 10.1016/j.placenta.2005.10.003; Kievit P, 2006, CELL METAB, V4, P123, DOI 10.1016/j.cmet.2006.06.010; Kleinridders A, 2009, CELL METAB, V10, P249, DOI 10.1016/j.cmet.2009.08.013; Knight ZA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011376; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Levin BE, 2004, AM J PHYSIOL-REG I, V286, pR143, DOI 10.1152/ajpregu.00393.2003; Lin S, 2000, BRAIN RES, V875, P89, DOI 10.1016/S0006-8993(00)02580-4; Loh K, 2011, CELL METAB, V14, P684, DOI 10.1016/j.cmet.2011.09.011; Low M J, 2004, J Endocrinol Invest, V27, P95; Metlakunta AS, 2008, ENDOCRINOLOGY, V149, P1121, DOI 10.1210/en.2007-1307; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Morton GJ, 2003, ENDOCRINOLOGY, V144, P2016, DOI 10.1210/en.2002-0115; Munzberg H, 2004, ENDOCRINOLOGY, V145, P4880, DOI 10.1210/en.2004-0726; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Ogus S, 2003, ENDOCRINOLOGY, V144, P2865, DOI 10.1210/en.2002-0178; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Picardi PK, 2008, ENDOCRINOLOGY, V149, P3870, DOI 10.1210/en.2007-1506; Qiu J, 2001, ENDOCRINOLOGY, V142, P348, DOI 10.1210/en.142.1.348; Reed AS, 2010, DIABETES, V59, P894, DOI 10.2337/db09-1024; Ricci MR, 2003, AM J PHYSIOL-REG I, V285, pR610, DOI 10.1152/ajpregu.00235.2003; Sahu A, 2002, J NEUROENDOCRINOL, V14, P887, DOI 10.1046/j.1365-2826.2002.00856.x; Satoh N, 1997, NEUROSCI LETT, V224, P149, DOI 10.1016/S0304-3940(97)00163-8; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Scott MM, 2009, J COMP NEUROL, V514, P518, DOI 10.1002/cne.22025; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Velloso LA, 2008, NEUROIMMUNOMODULAT, V15, P189, DOI 10.1159/000153423; Wang S, 2006, J BIOL CHEM, V281, P9439, DOI 10.1074/jbc.M504977200; White CL, 2009, AM J PHYSIOL-ENDOC M, V296, pE291, DOI 10.1152/ajpendo.90513.2008; Wilson BD, 1999, ENDOCRINOLOGY, V140, P2387, DOI 10.1210/en.140.5.2387; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Zabolotny JM, 2008, J BIOL CHEM, V283, P14230, DOI 10.1074/jbc.M800061200; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X	59	57	58	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2012	7	1							e30485	10.1371/journal.pone.0030485	http://dx.doi.org/10.1371/journal.pone.0030485			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909MH	22276206	Green Published, Green Submitted, gold			2023-01-03	WOS:000301568100050
J	Peters, W; Drueppel, V; Kusche-Vihrog, K; Schubert, C; Oberleithner, H				Peters, Wladimir; Drueppel, Verena; Kusche-Vihrog, Kristina; Schubert, Carola; Oberleithner, Hans			Nanomechanics and Sodium Permeability of Endothelial Surface Layer Modulated by Hawthorn Extract WS 1442	PLOS ONE			English	Article							ATOMIC-FORCE MICROSCOPY; CRATAEGUS EXTRACT; IN-VIVO; GLYCOCALYX; WS(R)-1442; SULFATE; FLOW; PROTEOGLYCAN; EFFICACY; BARRIER	The endothelial glycocalyx (eGC) plays a pivotal role in the physiology of the vasculature. By binding plasma proteins, the eGC forms the endothelial surface layer (ESL) which acts as an interface between bloodstream and endothelial cell surface. The functions of the eGC include mechanosensing of blood flow induced shear stress and thus flow dependent vasodilation. There are indications that levels of plasma sodium concentrations in the upper range of normal and beyond impair flow dependent regulation of blood pressure and may therefore increase the risk for hypertension. Substances therefore, that prevent sodium induced endothelial dysfunction may be attractive for the treatment of cardiovascular disease. By means of combined atomic force - epifluorescence microscopy we studied the impact of the hawthorn (Crcitaegus spp.) extract WS 1442, a herbal therapeutic with unknown mechanism of action, on the mechanics of the ESL of ex vivo murine aortae. Furthermore, we measured the impact of WS 1442 on the sodium permeability of endothelial EA.hy 926 cell rnonolayer. The data show that (i) the ESL contributes by about 11% to the total endothelial barrier resistance for sodium and (ii) WS 1442 strengthens the ESL resistance for sodium up to about 45%. This mechanism may explain some of the vasoprotective actions of this herbal therapeutic.	[Peters, Wladimir; Drueppel, Verena; Kusche-Vihrog, Kristina; Oberleithner, Hans] Univ Munster, Inst Physiol 2, Munster, Germany; [Schubert, Carola] Charite, Inst Gender Med, D-13353 Berlin, Germany	University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Peters, W (corresponding author), Univ Munster, Inst Physiol 2, Munster, Germany.	petersw@uni-muenster.de		Schubert, Carola/0000-0002-9116-9105	Deutsche Forschungsgemeinschaft [OB63/18]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The project was supported by a Kosseleck grant to Hans Oberleithner (OB63/18) of the Deutsche Forschungsgemeinschaft (http://www.dfg.de/index.jsp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AlMakdessi S, 1996, ARZNEIMITTELFORSCH, V46, P25; Anselm E, 2009, J CARDIOVASC PHARM, V53, P253, DOI 10.1097/FJC.0b013e31819ccfc9; Becker BF, 2010, BASIC RES CARDIOL, V105, P687, DOI 10.1007/s00395-010-0118-z; Brixius K, 2006, CARDIOVASC DRUG THER, V20, P177, DOI 10.1007/s10557-006-8723-7; Chappell D, 2010, SHOCK, V34, P133, DOI 10.1097/SHK.0b013e3181cdc363; Chatterjee SS, 1997, ARZNEIMITTEL-FORSCH, V47, P821; Curry FL, 2011, ANN BIOMED IN PRESS; Dvorak HF, 2010, CURR OPIN HEMATOL, V17, P225, DOI 10.1097/MOH.0b013e3283386638; Ebong EE, 2011, ARTERIOSCL THROM VAS, V31, P1908, DOI 10.1161/ATVBAHA.111.225268; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Freedman JE, 2001, CIRCULATION, V103, P2792, DOI 10.1161/01.CIR.103.23.2792; Gao LJ, 2009, ANN BIOMED ENG, V37, P1781, DOI 10.1007/s10439-009-9743-9; Holubarsch CJF, 2008, EUR J HEART FAIL, V10, P1255, DOI 10.1016/j.ejheart.2008.10.004; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Iyer S, 2009, NAT NANOTECHNOL, V4, P389, DOI [10.1038/nnano.2009.77, 10.1038/NNANO.2009.77]; Jacob M, 2006, ANESTHESIOLOGY, V104, P1223, DOI 10.1097/00000542-200606000-00018; Kasas S, 2008, PFLUG ARCH EUR J PHY, V456, P13, DOI 10.1007/s00424-008-0448-y; Koch E, 2011, PLANTA MED, V77, P1123, DOI 10.1055/s-0030-1270849; Koller M, 2006, MMW Fortschr Med, V148, P42; Kusche-Vihrog K, 2011, HYPERTENSION, V57, P231, DOI 10.1161/HYPERTENSIONAHA.110.163444; Leuchtgens H, 1993, Fortschr Med, V111, P352; Muller DJ, 2011, TRENDS CELL BIOL, V21, P461, DOI 10.1016/j.tcb.2011.04.008; O'Callaghan R, 2011, AM J PHYSIOL-LUNG C, V301, pL353, DOI 10.1152/ajplung.00342.2010; Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104; Oberleithner H, 2011, PFLUG ARCH EUR J PHY, V462, P519, DOI 10.1007/s00424-011-0999-1; Oberleithner H, 2011, BLOOD PURIFICAT, V31, P82, DOI 10.1159/000321842; Petri B, 2008, J IMMUNOL, V180, P6439, DOI 10.4049/jimmunol.180.10.6439; Pries AR, 2005, AM J PHYSIOL-HEART C, V289, pH2657, DOI 10.1152/ajpheart.00297.2005; Rehm M, 2004, ANESTHESIOLOGY, V100, P1211, DOI 10.1097/00000542-200405000-00025; Siegel G, 1996, BIOSENS BIOELECTRON, V11, P281, DOI 10.1016/0956-5663(96)88415-6; Siegel G, 1996, J AUTONOM NERV SYST, V57, P207, DOI 10.1016/0165-1838(95)00071-2; Sui XF, 2011, SMALL, V7, P1440, DOI 10.1002/smll.201002229; Tauchert M, 2002, AM HEART J, V143, P910, DOI 10.1067/mhj.2002.121463; Tauchert R, 1999, HERZ, V24, P465; Thi MM, 2004, P NATL ACAD SCI USA, V101, P16483, DOI 10.1073/pnas.0407474101; Tovar AMF, 2005, BBA-MOL BASIS DIS, V1740, P45, DOI 10.1016/j.bbadis.2005.02.008; Veveris M, 2004, LIFE SCI, V74, P1945, DOI 10.1016/j.lfs.2003.09.050; Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285, DOI 10.1152/ajpheart.2000.278.1.H285; Weikl A, 1996, Fortschr Med, V114, P291; Weinbaum S, 2003, P NATL ACAD SCI USA, V100, P7988, DOI 10.1073/pnas.1332808100; Wilsie LC, 2003, J BIOL CHEM, V278, P15758, DOI 10.1074/jbc.M208786200; Yamashita K, 2004, GLYCOCONJUGATE J, V21, P31, DOI 10.1023/B:GLYC.0000043744.03329.f4; Yuan W, 2010, ANN BIOMED ENG, V38, P1463, DOI 10.1007/s10439-010-9920-x; Zapfe G, 2001, PHYTOMEDICINE, V8, P262, DOI 10.1078/0944-7113-00041; Zick SM, 2008, EUR J HEART FAIL, V10, P587, DOI 10.1016/j.ejheart.2008.04.008	46	34	34	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 10	2012	7	1					264	270	e29972	10.1371/journal.pone.0029972	http://dx.doi.org/10.1371/journal.pone.0029972			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906OA	22253842	Green Published, Green Submitted, gold			2023-01-03	WOS:000301353900028
J	Epstein, AM; Jha, AK; Orav, EJ				Epstein, Arnold M.; Jha, Ashish K.; Orav, E. John			The Relationship between Hospital Admission Rates and Rehospitalizations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; DISEASE MANAGEMENT PROGRAMS; MEDICARE BENEFICIARIES; READMISSION RATES; SOCIOECONOMIC-STATUS; ADMINISTRATIVE DATA; 30-DAY READMISSION; RANDOMIZED-TRIALS; TRANSITIONAL CARE; CLINICAL-OUTCOMES	BACKGROUND Efforts to reduce hospital readmissions have focused primarily on improving transitional care. Yet variation in readmission rates may more closely reflect variation in the underlying hospitalization rates than differences in the quality of care during and after discharge. METHODS We used national Medicare data to calculate, for each local hospital referral region (HRR), the 30-day, 60-day, and 90-day readmission rates among patients discharged with congestive heart failure or pneumonia. We also calculated population-based all-cause admission rates among Medicare enrollees in each HRR. We examined the variation in HRR readmission rates that was explained by overall hospitalization rates versus differences in patients' coexisting conditions, quality of discharge planning, physician supply, and bed supply. RESULTS HRR readmission rates ranged from 11 to 32% for congestive heart failure and from 8 to 27% for pneumonia. In univariate analyses, all-cause admission rates accounted for the highest proportion of regional variation in readmission rates for congestive heart failure (28%, 34%, and 37% at 30, 60, and 90 days, respectively); the next highest proportions were explained by case mix (11%, 15%, and 18%) and the number of cardiologists per capita (12%, 14%, and 15%). Results for pneumonia were similar, except that the number of pulmonologists per capita accounted for a lower proportion of the variation (6%, 8%, and 7%, respectively). In multivariate analyses, admission rates accounted for 16 to 24% of the variation for congestive heart failure and 11 to 20% for pneumonia; no other factor accounted for more than 6%. CONCLUSIONS We found a substantial association between regional rates of rehospitalization and overall admission rates. Programs directed at shared savings from lower utilization of hospital services might be more successful in reducing readmissions than programs initiated to date. (Funded by the Commonwealth Fund.)	[Epstein, Arnold M.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Epstein, Arnold M.; Jha, Ashish K.; Orav, E. John] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	aepstein@hsph.harvard.edu	Hug, Balthasar L./G-1568-2010		Commonwealth Fund	Commonwealth Fund	Supported by the Commonwealth Fund.	[Anonymous], 2011, SUPPL SENS CAR; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Auerbach AD, 2010, J AM COLL SURGEONS, V211, P601, DOI 10.1016/j.jamcollsurg.2010.07.006; Auerbach AD, 2009, ANN INTERN MED, V150, P696, DOI 10.7326/0003-4819-150-10-200905190-00007; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Chin MH, 1997, AM J CARDIOL, V79, P1640, DOI 10.1016/S0002-9149(97)00214-2; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Dartmouth Medical School Center for the Evaluative Clinical Sciences, 1998, DARTM ATL HLTH CAR; Deswal A, 2004, J AM COLL CARDIOL, V43, P778, DOI 10.1016/j.jacc.2003.10.033; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Elliott MN, 2005, HEALTH SERV RES, V40, P2096, DOI 10.1111/j.1475-6773.2005.00476.x; Felker GM, 2004, J CARD FAIL, V10, P460, DOI 10.1016/j.cardfail.2004.02.011; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; Gonseth J, 2004, EUR HEART J, V25, P1570, DOI 10.1016/j.ehj.2004.04.022; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; HoltzEakin D, 2004, COMMUNICATION   1013; Hummel SL, 2010, CIRC-HEART FAIL, V3, P244, DOI 10.1161/CIRCHEARTFAILURE.109.884098; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; Jovicic Aleksandra, 2006, BMC Cardiovasc Disord, V6, P43, DOI 10.1186/1471-2261-6-43; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Joynt KE, 2011, CIRC-CARDIOVASC QUAL, V4, P53, DOI 10.1161/CIRCOUTCOMES.110.950964; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Krumholz HM, 1997, ARCH INTERN MED, V157, P99, DOI 10.1001/archinte.157.1.99; Krumholz HM, 2002, J AM COLL CARDIOL, V39, P83, DOI 10.1016/S0735-1097(01)01699-0; Krumholz HM, 2000, AM HEART J, V139, P72, DOI 10.1016/S0002-8703(00)90311-9; Lappe JM, 2004, ANN INTERN MED, V141, P446, DOI 10.7326/0003-4819-141-6-200409210-00010; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; O'Malley AJ, 2005, HEALTH SERV RES, V40, P2162, DOI 10.1111/j.1475-6773.2005.00470.x; O'Malley AJ, 2005, HEALTH SERV RES, V40, P2078, DOI 10.1111/j.1475-6773.2005.00471.x; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Philbin EF, 1999, J AM COLL CARDIOL, V33, P1560, DOI 10.1016/S0735-1097(99)00059-5; Philbin EF, 2001, AM J CARDIOL, V87, P1367, DOI 10.1016/S0002-9149(01)01554-5; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; PHILLIPS CO, 2004, JAMA-J AM MED ASSOC, V292, P1022; Rathore SS, 2006, AM HEART J, V152, P371, DOI 10.1016/j.ahj.2005.12.002; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Schneider J K, 1993, Clin Nurs Res, V2, P41, DOI 10.1177/105477389300200105; Smith DM, 2000, J CLIN EPIDEMIOL, V53, P1113, DOI 10.1016/S0895-4356(00)00236-5; Stewart S, 1998, ARCH INTERN MED, V158, P1067, DOI 10.1001/archinte.158.10.1067; Wennberg John E, 2002, Health Aff (Millwood), VSuppl Web Exclusives, pW96; Yamokoski LM, 2007, J CARD FAIL, V13, P8, DOI 10.1016/j.cardfail.2006.10.002; Zuckerman S, 2010, NEW ENGL J MED, V363, P54, DOI 10.1056/NEJMsa0909253	53	199	203	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2287	2295		10.1056/NEJMsa1101942	http://dx.doi.org/10.1056/NEJMsa1101942			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	861PN	22168643				2023-01-03	WOS:000298031800009
J	Ellis, L; Lehet, K; Ramakrishnan, S; Adelaiye, R; Miles, KM; Wang, D; Liu, S; Atadja, P; Carducci, MA; Pili, R				Ellis, Leigh; Lehet, Kristin; Ramakrishnan, Swathi; Adelaiye, Remi; Miles, Kiersten M.; Wang, Dan; Liu, Song; Atadja, Peter; Carducci, Michael A.; Pili, Roberto			Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITOR; PROSTATE-CANCER; MAMMALIAN TARGET; C-MYC; ANGIOGENESIS; COMBINATION; VORINOSTAT; CARCINOMA; RAPAMYCIN; PROTEINS	Specific inhibitors towards Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin Complex 1 (mTORC1) have been developed and demonstrate potential as treatments for patients with advanced and/or metastatic and castrate resistant prostate cancer (PCa). Further, deregulation of HDAC expression and mTORC1 activity are documented in PCa and provide rational targets to create new therapeutic strategies to treat PCa. Here we report the use of the c-Myc adenocarcinoma cell line from the c-Myc transgenic mouse with prostate cancer to evaluate the in vitro and in vivo antitumor activity of the combination of the HDAC inhibitor panobinostat with the mTORC1 inhibitor everolimus. Panobinostat/everolimus combination treatment resulted in significantly greater antitumor activity in mice bearing androgen sensitive Myc-CaP and castrate resistant Myc-CaP tumors compared to single treatments. We identified that panobinostat/everolimus combination resulted in enhanced anti-tumor activity mediated by decreased tumor growth concurrent with augmentation of p21 and p27 expression and the attenuation of angiogenesis and tumor proliferation via androgen receptor, c-Myc and HIF-1 alpha signaling. Also, we observed altered expression of microRNAs associated with these three transcription factors. Overall, our results demonstrate that low dose concurrent panobinostat/everolimus combination therapy is well tolerated and results in greater anti-tumor activity compared to single treatments in tumor bearing immuno-competent mice. Finally, our results suggest that response of selected miRs could be utilized to monitor panobinostat/everolimus in vivo activity.	[Ellis, Leigh; Lehet, Kristin; Ramakrishnan, Swathi; Adelaiye, Remi; Miles, Kiersten M.; Pili, Roberto] Roswell Pk Canc Inst, Grace Canc Drug Ctr, Genitourinary Program, Buffalo, NY 14263 USA; [Wang, Dan; Liu, Song] Roswell Pk Canc Inst, Dept Bioinformat, Buffalo, NY 14263 USA; [Atadja, Peter] Novartis Biomed Res Inst, Shanghai, Peoples R China; [Carducci, Michael A.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine	Ellis, L (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Genitourinary Program, Buffalo, NY 14263 USA.	Roberto.pili@roswellpark.org	Carducci, Michael/R-8164-2019; Ramakrishnan, Swathi/O-5054-2019	Adelaiye-Ogala, Remi/0000-0002-6581-7359	Department of Defense [PC040800]; National Cancer Institute [P50CA58236]; NCI [P30CA16056]; NATIONAL CANCER INSTITUTE [P50CA058236, P30CA006973, P30CA016056] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding provided by the Department of Defense-PC040800 (to LE) and the National Cancer Institute-P50CA58236 (to RP and MC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; In vivo bioluminescence imaging studies were performed through the Shared Tumor imaging Resource at Roswell Park Cancer Institute supported by NCI P30CA16056 (Trump, DL). We kindly thank past and present members of the Pili laboratory for insightful discussions.	Abbas A, 2008, EPIGENETICS-US, V3, P300, DOI 10.4161/epi.3.6.7273; Atadja P, 2004, CANCER RES, V64, P689, DOI 10.1158/0008-5472.CAN-03-2043; Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Bradley D, 2009, CANCER-AM CANCER SOC, V115, P5541, DOI 10.1002/cncr.24597; Chiong E, 2011, CLIN CANCER RES, V17, P2863, DOI 10.1158/1078-0432.CCR-09-3202; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Ellis L, 2011, PROSTATE; Ellis L, 2008, CLIN CANCER RES, V14, P4500, DOI 10.1158/1078-0432.CCR-07-4262; Ellis L, 2010, PHARMACEUTICALS, V3, P2441, DOI 10.3390/ph3082441; Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Emmenegger U, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.tps246; Evren S, 2010, PROSTATE, V70, P1429, DOI 10.1002/pros.21178; Garcia JA, 2008, MOL CANCER THER, V7, P1347, DOI 10.1158/1535-7163.MCT-07-2408; Glaser KB, 2003, MOL CANCER THER, V2, P151; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Gurel B, 2008, ADV ANAT PATHOL, V15, P319, DOI 10.1097/PAP.0b013e31818a5c19; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hao Y, 2011, CANC INVEST; Hwang JJ, 2010, J UROLOGY, V184, P2557, DOI 10.1016/j.juro.2010.07.035; Iacopino F, 2008, INT J ONCOL, V32, P1293; Jans J, 2010, UROLOGY, V75, P786, DOI 10.1016/j.urology.2009.08.024; Kaarbo M, 2010, CELL ONCOL, V32, P11, DOI 10.3233/CLO-2009-0487; Kim JW, 2010, CANCER RES, V70, P4820, DOI 10.1158/0008-5472.CAN-10-0659; Kramer OH, 2008, ONCOGENE, V27, P732, DOI 10.1038/sj.onc.1210677; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; Kulshreshtha R, 2007, CELL CYCLE, V6, P1426; Kumar-Sinha C, 2008, NAT REV CANCER, V8, P497, DOI 10.1038/nrc2402; Litvinov IV, 2003, J CLIN ENDOCR METAB, V88, P2972, DOI 10.1210/jc.2002-022038; Mahalingam D, 2010, CLIN CANCER RES, V16, P141, DOI 10.1158/1078-0432.CCR-09-1385; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pesta M, 2010, ANTICANCER RES, V30, P3579; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Qian DZ, 2004, CANCER RES, V64, P6626, DOI 10.1158/0008-5472.CAN-04-0540; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Rai JS, 2010, UROL ONCOL-SEMIN ORI, V28, P134, DOI 10.1016/j.urolonc.2009.03.023; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Ryan BM, 2009, CANCER TREAT REV, V35, P553, DOI 10.1016/j.ctrv.2009.05.003; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schayowitz A, 2010, BRIT J CANCER, V103, P1001, DOI 10.1038/sj.bjc.6605882; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Tessel MA, 2010, CURR OPIN ONCOL, V22, P592, DOI 10.1097/CCO.0b013e32833ea80c; Verheul HMW, 2008, CLIN CANCER RES, V14, P3589, DOI 10.1158/1078-0432.CCR-07-4306; Wang LG, 2008, INT J ONCOL, V33, P375, DOI 10.3892/ijo_00000018; Watson PA, 2005, CANCER RES, V65, P11565, DOI 10.1158/0008-5472.CAN-05-3441; Wedel S, 2011, LIFE SCI, V88, P418, DOI 10.1016/j.lfs.2010.12.017; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Wu Y, 2010, ANTICANCER RES, V30, P3895; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246	59	14	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2011	6	11							e27178	10.1371/journal.pone.0027178	http://dx.doi.org/10.1371/journal.pone.0027178			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HH	22087262	Green Published, gold, Green Submitted			2023-01-03	WOS:000297347700026
J	Cheng, LH; Jin, CM; Lv, W; Ding, QP; Han, X				Cheng, Lihua; Jin, Chengmeng; Lv, Wen; Ding, Qiuping; Han, Xu			Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian Cancer	PLOS ONE			English	Article							SOLID LIPID NANOPARTICLES; TOXICITY; RELEASE; DRUGS; CIS-DICHLORODIAMMINEPLATINUM(II); FORMULATION; LIPOSOMES; CARCINOMA; CELLS	Background: Cisplatin is a potent anticancer drug, but its clinical application has been limited due to its undesirable physicochemical characteristics and severe side effects. Better drug formulations for cisplatin are highly desired. Methodology/Principal Findings: Herein, we have developed a nanoparticle formulation for cisplatin with high encapsulation efficiency and reduced toxicity by using cisplatin-crosslinked carboxymethyl cellulose (CMC) core nanoparticles made from poly(lactide-co-glycolide)-monomethoxy-poly(polyethylene glycol) copolymers (PLGA-mPEG). The nanoparticles have an average diameter of approximately 80 nm measured by transmission electron microscope (TEM). The encapsulation efficiency of cisplatin in the nanoparticles is up to 72%. Meanwhile, we have also observed a controlled release of cisplatin in a sustained manner and dose-dependent treatment efficacy of cisplatin-loaded nanoparticles against IGROV1-CP cells. Moreover, the median lethal dose (LD50) of the cisplatin-loaded nanoparticles was more than 100 mg/kg by intravenous administration, which was much higher than that of free cisplatin. Conclusion: This developed cisplatin-loaded nanoparticle is a promising formulation for the delivery of cisplatin, which will be an effective therapeutic regimen of ovarian cancer without severe side effects and cumulative toxicity.	[Cheng, Lihua; Jin, Chengmeng; Ding, Qiuping; Han, Xu] Zhejiang Univ, Zhejiang California Int NanoSyst Inst, Hangzhou, Zhejiang, Peoples R China; [Lv, Wen] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Cheng, LH (corresponding author), Zhejiang Univ, Zhejiang California Int NanoSyst Inst, Hangzhou, Zhejiang, Peoples R China.	chenglihua75@gmail.com			China International Science and Technology Cooperation Foundation [2007DFC30306]; Zhejiang Province Technology Project Foundation [2009C11122]	China International Science and Technology Cooperation Foundation; Zhejiang Province Technology Project Foundation	The authors acknowledge support from the China International Science and Technology Cooperation Foundation (2007DFC30306, http://www.cistc.gov.cn/), and the Zhejiang Province Technology Project Foundation (2009C11122, http://www.zjkjt.gov.cn/html/index.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avgoustakis K, 2002, J CONTROL RELEASE, V79, P123, DOI 10.1016/S0168-3659(01)00530-2; Boulikas T, 2004, ONCOL REP, V11, P559; Boulikas T, 2009, EXPERT OPIN INV DRUG, V18, P1197, DOI 10.1517/13543780903114168; Cuong NV, 2009, CURR DRUG METAB, V10, P842, DOI 10.2174/138920009790274586; Doijad RC, 2008, INDIAN J PHARM SCI, V70, P203, DOI 10.4103/0250-474X.41456; Elvira C, 1997, J MATER SCI-MATER M, V8, P743, DOI 10.1023/A:1018504410878; Bosch ME, 2008, J PHARMACEUT BIOMED, V47, P451, DOI 10.1016/j.jpba.2008.01.047; Fujiyama J, 2003, J CONTROL RELEASE, V89, P397, DOI 10.1016/S0168-3659(03)00131-7; Gryparis EC, 2007, EUR J PHARM BIOPHARM, V67, P1, DOI 10.1016/j.ejpb.2006.12.017; Hirai M, 2010, INT J PHARMACEUT, V391, P274, DOI 10.1016/j.ijpharm.2010.02.030; Iseri S, 2007, TOXICOLOGY, V230, P256, DOI 10.1016/j.tox.2006.11.073; Jakupec MA, 2003, REV PHYSIOL BIOCH P, V146, P1, DOI 10.1007/s10254-002-0001-x; Jeong JH, 2000, COLLOID SURFACE B, V18, P371, DOI 10.1016/S0927-7765(99)00162-9; LAMBERT HE, 1985, BRIT MED J, V290, P889, DOI 10.1136/bmj.290.6472.889; Marsh S, 2007, J CLIN ONCOL, V25, P4528, DOI 10.1200/JCO.2006.10.4752; Miyamoto Yohei, 2007, J Toxicol Sci, V32, P311, DOI 10.2131/jts.32.311; Moreno D, 2008, EUR J PHARM BIOPHARM, V68, P503, DOI 10.1016/j.ejpb.2007.08.006; Nishiyama N, 2001, J CONTROL RELEASE, V74, P83, DOI 10.1016/S0168-3659(01)00314-5; Nosko M. M., 2010, Experimental Oncology, V32, P40; Sahin K, 2010, NUTR CANCER, V62, P988, DOI 10.1080/01635581.2010.509838; Takei T, 2005, J NUCL MED, V46, P794; Tian J, 2008, PHARMAZIE, V63, P593, DOI 10.1691/ph.2008.8017; Verma Anita K., 2008, Current Drug Delivery, V5, P120, DOI 10.2174/156720108783954806; WILTSHAW E, 1976, CANCER TREAT REP, V60, P55; Xiao CJ, 2004, J PHARM SCI-US, V93, P1718, DOI 10.1002/jps.20086	25	43	45	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2011	6	9							e25433	10.1371/journal.pone.0025433	http://dx.doi.org/10.1371/journal.pone.0025433			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BK	21966528	Green Published, Green Submitted, gold			2023-01-03	WOS:000295932100040
J	Nijhof, SL; Bleijenberg, G; Uiterwaal, CSPM; Kimpen, JLL; van de Putte, EM				Nijhof, Sanne L.; Bleijenberg, Gijs; Uiterwaal, Cuno S. P. M.; Kimpen, Jan L. L.; van de Putte, Elise M.			Effectiveness of internet-based cognitive behavioural treatment for adolescents with chronic fatigue syndrome (FITNET): a randomised controlled trial	LANCET			English	Article							CLINICAL-TRIAL; THERAPY; CHILDREN; EPIDEMIOLOGY; POPULATION; PREVALENCE; CHILDHOOD; ANXIETY	Background Chronic fatigue syndrome is characterised by persistent fatigue and severe disability. Cognitive behavioural therapy seems to be a promising treatment, but its availability is restricted. We developed Fatigue In Teenagers on the interNET (FITNET), the first dedicated internet-based therapeutic program for adolescents with this disorder, and compared its effectiveness with that of usual care. Methods Adolescents aged 12-18 years with chronic fatigue syndrome were assigned to FITNET or usual care in a 1: 1 ratio at one tertiary treatment centre in the Netherlands by use of a computer-generated blocked randomisation allocation schedule. The study was open label. Primary outcomes were school attendance, fatigue severity, and physical functioning, and were assessed at 6 months with computerised questionnaires. Analysis was by intention to treat. Thereafter, all patients were offered FITNET if needed. This trial is registered, number ISRCTN59878666. Findings 68 of 135 adolescents were assigned to FITNET and 67 to usual care, and 67 and 64, respectively, were analysed. FITNET was significantly more effective than was usual care for all dichotomised primary outcomes at 6 months-full school attendance (50 [75%] vs 10 [16%], relative risk 4.8, 95% CI 2.7-8.9; p<0.0001), absence of severe fatigue (57 [85%] vs 17 [27%], 3.2, 2.1-4.9; p<0.0001), and normal physical functioning (52 [78%] vs 13 [20%], 3.8, 2.3-6.3; p<0.0001). No serious adverse events were reported. Interpretation FITNET offers a readily accessible and highly effective treatment for adolescents with chronic fatigue syndrome. The results of this study justify implementation on a broader scale.	[Nijhof, Sanne L.; Kimpen, Jan L. L.; van de Putte, Elise M.] Univ Med Ctr Utrecht, Dept Paediat, Wilhelmina Childrens Hosp, NL-3508 AB Utrecht, Netherlands; [Uiterwaal, Cuno S. P. M.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 AB Utrecht, Netherlands; [Bleijenberg, Gijs] Radboud Univ Nijmegen, Med Ctr, Expert Ctr Chron Fatigue, NL-6525 ED Nijmegen, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	Nijhof, SL (corresponding author), Univ Med Ctr Utrecht, Dept Paediat, Off KE 04-133-1,Postbox 85090, NL-3508 AB Utrecht, Netherlands.	s.l.nijhof@umcutrecht.nl	Nijhof, Sanne/ABG-4294-2020; Bleijenberg, Gijs/E-6984-2010	Nijhof, Sanne/0000-0003-1538-5014; 	Netherlands Organisation for Health Research and Development [ZonMW 60-60800-98-013]	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This study was funded by the Netherlands Organisation for Health Research and Development (ID ZonMW 60-60800-98-013). We thank the patients and their parents who took part in this study, and Annemarie Gerritsen, Henriette Vermeer, Pauline Koetsier, Thea Berends, and Dennis Marcelissen who administered the therapy.	Bell DS, 2001, PEDIATRICS, V107, P994; Bleijenberg G., 2003, HDB CHRONIC FATIGUE, P493; Chalder T, 2003, BRIT MED J, V327, P654, DOI 10.1136/bmj.327.7416.654; Chalder T, 2010, PSYCHOL MED, V40, P1269, DOI 10.1017/S003329170999153X; Chalder T, 2002, ARCH DIS CHILD, V86, P95, DOI 10.1136/adc.86.2.95; Crawley E, 2009, ARCH DIS CHILD, V94, P752, DOI 10.1136/adc.2008.143537; Cuijpers P, 2008, J BEHAV MED, V31, P169, DOI 10.1007/s10865-007-9144-1; Dowsett E. J., 1997, J CHRONIC FATIGUE SY, V3, P29, DOI DOI 10.1300/J092V03N02_; Emmelkamp PMG, 2005, PSYCHOTHER PSYCHOSOM, V74, P336, DOI 10.1159/000087780; Farmer A, 2004, BRIT J PSYCHIAT, V184, P477, DOI 10.1192/bjp.184.6.477; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Jones JF, 2004, J ADOLESCENT HEALTH, V35, P34, DOI [10.1016/j.jadohealth.2003.09.007, 10.1016/S1054-139X(03)00372-0]; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Marshall GS, 1999, J PEDIATR-US, V134, P395, DOI 10.1016/S0022-3476(99)70195-2; Nijhof SL, 2011, PEDIATRICS, V127, pE1169, DOI 10.1542/peds.2010-1147; Nijhof SL, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-23; O'Kearney Richard, 2006, Cognitive Behaviour Therapy, V35, P43, DOI 10.1080/16506070500303456; PAPAY JP, 1986, J ABNORM CHILD PSYCH, V14, P279, DOI 10.1007/BF00915446; Patten CA, 2006, PATIENT EDUC COUNS, V64, P249, DOI 10.1016/j.pec.2006.03.001; Prins JB, 2001, LANCET, V357, P841, DOI 10.1016/S0140-6736(00)04198-2; Raat H, 2002, QUAL LIFE RES, V11, P575, DOI 10.1023/A:1016393311799; Rangel L, 2000, J ROY SOC MED, V93, P129, DOI 10.1177/014107680009300306; Rimes KA, 2007, PEDIATRICS, V119, pE603, DOI 10.1542/peds.2006-2231; Ritterband LM, 2009, ANN BEHAV MED, V38, P18, DOI 10.1007/s12160-009-9133-4; Spence SH, 2006, J CONSULT CLIN PSYCH, V74, P614, DOI 10.1037/0022-006X.74.3.614; Stulemeijer M, 2005, BMJ-BRIT MED J, V330, P14, DOI 10.1136/bmj.38301.587106.63; Tate DF, 2009, ANN BEHAV MED, V38, P40, DOI 10.1007/s12160-009-9131-6; Trautmann E, 2010, BEHAV RES THER, V48, P28, DOI 10.1016/j.brat.2009.09.004; Tummers M, 2010, J CONSULT CLIN PSYCH, V78, P724, DOI 10.1037/a0020052; van Geelen SM, 2007, CLIN PSYCHOL REV, V27, P885, DOI 10.1016/j.cpr.2007.01.010; van Geelen SM, 2010, ARCH PEDIAT ADOL MED, V164, P810, DOI 10.1001/archpediatrics.2010.145; Vercoulen JHMM, 1998, J PSYCHOSOM RES, V45, P507, DOI 10.1016/S0022-3999(98)00023-3; Vercoulen JHMM, 1996, LANCET, V347, P858, DOI 10.1016/S0140-6736(96)91345-8; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X	34	137	137	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 14	2012	379	9824					1412	1418		10.1016/S0140-6736(12)60025-7	http://dx.doi.org/10.1016/S0140-6736(12)60025-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	926BR	22385683				2023-01-03	WOS:000302806800029
J	Hoch, DB; Watson, AJ; Linton, DA; Bello, HE; Senelly, M; Milik, MT; Baim, MA; Jethwani, K; Fricchione, GL; Benson, H; Kvedar, JC				Hoch, Daniel B.; Watson, Alice J.; Linton, Deborah A.; Bello, Heather E.; Senelly, Marco; Milik, Mariola T.; Baim, Margaret A.; Jethwani, Kamal; Fricchione, Gregory L.; Benson, Herbert; Kvedar, Joseph C.			The Feasibility and Impact of Delivering a Mind-Body Intervention in a Virtual World	PLOS ONE			English	Article							RELAXATION RESPONSE; BEHAVIORAL TREATMENT; INTERNET; MEDITATION; PROGRAM; DISEASE; STRESS; TRIAL	Introduction: Mind-body medical approaches may ameliorate chronic disease. Stress reduction is particularly helpful, but face-to-face delivery systems cannot reach all those who might benefit. An online, 3-dimensional virtual world may be able to support the rich interpersonal interactions required of this approach. In this pilot study, we explore the feasibility of translating a face-to-face stress reduction program into an online virtual setting and estimate the effect size of the intervention. Methods and Findings: Domain experts in virtual world technology joined with mind body practitioners to translate an existing 8 week relaxation response-based resiliency program into an 8-week virtual world-based program in Second Life (TM) (SL). Twenty-four healthy volunteers with at least one month's experience in SL completed the program. Each subject filled out the Perceived Stress Scale (PSS) and the Symptom Checklist 90-Revised (SCL-90-R) before and after taking part. Participants took part in one of 3 groups of about 10 subjects. The participants found the program to be helpful and enjoyable. Many reported that the virtual environment was an excellent substitute for the preferred face-to-face approach. On quantitative measures, there was a general trend toward decreased perceived stress, (15.7 to 15.0), symptoms of depression, (57.6 to 57.0) and anxiety (56.8 to 54.8). There was a significant decrease of 2.8 points on the SCL-90-R Global Severity Index (p < 0.05). Conclusions: This pilot project showed that it is feasible to deliver a typical mind-body medical intervention through a virtual environment and that it is well received. Moreover, the small reduction in psychological distress suggests further research is warranted. Based on the data collected for this project, a randomized trial with less than 50 subjects would be appropriately powered if perceived stress is the primary outcome.	[Hoch, Daniel B.; Milik, Mariola T.; Baim, Margaret A.; Fricchione, Gregory L.; Benson, Herbert] Benson Henry Inst Mind Body Med, Boston, MA USA; [Jethwani, Kamal; Kvedar, Joseph C.] Partners Healthcare, Ctr Connected Hlth, Boston, MA USA; [Hoch, Daniel B.; Watson, Alice J.; Jethwani, Kamal; Fricchione, Gregory L.; Kvedar, Joseph C.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Hoch, Daniel B.; Baim, Margaret A.; Jethwani, Kamal; Fricchione, Gregory L.; Benson, Herbert; Kvedar, Joseph C.] Harvard Univ, Sch Med, Boston, MA USA; [Bello, Heather E.] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; [Linton, Deborah A.] Hlth 20, San Francisco, CA USA; [Senelly, Marco] OneVis Solut Inc, Austin, TX USA	Partners Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Hoch, DB (corresponding author), Benson Henry Inst Mind Body Med, Boston, MA USA.	dhoch@partners.org		Hoch, Daniel/0000-0002-4294-024X; Milik, Mariola/0000-0002-5859-4935	Partners Healthcare Information Systems Research Council	Partners Healthcare Information Systems Research Council	This research was supported by a grant from the Partners Healthcare Information Systems Research Council. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beard L, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1192; BEARY JF, 1974, PSYCHOSOM MED, V36, P115, DOI 10.1097/00006842-197403000-00003; Bee PE, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-60; BENSON H, 1975, LANCET, V2, P380, DOI 10.1016/S0140-6736(75)92895-0; BENSON H, 1978, PSYCHOTHER PSYCHOSOM, V30, P229, DOI 10.1159/000287304; BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; BENSON H, 1978, J HUM STRESS, V4, P38, DOI 10.1080/0097840X.1978.9934985; Boulos MNK, 2007, HEALTH INFO LIBR J, V24, P233, DOI [10.1111/j.1471-1842.2007.00733.x, 10.1111/J.1471-1842.2007.00733.x]; Cannon WB., 1915, BODILY CHANGES PAIN; Carlbring P, 2003, J BEHAV THER EXP PSY, V34, P129, DOI 10.1016/S0005-7916(03)00026-0; CAUDILL M, 1991, CLIN J PAIN, V7, P305, DOI 10.1097/00002508-199112000-00009; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Cohen S, 2011, J APPL SOCI IN PRESS; Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685; Cuijpers P, 2008, J BEHAV MED, V31, P169, DOI 10.1007/s10865-007-9144-1; DOMAR AD, 1990, FERTIL STERIL, V53, P246; Esch Tobias, 2003, Med Sci Monit, V9, pRA23; GOODALE IL, 1990, OBSTET GYNECOL, V75, P649; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Holzel BK, 2010, SOC COGN AFFECT NEUR, V5, P11, DOI 10.1093/scan/nsp034; HOFFMAN JW, 1982, SCIENCE, V215, P190, DOI 10.1126/science.7031901; Jacobs GD, 1996, BIOFEEDBACK SELF-REG, V21, P121, DOI 10.1007/BF02284691; JACOBS GD, 1993, BEHAV MODIF, V17, P498, DOI 10.1177/01454455930174005; Jacobs GD, 2001, J ALTERN COMPLEM MED, V7, pS93; Jacobs GD, 1996, AM J MED, V100, P212, DOI 10.1016/S0002-9343(97)89461-2; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lazar SW, 2000, NEUROREPORT, V11, P1581, DOI 10.1097/00001756-200005150-00041; Mandle C L, 1996, J Cardiovasc Nurs, V10, P4; Samuelson M, 2010, J ALTERN COMPLEM MED, V16, P187, DOI 10.1089/acm.2009.0142; Stefano GB, 2001, PHARMACOL RES, V43, P199, DOI 10.1006/phrs.2000.0765; WALLACE RK, 1971, AM J PHYSIOL, V221, P795, DOI 10.1152/ajplegacy.1971.221.3.795	31	24	24	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2012	7	3							e33843	10.1371/journal.pone.0033843	http://dx.doi.org/10.1371/journal.pone.0033843			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	948FM	22470483	gold, Green Published			2023-01-03	WOS:000304489000039
J	Weksberg, DC; Bilton, SD; Chang, EL				Weksberg, David C.; Bilton, Stephen D.; Chang, Eric L.			Use of a Deformable Atlas to Identify Cryptic Critical Structures in the Treatment of Glioblastoma Multiforme	PLOS ONE			English	Article							RADIATION-THERAPY; ADJUVANT TEMOZOLOMIDE; BRAIN RADIOTHERAPY; PHASE-III; TRIAL; OLIGODENDROGLIOMA; CONCOMITANT; HIPPOCAMPUS; METASTASES	Dose constraints for traditional neural critical structures (e.g. optic chiasm, brain stem) are a standard component of planning radiation therapy to the central nervous system. Increasingly, investigators are becoming interested in accounting for the dose delivered to other non-target neural structures (e.g. hippocampi), which are not easily identified on axial imaging. In this pilot study, a commercially available digital atlas was used to identify cryptic neural structures (hippocampus, optic radiations, and visual cortices) in 6 patients who received intensity modulated radiation therapy (IMRT) as part of multimodal management of glioblastoma multiforme (GBM). The patient's original IMRT plans were re-optimized, with avoidance parameters for the newly identified critical structures. Re-optimization was able to reduce both mean and maximum dose to the volumes of interest, with a more pronounced effect for contralateral structures. Mean dose was reduced by 11% and 3% to contralateral and ipsilateral structures, respectively, with comparable reduction in maximum dose of 10% and 2%, respectively. Importantly, target coverage was not compromised, with an average change in coverage of 0.2%. Overall, our results demonstrate the feasibility of incorporating tools for cryptic critical structure identification into the treatment planning process for GBM.	[Weksberg, David C.; Bilton, Stephen D.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Chang, Eric L.] Univ So Calif, Keck Sch Med, Norris Canc Hosp, Dept Radiat Oncol, Los Angeles, CA 90033 USA	University of Texas System; UTMD Anderson Cancer Center; University of Southern California	Weksberg, DC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.	eric.L.chang@usc.edu						Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483; Butler EB, 2007, CANCER INVEST, V25, P1, DOI 10.1080/07357900600970490; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Central Brain Tumor Registry of the United States, 2011, PRIM BRAIN CENTR NER; Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3; Chera BS, 2009, AM J CLIN ONCOL-CANC, V32, P20, DOI 10.1097/COC.0b013e318178e4e8; Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745, DOI 10.1016/S0360-3016(96)00619-0; Gondi V, 2010, INT J RADIAT ONCOL, V78, P1244, DOI 10.1016/j.ijrobp.2010.01.039; Hamilton JD, J COMPUTER IN PRESS; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Marsh JC, 2011, J MED IMAG RADIAT ON, V55, P442, DOI 10.1111/j.1754-9485.2011.02282.x; Rosenschold PM, ACTA ONCOL, V50, P777; Shah GD, 2007, J CLIN ONCOL, V25, P4730, DOI 10.1200/JCO.2007.12.5062; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; van den Bent MJ, 2003, CANCER-AM CANCER SOC, V97, P1276, DOI 10.1002/cncr.11187; Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497	18	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2012	7	3							e32098	10.1371/journal.pone.0032098	http://dx.doi.org/10.1371/journal.pone.0032098			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	943KB	22461883	Green Submitted, Green Published, gold			2023-01-03	WOS:000304118900002
J	Wu, VC; Lai, CF; Shiao, CC; Lin, YF; Wu, PC; Chao, CT; Hu, FC; Huang, TM; Yeh, YC; Tsai, IJ; Kao, TW; Han, YY; Wu, WC; Hou, CC; Young, GH; Ko, WJ; Tsai, TJ; Wu, KD				Wu, Vin-Cent; Lai, Chun-Fu; Shiao, Chih-Chung; Lin, Yu-Feng; Wu, Pei-Chen; Chao, Chia-Ter; Hu, Fu-Chang; Huang, Tao-Min; Yeh, Yu-Chang; Tsai, I-Jung; Kao, Tze-Wah; Han, Yin-Yi; Wu, Wen-Chung; Hou, Chun-Cheng; Young, Guang-Huar; Ko, Wen-Je; Tsai, Tun-Jun; Wu, Kwan-Dun			Effect of Diuretic Use on 30-Day Postdialysis Mortality in Critically Ill Patients Receiving Acute Dialysis	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; REPLACEMENT THERAPY; DOUBLE-BLIND; HEART-FAILURE; RISK-FACTORS; FUROSEMIDE; SURVIVAL; HEMOFILTRATION; DYSFUNCTION; DOPAMINE	Background: The impact of diuretic usage and dosage on the mortality of critically ill patients with acute kidney injury is still unclear. Methods and Results: In this prospective, multicenter, observational study, 572 patients with postsurgical acute kidney injury receiving hemodialysis were recruited and followed daily. Thirty-day postdialysis mortality was analyzed using Cox's proportional hazards model with time-dependent covariates. The mean age of the 572 patients was 60.8 +/- 16.6 years. Patients with lower serum creatinine (p = 0.031) and blood lactate (p = 0.033) at ICU admission, lower predialysis urine output (p = 0.001) and PaO2/FiO(2) (p = 0.039), as well as diabetes (p = 0.037) and heart failure (p = 0.049) were more likely to receive diuretics. A total of 280 (49.0%) patients died within 30 days after acute dialysis initiation. The analysis of 30-day postdialysis mortality by fitting propensity score-adjusted Cox's proportional hazards models with time-dependent covariates showed that higher 3-day accumulated diuretic doses after dialysis initiation (HR = 1.449, p = 0.021) could increase the hazard rate of death. Moreover, higher time-varying 3-day accumulative diuretic doses were associated with hypotension (p<0.001) and less intense hemodialysis (p<0.001) during the acute dialysis period. Background and Significance: Higher time-varying 3-day accumulative diuretic dose predicts mortality in postsurgical critically ill patients requiring acute dialysis. Higher diuretic doses are associated with hypotension and a lower intensity of dialysis. Caution should be employed before loop diuretics are administered to postsurgical patients during the acute dialysis period.	[Wu, Vin-Cent; Lai, Chun-Fu; Wu, Pei-Chen; Chao, Chia-Ter; Kao, Tze-Wah; Tsai, Tun-Jun; Wu, Kwan-Dun] Natl Taiwan Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan; [Shiao, Chih-Chung] St Marys Hosp, Div Nephrol, Dept Internal Med, Yilan, Taiwan; [Shiao, Chih-Chung] St Marys Med Nursing & Management Coll, Yilan, Taiwan; [Lin, Yu-Feng; Han, Yin-Yi; Young, Guang-Huar; Ko, Wen-Je] Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan; [Ko, Wen-Je] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Hu, Fu-Chang] Int Harvard Stat Consulting Co, Taipei, Taiwan; [Huang, Tao-Min] Dept Internal Med, Yun Lin Branch, Div Nephrol, Douliou City, Yun Lin County, Taiwan; [Yeh, Yu-Chang] Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tsai, I-Jung] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan; [Wu, Vin-Cent] NSARF Natl Taiwan Univ Hosp Study Grp Acute Renal, Taipei, Taiwan; [Wu, Wen-Chung] Miao Li Hosp, Sect Internal Med, Dept Hlth, Miaoli, Taiwan; [Hou, Chun-Cheng] Min Sheng Hosp, Dept Internal Med, Tao Yuan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Wu, VC (corresponding author), Natl Taiwan Univ Hosp, Div Nephrol, Dept Internal Med, Taipei, Taiwan.	kowj@ntu.edu.tw	Chao, Chia-Ter/H-7994-2019; Shiao, Chih-Chung/AAM-2716-2020; Huang, Tao Min/C-5379-2011	Chao, Chia-Ter/0000-0003-2892-7986; Shiao, Chih-Chung/0000-0003-2220-7574; Huang, Tao Min/0000-0002-9387-0798; LIN, YU-FENG/0000-0002-4350-7755; Tsai, I-Jung/0000-0003-3967-9412; HAN, YIN-YI/0000-0001-8831-7835; TSAI, TUN-JUN/0000-0002-1666-8940; Yeh, Yu-Chang/0000-0001-5143-5520; LAI, CHUN-FU/0000-0003-2109-1522; WU, VIN-CENT/0000-0001-7935-0991; WU, KWAN-DUN/0000-0002-3339-1509	Ta-Tung Kidney Foundation; Taiwan National Science Council [NSC 96-2314-B-002-164, NSC 96-2314-B-002-033-MY3, NSC 97-2314-B-002-155-MY2, NSC 98-2314-B-002-155-MY4];  [NTUH.098-001177];  [NTUH 100-001667]	Ta-Tung Kidney Foundation; Taiwan National Science Council(Ministry of Science and Technology, Taiwan); ; 	This study was supported by The Ta-Tung Kidney Foundation and Taiwan National Science Council (grant NSC 96-2314-B-002-164, NSC 96-2314-B-002-033-MY3, NSC 97-2314-B-002-155-MY2, NSC 98-2314-B-002-155-MY4) and NTUH.098-001177, NTUH 100-001667. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Berbece AN, 2006, KIDNEY INT; Bouchard J, 2009, KIDNEY INT, V76, P422, DOI 10.1038/ki.2009.159; Bragg-Gresham JL, 2007, AM J KIDNEY DIS, V49, P426, DOI 10.1053/j.ajkd.2006.12.012; Cantarovich F, 2004, AM J KIDNEY DIS, V44, P402, DOI 10.1053/j.ajkd.2004.05.021; CANTAROVICH F, 1973, BMJ-BRIT MED J, V4, P449, DOI 10.1136/bmj.4.5890.449; Chen YS, 2001, J HEART LUNG TRANSPL, V20, P850, DOI 10.1016/S1053-2498(01)00267-4; Chou YH, 2011, CRIT CARE, V15, DOI 10.1186/cc10252; Costanzo MR, 2007, J AM COLL CARDIOL, V49, P675, DOI 10.1016/j.jacc.2006.07.073; CUTLER RE, 1974, CLIN PHARMACOL THER, V15, P588; De Vecchis R, 2010, J CARDIOVASC MED, V11, P571, DOI 10.2459/JCM.0b013e32833d37b9; Dekker FW, 2008, KIDNEY INT, V74, P994, DOI 10.1038/ki.2008.328; DOCCI D, 1984, NEPHRON, V36, P74, DOI 10.1159/000183119; Elahi MM, 2004, EUR J CARDIO-THORAC, V26, P1027, DOI 10.1016/j.ejcts.2004.07.039; FRANCIS GS, 1985, ANN INTERN MED, V103, P1, DOI 10.7326/0003-4819-103-1-1; Huang TM, 2010, J AM SOC NEPHROL; Ko WJ, 2002, ANN THORAC SURG, V73, P538, DOI 10.1016/S0003-4975(01)03330-6; Lassnigg A, 2004, J AM SOC NEPHROL, V15, P1597, DOI 10.1097/01.ASN.0000130340.93930.DD; Lassnigg A, 2000, J AM SOC NEPHROL, V11, P97, DOI 10.1681/ASN.V11197; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Lindenauer PK, 2005, NEW ENGL J MED, V353, P349, DOI 10.1056/NEJMoa041895; Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005; Mehta RL, 2002, JAMA-J AM MED ASSOC, V288, P2547, DOI 10.1001/jama.288.20.2547; Metz Leah I, 2009, WMJ, V108, P109; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Reddy V G, 2002, J Postgrad Med, V48, P64; Shilliday IR, 1997, NEPHROL DIAL TRANSPL, V12, P2592, DOI 10.1093/ndt/12.12.2592; Stenestrand U, 2004, CIRCULATION, V110, P1896, DOI 10.1161/01.CIR.0000143136.51424.38; Tang Ignatius Y, 2004, Best Pract Res Clin Anaesthesiol, V18, P91, DOI 10.1016/j.bpa.2003.09.006; Uchino S, 2004, CRIT CARE MED, V32, P1669, DOI 10.1097/01.CCM.0000132892.51063.2F; Udani SM, 2009, SEMIN DIALYSIS, V22, P173, DOI 10.1111/j.1525-139X.2008.00542.x; van der Voort PHJ, 2009, CRIT CARE MED, V37, P533, DOI 10.1097/CCM.0b013e318195424d; Wijeysundera DN, 2006, ANESTHESIOLOGY, V104, P65, DOI 10.1097/00000542-200601000-00012; Woo MJ, 2008, STAT MED, V27, P3805, DOI 10.1002/sim.3278; Wu VC, 2006, CLIN INFECT DIS, V42, P66, DOI 10.1086/498509; Wu VC, 2011, KIDNEY INT IN PRESS; Wu VC, 2008, INTENS CARE MED, V34, P101, DOI 10.1007/s00134-007-0813-x; Wu VC, 2007, J AM COLL SURGEONS, V205, P266, DOI 10.1016/j.jamcollsurg.2007.04.006; Wu VC, 2010, AM J SURG, V199, P466, DOI 10.1016/j.amjsurg.2009.01.007; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	40	20	20	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2012	7	3							e30836	10.1371/journal.pone.0030836	http://dx.doi.org/10.1371/journal.pone.0030836			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931EO	22431960	Green Submitted, Green Published, gold			2023-01-03	WOS:000303198600003
J	Fee, C; Burstin, H; Maselli, JH; Hsia, RY				Fee, Christopher; Burstin, Helen; Maselli, Judith H.; Hsia, Renee Y.			Association of Emergency Department Length of Stay With Safety-Net Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING QUALITY; TIME; ANTIBIOTICS; ANALGESIA; VISITS; REFORM; IMPACT; PAIN	Context Performance measures, particularly pay for performance, may have unintended consequences for safety-net institutions caring for disproportionate shares of Medicaid or uninsured patients. Objective To describe emergency department (ED) compliance with proposed length-of-stay measures for admissions (8 hours or 480 minutes) and discharges, transfers, and observations (4 hours or 240 minutes) by safety-net status. Design, Setting, and Participants The 2008 National Hospital Ambulatory Medical Care Survey (NHAMCS) ED data were stratified by safety-net status (Centers for Disease Control and Prevention definition) and disposition (admission, discharge, observation, transfer). The 2008 NHAMCS is a national probability sample of 396 hospitals (90.2% unweighted response rate) and 34 134 patient records. Visits were excluded for patients younger than 18 years, missing length-of-stay data or dispositions of missing, other, left against medical advice, or dead on arrival. Median and 90th percentile ED lengths of stay were calculated for each disposition and admission/discharge sub-categories (critical care, psychiatric, routine) stratified by safety-net status. Multivariable analyses determined associations with length-of-stay measure compliance. Main Outcome Measures Emergency Department length-of-stay measure compliance by disposition and safety-net status. Results Of the 72.1% ED visits (N=24 719) included in the analysis, 42.3% were to safety-net EDs and 57.7% were to non-safety-net EDs. The median length of stay for safety-net was 269 minutes (interquartile range [IQR], 178-397 minutes) for admission vs 281 minutes (IQR, 178-401 minutes) for non-safety-net EDs; 156 minutes (IQR, 95-239 minutes) for discharge vs 148 minutes (IQR, 88-238 minutes); 355 minutes (IQR, 221-675 minutes) for observations vs 298 minutes (IQR, 195-440 minutes); and 235 minutes (IQR, 155-378 minutes) for transfers vs 239 minutes (IQR, 142-368 minutes). Safety-net status was not independently associated with compliance with ED length-of-stay measures; the odds ratio was 0.83 for admissions (95% CI, 0.52-1.34); 1.03 for discharges (95% CI, 0.83-1.27); 1.05 for observations (95% CI, 0.57-1.95), 1.30 for transfers (95% CI, 0.70-2.45]); or subcategories except for psychiatric discharges (1.67, [95% CI, 1.02-2.74]). Conclusion Compliance with proposed ED length-of-stay measures for admissions, discharges, transfers, and observations did not differ significantly between safety-net and non-safety-net hospitals. JAMA. 2012;307(5):476-482	[Fee, Christopher; Hsia, Renee Y.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA; [Maselli, Judith H.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Burstin, Helen] Natl Qual Forum, Washington, DC USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fee, C (corresponding author), Univ Calif San Francisco, Dept Emergency Med, 505 Parnassus Ave,POB 0208, San Francisco, CA 94143 USA.	christopher.fee@ucsf.edu			Google; NIH/NCRR/OD UCSF-CTSI [KL2 RR024130]; Robert Wood Johnson Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER	Google(Google Incorporated); NIH/NCRR/OD UCSF-CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The authors have completed and submitted the ICMJE form for Disclosure of Potential Conflicts of Interest. Dr Fee has reported that he received consultancy fees from Google and honoraria from the University of California, San Francisco Office of Continuing Medical Education for organizing and speaking at an annual CME course. Dr Burstin is a paid employee of the National Quality Forum. No other disclosures were reported.; This work was supported by grant KL2 RR024130 (Dr Hsia) from the NIH/NCRR/OD UCSF-CTSI and by the Robert Wood Johnson Foundation Physician Faculty Scholars Program (Dr Hsia).	Accreditation Council for Graduate Medical Education, EM MED GUID; [Anonymous], 2010, NAT HLTH HOSP NETW F; [Anonymous], 2009, NAT VOL CONS STAND E; Burt Catharine W, 2004, Vital Health Stat 13, P1; Carr BG, 2007, J TRAUMA, V63, P9, DOI 10.1097/TA.0b013e31805d8f6b; Centers for Disease Control and Prevention, NHAMCS EST PROC AMB; Centers for Disease Control and Prevention, 2010, NHAMCS SCOP SAMPL DE; Chang G, 2011, ANN EMERG MED, V58, P127, DOI 10.1016/j.annemergmed.2010.12.003; Fee C, 2007, ANN EMERG MED, V50, P501, DOI 10.1016/j.annemergmed.2007.08.003; Fee Christopher, 2007, Ann Emerg Med, V50, pe1, DOI 10.1016/j.annemergmed.2007.03.019; Graff L, 2002, ACAD EMERG MED, V9, P1091, DOI 10.1111/j.1553-2712.2002.tb01563.x; Healthcare Cost and Utilization Project, HEALTHC COST UT PROJ; Herring A, 2009, ACAD EMERG MED, V16, P609, DOI 10.1111/j.1553-2712.2009.00428.x; Kulstad EB, 2010, AM J EMERG MED, V28, P304, DOI 10.1016/j.ajem.2008.12.014; Mills AM, 2010, POSTGRAD MED, V122, P75, DOI 10.3810/pgm.2010.01.2101; Mills AM, 2009, ACAD EMERG MED, V16, P603, DOI 10.1111/j.1553-2712.2009.00441.x; Moskop JC, 2009, ANN EMERG MED, V53, P605, DOI 10.1016/j.annemergmed.2008.09.019; New Zealand Ministry of Health, EM DEP; Ontario Ministry of Health and Long-Term Care, ONT WAIT TIM EM ROOM; Pines JM, 2008, ACAD EMERG MED, V15, P825, DOI 10.1111/j.1553-2712.2008.00200.x; Pines JM, 2007, ANN EMERG MED, V50, P510, DOI 10.1016/j.annemergmed.2007.07.021; Pines JM, 2010, ACAD EMERG MED, V17, P834, DOI 10.1111/j.1553-2712.2010.00780.x; Pines JM, 2010, ACAD EMERG MED, V17, P276, DOI 10.1111/j.1553-2712.2009.00676.x; Pines JM, 2009, ACAD EMERG MED, V16, P617, DOI 10.1111/j.1553-2712.2009.00456.x; Pines JM, 2009, ACAD EMERG MED, V16, P403, DOI 10.1111/j.1553-2712.2009.00381.x; Sills MR, 2011, ANN EMERG MED, V57, P191, DOI 10.1016/j.annemergmed.2010.08.027; Smulowitz P, 2009, INTERN EMERG MED, V4, P501, DOI 10.1007/s11739-009-0313-9; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; Wang CJ, 2009, NEW ENGL J MED, V361, P1821, DOI 10.1056/NEJMp0907656; Weber EJ, 2011, ANN EMERG MED, V57, P79, DOI 10.1016/j.annemergmed.2010.08.013	30	41	41	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					476	482		10.1001/jama.2012.41	http://dx.doi.org/10.1001/jama.2012.41			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22298679	Bronze, Green Accepted			2023-01-03	WOS:000299728000028
J	Spence, D				Spence, Des			FROM THE FRONTLINE Bad medicine: medical nutrition	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						[Anonymous], NUTR SUPPORT ADULTS	1	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 18	2012	344								e451	10.1136/bmj.e451	http://dx.doi.org/10.1136/bmj.e451			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257980				2023-01-03	WOS:000300041900007
J	Chen, VV; Staub, RE; Baggett, S; Chimmani, R; Tagliaferri, M; Cohen, I; Shtivelman, E				Chen, Vivian; Staub, Richard E.; Baggett, Scott; Chimmani, Ramesh; Tagliaferri, Mary; Cohen, Isaac; Shtivelman, Emma			Identification and Analysis of the Active Phytochemicals from the Anti-Cancer Botanical Extract Bezielle	PLOS ONE			English	Article							BREAST-CANCER; SCUTELLARIA-BARBATA; FLAVONOIDS; CELLS; MECHANISMS; APOPTOSIS; APIGENIN; BZL101; DIPHENYLENEIODONIUM; PREVENTION	Bezielle is a botanical extract that has selective anti-tumor activity, and has shown a promising efficacy in the early phases of clinical testing. Bezielle inhibits mitochondrial respiration and induces reactive oxygen species (ROS) in mitochondria of tumor cells but not in non-transformed cells. The generation of high ROS in tumor cells leads to heavy DNA damage and hyper-activation of PARP, followed by the inhibition of glycolysis. Bezielle therefore belongs to a group of drugs that target tumor cell mitochondria, but its cytotoxicity involves inhibition of both cellular energy producing pathways. We found that the cytotoxic activity of the Bezielle extract in vitro co-purified with a defined fraction containing multiple flavonoids. We have isolated several of these Bezielle flavonoids, and examined their possible roles in the selective anti-tumor cytotoxicity of Bezielle. Our results support the hypothesis that a major Scutellaria flavonoid, scutellarein, possesses many if not all of the biologically relevant properties of the total extract. Like Bezielle, scutellarein induced increasing levels of ROS of mitochondrial origin, progressive DNA damage, protein oxidation, depletion of reduced glutathione and ATP, and suppression of both OXPHOS and glycolysis. Like Bezielle, scutellarein was selectively cytotoxic towards cancer cells. Carthamidin, a flavonone found in Bezielle, also induced DNA damage and oxidative cell death. Two well known plant flavonoids, apigenin and luteolin, had limited and not selective cytotoxicity that did not depend on their pro-oxidant activities. We also provide evidence that the cytotoxicity of scutellarein was increased when other Bezielle flavonoids, not necessarily highly cytotoxic or selective on their own, were present. This indicates that the activity of total Bezielle extract might depend on a combination of several different compounds present within it.	[Chen, Vivian; Staub, Richard E.; Baggett, Scott; Chimmani, Ramesh; Tagliaferri, Mary; Cohen, Isaac; Shtivelman, Emma] BioNovo Inc, Emeryville, CA USA		Chen, VV (corresponding author), BioNovo Inc, Emeryville, CA USA.	emmas@bionovo.com			BioNovo, Inc.; BioNovo	BioNovo, Inc.; BioNovo	This research was supported entirely by BioNovo, Inc. The funder played a role in the decision to research Bezielle as an anti-cancer agent, but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors declare a financial competing interest. The authors acknowledge that they are paid employees and stock holders of BioNovo, Inc, and that this study, in its entirety, was supported by funds from BioNovo. Bezielle (BZL101) is Bionovo's proprietary botanical drug candidate (FDA-IND: 59,521) for the treatment of metastatic breast cancer. Bionovo's United States Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovo's proprietary BezielleR formulation as a monotherapy for the treatment of breast cancer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Chen D, 2008, INT J MOL SCI, V9, P1196, DOI 10.3390/ijms9071196; Choi SI, 2007, ARCH PHARM RES, V30, P1328, DOI 10.1007/BF02980274; de Kok TM, 2008, EUR J NUTR, V47, P51, DOI 10.1007/s00394-008-2006-y; Fong S, 2008, CANCER BIOL THER, V7, P577, DOI 10.4161/cbt.7.4.5535; Horvathova K, 2001, NEOPLASMA, V48, P435; Le Marchand L, 2002, BIOMED PHARMACOTHER, V56, P296, DOI 10.1016/S0753-3322(02)00186-5; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Min K, 2008, FOOD CHEM TOXICOL, V46, P96, DOI 10.1016/j.fct.2007.07.002; Miyoshi N, 2007, ARCH BIOCHEM BIOPHYS, V466, P274, DOI 10.1016/j.abb.2007.07.026; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Murphy MP, 2011, CELL METAB, V13, P361, DOI 10.1016/j.cmet.2011.03.010; Ohigashi H, 2004, BIOFACTORS, V22, P49, DOI 10.1002/biof.5520220109; Parajuli P, 2009, PLANTA MED, V75, P41, DOI 10.1055/s-0028-1088364; Perez AT, 2010, BREAST CANCER RES TR, V120, P111, DOI 10.1007/s10549-009-0678-5; Plaumann B, 1996, ONCOGENE, V13, P1605; Rugo H, 2007, BREAST CANCER RES TR, V105, P17, DOI 10.1007/s10549-006-9430-6; SARACOGLU I, 1995, BIOL PHARM BULL, V18, P1396, DOI 10.1248/bpb.18.1396; Seelinger G, 2008, PLANTA MED, V74, P1667, DOI 10.1055/s-0028-1088314; Shukla S, 2010, PHARM RES-DORDR, V27, P962, DOI 10.1007/s11095-010-0089-7; Vargo MA, 2006, BIOCHEM PHARMACOL, V72, P681, DOI 10.1016/j.bcp.2006.06.010; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Xing JF, 2011, ACTA PHARM SIN; Yao H, 2010, J ENV SCI HLTH C, V29, P1; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661; Zhang JL, 2003, J ASIAN NAT PROD RES, V5, P249, DOI 10.1080/1028602031000105858	26	30	35	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2012	7	1							e30107	10.1371/journal.pone.0030107	http://dx.doi.org/10.1371/journal.pone.0030107			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	907XU	22272282	Green Published, Green Submitted, gold			2023-01-03	WOS:000301454400060
J	Mongini, F; Evangelista, A; Milani, C; Ferrero, L; Ciccone, G; Ugolini, A; Piedimonte, A; Sigaudo, M; Carlino, E; Banzatti, E; Galassi, C				Mongini, Franco; Evangelista, Andrea; Milani, Chantal; Ferrero, Luca; Ciccone, Giovannino; Ugolini, Alessandro; Piedimonte, Alessandro; Sigaudo, Monica; Carlino, Elisa; Banzatti, Emanuela; Galassi, Claudia			An Educational and Physical Program to Reduce Headache, Neck/Shoulder Pain in a Working Community: A Cluster-Randomized Controlled Trial	PLOS ONE			English	Article							CHRONIC NECK PAIN; GENERAL-POPULATION; BACK-PAIN; BURDEN; CARE; PREVALENCE; EXERCISE	Background: Noninvasive physical management is often prescribed for headache and neck pain. Systematic reviews, however, indicate that the evidence of its efficacy is limited. Our aim was to evaluate the effectiveness of a workplace educational and physical program in reducing headache and neck/shoulder pain. Methodology/Principal Findings: Cluster-randomized controlled trial. All municipal workers of the City of Turin, Italy, were invited to participate. Those who agreed were randomly assigned, according to their departments, to the intervention group (IG) or to the control group and were given diaries for the daily recording of pain episodes for 1 month (baseline). Subsequently, only the IG (119 departments, 923 workers) began the physical and educational program, whereas the control group (117 departments, 990 workers) did not receive any intervention. All participants were again given diaries for the daily recording of pain episodes after 6 months of intervention. The primary outcome was the change in the frequency of headache (expressed as the proportion of subjects with a >= 50% reduction of frequency; responder rate); among the secondary outcomes there were the absolute reduction of the number of days per month with headache and neck/shoulder pain. Differences between the two groups were evaluated using mixed-effect regression models. The IG showed a higher responder rate [risk ratio, 95% confidence interval (CI)] for headache (1.58; 1.28 to 1.92) and for neck/shoulder pain (1.53; 1.27 to 1.82), and a larger reduction of the days per month (95% CI) with headache (-1.72; -2.40 to -1.04) and with neck/shoulder pain (-2.51; -3.56 to -1.47). Conclusions: The program effectively reduced headache and neck/shoulder pain in a large working community and appears to be easily transferable to primary-care settings. Further trials are needed to investigate the program effectiveness in a clinical setting, for highly selected patients suffering from specific headache types.	[Mongini, Franco; Milani, Chantal; Ferrero, Luca; Ugolini, Alessandro; Piedimonte, Alessandro; Sigaudo, Monica; Carlino, Elisa; Banzatti, Emanuela] Univ Turin, Sect Headache Facial Pain, Dept Clin Pathophysiol, Turin, Italy; [Evangelista, Andrea; Ciccone, Giovannino; Galassi, Claudia] San Giovanni Battista Hosp, Canc Epidemiol Unit, Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Mongini, F (corresponding author), Univ Turin, Sect Headache Facial Pain, Dept Clin Pathophysiol, Turin, Italy.	franco.mongini@unito.it	Ugolini, Alessandro/E-9375-2017; Milani, Chantal/GNP-6710-2022; evangelista, andrea/A-7802-2013; Galassi, Claudia/K-3041-2016; Ciccone, Giovannino/K-3136-2016; Carlino, Elisa/AFS-4092-2022	Ugolini, Alessandro/0000-0002-2062-6014; Milani, Chantal/0000-0001-5224-1808; Galassi, Claudia/0000-0003-1502-4390; Ciccone, Giovannino/0000-0001-7644-9574; Carlino, Elisa/0000-0001-8472-656X; evangelista, andrea/0000-0003-1901-2805; Piedimonte, Alessandro/0000-0002-5705-2173	Compagnia di San Paolo; Regione Piemonte	Compagnia di San Paolo(Compagnia di San Paolo); Regione Piemonte(Regione Piemonte)	The study was funded by the Compagnia di San Paolo and the Regione Piemonte. Dr. Evangelista was partially supported by Master of Epidemiology, University of Turin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Adams G, 2004, J CLIN EPIDEMIOL, V57, P785, DOI 10.1016/j.jclinepi.2003.12.013; Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; [Anonymous], 1986, Pain Suppl, V3, pS1; Biondi DM, 2005, HEADACHE, V45, P738, DOI 10.1111/j.1526-4610.2005.05141.x; Bronfort G, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001878.PUB2; Campbell M, 2000, J Health Serv Res Policy, V5, P12; Chiu TTW, 2005, SPINE, V30, pE1, DOI 10.1097/01.brs.0000149082.68262.b1; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Ghaffari M, 2006, SPINE, V31, P2500, DOI 10.1097/01.brs.0000239133.29037.d0; Grimmer K, 2006, CEPHALALGIA, V26, P843, DOI 10.1111/j.1468-2982.2006.01120.x; Gross AR, 2000, COCHRANE DB SYST REV; Haines T, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005106.pub3; Hogg-Johnson S, 2008, SPINE, V33, pS39, DOI 10.1097/BRS.0b013e31816454c8; Hoving JL, 2006, CLIN J PAIN, V22, P370, DOI 10.1097/01.ajp.0000180185.79382.3f; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Kay TM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004250.pub3; McKenzie JA, 2009, HEADACHE, V49, P669, DOI 10.1111/j.1526-4610.2009.01411.x; Mongini F, 2008, CEPHALALGIA, V28, P541, DOI 10.1111/j.1468-2982.2008.01551.x; Mongini F, 2009, J PAIN, V10, P1138, DOI 10.1016/j.jpain.2009.01.324; Niere Kennneth, 2004, Physiother Res Int, V9, P149, DOI 10.1002/pri.318; Rains JC, 2005, HEADACHE, V45, pS92, DOI 10.1111/j.1526-4610.2005.4502003.x; Riddle DL, 2007, SPINE, V32, P132, DOI 10.1097/01.brs.0000250999.69978.24; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Sjaastad O, 2006, ACTA NEUROL SCAND, V114, P392, DOI 10.1111/j.1600-0404.2006.00717.x; Sjogren T, 2005, PAIN, V116, P119, DOI 10.1016/j.pain.2005.03.031; Snijders T. A., 2012, MULTILEVEL ANAL INTR; Steiner TJ, 2004, LANCET NEUROL, V3, P204, DOI 10.1016/S1474-4422(04)00703-3; Stovner LJ, 2007, CEPHALALGIA, V27, P193, DOI 10.1111/j.1468-2982.2007.01288.x; Stovner LJ, 2006, EUR J NEUROL, V13, P333, DOI 10.1111/j.1468-1331.2006.01184.x; van den Brink M, 2001, HEADACHE, V41, P11, DOI 10.1046/j.1526-4610.2001.111006011.x; Viljanen M, 2003, BRIT MED J, V327, P475, DOI 10.1136/bmj.327.7413.475; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wiendels NJ, 2006, CEPHALALGIA, V26, P1434, DOI 10.1111/j.1468-2982.2006.01210.x; Ylinen J, 2003, JAMA-J AM MED ASSOC, V289, P2509, DOI 10.1001/jama.289.19.2509; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	35	20	23	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 9	2012	7	1							e29637	10.1371/journal.pone.0029637	http://dx.doi.org/10.1371/journal.pone.0029637			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	102TA	22253751	Green Published, gold, Green Submitted			2023-01-03	WOS:000315865800013
J	Perren, TJ; Swart, AM; Pfisterer, J; Ledermann, JA; Pujade-Lauraine, E; Kristensen, G; Carey, MS; Beale, P; Cervantes, A; Kurzeder, C; du Bois, A; Sehouli, J; Kimmig, R; Stahle, A; Collinson, F; Essapen, S; Gourley, C; Lortholary, A; Selle, F; Mirza, MR; Leminen, A; Plante, M; Stark, D; Qian, WD; Parmar, MKB; Oza, AM				Perren, Timothy J.; Swart, Ann Marie; Pfisterer, Jacobus; Ledermann, Jonathan A.; Pujade-Lauraine, Eric; Kristensen, Gunnar; Carey, Mark S.; Beale, Philip; Cervantes, Andres; Kurzeder, Christian; du Bois, Andreas; Sehouli, Jalid; Kimmig, Rainer; Staehle, Anne; Collinson, Fiona; Essapen, Sharadah; Gourley, Charlie; Lortholary, Alain; Selle, Frederic; Mirza, Mansoor R.; Leminen, Arto; Plante, Marie; Stark, Dan; Qian, Wendi; Parmar, Mahesh K. B.; Oza, Amit M.		ICON7 Investigators	A Phase 3 Trial of Bevacizumab in Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAPERITONEAL CISPLATIN; III TRIAL; CARBOPLATIN-PACLITAXEL; 1ST-LINE TREATMENT; INTERGROUP TRIAL; ANGIOGENESIS; CYCLOPHOSPHAMIDE; EXPRESSION; GUIDELINES; TOPOTECAN	BACKGROUND Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women with this disease. METHODS We randomly assigned women with ovarian cancer to carboplatin (area under the curve, 5 or 6) and paclitaxel (175 mg per square meter of body-surface area), given every 3 weeks for 6 cycles, or to this regimen plus bevacizumab (7.5 mg per kilogram of body weight), given concurrently every 3 weeks for 5 or 6 cycles and continued for 12 additional cycles or until progression of disease. Outcome measures included progression-free survival, first analyzed per protocol and then updated, and interim overall survival. RESULTS A total of 1528 women from 11 countries were randomly assigned to one of the two treatment regimens. Their median age was 57 years; 90% had epithelial ovarian cancer, 69% had a serous histologic type, 9% had high-risk early-stage disease, 30% were at high risk for progression, and 70% had stage IIIC or IV ovarian cancer. Progression-free survival (restricted mean) at 36 months was 20.3 months with standard therapy, as compared with 21.8 months with standard therapy plus bevacizumab (hazard ratio for progression or death with bevacizumab added, 0.81; 95% confidence interval, 0.70 to 0.94; P=0.004 by the log-rank test). Nonproportional hazards were detected (i.e., the treatment effect was not consistent over time on the hazard function scale) (P<0.001), with a maximum effect at 12 months, coinciding with the end of planned bevacizumab treatment and diminishing by 24 months. Bevacizumab was associated with more toxic effects (most often hypertension of grade 2 or higher) (18%, vs. 2% with chemotherapy alone). In the updated analyses, progression-free survival (restricted mean) at 42 months was 22.4 months without bevacizumab versus 24.1 months with bevacizumab (P=0.04 by log-rank test); in patients at high risk for progression, the benefit was greater with bevacizumab than without it, with progression-free survival (restricted mean) at 42 months of 14.5 months with standard therapy alone and 18.1 months with bevacizumab added, with respective median overall survival of 28.8 and 36.6 months. CONCLUSIONS Bevacizumab improved progression-free survival in women with ovarian cancer. The benefits with respect to both progression-free and overall survival were greater among those at high risk for disease progression. (Funded by Roche and others; ICON7 Controlled-Trials.com number, ISRCTN91273375.)	[Perren, Timothy J.; Collinson, Fiona] St James Univ Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England; [Stark, Dan] Leeds Inst Mol Med, Leeds, W Yorkshire, England; [Essapen, Sharadah] Royal Surrey Cty Natl Hlth Serv NHS Fdn Trust, St Lukes Canc Ctr, Guildford, Surrey, England; [Qian, Wendi] Cambridge Univ Hosp NHS Fdn Trust, Cambridge Canc Trials Ctr, Cambridge, England; [Swart, Ann Marie; Qian, Wendi; Parmar, Mahesh K. B.] MRC CTU, London WL2B 6NH, England; [Ledermann, Jonathan A.] UCL, Biomed Res Ctr, Univ Coll London Hosp, London WC1E 6BT, England; [Pfisterer, Jacobus] Klin Gynakol & Geburtshilfe, Stadt Klinikum Solingen, Solingen, Germany; [Kurzeder, Christian] Univ Ulm Klinikum, Ulm, Germany; [du Bois, Andreas] Dr Horst Schmidt Klin, Wiesbaden, Germany; [Kimmig, Rainer] Univ Klinikum Essen, Essen, Germany; [Staehle, Anne] St Vincentius Kliniken, Karlsruhe, Germany; [Pujade-Lauraine, Eric] Univ Paris 05, Hop Univ Paris Ctr, AP HP, Paris, France; [Kristensen, Gunnar] Oslo Univ Hosp, Dept Gynecol Oncol, Oslo, Norway; [Kristensen, Gunnar] Oslo Univ Hosp, Inst Med Informat, Oslo, Norway; [Carey, Mark S.] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada; [Plante, Marie] Univ Laval, Dept Obstet & Gynecol, Quebec City, PQ, Canada; [Beale, Philip] Australia New Zealand Gynaecol Oncol Grp, Camperdown, NSW, Australia; [Cervantes, Andres] Univ Valencia, Dept Hematol & Med Oncol, Inst Hlth Res Hosp Clin, Valencia, Spain; [Sehouli, Jalid] Charite Campus Virchow Klinikum, Berlin, Germany; [Gourley, Charlie] Univ Edinburgh, Canc Res Ctr, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Lortholary, Alain] Ctr Catherine Sienne, Nantes, France; [Selle, Frederic] Hop Tenon, AP HP, Med Oncol Serv, F-75970 Paris, France; [Mirza, Mansoor R.] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark; [Leminen, Arto] Univ Helsinki, Cent Hosp, Womens Clin, Helsinki, Finland; [Oza, Amit M.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada	Saint James's University Hospital; University of Leeds; University of Cambridge; Medical Research Council Clinical Trials Unit; University College London Hospitals NHS Foundation Trust; University of London; University College London; Ulm University; University of Duisburg Essen; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Universite Paris Cite; University of Oslo; University of Oslo; University of British Columbia; Laval University; University of Valencia; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Edinburgh; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Parmar, MKB (corresponding author), MRC CTU, Aviat House,125 Kingsway, London WL2B 6NH, England.	mp@ctu.mrc.ac.uk	Gascon, Pere/F-7905-2015; Mahner, Sven/F-3560-2014; Menon, Usha/C-4716-2008; Perren, Timothy J/D-5387-2013; Jayson, Gordon C/O-8224-2015; Kimmig, Rainer/F-1176-2014; GLADIEFF, Laurence/O-5129-2014; friedlander, michael l/G-3490-2013; Solomayer, Erich/A-9580-2015; Cervantes, Andres/J-8713-2013	Menon, Usha/0000-0003-3708-1732; Perren, Timothy J/0000-0001-8472-8856; Jayson, Gordon C/0000-0002-8515-8944; GLADIEFF, Laurence/0000-0002-6980-9719; friedlander, michael l/0000-0002-6488-0604; Solomayer, Erich/0000-0002-2622-5676; Sorbe, Bengt/0000-0002-5063-631X; Ellard, Susan/0000-0001-5757-9787; joly, florence/0000-0001-6168-4942; Oza, Amit/0000-0002-9510-8641; Durando, Xavier/0000-0001-6035-3172; Sculpher, Mark/0000-0003-3746-9913; Earl, Helena/0000-0003-1549-8094; Beale, Philip/0000-0003-3628-4597; Cervantes, Andres/0000-0003-3806-3691; McNeish, Iain/0000-0002-9387-7586; Breitbach, Georg-Peter/0000-0002-8257-917X	Roche; National Institute for Health Research, through the National Cancer Research Network; MRC [MC_U122861379] Funding Source: UKRI; Medical Research Council [MC_U122861379] Funding Source: researchfish; Chief Scientist Office [SCD/11] Funding Source: researchfish	Roche(Roche Holding); National Institute for Health Research, through the National Cancer Research Network(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office	Supported by Roche and the National Institute for Health Research, through the National Cancer Research Network.	Alberts DS, 1996, NEW ENGL J MED, V335, P1950, DOI 10.1056/NEJM199612263352603; Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684; Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345; Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390; Cannistra SA, 2008, J CLIN ONCOL, V26, P3665, DOI 10.1200/JCO.2008.17.2676; Cannistra SA, 2007, J CLIN ONCOL, V25, P5180, DOI 10.1200/JCO.2007.12.0782; du Bois A, 2006, J CLIN ONCOL, V24, P1127, DOI 10.1200/JCO.2005.03.2938; Eskens FALM, 2008, EUR J CANCER, V44, P2350, DOI 10.1016/j.ejca.2008.07.042; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Garcia AA, 2008, J CLIN ONCOL, V26, P76, DOI 10.1200/JCO.2007.12.1939; Hoskins P, 2010, J NATL CANCER I, V102, P1547, DOI 10.1093/jnci/djq362; Huang S, 2000, CANCER RES, V60, P5334; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001; Pfisterer J, 2006, JNCI-J NATL CANCER I, V98, P1036, DOI 10.1093/jnci/djj296; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Rustin GJS, 2004, JNCI-J NATL CANCER I, V96, P487, DOI 10.1093/jnci/djh081; SANDLER AB, 2005, 41 ANN M AM SOC CLIN; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447	23	1456	1506	5	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2011	365	26					2484	2496		10.1056/NEJMoa1103799	http://dx.doi.org/10.1056/NEJMoa1103799			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868SD	22204725	Green Published			2023-01-03	WOS:000298544600009
J	Beck, EJ; Mandalia, S; Sangha, R; Sharott, P; Youle, M; Baily, G; Brettle, R; Gompels, M; Johnson, M; McCarron, B; Ong, E; Pozniak, A; Schwenk, A; Taylor, S; Walsh, J; Wilkins, E; Williams, I; Gazzard, B				Beck, Eduard J.; Mandalia, Sundhiya; Sangha, Roshni; Sharott, Peter; Youle, Mike; Baily, Guy; Brettle, Ray; Gompels, Mark; Johnson, Margaret; McCarron, Brendan; Ong, Ed; Pozniak, Anton; Schwenk, Achim; Taylor, Stephen; Walsh, John; Wilkins, Ed; Williams, Ian; Gazzard, Brian		NPMS-HHC Steering Grp	The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996-2008	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; LATE DIAGNOSIS; ENGLAND; WALES	Aim: To calculate use, cost and cost-effectiveness of people living with HIV (PLHIV) starting routine treatment and care before starting combination antiretroviral therapy (cART) and PLHIV starting first-line 2NRTIs+NNRTI or 2NRTIs+PIboosted, comparing PLHIV with CD4 <= 200 cells/mm(3) and CD4>200 cells/mm(3). Few studies have calculated the use, cost and cost-effectiveness of routine treatment and care before starting cART and starting cART above and below CD4 200 cells/mm(3). Methods: Use, costs and cost-effectiveness were calculated for PLHIV in routine pre-cART and starting first-line cART, comparing CD4 <= 200 cells/mm3 with CD4>200 cells/mm(3) (2008 UK prices). Results: cART naive patients CD4 <= 200 cells/mm(3) had an annual cost of 6,407 pound (95% CI 6,382 pound to 6,425) pound PPY compared with 2,758 pound (95% CI 2,752 pound to 2,761) pound PPY for those with CD4>200 cells/mm3; cost per life year gained of pre-cART treatment and care for those with CD4>200 cells/mm(3) was 1,776 pound (cost-saving to 2,752) pound. Annual cost for starting 2NRTIs+NNRTI or 2NRTIs+PIboosted with CD4 <= 200 cells/mm(3) was 12,812 pound (95% CI 12,685- pound 12,937) pound compared with 10,478 pound (95% CI 10,376- pound 10,581) pound for PLHIV with CD4>200 cells/mm(3). Cost per additional life-year gained on first-line therapy for those with CD4>200 cells/mm(3) was 4639 pound (3,967 pound to 2,960) pound. Conclusion: PLHIV starting to use HIV services before CD4 <= 200 cells/mm(3) is cost-effective and enables them to be monitored so they start cART with a CD4>200 cells/mm3, which results in better outcomes and is cost-effective. However, 25% of PLHIV accessing services continue to present with CD4 <= 200 cells/mm3. This highlights the need to investigate the cost-effectiveness of testing and early treatment programs for key populations in the UK.	[Beck, Eduard J.; Mandalia, Sundhiya; Sangha, Roshni; Youle, Mike; Gazzard, Brian] NPMS HHC CIC, Coordinating & Analyt Ctr, London, England; [Beck, Eduard J.] London Sch Hyg & Trop Med, London WC1, England; [Mandalia, Sundhiya; Gazzard, Brian] Univ London Imperial Coll Sci Technol & Med, London, England; [Sharott, Peter] London Procurement Programme, London Specialised Commissioning Grp, London, England; [Youle, Mike; Johnson, Margaret] Royal Free Hosp, London NW3 2QG, England; [Baily, Guy] Royal London Hosp, London E1 1BB, England; [Baily, Guy] Barts Hosp, London, England; [Brettle, Ray] Edinburgh Gen Hosp, Edinburgh, Midlothian, Scotland; [Gompels, Mark] Southmead Hosp, Bristol, Avon, England; [McCarron, Brendan] James Cook Univ Hosp, Middlesbrough, England; [Ong, Ed] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Beck, Eduard J.; Mandalia, Sundhiya; Pozniak, Anton; Gazzard, Brian] Chelsea & Westminster Hosp, London, England; [Schwenk, Achim] N Middlesex Hosp, London N18 1QX, England; [Taylor, Stephen] Birmingham Heartland Hosp, Birmingham, W Midlands, England; [Walsh, John] St Marys Hosp, London, England; [Wilkins, Ed] N Manchester Grp Hosp, N Manchester, England; [Williams, Ian] Mortimer Market Ctr, London, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Barts Health NHS Trust; Royal London Hospital; Southmead Hospital; James Cook University Hospital; Newcastle General Hospital; Imperial College London; Heart of England NHS Foundation Trust; Imperial College London	Beck, EJ (corresponding author), NPMS HHC CIC, Coordinating & Analyt Ctr, London, England.	becke@unaids.org		Ong, Edmund/0000-0002-6594-0509	Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	During 2010/2011, the NPMS-HHC was financially supported through a non-restrictive grant from Bristol-Myers Squibb, with no influence on the independence of the Steering Group and its editorial policy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler A, 2009, AIDS CARE, V21, P284, DOI 10.1080/09540120802183537; [Anonymous], 2011, NIH NEWS        0512; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; BAJKO MS, 2011, HIV STUD 76 DROP CAS; Beck EJ, 2008, INT J STD AIDS, V19, P297, DOI 10.1258/ijsa.2007.007236; Beck E.J., 2001, EFFECTIVE MANAGEMENT, P113; Beck EJ, 2004, AIDS, V18, P2411; BECK EJ, 2006, HIV PANDEMIC LOCAL G, P769; BECK EJ, 2010, USE COST HIV SERVICE; Brouwer WBF, 2005, BRIT MED J, V331, P446, DOI 10.1136/bmj.331.7514.446; Chadborn TR, 2006, AIDS, V20, P2371, DOI 10.1097/QAD.0b013e32801138f7; Chadborn TR, 2005, AIDS, V19, P513, DOI 10.1097/01.aids.0000162340.43310.08; Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x; Hankins CA, 2010, AIDS, V24, pS70, DOI 10.1097/01.aids.0000390709.04255.fd; *HLTH PROT AG, 2011, HLTH PROTECTION REPO, V4; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Mandalia S, 2002, HIV Med, V3, P254, DOI 10.1046/j.1468-1293.2002.00110.x; NEATON JD, 2009, STRATEGIC TIMING ANT; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2011, GUID US ANT AG HIV 1; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Schafer J.L., 1997, ANAL INCOMPLETE MULT; THAKKAR B, 1998, 226 SUGI; WHO, 2010, ANT THER HIV INF AD	24	31	32	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2011	6	12							e27830	10.1371/journal.pone.0027830	http://dx.doi.org/10.1371/journal.pone.0027830			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866GS	22194795	Green Published, gold, Green Submitted			2023-01-03	WOS:000298369100015
J	Jacobson, M; Earle, CC; Newhouse, JP				Jacobson, Mireille; Earle, Craig C.; Newhouse, Joseph P.			Geographic Variation in Physicians' Responses to a Reimbursement Change	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER		[Jacobson, Mireille] RAND Corp, Santa Monica, CA 90406 USA; [Earle, Craig C.] Canc Care Ontario, Toronto, ON, Canada; [Newhouse, Joseph P.] Harvard Univ, Sch Med, Boston, MA USA	RAND Corporation; Cancer Care Ontario; Harvard University; Harvard Medical School	Jacobson, M (corresponding author), RAND Corp, Santa Monica, CA 90406 USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022; Jacobson, Mireille/AAD-1190-2022	Jacobson, Mireille/0000-0002-4977-8783	NCI NIH HHS [R01 CA152043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA152043] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1999, DARTMOUTH ATLAS HLTH; *BOARDS TRUST FED, 2011, BOARDS TRUST FED 201; Earle CC, 2002, MED CARE, V40, P75; Gross CP, 2006, JAMA-J AM MED ASSOC, V296, P2815, DOI 10.1001/jama.296.23.2815; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563	5	26	26	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	2011	365	22					2049	2052		10.1056/NEJMp1110117	http://dx.doi.org/10.1056/NEJMp1110117			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	854MO	22047517	Green Accepted			2023-01-03	WOS:000297499000004
J	Schleit, J; Wall, VZ; Simko, M; Kaeberlein, M				Schleit, Jennifer; Wall, Valerie Z.; Simko, Marissa; Kaeberlein, Matt			The MDT-15 Subunit of Mediator Interacts with Dietary Restriction to Modulate Longevity and Fluoranthene Toxicity in Caenorhabditis elegans	PLOS ONE			English	Article							LIFE-SPAN EXTENSION; DNA ADDUCT FORMATION; CALORIC RESTRICTION; METABOLIC-ACTIVATION; BACTERIAL DEPRIVATION; AROMATIC-HYDROCARBONS; STRESS RESISTANCE; GENETIC PATHWAYS; PROTEIN; SIR2	Dietary restriction (DR), the limitation of calorie intake while maintaining proper nutrition, has been found to extend life span and delay the onset of age-associated disease in a wide range of species. Previous studies have suggested that DR can reduce the lethality of environmental toxins. To further examine the role of DR in toxin response, we measured life spans of the nematode Caenorhabditis elegans treated with the mutagenic polyaromatic hydrocarbon, fluoranthene (FLA). FLA is a direct byproduct of combustion, and is one of U. S. Environmental Protection Agency's sixteen priority environmental toxins. Treatment with 5 mu g/ml FLA shortened the life spans of ad libitum fed nematodes, and DR resulted in increased sensitivity to FLA. To determine the role of detoxifying enzymes in the toxicity of FLA, we tested nematodes with mutations in the gene encoding the MDT-15 subunit of mediator, a transcriptional coactivator that regulates genes involved in fatty acid metabolism and detoxification. Mutation of mdt-15 increased the life span of FLA treated animals compared to wild-type animals with no difference observed between DR and ad libitum fed mdt-15 animals. We also examined mutants with altered insulin-IGF-1-like signaling (IIS), which is known to modulate life span and stress resistance in C. elegans independently of DR. Mutation of the genes coding for the insulin-like receptor DAF-2 or the FOXO-family transcription factor DAF16 did not alter the animals' susceptibility to FLA compared to wild type. Taken together, our results suggest that certain compounds have increased toxicity when combined with a DR regimen through increased metabolic activation. This increased metabolic activation appears to be mediated through the MDT-15 transcription factor and is independent of the IIS pathway.	[Schleit, Jennifer; Wall, Valerie Z.; Simko, Marissa; Kaeberlein, Matt] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Schleit, J (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	kaeber@uw.edu		Kaeberlein, Matt/0000-0002-1311-3421	NIH [R01AG031108, ES007032]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG031108] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported in part by NIH Grant R01AG031108 to MK. JS was supported by the Environmental Pathology/Toxicology Training Grant (NIH Grant ES007032). MK is an Ellison Medical Foundation New Scholar in Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aidoo A, 1999, MUTAT RES-FUND MOL M, V430, P155, DOI 10.1016/S0027-5107(99)00197-9; BERG TF, 1994, FOOD CHEM TOXICOL, V32, P45, DOI 10.1016/0278-6915(84)90035-8; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004; Chen W, 1996, DRUG CHEM TOXICOL, V19, P21, DOI 10.3109/01480549609002194; Chou MW, 1997, TOXICOL LETT, V92, P21, DOI 10.1016/S0378-4274(97)00029-5; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; DELANEY JR, 2011, AGING CELL; Essumang DK, 2011, B ENVIRON CONTAM TOX, V86, P438, DOI 10.1007/s00128-011-0232-0; Gems D, 2005, MECH AGEING DEV, V126, P381, DOI 10.1016/j.mad.2004.09.001; GRAM TE, 1970, J PHARMACOL EXP THER, V175, P12; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Greer EL, 2009, ANN NY ACAD SCI, V1170, P688, DOI 10.1111/j.1749-6632.2009.04019.x; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; HANSON SK, 1978, TOXICOL LETT, V1, P301, DOI 10.1016/0378-4274(78)90011-5; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; Harper JM, 2006, MECH AGEING DEV, V127, P687, DOI 10.1016/j.mad.2006.04.002; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2007, AGEING RES REV, V6, P128, DOI 10.1016/j.arr.2007.04.001; Kaeberlein M, 2010, BIOESSAYS, V32, P96, DOI 10.1002/bies.200900171; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Leiser SF, 2011, AGING CELL, V10, P318, DOI 10.1111/j.1474-9726.2011.00672.x; Liao CY, 2010, AGING CELL, V9, P92, DOI 10.1111/j.1474-9726.2009.00533.x; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Mair W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004535; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; PEGRAM RA, 1989, MECH AGEING DEV, V48, P167, DOI 10.1016/0047-6374(89)90048-1; PESSAYRE D, 1980, BIOCHEM PHARMACOL, V29, P2219, DOI 10.1016/0006-2952(80)90201-4; Platt KL, 2008, MUTAT RES-GEN TOX EN, V650, P96, DOI 10.1016/j.mrgentox.2007.09.011; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Ramaiah SK, 2001, DRUG METAB DISPOS, V29, P1088; Ramaiah SK, 1998, TOXICOL SCI, V45, P233, DOI 10.1006/toxs.1998.2511; Rogers AN, 2011, CELL METAB, V14, P55, DOI 10.1016/j.cmet.2011.05.010; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; Seng JE, 1996, ARCH BIOCHEM BIOPHYS, V335, P42, DOI 10.1006/abbi.1996.0480; Shaikh ZA, 1999, TOXICOLOGY, V133, P93, DOI 10.1016/S0300-483X(99)00012-8; Shimada T, 2006, DRUG METAB PHARMACOK, V21, P257, DOI 10.2133/dmpk.21.257; Smith ED, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-49; Stanfel MN, 2009, BBA-GEN SUBJECTS, V1790, P1067, DOI 10.1016/j.bbagen.2009.06.007; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; STRUBELT O, 1981, TOXICOL APPL PHARM, V60, P66, DOI 10.1016/0041-008X(81)90136-8; Sutphin GL, 2008, EXP GERONTOL, V43, P130, DOI 10.1016/j.exger.2007.10.019; SUTPHIN GL, 2009, J VIS EXP; Taubert S, 2006, GENE DEV, V20, P1137, DOI 10.1101/gad.1395406; Taubert S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000021; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; WALKER RM, 1982, CAN J PHYSIOL PHARM, V60, P399, DOI 10.1139/y82-058; WARSHAWSKI D, 1992, ENV HLTH PERSPECT, V107, P317; Weindruch R., 1988, RETARDATION AGING DI; Xue WL, 2005, TOXICOL APPL PHARM, V206, P73, DOI 10.1016/j.taap.2004.11.006	70	7	9	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2011	6	11							e28036	10.1371/journal.pone.0028036	http://dx.doi.org/10.1371/journal.pone.0028036			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858IO	22132200	Green Published, Green Submitted, gold			2023-01-03	WOS:000297789900041
J	Green, TC; Black, R; Serrano, JMG; Budman, SH; Butler, SF				Green, Traci C.; Black, Ryan; Serrano, Jill M. Grimes; Budman, Simon H.; Butler, Stephen F.			Typologies of Prescription Opioid Use in a Large Sample of Adults Assessed for Substance Abuse Treatment	PLOS ONE			English	Article							NATIONAL EPIDEMIOLOGIC SURVEY; HUMAN-IMMUNODEFICIENCY-VIRUS; ADDICTION SEVERITY INDEX; LATENT CLASS ANALYSIS; NONMEDICAL USE; DRUG-USE; ILLICIT USE; SELF-REPORTS; SEEKING TREATMENT; COLLEGE-STUDENTS	Background: As a population, non-medical prescription opioid users are not well-defined. We aimed to derive and describe typologies of prescription opioid use and nonmedical use using latent class analysis in an adult population being assessed for substance abuse treatment. Methods: Latent class analysis was applied to data from 26,314 unique respondents, aged 18-70, self-reporting past month use of a prescription opioid out of a total of 138,928 cases (18.9%) collected by the Addiction Severity Index-Multimedia Version (ASI-MV (R)), a national database for near real-time prescription opioid abuse surveillance. Data were obtained from November 2005 through December 2009. Substance abuse treatment, criminal justice, and public assistance programs in the United States submitted data to the ASI-MV database (n = 538). Six indicators of the latent classes derived from responses to the ASI-MV, a version of the ASI modified to collect prescription opioid abuse and chronic pain experience. The latent class analysis included respondent home ZIP code random effects to account for nesting of respondents within ZIP code. Results: A four-class adjusted latent class model fit best and defined clinically interpretable and relevant subgroups: Use as prescribed, Prescribed misusers, Medically healthy abusers, and Illicit users. Classes varied on key variables, including race/ethnicity, gender, concurrent substance abuse, duration of prescription opioid abuse, mental health problems, and ASI composite scores. Three of the four classes (81% of respondents) exhibited high potential risk for fatal opioid overdose; 18.4% exhibited risk factors for blood-borne infections. Conclusions: Multiple and distinct profiles of prescription opioid use were detected, suggesting a range of use typologies at differing risk for adverse events. Results may help clinicians and policy makers better focus overdose and blood-borne infection prevention efforts and intervention strategies for prescription opioid abuse reduction.	[Green, Traci C.] Brown Med Sch, Providence, RI USA; [Green, Traci C.] Rhode Isl Hosp, Providence, RI USA; [Black, Ryan; Serrano, Jill M. Grimes; Budman, Simon H.; Butler, Stephen F.] Inflexxion Inc, Needham, MA USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Green, TC (corresponding author), Brown Med Sch, Providence, RI USA.	traci.c.green@gmail.com	Butler, Stephen/AAK-7902-2020	Butler, Stephen/0000-0002-6132-5883	National Research Service from the National Institute on Drug Abuse [5F31DA023862]; Lifespan/Tufts/Brown Center for AIDS Research [NIAID P30AI042853]; King Pharmaceuticals(R), Inc.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [F31DA023862] Funding Source: NIH RePORTER	National Research Service from the National Institute on Drug Abuse; Lifespan/Tufts/Brown Center for AIDS Research; King Pharmaceuticals(R), Inc.; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by a National Research Service Award grant (TCG) from the National Institute on Drug Abuse (5F31DA023862) and by a 2009 Developmental grant to TCG from Lifespan/Tufts/Brown Center for AIDS Research (NIAID P30AI042853). The writing of this paper was funded in part by an unrestricted grant to Inflexxion, Inc. from King Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in March 2011. JGS and SFB, who are employees of Inflexxion, were paid consultants to King Pharmaceuticals, Inc., in connection with the development of this manuscript. The views expressed in this paper are those of the authors and do not necessarily represent the views of Pfizer Pharmaceuticals, Inc. The funding sources had no part in the conception, design, data analysis, interpretation, writing, editing, or decision to publish this manuscript.	Agrawal A, 2007, ADDICTION, V102, P94, DOI 10.1111/j.1360-0443.2006.01630.x; Back SE, 2010, ADDICT BEHAV, V35, P1001, DOI 10.1016/j.addbeh.2010.06.018; Boyd CJ, 2006, DRUG ALCOHOL DEPEN, V81, P37, DOI 10.1016/j.drugalcdep.2005.05.017; Butler SF, 2004, PAIN, V112, P65, DOI 10.1016/j.pain.2004.07.026; Butler SF, 2008, J PAIN, V9, P360, DOI 10.1016/j.jpain.2007.11.014; Butler SF, 2008, PHARMACOEPIDEM DR S, V17, P1142, DOI 10.1002/pds.1659; Carise D, 2007, AM J PSYCHIAT, V164, P1750, DOI 10.1176/appi.ajp.2007.07050252; CHAISSON RE, 1987, AM J PUBLIC HEALTH, V77, P169, DOI 10.2105/AJPH.77.2.169; Chitwood DD, 2003, J PSYCHOACTIVE DRUGS, V35, P445, DOI 10.1080/02791072.2003.10400491; Connors GJ, 2003, ADDICTION, V98, P21, DOI 10.1046/j.1359-6357.2003.00585.x; Daniulaityte R, 2006, J DRUG ISSUES, V36, P787, DOI 10.1177/002204260603600402; Dasgupta N, 2006, DRUG ALCOHOL DEPEN, V82, P135, DOI 10.1016/j.drugalcdep.2005.08.019; Dasgupta N, 2010, AM J LIFESTYLE MED, V4, P32, DOI 10.1177/1559827609348462; Davis WR, 2008, DRUG ALCOHOL DEPEN, V92, P267, DOI 10.1016/j.drugalcdep.2007.08.008; Del Boca FK, 2003, ADDICTION, V98, P1, DOI 10.1046/j.1359-6357.2003.00586.x; Delucchi KL, 2004, DRUG ALCOHOL DEPEN, V74, P235, DOI 10.1016/j.drugalcdep.2003.12.014; Des Jarlais DC, 2007, ADDICTION, V102, P778, DOI 10.1111/j.1360-0443.2007.01764.x; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Draus PJ, 2006, SUBST USE MISUSE, V41, P1111, DOI 10.1080/10826080500411577; FDA, 2011, QUEST ANSW FDA REQ R; Ghandour LA, 2008, INT J METH PSYCH RES, V17, P89, DOI 10.1002/mpr.232; Girion L, 2011, DRUG DEATHS NOW OUTN; Goodman FDC, 2005, AM J HEALTH-SYST PH, V62, P2604, DOI 10.2146/ajhp040618; GOSSOP M, 1992, J ROY SOC MED, V85, P469; Gossop M, 1992, BR J ADDICT, V87; Grau LE, 2007, AM J ADDICTION, V16, P166, DOI 10.1080/10550490701375293; Green TC, 2008, DISTINGUISHING SIGNS, P979; Green TC, 2009, DRUG ALCOHOL DEPEN, V103, P65, DOI 10.1016/j.drugalcdep.2009.03.014; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Havens JR, 2011, DRUG ALCOHOL DEPEN, V115, P107, DOI 10.1016/j.drugalcdep.2010.11.003; Havens Jennifer R, 2008, J Opioid Manag, V4, P63; Havens JR, 2008, CHARACTERIZING OPIOI; HENDRIKS VM, 1989, J SUBST ABUSE TREAT, V6, P133, DOI 10.1016/0740-5472(89)90041-X; Hickman M, 2008, ADDICTION, V103, P1060, DOI 10.1111/j.1360-0443.2008.02134.x; Huang BJ, 2006, J CLIN PSYCHIAT, V67, P1062, DOI 10.4088/JCP.v67n0708; Jamison RN, 2000, J PAIN SYMPTOM MANAG, V19, P53, DOI 10.1016/S0885-3924(99)00144-X; Kaplan, 2004, HDB QUANTITATIVE MET, P345, DOI DOI 10.4135/9781412986311.N19; Kochanek KD, 2011, DEATHS PRELIMINARY D; Latkin CA, 2001, J SUBST ABUSE, V13, P89, DOI 10.1016/S0899-3289(01)00070-0; Lord S, 2003, J AM PHARM ASSOC, V49, P519, DOI DOI 10.1331/JAPHA.2009.08027; Manchikanti Laxmaiah, 2006, Pain Physician, V9, P215; MARMOR M, 1987, AIDS, V1, P39; McCabe SE, 2005, J SUBST ABUSE TREAT, V28, P225, DOI 10.1016/j.jsat.2004.12.009; McCabe SE, 2005, ADDICTION, V100, P96, DOI 10.1111/j.1360-0443.2005.00944.x; McCabe SE, 2005, DRUG ALCOHOL DEPEN, V77, P37, DOI 10.1016/j.drugalcdep.2004.07.005; McCabe SE, 2005, ADDICT BEHAV, V30, P789, DOI 10.1016/j.addbeh.2004.08.024; McCabe SE, 2007, ADDICT BEHAV, V32, P562, DOI 10.1016/j.addbeh.2006.05.022; McCabe SE, 2007, J ADOLESCENT HEALTH, V40, P76, DOI 10.1016/j.jadohealth.2006.07.016; McCabe SE, 2009, ARCH PEDIAT ADOL MED, V163, P739, DOI 10.1001/archpediatrics.2009.120; McCabe SE, 2009, DRUG ALCOHOL DEPEN, V102, P63, DOI 10.1016/j.drugalcdep.2009.01.007; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; McNees E, 2008, EXPLORATORY PROFILE; Monga N, 2007, DRUG ALCOHOL DEPEN, V88, P1, DOI 10.1016/j.drugalcdep.2006.08.029; Morasco BJ, 2011, PAIN, V152, P488, DOI 10.1016/j.pain.2010.10.009; Muthen LindaK., 2012, MPLUS USERS GUIDE, DOI DOI 10.1111/J.1532-5415.2004.52225.X; Neale J, 2003, DRUG ALCOHOL DEPEN, V71, P57, DOI 10.1016/S0376-8716(03)00053-X; NSDUH, 2007, 2007 NAT SURV DRUG U; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Office of Applied Studies, 2004, RES 2003 NAT SURV DR; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Passik Steven D, 2006, J Pain Palliat Care Pharmacother, V20, P5; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2007, TRENDS UNINTENTIONAL; Paulozzi LJ, 2008, TRENDS UNINTENTIONAL; Potter JS, 2004, DRUG ALCOHOL DEPEN, V76, P213, DOI 10.1016/j.drugalcdep.2004.05.001; Razak MH, 2003, JAIDS-J ACQ IMM DEF, V33, P259, DOI 10.1097/00126334-200306010-00023; Secades-Villa R, 2003, ADDICT BEHAV, V28, P1175, DOI 10.1016/S0306-4603(02)00219-8; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Simoni-Wastila L, 2004, SUBST USE MISUSE, V39, P1, DOI 10.1081/JA-120027764; Simoni-Wastila Linda, 2006, Am J Geriatr Pharmacother, V4, P380, DOI 10.1016/j.amjopharm.2006.10.002; Solbergsdottir E, 2004, J ADDICT DIS, V23, P29, DOI 10.1300/J069v23n01_03; Stohler R, 2000, EUR ADDICT RES, V6, P154, DOI 10.1159/000019019; Substance Abuse and Mental Health Services Administration, 2008, TREATM EP DAT SET TE; Teter CJ, 2005, J AM COLL HEALTH, V53, P253, DOI 10.3200/JACH.53.6.253-262; Tetrault JM, 2008, ADDICTION, V103, P258, DOI 10.1111/j.1360-0443.2007.02056.x; [United States Department of Health and Human Services Substance Abuse and Mental Health Services Administration OoAS], 2009, ICPSR30462V1 US DEP; Wang CL, 2005, AIDS, V19, P935, DOI 10.1097/01.aids.0000171407.30866.22; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Wisniewski AM, 2008, J ADDICT DIS, V27, P1, DOI 10.1300/J069v27n01_01; Wu LT, 2010, DRUG ALCOHOL DEPEN, V112, P69, DOI 10.1016/j.drugalcdep.2010.05.013; Yacoubian GS, 2002, J DRUG EDUC, V32, P261, DOI 10.2190/FAW4-6GNP-Q6N7-V5MB	82	49	49	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2011	6	11							e27244	10.1371/journal.pone.0027244	http://dx.doi.org/10.1371/journal.pone.0027244			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	849WB	22087270	Green Published, gold, Green Submitted			2023-01-03	WOS:000297154900094
J	Lederle, FA; Zylla, D; MacDonald, R; Wilt, TJ				Lederle, Frank A.; Zylla, Dylan; MacDonald, Roderick; Wilt, Timothy J.			Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline	ANNALS OF INTERNAL MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; LOW-MOLECULAR-WEIGHT; ACUTE ISCHEMIC-STROKE; LOW-DOSE HEPARIN; GRADUATED COMPRESSION STOCKINGS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; UNFRACTIONATED HEPARIN; ACUTELY ILL; PULMONARY-EMBOLISM	Background: Venous thromboembolism prophylaxis has been recommended for nonsurgical patients, but its effectiveness remains uncertain. Purpose: To assess the benefits and harms of prophylaxis in hospitalized adult medical patients and those with acute stroke. Data Sources: MEDLINE and the Cochrane Library from 1950 through April 2011, reference lists, and study authors. Study Selection: English-language randomized trials were included if they provided clinical outcomes and evaluated therapy with low-dose heparin or related agents or mechanical measures compared with placebo, no treatment, or other active prophylaxis in the target population. Data Extraction: Two independent investigators extracted data on study characteristics and clinical outcomes up to 120 days after randomization. The primary outcome was total mortality. Data Synthesis: In medical patients, heparin prophylaxis did not reduce total mortality but did result in fewer pulmonary embolisms (PEs) (odds ratio [OR], 0.69 [95% Cl, 0.52 to 0.90], but with evidence of publication bias) and an increase in all bleeding events (risk ratio [RR], 1.34 [Cl, 1.08 to 1.66]). Heparin prophylaxis had no statistically significant effect on any outcome in patients with acute stroke except for an increase in major bleeding events (OR, 1.66 [Cl, 1.20 to 2.28]). When trials of medical patients and those with stroke were considered together (18 studies; 36 122 patients), heparin prophylaxis reduced the incidence of PE (OR, 0.70 [Cl, 0.56 to 0.87]; absolute reduction, 3 events per 1000 patients treated [Cl, 1 to 5 events]) but increased the incidence of all bleeding (RR, 1.28 [Cl, 1.05 to 1.56]) and major bleeding events (OR, 1.61 [Cl, 1.23 to 2.10]), with an absolute increase of 9 bleeding events per 1000 patients treated (Cl, 2 to 18 events), 4 of which were major (Cl, 1 to 7 events). A reduction in total mortality approached statistical significance (RR, 0.93 [Cl, 0.86 to 1.00]; P = 0.056; absolute decrease, 6 deaths per 1000 patients treated [Cl, 0 to 11 deaths]). No statistically significant differences in clinical outcomes were observed in the 14 trials that compared unfractionated heparin with low-molecular-weight heparin. No improvements in clinical outcomes were seen in the 3 studies of mechanical prophylaxis in patients with stroke, but more patients had lower-extremity skin damage (RR, 4.02 [Cl, 2.34 to 6.91])-an increase of 39 events per 1000 patients treated (Cl, 17 to 77 events). Limitation: Non-English-language studies were not included, but these were few and small. Conclusion: Heparin prophylaxis had no significant effect on mortality, may have reduced PE in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit. No differences in benefits or harms were found according to type of heparin used. Mechanical prophylaxis provided no benefit and resulted in clinically important harm to patients with stroke. Primary Funding Source: American College of Physicians.	Minnesota Evidence Based Practice Ctr, Minneapolis, MN USA; Minneapolis Vet Affairs Med Ctr, Minneapolis, MN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Lederle, FA (corresponding author), Minneapolis Vet Affairs Med Ctr 111 O, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA.	frank.lederle@va.gov			American College of Physicians	American College of Physicians	By the American College of Physicians.	Alikhan R, 2003, BLOOD COAGUL FIBRIN, V14, P341, DOI 10.1097/00001721-200306000-00004; Aquino JP, 1990, FRAXIPARINE; BELCH JJ, 1981, SCOT MED J, V26, P115, DOI 10.1177/003693308102600205; Berge E, 2000, LANCET, V355, P1205, DOI 10.1016/S0140-6736(00)02085-7; Bergmann JF, 1996, THROMB HAEMOSTASIS, V76, P529; Bijsterveld NR, 2002, J AM COLL CARDIOL, V39, P811, DOI 10.1016/S0735-1097(01)01825-3; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; Bump GM, 2009, J HOSP MED, V4, P289, DOI 10.1002/jhm.450; Carrier M, 2010, ANN INTERN MED, V152, P578, DOI 10.7326/0003-4819-152-9-201005040-00008; Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C; Cook D, 2011, NEW ENGL J MED, V364, P1305; DAHAN R, 1986, HAEMOSTASIS, V16, P159; DeFrances Carol J, 2007, Vital Health Stat 13, P1; Dennis M, 2010, ANN INTERN MED, V153, P553, DOI 10.7326/0003-4819-153-9-201011020-00280; Dennis M, 2009, LANCET, V373, P1958, DOI 10.1016/S0140-6736(09)60941-7; Dentali F, 2007, ANN INTERN MED, V146, P278, DOI 10.7326/0003-4819-146-4-200702200-00007; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; DICKMANN U, 1988, KLIN WOCHENSCHR, V66, P1182, DOI 10.1007/BF01727666; Diener HC, 2006, STROKE, V37, P139, DOI 10.1161/01.STR.0000195182.67656.ee; DUMAS R, 1994, AGE AGEING, V23, P512, DOI 10.1093/ageing/23.6.512; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025; GALLUS AS, 1973, NEW ENGL J MED, V288, P545, DOI 10.1056/NEJM197303152881103; Gardlund B, 1996, LANCET, V347, P1357; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; GELMERS HJ, 1980, ACTA NEUROL SCAND, V61, P313; Goodman LR, 2005, RADIOLOGY, V234, P654, DOI 10.1148/radiol.2343041326; Green D., 1998, TOP STROKE REHABIL, V5, P68; HALKIN H, 1982, ANN INTERN MED, V96, P561, DOI 10.7326/0003-4819-96-5-561; Harenberg J, 1996, HAEMOSTASIS, V26, P127; HARENBERG J, 1990, THROMB RES, V59, P639, DOI 10.1016/0049-3848(90)90422-9; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hillbom M, 2002, ACTA NEUROL SCAND, V106, P84, DOI 10.1034/j.1600-0404.2002.01215.x; Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004; IBARRAPEREZ C, 1988, ANGIOLOGY, V39, P505, DOI 10.1177/000331978803900603; Joint Commission, 2009, JT COMM PERSPECT, V29, P4; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; KIERKEGAARD A, 1993, EUR HEART J, V14, P1365, DOI 10.1093/eurheartj/14.10.1365; King CS, 2007, CHEST, V131, P507, DOI 10.1378/chest.06-1861; Kleber FX, 2003, AM HEART J, V145, P614, DOI 10.1067/mhj.2003.189; Kucher N, 2005, NEW ENGL J MED, V352, P969, DOI 10.1056/NEJMoa041533; Kucher N, 2005, ARCH INTERN MED, V165, P341, DOI 10.1001/archinte.165.3.341; Lacut K, 2005, NEUROLOGY, V65, P865, DOI 10.1212/01.wnl.0000176073.80532.a2; Lechler E, 1996, HAEMOSTASIS, V26, P49; Lederle FA, 2006, AM J MED, V119, P54, DOI 10.1016/j.amjmed.2005.03.049; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; Levi M, 2007, AM J RESP CRIT CARE, V176, P483, DOI 10.1164/rccm.200612-1803OC; Lowe GDO, 2003, LANCET, V362, P504, DOI 10.1016/S0140-6736(03)14149-9; Luba Maria, 2007, Pol Arch Med Wewn, V117, P31; Mahe I, 2005, EUR J CLIN PHARMACOL, V61, P347, DOI 10.1007/s00228-005-0944-3; MCCARTHY ST, 1977, LANCET, V2, P800; MCCARTHY ST, 1986, AGE AGEING, V15, P84, DOI 10.1093/ageing/15.2.84; Mismetti P, 2000, THROMB HAEMOSTASIS, V83, P14; Muir KW, 2000, QJM-INT J MED, V93, P359, DOI 10.1093/qjmed/93.6.359; Orken DN, 2009, NEUROLOGIST, V15, P329, DOI 10.1097/NRL.0b013e3181a93bac; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; PAMBIANCO G, 1995, ARCH PHYS MED REHAB, V76, P324, DOI 10.1016/S0003-9993(95)80657-1; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; PRASAD BK, 1982, AGE AGEING, V11, P42, DOI 10.1093/ageing/11.1.42; PRINS MH, 1989, HAEMOSTASIS, V19, P245; Riess H, 2010, J THROMB HAEMOST, V8, P1209, DOI 10.1111/j.1538-7836.2010.03848.x; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Sandercock P, 1997, LANCET, V349, P1569; SANDSET PM, 1990, SEMIN THROMB HEMOST, V16, P25; Schellong SM, 2010, EXPERT OPIN PHARMACO, V11, P2953, DOI 10.1517/14656566.2010.521498; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sheldon T, 2002, BMJ-BRIT MED J, V325, P734, DOI 10.1136/bmj.325.7367.734; Sherman DG, 2007, LANCET, V369, P1347, DOI 10.1016/S0140-6736(07)60633-3; Shorr AF, 2008, CHEST, V133, P149, DOI 10.1378/chest.07-1826; TURPIE AGG, 1992, ANN INTERN MED, V117, P353, DOI 10.7326/0003-4819-117-5-353; TURPIE AGG, 1987, LANCET, V1, P523; Weber C, 2008, SUPPORT CARE CANCER, V16, P847, DOI 10.1007/s00520-007-0339-3; Wein L, 2007, ARCH INTERN MED, V167, P1476, DOI 10.1001/archinte.167.14.1476; Wille-Jorgensen P, 2005, THROMB HAEMOSTASIS, V93, P236, DOI 10.1160/TH04-09-0570	75	113	118	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					602	U91		10.7326/0003-4819-155-9-201111010-00008	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00008			27	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041949				2023-01-03	WOS:000296612400005
J	Lai, JN; Wu, CT; Chen, PC; Huang, CS; Chow, SN; Wang, JD				Lai, Jung-Nien; Wu, Chien-Tung; Chen, Pau-Chung; Huang, Chiun-Sheng; Chow, Song-Nan; Wang, Jung-Der			Increased Risk for Invasive Breast Cancer Associated with Hormonal Therapy: A Nation-Wide Random Sample of 65,723 Women Followed from 1997 to 2008	PLOS ONE			English	Article							PROGESTIN-REPLACEMENT THERAPY; HEALTH INITIATIVE WHI; POSTMENOPAUSAL WOMEN; MENOPAUSAL SYMPTOMS; ESTROGEN; TAIWAN; COHORT; CELLS	Background: Hormonal therapy (HT) either estrogen alone (E-alone) or estrogen plus progesterone (E+P) appears to increase the risk for breast cancer in Western countries. However, limited information is available on the association between HT and breast cancer in Asian women characterized mainly by dietary phytoestrogens intake and low prevalence of contraceptive pills prescription. Methodology: A total of 65,723 women (20-79 years of age) without cancer or the use of Chinese herbal products were recruited from a nation-wide one-million representative sample of the National Health Insurance of Taiwan and followed from 1997 to 2008. Seven hundred and eighty incidents of invasive breast cancer were diagnosed. Using a reference group that comprised 40,052 women who had never received a hormone prescription, Cox proportional hazard models were constructed to determine the hazard ratios for receiving different types of HT and the occurrence of breast cancer. Conclusions: 5,156 (20%) women ever used E+P, 2,798 (10.8%) ever used E-alone, and 17,717 (69%) ever used other preparation types. The Cox model revealed adjusted hazard ratios (HRs) of 2.05 (95% CI 1.37-3.07) for current users of E-alone and 8.65 (95% CI 5.45-13.70) for current users of E+P. Using women who had ceased to take hormonal medication for 6 years or more as the reference group, the adjusted HRs were significantly elevated and greater than current users and women who had discontinued hormonal medication for less than 6 years. Current users of either E-alone or E+P have an increased risk for invasive breast cancer in Taiwan, and precautions should be taken when such agents are prescribed.	[Lai, Jung-Nien] Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan; [Lai, Jung-Nien] Taipei City Hosp, Yangming Branch, Dept Obstet & Gynecol, Taipei, Taiwan; [Wu, Chien-Tung] Taipei City Hosp, Dept Chinese Med, Taipei, Taiwan; [Chen, Pau-Chung; Wang, Jung-Der] Natl Taiwan Univ, Inst Occupat Med & Ind Hyg, Coll Publ Hlth, Taipei 10764, Taiwan; [Huang, Chiun-Sheng] Natl Taiwan Univ, Coll Med, Dept Surg, Taipei 10764, Taiwan; [Huang, Chiun-Sheng] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chow, Song-Nan] Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ Hosp, Dept Occupat & Environm Med, Tainan 70428, Taiwan	National Yang Ming Chiao Tung University; Taipei City Hospital; Taipei City Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital	Lai, JN (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Tradit Med, Taipei 112, Taiwan.	jdwang121@gmail.com	Chen, Pau-Chung/H-5686-2011	Chen, Pau-Chung/0000-0002-6242-5974; Huang, Chiun-Sheng/0000-0002-6557-211X	National Health Research Institute; National Research Institute of Chinese Medicine	National Health Research Institute(National Health Research Institutes - Taiwan); National Research Institute of Chinese Medicine	This study was funded by the National Health Research Institute and National Research Institute of Chinese Medicine. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. And no additional external funding was received for this study. The database was kindly provided by the Bureau of National Health Insurance, the Department of Health, and the National Health Research Institutes.	Adlercreutz H, 2002, LANCET ONCOL, V3, P364, DOI 10.1016/S1470-2045(02)00777-5; Amato P, 2002, MENOPAUSE, V9, P145, DOI 10.1097/00042192-200203000-00010; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Bush TM, 2007, J GEN INTERN MED, V22, P1311, DOI 10.1007/s11606-007-0296-z; Centers for Disease Control and Prevention, 1979, INT CLASS DIS 9 REV; Chen SB, 2006, J CHROMATOGR A, V1121, P114, DOI 10.1016/j.chroma.2006.04.082; Chlebowski RT, 2010, J CLIN ONCOL, V28, P2690, DOI 10.1200/JCO.2009.24.8799; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cust Michael P, 2007, Menopause Int, V13, P141, DOI 10.1258/175404507783004285; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; Government Information Office, 2004, TAIW YB 2004; Haines CJ, 2005, MATURITAS, V52, P264, DOI 10.1016/j.maturitas.2005.03.012; Hines LM, 2010, CANCER-AM CANCER SOC, V116, P3215, DOI 10.1002/cncr.25154; Hsieh SC, 2008, PHARMACOEPIDEM DR S, V17, P609, DOI 10.1002/pds.1611; Hu CY, 2009, J STEROID BIOCHEM, V113, P209, DOI 10.1016/j.jsbmb.2008.12.019; Kuo DJ, 2007, MATURITAS, V58, P259, DOI 10.1016/j.maturitas.2007.08.013; Lau WS, 2009, BRIT J PHARMACOL, V156, P1136, DOI 10.1111/j.1476-5381.2009.00123.x; Lee SH, 2004, J NUTR BIOCHEM, V15, P452, DOI 10.1016/j.jnutbio.2004.01.007; Lyytinen H, 2006, OBSTET GYNECOL, V108, P1354, DOI 10.1097/01.AOG.0000241091.86268.6e; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; National Health Research Institutes, 2003, NAT HLTH INS RES DAT; Pedersen AT, 2003, HUM REPROD, V18, P2241, DOI 10.1093/humrep/deg435; Piersen Colleen E, 2003, Integr Cancer Ther, V2, P120, DOI 10.1177/1534735403002002004; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168; Stahlberg C, 2004, INT J CANCER, V109, P721, DOI 10.1002/ijc.20016; Tjonneland A, 2004, CANCER-AM CANCER SOC, V100, P2328, DOI 10.1002/cncr.20250; Weissmann-Brenner A, 2010, MED SCI MONITOR, V16, pPH35	30	12	12	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2011	6	10							e25183	10.1371/journal.pone.0025183	http://dx.doi.org/10.1371/journal.pone.0025183			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834NO	21998640	Green Published, gold, Green Submitted			2023-01-03	WOS:000295968700006
J	Reiss, LK; Kowallik, A; Uhlig, S				Reiss, Lucy Kathleen; Kowallik, Anke; Uhlig, Stefan			Recurrent Recruitment Manoeuvres Improve Lung Mechanics and Minimize Lung Injury during Mechanical Ventilation of Healthy Mice	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; END-EXPIRATORY PRESSURE; TIDAL VOLUME VENTILATION; PROTECTIVE VENTILATION; PULMONARY; ALVEOLAR; STRATEGY; INFLAMMATION; IMPAIRMENT; MODEL	Introduction: Mechanical ventilation (MV) of mice is increasingly required in experimental studies, but the conditions that allow stable ventilation of mice over several hours have not yet been fully defined. In addition, most previous studies documented vital parameters and lung mechanics only incompletely. The aim of the present study was to establish experimental conditions that keep these parameters within their physiological range over a period of 6 h. For this purpose, we also examined the effects of frequent short recruitment manoeuvres (RM) in healthy mice. Methods: Mice were ventilated at low tidal volume V-T = 8 mL/kg or high tidal volume V-T = 16 mL/kg and a positive end-expiratory pressure (PEEP) of 2 or 6 cmH(2)O. RM were performed every 5 min, 60 min or not at all. Lung mechanics were followed by the forced oscillation technique. Blood pressure (BP), electrocardiogram (ECG), heart frequency (HF), oxygen saturation and body temperature were monitored. Blood gases, neutrophil-recruitment, microvascular permeability and pro-inflammatory cytokines in bronchoalveolar lavage (BAL) and blood serum as well as histopathology of the lung were examined. Results: MV with repetitive RM every 5 min resulted in stable respiratory mechanics. Ventilation without RM worsened lung mechanics due to alveolar collapse, leading to impaired gas exchange. HF and BP were affected by anaesthesia, but not by ventilation. Microvascular permeability was highest in atelectatic lungs, whereas neutrophil-recruitment and structural changes were strongest in lungs ventilated with high tidal volume. The cytokines IL-6 and KC, but neither TNF nor IP-10, were elevated in the BAL and serum of all ventilated mice and were reduced by recurrent RM. Lung mechanics, oxygenation and pulmonary inflammation were improved by increased PEEP. Conclusions: Recurrent RM maintain lung mechanics in their physiological range during low tidal volume ventilation of healthy mice by preventing atelectasis and reduce the development of pulmonary inflammation.	[Reiss, Lucy Kathleen; Kowallik, Anke; Uhlig, Stefan] Rhein Westfal TH Aachen, Fac Med, Inst Pharmacol & Toxicol, Aachen, Germany	RWTH Aachen University	Reiss, LK (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Pharmacol & Toxicol, Aachen, Germany.	kreiss@ukaachen.de	Uhlig, Stefan/A-7290-2014	Uhlig, Stefan/0000-0003-2332-1280	Deutsche Forschungsgemeinschaft	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The work has been funded by the Deutsche Forschungsgemeinschaft (www.dfg.de). The funders have no role in study design, data collection and analysis, decision to pubish, or preparation of the manuscript.	Allen GB, 2006, AM J PHYSIOL-LUNG C, V291, pL710, DOI 10.1152/ajplung.00532.2005; Bai KJ, 2005, AM J RESP CRIT CARE, V172, P92, DOI 10.1164/rccm.200405-652OC; Bates JHT, 2009, IEEE ENG MED BIO, P170, DOI 10.1109/IEMBS.2009.5333302; Bates JHT, 2006, ANN BIOMED ENG, V34, P384, DOI 10.1007/s10439-005-9056-6; Beck-Schimmer B, 2010, BEST PRACT RES-CLIN, V24, P199, DOI 10.1016/j.bpa.2010.02.005; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Berul CI, 1996, CIRCULATION, V94, P2641, DOI 10.1161/01.CIR.94.10.2641; Boker A, 2004, ANESTHESIOLOGY, V100, P608, DOI 10.1097/00000542-200403000-00022; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cannas A, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-333; Cannizzaro V, 2009, RESP PHYSIOL NEUROBI, V169, P243, DOI 10.1016/j.resp.2009.09.012; Chavolla-Calderon M, 2003, J CLIN INVEST, V111, P973, DOI 10.1172/JCI200317458; Cuellar JM, 2004, BRAIN RES PROTOC, V13, P126, DOI 10.1016/j.brainresprot.2004.03.002; Dolinay T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001601; dos Santos CC, 2006, ANNU REV PHYSIOL, V68, P585, DOI 10.1146/annurev.physiol.68.072304.113443; Finigan JH, 2009, AM J PHYSIOL-LUNG C, V296, pL1002, DOI 10.1152/ajplung.90555.2008; Futier E, 2010, ANESTHESIOLOGY, V113, P1310, DOI 10.1097/ALN.0b013e3181fc640a; Gharib SA, 2009, PHYSIOL GENOMICS, V37, P239, DOI 10.1152/physiolgenomics.00027.2009; Haitsma JJ, 2006, MINERVA ANESTESIOL, V72, P117; Haitsma JJ, 2000, INTENS CARE MED, V26, P1515, DOI 10.1007/s001340000648; Halbertsma FJJ, 2008, CRIT CARE MED, V36, P2403, DOI 10.1097/CCM.0b013e318180266e; Halter JM, 2007, CRIT CARE, V11, DOI 10.1186/cc5695; Hauber HP, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-21; Hodgson C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006667.pub2; Hoetzel A, 2008, AM J RESP CRIT CARE, V177, P1223, DOI 10.1164/rccm.200708-1265OC; Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC; Hubmayr RD, 2002, AM J RESP CRIT CARE, V165, P1647, DOI 10.1164/rccm.2001080-01CP; Jiang Y, 2005, AM J RESP CRIT CARE, V171, P850, DOI 10.1164/rccm.200407-857OC; Kacmarek RM, 2007, RESP CARE, V52, P622; Laffey JG, 2003, CRIT CARE MED, V31, P2634, DOI 10.1097/01.CCM.0000089646.52395.BA; Lim SC, 2004, CRIT CARE MED, V32, P2371, DOI 10.1097/01.CCM.0000147445.73344.3A; Maniatis NA, 2009, AM J RESP CELL MOL, V41, P426, DOI 10.1165/rcmb.2008-0144OC; MEAD J, 1959, J APPL PHYSIOL, V14, P669, DOI 10.1152/jappl.1959.14.5.669; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Meier T, 2008, ANESTH ANALG, V107, P1265, DOI 10.1213/ane.0b013e3181806212; Muller HC, 2010, CRIT CARE, V14, DOI 10.1186/cc9209; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Pinheiro de Oliveira Roselaine, 2010, Crit Care, V14, pR39, DOI 10.1186/cc8919; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Seah AS, 2011, ANN BIOMED ENG, V39, P1505, DOI 10.1007/s10439-010-0237-6; Soutiere SE, 2004, J APPL PHYSIOL, V96, P1658, DOI 10.1152/japplphysiol.01098.2003; Spieth PM, 2009, AM J RESP CRIT CARE, V179, P684, DOI 10.1164/rccm.200806-975OC; Thammanomai A, 2008, J APPL PHYSIOL, V104, P1329, DOI 10.1152/japplphysiol.01002.2007; Thammanomai A, 2007, J APPL PHYSIOL, V103, P1551, DOI 10.1152/japplphysiol.00006.2007; Tsangaris I, 2003, EUR RESPIR J, V21, P495, DOI 10.1183/09031936.03.00037902; Uhlig S, 2004, AM J RESP CRIT CARE, V169, P314, DOI 10.1164/ajrccm.169.2.950; UHLIG S, 1994, J PHARMACOL TOXICOL, V31, P85, DOI 10.1016/1056-8719(94)90047-7; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; Uhlig U, 2011, COMPR PHYSIOL, V1, P635, DOI 10.1002/cphy.c100004; Vaneker M, 2007, ANESTHESIOLOGY, V107, P419, DOI 10.1097/01.anes.0000278908.22686.01; Vaporidi K, 2008, CRIT CARE MED, V36, P1277, DOI 10.1097/CCM.0b013e318169f30e; Verbrugge SJC, 2007, CLIN PHYSIOL FUNCT I, V27, P67, DOI 10.1111/j.1475-097X.2007.00722.x; Verbrugge SJC, 1998, BRIT J ANAESTH, V80, P360, DOI 10.1093/bja/80.3.360; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; von Bethmann AN, 1998, AM J RESP CRIT CARE, V157, P263, DOI 10.1164/ajrccm.157.1.9608052; Weingarten TN, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.032; Wilson MR, 2005, AM J PHYSIOL-LUNG C, V288, pL599, DOI 10.1152/ajplung.00304.2004; Wolthuis EK, 2009, CRIT CARE, V13, DOI 10.1186/cc7688; Yamamoto N, 2011, INT J CLIN ONCOL, V16, P84, DOI 10.1007/s10147-011-0201-y; Zosky GR, 2008, J APPL PHYSIOL, V105, P685, DOI 10.1152/japplphysiol.90328.2008	61	50	52	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24527	10.1371/journal.pone.0024527	http://dx.doi.org/10.1371/journal.pone.0024527			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822JR	21935418	Green Published, gold, Green Submitted			2023-01-03	WOS:000295041700039
J	Moynihan, R				Moynihan, Ray			REALITY CHECK Is your mum on drugs?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Mangin D, 2007, BMJ-BRIT MED J, V335, P285, DOI 10.1136/bmj.39241.630741.BE1; TRIMBLE J, IS YOUR MOM DRUGS FI; TRIMBLE J, IS YOUR MOM DRUGS OU	4	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 24	2011	343								d5184	10.1136/bmj.d5184	http://dx.doi.org/10.1136/bmj.d5184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	813ZN	21865271				2023-01-03	WOS:000294409900001
J	Tan, GG; Liao, WT; Dong, X; Yang, GJ; Zhu, ZY; Li, WH; Chai, YF; Lou, ZY				Tan, Guangguo; Liao, Wenting; Dong, Xin; Yang, Genjing; Zhu, Zhenyu; Li, Wuhong; Chai, Yifeng; Lou, Ziyang			Metabonomic Profiles Delineate the Effect of Traditional Chinese Medicine Sini Decoction on Myocardial Infarction in Rats	PLOS ONE			English	Article							FLIGHT MASS-SPECTROMETRY; FATTY-ACID OXIDATION; HEART-FAILURE; HPLC-MS; LIQUID-CHROMATOGRAPHY; H-1-NMR SPECTROSCOPY; SYSTEMS BIOLOGY; ISCHEMIC-HEART; FAILING HEART; HUMAN URINE	Background: In spite of great advances in target-oriented Western medicine for treating myocardial infarction (MI), it is still a leading cause of death in a worldwide epidemic. In contrast to Western medicine, Traditional Chinese medicine (TCM) uses a holistic and synergistic approach to restore the balance of Yin-Yang of body energy so the body's normal function can be restored. Sini decoction (SND) is a well-known formula of TCM which has been used to treat MI for many years. However, its holistic activity evaluation and mechanistic understanding are still lacking due to its complex components. Methodology/Principal Findings: A urinary metabonomic method based on nuclear magnetic resonance and ultra high-performance liquid chromatography coupled to mass spectrometry was developed to characterize MI-related metabolic profiles and delineate the effect of SND on MI. With Elastic Net for classification and selection of biomarkers, nineteen potential biomarkers in rat urine were screened out, primarily related to myocardial energy metabolism, including the glycolysis, citrate cycle, amino acid metabolism, purine metabolism and pyrimidine metabolism. With the altered metabolism pathways as possible drug targets, we systematically analyze the therapeutic effect of SND, which demonstrated that SND administration could provide satisfactory effect on MI through partially regulating the perturbed myocardial energy metabolism. Conclusions/Significance: Our results showed that metabonomic approach offers a useful tool to identify MI-related biomarkers and provides a new methodological cue for systematically dissecting the underlying efficacies and mechanisms of TCM in treating MI.	[Tan, Guangguo; Liao, Wenting; Dong, Xin; Yang, Genjing; Zhu, Zhenyu; Li, Wuhong; Chai, Yifeng; Lou, Ziyang] Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China; [Tan, Guangguo; Liao, Wenting; Zhu, Zhenyu; Li, Wuhong; Chai, Yifeng] Shanghai Key Lab Pharmaceut Metabolite Res, Shanghai, Peoples R China	Naval Medical University	Tan, GG (corresponding author), Second Mil Med Univ, Sch Pharm, Shanghai, Peoples R China.	louziyang@126.com			National Natural Science Fund of China [30873196]; Project of Modernization of Traditional Chinese Medicine of Shanghai [09dZ1975100]; Doctoral Innovation Foundation of Second Military Medical University	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Project of Modernization of Traditional Chinese Medicine of Shanghai; Doctoral Innovation Foundation of Second Military Medical University	The work was supported by the National Natural Science Fund of China (No. 30873196) and the Project of Modernization of Traditional Chinese Medicine of Shanghai (No. 09dZ1975100) as well as the Doctoral Innovation Foundation of Second Military Medical University (2011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362; Bauer John Anthony, 2008, Congest Heart Fail, V14, P283, DOI 10.1111/j.1751-7133.2008.00011.x; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Bijlsma S, 2006, ANAL CHEM, V78, P567, DOI 10.1021/ac051495j; Butt MS, 2011, CRIT REV FOOD SCI, V51, P383, DOI 10.1080/10408391003624848; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Efferth T, 2007, TRENDS MOL MED, V13, P353, DOI 10.1016/j.molmed.2007.07.001; Fiehn O, 2002, PLANT MOL BIOL, V48, P155, DOI 10.1023/A:1013713905833; Gika HG, 2007, J PROTEOME RES, V6, P3291, DOI 10.1021/pr070183p; Giovane A, 2008, J CELL BIOCHEM, V105, P648, DOI 10.1002/jcb.21875; GORDON A, 1995, CARDIOVASC RES, V30, P413, DOI 10.1016/0008-6363(95)00062-3; GUTH BD, 1990, CIRCULATION, V81, P1948, DOI 10.1161/01.CIR.81.6.1948; Han J, 2009, BIOANALYSIS, V1, P1665, DOI 10.4155/BIO.09.158; Hodson MP, 2007, ANAL BIOCHEM, V362, P182, DOI 10.1016/j.ab.2006.12.037; Holmes E, 1997, J PHARMACEUT BIOMED, V15, P1647, DOI 10.1016/S0731-7085(97)00066-6; Janis MT, 2008, EXPERT OPIN DRUG MET, V4, P665, DOI [10.1517/17425255.4.6.665 , 10.1517/17425250802095565]; Jin Minghua, 2003, Zhong Yao Cai, V26, P71; KOBAYASHI M, 1988, J PHARMACOL EXP THER, V246, P667; Lenz EM, 2005, BIOMARKERS, V10, P173, DOI 10.1080/13547500500094034; Lindon JC, 2006, PHARM RES, V23, P1075, DOI 10.1007/s11095-006-0025-z; Lv YH, 2010, J PHARMACEUT BIOMED, V52, P129, DOI 10.1016/j.jpba.2009.12.016; Maier LS, 2000, CARDIOVASC RES, V45, P913, DOI 10.1016/S0008-6363(99)00387-9; McNulty PH, 2000, METABOLISM, V49, P1365, DOI 10.1053/meta.2000.9510; Mendes-Silva W, 2003, THROMB RES, V112, P93, DOI 10.1016/j.thromres.2003.10.014; Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Nielsen S, 1997, P NATL ACAD SCI USA, V94, P5450, DOI 10.1073/pnas.94.10.5450; Pechlivanis A, 2010, J PROTEOME RES, V9, P6405, DOI 10.1021/pr100684t; Roepke TK, 2009, NAT MED, V15, P1186, DOI 10.1038/nm.2029; Sabatine MS, 2005, CIRCULATION, V112, P3868, DOI 10.1161/CIRCULATIONAHA.105.569137; Sangster T, 2006, ANALYST, V131, P1075, DOI 10.1039/b604498k; Singhuber J, 2009, J ETHNOPHARMACOL, V126, P18, DOI 10.1016/j.jep.2009.07.031; Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y; Somjen D, 2004, J STEROID BIOCHEM, V91, P147, DOI 10.1016/j.jsbmb.2004.04.003; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Stanley WC, 2005, PHYSIOL REV, V85, P1093, DOI 10.1152/physrev.00006.2004; Stanley WC, 2005, HEART FAIL REV, V10, P275, DOI 10.1007/s10741-005-7542-4; Tan GG, 2011, BIOMED CHROMATOGR, V25, P913, DOI 10.1002/bmc.1544; Theodoridis G, 2008, TRAC-TREND ANAL CHEM, V27, P251, DOI 10.1016/j.trac.2008.01.008; Torabi A, 2008, EUR HEART J, V29, P859, DOI 10.1093/eurheartj/ehn096; Trygg J, 2007, J PROTEOME RES, V6, P469, DOI 10.1021/pr060594q; Tuunanen H, 2011, CARDIOVASC RES, V90, P251, DOI 10.1093/cvr/cvr052; Verpoorte R, 2005, J ETHNOPHARMACOL, V100, P53, DOI 10.1016/j.jep.2005.05.033; Wang M, 2005, PHYTOTHER RES, V19, P173, DOI 10.1002/ptr.1624; Weir Robin A P, 2006, Curr Heart Fail Rep, V3, P175, DOI 10.1007/s11897-006-0019-5; Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278; Williams RE, 2005, MOL BIOSYST, V1, P166, DOI 10.1039/b500852b; Williams RE, 2005, J PHARMACEUT BIOMED, V38, P465, DOI 10.1016/j.jpba.2005.01.013; Wu W, 1999, Zhongguo Zhong Xi Yi Jie He Za Zhi, V19, P23; Yamaguchi F, 1997, J MOL CELL CARDIOL, V29, P753, DOI 10.1006/jmcc.1996.0319; Yaoita H, 1993, Int J Card Imaging, V9, P273, DOI 10.1007/BF01137154; YU SM, 1995, BRIT J PHARMACOL, V114, P1587, DOI 10.1111/j.1476-5381.1995.tb14943.x; Zhao MQ, 2003, ZHONGGUO ZHONG XI YI, V23, P1; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	54	76	82	1	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2012	7	4							e34157	10.1371/journal.pone.0034157	http://dx.doi.org/10.1371/journal.pone.0034157			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955JA	22493681	Green Published, Green Submitted, gold			2023-01-03	WOS:000305012700023
J	Tarasiuk, A; Reznor, G; Greenberg-Dotan, S; Reuveni, H				Tarasiuk, Ariel; Reznor, Gally; Greenberg-Dotan, Sari; Reuveni, Haim			Financial Incentive Increases CPAP Acceptance in Patients from Low Socioeconomic Background	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; HEALTH-CARE UTILIZATION; APNOEA/HYPOPNOEA SYNDROME; MEDICATION ADHERENCE; COST-EFFECTIVENESS; RISK-FACTOR; MORTALITY; HYPOPNEA; BENEFITS	Objective: We explored whether financial incentives have a role in patients' decisions to accept (purchase) a continuous positive airway pressure (CPAP) device in a healthcare system that requires cost sharing. Design: Longitudinal interventional study. Patients: The group receiving financial incentive (n = 137, 50.8 +/- 10.6 years, apnea/hypopnea index (AHI) 38.7 +/- 19.9 events/hr) and the control group (n = 121, 50.9 +/- 10.3 years, AHI 39.9 +/- 22) underwent attendant titration and a two-week adaptation to CPAP. Patients in the control group had a co-payment of $330-660; the financial incentive group paid a subsidized price of $55. Results: CPAP acceptance was 43% greater (p = 0.02) in the financial incentive group. CPAP acceptance among the low socioeconomic strata (n = 113) (adjusting for age, gender, BMI, tobacco smoking) was enhanced by financial incentive (OR, 95% CI) (3.43, 1.09-10.85), age (1.1, 1.03-1.17), AHI (>30 vs. <30) (4.87, 1.56-15.2), and by family/friends who had positive experience with CPAP (4.29, 1.05-17.51). Among average/high-income patients (n = 145) CPAP acceptance was affected by AHI (>30 vs. <30) (3.16, 1.14-8.75), living with a partner (8.82, 1.03-75.8) but not by the financial incentive. At one-year follow-up CPAP adherence was similar in the financial incentive and control groups, 35% and 39%, respectively (p = 0.82). Adherence rate was sensitive to education (+yr) (1.28, 1.06-1.55) and AHI (>30 vs. <30) (5.25, 1.34-18.5). Conclusions: Minimizing cost sharing reduces a barrier for CPAP acceptance among low socioeconomic status patients. Thus, financial incentive should be applied as a policy to encourage CPAP treatment, especially among low socioeconomic strata patients.	[Tarasiuk, Ariel; Reznor, Gally; Greenberg-Dotan, Sari; Reuveni, Haim] Ben Gurion Univ Negev, Fac Hlth Sci, Sleep Wake Disorders Unit, Dept Physiol,Soroka Univ,Med Ctr, Beer Sheva, Israel	Ben Gurion University; Soroka Medical Center	Tarasiuk, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Sleep Wake Disorders Unit, Dept Physiol,Soroka Univ,Med Ctr, Beer Sheva, Israel.	tarasiuk@bgu.ac.il			Israel Institute for Health Policy and Health Services Research [A/147/2003]	Israel Institute for Health Policy and Health Services Research	This study was supported by a grant from the Israel Institute for Health Policy and Health Services Research, award no. A/147/2003. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albarrak M, 2005, SLEEP, V28, P1306, DOI 10.1093/sleep/28.10.1306; Aloia MS, 2005, J CLIN SLEEP MED, V1, P346; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Martinez-Garcia MA, 2009, AM J RESP CRIT CARE, V180, P36, DOI 10.1164/rccm.200808-1341OC; Ayas NT, 2006, ARCH INTERN MED, V166, P977, DOI 10.1001/archinte.166.9.977; Bandura A, 1986, SOCIAL FDN THOUGHT A; Braithwaite RS, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000234; Brin YS, 2005, ISR MED ASSOC J, V7, P13; Chernew ME, 2008, HEALTH AFFAIR, V27, P103, DOI 10.1377/hlthaff.27.1.103; Chernew ME, 2010, HEALTH AFFAIR, V29, P530, DOI 10.1377/hlthaff.2009.0119; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; Fendrick A Mark, 2010, Am J Manag Care, V16, pS314; Fendrick AM, 2001, AM J MANAG CARE, V7, P861; Gay P, 2006, SLEEP, V29, P381, DOI 10.1093/sleep/29.3.381; Giuffrida A, 1997, BRIT MED J, V315, P703, DOI 10.1136/bmj.315.7110.703; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Greenberg Harly, 2004, Sleep Breath, V8, P185, DOI 10.1055/s-2004-860895; Guest JF, 2008, THORAX, V63, P860, DOI 10.1136/thx.2007.086454; Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; Ip MSM, 2004, AM J RESP CRIT CARE, V169, P348, DOI 10.1164/rccm.200306-767OC; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; Kushida CA, 2006, SLEEP, V29, P375, DOI 10.1093/sleep/29.3.375; Lettieri CJ, 2009, ANN INTERN MED, V151, P696, DOI 10.7326/0003-4819-151-10-200911170-00006; Maciejewski ML, 2010, HEALTH AFFAIR, V29, P2002, DOI 10.1377/hlthaff.2010.0571; Mackenbach JP, 2008, NEW ENGL J MED, V358, P2468, DOI 10.1056/NEJMsa0707519; Mahoney JJ, 2005, AM J MANAG CARE, V11, pS170; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502; McArdle N, 2001, THORAX, V56, P513, DOI 10.1136/thorax.56.7.513; McDaid C, 2009, Health Technol Assess, V13, piii, DOI 10.3310/hta13040; McDaid C, 2009, HEALTH TECHNOL ASSES, V13, P1; McDaid C, 2009, HEALTH TECHNOL ASSES, V13, P143, DOI DOI 10.3310/HTA13040; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Olsen S, 2008, EUR RESPIR J, V32, P710, DOI 10.1183/09031936.00127507; Platt AB, 2009, SLEEP, V32, P799, DOI 10.1093/sleep/32.6.799; Popescu G, 2001, THORAX, V56, P727, DOI 10.1136/thorax.56.9.727; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Reuveni H, 2008, EUR RESPIR J, V31, P273, DOI 10.1183/09031936.00097907; Reuveni H, 2004, SLEEP, V27, P1518, DOI 10.1093/sleep/27.8.1518; Reuveni H, 2002, HEALTH POLICY, V62, P1, DOI 10.1016/S0168-8510(02)00011-8; Simon-Tuval T, 2009, SLEEP, V32, P545, DOI 10.1093/sleep/32.4.545; Smith S, 2004, SLEEP MED, V5, P359, DOI 10.1016/j.sleep.2003.12.007; Stepnowsky CJ, 2002, SLEEP, V25, P758, DOI 10.1093/sleep/25.7.758; Sutherland K, 2008, MED CARE RES REV, V65, p36S, DOI 10.1177/1077558708324235; Tarasiuk A, 2008, J AM GERIATR SOC, V56, P247, DOI 10.1111/j.1532-5415.2007.01544.x; Tarasiuk A, 2006, CHEST, V130, P766, DOI 10.1378/chest.130.3.766; Weatherly HLA, 2009, INT J TECHNOL ASSESS, V25, P26, DOI 10.1017/S0266462309090047; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711	54	35	35	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2012	7	3							e33178	10.1371/journal.pone.0033178	http://dx.doi.org/10.1371/journal.pone.0033178			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	959UC	22479368	gold, Green Published			2023-01-03	WOS:000305339100037
J	Patel, AG; Flatten, KS; Schneider, PA; Dai, NT; McDonald, JS; Poirier, GG; Kaufmann, SH				Patel, Anand G.; Flatten, Karen S.; Schneider, Paula A.; Dai, Nga T.; McDonald, Jennifer S.; Poirier, Guy G.; Kaufmann, Scott H.			Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSE POLYMERASE; SINGLE-STRAND BREAK; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; REPLICATION FORKS; LEUKEMIA-CELLS; PARP INHIBITOR; POSTTRANSLATIONAL MODIFICATION; TRANSDOMINANT INHIBITION	Poly(ADP-ribose) polymerase-1 (PARP1) plays critical roles in the regulation of DNA repair. Accordingly, small molecule inhibitors of PARP are being developed as agents that could modulate the activity of genotoxic chemotherapy, such as topoisomerase I poisons. In this study we evaluated the ability of the PARP inhibitor veliparib to enhance the cytotoxicity of the topoisomerase I poisons topotecan and camptothecin (CPT). Veliparib increased the cell cycle and cytotoxic effects of topotecan in multiple cell line models. Importantly, this sensitization occurred at veliparib concentrations far below those required to substantially inhibit poly(ADP-ribose) polymer synthesis and at least an order of magnitude lower than those involved in selective killing of homologous recombination-deficient cells. Further studies demonstrated that veliparib enhanced the effects of CPT in wild-type mouse embryonic fibroblasts (MEFs) but not Parp1(-/-) MEFs, confirming that PARP1 is the critical target for this sensitization. Importantly, parental and Parp1(-/-) MEFs had indistinguishable CPT sensitivities, ruling out models in which PARP1 catalytic activity plays a role in protecting cells from topoisomerase I poisons. To the contrary, cells were sensitized to CPT in a veliparib-independent manner upon transfection with PARP1 E988K, which lacks catalytic activity, or the isolated PARP1 DNA binding domain. These results are consistent with a model in which small molecule inhibitors convert PARP1 into a protein that potentiates the effects of topoisomerase I poisons by binding to damaged DNA and preventing its normal repair.	[Patel, Anand G.; Flatten, Karen S.; Schneider, Paula A.; Dai, Nga T.; McDonald, Jennifer S.; Kaufmann, Scott H.] Mayo Clin, Div Oncol Res, Rochester, MN 55905 USA; [Patel, Anand G.; Kaufmann, Scott H.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; [Poirier, Guy G.] Univ Laval, Med Ctr, Quebec City, PQ G1V 4G2, Canada	Mayo Clinic; Mayo Clinic; Laval University	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Gonda 19-212,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.Scott@mayo.edu	Patel, Anand/G-9877-2018	Patel, Anand/0000-0002-1438-8275; Poirier, Guy/0000-0002-4869-1424; Kaufmann, Scott/0000-0002-4900-7145	National Institutes of Health [T32 GM072474, P50 CA136393, R01 CA73709]; Mayo Foundation for Research and Education; NATIONAL CANCER INSTITUTE [R01CA073709, P50CA136393] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM072474] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation for Research and Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health Grant T32 GM072474 and a pre-doctoral fellowship from the Mayo Foundation for Research and Education.; This work was supported, in whole or in part, by National Institutes of Health Grants P50 CA136393 and R01 CA73709.	Adjei AA, 1998, CLIN CANCER RES, V4, P683; Affar EB, 1999, BBA-GEN SUBJECTS, V1428, P137, DOI 10.1016/S0304-4165(99)00054-9; Aggarwal M, 2011, P NATL ACAD SCI USA, V108, P1525, DOI 10.1073/pnas.1006423108; Alexander B. M., 2011, J NEUROONCO IN PRESS; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Barrows LR, 1998, MUTAT RES-DNA REPAIR, V408, P103, DOI 10.1016/S0921-8777(98)00022-6; Bauer PI, 2000, INT J MOL MED, V5, P533; Bauer PI, 2001, FEBS LETT, V506, P239, DOI 10.1016/S0014-5793(01)02919-2; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; Calabrese CR, 2003, CLIN CANCER RES, V9, P2711; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COVEY JM, 1989, CANCER RES, V49, P5016; Delaney CA, 2000, CLIN CANCER RES, V6, P2860; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Duro E, 2010, MOL CELL, V40, P632, DOI 10.1016/j.molcel.2010.10.023; El-Khamisy SF, 2005, NATURE, V434, P108, DOI 10.1038/nature03314; Erlichman C, 2001, CANCER RES, V61, P739; FAKAN S, 1988, EXP CELL RES, V179, P517, DOI 10.1016/0014-4827(88)90289-3; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferraris DV, 2010, J MED CHEM, V53, P4561, DOI 10.1021/jm100012m; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200; Gagne JP, 2008, NUCLEIC ACIDS RES, V36, P6959, DOI 10.1093/nar/gkn771; Galvez-Peralta M, 2008, MOL PHARMACOL, V74, P724, DOI 10.1124/mol.108.047787; Goldwasser F, 1996, CANCER RES, V56, P4430; Haince J. F., 2001, CURRENT PROTOCOLS CE; Haince JF, 2008, J BIOL CHEM, V283, P1197, DOI 10.1074/jbc.M706734200; Haince JF, 2005, TRENDS MOL MED, V11, P456, DOI 10.1016/j.molmed.2005.08.003; Hans MA, 1999, ONCOGENE, V18, P7010, DOI 10.1038/sj.onc.1203178; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Interthal H, 2005, EMBO J, V24, P2224, DOI 10.1038/sj.emboj.7600694; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; KASID UN, 1989, J BIOL CHEM, V264, P18687; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; KAUFMANN SH, 1989, J BIOL CHEM, V264, P13946; Koch SSC, 2002, J MED CHEM, V45, P4961, DOI 10.1021/jm02059n; KOHN KW, 1976, BIOCHEMISTRY-US, V15, P4629, DOI 10.1021/bi00666a013; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Kummar S, 2009, J CLIN ONCOL, V27, P2705, DOI 10.1200/JCO.2008.19.7681; Kupper JH, 1996, CANCER RES, V56, P2715; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Leppard JB, 2003, MOL CELL BIOL, V23, P5919, DOI 10.1128/MCB.23.16.5919-5927.2003; Li XF, 2011, DRUG METAB DISPOS, V39, P1161, DOI 10.1124/dmd.110.037820; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Liu XS, 2009, MOL CANCER RES, V7, P1686, DOI 10.1158/1541-7786.MCR-09-0299; Marple T, 2006, MUTAT RES-FUND MOL M, V602, P110, DOI 10.1016/j.mrfmmm.2006.08.005; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606; Meng XW, 2011, J BIOL CHEM, V286, P35823, DOI 10.1074/jbc.M111.240432; Meng XW, 2003, J BIOL CHEM, V278, P47326, DOI 10.1074/jbc.M304793200; MULLER MT, 1985, BIOCHIM BIOPHYS ACTA, V824, P263, DOI 10.1016/0167-4781(85)90057-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Donnell L, 2010, MOL CELL, V40, P619, DOI 10.1016/j.molcel.2010.10.024; Okano S, 2003, MOL CELL BIOL, V23, P3974, DOI 10.1128/MCB.23.11.3974-3981.2003; Park SY, 2005, CANCER RES, V65, P3894, DOI 10.1158/0008-5472.CAN-04-4014; Park SY, 2002, CANCER RES, V62, P459; Patel AG, 2011, P NATL ACAD SCI USA, V108, P3406, DOI 10.1073/pnas.1013715108; Penning TD, 2009, J MED CHEM, V52, P514, DOI 10.1021/jm801171j; PIKE BL, 1970, J CELL PHYSIOL, V76, P77, DOI 10.1002/jcp.1040760111; Plo I, 2003, DNA REPAIR, V2, P1087, DOI 10.1016/S1568-7864(03)00116-2; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; POTMESIL M, 1988, CANCER RES, V48, P3537; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Segovis CM, 2009, J IMMUNOL, V182, P6933, DOI 10.4049/jimmunol.0803840; Smith LM, 2005, CLIN CANCER RES, V11, P8449, DOI 10.1158/1078-0432.CCR-05-1224; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Thomas HD, 2007, MOL CANCER THER, V6, P945, DOI 10.1158/1535-7163.MCT-06-0552; Tikhe JG, 2004, J MED CHEM, V47, P5467, DOI 10.1021/jm030513r; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; White AW, 2000, J MED CHEM, V43, P4084, DOI 10.1021/jm000950v; Yang SX, 2009, CANCER BIOL THER, V8, P2004, DOI 10.4161/cbt.8.21.9917; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Yung TMC, 2004, J BIOL CHEM, V279, P39686, DOI 10.1074/jbc.M402729200; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; Zhang YW, 2011, NUCLEIC ACIDS RES, V39, P3607, DOI 10.1093/nar/gkq1304	99	78	79	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2012	287	6					4198	4210		10.1074/jbc.M111.296475	http://dx.doi.org/10.1074/jbc.M111.296475			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	894EX	22158865	Green Published, hybrid			2023-01-03	WOS:000300410900053
J	Calias, P; Papisov, M; Pan, J; Savioli, N; Belov, V; Huang, Y; Lotterhand, J; Alessandrini, M; Liu, N; Fischman, AJ; Powell, JL; Heartlein, MW				Calias, Pericles; Papisov, Mikhail; Pan, Jing; Savioli, Nancy; Belov, Vasily; Huang, Yan; Lotterhand, Jason; Alessandrini, Mary; Liu, Nan; Fischman, Alan J.; Powell, Jan L.; Heartlein, Michael W.			CNS Penetration of Intrathecal-Lumbar Idursulfase in the Monkey, Dog and Mouse: Implications for Neurological Outcomes of Lysosomal Storage Disorder	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; ENZYME REPLACEMENT THERAPY; II HUNTER-SYNDROME; GROWTH FACTOR-II/MANNOSE-6-PHOSPHATE RECEPTOR; ADENOASSOCIATED VIRUS VECTOR; CENTRAL-NERVOUS-SYSTEM; MUCOPOLYSACCHARIDOSIS-II; CEREBROSPINAL-FLUID; TRANSFERRIN RECEPTOR; MONOCLONAL-ANTIBODY	A major challenge for the treatment of many central nervous system (CNS) disorders is the lack of convenient and effective methods for delivering biological agents to the brain. Mucopolysaccharidosis II (Hunter syndrome) is a rare inherited lysosomal storage disorder resulting from a deficiency of iduronate-2-sulfatase (I2S). I2S is a large, highly glycosylated enzyme. Intravenous administration is not likely to be an effective therapy for disease-related neurological outcomes that require enzyme access to the brain cells, in particular neurons and oligodendrocytes. We demonstrate that intracerebroventricular and lumbar intrathecal administration of recombinant I2S in dogs and nonhuman primates resulted in widespread enzyme distribution in the brain parenchyma, including remarkable deposition in the lysosomes of both neurons and oligodendrocytes. Lumbar intrathecal administration also resulted in enzyme delivery to the spinal cord, whereas little enzyme was detected there after intraventricular administration. Mucopolysaccharidosis II model is available in mice. Lumbar administration of recombinant I2S to enzyme deficient animals reduced the storage of glycosaminoglycans in both superficial and deep brain tissues, with concurrent morphological improvements. The observed patterns of enzyme transport from cerebrospinal fluid to the CNS tissues and the resultant biological activity (a) warrant further investigation of intrathecal delivery of I2S via lumbar catheter as an experimental treatment for the neurological symptoms of Hunter syndrome and (b) may have broader implications for CNS treatment with biopharmaceuticals.	[Calias, Pericles; Pan, Jing; Savioli, Nancy; Huang, Yan; Lotterhand, Jason; Alessandrini, Mary; Liu, Nan; Powell, Jan L.; Heartlein, Michael W.] Shire Human Genet Therapies Inc, Lexington, MA USA; [Papisov, Mikhail; Belov, Vasily] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Papisov, Mikhail; Belov, Vasily; Fischman, Alan J.] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; [Papisov, Mikhail; Belov, Vasily; Fischman, Alan J.] Shriners Burns Hosp, Dept Nucl Med, Boston, MA USA	Shire Pharmaceuticals Limited; Harvard University; Massachusetts General Hospital; Harvard University	Calias, P (corresponding author), Shire Human Genet Therapies Inc, Lexington, MA USA.	pcalias@shire.com	Belov, Vasily/AAC-9251-2020	Belov, Vasily/0000-0002-3185-2412; Papisov, Mikhail/0000-0003-4716-2122	Shire Human Genetic Therapies, Inc.	Shire Human Genetic Therapies, Inc.	This study was sponsored by Shire Human Genetic Therapies, Inc. The funders participated in the study design and conduct, data collection and analysis, decision to publish and preparation of the manuscript.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Ballantyne JC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005178; Barbu E, 2009, EXPERT OPIN DRUG DEL, V6, P553, DOI [10.1517/17425240902939143, 10.1517/17425240902939143 ]; Begley DJ, 2008, CURR PHARM DESIGN, V14, P1566, DOI 10.2174/138161208784705504; Belverud S, 2008, NEUROTHERAPEUTICS, V5, P114, DOI 10.1016/j.nurt.2007.10.070; Boado RJ, 2010, J DRUG TARGET, V18, P205, DOI 10.3109/10611860903353362; Boado RJ, 2010, MOL PHARMACEUT, V7, P237, DOI 10.1021/mp900235k; Boado RJ, 2009, J BIOTECHNOL, V144, P135, DOI 10.1016/j.jbiotec.2009.08.019; Boado RJ, 2009, BIOTECHNOL BIOENG, V102, P1251, DOI 10.1002/bit.22135; Brown PD, 2004, NEUROSCIENCE, V129, P957, DOI 10.1016/j.neuroscience.2004.07.003; Cearley CN, 2007, J NEUROSCI, V27, P9928, DOI 10.1523/JNEUROSCI.2185-07.2007; Chen FT, 2006, MOL GENET METAB, V87, P349, DOI 10.1016/j.ymgme.2005.11.017; Coloma MJ, 2000, PHARMACEUT RES, V17, P266, DOI 10.1023/A:1007592720793; Consiglio A, 2001, NAT MED, V7, P310, DOI 10.1038/85454; Davidson BL, 2003, NAT REV NEUROSCI, V4, P353, DOI 10.1038/nrn1104; Defrise M, 1997, IEEE T MED IMAGING, V16, P145, DOI 10.1109/42.563660; DICHIRO G, 1976, NEUROLOGY, V26, P1; Felice BR, 2011, TOXICOL PATHOL, V39, P879, DOI 10.1177/0192623311409595; FENSTERMACHER J, 1988, ANN NY ACAD SCI, V531, P29, DOI 10.1111/j.1749-6632.1988.tb51416.x; Garcia AR, 2007, J INHERIT METAB DIS, V30, P924, DOI 10.1007/s10545-007-0641-8; Ghafoor VL, 2007, AM J HEALTH-SYST PH, V64, P2447, DOI 10.2146/ajhp060204; GhersiEgea JF, 1996, NEUROSCIENCE, V75, P1271, DOI 10.1016/0306-4522(96)00281-3; Gooch JL, 2003, PEDIATR NEUROSURG, V39, P1, DOI 10.1159/000070870; Guffon N, 2009, J PEDIATR-US, V154, P733, DOI 10.1016/j.jpeds.2008.11.041; Hamano K, 2008, ACTA NEUROPATHOL, V115, P547, DOI 10.1007/s00401-007-0325-3; Hawkes C, 2002, EUR J NEUROSCI, V15, P33, DOI 10.1046/j.0953-816x.2001.01864.x; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; Hemsley KM, 2009, INT J CLIN PHARM TH, V47, pS118; Hsieh JC, 2006, NEUROSURG FOCUS, V21, P1; HUDSON HM, 1994, IEEE T MED IMAGING, V13, P601, DOI 10.1109/42.363108; Kakkis E, 2004, MOL GENET METAB, V83, P163, DOI 10.1016/j.ymgme.2004.07.003; Kakkis ED, 2002, EXPERT OPIN INV DRUG, V11, P675, DOI 10.1517/13543784.11.5.675; Kar S, 2006, NEUROBIOL AGING, V27, P199, DOI 10.1016/j.neurobiolaging.2005.03.005; Kerr JZ, 2001, CRIT REV ONCOL HEMAT, V37, P227, DOI 10.1016/S1040-8428(00)00115-3; Laterra J., 2000, PRINCIPLES NEURAL SC, P1288; Lattanzi A, 2010, HUM MOL GENET, V19, P2208, DOI 10.1093/hmg/ddq099; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; Luca T, 2005, MOL THER, V12, P669, DOI 10.1016/j.ymthe.2005.06.438; Martin R, 2008, PEDIATRICS, V121, pE377, DOI 10.1542/peds.2007-1350; Matheus MG, 2004, NEURORADIOLOGY, V46, P666, DOI 10.1007/s00234-004-1215-1; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Muenzer J, 2006, GENET MED, V8, P465, DOI 10.1097/01.gim.0000232477.37660.fb; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Papisov M, 2010, J NUCL MED, V51; Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90; Passini MA, 2002, J NEUROSCI, V22, P6437; Patel NK, 2007, ACTA NEUROCHIR SUPPL, V97, P135; Proescholdt MG, 2000, NEUROSCIENCE, V95, P577; Qi JY, 1998, PHYS MED BIOL, V43, P1001, DOI 10.1088/0031-9155/43/4/027; Rennels M L, 1990, Adv Neurol, V52, P431; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; RIESELBACH RE, 1962, NEW ENGL J MED, V267, P1273, DOI 10.1056/NEJM196212202672502; Segal MB, 2005, BLOOD-CEREBROSPINAL FLUID BARRIER, P83, DOI 10.1201/9781420023404.sec2; Shihabuddin LS, 2010, NEUROPHARMACOLOGY, V58, P845, DOI 10.1016/j.neuropharm.2009.12.015; *SHIR HUM GEN THER, 2010, EL PACK INS; Soderquist RG, 2010, EXPERT OPIN DRUG DEL, V7, P285, DOI 10.1517/17425240903540205; Tsai SY, 2007, EXP BRAIN RES, V182, P261, DOI 10.1007/s00221-007-1067-0; Vedolin L, 2007, AM J NEURORADIOL, V28, P1029, DOI 10.3174/ajnr.A0510; Vite CH, 2003, GENE THER, V10, P1874, DOI 10.1038/sj.gt.3302087; Voznyi YV, 2001, J INHERIT METAB DIS, V24, P675, DOI 10.1023/A:1012763026526; Woods NB, 2003, BLOOD, V101, P1284, DOI 10.1182/blood-2002-07-2238; Wu X, 2004, CELL MOL LIFE SCI, V61, P2588, DOI 10.1007/s00018-004-4206-9; Zhang Y, 2002, J GENE MED, V4, P183, DOI 10.1002/jgm.255	64	94	98	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2012	7	1							e30341	10.1371/journal.pone.0030341	http://dx.doi.org/10.1371/journal.pone.0030341			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885IH	22279584	Green Submitted, gold, Green Published			2023-01-03	WOS:000299771900061
J	Phelan, EA; Borson, S; Grothaus, L; Balch, S; Larson, EB				Phelan, Elizabeth A.; Borson, Soo; Grothaus, Louis; Balch, Steven; Larson, Eric B.			Association of Incident Dementia With Hospitalizations	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE SENSITIVE CONDITIONS; ALZHEIMERS-DISEASE; PREVENTABLE HOSPITALIZATIONS; HEALTH-CARE; OLDER PATIENTS; MEDICARE; RISK; POPULATION; DIAGNOSIS; ILLNESS	Context Dementia is associated with increased rates and often poorer outcomes of hospitalization, including worsening cognitive status. New evidence is needed to determine whether some admissions of persons with dementia might be potentially preventable. Objective To determine whether dementia onset is associated with higher rates of or different reasons for hospitalization, particularly for ambulatory care-sensitive conditions (ACSCs), for which proactive outpatient care might prevent the need for a hospital stay. Design, Setting, and Participants Retrospective analysis of hospitalizations among 3019 participants in Adult Changes in Thought (ACT), a longitudinal cohort study of adults aged 65 years or older enrolled in an integrated health care system. All participants had no dementia at baseline and those who had a dementia diagnosis during biennial screening contributed nondementia hospitalizations until diagnosis. Automated data were used to identify all hospitalizations of all participants from time of enrollment in ACT until death, disenrollment from the health plan, or end of follow-up, whichever came first. The study period spanned February 1, 1994, to December 31, 2007. Main Outcome Measures Hospital admission rates for patients with and without dementia, for all causes, by type of admission, and for ACSCs. Results Four hundred ninety-four individuals eventually developed dementia and 427 (86%) of these persons were admitted at least once; 2525 remained free of dementia and 1478 (59%) of those were admitted at least once. The unadjusted all-cause admission rate in the dementia group was 419 admissions per 1000 person-years vs 200 admissions per 1000 person-years in the dementia-free group. After adjustment for age, sex, and other potential confounders, the ratio of admission rates for all-cause admissions was 1.41 (95% confidence interval [CI], 1.23-1.61; P<.001), while for ACSCs, the adjusted ratio of admission rates was 1.78 (95% CI, 1.38-2.31; P<.001). Adjusted admission rates classified by body system were significantly higher in the dementia group for most categories. Adjusted admission rates for all types of ACSCs, including bacterial pneumonia, congestive heart failure, dehydration, duodenal ulcer, and urinary tract infection, were significantly higher among those with dementia. Conclusion Among our cohort aged 65 years or older, incident dementia was significantly associated with increased risk of hospitalization, including hospitalization for ACSCs. JAMA. 2012;307(2):165-172 www.jama.com	[Phelan, Elizabeth A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98104 USA; [Phelan, Elizabeth A.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth & Community Med, Seattle, WA 98104 USA; [Borson, Soo] Univ Washington, Dept Psychiat, Div Geriatr Psychiat, Seattle, WA 98104 USA; [Grothaus, Louis; Balch, Steven; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Phelan, EA (corresponding author), Univ Washington, Dept Med, Div Gerontol & Geriatr Med, 325 9th Ave,Box 359755, Seattle, WA 98104 USA.	phelane@uw.edu			National Institute on Aging (NIA); Paul Beeson Physician Faculty Scholars in Aging Research; University of Washington Alzheimer's Disease Research Center (NIA) [P50 AG 005136]; NIA [UO1 AG 06781]; NATIONAL INSTITUTE ON AGING [U01AG006781, P50AG005136, K23AG020982] Funding Source: NIH RePORTER	National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Paul Beeson Physician Faculty Scholars in Aging Research; University of Washington Alzheimer's Disease Research Center (NIA); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was conducted while Dr Phelan was a K23 recipient from the National Institute on Aging (NIA) and a Paul Beeson Physician Faculty Scholars in Aging Research Award recipient. Dr Borson received support from the University of Washington Alzheimer's Disease Research Center (NIA grant P50 AG 005136). ACT is supported by NIA grant UO1 AG 06781 (principal investigator: Dr Larson).	Albert SM, 1999, J GERONTOL A-BIOL, V54, pM267, DOI 10.1093/gerona/54.5.M267; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bradford A, 2009, ALZ DIS ASSOC DIS, V23, P306, DOI 10.1097/WAD.0b013e3181a6bebc; Breitner JCS, 2009, NEUROLOGY, V72, P1899, DOI 10.1212/WNL.0b013e3181a18691; BRESLOW NE, 1983, J AM STAT ASSOC, V78, P1, DOI 10.2307/2287093; Breslow NE, 1996, J AM STAT ASSOC, V91, P14, DOI 10.2307/2291379; Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; Culler SD, 1998, MED CARE, V36, P804, DOI 10.1097/00005650-199806000-00004; Davison A.C., 2003, STAT MODELS, DOI [10.1017/CBO9780511815850, DOI 10.1017/CBO9780511815850]; Ehlenbach WJ, 2010, JAMA-J AM MED ASSOC, V303, P763, DOI 10.1001/jama.2010.167; Fishman PA, 2003, MED CARE, V41, P84, DOI 10.1097/00005650-200301000-00011; Gutterman EM, 1999, J AM GERIATR SOC, V47, P1065, DOI 10.1111/j.1532-5415.1999.tb05228.x; Harris DP, 2009, J AM GERIATR SOC, V57, P2209, DOI 10.1111/j.1532-5415.2009.02572.x; Hilbe J.M., 2007, NEGATIVE BINOMIAL RE; Hill J, 2005, J ALZHEIMERS DIS, V8, P43; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; JORM AF, 1988, BRIT J PSYCHIAT, V152, P209, DOI 10.1192/bjp.152.2.209; Kruzikas D.T., 2000, HCUP FACT BOOK; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson E B, 1990, Aging (Milano), V2, P404; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; LEFEVRE F, 1992, ARCH INTERN MED, V152, P2074, DOI 10.1001/archinte.152.10.2074; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P704, DOI 10.1176/appi.ajp.157.5.704; Malone DC, 2009, AM J MANAG CARE, V15, P481; McCall N, 2001, HEALTH CARE FINANC R, V22, P127; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Natalwala A, 2008, DEMENT GERIATR COGN, V26, P499, DOI 10.1159/000171044; Oster A, 2003, MED CARE, V41, P198, DOI 10.1097/00005650-200302000-00002; Rudolph JL, 2010, J AM GERIATR SOC, V58, P1542, DOI 10.1111/j.1532-5415.2010.02924.x; Russo CA, 2006, HOSP ELDERLY POPULAT; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Saha S, 2007, MED CARE, V45, P712, DOI 10.1097/MLR.0b013e318053717c; Saunders KW, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P223; Taylor DH, 2004, J GERONTOL A-BIOL, V59, P762; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Tuppin P, 2009, DEMENT GERIATR COGN, V28, P225, DOI 10.1159/000238394; US Food and Drug Administration, NAT DRUG COD DIR; WAGNER EH, 1995, PATIENT EDUC COUNS, V26, P225, DOI 10.1016/0738-3991(95)00761-N; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; Zhan CL, 2004, HEALTH SERV RES, V39, P345, DOI 10.1111/j.1475-6773.2004.00231.x; Zhao Y, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-108	47	294	295	3	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	2012	307	2					165	172		10.1001/jama.2011.1964	http://dx.doi.org/10.1001/jama.2011.1964			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	875NP	22235087	Green Accepted, Bronze			2023-01-03	WOS:000299038300028
J	Mukherjee, J; Tremblay, JM; Leysath, CE; Ofori, K; Baldwin, K; Feng, XC; Bedenice, D; Webb, RP; Wright, PM; Smith, LA; Tzipori, S; Shoemaker, CB				Mukherjee, Jean; Tremblay, Jacqueline M.; Leysath, Clinton E.; Ofori, Kwasi; Baldwin, Karen; Feng, Xiaochuan; Bedenice, Daniela; Webb, Robert P.; Wright, Patrick M.; Smith, Leonard A.; Tzipori, Saul; Shoemaker, Charles B.			A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model	PLOS ONE			English	Article							G IMMUNE-COMPLEXES; MONOCLONAL-ANTIBODY; HIGH-AFFINITY; NEUROTOXIN; DOMAIN; AGENTS; NEUTRALIZATION; INHIBITORS; FRAGMENTS; CELLS	Antitoxins are needed that can be produced economically with improved safety and shelf life compared to conventional antisera-based therapeutics. Here we report a practical strategy for development of simple antitoxin therapeutics with substantial advantages over currently available treatments. The therapeutic strategy employs a single recombinant 'targeting agent' that binds a toxin at two unique sites and a 'clearing Ab' that binds two epitopes present on each targeting agent. Co-administration of the targeting agent and the clearing Ab results in decoration of the toxin with up to four Abs to promote accelerated clearance. The therapeutic strategy was applied to two Botulinum neurotoxin (BoNT) serotypes and protected mice from lethality in two different intoxication models with an efficacy equivalent to conventional antitoxin serum. Targeting agents were a single recombinant protein consisting of a heterodimer of two camelid anti-BoNT heavy-chain-only Ab VH (VHH) binding domains and two E-tag epitopes. The clearing mAb was an anti-E-tag mAb. By comparing the in vivo efficacy of treatments that employed neutralizing vs. non-neutralizing agents or the presence vs. absence of clearing Ab permitted unprecedented insight into the roles of toxin neutralization and clearance in antitoxin efficacy. Surprisingly, when a post-intoxication treatment model was used, a toxin-neutralizing heterodimer agent fully protected mice from intoxication even in the absence of clearing Ab. Thus a single, easy-to-produce recombinant protein was as efficacious as polyclonal antiserum in a clinically-relevant mouse model of botulism. This strategy should have widespread application in antitoxin development and other therapies in which neutralization and/or accelerated clearance of a serum biomolecule can offer therapeutic benefit.	[Mukherjee, Jean; Tremblay, Jacqueline M.; Ofori, Kwasi; Baldwin, Karen; Feng, Xiaochuan; Bedenice, Daniela; Tzipori, Saul; Shoemaker, Charles B.] Tufts Cummings Sch Vet Med, Dept Biomed Sci, North Grafton, MA USA; [Leysath, Clinton E.] NIAID, NIH, Bethesda, MD 20892 USA; [Webb, Robert P.; Wright, Patrick M.; Smith, Leonard A.] USA, Med Res Inst Infect Dis, Frederick, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Mukherjee, J (corresponding author), Tufts Cummings Sch Vet Med, Dept Biomed Sci, North Grafton, MA USA.	charles.shoemaker@tufts.edu		Webb, Robert/0000-0001-8253-8979	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH); Department of Health and Human Services [N01-AI-30050, U54 AI057159]; NIAID, Bethesda, MD, USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057159, ZIAAI001031, R29AI030050] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Department of Health and Human Services; NIAID, Bethesda, MD, USA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and the Department of Health and Human Services, under Contract No. N01-AI-30050 and Award Number U54 AI057159. Some work was also supported by the Intramural Research Program of the NIAID, Bethesda, MD, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIAID or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adekar SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003023; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P299; Arnon SS, 2006, NEW ENGL J MED, V354, P462, DOI 10.1056/NEJMoa051926; Casadevall A, 2002, EMERG INFECT DIS, V8, P833, DOI 10.3201/eid0808.010516; Cheng LW, 2009, INFECT IMMUN, V77, P4305, DOI 10.1128/IAI.00405-09; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Davies KA, 2002, ARTHRITIS RHEUM-US, V46, P1028, DOI 10.1002/art.10189; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; Eubanks LM, 2010, ACS MED CHEM LETT, V1, P268, DOI 10.1021/ml100074s; Gibbs WW, 2005, SCI AM, V293, P78, DOI 10.1038/scientificamerican0805-78; Hey T, 2005, TRENDS BIOTECHNOL, V23, P514, DOI 10.1016/j.tibtech.2005.07.007; Johansson AG, 1996, HEPATOLOGY, V24, P169, DOI 10.1053/jhep.1996.v24.pm0008707258; Lauwereys M, 1998, EMBO J, V17, P3512, DOI 10.1093/emboj/17.13.3512; Lovdal T, 2000, J CELL SCI, V113, P3255; Maass DR, 2007, J IMMUNOL METHODS, V324, P13, DOI 10.1016/j.jim.2007.04.008; Maass DR, 2007, INT J PARASITOL, V37, P953, DOI 10.1016/j.ijpara.2007.02.005; Mazuet C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012416; Meng Q, 2012, ANAL BIOCHEM, V421, P351, DOI 10.1016/j.ab.2011.09.030; Mohamed N, 2005, INFECT IMMUN, V73, P795, DOI 10.1128/IAI.73.2.795-802.2005; Mukherjee J, 2002, INFECT IMMUN, V70, P612, DOI 10.1128/IAI.70.2.612-619.2002; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; PEARCE LB, 1994, TOXICOL APPL PHARM, V128, P69, DOI 10.1006/taap.1994.1181; Pless DD, 2001, INFECT IMMUN, V69, P570, DOI 10.1128/IAI.69.1.570-574.2001; Pluckthun A, 1997, IMMUNOTECHNOLOGY, V3, P83, DOI 10.1016/S1380-2933(97)00067-5; Rahbarizadeh F, 2011, IMMUNOL INVEST, V40, P299, DOI 10.3109/08820139.2010.542228; Rainey GJA, 2004, NAT REV MICROBIOL, V2, P721, DOI 10.1038/nrmicro977; Sepulveda J, 2010, INFECT IMMUN, V78, P756, DOI 10.1128/IAI.01084-09; SKAPER SD, 1979, DEV NEUROSCI-BASEL, V2, P233, DOI 10.1159/000112485; Sobel J, 2005, CLIN INFECT DIS, V41, P1167, DOI 10.1086/444507; Tremblay JM, 2010, TOXICON, V56, P990, DOI 10.1016/j.toxicon.2010.07.003; van der Linden RHJ, 1999, BBA-PROTEIN STRUCT M, V1431, P37, DOI 10.1016/S0167-4838(99)00030-8; Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200; Walker K, 2010, IDRUGS, V13, P743; Webb RP, 2009, VACCINE, V27, P4490, DOI 10.1016/j.vaccine.2009.05.030	34	57	62	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2012	7	1							e29941	10.1371/journal.pone.0029941	http://dx.doi.org/10.1371/journal.pone.0029941			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904IR	22238680	Green Published, gold, Green Submitted			2023-01-03	WOS:000301188800050
J	Hu, LL; Chen, C; Huang, T; Cai, YD; Chou, KC				Hu, Le-Le; Chen, Chen; Huang, Tao; Cai, Yu-Dong; Chou, Kuo-Chen			Predicting Biological Functions of Compounds Based on Chemical-Chemical Interactions	PLOS ONE			English	Article							AMINOCYCLOPROPANE CARBOXYLIC-ACID; ORAL ANTIDIABETIC AGENTS; METABOLIC PATHWAYS; DIHYDROPYRIMIDINE DEHYDROGENASE; PROTEIN; THYMINE; BINDING; URACIL; EXPRESSION; MOLECULES	Given a compound, how can we effectively predict its biological function? It is a fundamentally important problem because the information thus obtained may benefit the understanding of many basic biological processes and provide useful clues for drug design. In this study, based on the information of chemical-chemical interactions, a novel method was developed that can be used to identify which of the following eleven metabolic pathway classes a query compound may be involved with: (1) Carbohydrate Metabolism, (2) Energy Metabolism, (3) Lipid Metabolism, (4) Nucleotide Metabolism, (5) Amino Acid Metabolism, (6) Metabolism of Other Amino Acids, (7) Glycan Biosynthesis and Metabolism, (8) Metabolism of Cofactors and Vitamins, (9) Metabolism of Terpenoids and Polyketides, (10) Biosynthesis of Other Secondary Metabolites, (11) Xenobiotics Biodegradation and Metabolism. It was observed that the overall success rate obtained by the method via the 5-fold cross-validation test on a benchmark dataset consisting of 3,137 compounds was 77.97%, which is much higher than 10.45%, the corresponding success rate obtained by the random guesses. Besides, to deal with the situation that some compounds may be involved with more than one metabolic pathway class, the method presented here is featured by the capacity able to provide a series of potential metabolic pathway classes ranked according to the descending order of their likelihood for each of the query compounds concerned. Furthermore, our method was also applied to predict 5,549 compounds whose metabolic pathway classes are unknown. Interestingly, the results thus obtained are quite consistent with the deductions from the reports by other investigators. It is anticipated that, with the continuous increase of the chemical-chemical interaction data, the current method will be further enhanced in its power and accuracy, so as to become a useful complementary vehicle in annotating uncharacterized compounds for their biological functions.	[Hu, Le-Le; Cai, Yu-Dong] Shanghai Univ, Inst Syst Biol, Shanghai, Peoples R China; [Hu, Le-Le; Chen, Chen] Shanghai Univ, Coll Sci, Dept Chem, Shanghai, Peoples R China; [Huang, Tao] Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Syst Biol, Shanghai, Peoples R China; [Huang, Tao] Shanghai Ctr Bioinformat Technol, Shanghai, Peoples R China; [Cai, Yu-Dong] Gordon Life Sci Inst, San Diego, CA USA	Shanghai University; Shanghai University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Hu, LL (corresponding author), Shanghai Univ, Inst Syst Biol, Shanghai, Peoples R China.	cai_yud@yahoo.com.cn	Chou, Kuo-Chen/A-8340-2009	cai, yudong/0000-0001-5664-7979	National Basic Research Program of China [2011CB510102, 2011CB510101]; Shanghai Municipal Education Commission [12ZZ087]	National Basic Research Program of China(National Basic Research Program of China); Shanghai Municipal Education Commission(Shanghai Municipal Education Commission (SHMEC))	This research is supported by the National Basic Research Program of China (2011CB510102, 2011CB510101) and Innovation Program of Shanghai Municipal Education Commission (12ZZ087). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong A, 2003, ORG LETT, V5, P2331, DOI 10.1021/ol0346887; BERGER R, 1984, CLIN CHIM ACTA, V141, P227, DOI 10.1016/0009-8981(84)90014-7; BLAKE DA, 1979, BIOCHEMISTRY-US, V18, P5475, DOI 10.1021/bi00591a033; Bogdanov P, 2010, IEEE ACM T COMPUT BI, V7, P208, DOI 10.1109/TCBB.2009.81; Cai YD, 2008, MOL DIVERS, V12, P131, DOI 10.1007/s11030-008-9085-9; Caspi R, 2008, NUCLEIC ACIDS RES, V36, pD623, DOI [10.1093/nar/gkt1103, 10.1093/nar/gkm900]; Cerny MA, 2006, J AM CHEM SOC, V128, P3346, DOI 10.1021/ja054938+; Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; CHOU KC, 1991, PROTEIN ENG, V4, P661, DOI 10.1093/protein/4.6.661; Chou KC, 2004, CURR MED CHEM, V11, P2105, DOI 10.2174/0929867043364667; CHOU KC, 1995, CRIT REV BIOCHEM MOL, V30, P275, DOI 10.3109/10409239509083488; Chou KC, 2007, ANAL BIOCHEM, V370, P1, DOI 10.1016/j.ab.2007.07.006; Chou KC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018258; Chou KC, 2011, J THEOR BIOL, V273, P236, DOI 10.1016/j.jtbi.2010.12.024; COOK AM, 1984, BIOCHEM J, V222, P315, DOI 10.1042/bj2220315; DAVIS CH, 1984, J BACTERIOL, V158, P347, DOI 10.1128/JB.158.1.347-350.1984; Dea-Ayuela MA, 2008, BIOORGAN MED CHEM, V16, P7770, DOI 10.1016/j.bmc.2008.07.023; Du QS, 2008, CURR PROTEIN PEPT SC, V9, P248, DOI 10.2174/138920308784534005; Dutta S, 2009, MOL BIOTECHNOL, V42, P1, DOI 10.1007/s12033-008-9127-7; Habuchi H, 2006, METHOD ENZYMOL, V416, P225, DOI 10.1016/S0076-6879(06)16014-0; Hu L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017668; Ihlenfeldt WD, 2009, J CHEMINFORMATICS, V1, DOI 10.1186/1758-2946-1-20; ISONO F, 1989, J ANTIBIOT, V42, P667, DOI 10.7164/antibiotics.42.667; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karaoz U, 2004, P NATL ACAD SCI USA, V101, P2888, DOI 10.1073/pnas.0307326101; Kobayashi K, 1998, Gan To Kagaku Ryoho, V25, P1217; Kourmpetis YAI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009293; Krentz AJ, 2005, DRUGS, V65, P385, DOI 10.2165/00003495-200565030-00005; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Leblanc A, 2008, PLANT PHYSIOL, V146, P1928, DOI 10.1104/pp.107.109363; Letovsky S, 2003, BIOINFORMATICS, V19, pi197, DOI 10.1093/bioinformatics/btg1026; Levetan C, 2007, CURR MED RES OPIN, V23, P945, DOI 10.1185/030079907X178766; Lu J, 2009, PROTEIN PEPTIDE LETT, V16, P969, DOI 10.2174/092986609788923374; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Mohler ML, 2009, MED RES REV, V29, P125, DOI 10.1002/med.20142; NAKANISHI Y, 1978, J BIOCHEM-TOKYO, V84, P575, DOI 10.1093/oxfordjournals.jbchem.a132162; Ng KL, 2010, COMPUT BIOL MED, V40, P300, DOI 10.1016/j.compbiomed.2010.01.001; Ohtake S, 2005, J BIOL CHEM, V280, P39115, DOI 10.1074/jbc.M508816200; PODSCHUN B, 1992, BIOCHEM BIOPH RES CO, V182, P609, DOI 10.1016/0006-291X(92)91776-M; RADCHENKO ED, 1983, BIOFIZIKA+, V28, P923; Ralph SG, 2007, PLANT PHYSIOL, V143, P410, DOI 10.1104/pp.106.089425; Remaud G, 2005, J CHROMATOGR B, V823, P98, DOI 10.1016/j.jchromb.2005.05.044; Schapire RE, 1999, MACH LEARN, V37, P297, DOI 10.1023/A:1007614523901; SCHWARTZ AW, 1977, BIOSYSTEMS, V9, P87, DOI 10.1016/0303-2647(77)90016-8; Sharan R, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100129; SILVERMAN RB, 1984, BIOCHEMISTRY-US, V23, P5206, DOI 10.1021/bi00317a019; SIMAGA S, 1978, Z NATURFORSCH C, V33, P1006; Simon AE, 2009, SCHIZOPHR RES, V108, P182, DOI 10.1016/j.schres.2008.11.004; Sirois S, 2004, J CHEM INF COMP SCI, V44, P1111, DOI 10.1021/ci034270n; SLOMIANY BL, 1993, BIOCHEM MOL BIOL INT, V29, P973; SUMI S, 1995, J CHROMATOGR B, V672, P233, DOI 10.1016/0378-4347(95)00228-B; TSUJI M, 1980, BIOCHIM BIOPHYS ACTA, V612, P373, DOI 10.1016/0005-2744(80)90120-5; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	54	15	19	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2011	6	12							e29491	10.1371/journal.pone.0029491	http://dx.doi.org/10.1371/journal.pone.0029491			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897SP	22220213	gold, Green Submitted, Green Published			2023-01-03	WOS:000300677000038
J	Benjamin, M; Gibbs, S				Benjamin, Malvyn; Gibbs, Simon			A PATIENT'S JOURNEY Amyloidosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gibbs, Simon] UCL Med Sch, Natl Amyloidosis Ctr, London NW3 2PF, England	University of London; University College London	Gibbs, S (corresponding author), UCL Med Sch, Natl Amyloidosis Ctr, Royal Free Campus, London NW3 2PF, England.	s.gibbs@ucl.ac.uk	Gibbs, Simon/K-4974-2019						0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d6326	10.1136/bmj.d6326	http://dx.doi.org/10.1136/bmj.d6326			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892DT	22088395	Bronze			2023-01-03	WOS:000300267600001
J	Yohannes, E; Ghosh, SK; Jiang, B; McCormick, TS; Weinberg, A; Hill, E; Faddoul, F; Chance, MR				Yohannes, Elizabeth; Ghosh, Santosh K.; Jiang, Bin; McCormick, Thomas S.; Weinberg, Aaron; Hill, Edward; Faddoul, Faddy; Chance, Mark R.			Proteomic Signatures of Human Oral Epithelial Cells in HIV-Infected Subjects	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; HEAT-SHOCK FACTOR-1; HUMAN-PAPILLOMAVIRUS; LYMPHOBLASTOID-CELLS; PROTEASE INHIBITORS; SIGNALING PATHWAYS; IN-VIVO; EXPRESSION; VIMENTIN	The oral epithelium, the most abundant structural tissue lining the oral mucosa, is an important line of defense against infectious microorganisms. HIV infected subjects on highly active antiretroviral therapy (HAART) are susceptible to comorbid viral, bacterial and fungal infections in the oral cavity. To provide an assessment of the molecular alterations of oral epithelia potentially associated with susceptibility to comorbid infections in such subjects, we performed various proteomic studies on over twenty HIV infected and healthy subjects. In a discovery phase two Dimensional Difference Gel Electrophoresis (2-D DIGE) analyses of human oral gingival epithelial cell (HOEC) lysates were carried out; this identified 61 differentially expressed proteins between HIV-infected on HAART subjects and healthy controls. Down regulated proteins in HIV-infected subjects include proteins associated with maintenance of protein folding and pro-and anti-inflammatory responses (e. g., heat-shock proteins, Cryab, Calr, IL-1RA, and Galectin-3-binding protein) as well as proteins involved in redox homeostasis and detoxification (e. g., Gstp1, Prdx1, and Ero1). Up regulated proteins include: protein disulfide isomerases, proteins whose expression is negatively regulated by Hsp90 (e. g., Ndrg1), and proteins that maintain cellular integrity (e. g., Vimentin). In a verification phase, proteins identified in the protein profiling experiments and those inferred from Ingenuity Pathway Analysis were analyzed using Western blotting analysis on separate HOEC lysate samples, confirming many of the discovery findings. Additionally in HIV-infected patient samples Heat Shock Factor 1 is down regulated, which explains the reduced heat shock responses, while activation of the MAPK signal transduction cascade is observed. Overall, HAART therapy provides an incomplete immune recovery of the oral epithelial cells of the oral cavity for HIV-infected subjects, and the toxic side effects of HAART and/or HIV chronicity silence expression of multiple proteins that in healthy subjects function to provide robust innate immune responses and combat cellular stress.	[Yohannes, Elizabeth; Chance, Mark R.] Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA; [Ghosh, Santosh K.; Jiang, Bin; Weinberg, Aaron; Hill, Edward; Faddoul, Faddy] Case Western Reserve Univ, Sch Dent Med, Cleveland, OH 44106 USA; [McCormick, Thomas S.] Case Western Reserve Univ, Dept Dermatol, Cleveland, OH 44106 USA; [Chance, Mark R.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Yohannes, E (corresponding author), Case Western Reserve Univ, Ctr Prote & Bioinformat, Cleveland, OH 44106 USA.	mark.chance@case.edu	Ghosh, Santosh K/I-5461-2019	Ghosh, Santosh K/0000-0001-5669-7853; McCormick, Thomas/0000-0002-3294-0326; Weinberg, Aaron/0000-0002-9960-7181	National Center for Research Resources [UL1-RR-024989]; National Institute on Drug Abuse [P20-DA-026133]; Center for AIDS Research [P30-AI-036219]; National Institute of Dental and Craniofacial Research [P01-DE-019759]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024989] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [P01DE019759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P20DA026133] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Center for AIDS Research; National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported in part by National Center for Research Resources Grant UL1-RR-024989 (CTSA), National Institute on Drug Abuse Grant P20-DA-026133, Center for AIDS Research Grant P30-AI-036219, and National Institute of Dental and Craniofacial Research Grant P01-DE-019759. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Baumgarth N, 2004, AM J PATHOL, V165, P707, DOI 10.1016/S0002-9440(10)63334-2; Bedimo Roger, 2008, Curr HIV/AIDS Rep, V5, P140, DOI 10.1007/s11904-008-0022-4; Besson C, 2001, BLOOD, V98, P2339, DOI 10.1182/blood.V98.8.2339; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Carter MM, 2007, ENVIRON MOL MUTAGEN, V48, P239, DOI 10.1002/em.20282; Cauda R, 1999, J ACQ IMMUN DEF SYND, V21, P20, DOI 10.1097/00126334-199905010-00003; Challacombe S J, 2006, Adv Dent Res, V19, P29; Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205; Chow YH, 2002, J ACQ IMMUN DEF SYND, V30, P1, DOI 10.1097/00126334-200205010-00001; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14; De Bernardis F, 2004, FEMS IMMUNOL MED MIC, V41, P27, DOI 10.1016/j.femsim.2003.12.006; Fu W, 2009, NUCLEIC ACIDS RES, V37, pD417, DOI 10.1093/nar/gkn708; Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x; Greenspan D, 2004, J DENT RES, V83, P145, DOI 10.1177/154405910408300212; Greenspan D, 1996, LANCET, V348, P729, DOI 10.1016/S0140-6736(96)02308-2; Greenspan D, 2001, LANCET, V357, P1411, DOI 10.1016/S0140-6736(00)04578-5; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Henderson B, 2006, INFECT IMMUN, V74, P3693, DOI 10.1128/IAI.01882-05; HIRATA F, 1990, ADV EXP MED BIOL, V279, P211; Hodgson T A, 2006, Adv Dent Res, V19, P57; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; HONER B, 1991, J CELL SCI, V100, P799; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; Ji JH, 2009, J ORAL PATHOL MED, V38, P591, DOI 10.1111/j.1600-0714.2009.00773.x; Joshi R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013974; Kebba A, 2005, J LEUKOCYTE BIOL, V78, P37, DOI 10.1189/jlb.0105049; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Kins S, 2003, AM J PATHOL, V163, P833, DOI 10.1016/S0002-9440(10)63444-X; Kocsis J, 2003, J MED VIROL, V71, P480, DOI 10.1002/jmv.10507; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; KULKARNI H, J ACQUIR IMMUNE DEFI; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Leao JC, 2009, CLINICS, V64, P459, DOI 10.1590/S1807-59322009000500014; LI X, J VIROL, V85, P715; Liu XA, 2003, J VIROL, V77, P3470, DOI 10.1128/JVI.77.6.3470-3476.2003; May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325; Miele L, 2003, J CLIN INVEST, V111, P19, DOI 10.1172/JCI200317506; MOIR S, ANN REV PATHOL, V6, P223; Muller F, 2000, EUR J CLIN INVEST, V30, P905, DOI 10.1046/j.1365-2362.2000.00727.x; Muller K, 2001, ATHEROSCLEROSIS, V156, P133, DOI 10.1016/S0021-9150(00)00641-9; Nibbe RK, 2009, MOL CELL PROTEOMICS, V8, P827, DOI 10.1074/mcp.M800428-MCP200; Nicchitta CV, 2003, NAT REV IMMUNOL, V3, P427, DOI 10.1038/nri1089; Nicolatou-Galitis O, 2004, ORAL DIS, V10, P145, DOI 10.1046/j.1601-0825.2003.00994.x; Pang S, 2000, J VIROL, V74, P10994, DOI 10.1128/JVI.74.23.10994-11000.2000; Paul S, 1999, J NEUROCHEM, V73, P1964; Perluigi M, 2009, J CELL MOL MED, V13, P1809, DOI 10.1111/j.1582-4934.2008.00465.x; Ptak RG, 2008, AIDS RES HUM RETROV, V24, P1497, DOI 10.1089/aid.2008.0113; RAWAT P, NUCL ACIDS RES; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073; Sundaram M, 2008, INT J INFECT DIS, V12, pE61, DOI 10.1016/j.ijid.2008.04.004; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Torres SM, 2007, ENVIRON MOL MUTAGEN, V48, P224, DOI 10.1002/em.20264; Volter C, 1996, INT J CANCER, V66, P453; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Yohannes E, 2008, MOL CELL PROTEOMICS, V7, P1270, DOI 10.1074/mcp.M700563-MCP200; Zai A, 1999, J CLIN INVEST, V103, P393, DOI 10.1172/JCI4890; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	68	20	20	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2011	6	11							e27816	10.1371/journal.pone.0027816	http://dx.doi.org/10.1371/journal.pone.0027816			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HV	22114700	gold, Green Published, Green Submitted			2023-01-03	WOS:000297555400120
J	Wang, G; Pan, L; Zhang, YG; Wang, YL; Zhang, ZW; Lu, JL; Zhou, P; Fang, YZ; Jiang, ST				Wang, Gang; Pan, Li; Zhang, Yongguang; Wang, Yonglu; Zhang, Zhongwang; Lu, Jianliang; Zhou, Peng; Fang, Yuzhen; Jiang, Shoutian			Intranasal Delivery of Cationic PLGA Nano/Microparticles- Loaded FMDV DNA Vaccine Encoding IL-6 Elicited Protective Immunity against FMDV Challenge	PLOS ONE			English	Article							MOUTH-DISEASE VIRUS; NANOPARTICLES; PARTICLES; MUCOSAL; IMMUNOGENICITY; SYSTEMS; ANTIGEN; INTERLEUKIN-6; IMMUNIZATION; NANOSPHERES	Mucosal vaccination has been demonstrated to be an effective means of eliciting protective immunity against aerosol infections of foot and mouth disease virus (FMDV) and various approaches have been used to improve mucosal response to this pathogen. In this study, cationic PLGA (poly(lactide-co-glycolide)) nano/microparticles were used as an intranasal delivery vehicle as a means administering FMDV DNA vaccine encoding the FMDV capsid protein and the bovine IL-6 gene as a means of enhancing mucosal and systemic immune responses in animals. Three eukaryotic expression plasmids with or without bovine IL-6 gene (pc-P12A3C, pc-IL2AP12A3C and pc-P12AIL3C) were generated. The two latter plasmids were designed with the IL-6 gene located either before or between the P12A and 3C genes, respectively, as a means of determining if the location of the IL-6 gene affected capsid assembly and the subsequent immune response. Guinea pigs and rats were intranasally vaccinated with the respective chitosan-coated PLGA nano/microparticles-loaded FMDV DNA vaccine formulations. Animals immunized with pc-P12AIL3C (followed by animals vaccinated with pc-P12A3C and pc-IL2AP12A3C) developed the highest levels of antigen-specific serum IgG and IgA antibody responses and the highest levels of sIgA (secretory IgA) present in mucosal tissues. However, the highest levels of neutralizing antibodies were generated in pc-IL2AP12A3C-immunized animals (followed by pc-P12AIL3C- and then in pc-P12A3C-immunized animals). pc-IL2AP12A3C-immunized animals also developed stronger cell mediated immune responses (followed by pc-P12AIL3C- and pc-P12A3C-immunized animals) as evidenced by antigen-specific T-cell proliferation and expression levels of IFN-gamma by both CD4+ and CD8+ splenic T cells. The percentage of animals protected against FMDV challenge following immunizations with pc-IL2AP12A3C, pc-P12AIL3C or pc-P12A3C were 3/5, 1/5 and 0/5, respectively. These data suggested that intranasal delivery of cationic PLGA nano/microparticles loaded with various FMDV DNA vaccine formulations encoding IL-6 as a molecular adjuvant enhanced protective immunity against FMDV, particularly pc-IL2AP12A3C with IL-6 gene located before P12A3C gene.	[Wang, Gang; Pan, Li; Zhang, Yongguang; Wang, Yonglu; Zhang, Zhongwang; Lu, Jianliang; Zhou, Peng; Fang, Yuzhen; Jiang, Shoutian] Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Minist Agr, State Key Lab Vet Etiol Biol,Natl Foot & Mouth Di, Lanzhou, Gansu, Peoples R China	Chinese Academy of Agricultural Sciences; Lanzhou Veterinary Research Institute, CAAS; Ministry of Agriculture & Rural Affairs	Wang, G (corresponding author), Chinese Acad Agr Sci, Lanzhou Vet Res Inst, Minist Agr, State Key Lab Vet Etiol Biol,Natl Foot & Mouth Di, Lanzhou, Gansu, Peoples R China.	yongguang.zhang@163.com			European Community [FP7/2007-2013, 226556]; Chinese "863" National Programs for High Technology Research and Development [2011AA10A211]; International Science and Technology Cooperation Program of Gansu Province [1011WCGA160]	European Community(European Commission); Chinese "863" National Programs for High Technology Research and Development(National High Technology Research and Development Program of China); International Science and Technology Cooperation Program of Gansu Province	This work was supported by grants from the European Community's Seventh Framework Programme (FP7/2007-2013)(No. 226556) http://ec.europa.eu/research/fp7/index_en.cfm, Chinese "863" National Programs for High Technology Research and Development (Grant No.: 2011AA10A211) http://www.most.gov.cn/, and the International Science and Technology Cooperation Program of Gansu Province (Grant No. 1011WCGA160) http://www.gsstc.gov.cn/index.php. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS CC, 1995, J GEN VIROL, V76, P3089, DOI 10.1099/0022-1317-76-12-3089; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Armer H, 2008, J VIROL, V82, P10556, DOI 10.1128/JVI.00907-08; Balamurugan V, 2003, VIRUS RES, V92, P141, DOI 10.1016/S0168-1702(02)00357-X; BARTELING SJ, 1991, VACCINE, V9, P75, DOI 10.1016/0264-410X(91)90261-4; Borchard G, 1996, J CONTROL RELEASE, V39, P131, DOI 10.1016/0168-3659(95)00146-8; Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3; Bordelon H, 2011, J NANOMATER, V2011, DOI 10.1155/2011/952060; Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897; Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014; Cao YM, 2009, VET MICROBIOL, V137, P10, DOI 10.1016/j.vetmic.2008.12.007; Cegnar M, 2004, EXP CELL RES, V301, P223, DOI 10.1016/j.yexcr.2004.07.021; Chorny M, 2002, J CONTROL RELEASE, V83, P389, DOI 10.1016/S0168-3659(02)00211-0; de Felipe P, 2004, TRAFFIC, V5, P616, DOI 10.1111/j.1398-9219.2004.00205.x; DU NX, 1989, VET IMMUNOLOGY; Goodwin S, 2009, J VIROL, V83, P11275, DOI 10.1128/JVI.01263-09; Guo HC, 2005, VACCINE, V23, P3236, DOI 10.1016/j.vaccine.2004.03.074; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; HEYDER J, 1984, J AEROSOL SCI, V15, P697, DOI 10.1016/0021-8502(84)90007-7; Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X; Kim SJ, 2003, VIROLOGY, V314, P84, DOI 10.1016/S0042-6822(03)00417-3; Kim SA, 2006, J GENE MED, V8, P1182, DOI 10.1002/jgm.941; Kumar MNVR, 2004, BIOMATERIALS, V25, P1771, DOI 10.1016/j.biomaterials.2003.08.069; La Flamme AC, 2000, J IMMUNOL, V164, P2419, DOI 10.4049/jimmunol.164.5.2419; LEWIS SA, 1991, J VIROL, V65, P6572, DOI 10.1128/JVI.65.12.6572-6580.1991; Mingxiao M, 2007, ANTIVIR RES, V76, P59, DOI 10.1016/j.antiviral.2007.05.003; Mizoe T, 2007, J CONTROL RELEASE, V122, P10, DOI 10.1016/j.jconrel.2007.06.001; Nafee N, 2007, NANOMED-NANOTECHNOL, V3, P173, DOI 10.1016/j.nano.2007.03.006; Ober BT, 1998, J VIROL, V72, P4866, DOI 10.1128/JVI.72.6.4866-4873.1998; Ogra PL, 2001, CLIN MICROBIOL REV, V14, P430, DOI 10.1128/CMR.14.2.430-445.2001; Otten GR, 2005, J VIROL, V79, P8189, DOI 10.1128/JVI.79.13.8189-8200.2005; Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6; Periwal SB, 1999, J VIROL, V73, P7633; Rice J, 1999, VACCINE, V17, P3030, DOI 10.1016/S0264-410X(99)00171-1; ROSEJOHN S, 1993, J BIOL CHEM, V268, P22084; Shiver JW, 1996, J PHARM SCI-US, V85, P1317, DOI 10.1021/js9600991; TERPSTRA C, 1976, VET MICROBIOL, V1, P71, DOI 10.1016/0378-1135(76)90011-0; Tsapis N, 2002, P NATL ACAD SCI USA, V99, P12001, DOI 10.1073/pnas.182233999; [王刚 WANG Gang], 2011, [生物学杂志, Journal of Biology], V28, P1; Wang X, 2008, VACCINE, V26, P5135, DOI 10.1016/j.vaccine.2008.03.088; Weiss R, 1999, VACCINE, V18, P815, DOI 10.1016/S0264-410X(99)00338-2; Wu CN, 2001, VACCINE, V20, P895, DOI 10.1016/S0264-410X(01)00385-1; Xu W, 2004, VACCINE, V22, P3603, DOI 10.1016/j.vaccine.2004.03.033; YANG HC, 1996, IMMUNOLOGY ANIMALS; Yu D., 1997, GUIDELINE ENTRY EXIT	45	48	56	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2011	6	11							e27605	10.1371/journal.pone.0027605	http://dx.doi.org/10.1371/journal.pone.0027605			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HU	22110686	Green Published, gold, Green Submitted			2023-01-03	WOS:000297555300033
J	Moore, W				Moore, Wendy			PAST CARING Backing the wrong horse	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 7	2011	343								d7187	10.1136/bmj.d7187	http://dx.doi.org/10.1136/bmj.d7187			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	848NH	22065676				2023-01-03	WOS:000297057800016
J	London, CA; Bear, MD; McCleese, J; Foley, KP; Paalangara, R; Inoue, T; Ying, WW; Barsoum, J				London, Cheryl A.; Bear, Misty D.; McCleese, Jennifer; Foley, Kevin P.; Paalangara, Reji; Inoue, Takayo; Ying, Weiwen; Barsoum, James			Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer	PLOS ONE			English	Article							MULTIPLE SIGNALING PATHWAYS; SHOCK-PROTEIN 90; MOLECULAR CHAPERONE; CANINE OSTEOSARCOMA; TUMOR-GROWTH; HEAT-SHOCK-PROTEIN-90; CELLS; EXPRESSION; MACHINERY; APOPTOSIS	Background: The novel water soluble compound STA-1474 is metabolized to ganetespib (formerly STA-9090), a potent HSP90 inhibitor previously shown to kill canine tumor cell lines in vitro and inhibit tumor growth in the setting of murine xenografts. The purpose of the following study was to extend these observations and investigate the safety and efficacy of STA-1474 in dogs with spontaneous tumors. Methods and Findings: This was a Phase 1 trial in which dogs with spontaneous tumors received STA-1474 under one of three different dosing schemes. Pharmacokinetics, toxicities, biomarker changes, and tumor responses were assessed. Twenty-five dogs with a variety of cancers were enrolled. Toxicities were primarily gastrointestinal in nature consisting of diarrhea, vomiting, inappetence and lethargy. Upregulation of HSP70 protein expression was noted in both tumor specimens and PBMCs within 7 hours following drug administration. Measurable objective responses were observed in dogs with malignant mast cell disease (n = 3), osteosarcoma (n = 1), melanoma (n = 1) and thyroid carcinoma (n = 1), for a response rate of 24% (6/25). Stable disease (>10 weeks) was seen in 3 dogs, for a resultant overall biological activity of 36% (9/25). Conclusions: This study provides evidence that STA-1474 exhibits biologic activity in a relevant large animal model of cancer. Given the similarities of canine and human cancers with respect to tumor biology and HSP90 activation, it is likely that STA-1474 and ganetespib will demonstrate comparable anti-cancer activity in human patients.	[London, Cheryl A.; Bear, Misty D.; McCleese, Jennifer] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Foley, Kevin P.] GlaxoSmithKline, Translat Biol, Collegeville, PA USA; [Paalangara, Reji] Intervet Schering Plough Anim Hlth, Summit, NJ USA; [Inoue, Takayo] Synta Pharmaceut Corp, Drug Metab & Pharmacokinet, Lexington, MA USA; [Ying, Weiwen] Synta Pharmaceut Corp, Discovery Chem, Lexington, MA USA; [Barsoum, James] Theracrine Inc, Cambridge, MA USA	University System of Ohio; Ohio State University; Merck & Company	London, CA (corresponding author), Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA.	london.20@osu.edu	London, Cheryl/E-6561-2012; Foley, Kevin/ABC-1041-2020	Foley, Kevin/0000-0001-5148-7689	Synta Pharmaceuticals Corp.; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000090] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025755] Funding Source: NIH RePORTER	Synta Pharmaceuticals Corp.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This clinical trial was supported by funding from Synta Pharmaceuticals Corp. The funders contributed to the study design, pharmacokinetic analysis and preparation of manuscript, but had no role in the treatment and evaluation of dogs in this study.	Al Shaer L, 2008, BRIT J HAEMATOL, V141, P483, DOI 10.1111/j.1365-2141.2008.07053.x; Bansal H, 2010, BLOOD; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Beloueche-Babari M, 2010, ONCOTARGET, V1, P185; Chun R, 2003, VET CLIN N AM-SMALL, V33, P491, DOI 10.1016/S0195-5616(03)00021-4; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Dakappagari N, 2010, BIOMARKERS, V15, P31, DOI 10.3109/13547500903261347; Erlichman C, 2009, EXPERT OPIN INV DRUG, V18, P861, DOI 10.1517/13543780902953699; Gray PJ, 2007, CANCER RES, V67, P11942, DOI 10.1158/0008-5472.CAN-07-3162; Holmes JL, 2008, CANCER RES, V68, P1187, DOI 10.1158/0008-5472.CAN-07-3268; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kang BH, 2009, J CLIN INVEST, V119, P454, DOI 10.1172/JCI37613; Lang SA, 2007, CLIN CANCER RES, V13, P6459, DOI 10.1158/1078-0432.CCR-07-1104; Leav I, 2010, AM J PATHOL, V176, P393, DOI 10.2353/ajpath.2010.090521; Lin TY, 2008, EXP HEMATOL, V36, P1266, DOI 10.1016/j.exphem.2008.05.001; London CA, 2003, CLIN CANCER RES, V9, P2755; McCleese JK, 2009, INT J CANCER, V125, P2792, DOI 10.1002/ijc.24660; McCollum AK, 2006, CANCER RES, V66, P10967, DOI 10.1158/0008-5472.CAN-06-1629; McDowell CL, 2009, INT J BIOL MACROMOL, V45, P310, DOI 10.1016/j.ijbiomac.2009.06.012; Mueller F, 2007, ANTICANCER RES, V27, P155; Neckers Len, 2005, Expert Opin Emerg Drugs, V10, P137, DOI 10.1517/14728214.10.1.137; Neznanov N, 2011, ONCOTARGET, V2, P209, DOI 10.18632/oncotarget.246; Paoloni M, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-625; Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Powers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Tsuchida Y, 2001, MED PEDIATR ONCOL, V37, P1, DOI 10.1002/mpo.1154; Vastag B, 2006, NAT BIOTECHNOL, V24, P1307, DOI 10.1038/nbt1106-1307; Veterinary Co-operative Oncology Group, VET COMP ONCOL, V2, P195; Wandinger SK, 2008, J BIOL CHEM, V283, P18473, DOI 10.1074/jbc.R800007200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Williams CR, 2007, J UROLOGY, V178, P1528, DOI 10.1016/j.juro.2007.05.120; Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012; Xu WP, 2007, CLIN CANCER RES, V13, P1625, DOI 10.1158/1078-0432.CCR-06-2966; Yano M, 1996, JPN J CANCER RES, V87, P908, DOI 10.1111/j.1349-7006.1996.tb02119.x; Zhao RM, 2005, BIOCHEM CELL BIOL, V83, P703, DOI 10.1139/O05-158	38	37	41	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 3	2011	6	11							e27018	10.1371/journal.pone.0027018	http://dx.doi.org/10.1371/journal.pone.0027018			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	850LV	22073242	Green Published, Green Submitted, gold			2023-01-03	WOS:000297197000021
J	Hawthorne, DJ; Dively, GP				Hawthorne, David J.; Dively, Galen P.			Killing Them with Kindness? In-Hive Medications May Inhibit Xenobiotic Efflux Transporters and Endanger Honey Bees	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; TRANSEPITHELIAL TRANSPORT; MALPIGHIAN TUBULES; INSECTICIDES; PESTICIDES; TOXICITY; VINBLASTINE; MECHANISMS	Background: Honey bees (Apis mellifera) have recently experienced higher than normal overwintering colony losses. Many factors have been evoked to explain the losses, among which are the presence of residues of pesticides and veterinary products in hives. Multiple residues are present at the same time, though most often in low concentrations so that no single product has yet been associated with losses. Involvement of a combination of residues to losses may however not be excluded. To understand the impact of an exposure to combined residues on honey bees, we propose a mechanism-based strategy, focusing here on Multi-Drug Resistance (MDR) transporters as mediators of those interactions. Methodology/Principal Findings: Using whole-animal bioassays, we demonstrate through inhibition by verapamil that the widely used organophosphate and pyrethroid acaricides coumaphos and tau-fluvalinate, and three neonicotinoid insecticides: imidacloprid, acetamiprid and thiacloprid are substrates of one or more MDR transporters. Among the candidate inhibitors of honey bee MDR transporters is the in-hive antibiotic oxytetracycline. Bees prefed oxytetracycline were significantly sensitized to the acaricides coumaphos and tau-fluvalinate, suggesting that the antibiotic may interfere with the normal excretion or metabolism of these pesticides. Conclusions/Significance: Many bee hives receive regular treatments of oxytetracycline and acaricides for prevention and treatment of disease and parasites. Our results suggest that seasonal co-application of these medicines to bee hives could increase the adverse effects of these and perhaps other pesticides. Our results also demonstrate the utility of a mechanism-based strategy. By identifying pesticides and apicultural medicines that are substrates and inhibitors of xenobiotic transporters we prioritize the testing of those chemical combinations most likely to result in adverse interactions.	[Hawthorne, David J.; Dively, Galen P.] Univ Maryland, Dept Entomol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Hawthorne, DJ (corresponding author), Univ Maryland, Dept Entomol, College Pk, MD 20742 USA.	djh@umd.edu	Serrano, Jose/A-2854-2009	Serrano, Jose/0000-0002-1565-5216	United States Department of Agriculture	United States Department of Agriculture(United States Department of Agriculture (USDA))	This work was supported by the United States Department of Agriculture. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bain LJ, 1997, ENVIRON HEALTH PERSP, V105, P812, DOI 10.1289/ehp.97105812; Bain LJ, 1996, TOXICOL APPL PHARM, V141, P288, DOI 10.1016/S0041-008X(96)80035-4; Buss DS, 2008, PESTIC BIOCHEM PHYS, V90, P141, DOI 10.1016/j.pestbp.2007.12.001; Callaghan A, 2002, ECOTOX ENVIRON SAFE, V52, P211, DOI 10.1006/eesa.2002.2186; Chauzat MP, 2009, ENVIRON ENTOMOL, V38, P514, DOI 10.1603/022.038.0302; Cox-Foster DL, 2007, SCIENCE, V318, P283, DOI 10.1126/science.1146498; DELAPLANE KS, 1994, AM BEE J, V134, P259; Didziapetris R, 2003, J DRUG TARGET, V11, P391, DOI 10.1080/10611860310001648248; Elbert A, 2008, PEST MANAG SCI, V64, P1099, DOI 10.1002/ps.1616; Faucon JP, 2005, PEST MANAG SCI, V61, P111, DOI 10.1002/ps.957; Frazier M, 2008, AM BEE J, V148, P521; Gaertner LS, 1998, J EXP BIOL, V201, P2637; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Iwasa T, 2004, CROP PROT, V23, P371, DOI 10.1016/j.cropro.2003.08.018; Johnson RM, 2009, J ECON ENTOMOL, V102, P474, DOI 10.1603/029.102.0202; Kerboeuf D, 2011, ANTIMICROB AGENTS CH, V55, P2224, DOI 10.1128/AAC.01477-10; Lanning CL, 1996, TOXICOL LETT, V85, P127, DOI 10.1016/0378-4274(96)03654-5; Laurent FM, 2003, J AGR FOOD CHEM, V51, P8005, DOI 10.1021/jf034310n; Leader JP, 2005, J EXP BIOL, V208, P4363, DOI 10.1242/jeb.01911; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Maus Christian, 2003, Bulletin of Insectology, V56, P51; Mayer F, 2009, J NEUROSCI, V29, P3538, DOI 10.1523/JNEUROSCI.5564-08.2009; Mullin CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009754; MURRAY CL, 1994, J NEUROBIOL, V25, P23, DOI 10.1002/neu.480250103; PILLING ED, 1993, PESTIC SCI, V39, P293, DOI 10.1002/ps.2780390407; Podsiadlowski L, 1998, COMP BIOCHEM PHYS B, V121, P443, DOI 10.1016/S0305-0491(98)10137-2; Porretta D, 2008, MED VET ENTOMOL, V22, P48, DOI 10.1111/j.1365-2915.2008.00712.x; Ratnieks FLW, 2010, SCIENCE, V327, P152, DOI 10.1126/science.1185563; Rortais A, 2005, APIDOLOGIE, V36, P71, DOI 10.1051/apido:2004071; Sammataro D, 1998, BEEKEEPERS HDB, P190; Sanford MT, 2010, STOREYS GUIDE KEEPIN; Schrickx J, 2007, J VET PHARMACOL THER, V30, P25, DOI 10.1111/j.1365-2885.2007.00808.x; Spivak M, 2001, APIDOLOGIE, V32, P555, DOI 10.1051/apido:2001103; Sturm A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-170; Tapadia MG, 2005, CELL STRESS CHAPERON, V10, P7, DOI 10.1379/CSC-67R.1; TSURUO T, 1981, CANCER RES, V41, P1967; Vache C, 2007, ENVIRON TOXICOL CHEM, V26, P1418, DOI 10.1897/06-552R.1; vanEngelsdorp D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006481; Winston M.L., 1991, BIOL HONEY BEE	39	63	65	1	73	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2011	6	11							e26796	10.1371/journal.pone.0026796	http://dx.doi.org/10.1371/journal.pone.0026796			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849WB	22073195	Green Published, Green Submitted, gold			2023-01-03	WOS:000297154900037
J	Kassaye, SG; Katzenstein, D				Kassaye, Seble G.; Katzenstein, David			The point of point-of-care testing	LANCET			English	Editorial Material							ART		[Katzenstein, David] Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA; [Kassaye, Seble G.] Elizabeth Glaser Pediat AIDS Fdn, Washington, DC USA	Stanford University	Katzenstein, D (corresponding author), Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.	davidkk@stanford.edu		katzenstein, david/0000-0002-8593-4560	FIC NIH HHS [U2R TW006878] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ALASSANE DP, 2011, J ACQ IMMUN DEF SYND, DOI DOI 10.1097/QAI.0B013E318235B378; Faal M, 2011, JAIDS-J ACQ IMM DEF, V58, pE54, DOI 10.1097/QAI.0b013e3182303921; Jani IV, 2011, LANCET, V378, P1572, DOI 10.1016/S0140-6736(11)61052-0; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Moon S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021409; Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182; Thairu L, 2011, AIDS CARE, V23, P814, DOI 10.1080/09540121.2010.541416; Zijenah LS, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-33	9	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 29	2011	378	9802					1532	1533		10.1016/S0140-6736(11)61520-1	http://dx.doi.org/10.1016/S0140-6736(11)61520-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844SL	22035547				2023-01-03	WOS:000296767500009
J	Chen, C; Scheffler, G; Chandra, A				Chen, Christopher; Scheffler, Gabriel; Chandra, Amitabh			Massachusetts' Health Care Reform and Emergency Department Utilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Chen, Christopher] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Scheffler, Gabriel] Yale Univ, Yale Law Sch, New Haven, CT USA; [Chandra, Amitabh] Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA	Washington University (WUSTL); Yale University; Harvard University	Chen, C (corresponding author), Washington Univ, Sch Med, St Louis, MO 63130 USA.							Chandra A, 2011, NEW ENGL J MED, V364, P293, DOI 10.1056/NEJMp1013067; KYL J, COMMUNICATION   1503; Long SK, 2010, HLTH REFORM MASSACHU; Newhouse JP, 1993, FREE ALL LESSONS RAN	4	51	51	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	2011	365	12								10.1056/NEJMp1109273	http://dx.doi.org/10.1056/NEJMp1109273			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	822WR	21899444				2023-01-03	WOS:000295081600002
J	Foley, RN; Gilbertson, DT; Murray, T; Collins, AJ				Foley, Robert N.; Gilbertson, David T.; Murray, Thomas; Collins, Allan J.			Long Interdialytic Interval and Mortality among Patients Receiving Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUDDEN-DEATH; SURVIVAL; TIME	Background Patients with end-stage renal disease requiring dialysis have limited tolerance of metabolic and volume-related deviations from normal ranges; in addition, the prevalence of cardiovascular disease is high among such patients. Given these problems, we hypothesized that a long interdialytic interval is associated with adverse events in patients receiving hemodialysis. Methods We studied 32,065 participants in the End-Stage Renal Disease Clinical Performance Measures Project, a nationally representative sample of U.S. patients receiving hemodialysis three times weekly, at the end of calendar years 2004 through 2007. We compared rates of death and cardiovascular-related hospital admissions on the day after the long (2-day) interdialytic interval with rates on other days. Results The mean age of the cohort was 62.2 years; 24.2% of the patients had been receiving dialysis treatment for 1 year or less. Over a mean follow-up interval of 2.2 years, the following event rates were higher on the day after the long interval than on other days: all-cause mortality (22.1 vs. 18.0 deaths per 100 person-years, P<0.001), mortality from cardiac causes (10.2 vs. 7.5, P<0.001), infection-related mortality (2.5 vs. 2.1, P=0.007), mortality from cardiac arrest (1.3 vs. 1.0, P=0.004), mortality from myocardial infarction (6.3 vs. 4.4, P<0.001), and admissions for myocardial infarction (6.3 vs. 3.9, P<0.001), congestive heart failure (29.9 vs. 16.9, P<0.001), stroke (4.7 vs. 3.1, P<0.001), dysrhythmia (20.9 vs. 11.0, P<0.001), and any cardiovascular event (44.2 vs. 19.7, P<0.001). Conclusions The long (2-day) interdialytic interval is a time of heightened risk among patients receiving hemodialysis. (Funded by the National Institutes of Health.)	[Foley, Robert N.; Gilbertson, David T.; Murray, Thomas; Collins, Allan J.] US Renal Data Syst, Minneapolis, MN 55404 USA; [Foley, Robert N.; Murray, Thomas; Collins, Allan J.] Univ Minnesota, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities	Foley, RN (corresponding author), US Renal Data Syst, 914 S 8th St,Suite S-406, Minneapolis, MN 55404 USA.	rfoley@usrds.org			National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases [HHSN267200715002C]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Funded by the National Institutes of Health.; Supported by a contract (HHSN267200715002C) from the National Institute of Diabetes and Digestive and Kidney Diseases.	Abbott KC, 2003, AM J KIDNEY DIS, V41, P796, DOI 10.1016/S0272-6386(03)00027-1; Bleyer AJ, 2006, KIDNEY INT, V69, P2268, DOI 10.1038/sj.ki.5000446; Bleyer AJ, 1999, JAMA-J AM MED ASSOC, V281, P1211, DOI 10.1001/jama.281.13.1211; Bleyer AJ, 1999, KIDNEY INT, V55, P1553, DOI 10.1046/j.1523-1755.1999.00391.x; Bliwise DL, 2001, JAMA-J AM MED ASSOC, V286, P2690, DOI 10.1001/jama.286.21.2690; BLIWISE DL, 2002, JAMA-J AM MED ASSOC, V287, P192; Centers for Medicare and Medicaid Services, 2008, REL REP 2000 ESRD CP; Chertow GM, 2011, NEW ENGL J MED, V364, P93; Chertow GM, 2010, NEW ENGL J MED, V363, P2287, DOI 10.1056/NEJMoa1001593; *CTR MED MED SERV, ESRD DEATH NOT END S; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Genovesi S, 2009, NEPHROL DIAL TRANSPL, V24, P2529, DOI 10.1093/ndt/gfp104; Karnik JA, 2001, KIDNEY INT, V60, P350, DOI 10.1046/j.1523-1755.2001.00806.x; Kjellstrand C M, 1975, Kidney Int Suppl, P30; Kjellstrand CM, 1978, KIDNEY INT S, V8, pS120; Lafrance JP, 2006, NEPHROL DIAL TRANSPL, V21, P1006, DOI 10.1093/ndt/gfk007; Office of Clinical Standards and Quality, 2000, 2000 ANN REP ESRD CL; Owen WF, 1999, AM J KIDNEY DIS, V34, pS5, DOI 10.1053/ajkd.1999.v34.aajkd0344b0005; Saran R, 2003, KIDNEY INT, V64, P254, DOI 10.1046/j.1523-1755.2003.00064.x; United States Renal Data System, 2010, 2010 USRDS ANN DAT R	20	302	321	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	2011	365	12					1099	1107		10.1056/NEJMoa1103313	http://dx.doi.org/10.1056/NEJMoa1103313			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822WR	21992122				2023-01-03	WOS:000295081600009
J	Miller, LH; Su, XZ				Miller, Louis H.; Su, Xinzhuan			Artemisinin: Discovery from the Chinese Herbal Garden	CELL			English	Editorial Material							FALCIPARUM; MEFLOQUINE; QINGHAOSU; DRUG	This year's Lasker DeBakey Clinical Research Award goes to Youyou Tu for the discovery of artemisinin and its use in the treatment of malaria-a medical advance that has saved millions of lives across the globe, especially in the developing world.	[Miller, Louis H.; Su, Xinzhuan] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Miller, LH (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.	lmiller@niaid.nih.gov		Su, Xinzhuan/0000-0003-3246-3248	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000892, ZIAAI000241] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000241-27] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		[Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; Charman SA, 2011, P NATL ACAD SCI USA, V108, P4400, DOI 10.1073/pnas.1015762108; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; JIANG JB, 1982, LANCET, V2, P285; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; Klonis N, 2011, P NATL ACAD SCI USA, V108, P11405, DOI 10.1073/pnas.1104063108; LI GQ, 1984, LANCET, V2, P1360; O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7; Ranson H, 2011, TRENDS PARASITOL, V27, P91, DOI 10.1016/j.pt.2010.08.004; Trape JF, 2011, LANCET INFECT DIS, V11, P925, DOI 10.1016/S1473-3099(11)70194-3; TRENHOLME GM, 1975, SCIENCE, V190, P792, DOI 10.1126/science.1105787; Tu YY, 1981, 4 M WHO SCI WORK GRO; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813; Zhang JF, 2006, DETAILED CHRONOLOGIC	15	260	277	2	120	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 16	2011	146	6					855	858		10.1016/j.cell.2011.08.024	http://dx.doi.org/10.1016/j.cell.2011.08.024			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	825GB	21907397	Green Accepted, Bronze			2023-01-03	WOS:000295258100006
J	Lecours, PB; Duchaine, C; Taillefer, M; Tremblay, C; Veillette, M; Cormier, Y; Marsolais, D				Lecours, Pascale Blais; Duchaine, Caroline; Taillefer, Michel; Tremblay, Claudine; Veillette, Marc; Cormier, Yvon; Marsolais, David			Immunogenic Properties of Archaeal Species Found in Bioaerosols	PLOS ONE			English	Article							HYPERSENSITIVITY PNEUMONITIS; DENDRITIC CELLS; CONVENTIONAL LIPOSOMES; METHANOGENIC ARCHAEA; RESPIRATORY VIRUSES; IN-VIVO; INFLAMMATION; RESPONSES; ADJUVANT; ACTIVATION	The etiology of bioaerosol-related pulmonary diseases remains poorly understood. Recently, archaea emerged as prominent airborne components of agricultural environments, but the consequences of airway exposure to archaea remain unknown. Since subcomponents of archaea can be immunogenic, we used a murine model to study the pulmonary immune responses to two archaeal species found in agricultural facilities: Methanobrevibacter smithii (MBS) and Methanosphaera stadtmanae (MSS). Mice were administered intranasally with 6.25, 25 or 100 mu g of MBS or MSS, once daily, 3 days a week, for 3 weeks. MSS induced more severe histopathological alterations than MBS with perivascular accumulation of granulocytes, pronounced thickening of the alveolar septa, alveolar macrophages accumulation and increased perivascular mononucleated cell accumulation. Analyses of bronchoalveolar lavage fluids revealed up to 3 times greater leukocyte accumulation with MSS compared to MBS. Instillation of 100 mu g of MBS or MSS caused predominant accumulation of monocyte/macrophages (4.5 x 10(5) and 4.8 x 10(5) cells/ml respectively) followed by CD4(+) T cells (1.38 x 10(5) and 1.94 x 10(5) cells/ml respectively), B cells (0.73 x 10(5) and 1.28 x 10(5) cells/ml respectively), and CD8(+) T cells (0.20 x 10(5) and 0.31 x 10(5) cells/ml respectively) in the airways. Both archaeal species induced similar titers of antigen-specific IgGs in plasma. MSS but not MBS caused an accumulation of eosinophils and neutrophils in the lungs, which surprisingly, correlated inversely with the size of the inoculum. Stronger immunogenicity of MSS was confirmed by a 3 fold higher accumulation of myeloid dendritic cells in the airways, compared to MBS. Thus, the dose and species of archaea determine the magnitude and nature of the pulmonary immune response. This is the first report of an immunomodulatory role of archaeal species found in bioaerosols.	[Lecours, Pascale Blais; Duchaine, Caroline; Taillefer, Michel; Veillette, Marc; Cormier, Yvon; Marsolais, David] Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Duchaine, Caroline] Univ Laval, Fac Sci & Genie, Dept Biochim Microbiol & Bioinformat, Quebec City, PQ G1K 7P4, Canada; [Tremblay, Claudine] Serv Preclin, Labs Charles River, Montreal, PQ, Canada; [Cormier, Yvon; Marsolais, David] Univ Laval, Fac Med, Dept Med, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Lecours, PB (corresponding author), Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.	David.Marsolais@criucpq.ulaval.ca			Institut de recherche Robert-Sauve en sante et en securite du travail (IRSST)/Canadian Centre for Health and Safety in Agriculture (CCHSA) [099-8640]; Respiratory Health Network of the Fonds de Recherche en Sante du Quebec; La chaire de pneumologie de la Fondation J-D Begin de l'Universite Laval; la Fondation de l'IUCPQ; department de medicine at Laval University	Institut de recherche Robert-Sauve en sante et en securite du travail (IRSST)/Canadian Centre for Health and Safety in Agriculture (CCHSA); Respiratory Health Network of the Fonds de Recherche en Sante du Quebec; La chaire de pneumologie de la Fondation J-D Begin de l'Universite Laval; la Fondation de l'IUCPQ; department de medicine at Laval University	This study was funded by the Institut de recherche Robert-Sauve en sante et en securite du travail (IRSST)/Canadian Centre for Health and Safety in Agriculture (CCHSA) (099-8640; www.irsst.qc.ca; www.cchsa-ccssma.usask.ca) (CD); Respiratory Health Network of the Fonds de Recherche en Sante du Quebec (http://rsr.chus.qc.ca) (DM, CD); and by La chaire de pneumologie de la Fondation J-D Begin de l'Universite Laval and la Fondation de l'IUCPQ (DM). PBL is a Canadian Institutes of Health Research Strategic Training Fellow in Public Health and the Agricultural Rural Ecosystem Training program (PHARE), and received research internship grant from Respiratory Health Network of the Fonds de Recherche en Sante du Quebec. MT has a scholarship from the department de medicine at Laval University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allers T, 2005, NAT REV GENET, V6, P58, DOI 10.1038/nrg1504; *ATS, 1998, RESP HLTH HAZ AGR AM, pS1; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Blanchet MR, 2004, AM J RESP CRIT CARE, V169, P903, DOI 10.1164/rccm.200210-1154OC; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cayer MP, 2007, CAN J MICROBIOL, V53, P92, DOI 10.1139/W06-105; CHEN W, 2010, HUM VACCIN, V6; Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x; Cormier Y, 2000, ARCH ENVIRON HEALTH, V55, P424, DOI 10.1080/00039890009604041; Dakhama A, 1999, AM J RESP CRIT CARE, V159, P1316, DOI 10.1164/ajrccm.159.4.9807085; *DEP HLTH HUM SERV, 2007, PUBL DHHS; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; Dutil S, 2009, J OCCUP ENVIRON HYG, V6, P121, DOI 10.1080/15459620802633957; Gilbert Y, 2010, J OCCUP ENVIRON HYG, V7, P280, DOI 10.1080/15459621003680227; Girard M, 2009, ALLERGY, V64, P322, DOI 10.1111/j.1398-9995.2009.01949.x; Girard M, 2010, CURR OPIN ALLERGY CL, V10, P99, DOI 10.1097/ACI.0b013e3283373bb8; Gudmundsson G, 1997, J CLIN INVEST, V99, P2386, DOI 10.1172/JCI119420; HUET J, 1983, EMBO J, V2, P1291, DOI 10.1002/j.1460-2075.1983.tb01583.x; Israel-Assayag E, 1999, J IMMUNOL, V163, P6794; Kates M, 1992, Biochem Soc Symp, V58, P51; Krishnan L, 2000, INFECT IMMUN, V68, P54, DOI 10.1128/IAI.68.1.54-63.2000; Krishnan L, 2001, J IMMUNOL, V166, P1885, DOI 10.4049/jimmunol.166.3.1885; Krishnan L, 2008, VACCINE, V26, P2043, DOI 10.1016/j.vaccine.2008.02.026; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, J IMMUNOL, V164, P2937, DOI 10.4049/jimmunol.164.6.2937; LECOURS R, 1986, THORAX, V41, P924, DOI 10.1136/thx.41.12.924; Liu YC, 2008, ANN NY ACAD SCI, V1125, P171, DOI 10.1196/annals.1419.019; Marsolais D, 2009, P NATL ACAD SCI USA, V106, P1560, DOI 10.1073/pnas.0812689106; Nance S, 2004, EUR J IMMUNOL, V34, P677, DOI 10.1002/eji.200324634; Nehme B, 2009, APPL ENVIRON MICROB, V75, P5445, DOI 10.1128/AEM.00726-09; Patel GB, 2007, VACCINE, V25, P8622, DOI 10.1016/j.vaccine.2007.09.042; Patel GB, 2010, EXPERT REV VACCINES, V9, P431, DOI 10.1586/ERV.10.34; Poole JA, 2007, J ALLERGY CLIN IMMUN, V120, P366, DOI 10.1016/j.jaci.2007.04.033; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Sprott GD, 2003, METHOD ENZYMOL, V373, P155; Sprott GD, 1999, BBA-MOL CELL BIOL L, V1440, P275, DOI 10.1016/S1388-1981(99)00130-4; Tolson Douglas L., 1996, Journal of Liposome Research, V6, P755, DOI 10.3109/08982109609039925; Wang ZP, 1996, AM J RESP CRIT CARE, V154, P1261, DOI 10.1164/ajrccm.154.5.8912733; Whitehead TR, 1999, FEMS MICROBIOL LETT, V179, P223, DOI 10.1111/j.1574-6968.1999.tb08731.x; Wiley JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007142; Yamabe K, 2010, MOL ORAL MICROBIOL, V25, P112, DOI 10.1111/j.2041-1014.2009.00548.x; Yamabe K, 2008, FEMS MICROBIOL LETT, V287, P69, DOI 10.1111/j.1574-6968.2008.01304.x	42	39	39	9	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2011	6	8							e23326	10.1371/journal.pone.0023326	http://dx.doi.org/10.1371/journal.pone.0023326			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808CT	21858070	Green Published, gold			2023-01-03	WOS:000293953500030
J	Katz, SJ; Morrow, M				Katz, Steven J.; Morrow, Monica			The Challenge of Individualizing Treatments for Patients With Breast Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							WOMEN		[Katz, Steven J.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; [Katz, Steven J.] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA; [Morrow, Monica] Mem Sloan Kettering Canc Ctr, Dept Clin Oncol, New York, NY 10021 USA; [Morrow, Monica] Cornell Univ, Weill Med Coll, New York, NY 10021 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Cornell University	Katz, SJ (corresponding author), Univ Michigan, Dept Med, 300 N Ingalls,Room 7E10, Ann Arbor, MI 48109 USA.	skatz@umich.edu	KATZ, STEVEN/ABH-8886-2020					Anderson WF, 2007, J CLIN ONCOL, V25, P3923, DOI 10.1200/JCO.2007.11.6079; Gilovich T., 2002, HEURISTICS BIASES PS, DOI DOI 10.1017/CBO9780511808098; Haidt J., 2006, HAPPINESS HYPOTHESIS; HEWITT M, 1999, ENSURING QUALITY CAN, P97; Lantz PM, 2005, HEALTH SERV RES, V40, P745, DOI 10.1111/j.1475-6773.2005.00383.x; Morrow M, 2011, LANCET, V378, P1804, DOI 10.1016/S0140-6736(11)61350-0; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Patlak M., 2010, POLICY ISSUES DEV PE; Schwartz B., 2004, PARADOX CHOICE	9	27	27	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2012	307	13					1379	1380		10.1001/jama.2012.409	http://dx.doi.org/10.1001/jama.2012.409			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919AY	22474200				2023-01-03	WOS:000302294200023
J	Bergh, S; Selbaek, G; Engedal, K				Bergh, Sverre; Selbaek, Geir; Engedal, Knut			Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NURSING-HOMES; CORNELL SCALE; PSYCHOTIC SYMPTOMS; ALZHEIMER-DISEASE; DEPRESSION; SERTRALINE; CITALOPRAM; EFFICACY; DISTURBANCES; RELIABILITY	Objective To determine the effect of discontinuing antidepressant treatment in people with dementia and neuropsychiatric symptoms. Design Double blind, randomised, parallel group, placebo controlled trial. Setting Norwegian nursing homes; residents recruited by 16 study centres in Norway from August 2008 to June 2010. Participants 128 patients with Alzheimer's disease, dementia or vascular dementia, and neuropsychiatric symptoms (but no depressive disorder), who had been prescribed escitalopram, citalopram, sertraline, or paroxetine for three months or more. We excluded patients with severe somatic disease or terminal illness, or who were unable to take tablets or capsules as prescribed. Interventions Antidepressant treatment was discontinued over one week in 63 patients, and continued in 68 patients. We assessed patients at baseline, four, seven, 13, and 25 weeks. Main outcome measures Primary outcomes were score differences between study groups in the Cornell scale of depression in dementia and the neuropsychiatric inventory (10 item version) after 25 weeks. Secondary outcomes were score differences in the clinical dementia rating scale, unified Parkinson's disease rating scale, quality of life-Alzheimer's disease scale, Lawton and Brody's physical self maintenance scale, and severe impairment battery. Results Using a linear multilevel model analysis, we found that the discontinued group had significantly higher scores on the Cornell scale after 25 weeks than the continuation group (difference -2.89 (95% confidence interval -4.76 to -1.02); P=0.003). We saw a similar result in the mean total score for the neuropsychiatric inventory after 25 weeks, but this difference was non-significant (-5.96 (-12.35 to 0.44); P=0.068). We confirmed these results by non-response analysis (>30% worsening on the Cornell scale)-significantly more patients worsened in the discontinuation group than in the continuation group (32 (54%) v 17 (29%); P=0.006). We found no significant differences between the groups for secondary outcomes. Forty seven (37%) patients withdrew from the study early. Conclusions Discontinuation of antidepressant treatment in patients with dementia and neuropsychiatric symptoms leads to an increase in depressive symptoms, compared with those patients who continue with treatment.	[Bergh, Sverre; Selbaek, Geir; Engedal, Knut] Innlandet Hosp Trust, Ctr Old Age Psychiat Res, N-2312 Ottestad, Norway; [Selbaek, Geir; Engedal, Knut] Oslo Univ Hosp, Norwegian Ctr Dementia Res, Oslo, Norway; [Engedal, Knut] Univ Oslo, Oslo, Norway	Innlandet Hospital Trust; University of Oslo; University of Oslo	Bergh, S (corresponding author), Innlandet Hosp Trust, Ctr Old Age Psychiat Res, N-2312 Ottestad, Norway.	sverre.bergh@sykehuset-innlandet.no		Selbaek, Geir/0000-0001-6511-8219	Innlandet Hospital Trust; Research Council of Norway; South-Eastern Norway Regional Health Authority	Innlandet Hospital Trust; Research Council of Norway(Research Council of Norway); South-Eastern Norway Regional Health Authority	The study was funded by unrestricted grants from the Innlandet Hospital Trust, the Research Council of Norway, and the South-Eastern Norway Regional Health Authority.	ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; Bains J., 2002, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD003944, DOI 10.1002/14651858.CD003944]; Ballard C, 1997, ACTA NEUROL SCAND, V96, P366; Ballard C, 2010, CNS DRUGS, V24, P729, DOI 10.2165/11319240-000000000-00000; Banerjee S, 2011, LANCET, V378, P403, DOI 10.1016/S0140-6736(11)60830-1; Barca ML, 2008, INT J GERIATR PSYCH, V23, P1058, DOI 10.1002/gps.2033; Barca ML, 2010, DEMENT GERIATR COGN, V29, P438, DOI 10.1159/000313533; Barca ML, 2009, INT J GERIATR PSYCH, V24, P417, DOI 10.1002/gps.2139; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Bergh S, 2008, INT J GERIATR PSYCH, V23, P877, DOI 10.1002/gps.2008; Coupland C, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4551; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Gaber S, 2001, ARCH GERONTOL GERIAT, P159; Henry G, 2011, AM J ALZHEIMERS DIS, V26, P169, DOI 10.1177/1533317511402051; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lyketsos CG, 2003, ARCH GEN PSYCHIAT, V60, P737, DOI 10.1001/archpsyc.60.7.737; Nelson JC, 2011, J AM GERIATR SOC, V59, P577, DOI 10.1111/j.1532-5415.2011.03355.x; NYTH AL, 1990, BRIT J PSYCHIAT, V157, P894, DOI 10.1192/bjp.157.6.894; PANISSET M, 1994, ARCH NEUROL-CHICAGO, V51, P41, DOI 10.1001/archneur.1994.00540130067012; Pollock BG, 2002, AM J PSYCHIAT, V159, P460, DOI 10.1176/appi.ajp.159.3.460; Pollock BG, 2007, AM J GERIAT PSYCHIAT, V15, P942, DOI 10.1097/JGP.0b013e3180cc1ff5; Rosenberg PB, 2010, AM J GERIAT PSYCHIAT, V18, P136, DOI 10.1097/JGP.0b013e3181c796eb; Seitz DP, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008191.pub2; Selbaek G, 2008, AM J GERIAT PSYCHIAT, V16, P528, DOI 10.1097/JGP.0b013e318167ae76; Selbaek G, 2007, INT J GERIATR PSYCH, V22, P843, DOI 10.1002/gps.1749; Selbaek G, 2012, INT PSYCHOGERIATR, V24, P62, DOI 10.1017/S104161021100086X; Siddique H, 2009, J CLIN PSYCHIAT, V70, P915, DOI 10.4088/JCP.08m04828; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; Steinberg M, 2004, INT J GERIATR PSYCH, V19, P19, DOI 10.1002/gps.1025; Thorgrimsen L, 2003, ALZ DIS ASSOC DIS, V17, P201, DOI 10.1097/00002093-200310000-00002; Weintraub D, 2010, AM J GERIAT PSYCHIAT, V18, P332, DOI 10.1097/JGP.0b013e3181cc0333; Wetzels R, 2010, INT PSYCHOGERIATR, V22, P1040, DOI 10.1017/S1041610210000918; Wetzels RB, 2010, AM J GERIAT PSYCHIAT, V18, P1054, DOI 10.1097/JGP.0b013e3181f60fa1	33	80	80	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 9	2012	344								e1566	10.1136/bmj.e1566	http://dx.doi.org/10.1136/bmj.e1566			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908HS	22408266	hybrid			2023-01-03	WOS:000301482100001
J	Baselga, J; Bradbury, I; Eidtmann, H; Di Cosimo, S; de Azambuja, E; Aura, C; Gomez, H; Dinh, P; Fauria, K; Van Dooren, V; Aktan, G; Goldhirsch, A; Chang, TW; Horvath, Z; Coccia-Portugal, M; Domont, J; Tseng, LM; Kunz, G; Sohn, JH; Semiglazov, V; Lerzo, G; Palacova, M; Probachai, V; Pusztai, L; Untch, M; Gelber, RD; Piccart-Gebhart, M				Baselga, Jose; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; Van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horvath, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard D.; Piccart-Gebhart, Martine		NeoALTTO Study Team	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial	LANCET			English	Article							ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; APOPTOSIS; GW572016; SAFETY; WOMEN; ERBB2	Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy. Methods In this parallel groups, randomised, open-label, phase 3 study undertaken between Jan 5, 2008, and May 27, 2010, women from 23 countries with HER2-positive primary breast cancer with tumours greater than 2 cm in diameter were randomly assigned to oral lapatinib (1500 mg), intravenous trastuzumab (loading dose 4 mg/kg, subsequent doses 2 mg/kg), or lapatinib (1000 mg) plus trastuzumab. Treatment allocation was by stratified, permuted blocks randomisation, with four stratification factors. Anti-HER2 therapy alone was given for the first 6 weeks; weekly paclitaxel (80 mg/m(2)) was then added to the regimen for a further 12 weeks, before definitive surgery was undertaken. After surgery, patients received adjuvant chemotherapy followed by the same targeted therapy as in the neoadjuvant phase to 52 weeks. The primary endpoint was the rate of pathological complete response (pCR), analysed by intention to treat. This trial is registered with ClinicalTrials.gov, NCT00553358. Findings 154 patients received lapatinib, 149 trastuzumab, and 152 the combination. pCR rate was significantly higher in the group given lapatinib and trastuzumab (78 of 152 patients [51.3%; 95% CI 43.1-59.5]) than in the group given trastuzumab alone (44 of 149 patients [29.5%; 22.4-37.5]; difference 21.1%, 9.1-34.2, p=0.0001). We recorded no significant difference in pCR between the lapatinib (38 of 154 patients [24.7%, 18.1-32.3]) and the trastuzumab (difference -4.8%, -17.6 to 8.2, p=0.34) groups. No major cardiac dysfunctions occurred. Frequency of grade 3 diarrhoea was higher with lapatinib (36 patients [23.4%]) and lapatinib plus trastuzumab (32 [21.1%]) than with trastuzumab (three [2.0%]). Similarly, grade 3 liver-enzyme alterations were more frequent with lapatinib (27 [17.5%]) and lapatinib plus trastuzumab (15 [9.9%]) than with trastuzumab (11 [7.4%]). Interpretation Dual inhibition of HER2 might be a valid approach to treatment of HER2-positive breast cancer in the neoadjuvant setting.	[Baselga, Jose] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Baselga, Jose; Di Cosimo, Serena; Fauria, Karine] SOLTI Breast Canc Res Grp, Barcelona, Spain; [Bradbury, Ian] Frontier Sci Scotland, Kincraig, Scotland; [Bradbury, Ian] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Eidtmann, Holger] Univ Hosp Kiel, Kiel, Germany; [Di Cosimo, Serena] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain; [Aura, Claudia] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [de Azambuja, Evandro; Van Dooren, Veerle] Inst Jules Bordet, Breast European Adjuvant Study Team, B-1000 Brussels, Belgium; [Dinh, Phuong] Inst Jules Bordet, Breast Int Grp, B-1000 Brussels, Belgium; [Piccart-Gebhart, Martine] Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium; [Gomez, Henry] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Aktan, Gursel] GlaxoSmithKline, Collegeville, PA USA; [Goldhirsch, Aron] European Inst Oncol, Milan, Italy; [Goldhirsch, Aron] St Anna Clin, Swiss Ctr Breast Hlth, Lugano, Switzerland; [Chang, Tsai-Wang] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan; [Horvath, Zsolt] Natl Inst Oncol, Budapest, Hungary; [Coccia-Portugal, Maria] Eastleigh Breast Care Ctr, Pretoria, South Africa; [Domont, Julien] Inst Gustave Roussy, Villejuif, France; [Tseng, Ling-Min] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Taipei 112, Taiwan; [Kunz, Georg] St Johannes Hosp, Dortmund, Germany; [Sohn, Joo Hyuk] Yonsei Univ, Coll Med, Seoul, South Korea; [Semiglazov, Vladimir] Petrov Res Inst Oncol, St Petersburg, Russia; [Lerzo, Guillermo] Invest Clin Ciudad Autonoma Buenos Aires, Buenos Aires, DF, Argentina; [Palacova, Marketa] Masarykuv Onkol Ustav, Brno, Czech Republic; [Probachai, Volodymyr] City Clin Hosp, Dnepropetrovsk, Ukraine; [Pusztai, Lajos] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Untch, Michael] Charite, Clin Gynaecol Gynaecol Oncol & Obstet, Breast Canc Ctr, D-13353 Berlin, Germany; [Gelber, Richard D.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Gelber, Richard D.] Frontier Sci & Technol Res Fdn Inc, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; SOLTI Breast Cancer Research Group; Queens University Belfast; University of Kiel; Schleswig Holstein University Hospital; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Institut Jules Bordet; Breast International Group; Institut Jules Bordet; Institut Jules Bordet; Instituto Nacional de Enfermedades Neoplasicas; GlaxoSmithKline; IRCCS European Institute of Oncology (IEO); National Cheng Kung University; National Cheng Kung University Hospital; National Institute of Oncology Hungary; UNICANCER; Gustave Roussy; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; St. Johannes Hospital; Yonsei University; Yonsei University Health System; N.N. Petrov Research Institute of Oncology; Masaryk Memorial Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Dana-Farber Cancer Institute; Frontier Science Foundation	Baselga, J (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA.	jbaselga@partners.org	Ferro, Antonella/AAA-8241-2020; Kwong, Ava/D-8005-2013; Pusztai, Lajos/AAB-2901-2019; Horvath, Zsolt/B-9524-2012; , Di Cosimo Serena/E-9418-2017	Ferro, Antonella/0000-0003-4109-6769; Kwong, Ava/0000-0002-6968-9489; Horvath, Zsolt/0000-0002-5376-7737; , Di Cosimo Serena/0000-0002-4666-8052; Sohn, Joohyuk/0000-0002-2303-2764; de Azambuja, Evandro/0000-0001-9501-4509; Ciruelos, Eva/0000-0002-2796-1042; Llombart Cussac, Antonio/0000-0003-4515-8293; Gomez, Henry/0000-0003-2660-1843; Hickish, Tamas/0000-0001-6770-7279; Semiglazov, Vladimir/0000-0003-0077-9619	GlaxoSmithKline; Roche; Novartis; Amgen; Abbott; AstraZeneca; Pfizer; Sanofi; Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Roche(Roche Holding); Novartis(Novartis); Amgen(Amgen); Abbott(Abbott Laboratories); AstraZeneca(AstraZeneca); Pfizer(Pfizer); Sanofi; Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JB has received honoraria from Roche. IB's institution has received funding from GlaxoSmithKline and Roche. HE has been a speaker and received travel grants from GlaxoSmithKline. SDC has been a speaker for GlaxoSmithKline. EdA has served on an advisory board and received a travelling grant from GlaxoSmithKline, and has been a speaker for Roche. KF's institution has received travelling grants from GlaxoSmithKline. VVD's and T-WC's institutions have received research funding from GlaxoSmithKline. AG has received honoraria from GlaxoSmithKline and Roche. T-WC has been a speaker for GlaxoSmithKline, Roche, Novartis, and Amgen; and has received consultancy funding from GlaxoSmithKline, Roche, Abbott, AstraZeneca, Novartis, and Amgen. LP has received consultancy fees from Pfizer, Sanofi, and Bristol-Myers Squibb; and research grants from Bristol-Myers Squibb and AstraZeneca. RDG's institution has received research funding from GlaxoSmithKline and Roche. MP-G has received honoraria from GlaxoSmithKline and Roche, and her institution has received research funding from GlaxoSmithKline. GA is a salaried employee of GlaxoSmithKline and retains stock and stock options at the company. The other authors declare that they have no conflicts of interest.	Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; Chang JCN, 2011, ASCO M S, V29, P505; Cox D.R., 1989, CONCISE ENCY STAT; Crown JP, 2007, J CLIN ONCOL, V25; Dang C, 2010, J CLIN ONCOL, V28, P2982, DOI 10.1200/JCO.2009.26.5900; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Fisher ER, 2002, CANCER-AM CANCER SOC, V95, P681, DOI 10.1002/cncr.10741; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Guarneri V, 2011, J CLIN ONCOL S, P507; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Holmes FA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.506; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Mohsin SK, 2005, J CLIN ONCOL, V23, P2460, DOI 10.1200/JCO.2005.00.661; Moy B, 2009, J CLIN ONCOL, V27; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Untch M, 2011, CANC RES S2, V70, pP1; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Xia WL, 2005, ONCOGENE, V24, P6213, DOI 10.1038/sj.onc.1208774	30	944	989	4	118	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					633	640		10.1016/S0140-6736(11)61847-3	http://dx.doi.org/10.1016/S0140-6736(11)61847-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22257673	Green Accepted			2023-01-03	WOS:000300629000034
J	Taylor, KG				Taylor, Kenneth G.			PERSONAL VIEW There's no evidence that 25% of hospital patients would be better off cared for out of hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material												kandgtaylor@blueyonder.co.uk						2011, BRIT MED J, V343; 2011, BRIT MED J, V343	2	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 25	2012	344								e587	10.1136/bmj.e587	http://dx.doi.org/10.1136/bmj.e587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277545				2023-01-03	WOS:000299778800018
J	Hotta, K; Kiura, K; Fujiwara, Y; Takigawa, N; Hisamoto, A; Ichihara, E; Tabata, M; Tanimoto, M				Hotta, Katsuyuki; Kiura, Katsuyuki; Fujiwara, Yoshiro; Takigawa, Nagio; Hisamoto, Akiko; Ichihara, Eiki; Tabata, Masahiro; Tanimoto, Mitsune			Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIALS; CISPLATIN PLUS GEMCITABINE; ADVANCED COLORECTAL-CANCER; CLINICAL-TRIALS; COMPARING CISPLATIN; SUPPORTIVE CARE; BREAST-CANCER; RESPONSE RATE; END-POINT; METAANALYSIS	Background: In advanced non-small-cell lung cancer (NSCLC), with the increasing number of active compounds available in salvage settings, survival after progression to first-line chemotherapy seems to have improved. A literature survey was conducted to examine whether survival post-progression (SPP) has improved over the years and to what degree SPP correlates with overall survival (OS). Methods and Findings: Median progression-free survival (MPFS) time and median survival time (MST) were extracted in phase III trials of first-line chemotherapy for advanced NSCLC. SPP was pragmatically defined as the time interval of MST minus MPFS. The relationship between MPFS and MST was modeled in a linear function. We used the coefficient of determination (r(2)) to assess the correlation between them. Seventy trials with 145 chemotherapy arms were identified. Overall, median SPP was 4.7 months, and a steady improvement in SPP was observed over the 20 years (9.414-day increase per year; p,<0.001) in parallel to the increase in MST (11.253-day increase per year; p<0.001); MPFS improved little (1.863-day increase per year). Overall, a stronger association was observed between MST and SPP (r(2) = 0.8917) than MST and MPFS time (r(2) = 0.2563), suggesting SPP and MPFS could account for 89% and 25% of the variation in MST, respectively. The association between MST and SPP became closer over the years (r(2) = 0.4428, 0.7242, and 0.9081 in 1988-1994, 1995-2001, and 2002-2007, respectively). Conclusions: SPP has become more closely associated with OS, potentially because of intensive post-study treatments. Even in advanced NSCLC, a PFS advantage is unlikely to be associated with an OS advantage any longer due to this increasing impact of SPP on OS, and that the prolongation of SPP might limit the original role of OS for assessing true efficacy derived from early-line chemotherapy in future clinical trials.	[Hotta, Katsuyuki; Kiura, Katsuyuki; Fujiwara, Yoshiro; Takigawa, Nagio; Hisamoto, Akiko; Ichihara, Eiki; Tabata, Masahiro; Tanimoto, Mitsune] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan	Okayama University	Hotta, K (corresponding author), Okayama Univ Hosp, Dept Resp Med, Okayama, Japan.	khotta@md.okayama-u.ac.jp	KIURA, Katsuyuki/B-1991-2011	Kiura, Katsuyuki/0000-0002-9172-9379				Bowater RJ, 2008, CANCER LETT, V262, P48, DOI 10.1016/j.canlet.2007.11.032; Broglio KR, 2009, JNCI-J NATL CANCER I, V101, P1642, DOI 10.1093/jnci/djp369; Burdett S, 2008, J CLIN ONCOL, V26, P4617, DOI 10.1200/JCO.2008.17.7162; Buyse M, 2007, J CLIN ONCOL, V25, P5218, DOI 10.1200/JCO.2007.11.8836; Di Leo A, 2003, J CLIN ONCOL, V21, P2045, DOI 10.1200/JCO.2003.99.089; FUJIWARA Y, 2010, ANN ONCOL IN PRESS; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Hotta K, 2005, CRIT REV ONCOL HEMAT, V55, P45, DOI 10.1016/j.critrevonc.2005.01.006; Hotta K, 2004, J CLIN ONCOL, V22, P3852, DOI 10.1200/JCO.2004.02.109; Hotta K, 2004, J CLIN ONCOL, V22, P3860, DOI 10.1200/JCO.2004.01.153; Hotta K, 2009, ANN ONCOL, V20, P829, DOI 10.1093/annonc/mdp020; Hotta K, 2004, ANN ONCOL, V15, P1782, DOI 10.1093/annonc/mdh476; HOTTA K, 2010, P AM SOC CLIN ONC; Hotta K, 2007, J THORAC ONCOL, V2, P402, DOI 10.1097/01.JTO.0000268673.95119.c7; Hotta K, 2007, CANCER-AM CANCER SOC, V109, P939, DOI 10.1002/cncr.22478; Hotta K, 2007, J THORAC ONCOL, V2, P96, DOI 10.1097/JTO.0b013e31802bb010; Hotta K, 2009, J THORAC ONCOL, V4, P311, DOI 10.1097/JTO.0b013e3181989bd2; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Louvet C, 2001, CANCER, V91, P2033, DOI 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J; Oze I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007835; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Piedbois P, 2004, J CLIN ONCOL, V22, P3839, DOI 10.1200/JCO.2004.06.924; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Saad ED, 2010, J CLIN ONCOL, V28, P1958, DOI 10.1200/JCO.2009.25.5414; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Soria JC, 2010, ANN ONCOL, V21, P2324, DOI 10.1093/annonc/mdq204; Yamanaka Takeharu, 2006, Int J Clin Oncol, V11, P167, DOI 10.1007/s10147-006-0580-7; Yothers G, 2007, J CLIN ONCOL, V25, P5153, DOI 10.1200/JCO.2007.13.6796	32	64	64	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2011	6	11							e26646	10.1371/journal.pone.0026646	http://dx.doi.org/10.1371/journal.pone.0026646			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HZ	22114662	gold, Green Published, Green Submitted			2023-01-03	WOS:000297555800007
J	Cools, F				Cools, Filip			A new method of surfactant administration in preterm infants	LANCET			English	Editorial Material							CPAP		Univ Ziekenhuis Brussel, B-1090 Brussels, Belgium	University Hospital Brussels; Vrije Universiteit Brussel	Cools, F (corresponding author), Univ Ziekenhuis Brussel, B-1090 Brussels, Belgium.	filip.cools@uzbrussel.be		Cools, Filip/0000-0002-6581-7009				Bhandari V, 2005, PEDIATRICS, V116, P352, DOI 10.1542/peds.2004-2123; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Gopel W, 2011, LANCET, V378, P1627, DOI 10.1016/S0140-6736(11)60986-0; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Seger N, 2009, COCHRANE DB SYST REV, V2; VERDER H, 1994, NEW ENGL J MED, V331, P1051, DOI 10.1056/NEJM199410203311603	7	5	5	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 5	2011	378	9803					1607	1608		10.1016/S0140-6736(11)61339-1	http://dx.doi.org/10.1016/S0140-6736(11)61339-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844ST	21963185				2023-01-03	WOS:000296768300008
J	Butala, NM; Desai, MM; Linnander, EL; Wong, YR; Mikhail, DG; Ott, LS; Spertus, JA; Bradley, EH; Aaty, AA; Abdelfattah, A; Gamal, A; Kholeif, H; El Baz, M; Allam, AH; Krumholz, HM				Butala, Neel M.; Desai, Mayur M.; Linnander, Erika L.; Wong, Y. Rex; Mikhail, Daoud G.; Ott, Lesli S.; Spertus, John A.; Bradley, Elizabeth H.; Aaty, Ahmed Abdel; Abdelfattah, Alia; Gamal, Ayman; Kholeif, Hatem; El Baz, Mohamed; Allam, A. H.; Krumholz, Harlan M.			Gender Differences in Presentation, Management, and In-Hospital Outcomes for Patients with AMI in a Lower-Middle Income Country: Evidence from Egypt	PLOS ONE			English	Article							ACUTE-CORONARY-SYNDROME; ACUTE MYOCARDIAL-INFARCTION; SEX-DIFFERENCES; WOMEN; MEN; SYMPTOMS; REGISTRY; IMPACT	Background: Many studies in high-income countries have investigated gender differences in the care and outcomes of patients hospitalized with acute myocardial infarction (AMI). However, little evidence exists on gender differences among patients with AMI in lower-middle-income countries, where the proportion deaths stemming from cardiovascular disease is projected to increase dramatically. This study examines gender differences in patients in the lower-middle-income country of Egypt to determine if female patients with AMI have a different presentation, management, or outcome compared with men. Methods and Findings: Using registry data collected over 18 months from 5 Egyptian hospitals, we considered 1204 patients (253 females, 951 males) with a confirmed diagnosis of AMI. We examined gender differences in initial presentation, clinical management, and in-hospital outcomes using t-tests and x(2) tests. Additionally, we explored gender differences in in-hospital death using multivariate logistic regression to adjust for age and other differences in initial presentation. We found that women were older than men, had higher BMI, and were more likely to have hypertension, diabetes mellitus, dyslipidemia, heart failure, and atrial fibrillation. Women were less likely to receive aspirin upon admission (p<0.01) or aspirin or statins at discharge (p = 0.001 and p<0.05, respectively), although the magnitude of these differences was small. While unadjusted in-hospital mortality was significantly higher for women (OR: 2.10; 95% CI: 1.54 to 2.87), this difference did not persist in the fully adjusted model (OR: 1.18; 95% CI: 0.55 to 2.55). Conclusions: We found that female patients had a different profile than men at the time of presentation. Clinical management of men and women with AMI was similar, though there are small but significant differences in some areas. These gender differences did not translate into differences in in-hospital outcome, but highlight differences in quality of care and represent important opportunities for improvement.	[Butala, Neel M.; Desai, Mayur M.; Bradley, Elizabeth H.; Krumholz, Harlan M.] Yale Univ, Robert Wood Johnson Clin Scholars Program, Dept Internal Med, Sch Med, New Haven, CT 06520 USA; [Desai, Mayur M.; Linnander, Erika L.; Wong, Y. Rex; Bradley, Elizabeth H.; Krumholz, Harlan M.] Yale Univ, Sch Publ Hlth, New Haven, CT USA; [Desai, Mayur M.; Mikhail, Daoud G.; Ott, Lesli S.; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Spertus, John A.] Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA; [Aaty, Ahmed Abdel] Univ Alexandria, Alexandria, Egypt; [Abdelfattah, Alia] Cairo Univ, Cairo, Egypt; [Gamal, Ayman] Medinat Nasr Hosp, Cairo, Egypt; [Kholeif, Hatem; El Baz, Mohamed; Allam, A. H.] Al Azhar Univ, Cairo, Egypt	Yale University; Yale University; Yale University; Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Al Azhar University	Butala, NM (corresponding author), Yale Univ, Robert Wood Johnson Clin Scholars Program, Dept Internal Med, Sch Med, New Haven, CT 06520 USA.	neel.butala@yale.edu	, Harlan/AAI-2875-2020; Spertus, John/ABD-3075-2021	Desai, Mayur/0000-0001-6616-0945; Linnander, Erika/0000-0002-3417-1049	National Bank of Egypt; Wilbur Downs Fellowship	National Bank of Egypt; Wilbur Downs Fellowship	This research was supported by the National Bank of Egypt and the Wilbur Downs Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfredsson J, 2007, HEART, V93, P1357, DOI 10.1136/hrt.2006.102012; Anand SS, 2005, J AM COLL CARDIOL, V46, P1845, DOI 10.1016/j.jacc.2005.05.091; Arslanian-Engoren C, 2006, AM J CARDIOL, V98, P1177, DOI 10.1016/j.amjcard.2006.05.049; Bello N, 2004, PROG CARDIOVASC DIS, V46, P287, DOI 10.1016/j.pcad.2003.08.001; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Centers for Medicare & Medicaid Services The Joint Commission, 2011, SPEC MAN NAT HOSP IN; Dey S, 2009, HEART, V95, P20, DOI 10.1136/hrt.2007.138537; El-Menyar A, 2009, AM J CARDIOL, V104, P1018, DOI 10.1016/j.amjcard.2009.06.003; Hasdai D, 2003, AM J CARDIOL, V91, P1466, DOI 10.1016/S0002-9149(03)00400-4; Heer T, 2006, AM J CARDIOL, V98, P160, DOI 10.1016/j.amjcard.2006.01.072; Hochman JS, 1999, NEW ENGL J MED, V341, P226, DOI 10.1056/NEJM199907223410402; Jneid H, 2008, CIRCULATION, V118, P2803, DOI 10.1161/CIRCULATIONAHA.108.789800; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Meischke H, 1998, AM J EMERG MED, V16, P363, DOI 10.1016/S0735-6757(98)90128-0; Njolstad I, 1996, CIRCULATION, V93, P450; Peterson ED, 2010, HEART, V96, P1798, DOI 10.1136/hrt.2010.200261; Radovanovic D, 2007, HEART, V93, P1369, DOI 10.1136/hrt.2006.106781; Safavi K, 2010, ASIA-PAC J PUBLIC HE, V22, p90S, DOI 10.1177/1010539510373017; Shafey O, 2003, TOBACCO CONTROL COUN; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; Song XT, 2007, CHINESE MED J-PEKING, V120, P1063, DOI 10.1097/00029330-200706020-00007; Srichaiveth Boonchu, 2007, Journal of the Medical Association of Thailand, V90, P65; Vaccarino V, 2005, NEW ENGL J MED, V353, P671, DOI 10.1056/NEJMsa032214; Vaccarino V, 1998, ARCH INTERN MED, V158, P2054, DOI 10.1001/archinte.158.18.2054; WHO, 2002, REDUCING RISKS PROMO; World Bank Group, 2011, COUNTR LEND GROUPS; World Health Organization, 2003, WORLD HLTH REP 2003; World Health Organization (WHO), 2006, HLTH SYST PROF EG; ZUBAID M, 2007, PRELIMINARY RESULTS	29	18	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2011	6	10							e25904	10.1371/journal.pone.0025904	http://dx.doi.org/10.1371/journal.pone.0025904			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834QT	22022463	Green Submitted, gold, Green Published			2023-01-03	WOS:000295978600031
J	Merry, AF; Webster, CS; Hannam, J; Mitchell, SJ; Henderson, R; Reid, P; Edwards, KE; Jardim, A; Pak, N; Cooper, J; Hopley, L; Frampton, C; Short, TG				Merry, Alan F.; Webster, Craig S.; Hannam, Jacqueline; Mitchell, Simon J.; Henderson, Robert; Reid, Papaarangi; Edwards, Kylie-Ellen; Jardim, Anisoara; Pak, Nick; Cooper, Jeremy; Hopley, Lara; Frampton, Chris; Short, Timothy G.			Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: prospective randomised clinical evaluation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATION ERROR; INTENSIVE-CARE; SAFETY; WORKLOAD; TECHNOLOGY; HAWTHORNE; ACCURACY; TIME	Objective To clinically evaluate a new patented multimodal system (SAFERSleep) designed to reduce errors in the recording and administration of drugs in anaesthesia. Design Prospective randomised open label clinical trial. Setting Five designated operating theatres in a major tertiary referral hospital. Participants Eighty nine consenting anaesthetists managing 1075 cases in which there were 10 764 drug administrations. Intervention Use of the new system (which includes customised drug trays and purpose designed drug trolley drawers to promote a well organised anaesthetic workspace and aseptic technique; pre-filled syringes for commonly used anaesthetic drugs; large legible colour coded drug labels; a barcode reader linked to a computer, speakers, and touch screen to provide automatic auditory and visual verification of selected drugs immediately before each administration; automatic compilation of an anaesthetic record; an on-screen and audible warning if an antibiotic has not been administered within 15 minutes of the start of anaesthesia; and certain procedural rules-notably, scanning the label before each drug administration) versus conventional practice in drug administration with a manually compiled anaesthetic record. Main outcome measures Primary: composite of errors in the recording and administration of intravenous drugs detected by direct observation and by detailed reconciliation of the contents of used drug vials against recorded administrations; and lapses in responding to an intermittent visual stimulus (vigilance latency task). Secondary: outcomes in patients; analyses of anaesthetists' tasks and assessments of workload; evaluation of the legibility of anaesthetic records; evaluation of compliance with the procedural rules of the new system; and questionnaire based ratings of the respective systems by participants. Results The overall mean rate of drug errors per 100 administrations was 9.1 (95% confidence interval 6.9 to 11.4) with the new system (one in 11 administrations) and 11.6 (9.3 to 13.9) with conventional methods (one in nine administrations) (P=0.045 for difference). Most were recording errors, and, though fewer drug administration errors occurred with the new system, the comparison with conventional methods did not reach significance. Rates of errors in drug administration were lower when anaesthetists consistently applied two key principles of the new system (scanning the drug barcode before administering each drug and keeping the voice prompt active) than when they did not: mean 6.0 (3.1 to 8.8) errors per 100 administrations v 9.7 (8.4 to 11.1) respectively (P=0.004). Lapses in the vigilance latency task occurred in 12% (58/471) of cases with the new system and 9% (40/473) with conventional methods (P=0.052). The records generated by the new system were more legible, and anaesthetists preferred the new system, particularly in relation to long, complex, and emergency cases. There were no differences between new and conventional systems in respect of outcomes in patients or anaesthetists' workload. Conclusions The new system was associated with a reduction in errors in the recording and administration of drugs in anaesthesia, attributable mainly to a reduction in recording errors. Automatic compilation of the anaesthetic record increased legibility but also increased lapses in a vigilance latency task and decreased time spent watching monitors.	[Merry, Alan F.; Hannam, Jacqueline; Mitchell, Simon J.; Edwards, Kylie-Ellen; Jardim, Anisoara; Pak, Nick; Cooper, Jeremy; Hopley, Lara; Short, Timothy G.] Univ Auckland, Dept Anaesthesiol, Fac Med & Hlth Sci, Auckland 1142, New Zealand; [Merry, Alan F.; Mitchell, Simon J.; Cooper, Jeremy; Hopley, Lara; Short, Timothy G.] Auckland City Hosp, Dept Anaesthesia, Auckland, New Zealand; [Webster, Craig S.] Univ Auckland, Ctr Med & Hlth Sci Educ, Auckland 1142, New Zealand; [Henderson, Robert] Air New Zealand, Human Factors Grp, Auckland 1142, New Zealand; [Frampton, Chris] Univ Otago, Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch 8140, New Zealand	University of Auckland; Auckland City Hospital; University of Auckland; University of Otago	Merry, AF (corresponding author), Univ Auckland, Dept Anaesthesiol, Fac Med & Hlth Sci, Private Bag 92-019, Auckland 1142, New Zealand.	a.merry@auckland.ac.nz	Reid, Papaarangi M/J-3851-2017	Reid, Papaarangi M/0000-0003-2364-4776; Webster, Craig/0000-0002-6997-4263; Merry, Alan/0000-0001-7100-009X; Mitchell, Simon/0000-0002-5149-6371; Hannam, Jacqueline A/0000-0003-2974-7397; Short, Timothy/0000-0001-9374-1710	Health Research Council of New Zealand [07/269R]; Green Lane Research and Educational Fund	Health Research Council of New Zealand(Health Research Council of New Zealand); Green Lane Research and Educational Fund	This project was supported by grant 07/269R from the Health Research Council of New Zealand and a supplementary grant from the Green Lane Research and Educational Fund. These funders were not involved in the study design; in collection, analysis and interpretation of data; in writing the report; or in the decision to submit the article for publication.	Abeysekera A, 2005, ANAESTHESIA, V60, P220, DOI 10.1111/j.1365-2044.2005.04123.x; *AM SOC TEST MAT, 1995, STAND SPEC US APPL D; *AUSTR NZ COLL AN, 2001, 6 PS AUSTR NZ COLL A; BLOCK FE, 1989, J CLIN MONITOR, V5, P284, DOI 10.1007/BF01618261; Borg G, 1977, SIMPLE RATING METHOD; *CAN STAND ASS, 1998, Z264398 CAN STAND AS; CURRIE M, 1993, ANAESTH INTENS CARE, V21, P596, DOI 10.1177/0310057X9302100517; Davis P, 2006, LANCET, V367, P1920, DOI 10.1016/S0140-6736(06)68847-8; De Amici D, 2000, ANESTH ANALG, V91, P1043, DOI 10.1097/00000539-200010000-00068; Department of Health, 2000, ORG MEM REP EXP GROU; DeYoung JL, 2009, AM J HEALTH-SYST PH, V66, P1110, DOI 10.2146/ajhp080355; DRIPPS RD, 1997, INTRO ANESTHESIA; Eichhorn J, 2010, CIRCULATION, V25, P1; Evley R, 2010, BRIT J ANAESTH, V105, P289, DOI 10.1093/bja/aeq194; GIBBS RF, 1989, J CLIN MONITOR, V5, P251, DOI 10.1007/BF01618257; Helmons PJ, 2009, AM J HEALTH-SYST PH, V66, P1202, DOI 10.2146/ajhp080357; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; *INT ORG STAND, 2008, 268252008 ISO; KENNEDY PJ, 1976, ANESTH ANALG, V55, P374; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; MCDONALD JS, 1988, BRIT J ANAESTH, V61, P738, DOI 10.1093/bja/61.6.738; Merry AF, 2008, ANAESTHESIA, V63, P1349, DOI 10.1111/j.1365-2044.2008.05638.x; MERRY AF, 1995, NEW ZEAL MED J, V108, P185; Merry AF, 2002, ANAESTHESIA, V57, P256, DOI 10.1046/j.0003-2409.2001.02397.x; Merry AF, 2001, ANESTH ANALG, V93, P385, DOI 10.1097/00000539-200108000-00030; Merry AF, 2008, NEW ZEAL MED J, V121, P6; Orser BA, 2004, CAN J ANAESTH, V51, P756, DOI 10.1007/BF03018447; ORSER BA, 1994, CAN J ANAESTH, V41, P120, DOI 10.1007/BF03009804; PARSONS HM, 1974, SCIENCE, V183, P922, DOI 10.1126/science.183.4128.922; Poon EG, 2010, NEW ENGL J MED, V362, P1698, DOI 10.1056/NEJMsa0907115; Reich DL, 2000, ANESTH ANALG, V91, P612, DOI 10.1213/00000539-200009000-00022; ROWE L, 1992, BRIT J ANAESTH, V68, P381, DOI 10.1093/bja/68.4.381; Runciman B., 2007, SAFETY ETHICS HEALTH; Schiff GD, 2010, NEW ENGL J MED, V362, P1066, DOI 10.1056/NEJMp0911734; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; *STAND NZ, 1996, ASNZS43751996; Stewart M, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-19; Storr Julie Ann, 2009, World Hosp Health Serv, V45, P23; Tenner Edward., 1997, WHY THINGS BITE BACK; Webster CS, 2010, ANAESTHESIA, V65, P490, DOI 10.1111/j.1365-2044.2010.06325.x; Webster CS, 2005, ANAESTHESIA, V60, P843, DOI 10.1111/j.1365-2044.2005.04331.x; Webster CS, 2004, ANAESTHESIA, V59, P80, DOI 10.1111/j.1365-2044.2004.03457.x; Webster CS, 2001, ANAESTH INTENS CARE, V29, P494, DOI 10.1177/0310057X0102900508; Weinger M B, 1996, Acta Anaesthesiol Sin, V34, P27; Weinger MB, 2004, ANESTH ANALG, V98, P1419, DOI 10.1213/01.ANE.0000106838.66901.D2; Weinger MB, 1997, ANESTHESIOLOGY, V87, P144, DOI 10.1097/00000542-199707000-00019; WEINGER MB, 1994, ANESTHESIOLOGY, V80, P77, DOI 10.1097/00000542-199401000-00015; ZOLLINGER RM, 1977, J SURG RES, V22, P419, DOI 10.1016/0022-4804(77)90165-2	48	122	124	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 22	2011	343								d5543	10.1136/bmj.d5543	http://dx.doi.org/10.1136/bmj.d5543			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	826AJ	21940742	hybrid, Green Published			2023-01-03	WOS:000295323400001
J	Antoniou, T; Gomes, T; Mamdani, MM; Yao, Z; Hellings, C; Garg, AX; Weir, MA; Juurlink, DN				Antoniou, Tony; Gomes, Tara; Mamdani, Muhammad M.; Yao, Zhan; Hellings, Chelsea; Garg, Amit X.; Weir, Matthew A.; Juurlink, David N.			Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							CONGESTIVE-HEART-FAILURE; MECHANISM; THERAPY; DYSFUNCTION; INHIBITORS; MORBIDITY; COHORT	Objectives To characterise the risk of admission to hospital for hyperkalaemia in elderly patients treated with trimethoprim-sulfamethoxazole in combination with spironolactone. Design Population based nested case-control study. Setting Ontario, Canada, from 1 April 1992 to 1 March 2010. Participants Cases were residents of Ontario aged 66 years or above receiving chronic treatment with spironolactone and admitted to hospital with hyperkalaemia within 14 days of receiving a prescription for either trimethoprim-sulfamethoxazole, amoxicillin, norfloxacin, or nitrofurantoin. Up to four controls for each case were identified from the same cohort, matched on age, sex, and presence or absence of chronic kidney disease and diabetes, and required to have received one of the study antibiotics within 14 days before the case's index date. Main outcome measures Odds ratio for association between admission to hospital with hyperkalaemia and receipt of a study antibiotic in the preceding 14 days, adjusted for conditions and drugs that may influence risk of hyperkalaemia. Results During the 18 year study period, 6903 admissions for hyperkalaemia were identified, 306 of which occurred within 14 days of antibiotic use. Of these, 248 (81%) cases were matched to 783 controls. 10.8% (17 859/165 754) of spironolactone users received at least one prescription for trimethoprim-sulfamethoxazole. Compared with amoxicillin, prescription of trimethoprim-sulfamethoxazole was associated with a marked increase in the risk of admission to hospital for hyperkalaemia (adjusted odds ratio 12.4, 95% confidence interval 7.1 to 21.6). The population attributable fraction was 59.7%, suggesting that approximately 60% of all cases of hyperkalaemia in older patients taking spironolactone and treated with an antibiotic for a urinary tract infection could be avoided if trimethoprim-sulfamethoxazole was not prescribed. Treatment with nitrofurantoin was also associated with an increase in the risk of hyperkalaemia (adjusted odds ratio 2.4, 1.3 to 4.6), but no such risk was found with norfloxacin (adjusted odds ratio 1.6, 0.8 to 3.4) Conclusions Among older patients receiving spironolactone, treatment with trimethoprim-sulfamethoxazole was associated with a major increase in the risk of admission to hospital for hyperkalaemia. This drug combination should be avoided when possible.	[Antoniou, Tony; Gomes, Tara; Mamdani, Muhammad M.; Juurlink, David N.] Univ Toronto, Toronto, ON, Canada; [Antoniou, Tony] St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada; [Gomes, Tara; Mamdani, Muhammad M.; Yao, Zhan; Hellings, Chelsea; Garg, Amit X.; Juurlink, David N.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Mamdani, Muhammad M.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Mamdani, Muhammad M.] King Saud Univ, Riyadh, Saudi Arabia; [Garg, Amit X.; Weir, Matthew A.] Univ Western Ontario, Div Nephrol, London, ON, Canada; [Juurlink, David N.] Sunnybrook Res Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; King Saud University; Western University (University of Western Ontario); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Antoniou, T (corresponding author), 410 Sherbourne St,4th Floor, Toronto, ON M4X 1K2, Canada.	tantoniou@smh.toronto.on.ca	Hug, Balthasar L./G-1568-2010; Garg, Amit X/G-3295-2011; Weir, Matthew/G-3354-2011	Gomes, Tara/0000-0002-1468-1965	Ontario HIV Treatment Network; Canadian Institutes of Health Research; Ontario Drug Policy Research Network; Institute for Clinical Evaluative Sciences (ICES); Ontario Ministry of Health and Long-Term Care (MOHLTC); GlaxoSmithKline; Merck; Pfizer	Ontario HIV Treatment Network; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Drug Policy Research Network; Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Pfizer(Pfizer)	TA is supported by a post-doctoral fellowship award from the Ontario HIV Treatment Network. AG is supported by a clinician scientist award from the Canadian Institutes of Health Research. This project was supported by research funds from the Ontario Drug Policy Research Network and by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred.; All authors have completed the Unified Competing Interest form at www.icmje.org_disclosure.pdf (available on request from the corresponding author). During the past three years, TA has received unrestricted research grants from GlaxoSmithKline, Merck, and Pfizer for different studies. All other authors declare no support from any company for the submitted work; no relationships with any companies that might have an interest in the submitted work in the previous 3 years; and no non-financial interests that may be relevant to the submitted work.	APPEL GB, 1981, NEPHRON, V27, P313, DOI 10.1159/000182077; Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Bozkurt B, 2003, J AM COLL CARDIOL, V41, P211, DOI 10.1016/S0735-1097(02)02694-3; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cruz CS, 2003, NEPHROL DIAL TRANSPL, V18, P1814, DOI 10.1093/ndt/gfg295; Desai AS, 2007, J AM COLL CARDIOL, V50, P1959, DOI 10.1016/j.jacc.2007.07.067; EiamOng S, 1996, KIDNEY INT, V49, P1372, DOI 10.1038/ki.1996.193; Hanley JA, 2001, J EPIDEMIOL COMMUN H, V55, P508, DOI 10.1136/jech.55.7.508; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Jager LP, 1997, EUR J PHARMACOL, V331, P325, DOI 10.1016/S0014-2999(97)01052-2; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Juurlink DN, 2003, JAMA-J AM MED ASSOC, V289, P1652, DOI 10.1001/jama.289.13.1652; Lim PO, 2001, J HYPERTENS, V19, P353, DOI 10.1097/00004872-200103000-00001; LUBIN JH, 1984, BIOMETRICS, V40, P63, DOI 10.2307/2530744; Mamdani M, 2004, LANCET, V363, P1751, DOI 10.1016/S0140-6736(04)16299-5; MARINELLA MA, 1997, INFECT DIS CLIN PRAC, V6, P257; Martin Jennifer, 2003, N Z Med J, V116, pU542; Masoudi FA, 2005, CIRCULATION, V112, P39, DOI 10.1161/CIRCULATIONAHA.104.527549; Park-Wyllie LY, 2006, NEW ENGL J MED, V354, P1352, DOI 10.1056/NEJMoa055191; Perazella MA, 2000, DRUG SAFETY, V22, P227, DOI 10.2165/00002018-200022030-00006; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; PONCE SP, 1985, MEDICINE, V64, P357, DOI 10.1097/00005792-198511000-00001; Rocha R, 2002, DRUGS, V62, P723, DOI 10.2165/00003495-200262050-00001; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schrier RW, 2010, CLIN J AM SOC NEPHRO, V5, P1132, DOI 10.2215/CJN.01410210; Svensson M, 2004, J CARD FAIL, V10, P297, DOI 10.1016/j.cardfail.2003.10.012; VELAZQUEZ H, 1993, ANN INTERN MED, V119, P296, DOI 10.7326/0003-4819-119-4-199308150-00008	28	45	46	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 12	2011	343								d5228	10.1136/bmj.d5228	http://dx.doi.org/10.1136/bmj.d5228			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822UZ	21911446	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000295076500001
J	Kidoya, H; Kunii, N; Naito, H; Muramatsu, F; Okamoto, Y; Nakayama, T; Takakura, N				Kidoya, H.; Kunii, N.; Naito, H.; Muramatsu, F.; Okamoto, Y.; Nakayama, T.; Takakura, N.			The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy	ONCOGENE			English	Article						tumor angiogenesis; immune therapy; vascular normalization; vascular maturation; apelin/APJ	KILLER T-CELLS; V-ALPHA-14 NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; IN-VIVO; ENDOTHELIAL-CELLS; ANGIOGENIC FACTOR; BLOOD-VESSELS; APJ RECEPTOR; CANCER; ACTIVATION	Immature and unstable tumor vasculature provides an aberrant tumor microenvironment and leads to resistance of tumors to conventional therapy. Hence, normalization of tumor vessels has been reported to improve the effect of immuno-, chemo- and radiation therapy. However, the humoral factors, which can effectively induce maturation of tumor vasculature, have not been elucidated. In this study, we found that the novel peptide apelin and its receptor APJ can induce the morphological and functional maturation of blood vessels in tumors. This apelin-induced tumor vascular maturation enhances the efficacy of cancer dendritic cell-based immunotherapy and significantly suppresses tumor growth by promoting the infiltration of invariant natural killer T cells into the central region of the tumor and thereby robustly inducing apoptosis of tumor cells. Additionally, we showed APJ expression to be enhanced in the tumor endothelium in comparison with normal-state endothelial cells. These findings provide a new target for tumor vascular-specific maturation, which is expected to improve the efficacy of conventional cancer therapies. Oncogene (2012) 31, 3254-3264; doi:10.1038/onc.2011.489; published online 31 October 2011	[Kidoya, H.; Naito, H.; Muramatsu, F.; Takakura, N.] Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Kunii, N.; Okamoto, Y.] Chiba Univ, Grad Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Chiba, Japan; [Kunii, N.; Nakayama, T.] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan	Osaka University; Chiba University; Chiba University	Takakura, N (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp	Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; Naito, Hisamichi/0000-0002-0750-1743	Japan Society for the Promotion of Science (JSPS) and Research [KAKENHI 21890124]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; YASUDA Medical Foundation	Japan Society for the Promotion of Science (JSPS) and Research; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); YASUDA Medical Foundation	We thank Ms C Takeshita, Ms K Fukuhara and Ms N Fujimoto for technical assistance. Financial support: This work was supported by Grant-in-Aid for Research Activity Start-up (KAKENHI 21890124) from the Japan Society for the Promotion of Science (JSPS) and Research; a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; and the YASUDA Medical Foundation.	Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Dai TY, 2006, EUR J PHARMACOL, V553, P222, DOI 10.1016/j.ejphar.2006.09.034; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Dings RPM, 2011, CLIN CANCER RES, V17, P3134, DOI 10.1158/1078-0432.CCR-10-2443; Eyries M, 2008, CIRC RES, V103, P432, DOI 10.1161/CIRCRESAHA.108.179333; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Gerber HP, 2005, CANCER RES, V65, P671; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Kalin RE, 2007, DEV BIOL, V305, P599, DOI 10.1016/j.ydbio.2007.03.004; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kawano T, 1999, CANCER RES, V59, P5102; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982; Kidoya H, 2010, BLOOD, V115, P3166, DOI 10.1182/blood-2009-07-232306; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kunii N, 2009, CANCER SCI, V100, P1092, DOI 10.1111/j.1349-7006.2009.01135.x; Lago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007; Lambrecht NWG, 2006, PHYSIOL GENOMICS, V25, P153, DOI 10.1152/physiolgenomics.00271.2005; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Nieda M, 2001, BLOOD, V97, P2067, DOI 10.1182/blood.V97.7.2067; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Seino K, 2005, SPRINGER SEMIN IMMUN, V27, P65, DOI 10.1007/s00281-004-0194-y; Shin T, 2001, INT J CANCER, V91, P523, DOI 10.1002/1097-0215(20010215)91:4<523::AID-IJC1087>3.0.CO;2-L; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Smyth MJ, 2002, BLOOD, V99, P1259, DOI 10.1182/blood.V99.4.1259; Sorli SC, 2007, ONCOGENE, V26, P7692, DOI 10.1038/sj.onc.1210573; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004; Yamada Y, 2006, J EXP MED, V203, P1055, DOI 10.1084/jem.20050373	52	56	66	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3254	3264		10.1038/onc.2011.489	http://dx.doi.org/10.1038/onc.2011.489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22037214	Bronze			2023-01-03	WOS:000306113400005
J	Thompson, AJ; McGonigle, I; Duke, R; Johnston, GAR; Lummis, SCR				Thompson, Andrew J.; McGonigle, Ian; Duke, Rujee; Johnston, Graham A. R.; Lummis, Sarah C. R.			A single amino acid determines the toxicity of Ginkgo biloba extracts	FASEB JOURNAL			English	Article						Cys-loop receptor; picrotoxin; antagonist	DROSOPHILA GABA RECEPTOR; BINDING; RDL; PICROTOXININ; ANTAGONIST; MUTATIONS; FIPRONIL	Ginkgo biloba extracts are currently used for a wide range of health-related conditions. Some of the medical benefits of these extracts are controversial, but their lack of toxicity in humans is not in doubt. These extracts are, however, highly toxic to insects. Their active components (ginkgolides and bilobalide) have structures similar to the convulsant picrotoxin, a GABA(A) receptor antagonist, so their lack of toxicity in mammals is puzzling. Here, we show that the different compositions of insect and vertebrate GABA receptor pores are responsible for the differing toxicities. Insect GABA receptors contain Ala at their 2' position in the pore. Substitution with Val, which is the equivalent residue in vertebrate GABA(A) receptor alpha-subunits, decreases ginkgolide potency by up to 10,000-fold. The reverse mutation in vertebrate GABA(A) alpha 1 subunits increased the sensitivity of alpha 1 beta 2 and alpha 1 beta 2 gamma 2 receptors to ginkgolides. Mutant cycle analysis demonstrates a strong interaction between the ginkgolides and the 2' residue, a result supported by in silico docking of compounds into a model of the pore. We conclude that the insecticidal activity of G. biloba extracts can be attributed to their effects at insect GABA receptors, and the presence of a Val at the 2' position in vertebrate GABA(A) receptors explains why these compounds are not similarly toxic to humans.-Thompson, A. J., McGonigle, I., Duke, R., Johnston, G. A. R., Lummis, S. C. R. A single amino acid determines the toxicity of Ginkgo biloba extracts. FASEB J. 26, 1884-1891 (2012). www.fasebj.org	[Thompson, Andrew J.; McGonigle, Ian; Lummis, Sarah C. R.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Duke, Rujee; Johnston, Graham A. R.] Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Cambridge; University of Sydney	Lummis, SCR (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	sl120@cam.ac.uk	Johnston, Graham/AAJ-9569-2021; Johnston, Graham AR/B-9827-2009	Johnston, Graham/0000-0001-8872-4078; Thompson, Andrew/0000-0002-7046-6792; McGonigle, Ian/0000-0003-0837-080X	University of Sydney	University of Sydney(University of Sydney)	The authors thank The Wellcome Trust (81925; S. C. R. L., A.J.T.; S. C. R. L. is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science), the UK Medical Research Council (I. M. held a MRC studentship), the National Health and Medical Research Council of Australia (R. D.; G.A.R.J.) and the University of Sydney (a travel grant to S. C. R. L.). A.J.T. and I. M. conducted the experiments; R. D. and G.A.R.J. contributed new reagents or analytic tools; A.J.T. and S. C. R. L. performed data analysis; A.J.T., S. C. R. L., I. M., R. D., and G.A.R.J. wrote or contributed to the writing of the manuscript; A.J.T. and S. C. R. L. participated in research design; S. C. R. L. and G.A.R.J. acquired funding for the research. The authors declare no conflicts of interest.	Ahlemeyer B, 2003, CELL MOL LIFE SCI, V60, P1779, DOI 10.1007/s00018-003-3080-1; Ahn YJ, 1997, ACS SYM SER, V658, P90; Buckingham SD, 2005, MOL PHARMACOL, V68, P942, DOI 10.1124/mol.105.015313; Chen LG, 2006, P NATL ACAD SCI USA, V103, P5185, DOI 10.1073/pnas.0600370103; Drieu K, 2000, PROSTAG LEUKOTR ESS, V63, P293, DOI 10.1054/plef.2000.0217; Erkkila BE, 2008, BIOPHYS J, V94, P4299, DOI 10.1529/biophysj.107.118455; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Harrison JB, 1996, CELL TISSUE RES, V284, P269, DOI 10.1007/s004410050587; Heads JA, 2008, J NEUROCHEM, V105, P1418, DOI 10.1111/j.1471-4159.2008.05244.x; Hori T., 1997, GINKGO BILOBA GLOBAL; Horovitz A, 1996, FOLD DES, V1, pR121, DOI 10.1016/S1359-0278(96)00056-9; Jensen AA, 2010, J BIOL CHEM, V285, P10141, DOI 10.1074/jbc.M109.079319; Le Goff G, 2005, J NEUROCHEM, V92, P1295, DOI 10.1111/j.1471-4159.2004.02922.x; Ludmerer SW, 2002, BIOCHEMISTRY-US, V41, P6548, DOI 10.1021/bi015920o; MILLAR NS, 1994, P ROY SOC B-BIOL SCI, V258, P307, DOI 10.1098/rspb.1994.0178; MILLER TA, 1979, PESTIC BIOCHEM PHYS, V10, P128, DOI 10.1016/0048-3575(79)90014-2; OLSEN RW, 1982, ANNU REV PHARMACOL, V22, P245, DOI 10.1146/annurev.pa.22.040182.001333; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sedelnikova A, 2006, J PHYSIOL-LONDON, V577, P569, DOI 10.1113/jphysiol.2006.120287; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sieghart W, 2006, ADV PHARMACOL, V54, P231, DOI 10.1016/S1054-3589(06)54010-4; Thompson AJ, 2011, J PHYSIOL-LONDON, V589, P4243, DOI 10.1113/jphysiol.2011.208439; Thompson AJ, 2011, MOL PHARMACOL, V80, P183, DOI 10.1124/mol.111.071415; Thompson AJ, 2010, Q REV BIOPHYS, V43, P449, DOI 10.1017/S0033583510000168; Tomlin C D S, 2006, PESTICIDE MANUAL WOR, P462; Woelkart K, 2010, PHYTOTHER RES, V24, P445, DOI 10.1002/ptr.3074; Xie JS, 2008, J CHROMATOGR B, V864, P87, DOI 10.1016/j.jchromb.2008.01.045; Zhao XL, 2003, J PHARMACOL EXP THER, V306, P914, DOI 10.1124/jpet.103.051839	28	16	17	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2012	26	5					1884	1891		10.1096/fj.11-192765	http://dx.doi.org/10.1096/fj.11-192765			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	937TD	22253475	Green Published			2023-01-03	WOS:000303680800017
J	Lindenauer, PK; Lagu, T; Shieh, MS; Pekow, PS; Rothberg, MB				Lindenauer, Peter K.; Lagu, Tara; Shieh, Meng-Shiou; Pekow, Penelope S.; Rothberg, Michael B.			Association of Diagnostic Coding With Trends in Hospitalizations and Mortality of Patients With Pneumonia, 2003-2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE SEPSIS; PERFORMANCE-MEASURES; UNITED-STATES; OUTCOMES; CARE; GUIDELINES; MANAGEMENT; OLDER	Context Recent reports suggest that the mortality rate of patients hospitalized with pneumonia has steadily declined. While this may be the result of advances in clinical care or improvements in quality, it may also represent an artifact of changes in diagnostic coding. Objective To compare estimates of trends in hospitalizations and inpatient mortality among patients with pneumonia using 2 approaches to case definition: one limited to patients with a principal diagnosis of pneumonia, and another that includes patients with a secondary diagnosis of pneumonia if the principal diagnosis is sepsis or respiratory failure. Design, Setting, and Participants Trends study using data from the 2003-2009 releases of the Nationwide Inpatient Sample. Main Outcome Measures Change in the annual hospitalization rate and change in inpatient mortality over time. Results From 2003 to 2009, the annual hospitalization rate for patients with a principal diagnosis of pneumonia declined 27.4%, from 5.5 to 4.0 per 1000, while the age-and sex-adjusted mortality decreased from 5.8% to 4.2% (absolute risk reduction [ARR], 1.6%; 95% CI, 1.4%-1.9%; relative risk reduction [RRR], 28.2%; 95% CI, 25.2%-31.2%). Over the same period, hospitalization rates of patients with a principal diagnosis of sepsis and a secondary diagnosis of pneumonia increased 177.6% from 0.4 to 1.1 per 1000, while inpatient mortality decreased from 25.1% to 22.2% (ARR, 3.0%; 95% CI, 1.6%-4.4%; RRR, 12%; 95% CI, 7.5%-16.1%); hospitalization rates for patients with a principal diagnosis of respiratory failure and a secondary diagnosis of pneumonia increased 9.3% from 0.44 to 0.48 per 1000 and mortality declined from 25.1% to 19.2% (ARR, 6.0%; 95% CI, 4.6%-7.3%; RRR, 23.7%; 95% CI, 19.7%-27.8%). However, when the 3 groups were combined, the hospitalization rate declined only 12.5%, from 6.3 to 5.6 per 1000, while the age-and sex-adjusted inpatient mortality rate increased from 8.3% to 8.8% (AR increase, 0.5%; 95% CI, 0.1%-0.9%; RR increase, 6.0%; 95% CI, 3.3%-8.8%). Over this same time frame, the age-, sex-, and comorbidity-adjusted mortality rate declined from 8.3% to 7.8% (ARR, 0.5%; 95% CI, 0.2%-0.9%; RRR, 6.3%; 95% CI, 3.8%-8.8%). Conclusions From 2003 to 2009, hospitalization and inpatient mortality rates for patients with a principal diagnosis of pneumonia decreased substantially, whereas hospitalizations with a principal diagnosis of sepsis or respiratory failure accompanied by a secondary diagnosis of pneumonia increased and mortality declined. However, when the 3 pneumonia diagnoses were combined, the decline in the hospitalization rate was attenuated and inpatient mortality was little changed, suggesting an association of these results with temporal trends in diagnostic coding. JAMA. 2012;307(13):1405-1413	[Lindenauer, Peter K.; Lagu, Tara; Shieh, Meng-Shiou; Pekow, Penelope S.; Rothberg, Michael B.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA 01199 USA; [Lindenauer, Peter K.; Lagu, Tara; Rothberg, Michael B.] Baystate Med Ctr, Div Gen Med & Geriatr, Springfield, MA 01199 USA; [Lindenauer, Peter K.; Lagu, Tara; Rothberg, Michael B.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Pekow, Penelope S.] Univ Massachusetts, Dept Publ Hlth, Div Biostat & Epidemiol, Amherst, MA 01003 USA	Baystate Medical Center; Baystate Medical Center; Tufts University; Massachusetts Department of Public Health; University of Massachusetts System; University of Massachusetts Amherst	Lindenauer, PK (corresponding author), Baystate Med Ctr, Ctr Qual Care Res, 280 Chestnut St,3rd Floor, Springfield, MA 01199 USA.	peter.lindenauer@bhs.org	Lagu, Tara/GPT-5173-2022	Lagu, Tara/0000-0001-6155-5796				[Anonymous], 2007, ICD 9 CM COD GUID PU; [Anonymous], 2007, ICD 9 CM COD GUID SE; [Anonymous], 2007, ICD 9 CM COD GUID PN; Baker DW, 2002, MED CARE, V40, P879, DOI 10.1097/00005650-200210000-00006; Bratzler DW, 2008, CLIN INFECT DIS, V47, pS193, DOI 10.1086/591404; Bratzler DW, 2007, CURR OPIN INFECT DIS, V20, P182, DOI 10.1097/QCO.0b013e3280495468; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Centers for Medicare and Medicaid Services, PREM HOSP QUAL INC D; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; Drye EE, 2012, ANN INTERN MED, V156, P19, DOI 10.7326/0003-4819-156-1-201201030-00004; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FastStats, FASTSTATS PNEUM; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Healthcare Cost and Utilization Project, OV NAT IMP SAMPL; Kumar G, 2011, CHEST, V140, P1223, DOI 10.1378/chest.11-0352; Lagu T, 2012, CRIT CARE MED, V40, P754, DOI 10.1097/CCM.0b013e318232db65; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Lindenauer Peter K, 2010, J Hosp Med, V5, pE12, DOI 10.1002/jhm.822; Meehan TP, 2001, AM J MED, V111, P203, DOI 10.1016/S0002-9343(01)00803-8; Metersky ML, 2000, ARCH INTERN MED, V160, P3385, DOI 10.1001/archinte.160.22.3385; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Rothberg MB, 2010, HEALTH AFFAIR, V29, P1523, DOI 10.1377/hlthaff.2009.0287; Ruhnke GW, 2011, AM J MED, V124, P171, DOI 10.1016/j.amjmed.2010.08.019; The Joint Commission, IMPR AM HOSP JOINT C; The Joint Commission, FACTS ORYX HOSP NAT; Venditti M, 2009, ANN INTERN MED, V150, P19, DOI 10.7326/0003-4819-150-1-200901060-00005; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Whittle J, 1997, Am J Med Qual, V12, P187, DOI 10.1177/0885713X9701200404; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778; Yealy DM, 2005, ANN INTERN MED, V143, P881, DOI 10.7326/0003-4819-143-12-200512200-00006; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	35	228	230	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2012	307	13					1405	1413		10.1001/jama.2012.384	http://dx.doi.org/10.1001/jama.2012.384			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919AY	22474204	Bronze			2023-01-03	WOS:000302294200027
J	Zgierska, A; Miller, M; Rabago, D				Zgierska, Aleksandra; Miller, Michael; Rabago, David			Patient Satisfaction, Prescription Drug Abuse, and Potential Unintended Consequences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC NONCANCER PAIN		[Zgierska, Aleksandra; Rabago, David] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI 53715 USA; [Miller, Michael] Univ Wisconsin, Dept Psychiat, Sch Med & Publ Hlth, Madison, WI 53715 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Zgierska, A (corresponding author), Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, 1100 Delaplaine Ct, Madison, WI 53715 USA.	aleksandra.zgierska@fammed.wisc.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K23AA017508] Funding Source: NIH RePORTER; NIAAA NIH HHS [K23 AA017508] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7; Brett AS, 2012, JAMA-J AM MED ASSOC, V307, P149, DOI 10.1001/jama.2011.1999; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Frantsve LME, 2007, PAIN MED, V8, P25, DOI 10.1111/j.1526-4637.2007.00250.x; Gugelmann HM, 2011, JAMA-J AM MED ASSOC, V306, P2258, DOI 10.1001/jama.2011.1712; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Matthias MS, 2010, PAIN MED, V11, P1688, DOI 10.1111/j.1526-4637.2010.00980.x; Office of National Drug Control Policy US Executive Office of the President, 2011, EP RESP AM PRESCR DR; Substance Abuse and Mental Health Services Administration, 2010, RES 2009 NAT SURV DR, VI	10	136	137	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2012	307	13					1377	1378		10.1001/jama.2012.419	http://dx.doi.org/10.1001/jama.2012.419			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	919AY	22474199	Green Accepted			2023-01-03	WOS:000302294200022
J	Mathews, SC; Mallidi, J; Kulkarni, K; Toth, PP; Jones, SR				Mathews, Simon C.; Mallidi, Jaya; Kulkarni, Krishnaji; Toth, Peter P.; Jones, Steven R.			Achieving Secondary Prevention Low-Density Lipoprotein Particle Concentration Goals Using Lipoprotein Cholesterol-Based Data	PLOS ONE			English	Article							CORONARY-ARTERY-DISEASE; MAGNETIC-RESONANCE SPECTROSCOPY; ISCHEMIC-HEART-DISEASE; CARDIOVASCULAR-DISEASE; POSITION STATEMENT; RISK; SIZE; ATHEROSCLEROSIS; THERAPY; NUMBER	Background: Epidemiologic studies suggest that LDL particle concentration (LDL-P) may remain elevated at guideline recommended LDL cholesterol goals, representing a source of residual risk. We examined the following seven separate lipid parameters in achieving the LDL-P goal of < 1000 nmol/L goal for very high risk secondary prevention: total cholesterol to HDL cholesterol ratio, TC/HDL, < 3; a composite of ATP-III very high risk targets, LDL-C < 70 mg/dL, non-HDL-C < 100 mg/dL and TG < 150 mg/dL; a composite of standard secondary risk targets, LDL-C < 100, non-HDL-C < 130, TG < 150; LDL phenotype; HDL-C >= 40; TG < 150; and TG/HDL-C < 3. Methods: We measured ApoB, ApoAI, ultracentrifugation lipoprotein cholesterol and NMR lipoprotein particle concentration in 148 unselected primary and secondary prevention patients. Results: TC/ HDL- C < 3 effectively discriminated subjects by LDL-P goal (F = 84.1, p < 10(-6)). The ATP- III very high risk composite target (LDL-C < 70, nonHDL-C < 100, TG < 150) was also effective (F = 42.8, p < 10(-5)). However, the standard secondary prevention composite (LDL-C < 100, non-HDL-C < 130, TG < 150) was also effective but yielded higher LDL-P than the very high risk composite (F = 42.0, p < 10(-5)) with upper 95% confidence interval of LDL-P less than 1000 nmol/ L. TG < 150 and TG/HDL-C < 3 cutpoints both significantly discriminated subjects but the LDL-P upper 95% confidence intervals fell above goal of 1000 nmol/ L (F = 15.8, p = 0.0001 and F = 9.7, p = 0.002 respectively). LDL density phenotype neared significance ( F = 2.85, p = 0.094) and the HDL-C cutpoint of 40 mg/dL did not discriminate (F = 0.53, p = 0.47) alone or add discriminatory power to ATP-III targets. Conclusions: A simple composite of ATP-III very high risk lipoprotein cholesterol based treatment targets or TC/HDL-C ratio < 3 most effectively identified subjects meeting the secondary prevention target level of LDL- P < 1000 nmol/L, providing a potential alternative to advanced lipid testing in many clinical circumstances.	[Mathews, Simon C.; Jones, Steven R.] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD 21218 USA; [Mallidi, Jaya] Johns Hopkins Univ, Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Mallidi, Jaya] Tufts Univ, Dept Internal Med, Baystate Med Ctr, Springfield, MA USA; [Kulkarni, Krishnaji] Atherotech Diagnost Lab, Birmingham, AL USA; [Toth, Peter P.] CGH Med Ctr, Sterling, IL USA; [Toth, Peter P.] Univ Illinois, Sch Med, Peoria, IL USA	Johns Hopkins University; Johns Hopkins University; Baystate Medical Center; Tufts University; University of Illinois System; University of Illinois Peoria	Mathews, SC (corresponding author), Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD 21218 USA.	sjones64@jhmi.edu	Mathews, Simon/AAU-9176-2020; Toth, Peter/GMW-6552-2022		Atherotech Diagnostics	Atherotech Diagnostics	The costs of acquisition and subsequent analysis of blood specimens was supported by a grant from Atherotech Diagnostics (http://www.atherotech. com). Dr. Kulkarni, Director of Research for Atherotech, collaborated in the analysis of the specimens and provided advice and guidance concerning the laboratory methods used in obtaining data. The statistical analysis, interpretation of the data and preparation of the manuscript took place independent of any involvement with the funding organization, Atherotech. The funders had no role in study design, decision to publish, or preparation of the manuscript.	Barter PJ, 2006, J INTERN MED, V259, P247, DOI 10.1111/j.1365-2796.2006.01616.x; Blake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9; Boizel R, 2000, DIABETES CARE, V23, P1679, DOI 10.2337/diacare.23.11.1679; Brunzell JD, 2008, J AM COLL CARDIOL, V51, P1512, DOI 10.1016/j.jacc.2008.02.034; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Contois JH, 2009, CLIN CHEM, V55, P407, DOI 10.1373/clinchem.2008.118356; Cromwell WC, 2007, J CLIN LIPIDOL, V1, P583, DOI 10.1016/j.jacl.2007.10.001; Cromwell WC, 2006, AM J CARDIOL, V98, P1599, DOI 10.1016/j.amjcard.2006.07.036; Cromwell William C, 2009, Curr Cardiol Rep, V11, P468; El Harchaoui K, 2007, J AM COLL CARDIOL, V49, P547, DOI 10.1016/j.jacc.2006.09.043; Gardner CD, 1996, JAMA-J AM MED ASSOC, V276, P875, DOI 10.1001/jama.276.11.875; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Jeyarajah EJ, 2006, CLIN LAB MED, V26, P847, DOI 10.1016/j.cll.2006.07.006; KULKARNI KR, 1994, J LIPID RES, V35, P159; Kulkarni KR, 2006, CLIN LAB MED, V26, P787, DOI 10.1016/j.cll.2006.07.004; Kuller L, 2002, ARTERIOSCL THROM VAS, V22, P1175, DOI 10.1161/01.ATV.0000022015.97341.3A; Lamarche B, 2001, CAN J CARDIOL, V17, P859; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; McLaughlin T, 2003, ANN INTERN MED, V139, P802, DOI 10.7326/0003-4819-139-10-200311180-00007; McPherson R, 2006, CAN J CARDIOL, V22, P913, DOI 10.1016/S0828-282X(06)70310-5; Mora S, 2007, ATHEROSCLEROSIS, V192, P211, DOI 10.1016/j.atherosclerosis.2006.05.007; Mora S, 2009, CIRCULATION, V119, P931, DOI 10.1161/CIRCULATIONAHA.108.816181; Nielsen LB, 1996, ATHEROSCLEROSIS, V123, P1, DOI 10.1016/0021-9150(96)05802-9; O'Keefe JH, 2004, J AM COLL CARDIOL, V43, P2142, DOI 10.1016/j.jacc.2004.03.046; Otvos James D, 2002, Clin Lab, V48, P171; Otvos JD, 2006, CIRCULATION, V113, P1556, DOI 10.1161/CIRCULATIONAHA.105.565135; Otvos JD, 2002, AM J CARDIOL, V90, p22I; Rosenson RS, 2002, AM J CARDIOL, V90, P89, DOI 10.1016/S0002-9149(02)02427-X; Sniderman AD, 2008, J CLIN LIPIDOL, V2, P36, DOI 10.1016/j.jacl.2007.12.006; St-Pierre AC, 2005, ARTERIOSCL THROM VAS, V25, P553, DOI 10.1161/01.ATV.0000154144.73236.f4; Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890	32	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2012	7	3							e33692	10.1371/journal.pone.0033692	http://dx.doi.org/10.1371/journal.pone.0033692			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SR	22479428	Green Published, gold, Green Submitted			2023-01-03	WOS:000304523400028
J	Wu, WT; Li, H; Wang, HB; Zhao, XY; Gao, ZQ; Qiao, R; Zhang, W; Qian, J; Wang, JC; Chen, HY; Wei, QY; Han, BH; Lu, DR				Wu, Wenting; Li, Huan; Wang, Huibo; Zhao, Xueying; Gao, Zhiqiang; Qiao, Rong; Zhang, Wei; Qian, Ji; Wang, Jiucun; Chen, Hongyan; Wei, Qingyi; Han, Baohui; Lu, Daru			Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients	PLOS ONE			English	Article							REPAIR GENE XPD; SINGLE NUCLEOTIDE POLYMORPHISMS; PROGNOSTIC-FACTORS; EXCISION-REPAIR; SURVIVAL; CISPLATIN; RISK; ASSOCIATION; POPULATION; CARCINOMA	Purpose: Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair thatremoves platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. Experimental Design: 353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. Four potentially functional XPD polymorphisms (Arg(156)Arg, Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing. Results: Variant genotypes of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln were significantly associated with poorer NSCLC survival (P = 0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) also exhibited significant risk effect on NSCLC survival (log-rank P = 0.001). This effect was more predominant for patients with stage IIIB disease (P = 2.21 x 10(-4), log-rank test). Increased risks for variant haplotypes of XPD were also observed among patients with performance status of 0-1 and patients with adenocarcinoma. However, no significant associations were found between these polymorphisms, chemotherapy response and PFS. Conclusions: Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.	[Wu, Wenting; Li, Huan; Zhao, Xueying; Qian, Ji; Wang, Jiucun; Chen, Hongyan; Lu, Daru] Fudan Univ, Inst Genet, Sch Life Sci, State Key Lab Genet Engn,Ctr Fudan VARI Genet Epi, Shanghai 200433, Peoples R China; [Wu, Wenting; Li, Huan; Zhao, Xueying; Qian, Ji; Wang, Jiucun; Chen, Hongyan; Lu, Daru] Fudan Univ, Inst Genet, Sch Life Sci, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China; [Wu, Wenting] Univ Calif San Diego, Dept Psychiat, Beyster Ctr Genom Psychiat Dis, La Jolla, CA 92093 USA; [Gao, Zhiqiang; Qiao, Rong; Zhang, Wei; Han, Baohui] Shanghai Jiao Tong Univ, Dept Resp Dis, Shanghai Chest Hosp, Shanghai 200030, Peoples R China; [Wang, Huibo] Univ Alabama Birmingham, Ctr Comprehens Canc, Div Hematol & Oncol, Birmingham, AL 35294 USA; [Wei, Qingyi] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Fudan University; Fudan University; University of California System; University of California San Diego; Shanghai Jiao Tong University; University of Alabama System; University of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer Center	Wu, WT (corresponding author), Fudan Univ, Inst Genet, Sch Life Sci, State Key Lab Genet Engn,Ctr Fudan VARI Genet Epi, Shanghai 200433, Peoples R China.	xkyyhan@gmail.com; drlu@fudan.edu.cn	wu, wenting/Q-4979-2016	wu, wenting/0000-0003-0982-771X	China National High-Tech Research and Development Program [2012AA02A517, 2012AA02A518]; Shanghai Science and Technology Research Program [06DZ19501, 09JC1402200, 10410709100]; Scientific and technological support plans from Jiangsu province [BE2010715]; Natural Science Foundation of China [30800622]; Shanghai Subject Chief Scientist for Public Health [08GWD07]	China National High-Tech Research and Development Program(National High Technology Research and Development Program of China); Shanghai Science and Technology Research Program; Scientific and technological support plans from Jiangsu province; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Subject Chief Scientist for Public Health	This work was supported in part by China National High-Tech Research and Development Program Grant (2012AA02A517, 2012AA02A518), Shanghai Science and Technology Research Program (06DZ19501, 09JC1402200, 10410709100), Scientific and technological support plans from Jiangsu province (BE2010715), Natural Science Foundation of China (30800622) and Shanghai Subject Chief Scientist for Public Health 08GWD07. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azuma K, 2007, CANCER SCI, V98, P1336, DOI 10.1111/j.1349-7006.2007.00557.x; Brundage MD, 2002, CHEST, V122, P1037, DOI 10.1378/chest.122.3.1037; Butkiewicz D, 2001, CARCINOGENESIS, V22, P593, DOI 10.1093/carcin/22.4.593; Chng W, 2006, LEUKEMIA, V20, P807, DOI 10.1038/sj.leu.2404172; de las Penas R, 2006, ANN ONCOL, V17, P668, DOI 10.1093/annonc/mdj135; Dybdahl M, 1999, CANCER EPIDEM BIOMAR, V8, P77; Einhorn LH, 2008, J CLIN ONCOL, V26, P3485, DOI 10.1200/JCO.2008.17.2056; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Gandara DR, 2009, J CLIN ONCOL, V27, P3540, DOI 10.1200/JCO.2008.20.8793; Gao WM, 2003, CARCINOGENESIS, V24, P1671, DOI 10.1093/carcin/bgg115; Gurubhagavatula S, 2004, J CLIN ONCOL, V22, P2594, DOI 10.1200/JCO.2004.08.067; Heist RS, 2008, J CLIN ONCOL, V26, P5596, DOI 10.1200/JCO.2008.18.0406; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Laine JP, 2007, DNA REPAIR, V6, P1264, DOI 10.1016/j.dnarep.2007.02.010; Liang G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Lunn RM, 2000, CARCINOGENESIS, V21, P551, DOI 10.1093/carcin/21.4.551; Monaco Regina, 2009, J Carcinog, V8, P12, DOI 10.4103/1477-3163.54918; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Park DJ, 2001, CANCER RES, V61, P8654; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Ring BZ, 2009, MODERN PATHOL, V22, P1032, DOI 10.1038/modpathol.2009.60; Ryu JS, 2004, LUNG CANCER, V44, P311, DOI 10.1016/j.lungcan.2003.11.019; Seker H, 2001, CANCER RES, V61, P7430; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Spitz MR, 2001, CANCER RES, V61, P1354; Sturgis EM, 2002, ARCH OTOLARYNGOL, V128, P1084, DOI 10.1001/archotol.128.9.1084; Wakefield J, 2007, AM J HUM GENET, V81, P208, DOI 10.1086/519024; Winsey SL, 2000, CANCER RES, V60, P5612; Wolfe KJ, 2007, PHARMACOGENET GENOM, V17, P897, DOI 10.1097/FPC.0b013e3280115e63; Wu Q, 2005, EMBO REP, V6, P551, DOI 10.1038/sj.embor.7400418; Wu WT, 2009, CLIN CANCER RES, V15, P3889, DOI 10.1158/1078-0432.CCR-08-2715; Yao CY, 2009, ASIAN PAC J CANCER P, V10, P859; Yin M, 2011, LUNG CANCER, V72, P370, DOI 10.1016/j.lungcan.2010.10.011	35	196	203	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2012	7	3							e33200	10.1371/journal.pone.0033200	http://dx.doi.org/10.1371/journal.pone.0033200			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SR	22479369	Green Submitted, gold, Green Published			2023-01-03	WOS:000304523400013
J	Li, CY; Song, YY; Luan, SH; Wan, PX; Li, NY; Tang, J; Han, Y; Xiong, CJ; Wang, ZC				Li, Chaoyang; Song, Yiyue; Luan, Shaohong; Wan, Pengxia; Li, Naiyang; Tang, Jing; Han, Yu; Xiong, Cuiju; Wang, Zhichong			Research on the Stability of a Rabbit Dry Eye Model Induced by Topical Application of the Preservative Benzalkonium Chloride	PLOS ONE			English	Article							OCULAR SURFACE; MOUSE MODEL; EPITHELIAL PROLIFERATION; INFLAMMATORY MARKERS; PREVALENCE; TIMOLOL; CELLS; VIVO	Background: Dry eye is a common disease worldwide, and animal models are critical for the study of it. At present, there is no research about the stability of the extant animal models, which may have negative implications for previous dry eye studies. In this study, we observed the stability of a rabbit dry eye model induced by the topical benzalkonium chloride (BAC) and determined the valid time of this model. Methods and Findings: Eighty white rabbits were randomly divided into four groups. One eye from each rabbit was randomly chosen to receive topical 0.1% BAC twice daily for 2 weeks (Group BAC-W2), 3 weeks (Group BAC-W3), 4 weeks (Group BAC-W4), or 5 weeks (Group BAC-W5). Fluorescein staining, Schirmer's tests, and conjunctival impression cytology were performed before BAC treatment (normal) and on days 0, 7, 14 and 21 after BAC removal. The eyeballs were collected at these time points for immunofluorescence staining, hematoxylin and eosin (HE) staining, and electron microscopy. After removing BAC, the signs of dry eye in Group BAC-W2 lasted one week. Compared with normal, there were still significant differences in the results of Schirmer's tests and fluorescein staining in Groups BAC-W3 and BAC-W4 on day 7 (P<0.05) and in Group BAC-W5 on day 14 (P<0.05). Decreases in goblet cell density remained stable in the three experimental groups at all time points (P<0.001). Decreased levels of mucin-5 subtype AC (MUC5AC), along with histopathological and ultrastructural disorders of the cornea and conjunctiva could be observed in Group BAC-W4 and particularly in Group BACW5 until day 21. Conclusions: A stable rabbit dry eye model was induced by topical 0.1% BAC for 5 weeks, and after BAC removal, the signs of dry eye were sustained for 2 weeks (for the mixed type of dry eye) or for at least 3 weeks (for mucin-deficient dry eye).	[Li, Chaoyang; Luan, Shaohong; Wan, Pengxia; Li, Naiyang; Xiong, Cuiju; Wang, Zhichong] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China; [Tang, Jing; Han, Yu] Peoples Hosp Leshan, Dept Ophthalmol, Leshan, Peoples R China	Sun Yat Sen University	Li, CY (corresponding author), Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.	wzc001@hotmail.com	Li, Chao/GSM-8117-2022	Li, Chao/0000-0001-6110-6210	National Natural Science Foundation of China [30973246]; Science and Technology Planning Project of Guangdong Province, China [2009A030200004]; Medical Science Foundation of Guangdong Province, China [B2011106]; National Science Foundation of Guangdong Province, China [S2011040004327]; state key lab.	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangdong Province, China; Medical Science Foundation of Guangdong Province, China; National Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); state key lab.	This study was supported by the National Natural Science Foundation of China Grant No. 30973246 (W.Z.C.) (http://www.nsfc.gov.cn), the Science and Technology Planning Project of Guangdong Province, China, No. 2009A030200004 (W.Z.C.) (http://www.gdstc.gov.cn), the Medical Science Foundation of Guangdong Province, China, No. B2011106 (W.Z.C.) (http://www.gdwst.gov.cn), the Doctor Initiating Project of the National Science Foundation of Guangdong Province, China, No. S2011040004327 (W.Z.C.), and grant from the fundamental research funds of state key lab. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manscript.	Barabino S, 2005, INVEST OPHTH VIS SCI, V46, P2766, DOI 10.1167/iovs.04-1326; Barabino S, 2007, EXP EYE RES, V84, P973, DOI 10.1016/j.exer.2007.02.003; Baudouin C, 1997, INVEST OPHTH VIS SCI, V38, P1458; Baudouin C, 2004, OPHTHALMOLOGY, V111, P2186, DOI 10.1016/j.ophtha.2004.06.023; BAUDOUIN C, 1992, BRIT J OPHTHALMOL, V76, P545, DOI 10.1136/bjo.76.9.545; Baudouin C, 2008, OPHTHALMOLOGY, V115, P109, DOI 10.1016/j.ophtha.2007.01.036; Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001; Becquet F, 1998, CURR EYE RES, V17, P419, DOI 10.1080/02713689808951223; Chen W, 2008, INVEST OPHTH VIS SCI, V49, P1386, DOI 10.1167/iovs.07-0744; Chen W, 2009, EXP EYE RES, V89, P311, DOI 10.1016/j.exer.2009.03.015; Dursun D, 2002, INVEST OPHTH VIS SCI, V43, P632; Fabiani C, 2009, EXP EYE RES, V89, P166, DOI 10.1016/j.exer.2009.03.003; FUJIHARA T, 1995, J OCUL PHARMACOL TH, V11, P503, DOI 10.1089/jop.1995.11.503; GILBARD JP, 1988, INVEST OPHTH VIS SCI, V29, P374; GREEN K, 1987, J TOXICOL-CUTAN OCUL, V6, P89, DOI 10.3109/15569528709052168; HIKICHI T, 1995, GRAEF ARCH CLIN EXP, V233, P555, DOI 10.1007/BF00404705; Ishibashi T, 2003, J GLAUCOMA, V12, P486, DOI 10.1097/00061198-200312000-00008; Jean MD, 1999, INVEST OPHTH VIS SCI, V40, P619; KASWAN RL, 1989, ARCH OPHTHALMOL-CHIC, V107, P1210, DOI 10.1001/archopht.1989.01070020276038; Kunert KS, 2002, ARCH OPHTHALMOL-CHIC, V120, P330; Lemp Michael A., 1995, CLAO Journal, V21, P221; Lemp MA, 2007, OCUL SURF, V5, P75; Lin PY, 2003, OPHTHALMOLOGY, V110, P1096, DOI 10.1016/S0161-6420(03)00262-8; Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145; Maitchouk DY, 2000, ARCH OPHTHALMOL-CHIC, V118, P246; Niederkorn JY, 2006, J IMMUNOL, V176, P3950, DOI 10.4049/jimmunol.176.7.3950; Pisella PJ, 2004, INVEST OPHTH VIS SCI, V45, P1360, DOI 10.1167/iovs.03-1067; Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5; Spurr-Michaud S, 2007, EXP EYE RES, V84, P939, DOI 10.1016/j.exer.2007.01.018; Steuhl K P, 1991, Fortschr Ophthalmol, V88, P865; Stewart Paul, 2005, Eye Contact Lens, V31, P175, DOI 10.1097/01.ICL.0000161705.19602.C9; SULLIVAN DA, 1986, EXP EYE RES, V42, P131, DOI 10.1016/0014-4835(86)90037-0; SULLIVAN DA, 1984, IMMUNOLOGY, V52, P234; Susi B, 1999, OPHTHALMIC RES, V31, P229; Uematsu M, 2007, OPHTHAL RES, V39, P308, DOI 10.1159/000109986; Watanabe Hitoshi, 2002, Cornea, V21, pS17, DOI 10.1097/00003226-200203001-00005; Wilson G, 1995, J Am Optom Assoc, V66, P435; Xiong C, 2008, INVEST OPHTH VIS SCI, V49, P1850, DOI 10.1167/iovs.07-0720; Yeh S, 2003, INVEST OPHTH VIS SCI, V44, P124, DOI 10.1167/iovs.02-0581	39	47	52	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2012	7	3							e33688	10.1371/journal.pone.0033688	http://dx.doi.org/10.1371/journal.pone.0033688			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	932RV	22438984	Green Published, Green Submitted, gold			2023-01-03	WOS:000303309100088
J	Lehner, M; Gotz, G; Proff, J; Schaft, N; Dorrie, J; Full, F; Ensser, A; Muller, YA; Cerwenka, A; Abken, H; Parolini, O; Ambros, PF; Kovar, H; Holter, W				Lehner, Manfred; Goetz, Gabriel; Proff, Julia; Schaft, Niels; Doerrie, Jan; Full, Florian; Ensser, Armin; Muller, Yves A.; Cerwenka, Adelheid; Abken, Hinrich; Parolini, Ornella; Ambros, Peter F.; Kovar, Heinrich; Holter, Wolfgang			Redirecting T Cells to Ewing's Sarcoma Family of Tumors by a Chimeric NKG2D Receptor Expressed by Lentiviral Transduction or mRNA Transfection	PLOS ONE			English	Article							RECOMBINANT IMMUNORECEPTORS; ADOPTIVE IMMUNOTHERAPY; CD28 COSTIMULATION; PROGNOSTIC-FACTORS; LYMPHOCYTES; CYTOTOXICITY; ACTIVATION; DNAM-1; SECRETION; ASYMMETRY	We explored the possibility to target Ewing's sarcoma family of tumors (ESFT) by redirecting T cells. To this aim, we considered NKG2D-ligands (NKG2D-Ls) as possible target antigens. Detailed analysis of the expression of MICA, MICB, ULBP-1, -2, and -3 in fourteen ESFT cell lines revealed consistent expression of at least one NKG2D-L. Thus, for redirecting T cells, we fused a CD3 zeta/CD28-derived signaling domain to the ectodomain of NKG2D, however, opposite transmembrane orientation of this signaling domain and NKG2D required inverse orientation fusion of either of them. We hypothesized that the particularly located C-terminus of the NKG2D ectodomain should allow reengineering of the membrane anchoring from a native N-terminal to an artificial C-terminal linkage. Indeed, the resulting chimeric NKG2D receptor (chNKG2D) was functional and efficiently mediated ESFT cell death triggered by activated T cells. Notably, ESFT cells with even low NKG2D-L expression were killed by CD8(pos) and also CD4(pos) cells. Both, mRNA transfection and lentiviral transduction resulted in high level surface expression of chNKG2D. However, upon target-cell recognition receptor surface levels were maintained by tranfected RNA only during the first couple of hours after transfection. Later, target-cell contact resulted in strong and irreversible receptor down-modulation, whereas lentivirally mediated expression of chNKG2D remained constant under these conditions. Together, our study defines NKG2D-Ls as targets for a CAR-mediated T cell based immunotherapy of ESFT. A comparison of two different methods of gene transfer reveals strong differences in the susceptibility to ligand-induced receptor down-modulation with possible implications for the applicability of RNA transfection.	[Lehner, Manfred; Goetz, Gabriel; Proff, Julia; Holter, Wolfgang] Univ Erlangen Nurnberg, Lab Cellular Therapy, Childrens Univ Hosp, Univ Klinikum Erlangen, D-91054 Erlangen, Germany; [Schaft, Niels; Doerrie, Jan] Univ Erlangen Nurnberg, Dept Dermatol, Univ Klinikum Erlangen, Erlangen, Germany; [Full, Florian; Ensser, Armin] Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Erlangen, Germany; [Muller, Yves A.] Univ Erlangen Nurnberg, Lehrstuhl Biotech, Dept Biol, Erlangen, Germany; [Cerwenka, Adelheid] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Abken, Hinrich] Univ Cologne, CMMC, D-50931 Cologne, Germany; [Parolini, Ornella] Fdn Poliambulanza Ist Osped, Ctr Ric E Menni, Brescia, Italy; [Ambros, Peter F.; Kovar, Heinrich] St Anna Hosp, CCRI, Vienna, Austria	University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne; Saint Anna Children's Hospital	Lehner, M (corresponding author), Univ Erlangen Nurnberg, Lab Cellular Therapy, Childrens Univ Hosp, Univ Klinikum Erlangen, D-91054 Erlangen, Germany.	manfred.lehner@uk-erlangen.de	Ambros, Peter/AAA-1266-2021; Muller, Yves A/R-5397-2016; Schaft, Niels/H-3713-2011; Dörrie, Jan/H-3678-2011; PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020	Ambros, Peter/0000-0002-5507-7211; Muller, Yves A/0000-0003-0519-8928; Schaft, Niels/0000-0001-8236-9298; Dörrie, Jan/0000-0002-3478-0741; PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430; Cerwenka, Adelheid/0000-0001-6977-3536; Lehner, Manfred/0000-0002-5776-4218; Full, Florian/0000-0003-1900-5891; Kovar, Heinrich/0000-0001-6873-9109	Wilhelm Sander-Foundation [2002.034.1, 2009.002.1]; Staedtler-Foundation [24/09]; Interdisciplinary Center for Clinical Research (IZKF: Genesis, Diagnostics and Therapy of Inflammation Processes); German Research Foundation (DFG) [SCHA 1247/1-1, EN 423/2-1, SFB796]; Fondazione Berlucchi, Brescia, Italy	Wilhelm Sander-Foundation; Staedtler-Foundation; Interdisciplinary Center for Clinical Research (IZKF: Genesis, Diagnostics and Therapy of Inflammation Processes); German Research Foundation (DFG)(German Research Foundation (DFG)); Fondazione Berlucchi, Brescia, Italy	This work was financially supported by the Wilhelm Sander-Foundation (project Nr. 2002.034.1 and 2009.002.1), Staedtler-Foundation (project 24/09), the Interdisciplinary Center for Clinical Research (IZKF: Genesis, Diagnostics and Therapy of Inflammation Processes), the German Research Foundation (DFG: project SCHA 1247/1-1), EN 423/2-1, and SFB796) and a grant from the Fondazione Berlucchi, Brescia, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barber A, 2008, EXP HEMATOL, V36, P1318, DOI 10.1016/j.exphem.2008.04.010; Barber A, 2007, CANCER RES, V67, P5003, DOI 10.1158/0008-5472.CAN-06-4047; Barber DL, 2003, J IMMUNOL, V171, P27, DOI 10.4049/jimmunol.171.1.27; Birkholz K, 2009, GENE THER, V16, P596, DOI 10.1038/gt.2008.189; Brinkrolf P, 2009, INT J CANCER, V125, P879, DOI 10.1002/ijc.24461; Cho D, 2010, CLIN CANCER RES, V16, P3901, DOI 10.1158/1078-0432.CCR-10-0735; Cooper LJN, 2000, J VIROL, V74, P8207, DOI 10.1128/JVI.74.17.8207-8212.2000; Eagle RA, 2009, EUR J IMMUNOL, V39, P3207, DOI 10.1002/eji.200939502; Full F, 2010, J VIROL, V84, P4083, DOI 10.1128/JVI.02117-09; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Hombach A, 2001, J IMMUNOL, V167, P6123, DOI 10.4049/jimmunol.167.11.6123; James SE, 2010, J IMMUNOL, V184, P4284, DOI 10.4049/jimmunol.0903701; James ST, 2008, J IMMUNOL, V180, P7028, DOI 10.4049/jimmunol.180.10.7028; Kloess S, 2010, EUR J IMMUNOL, V40, P3255, DOI 10.1002/eji.201040568; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; KOVAR H, 1993, ONCOGENE, V8, P2683; Lakshmikanth T, 2009, J CLIN INVEST, V119, P1251, DOI 10.1172/JCI36022; Leavey PJ, 2008, PEDIATR BLOOD CANCER, V51, P334, DOI 10.1002/pbc.21618; Lehner M, 2007, J IMMUNOTHER, V30, P312, DOI 10.1097/01.cji.0000211345.11707.46; Loskog A, 2006, LEUKEMIA, V20, P1819, DOI 10.1038/sj.leu.2404366; McFarland BJ, 2003, STRUCTURE, V11, P411, DOI 10.1016/S0969-2126(03)00047-9; Meidenbauer N, 2003, J IMMUNOL, V170, P2161, DOI 10.4049/jimmunol.170.4.2161; Miser JS, 2007, PEDIATR BLOOD CANCER, V49, P894, DOI 10.1002/pbc.21233; Mitchell MS, 2002, J CLIN ONCOL, V20, P1075, DOI 10.1200/JCO.20.4.1075; Mitsiades N, 1998, AM J PATHOL, V153, P1947, DOI 10.1016/S0002-9440(10)65708-2; Molinero LL, 2002, J LEUKOCYTE BIOL, V71, P791; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; Rodriguez-Galindo C, 2007, CANCER-AM CANCER SOC, V110, P375, DOI 10.1002/cncr.22821; Rosenberg SA, 2009, CURR OPIN IMMUNOL, V21, P233, DOI 10.1016/j.coi.2009.03.002; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; de Hooge ASK, 2007, CLIN CANCER RES, V13, P206, DOI 10.1158/1078-0432.CCR-06-1457; Sadelain M, 2009, CURR OPIN IMMUNOL, V21, P215, DOI 10.1016/j.coi.2009.02.009; Salih HR, 2006, HUM IMMUNOL, V67, P188, DOI 10.1016/j.humimm.2006.02.008; Salmon P, 2000, BLOOD, V96, P3392; Saphire EO, 2002, J MOL BIOL, V319, P9, DOI 10.1016/S0022-2836(02)00244-9; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sun Q, 2002, BLOOD, V99, P3302, DOI 10.1182/blood.V99.9.3302; Textor S, 2008, INT J CANCER, V123, P2343, DOI 10.1002/ijc.23733; Thomas S, 2011, BLOOD, V118, P319, DOI 10.1182/blood-2010-12-326736; van Valen F, 1999, HUMAN CELL CULTURE, V1, P55; Van Valen F, 2000, INT J CANCER, V88, P252, DOI 10.1002/1097-0215(20001015)88:2<252::AID-IJC17>3.0.CO;2-U; Verhoeven DHJ, 2008, MOL IMMUNOL, V45, P3917, DOI 10.1016/j.molimm.2008.06.016; Verneris MR, 2004, BLOOD, V103, P3065, DOI 10.1182/blood-2003-06-2125; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; Waldhauer I, 2006, CANCER RES, V66, P2520, DOI 10.1158/0008-5472.CAN-05-2520; Zhang T, 2005, BLOOD, V106, P1544, DOI 10.1182/blood-2004-11-4365; Zhang T, 2006, CANCER RES, V66, P5927, DOI 10.1158/0008-5472.CAN-06-0130; Zhao YB, 2010, CANCER RES, V70, P9053, DOI 10.1158/0008-5472.CAN-10-2880	51	85	98	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2012	7	2							e31210	10.1371/journal.pone.0031210	http://dx.doi.org/10.1371/journal.pone.0031210			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925DP	22355347	Green Submitted, Green Published, gold			2023-01-03	WOS:000302741300047
J	Jackevicius, CA; Chou, MM; Ross, JS; Shah, ND; Krumholz, HM				Jackevicius, Cynthia A.; Chou, Mindy M.; Ross, Joseph S.; Shah, Nilay D.; Krumholz, Harlan M.			Generic Atorvastatin and Health Care Costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA 91766 USA; [Jackevicius, Cynthia A.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Jackevicius, Cynthia A.] Univ Toronto, Toronto, ON, Canada; [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Chou, Mindy M.] Indian Hlth Serv, San Fidel, NM USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale Univ, Sch Med, New Haven, CT USA; [Ross, Joseph S.; Krumholz, Harlan M.] Yale New Haven Med Ctr, New Haven, CT 06504 USA; [Shah, Nilay D.] Mayo Clin, Rochester, MN USA	Western University of Health Sciences; University of Toronto; University of Toronto; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Yale University; Yale University; Mayo Clinic	Jackevicius, CA (corresponding author), Western Univ Hlth Sci, Pomona, CA 91766 USA.		, Harlan/AAI-2875-2020	Ross, Joseph/0000-0002-9218-3320	NATIONAL INSTITUTE ON AGING [K08AG032886] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01 HL105270] Funding Source: Medline; NIA NIH HHS [K08 AG032886, K08 AG032886-04] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Food and Drug Administration, 2011, OR BOOK APPR DRUG PR; Kale MS, 2011, ARCH INTERN MED, V171, P1856, DOI 10.1001/archinternmed.2011.501; Peterson M., 2011, PFIZER MAY GET GENER; Stiles S., TIE ANNOUNCED SATURN; 2011, IMS HLTH        0407	5	52	54	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					201	204		10.1056/NEJMp1113112	http://dx.doi.org/10.1056/NEJMp1113112			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877RZ	22149736	Green Accepted			2023-01-03	WOS:000299201400004
J	Sauve, S; Buijs, D; Gingras, G; Aubin, Y				Sauve, Simon; Buijs, Daniel; Gingras, Genevieve; Aubin, Yves			Interactions between the Conserved Hydrophobic Region of the Prion Protein and Dodecylphosphocholine Micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; MEMBRANE-PROTEINS; PEPTIDE; VISUALIZATION; SPECTROSCOPY; SIMULATIONS; ORIENTATION; RESIDUES; DYNAMICS; SYSTEM	The three-dimensional structure of PrP110-136, a peptide encompassing the conserved hydrophobic region of the human prion protein, has been determined at high resolution in dodecylphosphocholine micelles by NMR. The results support the conclusion that the (PrP)-Pr-Ctm, a transmembrane form of the prion protein, adopts a different conformation than the reported structures of the normal prion protein determined in solution. Paramagnetic relaxation enhancement studies with gadolinium-diethylenetriaminepentaacetic acid indicated that the conserved hydrophobic region peptide is not inserted symmetrically in the micelle, thus suggesting the presence of a guanidium-phosphate ion pair involving the side chain of the terminal arginine and the detergent headgroup. Titration of dodecylphosphocholine into a solution of PrP110-136 revealed the presence of a surface-bound species. In addition, paramagnetic probes located the surface-bound peptide somewhere below the micelle-water interface when using the inserted helix as a positional reference. This localization of the unknown population would allow a similar ion pair interaction.	[Sauve, Simon; Buijs, Daniel; Gingras, Genevieve; Aubin, Yves] Hlth Canada, Ctr Vaccine Evaluat, Biol & Genet Therapies Directorate, Ottawa, ON K1A 0K9, Canada; [Buijs, Daniel; Aubin, Yves] Carleton Univ, Dept Chem, Ottawa, ON K1S 5B6, Canada	Health Canada; Carleton University	Aubin, Y (corresponding author), 251 Sir Frederick Banting Driveway, Ottawa, ON K1A 0K9, Canada.	yves.aubin@hc-sc.gc.ca			Bovine Sponqiform Encephalopathy initiative of the Government of Canada; National Science and Engineering Research Council	Bovine Sponqiform Encephalopathy initiative of the Government of Canada; National Science and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by the Bovine Sponqiform Encephalopathy initiative of the Government of Canada.; Supported by a National Science and Engineering Research Council discovery grant. To whom correspondence should be addressed: 251 Sir Frederick Banting Driveway, Ottawa, ON K1A 0K9, Canada. Fax: 613-941-8933; E-mail: yves.aubin@hc-sc.gc.ca.	Baker M, 2010, NAT METHODS, V7, P429, DOI 10.1038/nmeth0610-429; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; Bremer J, 2010, NAT NEUROSCI, V13, P310, DOI 10.1038/nn.2483; Chakrabarti O, 2009, TRENDS BIOCHEM SCI, V34, P287, DOI 10.1016/j.tibs.2009.03.001; Cobb NJ, 2009, BIOCHEMISTRY-US, V48, P2574, DOI 10.1021/bi900108v; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Di Natale G, 2005, ORG BIOMOL CHEM, V3, P490, DOI 10.1039/b407928k; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Glover KJ, 1999, ANAL BIOCHEM, V272, P270, DOI 10.1006/abio.1999.4182; Glover KJ, 2001, BIOCHEMISTRY-US, V40, P13137, DOI 10.1021/bi011485m; Gobl C, 2010, J PHYS CHEM B, V114, P4717, DOI 10.1021/jp9114089; Guntert P, 2003, PROG NUCL MAG RES SP, V43, P105, DOI 10.1016/S0079-6565(03)00021-9; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Hodak M, 2009, P NATL ACAD SCI USA, V106, P11576, DOI 10.1073/pnas.0903807106; Hornemann S, 2009, J BIOL CHEM, V284, P22713, DOI 10.1074/jbc.M109.000430; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kuwata K, 2003, P NATL ACAD SCI USA, V100, P14790, DOI 10.1073/pnas.2433563100; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Lazaridis T, 2005, J PHYS CHEM B, V109, P15098, DOI 10.1021/jp0516801; Liang BY, 2006, J AM CHEM SOC, V128, P4389, DOI 10.1021/ja0574825; Luhrs TT, 2006, J MOL BIOL, V357, P833, DOI 10.1016/j.jmb.2006.01.016; Moore RA, 2009, CURR OPIN STRUC BIOL, V19, P14, DOI 10.1016/j.sbi.2008.12.007; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Opella SJ, 2004, CHEM REV, V104, P3587, DOI 10.1021/cr0304121; Palladino P, 2010, J FLUORESC, V20, P191, DOI 10.1007/s10895-009-0537-0; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Respondek M, 2007, J AM CHEM SOC, V129, P5228, DOI 10.1021/ja069004f; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; Su YC, 2010, BIOCHEMISTRY-US, V49, P6009, DOI 10.1021/bi100642n; Tanford C., 1980, HYDROPHOBIC EFFECT F; Tang M, 2007, J AM CHEM SOC, V129, P11438, DOI 10.1021/ja072511s; Wang F, 2010, SCIENCE, V327, P1132, DOI 10.1126/science.1183748; Will R. G., 2004, PRION BIOL DIS, P631; Wuthrich K, 2001, ADV PROTEIN CHEM, V57, P55; Wymore T, 1999, J MOL STRUCT, V485, P195, DOI 10.1016/S0022-2860(99)00090-3; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	39	14	14	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2012	287	3					1915	1922		10.1074/jbc.M111.279364	http://dx.doi.org/10.1074/jbc.M111.279364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	879HT	22128151	Green Published, hybrid			2023-01-03	WOS:000299321000032
J	Moynihan, R				Moynihan, Ray			REALITY CHECK Forget sponsorship and free trips-welcome to Pharmacare	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Association of the British Pharmaceutical Industry, 2009, ABPI GUID NOT JOINT; Department of Health Association of British Pharmaceutical Industries, 2010, MOV SPONS JOINT WORK; Healy D, 2006, PLOS MED, V3, P441, DOI 10.1371/journal.pmed.0030185; Johnson & Johnson, FORM 10 Q Q REP FIL; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; McCartney M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7685; Moynihan R., 2011, CRIKEY          0526; Spurling GK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000352	8	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 4	2012	344								d8316	10.1136/bmj.d8316	http://dx.doi.org/10.1136/bmj.d8316			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874UF	22218100				2023-01-03	WOS:000298982900027
J	Pujades-Rodriguez, M; Dantony, E; Pinoges, L; Ecochard, R; Etard, JF; Carrillo-Casas, E; Szumilin, E				Pujades-Rodriguez, Mar; Dantony, Emmanuelle; Pinoges, Loretxu; Ecochard, Rene; Etard, Jean-Francois; Carrillo-Casas, Esther; Szumilin, Elisabeth		AIDS Working Grp Med Sans	Toxicity Associated with Stavudine Dose Reduction from 40 to 30 mg in First-Line Antiretroviral Therapy	PLOS ONE			English	Article							DISTAL SENSORY POLYNEUROPATHY; BODY-COMPOSITION; HIV-INFECTION; RISK-FACTORS; NEUROPATHY; LIPODYSTROPHY; TENOFOVIR; REGIMENS; COHORT; TRIAL	Background: To compare the incidence and timing of toxicity associated with the use of a reduced dose of stavudine from 40 to 30 mg in first-line antiretroviral therapy (ART) for HIV treatment and to investigate associated risk factors. Methods: Multicohort study including 23 HIV programs in resource-limited countries. Adults enrolled between January 2005 and December 2009. Four-year rates of all-cause and stavudine-specific toxicity were estimated. Multilevel mixed-effect Poisson and accelerated failure models were used to investigate factors associated with toxicity and timing of diagnosis. Findings: A total of 48,785 patients contributed 62,505 person-years of follow-up. Rate of all-cause toxicity was 7.80 (95%CI 7.59-8.03) per 100 person-years, but varied greatly across sites (range 0.41-21.76). Patients treated with stavudine 40 mg had higher rates of toxicity (adjusted rate ratio [aRR] 1.18, 95%CI 1.06-1.30 during the first year of ART; and 1.51, 95%CI 1.32-1.71 during the second year). Women, older age, initial advanced clinical stage, and low CD4 count were associated with increased toxicity rate ratios. Timing of lipodystrophy and peripheral neuropathy diagnosis were 12% and 13% shorter, respectively, in patients treated with stavudine 40 mg than in those receiving 30 mg stavudine dose (P = 0.03 and 0.07, respectively). Insterpretation: Higher rates of drug-related toxicity were reported in patients receiving stavudine 40 mg compared with 30 mg, and the time to toxicity diagnosis was shorter in patients treated with the higher dose. Higher rates of toxicity were observed during the first two years of ART.	[Pujades-Rodriguez, Mar; Pinoges, Loretxu; Etard, Jean-Francois] Epictr, Dept Clin Res, Paris, France; [Dantony, Emmanuelle; Ecochard, Rene] Hosp Civils Lyon, Serv Biostat, Lyon, France; [Dantony, Emmanuelle; Ecochard, Rene] Ctr Natl Rech Sci, Unite Mixte Rech 5558, Villeurbanne, France; [Dantony, Emmanuelle; Ecochard, Rene] Univ Lyon, Serv Biostat, Lyon, France; [Etard, Jean-Francois] Inst Rech Dev, Unite Mixte Int 233, Montpellier, France; [Carrillo-Casas, Esther] MSF AIDS Working Grp, Dept Med, Amsterdam, Netherlands; [Szumilin, Elisabeth] MSF AIDS Working Grp, Dept Med, Paris, France	CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); VetAgro Sup; Institut de Recherche pour le Developpement (IRD); Doctors Without Borders; Doctors Without Borders; Sanofi-Aventis; Sanofi France	Pujades-Rodriguez, M (corresponding author), Epictr, Dept Clin Res, Paris, France.	mar.pujades@epicentre.msf.org	Pujades-Rodriguez, Mar/G-4388-2014; Pujades-Rodriguez, Mar/T-1129-2018; Etard, Jean François/A-9630-2008; Etard, Jean-Francois/V-4865-2019	Pujades-Rodriguez, Mar/0000-0002-7778-3520; Pujades-Rodriguez, Mar/0000-0002-1375-1028; Etard, Jean François/0000-0002-4873-0788; Etard, Jean-Francois/0000-0002-4873-0788; Dantony, Emmanuelle/0000-0001-5143-0666	World Health Organization through the Gates Foundation pharmacovigilance initiative; Medecins Sans Frontieres (MSF); MSF AIDS Working Group	World Health Organization through the Gates Foundation pharmacovigilance initiative; Medecins Sans Frontieres (MSF); MSF AIDS Working Group	Funding to perform this work was given by the World Health Organization through the Gates Foundation pharmacovigilance initiative, and Medecins Sans Frontieres (MSF). The World Health Organization and the Gates Foundation had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MSF staff participated in data collection (through their work in routine projects in collaboration with the Ministry of Health) and preparation of the manuscript (ECC and ES are members of the medical department of MSF). The other authors work for Epicentre, which is a non-profit organisation created by MSF to conduct operational research/evaluations in MSF-supported projects to improve the quality of care provided and evaluate activities/strategies.; The authors thank Micheline Diepart, Chris Duncombe and Marco Vitoria from the World Health Organization for their support to this work; the ministries of health of the countries and the MSF field teams for their daily work and effort to provide care to the patients and for data collection; the members of the MSF AIDS Working Group for their advice and support; and the Epicentre FUCHIA team for their support in data collection and data quality maintenance. We also thank Oliver Yun for his editorial work.	Ait-Mohand H, 2008, HIV MED, V9, P738, DOI 10.1111/j.1468-1293.2008.00616.x; ANDERSON RE, 1995, J INFECT DIS, V171, pS118, DOI 10.1093/infdis/171.Supplement_2.S118; Boulassel MR, 2006, J MED VIROL, V78, P1158, DOI 10.1002/jmv.20676; BROWNE MJ, 1993, J INFECT DIS, V167, P21, DOI 10.1093/infdis/167.1.21; Childs EA, 1999, NEUROLOGY, V52, P607, DOI 10.1212/WNL.52.3.607; Evans SR, 2011, AIDS, V25, P919, DOI 10.1097/QAD.0b013e328345889d; HANVANICH M, 2003, ANTIVIR THER, V8; Hill A, 2007, EXPERT OPIN PHARMACO, V8, P679, DOI 10.1517/14656566.8.5.679; Keswani SC, 2002, AIDS, V16, P2105, DOI 10.1097/00002030-200211080-00002; Lichtenstein KA, 2005, CLIN INFECT DIS, V40, P148, DOI 10.1086/426076; Lopez OL, 2004, EUR J NEUROL, V11, P97, DOI 10.1046/j.1351-5101.2003.00713.x; McComsey GA, 2008, CLIN INFECT DIS, V46, P1290, DOI 10.1086/529384; Mercier S, 2009, JAIDS-J ACQ IMM DEF, V51, P224, DOI 10.1097/QAI.0b013e31819c16f4; Milinkovic A, 2007, ANTIVIR THER, V12, P407; Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007; PETERSEN EA, 1995, J INFECT DIS, V171, pS131, DOI 10.1093/infdis/171.Supplement_2.S131; Pujades-Rodriguez M, 2010, JAMA-J AM MED ASSOC, V304, P303, DOI 10.1001/jama.2010.980; Pujari SN, 2005, JAIDS-J ACQ IMM DEF, V39, P199; RIBERA E, 2011, RANDOMIZED STUDY COM; Robinson-Papp J, 2010, PAIN, V151, P732, DOI 10.1016/j.pain.2010.08.045; Rosen S, 2008, JAIDS-J ACQ IMM DEF, V48, P334, DOI 10.1097/QAI.0b013e31817ae5ef; Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426; Sanchez-Conde M, 2005, HIV CLIN TRIALS, V6, P197, DOI 10.1310/ED57-EU48-RK6A-E5U0; Schifitto G, 2002, NEUROLOGY, V58, P1764, DOI 10.1212/WNL.58.12.1764; Simpson DM, 2006, NEUROLOGY, V66, P1679, DOI 10.1212/01.wnl.0000218303.48113.5d; Simpson DM, 1998, AIDS, V12, P2425, DOI 10.1097/00002030-199818000-00011; Skopelitis EE, 2006, INT J STD AIDS, V17, P467, DOI 10.1258/095646206777689062; Tagliati M, 1999, ARCH NEUROL-CHICAGO, V56, P84, DOI 10.1001/archneur.56.1.84; Vivithanaporn P, 2010, NEUROLOGY, V75, P1150, DOI 10.1212/WNL.0b013e3181f4d5bb; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; *WHO, ADD 2006 WHO GUID AN; WOLF E, 2004, LOW DOSE STAVUDINE L	32	13	14	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2011	6	11							e28112	10.1371/journal.pone.0028112	http://dx.doi.org/10.1371/journal.pone.0028112			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858IO	22132226	Green Published, gold, Green Submitted			2023-01-03	WOS:000297789900048
J	Kocher, RP; Adashi, EY				Kocher, Robert P.; Adashi, Eli Y.			Hospital Readmissions and the Affordable Care Act Paying for Coordinated Quality Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Adashi, Eli Y.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02905 USA; [Kocher, Robert P.] Brookings Inst, Washington, DC 20036 USA	Brown University; Brookings Institution	Adashi, EY (corresponding author), Brown Univ, Warren Alpert Med Sch, 101 Dudley St, Providence, RI 02905 USA.	Eli_Adashi@brown.edu						Centers for Medicare and Medicaid Services, 2011, MED DEM DET COMM BAS; Centers for Medicare & Medicaid Services, FY 2012 IPPS PROP RU; Centers for Medicare & Medicaid Services, 2011, MED DEM IND HOM DEM; Centers for Medicare & Medicaid Services, 2011, CMS LAUNCH TOOLS IN; HealthCare, 2011, REP C NAT STRAT QUAL; Jencks SF, 2010, ANN INTERN MED, V153, P757, DOI 10.7326/0003-4819-153-11-201012070-00010; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Medicare Payment Advisory Commission, 2011, REP C ENH MED TECHN; US Department of Health and Human Services, STRAT PLA 2010 2015; USAID, 2011, WOM WAT WAT ALL CAMP	10	362	363	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2011	306	16					1794	1795		10.1001/jama.2011.1561	http://dx.doi.org/10.1001/jama.2011.1561			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837HH	22028355				2023-01-03	WOS:000296181600024
J	Johnell, K; Fischer, H				Johnell, Kristina; Fischer, Hakan			Dopaminergic and Serotonergic Drug Use: A Nationwide Register-Based Study of Over 1 300 000 Older People	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; AGE-DEPENDENT DECLINE; HUMAN BRAIN; F-18 SETOPERONE; RECEPTORS; ANTIDEPRESSANTS; DISEASE; PET; ACTIVATION; MANAGEMENT	Objective: To investigate the use of dopaminergic and serotonergic drugs in elderly people. Methods: We analyzed data on age, sex and dispensed drugs for individuals aged >= 65 years registered in the Swedish Prescribed Drug Register from July to September 2008 (n = 1 347 564; 81% of the total population aged >= 65 years in Sweden). Main outcome measures were dopaminergic (enhancing and/or lowering) and serotonergic (enhancing and/or lowering) drugs and combinations of these. Results: Dopaminergic and serotonergic drugs were used by 5.6% and 13.2% the participants, respectively. Female gender was related to use of both dopaminergic and, particularly, serotonergic drugs. Higher age was associated with use of dopamine lowering drugs and serotonergic drugs, whereas the association with use of dopamine enhancing drugs declined in the oldest old. The occurrence of combinations of dopaminergic and serotonergic drugs was generally low, with dopamine lowering + serotonin lowering drug the most common combination (1.6%). Female gender was associated with all of the combinations of dopaminergic and serotonergic drugs, whereas age showed a mixed pattern. Conclusion: Approximately one out of ten older patients uses serotonergic drugs and one out of twenty dopaminergic drugs. The frequent use of dopaminergic and serotonergic drugs in the elderly patients is a potential problem due to the fact that aging is associated with a down-regulation of both these monoaminergic systems. Future studies are needed for evaluation of the impact of these drugs on different cognitive and emotional functions in old age.	[Johnell, Kristina; Fischer, Hakan] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Fischer, Hakan] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Johnell, K (corresponding author), Karolinska Inst, Aging Res Ctr, Stockholm, Sweden.	kristina.johnell@ki.se		Fischer, Hakan/0000-0001-6710-1744	Swedish Research Council [dnr 2007-5870]; Konung Gustav V:s och Drottning Victorias Frimurarstiftelse	Swedish Research Council(Swedish Research CouncilEuropean Commission); Konung Gustav V:s och Drottning Victorias Frimurarstiftelse	This study was supported financially by a grant from the Swedish Research Council (dnr 2007-5870) and from Konung Gustav V:s och Drottning Victorias Frimurarstiftelse (HF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANTONINI A, 1993, ARCH NEUROL-CHICAGO, V50, P474, DOI 10.1001/archneur.1993.00540050026010; Arbouw MEL, 2011, OSTEOPOROSIS INT, V22, P2197, DOI 10.1007/s00198-010-1455-3; ARBOUW ME, 2010, OSTEOPOROS INT; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; Backman L, 2010, NEUROSCI BIOBEHAV R, V34, P670, DOI 10.1016/j.neubiorev.2009.12.008; Bannon MJ, 1997, NEUROLOGY, V48, P969, DOI 10.1212/WNL.48.4.969; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; BLIN J, 1993, BRAIN, V116, P497, DOI 10.1093/brain/116.3.497; Chan DKY, 2008, GERIATRICS-US, V63, P22; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; DESPLENTER F, INT PSYCHOG IN PRESS; Fischer H, 2010, BIOL PSYCHIAT, V67, P575, DOI 10.1016/j.biopsych.2009.12.013; Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071; Ginzburg R, 2009, ANN PHARMACOTHER, V43, P98, DOI 10.1345/aph.1L264; Giron MST, 2005, INT J GERIATR PSYCH, V20, P201, DOI 10.1002/gps.1273; Glickstein SB, 2005, CEREB CORTEX, V15, P1016, DOI 10.1093/cercor/bhh202; Haider SI, 2008, CLIN THER, V30, P419, DOI 10.1016/j.clinthera.2008.02.010; Hasnain M, 2009, AM J MED, V122, P614, DOI 10.1016/j.amjmed.2009.01.025; Haukka J, 2007, EUR J CLIN PHARMACOL, V63, P1069, DOI 10.1007/s00228-007-0349-6; Hovstadius Bo, 2009, BMC Clin Pharmacol, V9, P11, DOI 10.1186/1472-6904-9-11; JEDENIUS E, SCAND J PRI IN PRESS; JOHNELL K, EUR J CLIN IN PRESS; Johnell K, 2007, ANN PHARMACOTHER, V41, P1243, DOI 10.1345/aph.1K154; Johnell O, 2005, OSTEOPOROSIS INT, V16, pS3, DOI 10.1007/s00198-004-1702-6; Kaasinen V, 2000, NEUROBIOL AGING, V21, P683, DOI 10.1016/S0197-4580(00)00149-4; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Lotrich FE, 2005, J CLIN PHARMACOL, V45, P1106, DOI 10.1177/0091270005280297; Lovheim H, 2008, PHARMACOEPIDEM DR S, V17, P912, DOI 10.1002/pds.1600; Luciana M, 1998, CEREB CORTEX, V8, P218, DOI 10.1093/cercor/8.3.218; Meltzer HY, 2011, PSYCHOPHARMACOLOGY, V213, P289, DOI 10.1007/s00213-010-2137-8; Mottram P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003491.pub2; Mozley LH, 2001, AM J PSYCHIAT, V158, P1492, DOI 10.1176/appi.ajp.158.9.1492; Munafo MR, 2008, BIOL PSYCHIAT, V63, P852, DOI 10.1016/j.biopsych.2007.08.016; PARABIAGHI A, EUR J CLIN IN PRESS; Rajji TK, 2008, DRUG AGING, V25, P841, DOI 10.2165/00002512-200825100-00003; RINNE JO, 1990, BRAIN RES, V508, P349, DOI 10.1016/0006-8993(90)90423-9; Stein M, 2010, CURR TOP BEHAV NEURO, V2, P469, DOI 10.1007/7854_2009_35; Treit D, 2010, CURR TOP BEHAV NEURO, V2, P121, DOI 10.1007/7854_2009_17; Verdel BM, 2011, CLIN PHARMACOL THER, V89, P89, DOI 10.1038/clpt.2010.240; Verhoeff NPLG, 2000, PSYCHIAT RES-NEUROIM, V99, P123, DOI 10.1016/S0165-1781(00)00198-0; Wang Y, 1998, SYNAPSE, V30, P56, DOI 10.1002/(SICI)1098-2396(199809)30:1<56::AID-SYN7>3.0.CO;2-J; Wettermark B, 2007, PHARMACOEPIDEM DR S, V16, P726, DOI 10.1002/pds.1294	42	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 15	2011	6	8							e23750	10.1371/journal.pone.0023750	http://dx.doi.org/10.1371/journal.pone.0023750			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808CV	21858217	Green Submitted, Green Published, gold			2023-01-03	WOS:000293953700041
J	Avery, AJ; Rodgers, S; Cantrill, JA; Armstrong, S; Cresswell, K; Eden, M; Elliott, RA; Howard, R; Kendrick, D; Morris, CJ; Prescott, RJ; Swanwick, G; Franklin, M; Putman, K; Boyd, M; Sheikh, A				Avery, Anthony J.; Rodgers, Sarah; Cantrill, Judith A.; Armstrong, Sarah; Cresswell, Kathrin; Eden, Martin; Elliott, Rachel A.; Howard, Rachel; Kendrick, Denise; Morris, Caroline J.; Prescott, Robin J.; Swanwick, Glen; Franklin, Matthew; Putman, Koen; Boyd, Matthew; Sheikh, Aziz			A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis	LANCET			English	Article							ADVERSE DRUG EVENTS; CLINICAL-TRIALS; PRIMARY-CARE; ADMISSIONS; QUALITY	Background Medication errors are common in primary care and are associated with considerable risk of patient harm. We tested whether a pharmacist-led, information technology-based intervention was more effective than simple feedback in reducing the number of patients at risk of measures related to hazardous prescribing and inadequate blood-test monitoring of medicines 6 months after the intervention. Methods In this pragmatic, cluster randomised trial general practices in the UK were stratified by research site and list size, and randomly assigned by a web-based randomisation service in block sizes of two or four to one of two groups. The practices were allocated to either computer-generated simple feedback for at-risk patients (control) or a pharmacist-led information technology intervention (PINCER), composed of feedback, educational outreach, and dedicated support. The allocation was masked to general practices, patients, pharmacists, researchers, and statisticians. Primary outcomes were the proportions of patients at 6 months after the intervention who had had any of three clinically important errors: non-selective non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to those with a history of peptic ulcer without co-prescription of a proton-pump inhibitor; beta blockers prescribed to those with a history of asthma; long-term prescription of angiotensin converting enzyme (ACE) inhibitor or loop diuretics to those 75 years or older without assessment of urea and electrolytes in the preceding 15 months. The cost per error avoided was estimated by incremental cost-effectiveness analysis. This study is registered with Controlled-Trials.com, number ISRCTN21785299. Findings 72 general practices with a combined list size of 480 942 patients were randomised. At 6 months' follow-up, patients in the PINCER group were significantly less likely to have been prescribed a non-selective NSAID if they had a history of peptic ulcer without gastroprotection (OR 0.58, 95% CI 0.38-0.89); a beta blocker if they had asthma (0.73, 0.58-0.91); or an ACE inhibitor or loop diuretic without appropriate monitoring (0.51, 0.34-0.78). PINCER has a 95% probability of being cost effective if the decision-maker's ceiling willingness to pay reaches 75 pound per error avoided at 6 months. Interpretation The PINCER intervention is an effective method for reducing a range of medication errors in general practices with computerised clinical records.	[Avery, Anthony J.; Kendrick, Denise] Univ Nottingham, Sch Med, Queens Med Ctr, Div Primary Care, Nottingham NG7 2UH, England; [Rodgers, Sarah] Univ Nottingham, NIHR Collaborat Leadership Appl Hlth Res & Care N, Div Primary Care, Nottingham NG7 2UH, England; [Elliott, Rachel A.; Franklin, Matthew; Boyd, Matthew] Univ Nottingham, Sch Pharm, Div Social Res Med & Hlth, Nottingham NG7 2UH, England; [Cantrill, Judith A.; Eden, Martin] Univ Manchester, Sch Pharm & Pharmaceut Sci, Drug Usage & Pharm Practice Grp, Manchester, Lancs, England; [Armstrong, Sarah] NIHR Res Design Serv, Div Primary Care, Nottingham, England; [Cresswell, Kathrin; Prescott, Robin J.; Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, eHlth Res Grp, Edinburgh, Midlothian, Scotland; [Howard, Rachel] Univ Reading, Sch Pharm, Reading, Berks, England; [Morris, Caroline J.] Univ Otago, Wellington Sch Med & Hlth Sci, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; [Swanwick, Glen] NHS Nottinghamshire Cty, Qual & Governance Directorate, Res & Evaluat Team, Consumers Res Advisory Grp, Mansfield, Notts, England; [Putman, Koen] Vrije Univ Brussel, Fac Med & Pharm, Dept Med Sociol & Hlth Sci, Brussels, Belgium	University of Nottingham; University of Nottingham; University of Nottingham; University of Manchester; University of Edinburgh; University of Reading; University of Otago; Vrije Universiteit Brussel	Avery, AJ (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, Div Primary Care, Nottingham NG7 2UH, England.	tony.avery@nottingham.ac.uk	Howard, Rachel/C-8993-2013; Sheikh, Aziz/D-2818-2009; Boyd, Matthew/ABE-4187-2021; Elliott, Rachel/P-5894-2018; Franklin, Matthew/J-8109-2019; Putman, Koen/ABG-6361-2021	Sheikh, Aziz/0000-0001-7022-3056; Boyd, Matthew/0000-0003-2997-5090; Elliott, Rachel/0000-0002-3650-0168; Franklin, Matthew/0000-0002-2774-9439; Putman, Koen/0000-0002-7235-3759; Avery, Anthony/0000-0001-7591-4438; Morris, Caroline/0000-0002-8751-0657; Kendrick, Denise/0000-0003-3603-6542; Eden, Martin/0000-0002-1542-2527; Rodgers, Sarah/0000-0003-1676-1982	Patient Safety Research Portfolio, Department of Health, England; Department of Health's Patient Safety Research Portfolio; National Institute for Health Research [SPCR-042] Funding Source: researchfish	Patient Safety Research Portfolio, Department of Health, England; Department of Health's Patient Safety Research Portfolio; National Institute for Health Research(National Institute for Health Research (NIHR))	Patient Safety Research Portfolio, Department of Health, England.; The study was funded by a research grant awarded by the Department of Health's Patient Safety Research Portfolio. We thank the PINCER trial pharmacists, primary care trusts, general practices, and patients who took part in the study; Rachel Illingworth for facilitating the employment and management of the trial pharmacists; Sharon Mills for administrative support and assistance with collation of the costs for the pharmacists' interventions; Clive Morris and colleagues from The Computer Room (www.tcrnottingham.com) and Ed Longridge for their input about data extraction from general practices; Casey Quinn for contributions to the analysis of incremental cost-effectiveness ratios; Tom Turner for provision of advice about written materials that were issued to patients; Richard Lilford and colleagues from the Patient Safety Research Portfolio for their support. Finally, we thank the members of the independent Trial Steering Committee, Philip Hannaford (chair), Martin Buxton, and Marjorie Weiss; and the Data Monitoring and Ethics Committee, Richard Baker (chair), Christine Bond, and Peter Donnan for overseeing the trial.	Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Avery AJ, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-28; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387; Catwell L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000126; Chen YF, 2005, DRUG SAFETY, V28, P67, DOI 10.2165/00002018-200528010-00005; Department for Communities and Local Government, 2004, IND DEPR 2004; Department of Health, 2000, ORG MEM REP EXP GROU; Elashoff J, 2005, NQUERY ADVISOR VERSI; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Garfield S, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-50; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; GRIMSHAW JM, 2001, MED CARE S2, V39, P2, DOI DOI 10.1097/00005650-200108002-00002; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hilbe J.M., 2007, NEGATIVE BINOMIAL RE; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Howard RL, 2003, QUAL SAF HEALTH CARE, V12, P280, DOI 10.1136/qhc.12.4.280; Karnon J, 2009, J EVAL CLIN PRACT, V15, P299, DOI 10.1111/j.1365-2753.2008.01000.x; Kerry SM, 1998, BRIT MED J, V316, P1455, DOI 10.1136/bmj.316.7142.1455; Kohn LT, 1999, ERR IS HUMAN BUILDIN; Lilford RJ, 2007, BMJ-BRIT MED J, V335, P648, DOI 10.1136/bmj.39317.641296.AD; Medical Research Council (MRC), 2000, FRAM DEV EV RCTS COM; OBRIEN MAT, 2000, COCHRANE DB SYST REV, V2; Richmond S, 2010, BR J GEN PRACT, pe10; Royal S, 2006, QUAL SAF HEALTH CARE, V15, P23, DOI 10.1136/qshc.2004.012153; Schedlbauer A, 2009, J AM MED INFORM ASSN, V16, P531, DOI 10.1197/jamia.M2910; Schnipper JL, 2010, CIRC-CARDIOVASC QUAL, V3, P212, DOI 10.1161/CIRCOUTCOMES.109.921833; Shih WCJ, 2002, CURR CONTR TRIALS C, V3, DOI 10.1186/1468-6708-3-4; Smith J., 2004, BUILDING SAFER NHS P; StataCorp LP, 2008, STAT DAT AN STAT SOF; Winterstein Almut G., 2000, Pharmacoepidemiology and Drug Safety, V9, pS147	34	240	250	1	58	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 7	2012	379	9823					1310	1319		10.1016/S0140-6736(11)61817-5	http://dx.doi.org/10.1016/S0140-6736(11)61817-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	922FB	22357106	Bronze, Green Published			2023-01-03	WOS:000302531100028
J	Scartozzi, M; Faloppi, L; Bianconi, M; Giampieri, R; Maccaroni, E; Bittoni, A; Del Prete, M; Loretelli, C; Belvederesi, L; Baroni, GS; Cascinu, S				Scartozzi, Mario; Faloppi, Luca; Bianconi, Maristella; Giampieri, Riccardo; Maccaroni, Elena; Bittoni, Alessandro; Del Prete, Michela; Loretelli, Cristian; Belvederesi, Laura; Baroni, Gianluca Svegliati; Cascinu, Stefano			The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management	PLOS ONE			English	Article							UNRESECTABLE HEPATOCELLULAR-CARCINOMA; METASTATIC COLORECTAL ADENOCARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1; ENDOTHELIAL GROWTH-FACTOR; LIPIODOL CHEMOEMBOLIZATION; PTK787/ZK 222584; CONTROLLED-TRIAL; PHASE-III; CANCER; EXPRESSION	In many tumor types serum lactate dehydrogenase (LDH) levels is an indirect marker of tumor hypoxia, neo-angiogenesis and worse prognosis. However data about hepatocellular carcinoma (HCC) are lacking in the clinical setting of patients undergoing transarterial-chemoembolization (TACE) in whom hypoxia and neo-angiogenesis may represent a molecular key to treatment failure. Aim of our analysis was to evaluate the role of LDH pre-treatment levels in determining clinical outcome for patients with HCC receiving TACE. One hundred and fourteen patients were available for our analysis. For all patients LDH values were collected within one month before the procedure. We divided our patients into two groups, according to LDH serum concentration registered before TACE (first: LDH <= 450 U/l 84 patients; second: LDH>450 U/l 30 patients). Patients were classified according to the variation in LDH serum levels pre- and post-treatment (increased: 62 patients vs. decreased 52 patients). No statistically significant differences were found between the groups for all clinical characteristics analyzed (gender, median age, performance status ECOG, staging systems). In patients with LDH values below 450 U/l median time to progression (TTP) was 16.3 months, whereas it was of 10.1 months in patients above the cut-off (p = 0.0085). Accordingly median overall survival (OS) was 22.4 months and 11.7 months (p = 0.0049). In patients with decreased LDH values after treatment median TTP was 12.4 months, and median OS was 22.1 months, whereas TTP was 9.1 months and OS was 9.5 in patients with increased LDH levels (TTP: p = 0.0087; OS: p<0.0001). In our experience, LDH seemed able to predict clinical outcome for HCC patients undergoing TACE. Given the correlation between LDH levels and tumor angiogenesis we can speculate that patients with high LDH pretreatment levels may be optimal candidates for clinical trial exploring a multimodality treatment approach with TACE and anti-VEGF inhibitors in order to improve TTP and OS.	[Scartozzi, Mario; Giampieri, Riccardo; Loretelli, Cristian; Belvederesi, Laura; Cascinu, Stefano] Univ Politecn Marche, Azienda Osped Univ Osped Riuniti Umberto I Lancis, Clin Oncol Med, Ancona, Italy; [Faloppi, Luca; Bianconi, Maristella; Maccaroni, Elena; Bittoni, Alessandro; Del Prete, Michela] Univ Politecn Marche, Clin Oncol Med, Scuola Specializzaz Oncol Med, Ancona, Italy; [Baroni, Gianluca Svegliati] Univ Politecn Marche, Azienda Osped Univ Osped Riuniti Umberto I Lancis, Gastroenterol Clin, Ancona, Italy	Marche Polytechnic University; Marche Polytechnic University; Marche Polytechnic University	Scartozzi, M (corresponding author), Univ Politecn Marche, Azienda Osped Univ Osped Riuniti Umberto I Lancis, Clin Oncol Med, Ancona, Italy.	marioscartozzi@gmail.com	Loretelli, Cristian/AAO-7678-2020; Cascinu, Stefano/G-2399-2017; Faloppi, Luca/K-1030-2016; Cascinu, Stefano/AAN-1923-2020; pierantonelli, irene/B-4187-2014; Maccaroni, Elena/K-1232-2018	Cascinu, Stefano/0000-0003-2215-0731; Faloppi, Luca/0000-0003-3689-3085; Maccaroni, Elena/0000-0003-3212-4246; svegliati-baroni, gianluca/0000-0003-4399-3359; Loretelli, Cristian/0000-0002-7583-8540; SCARTOZZI, MARIO/0000-0001-5977-5546; Bianconi, Maristella/0000-0003-3475-2529				Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Bruix J, 1998, HEPATOLOGY, V27, P1578, DOI 10.1002/hep.510270617; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; CHAO Y, 2003, ANN SURG ONCOL, P55; Faloppi L, 2011, CANCER TREAT REV, V37, P169, DOI 10.1016/j.ctrv.2010.08.001; Hecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496; Holbrook JJ., 1975, ENZYMES, P191; Kohles N, 2012, TUMOR BIOL, V33, P33, DOI 10.1007/s13277-011-0237-7; Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5; Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; MARKERT CL, 1963, SCIENCE, V140, P1329, DOI 10.1126/science.140.3573.1329; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Montalto G, 2002, ANN NY ACAD SCI, V963, P13, DOI 10.1111/j.1749-6632.2002.tb04090.x; O'Suilleabhain CB, 2003, BRIT J SURG, V90, P325, DOI 10.1002/bjs.4045; OBERTI F, 1995, NEW ENGL J MED, V332, P1256; Okada S, 1998, HEPATO-GASTROENTEROL, V45, P1259; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pelletier G, 1998, J HEPATOL, V29, P129, DOI 10.1016/S0168-8278(98)80187-6; Poon RTP, 2004, BRIT J SURG, V91, P1354, DOI 10.1002/bjs.4594; Scartozzi M, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-164; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI 10.1200/JCO.2010.29.5436; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu XZ, 2010, WORLD J GASTROENTERO, V16, P4084, DOI 10.3748/wjg.v16.i32.4084	29	42	44	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2012	7	3							e32653	10.1371/journal.pone.0032653	http://dx.doi.org/10.1371/journal.pone.0032653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	943KB	22461886	Green Published, gold, Green Submitted			2023-01-03	WOS:000304118900005
J	Tang, ACL; Hwang, GL; Tsai, SJ; Chang, MY; Tang, ZCW; Tsai, MD; Luo, CY; Hoffman, AS; Hsieh, PCH				Tang, Alan C. L.; Hwang, Gan-Lin; Tsai, Shih-Jung; Chang, Min-Yao; Tang, Zack C. W.; Tsai, Meng-Da; Luo, Chwan-Yao; Hoffman, Allan S.; Hsieh, Patrick C. H.			Biosafety of Non-Surface Modified Carbon Nanocapsules as a Potential Alternative to Carbon Nanotubes for Drug Delivery Purposes	PLOS ONE			English	Article							STRUCTURAL DEFECTS PLAY; ACUTE LUNG TOXICITY; IN-VIVO; MAJOR ROLE; BIODISTRIBUTION; TISSUE; RATS; C-60	Background: Carbon nanotubes (CNTs) have found wide success in circuitry, photovoltaics, and other applications. In contrast, several hurdles exist in using CNTs towards applications in drug delivery. Raw, non-modified CNTs are widely known for their toxicity. As such, many have attempted to reduce CNT toxicity for intravenous drug delivery purposes by post-process surface modification. Alternatively, a novel sphere-like carbon nanocapsule (CNC) developed by the arc-discharge method holds similar electric and thermal conductivities, as well as high strength. This study investigated the systemic toxicity and biocompatibility of different non-surface modified carbon nanomaterials in mice, including multiwalled carbon nanotubes (MWCNTs), single-walled carbon nanotubes (SWCNTs), carbon nanocapsules (CNCs), and C-60 fullerene (C-60). The retention of the nanomaterials and systemic effects after intravenous injections were studied. Methodology and Principal Findings: MWCNTs, SWCNTs, CNCs, and C-60 were injected intravenously into FVB mice and then sacrificed for tissue section examination. Inflammatory cytokine levels were evaluated with ELISA. Mice receiving injection of MWCNTs or SWCNTs at 50 mu g/g b.w. died while C-60 injected group survived at a 50% rate. Surprisingly, mortality rate of mice injected with CNCs was only at 10%. Tissue sections revealed that most carbon nanomaterials retained in the lung. Furthermore, serum and lung-tissue cytokine levels did not reveal any inflammatory response compared to those in mice receiving normal saline injection. Conclusion: Carbon nanocapsules are more biocompatible than other carbon nanomaterials and are more suitable for intravenous drug delivery. These results indicate potential biomedical use of non-surface modified carbon allotrope. Additionally, functionalization of the carbon nanocapsules could further enhance dispersion and biocompatibility for intravenous injection.	[Tang, Alan C. L.; Tang, Zack C. W.; Hsieh, Patrick C. H.] Natl Cheng Kung Univ & Hosp, Inst Clin Med, Tainan, Taiwan; [Hwang, Gan-Lin; Tsai, Shih-Jung] Nano Powder & Thin Film Technol Ctr, Ind Technol Res Inst, Tainan, Taiwan; [Chang, Min-Yao; Hsieh, Patrick C. H.] Natl Cheng Kung Univ & Hosp, Inst Biomed Engn, Tainan, Taiwan; [Hwang, Gan-Lin; Tsai, Shih-Jung; Hsieh, Patrick C. H.] Natl Cheng Kung Univ & Hosp, Ctr Micro Nano Sci & Technol, Tainan, Taiwan; [Tsai, Meng-Da; Luo, Chwan-Yao; Hsieh, Patrick C. H.] Natl Cheng Kung Univ & Hosp, Dept Surg, Tainan, Taiwan; [Hoffman, Allan S.; Hsieh, Patrick C. H.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Hsieh, Patrick C. H.] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; Industrial Technology Research Institute - Taiwan; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; University of Washington; University of Washington Seattle; Academia Sinica - Taiwan	Hsieh, PCH (corresponding author), Natl Cheng Kung Univ & Hosp, Inst Clin Med, Tainan, Taiwan.	phsieh@mail.ncku.edu.tw			National Science Council [99-2627-M-006-009]; Center for Micro/Nano Science and Technology of National Cheng Kung University [99C028]	National Science Council(Ministry of Science and Technology, Taiwan); Center for Micro/Nano Science and Technology of National Cheng Kung University	This research was financially supported by the National Science Council (99-2627-M-006-009) and the Center for Micro/Nano Science and Technology of National Cheng Kung University (99C028). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aillon KL, 2009, ADV DRUG DELIVER REV, V61, P457, DOI 10.1016/j.addr.2009.03.010; Baker GL, 2008, TOXICOL SCI, V101, P122, DOI 10.1093/toxsci/kfm243; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Bhirde AA, 2009, ACS NANO, V3, P307, DOI 10.1021/nn800551s; Burke AR, 2011, BIOMATERIALS, V32, P5970, DOI 10.1016/j.biomaterials.2011.04.059; Cheng WH, 2004, J LIGHTWAVE TECHNOL, V22, P2177, DOI 10.1109/JLT.2004.833250; Cheung W, 2010, ADV DRUG DELIVER REV, V62, P633, DOI 10.1016/j.addr.2010.03.007; Deng X, 2007, CARBON, V45, P1419, DOI 10.1016/j.carbon.2007.03.035; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Dobrovolskaia MA, 2009, NAT NANOTECHNOL, V4, P411, DOI [10.1038/nnano.2009.175, 10.1038/NNANO.2009.175]; Fenoglio I, 2008, CHEM RES TOXICOL, V21, P1690, DOI 10.1021/tx800100s; Harrison BS, 2007, BIOMATERIALS, V28, P344, DOI 10.1016/j.biomaterials.2006.07.044; Huang HC, 2006, THIN SOLID FILMS, V515, P1033, DOI 10.1016/j.tsf.2006.07.071; Huang HC, 2006, THIN SOLID FILMS, V511, P203, DOI 10.1016/j.tsf.2005.12.127; Hwang GL, 2003, CHEM MATER, V15, P1353, DOI 10.1021/cm020747j; Hwang GL, 2002, US patent, Patent No. 7156958; Jeong SH, 2002, CHEM MATER, V14, P1859, DOI 10.1021/cm011620h; Kostarelos K, 2009, NAT NANOTECHNOL, V4, P627, DOI 10.1038/nnano.2009.241; Kostarelos K, 2008, NAT BIOTECHNOL, V26, P774, DOI 10.1038/nbt0708-774; Kubota R, 2011, TOXICOL LETT, V206, P172, DOI 10.1016/j.toxlet.2011.07.010; Lacerda L, 2006, ADV DRUG DELIVER REV, V58, P1460, DOI 10.1016/j.addr.2006.09.015; LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876; Li C, 2007, J MATER CHEM, V17, P2406, DOI 10.1039/b618518e; Muller J, 2008, CHEM RES TOXICOL, V21, P1698, DOI 10.1021/tx800101p; Podesta JE, 2009, SMALL, V5, P1176, DOI 10.1002/smll.200801572; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Ryman-Rasmussen JP, 2009, NAT NANOTECHNOL, V4, P747, DOI [10.1038/nnano.2009.305, 10.1038/NNANO.2009.305]; Saito N, 2009, CHEM SOC REV, V38, P1897, DOI 10.1039/b804822n; Sato Y, 2008, ACS NANO, V2, P348, DOI 10.1021/nn700324z; Shvedova AA, 2009, PHARMACOL THERAPEUT, V121, P192, DOI 10.1016/j.pharmthera.2008.10.009; Singh R, 2006, P NATL ACAD SCI USA, V103, P3357, DOI 10.1073/pnas.0509009103; Su TT, 2006, IEEE C EM TECHN NAN; Tong DG, 2010, PLASMA CHEM PLASMA P, V30, P897, DOI 10.1007/s11090-010-9262-3; Xu JY, 2007, CARBON, V45, P1865, DOI 10.1016/j.carbon.2007.04.030; Yang K, 2010, NANO LETT, V10, P3318, DOI 10.1021/nl100996u; Yang WR, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/41/412001; Zhang DY, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/17/175101; Zhang Y, 2010, DRUG DISCOV TODAY, V15, P428, DOI 10.1016/j.drudis.2010.04.005	38	32	32	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2012	7	3							e32893	10.1371/journal.pone.0032893	http://dx.doi.org/10.1371/journal.pone.0032893			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940QX	22457723	Green Published, gold, Green Submitted			2023-01-03	WOS:000303909200009
J	Tou, WI; Chen, CYC				Tou, Weng Ieong; Chen, Calvin Yu-Chian			In Silico Investigation of Potential Src Kinase Ligands from Traditional Chinese Medicine	PLOS ONE			English	Article							PHASE-II TRIAL; GENETIC FUNCTION APPROXIMATION; METASTATIC BREAST-CANCER; SARACATINIB AZD0530; EXPERIMENTAL-DESIGN; OUABAIN; INHIBITORS; DASATINIB; HYPERTENSION; DISCOVERY	Src kinase is an attractive target for drug development based on its established relationship with cancer and possible link to hypertension. The suitability of traditional Chinese medicine (TCM) compounds as potential drug ligands for further biological evaluation was investigated using structure-based, ligand-based, and molecular dynamics (MD) analysis. Isopraeroside IV, 9alpha-hydroxyfraxinellone-9-O-beta-D-glucoside (9HFG) and aurantiamide were the top three TCM candidates identified from docking. Hydrogen bonds and hydrophobic interactions were the primary forces governing docking stability. Their stability with Src kinase under a dynamic state was further validated through MD and torsion angle analysis. Complexes formed by TCM candidates have lower total energy estimates than the control Sacaratinib. Four quantitative-structural activity relationship (QSAR) in silico verifications consistently suggested that the TCM candidates have bioactive properties. Docking conformations of 9HFG and aurantiamide in the Src kinase ATP binding site suggest potential inhibitor-like characteristics, including competitive binding at the ATP binding site (Lys295) and stabilization of the catalytic cleft integrity. The TCM candidates have significantly lower ligand internal energies and are estimated to form more stable complexes with Src kinase than Saracatinib. Structure-based and ligand-based analysis support the drug-like potential of 9HFG and aurantiamide and binding mechanisms reveal the tendency of these two candidates to compete for the ATP binding site.	[Tou, Weng Ieong] China Med Univ, Sch Med, Taichung, Taiwan; [Tou, Weng Ieong; Chen, Calvin Yu-Chian] China Med Univ, Lab Computat & Syst Biol, Taichung, Taiwan; [Chen, Calvin Yu-Chian] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Chen, Calvin Yu-Chian] Asia Univ, Dept Biomed Informat, Taichung, Taiwan; [Chen, Calvin Yu-Chian] China Med Univ Beigang Hosp, Yunlin, Taiwan	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; Asia University Taiwan	Tou, WI (corresponding author), China Med Univ, Sch Med, Taichung, Taiwan.	ycc929@MIT.EDU	; Chen, Calvin Yu-Chian/E-9402-2010	Chen, Calvin Yu-Chian/0000-0001-9213-9832; Chen, Calvin Yu-Chian/0000-0003-3306-250X; Tou, Weng Ieong/0000-0003-4411-0546	National Science Council of Taiwan (NSC) [100-2325-B-039-001]; Committee on Chinese Medicine and Pharmacy [CCMP100-RD-030]; China Medical University; Asia University [DMR-101-094]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH101-TD-B-111-004]; Taiwan Department of Health Cancer Research Center of Excellence [DOH101-TD-C-111-005]	National Science Council of Taiwan (NSC)(Ministry of Science and Technology, Taiwan); Committee on Chinese Medicine and Pharmacy; China Medical University(China Medical University); Asia University; Taiwan Department of Health Clinical Trial and Research Center of Excellence; Taiwan Department of Health Cancer Research Center of Excellence	This research was supported by grants from the National Science Council of Taiwan (NSC 100-2325-B-039-001), Committee on Chinese Medicine and Pharmacy (CCMP100-RD-030), China Medical University and Asia University (DMR-101-094). This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH101-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (DOH101-TD-C-111-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aleshin A, 2010, NEOPLASIA, V12, P599, DOI 10.1593/neo.10328; [Anonymous], SYBYL X; Bianchi G, 2005, AM J PHYSIOL-REG I, V289, pR1536, DOI 10.1152/ajpregu.00441.2005; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Brooks HD, 2011, CANCER-AM CANCER SOC, V117, P2112, DOI 10.1002/cncr.25769; Chang CL, 2011, GENOME RES, V21, P21, DOI 10.1101/gr.110593.110; Chang KW, 2011, J BIOMOL STRUCT DYN, V29, P243, DOI 10.1080/073911011010524988; Chang PC, 2011, J BIOMOL STRUCT DYN, V29, P471, DOI 10.1080/07391102.2011.10507399; Chang SS, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002315; Chang TT, 2011, J BIOMOL STRUCT DYN, V28, P773, DOI 10.1080/07391102.2011.10508605; Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939; Chen CY, 2010, J MOL GRAPH MODEL, V29, P21, DOI 10.1016/j.jmgm.2010.04.002; Chen CY, 2009, ACTA PHARMACOL SIN, V30, P1186, DOI 10.1038/aps.2009.100; Chen KC, 2011, SOFT MATTER, V7, P4001, DOI 10.1039/c0sm01548b; Choi SY, 2005, PHYTOTHER RES, V19, P839, DOI 10.1002/ptr.1424; Cortes JE, 2011, BLOOD, V118, P4567, DOI 10.1182/blood-2011-05-355594; Ferrandi M, 2004, J BIOL CHEM, V279, P33306, DOI 10.1074/jbc.M402187200; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; Ferrandi M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001815; Ferrari P, 2010, BBA-MOL BASIS DIS, V1802, P1254, DOI 10.1016/j.bbadis.2010.01.009; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Fury MG, 2011, ANTICANCER RES, V31, P249; Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016; Gianni D, 2010, MOL BIOL CELL, V21, P4287, DOI 10.1091/mbc.E10-08-0685; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Hasegawa K, 2010, CURR COMPUT-AID DRUG, V6, P24, DOI 10.2174/157340910790980124; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Herold CI, 2011, CLIN CANCER RES, V17, P6061, DOI 10.1158/1078-0432.CCR-11-1071; Irwin ME, 2011, CANCER BIOL THER, V12, P718, DOI 10.4161/cbt.12.8.16907; Jamois EA, 2004, ABSTR PAP AM CHEM S, V227, pU905; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Johnson ML, 2011, J THORAC ONCOL, V6, P1128, DOI 10.1097/JTO.0b013e3182161508; Keller TH, 2006, CURR OPIN CHEM BIOL, V10, P357, DOI 10.1016/j.cbpa.2006.06.014; Khan MTH, 2010, CURR DRUG METAB, V11, P285; Kim HS, 2011, CLIN CANCER RES, V17, P1713, DOI 10.1158/1078-0432.CCR-10-2081; Kim JH, 2004, BIOINFORMATICS, V20, P3179, DOI 10.1093/bioinformatics/bth382; Kluger HM, 2011, CANCER-AM CANCER SOC, V117, P2202, DOI 10.1002/cncr.25766; Kowar TR, 1998, J CHEM INF COMP SCI, V38, P858, DOI 10.1021/ci980205f; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799; Mackay HJ, 2012, INVEST NEW DRUG, V30, P1158, DOI 10.1007/s10637-011-9650-4; Manunta P, 2009, J HYPERTENS, V27, P9, DOI 10.1097/HJH.0b013e32831cf2c6; Mayer EL, 2011, CLIN CANCER RES, V17, P6897, DOI 10.1158/1078-0432.CCR-11-0070; Miyake T, 2012, ONCOGENE, V31, P1431, DOI 10.1038/onc.2011.332; Montes M, 2007, PROTEINS, V68, P712, DOI 10.1002/prot.21405; Noronha G, 2007, BIOORG MED CHEM LETT, V17, P602, DOI 10.1016/j.bmcl.2006.11.006; Oneyama C, 2012, ONCOGENE, V31, P1623, DOI 10.1038/onc.2011.367; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Scheiner-Bobis G, 2001, NAT MED, V7, P1288, DOI 10.1038/nm1201-1288; Sharma MR, 2012, INVEST NEW DRUG, V30, P1211, DOI 10.1007/s10637-011-9681-x; Slinker BK, 2008, CIRCULATION, V117, P1732, DOI 10.1161/CIRCULATIONAHA.106.654376; Sun MF, 2011, J BIOMOL STRUCT DYN, V28, P895, DOI 10.1080/07391102.2011.10508616; Thomas S, 2011, CANCER RES, V71, P832, DOI 10.1158/0008-5472.CAN-10-0730; Tsai TY, 2011, J COMPUT AID MOL DES, V25, P525, DOI 10.1007/s10822-011-9438-9; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yang SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028793; Yang SC, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002189; Yoon JS, 2008, J NAT PROD, V71, P208, DOI 10.1021/np070588o; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	61	20	20	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2012	7	3							e33728	10.1371/journal.pone.0033728	http://dx.doi.org/10.1371/journal.pone.0033728			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	939YN	22470466	Green Published, gold, Green Submitted			2023-01-03	WOS:000303857100043
J	Moynihan, R				Moynihan, Ray			REALITY CHECK Assaulting alternative medicine: worthwhile or witch hunt?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Clinical evidence, WHAT CONCL HAS CLIN; Elshaug A, 2011, TRANSF HLTH EC INT H; Furlan AD, 2010, AHRQ PUBLICATION; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Wulff KC, 2011, HEALTH AFFAIR, V30, P2269, DOI 10.1377/hlthaff.2011.0159	5	9	9	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 15	2012	344								e1075	10.1136/bmj.e1075	http://dx.doi.org/10.1136/bmj.e1075			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	896IB	22337786	Green Submitted			2023-01-03	WOS:000300557800007
J	Mirnezami, R; Nicholson, J; Darzi, A				Mirnezami, Reza; Nicholson, Jeremy; Darzi, Ara			Preparing for Precision Medicine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH		[Mirnezami, Reza; Darzi, Ara] Univ London Imperial Coll Sci Technol & Med, Sect Biosurg & Surg Technol, Dept Surg & Canc, London, England; [Nicholson, Jeremy] Univ London Imperial Coll Sci Technol & Med, Sect Biomol Med, Dept Surg & Canc, London, England	Imperial College London; Imperial College London	Mirnezami, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Biosurg & Surg Technol, Dept Surg & Canc, London, England.		Nicholson, Jeremy K/B-3395-2012	Nicholson, Jeremy K/0000-0002-8123-8349				Committee on a Framework for Developing a New Taxonomy of Disease; National Research Council, 2011, PREC MED BUILD KNOWL; Katsanis SH, 2008, SCIENCE, V320, P53, DOI 10.1126/science.1156604; Mayor S, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6215; Scheuner MT, 2009, GENET MED, V11, P510, DOI 10.1097/GIM.0b013e3181a53331	4	442	470	2	138	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					489	491		10.1056/NEJMp1114866	http://dx.doi.org/10.1056/NEJMp1114866			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22256780				2023-01-03	WOS:000299991300004
J	Meyer, RM; Gospodarowicz, MK; Connors, JM; Pearcey, RG; Wells, WA; Winter, JN; Horning, SJ; Dar, AR; Shustik, C; Stewart, DA; Crump, M; Djurfeldt, MS; Chen, BSE; Shepherd, LE				Meyer, Ralph M.; Gospodarowicz, Mary K.; Connors, Joseph M.; Pearcey, Robert G.; Wells, Woodrow A.; Winter, Jane N.; Horning, Sandra J.; Dar, A. Rashid; Shustik, Chaim; Stewart, Douglas A.; Crump, Michael; Djurfeldt, Marina S.; Chen, Bingshu E.; Shepherd, Lois E.		NCIC Clinical Trials Grp; Eastern Cooperative Oncology Grp	ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-PRACTICE GUIDELINES; COOPERATIVE-ONCOLOGY-GROUP; FIELD RADIOTHERAPY; RANDOMIZED-TRIALS; INTERGROUP TRIAL; DISEASE; CHEMOTHERAPY; VINBLASTINE; DOXORUBICIN; BLEOMYCIN	Background Chemotherapy plus radiation treatment is effective in controlling stage IA or IIA nonbulky Hodgkin's lymphoma in 90% of patients but is associated with late treatment-related deaths. Chemotherapy alone may improve survival because it is associated with fewer late deaths. Methods We randomly assigned 405 patients with previously untreated stage IA or IIA nonbulky Hodgkin's lymphoma to treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or to treatment with subtotal nodal radiation therapy, with or without ABVD therapy. Patients in the ABVD-only group, both those with a favorable risk profile and those with an unfavorable risk profile, received four to six cycles of ABVD. Among those assigned to subtotal nodal radiation therapy, patients who had a favorable risk profile received subtotal nodal radiation therapy alone and patients with an unfavorable risk profile received two cycles of ABVD plus subtotal nodal radiation therapy. The primary end point was 12-year overall survival. Results The median length of follow-up was 11.3 years. At 12 years, the rate of overall survival was 94% among those receiving ABVD alone, as compared with 87% among those receiving subtotal nodal radiation therapy (hazard ratio for death with ABVD alone, 0.50; 95% confidence interval [CI], 0.25 to 0.99; P=0.04); the rates of freedom from disease progression were 87% and 92% in the two groups, respectively (hazard ratio for disease progression, 1.91; 95% CI, 0.99 to 3.69; P=0.05); and the rates of event-free survival were 85% and 80%, respectively (hazard ratio for event, 0.88; 95% CI, 0.54 to 1.43; P=0.60). Among the patients randomly assigned to ABVD alone, 6 patients died from Hodgkin's lymphoma or an early treatment complication and 6 died from another cause; among those receiving radiation therapy, 4 deaths were related to Hodgkin's lymphoma or early toxic effects from the treatment and 20 were related to another cause. Conclusions Among patients with Hodgkin's lymphoma, ABVD therapy alone, as compared with treatment that included subtotal nodal radiation therapy, was associated with a higher rate of overall survival owing to a lower rate of death from other causes. (Funded by the Canadian Cancer Society and the National Cancer Institute; HD.6ClinicalTrials.govnumber, NCT00002561.)	[Meyer, Ralph M.] Queens Univ, Canc Res Inst, Kingston, ON K7L 3N6, Canada; [Meyer, Ralph M.; Djurfeldt, Marina S.; Chen, Bingshu E.; Shepherd, Lois E.] NCIC Clin Trials Grp, Kingston, ON, Canada; [Gospodarowicz, Mary K.; Wells, Woodrow A.; Crump, Michael] Univ Toronto, Toronto, ON, Canada; [Connors, Joseph M.] British Columbia Canc Agcy Ctr Lymphoid Canc, Vancouver, BC, Canada; [Pearcey, Robert G.] Univ Alberta, Edmonton, AB, Canada; [Dar, A. Rashid] Univ Western Ontario, London, ON, Canada; [Shustik, Chaim] McGill Univ, Montreal, PQ, Canada; [Stewart, Douglas A.] Univ Calgary, Calgary, AB, Canada; [Winter, Jane N.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA	Queens University - Canada; Queens University - Canada; Canadian Cancer Trials Group; University of Toronto; University of Alberta; Western University (University of Western Ontario); McGill University; University of Calgary; Northwestern University; Feinberg School of Medicine; Stanford University	Meyer, RM (corresponding author), Queens Univ, Canc Res Inst, 10 Stuart St, Kingston, ON K7L 3N6, Canada.	rmeyer@ctg.queensu.ca	Connors, Joseph/AAF-5284-2019	Connors, Joseph/0000-0002-1361-7531; Chen, Bingshu/0000-0001-6139-0696; Winter, Jane/0000-0001-7542-3305	Canadian Cancer Society from the National Cancer Institute of Canada [015469]; Canadian Cancer Society Research Institute [21039]; National Cancer Institute, National Institutes of Health [CA077202]; National Cancer Institute [CA17145, CA21115]; Amgen Canada; Ariad Pharmaceuticals; Astex Therapeutics; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Ortho; Lilly; Merck Frosst Canada; Novartis; Oncothyreon; Ortho Biotech; Pfizer; Roche; SBIO; Sanofi; Schering Canada; ZymoGenetics; Imedex; Physicians' Education Resource; Lundbeck; Millennium; Janssen; NATIONAL CANCER INSTITUTE [U10CA077202, U10CA021115, U10CA017145] Funding Source: NIH RePORTER	Canadian Cancer Society from the National Cancer Institute of Canada; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Amgen Canada(Amgen); Ariad Pharmaceuticals; Astex Therapeutics; AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Celgene(Bristol-Myers SquibbCelgene Corporation); GlaxoSmithKline(GlaxoSmithKline); Janssen-Ortho; Lilly(Eli Lilly); Merck Frosst Canada; Novartis(Novartis); Oncothyreon; Ortho Biotech; Pfizer(Pfizer); Roche(Roche Holding); SBIO; Sanofi; Schering Canada; ZymoGenetics; Imedex; Physicians' Education Resource; Lundbeck(Lundbeck Corporation); Millennium(Takeda Pharmaceutical Company Ltd); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The NCIC Clinical Trials Group was supported by funds from the Canadian Cancer Society, through grants from the National Cancer Institute of Canada (015469) and the Canadian Cancer Society Research Institute (21039), and by the National Cancer Institute, National Institutes of Health (CA077202); the Eastern Cooperative Oncology Group was supported by grants (CA17145 and CA21115) from the National Cancer Institute.; Dr. Meyer reports receiving honoraria from Lilly for serving on a data and safety monitoring committee and from Celgene for serving on an independent response assessment committee. In addition, the NCIC Clinical Trials Group, of which he is the director, has received research funding from Amgen Canada, Ariad Pharmaceuticals, Astex Therapeutics, AstraZeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen-Ortho, Lilly, Merck Frosst Canada, Novartis, Oncothyreon, Ortho Biotech, Pfizer, Roche, SBIO, Sanofi, Schering Canada, and ZymoGenetics. Dr. Winter reports having research grants pending with Novartis, Millennium, Seattle Genetics, Pfizer, and Lilly, receiving lecture fees from Imedex and Physicians' Education Resource, and holding stock options with GlaxoSmithKline; Dr. Horning, being employed by Genentech and holding stock options with Roche; Dr. Shustik, receiving consulting and lecture fees from Janssen-Ortho, Roche, and Celgene; and Dr. Crump, receiving consulting fees from Celgene, Lundbeck, Millennium, and Janssen and lecture fees from Roche. No other potential conflict of interest relevant to this article was reported.	Canellos GP, 2005, J CLIN ONCOL, V23, P4574, DOI 10.1200/JCO.2005.01.911; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; CARDE P, 1993, J CLIN ONCOL, V11, P2258, DOI 10.1200/JCO.1993.11.11.2258; Diehl V, 2007, NEW ENGL J MED, V357, P1968, DOI 10.1056/NEJMe078173; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Duggan DB, 2003, J CLIN ONCOL, V21, P607, DOI 10.1200/JCO.2003.12.086; Engert A, 2010, ANN ONCOL, V21, pv168, DOI 10.1093/annonc/mdq181; Engert A, 2007, J CLIN ONCOL, V25, P3495, DOI 10.1200/JCO.2006.07.0482; Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Gallamini A, 2011, LEUKEMIA LYMPHOMA, V52, P583, DOI 10.3109/10428194.2010.551162; Hagenbeek A, 2000, BLOOD, V96, p575A; Herbst C, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007110.pub2; Hoppe RT, 2011, J NATL COMPR CANC NE, V9, P1020, DOI 10.6004/jnccn.2011.0086; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Laskar S, 2004, J CLIN ONCOL, V22, P62, DOI 10.1200/JCO.2004.01.021; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Lister TA, 1990, J CLIN ONCOL, V8, P1602; Longo DL, 2009, CANCER J, V15, P114, DOI 10.1097/PPO.0b013e3181a2dc07; MANTEL N, 1959, J NATL CANCER I, V22, P719; Meyer R, 2003, BLOOD, V102, p26A; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Meyer RM, 2004, HEMATOLOGY, V1, P184; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; Ng AK, 2011, J CLIN ONCOL, V29, P1885, DOI 10.1200/JCO.2010.32.8427; Press OW, 2001, J CLIN ONCOL, V19, P4238, DOI 10.1200/JCO.2001.19.22.4238; Radford J, 2008, HEMATOLOGY AM SOC HE, V1, P321; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Swerdlow AJ, 2007, J NATL CANCER I, V99, P206, DOI 10.1093/jnci/djk029; Terasawa T, 2009, J CLIN ONCOL, V27, P1906, DOI 10.1200/JCO.2008.16.0861; Tomlinson G, 2010, JAMA-J AM MED ASSOC, V303, P267, DOI 10.1001/jama.2009.2017	32	280	291	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	2012	366	5					399	408		10.1056/NEJMoa1111961	http://dx.doi.org/10.1056/NEJMoa1111961			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884QX	22149921	Green Accepted, Bronze			2023-01-03	WOS:000299724400005
J	Bear, HD; Tang, G; Rastogi, P; Geyer, CE; Robidoux, A; Atkins, JN; Baez-Diaz, L; Brufsky, AM; Mehta, RS; Fehrenbacher, L; Young, JA; Senecal, FM; Gaur, R; Margolese, RG; Adams, PT; Gross, HM; Costantino, JP; Swain, SM; Mamounas, EP; Wolmark, N				Bear, Harry D.; Tang, Gong; Rastogi, Priya; Geyer, Charles E., Jr.; Robidoux, Andre; Atkins, James N.; Baez-Diaz, Luis; Brufsky, Adam M.; Mehta, Rita S.; Fehrenbacher, Louis; Young, James A.; Senecal, Francis M.; Gaur, Rakesh; Margolese, Richard G.; Adams, Paul T.; Gross, Howard M.; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman			Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; PHASE-III; PREOPERATIVE CHEMOTHERAPY; DOCETAXEL; PACLITAXEL; THERAPY; TRIAL; WOMEN	BACKGROUND Bevacizumab and the antimetabolites capecitabine and gemcitabine have been shown to improve outcomes when added to taxanes in patients with metastatic breast cancer. The primary aims of this trial were to determine whether the addition of capecitabine or gemcitabine to neoadjuvant chemotherapy with docetaxel, followed by doxorubicin plus cyclophosphamide, would increase the rates of pathological complete response in the breast in women with operable, human epidermal growth factor receptor 2 (HER2)-negative breast cancer and whether adding bevacizumab to these chemotherapy regimens would increase the rates of pathological complete response. METHODS We randomly assigned 1206 patients to receive neoadjuvant therapy consisting of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel (75 mg per square meter on day 1) plus capecitabine (825 mg per square meter twice a day on days 1 to 14), or docetaxel (75 mg per square meter on day 1) plus gemcitabine (1000 mg per square meter on days 1 and 8) for four cycles, with all regimens followed by treatment with doxorubicin-cyclophosphamide for four cycles. Patients were also randomly assigned to receive or not to receive bevacizumab (15 mg per kilogram of body weight) for the first six cycles of chemotherapy. RESULTS The addition of capecitabine or gemcitabine to docetaxel therapy, as compared with docetaxel therapy alone, did not significantly increase the rate of pathological complete response (29.7% and 31.8%, respectively, vs. 32.7%; P = 0.69). Both capecitabine and gemcitabine were associated with increased toxic effects - specifically, the hand-foot syndrome, mucositis, and neutropenia. The addition of bevacizumab significantly increased the rate of pathological complete response (28.2% without bevacizumab vs. 34.5% with bevacizumab, P = 0.02). The effect of bevacizumab on the rate of pathological complete response was not the same in the hormone-receptor-positive and hormone-receptor-negative subgroups. The addition of bevacizumab increased the rates of hypertension, left ventricular systolic dysfunction, the hand-foot syndrome, and mucositis. CONCLUSIONS The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response, which was the primary end point of this study. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00408408.)	[Bear, Harry D.; Tang, Gong; Rastogi, Priya; Geyer, Charles E., Jr.; Robidoux, Andre; Atkins, James N.; Baez-Diaz, Luis; Brufsky, Adam M.; Mehta, Rita S.; Fehrenbacher, Louis; Young, James A.; Senecal, Francis M.; Gaur, Rakesh; Margolese, Richard G.; Adams, Paul T.; Gross, Howard M.; Costantino, Joseph P.; Swain, Sandra M.; Mamounas, Eleftherios P.; Wolmark, Norman] Natl Surg Adjuvant Breast & Bowel Project NSABP, Pittsburgh, PA USA; [Tang, Gong; Costantino, Joseph P.] Univ Pittsburgh, Grad Sch Publ Hlth, NSABP Biostat Ctr, Pittsburgh, PA USA; [Tang, Gong; Costantino, Joseph P.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Rastogi, Priya; Brufsky, Adam M.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15261 USA; [Wolmark, Norman] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Bear, Harry D.] Virginia Commonwealth Univ, Virginia Sch Med, Coll Med, Richmond, VA 23284 USA; [Bear, Harry D.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA; [Geyer, Charles E., Jr.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Robidoux, Andre] Ctr Hosp Univ Montreal, Montreal, PQ, Canada; [Margolese, Richard G.] McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada; [Atkins, James N.] SE Canc Control Consortium Community Clin Oncol P, Goldsboro, NC USA; [Baez-Diaz, Luis] Minority Based CCOP, San Juan, PR USA; [Mehta, Rita S.] Univ Calif Irvine, Orange, CA USA; [Fehrenbacher, Louis] Kaiser Permanente Oncol Clin Trials, Vallejo, CA USA; [Young, James A.] Colorado Canc Res Program, Colorado Springs, CO USA; [Senecal, Francis M.] NW Med Specialties, Tacoma, WA USA; [Gaur, Rakesh] CCOP, Kansas City, MO USA; [Adams, Paul T.] Genesys Reg Med Ctr, Grand Blanc, MI USA; [Gross, Howard M.] CCOP, Dayton, OH USA; [Mamounas, Eleftherios P.] Aultman Hosp, Ctr Canc, Canton, OH USA; [Swain, Sandra M.] Medstar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Allegheny General Hospital; Virginia Commonwealth University; Virginia Commonwealth University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Universite de Montreal; McGill University; University of California System; University of California Irvine; Kaiser Permanente; MedStar Washington Hospital Center	Bear, HD (corresponding author), VCUHS, Div Surg Oncol, Box 980011, Richmond, VA 23298 USA.	hdbear@vcu.edu	Brufsky, Adam/AAE-7470-2020; Geyer, Charles/AGY-0119-2022	Geyer, Charles/0000-0002-2379-5702; Swain, Sandra/0000-0002-1320-3830; Brufsky, Adam/0000-0001-8080-7960; , Gong/0000-0002-6247-4338	National Cancer Institute [U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, U10-CA-44066]; Department of Health and Human Services; Public Health Service; F. Hoffmann-La Roche; Genentech USA; Eli Lilly; NATIONAL CANCER INSTITUTE [U10CA044066, U10CA037377, U10CA069651, U10CA069974, P30CA062203, U10CA012027, U10CA180844] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Health and Human Services; Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); F. Hoffmann-La Roche(Hoffmann-La Roche); Genentech USA(Roche HoldingGenentech); Eli Lilly(Eli Lilly); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974, and U10-CA-44066), the Department of Health and Human Services, the Public Health Service, F. Hoffmann-La Roche, Genentech USA, and Eli Lilly.	Albain KS, 2008, J CLIN ONCOL, V26, P3950, DOI 10.1200/JCO.2007.11.9362; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Bear HD, 2003, J CLIN ONCOL, V21, P4165, DOI 10.1200/JCO.2003.12.005; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096, DOI 10.2307/2281208; Fisher B, 1997, J CLIN ONCOL, V15, P2483, DOI 10.1200/JCO.1997.15.7.2483; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Gianni L, 2009, J CLIN ONCOL, V27, P2474, DOI 10.1200/JCO.2008.19.2567; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hunt KK, 2009, ANN SURG, V250, P558, DOI 10.1097/SLA.0b013e3181b8fd5e; Joensuu H, 2010, CANC RES S2, V70, p84s; Mamounas EP, 2005, J CLIN ONCOL, V23, P2694, DOI 10.1200/JCO.2005.05.188; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; O'Shaughnessy J, 2010, CANCER RES, V70, p85s; Poole CJ, 2008, J CLIN ONCOL S, V26, p8s; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Verma N, 2011, J CLIN ONCOL, V29, P603, DOI 10.1200/JCO.2010.32.9060; von Minckwitz G, 2012, NEW ENGL J MED, V366, P299, DOI 10.1056/NEJMoa1111065	25	354	373	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					310	320		10.1056/NEJMoa1111097	http://dx.doi.org/10.1056/NEJMoa1111097			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276821	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000299464100002
J	von Minckwitz, G; Eidtmann, H; Rezai, M; Fasching, PA; Tesch, H; Eggemann, H; Schrader, I; Kittel, K; Hanusch, C; Kreienberg, R; Solbach, C; Gerber, B; Jackisch, C; Kunz, G; Blohmer, JU; Huober, J; Hauschild, M; Fehm, T; Muller, BM; Denkert, C; Loibl, S; Nekljudova, V; Untch, M				von Minckwitz, Gunter; Eidtmann, Holger; Rezai, Mahdi; Fasching, Peter A.; Tesch, Hans; Eggemann, Holm; Schrader, Iris; Kittel, Kornelia; Hanusch, Claus; Kreienberg, Rolf; Solbach, Christine; Gerber, Bernd; Jackisch, Christian; Kunz, Georg; Blohmer, Jens-Uwe; Huober, Jens; Hauschild, Maik; Fehm, Tanja; Mueller, Berit Maria; Denkert, Carsten; Loibl, Sibylle; Nekljudova, Valentina; Untch, Michael		German Breast Grp; Arbeitsgemeinschaft Gynakologische	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III; TRIAL; TRASTUZUMAB; DOCETAXEL; SURVIVAL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; THERAPY	Background Bevacizumab, a monoclonal antibody against vascular endothelial growth factor A, has shown clinical efficacy in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. We evaluated the efficacy, measured according to the rate of pathological complete response (absence of invasive and intraductal disease in the breast and the axillary lymph nodes), and the safety of adding bevacizumab to neoadjuvant chemotherapy in patients with early-stage breast cancer. Methods We randomly assigned 1948 patients with a median tumor size of 40 mm on palpation to receive neoadjuvant epirubicin and cyclophosphamide followed by docetaxel, with or without concomitant bevacizumab. Patients with untreated HER2-negative breast cancer were eligible if they had large tumors, hormone-receptor-negative disease, or hormone-receptor-positive disease with palpable nodes or positive findings on sentinel-node biopsy, and no increased cardiovascular or bleeding risk. Results Overall, the rates of pathological complete response were 14.9% with epirubicin and cyclophosphamide followed by docetaxel and 18.4% with epirubicin and cyclophosphamide followed by docetaxel plus bevacizumab (odds ratio with addition of bevacizumab, 1.29; 95% confidence interval, 1.02 to 1.65; P = 0.04); the corresponding rates of pathological complete response were 27.9% and 39.3% among 663 patients with triple-negative tumors (P = 0.003) and 7.8% and 7.7% among 1262 patients with hormone-receptor-positive tumors (P = 1.00). Breast-conserving surgery was possible in 66.6% of the patients in both groups. The addition of bevacizumab, as compared with neoadjuvant therapy alone, was associated with a higher incidence of grade 3 or 4 toxic effects (febrile neutropenia, mucositis, the hand-foot syndrome, infection, and hypertension) but with a similar incidence of surgical complications. Conclusions The addition of bevacizumab to neoadjuvant chemotherapy significantly increased the rate of pathological complete response among patients with HER2-negative early-stage breast cancer. Efficacy was restricted primarily to patients with triple-negative tumors, in whom the pathological complete response is considered to be a reliable predictor of long-term outcome. (Funded by Sanofi-Aventis and Roche, Germany; ClinicalTrials.gov number, NCT00567554.)	[von Minckwitz, Gunter; Loibl, Sibylle; Nekljudova, Valentina] GBG Forsch, German Breast Grp, D-63263 Neu Isenburg, Germany; [Eidtmann, Holger] Univ Frauenklin, Kiel, Germany; [Rezai, Mahdi] Luisenkrankenhaus, Dusseldorf, Germany; [Fasching, Peter A.] Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr Erlangen Nuremberg, Univ Hosp Erlangen, Dept Gynecol & Obstet, Erlangen, Germany; [Tesch, Hans] Onkol Bethanien, Frankfurt, Germany; [Eggemann, Holm] Univ Frauenklin, Magdeburg, Germany; [Schrader, Iris] Henrietten Stiftung, Hannover, Germany; [Kittel, Kornelia] Onkol Praxis, Berlin, Germany; [Blohmer, Jens-Uwe] St Gertrauden Hosp, Berlin, Germany; [Mueller, Berit Maria; Denkert, Carsten] Charite, Inst Pathol, Berlin, Germany; [Hanusch, Claus] Klinikum Roten Kreuz, Munich, Germany; [Kreienberg, Rolf] Univ Frauenklin, Ulm, Germany; [Solbach, Christine] Univ Frauenklin, Frankfurt, Germany; [Gerber, Bernd] Univ Frauenklin, Rostock, Germany; [Jackisch, Christian] Stadt Kliniken, Offenbach, Germany; [Kunz, Georg] St Johannes Hosp, Dortmund, Germany; [Hauschild, Maik] Frauenklin, Rheinfelden, Germany; [Fehm, Tanja] Univ Frauenklin, Tubingen, Germany; [Untch, Michael] HELIOS Klin, Berlin, Germany; [Huober, Jens] Kantonsspital, St Gallen, Switzerland	German Breast Group; University of Kiel; Schleswig Holstein University Hospital; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ulm University; University of Rostock; Sana Klinikum Offenbach; St. Johannes Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helios Kliniken; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	von Minckwitz, G (corresponding author), GBG Forsch, German Breast Grp, Martin Behaim Str 12, D-63263 Neu Isenburg, Germany.	gunter.vonminckwitz@germanbreastgroup.de	Denkert, Carsten/AHE-2675-2022; Fasching, Peter A/ABH-9912-2020	Fasching, Peter A/0000-0003-4885-8471; Blohmer, Jens-Uwe/0000-0002-7969-250X; Fehm, Tanja/0000-0002-4926-0108; Denkert, Carsten/0000-0002-2249-0982	Sanofi-Aventis; Roche, Germany; Roche; Novartis; Pfizer; Amgen; Celgene; Eisai; Bristol-Myers Squibb; GlaxoSmithKline	Sanofi-Aventis(Sanofi-Aventis); Roche, Germany(Roche Holding); Roche(Roche Holding); Novartis(Novartis); Pfizer(Pfizer); Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Eisai(Eisai Co Ltd); Bristol-Myers Squibb(Bristol-Myers Squibb); GlaxoSmithKline(GlaxoSmithKline)	Supported by grants from Sanofi-Aventis and Roche, Germany.; Dr. von Minckwitz reports receiving research grants, consulting fees, and lecture (including speakers' bureau) fees from Roche and Sanofi-Aventis; Dr. Eidtmann, receiving payment for board membership and reimbursement for travel expenses from Roche; Dr. Fasching, receiving grant support from Novartis and lecture fees from Pfizer, Roche, and Novartis; Dr. Tesch, receiving consulting fees from Amgen, Roche, Novartis, Celgene, and Eisai; Dr. Kreienberg, receiving payment for board membership from AstraZeneca and consulting fees from Novartis and Pfizer; Dr. Jackisch, receiving reimbursement for travel expenses from Roche and Amgen; Dr. Huober, receiving consulting fees from Amgen, Roche, Bristol-Myers Squibb, and Sanofi-Aventis, grant support from GlaxoSmithKline, and lecture (including speakers' bureau) fees from Sanofi-Aventis and Roche; Dr. Denkert, holding stock options in Sividon Diagnostics; and Dr. Loibl, receiving grant support, lecture (including speakers' bureau) fees, and reimbursement for travel expenses from Roche. No other potential conflict of interest relevant to this article was reported.	America Joint Committee on Cancer, 2010, AJCC CANC STAG MAN; Bear HD, 2012, NEW ENGL J MED, V366, P310, DOI 10.1056/NEJMoa1111097; Bear HD, 2011, J CLIN ONCOL S, V29, P1005; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Golshan M, 2011, ANN SURG ONCOL, V18, P733, DOI 10.1245/s10434-010-1366-8; Huober J, 2010, BREAST CANCER RES TR, V124, P133, DOI 10.1007/s10549-010-1103-9; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Miles D, 2011, J CLIN ONCOL, V29, P83, DOI 10.1200/JCO.2010.30.2794; Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457; Miller K, 2009, J CLIN ONCOL S, V27, p488s; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Pocock S. J., 1975, BIOMETRICS, V31, P102; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Untch M, 2011, J CLIN ONCOL, V29, P3351, DOI 10.1200/JCO.2010.31.4930; Untch M, 2010, J CLIN ONCOL, V28, P2024, DOI 10.1200/JCO.2009.23.8451; von Minckwitz G, 2005, J CLIN ONCOL, V23, P2676, DOI 10.1200/JCO.2005.05.078; von Minckwitz G, 2011, ANN ONCOL, V22, P301, DOI 10.1093/annonc/mdq350; von Minckwitz G, J CLIN ONCO IN PRESS; von Minckwitz G, 2008, JNCI-J NATL CANCER I, V100, P542, DOI 10.1093/jnci/djn085; von Minckwitz G, 2011, BREAST CANCER RES TR, V125, P145, DOI 10.1007/s10549-010-1228-x	24	389	393	3	56	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 26	2012	366	4					299	309		10.1056/NEJMoa1111065	http://dx.doi.org/10.1056/NEJMoa1111065			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EQ	22276820	Bronze			2023-01-03	WOS:000299464100001
J	Nacher, JC; Schwartz, JM				Nacher, Jose C.; Schwartz, Jean-Marc			Modularity in Protein Complex and Drug Interactions Reveals New Polypharmacological Properties	PLOS ONE			English	Article							COMMUNITY STRUCTURE; NETWORK MOTIFS; TARGETS; DEFICIENCY; ALZHEIMERS; PREDICTION; FEATURES; BIOLOGY; YEAST	Recent studies have highlighted the importance of interconnectivity in a large range of molecular and human disease-related systems. Network medicine has emerged as a new paradigm to deal with complex diseases. Connections between protein complexes and key diseases have been suggested for decades. However, it was not until recently that protein complexes were identified and classified in sufficient amounts to carry out a large-scale analysis of the human protein complex system. We here present the first systematic and comprehensive set of relationships between protein complexes and associated drugs and analyzed their topological features. The network structure is characterized by a high modularity, both in the bipartite graph and in its projections, indicating that its topology is highly distinct from a random network and that it contains a rich and heterogeneous internal modular structure. To unravel the relationships between modules of protein complexes, drugs and diseases, we investigated in depth the origins of this modular structure in examples of particular diseases. This analysis unveils new associations between diseases and protein complexes and highlights the potential role of polypharmacological drugs, which target multiple cellular functions to combat complex diseases driven by gain-of-function mutations.	[Nacher, Jose C.] Future Univ Hakodate, Dept Complex & Intelligent Syst, Hakodate, Hokkaido, Japan; [Schwartz, Jean-Marc] Univ Manchester, Fac Life Sci, Manchester Interdisciplinary Bioctr, Manchester, Lancs, England	Future University Hakodate; University of Manchester	Nacher, JC (corresponding author), Future Univ Hakodate, Dept Complex & Intelligent Syst, Hakodate, Hokkaido, Japan.	nacher@fun.ac.jp	Schwartz, Jean-Marc/AAS-8274-2020	Schwartz, Jean-Marc/0000-0002-6472-0184	MEXT Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [23700352] Funding Source: KAKEN	MEXT Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was partially supported by a Grant-in-Aid for Scientific Research from MEXT Ministry of Education, Culture, Sports, Science and Technology, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Arenas A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.114102; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Bergmans BA, 2010, LANCET NEUROL, V9, P215, DOI 10.1016/S1474-4422(09)70332-1; Beyer A, 2005, BIOINFORMATICS, V21, P1610, DOI 10.1093/bioinformatics/bti223; Bulgakova NA, 2009, J CELL SCI, V122, P2587, DOI 10.1242/jcs.023648; CHIGNELL CF, 1969, MOL PHARMACOL, V5, P244; Csermely P, 2005, TRENDS PHARMACOL SCI, V26, P178, DOI 10.1016/j.tips.2005.02.007; Danon L, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/09/P09008; Diao YB, 2007, J THEOR BIOL, V247, P608, DOI 10.1016/j.jtbi.2007.04.007; Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058; Endy D, 2001, NATURE, V409, P391, DOI 10.1038/35053181; Farkas IJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001950; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Fraser HB, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r252; Gandhi TKB, 2006, NAT GENET, V38, P285, DOI 10.1038/ng1747; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Guillaume JL, 2006, PHYSICA A, V371, P795, DOI 10.1016/j.physa.2006.04.047; Guimera R, 2005, NATURE, V433, P895, DOI 10.1038/nature03288; Guimera R, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.036102; Halperin I, 2009, NEUROTHERAPEUTICS, V6, P128, DOI 10.1016/j.nurt.2008.10.033; Hannum G, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000782; Hlavacek WS, 2003, BIOTECHNOL BIOENG, V84, P783, DOI 10.1002/bit.10842; Hoglinger GU, 2007, P NATL ACAD SCI USA, V104, P3585, DOI 10.1073/pnas.0611671104; Kovacs IA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012528; Laudon H, 2007, PHYSIOL BEHAV, V92, P115, DOI 10.1016/j.physbeh.2007.05.037; Lee SH, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-126; Ma'ayan A, 2007, MT SINAI J MED, V74, P27, DOI 10.1002/msj.20002; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107; Nacher Jose C., 2008, BMC Pharmacology, V8, P5, DOI 10.1186/1471-2210-8-5; Newman M. E. J., 2004, PHYS REV, V69; Osborne JD, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S6; Palla G, 2005, NATURE, V435, P814, DOI 10.1038/nature03607; Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228; Park K, 2008, PROTEINS, V71, P960, DOI 10.1002/prot.21780; Pereira-Leal JB, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r51; Rodriguez-Soca Y, 2010, J PROTEOME RES, V9, P1182, DOI 10.1021/pr900827b; Rubin GM, 2001, NATURE, V409, P820, DOI 10.1038/35057277; Ruepp A, 2010, NUCLEIC ACIDS RES, V38, pD497, DOI 10.1093/nar/gkp914; Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; Smith PD, 2003, P NATL ACAD SCI USA, V100, P13650, DOI 10.1073/pnas.2232515100; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Spiro Zoltan, 2008, J Biol, V7, P20, DOI 10.1186/jbiol81; Taylor IW, 2009, NAT BIOTECHNOL, V27, P199, DOI 10.1038/nbt.1522; Van der Schyf CJ, 2006, J NEUROCHEM, V99, P1033, DOI 10.1111/j.1471-4159.2006.04141.x; Van Laarhoven P.J., 1987, SIMULATED ANNEALING, P7, DOI DOI 10.1007/978-94-015-7744-1; Vanunu O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000641; Veselovsky AV, 2007, CURR COMPUT-AID DRUG, V3, P51, DOI 10.2174/157340907780058754; Wang CQ, 2011, J DRUG TARGET, V19, P354, DOI 10.3109/1061186X.2010.504261; Wang XJ, 2011, BRIEF FUNCT GENOMICS, V10, P280, DOI 10.1093/bfgp/elr024; Wegener E., 2008, V186, P237, DOI 10.1007/978-3-540-72843-6_10; Xiong H, 2009, J CLIN INVEST, V119, P650, DOI 10.1172/JCI37617; Xu JZ, 2006, BIOINFORMATICS, V22, P2800, DOI 10.1093/bioinformatics/btl467; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338	58	39	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2012	7	1							e30028	10.1371/journal.pone.0030028	http://dx.doi.org/10.1371/journal.pone.0030028			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	885IH	22279562	gold, Green Published, Green Submitted			2023-01-03	WOS:000299771900040
J	Snyder, L				Snyder, Lois		Amer Coll Phys Ethics	American College of Physicians Ethics Manual Sixth Edition	ANNALS OF INTERNAL MEDICINE			English	Article							CONCIERGE MEDICINE; INDUSTRY RELATIONS; PALLIATIVE CARE; OF-PHYSICIANS; PATIENT; HEALTH; COMMUNICATION; CONSULTATION; OBLIGATIONS; PRINCIPLES	Medicine, law, and social values are not static. Reexamining the ethical tenets of medicine and their application in new circumstances is a necessary exercise. The sixth edition of the American College of Physicians (ACP) Ethics Manual covers emerging issues in medical ethics and revisits older ones that are still very pertinent. It reflects on many of the ethical tensions in medicine and attempts to shed light on how existing principles extend to emerging concerns. In addition, by reiterating ethical principles that have provided guidance in resolving past ethical problems, the Manual may help physicians avert future problems. The Manual is not a substitute for the experience and integrity of individual physicians, but it may serve as a reminder of the shared duties of the medical profession.	[Snyder, Lois] Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Snyder, L (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@acponline.org			ACP; American Medical Group Association Hypertention Learning Foundation; Medical College of Wisconsin; RWF; NIH; HRSA; Komen; GlaxoSmithKline; American Cancer Society	ACP; American Medical Group Association Hypertention Learning Foundation; Medical College of Wisconsin(General Electric); RWF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); Komen(Susan G. Komen Breast Cancer Foundation); GlaxoSmithKline(GlaxoSmithKline); American Cancer Society(American Cancer Society)	Financial support for the development of the Manual came exclusively from the ACP operating budget.; Ms. Snyder: Other relationships: Member of Society of General Internal Medicine Ethics Committee. Dr. Hood: Employment: ACP (president-elect, 2010-2012); Grants/grants pending: American Medical Group Association Hypertention Learning Foundation; Payment for lectures including service on speakers bureaus: American Society of Nephrology; Stock/stock options: mutual funds. Dr. Kutty: Employment: The Medical College of Wisconsin; Royalties: Wolters Kluwer; Stock/stock options: Medtronic. Dr. Fins: Support for travel to meetings for the study or other purposes: ACP; Board membership: ACP Foundation; Employment: Weill Cornell; Grants/grants pending: RWF; Payment for lectures including service on speakers bureaus: various entities; Royalties: Jones and Bartlett; Payment for development of educational presentations: Weill Cornell. Dr. Lopez: Grant: NIH, HRSA, Komen; Consulting fee or honorarium: GlaxoSmithKline; Grants/grants pending: American Cancer Society, NIH, Komen. Dr. Braddock: Board membership: Foundation for Informed Medical Decision Making. Dr. Calvano: Travel/accommodations/meeting expenses unrelated to activities listed: ACP. Dr. Faber-Langendoen: Support for travel to meetings for the study or other purposes: ACP; Employment: SUNY Upstate Medical University; Travel/accommodations/meeting expenses unrelated to activities listed: ACP. Dr. Herrin: Payment for lectures including service on speakers bureaus: Gentech Speakers Bureau. Dr. Mir: Employment: NSLUHS. Dr. Moreno: Support for travel to meetings for the study or other purposes: ACP; Other relationships: Governor, American College of Legal Medicine (February 2011-present); member and pro bono consultant, Physicians for Human Rights (1997-present); member of Board of Directors and President Elect, Texas Chapter of the ACP and ACP Services; pro bono advisor, Center for Survivors of Torture. Mr. Pasha: Support for travel to meetings for the study or other purposes: ACP. Dr. Turner: Employment: Annals of Internal Medicine Executive Deputy Editor, November 2009-November 2010. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-1111.	Amdur RJ, 2002, I REV BOARD MANAGEME; Amer College Physicians, 2004, ANN INTERN MED, V141, P226, DOI 10.7326/0003-4819-141-3-200408030-00015; American College of Legal Medicine, 2001, LEG MED; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P327; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P245; American Medical Association, 1999, AMA COD MED ETH; American Medical Association, 2006, AMA COD MED ETH; American Medical Association, 2011, GUID PHYS PAT EL COM, P28; Annas GJ, 2009, NEW ENGL J MED, V361, P196, DOI 10.1056/NEJMhle0811035; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 2001, PAT ED CAR END LIF P; [Anonymous], 2003, NIH PUBL; [Anonymous], 2001, PAT ED CAR END OF LI; [Anonymous], PHYS ORDERS LIFE SUS; [Anonymous], 2011, COMP ACCR MAN HOSP C; [Anonymous], 2000, RECR HUM SUBJ SAMPL; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Aulisio MP, 2000, ANN INTERN MED, V133, P59, DOI 10.7326/0003-4819-133-1-200007040-00012; Beauchamp TL, 2008, PRINCIPLES BIOMEDICA, V6th; Berger JT, 2008, ANN INTERN MED, V149, P48, DOI 10.7326/0003-4819-149-1-200807010-00010; Berger JT, 2005, CANCER INVEST, V23, P94, DOI 10.1081/CNV-200046398; Berger JT, 2001, J CLIN ETHIC, V12, P375; Boisaubin EV, 2001, AM J MED SCI, V322, P31, DOI 10.1097/00000441-200107000-00006; Braddock CH, 2005, J GEN INTERN MED, V20, P1057, DOI 10.1111/j.1525-1497.2005.00217.x; Braddock CH, PATIENT CTR IN PRESS; Brendel DH, 2007, HARVARD REV PSYCHIAT, V15, P43, DOI 10.1080/10673220701298399; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; BURNUM JF, 1991, NEW ENGL J MED, V324, P1130, DOI 10.1056/NEJM199104183241611; Carlisle J, 2006, J MED ETHICS, V32, P133, DOI 10.1136/jme.2004.011262; Carnahan SJ, 2007, J LAW MED ETHICS, V35, P211, DOI 10.1111/j.1748-720X.2007.00125.x; Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Carroll RJ, 1999, ACP ASIM OBSERVE JAN; Casarett D, 2005, NEW ENGL J MED, V353, P2607, DOI 10.1056/NEJMsb052907; Cassarett D, 2001, ACP OBSERVER     MAR; Chretien KC, 2009, JAMA-J AM MED ASSOC, V302, P1309, DOI 10.1001/jama.2009.1387; Council for International Organizations of Medical Sciences, 2002, Bull Med Ethics, P17; Council of Medical Specialty Societies, 2011, VOL COD INT COMP; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Coyle SL, 2002, ANN INTERN MED, V136, P403, DOI 10.7326/0003-4819-136-5-200203050-00015; Crawley LM, 2001, PHYS GUIDE END LIFE, P35; Crook ED, 2005, ETHICAL CHOICES CASE, P148; Daugherty CK, 2008, J CLIN ONCOL, V26, P1371, DOI 10.1200/JCO.2007.13.5335; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Department of Health and Human Services, 1995, INT MISC RES REP COM; Drazen JM, 2010, ANN INTERN MED, V152, P125, DOI [10.7326/0000605-200901190-00160, 10.7326/0003-4819-152-2-200901190-00160]; Drazen JM, 2000, NEW ENGL J MED, V343, P1643, DOI 10.1056/NEJM200011303432212; Eastwood GL, 2009, J GEN INTERN MED, V24, P1333, DOI 10.1007/s11606-009-1127-1; Eggly S, 2006, J CLIN ONCOL, V24, P716, DOI 10.1200/JCO.2005.03.0577; Farber N, 2011, DIFFICULT PATIENT SH; Federation of State Medical Boards of the United States, 2002, MOD GUID APP US INT; Fins JJ, 2005, J PAIN SYMPTOM MANAG, V29, P55, DOI 10.1016/j.jpainsymman.2004.07.004; Fins JJ, 2004, ARCH NEUROL-CHICAGO, V61, P1354, DOI 10.1001/archneur.61.9.1354; Fletcher JC, 1996, J CLIN ETHIC, V7, P122; Fontanarosa PB, 2005, JAMA-J AM MED ASSOC, V294, P110, DOI 10.1001/jama.294.1.110; Gazelle G, 1998, NEW ENGL J MED, V338, P467, DOI 10.1056/NEJM199802123380712; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; Ginsburg J, 2001, ANN INTERN MED, V134, P787, DOI 10.7326/0003-4819-136-9-200205070-00023; Groves James E., 2002, Prim Care Companion J Clin Psychiatry, V4, P215; Herrin V, 2000, ACP ASIM OBSERVE FEB; Hochman M, 2010, JAMA-J AM MED ASSOC, V303, P951, DOI 10.1001/jama.2010.240; Institute of Medicine, 1997, APP DEATH IMPR CAR E; Institute of Medicine, 2009, GUID EST CRIS STAND; Institute of Medicine, 1999, ERR IS HUM BUILD SAF; International Committee of Medical Journal Editors, 2011, BIOM J UNPUB; Jain SH, 2009, NEW ENGL J MED, V361, P649, DOI 10.1056/NEJMp0901277; Jecker N. S., 2007, FEMINISM MORAL THEOR, V2nd; Jonsen A.R., 1998, BIRTH BIOETHICS; Juarez JA, 2006, FAM MED, V38, P97; Kahn MW, 2009, NEW ENGL J MED, V361, P442, DOI 10.1056/NEJMp0902021; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; Karlawish JHT, 2003, NEW ENGL J MED, V348, P1389, DOI 10.1056/NEJMsb030172; Kirschner N, 2010, PATIENT CTR MED HOM; Lampert R, 2010, HRS EXP CONS STAT M; LaPuma J, 1995, Trends Health Care Law Ethics, V10, P73; Lee LM, 2009, JAMA-J AM MED ASSOC, V302, P82, DOI 10.1001/jama.2009.958; LIND SE, 1988, CLIN RES, V36, P546; Lo B, 1999, ANN INTERN MED, V130, P772, DOI 10.7326/0003-4819-130-9-199905040-00018; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lyckholm LJ, 1998, JAMA-J AM MED ASSOC, V280, P1944, DOI 10.1001/jama.280.22.1944; Mann JM, 1999, HLTH HUM RIGHTS READ; Mattke Angela, 2009, Acad Med, V84, P191, DOI 10.1097/01.ACM.0000345394.25069.61; McGuire AL, 2006, SCIENCE, V312, P370, DOI 10.1126/science.1125339; McGuire AL, 2008, JAMA-J AM MED ASSOC, V300, P2669, DOI 10.1001/jama.2008.803; MCMURRAY RJ, 1991, JAMA-J AM MED ASSOC, V266, P2741, DOI 10.1001/jama.1991.03470190089035; Mitnick S, 2010, J GEN INTERN MED, V25, P255, DOI 10.1007/s11606-009-1206-3; Nahan RL, 2007, 18 NAT CTR HLTH STAT; *NAT CTR COMPL ALT, WHAT IS COMPL ALT ME; National Commission on Correctional Health Care, 1996, CHARG INM FEE HLTH C; New York State Department of Health/New York State Task Force on Life & the Law, 2007, ALL VENT INFL PAND; Nunez AE, 2000, ACAD MED, V75, P1071, DOI 10.1097/00001888-200011000-00011; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Pellegrino ED, 1999, JAMA-J AM MED ASSOC, V282, P984, DOI 10.1001/jama.282.10.984; Povar GJ, 1999, ANN INTERN MED, V131, P863, DOI 10.7326/0003-4819-131-11-199912070-00012; Povar GJ, 2004, ANN INTERN MED, V141, P131, DOI 10.7326/0003-4819-141-2-200407200-00012; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Rich EC, 2004, J GEN INTERN MED, V19, P273, DOI 10.1111/j.1525-1497.2004.30401.x; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; Sabatino CP, 1999, J LAW MED ETHICS, V27, P297, DOI 10.1111/j.1748-720X.1999.tb01465.x; Salzman JG, 2007, ANN EMERG MED, V50, P448, DOI 10.1016/j.annemergmed.2006.10.013; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Shelley BM, 2009, ANN FAM MED, V7, P139, DOI 10.1370/afm.947; Snyder L, 2007, BIOMED ETHICS REV, P1, DOI 10.1007/978-1-59745-381-3; SNYDER L, 1990, ANN INTERN MED, V112, P802, DOI 10.7326/0003-4819-112-11-802; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Snyder L, 1998, J AM GERIATR SOC, V46, P378, DOI 10.1111/j.1532-5415.1998.tb01058.x; SNYDER L, 1990, ANN INTERN MED, V113, P789, DOI 10.7326/0003-4819-113-10-789; Snyder L, 1996, ETHICAL CHOICES CASE, P105; Snyder L, 2005, ETHICAL CHOICES CASE, P130; Snyder L, 2005, ETHICAL CHOICES CASE, P77; Snyder L, 2001, PHYS GUIDE END OF LI; Snyder L, 2007, ANN INTERN MED, V147, P792, DOI 10.7326/0003-4819-147-11-200712040-00011; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Steinbrook R, 2008, NEW ENGL J MED, V359, P2513, DOI 10.1056/NEJMp0809394; Stillman M, 2010, ANN INTERN MED, V152, P391, DOI 10.7326/0003-4819-152-6-201003160-00009; Stott D, 2008, STUDENT BMJ, V16, P280; Sulmasy DP, 2007, J AM GERIATR SOC, V55, P1981, DOI 10.1111/j.1532-5415.2007.01473.x; Sulmasy DP, 2010, JAMA-J AM MED ASSOC, V304, P1946, DOI 10.1001/jama.2010.1595; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; Thompson LA, 2008, J GEN INTERN MED, V23, P954, DOI 10.1007/s11606-008-0538-8; Tulsky JA, 1997, ACP OBSERVER     MAR; Turton FE, 2008, ANN INTERN MED, V148, P887, DOI 10.7326/0003-4819-148-11-200806030-00022; Turton FE, 2007, ANN INTERN MED, V146, P469, DOI 10.7326/0003-4819-146-6-200703200-00019; United Nations, 1955, 1 C PREV CRIM TREATM; Veatch R. M., 2000, TRANSPLANTATION ETHI; Vedula SS, 2009, NEW ENGL J MED, V361, P1963, DOI 10.1056/NEJMsa0906126; Veterans Health Administration's National Center for Ethics in Health Care, 2010, M CHALL PAND INFL ET; Weiner J, 2005, ETHICAL CHOICES CASE, P136; Weiner J, 2005, ETHICAL CHOICES CASE, P99; Weiner J, 2005, ETHICAL CHOICES CASE, P143; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; Williams MA, 2003, CRIT CARE MED, V31, P1568, DOI 10.1097/01.CCM.0000063090.21056.A6; World Health Organization, 2009, WHO PANDEMIC INFLUEN; World Medical Association Declaration of Helsinki, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]	136	207	210	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 3	2012	156	1	2						73	10.7326/0003-4819-156-1-201201031-00001	http://dx.doi.org/10.7326/0003-4819-156-1-201201031-00001			32	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	886SP	22213573				2023-01-03	WOS:000299874500001
J	Jiang, J				Jiang, Jessie			PATENTS Protecting China's national treasure	NATURE			English	Editorial Material																			0	2	2	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S93	S93		10.1038/480S93a	http://dx.doi.org/10.1038/480S93a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190090	Bronze			2023-01-03	WOS:000298318000006
J	Maude, RJ; Hoque, G; Hasan, MU; Abu Sayeed; Akter, S; Samad, R; Alam, B; Bin Yunus, E; Rahman, R; Rahman, W; Chowdhury, R; Seal, T; Charunwatthana, P; Chang, CC; White, NJ; Abul Faiz, M; Day, NPJ; Dondorp, AM; Hossain, A				Maude, Richard J.; Hoque, Gofranul; Hasan, Mahtab Uddin; Abu Sayeed; Akter, Shahena; Samad, Rasheda; Alam, Badrul; Bin Yunus, Emran; Rahman, Ridwanur; Rahman, Waliur; Chowdhury, Romal; Seal, Tapan; Charunwatthana, Prakaykaew; Chang, Christina C.; White, Nicholas J.; Abul Faiz, M.; Day, Nicholas P. J.; Dondorp, Arjen M.; Hossain, Amir			Timing of Enteral Feeding in Cerebral Malaria in Resource-Poor Settings: A Randomized Trial	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; MECHANICALLY VENTILATED PATIENTS; SEVERE FALCIPARUM-MALARIA; RISK-FACTORS; NUTRITION; ASPIRATION; PNEUMONIA; PERMEABILITY; ARTESUNATE; FREQUENCY	Background: Early start of enteral feeding is an established treatment strategy in intubated patients in intensive care since it reduces invasive bacterial infections and length of hospital stay. There is equipoise whether early enteral feeding is also beneficial in non-intubated patients with cerebral malaria in resource poor settings. We hypothesized that the risk of aspiration pneumonia might outweigh the potential benefits of earlier recovery and prevention of hypoglycaemia. Method and Findings: A randomized trial of early (day of admission) versus late (after 60 hours in adults or 36 hours in children) start of enteral feeding was undertaken in patients with cerebral malaria in Chittagong, Bangladesh from May 2008 to August 2009. The primary outcome measures were incidence of aspiration pneumonia, hypoglycaemia and coma recovery time. The trial was terminated after inclusion of 56 patients because of a high incidence of aspiration pneumonia in the early feeding group (9/27 (33%)), compared to the late feeding group (0/29 (0%)), p = 0.001). One patient in the late feeding group, and none in the early group, had hypoglycaemia during admission. There was no significant difference in overall mortality (9/27 (33%) vs 6/29 (21%), p = 0.370), but mortality was 5/9 (56%) in patients with aspiration pneumonia. Conclusions: In conclusion, early start of enteral feeding is detrimental in non-intubated patients with cerebral malaria in many resource-poor settings. Evidence gathered in resource rich settings is not necessarily transferable to resource-poor settings.	[Maude, Richard J.; Charunwatthana, Prakaykaew; Chang, Christina C.; White, Nicholas J.; Day, Nicholas P. J.; Dondorp, Arjen M.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Maude, Richard J.; White, Nicholas J.; Day, Nicholas P. J.; Dondorp, Arjen M.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX3 9DU, England; [Hoque, Gofranul; Hasan, Mahtab Uddin; Abu Sayeed; Samad, Rasheda; Alam, Badrul; Bin Yunus, Emran; Rahman, Waliur; Chowdhury, Romal; Seal, Tapan; Hossain, Amir] Chittagong Med Coll Hosp, Chittagong, Bangladesh; [Rahman, Ridwanur] Hossain Shahid Sohrawardy Med Coll, Dhaka, Bangladesh; [Abul Faiz, M.] Sir Salimullah Med Coll, Dhaka, Bangladesh	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford; Chittagong Medical College; Sir Salimullah Medical College	Maude, RJ (corresponding author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.	arjen@tropmedres.ac	Maude, Richard James/AAV-3567-2020; Rahman, Ridwanur/K-2637-2019; White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	Maude, Richard James/0000-0002-5355-0562; White, Nick/0000-0002-1897-1978; Chang, Christina Catherine/0000-0003-0109-0725	Wellcome Trust of Great Britain [077166/Z/05/Z]	Wellcome Trust of Great Britain(Wellcome Trust)	This study was funded by the Wellcome Trust of Great Britain (www.wellcome.ac.uk, grant number 077166/Z/05/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BeierHolgersen R, 1996, GUT, V39, P833, DOI 10.1136/gut.39.6.833; Bosscha K, 1998, CRIT CARE MED, V26, P1510, DOI 10.1097/00003246-199809000-00017; Bozza FA, 2010, LANCET INFECT DIS, V10, P290, DOI 10.1016/S1473-3099(10)70074-8; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035, DOI 10.1093/ajcn/51.6.1035; Davies AR, 2002, CRIT CARE MED, V30, P586, DOI 10.1097/00003246-200203000-00016; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Faiz MA, 2005, LANCET, V366, P717; GIANOTTI L, 1994, CRIT CARE MED, V22, P265, DOI 10.1097/00003246-199402000-00018; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Heyland DK, 2001, CRIT CARE MED, V29, P1495, DOI 10.1097/00003246-200108000-00001; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Metheny NA, 2006, CRIT CARE MED, V34, P1007, DOI 10.1097/01.CCM.0000206106.65220.59; Metheny NA, 2008, AM J CRIT CARE, V17, P512; Metheny NA, 2010, NURS RES, V59, P18, DOI 10.1097/NNR.0b013e3181c3ba05; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010; WHITE NJ, 1983, NEW ENGL J MED, V309, P61, DOI 10.1056/NEJM198307143090201; *WHO, WHO MAL TREATM GUID; Woo SH, 2010, NUTR CLIN PRACT, V25, P205, DOI 10.1177/0884533610361605; World Health Organization, 1999, MAN SEV MALN MAN PHY	26	33	33	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2011	6	11							e27273	10.1371/journal.pone.0027273	http://dx.doi.org/10.1371/journal.pone.0027273			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HV	22110624	gold, Green Submitted, Green Published			2023-01-03	WOS:000297555400032
J	Reveiz, L; Chapman, E; Ramon-Pardo, P; Koehlmoos, TP; Cuervo, LG; Aldighieri, S; Chambliss, A				Reveiz, Ludovic; Chapman, Evelina; Ramon-Pardo, Pilar; Koehlmoos, Tracey Perez; Cuervo, Luis Gabriel; Aldighieri, Sylvain; Chambliss, Amy			Chemoprophylaxis in Contacts of Patients with Cholera: Systematic Review and Meta-Analysis	PLOS ONE			English	Review							VIBRIO-CHOLERAE; MOLECULAR CHARACTERIZATION; ANTIMICROBIAL AGENTS; FAMILY CONTACTS; TETRACYCLINE; RESISTANCE; EPIDEMIC; SINGLE; TRANSMISSION; PROPHYLAXIS	Introduction: There is a pressing need for effective measures to prevent the spread of cholera. Our systematic review assesses the effects of chemoprophylaxis in preventing cholera among exposed contacts. Methods and Findings: We considered published and unpublished reports of studies up to July 2011. For this we searched: PubMed (1966 to July, 2011), Embase (1980 to July 2011), Cochrane Central Register of Controlled Trials (6; 2011), LILACS (1982 to July, 2011), the International Clinical Trials Registry Platform (July 2011) and references of identified publications. We included controlled clinical trials (randomized and non-randomized) in which chemoprophylaxis was used to prevent cholera among patient contacts. The main outcome measures were hospitalization and laboratory diagnosis of cholera in contacts for cholera patients. We assessed the risk of bias. We identified 2638 references and these included 2 randomized trials and 5 controlled trials that added up to a total of 4,154 participants. The risk of bias scored high for most trials. The combined results from two trials found that chemoprophylaxis reduced hospitalization of contacts during the follow-up period by 8-12 days (2826 participants; RR 0.54 95% CI 0.40-0.74;I-2 0%). A meta-analysis of five trials found a significant reduction in disease among contacts with at least one positive sample who received chemoprophylaxis during the overall follow-up (range 4-15 days) (1,414 participants; RR 0.35 95% CI 0.18-0.66;I-2 74%). A significant reduction in the number of positive samples was also found with chemoprophylaxis (3 CCT; 6,918 samples; RR 0.39 95% CI 0.29-0.51;I-2 0%). Conclusion: Our findings suggest that chemoprophylaxis has a protective effect among household contacts of people with cholera but the results are based on studies with a high risk of bias. Hence, there is a need for adequate reliable research that allows balancing benefits and harms by evaluating the effects of chemoprophylaxis.	[Reveiz, Ludovic; Chapman, Evelina; Cuervo, Luis Gabriel] WHO, Publ Policies & Res Hlth Hlth Syst Based Primary, Washington, DC USA; [Ramon-Pardo, Pilar] WHO, Int Hlth Regulat Alert & Response & Epidem Dis Pa, Washington, DC USA; [Koehlmoos, Tracey Perez] Int Ctr Diarrheal Dis Res, Hlth & Family Planning Syst Programme, Dhaka, Bangladesh; [Aldighieri, Sylvain] WHO, PAHO Communicable Dis Unit, Epidem Alert & Response Team, Washington, DC USA; [Chambliss, Amy] Georgetown Univ, Dept Int Hlth, Sch Nursing & Hlth Studies, Washington, DC USA	World Health Organization; World Health Organization; International Centre for Diarrhoeal Disease Research (ICDDR); World Health Organization; Georgetown University	Reveiz, L (corresponding author), WHO, Publ Policies & Res Hlth Hlth Syst Based Primary, Washington, DC USA.	reveizl@paho.org	chapman, evelina/AAQ-1078-2020; Cuervo, Luis Gabriel/A-9464-2009	Cuervo, Luis Gabriel/0000-0003-2732-5019; Chapman, Evelina/0000-0001-5979-6718				[Anonymous], GLOBAL TASK FORCE CH; Centers for Disease Control and Prevention (CDC), 2010, MMWR Morb Mortal Wkly Rep, V59, P1411; DEB BC, 1976, B WORLD HEALTH ORGAN, V54, P171; Dromigny JA, 2002, EMERG INFECT DIS, V8, P336, DOI 10.3201/eid0803.010258; ECHEVARRIA J, 1995, CLIN INFECT DIS, V20, P1480, DOI 10.1093/clinids/20.6.1480; GANGAROSA EJ, 1966, B WORLD HEALTH ORGAN, V35, P669; GHARAGOZLOO RA, 1970, BMJ-BRIT MED J, V4, P281, DOI 10.1136/bmj.4.5730.281; Ghosh A, 2011, INDIAN J MED RES, V133, P225; Guevart E, 2006, MED MALADIES INFECT, V36, P329, DOI 10.1016/j.medmal.2005.11.020; Guevart Edouard, 2007, Sante, V17, P63; Guevart Edouard, 2005, Sante, V15, P225; Higgins J., 2009, COCHRANE HDB SYSTEMA; ISLAM MR, 1987, GUT, V28, P1029, DOI 10.1136/gut.28.8.1029; *JOINT ICMR GWB WH, 1970, B WORLD HEALTH ORGAN, V43, P389; Karki R, 2010, JPN J INFECT DIS, V63, P185; Keramat F., 2008, Eastern Mediterranean Health Journal, V14, P768; KHAN MU, 1982, J TROP MED HYG, V85, P27; Kingston JJ, 2009, J MICROBIOL, V47, P110, DOI 10.1007/s12275-008-0162-7; Lapeyssonnie L, 1971, Med Trop (Mars), V31, P127; Manga N M, 2008, Med Trop (Mars), V68, P589; MCCORMACK WM, 1968, B WORLD HEALTH ORGAN, V38, P787; MHALU FS, 1979, LANCET, V1, P345; Ngandjio A, 2009, FOODBORNE PATHOG DIS, V6, P49, DOI 10.1089/fpd.2008.0127; Okuda J, 2010, ANTIMICROB AGENTS CH, V54, P4917, DOI 10.1128/AAC.01652-09; *PAN AM HLTH ORG, 2010, PAHO RESP CHOL OUTBR; PIERCE NF, 1968, BMJ-BRIT MED J, V3, P277, DOI 10.1136/bmj.3.5613.277; Ranjbar M, 2010, TROP DOCT, V40, P214, DOI 10.1258/td.2010.100015; SACK DA, 1978, ANTIMICROB AGENTS CH, V14, P462, DOI 10.1128/AAC.14.3.462; Saha D, 2005, LANCET, V366, P1085, DOI 10.1016/S0140-6736(05)67290-X; Schulz KF, 2010, LANCET, V375, P1144, DOI 10.1016/S0140-6736(10)60413-8; SENGUPTA PG, 1978, B WORLD HEALTH ORGAN, V56, P323; TOWNER KJ, 1980, B WORLD HEALTH ORGAN, V58, P747; United Nations, 2008, MILL DEV GOALS REP; Usubutun S, 1997, Eur J Emerg Med, V4, P145, DOI 10.1097/00063110-199709000-00006; WEBER JT, 1994, EPIDEMIOL INFECT, V112, P1, DOI 10.1017/S0950268800057368; Weil AA, 2009, CLIN INFECT DIS, V49, P1473, DOI 10.1086/644779; World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P117; Zuckerman JN, 2007, LANCET INFECT DIS, V7, P521, DOI 10.1016/S1473-3099(07)70138-X; [No title captured]; 2011, PRELIMINAIRE DATA MI; 2010, MMWR MORB MORTAL WEE, V59, P1473	41	17	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2011	6	11							e27060	10.1371/journal.pone.0027060	http://dx.doi.org/10.1371/journal.pone.0027060			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HU	22102873	Green Published, gold			2023-01-03	WOS:000297555300008
J	Sjoberg, C; Edward, C; Fastbom, J; Johnell, K; Landahl, S; Narbro, K; Wallerstedt, SM				Sjoberg, Christina; Edward, Christina; Fastbom, Johan; Johnell, Kristina; Landahl, Sten; Narbro, Kristina; Wallerstedt, Susanna Maria			Association between Multi-Dose Drug Dispensing and Quality of Drug Treatment - A Register-Based Study	PLOS ONE			English	Article								Background: In the elderly in Scandinavia, multi-dose drug dispensing (MDD) is a common alternative to ordinary prescriptions (OP). MDD patients receive their drugs in unit bags, one for each dose occasion. The prescribing procedure differs between MDD and OP. The aim of the present study was to investigate the association between MDD and quality of drug treatment (QDT). Methodology/Principal Findings: A cross-sectional study was performed of all inhabitants in Region Vastra Gotaland alive on December 31st 2007, aged >= 65 years, with >= 1 prescribed drug and >= 2 health care visits for >= 2 diagnoses for obstructive pulmonary disease, diabetes mellitus, and/or cardiovascular disease in 2005-2007 (n = 24,146). For each patient, drug treatment on December 31st 2007 was estimated from drugs registered in the Swedish Prescribed Drug Register. QDT was evaluated according to established quality indicators (>= 10 drugs, Long-acting benzodiazepines, Drugs with anticholinergic action, >= 3 psychotropics, and Drugs combinations that should be avoided). Logistic regression, with adjustments for age, sex, burden of disease, and residence, was performed to investigate the association between MDD and QDT. Mean age was 77 years, 51% were females, and 20% used MDD. For all quality indicators, the proportion of patients with poor QDT was greater in patients with MDD than in patients with OP (all P < 0.0001). Unadjusted and adjusted odds ratios (95% confidence intervals) for poor QDT (MDD patients vs. OP patients) ranged from 1.47 (1.30-1.65) to 7.08 (6.30-7.96) and from 1.36 (1.18-1.57) to 5.48 (4.76-6.30), respectively. Conclusions/Significance: Patients with MDD have poorer QDT than patients with OP. This cannot be explained by differences in age, sex, burden of disease, or residence. These findings must be taken into account when designing alternative prescribing systems. Further research is needed to evaluate causative factors and if the findings also apply to other dose dispensing systems.	[Sjoberg, Christina] Sahlgrenska Univ Hospital Molndal, Dept Geriatr, Molndal, Sweden; [Edward, Christina] Cty Council Kalmar, Pharmaceut Unit, Dept Hlth, Kalmar, Sweden; [Fastbom, Johan; Johnell, Kristina] Stockholm Univ, S-10691 Stockholm, Sweden; [Fastbom, Johan; Johnell, Kristina] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Landahl, Sten] Univ Gothenburg, Sahlgrenska Univ Hosp Molndal, Dept Publ Hlth & Community Med, Geriatr Unit, Molndal, Sweden; [Narbro, Kristina] Reg Vastra Gotaland, Dept Hlth Adm, Reg Secretariat, Gothenburg, Sweden; [Wallerstedt, Susanna Maria] Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden	Sahlgrenska University Hospital; Stockholm University; Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital	Sjoberg, C (corresponding author), Sahlgrenska Univ Hospital Molndal, Dept Geriatr, Molndal, Sweden.	christina.a.sjoberg@vgregion.se	Wallerstedt, Susanna/AAE-5607-2020	Wallerstedt, Susanna/0000-0001-7238-1680; Landahl, Sten/0000-0001-7251-9192	Swedish National Board of Health and Welfare	Swedish National Board of Health and Welfare	The study was supported by the Swedish National Board of Health and Welfare. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; Bjerrum L, 1997, EUR J CLIN PHARMACOL, V53, P7, DOI 10.1007/s002280050329; Gaist D, 2002, NEUROLOGY, V58, P1333, DOI 10.1212/WNL.58.9.1333; Hidle Unn, 2007, J N Y State Nurses Assoc, V38, P4; Hovstadius Bo, 2010, BMC Clin Pharmacol, V10, P16, DOI 10.1186/1472-6904-10-16; Johnell K, 2008, SCAND J PRIM HEALTH, V26, P86, DOI 10.1080/02813430802022196; Johnell K, 2007, DRUG SAFETY, V30, P911, DOI 10.2165/00002018-200730100-00009; Johnell K, 2007, ANN PHARMACOTHER, V41, P1243, DOI 10.1345/aph.1K154; Johnell K, 2009, ANN PHARMACOTHER, V43, P1233, DOI 10.1345/aph.1M147; Kragh Annika, 2004, Lakartidningen, V101, P994; NORDLING S, 2009, WHAT ARE BENEFITS MU; SJOQVIST F, 2011, PHARM SPECIALITIES S; Socialstyrelsen, 2010, IND GOD LAK HOS ALDR; Statens beredning for medicinsk utvardering (Swedish Council on Technology Assessment in Health Care), 2009, 193 STAT BER MED UTV; *SVER KOMM LANDST, 2010, OPPN JAMF HALS SJUKV; STAT SWEDEN WEBSITE	16	35	35	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2011	6	10							e26574	10.1371/journal.pone.0026574	http://dx.doi.org/10.1371/journal.pone.0026574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	846PP	22066000	Green Published, gold, Green Submitted			2023-01-03	WOS:000296916000016
J	Feng, Y; Zhao, WH; Feng, YM; Dai, JJ; Li, Z; Zhang, XY; Liu, L; Bai, J; Zhang, HT; Lu, L; Xia, XS				Feng, Yue; Zhao, Wenhua; Feng, Yuemei; Dai, Jiejie; Li, Zheng; Zhang, Xiaoyan; Liu, Li; Bai, Jie; Zhang, Huatang; Lu, Ling; Xia, Xueshan			A Novel Genotype of GB Virus C: Its Identification and Predominance among Injecting Drug Users in Yunnan, China	PLOS ONE			English	Article							HEPATITIS-G VIRUS; C/HEPATITIS-G-VIRUS; PHYLOGENETIC ANALYSIS; SYNTHETIC PEPTIDES; SOUTHERN CHINA; MOLECULAR EPIDEMIOLOGY; 5'-UNTRANSLATED REGION; BLOOD-DONORS; HIV; INFECTION	GB virus C (GBV-C) is prevalent globally and particularly among individuals at risk of parental exposures. Based on genetic diversity, this virus is now classified into six genotypes and many subtypes with distinct geographical distribution. In this study, 120 Injecting Drug Users (IDUs) were recruited from Yunnan province, China. Among them, 43 (35.8%) were positive for GBV-C RNA, 70 (58.3%) and 103 (85.8%) sero-positive for HIV-1 and HCV respectively. This revealed 18.3% of IDUs having GBV-C/HIV/HCV triple infection, which is significantly higher than 7.5% of GBV-C/HIV-1 and 10% of GBV-C/HCV dual infection rates (P<0.05). Based on 5'UTR sequences, the identified 43 viral isolates can be classified into three phylogenetic groups: one (2.3%) and two (4.7%) belonged to genotype 3 and 4, respectively, and the remaining 40 (93%) formed a new group with 97% of bootstrap support. This new GBV-C group was further confirmed by characterizing the E2 region and full-length genome sequences. Analysis of 187 nt 5'UTR sequence showed three previous reported isolates from Southeast Asia were re-classified into this new group. It implies they have the same origin with strains from Yunnan. Although we provisionally assigned this new group as GBV-C genotype 7, a simpler five groups of GBV-C nomenclature is recommended. Genotype 4, 6 and the newly designated genotype 7 could be reclassified as one group, which may represent a single GBV-C genotype. The classification of the other four groups was corresponding to that of previous reported genotype 1, 2, 3 and 5. Furthermore, the diversity of amino acid sequence in the E2 region was analyzed. The inhibitory effect of GBV-C genotype 7 on HIV-1 cell entry could be deduced. Since GBV-C may have a beneficial effect on AIDS disease progression and interact with HCV during co-infection, this finding may raise interests in future studies on this virus that was previously thought to be a "non-pathogenic virus''.	[Feng, Yue; Liu, Li; Bai, Jie; Xia, Xueshan] Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Kunming, Yunnan, Peoples R China; [Feng, Yue; Liu, Li; Bai, Jie; Xia, Xueshan] Kunming Univ Sci & Technol, Fac Life Sci & Technol, Kunming, Yunnan, Peoples R China; [Zhao, Wenhua] Key Lab Trop & Subtrop Anim Viral Dis Yunnan Prov, Kunming, Yunnan, Peoples R China; [Feng, Yuemei; Zhang, Huatang] Chinese Acad Sci & Yunnan Prov, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Kunming, Peoples R China; [Dai, Jiejie] Chinese Acad Med Sci, Inst Med Biol, Kunming, Yunnan, Peoples R China; [Dai, Jiejie] Peking Union Med Coll, Kunming, Yunnan, Peoples R China; [Li, Zheng] Kunming Med Coll, Affiliated Kunhua Hosp, Clin Lab, Ctr Yunnan Prov, Kunming, Peoples R China; [Zhang, Xiaoyan] Fudan Univ, Res Ctr Shanghai Publ Hlth Clin Ctr, Inst Biomed Sci, Shanghai, Peoples R China; [Lu, Ling] Univ Kansas, Med Ctr, Dept Pathol, Viral Oncol Ctr, Kansas City, KS 66103 USA; Sun Yat Sen Univ, Affiliated Hosp 3, Lab Hepatol, Guangzhou 510275, Guangdong, Peoples R China	Kunming University of Science & Technology; Kunming University of Science & Technology; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Medical Biology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Kunming Medical University; Fudan University; University of Kansas; University of Kansas Medical Center; Sun Yat Sen University	Feng, Y (corresponding author), Kunming Univ Sci & Technol, Fac Environm Sci & Engn, Kunming, Yunnan, Peoples R China.	oliverxia2000@yahoo.com.cn		zhao, wenhua/0000-0003-0811-7978	Natural Science Foundation of China (NSFC) [30960346, 30960005]; National Basic Research Program of China (973 Program) [2009CB522502]; Chinese Key Projects in the National Science & Technology Pillar Program [2009BAI83B02]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080734] Funding Source: NIH RePORTER	Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China (973 Program)(National Basic Research Program of China); Chinese Key Projects in the National Science & Technology Pillar Program; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was financially supported by grants from the Natural Science Foundation of China (NSFC) (No. 30960346 and No. 30960005) and the National Basic Research Program of China (973 Program, 2009CB522502), and partially supported by Chinese Key Projects in the National Science & Technology Pillar Program during the Eleventh Five-Year Plan Period (2009BAI83B02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham P, 2007, INDIAN J MED RES, V125, P717; Alcalde R, 2010, VIRUS RES, V151, P148, DOI 10.1016/j.virusres.2010.04.008; An P, 1997, J GEN VIROL, V78, P2477, DOI 10.1099/0022-1317-78-10-2477; Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076; Beyrer C, 2005, AIDS, V19, P1535, DOI 10.1097/01.aids.0000183122.01583.c7; Beyrer C, 2000, AIDS, V14, P75, DOI 10.1097/00002030-200001070-00009; Bjorkman P, 2001, VOX SANG, V81, P148, DOI 10.1046/j.1423-0410.2001.00098.x; Branco C, 2010, J MED VIROL, V82, P452, DOI 10.1002/jmv.21703; Fukushi S, 1996, BIOCHEM BIOPH RES CO, V226, P314, DOI 10.1006/bbrc.1996.1353; Garten RJ, 2005, CLIN INFECT DIS, V41, pS18, DOI 10.1086/429491; George Sarah L, 2005, Curr Gastroenterol Rep, V7, P54, DOI 10.1007/s11894-005-0067-0; Handajani R, 2000, J CLIN MICROBIOL, V38, P662, DOI 10.1128/JCM.38.2.662-668.2000; Hekmat S, 2008, J MED VIROL, V80, P1941, DOI 10.1002/jmv.21314; Herrera E, 2010, J MED CHEM, V53, P6054, DOI 10.1021/jm100452c; Herrera E, 2009, J PHYS CHEM B, V113, P7383, DOI 10.1021/jp900707t; Hwang SJ, 1999, J MED VIROL, V57, P85, DOI 10.1002/(SICI)1096-9071(199901)57:1&lt;85::AID-JMV13&gt;3.0.CO;2-2; Jung S, 2007, AIDS, V21, P645, DOI 10.1097/QAD.0b013e32803277c7; Laeyendecker O, 2005, JAIDS-J ACQ IMM DEF, V38, P356; Lai S, 2001, J ACQ IMMUN DEF SYND, V26, P365, DOI 10.1097/00126334-200104010-00014; Larios C, 2005, LUMINESCENCE, V20, P279, DOI 10.1002/bio.850; Larios C, 2005, ARCH BIOCHEM BIOPHYS, V442, P149, DOI 10.1016/j.abb.2005.06.027; Li G, 2002, WORLD J GASTROENTERO, V8, P1081, DOI 10.3748/wjg.v8.i6.1081; LI G, 2002, WORLD J GASTROENTERO, V9, P1739; Liu HF, 2003, J MED VIROL, V71, P385, DOI 10.1002/jmv.10491; Lu L, 2001, VIRUS RES, V73, P131, DOI 10.1016/S0168-1702(00)00231-8; Mphahlele MJ, 1998, LIVER, V18, P143; Muerhoff AS, 2006, J MED VIROL, V78, P105, DOI 10.1002/jmv.20510; Muerhoff AS, 2005, J GEN VIROL, V86, P1729, DOI 10.1099/vir.0.80854-0; Muerhoff AS, 1996, J HEPATOL, V25, P379, DOI 10.1016/S0168-8278(96)80125-5; Petrik J, 1998, GUT, V42, P103, DOI 10.1136/gut.42.1.103; Sathar MA, 2004, CLIN INFECT DIS, V38, P405, DOI 10.1086/381092; Schleicher SB, 2003, J MED VIROL, V71, P226, DOI 10.1002/jmv.10474; Schwarze-Zander C, 2006, J INFECT DIS, V194, P410, DOI 10.1086/505713; Shang H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010631; Shankar EM, 2008, T ROY SOC TROP MED H, V102, P1176, DOI 10.1016/j.trstmh.2008.04.034; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; Smith DB, 2000, J GEN VIROL, V81, P769, DOI 10.1099/0022-1317-81-3-769; Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137; Stark K, 1996, J INFECT DIS, V174, P1320, DOI 10.1093/infdis/174.6.1320; Takebe Y, 2004, PEDIATR INT, V46, P236, DOI 10.1046/j.1442-200x.2004.01869.x; Tee KK, 2008, J VIROL, V82, P9206, DOI 10.1128/JVI.00399-08; Wang YZ, 2009, J CLIN VIROL, V44, P195, DOI 10.1016/j.jcv.2008.12.009; Xia XS, 2008, J MED VIROL, V80, P1740, DOI 10.1002/jmv.21287; Xia XS, 2008, J MED VIROL, V80, P1142, DOI 10.1002/jmv.21204; Yu XF, 2003, AIDS RES HUM RETROV, V19, P1051, DOI 10.1089/088922203322588422; Zhou YQ, 2010, J CLIN VIROL, V49, P272, DOI 10.1016/j.jcv.2010.08.007	46	45	48	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 6	2011	6	10							e21151	10.1371/journal.pone.0021151	http://dx.doi.org/10.1371/journal.pone.0021151			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834NO	21998624	Green Published, gold, Green Submitted			2023-01-03	WOS:000295968700001
J	Szymanska, B; Wilczynska-Kalak, U; Kang, MH; Liem, NLM; Carol, H; Boehm, I; Groepper, D; Reynolds, CP; Stewart, CF; Lock, RB				Szymanska, Barbara; Wilczynska-Kalak, Urszula; Kang, Min H.; Liem, Natalia L. M.; Carol, Hernan; Boehm, Ingrid; Groepper, Daniel; Reynolds, C. Patrick; Stewart, Clinton F.; Lock, Richard B.			Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts	PLOS ONE			English	Article							B-CELL PRECURSOR; TERM-FOLLOW-UP; CHILDHOOD LEUKEMIA; MIMETIC ABT-737; SCID MICE; DEXAMETHASONE; ASPARAGINASE; CANCER; VINCRISTINE; RESISTANCE	Current regimens for induction therapy of pediatric acute lymphoblastic leukemia (ALL), or for re-induction post relapse, use a combination of vincristine (VCR), a glucocorticoid, and L-asparaginase (ASP) with or without an anthracycline. With cure rates now approximately 80%, robust pre-clinical models are necessary to prioritize active new drugs for clinical trials in relapsed/refractory patients, and the ability of these models to predict synergy/antagonism with established therapy is an essential attribute. In this study, we report optimization of an induction-type regimen by combining VCR, dexamethasone (DEX) and ASP (VXL) against ALL xenograft models established from patient biopsies in immune-deficient mice. We demonstrate that the VXL combination was synergistic in vitro against leukemia cell lines as well as in vivo against ALL xenografts. In vivo, VXL treatment caused delays in progression of individual xenografts ranging from 22 to > 146 days. The median progression delay of xenografts derived from long-term surviving patients was 2-fold greater than that of xenografts derived from patients who died of their disease. Pharmacokinetic analysis revealed that systemic DEX exposure in mice increased 2-fold when administered in combination with VCR and ASP, consistent with clinical findings, which may contribute to the observed synergy between the 3 drugs. Finally, as proof-of-principle we tested the in vivo efficacy of combining VXL with either the Bcl-2/Bcl-xL/Bcl-w inhibitor, ABT-737, or arsenic trioxide to provide evidence of a robust in vivo platform to prioritize new drugs for clinical trials in children with relapsed/refractory ALL.	[Szymanska, Barbara; Wilczynska-Kalak, Urszula; Liem, Natalia L. M.; Carol, Hernan; Boehm, Ingrid; Lock, Richard B.] Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia; [Kang, Min H.; Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA; [Groepper, Daniel; Stewart, Clinton F.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN USA	Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Szymanska, B (corresponding author), Univ New S Wales, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia.	rlock@ccia.unsw.edu.au	Lock, Richard/G-4253-2013; Stewart, Clinton/N-3822-2018; Carol, Hernan/F-5750-2013	Stewart, Clinton/0000-0002-1546-9720; Carol, Hernan/0000-0002-9443-8032; Reynolds, C. Patrick/0000-0002-2827-8536; Kang, Min H/0000-0003-3603-7035; Stacey, Ingrid/0000-0002-3032-6031; Lock, Richard/0000-0002-3436-9071	University of Southern California-Children's Hospital Los Angeles Institute for Pediatric Clinical Research; Children's Cancer Institute Australia for Medical Research	University of Southern California-Children's Hospital Los Angeles Institute for Pediatric Clinical Research; Children's Cancer Institute Australia for Medical Research	This work was supported by the University of Southern California-Children's Hospital Los Angeles Institute for Pediatric Clinical Research and by the Children's Cancer Institute Australia for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertsen BK, 2001, BRIT J CLIN PHARMACO, V52, P433, DOI 10.1046/j.0306-5251.2001.01464.x; Arico M, 2010, J CLIN ONCOL, V28, P4755, DOI 10.1200/JCO.2010.30.1325; Avramis VI, 2005, CLIN PHARMACOKINET, V44, P367, DOI 10.2165/00003088-200544040-00003; Bachmann PS, 2007, CANCER RES, V67, P4482, DOI 10.1158/0008-5472.CAN-06-4244; Bachmann PS, 2010, BLOOD, V116, P3013, DOI 10.1182/blood-2010-05-284968; Baersch G, 1997, KLIN PADIATR, V209, P178, DOI 10.1055/s-2008-1043947; Beal SL, 2006, NONMEM USERS GUIDE I; Borgmann A, 2000, PEDIATR HEMAT ONCOL, V17, P635, DOI 10.1080/08880010050211349; Bornhauser BC, 2007, BLOOD, V110, P2084, DOI 10.1182/blood-2006-12-060970; Chessells JM, 2003, BRIT J HAEMATOL, V123, P396, DOI 10.1046/j.1365-2141.2003.04584.x; Deng J, 2007, CANCER CELL, V12, P171, DOI 10.1016/j.ccr.2007.07.001; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Ek O, 1998, LEUKEMIA LYMPHOMA, V31, P143, DOI 10.3109/10428199809057594; Frost BM, 2003, ACTA PAEDIATR, V92, P551, DOI 10.1080/08035320310000000; Gaynon PS, 2005, BRIT J HAEMATOL, V131, P579, DOI 10.1111/j.1365-2141.2005.05773.x; High LM, 2010, MOL PHARMACOL, V77, P483, DOI 10.1124/mol.109.060780; Horton TM, 2010, PEDIATR BLOOD CANCER, V54, P872, DOI 10.1002/pbc.22414; INABA M, 1988, JPN J CANCER RES, V79, P509, DOI 10.1111/j.1349-7006.1988.tb01620.x; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kang MH, 2007, BLOOD, V110, P2057, DOI 10.1182/blood-2007-03-080325; Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keshelava N, 2005, METH MOLEC MED, V110, P139; Ko RH, 2010, J CLIN ONCOL, V28, P648, DOI 10.1200/JCO.2009.22.2950; Kola I, 2004, NAT REV DRUG DISCOV, V3, P711, DOI 10.1038/nrd1470; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Liem NLM, 2004, BLOOD, V103, P3905, DOI 10.1182/blood-2003-08-2911; Litzow MR, 2006, HAEMATOLOGICA, V91, P1105; Lock RB, 2002, BLOOD, V99, P4100, DOI 10.1182/blood.V99.11.4100; Lock R, 2008, PEDIATR BLOOD CANCER, V50, P1181, DOI 10.1002/pbc.21433; Lonnerholm G, 2008, BRIT J HAEMATOL, V142, P616, DOI 10.1111/j.1365-2141.2008.07235.x; Moore VD, 2008, BLOOD, V111, P2300, DOI 10.1182/blood-2007-06-098012; Narta UK, 2006, CRIT REV ONCOL HEMAT; Nijmeijer BA, 2001, EXP HEMATOL, V29, P322, DOI 10.1016/S0301-472X(00)00669-X; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Peterson JK, 2004, EUR J CANCER, V40, P837, DOI 10.1016/j.ejca.2004.01.003; Pieters R, 2008, BLOOD, V112, P4832, DOI 10.1182/blood-2008-04-149443; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Pui CH, 2010, J FORMOS MED ASSOC, V109, P777, DOI 10.1016/S0929-6646(10)60123-4; Puisset F, 2005, BRIT J CLIN PHARMACO, V60, P45, DOI 10.1111/j.1365-2125.2005.02384.x; Rose WC, 2004, CLIN CANCER RES, V10, P7413, DOI 10.1158/1078-0432.CCR-04-1045; Schwartz C L, 1999, Oncologist, V4, P45; Skinner R, 2006, LANCET ONCOL, V7, P489, DOI 10.1016/S1470-2045(06)70724-0; Steele JPC, 1997, BLOOD, V90, P2015, DOI 10.1182/blood.V90.5.2015; Su N, 2008, PEDIATR BLOOD CANCER, V50, P274, DOI 10.1002/pbc.21213; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Toth GG, 2002, INT J DERMATOL, V41, P525, DOI 10.1046/j.1365-4362.2002.15452.x; Vogler M, 2009, CELL DEATH DIFFER, V16, P360, DOI 10.1038/cdd.2008.137; Whiteford CC, 2007, CANCER RES, V67, P32, DOI 10.1158/0008-5472.CAN-06-0610; Yang J, 2008, ACTA OTO-LARYNGOL, V128, P496, DOI 10.1080/00016480701558906; Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404; Zamboni WC, 1998, J NATL CANCER I, V90, P505, DOI 10.1093/jnci/90.7.505	53	44	44	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2012	7	3							e33894	10.1371/journal.pone.0033894	http://dx.doi.org/10.1371/journal.pone.0033894			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SR	22479469	Green Published, gold, Green Submitted			2023-01-03	WOS:000304523400043
J	Ferguson, J; Docherty, G; Bauld, L; Lewis, S; Lorgelly, P; Boyd, KA; McEwen, A; Coleman, T				Ferguson, Janet; Docherty, Graeme; Bauld, Linda; Lewis, Sarah; Lorgelly, Paula; Boyd, Kathleen Anne; McEwen, Andy; Coleman, Tim			Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING-CESSATION; CIGARETTE; SMOKERS	Objective To compare the effects of free nicotine replacement therapy or proactive telephone counselling in addition to standard smoking cessation support offered through a telephone quitline. Design Parallel group, 2x2 factorial, randomised controlled trial. Setting National quitline, England. Participants 2591 non-pregnant smokers aged 16 or more residing in England who called the quitline between February 2009 and February 2010 and agreed to set a quit date: 648 were each randomised to standard support, proactive support, or proactive support with nicotine replacement therapy, and 647 were randomised to standard support with nicotine replacement therapy. Interventions Two interventions were offered in addition to standard support: six weeks' nicotine replacement therapy, provided free, and proactive counselling sessions (repeat telephone calls from, and interaction with, cessation advisors). Main outcome measures The primary outcome was self reported smoking cessation for six or more months after the quit date. The secondary outcome was cessation validated by exhaled carbon monoxide measured at six or more months. Results At six months, 17.7% (n=229) of those offered nicotine replacement therapy reported smoking cessation compared with 20.1% (n=261) not offered such therapy (odds ratio 0.85, 95% confidence interval 0.70 to 1.04), and 18.2% (n=236) offered proactive counselling reported smoking cessation compared with 19.6% (n=254) offered standard support (0.91, 0.75 to 1.11). Data validated by carbon monoxide readings changed the findings for nicotine replacement therapy only, with smoking cessation validated in 6.6% (85/1295) of those offered nicotine replacement therapy compared with 9.4% (122/1296) not offered such therapy (0.67, 0.50 to 0.90). Conclusions Offering free nicotine replacement therapy or additional (proactive) counselling to standard helpline support had no additional effect on smoking cessation.	[Coleman, Tim] Univ Nottingham, Sch Med, Queens Med Ctr, UK Ctr Tobacco Control Studies,Div Primary Care, Nottingham NG7 2RD, England; [Coleman, Tim] Univ Nottingham, Sch Med, Queens Med Ctr, NIHR Sch Primary Care Res, Nottingham NG7 2RD, England; [Docherty, Graeme; Lewis, Sarah] Univ Nottingham, City Hosp Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Docherty, Graeme; Lewis, Sarah] Univ Nottingham, City Hosp Nottingham, UK Ctr Tobacco Control Studies, Nottingham NG7 2RD, England; [McEwen, Andy] UCL, UCL Epidemiol & Publ Hlth, London WC1E 6BT, England; [McEwen, Andy] UCL, UK Ctr Tobacco Control Studies, London WC1E 6BT, England; [Lorgelly, Paula] Monash Univ, Ctr Hlth Econ, Clayton, Vic 3800, Australia; [Ferguson, Janet; Boyd, Kathleen Anne] Univ Glasgow, Ctr Populat & Hlth Sci, Glasgow G12 8QQ, Lanark, Scotland; [Bauld, Linda] Univ Stirling, Stirling Management Sch, Stirling FK9 4LA, Scotland; [Bauld, Linda] Univ Stirling, UK Ctr Tobacco Control Studies, Stirling FK9 4LA, Scotland	University of Nottingham; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of London; University College London; University of London; University College London; Monash University; University of Glasgow; University of Stirling; University of Stirling	Coleman, T (corresponding author), Univ Nottingham, Sch Med, Queens Med Ctr, UK Ctr Tobacco Control Studies,Div Primary Care, Nottingham NG7 2RD, England.	tim.coleman@nottingham.ac.uk		Docherty, Graeme/0000-0002-4996-5554; Lorgelly, Paula/0000-0002-8990-9514; Coleman, Tim/0000-0002-7303-4805; Boyd, Kathleen/0000-0002-9764-0113	English Department of Health; UK Centre for Tobacco Control Studies The Department of Health; Cancer Research UK [14135] Funding Source: researchfish; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish	English Department of Health; UK Centre for Tobacco Control Studies The Department of Health; Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This study was funded by the English Department of Health, with additional funding from the UK Centre for Tobacco Control Studies The Department of Health paid for the nicotine replacement therapy. Views expressed in this publication are those of the authors and not necessarily those of the Department of Health. No third party (including funder) has reviewed or influenced the writing of this manuscript.	An LC, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.014555; Carlin-Menter S, 2011, J PUBLIC HEALTH MAN, V17, pE9, DOI 10.1097/PHH.0b013e318208e730; EQ-5D, 2011, EQ5D; Ferguson J, 2005, ADDICTION, V100, P59, DOI 10.1111/j.1360-0443.2005.01028.x; Fidler JA, 2011, ADDICTION, V106, P631, DOI 10.1111/j.1360-0443.2010.03226.x; Gilbert H, 2006, ADDICTION, V101, P590, DOI 10.1111/j.1360-0443.2006.01398.x; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Hedeker D, 2007, ADDICTION, V102, P1564, DOI 10.1111/j.1360-0443.2007.01946.x; Hollis JF, 2007, TOB CONTROL, V16, pI53, DOI 10.1136/tc.2006.019794; Hughes J., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000031.PUB2; Hughes JR, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000031.pub3, 10.1002/14651858.CD000031.pub4]; Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; McAfee TA, 2008, AM J PREV MED, V35, P103, DOI 10.1016/j.amepre.2008.04.017; McNeill A, 2005, ADDICTION, V100, P1, DOI 10.1111/j.1360-0443.2005.01022.x; Murray RL, 2009, ADDICTION, V104, P1901, DOI 10.1111/j.1360-0443.2009.02647.x; Ossip DJ, 2009, NICOTINE TOB RES, V11, P408, DOI 10.1093/ntr/ntp005; Platt S, 1997, BRIT MED J, V314, P1371; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000146.pub3; Stead LF, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001007.PUB2; Stead LF, 2007, TOB CONTROL, V16, pI3, DOI 10.1136/tc.2006.019737; Tobacco Advisory Group of the Royal College of Physicians, 2005, GOING SMOK FREE CAS; Tobacco Advisory Group of the Royal College of Physicians, 2000, NIC ADD BRIT; Tonstad S, 2006, JAMA-J AM MED ASSOC, V296, P64, DOI 10.1001/jama.296.1.64; UK Statistics Authority, IND MULT DEPR IMD 20; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660	27	38	38	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2012	344								e1696	10.1136/bmj.e1696	http://dx.doi.org/10.1136/bmj.e1696			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	962YP	22446739	hybrid, Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000305587600001
J	Chien, YW; Levin, BR; Klugman, KP				Chien, Yu-Wen; Levin, Bruce R.; Klugman, Keith P.			The Anticipated Severity of a "1918-Like" Influenza Pandemic in Contemporary Populations: The Contribution of Antibacterial Interventions	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; PNEUMOCOCCAL BACTEREMIA; STAPHYLOCOCCUS-AUREUS; BACTERIAL PNEUMONIA; IMMUNE-RESPONSE; HOST IMMUNE; EPIDEMIOLOGY; CHILDREN	Recent studies have shown that most of deaths in the 1918 influenza pandemic were caused by secondary bacterial infections, primarily pneumococcal pneumonia. Given the availability of antibiotics and pneumococcal vaccination, how will contemporary populations fare when they are next confronted with pandemic influenza due to a virus with the transmissibility and virulence of that of 1918? To address this question we use a mathematical model and computer simulations. Our model considers the epidemiology of both the influenza virus and pneumonia-causing bacteria and allows for co-infection by these two agents as well as antibiotic treatment, prophylaxis and pneumococcal vaccination. For our simulations we use influenza transmission and virulence parameters estimated from 1918 pandemic data. We explore the anticipated rates of secondary pneumococcal pneumonia and death in populations with different prevalence of pneumococcal carriage and contributions of antibiotic prophylaxis, treatment, and vaccination to these rates. Our analysis predicts that in countries with lower prevalence of pneumococcal carriage and access to antibiotics and pneumococcal conjugate vaccines, there would substantially fewer deaths due to pneumonia in contemporary populations confronted with a 1918-like virus than that observed in the 1918. Our results also predict that if the pneumococcal carriage prevalence is less than 40%, the positive effects of antibiotic prophylaxis and treatment would be manifest primarily at of level of individuals. These antibiotic interventions would have little effect on the incidence of pneumonia in the population at large. We conclude with the recommendation that pandemic preparedness plans should consider co-infection with and the prevalence of carriage of pneumococci and other bacteria responsible for pneumonia. While antibiotics and vaccines will certainly reduce the rate of individual mortality, the factor contributing most to the relatively lower anticipated lethality of a pandemic with a 1918-like influenza virus in contemporary population is the lower prevalence of pneumococcal carriage.	[Chien, Yu-Wen] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Levin, Bruce R.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA; [Klugman, Keith P.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health; Emory University; Emory University; Rollins School Public Health	Chien, YW (corresponding author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.	yuwen32@gmail.com			Pfizer Vaccines; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM091875] Funding Source: NIH RePORTER	Pfizer Vaccines; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	KPK has received research funding unrelated to the current paper from Pfizer Vaccines and has consulted for Pfizer Vaccines, Merck, GSK and Sanofi-Aventis. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials. YC and BRL report no conflict of interest.	Abdullahi O, 2008, PEDIATR INFECT DIS J, V27, P59, DOI 10.1097/INF.0b013e31814da70c; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; [Anonymous], 1958, BMJ-BRIT MED J, V1, P908; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; Bassetti S, 2005, INFECT CONT HOSP EP, V26, P196, DOI 10.1086/502526; Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; BRIMBLECOMBE FSW, 1958, BRIT MED J, V1, P119, DOI 10.1136/bmj.1.5063.119; Brundage JF, 2006, LANCET INFECT DIS, V6, P303, DOI 10.1016/S1473-3099(06)70466-2; Brundage JF, 2008, EMERG INFECT DIS, V14, P1193, DOI 10.3201/eid1408.071313; Brundage JF, 2007, J INFECT DIS, V196, P1717, DOI 10.1086/522355; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Chen CJ, 2007, DIAGN MICR INFEC DIS, V59, P265, DOI 10.1016/j.diagmicrobio.2007.05.012; Chien YW, 2010, J INFECT DIS, V202, P1639, DOI 10.1086/657144; Chien YW, 2009, NEW ENGL J MED, V361, P2582, DOI 10.1056/NEJMc0908216; Domenech A, 2011, J ANTIMICROB CHEMOTH, V66, P487, DOI 10.1093/jac/dkq480; EICHENWALD HF, 1960, AM J DIS CHILD, V100, P161, DOI 10.1001/archpedi.1960.04020040163003; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; FINLAND M, 1972, CLIN PHARMACOL THER, V13, P469; Frost WH, 1919, J AMER MED ASSOC, V73, P313, DOI 10.1001/jama.1919.02610310007003; GWALTNEY JM, 1975, J INFECT DIS, V132, P62, DOI 10.1093/infdis/132.1.62; HERS JFP, 1958, LANCET, V2, P1141; Hill PC, 2006, CLIN INFECT DIS, V43, P673, DOI 10.1086/506941; Hogberg L, 2007, J CLIN MICROBIOL, V45, P948, DOI 10.1128/JCM.01913-06; Hussain M, 2005, EPIDEMIOL INFECT, V133, P891, DOI 10.1017/S0950268805004012; Kash JC, 2004, J VIROL, V78, P9499, DOI 10.1128/JVI.78.17.9499-9511.2004; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; Klugman KP, 2009, VACCINE, V27, pC9, DOI 10.1016/j.vaccine.2009.06.007; Klugman KP, 2009, EMERG INFECT DIS, V15, P346, DOI 10.3201/eid1502.081208; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; LEVINS R, 1966, AM SCI, V54, P421; Lynch JP, 2009, SEMIN RESP CRIT CARE, V30, P189, DOI 10.1055/s-0029-1202938; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; Marston BJ, 1997, ARCH INTERN MED, V157, P1709, DOI 10.1001/archinte.157.15.1709; McCullers JA, 2002, J INFECT DIS, V186, P341, DOI 10.1086/341462; McCullers JA, 2010, J INFECT DIS, V202, P1287, DOI 10.1086/656333; Michelow IC, 2004, PEDIATRICS, V113, P701, DOI 10.1542/peds.113.4.701; Miller MA, 2008, J INFECT DIS, V198, P305, DOI 10.1086/589716; Mills CE, 2004, NATURE, V432, P904, DOI 10.1038/nature03063; Moore MR, 2004, J INFECT DIS, V190, P2031, DOI 10.1086/425422; Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708; Olson DR, 2005, P NATL ACAD SCI USA, V102, P11059, DOI 10.1073/pnas.0408290102; Palacios G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008540; Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Porath A, 1997, J INFECTION, V34, P41, DOI 10.1016/S0163-4453(97)80008-4; Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547; Rosen FS, 2007, ENT-EAR NOSE THROAT, V86, P38, DOI 10.1177/014556130708600116; Rubin JL, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-14; Schrag SJ, 2001, JAMA-J AM MED ASSOC, V286, P49, DOI 10.1001/jama.286.1.49; Sherertz RJ, 1996, ANN INTERN MED, V124, P539, DOI 10.7326/0003-4819-124-6-199603150-00001; Shinde V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014809; Simonsen L, 2007, MOL BIOL EVOL, V24, P1811, DOI 10.1093/molbev/msm103; Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10; Stillman EG, 1917, J EXP MED, V26, P513, DOI 10.1084/jem.26.4.513; Stillman EG, 1916, J EXP MED, V24, P651, DOI 10.1084/jem.24.6.651; Sydenstricker VPW, 1917, B JOHNS HOPKINS HOSP, V28, P312; Syrjanen RK, 2001, J INFECT DIS, V184, P451, DOI 10.1086/322048; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Yu VL, 2003, CLIN INFECT DIS, V37, P230, DOI 10.1086/377534	61	10	10	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2012	7	1							e29219	10.1371/journal.pone.0029219	http://dx.doi.org/10.1371/journal.pone.0029219			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909NE	22291887	Green Submitted, Green Published, gold			2023-01-03	WOS:000301570600003
J	Feng, ZE; Guo, W; Zhang, CP; Xu, Q; Zhang, P; Sun, J; Zhu, HG; Wang, ZH; Li, J; Wang, LZ; Wang, BS; Ren, GX; Ji, T; Tu, WY; Yang, XH; Qiu, WL; Mao, L; Zhang, ZY; Chen, WT				Feng, Zhien; Guo, Wei; Zhang, Chenping; Xu, Qin; Zhang, Ping; Sun, Jian; Zhu, Hanguang; Wang, Zhonghe; Li, Jiang; Wang, Lizhen; Wang, Bingshun; Ren, Guoxin; Ji, Tong; Tu, Wenyong; Yang, Xihu; Qiu, Weiliu; Mao, Li; Zhang, Zhiyuan; Chen, Wantao			CCND1 as a Predictive Biomarker of Neoadjuvant Chemotherapy in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma	PLOS ONE			English	Article							CYCLIN D1 EXPRESSION; INDUCTION CHEMOTHERAPY; RANDOMIZED TRIAL; GENE AMPLIFICATION; INITIAL TREATMENT; PROGNOSTIC VALUE; CANCER; MANAGEMENT; ADJUVANT; SURVIVAL	Background: Cyclin D1 (CCND1) has been associated with chemotherapy resistance and poor prognosis. In this study, we tested the hypothesis that CCND1 expression determines response and clinical outcomes in locally advanced head and neck squamous cell carcinoma (HNSCC) patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Methodology and Findings: 224 patients with HNSCC were treated with either cisplatin-based chemotherapy followed by surgery and radiotherapy (neoadjuvant group, n = 100) or surgery and radiotherapy (non-neoadjuvant group, n = 124). CCND1 expression was assessed by immunohistochemistry. CCND1 levels were analyzed with chemotherapy response, disease-free survival (DFS) and overall survival (OS). There was no significant difference between the neoadjuvant group and non-neoadjuvant group in DFS and OS (p = 0.929 and p = 0.760) when patients treated with the indiscriminate administration of cisplatin-based chemotherapy. However, in the neoadjuvant group, patients whose tumors showed a low CCND1 expression more likely respond to chemotherapy (p < 0.001) and had a significantly better OS and DFS than those whose tumors showed a high CCND1 expression (73% vs 8%, p < 0.001; 63% vs 6%, p < 0.001). Importantly, patients with a low CCND1 expression in neoadjuvant group received more survival benefits than those in non-neoadjuvant group (p = 0.016), however patients with a high CCND1 expression and treated with neoadjuvant chemotherapy had a significantly poor OS compared to those treated with surgery and radiotherapy (p = 0.032). A multivariate survival analysis also showed CCND1 expression was an independent predictive factor (p < 0.001). Conclusions: This study suggests that some but not all patients with HNSCC may benefit from neoadjuvant chemotherapy with cisplatin-based regimen and CCND1 expression may serve as a predictive biomarker in selecting patients undergo less than two cycles of neoadjuvant chemotherapy.	[Feng, Zhien; Guo, Wei; Zhang, Chenping; Xu, Qin; Zhang, Ping; Sun, Jian; Zhu, Hanguang; Wang, Zhonghe; Ren, Guoxin; Ji, Tong; Tu, Wenyong; Yang, Xihu; Qiu, Weiliu; Zhang, Zhiyuan; Chen, Wantao] Shanghai Jiao Tong Univ, Dept Oral & Maxillofacial Surg, Sch Med, Peoples Hosp 9, Shanghai 200030, Peoples R China; [Feng, Zhien; Zhang, Chenping; Xu, Qin; Zhang, Ping; Li, Jiang; Wang, Lizhen; Yang, Xihu; Qiu, Weiliu; Mao, Li; Zhang, Zhiyuan; Chen, Wantao] Shanghai Key Lab Stomatol, Shanghai, Peoples R China; [Li, Jiang; Wang, Lizhen] Shanghai Jiao Tong Univ, Dept Oral Pathol, Sch Med, Peoples Hosp 9, Shanghai 200030, Peoples R China; [Wang, Bingshun] Shanghai Jiao Tong Univ, Dept Biostat, Sch Med, Inst Med Sci, Shanghai 200030, Peoples R China; [Mao, Li] Univ Maryland, Sch Dent, Dept Oncol & Diagnost Sci, Baltimore, MD 21201 USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University System of Maryland; University of Maryland Baltimore	Feng, ZE (corresponding author), Shanghai Jiao Tong Univ, Dept Oral & Maxillofacial Surg, Sch Med, Peoples Hosp 9, Shanghai 200030, Peoples R China.	zhzhy@omschina.org.cn; chenwantao2002@gmail.com	Mao, Li/C-7570-2011; Wang, Bing-shun/B-8698-2013; Feng, Zhien/O-2982-2018; zhang, zhiyuan/GRS-2141-2022	Mao, Li/0000-0001-7263-3358; Feng, Zhien/0000-0003-1952-6734; Wang, Bingshun/0000-0002-0435-2543	Science and Technology Commission of Shanghai Municipality [08JC1414400, 09431902200, 10DZ1951300, 10XD1402500]; National Natural Science Foundation of China [30330580, 30973343]; Shanghai Leading Academic Discipline Project [S30206]	Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Leading Academic Discipline Project(Shanghai Leading Academic Discipline Project)	Dr. Chen, Dr. Zhiyuan Zhang, Dr. Mao, Dr. Chenping Zhang, Dr. Ping Zhang, Dr. Xu, Dr. Guo, Dr. Feng, Dr. Zhu, Dr. Sun and Dr. Qiu were supported in part by grants from Science and Technology Commission of Shanghai Municipality (08JC1414400, 09431902200 and 10DZ1951300). Dr. Chen, Dr. Ping Zhang and Dr. Xu were supported in part by grants from the National Natural Science Foundation of China (Grant No. 30330580, 30973343) and from Project of Science and Technology Commission of Shanghai Municipality (10XD1402500). Dr. Chen, Dr. Qiu, Dr. Ping Zhang, Dr. Xu, Dr. Li and Dr. Lizhen Wang were supported in part by funds from the Shanghai Leading Academic Discipline Project (S30206). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelstein DJ, 2006, J CLIN ONCOL, V24, P2624, DOI 10.1200/JCO.2005.05.3629; Akervall JA, 1997, CANCER, V79, P380; Allen PJ, 2003, J GASTROINTEST SURG, V7, P109, DOI 10.1016/S1091-255X(02)00121-X; Ancona E, 1997, ANN SURG, V226, P714, DOI 10.1097/00000658-199712000-00008; Beauvillain C, 1997, LARYNGOSCOPE, V107, P648, DOI 10.1097/00005537-199705000-00017; BROWMAN GP, 1994, CANCER INVEST, V12, P662, DOI 10.3109/07357909409023052; Chen Wantao, 2002, Zhonghua Kou Qiang Yi Xue Za Zhi, V37, P404; COGNETTI F, 1989, J CLIN ONCOL, V7, P829, DOI 10.1200/JCO.1989.7.7.829; Domenge C, 2000, BRIT J CANCER, V83, P1594, DOI 10.1054/bjoc.2000.1512; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; ElSayed S, 1996, J CLIN ONCOL, V14, P838, DOI 10.1200/JCO.1996.14.3.838; FERLAY J, 2010, 10 IARC; Glynne-Jones R, 2008, J CLIN ONCOL, V26, P3669, DOI 10.1200/JCO.2008.18.1651; Glynne-Jones R, 2007, J CLIN ONCOL, V25, P5281, DOI 10.1200/JCO.2007.12.3133; Hitt R, 2005, EUR J CANCER, V41, P453, DOI 10.1016/j.ejca.2004.10.014; Izzo JG, 1998, ONCOGENE, V17, P2313, DOI 10.1038/sj.onc.1202153; JARES P, 1994, CANCER RES, V54, P4813; Kelsen DP, 2007, J CLIN ONCOL, V25, P3719, DOI 10.1200/JCO.2006.10.4760; KIES MS, 1985, OTOLARYNG HEAD NECK, V93, P199, DOI 10.1177/019459988509300213; Law S, 1997, J THORAC CARDIOV SUR, V114, P210, DOI 10.1016/S0022-5223(97)70147-8; Lee DJ, 1997, CLIN CANCER RES, V3, P501; Licitra L, 2003, J CLIN ONCOL, V21, P327, DOI 10.1200/JCO.2003.06.146; MUNRO AJ, 1995, BRIT J CANCER, V71, P83, DOI 10.1038/bjc.1995.17; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; Petak I, 2010, NAT REV DRUG DISCOV, V9, P523, DOI 10.1038/nrd3135; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Rudas M, 2008, CLIN CANCER RES, V14, P1767, DOI 10.1158/1078-0432.CCR-07-4122; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vokes EE, 1996, ANN ONCOL, V7, P15; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; Yu ZW, 2005, CLIN CANCER RES, V11, P1160; Zhang P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-224; Zhou XJ, 2009, INT J CANCER, V124, P483, DOI 10.1002/ijc.23964	33	53	55	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2011	6	10							e26399	10.1371/journal.pone.0026399	http://dx.doi.org/10.1371/journal.pone.0026399			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	846PP	22065993	Green Published, Green Submitted, gold			2023-01-03	WOS:000296916000009
J	Fielding, K; Koba, A; Grant, AD; Charalambous, S; Day, J; Spak, C; Wald, A; Huang, ML; Corey, L; Churchyard, GJ				Fielding, Katherine; Koba, Ai; Grant, Alison D.; Charalambous, Salome; Day, John; Spak, Cedric; Wald, Anna; Huang, Meei-Li; Corey, Lawrence; Churchyard, Gavin J.			Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS DISEASE; END-ORGAN-DISEASE; HIV-1-INFECTED WOMEN; AIDS PATIENTS; PROGRESSION; CMV; PLASMA; SURVIVAL; LOAD; DNA	Background: Cytomegalovirus (CMV) viremia has been shown to be an independent risk factor for increased mortality among HIV-infected individuals in the developing world. While CMV infection is nearly ubiquitous in resource-poor settings, few data are available on the role of subclinical CMV reactivation on HIV. Methods: Using a cohort of mineworkers with stored plasma samples, we investigated the association between CMV DNA concentration and mortality prior to antiretroviral therapy availability. Results: Among 1341 individuals (median CD4 count 345 cells/mu l, 70% WHO stage 1 or 2, median follow-up 0.9 years), 70 (5.2%) had CMV viremia at baseline; 71 deaths occurred. In univariable analysis CMV viremia at baseline was associated with a three-fold increase in mortality (hazard ratio [HR] 3.37; 95% confidence intervals [CI] 1.60, 7.10). After adjustment for CD4 count, WHO stage and HIV viral load (N = 429 with complete data), the association was attenuated (HR 2.27; 95% CI 0.88, 5.83). Mortality increased with higher CMV viremia (>= 1,000 copies/ml vs. no viremia, adjusted HR 3.65, 95% CI: 1.29, 10.41). Results were similar using time-updated CMV viremia. Conclusions: High copy number, subclinical CMV viremia was an independent risk factor for mortality among male HIV-infected adults in South Africa with relatively early HIV disease. Studies to determine whether anti-CMV therapy to mitigate high copy number viremia would increase lifespan are warranted.	[Fielding, Katherine; Churchyard, Gavin J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England; [Koba, Ai; Grant, Alison D.; Day, John] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England; [Charalambous, Salome; Day, John; Churchyard, Gavin J.] Aurum Inst, Johannesburg, South Africa; [Spak, Cedric; Wald, Anna; Corey, Lawrence] Univ Washington, Dept Med, Seattle, WA USA; [Wald, Anna; Huang, Meei-Li; Corey, Lawrence] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Wald, Anna] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Wald, Anna; Corey, Lawrence] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Fielding, K (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.	Katherine.fielding@lshtm.ac.uk	Wald, Anna/B-6272-2012; Corey, Lawrence/AAE-1796-2020	Wald, Anna/0000-0003-3486-6438; Corey, Lawrence/0000-0002-2179-2436; Charalambous, Salome/0000-0001-7143-1009; Churchyard, Gavin/0000-0002-4269-3699	Anglogold; National Institutes of Health (NIH) [AI-30731]; Fred Hutchinson ALC [CA018029]; UK Department of Health; AngloGold Health Services; Medical Research Council [G0700837] Funding Source: researchfish; National Institute for Health Research [PHCS/03/01] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P01CA018029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER; MRC [G0700837] Funding Source: UKRI	Anglogold; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fred Hutchinson ALC; UK Department of Health; AngloGold Health Services; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by financial support from Anglogold. Additional laboratory work was funded by National Institutes of Health (NIH) Grant AI-30731 and the Fred Hutchinson ALC award grant number CA018029. Alison Grant was supported by a Public Health Career Scientist Award from the UK Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts. 1. The parent study referred to in the manuscript was funded by Anglogold. 2. Aurum Health Research, which at the time was a wholly owned subsidiary company of AngloGold Health Services, provided salary support to KF, SC, JD and GJC. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Adjei AA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-111; Boeckh M, 2004, J CLIN MICROBIOL, V42, P1142, DOI 10.1128/JCM.42.3.1142-1148.2004; Bowen EF, 1996, AIDS, V10, P1515, DOI 10.1097/00002030-199611000-00009; Burak KW, 2002, LIVER TRANSPLANT, V8, P362, DOI 10.1053/jlts.2002.32282; Charalambous S, 2004, AIDS CARE, V16, P47, DOI 10.1080/09540120310001633967; Day JH, 2004, J INFECT DIS, V190, P1677, DOI 10.1086/424851; Deayton JR, 2004, LANCET, V363, P2116, DOI 10.1016/S0140-6736(04)16500-8; DREW WL, 1992, CLIN INFECT DIS, V14, P608, DOI 10.1093/clinids/14.2.608-a; Erice A, 2003, CLIN INFECT DIS, V37, P567, DOI 10.1086/375843; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; George B, 2010, TRANSPL INFECT DIS, V12, P322, DOI 10.1111/j.1399-3062.2010.00504.x; Griffiths PP, 2006, J CLIN VIROL, V35, P489, DOI 10.1016/j.jcv.2005.10.016; Jabs DA, 2005, OPHTHALMOLOGY, V112, P771, DOI 10.1016/j.ophtha.2004.10.049; Kempen JH, 2003, CLIN INFECT DIS, V37, P1365, DOI 10.1086/379077; Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203; Micol R, 2009, JAIDS-J ACQ IMM DEF, V51, P486, DOI 10.1097/QAI.0b013e3181a254c2; Robain M, 2001, AIDS, V15, P251, DOI 10.1097/00002030-200101260-00016; SABIN CA, 1995, EPIDEMIOL INFECT, V114, P361, DOI 10.1017/S095026880005799X; Slyker JA, 2009, AIDS, V23, P117, DOI 10.1097/QAD.0b013e32831c8abd; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; WEBSTER A, 1989, LANCET, V2, P681; Wohl DA, 2005, JAIDS-J ACQ IMM DEF, V38, P538, DOI 10.1097/01.qai.0000155204.96973.c3; Zuckerman RA, 2007, J INFECT DIS, V196, P1500, DOI 10.1086/522523	23	31	35	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2011	6	10							e25571	10.1371/journal.pone.0025571	http://dx.doi.org/10.1371/journal.pone.0025571			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834PW	22022413	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000295976000021
J	Teismann, H; Okamoto, H; Pantev, C				Teismann, Henning; Okamoto, Hidehiko; Pantev, Christo			Short and Intense Tailor-Made Notched Music Training against Tinnitus: The Tinnitus Frequency Matters	PLOS ONE			English	Article							HUMAN AUDITORY-CORTEX; SHORT-TERM PLASTICITY; CORTICAL REORGANIZATION; SYNAPTIC MECHANISMS; NEUROSCIENCE; ENHANCEMENT; PAIN	Tinnitus is one of the most common diseases in industrialized countries. Here, we developed and evaluated a short-term (5 subsequent days) and intensive (6 hours/day) tailor-made notched music training (TMNMT) for patients suffering from chronic, tonal tinnitus. We evaluated (i) the TMNMT efficacy in terms of behavioral and magnetoencephalographic outcome measures for two matched patient groups with either low (<= 8 kHz, N = 10) or high (. 8 kHz, N = 10) tinnitus frequencies, and the (ii) persistency of the TMNMT effects over the course of a four weeks post-training phase. The results indicated that the short-term intensive TMNMT took effect in patients with tinnitus frequencies <= 8 kHz: subjective tinnitus loudness, tinnitus-related distress, and tinnitus-related auditory cortex evoked activity were significantly reduced after TMNMT completion. However, in the patients with tinnitus frequencies >8 kHz, significant changes were not observed. Interpreted in their entirety, the results also indicated that the induced changes in auditory cortex evoked neuronal activity and tinnitus loudness were not persistent, encouraging the application of the TMNMT as a longer-term training. The findings are essential in guiding the intended transfer of this neuro-scientific treatment approach into routine clinical practice.	[Teismann, Henning; Okamoto, Hidehiko; Pantev, Christo] Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany; [Okamoto, Hidehiko] Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 444, Japan	University of Munster; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Teismann, H (corresponding author), Univ Munster, Inst Biomagnetism & Biosignalanal, Munster, Germany.	h.teismann@uni-muenster.de	Okamoto, Hidehiko/A-7934-2008	Okamoto, Hidehiko/0000-0003-2799-3340	Deutsche Forschungsgemeinschaft [Pa 392/10-3, Pa 392/13-1]; Tinnitus Research Initiative; Japan Society for the Promotion of Science for Young Scientists; Strategic Research Program for Brain Sciences (Development of Biomarker Candidates for Social Behavior)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Tinnitus Research Initiative; Japan Society for the Promotion of Science for Young Scientists(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Strategic Research Program for Brain Sciences (Development of Biomarker Candidates for Social Behavior)	This work was supported by grants from the Deutsche Forschungsgemeinschaft (Pa 392/10-3, Pa 392/13-1), the Tinnitus Research Initiative, the Japan Society for the Promotion of Science for Young Scientists, and the Strategic Research Program for Brain Sciences (Development of Biomarker Candidates for Social Behavior). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahveninen J, 2006, P NATL ACAD SCI USA, V103, P14608, DOI 10.1073/pnas.0510480103; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Diesch E, 2004, EUR J NEUROSCI, V19, P1093, DOI 10.1111/j.0953-816X.2004.03191.x; Diesch E, 2010, NEUROIMAGE, V50, P1545, DOI 10.1016/j.neuroimage.2010.01.067; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Eggermont JJ, 2006, ACTA OTO-LARYNGOL, V126, P9, DOI 10.1080/03655230600895259; Eggermont JJ, 2004, TRENDS NEUROSCI, V27, P676, DOI 10.1016/j.tins.2004.08.010; Engelien A, 2000, HEARING RES, V148, P153, DOI 10.1016/S0378-5955(00)00148-9; Fastl H., 2007, PSYCHOACOUSTICS FACT, V3rd; Feldman DE, 2009, ANNU REV NEUROSCI, V32, P33, DOI 10.1146/annurev.neuro.051508.135516; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; GOEBEL G, 1994, HNO, V42, P166; Hardt J, 2000, EUR J PAIN-LONDON, V4, P137, DOI 10.1053/eujp.2000.0162; Heller AJ, 2003, OTOLARYNG CLIN N AM, V36, P239, DOI 10.1016/S0030-6665(02)00160-3; Henry J A, 2000, J Am Acad Audiol, V11, P138; Jaaskelainen IP, 2007, TRENDS NEUROSCI, V30, P653, DOI 10.1016/j.tins.2007.09.003; JASTREBOFF PJ, 1990, NEUROSCI RES, V8, P221, DOI 10.1016/0168-0102(90)90031-9; Kim DK, 2011, J LARYNGOL OTOL, V125, P246, DOI 10.1017/S0022215110002380; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; Langguth B, 2009, EXPERT OPIN EMERG DR, V14, P687, DOI 10.1517/14728210903206975; Lefaucheur JP, 2009, NEUROPHYSIOL CLIN, V39, P1, DOI 10.1016/j.neucli.2008.11.001; Lugli Marco, 2009, Int Tinnitus J, V15, P51; Moller AR., 2010, TXB TINNITUS; Moore BCJ, 2010, HEARING RES, V261, P51, DOI 10.1016/j.heares.2010.01.003; Muhlnickel W, 1998, P NATL ACAD SCI USA, V95, P10340, DOI 10.1073/pnas.95.17.10340; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Norena AJ, 2011, NEUROSCI BIOBEHAV R, V35, P1089, DOI 10.1016/j.neubiorev.2010.11.003; Okamoto H, 2010, J COGN NEUROSCI; Okamoto H, 2010, P NATL ACAD SCI USA, V107, P1207, DOI 10.1073/pnas.0911268107; Oswald AMM, 2006, CURR OPIN NEUROBIOL, V16, P371, DOI 10.1016/j.conb.2006.06.015; Pan T, 2009, INT J AUDIOL, V48, P277, DOI 10.1080/14992020802581974; Pantev C, 1999, BRAIN RES, V842, P192, DOI 10.1016/S0006-8993(99)01835-1; Petkov CI, 2004, NAT NEUROSCI, V7, P658, DOI 10.1038/nn1256; Rauschecker JP, 2010, NEURON, V66, P819, DOI 10.1016/j.neuron.2010.04.032; Roberts LE, 2010, J NEUROSCI, V30, P14972, DOI 10.1523/JNEUROSCI.4028-10.2010; Stracke Henning, 2010, Commun Integr Biol, V3, P274; TESCHE CD, 1995, ELECTROEN CLIN NEURO, V95, P189, DOI 10.1016/0013-4694(95)00064-6; Zito K, 2002, NEURON, V35, P1015, DOI 10.1016/S0896-6273(02)00903-0	41	39	43	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24685	10.1371/journal.pone.0024685	http://dx.doi.org/10.1371/journal.pone.0024685			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822JR	21935438	Green Published, gold, Green Submitted			2023-01-03	WOS:000295041700049
J	Ncaca, LN; Kranzer, K; Orrell, C				Ncaca, Lisa-Noelle; Kranzer, Katharina; Orrell, Catherine			Treatment Interruption and Variation in Tablet Taking Behaviour Result in Viral Failure: A Case-Control Study from Cape Town, South Africa	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS; HIV-INFECTION; ADHERENCE; DISCONTINUATION; RESISTANCE; COHORT; SUPPRESSION; OUTCOMES; IMPACT	Background: Understanding of the impact of non-structured treatment interruption (TI) and variation in tablet-taking on failure of first-line antiretroviral therapy (ART) is limited in a resource-poor setting. Methods: A retrospective matched case-control analysis. Individuals failing ART were matched by time on ART with 4 controls. Viral load (VL) and CD4 count were completed 4-monthly. Adherence percentages, from tablet returns, were calculated 4-monthly (interval) and from ART start (cumulative). Variation between intervals and TI (>27 days off ART) were recorded. Conditional multivariate logistic regression analysis was performed to estimate the effect of cumulative adherence <90%, at least one episode of adherence variation >10% and TI on virological failure. Age, gender, baseline log VL and CD4 were included as possible confounders in the multivariate model. Results: 244 patients (44 cases, 200 controls) were included. Median age was 32 years (IQR28-37), baseline CD4 108 cells/mm3 (IQR56-151), VL 4.82 log (IQR4.48-5.23). 94% (96% controls, 86% failures) had cumulative adherence >90%. The odds of failure increased 3 times (aOR 3.01, 95% CI 0.81-11.21) in individuals with cumulative adherence <90%, 2.2 times (aOR 2.20, 95% CI 1.04-4.64) in individuals with at least one episode of fluctuating adherence of >10% and 4.01 times (aOR 4.01, 95% CI 1.45-11.10) in individuals with TIs. For individuals with TI and cumulative adherence >95%, the odds of failing were 5.65 (CI 1.40-22.85). Conclusion: It is well known that poor cumulative adherence increases risk of virological failure, but less well understood that TI and variations in tablet-taking also play a key role, despite otherwise excellent adherence.	[Ncaca, Lisa-Noelle; Kranzer, Katharina; Orrell, Catherine] Univ Cape Town, Desmond Tutu HIV Fdn, ZA-7925 Cape Town, South Africa; [Kranzer, Katharina] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England	University of Cape Town; University of London; London School of Hygiene & Tropical Medicine	Ncaca, LN (corresponding author), Univ Cape Town, Desmond Tutu HIV Fdn, ZA-7925 Cape Town, South Africa.	catherine.orrell@hiv-reseaarch.org.za	Kranzer, Katharina/O-8845-2014; Orrell, Catherine/AAF-3405-2019	Kranzer, Katharina/0000-0001-5691-7270; Orrell, Catherine/0000-0003-1134-7475	USAID; Welltrust Trust	USAID(United States Agency for International Development (USAID)); Welltrust Trust	Lisa-Noelle Ncaca and Catherine Orrell receive funding through the USAID funded Anova Program. Katharina Kranzer receives funding through the Welltrust Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson J, 2008, AIDS, V22, P349, DOI 10.1097/QAD.0b013e3282f4709a; Bangsberg DR, 2006, CLIN INFECT DIS, V43, P939, DOI 10.1086/507526; Berg KM, 2006, JAIDS-J ACQ IMM DEF, V43, pS79, DOI 10.1097/01.qai.0000248337.97814.66; Bisson GP, 2008, JAIDS-J ACQ IMM DEF, V49, P107, DOI 10.1097/QAI.0b013e3181820141; DARMINIO MA, 2005, J ACQ IMMUN DEF SYND, V38, P407; Datay MI, 2010, JAIDS-J ACQ IMM DEF, V54, P489, DOI 10.1097/QAI.0b013e3181d91788; *DEP HLTH, 2010, STAT SO AFR MID POP; Hirschel B, 2009, AIDS, V23, P757, DOI 10.1097/QAD.0b013e328321b791; Kiguba R, 2007, JAIDS-J ACQ IMM DEF, V45, P218, DOI 10.1097/QAI.0b013e31805d8ae3; Knobel H, 2009, HIV MED, V10, P364, DOI 10.1111/j.1468-1293.2009.00696.x; Kranzer K, 2010, JAIDS-J ACQ IMM DEF, V55, pE17, DOI 10.1097/QAI.0b013e3181f275fd; Li XH, 2005, JAIDS-J ACQ IMM DEF, V38, P320; Liu HH, 2001, ANN INTERN MED, V134, P968, DOI 10.7326/0003-4819-134-10-200105150-00011; Maggiolo F, 2005, CLIN INFECT DIS, V40, P158, DOI 10.1086/426595; Maggiolo F, 2007, HIV CLIN TRIALS, V8, P282, DOI 10.1310/hct0805-282; Nachega Jean B., 2011, Infectious Disorders - Drug Targets, V11, P167; National Department of Health, 2004, S AFR NAT ANT TREAT; Olsen CH, 2007, HIV MED, V8, P96, DOI 10.1111/j.1468-1293.2007.00436.x; Orrell C, 2007, ANTIVIR THER, V12, P83; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Parienti JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002783; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pogany K, 2007, JAIDS-J ACQ IMM DEF, V44, P395, DOI 10.1097/QAI.0b013e31802f83bc; Taffe P, 2002, AIDS, V16, P747, DOI 10.1097/00002030-200203290-00010; Touloumi G, 2006, JAIDS-J ACQ IMM DEF, V42, P554, DOI 10.1097/01.qai.0000230321.85911.db; Walker AS, 2008, AIDS, V22, P237, DOI 10.1097/QAD.0b013e3282f2d760	26	13	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2011	6	8							e23088	10.1371/journal.pone.0023088	http://dx.doi.org/10.1371/journal.pone.0023088			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806AM	21858001	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000293773300019
J	Liang, H; Baudouin, C; Labbe, A; Riancho, L; Brignole-Baudouin, F				Liang, Hong; Baudouin, Christophe; Labbe, Antoine; Riancho, Luisa; Brignole-Baudouin, Francoise			Conjunctiva-Associated Lymphoid Tissue (CALT) Reactions to Antiglaucoma Prostaglandins with or without BAK-Preservative in Rabbit Acute Toxicity Study	PLOS ONE			English	Article							VIVO CONFOCAL MICROSCOPY; IN-VIVO; OCULAR SURFACE; BENZALKONIUM CHLORIDE; INFLAMMATORY MARKERS; FREE TAFLUPROST; LATANOPROST; TRAVOPROST; BIMATOPROST; EXPRESSION	Conjunctiva-associated lymphoid tissue (CALT) is closely associated with ocular surface immunity. This study investigated the effects of antiglaucoma prostaglandin analogs with or without benzalkonium chloride (BAK) preservative on organized CALT using an acute toxic model. A total of 48 albino rabbits were used and seven groups of treatments were constituted. Solutions (50 mu l) of PBS, 0.02% BAK, (0.02%BAK+)latanoprost, (0.015% BAK+)travoprost, (0.005%BAK+)bimatoprost, (BAK-free)travoprost preserved with the SofZia (R) system or(BAK-free) tafluprost were instilled 15 times at 5-min intervals in both eyes. CALT changes were analyzed using in vivo confocal microscopy (IVCM), immunohistology in cryosections for detecting MUC-5AC+ mucocytes and CD45+ hematopoietic cells. Antiglaucoma eye drops stimulated inflammatory cell infiltration in the CALT, and seemed to be primarily related to the concentration of their BAK content. The CALT reaction after instillation of BAK-containing eye drops was characterized by inflammatory cell infiltration in the dome and intrafollicular layers and by cell circulation inside the lymph vessels. CD45 was strongly expressed in the CALT after instillation of all BAK-containing solutions at 4 h and decreased at 24 h. The number of MUC-5AC+ mucocytes around the CALT structure decreased dramatically after instillation of BAK-containing solutions. This study showed for the first time the in vivo aspect of rabbit CALT after toxic stimuli, confirming the concentration-dependent toxic effects of BAK. IVCM-CALT analysis could be a pertinent tool in the future for understanding the immunotoxicologic challenges in the ocular surface and would provide useful criteria for evaluating newly developed eye drops.	[Liang, Hong; Baudouin, Christophe; Labbe, Antoine; Riancho, Luisa; Brignole-Baudouin, Francoise] INSERM, U968, Paris, France; [Liang, Hong; Baudouin, Christophe; Labbe, Antoine; Riancho, Luisa; Brignole-Baudouin, Francoise] Univ Paris 06, UPMC, UMR S 968, Inst Vis, Paris, France; [Liang, Hong; Baudouin, Christophe; Labbe, Antoine; Riancho, Luisa; Brignole-Baudouin, Francoise] CNRS, UMR 7210, Paris, France; [Liang, Hong; Baudouin, Christophe; Labbe, Antoine; Brignole-Baudouin, Francoise] INSERM, DHOS CIC 503, Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France; [Baudouin, Christophe; Brignole-Baudouin, Francoise] Hop Ambroise Pare, AP HP, Serv Ophtalmol, Boulogne, France; [Baudouin, Christophe; Labbe, Antoine] Univ Versailles St Quentin En Yvelines, Versailles, France; [Brignole-Baudouin, Francoise] Univ Paris 05, Fac Sci Pharmaceut & Biol, Toxicol Lab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHNO des Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Liang, H (corresponding author), INSERM, U968, Paris, France.	frbaudouin@aol.com	Liang, Hong/V-4518-2019	Liang, Hong/0000-0002-0579-8651; Labbe, Antoine/0000-0003-3057-3558; Baudouin, Christophe/0000-0003-1743-6698; BRIGNOLE-BAUDOUIN, FRANCOISE/0000-0002-2006-5384	INSERM, UMR_S968, Institut de la Vision	INSERM, UMR_S968, Institut de la Vision	This study was supported by unrestricted academic grants from INSERM, UMR_S968, Institut de la Vision. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alagoz G, 2008, OPHTHALMOLOGICA, V222, P161, DOI 10.1159/000126078; Banerjee S, 2003, BRIT J OPHTHALMOL, V87, P1515, DOI 10.1136/bjo.87.12.1515; Baudouin C, 2005, J ALLERGY CLIN IMMUN, V116, P614, DOI 10.1016/j.jaci.2005.05.033; Baudouin C, 2004, OPHTHALMOLOGY, V111, P2186, DOI 10.1016/j.ophtha.2004.06.023; Baudouin C, 2008, OPHTHALMOLOGY, V115, P109, DOI 10.1016/j.ophtha.2007.01.036; Baudouin C, 2007, INVEST OPHTH VIS SCI, V48, P4123, DOI 10.1167/iovs.07-0266; Baudouin C, 2010, PROG RETIN EYE RES, V29, P312, DOI 10.1016/j.preteyeres.2010.03.001; Brasnu E, 2008, CURR EYE RES, V33, P303, DOI 10.1080/02713680801971857; Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P2525; FRANKLIN RM, 1984, INVEST OPHTH VIS SCI, V25, P181; Gerberick GF, 2002, TOXICOL SCI, V68, P420, DOI 10.1093/toxsci/68.2.420; ICHIJIMA H, 1992, CORNEA, V11, P221; Jean MD, 1999, INVEST OPHTH VIS SCI, V40, P619; Knop E, 2005, OCUL SURF, V3, pS180; Knop N, 2005, J ANAT, V207, P409, DOI 10.1111/j.1469-7580.2005.00470.x; Knop N, 2010, DEV OPHTHALMOL, V45, P23, DOI 10.1159/000315017; Konstas AGP, 2005, OPHTHALMOLOGY, V112, P262, DOI 10.1016/j.ophtha.2004.08.022; Liang H, 2008, BRIT J OPHTHALMOL, V92, P1275, DOI 10.1136/bjo.2008.138768; Liang H, 2008, MOL VIS, V14, P204; Liang H, 2006, MOL VIS, V12, P1392; Liang H, 2010, INVEST OPHTH VIS SCI, V51, P1008, DOI 10.1167/iovs.09-3509; Liang H, 2009, MOL VIS, V15, P1690; Malvitte L, 2007, BRIT J OPHTHALMOL, V91, P29, DOI 10.1136/bjo.2006.101485; Martone G, 2009, AM J OPHTHALMOL, V147, P725, DOI 10.1016/j.ajo.2008.10.019; Patel DV, 2009, BRIT J OPHTHALMOL, V93, P853, DOI 10.1136/bjo.2008.150615; Pauly A, 2009, INVEST OPHTH VIS SCI, V50, P1644, DOI 10.1167/iovs.08-2992; Peebo BB, 2010, INVEST OPHTH VIS SCI, V51, P830, DOI 10.1167/iovs.09-4407; Seo KY, 2010, J IMMUNOL, V185, P3610, DOI 10.4049/jimmunol.1000680; Steven P, 2008, INVEST OPHTH VIS SCI, V49, P1512, DOI 10.1167/iovs.07-0809; Uter W, 2008, CONTACT DERMATITIS, V58, P359, DOI 10.1111/j.1600-0536.2008.01327.x; WILLIS CM, 1990, J INVEST DERMATOL, V95, P711, DOI 10.1111/1523-1747.ep12514510	31	26	28	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2012	7	3							e33913	10.1371/journal.pone.0033913	http://dx.doi.org/10.1371/journal.pone.0033913			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	939TA	22442734	Green Submitted, Green Published, gold			2023-01-03	WOS:000303836500075
J	Kwon, S; Kim, D; Park, BK; Cho, S; Kim, KD; Kim, YE; Park, CS; Ahn, HJ; Seo, JN; Choi, KC; Kim, DS; Lee, Y; Kwon, HJ				Kwon, Sanghoon; Kim, Dongbum; Park, Byoung Kwon; Cho, Sunhee; Kim, Kwang Dong; Kim, Young-Eun; Park, Cheung-Seog; Ahn, Hyun-Jong; Seo, Jae-Nam; Choi, Kyung-Chan; Kim, Doo-Sik; Lee, Younghee; Kwon, Hyung-Joo			Prevention and Therapy of Hepatocellular Carcinoma by Vaccination with TM4SF5 Epitope-CpG-DNA-Liposome Complex without Carriers	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; GENE-TRANSCRIPTION; DELIVERY-SYSTEMS; IMMUNE-RESPONSE; DENDRITIC CELLS; INNATE IMMUNITY; BACTERIAL-DNA; IN-VIVO; OLIGODEOXYNUCLEOTIDES; PEPTIDE	Although peptide vaccines have been actively studied in various animal models, their efficacy in treatment is limited. To improve the efficacy of peptide vaccines, we previously formulated an efficacious peptide vaccine without carriers using the natural phosphodiester bond CpG-DNA and a special liposome complex (Lipoplex(O)). Here, we show that immunization of mice with a complex consisting of peptide and Lipoplex(O) without carriers significantly induces peptide-specific IgG2a production in a CD4(+) cells-and Th1 differentiation-dependent manner. The transmembrane 4 superfamily member 5 protein (TM4SF5) has gained attention as a target for hepatocellular carcinoma (HCC) therapy because it induces uncontrolled growth of human HCC cells via the loss of contact inhibition. Monoclonal antibodies specific to an epitope of human TM4SF5 (hTM4SF5R2-3) can recognize native mouse TM4SF5 and induce functional effects on mouse cancer cells. Pre-immunization with a complex of the hTM4SF5R2-3 epitope and Lipoplex(O) had prophylactic effects against tumor formation by HCC cells implanted in an mouse tumor model. Furthermore, therapeutic effects were revealed regarding the growth of HCC when the vaccine was injected into mice after tumor formation. These results suggest that our improved peptide vaccine technology provides a novel prophylaxis measure as well as therapy for HCC patients with TM4SF5-positive tumors.	[Kwon, Sanghoon; Kim, Dongbum; Park, Byoung Kwon; Cho, Sunhee; Kwon, Hyung-Joo] Hallym Univ, Coll Med, Dept Microbiol, Gangwon Do, South Korea; [Kim, Kwang Dong] Gyeongsang Natl Univ, PMBBRC, Div Appl Life Sci, Program BK21, Jinju, South Korea; [Kim, Young-Eun; Lee, Younghee] Chungbuk Natl Univ, Coll Nat Sci, Dept Biochem, Chungbuk, South Korea; [Park, Cheung-Seog; Ahn, Hyun-Jong] Kyung Hee Univ, Coll Med, Dept Microbiol, Seoul, South Korea; [Seo, Jae-Nam; Choi, Kyung-Chan] Hallym Univ, Coll Med, Dept Pathol, Gangwon Do, South Korea; [Kim, Doo-Sik] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Seoul 120749, South Korea; [Kwon, Hyung-Joo] Hallym Univ, Coll Med, Ctr Med Sci Res, Gangwon Do, South Korea	Hallym University; Gyeongsang National University; Chungbuk National University; Kyung Hee University; Hallym University; Yonsei University; Hallym University	Kwon, S (corresponding author), Hallym Univ, Coll Med, Dept Microbiol, Gangwon Do, South Korea.	yhl4177@cbnu.ac.kr; hjookwon@hallym.ac.kr			Stem Cell Research Center [SC2260]; National Research Foundation [20090081761, 20090083296, 2009-0093812]; Ministry of Education, Science and Technology in the Republic of Korea	Stem Cell Research Center; National Research Foundation; Ministry of Education, Science and Technology in the Republic of Korea(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by a grant (SC2260) from the Stem Cell Research Center of the 21st Century Frontier Research Program, and grants from the National Research Foundation (20090081761, 20090083296, 2009-0093812) funded by the Ministry of Education, Science and Technology in the Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albiger B, 2007, CELL MICROBIOL, V9, P633, DOI 10.1111/j.1462-5822.2006.00814.x; ALLEY MC, 1988, CANCER RES, V48, P589; Ben-Yedidia T, 1999, INT IMMUNOL, V11, P1043, DOI 10.1093/intimm/11.7.1043; Ben-Yedidia T, 2007, EXPERT REV VACCINES, V6, P939, DOI 10.1586/14760584.6.6.939; BenYedidia T, 1997, CURR OPIN BIOTECH, V8, P442, DOI 10.1016/S0958-1669(97)80066-3; Bhan U, 2007, J IMMUNOL, V179, P3937, DOI 10.4049/jimmunol.179.6.3937; Bhowmick S, 2010, J CONTROL RELEASE, V141, P199, DOI 10.1016/j.jconrel.2009.09.018; Bijker MS, 2007, EXPERT REV VACCINES, V6, P591, DOI 10.1586/14760584.6.4.591; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]; Cai GF, 2000, J IMMUNOL, V165, P2619, DOI 10.4049/jimmunol.165.5.2619; Carson DA, 1997, J EXP MED, V186, P1621, DOI 10.1084/jem.186.10.1621; Chang JS, 2001, VACCINE, V19, P3608, DOI 10.1016/S0264-410X(01)00104-9; Chikh G, 2002, BIOSCIENCE REP, V22, P339, DOI 10.1023/A:1020151025412; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Davis HL, 1998, J IMMUNOL, V160, P870; Deng GM, 1999, NAT MED, V5, P702, DOI 10.1038/9554; Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Gregoriadis G, 1996, J DRUG TARGET, V3, P469, DOI 10.3109/10611869609015966; Gursel I, 2001, J IMMUNOL, V167, P3324, DOI 10.4049/jimmunol.167.6.3324; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Henriksen-Lacey M, 2011, EXPERT OPIN DRUG DEL, V8, P505, DOI 10.1517/17425247.2011.558081; JIN FS, 1991, J IMMUNOL, V146, P1806; Kim D, 2011, BMB REP, V44, P607, DOI 10.5483/BMBRep.2011.44.9.607; Kim D, 2011, BMC IMMUNOL, V12, DOI 10.1186/1471-2172-12-29; Kim D, 2009, BIOCHEM BIOPH RES CO, V379, P362, DOI 10.1016/j.bbrc.2008.12.063; Kim H, 2012, CANCER LETT, V314, P198, DOI 10.1016/j.canlet.2011.09.030; Klinman DM, 2004, IMMUNOL REV, V199, P201, DOI 10.1111/j.0105-2896.2004.00148.x; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 1998, J IMMUNOL, V161, P2428; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Lee KW, 2006, MOL IMMUNOL, V43, P2107, DOI 10.1016/j.molimm.2005.12.004; Lee KW, 2004, MOL IMMUNOL, V41, P955, DOI 10.1016/j.molimm.2004.06.022; Lee SA, 2008, J CLIN INVEST, V118, P1354, DOI 10.1172/JCI33768; Lee SA, 2011, FRONT BIOSCI-LANDMRK, V16, P1752, DOI 10.2741/3818; Lee SA, 2009, HEPATOLOGY, V49, P1316, DOI 10.1002/hep.22777; Lekishvili T, 2008, J CELL SCI, V121, P685, DOI 10.1242/jcs.020347; Li WM, 2003, VACCINE, V21, P3319, DOI 10.1016/S0264-410X(03)00172-5; Linehan LA, 1998, J IMMUNOL, V161, P302; Lipford GB, 2000, J IMMUNOL, V165, P1228, DOI 10.4049/jimmunol.165.3.1228; Matsukawa A, 2001, J EXP MED, V193, P679, DOI 10.1084/jem.193.6.679; Mbow ML, 2010, CURR OPIN IMMUNOL, V22, P411, DOI 10.1016/j.coi.2010.04.004; Motomura Y, 2008, INT J ONCOL, V32, P985; Muller-Pillasch F, 1998, GENE, V208, P25, DOI 10.1016/S0378-1119(97)00633-1; Nakatsura T, 2003, BIOCHEM BIOPH RES CO, V306, P16, DOI 10.1016/S0006-291X(03)00908-2; Schreiber TH, 2010, SEMIN IMMUNOL, V22, P105, DOI 10.1016/j.smim.2010.02.001; Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Stamm LM, 1998, J IMMUNOL, V161, P6180; Suzuki Y, 2004, CANCER RES, V64, P8754, DOI 10.1158/0008-5472.CAN-04-1691; Walker PS, 1999, P NATL ACAD SCI USA, V96, P6970, DOI 10.1073/pnas.96.12.6970; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Yoshiji H, 1999, CANCER RES, V59, P4413; Yoshiji H, 2001, CLIN CANCER RES, V7, P1073; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	55	23	26	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2012	7	3							e33121	10.1371/journal.pone.0033121	http://dx.doi.org/10.1371/journal.pone.0033121			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920DF	22427965	Green Published, gold, Green Submitted			2023-01-03	WOS:000302381500095
J	Norgaard, M; Ehrenstein, V; Nielsen, RB; Bakketeig, LS; Sorensen, HT				Norgaard, Mette; Ehrenstein, Vera; Nielsen, Rikke Beck; Bakketeig, Leiv Sigmund; Sorensen, Henrik Toft			Maternal Use of Antibiotics, Hospitalisation for Infection during Pregnancy, and Risk of Childhood Epilepsy: A Population-Based Cohort Study	PLOS ONE			English	Article							PRENATAL EXPOSURE; BIRTH; SEIZURES; EPIDEMIOLOGY; SEASONALITY; REGISTER; SYSTEM	Background: Maternal infection during pregnancy may be a risk factor for epilepsy in offspring. Use of antibiotics is a valid marker of infection. Methodology/Principal Findings: To examine the relationship between maternal infection during pregnancy and risk of childhood epilepsy we conducted a historical cohort study of singletons born in northern Denmark from 1998 through 2008 who survived >= 29 days. We used population-based medical databases to ascertain maternal use of antibiotics or hospital contacts with infection during pregnancy, as well as first-time hospital contacts with a diagnosis of epilepsy among offspring. We compared incidence rates (IR) of epilepsy among children of mothers with and without infection during pregnancy. We examined the outcome according to trimester of exposure, type of antibiotic, and total number of prescriptions, using Poisson regression to estimate incidence rate ratios (IRRs) while adjusting for covariates. Among 191 383 children in the cohort, 948 (0.5%) were hospitalised or had an outpatient visit for epilepsy during follow-up, yielding an IR of 91 per 100 000 person-years (PY). The five-year cumulative incidence of epilepsy was 4.5 per 1000 children. Among children exposed prenatally to maternal infection, the IR was 117 per 100 000 PY, with an adjusted IRR of 1.40 (95% confidence interval (CI): 1.22-1.61), compared with unexposed children. The association was unaffected by trimester of exposure, antibiotic type, or prescription count. Conclusions/Significance: Prenatal exposure to maternal infection is associated with an increased risk of epilepsy in childhood. The similarity of estimates across types of antibiotics suggests that processes common to all infections underlie this outcome, rather than specific pathogens or drugs.	[Norgaard, Mette; Ehrenstein, Vera; Nielsen, Rikke Beck; Sorensen, Henrik Toft] Aarhus Univ Hosp, Inst Clin Med, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark; [Bakketeig, Leiv Sigmund] Norwegian Inst Publ Hlth, Nydalen, Norway	Aarhus University; Norwegian Institute of Public Health (NIPH)	Norgaard, M (corresponding author), Aarhus Univ Hosp, Inst Clin Med, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark.	mn@dce.au.dk	Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Norgaard, Mette/0000-0001-6110-5891; Ehrenstein, Vera/0000-0002-3415-3254	Department of Clinical Epidemiology, Aarhus University Hospital, Denmark	Department of Clinical Epidemiology, Aarhus University Hospital, Denmark	The study was funded by a Research Grant from the Department of Clinical Epidemiology, Aarhus University Hospital, Denmark. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Andersen TF, 1999, DAN MED BULL, V46, P263; Arts WFM, 2009, EUR J PAEDIATR NEURO, V13, P93, DOI 10.1016/j.ejpn.2008.02.010; Balslev Thomas, 2004, Ugeskr Laeger, V166, P3932; Browne TR, 2001, NEW ENGL J MED, V344, P1145, DOI 10.1056/NEJM200104123441507; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; Christensen J, 2007, EPILEPSY RES, V75, P162, DOI 10.1016/j.eplepsyres.2007.05.009; Cowan LD, 2002, MENT RETARD DEV D R, V8, P171, DOI 10.1002/mrdd.10035; Crider KS, 2009, ARCH PEDIAT ADOL MED, V163, P978, DOI 10.1001/archpediatrics.2009.188; Ehrenstein V, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-23; Ehrenstein V, 2007, PEDIATRICS, V119, pE554, DOI 10.1542/peds.2006-1308; Ehrenstein Vera, 2010, Clin Epidemiol, V2, P273, DOI 10.2147/CLEP.S13458; Ekman GS, 2010, BRIT J SURG, V97, P1722, DOI 10.1002/bjs.7261; Fabene PF, 2010, J NEUROIMMUNOL, V224, P22, DOI 10.1016/j.jneuroim.2010.05.016; Frank L, 2000, SCIENCE, V287, P2398, DOI 10.1126/science.287.5462.2398; FRIIS H, 1989, SCAND J INFECT DIS, V21, P551, DOI 10.3109/00365548909037884; Glass HC, 2009, J PEDIATR-US, V154, P24, DOI 10.1016/j.jpeds.2008.07.008; Greenwood R, 1998, PAEDIATR PERINAT EP, V12, P76, DOI 10.1046/j.1365-3016.1998.0120s1076.x; Guerrini R, 2006, LANCET, V367, P499, DOI 10.1016/S0140-6736(06)68182-8; HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x; Jurek AM, 2005, INT J EPIDEMIOL, V34, P680, DOI 10.1093/ije/dyi060; Kannoth S, 2009, EPILEPSY BEHAV, V16, P58, DOI 10.1016/j.yebeh.2009.07.019; Knudsen LB, 1998, DAN MED BULL, V45, P320; Koepsell TD, 2003, EPIDEMIOLOGIC METHOD, Vix; Lieberman E, 2000, PEDIATRICS, V106, P983, DOI 10.1542/peds.106.5.983; Nuutinen M, 1989, Arctic Med Res, V48, P175; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Pedersen CB, 2006, DAN MED BULL, V53, P441; Procopio M, 2006, SEIZURE-EUR J EPILEP, V15, P17, DOI 10.1016/j.seizure.2005.10.001; Procopio M, 1998, ACTA NEUROL SCAND, V98, P297; Sen Wu C, 2008, PEDIATRICS, V122, P1072, DOI 10.1542/peds.2007-3666; Sun YL, 2006, EPIDEMIOLOGY, V17, P296, DOI 10.1097/01.ede.0000208478.47401.b6; Sun Y, 2008, PEDIATRICS, V121, pE1100, DOI 10.1542/peds.2007-2316; Sun Y, 2008, AM J EPIDEMIOL, V167, P262, DOI 10.1093/aje/kwm316; Sun YL, 2011, PAEDIATR PERINAT EP, V25, P53, DOI 10.1111/j.1365-3016.2010.01143.x; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Whitehead E, 2006, PEDIATRICS, V117, P1298, DOI 10.1542/peds.2005-1660	37	23	24	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2012	7	1							e30850	10.1371/journal.pone.0030850	http://dx.doi.org/10.1371/journal.pone.0030850			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910ME	22295115	Green Submitted, Green Published, gold			2023-01-03	WOS:000301640600060
J	Wu, HY; Hung, KY; Huang, TM; Hu, FC; Peng, YS; Huang, JW; Lin, SL; Chen, YM; Chu, TS; Tsai, TJ; Wu, KD				Wu, Hon-Yen; Hung, Kuan-Yu; Huang, Tao-Min; Hu, Fu-Chang; Peng, Yu-Sen; Huang, Jenq-Wen; Lin, Shuei-Liong; Chen, Yung-Ming; Chu, Tzong-Shinn; Tsai, Tun-Jun; Wu, Kwan-Dun			Safety Issues of Long-Term Glucose Load in Patients on Peritoneal Dialysis-A 7-Year Cohort Study	PLOS ONE			English	Article							STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; SURVIVAL; THERAPY; RISK	Background: Effects of long-term glucose load on peritoneal dialysis (PD) patient safety and outcomes have seldom been reported. This study demonstrates the influence of long-term glucose load on patient and technique survival. Methods: We surveyed 173 incident PD patients. Long-term glucose load was evaluated by calculating the average dialysate glucose concentration since initiation of PD. Risk factors were assessed by fitting Cox's models with repeatedly measured time-dependent covariates. Results: We noted that older age, higher glucose concentration, and lower residual renal function (RRF) were significantly associated with a worse patient survival. We found that female gender, absence of diabetes, lower glucose concentration, use of icodextrin, higher serum high density lipoprotein cholesterol, and higher RRF were significantly associated with a better technique survival. Conclusions: Long-term glucose load predicted mortality and technique failure in chronic PD patients. These findings emphasize the importance of minimizing glucose load in PD patients.	[Wu, Hon-Yen; Peng, Yu-Sen] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan; [Wu, Hon-Yen; Hung, Kuan-Yu; Huang, Tao-Min; Peng, Yu-Sen; Huang, Jenq-Wen; Lin, Shuei-Liong; Chen, Yung-Ming; Chu, Tzong-Shinn; Tsai, Tun-Jun; Wu, Kwan-Dun] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Hung, Kuan-Yu] Natl Taiwan Univ Hosp, Ctr Qual Management, Taipei, Taiwan; [Hu, Fu-Chang] Natl Taiwan Univ Hosp, Natl Ctr Excellence Gen Clin Trial & Res, Taipei, Taiwan; [Wu, Hon-Yen; Huang, Tao-Min; Chen, Yung-Ming] Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Yunlin, Taiwan; [Hu, Fu-Chang] Int Harvard Stat Consulting Co, Taipei, Taiwan	Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Wu, HY (corresponding author), Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan.	kyhung@ntu.edu.tw; 007378@ntuh.gov.tw	Lin, Shuei-Liong/AGR-2002-2022; peng, yu/GXW-2071-2022; Huang, Tao Min/C-5379-2011	Lin, Shuei-Liong/0000-0002-1041-5571; Huang, Tao Min/0000-0002-9387-0798; HUANG, JENQ-WEN/0000-0001-8011-2317; CHEN, YUNG-MING/0000-0002-9241-1258; CHU, TZONG-SHINN/0000-0002-5291-2509; WU, KWAN-DUN/0000-0002-3339-1509; TSAI, TUN-JUN/0000-0002-1666-8940; HUNG, KUAN-YU/0000-0003-3472-5512	National Science Council of Taiwan [NSC-95-2314-B-002-238-MY2]; Ta-Tung Kidney Foundation; Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan); Yun-Lin Branch, National Taiwan University Hospital, Yun-Lin, Taiwan [NTUHYL.97.S007, NTUHYL.98.S010]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Ta-Tung Kidney Foundation; Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan); Yun-Lin Branch, National Taiwan University Hospital, Yun-Lin, Taiwan	This work was supported by grants from the National Science Council of Taiwan (to Kuan-Yu Hung; NSC-95-2314-B-002-238-MY2), the Ta-Tung Kidney Foundation, and the Mrs. Hsiu-Chin Lee Kidney Research Foundation (Taipei, Taiwan), and grants from the Yun-Lin Branch, National Taiwan University Hospital (to Hon-Yen Wu; NTUHYL.97.S007 and NTUHYL.98.S010, Yun-Lin, Taiwan). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi Y, 2006, PERITON DIALYSIS INT, V26, P405; Bergstrom J, 1998, PERITON DIALYSIS INT, V18, P467; Chaudhary K, 2008, PERITON DIALYSIS INT, V28, P113; Davies SJ, 2005, KIDNEY INT, V67, P1609, DOI 10.1111/j.1523-1755.2005.00243.x; Davies SJ, 2001, J AM SOC NEPHROL, V12, P1046, DOI 10.1681/ASN.V1251046; GRODSTEIN GP, 1981, KIDNEY INT, V19, P564, DOI 10.1038/ki.1981.53; Ho-dac-Pannekeet MM, 2006, NEPHROL DIAL TRANSPL, V21, pii60; Holmes C, 2006, KIDNEY INT, V70, pS104, DOI 10.1038/sj.ki.5001924; Laird NM, 1983, KIDNEY INT S, pS101; Li PKT, 2009, PERITON DIALYSIS INT, V29, pS149; Liu J, 2006, SEMIN DIALYSIS, V19, P32, DOI 10.1111/j.1525-139X.2006.00117.x; Lo WK, 2005, KIDNEY INT, V67, P2032, DOI 10.1111/j.1523-1755.2005.00305.x; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Peng YS, 2007, NEPHROL DIAL TRANSPL, V22, P857, DOI 10.1093/ndt/gfl666; *PER DIAL AD WORK, 2006, AM J KIDNEY DIS S, V48, pS98; TWARDOWSKI ZJ, 1987, PERITON DIALYSIS INT, V7, P138; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Wu HY, 2008, AM J NEPHROL, V28, P765, DOI 10.1159/000128608; Wu HY, 2010, PERITON DIALYSIS INT, V30, P448, DOI 10.3747/pdi.2009.00063	19	31	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2012	7	1							e30337	10.1371/journal.pone.0030337	http://dx.doi.org/10.1371/journal.pone.0030337			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909NE	22303440	Green Published, gold, Green Submitted			2023-01-03	WOS:000301570600033
J	Yu, CR; Lee, YS; Mahdi, RM; Surendran, N; Egwuagu, CE				Yu, Cheng-Rong; Lee, Yun Sang; Mahdi, Rashid M.; Surendran, Narayanan; Egwuagu, Charles E.			Therapeutic Targeting of STAT3 (Signal Transducers and Activators of Transcription 3) Pathway Inhibits Experimental Autoimmune Uveitis	PLOS ONE			English	Article							BLOOD-BRAIN-BARRIER; T(H)17 CELL-DIFFERENTIATION; CENTRAL-NERVOUS-SYSTEM; T-CELLS; MULTIPLE-SCLEROSIS; IN-VIVO; ENCEPHALOMYELITIS; ADHESION; DISEASE; UVEORETINITIS	Mice with targeted deletion of STAT3 in CD4(+) T-cells do not develop experimental autoimmune uveitis (EAU) or experimental autoimmune encephalomyelitis (EAE), in part, because they cannot generate pathogenic Th17 cells. In this study, we have used ORLL-NIH001, a small synthetic compound that inhibits transcriptional activity of STAT3, to ameliorate EAU, an animal model of human posterior uveitis. We show that by attenuating inflammatory properties of uveitogenic lymphocytes, ORLL-NIH001 inhibited the recruitment of inflammatory cells into the retina during EAU and prevented the massive destruction of the neuroretina caused by pro-inflammatory cytokines produced by the autoreactive lymphocytes. Decrease in disease severity observed in ORLL-NIH001-treated mice, correlated with the down-regulation of alpha 4 beta 1 and alpha 4 beta 7 integrin activation and marked reduction of CCR6 and CXCR3 expression, providing a mechanism by which ORLL-NIH001 mitigated EAU. Furthermore, we show that ORLL-NIH001 inhibited the expansion of human Th17 cells, underscoring its potential as a drug for the treatment of human uveitis. Two synthetic molecules that target the Th17 lineage transcription factors, ROR gamma t and ROR alpha, have recently been suggested as potential drugs for inhibiting Th17 development and treating CNS inflammatory diseases. However, inhibiting STAT3 pathways completely blocks Th17 development, as well as, prevents trafficking of inflammatory cells into CNS tissues, making STAT3 a more attractive therapeutic target. Thus, use of ORLL-NIH001 to target the STAT3 transcription factor, thereby antagonizing Th17 expansion and expression of proteins that mediate T cell chemotaxis, provides an attractive new therapeutic approach for treatment of posterior uveitis and other CNS autoimmune diseases mediated by Th17 cells.	[Yu, Cheng-Rong; Lee, Yun Sang; Mahdi, Rashid M.; Egwuagu, Charles E.] NEI, Mol Immunol Sect, NIH, Bethesda, MD 20892 USA; [Surendran, Narayanan] Orchid Res Labs Ltd, Madras, Tamil Nadu, India	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Egwuagu, CE (corresponding author), NEI, Mol Immunol Sect, NIH, Bethesda, MD 20892 USA.	egwuaguc@nei.nih.gov		Yu, Cheng-Rong/0000-0001-7246-0362	National Eye Institute; National Institutes of Health;  [EY000350-11 DIR]; NATIONAL EYE INSTITUTE [ZIAEY000315, Z01EY000350, ZIAEY000350] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The National Eye Institute and National Institutes of Health Intramural Research Programs funded this research. Funding was for the study entitled "Development of Immunologic therapies against uveitis'' (Project # EY000350-11 DIR). This study was conducted as part of our service and duty as US government employees. The study design, data collection and analysis, decision to publish, or preparation of the manuscript were by individuals listed in this manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amadi-Obi A, 2007, NAT MED, V13, P711, DOI 10.1038/nm1585; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; CASPI RR, 1988, J IMMUNOL, V140, P1490; CHAN CC, 1990, J AUTOIMMUN, V3, P247, DOI 10.1016/0896-8411(90)90144-H; Coisne C, 2009, J IMMUNOL, V182, P5909, DOI 10.4049/jimmunol.0803418; Doring A, 2011, EUR J IMMUNOL, V41, P813, DOI 10.1002/eji.201040912; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Egwuagu CE, 2009, CYTOKINE, V47, P149, DOI 10.1016/j.cyto.2009.07.003; Engelhardt B, 1998, J CLIN INVEST, V102, P2096, DOI 10.1172/JCI4271; Engelhardt B, 2008, CURR PHARM DESIGN, V14, P1555, DOI 10.2174/138161208784705432; Forrester John V, 2007, Chem Immunol Allergy, V92, P228, DOI 10.1159/000099274; FORRESTER JV, 1992, CURR EYE RES, V11, P33, DOI 10.3109/02713689208999509; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; Huh JR, 2011, NATURE, V472, P486, DOI 10.1038/nature09978; Ivanov II, 2007, SEMIN IMMUNOL, V19, P409, DOI 10.1016/j.smim.2007.10.011; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jabs DA, 2000, AM J OPHTHALMOL, V130, P492, DOI 10.1016/S0002-9394(00)00659-0; Jain P, 2010, J IMMUNOL, V184, P7196, DOI 10.4049/jimmunol.0901404; Jetten AM, 2011, NATURE, V472, P421, DOI 10.1038/472421a; Kanwar JR, 2000, J NEUROIMMUNOL, V103, P146, DOI 10.1016/S0165-5728(99)00245-3; Kanwar JR, 2000, IMMUNOL CELL BIOL, V78, P641, DOI 10.1046/j.1440-1711.2000.00947.x; KORN T, 2009, ANN REV IMMUNOL; Krutzik PO, 2011, METHODS MOL BIOL, V699, P179, DOI 10.1007/978-1-61737-950-5_9; La Heij E, 1998, BRIT J OPHTHALMOL, V82, P432; Laschinger M, 2000, J NEUROIMMUNOL, V102, P32, DOI 10.1016/S0165-5728(99)00156-3; Lee YS, 2011, IMMUNOLOGY, V132, P492, DOI 10.1111/j.1365-2567.2010.03379.x; Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070; Luger D, 2008, J EXP MED; NUSSENBLATT RB, 1991, INVEST OPHTH VIS SCI, V32, P3131; NUSSENBLATT RB, 1990, INT OPHTHALMOL, V14, P303, DOI 10.1007/BF00163549; Shi GP, 2008, J IMMUNOL, V181, P7205, DOI 10.4049/jimmunol.181.10.7205; Shi GP, 2009, J IMMUNOL, V183, P7547, DOI 10.4049/jimmunol.0900519; Solt LA, 2011, NATURE, V472, P491, DOI 10.1038/nature10075; Steinman L, 2009, NAT REV IMMUNOL, V9, P440, DOI 10.1038/nri2548; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	38	36	37	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2012	7	1							e29742	10.1371/journal.pone.0029742	http://dx.doi.org/10.1371/journal.pone.0029742			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	058VE	22238646	Green Published, Green Submitted, gold			2023-01-03	WOS:000312662100033
J	de Boer, HJ; Vongsombath, C; Kafer, J				de Boer, Hugo J.; Vongsombath, Chanda; Kaefer, Jos			A Fly in the Ointment: Evaluation of Traditional Use of Plants to Repel and Kill Blowfly Larvae in Fermented Fish	PLOS ONE			English	Article							CHRYSOMYA-MEGACEPHALA; MUSCA-DOMESTICA; DIPTERA; CALLIPHORIDAE; FOODS	Introduction: In rural areas in Laos, fly larvae infestations are common in fermenting fish. Blowflies (Chrysomya megacephala, Diptera: Calliphoridae) are attracted to oviposit (and/ or larviposit) onto fermenting fish which results in infestations with fly larvae. Knowledge of traditional use of plants to repel larvae during the production of fermented fish is common and widespread in Lao PDR. Research Questions: How effective are the most salient species in repelling, and killing fly larvae in fermenting fish? Material and Methods: The three plant species most frequently reported to repel fly larvae during an ethnobotanical survey throughout Lao PDR were tested for repellence and larvicidal activity of fly larvae infesting fermented fish. The lethality and repellence of Tadehagi triquetrum (L.) H. Ohashi (Fabaceae), Uraria crinita (L.) Desv. ex DC. (Fabaceae) and Bambusa multiplex (Lour.) Raeusch. ex Schult. & Schult. f. (Poaceae) were tested in an experimental design using fermenting fish in Vientiane, Lao PDR. Results: The repellent effect of fresh material of T. triquetrum and U. crinita, and the larvicidal effect of fresh B. multiplex, is significantly more effective than that of dried material of the same species, and the total effect (repellence and larvicidal effect combined) for each of the three species was significantly more effective for fresh than for dry material. Fresh material of T. triquetrum, U. crinita, or B. multiplex added on top of the fermenting fish repelled 50%, 54%, 37%, and killed 22%, 28%, and 40% of fly larvae. The total effect was not significantly different per species at 72%, 82%, and 77%, respectively. Discussion and Conclusions: The three most salient species are effective in repelling and killing fly larvae in the production of fermented fish, and may be essential to augment food safety during traditional fermentation in open jars.	[de Boer, Hugo J.; Vongsombath, Chanda] Uppsala Univ, Evolutionary Biol Ctr, Dept Systemat Biol, Uppsala, Sweden; [Vongsombath, Chanda] Natl Univ Laos, Fac Sci, Dept Biol, Viangchan, Laos; [Kaefer, Jos] Univ Lyon 1, CNRS, UMR5558, Lab Biometrie & Biol Evolut, F-69622 Villeurbanne, France	Uppsala University; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	de Boer, HJ (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Systemat Biol, Uppsala, Sweden.	chanda.vongsombath@ebc.uu.se	de Boer, Hugo/B-5640-2015; de Boer, Hugo Joris/AAS-7585-2020; Käfer, Jos/E-7714-2017; Käfer, Jos/AAR-1547-2021	de Boer, Hugo/0000-0003-1985-7859; de Boer, Hugo Joris/0000-0003-1985-7859; Käfer, Jos/0000-0002-0561-8008; Käfer, Jos/0000-0002-0561-8008	Sida-Swedish Agency of Research Cooperation; Developing Countries (SAREC) bilateral program; Lao PDR; Sida-SAREC [SWE-2005-338]; Helge Ax:son Johnsons Stiftelse; Regnells botaniska resestipendium; Smalands nation's Anna Maria Lundins stipendiefond	Sida-Swedish Agency of Research Cooperation; Developing Countries (SAREC) bilateral program; Lao PDR; Sida-SAREC; Helge Ax:son Johnsons Stiftelse; Regnells botaniska resestipendium; Smalands nation's Anna Maria Lundins stipendiefond	This work was supported by: Sida-Swedish Agency of Research Cooperation with Developing Countries (SAREC) bilateral program with Lao PDR (to C.V.); Sida-SAREC Grant SWE-2005-338, Helge Ax:son Johnsons Stiftelse; Regnells botaniska resestipendium, and Smalands nation's Anna Maria Lundins stipendiefond (to H.d.B.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burkill IH, 1930, GARDENS B STRAITS SE, V6, P165, DOI DOI 10.1093/BIOINFORMATICS/BTP348; Chuakul, 2002, THAI J PHARM, V9, P22; Cooke R. D., 1993, FISH FERMENTATION TE, P291; de Boer H, 2010, J MED ENTOMOL, V47, P400, DOI 10.1603/ME09273; De Jesus AJ, 2004, INT J FOOD MICROBIOL, V93, P259, DOI 10.1016/j.ijfoodmicro.2003.12.003; ESSER JR, 1991, B ENTOMOL RES, V81, P33, DOI 10.1017/S0007485300053219; Forster M, 2007, PARASITOL RES, V101, P243, DOI 10.1007/s00436-007-0522-y; GREENBERG B, 1970, Infection and Immunity, V2, P800; Hamid F, 2004, PHARM BIOL, V42, P114, DOI 10.1080/13880200490510892; Hamid H, 2007, PHARM BIOL, V45, P140, DOI 10.1080/13880200601113107; Hinna Hamid, 2006, Hamdard Medicus, V49, P31; Ishige N., 1993, FISH FERMENTATION TE, P13; Jones DA, 1998, PHYTOCHEMISTRY, V47, P155, DOI 10.1016/S0031-9422(97)00425-1; LAWSON JR, 1990, PARASITOLOGY, V100, P143, DOI 10.1017/S0031182000060224; Lee CH, 1997, FOOD CONTROL, V8, P259, DOI 10.1016/S0956-7135(97)00015-7; [李树荣 Li Shurong], 2003, [云南农业大学学报, Journal of Yunnan Agricultural University], V18, P170; LI SR, 2002, J YUNNAN AGR SCI TEC, V5, P38; Liu T., 1952, LIST EC PLANTS TAIWA; LWIN KS, 1968, UNION BURMA J LIFE S, V1, P166; Phithakpol B., 1993, FISH FERMENTATION TE, P155; Satya S, 2010, TRENDS FOOD SCI TECH, V21, P181, DOI 10.1016/j.tifs.2009.11.002; SUCHARIT S, 1998, MED ENTOMOLOGY, P408; Sukontason Kabkaew L., 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P38; Wells JD, 1999, J MED ENTOMOL, V36, P638, DOI 10.1093/jmedent/36.5.638; Xiang W, 2005, J AGR FOOD CHEM, V53, P267, DOI 10.1021/jf0483117; Yen GC, 2001, FOOD CHEM, V74, P471, DOI 10.1016/S0308-8146(01)00165-0; Zhang BC, 2016, J BASIC MICROB, V56, P670, DOI 10.1002/jobm.201500751	27	2	3	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e29521	10.1371/journal.pone.0029521	http://dx.doi.org/10.1371/journal.pone.0029521			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	870JO	22206019	gold, Green Published, Green Submitted			2023-01-03	WOS:000298665600041
J	Hu, J; Zhang, JH; Zhao, W; Zhang, YL; Zhang, L; Shang, HC				Hu, Jing; Zhang, Junhua; Zhao, Wei; Zhang, Yongling; Zhang, Li; Shang, Hongcai			Cochrane Systematic Reviews of Chinese Herbal Medicines: An Overview	PLOS ONE			English	Review							COMPLEMENTARY MEDICINE; QUALITY; METAANALYSES; METHODOLOGY	Objectives: Our study had two objectives: a) to systematically identify all existing systematic reviews of Chinese herbal medicines (CHM) published in Cochrane Library; b) to assess the methodological quality of included reviews. Methodology/Principal Findings: We performed a systematic search of the Cochrane Database of Systematic Reviews (CDSR, Issue 5, 2010) to identify all reviews of CHM. A total of fifty-eight reviews were eligible for our study. Twenty-one of the included reviews had at least one Traditional Chinese Medicine (TCM) practitioner as its co-author. 7 reviews didn't include any primary study, the remaining reviews (n = 51) included a median of 9 studies and 936 participants. 50% of reviews were last assessed as up-to-date prior to 2008. The questions addressed by 39 reviews were broad in scope, in which 9 reviews combined studies with different herbal medicines. For OQAQ, the mean of overall quality score (item 10) was 5.05 (95% CI; 4.58-5.52). All reviews assessed the methodological quality of primary studies, 16% of included primary studies used adequate sequence generation and 7% used adequate allocation concealment. Of the 51 nonempty reviews, 23 reviews were reported as being inconclusive, while 27 concluded that there might be benefit of CHM, which was limited by the poor quality or inadequate quantity of included studies. 58 reviews reported searching a median of seven electronic databases, while 10 reviews did not search any Chinese database. Conclusions: Now CDSR has included large numbers of CHM reviews, our study identified some areas which could be improved, such as almost half of included reviews did not have the participation of TCM practitioners and were not up-to-date according to Cochrane criteria, some reviews pooled the results of different herbal medicines and ignored the searching of Chinese databases.	[Hu, Jing; Zhang, Junhua; Zhao, Wei; Zhang, Yongling; Zhang, Li; Shang, Hongcai] Tianjin Univ Tradit Chinese Med, Res Inst Tradit Chinese Med, Tianjin, Peoples R China; [Hu, Jing] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China	Tianjin University of Traditional Chinese Medicine; Peking University	Shang, HC (corresponding author), Tianjin Univ Tradit Chinese Med, Res Inst Tradit Chinese Med, Tianjin, Peoples R China.	shanghongcai@foxmail.com	shang, hongcai/H-1257-2014	zhang, Junhua/0000-0003-4043-1967	National Significant Projects of New Drugs Creation [2008ZX09312-001]; program of New Century Excellent Talents in University [NCET-09-0900]	National Significant Projects of New Drugs Creation; program of New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This study was supported in part by the National Significant Projects of New Drugs Creation (No. 2008ZX09312-001) and the program of New Century Excellent Talents in University (NCET-09-0900). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADAMS D, 2009, COCHRANE DB SYST REV, V4; ARNOLD E, 2008, COCHRANE DB SYST REV, V4; BIRKS J, 2009, COCHRANE DB SYST REV, V2; Cao WZ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005568.pub2; Chan E, 2010, CURR OPIN DRUG DISC, V13, P50; CHEN J, 2009, COCHRANE DB SYST REV, V1; Chen X, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006305.pub2; CHEN XY, 2010, COCHRANE DB SYST REV, V2; Cui X, 2010, COCHRANE DB SYST REV, V1; Delaney A, 2007, CRIT CARE MED, V35, P589, DOI 10.1097/01.CCM.0000253394.15628.FD; DONG R, 2009, COCHRANE DB SYST REV, V1; DUAN X, 2009, COCHRANE DB SYST REV, V4; EVANS JR, 2009, COCHRANE DB SYST REV, V2; Ezzo J, 1998, JAMA-J AM MED ASSOC, V280, P1628, DOI 10.1001/jama.280.18.1628; Firenzuoli F, 2007, EVID-BASED COMPL ALT, V4, P37, DOI 10.1093/ecam/nem096; FLOWER A, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651868; GAGNIER JJ, 2010, COCHRANE DB SYST REV, V2; GAN T, 2010, COCHRANE DB SYST REV, V1; Grant SJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006690.pub2; GREEN S, 2008, COCHRANE HDB; GUO RL, 2009, COCHRANE DB SYST REV, V1; HILTON MP, 2010, COCHRANE DB SYST REV, V3; [胡丹 Hu Dan], 2010, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V10, P488; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; JING Z, 2009, COCHRANE DB SYST REV, V3; Li Q, 2009, COCHRANE DB SYST REV, V3; [李廷谦 LI Tingqian], 2007, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V7, P180; LI W, 2009, COCHRANE DB SYST REV, V3; LI WJ, 2010, COCHRANE DB SYST REV, V1; Liu Jian-ping, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P306; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU JP, 2009, COCHRANE DB SYST REV, V2; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU JP, 2008, COCHRANE DB SYST REV, V4; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU JP, 2009, COCHRANE DB SYST REV, V1; LIU XM, 2008, COCHRANE DB SYST REV, V4; Lui S, 2010, ACUPUNCT MED, V28, P149, DOI 10.1136/aim.2010.002444; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Moseley AM, 2009, J CLIN EPIDEMIOL, V62, P1021, DOI 10.1016/j.jclinepi.2008.09.018; Nicolai S. P. A., 2009, COCHRANE DB SYST REV, V2; OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B; [艾昌林 Ai Changlin], 2010, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V10, P749; RATHBONE J, 2008, COCHRANE DB SYST REV, V3; SHI YY, 2010, COCHRANE DB SYST REV, V2; TAN Y, 2009, COCHRANE DB SYST REV, V1; Tindle HA, 2005, ALTERN THER HEALTH M, V11, P42; UAN W, 2009, COCHRANE DB SYST REV, V3; Vickers A, 1999, BRIT MED J, V319, P1050, DOI 10.1136/bmj.319.7216.1050; WANG DF, 2009, COCHRANE DB SYST REV, V1; WANG Q, 2009, COCHRANE DB SYST REV, V3; WANG Q, 2009, COCHRANE DB SYST REV, V1; WEI JF, 2010, COCHRANE DB SYST REV, V2; WU B, 2008, COCHRANE DB SYST REV, V4; WU HM, 2009, COCHRANE DB SYST REV, V2; WU T, 2009, COCHRANE DB SYST REV, V2, P5382; WU TX, 2009, COCHRANE DB SYST REV, V1; WU TX, 2008, COCHRANE DB SYST REV, V4; WU TX, 2009, COCHRANE DB SYST REV, V1; Yang W, 2009, COCHRANE DB SYST REV, V2; YANG X, 2010, COCHRANE DB SYST REV, V1; Yuan Y, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005569.pub2; YUE JR, 2008, COCHRANE DB SYST REV, V3; ZENG XR, 2009, COCHRANE DB SYST REV, V1; ZENG XX, 2009, COCHRANE DB SYST REV, V1; Zhang JH, 2007, J ALTERN COMPLEM MED, V13, P797, DOI 10.1089/acm.2007.7195; ZHANG MM, 2009, COCHRANE DB SYST REV, V1; ZHANG WY, 2009, COCHRANE DB SYST REV, V4; ZHANG XG, 2010, COCHRANE DB SYST REV, V2; ZHENG YL, 2010, COCHRANE DB SYST REV, V2; ZHU ZS, 2009, COCHRANE DB SYST REV, V1; Zhuo Q., 2010, COCHRANE DB SYST REV, V5; ZHUO Q, 2008, COCHRANE DB SYST REV, V4; 商洪才, 2010, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V10, P640	76	43	45	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e28696	10.1371/journal.pone.0028696	http://dx.doi.org/10.1371/journal.pone.0028696			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866FK	22174870	gold, Green Published, Green Submitted			2023-01-03	WOS:000298365700062
J	Phua, J				Phua, Jason			Do You Still Feel It?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Univ Singapore Hosp, Dept Med, Div Resp & Crit Care Med, Singapore 117548, Singapore	National University of Singapore	Phua, J (corresponding author), Natl Univ Singapore Hosp, Dept Med, Div Resp & Crit Care Med, Singapore 117548, Singapore.	jason_phua@nuhs.edu.sg							0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2011	306	15					1632	1633		10.1001/jama.2011.1472	http://dx.doi.org/10.1001/jama.2011.1472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834MA	22009086				2023-01-03	WOS:000295963200001
J	Fabrichny, IP; Mondielli, G; Conrod, S; Martin-Eauclaire, MF; Bourne, Y; Marchot, P				Fabrichny, Igor P.; Mondielli, Gregoire; Conrod, Sandrine; Martin-Eauclaire, Marie-France; Bourne, Yves; Marchot, Pascale			Structural Insights into Antibody Sequestering and Neutralizing of Na+ Channel alpha-Type Modulator from Old World Scorpion Venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS-HECTOR; PROTEIN RECOGNITION SITES; TOXIN-II; MONOCLONAL-ANTIBODIES; SODIUM-CHANNELS; FUNCTIONAL-EVALUATION; STRUCTURE REFINEMENT; SECONDARY-STRUCTURE; CRYSTAL-STRUCTURES; AMM-VIII	The Old World scorpion Androctonus australis hector (Aah) produces one of the most lethal venoms for humans. Peptidic alpha-toxins AahI to AahIV are responsible for its potency, with AahII accounting for half of it. All four toxins are high affinity blockers of the fast inactivation phase of mammalian voltage-activated Na+ channels. However, the high antigenic polymorphism of alpha-toxins prevents production of a polyvalent neutralizing antiserum, whereas the determinants dictating their trapping by neutralizing antibodies remain elusive. From an anti-AahII mAb, we generated an antigen binding fragment (Fab) with high affinity and selectivity for AahII and solved a 2.3 angstrom-resolution crystal structure of the complex. Sequestering of the C-terminal region of the bound toxin within a groove formed by the Fab combining loops is associated with a toxin orientation and main and side chain conformations that dictate the AahII antigenic specificity and efficient neutralization. From an anti-AahI mAb, we also preformed and crystallized a high affinity AahI-Fab complex. The 1.6 angstrom-resolution structure solved revealed a Fab molecule devoid of a bound AahI and with combining loops involved in packing interactions, denoting expulsion of the bound antigen upon crystal formation. Comparative analysis of the groove-like combining site of the toxin-bound anti-AahII Fab and planar combining surface of the unbound anti-AahI Fab along with complementary data from a flexible docking approach suggests occurrence of distinctive trapping orientations for the two toxins relative to their respective Fab. This study provides complementary templates for designing new molecules aimed at capturing Aah alpha-toxins and suitable for immunotherapy.	[Bourne, Yves; Marchot, Pascale] Aix Marseille Univ, CNRS, UMR 7257, F-13288 Marseille 09, France; [Fabrichny, Igor P.; Mondielli, Gregoire; Conrod, Sandrine; Martin-Eauclaire, Marie-France; Marchot, Pascale] Aix Marseille Univ, CNRS, UMR 6231,CRN2M,CS80011, Inst Federatif Rech Jean Roche,Fac Med Secteur No, F-13344 Marseille 15, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Bourne, Y (corresponding author), Aix Marseille Univ, CNRS, UMR 7257, Campus Luminy Case 932, F-13288 Marseille 09, France.	fabri@ibcgenerium.ru; yves.bourne@afmb.univ-mrs.fr; pascale.marchot@univ-amu.fr	MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022	MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548; Mondielli, Gregoire/0000-0001-9608-7961	CNRS; Fondation pour la Recherche Medicale; Association Francaise contre les Myopathies; FRM	CNRS(Centre National de la Recherche Scientifique (CNRS)); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); FRM(Fondation pour la Recherche Medicale)	Recipients of postdoctoral grants from the CNRS and the Fondation pour la Recherche Medicale and Ph.D. grants from the Association Francaise contre les Myopathies and the FRM, respectively.	Alami M, 2003, BIOCHEM J, V375, P551, DOI 10.1042/BJ20030688; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Alvarenga L, 2010, VACCINE, V28, P970, DOI 10.1016/j.vaccine.2009.10.135; Aubrey N, 2004, TOXICON, V43, P233, DOI 10.1016/j.toxicon.2003.11.024; Aubrey N, 2003, CELL MOL LIFE SCI, V60, P617, DOI 10.1007/s000180300053; BAHRAOUI E, 1986, MOL IMMUNOL, V23, P357, DOI 10.1016/0161-5890(86)90133-1; BAHRAOUI E, 1988, J IMMUNOL, V141, P214; BAHRAOUI EM, 1986, J IMMUNOL, V136, P3371; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Ben Abderrazek R, 2011, PROTEIN ENG DES SEL, V24, P727, DOI 10.1093/protein/gzr037; Ben Abderrazek R, 2009, BIOCHEM J, V424, P263, DOI 10.1042/BJ20090697; Canul-Tec JC, 2011, J BIOL CHEM, V286, P20892, DOI 10.1074/jbc.M111.238410; Catterall WA, 2007, TOXICON, V49, P124, DOI 10.1016/j.toxicon.2006.09.022; Chakrabarti P, 2007, PROG BIOPHYS MOL BIO, V95, P83, DOI 10.1016/j.pbiomolbio.2007.03.016; Chippaux JP, 2008, ACTA TROP, V107, P71, DOI 10.1016/j.actatropica.2008.05.021; Clot-Faybesse O, 1999, FEBS LETT, V458, P313, DOI 10.1016/S0014-5793(99)01179-5; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; de la Vega RCR, 2005, TOXICON, V46, P831, DOI 10.1016/j.toxicon.2005.09.006; de la Vega RCR, 2007, TOXICON, V49, P171, DOI 10.1016/j.toxicon.2006.09.016; Delano W.L, 2002, DELANO SCI; DELORI P, 1981, TOXICON, V19, P393, DOI 10.1016/0041-0101(81)90044-1; DEVAUX C, 1993, MOL IMMUNOL, V30, P1061, DOI 10.1016/0161-5890(93)90152-2; Devaux C, 1997, FEBS LETT, V412, P456, DOI 10.1016/S0014-5793(97)00826-0; Devaux C, 2002, J IMMUNOL METHODS, V271, P37, DOI 10.1016/S0022-1759(02)00338-1; Devaux C, 2001, EUR J BIOCHEM, V268, P694, DOI 10.1046/j.1432-1327.2001.01923.x; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Duarte CG, 2010, VACCINE, V28, P1168, DOI 10.1016/j.vaccine.2009.11.039; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; ELAYEB M, 1983, MOL IMMUNOL, V20, P697, DOI 10.1016/0161-5890(83)90047-0; ELAYEB M, 1984, MOL IMMUNOL, V21, P223, DOI 10.1016/0161-5890(84)90077-4; ELAYEB M, 1986, BIOCHEMISTRY-US, V25, P6671, DOI 10.1021/bi00369a052; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Espino-Solis GP, 2009, J PROTEOMICS, V72, P183, DOI 10.1016/j.jprot.2009.01.020; Gazarian KG, 2005, VACCINE, V23, P3357, DOI 10.1016/j.vaccine.2004.12.027; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GRANIER C, 1989, MOL IMMUNOL, V26, P503, DOI 10.1016/0161-5890(89)90001-1; Granier C., 2009, ANIMAL TOXINS STAT 2, P123; Guan RJ, 2004, J MOL BIOL, V341, P1189, DOI 10.1016/j.jmb.2004.06.067; Gur M, 2011, J BIOL CHEM, V286, P35209, DOI 10.1074/jbc.M111.259507; He XL, 1999, J MOL BIOL, V292, P125, DOI 10.1006/jmbi.1999.3036; Hmila I, 2008, MOL IMMUNOL, V45, P3847, DOI 10.1016/j.molimm.2008.04.011; Hmila I, 2010, FASEB J, V24, P3479, DOI 10.1096/fj.09-148213; HOUSSET D, 1994, J MOL BIOL, V238, P88, DOI 10.1006/jmbi.1994.1270; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOVER E, 1978, BIOCHEM BIOPH RES CO, V85, P377, DOI 10.1016/S0006-291X(78)80053-9; Juste M, 2007, CELL MOL LIFE SCI, V64, P206, DOI 10.1007/s00018-006-6401-3; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KHARRAT R, 1990, TOXICON, V28, P509, DOI 10.1016/0041-0101(90)90295-I; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Legros C, 2005, BBA-GEN SUBJECTS, V1723, P91, DOI 10.1016/j.bbagen.2005.01.008; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Marchot P, 1996, PROTEIN SCI, V5, P672; MARTIN MF, 1987, J BIOL CHEM, V262, P4452; MARTIN MF, 1986, TOXICON, V24, P1131, DOI 10.1016/0041-0101(86)90139-X; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Martin-Eauclaire MF, 2006, VACCINE, V24, P1990, DOI 10.1016/j.vaccine.2005.11.016; Meddeb-Mouelhi F, 2003, TOXICON, V42, P785, DOI 10.1016/j.toxicon.2003.10.021; MIKOU A, 1992, J BIOMOL NMR, V2, P57, DOI 10.1007/BF02192800; Moreau V, 2006, BIOINFORMATICS, V22, P1088, DOI 10.1093/bioinformatics/btl012; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Quintero-Hernandez V, 2007, MOL IMMUNOL, V44, P1307, DOI 10.1016/j.molimm.2006.05.009; Riano-Umbarila L, 2005, FEBS J, V272, P2591, DOI 10.1111/j.1742-4658.2005.04687.x; Riano-Umbarila L, 2011, J BIOL CHEM, V286, P6143, DOI 10.1074/jbc.M110.189175; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sami-Merah S, 2008, INT IMMUNOPHARMACOL, V8, P1386, DOI 10.1016/j.intimp.2008.05.011; Soding J, 2005, BIOINFORMATICS, V21, P951, DOI 10.1093/bioinformatics/bti125; Stanfield RL, 2006, J MOL BIOL, V357, P1566, DOI 10.1016/j.jmb.2006.01.023; Sun YM, 2003, J BIOL CHEM, V278, P24125, DOI 10.1074/jbc.M211931200; YAHI N, 1992, TOXICON, V30, P723, DOI 10.1016/0041-0101(92)90006-Q; Ye X, 2005, J MOL BIOL, V353, P788, DOI 10.1016/j.jmb.2005.08.068; YPEREZ GG, 1988, TOXICON, V26, P1102	76	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2012	287	17					14136	14148		10.1074/jbc.M111.315382	http://dx.doi.org/10.1074/jbc.M111.315382			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941VZ	22371498	Green Published, hybrid			2023-01-03	WOS:000303996300066
J	Orrow, G; Kinmonth, AL; Sanderson, S; Sutton, S				Orrow, Gillian; Kinmonth, Ann-Louise; Sanderson, Simon; Sutton, Stephen			Effectiveness of physical activity promotion based in primary care: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EXERCISE-REFERRAL SCHEMES; ACTIVITY INTERVENTIONS; IMPROVE FITNESS; RISK; PRESCRIPTION; ADVICE; PEOPLE; ADULTS	Objectives To determine whether trials of physical activity promotion based in primary care show sustained effects on physical activity or fitness in sedentary adults, and whether exercise referral interventions are more effective than other interventions. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, CINAHL, PsycINFO, EMBASE, SPORTDiscus, Centre for Reviews and Dissemination, the Cochrane Library, and article reference lists. Review methods Review of randomised controlled trials of physical activity promotion in sedentary adults recruited in primary care, with minimum follow-up of 12 months, reporting physical activity or fitness (or both) as outcomes, and using intention to treat analyses. Two reviewers independently assessed studies for inclusion, appraised risk of bias, and extracted data. Pooled effect sizes were calculated using a random effects model. Results We included 15 trials (n=8745). Most interventions took place in primary care, included health professionals in delivery, and involved advice or counselling given face to face or by phone (or both) on multiple occasions. Only three trials investigated exercise referral. In 13 trials presenting self reported physical activity, we saw small to medium positive intervention effects at 12 months (odds ratio 1.42, 95% confidence interval 1.17 to 1.73; standardised mean difference 0.25, 0.11 to 0.38). The number needed to treat with an intervention for one additional sedentary adult to meet internationally recommended levels of activity at 12 months was 12 (7 to 33). In four trials reporting cardiorespiratory fitness, a medium positive effect at 12 months was non-significant (standardised mean difference 0.51, -0.18 to 1.20). Three trials of exercise referral found small non-significant effects on self reported physical activity at 12 months (odds ratio 1.38; 0.98 to 1.95; standardised mean difference 0.20, -0.21 to 0.61). Conclusions Promotion of physical activity to sedentary adults recruited in primary care significantly increases physical activity levels at 12 months, as measured by self report. We found insufficient evidence to recommend exercise referral schemes over advice or counselling interventions. Primary care commissioners should consider these findings while awaiting further trial evaluation of exercise referral schemes and other primary care interventions, with longer follow-up and use of objective measures of outcome.	[Orrow, Gillian; Kinmonth, Ann-Louise; Sanderson, Simon; Sutton, Stephen] Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England	University of Cambridge	Orrow, G (corresponding author), Univ Cambridge, Inst Publ Hlth, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England.	ghlo2@medschl.cam.ac.uk		Sutton, Stephen/0000-0003-1610-0404	National Institute for Health Research (NIHR) at the UK Department of Health; University of Cambridge; NIHR [RP-PG-0608-10079]; NIHR School for Primary Care Research; MRC [G0200391] Funding Source: UKRI; Medical Research Council [G0200391] Funding Source: researchfish; National Institute for Health Research [PB-PG-0110-20199, NF-SI-0507-10182, ACF-2008-14-008, RP-PG-0608-10079] Funding Source: researchfish	National Institute for Health Research (NIHR) at the UK Department of Health(National Institute for Health Research (NIHR)); University of Cambridge(University of Cambridge); NIHR(National Institute for Health Research (NIHR)); NIHR School for Primary Care Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	GO is funded by an academic clinical fellowship from the National Institute for Health Research (NIHR) at the UK Department of Health. ALK is funded by the University of Cambridge and is an NIHR senior investigator. SSu's contribution to the study was funded by an NIHR Programme Grant for Applied Research (RP-PG-0608-10079). SSa's contribution was funded by the NIHR School for Primary Care Research.	Abraham C, 2008, HEALTH PSYCHOL, V27, P379, DOI 10.1037/0278-6133.27.3.379; Cardone A, 2011, EQUIPP EUROPE QUITTI; Chambers R., 2000, HEALTH EDUC J, V59, P90, DOI [10.1177/001789690005900108, DOI 10.1177/001789690005900108]; Chartered Society of Physiotherapists, 2008, REC MIND BOD; Chief medical officers of England Scotland Wales and Northern Island, 2011, START ACT STAY ACT R; Craig A, 2001, NATL QUALITY ASSURAN; Department of Health, 2010, DIR SECR STAT PRIM M; Eakin EG, 2000, J FAM PRACTICE, V49, P158; Eaton CB, 1998, BRIT J SPORT MED, V32, P11, DOI 10.1136/bjsm.32.1.11; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Foster C., 2005, COCHRANE DB SYST REV, V1, P1, DOI 10.1002/14651858.cd003180.pub2; Garrett S, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X561249; Halbert JA, 2000, MED J AUSTRALIA, V173, P84, DOI 10.5694/j.1326-5377.2000.tb139250.x; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Harrison RA, 2004, J PUBLIC HLTH, V271, P25; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins J.P.T, 2009, COCHRANE HDB SYSTEMA, P187; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hillsdon M, 2002, INT J EPIDEMIOL, V31, P808, DOI 10.1093/ije/31.4.808; Jimmy G, 2005, PATIENT EDUC COUNS, V56, P323, DOI 10.1016/j.pec.2004.03.006; Joint Health Surveys Unit, 2009, HLTH SURV ENGL 2008; Kaner EFS, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004148.pub3, 10.1002/14651858.CD004148.pub4]; Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7; Kolt GS, 2007, J AM GERIATR SOC, V55, P986, DOI 10.1111/j.1532-5415.2007.01203.x; Lamb SE, 2002, J EPIDEMIOL COMMUN H, V56, P246, DOI 10.1136/jech.56.4.246; Lawlor DA, 2001, J PUBLIC HEALTH MED, V23, P219, DOI 10.1093/pubmed/23.3.219; Lawton BA, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2509; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Morey MC, 2009, J AM GERIATR SOC, V57, P1166, DOI 10.1111/j.1532-5415.2009.02301.x; Muller-Riemenschneider F, 2008, PREV MED, V47, P354, DOI 10.1016/j.ypmed.2008.07.006; National Institute for Health & Clinical Excellence, 2006, 4 COMM US METH INCR; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Pavey TG, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6462; Petrella RJ, 2003, AM J PREV MED, V24, P316, DOI 10.1016/S0749-3797(03)00022-9; Riddoch C, 1998, EFFECTIVENESS PHYS A; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; Smith B J, 2004, J Sci Med Sport, V7, P67, DOI 10.1016/S1440-2440(04)80280-9; Stead LF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000165.pub3; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125; van Doorslaer E, 2006, CAN MED ASSOC J, V174, P177, DOI 10.1503/cmaj.050584; van Sluijs EMF, 2005, AM J PUBLIC HEALTH, V95, P1825, DOI 10.2105/AJPH.2004.044537; Williams NH, 2009, BRIT J SPORT MED, V43, P106, DOI 10.1136/bjsm.2008.051458; Williams NH, 2007, BRIT J GEN PRACT, V57, P979, DOI 10.3399/096016407782604866; Woodcock J, 2011, INT J EPIDEMIOL, V40, P121, DOI 10.1093/ije/dyq104	44	375	377	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2012	344								e1389	10.1136/bmj.e1389	http://dx.doi.org/10.1136/bmj.e1389			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923DY	22451477	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000302600700001
J	Lee, J; Kim, D; Choi, J; Choi, H; Ryu, JH; Jeong, J; Park, EJ; Kim, SH; Kim, S				Lee, Junghun; Kim, Donghyun; Choi, Jonghyun; Choi, Hyounjeong; Ryu, Jae-Ha; Jeong, Jinhyun; Park, Eun-Jin; Kim, Seon-Hee; Kim, Sunyoung			Dehydrodiconiferyl Alcohol Isolated from Cucurbita moschata Shows Anti-adipogenic and Anti-lipogenic Effects in 3T3-L1 Cells and Primary Mouse Embryonic Fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CLONAL EXPANSION; GROWTH-FACTOR-I; ADIPOCYTE DIFFERENTIATION; ADIPOSE-TISSUE; TRANSGENIC MICE; BINDING PROTEINS; GENE-EXPRESSION; STEM-CELL; OBESITY; LIGNIN	A water-soluble extract from the stems of Cucurbita moschata, code named PG105, was previously found to contain strong anti-obesity activities in a high fat diet-induced obesity mouse model. One of its biological characteristics is that it inhibits 3T3-L1 adipocyte differentiation. To isolate the biologically active compound(s), conventional solvent fractionation was performed, and the various fractions were tested for anti-adipogenic activity using Oil Red O staining method. A single spot on thin layer chromatography of the chloroform fraction showed a potent anti-adipogenic activity. When purified, the structure of its major component was resolved as dehydrodiconiferyl alcohol (DHCA), a lignan, by NMR and mass spectrometry analysis. In 3T3-L1 cells, synthesized DHCA significantly reduced the expression of several adipocyte marker genes, including peroxisome proliferator-activated receptor gamma (Pparg), CCAAT/enhancer-binding protein alpha (Cebpa), fatty acid-binding protein 4 (Fabp4), sterol response element-binding protein-1c (Srebp1c), and stearoyl-coenzyme A desaturase-1 (Scd), and decreased lipid accumulation without affecting cell viability. DHCA also suppressed the mitotic clonal expansion of preadipocytes (an early event of adipogenesis), probably by suppressing the DNA binding activity of C/EBP beta, and lowered the production level of cyclinA and cyclin-dependent kinase 2 (Cdk2), coinciding with the decrease in DNA synthesis and cell division. In addition, DHCA directly inhibited the expression of SREBP-1c and SCD-1. Similar observations were made, using primary mouse embryonic fibroblasts. Taken together, our data indicate that DHCA may contain dual activities, affecting both adipogenesis and lipogenesis.	[Lee, Junghun; Kim, Donghyun; Choi, Jonghyun; Choi, Hyounjeong; Kim, Sunyoung] Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea; [Ryu, Jae-Ha] Sookmyung Womens Univ, Coll Pharm, Seoul 140742, South Korea; [Jeong, Jinhyun] Yonsei Univ, Coll Pharm, Inchon 406840, South Korea; [Park, Eun-Jin; Kim, Seon-Hee] Viromed Co Ltd, Seoul 151747, South Korea	Seoul National University (SNU); Sookmyung Women's University; Yonsei University	Kim, S (corresponding author), Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea.	sunyoung@snu.ac.kr	Kim, Donghyun/J-3609-2019	Kim, Donghyun/0000-0002-5137-2213; Lee, Junghun/0000-0003-4524-0625	National Research Foundation of Korea [2011-0030699]; Brain Research Center [2011 K000287]; Ministry of Education, Science and Technology	National Research Foundation of Korea(National Research Foundation of Korea); Brain Research Center; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported in part by Grants 2011-0030699 (to J.-H.R.), and 2011 K000287 (to S.K.) from the National Research Foundation of Korea, and the Brain Research Center of the 21st Century Frontier Research Program, respectively, funded by the Ministry of Education, Science and Technology, in which Viromed Co., Ltd. is a participating company.	ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Auld CA, 2007, J CELL BIOCHEM, V100, P204, DOI 10.1002/jcb.21063; Barcelo AR, 2003, FUNCT PLANT BIOL, V30, P577, DOI 10.1071/FP02096; Byers T, 2007, J NUTR, V137, P488, DOI 10.1093/jn/137.2.488; Choi HJ, 2007, BIOCHEM BIOPH RES CO, V359, P419, DOI 10.1016/j.bbrc.2007.05.107; Cook A., 2008, ADIPOSE; Dani C, 1999, CELLS TISSUES ORGANS, V165, P173, DOI 10.1159/000016697; Deedwania P C, 2006, J Assoc Physicians India, V54, P797; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Fajas L, 2003, ANN MED, V35, P79, DOI 10.1080/07853890310009999; FREUDENBERG K, 1965, SCIENCE, V148, P595, DOI 10.1126/science.148.3670.595; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gang DR, 1999, CHEM BIOL, V6, P143, DOI 10.1016/S1074-5521(99)89006-1; Gnudi L, 1996, P NUTR SOC, V55, P191, DOI 10.1079/PNS19960020; Greenwood M R, 1977, Curr Concepts Nutr, V5, P119; Gregoire FM, 2001, EXP BIOL MED, V226, P997, DOI 10.1177/153537020122601106; Harp JB, 2004, CURR OPIN LIPIDOL, V15, P303, DOI 10.1097/00041433-200406000-00010; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; HIRSCH J, 1969, J LIPID RES, V10, P77; Hu K, 2006, ARCH PHARM RES, V29, P563, DOI 10.1007/BF02969265; Jin SH, 2000, J BIOL CHEM, V275, P34344, DOI 10.1074/jbc.M004927200; Kim J, 2007, P NATL ACAD SCI USA, V104, P1800, DOI 10.1073/pnas.0611137104; KNITTLE JL, 1979, J CLIN INVEST, V63, P239, DOI 10.1172/JCI109295; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Koutnikova H, 2001, ANN MED, V33, P556, DOI 10.3109/07853890108995966; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee H, 2009, J BIOL CHEM, V284, P10601, DOI 10.1074/jbc.M808742200; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; Liu J, 2005, CELL METAB, V2, P165, DOI 10.1016/j.cmet.2005.08.006; Liu KN, 2002, MOL CELL ENDOCRINOL, V194, P51, DOI 10.1016/S0303-7207(02)00188-0; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; Ntambi JM, 2000, J NUTR, V130, p3122S, DOI 10.1093/jn/130.12.3122S; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Tang QQ, 2005, P NATL ACAD SCI USA, V102, P9766, DOI 10.1073/pnas.0503891102; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tchoukalova YD, 2000, OBES RES, V8, P664, DOI 10.1038/oby.2000.85; Teng RF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1526; Wolins NE, 2006, J LIPID RES, V47, P450, DOI 10.1194/jlr.D500037-JLR200; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	47	36	37	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2012	287	12					8839	8851		10.1074/jbc.M111.263434	http://dx.doi.org/10.1074/jbc.M111.263434			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	912KV	22262865	hybrid, Green Published			2023-01-03	WOS:000301797800016
J	Kmietowicz, Z				Kmietowicz, Zosia			BMJ GROUP IMPROVING HEALTH AWARDS Sports and exercise doctors: the unsung heroes of champions	BRITISH MEDICAL JOURNAL			English	Editorial Material												zkmietowicz@bmj.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 14	2012	344								e1787	10.1136/bmj.e1787	http://dx.doi.org/10.1136/bmj.e1787			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913BY	22418414				2023-01-03	WOS:000301847600014
J	Blinderman, CD; Krakauer, EL; Solomon, MZ				Blinderman, Craig D.; Krakauer, Eric L.; Solomon, Mildred Z.			Time to Revise the Approach to Determining Cardiopulmonary Resuscitation Status	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Blinderman, Craig D.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA; [Solomon, Mildred Z.] Harvard Univ, Sch Med, Div Med Eth, Boston, MA USA; [Krakauer, Eric L.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Krakauer, Eric L.; Solomon, Mildred Z.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Palliat Care Serv, Boston, MA 02114 USA; [Krakauer, Eric L.] Massachusetts Gen Hosp, Optimum Care Comm, Boston, MA 02114 USA; [Solomon, Mildred Z.] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA	Columbia University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital	Blinderman, CD (corresponding author), Columbia Univ, Med Ctr, Dept Anesthesiol, 622 W 168th St,PH5-530B, New York, NY 10032 USA.	cdb21@columbia.edu						Billings JA, 2011, ARCH INTERN MED, V171, P849, DOI 10.1001/archinternmed.2011.180; Brett AS, 2012, JAMA-J AM MED ASSOC, V307, P149, DOI 10.1001/jama.2011.1999; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Halpern SD, 2007, NEW ENGL J MED, V357, P1340, DOI 10.1056/NEJMsb071595; Kane RS, 1997, J AM GERIATR SOC, V45, P154, DOI 10.1111/j.1532-5415.1997.tb04500.x; Larkin GL, 2010, RESUSCITATION, V81, P302, DOI 10.1016/j.resuscitation.2009.11.021; [Standards for cardiopulmonary resuscitation (CPR) emergency cardiac care (ECC)], 1974, JAMA, V227, P837	7	52	52	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					917	918		10.1001/jama.2012.236	http://dx.doi.org/10.1001/jama.2012.236			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396511				2023-01-03	WOS:000301172100017
J	Khodja, NI; Chataigneau, T; Auger, C; Schini-Kerth, VB				Khodja, Noureddine Idris; Chataigneau, Thierry; Auger, Cyril; Schini-Kerth, Valerie B.			Grape-Derived Polyphenols Improve Aging-Related Endothelial Dysfunction in Rat Mesenteric Artery: Role of Oxidative Stress and the Angiotensin System	PLOS ONE			English	Article							RED WINE POLYPHENOLS; EDHF-MEDIATED RELAXATIONS; PORCINE CORONARY-ARTERIES; II-INDUCED HYPERTENSION; NITRIC-OXIDE SYNTHASE; HYPERPOLARIZING FACTOR; DEPENDENT RELAXATIONS; SUPEROXIDE-PRODUCTION; REDUCED EXPRESSION; ENZYME-INHIBITION	Aging is characterized by the development of an endothelial dysfunction, which affects both the nitric oxide (NO)- and the endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxations, associated with vascular oxidative stress and the activation of the angiotensin system. This study investigated whether red wine polyphenols (RWPs), antioxidants and potent stimulators of NO-and EDHF-mediated relaxations improve aging-related endothelial dysfunction, and, if so, examined the underlying mechanism. Mesenteric artery reactivity was determined in organ chambers, vascular oxidative stress by dihydroethidine and MitoSOX staining, and expression of target proteins by immunohistochemical staining. Control young rats (16 weeks) received solvent (ethanol, 3% v/v), and middle-aged rats (46 weeks) either solvent or RWPs (100 mg/kg/day) in the drinking water. The acetylcholine-induced endothelium-dependent NO component was slightly reduced whereas the EDHF component was markedly blunted in rings of middle-aged rats compared to young rats. The endothelial dysfunction was associated with oxidative stress, an upregulation of angiotensin II and AT1 receptors and a down-regulation of SKCa, IKCa, and angiotensin converting enzyme. Intake of RWPs for either one or two weeks improved the NO and the EDHF components of the relaxation, and normalized oxidative stress, the expression of SKCa, IKCa and the components of the angiotensin system. The protective effect of the 2-week RWPs treatment persisted for one and two weeks following stopping intake of RWPs. Thus, intake of RWPs caused a persistent improvement of the endothelial function, particularly the EDHF component, in middle-aged rats and this effect seems to involve the normalization of the expression of SKCa, IKCa and the angiotensin system.	[Khodja, Noureddine Idris; Chataigneau, Thierry; Auger, Cyril; Schini-Kerth, Valerie B.] Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Khodja, NI (corresponding author), Univ Strasbourg, Fac Pharm, Lab Biophoton & Pharmacol, UMR CNRS 7213, Illkirch Graffenstaden, France.	valerie.schini-kerth@unistra.fr	Auger, Cyril/N-4702-2016		Office National Interprofessionnel des Fruits, des Legumes, des Vins et de l'Horticulture (Action Vin Sante, France)	Office National Interprofessionnel des Fruits, des Legumes, des Vins et de l'Horticulture (Action Vin Sante, France)	This work was supported, in part, by the Office National Interprofessionnel des Fruits, des Legumes, des Vins et de l'Horticulture (Action Vin & Sante, France). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Aranda R, 2007, FREE RADICAL RES, V41, P1195, DOI 10.1080/10715760701481461; Armstead WM, 2003, ANESTHESIOLOGY, V98, P1378, DOI 10.1097/00000542-200306000-00012; ATKINSON J, 1994, AM J PHYSIOL, V267, pR136, DOI 10.1152/ajpregu.1994.267.1.R136; Briones A. M., 2005, Autonomic & Autacoid Pharmacology, V25, P155, DOI 10.1111/j.1474-8673.2005.00344.x; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0; Chen WG, 2010, BIOCHEMISTRY-US, V49, P3129, DOI 10.1021/bi9016632; Cosentino F, 2001, ARTERIOSCL THROM VAS, V21, P496, DOI 10.1161/01.ATV.21.4.496; Csiszar A, 2002, CIRC RES, V90, P1159, DOI 10.1161/01.RES.0000020401.61826.EA; Dal-Ros S, 2011, BIOCHEM BIOPH RES CO, V404, P743, DOI 10.1016/j.bbrc.2010.12.060; Dal-Ros S, 2010, GASTROENTEROLOGY, V138, P1574, DOI 10.1053/j.gastro.2009.10.040; Dal-Ros S, 2009, J PHARMACOL EXP THER, V328, P478, DOI 10.1124/jpet.108.145326; Edwards G, 2010, PFLUG ARCH EUR J PHY, V459, P863, DOI 10.1007/s00424-010-0817-1; Feletou M, 2006, AM J PHYSIOL-HEART C, V291, pH985, DOI 10.1152/ajpheart.00292.2006; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Goto K, 2000, HYPERTENSION, V36, P581, DOI 10.1161/01.HYP.36.4.581; Goto K, 2004, CLIN EXP PHARMACOL P, V31, P650, DOI 10.1111/j.1440-1681.2004.04054.x; Hamilton CA, 2001, HYPERTENSION, V37, P529, DOI 10.1161/01.HYP.37.2.529; Hilgers RHP, 2007, AM J PHYSIOL-HEART C, V292, pH2275, DOI 10.1152/ajpheart.00949.2006; HONGO K, 1988, STROKE, V19, P892, DOI 10.1161/01.STR.19.7.892; Kansui Y, 2002, J HYPERTENS, V20, P439, DOI 10.1097/00004872-200203000-00019; Kawai Y, 2008, J BIOL CHEM, V283, P9424, DOI 10.1074/jbc.M706571200; KUNG CF, 1995, HYPERTENSION, V25, P194, DOI 10.1161/01.HYP.25.2.194; Lavrentyev EN, 2007, CIRC RES, V101, P455, DOI 10.1161/CIRCRESAHA.107.151852; Lemarie CA, 2010, J RENIN-ANGIO-ALDO S, V11, P19, DOI 10.1177/1470320309347785; Long DA, 2005, KIDNEY INT, V68, P2154, DOI 10.1111/j.1523-1755.2005.00671.x; Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200; Matz RL, 2000, BRIT J PHARMACOL, V131, P303, DOI 10.1038/sj.bjp.0703568; Modrick ML, 2009, AM J PHYSIOL-HEART C, V296, pH1914, DOI 10.1152/ajpheart.00300.2009; Mukai Y, 2002, ARTERIOSCL THROM VAS, V22, P1445, DOI 10.1161/01.ATV.0000029121.63691.CE; NAKASHIMA M, 1993, J CLIN INVEST, V92, P2867, DOI 10.1172/JCI116907; Ndiaye M, 2004, BRIT J PHARMACOL, V142, P1131, DOI 10.1038/sj.bjp.0705774; Ndiaye M, 2003, BIOCHEM BIOPH RES CO, V310, P371, DOI 10.1016/j.bbrc.2003.09.028; Negishi H, 2004, J NUTR, V134, P38, DOI 10.1093/jn/134.1.38; Newaz MA, 2006, J CARDIOVASC PHARM, V48, P88, DOI 10.1097/01.fjc.0000245402.62864.0a; Oudot A, 2006, FREE RADICAL BIO MED, V40, P2214, DOI 10.1016/j.freeradbiomed.2006.02.020; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Sarr M, 2006, CARDIOVASC RES, V71, P794, DOI 10.1016/j.cardiores.2006.05.022; Schmidt TS, 2007, CLIN SCI, V113, P47, DOI 10.1042/CS20070108; Shimokawa H, 1996, J CARDIOVASC PHARM, V28, P703, DOI 10.1097/00005344-199611000-00014; Taddei S, 2001, HYPERTENSION, V38, P274, DOI 10.1161/01.HYP.38.2.274; Urakami-Harasawa L, 1997, J CLIN INVEST, V100, P2793, DOI 10.1172/JCI119826; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Wong SL, 2009, CIRC RES, V104, P228, DOI 10.1161/CIRCRESAHA.108.179770; Wu SZ, 2007, GERONTOLOGY, V53, P234, DOI 10.1159/000100961; Yang YM, 2009, AM J PHYSIOL-HEART C, V297, pH1829, DOI 10.1152/ajpheart.00230.2009; Ying CJ, 2003, HYPERTENS RES, V26, P823, DOI 10.1291/hypres.26.823; Zhu JH, 2010, ASIAN J ANDROL, V12, P599, DOI 10.1038/aja.2009.97	48	42	42	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2012	7	2							e32039	10.1371/journal.pone.0032039	http://dx.doi.org/10.1371/journal.pone.0032039			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927OV	22384133	gold, Green Submitted, Green Published			2023-01-03	WOS:000302918500056
J	Tang, SN; Fu, JS; Shankar, S; Srivastava, RK				Tang, Su-Ni; Fu, Junsheng; Shankar, Sharmila; Srivastava, Rakesh K.			EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer	PLOS ONE			English	Article							NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; GREEN-TEA CONSUMPTION; (-)-EPIGALLOCATECHIN GALLATE; CELL-CYCLE; MOLECULAR TARGETS; FACTOR RECEPTOR; SUPPRESSION; POLYPHENOLS; ACTIVATION	Background: Signal Transducer and Activator of Transcription 3 (STAT3) is an oncogene, which promotes cell survival, proliferation, motility and progression in cancer cells. Targeting STAT3 signaling may lead to the development of novel therapeutic approaches for human cancers. Here, we examined the effects of epigallocathechin gallate (EGCG) on STAT3 signaling in pancreatic cancer cells, and assessed the therapeutic potential of EGCG with gemcitabine or JAK3 inhibitor CP690550 (Tasocitinib) for the treatment and/or prevention of pancreatic cancer. Methodology/Principal Findings: Cell viability and apoptosis were measured by XTT assay and TUNEL staining, respectively. Gene and protein expressions were measured by qRT-PCR and Western blot analysis, respectively. The results revealed that EGCG inhibited the expression of phospho and total JAK3 and STAT3, STAT3 transcription and activation, and the expression of STAT3-regulated genes, resulting in the inhibition of cell motility, migration and invasion, and the induction of caspase-3 and PARP cleavage. The inhibition of STAT3 enhanced the inhibitory effects of EGCG on cell motility and viability. Additionally, gemcitabine and CP690550 alone inhibited STAT3 target genes and synergized with EGCG to inhibit cell viability and induce apoptosis in pancreatic cancer cells. Conclusions/Significance: Overall, these results suggest that EGCG suppresses the growth, invasion and migration of pancreatic cancer cells, and induces apoptosis by interfering with the STAT3 signaling pathway. Moreover, EGCG further enhanced the therapeutic potential of gemcitabine and CP690550 against pancreatic cancer.	[Tang, Su-Ni; Srivastava, Rakesh K.] Univ Kansas, Med Ctr, Ctr Canc, Dept Pharmacol Toxicol & Therapeut & Med, Kansas City, KS 66103 USA; [Fu, Junsheng; Shankar, Sharmila] Univ Kansas, Med Ctr, Ctr Canc, Dept Pathol & Lab Med, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Tang, SN (corresponding author), Univ Kansas, Med Ctr, Ctr Canc, Dept Pharmacol Toxicol & Therapeut & Med, Kansas City, KS 66103 USA.	rsrivastava@kumc.edu			National Institutes of Health [R01CA125262, RO1CA114469, RO1CA125262-02S1]; Kansas Bioscience Authority; NATIONAL CANCER INSTITUTE [R01CA125262, R01CA114469] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Kansas Bioscience Authority; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the grants from the National Institutes of Health (R01CA125262,RO1CA114469 and RO1CA125262-02S1) and the Kansas Bioscience Authority. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulghani J, 2008, AM J PATHOL, V172, P1717, DOI 10.2353/ajpath.2008.071054; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Aggarwal BB, 2006, ANN NY ACAD SCI, V1091, P151, DOI 10.1196/annals.1378.063; Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Akaishi H, 1998, INT IMMUNOL, V10, P1747, DOI 10.1093/intimm/10.11.1747; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; [Anonymous], 2004, AM J TRANSPLANT, V4, P51, DOI 10.1046/j.1600-6143.2003.00281.x; Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314; Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863; Borie Dominic C, 2003, Curr Opin Investig Drugs, V4, P1297; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Changelian PS, 2008, BLOOD, V111, P2155, DOI 10.1182/blood-2007-09-115030; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chrencik JE, 2010, J MOL BIOL, V400, P413, DOI 10.1016/j.jmb.2010.05.020; Cooper JE, 2010, CLIN NEPHROL, V73, P333; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Dong ZG, 1997, CANCER RES, V57, P4414; Dreosti IE, 1997, CRIT REV FOOD SCI, V37, P761, DOI 10.1080/10408399709527801; Fujiki H, 2002, CANCER LETT, V188, P9, DOI 10.1016/S0304-3835(02)00379-8; Ghaneh P, 2007, GUT, V56, P1134, DOI 10.1136/gut.2006.103333; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Gupta S, 2004, ONCOGENE, V23, P2507, DOI 10.1038/sj.onc.1207353; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Ji BT, 1997, INT J CANCER, V70, P255, DOI 10.1002/(SICI)1097-0215(19970127)70:3&lt;255::AID-IJC1&gt;3.0.CO;2-W; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayed H, 2006, PANCREAS, V32, P119, DOI 10.1097/01.mpa.0000202937.55460.0c; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Konoeda F, 2010, BIOCHEM BIOPH RES CO, V402, P500, DOI 10.1016/j.bbrc.2010.10.058; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Lee N, 2004, J COMP NEUROL, V474, P535, DOI 10.1002/cne.20140; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V; Liau SS, 2008, CLIN CANCER RES, V14, P1470, DOI 10.1158/1078-0432.CCR-07-1450; Nakachi K, 2000, BIOFACTORS, V13, P49, DOI 10.1002/biof.5520130109; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Park HB, 2010, TRANSPLANTATION, V90, P825, DOI 10.1097/TP.0b013e3181f24e59; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlieman MG, 2003, BRIT J CANCER, V89, P2110, DOI 10.1038/sj.bjc.6601396; Schreiner SJ, 2002, J BIOL CHEM, V277, P45680, DOI 10.1074/jbc.M204255200; Shankar S, 2007, FRONT BIOSCI-LANDMRK, V12, P4881, DOI 10.2741/2435; Shankar S, 2007, FRONT BIOSCI-LANDMRK, V12, P5039, DOI 10.2741/2446; Shankar S, 2008, FRONT BIOSCI-LANDMRK, V13, P440, DOI 10.2741/2691; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Siegelin MD, 2008, NEUROSCI LETT, V448, P161, DOI 10.1016/j.neulet.2008.10.036; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; SPORN MB, 1976, CANCER RES, V36, P2699; STONER GD, 1995, J CELL BIOCHEM, P169; Syed DN, 2007, ONCOGENE, V26, P673, DOI 10.1038/sj.onc.1209829; Tak PP, 2011, ARTHRITIS RES THER, V13, DOI [10.1186/ar3096, 10.1186/1478-6354-13-S1-S5]; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Tomillero A, 2009, Methods Find Exp Clin Pharmacol, V31, P661; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; West K, 2009, CURR OPIN INVEST DR, V10, P491; YU GP, 1995, CANCER CAUSE CONTROL, V6, P532, DOI 10.1007/BF00054162; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zapatka M, 2007, ONCOGENE, V26, P1417, DOI 10.1038/sj.onc.1209918	72	81	86	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 13	2012	7	2							e31067	10.1371/journal.pone.0031067	http://dx.doi.org/10.1371/journal.pone.0031067			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925BB	22348037	gold, Green Published, Green Submitted			2023-01-03	WOS:000302733900021
J	Jolly, K; Ingram, L; Khan, KS; Deeks, JJ; Freemantle, N; MacArthur, C				Jolly, Kate; Ingram, Lucy; Khan, Khalid S.; Deeks, Jonathan J.; Freemantle, Nick; MacArthur, Christine			Systematic review of peer support for breastfeeding continuation: metaregression analysis of the effect of setting, intensity, and timing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; LOW-INCOME; COUNSELORS; PROMOTION; DURATION; INTERVENTION; BANGLADESH; EFFICACY; INFANTS; MOTHERS	Objective To examine the effect of setting, intensity, and timing of peer support on breast feeding. Design Systematic review and metaregression analysis of randomised controlled trials. Data sources Cochrane Library, Medline, CINAHL, the National Research Register, and British Nursing Index were searched from inception or from 1980 to 2011. Review methods Study selection, data abstraction, and quality assessment were carried out independently and in duplicate. Risk ratios and 95% confidence intervals were calculated for individual studies and pooled. Effects were estimated for studies grouped according to setting (high income countries, low or middle income countries, and the United Kingdom), intensity (<5 and >= 5 planned contacts), and timing of peer support (postnatal period with or without antenatal care), and analysed using metaregression for any and exclusive breast feeding at last study follow-up. Results Peer support interventions had a significantly greater effect on any breast feeding in low or middle income countries (P<0.001), reducing the risk of not breast feeding at all by 30% (relative risk 0.70, 95% confidence interval 0.60 to 0.82) compared with a reduction of 7% (0.93, 0.87 to 1.00) in high income countries. Similarly, the risk of non-exclusive breast feeding decreased significantly more in low or middle income countries than in high income countries: 37% (0.63, 0.52 to 0.78) compared with 10% (0.90, 0.85 to 0.97); P=0.01. No significant effect on breast feeding was observed in UK based studies. Peer support had a greater effect on any breastfeeding rates when given at higher intensity (P=0.02) and only delivered in the postnatal period (P<0.001), although no differences were observed of its effect on exclusive breastfeeding rates by intensity or timing. Conclusion Although peer support interventions increase breastfeeding continuation in low or middle income countries, especially exclusive breast feeding, this does not seem to apply in high income countries, particularly the United Kingdom, where breastfeeding support is part of routine postnatal healthcare. Peer support of low intensity does not seem to be effective. Policy relating to provision of peer support should be based on more specific evidence on setting and any new peer services in high income countries need to undergo concurrent evaluation.	[Jolly, Kate; Ingram, Lucy; Deeks, Jonathan J.; MacArthur, Christine] Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England; [Khan, Khalid S.] Barts & London Queen Marys Sch Med & Dent, London, England; [Freemantle, Nick] UCL, Dept Primary Care & Populat Hlth, London, England	University of Birmingham; University of London; Queen Mary University London; University of London; University College London	Jolly, K (corresponding author), Univ Birmingham, Dept Publ Hlth Epidemiol & Biostat, Birmingham B15 2TT, W Midlands, England.	C.B.Jolly@bham.ac.uk	Deeks, Jon/AAV-5745-2020; Khan, Khalid S/AAT-8824-2020; MacArthur, Christine/ABA-8601-2021; Jolly, Kate/AAA-1341-2019	Deeks, Jon/0000-0002-8850-1971; Khan, Khalid S/0000-0001-5084-7312; MacArthur, Christine/0000-0003-0434-2158; Jolly, Kate/0000-0002-6224-2115; Freemantle, Nick/0000-0001-5807-5740	National Institute for Health Research	National Institute for Health Research(National Institute for Health Research (NIHR))	KJ, CM, and LI are part funded by the National Institute for Health Research through the Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research, the Department of Health, University of Birmingham, University College London, or the CLAHRC-BBC steering group.	Agrasada GV, 2005, ACTA PAEDIATR, V94, P1109, DOI 10.1080/08035250510025752; Anderson AK, 2005, ARCH PEDIAT ADOL MED, V159, P836, DOI 10.1001/archpedi.159.9.836; Arifeen S, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e67; Arifeen SE, 2009, LANCET, V374, P393, DOI 10.1016/S0140-6736(09)60828-X; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bick DE, 1998, MIDWIFERY, V14, P242, DOI 10.1016/S0266-6138(98)90096-1; Bolling K, 2007, INFANT FEEDING SURVE; Britton C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub3; Chapman DJ, 2004, ARCH PEDIAT ADOL MED, V158, P897, DOI 10.1001/archpedi.158.9.897; Coutinho SB, 2005, LANCET, V366, P1094, DOI 10.1016/S0140-6736(05)67421-1; Deeks J, 2006, COCHRANE HDB SYSTEMA; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; Dennis CL, 2003, INT J NURS STUD, V40, P321, DOI 10.1016/S0020-7489(02)00092-5; Dennis CL, 2002, CAN MED ASSOC J, V166, P21; Di Meglio G, 2010, BREASTFEED MED, V5, P41, DOI 10.1089/bfm.2009.0016; Graffy J, 2004, BRIT MED J, V328, P26, DOI 10.1136/bmj.328.7430.26; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoddinott P, 2011, MATERN CHILD NUTR, V7, P221, DOI 10.1111/j.1740-8709.2011.00336.x; Hopkinson J, 2009, J HUM LACT, V25, P287, DOI 10.1177/0890334409335482; Jakobsen MS, 1999, ACTA PAEDIATR, V88, P741, DOI 10.1080/08035259950169026; Jolly K, 2011, MIDWIFERY; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Leite AJM, 2005, ACTA PAEDIATR, V94, P741, DOI 10.1080/08035250410023854; Lewin S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004015.pub3; McInnes RJ, 2000, J PUBLIC HEALTH MED, V22, P138, DOI 10.1093/pubmed/22.2.138; Merewood A, 2006, ARCH PEDIAT ADOL MED, V160, P681, DOI 10.1001/archpedi.160.7.681; MONGEON M, 1995, CAN J PUBLIC HEALTH, V86, P124; Morrell CJ, 2000, BRIT MED J, V321, P593, DOI 10.1136/bmj.321.7261.593; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Muirhead PE, 2006, BRIT J GEN PRACT, V56, P191; NIfHaC, 2009, IMPR HLTH NUTR PREG; The World Bank, 2011, COUNTR LEND GROUPS; Tylleskar T, 2011, LANCET, V378, P420, DOI 10.1016/S0140-6736(11)60738-1; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Watt RG, 2009, J EPIDEMIOL COMMUN H, V63, P156, DOI 10.1136/jech.2008.077115; World Health Organization, 2001, OPT DUR EXCL BREASTF; World Health Organization, 2001, INF YOUNG CHILDR FEE; World Health Organization, 1991, INN DECL PROT PROM S	40	98	103	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 25	2012	344								d8287	10.1136/bmj.d8287	http://dx.doi.org/10.1136/bmj.d8287			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	885KV	22277543	Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000299778800011
J	Yoo, DE; Park, JT; Oh, HJ; Kim, SJ; Lee, MJ; Shin, DH; Han, SH; Yoo, TH; Choi, KH; Kang, SW				Yoo, Dong Eun; Park, Jung Tak; Oh, Hyung Jung; Kim, Seung Jun; Lee, Mi Jung; Shin, Dong Ho; Han, Seung Hyeok; Yoo, Tae-Hyun; Choi, Kyu Hun; Kang, Shin-Wook			Good Glycemic Control Is Associated with Better Survival in Diabetic Patients on Peritoneal Dialysis: A Prospective Observational Study	PLOS ONE			English	Article							GLUCOSE CONTROL; MORTALITY; COMPLICATIONS; PREDICTOR; THERAPY	Background: The effect of glycemic control after starting peritoneal dialysis (PD) on the survival of diabetic PD patients has largely been unexplored, especially in Asian population. Methods: We conducted a prospective observational study, in which 140 incident PD patients with diabetes were recruited. Patients were divided into tertiles according to the means of quarterly HbA1C levels measured during the first year after starting PD. We examined the association between HbA1C and all-cause mortality using Cox proportional hazards models. Results: The mean age was 58.7 years, 59.3% were male, and the mean follow-up duration was 3.5 years (range 0.4-9.5 years). The mean HbA1C levels were 6.3%, 7.1%, and 8.5% in the 1st, 2nd, and 3rd tertiles, respectively. Compared to the 1st tertile, the all-cause mortality rates were higher in the 2nd [hazard ratio (HR), 4.16; 95% confidence interval (CI), 0.91-18.94; p = 0.065] and significantly higher in the 3rd (HR, 13.16; 95% CI, 2.67-64.92; p = 0.002) tertiles (p for trend = 0.005), after adjusting for confounding factors. Cardiovascular mortality, however, did not differ significantly among the tertiles (p for trend = 0.682). In contrast, non-cardiovascular deaths, most of which were caused by infection, were more frequent in the 2nd (HR, 7.67; 95% CI, 0.68-86.37; p = 0.099) and the 3rd (HR, 51.24; 95% CI, 3.85-681.35; p = 0.003) tertiles than the 1st tertile (p for trend = 0.007). Conclusions: Poor glycemic control is associated with high mortality rates in diabetic PD patients, suggesting that better glycemic control may improve the outcomes of these patients.	[Yoo, Dong Eun; Park, Jung Tak; Oh, Hyung Jung; Kim, Seung Jun; Lee, Mi Jung; Shin, Dong Ho; Han, Seung Hyeok; Yoo, Tae-Hyun; Choi, Kyu Hun; Kang, Shin-Wook] Yonsei Univ, Coll Med, Dept Internal Med, Severance Biomed Sci Inst, Seoul, South Korea	Yonsei University; Yonsei University Health System	Yoo, DE (corresponding author), Yonsei Univ, Coll Med, Dept Internal Med, Severance Biomed Sci Inst, Seoul, South Korea.	kswkidney@yuhs.ac	Han, Seung Hyeok/W-8825-2019; Kim, Seung Jun/N-5248-2019; Han, Seung Hyeok/K-4559-2018	Han, Seung Hyeok/0000-0001-7923-5635; Kim, Seung Jun/0000-0002-6913-6358; Han, Seung Hyeok/0000-0001-7923-5635; Kang, Shin-Wook/0000-0002-5677-4756; Park, Jung Tak/0000-0002-2325-8982; Yoo, Tae-Hyun/0000-0002-9183-4507; Lee, Mi Jung/0000-0001-8888-029X; Choi, Kyu Hun/0000-0003-0095-9011	Yonsei University; National Research Foundation of Korea; Korea government (MEST) [2011-0030711]; Ministry of Health and Welfare, Republic of Korea [A102065]	Yonsei University; National Research Foundation of Korea(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, by the National Research Foundation of Korea grant funded by the Korea government (MEST) (No. 2011-0030711), and by a grant of the Korea Healthcare Technology Research & Development Project, Ministry of Health and Welfare, Republic of Korea (A102065). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI 10.2337/dc11-S011; BLAGG CR, 1991, AM J KIDNEY DIS, V17, P458, DOI 10.1016/S0272-6386(12)80641-X; Bopp C, 2008, CRIT CARE, V12, DOI 10.1186/cc6164; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chung SH, 2010, NEPHROL DIAL TRANSPL, V25, P3742, DOI 10.1093/ndt/gfq233; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Duong U, 2011, CLIN J AM SOC NEPHRO, V6, P1041, DOI 10.2215/CJN.08921010; Genuth S, 2003, DIABETES CARE, V26, P3160; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Jin Dong Chan, 2011, Korean Journal of Internal Medicine, V26, P123, DOI 10.3904/kjim.2011.26.2.123; Kalantar-Zadeh K, 2007, DIABETES CARE, V30, P1049, DOI 10.2337/dc06-2127; KREDIET RT, 1986, NEPHRON, V42, P133, DOI 10.1159/000183652; Morioka T, 2001, DIABETES CARE, V24, P909, DOI 10.2337/diacare.24.5.909; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Oomichi T, 2006, DIABETES CARE, V29, P1496, DOI 10.2337/dc05-1887; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shurraw S, 2010, AM J KIDNEY DIS, V55, P875, DOI 10.1053/j.ajkd.2009.12.038; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; United States Renal Data System, 2010, AM J KIDNEY DIS, V52, pS212; Wade CE, 2008, CRIT CARE, V12, DOI 10.1186/cc7012; WATSON PE, 1980, AM J CLIN NUTR, V33, P27, DOI 10.1093/ajcn/33.1.27; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Williams ME, 2006, KIDNEY INT, V70, P1503, DOI 10.1038/sj.ki.5001789; Wu MS, 1999, PERITON DIALYSIS INT, V19, pS179	26	26	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2012	7	1							e30072	10.1371/journal.pone.0030072	http://dx.doi.org/10.1371/journal.pone.0030072			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909NE	22291903	gold, Green Submitted, Green Published			2023-01-03	WOS:000301570600013
J	Fuertes, N				Fuertes, Natalia			End-of-life decisions in Argentina	LANCET			English	Editorial Material									Univ Buenos Aires, Fac Med, Buenos Aires, DF, Argentina	University of Buenos Aires	Fuertes, N (corresponding author), Univ Buenos Aires, Fac Med, C1121ABG, Buenos Aires, DF, Argentina.	nvfuertes@gmail.com						Anon, 2011, TELAM ARGENTINA 1201; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Field C, 2009, BRIT J HOSP MED, V70, P280, DOI 10.12968/hmed.2009.70.5.42226; Ramsay C, 2011, ARGENTINA INDEP 1026; Rietjens JAC, 2009, J BIOETHIC INQ, V6, P271, DOI 10.1007/s11673-009-9172-3; The commission on assisted dying, 2012, REP COMM ASS DYING	6	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	2012	379	9811					105	105		10.1016/S0140-6736(12)60042-7	http://dx.doi.org/10.1016/S0140-6736(12)60042-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879GM	22243815				2023-01-03	WOS:000299317700016
J	Gallet, P; Phulpin, B; Merlin, JL; Leroux, A; Bravetti, P; Mecellem, H; Tran, N; Dolivet, G				Gallet, Patrice; Phulpin, Berengere; Merlin, Jean-Louis; Leroux, Agnes; Bravetti, Pierre; Mecellem, Hinda; Nguyen Tran; Dolivet, Gilles			Long-Term Alterations of Cytokines and Growth Factors Expression in Irradiated Tissues and Relation with Histological Severity Scoring	PLOS ONE			English	Article							INDUCED LUNG INJURY; RADIATION PNEUMONITIS; IONIZING-RADIATION; STROMAL CELLS; INFLAMMATORY CYTOKINES; THORACIC RADIOTHERAPY; FACTOR-BETA; HYPOXIA; FIBROSIS; RAT	Purpose: Beside its efficacy in cancer treatment, radiotherapy induces degeneration of healthy tissues within the irradiated area. The aim of this study was to analyze the variations of proinflammatory (IL-1 alpha, IL-2, IL-6, TNF-alpha, IFN-gamma), profibrotic (TGF-beta 1), proangiogneic (VEGF) and stem cell mobilizing (GM-CSF) cytokines and growth factors in an animal model of radiation-induced tissue degeneration. Materials and Methods: 24 rats were irradiated unilaterally on the hindlimb at a monodose of 30 Gy. Six weeks (n = 8), 6 months (n = 8) and 1 year (n = 8) after irradiation the mediators expression in skin and muscle were analyzed using Western blot and the Bio-Plex (R) protein array (BPA) technology. Additional histological severity for fibrosis, inflammation, vascularity and cellularity alterations scoring was defined from histology and immnunohistochemistry analyses. Results: A significant increase of histological severity scoring was found in irradiated tissue. Skin tissues were more radiosensitive than muscle. A high level of TGF-beta 1 expression was found throughout the study and a significant relation was evidenced between TGF-beta 1 expression and fibrosis scoring. Irradiated tissue showed a chronic inflammation (IL-2 and TNF-alpha significantly increased). Moreover a persistent expression of GM-CSF and VEGF was found in all irradiated tissues. The vascular score was related to TGF-beta 1 expression and the cellular alterations score was significantly related with the level of IL-2, VEGF and GM-CSF. Conclusion: The results achieved in the present study underline the complexity and multiplicity of radio-induced alterations of cytokine network. It offers many perspectives of development, for the comprehension of the mechanisms of late injuries or for the histological and molecular evaluation of the mode of action and the efficacy of rehabilitation techniques.	[Gallet, Patrice; Phulpin, Berengere; Merlin, Jean-Louis; Leroux, Agnes; Dolivet, Gilles] Nancy Univ, SiGReTO, EA4421, Fac Med, Vandoeuvre Les Nancy, France; [Phulpin, Berengere; Dolivet, Gilles] Ctr Alexis Vautrin, Dept Surg Oncol, Head & Neck Surg Unit, Vandoeuvre Les Nancy, France; [Phulpin, Berengere; Dolivet, Gilles] Ctr Alexis Vautrin, Dept Surg Oncol, Dent Unit, Vandoeuvre Les Nancy, France; [Merlin, Jean-Louis; Leroux, Agnes] Ctr Alexis Vautrin, Pathol & Tumor Biol Dept, Vandoeuvre Les Nancy, France; [Bravetti, Pierre] Nancy Univ, Fac Dent, Dept Oral Surg, Nancy, France; [Mecellem, Hinda] Ctr Alexis Vautrin, Dept Radiotherapy, Vandoeuvre Les Nancy, France; [Nguyen Tran] Nancy Univ, Fac Med, INSERM, Sch Surg,U961, Vandoeuvre Les Nancy, France	Universite de Lorraine; UNICANCER; Institut de cancerologie de Lorraine (ICL); UNICANCER; Institut de cancerologie de Lorraine (ICL); UNICANCER; Institut de cancerologie de Lorraine (ICL); Universite de Lorraine; UNICANCER; Institut de cancerologie de Lorraine (ICL); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Gallet, P (corresponding author), Nancy Univ, SiGReTO, EA4421, Fac Med, Vandoeuvre Les Nancy, France.	b.phulpin@nancy.unicancer.fr			French Ligue contre le cancer, Comites Lorrains	French Ligue contre le cancer, Comites Lorrains	This work was granted by the French Ligue contre le cancer, Comites Lorrains. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anscher MS, 1998, INT J RADIAT ONCOL, V41, P1029, DOI 10.1016/S0360-3016(98)00154-0; Arpin D, 2005, J CLIN ONCOL, V23, P8748, DOI 10.1200/JCO.2005.01.7145; Barthelemy-Brichant N, 2004, INT J RADIAT ONCOL, V58, P758, DOI 10.1016/S0360-3016(03)01614-6; Calveley VL, 2005, INT J RADIAT BIOL, V81, P887, DOI 10.1080/09553000600568002; Castro SV, 2010, BIOMARK MED, V4, P133, DOI 10.2217/BMM.09.79; Cha C, 2004, ANN SURG, V239, P903, DOI 10.1097/01.sla.0000128686.51815.8b; Chen YY, 2005, INT J RADIAT ONCOL, V62, P260, DOI 10.1016/j.ijrobp.2005.01.041; Coppes RP, 2009, SEMIN RADIAT ONCOL, V19, P112, DOI 10.1016/j.semradonc.2008.11.005; Dantzer D, 2003, J SURG ONCOL, V83, P185, DOI 10.1002/jso.10242; Denham JW, 2002, RADIOTHER ONCOL, V63, P129, DOI 10.1016/S0167-8140(02)00060-9; Dorr W, 2001, RADIOTHER ONCOL, V61, P223, DOI 10.1016/S0167-8140(01)00429-7; Ebrahimian TG, 2009, ARTERIOSCL THROM VAS, V29, P503, DOI 10.1161/ATVBAHA.108.178962; Fajardo LF, 2005, ACTA ONCOL, V44, P13, DOI 10.1080/02841860510007440; Fedorocko P, 2002, INT J RADIAT BIOL, V78, P305, DOI 10.1080/09553000110104614; Fleckenstein K, 2007, SEMIN RADIAT ONCOL, V17, P89, DOI 10.1016/j.semradonc.2006.11.004; Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101; Fu XL, 2001, INT J RADIAT ONCOL, V50, P899, DOI 10.1016/S0360-3016(01)01524-3; Galiano RD, 2004, AM J PATHOL, V164, P1935, DOI 10.1016/S0002-9440(10)63754-6; Gaugler M-H, 2005, BRIT J RADIOL, V78, P100, DOI [10.1259/bjr/24511652, DOI 10.1259/BJR/24511652]; Girinsky T, 2000, J MAL VASCUL, V25, P321; Han SK, 2006, INT J RADIAT BIOL, V82, P686, DOI 10.1080/09553000600930699; Hart JP, 2005, INT J RADIAT ONCOL, V63, P1448, DOI 10.1016/j.ijrobp.2005.05.032; Hill RP, 2001, INT J RADIAT ONCOL, V49, P353, DOI 10.1016/S0360-3016(00)01484-X; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Hogle William P, 2006, Semin Oncol Nurs, V22, P212, DOI 10.1016/j.soncn.2006.07.004; HOPEWELL JW, 1989, FRONT RADIAT THER ON, V23, P85; Lefaix JL, 1998, HEALTH PHYS, V75, P375, DOI 10.1097/00004032-199810000-00003; Li YQ, 2001, CANCER RES, V61, P3348; Linard C, 2004, INT J RADIAT ONCOL, V58, P427, DOI 10.1016/j.ijrobp.2003.09.039; Liu Y, 2008, J RADIAT RES, V49, P261, DOI 10.1269/jrr.07099; Liu YB, 2006, J SURG RES, V136, P336, DOI 10.1016/j.jss.2006.07.037; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; Martin M, 1997, ONCOGENE, V15, P981, DOI 10.1038/sj.onc.1201433; Martin M, 2000, Cancer Radiother, V4, P369, DOI 10.1016/S1278-3218(00)00010-X; McFarlin K, 2006, WOUND REPAIR REGEN, V14, P471, DOI 10.1111/j.1743-6109.2006.00153.x; Milliat F., 2008, Annales de Cardiologie et d'Angeiologie, V57, P139, DOI 10.1016/j.ancard.2008.02.015; Okunieff P, 2005, INT J RADIAT ONCOL, V62, P273, DOI 10.1016/j.ijrobp.2005.01.034; Phulpin B, 2009, PLAST RECONSTR SURG, V123, P1187, DOI 10.1097/PRS.0b013e31819f2928; Rabbani ZN, 2010, RADIAT RES, V173, P165, DOI 10.1667/RR1816.1; RANDALL K, 1995, INT J RADIAT BIOL, V68, P301, DOI 10.1080/09553009514551231; Rieder F, 2011, INFLAMM BOWEL DIS; ROBERTS WG, 1995, J CELL SCI, V108, P2369; Rochefort GY, 2006, STEM CELLS, V24, P2202, DOI 10.1634/stemcells.2006-0164; Romagnani S, 2006, CLIN EXP ALLERGY, V36, P1357, DOI 10.1111/j.1365-2222.2006.02606.x; Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087; Rube CE, 2005, INT J RADIAT ONCOL, V61, P1482, DOI 10.1016/j.ijrobp.2004.12.072; Rube CE, 2000, INT J RADIAT ONCOL, V47, P1033, DOI 10.1016/S0360-3016(00)00482-X; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; Schultze-Mosgau S, 2005, INT J RADIAT ONCOL, V61, P1189, DOI 10.1016/j.ijrobp.2004.12.008; Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4; Travis EL, 2001, SEMIN RADIAT ONCOL, V11, P184, DOI 10.1053/srao.2001.25243; von Bultzingslowen I, 2006, SUPPORT CARE CANCER, V14, P519, DOI 10.1007/s00520-006-0052-7; Vujaskovic Z, 2001, INT J RADIAT ONCOL, V50, P851, DOI 10.1016/S0360-3016(01)01593-0; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Williams J, 2003, SEMIN RADIAT ONCOL, V13, P182, DOI 10.1016/S1053-4296(03)00045-6; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	56	57	61	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2011	6	12							e29399	10.1371/journal.pone.0029399	http://dx.doi.org/10.1371/journal.pone.0029399			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	884DI	22216271	Green Published, gold, Green Submitted			2023-01-03	WOS:000299684700052
J	van der Greef, J				van der Greef, Jan			PERSPECTIVE All systems go	NATURE			English	Editorial Material									[van der Greef, Jan] Leiden Univ, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC		jan.vandergreef@tno.nl						Huber M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4163; Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032; van Wietmarschen H., 2009, CLIN RHEUMATOL, V15, P330; Wei HY, PLOS ONE IN PRESS	4	47	48	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S87	S87		10.1038/480S87a	http://dx.doi.org/10.1038/480S87a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190087	Bronze			2023-01-03	WOS:000298318000003
J	Presicce, P; Orsborn, K; King, E; Pratt, J; Fichtenbaum, CJ; Chougnet, CA				Presicce, Pietro; Orsborn, Kris; King, Eileen; Pratt, Jesse; Fichtenbaum, Carl J.; Chougnet, Claire A.			Frequency of Circulating Regulatory T Cells Increases during Chronic HIV Infection and Is Largely Controlled by Highly Active Antiretroviral Therapy	PLOS ONE			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; DISEASE PROGRESSION; IMMUNE ACTIVATION; ECTONUCLEOTIDASE CD39; CUTTING EDGE; EXPRESSION; CD4(+); RESTORATION; DISTINCT; CTLA-4	Regulatory T cells (Tregs) act by suppressing the activation and effector functions of innate and adaptive immune responses. HIV infection impacts Treg proportion and phenotype, although discrepant results have been reported depending on the patient population and the way Tregs were characterized. The effects of highly active antiretroviral therapy (HAART) on Treg frequency have not been thoroughly documented. We performed a detailed longitudinal analysis of Treg frequency and phenotype in 11 HIV-infected individuals enrolled in a single, prospective clinical trial, in which all patients underwent the same treatment protocol and were sampled at the same time points. Tregs were characterized for their expression of molecules associated with activation, cell cycle, apoptosis, or function, and compared to circulating Tregs from a group of age-matched healthy individuals. Our results revealed increased proportions, but reduced absolute numbers of circulating CD3(+)CD4(+)FOXP3(+) Tregs in chronically infected HIV-infected patients. Treg frequency was largely normalized by HAART. Importantly, we show that similar conclusions were drawn regardless of the combination of markers used to define Tregs. Our results also showed increased expression of cell cycle markers (Ki67 and cyclin B) in Tregs from untreated infected individuals, which were decreased by HAART. However, the Treg phenotype in untreated patients was not consistent with a higher level of generalized activation, as they expressed very low levels of CD69, slightly elevated levels of HLA-DR and similar levels of GARP compared to Tregs from uninfected donors. Moreover, none of these markers was significantly changed by HAART. Treg expression of CTLA-4 and cytotoxic molecules was identical between patients and controls. The most striking difference in terms of functional molecules was the high expression of CD39 by Tregs in untreated patients, which HAART only partially controlled.	[Presicce, Pietro; Orsborn, Kris; Chougnet, Claire A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Mol Immunol,Res Fdn,Dept Pediat, Cincinnati, OH 45221 USA; [King, Eileen; Pratt, Jesse] Cincinnati Childrens Hosp, Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA; [Fichtenbaum, Carl J.] Univ Cincinnati, Coll Med, Dept Med, Div Infect Dis, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Presicce, P (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Div Mol Immunol,Res Fdn,Dept Pediat, Cincinnati, OH 45221 USA.	Claire.Chougnet@cchmc.org	King, Eileen/Q-1815-2015; Presicce, Pietro/AAN-8719-2020	Presicce, Pietro/0000-0002-2690-1814; Fichtenbaum, Carl/0000-0002-6778-7253	United States National Institutes of Health (NIH) [R01 AI068524]; NIH/NCRR [5UL1RR026314-02]; Abbott Laboratories; Gilead Sciences; PHS [P30 DK078392]; CEMH [1P30DK090971-01]; DHC [AR47363]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392, P30DK090971] Funding Source: NIH RePORTER	United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Abbott Laboratories(Abbott Laboratories); Gilead Sciences(Gilead Sciences); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); CEMH; DHC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	PP, KO and CAC were partially supported by United States National Institutes of Health (NIH) R01 AI068524. This publication was also partially supported by an Institutional Clinical and Translational Science Award, NIH/NCRR 5UL1RR026314-02. CJF received grant funding from Abbott Laboratories and Gilead Sciences. The authors acknowledge the Research Flow Cytometry Core, and the support provided in part by PHS Grant P30 DK078392, CEMH Grant 1P30DK090971-01 and DHC Grant AR47363. The funders had no role in the design of the study, data collection and analysis, decision to publish, or preparation of the manuscript.	Allers K, 2010, J VIROL, V84, P3259, DOI 10.1128/JVI.01715-09; Andersson J, 2005, J IMMUNOL, V174, P3143, DOI 10.4049/jimmunol.174.6.3143; Aswad F, 2005, J IMMUNOL, V175, P3075, DOI 10.4049/jimmunol.175.5.3075; Becker C, 2009, BLOOD, V114, P1263, DOI 10.1182/blood-2009-02-206730; Bi X, 2009, EUR J IMMUNOL, V39, P301, DOI 10.1002/eji.200838667; Boasso A, 2006, AIDS REV, V8, P141; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Brichacek B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012831; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Eller MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018779; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Gaardbo JC, 2008, CLIN EXP IMMUNOL, V154, P80, DOI 10.1111/j.1365-2249.2008.03725.x; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Grossman WJ, 2004, IMMUNITY, V21, P589, DOI 10.1016/j.immuni.2004.09.002; Kaufmann DE, 2007, NAT IMMUNOL, V8, P1246, DOI 10.1038/ni1515; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kurtulus S, 2010, IMMUNOL REV, V236, P54, DOI 10.1111/j.1600-065X.2010.00920.x; Lages CS, 2008, J IMMUNOL, V181, P1835, DOI 10.4049/jimmunol.181.3.1835; Lederman MM, 2001, AIDS, V15, pS11, DOI 10.1097/00002030-200102002-00003; Li S, 2008, J VIROL, V82, P21, DOI 10.1128/JVI.01768-07; Liao H, 2010, J BIOL CHEM, V285, P14791, DOI 10.1074/jbc.M110.116905; Lim A, 2007, AIDS, V21, P1525, DOI 10.1097/QAD.0b013e32825eab8b; Lim A, 2009, JAIDS-J ACQ IMM DEF, V51, P248, DOI 10.1097/QAI.0b013e3181a74fad; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Liu JU, 2009, J IMMUNOL, V182, P3855, DOI 10.4049/jimmunol.0803330; Meintjes G, 2008, AM J RESP CRIT CARE, V178, P1083, DOI 10.1164/rccm.200806-858OC; Moncrieffe H, 2010, J IMMUNOL, V185, P134, DOI 10.4049/jimmunol.0803474; Moreno Fernandez ME, 2011, BLOOD IN PRESS; Moreno-Fernandez ME, 2009, J VIROL, V83, P12925, DOI 10.1128/JVI.01352-09; Nigam P, 2010, J IMMUNOL, V184, P1690, DOI 10.4049/jimmunol.0902955; Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110; Nilsson J, 2006, BLOOD, V108, P3808, DOI 10.1182/blood-2006-05-021576; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Paiardini M, 2004, AIDS, V18, P393, DOI 10.1097/00002030-200402200-00004; Pandrea I, 2008, J IMMUNOL, V181, P6687, DOI 10.4049/jimmunol.181.10.6687; Piedimonte G, 1999, AIDS, V13, P1159, DOI 10.1097/00002030-199907090-00003; Presicce P, 2010, CYTOM PART A, V77A, P571, DOI 10.1002/cyto.a.20875; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sachdeva M, 2010, JAIDS-J ACQ IMM DEF, V54, P447, DOI 10.1097/QAI.0b013e3181e0c7d0; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schulze Zur Wiesch J, 2010, J VIROL; Sitkovsky M, 2008, BRIT J PHARMACOL, V153, pS457, DOI 10.1038/bjp.2008.23; Tan D, 2008, HIV MED, V9, P307, DOI 10.1111/j.1468-1293.2008.00565.x; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Wang R, 2009, P NATL ACAD SCI USA, V106, P13439, DOI 10.1073/pnas.0901965106; Weiss L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011659; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Xing SJ, 2010, JAIDS-J ACQ IMM DEF, V54, P455, DOI 10.1097/QAI.0b013e3181e453b9; Zhang SM, 2010, FASEB J, V24, P495, DOI 10.1096/fj.09-143925	53	57	63	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2011	6	12							e28118	10.1371/journal.pone.0028118	http://dx.doi.org/10.1371/journal.pone.0028118			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863NX	22162758	gold, Green Submitted, Green Published			2023-01-03	WOS:000298172800016
J	Heagerty, AM				Heagerty, Anthony M.			Secondary prevention of heart disease and stroke: work to do	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; BLOOD-PRESSURE; METAANALYSIS; INDIVIDUALS; GUIDELINES; MANAGEMENT		Univ Manchester, Cardiovasc Res Grp, Manchester M13 9NT, Lancs, England	University of Manchester	Heagerty, AM (corresponding author), Univ Manchester, Cardiovasc Res Grp, Manchester M13 9NT, Lancs, England.	tony.heagerty@manchester.ac.uk		Heagerty, Anthony/0000-0002-9043-2119				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Catapano AL, 2011, ATHEROSCLEROSIS, V217, P1, DOI 10.1016/j.atherosclerosis.2011.06.011; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Mancia G, 2009, J HYPERTENS, V27, P2121, DOI 10.1097/HJH.0b013e328333146d; Mihaylova B, 2005, LANCET, V365, P1779, DOI 10.1016/S0140-6736(05)63014-0; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Yusuf S, 2011, LANCET, DOI [10.1016/S0140-6736(11)61302-0, DOI 10.1016/S0140-6736(11)61302-0]	8	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	2011	378	9798					1200	1202		10.1016/S0140-6736(11)61302-0	http://dx.doi.org/10.1016/S0140-6736(11)61302-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	831IO	21872919				2023-01-03	WOS:000295723600005
J	Visintin, C; Mugglestone, MA; James, D; Kilby, MD				Visintin, Cristina; Mugglestone, Moira A.; James, David; Kilby, Mark D.		Guideline Dev Grp	GUIDELINES Antenatal care for twin and triplet pregnancies: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material							GESTATIONS		[Visintin, Cristina; Mugglestone, Moira A.; James, David] Natl Collaborating Ctr Womens & Childrens Hlth, London W1T 2QA, England; [Kilby, Mark D.] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Kilby, Mark D.] Birmingham Womens Fdn Trust, Birmingham B15 2TG, W Midlands, England	University of Birmingham	Mugglestone, MA (corresponding author), Natl Collaborating Ctr Womens & Childrens Hlth, London W1T 2QA, England.	mmugglestone@ncc-wch.org.uk	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Nherera, Leo/P-1567-2018	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Bricker, Leanne/0000-0001-7713-2771; Nherera, Leo/0000-0003-1758-9504; Thilaganathan, Basky/0000-0002-5531-4301				[Anonymous], 2008, ANT CAR ROUT CAR HLT; CHAN A, 2008, PREGNANCY OUTCOME S; Department of Health, 2010, EQ EXC LIB NHS; EDWARDS MS, 1995, ULTRASOUND OBST GYN, V6, P43, DOI 10.1046/j.1469-0705.1995.06010043.x; Elliott JP, 2005, SEMIN PERINATOL, V29, P305, DOI 10.1053/j.semperi.2005.08.001; Laws PJ., 2008, AUSTR MOTHERS BABIES; LIPITZ S, 1994, AM J OBSTET GYNECOL, V170, P874, DOI 10.1016/S0002-9378(94)70301-9; Luke B, 2003, AM J OBSTET GYNECOL, V189, P934, DOI 10.1067/S0002-9378(03)01054-8; *NAT I HLTH CLIN E, 2006, SEPT AMN TREATM TWIN; *NAT I HLTH CLIN E, 2006, INTR LAS ABL PLAC VE; National Institute for Health and Clinical Excellence, 2011, MULT PREGN MAN TWIN; Roberts CL, 2002, INT J GYNECOL OBSTET, V78, P213, DOI 10.1016/S0020-7292(02)00147-9; *SEMACH, 2009, CONF ENQ MAT CHILD H; Tucker J, 2004, BRIT MED J, V329, P675, DOI 10.1136/bmj.329.7467.675	14	32	35	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2011	343								d5714	10.1136/bmj.d5714	http://dx.doi.org/10.1136/bmj.d5714			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829JZ	21957208				2023-01-03	WOS:000295577100003
J	Selker, HP; Beshansky, JR; Sheehan, PR; Massaro, JM; Griffith, JL; D'Agostino, RB; Ruthazer, R; Atkins, JM; Sayah, AJ; Levy, MK; Richards, ME; Aufderheide, TP; Braude, DA; Pirrallo, RG; Doyle, DD; Frascone, RJ; Kosiak, DJ; Leaming, JM; Van Gelder, CM; Walter, GP; Wayne, MA; Woolard, RH; Opie, LH; Rackley, CE; Apstein, CS; Udelson, JE				Selker, Harry P.; Beshansky, Joni R.; Sheehan, Patricia R.; Massaro, Joseph M.; Griffith, John L.; D'Agostino, Ralph B.; Ruthazer, Robin; Atkins, James M.; Sayah, Assaad J.; Levy, Michael K.; Richards, Michael E.; Aufderheide, Tom P.; Braude, Darren A.; Pirrallo, Ronald G.; Doyle, Delanor D.; Frascone, Ralph J.; Kosiak, Donald J.; Leaming, James M.; Van Gelder, Carin M.; Walter, Gert-Paul; Wayne, Marvin A.; Woolard, Robert H.; Opie, Lionel H.; Rackley, Charles E.; Apstein, Carl S.; Udelson, James E.			Out-of-Hospital Administration of Intravenous Glucose-Insulin-Potassium in Patients With Suspected Acute Coronary Syndromes The IMMEDIATE Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PREDICTIVE INSTRUMENT; FATTY-ACIDS; INFUSION; MORTALITY; THERAPY; MULTICENTER; ARRHYTHMIAS; ISCHEMIA; ASSIST	Context Laboratory studies suggest that in the setting of cardiac ischemia, immediate intravenous glucose-insulin-potassium (GIK) reduces ischemia-related arrhythmias and myocardial injury. Clinical trials have not consistently shown these benefits, possibly due to delayed administration. Objective To test out-of hospital emergency medical service (EMS) administration of GIK in the first hours of suspected acute coronary syndromes (ACS). Design, Setting, and Participants Randomized, placebo-controlled, double-blind effectiveness trial in 13 US cities (36 EMS agencies), from December 2006 through July 31, 2011, in which paramedics, aided by electrocardiograph (ECG)-based decision support, randomized 911 (871 enrolled) patients (mean age, 63.6 years; 71.0% men) with high probability of ACS. Intervention Intravenous GIK solution (n=411) or identical-appearing 5% glucose placebo (n=460) administered by paramedics in the out-of-hospital setting and continued for 12 hours. Main Outcome Measures The prespecified primary end point was progression of ACS to myocardial infarction (MI) within 24 hours, as assessed by biomarkers and ECG evidence. Prespecified secondary end points included survival at 30 days and a composite of prehospital or in-hospital cardiac arrest or in-hospital mortality, analyzed by intent-to-treat and by presentation with ST-segment elevation. Results There was no significant difference in the rate of progression to MI among patients who received GIK (n=200; 48.7%) vs those who received placebo (n=242; 52.6%) (odds ratio [OR], 0.88; 95% CI, 0.66-1.13; P=.28). Thirty-day mortality was 4.4% with GIK vs 6.1% with placebo (hazard ratio [HR], 0.72; 95% CI, 0.40-1.29; P=.27). The composite of cardiac arrest or in-hospital mortality occurred in 4.4% with GIK vs 8.7% with placebo (OR, 0.48; 95% CI, 0.27-0.85; P=.01). Among patients with ST-segment elevation (163 with GIK and 194 with placebo), progression to MI was 85.3% with GIK vs 88.7% with placebo (OR, 0.74; 95% CI, 0.40-1.38; P=.34); 30-day mortality was 4.9% with GIK vs 7.7% with placebo (HR, 0.63; 95% CI, 0.27-1.49; P=.29). The composite outcome of cardiac arrest or in-hospital mortality was 6.1% with GIK vs 14.4% with placebo (OR, 0.39; 95% CI, 0.18-0.82; P=.01). Serious adverse events occurred in 6.8% (n=28) with GIK vs 8.9% (n=41) with placebo (P=.26). Conclusions Among patients with suspected ACS, out-of-hospital administration of intravenous GIK, compared with glucose placebo, did not reduce progression to MI. Compared with placebo, GIK administration was not associated with improvement in 30-day survival but was associated with lower rates of the composite outcome of cardiac arrest or in-hospital mortality.	[Selker, Harry P.; Beshansky, Joni R.; Sheehan, Patricia R.; Griffith, John L.; Ruthazer, Robin] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Cardiovasc Hlth Serv Res, Boston, MA 02111 USA; [Udelson, James E.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Massaro, Joseph M.] Boston Univ, Dept Biostat, Boston, MA 02215 USA; [D'Agostino, Ralph B.] Boston Univ, Dept Math, Boston, MA 02215 USA; [Atkins, James M.] Univ Texas SW Med Sch, Dept Med, Dallas, TX USA; [Sayah, Assaad J.] Cambridge Hlth Alliance, Dept Emergency Med, Cambridge, MA USA; [Levy, Michael K.] Alaska Reg Hosp, Anchorage, AK USA; [Richards, Michael E.; Braude, Darren A.] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Braude, Darren A.] Univ New Mexico, Sch Med, Dept Anesthesia, Albuquerque, NM 87131 USA; [Aufderheide, Tom P.; Pirrallo, Ronald G.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Doyle, Delanor D.] Med Ctr Cent Georgia, Dept Emergency Med, Macon, GA USA; [Frascone, Ralph J.] Reg Hosp EMS, St Paul, MN USA; [Kosiak, Donald J.] Avera Med Grp, Sioux Falls, SD USA; [Leaming, James M.] Penn State Hershey Med Ctr, Dept Emergency Med, Hershey, PA USA; [Van Gelder, Carin M.] Johnson Mem Hosp, Dept Emergency Med, Stafford, CT USA; [Van Gelder, Carin M.] Windham Community Mem Hosp, Willimantic, CT USA; [Walter, Gert-Paul] Emerson Hosp, Dept Emergency Med, Concord, MA USA; [Wayne, Marvin A.] St Joseph Med Ctr, Dept Emergency Med, Bellingham, WA USA; [Woolard, Robert H.] Texas Tech Univ Hlth Sci Ctr, Dept Emergency Med, El Paso, TX USA; [Opie, Lionel H.] Univ Cape Town, Dept Med, Hatter Cardiovasc Res Inst Africa, ZA-7925 Cape Town, South Africa; [Rackley, Charles E.] Georgetown Med Ctr, Lipid Disorders Ctr, Washington, DC USA; [Udelson, James E.] Tufts Med Ctr, Div Cardiol, Ctr Cardiovasc, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Boston University; Boston University; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Cambridge Health Alliance; University of New Mexico; University of New Mexico; Medical College of Wisconsin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Texas Tech University System; Texas Tech University Health Science Center; University of Cape Town; Georgetown University; Tufts Medical Center	Selker, HP (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Cardiovasc Hlth Serv Res, 800 Washington St,63, Boston, MA 02111 USA.	hselker@tuftsmedicalcenter.org		Pirrallo, Ronald/0000-0002-8321-3866; Massaro, Joseph/0000-0002-2682-4812	NIH, NHLBI; IMMEDIATE Trial scientific advisory committee; NIH from the National Heart, Lung, and Blood Institute [U01HL077821, U01HL077826, U01HL077823]; National Center for Advancing Translational Sciences [UL1RR025752]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077823, U01HL077821, U01HL077826] Funding Source: NIH RePORTER	NIH, NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); IMMEDIATE Trial scientific advisory committee; NIH from the National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Selker, principal investigator, reported institutional receipt of grant funds and indirect payment for his work and travel expenses; the institution's grant paid for honoraria to members of the scientific advisory committee, DSMB, and Harvard Clinical Research Institute for event adjudication and statistical analysis, Curlin Inc for intravenous pumps, and Philips Healthcare for ECG decision support software. Dr Selker also reported an expired patent for the TPI ECG software, but no royalties are received. Ms Beshansky, co-principal investigator, reported institutional and indirect receipt of grant support and support for travel expenses. Dr Massaro reported grant support provided to his institution and direct receipt of funds, in addition to support for travel. Drs D'Agostino and Atkins reported institutional grant support and support for travel expenses. Drs Braude, Doyle, Frascone, Griffith, Leaming, Richards, Udelson, and Woolard, Ms Ruthazer, and Ms Sheehan reported grant support (NIH, NHLBI) provided to their institution. Dr Kosiak reported institutional and direct receipt of funds in support for travel expenses and fees for data review and training. Dr Rackley reported direct receipt of funds for fees for participating on the IMMEDIATE Trial scientific advisory committee. Dr Opie reported consulting fees, support for travel, and fees for scientific advisory committee participation; direct payment for employment (salary) and grants pending (Medical Research Council); and institutional payment for travel (European Society of Cardiology Task Force) outside of the submitted work. Dr Pirrallo reported institutional grant support and support for travel expenses; and relevant but outside of the submitted work he reported direct payment for board membership in National Association of EMS Physicians. Dr Sayah reported institutional receipt of grant support and fees for participating in review activities. Dr Van Gelder reported institutional and direct receipt of grant funds and institutional receipt of funds for provision of equipment and administrative support. Dr Aufderheide reported institutional grant support, support for travel expenses, and provision for software and equipment; also reported as relevant but outside of the submitted work: board membership (volunteer at Citizen CPR Foundation and Take Heart America), consultant (funds to institution, Medtronic Inc), 5 pending emergency research grants (funds to institution, NHLBI, NINDS, Leducq Foundation, Medtronic Foundation); and volunteer member (BLS Subcommittee and Research Working Group, AHA). Dr Wayne reported grant support provided to his institution and direct receipt of funds; also reported, as relevant but outside of the submitted work: direct payment for employment as emergency medicine physician, EMS director, expert testimony, royalties (chest tube by Cook Critical Care), payment for development of educational presentations, and travel expenses for a nonprofit foundation administration. Dr Walter reported institutional receipt of funds for equipment, administrative support, paramedic training, and investigator effort; also reported, relevant but outside the submitted work: receipt of funds for employment as the medical director for the paramedic service at Emerson Hospital. Drs Levy and Apstein reported no conflicts of interest.; This work was funded by an NIH cooperative agreement from the National Heart, Lung, and Blood Institute (grants U01HL077821, U01HL077826, U01HL077823). National Center for Research Resources (grant UL1RR025752), now at the National Center for Advancing Translational Sciences, provided laboratory testing. Insulin was donated by Eli Lilly and Company. ECG-based decision support software was donated by Physio-Control and Zoll Medical.	Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; Apstein CS, 2005, JAMA-J AM MED ASSOC, V293, P2596, DOI 10.1001/jama.293.21.2596; Apstein CS, 1999, CARDIOVASC DRUG THER, V13, P185, DOI 10.1023/A:1007757407246; Beshansky JR, 2010, CLIN TRIALS, V7, P428; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FathOrdoubadi F, 1997, CIRCULATION, V96, P1152, DOI 10.1161/01.CIR.96.4.1152; KURIEN VA, 1969, LANCET, V2, P185; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; Oliver MF, 2002, EUR HEART J, V23, P1797, DOI 10.1053/euhj.2002.3373; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE LH, 1975, CIRCULATION, V52, P49, DOI 10.1161/01.CIR.52.1.49; RACKLEY CE, 1981, AM HEART J, V102, P1038, DOI 10.1016/0002-8703(81)90488-9; Selker HP, 2012, AM HEART J, V163, P315, DOI 10.1016/j.ahj.2012.02.002; Selker HP, 2011, PREHOSP EMERG CARE, V15, P139, DOI 10.3109/10903127.2010.545478; Selker HP, 2003, AM J CARDIOL, V91, P280, DOI 10.1016/S0002-9149(02)03155-7; Selker HP, 2002, ANN INTERN MED, V137, P87, DOI 10.7326/0003-4819-137-2-200207160-00006; Selker HP, 1998, ANN INTERN MED, V129, P845, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00002; Timmer JR, 2006, J AM COLL CARDIOL, V47, P1730, DOI 10.1016/j.jacc.2006.01.040; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1	21	164	173	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 9	2012	307	18					1925	1933		10.1001/jama.2012.426	http://dx.doi.org/10.1001/jama.2012.426			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	938OD	22452807	Green Accepted, Bronze			2023-01-03	WOS:000303741900026
J	Ryan, D; Price, D; Musgrave, SD; Malhotra, S; Lee, AJ; Ayansina, D; Sheikh, A; Tarassenko, L; Pagliari, C; Pinnock, H				Ryan, Dermot; Price, David; Musgrave, Stan D.; Malhotra, Shweta; Lee, Amanda J.; Ayansina, Dolapo; Sheikh, Aziz; Tarassenko, Lionel; Pagliari, Claudia; Pinnock, Hilary			Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD ASTHMA; PRIMARY-CARE; LONG-TERM; MANAGEMENT; QUALITY; QUESTIONNAIRE; TECHNOLOGY; VALIDATION; OUTCOMES; SYSTEM	Objective To determine whether mobile phone based monitoring improves asthma control compared with standard paper based monitoring strategies. Design Multicentre randomised controlled trial with cost effectiveness analysis. Setting UK primary care. Participants 288 adolescents and adults with poorly controlled asthma (asthma control questionnaire (ACQ) score >= 1.5) from 32 practices. Intervention Participants were centrally randomised to twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback prompting action according to an agreed plan or paper based monitoring. Main outcome measures Changes in scores on asthma control questionnaire and self efficacy (knowledge, attitude, and self efficacy asthma questionnaire (KASE-AQ)) at six months after randomisation. Assessment of outcomes was blinded. Analysis was on an intention to treat basis. Results There was no significant difference in the change in asthma control or self efficacy between the two groups (ACQ: mean change 0.75 in mobile group v 0.73 in paper group, mean difference in change -0.02 (95% confidence interval -0.23 to 0.19); KASE-AQ score: mean change -4.4 v -2.4, mean difference 2.0 (-0.3 to 4.2)). The numbers of patients who had acute exacerbations, steroid courses, and unscheduled consultations were similar in both groups, with similar healthcare costs. Overall, the mobile phone service was more expensive because of the expenses of telemonitoring. Conclusions Mobile technology does not improve asthma control or increase self efficacy compared with paper based monitoring when both groups received clinical care to guidelines standards. The mobile technology was not cost effective.	[Ryan, Dermot; Price, David; Musgrave, Stan D.; Malhotra, Shweta] Univ Aberdeen, Acad Ctr Primary Care, Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Lee, Amanda J.; Ayansina, Dolapo] Univ Aberdeen, Med Stat Team, Div Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Sheikh, Aziz; Pinnock, Hilary] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; [Tarassenko, Lionel] Univ Oxford, Inst Biomed Engn, Oxford OX3 7DQ, England; [Pagliari, Claudia] Univ Edinburgh, eHth Res Grp, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland	University of Aberdeen; University of Aberdeen; University of Edinburgh; University of Oxford; University of Edinburgh	Ryan, D (corresponding author), Woodbrook Med Ctr, 28 Bridge St, Loughborough LE11 1NH, Leics, England.	dermotryan@doctors.org.uk	Price, David/H-2837-2019; Ryan, Dermot/AAJ-2329-2021; Ayansina, Dolapo/AAP-1663-2020; Pagliari, Claudia C/P-6412-2018; Sheikh, Aziz/D-2818-2009	Price, David/0000-0002-9728-9992; Ryan, Dermot/0000-0002-4115-7376; Pagliari, Claudia C/0000-0001-5791-7723; Sheikh, Aziz/0000-0001-7022-3056; Ayansina, Dolapo/0000-0001-7684-8620	Asthma UK [07/047]; chief scientist's office of the Scottish Government; UK National Health Service; Aerocrine; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck; Mundipharma; Novartis; Nycomed; Pfizer; Teva; Merck and Co; AKL Technologies; Chiesi; Mundipharma AS; Napp; NIHR Biomedical Research Centre; Chief Scientist Office [PCRCA/08/01] Funding Source: researchfish	Asthma UK; chief scientist's office of the Scottish Government; UK National Health Service; Aerocrine; AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Mundipharma; Novartis(Novartis); Nycomed; Pfizer(Pfizer); Teva(Teva Pharmaceutical Industries); Merck and Co(Merck & Company); AKL Technologies; Chiesi(Chiesi Pharmaceuticals Inc); Mundipharma AS; Napp; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Chief Scientist Office	This study was funded by Asthma UK (project ID 07/047). Piko peak flow meters were donated by nSpire Health. HP is supported by a primary care research career award from the chief scientist's office of the Scottish Government.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: DR has spoken on behalf of AstraZeneca, Nycomed, MSD, AlkAbello, Chiesi, Novartis, Pfizer and BoehringerIingelheim. He has undertaken advisory work for Astra Zeneca, MSD, Novartis, Uriach, Mundipharma, Orion, and Napp. DP has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, and Teva. In the past five years, he or his research team have received grants and support for research in respiratory disease from UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer, and Teva. He has spoken for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Pfizer, and Teva. He has shares in AKL, which produces phytopharmaceuticals. He is the sole owner of Research in Real Life. SDM has received institutional grant support from Merck and Co, AKL Technologies, Chiesi, and Mundipharma AS serves on WHO's mHealth and Information Technology for Patient Safety Expert Working Groups and is an adviser to NHS Connecting for Health's Evaluation Programme. He is a consultant to ALK and Phadia and has received support from Napp, Pfizer, and Chiesi for research advice. LT is a cofounder of, advisor to, and holds shares in OBS Medical. He contributed to the design of t+ asthma and of the trial, but had no role in the day-to-day conduct of the study or statistical analysis. His work on telehealthcare is funded by the NIHR Biomedical Research Centre Programme. HP has spoken for AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Pfizer, and Teva and undertaken advisory group work for Chiesi.	British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Black AD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000387; British Medical Association and Royal Pharmaceutical Society, 2008, BRIT NAT FORM SEPT 2; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Catwell L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000126; Clatworthy Jane, 2009, Prim Care Respir J, V18, P300, DOI 10.4104/pcrj.2009.00037; Cleland J, 2007, J TELEMED TELECARE, V13, P85, DOI 10.1258/135763307780096230; Cobern W, ASTHMA SELF MANAGEME; Craig P., 2008, DEV EVALUATING COMPL; Curtis L., UNIT COSTS HLTH SOCI; Department of Health, NAT SCHED REF COSTS; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; GINA, 2010, GLOB STRAT ASTHM MAN; Glasziou P, 2005, BMJ-BRIT MED J, V330, P644, DOI 10.1136/bmj.330.7492.644; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Howie JGR, 1998, FAM PRACT, V15, P165, DOI 10.1093/fampra/15.2.165; International Telecommunication Union, 2010, KEY GLOB TEL IND WOR; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 2001, AM J RESP CRIT CARE, V163, P642; Lemaigre V, 2005, CHEST, V128, P3133, DOI 10.1378/chest.128.5.3133; Liu WT, 2011, EUR RESPIR J, V37, P310, DOI 10.1183/09031936.00000810; Masoli M, 2003, GLOBAL BURDEN ASTHMA; McIvor RA, 2008, LANCET, V372, P1021, DOI 10.1016/S0140-6736(08)61423-3; McLean S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007717.pub2; McLean S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d120; Ostojic V, 2005, TELEMED J E-HEALTH, V11, P28, DOI 10.1089/tmj.2005.11.28; Pinnock H, 2007, CLIN EXP ALLERGY, V37, P794, DOI 10.1111/j.1365-2222.2007.02708.x; Pinnock H, 2005, J CLIN EPIDEMIOL, V58, P809, DOI 10.1016/j.jclinepi.2005.01.010; Pinnock H, 2010, PRIM CARE RESP J, V19, P75, DOI 10.4104/pcrj.2010.00006; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Reddel HK, 2002, BRIT MED J, V324, P146, DOI 10.1136/bmj.324.7330.146; Ryan D, 2005, J TELEMED TELECARE, V11, P43, DOI 10.1258/1357633054461714; Ryan Dermot, 2009, Prim Care Respir J, V18, P343, DOI 10.4104/pcrj.2009.00064; van der Meer V, 2007, CHEST, V132, P112, DOI 10.1378/chest.06-2787; van der Meer V, 2009, ANN INTERN MED, V151, P110, DOI 10.7326/0003-4819-151-2-200907210-00008; White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144; Yoos HL, 2002, ANN ALLERG ASTHMA IM, V88, P283, DOI 10.1016/S1081-1206(10)62010-8	46	129	132	2	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2012	344								e1756	10.1136/bmj.e1756	http://dx.doi.org/10.1136/bmj.e1756			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CQ	22446569	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000301849400002
J	Whyte, MP; Greenberg, CR; Salman, NJ; Bober, MB; McAlister, WH; Wenkert, D; Van Sickle, BJ; Simmons, JH; Edgar, TS; Bauer, ML; Hamdan, MA; Bishop, N; Lutz, RE; McGinn, M; Craig, S; Moore, JN; Taylor, JW; Cleveland, RH; Cranley, WR; Lim, R; Thacher, TD; Mayhew, JE; Downs, M; Millan, JL; Skrinar, AM; Crine, P; Landy, H				Whyte, Michael P.; Greenberg, Cheryl R.; Salman, Nada J.; Bober, Michael B.; McAlister, William H.; Wenkert, Deborah; Van Sickle, Bradley J.; Simmons, Jill H.; Edgar, Terence S.; Bauer, Martin L.; Hamdan, Mohamed A.; Bishop, Nick; Lutz, Richard E.; McGinn, Mairead; Craig, Stanley; Moore, Jean N.; Taylor, John W.; Cleveland, Robert H.; Cranley, William R.; Lim, Ruth; Thacher, Tom D.; Mayhew, Jill E.; Downs, Matthew; Millan, Jose Luis; Skrinar, Alison M.; Crine, Philippe; Landy, Hal			Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSPECIFIC ALKALINE-PHOSPHATASE; INFANTILE HYPOPHOSPHATASIA; MURINE HYPOPHOSPHATASIA; INTRAVENOUS-INFUSION; BONE; DISEASE; GENE; PYRIDOXAL-5'-PHOSPHATE; TRANSPLANTATION; MINERALIZATION	BACKGROUND Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice. METHODS We enrolled infants and young children with life-threatening or debilitating perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-0040. The primary objective was the healing of rickets, as assessed by means of radiographic scales. Motor and cognitive development, respiratory function, and safety were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040. RESULTS Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. Healing of rickets at 6 months in 9 patients was accompanied by improvement in developmental milestones and pulmonary function. Elevated plasma levels of the TNSALP substrates inorganic pyrophosphate and pyridoxal 5'-phosphate diminished. Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia, ectopic calcification, or definite drug-related serious adverse events. Low titers of anti-ENB-0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment. CONCLUSIONS ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.)	[Whyte, Michael P.; Wenkert, Deborah] Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63131 USA; [Whyte, Michael P.] Washington Univ, Sch Med, Div Bone & Mineral Dis, Barnes Jewish Hosp, St Louis, MO 63130 USA; [McAlister, William H.] Washington Univ, Sch Med, St Louis Childrens Hosp, Mallinckrodt Inst Radiol, St Louis, MO 63130 USA; [Greenberg, Cheryl R.] Univ Manitoba, Winnipeg, MB, Canada; [Greenberg, Cheryl R.] Winnipeg Reg Hlth Author, Winnipeg, MB, Canada; [Salman, Nada J.; Hamdan, Mohamed A.] Tawam Hosp, Al Ain, U Arab Emirates; [Bober, Michael B.] Alfred I Dupont Hosp Children, Wilmington, DE USA; [Van Sickle, Bradley J.; Simmons, Jill H.] Vanderbilt Childrens Hosp, Nashville, TN USA; [Edgar, Terence S.; Taylor, John W.] Prevea Hlth Clin, Green Bay, WI USA; [Taylor, John W.] St Vincents Hosp, Green Bay, WI USA; [Bauer, Martin L.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA; [Bishop, Nick] Sheffield Childrens Hosp, Sheffield, S Yorkshire, England; [McGinn, Mairead; Craig, Stanley] Royal Belfast Hosp Sick Children, Belfast, Antrim, North Ireland; [Lutz, Richard E.] Univ Nebraska Med Ctr, Omaha, NE USA; [Moore, Jean N.] St Johns Hosp, Springfield, MO USA; [Cleveland, Robert H.] Childrens Hosp, Boston, MA 02115 USA; [Cranley, William R.] Boston Med Ctr, Boston, MA USA; [Lim, Ruth] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Thacher, Tom D.] Mayo Clin, Rochester, MN USA; [Mayhew, Jill E.; Skrinar, Alison M.; Crine, Philippe; Landy, Hal] Enobia Pharma, Montreal, PQ, Canada; [Downs, Matthew] Stat Collaborat, Washington, DC USA; [Millan, Jose Luis] Sanford Burnham Med Res Inst, La Jolla, CA USA	Barnes-Jewish Hospital; Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); University of Manitoba; Nemours Alfred I. duPont Hospital for Children; Vanderbilt University; University of Arkansas System; University of Arkansas Medical Sciences; Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Nebraska System; University of Nebraska Medical Center; Saint Johns Mercy Medical Center; Harvard University; Boston Children's Hospital; Boston Medical Center; Harvard University; Massachusetts General Hospital; Mayo Clinic; Sanford Burnham Prebys Medical Discovery Institute	Whyte, MP (corresponding author), Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, 2001 S Lindbergh Blvd, St Louis, MO 63131 USA.	mwhyte@shrinenet.org	Thacher, Tom/B-3356-2009; Bober, Michael/AAH-4553-2021; Downs, Matt/S-7646-2019	Thacher, Tom/0000-0002-7644-8173; Simmons, Jill/0000-0002-4189-6718; Bober, Michael/0000-0002-6178-1264	Enobia Pharma Hospital for Children; Shriners Hospital for Children; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012889] Funding Source: NIH RePORTER	Enobia Pharma Hospital for Children; Shriners Hospital for Children; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	Supported by Enobia Pharma and Shriners Hospitals for Children.	Anderson HC, 1997, AM J PATHOL, V151, P1555; [Anonymous], 2005, BAYL SCAL INF TODDL; Baumgartner-Sigl S, 2007, BONE, V40, P1655, DOI 10.1016/j.bone.2007.01.020; Beal S, 1989, NONMEM USERS GUIDE 1; Cahill RA, 2007, J CLIN ENDOCR METAB, V92, P2923, DOI 10.1210/jc.2006-2131; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Collmann H, 2009, CHILD NERV SYST, V25, P217, DOI 10.1007/s00381-008-0708-3; Fedde KN, 1999, J BONE MINER RES, V14, P2015, DOI 10.1359/jbmr.1999.14.12.2015; FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0; Fleisch H, 1995, BISPHOSPHONATES BONE, P149; FRASER D, 1957, AM J MED, V22, P730, DOI 10.1016/0002-9343(57)90124-9; Greenberg CR, 2009, 16 ANN CLIN GEN M AM; Ish-Shalom S, 1986, 8 ANN SCI M AM SOC B; McKee MD, 2011, J DENT RES, V90, P470, DOI 10.1177/0022034510393517; Millan J.L., 2006, MAMMALIAN ALKALINE P; Millan JL, 2008, J BONE MINER RES, V23, P777, DOI 10.1359/JBMR.071213; MORNET E, 2006, TISSUE NONSPECIFIC A; Mumm S, 2002, MOL GENET METAB, V75, P143, DOI 10.1006/mgme.2001.3283; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; PRESTON CJ, 1986, BRIT MED J, V292, P79, DOI 10.1136/bmj.292.6513.79; RATHBUN JC, 1948, AM J DIS CHILD, V75, P822, DOI 10.1001/archpedi.1948.02030020840003; RUSSELL RGG, 1965, LANCET, V2, P461; Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221; SESHIA SS, 1990, ARCH DIS CHILD, V65, P130, DOI 10.1136/adc.65.1.130; Thacher TD, 2000, J TROP PEDIATRICS, V46, P132, DOI 10.1093/tropej/46.3.132; van den Bos T, 2005, J DENT RES, V84, P1021, DOI 10.1177/154405910508401110; WEISS MJ, 1988, P NATL ACAD SCI USA, V85, P7666, DOI 10.1073/pnas.85.20.7666; Wenkert D, 2011, J BONE MINER RES, V26, P2389, DOI 10.1002/jbmr.454; Whyte MP, 2007, J CLIN ENDOCR METAB, V92, P1203, DOI 10.1210/jc.2006-1902; Whyte MP, 2012, PEDIATRIC BONE: BIOLOGY & DISEASES, 2ND EDITION, P771, DOI 10.1016/B978-0-12-382040-2.10028-0; Whyte MP, 2008, PRINCIPLES OF BONE BIOLOGY, VOL 2, 3RD EDITION, P1573, DOI 10.1016/B978-0-12-373884-4.00080-X; Whyte MP, 2000, J BONE MINER RES, V15, pS483; WHYTE MP, 1988, J CLIN INVEST, V81, P1234, DOI 10.1172/JCI113440; WHYTE MP, 1984, J PEDIATR-US, V105, P926, DOI 10.1016/S0022-3476(84)80079-7; Whyte MP, 2003, J BONE MINER RES, V18, P624, DOI 10.1359/jbmr.2003.18.4.624; WHYTE MP, 1992, J BONE MINER RES, V7, pS155; WHYTE MP, 1982, J PEDIATR-US, V101, P379, DOI 10.1016/S0022-3476(82)80061-9; WHYTE MP, 1985, J CLIN INVEST, V76, P752, DOI 10.1172/JCI112031; Wilcoxon F., 1945, BIOMETRICS B, V6, P80; Yadav MC, 2011, BONE, V49, P250, DOI 10.1016/j.bone.2011.03.770	40	344	376	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 8	2012	366	10					904	913		10.1056/NEJMoa1106173	http://dx.doi.org/10.1056/NEJMoa1106173			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CY	22397652	Green Published, Bronze			2023-01-03	WOS:000301172500007
J	Gonzalez-Candelas, F; Astray, J; Alonso, J; Castro, A; Canton, R; Galan, JC; Garin, O; Saez, M; Soldevila, N; Baricot, M; Castilla, J; Godoy, P; Delgado-Rodriguez, M; Martin, V; Mayoral, JM; Pumarola, T; Quintana, JM; Tamames, S; Dominguez, A				Gonzalez-Candelas, Fernando; Astray, Jenaro; Alonso, Jordi; Castro, Ady; Canton, Rafael; Carlos Galan, Juan; Garin, Olatz; Saez, Marc; Soldevila, Nuria; Baricot, Maretva; Castilla, Jesus; Godoy, Pere; Delgado-Rodriguez, Miguel; Martin, Vicente; Maria Mayoral, Jose; Pumarola, Tomas; Maria Quintana, Jose; Tamames, Sonia; Dominguez, Angela		CIBERESP Cases Controls Pandemic	Sociodemographic Factors and Clinical Conditions Associated to Hospitalization in Influenza A (H1N1) 2009 Virus Infected Patients in Spain, 2009-2010	PLOS ONE			English	Article							RISK-FACTORS; ADVISORY-COMMITTEE; A(H1N1) INFECTION; OUTCOMES; VACCINE; DEATH; WOMEN; RECOMMENDATIONS; MORTALITY; CHILDREN	The emergence and pandemic spread of a new strain of influenza A (H1N1) virus in 2009 resulted in a serious alarm in clinical and public health services all over the world. One distinguishing feature of this new influenza pandemic was the different profile of hospitalized patients compared to those from traditional seasonal influenza infections. Our goal was to analyze sociodemographic and clinical factors associated to hospitalization following infection by influenza A(H1N1) virus. We report the results of a Spanish nationwide study with laboratory confirmed infection by the new pandemic virus in a case-control design based on hospitalized patients. The main risk factors for hospitalization of influenza A (H1N1) 2009 were determined to be obesity (BMI >= 40, with an odds-ratio [OR] 14.27), hematological neoplasia (OR 10.71), chronic heart disease, COPD (OR 5.16) and neurological disease, among the clinical conditions, whereas low education level and some ethnic backgrounds (Gypsies and Amerinds) were the sociodemographic variables found associated to hospitalization. The presence of any clinical condition of moderate risk almost triples the risk of hospitalization (OR 2.88) and high risk conditions raise this value markedly (OR 6.43). The risk of hospitalization increased proportionally when for two (OR 2.08) or for three or more (OR 4.86) risk factors were simultaneously present	[Gonzalez-Candelas, Fernando] Univ Valencia, CSISP, Unidad Mixta Genom & Salud, Valencia, Spain; [Gonzalez-Candelas, Fernando; Alonso, Jordi; Canton, Rafael; Carlos Galan, Juan; Garin, Olatz; Saez, Marc; Soldevila, Nuria; Baricot, Maretva; Castilla, Jesus; Godoy, Pere; Delgado-Rodriguez, Miguel; Martin, Vicente; Maria Quintana, Jose; Dominguez, Angela] CIBER Epidemiol & Salud Publ, Madrid, Spain; [Astray, Jenaro] Comunidad Madrid, Subdirecc Vigilancia, Madrid, Spain; [Alonso, Jordi] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Alonso, Jordi; Garin, Olatz] Hosp del Mar, Inst Recerca, Inst Municipal Invest Med, Unitat Recerca Serv Sanitaris, Barcelona, Spain; [Castro, Ady] CIBER Enfermedades Resp, Madrid, Spain; [Canton, Rafael; Carlos Galan, Juan] Hosp Univ Ramon y Cajal, Microbiol Serv, Madrid, Spain; [Saez, Marc] Univ Girona, Dept Econ, Girona, Spain; [Castilla, Jesus] Inst Salud Publ Navarra, Pamplona, Spain; [Godoy, Pere] Generalitat Catalunya, Dept Salut, Barcelona, Spain; [Delgado-Rodriguez, Miguel] Univ Jaen, Div Med Prevent & Salud Publ, Jaen, Spain; [Martin, Vicente] Univ Leon, Inst Biomed, E-24071 Leon, Spain; [Maria Mayoral, Jose] Serv Vigilancia Andalucia, Seville, Spain; [Pumarola, Tomas] REIPI, Madrid, Spain; [Maria Quintana, Jose] Fdn Vasca Innovac & Invest Sanitarias, Sondika, Spain; [Tamames, Sonia] Direcc Gen Salud Publ Desarrollo & Innovaci, Valladolid, Spain; [Dominguez, Angela] Univ Barcelona, Dept Salut Publ, Barcelona, Spain	University of Valencia; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Hospital Universitario Ramon y Cajal; Universitat de Girona; Public Health Institute of Navarra; Universidad de Jaen; Universidad de Leon; University of Barcelona	Gonzalez-Candelas, F (corresponding author), Univ Valencia, CSISP, Unidad Mixta Genom & Salud, Valencia, Spain.	fernando.gonzalez@uv.es	Martin, Vicente/A-1597-2008; Barbé, Ferran/A-5988-2010; PIJOAN, JOSE I/E-5464-2012; Fernandez Natal, Isabel/C-9328-2015; DE LA TORRE, ANTONIO JOSÉ MOLINA/T-8682-2019; Godoy, Pere/A-7662-2010; CANTON, RAFAEL/ABF-6353-2020; Pumarola, Tomàs/AAB-5532-2019; Castilla, Jesus/B-9048-2008; Cantón, Rafael/AAP-8669-2021; Martin, Vicente/ABF-2276-2021; Martin, Vicente/GRE-8306-2022; Garin, Olatz/K-5468-2013; Astigarraga, I/I-1215-2014; Alonso, Jordi/A-5514-2010; Castro-Acosta, Ady Angelica/H-4163-2011; /B-4328-2009; Candelas, Fernando Gonzalez/G-5681-2010; Astigarraga, Maria Iciar/E-2960-2012; Suñe, Tomàs Pumarola/F-7583-2017	Martin, Vicente/0000-0003-0552-2804; Barbé, Ferran/0000-0002-2340-8928; Fernandez Natal, Isabel/0000-0002-2701-9815; DE LA TORRE, ANTONIO JOSÉ MOLINA/0000-0002-5948-6397; Godoy, Pere/0000-0002-2896-7286; Pumarola, Tomàs/0000-0002-5171-7461; Castilla, Jesus/0000-0002-6396-7265; Martin, Vicente/0000-0003-0552-2804; Garin, Olatz/0000-0001-6193-0779; Astigarraga, I/0000-0002-5012-0137; Alonso, Jordi/0000-0001-8627-9636; Castro-Acosta, Ady Angelica/0000-0001-7591-6011; /0000-0002-5948-6397; Candelas, Fernando Gonzalez/0000-0002-0879-5798; Suñe, Tomàs Pumarola/0000-0002-5171-7461; Torner, Nuria/0000-0003-0143-5295; Espana, Pedro Pablo/0000-0001-5723-8253; Quintana, Jose M./0000-0003-2170-7876; Canton, Rafael/0000-0003-1675-3173; Tamames, Sonia/0000-0001-5548-2594; Lopez-Contreras, Joaquin/0000-0002-3166-4016	Instituto de Salud Carlos III/Ministerio de Ciencia e Innovacion, Spain [GR09/0030]	Instituto de Salud Carlos III/Ministerio de Ciencia e Innovacion, Spain(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government)	Funding was provided by project GR09/0030 of the Instituto de Salud Carlos III/Ministerio de Ciencia e Innovacion, Spain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altmann M, 2011, EMERG INFECT DIS, V17, P186, DOI 10.3201/eid1702.101090; Baker M, 2009, EUROSURVEILLANCE, V14, P1; Bandaranayake D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013211; Banzhoff A, 2011, HUM VACCINES, V7, P539, DOI 10.4161/hv.7.5.14821; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Bewick T, 2011, THORAX, V66, P247, DOI 10.1136/thx.2010.151522; Brandsaeter BJ, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-75; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Carcione D, 2010, EMERG INFECT DIS, V16, P1388, DOI 10.3201/eid1609.100076; Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262; Dominguez A, 2011, REV ESP SALUD PUBLIC, V85, P3, DOI 10.1590/S1135-57272011000100002; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Falagas ME, 2011, EPIDEMIOL INFECT, V139, P27, DOI 10.1017/S0950268810002037; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Garcia-Garcia L, 2009, BMJ-BRIT MED J, V339, pb3028; General Directorate of Epidemiology MoHM Pan American Health Organization World Health Organization Public Health Agency of Canada CDC (United States), 2009, OUTBR SWIN OR INFL H, P1; Gilca R, 2011, INFLUENZA OTHER RESP, V5, P247, DOI 10.1111/j.1750-2659.2011.00204.x; Ginsberg M., 2009, Morbidity and Mortality Weekly Report, V58, P400; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Ikematsu H, 2010, HUM VACCINES, V6, P888, DOI 10.4161/hv.6.11.12851; Ismail HIM, 2011, EMERG INFECT DIS, V17, P708, DOI 10.3201/eid1704.101212; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Miller MA, 2009, NEW ENGL J MED, V360, P2595, DOI 10.1056/NEJMp0903906; Morgan OW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009694; Nguyen-Van-Tam JS, 2010, THORAX, V65, P645, DOI 10.1136/thx.2010.135210; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Pebody RG, 2010, EUROSURVEILLANCE, V15; Puig-Barbera J, 2010, VACCINE, V28, P7460, DOI 10.1016/j.vaccine.2010.09.042; Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044; Schlesselman JJ, 1982, CASE CONTROLS STUDIE; Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258; Slopen M. E., 2010, Morbidity and Mortality Weekly Report, V58, P1436; Sun GW, 1996, J CLIN EPIDEMIOL, V49, P907, DOI 10.1016/0895-4356(96)00025-X; Surveillance Group for New Influenza A(H1N1) Virus Investigation and Control in Spain, 2009, EUROSURVEILLANCE, V14, P19209; Tavares F, 2011, VACCINE, V29, P6358, DOI 10.1016/j.vaccine.2011.04.114; Valenciano M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000388; Van Kerkhove MD, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001053; Vasoo S, 2010, EMERG INFECT DIS, V16, P1594, DOI 10.3201/eid1610.091889; Verrall A, 2010, EMERG INFECT DIS, V16, P100, DOI 10.3201/eid1601.090994; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; World Health Organization, 2009, CDC PROT REALTIME RT; Yu HJ, 2011, CLIN INFECT DIS, V52, P457, DOI 10.1093/cid/ciq144; [No title captured]	50	13	13	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2012	7	3							e33139	10.1371/journal.pone.0033139	http://dx.doi.org/10.1371/journal.pone.0033139			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KK	22412995	Green Published, gold, Green Submitted			2023-01-03	WOS:000303060800083
J	Zafeiropoulou, K; Bita, T; Polykratis, A; Karabina, S; Vlachojannis, J; Katsoris, P				Zafeiropoulou, Kalliopi; Bita, Theodora; Polykratis, Apostolos; Karabina, Stella; Vlachojannis, John; Katsoris, Panagiotis			Hemodialysis Removes Uremic Toxins That Alter the Biological Actions of Endothelial Cells	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; GLYCATION END-PRODUCTS; MYOCARDIAL-INFARCTION; VASCULAR ENDOTHELIUM; REGULATORY FUNCTIONS; MATRIX METALLOPROTEINASES; CAROTID ATHEROSCLEROSIS; PARACRINE FUNCTIONS	Chronic kidney disease is linked to systemic inflammation and to an increased risk of ischemic heart disease and atherosclerosis. Endothelial dysfunction associates with hypertension and vascular disease in the presence of chronic kidney disease but the mechanisms that regulate the activation of the endothelium at the early stages of the disease, before systemic inflammation is established remain obscure. In the present study we investigated the effect of serum derived from patients with chronic kidney disease either before or after hemodialysis on the activation of human endothelial cells in vitro, as an attempt to define the overall effect of uremic toxins at the early stages of endothelial dysfunction. Our results argue that uremic toxins alter the biological actions of endothelial cells and the remodelling of the extracellular matrix before signs of systemic inflammatory responses are observed. This study further elucidates the early events of endothelial dysfunction during toxic uremia conditions allowing more complete understanding of the molecular events as well as their sequence during progressive renal failure.	[Zafeiropoulou, Kalliopi; Polykratis, Apostolos; Karabina, Stella; Katsoris, Panagiotis] Univ Patras, Dept Biol, Patras, Achaia, Greece; [Bita, Theodora; Vlachojannis, John] Univ Hosp Patras, Dept Internal Med Nephrol, Patras, Achaia, Greece	University of Patras; University of Patras	Zafeiropoulou, K (corresponding author), Univ Patras, Dept Biol, Patras, Achaia, Greece.	katsopan@upatras.gr		Polykratis, Apostolos/0000-0001-6720-3302				Andrews KL, 2000, AM J PATHOL, V157, P303, DOI 10.1016/S0002-9440(10)64541-5; ANGGARD EE, 1992, JPN J PHARMACOL, V58, pP200; Annuk M, 2003, KIDNEY INT, V63, pS50, DOI 10.1046/j.1523-1755.63.s84.2.x; Baradaran A, 2005, SAUDI J KIDNEY DIS T, V16, P288; Bolton CH, 2001, NEPHROL DIAL TRANSPL, V16, P1189, DOI 10.1093/ndt/16.6.1189; Brodsky SV, 2002, AM J PHYSIOL-RENAL, V282, pF1140, DOI 10.1152/ajprenal.00329.2001; Caramelo C, 1996, CIRC RES, V79, P1031, DOI 10.1161/01.RES.79.5.1031; Caron A, 2005, CAN J PHYSIOL PHARM, V83, P287, DOI 10.1139/Y05-011; Chappey O, 1997, Rev Prat, V47, P2223; Chen HJ, 2003, AM J PHYSIOL-HEART C, V284, pH1612, DOI 10.1152/ajpheart.00992.2002; Cheng S, 2006, FASEB J, V20, P1898, DOI 10.1096/fj.06-5898fje; Chung TW, 2004, J GASTROEN HEPATOL, V19, P565, DOI 10.1111/j.1440-1746.2004.03344.x; Costa-Hong V, 2009, ARQ BRAS CARDIOL, V92, P381; Cross J, 2002, BLOOD PURIFICAT, V20, P459, DOI 10.1159/000063552; de Nooijer R, 2006, ARTERIOSCL THROM VAS, V26, P340, DOI 10.1161/01.ATV.0000197795.56960.64; Djuric T, 2008, CLIN BIOCHEM, V41, P1326, DOI 10.1016/j.clinbiochem.2008.08.081; Fleming I, 1996, MOL CELL BIOCHEM, V157, P137; Florys Bozena, 2006, Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw, V12, P184; Gareus R, 2008, CELL METAB, V8, P372, DOI 10.1016/j.cmet.2008.08.016; GUERRA R, 1989, BLOOD VESSELS, V26, P300; Hansson G, 1997, Lakartidningen, V94, P852; HANSSON GK, 1987, ACTA MED SCAND, P11; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Hansson J, 2009, EUR J CARDIOV PREV R, V16, P297, DOI 10.1097/HJR.0b013e3283213108; Hayakawa H, 1999, J HYPERTENS, V17, P611, DOI 10.1097/00004872-199917050-00004; Hayashidani S, 2003, AM J PHYSIOL-HEART C, V285, pH1229, DOI 10.1152/ajpheart.00207.2003; Ho FM, 2007, J CELL BIOCHEM, V101, P442, DOI 10.1002/jcb.21192; Ishikawa M, 2001, AM J CARDIOL, V88, P1203, DOI 10.1016/S0002-9149(01)02064-1; Jaconbson SH, 2002, AM J NEPHROL, V22, P42, DOI 10.1159/000046673; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jefferis BJ, 2010, ATHEROSCLEROSIS, V208, P557, DOI 10.1016/j.atherosclerosis.2009.08.018; Johnson TS, 2002, EXP NEPHROL, V10, P182; Kandalam V, 2010, AM J PHYSIOL-HEART C, V299, pH1012, DOI 10.1152/ajpheart.00246.2010; Kandalam V, 2010, CIRC RES, V106, P796, DOI 10.1161/CIRCRESAHA.109.209189; Karbowska A, 2009, TRANSPL P, V41, P3052, DOI 10.1016/j.transproceed.2009.07.080; Kelly D, 2008, EUR J HEART FAIL, V10, P133, DOI 10.1016/j.ejheart.2007.12.009; Kharbanda RK, 2001, CORONARY ARTERY DIS, V12, P485, DOI 10.1097/00019501-200109000-00007; KITAGAWA S, 1994, LIFE SCI, V55, P491, DOI 10.1016/0024-3205(94)00741-1; KORNERUP HJ, 1976, ACTA MED SCAND, V200, P257; Kunz K, 1999, NEPHROL DIAL TRANSPL, V14, P1934, DOI 10.1093/ndt/14.8.1934; LAZARUS JM, 1974, ARCH INTERN MED, V133, P1059, DOI 10.1001/archinte.133.6.1059; Lee WY, 2011, BIOMATERIALS, V32, P5558, DOI 10.1016/j.biomaterials.2011.04.031; Lehrke M, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-50; Libby P, 2006, Handb Exp Pharmacol, P285; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Linden E, 2008, CLIN J AM SOC NEPHRO, V3, P691, DOI 10.2215/CJN.04291007; Lindsey ML, 2004, HEART FAIL REV, V9, P7, DOI 10.1023/B:HREV.0000011390.44039.b7; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; Maier JAM, 2004, BBA-MOL BASIS DIS, V1689, P13, DOI 10.1016/j.bbadis.2004.01.002; Matsuda H, 2004, HYPERTENSION, V43, P603, DOI 10.1161/01.HYP.0000118053.42262.71; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Matsusaka H, 2005, AM J PHYSIOL-HEART C, V289, pH1858, DOI 10.1152/ajpheart.00216.2005; Ruilope LM, 2007, VASC HEALTH RISK MAN, V3, P1; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Musial K, 2011, CELL STRESS CHAPERON, V16, P97, DOI 10.1007/s12192-010-0214-x; Mysliwiec M, 2004, Rocz Akad Med Bialymst, V49, P151; Napoli C, 2002, STROKE, V33, P2864; Nin JWM, 2009, DIABETOLOGIA, V52, P705, DOI 10.1007/s00125-009-1263-5; Pawlak K, 2011, CLIN BIOCHEM, V44, P838, DOI 10.1016/j.clinbiochem.2011.03.143; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Pradhan-Palikhe P, 2010, SCAND J IMMUNOL, V72, P150, DOI 10.1111/j.1365-3083.2010.02418.x; RYAN JW, 1982, ADV VET SCI COMP MED, V26, P79; Sahin G, 2007, BLOOD PURIFICAT, V25, P309, DOI 10.1159/000106103; Schaefer L, 1996, KIDNEY INT, V49, P75, DOI 10.1038/ki.1996.10; Schwedler SB, 2002, KIDNEY INT, V62, P301, DOI 10.1046/j.1523-1755.2002.00423.x; Seimon T, 2009, J LIPID RES, V50, pS382, DOI 10.1194/jlr.R800032-JLR200; Song GD, 2010, WOUND REPAIR REGEN, V18, P426, DOI 10.1111/j.1524-475X.2010.00595.x; Szczepanska Maria, 2005, Pol Merkur Lekarski, V18, P17; Tabas I, 2007, CURR DRUG TARGETS, V8, P1288, DOI 10.2174/138945007783220623; TAKAGI M, 1994, BLOOD COAGUL FIBRIN, V5, P713, DOI 10.1097/00001721-199410000-00006; Tarin C, 2009, ARTERIOSCL THROM VAS, V29, P27, DOI 10.1161/ATVBAHA.108.169623; Thorp E, 2009, J LEUKOCYTE BIOL, V86, P1089, DOI 10.1189/jlb.0209115; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHINSBERGH VWM, 1992, MOL CELL BIOCHEM, V116, P163, DOI 10.1007/BF01270584; Wakatsuki S, 2008, EXPERT OPIN THER TAR, V12, P1469, DOI 10.1517/14728220802551140 ; Wang Chang-qian, 2005, Zhonghua Xinxueguanbing Zazhi, V33, P405; Zoccali C, 2006, J AM SOC NEPHROL, V17, pS64, DOI 10.1681/ASN.2005121345; Zureik M, 2005, J HYPERTENS, V23, P2263, DOI 10.1097/01.hjh.0000191245.68443.24	78	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2012	7	2							e30975	10.1371/journal.pone.0030975	http://dx.doi.org/10.1371/journal.pone.0030975			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926ZZ	22383985	gold, Green Submitted, Green Published			2023-01-03	WOS:000302875500008
J	Guallar-Castillon, P; Rodriguez-Artalejo, F; Lopez-Garcia, E; Leon-Munoz, LM; Amiano, P; Ardanaz, E; Arriola, L; Barricarte, A; Buckland, G; Chirlaque, MD; Dorronsoro, M; Huerta, JM; Larranaga, N; Marin, P; Martinez, C; Molina, E; Navarro, C; Quiros, JR; Rodriguez, L; Sanchez, MJ; Gonzalez, CA; Moreno-Iribas, C				Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.; Amiano, Pilar; Ardanaz, Eva; Arriola, Larraitz; Barricarte, Aurelio; Buckland, Genevieve; Chirlaque, Maria-Dolores; Dorronsoro, Miren; Huerta, Jose-Maria; Larranaga, Nerea; Marin, Pilar; Martinez, Carmen; Molina, Esther; Navarro, Carmen; Ramon Quiros, J.; Rodriguez, Laudina; Jose Sanchez, Maria; Gonzalez, Carlos A.; Moreno-Iribas, Conchi			Consumption of fried foods and risk of coronary heart disease: Spanish cohort of the European Prospective Investigation into Cancer and Nutrition study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; ENDOTHELIAL FUNCTION; DIETARY PATTERNS; FATTY-ACIDS; MEAL RICH; OLIVE OIL; SPAIN; FISH; EPIDEMIOLOGY; HYPERTENSION	Objective To assess the association between consumption of fried foods and risk of coronary heart disease. Design Prospective cohort study. Setting Spanish cohort of the European Prospective Investigation into Cancer and Nutrition. Participants 40 757 adults aged 29-69 and free of coronary heart disease at baseline (1992-6), followed up until 2004. Main outcome measures Coronary heart disease events and vital status identified by record linkage with hospital discharge registers, population based registers of myocardial infarction, and mortality registers. Results During a median follow-up of 11 years, 606 coronary heart disease events and 1135 deaths from all causes occurred. Compared with being in the first (lowest) quarter of fried food consumption, the multivariate hazard ratio of coronary heart disease in the second quarter was 1.15 (95% confidence interval 0.91 to 1.45), in the third quarter was 1.07 (0.83 to 1.38), and in the fourth quarter was 1.08 (0.82 to 1.43; P for trend 0.74). The results did not vary between those who used olive oil for frying and those who used sunflower oil. Likewise, no association was observed between fried food consumption and all cause mortality: multivariate hazard ratio for the highest versus the lowest quarter of fried food consumption was 0.93 (95% confidence interval 0.77 to 1.14; P for trend 0.98). Conclusion In Spain, a Mediterranean country where olive or sunflower oil is used for frying, the consumption of fried foods was not associated with coronary heart disease or with all cause mortality.	[Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.] Autonomous Univ Madrid, Sch Med, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain; [Guallar-Castillon, Pilar; Rodriguez-Artalejo, Fernando; Lopez-Garcia, Esther; Leon-Munoz, Luz M.; Amiano, Pilar; Ardanaz, Eva; Arriola, Larraitz; Barricarte, Aurelio; Chirlaque, Maria-Dolores; Dorronsoro, Miren; Huerta, Jose-Maria; Larranaga, Nerea; Marin, Pilar; Martinez, Carmen; Molina, Esther; Navarro, Carmen; Jose Sanchez, Maria; Moreno-Iribas, Conchi] CIBER Epidemiol & Salud Publ, Madrid, Spain; [Amiano, Pilar; Arriola, Larraitz; Dorronsoro, Miren; Larranaga, Nerea] Basque Govt, Inst Invest IIS BioDonostia, Publ Hlth Div Gipuzkoa, Donostia San Sebastian, Spain; [Ardanaz, Eva; Barricarte, Aurelio; Marin, Pilar; Moreno-Iribas, Conchi] Publ Hlth Inst Navarra, Pamplona, Spain; [Moreno-Iribas, Conchi] Autonomous Univ Barcelona, Dept Obstet & Gynecol, Dept Pediat, Barcelona, Spain; [Buckland, Genevieve; Gonzalez, Carlos A.] Hosp Llobregat, Catalan Inst Oncol, Canc Epidemiol Res Programme, Unit Nutr Environm & Canc, Barcelona, Spain; [Chirlaque, Maria-Dolores; Huerta, Jose-Maria; Navarro, Carmen] Murcia Reg Hlth Council, Dept Epidemiol, Murcia, Spain; [Navarro, Carmen] Univ Murcia, Dept Publ Hlth & Prevent Med, E-30001 Murcia, Spain; [Martinez, Carmen; Molina, Esther; Jose Sanchez, Maria] Andalusian Sch Publ Hlth, Granada, Spain; [Ramon Quiros, J.; Rodriguez, Laudina] Publ Hlth & Hlth Planning Directorate, Oviedo, Asturias, Spain	Autonomous University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Basque Government; Public Health Institute of Navarra; Autonomous University of Barcelona; Catalan Institute of Oncology; Murcia Regional Health Council; University of Murcia; Escuela Andaluza de Salud Publica	Guallar-Castillon, P (corresponding author), Autonomous Univ Madrid, Sch Med, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain.	mpilar.guallar@uam.es	Sánchez, Maria-José/D-1087-2011; González, Carlos A A/O-4651-2014; Guallar-Castillon, Pilar/F-1533-2016; Huerta, José María/N-8654-2015; León-Muñoz, Luz M/H-8275-2017; Lopez-Garcia, Esther/A-8894-2019	Sánchez, Maria-José/0000-0003-4817-0757; González, Carlos A A/0000-0003-2822-9715; Guallar-Castillon, Pilar/0000-0003-4759-6713; Huerta, José María/0000-0002-9637-3869; Arriola, Larraitz/0000-0001-8487-7181; Navarro, Carmen/0000-0001-8896-7483; Larranaga, Nerea/0000-0002-9993-9880; Buckland, Genevieve/0000-0003-2060-6598; Leon-Munoz, Luz Maria/0000-0001-5447-5907; Molina-Montes, Esther/0000-0002-0428-2426	FIS [PI04-0257, PI06-0366, PI04-2342, PI04-1822, PI04-1821, PI04-2188, PI08-0166]; RETIC of the Instituto de Salud Carlos III [RD06/0020]; Spanish regional government of Andalusia; Spanish regional government of Asturias; Spanish regional government of Basque Country; Spanish regional government of Murcia; Spanish regional government of Navarra; Catalan Institute of Oncology; Ministry of Education	FIS(Instituto de Salud Carlos III); RETIC of the Instituto de Salud Carlos III(Instituto de Salud Carlos III); Spanish regional government of Andalusia; Spanish regional government of Asturias(Principality of Asturias); Spanish regional government of Basque Country; Spanish regional government of Murcia; Spanish regional government of Navarra; Catalan Institute of Oncology; Ministry of Education	This study was funded by research grants from FIS (PI04-0257, PI06-0366, PI04-2342, PI04-1822, PI04-1821, PI04-2188, and PI08-0166); RETIC (RD06/0020) of the Instituto de Salud Carlos III; and funds from the Spanish regional governments of Andalusia, Asturias, Basque Country, Murcia, and Navarra, and the Catalan Institute of Oncology. EL-G has a Ramon y Cajal contract from the Ministry of Education. Authors of this report, and not the funding agencies, are responsible for its content. The funder did not have any role in the study design; collection, analysis, and interpretation of the data; the writing of the report; and the decision to submit the article for publication.	[Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS91; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS110; [Anonymous], 1997, Int J Epidemiol, V26 Suppl 1, pS100; Ansorena D, 2010, J FOOD SCI, V75, pH62, DOI 10.1111/j.1750-3841.2009.01472.x; Astrup A, 2011, AM J CLIN NUTR, V93, P684, DOI 10.3945/ajcn.110.004622; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P622, DOI 10.1017/S1368980010002752; Bingham S, 2004, NAT REV CANCER, V4, P206, DOI 10.1038/nrc1298; Boskou G, 2006, EUR J LIPID SCI TECH, V108, P109, DOI 10.1002/ejlt.200500236; Burke BS, 1947, J AM DIET ASSOC, V23, P104; Casal S, 2010, FOOD CHEM TOXICOL, V48, P2972, DOI 10.1016/j.fct.2010.07.036; Danesh J, 2007, EUR J EPIDEMIOL, V22, P129, DOI 10.1007/s10654-006-9096-8; Donfrancesco C, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-53; Drewnowski A, 2010, FAT DETECTION TASTE; Echarte M, 2001, J FOOD PROTECT, V64, P1062, DOI 10.4315/0362-028X-64.7.1062; Fillion L, 1998, INT J FOOD SCI NUTR, V49, P157, DOI 10.3109/09637489809089395; Gallina-Toschi T, 2005, J SEP SCI, V28, P859, DOI 10.1002/jssc.200500044; Guallar-Castillon P, 2007, AM J CLIN NUTR, V86, P198, DOI 10.1093/ajcn/86.1.198; Haftenberger M, 2002, PUBLIC HEALTH NUTR, V5, P1163, DOI 10.1079/PHN2002397; He K, 2008, AM J CLIN NUTR, V88, P1111, DOI 10.1093/ajcn/88.4.1111; He K, 2009, AM J CARDIOL, V103, P1238, DOI 10.1016/j.amjcard.2009.01.016; Huerta JM, 2009, REV ESP CARDIOL, V62, P143, DOI 10.1016/S0300-8932(09)70156-3; Iqbal R, 2008, CIRCULATION, V118, P1929, DOI 10.1161/CIRCULATIONAHA.107.738716; Kabagambe EK, 2003, EUR J CLIN NUTR, V57, P1447, DOI 10.1038/sj.ejcn.1601709; LITIN L, 1993, NEW ENGL J MED, V329, P1969, DOI 10.1056/NEJM199312233292620; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; Majumder K, 2009, J AGR FOOD CHEM, V57, P471, DOI 10.1021/jf8028557; Mozaffarian D, 2003, CIRCULATION, V107, P1372, DOI 10.1161/01.CIR.0000055315.79177.16; Nielsen SJ, 2002, OBES RES, V10, P370, DOI 10.1038/oby.2002.51; Pokorn Jan, 2003, Forum Nutr, V56, P348; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Samra R.A., 2010, FAT DETECTION TASTE; SANCHEZMUNIZ FJ, 1994, Z ERNAHRUNGSWISS, V33, P16, DOI 10.1007/BF01610575; Sayon-Orea C, 2011, NUTR METAB CARDIOVAS; Slimani N, 1991, EUROPEAN PROSPECTIVE; Soriguer F, 2003, AM J CLIN NUTR, V78, P1092, DOI 10.1093/ajcn/78.6.1092; Sutherland WHF, 1999, ARTERIOSCL THROM VAS, V19, P1340, DOI 10.1161/01.ATV.19.5.1340; Tormo MJ, 2000, J EPIDEMIOL COMMUN H, V54, P221, DOI 10.1136/jech.54.3.221; Varela-Moreiras G, 2010, EUR J CLIN NUTR, V64, pS37, DOI 10.1038/ejcn.2010.208; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Williams MJA, 1999, J AM COLL CARDIOL, V33, P1050, DOI 10.1016/S0735-1097(98)00681-0; Williams MJA, 2001, NUTR METAB CARDIOVAS, V11, P147	42	59	59	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2012	344								e363	10.1136/bmj.e363	http://dx.doi.org/10.1136/bmj.e363			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885KP	22275385	Green Published, hybrid			2023-01-03	WOS:000299778200002
J	Campos-Rodriguez, F; Martinez-Garcia, MA; de la Cruz-Moron, I; Almeida-Gonzalez, C; Catalan-Serra, P; Montserrat, JM				Campos-Rodriguez, Francisco; Martinez-Garcia, Miguel A.; de la Cruz-Moron, Ines; Almeida-Gonzalez, Carmen; Catalan-Serra, Pablo; Montserrat, Josep M.			Cardiovascular Mortality in Women With Obstructive Sleep Apnea With or Without Continuous Positive Airway Pressure Treatment A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							ALL-CAUSE MORTALITY; RISK-FACTOR; FOLLOW-UP; HYPOPNEA; STROKE; DIAGNOSIS; SURVIVAL; OUTCOMES; DISEASE; DEATH	Background: Obstructive sleep apnea (OSA) is a risk factor for cardiovascular death in men, but whether it is also a risk factor in women is unknown. Objective: To investigate whether OSA is a risk factor for cardiovascular death in women and assess whether continuous positive airway pressure (CPAP) treatment is associated with a change in risk. Design: Prospective, observational cohort study. Setting: 2 sleep clinics in Spain. Patients: All women consecutively referred for suspected OSA between 1998 and 2007. Intervention: Every woman had a diagnostic sleep study. Women with an apnea-hypopnea index (AHI) less than 10 were the control group. Obstructive sleep apnea was diagnosed when the AHI was 10 or higher (classified as mild to moderate [AHI of 10 to 29] or severe [AHI >= 30]).Patients with OSA were classified as CPAP-treated (adherence >= 4 hours per day) or untreated (adherence >= 4 hours per day or not prescribed). Participants were followed until December 2009. Measurements: The end point was cardiovascular death. Results: 1116 women were studied (median follow-up, 72 months [interquartile range, 52 to 88 months]). The control group had a lower cardiovascular mortality rate (0.28 per 100 person-years [95% CI, 0.10 to 0.91]) than the untreated groups with mild to moderate OSA (0.94 per 100 person-years [CI, 0.10 to 2.40]; P = 0.034) or severe OSA (3.71 per 100 person-years [CI, 0.09 to 7.50]; P < 0.001). Compared with the control group, the fully adjusted hazard ratios for cardiovascular mortality were 3.50 (CI, 1.23 to 9.98) for the untreated, severe OSA group; 0.55 (CI, 0.17 to 1.74) for the CPAP-treated, severe OSA group; 1.60 (CI, 0.52 to 4.90) for the untreated, mild to moderate OSA group; and 0.19 (CI, 0.02 to 1.67) for the CPAP-treated, mild to moderate OSA group. Limitation: The study was observational and not randomized, and OSA was diagnosed by 2 different methods. Conclusion: Severe OSA is associated with cardiovascular death in women, and adequate CPAP treatment may reduce this risk.	[Campos-Rodriguez, Francisco] Valme Univ Hosp, Sleep Disordered Breathing Unit, Resp Dept, Seville 41014, Spain; La Fe Univ, Valencia, Spain; Polytech Hosp, Valencia, Spain; Requena Gen Hosp, Valencia, Spain; Hosp Clin Barcelona, Barcelona, Spain; CIBERes Enfermedades Respiratorias, Madrid, Spain	Hospital Valme; University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Campos-Rodriguez, F (corresponding author), Valme Univ Hosp, Sleep Disordered Breathing Unit, Resp Dept, Ctra Cadiz S-N, Seville 41014, Spain.	fracamrod@gmail.com	Almeida-González, Carmen V./O-9461-2017; González, Carmen Victoria Almeida/P-7944-2019; Martinez-Garcia, Miguel/AAA-6349-2019	Almeida-González, Carmen V./0000-0001-8202-0790; González, Carmen Victoria Almeida/0000-0001-8202-0790; Martinez-Garcia, Miguel/0000-0002-7321-1891; Catalan Serra, Pablo/0000-0001-6001-1850; Campos-Rodriguez, Francisco/0000-0002-2632-3073; MONTSERRAT, Josep Maria/0000-0003-3098-4605				AncoliIsrael S, 1996, SLEEP, V19, P277, DOI 10.1093/sleep/19.4.277; Martinez-Garcia MA, 2009, AM J RESP CRIT CARE, V180, P36, DOI 10.1164/rccm.200808-1341OC; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Campos-Rodriguez F, 2005, CHEST, V128, P624, DOI 10.1378/chest.128.2.624; Chiner E, 1999, Arch Bronconeumol, V35, P422; Doherty LS, 2005, CHEST, V127, P2076, DOI 10.1378/chest.127.6.2076; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Duran J, 1996, ARCH BRONCONEUMOL, V32, P3; Faux MD, 2004, SLEEP, V27, P1113, DOI 10.1093/sleep/27.6.1113; Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832; Gottlieb DJ, 2010, CIRCULATION, V122, P352, DOI 10.1161/CIRCULATIONAHA.109.901801; Gugger M, 1997, EUR RESPIR J, V10, P587; Lavie P, 2005, EUR RESPIR J, V25, P514, DOI 10.1183/09031936.05.00051504; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marshall NS, 2008, SLEEP, V31, P1079; Montserrat J M, 1998, Arch Bronconeumol, V34, P204; Morrish E, 2008, RESP MED, V102, P1231, DOI 10.1016/j.rmed.2008.04.014; Peker Y, 2006, EUR RESPIR J, V28, P596, DOI 10.1183/09031936.06.00107805; Peker Y, 2000, AM J RESP CRIT CARE, V162, P81, DOI 10.1164/ajrccm.162.1.9905035; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; Quintana-Gallego E, 2004, RESP MED, V98, P984, DOI 10.1016/j.rmed.2004.03.002; Rechtschaffen A., 1968, MANUAL STANDARDIZED; Redline S, 2010, AM J RESP CRIT CARE, V182, P269, DOI 10.1164/rccm.200911-1746OC; Sahlin C, 2008, ARCH INTERN MED, V168, P297, DOI 10.1001/archinternmed.2007.70; Shepertycky MR, 2005, SLEEP, V28, P309; Tordera MP, 2005, ARCH BRONCONEUMOL, V41, P1; Veale D, 2000, EUR RESPIR J, V15, P326, DOI 10.1034/j.1399-3003.2000.15b18.x; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Young T, 1998, THORAX, V53, pS16, DOI 10.1136/thx.53.2008.S16; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1996, ARCH INTERN MED, V156, P2445, DOI 10.1001/archinte.156.21.2445; Young T, 2008, SLEEP, V31, P1071	32	262	271	3	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2					115	W22		10.7326/0003-4819-156-2-201201170-00006	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	894IW	22250142				2023-01-03	WOS:000300421400002
J	Qu, ZQ; Zhou, Y; Zeng, YS; Lin, YK; Li, Y; Zhong, ZQ; Chan, WY				Qu, Ze-qiang; Zhou, Yan; Zeng, Yuan-shan; Lin, Yu-kun; Li, Yan; Zhong, Zhi-qiang; Chan, Wood Yee			Protective Effects of a Rhodiola Crenulata Extract and Salidroside on Hippocampal Neurogenesis against Streptozotocin-Induced Neural Injury in the Rat	PLOS ONE			English	Article							PEROXIDE-INDUCED APOPTOSIS; OXIDATIVE STRESS; STEM-CELLS; INTRACEREBROVENTRICULAR STREPTOZOTOCIN; COGNITIVE IMPAIRMENT; ENERGY-METABOLISM; DENTATE GYRUS; ROSEA EXTRACT; OLIVE OIL; TYROSOL	Previously we have demonstrated that a Rhodiola crenulata extract (RCE), containing a potent antioxidant salidroside, promotes neurogenesis in the hippocampus of depressive rats. The current study was designed to further investigate the protective effect of the RCE on neurogenesis in a rat model of Alzheimer's disease (AD) induced by an intracerebroventricular injection of streptozotocin (STZ), and to determine whether this neuroprotective effect is induced by the antioxidative activity of salidroside. Our results showed that pretreatment with the RCE significantly improved the impaired neurogenesis and simultaneously reduced the oxidative stress in the hippocampus of AD rats. In vitro studies revealed that (1) exposure of neural stem cells (NSCs) from the hippocampus to STZ strikingly increased intracellular reactive oxygen species (ROS) levels, induced cell death and perturbed cell proliferation and differentiation, (2) hydrogen peroxide induced similar cellular activities as STZ, (3) pre-incubation of STZ-treated NSCs with catalase, an antioxidant, suppressed all these cellular activities induced by STZ, and (4) likewise, pre-incubation of STZ-treated NSCs with salidroside, also an antioxidant, suppressed all these activities as catalase: reduction of ROS levels and NSC death with simultaneous increases in proliferation and differentiation. Our findings indicated that the RCE improved the impaired hippocampal neurogenesis in the rat model of AD through protecting NSCs by its main ingredient salidroside which scavenged intracellular ROS.	[Qu, Ze-qiang; Zhou, Yan; Zeng, Yuan-shan; Lin, Yu-kun; Li, Yan; Zhong, Zhi-qiang] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Histol & Embryol, Div Neurosci, Guangzhou 510275, Guangdong, Peoples R China; [Zeng, Yuan-shan] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510275, Guangdong, Peoples R China; [Chan, Wood Yee] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Chinese University of Hong Kong	Qu, ZQ (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Histol & Embryol, Div Neurosci, Guangzhou 510275, Guangdong, Peoples R China.	zengysh@mail.sysu.edu.cn; wy-chan@cuhk.edu.hk	Chan, Wood Yee/R-6692-2018	Chan, Wood Yee/0000-0002-7114-1463	Administrative Bureau of Chinese Traditional Medicine of Guangdong Province [2007109]	Administrative Bureau of Chinese Traditional Medicine of Guangdong Province	This research was supported by a research grant of the Administrative Bureau of Chinese Traditional Medicine of Guangdong Province (No. 2007109) to YSZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe K, 1999, BRAIN RES, V830, P146, DOI 10.1016/S0006-8993(99)01421-3; Abidov M, 2003, B EXP BIOL MED+, V136, P585, DOI 10.1023/B:BEBM.0000020211.24779.15; Agostinho P, 2010, CURR PHARM DESIGN, V16, P2766, DOI 10.2174/138161210793176572; Ande SR, 2008, YEAST, V25, P349, DOI 10.1002/yea.1592; Beauquis J, 2006, EUR J NEUROSCI, V23, P1539, DOI 10.1111/j.1460-9568.2006.04691.x; Bolzan AD, 2002, MUTAT RES-REV MUTAT, V512, P121, DOI 10.1016/S1383-5742(02)00044-3; Bu Y, 2007, NEUROSCI LETT, V414, P218, DOI 10.1016/j.neulet.2006.08.094; Butterfield DA, 2006, EUR J PHARMACOL, V545, P39, DOI 10.1016/j.ejphar.2006.06.026; Cai L, 2008, ACTA BIOCH BIOPH SIN, V40, P796, DOI [10.1111/j.1745-7270.2008.00463.x, 10.1093/abbs/40.9.796]; Cao LL, 2006, J ASIAN NAT PROD RES, V8, P159, DOI 10.1080/1028602042000325645; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; Chen QG, 2009, PHYTOMEDICINE, V16, P830, DOI 10.1016/j.phymed.2009.03.011; Chen X, 2008, BRAIN RES, V1238, P189, DOI 10.1016/j.brainres.2008.07.051; Chen X, 2009, MOL CELL BIOCHEM, V332, P85, DOI 10.1007/s11010-009-0177-3; Cruz-Sanchez FF, 2010, J NEUROL SCI, V299, P163, DOI 10.1016/j.jns.2010.08.029; Cui SY, 2003, ANAL BIOANAL CHEM, V377, P370, DOI 10.1007/s00216-003-2045-4; De Sanctis R, 2004, BIOFACTORS, V20, P147, DOI 10.1002/biof.5520200304; Di Benedetto R, 2007, NUTR METAB CARDIOVAS, V17, P535, DOI 10.1016/j.numecd.2006.03.005; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Duittoz AH, 2001, J NEUROSCI METH, V107, P131, DOI 10.1016/S0165-0270(01)00363-6; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gibson GE, 2005, NEUROBIOL AGING, V26, P575, DOI 10.1016/j.neurobiolaging.2004.07.017; Gille L, 2002, PHARMACOL TOXICOL, V90, P317, DOI 10.1034/j.1600-0773.2002.900605.x; Giovannini L, 2002, INT J TISSUE REACT, V24, P53; Grunblatt E, 2007, J NEUROCHEM, V101, P757, DOI 10.1111/j.1471-4159.2006.04368.x; Grundke-Iqbal I, 2002, NEUROBIOL AGING, V23, pS563; Guglielmotto M, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/neuro.24.003.2010; Guglielmotto M, 2009, THESCIENTIFICWORLDJO, V9, P781, DOI 10.1100/tsw.2009.93; Guo JS, 2007, NEUROREPORT, V18, P863, DOI 10.1097/WNR.0b013e32811d6d36; Herrera DG, 2003, P NATL ACAD SCI USA, V100, P7919, DOI 10.1073/pnas.1230907100; Hoyer S, 2008, J NEURAL TRANSM, V115, P1241, DOI 10.1007/s00702-008-0079-7; Ishrat T, 2006, BEHAV BRAIN RES, V171, P9, DOI 10.1016/j.bbr.2006.03.009; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jin K, 2006, BRAIN RES, V1085, P183, DOI 10.1016/j.brainres.2006.02.081; Johnston APW, 2007, AM J PHYSIOL-CELL PH, V292, pC1033, DOI 10.1152/ajpcell.00338.2006; Kanupriya D, 2005, MOL CELL BIOCHEM, V275, P1, DOI 10.1007/s11010-005-7637-1; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Khanum F, 2005, COMPR REV FOOD SCI F, V4, P55, DOI 10.1111/j.1541-4337.2005.tb00073.x; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; LAZAROVA MB, 1986, METHOD FIND EXP CLIN, V8, P547; Ledergerber D, 2006, EXP NEUROL, V199, P130, DOI 10.1016/j.expneurol.2006.02.010; Lee SH, 2008, J CELL PHYSIOL, V216, P269, DOI 10.1002/jcp.21402; Lester-Coll N, 2006, J ALZHEIMERS DIS, V9, P13; Li XF, 2011, BRAIN RES, V1382, P9, DOI 10.1016/j.brainres.2011.01.015; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Loru D, 2009, TOXICOL IND HEALTH, V25, P301, DOI 10.1177/0748233709103028; Manda K, 2009, J PINEAL RES, V46, P71, DOI 10.1111/j.1600-079X.2008.00632.x; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; Nakamura S, 2008, CHEM PHARM BULL, V56, P536, DOI 10.1248/cpb.56.536; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ouyang JF, 2010, J PHARM PHARMACOL, V62, P530, DOI 10.1211/jpp.62.04.0017; Pabbidi RM, 2008, MOL PHARMACOL, V73, P995, DOI 10.1124/mol.107.041707; Pang Y, 2000, J NEUROSCI RES, V62, P510, DOI 10.1002/1097-4547(20001115)62:4<510::AID-JNR5>3.3.CO;2-6; Paxinos G, RAT BRAIN STEREOTAXI, V6th; PETKOV V D, 1986, Acta Physiologica et Pharmacologica Bulgarica, V12, P3; Qian EW, 2011, J ETHNOPHARMACOL, V133, P308, DOI 10.1016/j.jep.2010.09.025; Qin Ya-jing, 2008, Zhongguo Zhong Yao Za Zhi, V33, P2842; Qu ZQ, 2009, BIOMED ENVIRON SCI, V22, P318, DOI 10.1016/S0895-3988(09)60062-3; Rivas-Arancibia S, 2010, TOXICOL SCI, V113, P187, DOI 10.1093/toxsci/kfp252; Sato M, 2005, ARTERIOSCL THROM VAS, V25, P341, DOI 10.1161/01.ATV.0000152608.29351.8f; Sauerzweig S, 2009, J NEUROSCI METH, V177, P149, DOI 10.1016/j.jneumeth.2008.10.009; Sonkusare S, 2005, LIFE SCI, V77, P1, DOI 10.1016/j.lfs.2004.10.036; Spasov AA, 2000, PHYTOMEDICINE, V7, P85, DOI 10.1016/S0944-7113(00)80078-1; St-Laurent-Thibault C, 2011, CURR ALZHEIMER RES, V8, P543, DOI 10.2174/156720511796391845; Sugaya K, 2006, PANMINERVA MED, V48, P87; Sultana R, 2010, J ALZHEIMERS DIS, V19, P341, DOI 10.3233/JAD-2010-1222; Taupin Philippe, 2010, Central Nervous System Agents in Medicinal Chemistry, V10, P16; Tyurina YY, 2000, TOXICOLOGY, V148, P93, DOI 10.1016/S0300-483X(00)00199-2; Uchida Y, 2007, J BIOL CHEM, V282, P19700, DOI 10.1074/jbc.M703099200; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wen PH, 2004, EXP NEUROL, V188, P224, DOI 10.1016/j.expneurol.2004.04.002; Wing SL, 2003, WILD ENVIRON MED, V14, P9, DOI 10.1580/1080-6032(2003)014[0009:LOEORO]2.0.CO;2; Xiong Y, 2009, BIOMATERIALS, V30, P3711, DOI 10.1016/j.biomaterials.2009.03.046; Yu PZ, 2007, CHEM BIODIVERS, V4, P508, DOI 10.1002/cbdv.200790043; Yu S, 2008, CELL MOL NEUROBIOL, V28, P1067, DOI 10.1007/s10571-008-9284-z; Zafrilla P, 2006, CURR MED CHEM, V13, P1075, DOI 10.2174/092986706776360978; Zhang L, 2007, EUR J PHARMACOL, V564, P18, DOI 10.1016/j.ejphar.2007.01.089; Zhang L, 2010, NEUROCHEM INT, V57, P547, DOI 10.1016/j.neuint.2010.06.021; Zhang SQ, 2011, MOL CELL BIOCHEM, V354, P161, DOI 10.1007/s11010-011-0815-4; Zhang ZJ, 2009, CHIN J INTEGR MED, V15, P177, DOI 10.1007/s11655-009-0177-x; Zhong H, 2010, J PHARMACOL SCI, V114, P399, DOI 10.1254/jphs.10078FP; Ziabreva I, 2006, J PSYCHOSOM RES, V61, P311, DOI 10.1016/j.jpsychores.2006.07.017	83	139	152	3	62	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2012	7	1							e29641	10.1371/journal.pone.0029641	http://dx.doi.org/10.1371/journal.pone.0029641			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	903NK	22235318	Green Published, gold, Green Submitted			2023-01-03	WOS:000301123400080
J	Shapira, S; Kazanov, D; Weisblatt, S; Starr, A; Arber, N; Kraus, S				Shapira, Shiran; Kazanov, Dina; Weisblatt, Samuel; Starr, Alex; Arber, Nadir; Kraus, Sarah			The CD24 Protein Inducible Expression System Is an Ideal Tool to Explore the Potential of CD24 as an Oncogene and a Target for Immunotherapy in Vitro and in Vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLLED GENE-EXPRESSION; CELL-PROLIFERATION; B-CELLS; TETRACYCLINE; CANCER; APOPTOSIS; INTERNALIZATION; CARCINOGENESIS; PRECURSORS; ADHESION	CD24 is a cell surface, heavily glycosylated glycosylphosphatidylinositol-anchored mucin-like protein that is overexpressed in various human malignancies. To accurately analyze CD24 function and dissect its biological role in a defined genetic background, it is critical to tightly regulate its expression and be able to turn it on/off in a restricted environment and at a specific time, rho tetracycline-induced expression system is most promising as it exhibits such regulation, lack of pleiotropic effects, and high and rapid induction levels. To evaluate the oncogenic and immunotherapeutic potential of CD24 by applying the Tet-On system, the human CD24 gene was cloned downstream to two tetracycline operator sequences, resulting in pCDNA4/TO-CD24, which was then transfected into tetracycline (Tet) repressor-expressing cells (293T-REx), allowing tight on/off regulation, thereby resulting in a very low background or leaky CD24 expression. Selected clones were chosen for further studies and characterized in vitro and in vivo, and several treatment modalities were examined. In addition, the role of CD24 in promoting cell proliferation and tumor growth was studied. The tetracycline-dependent system was successfully implemented. Tetracycline treatment induced CD24 expression in a dose- and time-dependent fashion, which was abrogated following treatment with anti-CD24 monoclonal antibodies (mAbs). CD24-induced expression led to an increased proliferation rate that was inhibited by mAb treatment. In vivo, significantly larger tumors were developed in tetracycline-fed mice. The CD24 Tet-On system is a good model to unravel the role and underlying CD24 pathogenesis in vivo. This valuable tool allows the successful study of novel treatment options, whose effectiveness depends on the CD24 expression level. This set of experiments supports CD24 oncogenic properties.	[Shapira, Shiran; Kazanov, Dina; Weisblatt, Samuel; Arber, Nadir; Kraus, Sarah] Tel Aviv Med Ctr & Sch Med, Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, IL-64239 Tel Aviv, Israel; [Starr, Alex] Tel Aviv Sourasky Med Ctr, Lung & Allergy Inst, IL-64239 Tel Aviv, Israel; [Starr, Alex] Tel Aviv Univ, Dept Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Shapira, Shiran; Weisblatt, Samuel; Arber, Nadir; Kraus, Sarah] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Arber, N (corresponding author), Tel Aviv Med Ctr & Sch Med, Tel Aviv Sourasky Med Ctr, Integrated Canc Prevent Ctr, 3-3rd Fl,Arison Med Tower,6 Weizmann St, IL-64239 Tel Aviv, Israel.	nadir@tasmc.health.gov.il		Arber, Nadir/0000-0001-5283-6991; Starr, Alexander/0000-0002-9329-3740	Deutsches Krebsforschungszentrum (DFKZ); Israel Ministry of Science and Technology (MOST)	Deutsches Krebsforschungszentrum (DFKZ); Israel Ministry of Science and Technology (MOST)	This work was supported in part by the Cooperation Program in Cancer Research of the Deutsches Krebsforschungszentrum (DFKZ) and the Israel Ministry of Science and Technology (MOST).	Aiba A, 2007, NEUROSCI RES, V58, P113, DOI 10.1016/j.neures.2007.01.009; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Chappel MS, 1996, J EXP MED, V184, P1639, DOI 10.1084/jem.184.5.1639; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; Kim HJ, 2007, CANCER LETT, V258, P98, DOI 10.1016/j.canlet.2007.08.025; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Li O, 2004, J EXP MED, V200, P1083, DOI 10.1084/jem.20040779; Lim SC, 2005, PATHOL RES PRACT, V201, P479, DOI 10.1016/j.prp.2005.05.004; Matzke AJM, 2003, PLANT MOL BIOL REP, V21, P9, DOI 10.1007/BF02773392; Mazor Y, 2007, J IMMUNOL METHODS, V321, P41, DOI 10.1016/j.jim.2007.01.008; MUCCI D, 1995, INFECT IMMUN, V63, P2912, DOI 10.1128/IAI.63.8.2912-2918.1995; Nieoullon V, 2005, MOL CELL NEUROSCI, V28, P462, DOI 10.1016/j.mcn.2004.10.007; Nieoullon V, 2007, CELL TISSUE RES, V329, P457, DOI 10.1007/s00441-007-0395-5; Nizard P, 2001, PROTEIN ENG, V14, P439, DOI 10.1093/protein/14.6.439; Park YN, 2005, EUKARYOT CELL, V4, P1328, DOI 10.1128/EC.4.8.1328-1342.2005; Petry IB, 2010, CLIN CANCER RES, V16, P451, DOI 10.1158/1078-0432.CCR-09-1617; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sagiv E, 2006, BIOMED PHARMACOTHER, V60, P280, DOI 10.1016/j.biopha.2006.06.006; Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463; Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028; Sagiv Eyal, 2008, Expert Rev Gastroenterol Hepatol, V2, P125, DOI 10.1586/17474124.2.1.125; Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567; Taguchi T, 2003, J IMMUNOL, V170, P252, DOI 10.4049/jimmunol.170.1.252; Wang WF, 2010, CANCER SCI, V101, P112, DOI 10.1111/j.1349-7006.2009.01370.x; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939; Yin DX, 1996, ANAL BIOCHEM, V235, P195, DOI 10.1006/abio.1996.0112	30	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	2011	286	47					40548	40555		10.1074/jbc.M111.286534	http://dx.doi.org/10.1074/jbc.M111.286534			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	852AN	21976680	Green Published, hybrid			2023-01-03	WOS:000297315400014
J	Konar, A; Shah, N; Singh, R; Saxena, N; Kaul, SC; Wadhwa, R; Thakur, MK				Konar, Arpita; Shah, Navjot; Singh, Rumani; Saxena, Nishant; Kaul, Sunil C.; Wadhwa, Renu; Thakur, Mahendra K.			Protective Role of Ashwagandha Leaf Extract and Its Component Withanone on Scopolamine-Induced Changes in the Brain and Brain-Derived Cells	PLOS ONE			English	Article							MESSENGER-RNA LEVELS; INDUCED AMNESIA; BACOPA-MONNIERA; GENE-EXPRESSION; BDNF GENE; MEMORY; RECEPTORS; GROWTH; INVOLVEMENT; PROMOTERS	Background: Scopolamine is a well-known cholinergic antagonist that causes amnesia in human and animal models. Scopolamine-induced amnesia in rodent models has been widely used to understand the molecular, biochemical, behavioral changes, and to delineate therapeutic targets of memory impairment. Although this has been linked to the decrease in central cholinergic neuronal activity following the blockade of muscarinic receptors, the underlying molecular and cellular mechanism(s) particularly the effect on neuroplasticity remains elusive. In the present study, we have investigated (i) the effects of scopolamine on the molecules involved in neuronal and glial plasticity both in vivo and in vitro and (ii) their recovery by alcoholic extract of Ashwagandha leaves (i-Extract). Methodology/Principal Findings: As a drug model, scopolamine hydrobromide was administered intraperitoneally to mice and its effect on the brain function was determined by molecular analyses. The results showed that the scopolamine caused downregulation of the expression of BDNF and GFAP in dose and time dependent manner, and these effects were markedly attenuated in response to i-Extract treatment. Similar to our observations in animal model system, we found that the scopolamine induced cytotoxicity in IMR32 neuronal and C6 glioma cells. It was associated with downregulation of neuronal cell markers NF-H, MAP2, PSD-95, GAP-43 and glial cell marker GFAP and with upregulation of DNA damage- gamma H2AX and oxidative stress-ROS markers. Furthermore, these molecules showed recovery when cells were treated with i-Extract or its purified component, withanone. Conclusion: Our study suggested that besides cholinergic blockade, scopolamine-induced memory loss may be associated with oxidative stress and Ashwagandha i-Extract, and withanone may serve as potential preventive and therapeutic agents for neurodegenerative disorders and hence warrant further molecular analyses.	[Konar, Arpita; Thakur, Mahendra K.] Banaras Hindu Univ, Dept Zool, Biochem & Mol Biol Lab, Varanasi 221005, Uttar Pradesh, India; [Shah, Navjot; Singh, Rumani; Saxena, Nishant; Kaul, Sunil C.; Wadhwa, Renu] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan	Banaras Hindu University (BHU); National Institute of Advanced Industrial Science & Technology (AIST)	Konar, A (corresponding author), Banaras Hindu Univ, Dept Zool, Biochem & Mol Biol Lab, Varanasi 221005, Uttar Pradesh, India.	renu-wadhwa@aist.go.jp; mkt_bhu@yahoo.com	Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192; Konar, Arpita/0000-0002-1761-1065	Council of Scientific and Industrial Research (CSIR), India; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Honjo International Scholarship Foundation, Japan; Department of Science and Technology [SR/SO/HS-54/2008]; Indian Council of Medical Research, Government of India [3/6/2004-BMS]; AIST (Japan)	Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Honjo International Scholarship Foundation, Japan; Department of Science and Technology(Department of Science & Technology (India)); Indian Council of Medical Research, Government of India(Indian Council of Medical Research (ICMR)); AIST (Japan)	A. Konar is a recipient of Junior Research Fellowship from the Council of Scientific and Industrial Research (CSIR), India. N. Shah and R. Singh are supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) scholarships, Japan. N. Saxena is supported by Honjo International Scholarship Foundation, Japan. The work was supported by grants from the Department of Science and Technology (SR/SO/HS-54/2008) and Indian Council of Medical Research (3/6/2004-BMS), Government of India to M. K. Thakur, and from AIST (Japan) to S.C. Kaul and R. Wadhwa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abhinav Kanwal, 2010, Pharmacology and Pharmacy, V1, P1, DOI 10.4103/0976-500X.64527; Acosta JI, 2009, HORM BEHAV, V55, P454, DOI 10.1016/j.yhbeh.2008.11.008; Agrawal R, 2009, INDIAN J PHARMACOL, V41, P192, DOI 10.4103/0253-7613.56072; Ahmed T, 2009, PHARMACOL BIOCHEM BE, V91, P554, DOI 10.1016/j.pbb.2008.09.010; Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Arancio O, 2007, CURR OPIN NEUROBIOL, V17, P325, DOI 10.1016/j.conb.2007.03.013; BERZAGHI MD, 1993, J NEUROSCI, V13, P3818; Bhatnagar M, 2009, NEUROCHEM RES, V34, P1975, DOI 10.1007/s11064-009-9987-7; BLOKLAND A, 2005, SCOPOLAMINE REV, V1; Brouillette J, 2007, J NEUROCHEM, V102, P1978, DOI 10.1111/j.1471-4159.2007.04666.x; Budson AE, 2005, NEW ENGL J MED, V352, P692, DOI 10.1056/NEJMra041071; Cho WS, 2010, HUM MOL GENET, V19, P3169, DOI 10.1093/hmg/ddq227; Choudhary MI, 2004, CHEM PHARM BULL, V52, P1358, DOI 10.1248/cpb.52.1358; Das A, 2002, PHARMACOL BIOCHEM BE, V73, P893, DOI 10.1016/S0091-3057(02)00940-1; Drozdov OL, 2003, NEUROPHYSIOLOGY+, V35, P98, DOI 10.1023/A:1026060607740; French SJ, 1999, MOL BRAIN RES, V67, P124, DOI 10.1016/S0169-328X(99)00048-0; Garzon D, 2002, J NEUROCHEM, V82, P1058, DOI 10.1046/j.1471-4159.2002.01030.x; GILBEA FJ, 2010, HIPPOCAMPUS; Guizzetti M, 2003, NEUROSCIENCE, V120, P941, DOI 10.1016/S0306-4522(03)00401-9; Hsieh MT, 2003, LIFE SCI, V73, P1007, DOI 10.1016/S0024-3205(03)00372-2; Hung CH, 2004, NEUROSCI LETT, V364, P63, DOI 10.1016/j.neulet.2004.02.074; KOKAIA Z, 1994, EUR J NEUROSCI, V6, P587, DOI 10.1111/j.1460-9568.1994.tb00303.x; Komulainen P, 2008, NEUROBIOL LEARN MEM, V90, P596, DOI 10.1016/j.nlm.2008.07.014; Koshimizu H, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-27; Kotani S, 2006, NEUROSCIENCE, V142, P505, DOI 10.1016/j.neuroscience.2006.06.035; Kuboyama T, 2005, BRIT J PHARMACOL, V144, P961, DOI 10.1038/sj.bjp.0706122; Kurosinski P, 2002, ARCH NEUROL-CHICAGO, V59, P1524, DOI 10.1001/archneur.59.10.1524; Lee B, 2010, J PHARM PHARMACOL, V62, P263, DOI 10.1211/jpp.62.02.0015; Lee JH, 2010, J PHARM PHARMACOL, V62, P1, DOI [10.1211/jpp/62.01.0001, 10.1211/jpp.62.01.0001]; Lee YB, 2004, J NUTR, V134, P1827, DOI 10.1093/jn/134.7.1827; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Nathanson NM, 2000, P NATL ACAD SCI USA, V97, P6245, DOI 10.1073/pnas.97.12.6245; Power JM, 2002, J NEUROSCI, V22, P3454; Rattiner LM, 2004, LEARN MEMORY, V11, P727, DOI 10.1101/lm.83304; Saraf MK, 2008, NEUROSCIENCE, V155, P476, DOI 10.1016/j.neuroscience.2008.05.043; Schliebs R, 1997, NEUROCHEM INT, V30, P181, DOI 10.1016/S0197-0186(96)00025-3; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; SILVA AL, 2009, PSYCHOPHARMACOLOGY, V202, P165; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Tohda C, 2009, BRIT J PHARMACOL, V157, P1427, DOI 10.1111/j.1476-5381.2009.00313.x; VanDeMark KL, 2009, ALCOHOL CLIN EXP RES, V33, P1945, DOI 10.1111/j.1530-0277.2009.01032.x; VANDERWOLF CH, 1991, BEHAV BRAIN RES, V44, P217, DOI 10.1016/S0166-4328(05)80027-0; Wakabayashi T, 1999, BIOTECHNIQUES, V26, P302, DOI 10.2144/99262st04; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013536; Xu Q, 2008, J NEUROSCI, V28, P1452, DOI 10.1523/JNEUROSCI.3253-07.2008; Yamada K, 2003, J PHARMACOL SCI, V91, P267	50	114	114	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2011	6	11							e27265	10.1371/journal.pone.0027265	http://dx.doi.org/10.1371/journal.pone.0027265			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HG	22096544	gold, Green Published, Green Submitted			2023-01-03	WOS:000297553900028
J	Kallio, S; Hyona, J; Revonsuo, A; Sikka, P; Nummenmaa, L				Kallio, Sakari; Hyona, Jukka; Revonsuo, Antti; Sikka, Pilleriin; Nummenmaa, Lauri			The Existence of a Hypnotic State Revealed by Eye Movements	PLOS ONE			English	Article							ANTERIOR CINGULATE CORTEX; HYPNOSIS	Hypnosis has had a long and controversial history in psychology, psychiatry and neurology, but the basic nature of hypnotic phenomena still remains unclear. Different theoretical approaches disagree as to whether or not hypnosis may involve an altered mental state. So far, a hypnotic state has never been convincingly demonstrated, if the criteria for the state are that it involves some objectively measurable and replicable behavioural or physiological phenomena that cannot be faked or simulated by non-hypnotized control subjects. We present a detailed case study of a highly hypnotizable subject who reliably shows a range of changes in both automatic and volitional eye movements when given a hypnotic induction. These changes correspond well with the phenomenon referred to as the "trance stare" in the hypnosis literature. Our results show that this 'trance stare' is associated with large and objective changes in the optokinetic reflex, the pupillary reflex and programming a saccade to a single target. Control subjects could not imitate these changes voluntarily. For the majority of people, hypnotic induction brings about states resembling normal focused attention or mental imagery. Our data nevertheless highlight that in some cases hypnosis may involve a special state, which qualitatively differs from the normal state of consciousness.	[Kallio, Sakari; Revonsuo, Antti; Sikka, Pilleriin] Univ Skovde, Sch Humanities & Informat, Skovde, Sweden; [Kallio, Sakari; Revonsuo, Antti; Sikka, Pilleriin] Univ Turku, Ctr Cognit Neurosci, Turku, Finland; [Kallio, Sakari; Hyona, Jukka; Revonsuo, Antti; Sikka, Pilleriin] Univ Turku, Dept Psychol, Turku, Finland; [Nummenmaa, Lauri] Aalto Univ, Sch Sci, Low Temp Lab, Brain Res Unit, Espoo, Finland; [Nummenmaa, Lauri] Aalto Univ, Sch Sci, Dept Biomed Engn & Computat Sci, Espoo, Finland; [Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, Turku, Finland	University of Skovde; University of Turku; University of Turku; Aalto University; Aalto University; University of Turku	Kallio, S (corresponding author), Univ Skovde, Sch Humanities & Informat, Skovde, Sweden.	sakari.kallio@his.se	Hyönä, Jukka/K-5280-2019; Nummenmaa, Lauri/G-6910-2012	Hyönä, Jukka/0000-0002-5950-3361; Nummenmaa, Lauri/0000-0002-2497-9757; Lauwereyns, Jan/0000-0003-0551-2550; Sikka, Pilleriin/0000-0002-1926-6138	Signe and Ane Gyllenberg Foundation; Academy of Finland; Aalto University [121031]	Signe and Ane Gyllenberg Foundation; Academy of Finland(Academy of Finland); Aalto University	This study was supported by the Signe and Ane Gyllenberg Foundation (http://www.gyllenberg-foundation.fi/en/foundation/) (S. K. and P. S.), the Academy of Finland and by the aivoAALTO Grant (121031) from Aalto University (L.N.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDERSON TJ, 1994, BRAIN, V117, P1073, DOI 10.1093/brain/117.5.1073; Capgras J., 1923, B SOC CLIN MED MENT, V11, P6; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; DIETRICH M, 2009, ANN NY ACAD SCI, V1664, P282; Egner T, 2005, NEUROIMAGE, V27, P969, DOI 10.1016/j.neuroimage.2005.05.002; Findlay JM, 1999, BEHAV BRAIN SCI, V22, P661, DOI 10.1017/S0140525X99002150; Fingelkurts AA, 2007, CONT HYPNOSIS, V24, P3, DOI DOI 10.1002/CH.327; Fingelkurts AA, 2007, NEUROPSYCHOLOGIA, V45, P1452, DOI 10.1016/j.neuropsychologia.2006.11.018; Gauld A., 1992, HIST HYPNOTISM; Gruzelier J., 2005, CONT HYPN, V22, P1; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Hilgard E. R., 1965, HYPNOTIC SUSCEPTIBIL; Hubbard EM, 2005, NEURON, V48, P509, DOI 10.1016/j.neuron.2005.10.012; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; Ilg UJ, 1997, PROG NEUROBIOL, V53, P293, DOI 10.1016/S0301-0082(97)00039-7; Kallio S, 1999, NEUROREPORT, V10, P3579, DOI 10.1097/00001756-199911260-00021; Kallio S., 2005, CONT HYPNOSIS, V22, P46, DOI DOI 10.1002/(ISSN)1557-0711; Kallio S., 2003, CONT HYPNOSIS, V20, P111, DOI [10.1002/ch.273, DOI 10.1002/CH.273]; KIRSCH I, 1995, AM PSYCHOL, V50, P846, DOI 10.1037/0003-066X.50.10.846; LILIENFELD SO, 2009, 50 GREAT MYTHS POP P; LINDSAY S, 1993, INT J CLIN EXP HYP, V41, P92, DOI 10.1080/00207149308414540; Maquet P, 1999, BIOL PSYCHIAT, V45, P327, DOI 10.1016/S0006-3223(97)00546-5; McGeown WJ, 2009, CONSCIOUS COGN, V18, P848, DOI 10.1016/j.concog.2009.09.001; NOREIKA V, 2011, INT J CLIN IN PRESS; Oakley DA, 2009, TRENDS COGN SCI, V13, P264, DOI 10.1016/j.tics.2009.03.004; PAUS T, 1993, J NEUROPHYSIOL, V70, P453, DOI 10.1152/jn.1993.70.2.453; Pierrot-Deseilligny C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005; Rainville P, 2002, J COGNITIVE NEUROSCI, V14, P887, DOI 10.1162/089892902760191117; Shor RE, 1962, HARVARD GROUP SCALE; TADA T, 1990, PERCEPT MOTOR SKILL, V71, P832; WEITZENHOFFER A M, 1969, American Journal of Clinical Hypnosis, V11, P221; WEITZENHOFFER A M, 1971, American Journal of Clinical Hypnosis, V14, P102; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; Weitzenhoffer A. M., 2000, PRACTICE HYPNOTISM; WEITZENHOFFER AM, 1969, PERCEPT MOTOR SKILL, V28, P671, DOI 10.2466/pms.1969.28.2.671; Weitzenhoffer AM, 1980, AM J CLIN HYPN, V44, P69	36	15	15	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 24	2011	6	10							e26374	10.1371/journal.pone.0026374	http://dx.doi.org/10.1371/journal.pone.0026374			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841MA	22039474	Green Published, gold			2023-01-03	WOS:000296515200016
J	Samaha, AN; Minogianis, EA; Nachar, W				Samaha, Anne-Noel; Minogianis, Ellie-Anna; Nachar, Walid			Cues Paired with either Rapid or Slower Self-Administered Cocaine Injections Acquire Similar Conditioned Rewarding Properties	PLOS ONE			English	Article							INTRAVENOUS COCAINE; ATTENTIONAL BIAS; D-AMPHETAMINE; DELIVERY; ACQUISITION; RATS; SENSITIZATION; REINSTATEMENT; STIMULUS; ALTERS	The faster drugs of abuse reach the brain, the more addictive they can be. It is not known why this is. Environmental stimuli associated with drugs can promote the development and persistence of addiction by invigorating and precipitating drug-seeking behaviour. We determined, therefore, whether cues associated with the self-administration of rapidly delivered cocaine (injected intravenously over 5 versus 90 seconds) would acquire greater conditioned rewarding properties, as assessed by the performance of an operant response reinforced solely by the cues. Rats nose-poked for intravenous cocaine infusions delivered either over 5 or 90 seconds. Discrete visual cues accompanied each infusion. The rats could then press a lever to obtain the cues-now a conditioned reward-or an inactive lever. Rats in both the 5- and 90-second groups pressed more on the active versus inactive lever following extensive (24 sessions) but not following limited (3 sessions) self-administration training. There were no group differences in this behaviour. Following withdrawal from cocaine self-administration, lever discrimination progressively abated in both groups and was lost by withdrawal day 30. However, the rewarding properties of the cues were not "forgotten" because on withdrawal days 32-33, amphetamine selectively enhanced active-lever pressing, and did so to a similar extent in both groups. Thus, cues paired with rapid or slower cocaine delivery acquire similar conditioned rewarding properties. We conclude, therefore, that the rapid delivery of cocaine to the brain promotes addiction by mechanisms that might not involve a greater ability of drug cues to control behaviour.	[Samaha, Anne-Noel; Minogianis, Ellie-Anna; Nachar, Walid] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Samaha, Anne-Noel] Univ Montreal, Fac Med, CNS Res Grp, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Samaha, AN (corresponding author), Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.	Anna.samaha@umontreal.ca			Canadian Institutes of Health Research [97841]; Fonds de la Recherche en Sante du Quebec [16193]; Canada Foundation for Innovation [24326]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR)	This research was supported by an operating grant from the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca/e/193.html) to ANS (Grant No. 97841), a salary award from the Fonds de la Recherche en Sante du Quebec (http://www.frsq.gouv.qc.ca/en/index.shtml) to ANS (Grant No. 16193) and an infrastructure grant from the Canada Foundation for Innovation (http://www.innovation.ca/en) to ANS (Grant No. 24326). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu ME, 2001, PSYCHOPHARMACOLOGY, V154, P76, DOI 10.1007/s002130000624; Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774; BALSTER RL, 1973, J EXP ANAL BEHAV, V20, P119, DOI 10.1901/jeab.1973.20-119; BEDARD AM, 2011, CHRONIC TREATMENT TY; Brown PL, 2005, PSYCHOPHARMACOLOGY, V181, P299, DOI 10.1007/s00213-005-2244-0; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Carroll ME, 1997, PSYCHOPHARMACOLOGY, V129, P206, DOI 10.1007/s002130050182; Chen CY, 2004, PSYCHOPHARMACOLOGY, V172, P78, DOI 10.1007/s00213-003-1624-6; Crombag HS, 2008, PHARMACOL BIOCHEM BE, V90, P797, DOI 10.1016/j.pbb.2008.06.003; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; DEWIT H, 1993, PSYCHOPHARMACOLOGY, V112, P324, DOI 10.1007/BF02244928; Di Ciano P, 2004, NEUROPHARMACOLOGY, V47, P202, DOI 10.1016/j.neuropharm.2004.06.005; Di Ciano P, 2008, NEUROPSYCHOPHARMACOL, V33, P1426, DOI 10.1038/sj.npp.1301542; DICKINSON A, 1987, Q J EXP PSYCHOL-B, V39, P201; DICKINSON A, 1978, ANNU REV PSYCHOL, V29, P587, DOI 10.1146/annurev.ps.29.020178.003103; DMELLO GD, 1977, BRIT J PHARMACOL, V61, P415, DOI 10.1111/j.1476-5381.1977.tb08434.x; Duka T, 2004, PSYCHOPHARMACOLOGY, V176, P353, DOI 10.1007/s00213-004-1906-7; EHRMAN RN, 1992, PSYCHOPHARMACOLOGY, V107, P523, DOI 10.1007/BF02245266; Ferrario CR, 2008, BRAIN RES, V1209, P151, DOI 10.1016/j.brainres.2008.02.081; Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI 10.1016/j.drugalcdep.2008.03.030; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GORELICK DA, 1992, AM J DRUG ALCOHOL AB, V18, P13, DOI 10.3109/00952999209001607; GOSSOP M, 1992, BRIT J ADDICT, V87, P1527; GOSSOP M, 1994, BRIT J PSYCHIAT, V164, P660, DOI 10.1192/bjp.164.5.660; Hatsukami DK, 1996, JAMA-J AM MED ASSOC, V276, P1580; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; Jones R T, 1990, NIDA Res Monogr, V99, P30; KATO S, 1987, PHARMACOL BIOCHEM BE, V28, P407; KELLEHER ROGER T., 1962, JOUR EXPTL ANALYSIS BEHAVIOR, V5, P543, DOI 10.1901/jeab.1962.5-s543; LEVINE DG, 1974, AM J PSYCHIAT, V131, P297, DOI 10.1176/ajp.131.3.297; Liu Y, 2005, EUR J NEUROSCI, V22, P195, DOI 10.1111/j.1460-9568.2005.04195.x; LOVIBOND PF, 1983, J EXP PSYCHOL ANIM B, V9, P225, DOI 10.1037/0097-7403.9.3.225; Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN; Nelson RA, 2006, DRUG ALCOHOL DEPEN, V82, P19, DOI 10.1016/j.drugalcdep.2005.08.004; O'Brien MS, 2005, NEUROPSYCHOPHARMACOL, V30, P1006, DOI 10.1038/sj.npp.1300681; OBRIEN CP, 1992, ANN NY ACAD SCI, V654, P400, DOI 10.1111/j.1749-6632.1992.tb25984.x; Panlilio LV, 1996, PSYCHOPHARMACOLOGY, V125, P202, DOI 10.1007/BF02247329; Panlilio LV, 1998, PSYCHOPHARMACOLOGY, V137, P253, DOI 10.1007/s002130050618; PORRINO LJ, 1993, PSYCHOPHARMACOLOGY, V112, P343, DOI 10.1007/BF02244931; RESCORLA RA, 1967, PSYCHOL REV, V74, P151, DOI 10.1037/h0024475; ROBBINS TW, 1983, PSYCHOPHARMACOLOGY, V80, P113, DOI 10.1007/BF00427952; ROBBINS TW, 1978, PSYCHOPHARMACOLOGY, V58, P79, DOI 10.1007/BF00426794; Robinson TE, 2009, BIOL PSYCHIAT, V65, P869, DOI 10.1016/j.biopsych.2008.09.006; Samaha AN, 2004, J NEUROSCI, V24, P6362, DOI 10.1523/JNEUROSCI.1205-04.2004; Samaha AN, 2005, BIOL PSYCHIAT, V57, P351, DOI 10.1016/j.biopsych.2004.11.040; Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007; Samaha AN, 2002, J NEUROSCI, V22, P3244, DOI 10.1523/JNEUROSCI.22-08-03244.2002; Saunders BT, 2010, BIOL PSYCHIAT, V67, P730, DOI 10.1016/j.biopsych.2009.11.015; Schindler CW, 2011, PHARMACOL BIOCHEM BE, V99, P301, DOI 10.1016/j.pbb.2011.05.005; Schoenmakers T, 2008, PSYCHOPHARMACOLOGY, V197, P169, DOI 10.1007/s00213-007-1023-5; Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x; Uslaner JM, 2006, BEHAV BRAIN RES, V169, P320, DOI 10.1016/j.bbr.2006.02.001; Wakabayashi KT, 2010, J NEUROSCI, V30, P11346, DOI 10.1523/JNEUROSCI.2524-10.2010; Wise RA, 2011, NAT REV NEUROSCI, V12, DOI 10.1038/nrn3043-c2; Wise RA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002846	56	13	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 19	2011	6	10							e26481	10.1371/journal.pone.0026481	http://dx.doi.org/10.1371/journal.pone.0026481			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841JB	22039496	Green Published, Green Submitted, gold			2023-01-03	WOS:000296507500074
J	Herwaldt, BL; Linden, JV; Bosserman, E; Young, C; Olkowska, D; Wilson, M				Herwaldt, Barbara L.; Linden, Jeanne V.; Bosserman, Elizabeth; Young, Carolyn; Olkowska, Danuta; Wilson, Marianna			Transfusion-Associated Babesiosis in the United States: A Description of Cases	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSMITTED BABESIOSIS; BLOOD-TRANSFUSION; WASHINGTON-STATE; TRANSMISSION; MICROTI; MINNESOTA; INFECTION; DISEASE; INFANT	Background: Babesiosis is a potentially life-threatening disease caused by intraerythrocytic parasites, which usually are tickborne but also are transmissible by transfusion. Tickborne transmission of Babesia microti mainly occurs in 7 states in the Northeast and the upper Midwest of the United States. No Babesia test for screening blood donors has been licensed. Objective: To ascertain and summarize data on U. S. transfusion-associated Babesia cases identified since the first described case in 1979. Design: Case series. Setting: United States. Patients: Case patients were transfused during 1979-2009 and had posttransfusion Babesia infection diagnosed by 2010, without reported evidence that another transmission route was more likely than transfusion. Implicated donors had laboratory evidence of infection. Potential cases were excluded if all pertinent donors tested negative. Measurements: Distributions of ascertained cases according to Babesia species and period and state of transfusion. Results: 159 transfusion-associated B. microti cases were included; donors were implicated for 136 (86%). The case patients' median age was 65 years (range, <1 to 94 years). Most cases were associated with red blood cell components; 4 were linked to whole blood-derived platelets. Cases occurred in all 4 seasons and in 22 (of 31) years, but 77% (122 cases) occurred during 2000-2009. Cases occurred in 19 states, but 87% (138 cases) were in the 7 main B. microti-endemic states. In addition, 3 B. duncani cases were documented in western states. Limitation: The extent to which cases were not diagnosed, investigated, reported, or ascertained is unknown. Conclusion: Donor-screening strategies that mitigate the risk for transfusion transmission are needed. Babesiosis should be included in the differential diagnosis of unexplained posttransfusion hemolytic anemia or fever, regardless of the season or U. S. region.	[Herwaldt, Barbara L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; Rhode Isl Blood Ctr, Providence, RI USA	Centers for Disease Control & Prevention - USA; State University of New York (SUNY) System; Wadsworth Center	Herwaldt, BL (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30333 USA.	bherwaldt@cdc.gov						Asad S, 2009, TRANSFUSION, V49, P2564, DOI 10.1111/j.1537-2995.2009.02380.x; Bachowski G, 2009, TRANSFUSION, V49, p35A; Blue D, 2009, TRANSFUSION, V49, P8, DOI 10.1111/j.1537-2995.2008.01883.x; Brennan MB, 2010, 5 DEC INT C HEALTHC; CABLE RG, 2001, BLOOD SAFETY SURVEIL, P399; Cangelosi JJ, 2008, VOX SANG, V95, P331, DOI 10.1111/j.1423-0410.2008.01094.x; Cirino CM, 2008, ANN INTERN MED, V148, P794, DOI 10.7326/0003-4819-148-10-200805200-00018; Conrad PA, 2006, INT J PARASITOL, V36, P779, DOI 10.1016/j.ijpara.2006.03.008; Dobroszycki J, 1999, JAMA-J AM MED ASSOC, V281, P927, DOI 10.1001/jama.281.10.927; Evenson DA, 1998, J CLIN APHERESIS, V13, P32, DOI 10.1002/(SICI)1098-1101(1998)13:1<32::AID-JCA7>3.3.CO;2-1; Food and Drug Administration, 2010, M BLOOD PROD ADV COM; Fox LAM, 2006, PEDIATR INFECT DIS J, V25, P169, DOI 10.1097/01.inf.0000195438.09628.b0; GERBER MA, 1994, J INFECT DIS, V170, P231, DOI 10.1093/infdis/170.1.231; GORDON S, 1984, CHEST, V86, P633, DOI 10.1378/chest.86.4.633; GRABOWSKI EF, 1982, ANN INTERN MED, V96, P466, DOI 10.7326/0003-4819-96-4-446; Gubernot DM, 2009, TRANSFUSION, V49, P2759, DOI 10.1111/j.1537-2995.2009.02429.x; Gubernot DM, 2009, CLIN INFECT DIS, V48, P25, DOI 10.1086/595010; Herman JH, 2010, J CLIN APHERESIS, V25, P358, DOI 10.1002/jca.20262; Herwaldt BL, 2004, EMERG INFECT DIS, V10, P622, DOI 10.3201/eid1004.030377; Herwaldt BL, 1997, J INFECT DIS, V175, P1259, DOI 10.1086/593812; Herwaldt BL, 2003, EMERG INFECT DIS, V9, P184; Herwaldt BL, 1996, ANN INTERN MED, V124, P643, DOI 10.7326/0003-4819-124-7-199604010-00004; Herwaldt BL, 2002, TRANSFUSION, V42, P1154, DOI 10.1046/j.1537-2995.2002.00189.x; JACOBY GA, 1980, NEW ENGL J MED, V303, P1098, DOI 10.1056/NEJM198011063031906; Kain KC, 2001, CAN MED ASSOC J, V164, P1721; Kjemtrup AM, 2002, TRANSFUSION, V42, P1482, DOI 10.1046/j.1537-2995.2002.00245.x; Kurkjian K, 2010, ANN C COUNC STAT TER; Laird TW, 2005, MIL MED, V170, P295, DOI 10.7205/MILMED.170.4.295; Leiby DA, 2011, CLIN MICROBIOL REV, V24, P14, DOI 10.1128/CMR.00022-10; Linden JV, 2010, TRANSFUSION, V50, p39A; Linden JV, 2000, TRANSFUSION, V40, p96S; Linden JV, 2000, TRANSFUSION, V40, P285, DOI 10.1046/j.1537-2995.2000.40030285.x; Lux JZ, 2003, EMERG INFECT DIS, V9, P116, DOI 10.3201/eid0901.020149; MARCUS LC, 1982, JAMA-J AM MED ASSOC, V248, P465, DOI 10.1001/jama.248.4.465; MINTZ ED, 1991, TRANSFUSION, V31, P365, DOI 10.1046/j.1537-2995.1991.31491213305.x; Ngo V, 2009, EMERG INFECT DIS, V15, P785, DOI 10.3201/eid1505.081562; Nicholson GT, 2010, CONGENIT HEART DIS, V5, P607, DOI 10.1111/j.1747-0803.2010.00384.x; Pantanowitz L, 2002, TRANSFUS MED REV, V16, P131, DOI 10.1053/tmrv.2002.31462; Perdrizet GA, 2000, TRANSPLANTATION, V70, P205; PRZYJEMSKI CJ, 1981, NEW ENGL J MED, V304, P733; QUICK RE, 1993, ANN INTERN MED, V119, P284, DOI 10.7326/0003-4819-119-4-199308150-00006; Raju M, 2007, PEDIATR INFECT DIS J, V26, P181, DOI 10.1097/01.inf.0000250622.11505.8f; SMITH RP, 1986, JAMA-J AM MED ASSOC, V256, P2726, DOI 10.1001/jama.256.19.2726; Stramer SL, 2009, TRANSFUSION, V49, p1S, DOI 10.1111/j.1537-2995.2009.02279.x; Tonnetti L, 2009, TRANSFUSION, V49, P2557, DOI 10.1111/j.1537-2995.2009.02317.x; WESTERN KA, 1970, NEW ENGL J MED, V283, P854, DOI 10.1056/NEJM197010152831607; WITTNER M, 1982, ANN INTERN MED, V96, P601, DOI 10.7326/0003-4819-96-5-601; Wormser GP, 2011, AM SURGEON, V77, P345; Wudhikarn K, 2011, AM J MED, V124, P800, DOI 10.1016/j.amjmed.2011.03.009; Young C, 2009, TRANSFUSION, V49, P2548, DOI 10.1111/j.1537-2995.2009.02494.x; Zhao Y, 2009, TRANSFUSION, V49, P2583, DOI 10.1111/j.1537-2995.2009.02454.x	51	204	213	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2011	155	8					509	U83		10.7326/0003-4819-155-8-201110180-00362	http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00362			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835WB	21893613				2023-01-03	WOS:000296066300016
J	Nicholas, LH; Langa, KM; Iwashyna, TJ; Weir, DR				Nicholas, Lauren Hersch; Langa, Kenneth M.; Iwashyna, Theodore J.; Weir, David R.			Regional Variation in the Association Between Advance Directives and End-of-Life Medicare Expenditures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT PREFERENCES; HEALTH-CARE; OUTCOMES; QUALITY; VALIDATION; DEATH	Context It is unclear if advance directives (living wills) are associated with end-of-life expenditures and treatments. Objective To examine regional variation in the associations between treatment-limiting advance directive use, end-of-life Medicare expenditures, and use of palliative and intensive treatments. Design, Setting, and Patients Prospectively collected survey data from the Health and Retirement Study for 3302 Medicare beneficiaries who died between 1998 and 2007 linked to Medicare claims and the National Death Index. Multivariable regression models examined associations between advance directives, end-of-life Medicare expenditures, and treatments by level of Medicare spending in the decedent's hospital referral region. Main Outcome Measures Medicare expenditures, life-sustaining treatments, hospice care, and in-hospital death over the last 6 months of life. Results Advance directives specifying limits in care were associated with lower spending in hospital referral regions with high average levels of end-of-life expenditures (-$5585 per decedent; 95% CI, -$10 903 to -$267), but there was no difference in spending in hospital referral regions with low or medium levels of end-of-life expenditures. Directives were associated with lower adjusted probabilities of in-hospital death in high-and medium-spending regions (-9.8%; 95% CI, -16% to -3% in high-spending regions; -5.3%; 95% CI, -10% to -0.4% in medium-spending regions). Advance directives were associated with higher adjusted probabilities of hospice use in high-and medium-spending regions (17%; 95% CI, 11% to 23% in high-spending regions, 11%; 95% CI, 6% to 16% in medium-spending regions), but not in low-spending regions. Conclusion Advance directives specifying limitations in end-of-life care were associated with significantly lower levels of Medicare spending, lower likelihood of in-hospital death, and higher use of hospice care in regions characterized by higher levels of end-of-life spending. JAMA. 2011;306(13):1447-1453	[Nicholas, Lauren Hersch; Langa, Kenneth M.; Iwashyna, Theodore J.; Weir, David R.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Langa, Kenneth M.; Iwashyna, Theodore J.] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA; [Langa, Kenneth M.; Iwashyna, Theodore J.] Vet Affairs Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nicholas, LH (corresponding author), 3005 Inst Social Res, 426 Thompson St, Ann Arbor, MI 48104 USA.	lnichola@umich.edu		Iwashyna, Theodore/0000-0002-4226-9310; Langa, Kenneth/0000-0002-2798-1836	National Institutes of Health [U01 AG09740, R01 AG030155, K08 HL091249]; Michigan Institute for Clinical and Health Research [UL1RR024986]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD041028] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL091249] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030155, U01AG009740, T32AG000221, P30AG012846] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Michigan Institute for Clinical and Health Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grants U01 AG09740, R01 AG030155, K08 HL091249 from the National Institutes of Health and Clinical and Translational Science Award grant UL1RR024986 from the Michigan Institute for Clinical and Health Research.	Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Barnato AE, 2009, MED CARE, V47, P1098, DOI 10.1097/MLR.0b013e3181993191; Barnato AE, 2009, J GEN INTERN MED, V24, P695, DOI 10.1007/s11606-009-0952-6; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; *DARTM, DARTM ATL HLTH CAR D; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fried TR, 2011, J AM GERIATR SOC, V59, P1105, DOI 10.1111/j.1532-5415.2011.03412.x; Greene W., 2018, ECONOMETRIC ANAL; Juster FT, 1995, J HUM RESOUR, V30, pS7, DOI 10.2307/146277; Kelley AS, 2011, ANN INTERN MED, V154, P235, DOI 10.7326/0003-4819-154-4-201102150-00004; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; McPherson CJ, 2003, SOC SCI MED, V56, P95, DOI 10.1016/S0277-9536(02)00011-4; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Riley GF, 2010, HEALTH SERV RES, V45, P565, DOI 10.1111/j.1475-6773.2010.01082.x; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Taylor JS, 1999, CAN FAM PHYSICIAN, V45, P2408; Teno J, 1997, J AM GERIATR SOC, V45, P513, DOI 10.1111/j.1532-5415.1997.tb05180.x; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Xu Jiaquan, 2010, Natl Vital Stat Rep, V58, P1; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	28	213	214	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2011	306	13					1447	1453		10.1001/jama.2011.1410	http://dx.doi.org/10.1001/jama.2011.1410			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	828MZ	21972306	Green Accepted			2023-01-03	WOS:000295506900023
J	Quill, TE; Holloway, R				Quill, Timothy E.; Holloway, Robert			Time-Limited Trials Near the End of Life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							COMMUNICATION; PREFERENCES; CARE		[Quill, Timothy E.] Univ Rochester, Med Ctr, Palliat Care Program, Ctr Eth Humanities & Palliat Care, Rochester, NY 14642 USA; [Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; [Holloway, Robert] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Quill, TE (corresponding author), Univ Rochester, Med Ctr, Palliat Care Program, Ctr Eth Humanities & Palliat Care, 601 Elmwood Ave,Box 687, Rochester, NY 14642 USA.	timothy_quill@urmc.rochester.edu						Berwick DM, 1998, ANN INTERN MED, V128, P651, DOI 10.7326/0003-4819-128-8-199804150-00009; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Chung GS, 2012, J MED ETHICS, V38, P77, DOI 10.1136/jme.2010.040618; Hagerty RG, 2004, J CLIN ONCOL, V22, P1721, DOI 10.1200/JCO.2004.04.095; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Quill TE, 2009, ANN INTERN MED, V151, P345, DOI 10.7326/0003-4819-151-5-200909010-00010; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359; Ubel PA, 2005, HEALTH PSYCHOL, V24, pS57, DOI 10.1037/0278-6133.24.4.S57; Wendler D, 2011, ANN INTERN MED, V154, P336, DOI 10.7326/0003-4819-154-5-201103010-00008	10	132	134	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2011	306	13					1483	1484		10.1001/jama.2011.1413	http://dx.doi.org/10.1001/jama.2011.1413			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	828MZ	21972312				2023-01-03	WOS:000295506900029
J	Li, LF; Chen, BX; Tsai, YH; Kao, WWY; Yang, CT; Chu, PH				Li, Li-Fu; Chen, Bao-Xiang; Tsai, Ying-Huang; Kao, Winston W. -Y.; Yang, Cheng-Ta; Chu, Pao-Hsien			Lumican Expression in Diaphragm Induced by Mechanical Ventilation	PLOS ONE			English	Article							ACUTE LUNG INJURY; RESPIRATORY-DISTRESS-SYNDROME; INDUCED PULMONARY-FIBROSIS; GROWTH-FACTOR-BETA; OXIDATIVE STRESS; TISSUE-REPAIR; TGF-BETA; DYSFUNCTION; PROTEOGLYCANS; ACTIVATION	Background: Diaphragmatic dysfunction found in the patients with acute lung injury required prolonged mechanical ventilation. Mechanical ventilation can induce production of inflammatory cytokines and excess deposition of extracellular matrix proteins via up-regulation of transforming growth factor (TGF)-beta 1. Lumican is known to participate in TGF-beta 1 signaling during wound healing. The mechanisms regulating interactions between mechanical ventilation and diaphragmatic injury are unclear. We hypothesized that diaphragmatic damage by short duration of mechanical stretch caused up-regulation of lumican that modulated TGF-beta 1 signaling. Methods: Male C57BL/6 mice, either wild-type or lumican-null, aged 3 months, weighing between 25 and 30 g, were exposed to normal tidal volume (10 ml/kg) or high tidal volume (30 ml/kg) mechanical ventilation with room air for 2 to 8 hours. Nonventilated mice served as control groups. Results: High tidal volume mechanical ventilation induced interfibrillar disassembly of diaphragmatic collagen fiber, lumican activation, type I and III procollagen, fibronectin, and alpha-smooth muscle actin (alpha-SMA) mRNA, production of free radical and TGF-beta 1 protein, and positive staining of lumican in diaphragmatic fiber. Mechanical ventilation of lumican deficient mice attenuated diaphragmatic injury, type I and III procollagen, fibronectin, and alpha-SMA mRNA, and production of free radical and TGF-beta 1 protein. No significant diaphragmatic injury was found in mice subjected to normal tidal volume mechanical ventilation. Conclusion: Our data showed that high tidal volume mechanical ventilation induced TGF-beta 1 production, TGF-beta 1-inducible genes, e. g., collagen, and diaphragmatic dysfunction through activation of the lumican.	[Li, Li-Fu; Tsai, Ying-Huang; Yang, Cheng-Ta] Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Taipei 10591, Taiwan; [Li, Li-Fu; Yang, Cheng-Ta; Chu, Pao-Hsien] Chang Gung Univ, Dept Med, Coll Med, Tao Yuan, Taiwan; [Chen, Bao-Xiang] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Tao Yuan, Taiwan; [Chen, Bao-Xiang; Tsai, Ying-Huang] Chang Gung Univ, Dept Resp Care, Coll Med, Tao Yuan, Taiwan; [Chen, Bao-Xiang] Natl Taiwan Univ Hosp, Sect Resp Care, Dept Integrated Diagnotherapeut, Taipei, Taiwan; [Kao, Winston W. -Y.] Univ Cincinnati, Coll Med, Dept Ophthalmol, Crawley Vis Res Ctr, Cincinnati, OH USA; [Chu, Pao-Hsien] Chang Gung Mem Hosp, Cardiovasc Div 1, Dept Internal Med, Taipei 10591, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung University; National Taiwan University; National Taiwan University Hospital; University System of Ohio; University of Cincinnati; Chang Gung Memorial Hospital	Li, LF (corresponding author), Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Dept Internal Med, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	yang1946@adm.cgmh.org.tw; pchu@adm.cgmh.org.tw	Chu, Pao-Hsien/P-5249-2019; Chu, Pao-Hsien/G-3685-2010	Chu, Pao-Hsien/0000-0003-0361-6348; Yang, Cheng-Ta/0000-0003-1846-1027	National Science Council, Taiwan [98-2314-B-182A-084-MY3, 96-2314-B-182-026-, 97-2314-B-182-028-MY2, 99-2314-B-182-042-MY3]; NIH/NEI [EY011845]; Research to Prevent Blindness; Ohio Lions Eye Research Foundations; NATIONAL EYE INSTITUTE [R01EY011845] Funding Source: NIH RePORTER	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); NIH/NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Ohio Lions Eye Research Foundations; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The work was supported by National Science Council, Taiwan 98-2314-B-182A-084-MY3 (L.-F.Li); 96-2314-B-182-026-, 97-2314-B-182-028-MY2, and 99-2314-B-182-042-MY3 (P.-H. Chu); and NIH/NEI grant EY011845, Research to Prevent Blindness and Ohio Lions Eye Research Foundations (W.W.Y. Kao). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agostini Carlo, 2006, Proc Am Thorac Soc, V3, P357, DOI 10.1513/pats.200601-010TK; Al-Jamal R, 2001, AM J PHYSIOL-LUNG C, V281, pL1078, DOI 10.1152/ajplung.2001.281.5.L1078; Bai KJ, 2005, AM J RESP CRIT CARE, V172, P92, DOI 10.1164/rccm.200405-652OC; Bartram U, 2004, CHEST, V125, P754, DOI 10.1378/chest.125.2.754; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chakravarti S, 2006, DEV DYNAM, V235, P2493, DOI 10.1002/dvdy.20868; Chaudhary NI, 2006, AM J RESP CRIT CARE, V173, P769, DOI 10.1164/rccm.200505-717OC; Chen J, 2005, DIABETES, V54, P2143, DOI 10.2337/diabetes.54.7.2143; de Carvalho MEP, 2007, CRIT CARE, V11, DOI 10.1186/cc5702; Dolhnikoff M, 1998, AM J RESP CELL MOL, V19, P582, DOI 10.1165/ajrcmb.19.4.2979; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Fahy RJ, 2003, AM J RESP CELL MOL, V28, P499, DOI 10.1165/rcmb.2002-0092OC; Held HD, 2001, AM J RESP CRIT CARE, V163, P711, DOI 10.1164/ajrccm.163.3.2003001; Higashiyama H, 2007, EXP MOL PATHOL, V83, P39, DOI 10.1016/j.yexmp.2006.12.003; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Jubran A, 2006, RESPIR CARE, V51, P1054; Kao WWY, 2006, EXP EYE RES, V82, P3, DOI 10.1016/j.exer.2005.08.012; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Li LF, 2004, AM J RESP CRIT CARE, V169, P518, DOI 10.1164/rccm.200305-660OC; Li LF, 2011, TRANSL RES, V157, P293, DOI 10.1016/j.trsl.2010.12.009; Li LF, 2008, CRIT CARE, V12, DOI 10.1186/cc6983; Ludwig MS, 2007, J APPL PHYSIOL, V103, P735, DOI 10.1152/japplphysiol.00751.2007; Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS; McClung JM, 2009, CRIT CARE MED, V37, P1373, DOI 10.1097/CCM.0b013e31819cef63; Moriondo A, 2007, J APPL PHYSIOL, V103, P747, DOI 10.1152/japplphysiol.00056.2007; Petrof BJ, 2010, CURR OPIN CRIT CARE, V16, P19, DOI 10.1097/MCC.0b013e328334b166; Pittet JF, 2001, J CLIN INVEST, V107, P1537, DOI 10.1172/JCI11963; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Takala TE, 2000, SCAND J MED SCI SPOR, V10, P321, DOI 10.1034/j.1600-0838.2000.010006321.x; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vassilakopoulos T, 2008, INTENS CARE MED, V34, P7, DOI 10.1007/s00134-007-0866-x; Whidden MA, 2009, J APPL PHYSIOL, V106, P385, DOI 10.1152/japplphysiol.91106.2008; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306; Zergeroglu MA, 2003, J APPL PHYSIOL, V95, P1116, DOI 10.1152/japplphysiol.00824.2002	34	27	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2011	6	9							e24692	10.1371/journal.pone.0024692	http://dx.doi.org/10.1371/journal.pone.0024692			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CN	21931815	Green Published, Green Submitted, gold			2023-01-03	WOS:000294803100057
J	Jiang, YW; Yin, WJ; Zhou, LH; Yan, TT; Zhou, Q; Du, YY; Shen, ZZ; Shao, ZM; Lu, JS				Jiang, Yiwei; Yin, Wenjin; Zhou, Liheng; Yan, Tingting; Zhou, Qiong; Du, Yueyao; Shen, Zhenzhou; Shao, Zhimin; Lu, Jinsong			First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis	PLOS ONE			English	Article							TRIPLE-NEGATIVE TUMORS; THYMIDINE PHOSPHORYLASE; COMBINATION THERAPY; ANTITUMOR-ACTIVITY; DOCETAXEL; CHEMOTHERAPY; PLUS; CYCLOPHOSPHAMIDE; EPIRUBICIN; TRIAL	Background: Capecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. Therefore, it is essential to evaluate the efficacy of capecitabine in the adjuvant setting. There have been two large randomized studies to determine whether patients with high-risk early breast cancer benefit from the addition of capecitabine to standard chemotherapy, but they have yielded inconsistent results. We first undertook a meta-analysis to evaluate the efficacy of the addition of capecitabine over standard treatment. Methods: PubMed, EBSCO, Web of Science, conference proceedings and key trials were searched from 1998 to 2011. The hazard ratio (HR) was used to evaluate the efficacy of a taxane-anthracycline regimen and a taxane-anthracycline-capecitabine regimen in early breast cancer. All of the data from each study use either fixed-effects or random-effects by Stata. Findings: We found significant improvement in the additional capecitabine arm versus control in disease-free survival (DFS) (HR = 0.83, 95% CI: 0.71-0.98, P = 0.027), overall survival (OS) (HR = 0.71, 95% CI: 0.57-0.88, P = 0.002), distant recurrence (HR = 0.79, 95% CI: 0.66-0.94, P = 0.008) and the death from breast cancer only (HR = 0.65, 95% CI: 0.51-0.83, P = 0.001). Meanwhile, the subgroup analysis revealed that capecitabine improved the DFS in triple negative (HR = 0.71, 95% CI: 0.53-0.96, P = 0.028), hormone receptor negative (HR = 0.73, CI: 0.56-0.94, P = 0.017) and HER2 negative (HR = 0.81, CI: 0.67-0.98, P = 0.034) patients. Conclusion: Due to the synergistic effect of taxane and capecitabine, taxane-anthracycline-capecitabine regimen may effectively improve the efficacy in the adjuvant setting and may be a novel generation of adjuvant chemotherapy regimen. The results of the current meta-analysis support this hypothesis and indicate that taxane-based regimen with capecitabine may be an effective, convenient, and well tolerated regimen in patients with early breast cancer.	[Jiang, Yiwei; Yan, Tingting; Zhou, Qiong; Du, Yueyao] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China; [Yin, Wenjin; Zhou, Liheng; Shen, Zhenzhou; Shao, Zhimin; Lu, Jinsong] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai 200433, Peoples R China	Fudan University; Fudan University	Jiang, YW (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China.	lujjss@yahoo.com.cn	Yin, Wenjin/L-6020-2019	Yin, Wenjin/0000-0002-2129-7443				Airoldi M, 2001, BREAST CANCER RES TR, V70, P185, DOI 10.1023/A:1013070612986; ARCAMONE F, 1978, EXPERIENTIA, V34, P1255, DOI 10.1007/BF01981401; Bevers TB, 2009, J NATL COMPR CANC NE, V7, P1060, DOI 10.6004/jnccn.2009.0070; Campone M, 2005, CRIT REV ONCOL HEMAT, V55, P167, DOI 10.1016/j.critrevonc.2005.04.003; De Laurentiis M, 2010, CANCER TREAT REV, V36, pS80, DOI 10.1016/S0305-7372(10)70025-6; Fujimoto-Ouchi K, 2001, CLIN CANCER RES, V7, P1079; Hayes DF, 2007, NEW ENGL J MED, V357, P1496, DOI 10.1056/NEJMoa071167; Joensuu H, 2010, CANC RES; Joensuu H, 2012, J CLIN ONCOL, V30, P11, DOI 10.1200/JCO.2011.35.4639; Joensuu H, 2009, LANCET ONCOL, V10, P1145, DOI 10.1016/S1470-2045(09)70307-9; Kaye SB, 1998, BRIT J CANCER, V78, P1, DOI 10.1038/bjc.1998.747; Kurosumi M, 2000, ONCOL REP, V7, P945; Lin YP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-342; Loesch D, 2010, J CLIN ONCOL, V28, P2958, DOI 10.1200/JCO.2009.24.1000; Martin M, 2010, NEW ENGL J MED, V363, P2200, DOI 10.1056/NEJMoa0910320; Morales S, 2004, CANCER CHEMOTH PHARM, V53, P75, DOI 10.1007/s00280-003-0690-0; Moreno-Aspitia A, 2009, CLIN THER, V31, P1619, DOI 10.1016/j.clinthera.2009.08.005; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; O'Shaughnessy JA, 2001, ANN ONCOL, V12, P1247, DOI 10.1023/A:1012281104865; OSHAUGHNESSY J, 2010, CANC RES; Poole Christopher, 2004, Oncology (Williston Park), V18, P23; Sawada N, 1998, CLIN CANCER RES, V4, P1013; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Steger GG, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.530; Yin WJ, 2009, BREAST CANCER RES TR, V115, P325, DOI 10.1007/s10549-008-0096-0	25	18	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2012	7	3							e32474	10.1371/journal.pone.0032474	http://dx.doi.org/10.1371/journal.pone.0032474			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TC	22396769	gold, Green Submitted, Green Published			2023-01-03	WOS:000303006500021
J	Mulla, O; Prowse, S; Sanders, T; Nix, P				Mulla, Omar; Prowse, Simon; Sanders, Tim; Nix, Paul			10-MINUTE CONSULTATION Epistaxis	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Mulla, Omar; Prowse, Simon; Nix, Paul] Leeds Gen Infirm, Dept Ear Nose & Throat, Leeds LS1 3EX, W Yorkshire, England; [Sanders, Tim] Shap Med Practice, Penrith CA10 3LW, England	Leeds General Infirmary; University of Leeds	Mulla, O (corresponding author), Leeds Gen Infirm, Dept Ear Nose & Throat, Leeds LS1 3EX, W Yorkshire, England.	omarmulla@doctors.org.uk		Nix, Paul/0000-0002-7284-710X					0	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 23	2012	344								e1097	10.1136/bmj.e1097	http://dx.doi.org/10.1136/bmj.e1097			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	900JY	22362457				2023-01-03	WOS:000300884400001
J	Holmgren, T; Hallgren, HB; Oberg, B; Adolfsson, L; Johansson, K				Holmgren, Theresa; Hallgren, Hanna Bjornsson; Oberg, Birgitta; Adolfsson, Lars; Johansson, Kajsa			Effect of specific exercise strategy on need for surgery in patients with subacromial impingement syndrome: randomised controlled study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHOULDER IMPINGEMENT; ROTATOR CUFF; ACHILLES TENDINOPATHY; NONOPERATIVE TREATMENT; SUPERVISED EXERCISES; ARTHROSCOPIC SURGERY; CLINICAL-OUTCOMES; REHABILITATION; PAIN; PHYSIOTHERAPY	Objective To evaluate if a specific exercise strategy, targeting the rotator cuff and scapula stabilisers, improves shoulder function and pain more than unspecific exercises in patients with subacromial impingement syndrome, thereby decreasing the need for arthroscopic subacromial decompression. Design Randomised, participant and single assessor blinded, controlled study. Setting Department of orthopaedics in a Swedish university hospital. Participants 102 patients with long standing (over six months) persistent subacromial impingement syndrome in whom earlier conservative treatment had failed, recruited through orthopaedic specialists. Interventions The specific exercise strategy consisted of strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers in combination with manual mobilisation. The control exercise programme consisted of unspecific movement exercises for the neck and shoulder. Patients in both groups received five to six individual guided treatment sessions during 12 weeks. In between these supervised sessions the participants performed home exercises once or twice a day for 12 weeks. Main outcome measures The primary outcome was the Constant-Murley shoulder assessment score evaluating shoulder function and pain. Secondary outcomes were patients' global impression of change because of treatment and decision regarding surgery. Results Most (97, 95%) participants completed the 12 week study. There was a significantly greater improvement in the Constant-Murley score in the specific exercise group than in the control exercise group (24 points (95% confidence interval 19 to 28.0) v 9 points (5 to 13); mean difference between group: 15 points (8.5 to 20.6)). Significantly more patients in the specific exercise group reported successful outcome (defined as large improvement or recovered) in the patients' global assessment of change because of treatment: 69% (35/51) v 24% (11/46); odds ratio 7.6, 3.1 to 18.9; P<0.001. A significantly lower proportion of patients in the specific exercise group subsequently chose to undergo surgery: 20% (10/51) v 63% (29/46); odds ratio 7.7, 3.1 to 19.4; P<0.001). Conclusion A specific exercise strategy, focusing on strengthening eccentric exercises for the rotator cuff and concentric/eccentric exercises for the scapula stabilisers, is effective in reducing pain and improving shoulder function in patients with persistent subacromial impingement syndrome. By extension, this exercise strategy reduces the need for arthroscopic subacromial decompression within the three month timeframe used in the study.	[Holmgren, Theresa; Oberg, Birgitta; Johansson, Kajsa] Linkoping Univ, Dept Med & Hlth Sci, Div Physiotherapy, SE-58183 Linkoping, Sweden; [Hallgren, Hanna Bjornsson; Adolfsson, Lars] Linkoping Univ Hosp, Dept Orthopaed, SE-58185 Linkoping, Sweden	Linkoping University; Linkoping University	Holmgren, T (corresponding author), Linkoping Univ, Dept Med & Hlth Sci, Div Physiotherapy, SE-58183 Linkoping, Sweden.	theresa.holmgren@liu.se	Johansson, Kajsa/AET-7150-2022; adolfsson, lars/D-4837-2017	adolfsson, lars/0000-0001-7873-3093	physiotherapy orthopaedic department of the University Hospital in Linkoping, Sweden; research council in the south east of Sweden (FORSS)	physiotherapy orthopaedic department of the University Hospital in Linkoping, Sweden; research council in the south east of Sweden (FORSS)	We acknowledge the support and contribution of the physiotherapy orthopaedic department of the University Hospital in Linkoping, Sweden. We also thank Henrik Magnusson for all statistical assistance.; This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. TH is funded in part by the research council in the south east of Sweden (FORSS).	Andersen NH, 1999, J SHOULDER ELB SURG, V8, P99, DOI 10.1016/S1058-2746(99)90000-9; Arroll B, 2005, BRIT J GEN PRACT, V55, P224; Bennell K, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2756; Bernhardsson S, 2011, CLIN REHABIL, V25, P69, DOI 10.1177/0269215510376005; Bohmer Audhild S., 1998, Physiotherapy Theory and Practice, V14, P93, DOI 10.3109/09593989809057152; Brox JI, 1999, J SHOULDER ELB SURG, V8, P102, DOI 10.1016/S1058-2746(99)90001-0; BROX JI, 1993, BMJ-BRIT MED J, V307, P899, DOI 10.1136/bmj.307.6909.899; Buchbinder R, COCHRANE DB SYST REV, V200, DOI DOI 10.1002/14651858.CD004016; Bullock MP, 2005, MANUAL THER, V10, P28, DOI 10.1016/j.math.2004.07.002; Camargo Paula R., 2009, Physiotherapy Theory and Practice, V25, P463, DOI [10.1080/09593980802662145, 10.3109/09593980802662145]; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Coghlan JA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005619.pub2; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Cools AM, 2005, J ATHL TRAINING, V40, P104; Cools AM, 2003, AM J SPORT MED, V31, P542, DOI 10.1177/03635465030310041101; Cools AM, 2007, AM J SPORT MED, V35, P1744, DOI 10.1177/0363546507303560; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; Deutscher D, 2009, ARCH PHYS MED REHAB, V90, P1349, DOI 10.1016/j.apmr.2009.02.005; Dickens VA, 2005, PHYSIOTHERAPY, V91, P159, DOI 10.1016/j.physio.2004.10.008; Dorrestijn O, 2009, J SHOULDER ELB SURG, V18, P652, DOI 10.1016/j.jse.2009.01.010; Ellenbecker TS, 2010, BRIT J SPORT MED, V44, P319, DOI 10.1136/bjsm.2009.058875; Ellman H, 1987, Arthroscopy, V3, P173, DOI 10.1016/S0749-8063(87)80061-0; Frost P, 2002, AM J IND MED, V41, P11, DOI 10.1002/ajim.10019; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Haahr JP, 2005, ANN RHEUM DIS, V64, P760, DOI 10.1136/ard.2004.021188; HAWKINS RJ, 1980, AM J SPORT MED, V8, P151, DOI 10.1177/036354658000800302; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; JOBE FW, 1983, CLIN ORTHOP RELAT R, P117; Johansson K, 2002, BRIT J GEN PRACT, V52, P145; Jonsson P, 2006, KNEE SURG SPORT TR A, V14, P76, DOI 10.1007/s00167-004-0611-8; Jonsson P, 2005, BRIT J SPORT MED, V39, P847, DOI 10.1136/bjsm.2005.018630; Kelly SM, 2010, CLIN REHABIL, V24, P99, DOI 10.1177/0269215509342336; Ketola S, 2009, J BONE JOINT SURG BR, V91B, P1326, DOI 10.1302/0301-620X.91B10.22094; Kibler W Ben, 2006, Instr Course Lect, V55, P35; Kingma JJ, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.030916; Krogsboll LT, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-1; Kromer TO, 2009, J REHABIL MED, V41, P870, DOI 10.2340/16501977-0453; Kuhn JE, 2009, J SHOULDER ELB SURG, V18, P138, DOI 10.1016/j.jse.2008.06.004; LEROUX JL, 1995, REV RHUM, V62, P423; Lewis JS, 2005, J SHOULDER ELB SURG, V14, P385, DOI 10.1016/J.JSE.2004.08.007; Lombardi I, 2008, ARTHRIT RHEUM-ARTHR, V59, P615, DOI 10.1002/art.23576; Ludewig PM, 2000, PHYS THER, V80, P276, DOI 10.1093/ptj/80.3.276; Magnussen RA, 2009, CLIN J SPORT MED, V19, P54, DOI 10.1097/JSM.0b013e31818ef090; McClure PW, 2006, PHYS THER, V86, P1075, DOI 10.1093/ptj/86.8.1075; Michener Lori A, 2004, J Hand Ther, V17, P152, DOI 10.1197/j.jht.2004.02.004; Miranda H, 2001, OCCUP ENVIRON MED, V58, P528, DOI 10.1136/oem.58.8.528; Morrison DS, 1997, J BONE JOINT SURG AM, V79A, P732, DOI 10.2106/00004623-199705000-00013; NEER CS, 1977, ORTHOP CLIN N AM, V8, P583; Patel VR, 1999, J SHOULDER ELB SURG, V8, P231, DOI 10.1016/S1058-2746(99)90134-9; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Rees JD, 2009, BRIT J SPORT MED, V43, P242, DOI 10.1136/bjsm.2008.052910; Seitz AL, 2011, CLIN BIOMECH, V26, P1, DOI 10.1016/j.clinbiomech.2010.08.001; Silbernagel KG, 2007, AM J SPORT MED, V35, P897, DOI 10.1177/0363546506298279; Soyer J, 2003, ARTHROSCOPY, V19, P34, DOI 10.1053/jars.2003.50005; Thomas E, 2005, ANN RHEUM DIS, V64, P1056, DOI 10.1136/ard.2004.029959; Thomee R, 1997, PHYS THER, V77, P1690, DOI 10.1093/ptj/77.12.1690; Thorstensson CA, 2006, DISABIL REHABIL, V28, P51, DOI 10.1080/09638280500163927; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; Tyler TF, 2000, AM J SPORT MED, V28, P668; Virta L, 2009, EUR J PHYSIOTHER, V11, P166, DOI 10.1080/14038190802460481; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	61	147	149	1	54	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 20	2012	344								e787	10.1136/bmj.e787	http://dx.doi.org/10.1136/bmj.e787			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900IY	22349588	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000300881600009
J	Dasgupta, I; Tanifum, EA; Srivastava, M; Phatak, SS; Cavasotto, CN; Analoui, M; Annapragada, A				Dasgupta, Indrani; Tanifum, Eric A.; Srivastava, Mayank; Phatak, Sharangdhar S.; Cavasotto, Claudio N.; Analoui, Mostafa; Annapragada, Ananth			Non Inflammatory Boronate Based Glucose-Responsive Insulin Delivery Systems	PLOS ONE			English	Article							NUCLEAR TRANSLOCATION; PHASE-BEHAVIOR; CONCANAVALIN-A; KAPPA-B; CHOLESTEROL; MEMBRANES; MIXTURES	Boronic acids, known to bind diols, were screened to identify non-inflammatory cross-linkers for the preparation of glucose sensitive and insulin releasing agglomerates of liposomes (Agglomerated Vesicle Technology-AVT). This was done in order to select a suitable replacement for the previously used cross-linker, ConcanavalinA (ConA), a lectin known to have both toxic and inflammatory effects in vivo. Lead-compounds were selected from screens that involved testing for inflammatory potential, cytotoxicity and glucose-binding. These were then conjugated to insulin-encapsulating nanoparticles and agglomerated via sugar-boronate ester linkages to form AVTs. In vitro, the particles demonstrated triggered release of insulin upon exposure to physiologically relevant concentrations of glucose (10 mmoles/L-40 mmoles/L). The agglomerates were also shown to be responsive to multiple spikes in glucose levels over several hours, releasing insulin at a rate defined by the concentration of the glucose trigger.	[Dasgupta, Indrani; Phatak, Sharangdhar S.; Cavasotto, Claudio N.] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA; [Tanifum, Eric A.; Srivastava, Mayank; Annapragada, Ananth] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Tanifum, Eric A.; Srivastava, Mayank; Annapragada, Ananth] Baylor Coll Med, Houston, TX 77030 USA; [Analoui, Mostafa] Cense Biosci Inc, Manvel, TX USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; Baylor College of Medicine	Dasgupta, I (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA.	avannapr@texaschildrenshospital.org	Annapragada, Ananth/GOK-1576-2022; Cavasotto, Claudio/GQY-7627-2022	Annapragada, Ananth/0000-0002-3156-9617; Cavasotto, Claudio/0000-0002-1372-0379	Gillson-Longenbaugh Foundation; SBIR [1R43DK083819-01]; National Cancer Institute [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R43DK083819] Funding Source: NIH RePORTER	Gillson-Longenbaugh Foundation; SBIR; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by an unrestricted gift from Gillson-Longenbaugh Foundation and SBIR (1R43DK083819-01) awarded to Cense Biosciences, Inc.. The NMR spectra were acquired at NMR facility at the M.D. Anderson Cancer Center which is supported by the National Cancer Institute Cancer Center support grant CA016672. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexeev VL, 2003, ANAL CHEM, V75, P2316, DOI 10.1021/ac030021m; Ballerstadt R, 2006, BIOSENS BIOELECTRON, V22, P275, DOI 10.1016/j.bios.2006.01.008; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bhavane R, 2003, J CONTROL RELEASE, V93, P15, DOI 10.1016/S0168-3659(03)00359-6; Bhavane R, 2007, INT J NANOMED, V2, P407; BROWNLEE M, 1979, SCIENCE, V206, P1190, DOI 10.1126/science.505005; Dowlut M, 2006, J AM CHEM SOC, V128, P4226, DOI 10.1021/ja057798c; George TC, 2006, J IMMUNOL METHODS, V311, P117, DOI 10.1016/j.jim.2006.01.018; Hermanson GT, 1996, BIOCONJUGATE TECHNIQ, P169; Hoogwerf BJ, 2005, INT J DIABETES DEV C, V25, P63, DOI DOI 10.4103/0973-3930.22774; Hovorka R, 2006, DIABETIC MED, V23, P1, DOI 10.1111/j.1464-5491.2005.01672.x; Jin XJ, 2009, BIOMACROMOLECULES, V10, P1337, DOI 10.1021/bm8010006; Kabilan S, 2004, IEEE SENS P OCT 24 2; Karathanasis E, 2007, INT J NANOMED, V2, P501; KUIVILA HG, 1954, J ORG CHEM, V19, P780, DOI 10.1021/jo01370a013; Li SQ, 2009, BIOMACROMOLECULES, V10, P113, DOI 10.1021/bm8009768; Mannock DA, 2010, BBA-BIOMEMBRANES, V1798, P376, DOI 10.1016/j.bbamem.2009.09.002; Matsumoto A, 2003, BIOMACROMOLECULES, V4, P1410, DOI 10.1021/bm034139o; McDonough PM, 2009, ASSAY DRUG DEV TECHN, V7, P440, DOI 10.1089/adt.2009.0196; Morelock MM, 2005, ASSAY DRUG DEV TECHN, V3, P483, DOI 10.1089/adt.2005.3.483; Norrlid CJ, 1995, J AM CHEM SOC, V117, P1479; Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t; Schneider HJ, 2007, SENSORS-BASEL, V7, P1578, DOI 10.3390/s7081578; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SMUTZER G, 1985, BIOCHIM BIOPHYS ACTA, V814, P274, DOI 10.1016/0005-2736(85)90445-6; Springsteen G, 2002, TETRAHEDRON, V58, P5291, DOI 10.1016/S0040-4020(02)00489-1; Tanna S, 2006, BIOMATERIALS, V27, P1586, DOI 10.1016/j.biomaterials.2005.08.011; Tonyushkina Ksenia, 2009, J Diabetes Sci Technol, V3, P971; Wang BL, 2009, LANGMUIR, V25, P12522, DOI 10.1021/la901776a; Yu S, 2009, J MEMBRANE SCI, V339, P138, DOI 10.1016/j.memsci.2009.04.041	30	11	16	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2012	7	1							e29585	10.1371/journal.pone.0029585	http://dx.doi.org/10.1371/journal.pone.0029585			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	907XU	22272238	Green Submitted, Green Published, gold			2023-01-03	WOS:000301454400017
J	Baselga, J; Cortes, J; Kim, SB; Im, SA; Hegg, R; Im, YH; Roman, L; Pedrini, JL; Pienkowski, T; Knott, A; Clark, E; Benyunes, MC; Ross, G; Swain, SM				Baselga, Jose; Cortes, Javier; Kim, Sung-Bae; Im, Seock-Ah; Hegg, Roberto; Im, Young-Hyuck; Roman, Laslo; Pedrini, Jose Luiz; Pienkowski, Tadeusz; Knott, Adam; Clark, Emma; Benyunes, Mark C.; Ross, Graham; Swain, Sandra M.		CLEOPATRA Study Grp	Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; MONOCLONAL-ANTIBODY; RECEPTOR; ERBB2; INHIBITOR; TOXICITY; EFFICACY; PROTEINS; THERAPY; HER2	BACKGROUND The anti-human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT00567190.)	[Baselga, Jose] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Baselga, Jose] Harvard Univ, Sch Med, Boston, MA USA; [Cortes, Javier] Vall dHebron Inst Oncol, Barcelona, Spain; [Kim, Sung-Bae] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea; [Im, Seock-Ah] Seoul Natl Univ, Coll Med, Dept Internal Med, Div Hematol & Med Oncol, Seoul 151, South Korea; [Im, Young-Hyuck] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Med Oncol,Dept Internal Med, Seoul, South Korea; [Hegg, Roberto] Univ Sao Paulo, Hosp Perola Byington, Sao Paulo, Brazil; [Hegg, Roberto] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil; [Roman, Laslo] Leningrad Reg Oncol Dispensary, St Petersburg, Russia; [Pedrini, Jose Luiz] Conceicao Hosp, Mastol Unit, Ctr Pesquisas Med & Ensaios Clin, Porto Alegre, RS, Brazil; [Pienkowski, Tadeusz] Ctr Onkol, Warsaw, Poland; [Knott, Adam; Clark, Emma; Ross, Graham] Roche, Welwyn Garden City, England; [Benyunes, Mark C.] Genentech Inc, San Francisco, CA 94080 USA; [Swain, Sandra M.] MedStar Washington Hosp Ctr, Washington Canc Inst, Washington, DC USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Vall d'Hebron Institut d'Oncologia (VHIO); University of Ulsan; Asan Medical Center; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; Universidade de Sao Paulo; Universidade de Sao Paulo; Roche Holding; Roche Holding; Genentech; MedStar Washington Hospital Center	Baselga, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA.	jbaselga@partners.org	Calvo, Lourdes/M-2352-2014; Andrade, Jurandyr M/B-2025-2013; MORALES, SERAFIN/L-7216-2019; Aktas, Bahriye/F-1019-2014; de Azevedo, Sergio Jobim/P-5115-2015; Im, Seock-Ah/J-5620-2012	Andrade, Jurandyr M/0000-0003-3619-0582; MORALES, SERAFIN/0000-0001-7445-4193; Hegg, Roberto/0000-0002-6453-8155; Pienkowski, Tadeusz/0000-0002-0110-5950; Ciruelos, Eva/0000-0002-2796-1042; Biganzoli, Laura/0000-0001-7989-8658; Cortes, Javier/0000-0001-7623-1583; Di Leo, Angelo/0000-0002-3665-9056; Coudert, Bruno/0000-0001-9445-2216; Swain, Sandra/0000-0002-1320-3830	F. Hoffmann-La Roche/Genentech, a member of the Roche Group; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	F. Hoffmann-La Roche/Genentech, a member of the Roche Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by F. Hoffmann-La Roche/Genentech, a member of the Roche Group. Support for writing assistance by a third party (Vilma Graupner, Ph.D.) was provided by F. Hoffmann-La Roche.	Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Burris HA, 2011, J CLIN ONCOL, V29, P398, DOI 10.1200/JCO.2010.29.5865; Burstein HJ, 2011, SEMIN ONCOL, V38, pS17, DOI 10.1053/j.seminoncol.2011.04.002; Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 1, pS1; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Geyer CE, 2007, NEW ENGL J MED, V356, P1487; Gianni L, 2010, 33 ANN SAN ANT BREAS; Hsieh AC, 2007, BRIT J CANCER, V97, P453, DOI 10.1038/sj.bjc.6603910; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Molina MA, 2001, CANCER RES, V61, P4744; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Portera CC, 2008, CLIN CANCER RES, V14, P3641, DOI 10.1158/1078-0432.CCR-14-11-COR; Portera CC, 2008, CLIN CANCER RES, V14, P2710, DOI 10.1158/1078-0432.CCR-07-4636; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Scheuer W, 2009, CANCER RES, V69, P9330, DOI 10.1158/0008-5472.CAN-08-4597; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Valero V, 2011, J CLIN ONCOL, V29, P149, DOI 10.1200/JCO.2010.28.6450; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	28	1717	1794	7	222	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 12	2012	366	2					109	119		10.1056/NEJMoa1113216	http://dx.doi.org/10.1056/NEJMoa1113216			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874VA	22149875	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000298985000005
J	Singh, T; Sharma, SD; Katiyar, SK				Singh, Tripti; Sharma, Som D.; Katiyar, Santosh K.			Grape Proanthocyanidins Induce Apoptosis by Loss of Mitochondrial Membrane Potential of Human Non-Small Cell Lung Cancer Cells In Vitro and In Vivo	PLOS ONE			English	Article							DEPENDENT KINASES; CYCLE CONTROL; BCL-2 FAMILY; INHIBIT; GROWTH; PROTEIN; DEATH; ACTIVATION; BERBERINE; THERAPY	Lung cancer remains the leading cause of cancer-related deaths worldwide, and non-small cell lung cancer (NSCLC) represents approximately 80% of total lung cancer cases. The use of non-toxic dietary phytochemicals can be considered as a chemotherapeutic strategy for the management of the NSCLC. Here, we report that grape seed proanthocyanidins (GSPs) induce apoptosis of NSCLC cells, A549 and H1299, in vitro which is mediated through increased expression of pro-apoptotic protein Bax, decreased expression of anti-apoptotic proteins Bcl2 and Bcl-xl, disruption of mitochondrial membrane potential, and activation of caspases 9, 3 and poly (ADP-ribose) polymerase (PARP). Pre-treatment of A549 and H1299 cells with the caspase-3 inhibitor (z-DEVD-fmk) significantly blocked the GSPs-induced apoptosis of these cells confirmed that GSPs-induced apoptosis is mediated through activation of caspases-3. Treatments of A549 and H1299 cells with GSPs resulted in an increase in G1 arrest. G0/G1 phase of the cell cycle is known to be controlled by cyclin dependent kinases (Cdk), cyclin-dependent kinase inhibitors (Cdki) and cyclins. Our western blot analyses showed that GSPs-induced G1 cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), and a simultaneous decrease in the levels of Cdk2, Cdk4, Cdk6 and cyclins. Further, administration of 50, 100 or 200 mg GSPs/kg body weight of mice by oral gavage (5 d/week) markedly inhibited the growth of s.c. A549 and H1299 lung tumor xenografts in athymic nude mice, which was associated with the induction of apoptotic cell death, increased expression of Bax, reduced expression of anti-apoptotic proteins and activation of caspase-3 in tumor xenograft cells. Based on the data obtained in animal study, human equivalent dose of GSPs was calculated, which seems affordable and attainable. Together, these results suggest that GSPs may represent a potential therapeutic agent for the non-small cell lung cancer.	[Singh, Tripti; Sharma, Som D.; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; [Katiyar, Santosh K.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL USA; [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Singh, T (corresponding author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.	skatiyar@uab.edu			Veterans Administration Merit Review Award	Veterans Administration Merit Review Award(US Department of Veterans Affairs)	This work was supported by funds from the Veterans Administration Merit Review Award (SKK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar S, 2009, CLIN CANCER RES, V15, P821, DOI 10.1158/1078-0432.CCR-08-1901; America Cancer Society, 2011, CANC FACTS FIG; Bagchi D, 1997, RES COMMUN MOL PATH, V95, P179; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Donovan M, 2004, BBA-MOL CELL RES, V1644, P133, DOI 10.1016/j.bbamcr.2003.08.011; Facino RM, 1996, PLANTA MED, V62, P495, DOI 10.1055/s-2006-957956; Ferrigno D, 2000, LUNG CANCER-J IASLC, V29, P91, DOI 10.1016/S0169-5002(00)00112-4; Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GRANA X, 1995, ONCOGENE, V11, P211; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448; Mantena SK, 2006, CARCINOGENESIS, V27, P1682, DOI 10.1093/carcin/bgl030; Mantena SK, 2006, CARCINOGENESIS, V27, P2018, DOI 10.1093/carcin/bgl043; Maziak DE, 2004, ANN THORAC SURG, V77, P1484, DOI 10.1016/j.athoracsur.2003.07.017; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sharma SD, 2007, MOL CANCER THER, V6, P995, DOI 10.1158/1535-7163.MCT-06-0661; Sharma SD, 2010, MOL CANCER THER, V9, P569, DOI 10.1158/1535-7163.MCT-09-0638; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393; Ye X, 1999, MOL CELL BIOCHEM, V196, P99, DOI 10.1023/A:1006926414683; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	41	70	73	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2011	6	11							e27444	10.1371/journal.pone.0027444	http://dx.doi.org/10.1371/journal.pone.0027444			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HZ	22087318	Green Published, gold, Green Submitted			2023-01-03	WOS:000297349700046
J	Gitler, AD				Gitler, Aaron D.			Another Reason to Exercise	SCIENCE			English	Editorial Material							SPINOCEREBELLAR ATAXIA TYPE-1; CAG REPEAT; EXPANSION; DISEASE; SCA1; NEURODEGENERATION; MECHANISMS		Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Gitler, AD (corresponding author), Univ Penn, Perelman Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA.	gitler@mail.med.upenn.edu		Gitler, Aaron/0000-0001-8603-1526				Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Dibble LE, 2009, J NEUROL PHYS THER, V33, P14, DOI 10.1097/NPT.0b013e3181990fcc; Duvick L, 2010, NEURON, V67, P929, DOI 10.1016/j.neuron.2010.08.022; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; Forman MS, 2004, NAT MED, V10, P1055, DOI 10.1038/nm1113; Fryer JD, 2011, SCIENCE, V334, P690, DOI 10.1126/science.1212673; Gatchel JR, 2005, NAT REV GENET, V6, P743, DOI 10.1038/nrg1691; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Rolland Y, 2008, J AM MED DIR ASSOC, V9, P390, DOI 10.1016/j.jamda.2008.02.007; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Watase K, 2007, PLOS MED, V4, P836, DOI 10.1371/journal.pmed.0040182; Zoghbi HY, 2009, J BIOL CHEM, V284, P7425, DOI 10.1074/jbc.R800041200	15	3	4	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					606	607		10.1126/science.1214714	http://dx.doi.org/10.1126/science.1214714			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053033				2023-01-03	WOS:000296494700034
J	Barry, MJ; Meleth, S; Lee, JY; Kreder, KJ; Avins, AL; Nickel, JC; Roehrborn, CG; Crawford, ED; Foster, HE; Kaplan, SA; McCullough, A; Andriole, GL; Naslund, MJ; Williams, OD; Kusek, JW; Meyers, CM; Betz, JM; Cantor, A; McVary, KT				Barry, Michael J.; Meleth, Sreelatha; Lee, Jeannette Y.; Kreder, Karl J.; Avins, Andrew L.; Nickel, J. Curtis; Roehrborn, Claus G.; Crawford, E. David; Foster, Harris E., Jr.; Kaplan, Steven A.; McCullough, Andrew; Andriole, Gerald L.; Naslund, Michael J.; Williams, O. Dale; Kusek, John W.; Meyers, Catherine M.; Betz, Joseph M.; Cantor, Alan; McVary, Kevin T.		Complementary Alternative Med Urol	Effect of Increasing Doses of Saw Palmetto Extract on Lower Urinary Tract Symptoms A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENIGN PROSTATIC HYPERPLASIA; CLINICAL-TRIAL; HEALTH-STATUS; IMPACT INDEX; SCALE; MEN; PHYTOTHERAPY; VALIDATION; THERAPY	Context Saw palmetto fruit extracts are widely used for treating lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH); however, recent clinical trials have questioned their efficacy, at least at standard doses (320 mg/d). Objective To determine the effect of saw palmetto extract (Serenoa repens, from saw palmetto berries) at up to 3 times the standard dose on lower urinary tract symptoms attributed to BPH. Design, Setting, and Participants A double-blind, multicenter, placebo-controlled randomized trial at 11 North American clinical sites conducted between June 5, 2008, and October 10, 2010, of 369 men aged 45 years or older, with a peak urinary flow rate of at least 4 mL/s, an American Urological Association Symptom Index (AUASI) score of between 8 and 24 at 2 screening visits, and no exclusions. Interventions One, 2, and then 3 doses (320 mg/d) of saw palmetto extract or placebo, with dose increases at 24 and 48 weeks. Main Outcome Measures Difference in AUASI score between baseline and 72 weeks. Secondary outcomes included measures of urinary bother, nocturia, peak uroflow, post-void residual volume, prostate-specific antigen level, participants' global assessments, and indices of sexual function, continence, sleep quality, and prostatitis symptoms. Results Between baseline and 72 weeks, mean AUASI scores decreased from 14.42 to 12.22 points (-2.20 points; 95% CI, -3.04 to -0.36) with saw palmetto extract and from 14.69 to 11.70 points (-2.99 points; 95% CI, -3.81 to -2.17) with placebo. The group mean difference in AUASI score change from baseline to 72 weeks between the saw palmetto extract and placebo groups was 0.79 points favoring placebo (upper bound of the 1-sided 95% CI most favorable to saw palmetto extract was 1.77 points, 1-sided P=.91). Saw palmetto extract was no more effective than placebo for any secondary outcome. No clearly attributable adverse effects were identified. Conclusion Increasing doses of a saw palmetto fruit extract did not reduce lower urinary tract symptoms more than placebo.	[Barry, Michael J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Meleth, Sreelatha; Williams, O. Dale; Cantor, Alan] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Lee, Jeannette Y.] Univ Arkansas Med Sci, Dept Biostat, Little Rock, AR 72205 USA; [Kreder, Karl J.] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; [Avins, Andrew L.] No Calif Kaiser Permanente, Div Res, Oakland, CA USA; [Nickel, J. Curtis] Queens Univ, Dept Urol, Kingston, ON, Canada; [Roehrborn, Claus G.] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Crawford, E. David] Univ Colorado, Sect Urol Oncol, Denver, CO 80202 USA; [Foster, Harris E., Jr.] Yale Univ, Sch Med, Urol Sect, New Haven, CT USA; [Kaplan, Steven A.] Weill Cornell Med Coll, Dept Urol, New York, NY USA; [McCullough, Andrew] NYU, Urol Associates, New York, NY USA; [Andriole, Gerald L.] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA; [Naslund, Michael J.] Univ Maryland, Maryland Prostate Ctr, Baltimore, MD 21201 USA; [Kusek, John W.] NIDDK, Bethesda, MD USA; [Meyers, Catherine M.] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA; [Betz, Joseph M.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA; [McVary, Kevin T.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham; University of Arkansas System; University of Arkansas Medical Sciences; University of Iowa; Kaiser Permanente; Queens University - Canada; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Denver; Yale University; Cornell University; New York University; Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; National Institutes of Health (NIH) - USA; Northwestern University; Feinberg School of Medicine	Barry, MJ (corresponding author), Massachusetts Gen Hosp, Dept Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.	mbarry@partners.org		Kreder, Karl/0000-0002-8981-5286	GlaxoSmithKline; Pfizer; Watson; Astellas; Ferring; Taris; Triton; Farr Labs; Trillium; Cernelle; Johnson Johnson; Amgen; Bayer; Caris; France Foundation; GenProbe; Steba Biotech; Ortho-Clinical Diagnostics; Ferring Pharmaceuticals; Lilly/ICOS; Allergan; National Institute of Diabetes and Digestive and Kidney Diseases; Watson Pharm; Neotract; National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases [U01 DK63795, U01 DK63797, U01 DK63825, U01 DK63835, U01 DK63866, U01 DK63833, U01 DK63862, U01 DK63840, U01 DK63883, U01 DK63831, U01 DK63778, U01 DK63788]; National Center for Complementary and Alternative Medicine; Office of Dietary Supplements, NIH; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK063788, U01DK063862, U01DK063840, U01DK063825, U01DK063833, U01DK063795, U01DK063866, U01DK063883, U01DK063797, U01DK063778, U01DK063835, U01DK063831] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Watson; Astellas(Astellas Pharmaceuticals); Ferring(Ferring Pharmaceuticals); Taris; Triton; Farr Labs; Trillium(University of Toronto); Cernelle; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Amgen(Amgen); Bayer(Bayer AG); Caris; France Foundation; GenProbe; Steba Biotech; Ortho-Clinical Diagnostics; Ferring Pharmaceuticals(Ferring Pharmaceuticals); Lilly/ICOS(Eli Lilly); Allergan(AbbVieAllergan); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Watson Pharm; Neotract; National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Barry reported serving on the board of and receiving salary support as president of the not-for-profit (501[3]c) Foundation for Informed Medical Decision Making (http://www.fimdm.org), which develops content for patient education programs. The foundation has an arrangement with a for-profit company, Health Dialog, to coproduce and market these programs to health care organizations. Dr Lee reported that funds were paid to her institution for consultancy to Merck. Dr Nickel reported receiving consultation funds from GlaxoSmithKline, Pfizer, Watson, Astellas, Ferring, Taris, Triton, Farr Labs, Trillium, Cernelle, and Johnson & Johnson; having provided expert testimony for GlaxoSmithKline; and having received payment for development of educational presentations from the Canadian Urological Association. Dr Crawford reported receiving payment for lectures from Ferring Pharmaceuticals and GlaxoSmithKline. Dr Andriole reported receiving consultation funds from Amgen, Bayer, Caris, France Foundation, GenProbe, GlaxoSmithKline, Steba Biotech, Ortho-Clinical Diagnostics, and Ferring Pharmaceuticals; having received royalties from Up to Date; receiving payment for development of educational presentations from Amgen; having stock and/or stock options in Envisioneering Medical, Viking Medical, Augmenix, and Cambridge Endo; and receiving travel, accommodations, and meeting expenses from Amgen, Augmenix, Bayer, Cambridge Endo, Caris, France Foundation, GenProbe, Myriad Genetics, Steba Biotech, and Ortho Clinical Diagnostics. Dr Naslund reported receiving payment for lectures from GlaxoSmithKline and sanofi-aventis, as well as payment for development of educational presentations for France Foundation. Dr McVary reported receiving consultancy funds from Lilly/ICOS, Allergan, National Institute of Diabetes and Digestive and Kidney Diseases, Watson Pharm, and Neotract, as well as payment for lectures from GlaxoSmithKline. No other disclosures were reported.; This study was funded by cooperative agreements U01 DK63795, U01 DK63797, U01 DK63825, U01 DK63835, U01 DK63866, U01 DK63833, U01 DK63862, U01 DK63840, U01 DK63883, U01 DK63831, U01 DK63778, and U01 DK63788 from the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases. Support was also provided by the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements, NIH. Saw palmetto fruit extract and matching placebo were donated by Rottapharm/Madaus, Cologne, Germany. This study was conducted under an Investigational New Drug Application from the US Food and Drug Administration.	AUA Practise Guidelines Committee, 2003, J UROLOGY, V170, P530, DOI 10.1097/01.ju.0000078083.38675.79; Avins AL, 2008, COMPLEMENT THER MED, V16, P147, DOI 10.1016/j.ctim.2007.10.005; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; BARRY MJ, 1995, MED CARE, V33, pAS145; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bent S, 2006, NEW ENGL J MED, V354, P557, DOI 10.1056/NEJMoa053085; Buck AC, 2004, J UROLOGY, V172, P1792, DOI 10.1097/01.ju.0000140503.11467.8e; Chapple CR, 2006, EUR UROL, V49, P651, DOI 10.1016/j.eururo.2006.02.018; Dedhia RC, 2008, J UROLOGY, V179, P2119, DOI 10.1016/j.juro.2008.01.094; Donovan JL, 2000, J UROLOGY, V164, P1948, DOI 10.1016/S0022-5347(05)66926-1; Gerber GS, 2000, J UROLOGY, V163, P1408, DOI 10.1016/S0022-5347(05)67631-8; JACOBSEN SJ, 1995, ARCH INTERN MED, V155, P477, DOI 10.1001/archinte.155.5.477; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Knottnerus JA, 2001, J CLIN EPIDEMIOL, V54, P109, DOI 10.1016/S0895-4356(00)00276-6; Lee J, 2009, CLIN TRIALS, V6, P628, DOI 10.1177/1740774509352199; Lee JY, 2011, J ALTERN COMPLEM MED, V17, P469, DOI 10.1089/acm.2010.0300; Litwin MS, 1999, J UROLOGY, V162, P369, DOI 10.1016/S0022-5347(05)68562-X; Maccagnano C, 2006, EUR UROL SUPPL, V5, P430, DOI 10.1016/j.eursup.2006.02.006; McConnell JD, 2003, NEW ENGL J MED, V349, P2387, DOI 10.1056/NEJMoa030656; Nickel JC, 2006, CURR OPIN UROL, V16, P5, DOI 10.1097/01.mou.0000193365.46081.cd; O'Leary MP, 2008, BJU INT, V101, P1531, DOI 10.1111/j.1464-410X.2008.07574.x; Pais P, 2010, ADV THER, V27, P555, DOI 10.1007/s12325-010-0041-6; Rosen RC, 2007, UROLOGY, V69, P805, DOI 10.1016/j.urology.2007.02.036; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Tacklind J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001423.pub2; *US PHARM CONV, 2010, US PHARM SAW PALM EX; Wilt T, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001423	28	101	104	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2011	306	12					1344	1351		10.1001/jama.2011.1364	http://dx.doi.org/10.1001/jama.2011.1364			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825FQ	21954478	Bronze, Green Accepted			2023-01-03	WOS:000295257000023
J	Maher, AR; Maglione, M; Bagley, S; Suttorp, M; Hu, JH; Ewing, B; Wang, Z; Timmer, M; Sultzer, D; Shekelle, PG				Maher, Alicia Ruelaz; Maglione, Margaret; Bagley, Steven; Suttorp, Marika; Hu, Jian-Hui; Ewing, Brett; Wang, Zhen; Timmer, Martha; Sultzer, David; Shekelle, Paul G.			Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							OBSESSIVE-COMPULSIVE DISORDER; GENERALIZED ANXIETY DISORDER; SEROTONIN REUPTAKE INHIBITORS; PLACEBO-CONTROLLED TRIAL; NURSING-HOME RESIDENTS; FUMARATE QUETIAPINE XR; A-DOUBLE-BLIND; ALZHEIMERS-DISEASE; BEHAVIORAL DISTURBANCES; PSYCHOLOGICAL SYMPTOMS	Context Atypical antipsychotic medications are commonly used for off-label conditions such as agitation in dementia, anxiety, and obsessive-compulsive disorder. Objective To perform a systematic review on the efficacy and safety of atypical antipsychotic medications for use in conditions lacking approval for labeling and marketing by the US Food and Drug Administration. Data Sources and Study Selection Relevant studies published in the English language were identified by searches of 6 databases (PubMed, EMBASE, CINAHL, PsycInfo, Cochrane DARE, and CENTRAL) from inception through May 2011. Controlled trials comparing an atypical antipsychotic medication (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, asenapine, iloperidone, or paliperidone) with placebo, another atypical antipsychotic medication, or other pharmacotherapy for adult off-label conditions were included. Observational studies with sample sizes of greater than 1000 patients were included to assess adverse events. Data Extraction Independent article review and study quality assessment by 2 investigators. Data Synthesis Of 12 228 citations identified, 162 contributed data to the efficacy review. Among 14 placebo-controlled trials of elderly patients with dementia reporting a total global outcome score that includes symptoms such as psychosis, mood alterations, and aggression, small but statistically significant effects sizes ranging from 0.12 and 0.20 were observed for aripiprazole, olanzapine, and risperidone. For generalized anxiety disorder, a pooled analysis of 3 trials showed that quetiapine was associated with a 26% greater likelihood of a favorable response (defined as at least 50% improvement on the Hamilton Anxiety Scale) compared with placebo. For obsessive-compulsive disorder, risperidone was associated with a 3.9-fold greater likelihood of a favorable response (defined as a 25% improvement on the Yale-Brown Obsessive Compulsive Scale) compared with placebo. In elderly patients, adverse events included an increased risk of death (number needed to harm [NNH]=87), stroke (NNH=53 for risperidone), extrapyramidal symptoms (NNH=10 for olanzapine; NNH=20 for risperidone), and urinary tract symptoms (NNH range=16-36). In nonelderly adults, adverse events included weight gain (particularly with olanzapine), fatigue, sedation, akathisia (for aripiprazole), and extrapyramidal symptoms. Conclusions Benefits and harms vary among atypical antipsychotic medications for off-label use. For global behavioral symptom scores associated with dementia in elderly patients, small but statistically significant benefits were observed for aripiprazole, olanzapine, and risperidone. Quetiapine was associated with benefits in the treatment of generalized anxiety disorder, and risperidone was associated with benefits in the treatment of obsessive-compulsive disorder; however, adverse events were common. JAMA. 2011;306(12):1359-1369	[Maher, Alicia Ruelaz; Maglione, Margaret; Suttorp, Marika; Hu, Jian-Hui; Ewing, Brett; Wang, Zhen; Timmer, Martha; Shekelle, Paul G.] So Calif Evidence Based Practice Ctr, RAND Hlth, Santa Monica, CA 90401 USA; [Bagley, Steven] VA Palo Alto Healthcare Syst, Palo Alto, CA USA; [Sultzer, David; Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA; [Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Maher, AR (corresponding author), So Calif Evidence Based Practice Ctr, RAND Hlth, 1776 Main St, Santa Monica, CA 90401 USA.	Alicia.Ruelaz@cshs.org	Zhen, Wang/S-7244-2019; Hug, Balthasar L./G-1568-2010; Wang, Zhen/D-5991-2013	Wang, Zhen/0000-0002-9368-6149; Bagley, Steven/0000-0003-2187-7955	Eli Lilly; RAND Corporation; Agency for Healthcare Research and Quality [HHSA2902007100621]; Department of Veterans Affairs	Eli Lilly(Eli Lilly); RAND Corporation; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Department of Veterans Affairs(US Department of Veterans Affairs)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Sultzer reported that he received research support for an Alzheimer disease study from Eli Lilly (no direct or indirect salary was paid to him) and consulting fees from RAND Corporation for his work as member of a technical expert panel for the Agency for Healthcare Research and Quality that performed the initial analysis. No other disclosures were reported.; This article is based on research conducted by the Southern California Evidence-Based Practice Center under contract HHSA2902007100621 with the Agency for Healthcare Research and Quality. This work was commissioned by the Agency for Healthcare Research and Quality as an update to an earlier report. Drs Sultzer and Shekelle are also supported by the Department of Veterans Affairs.	*AHRQ, EFF COMP EFF OFF LAB; Alexander GC, 2011, PHARMACOEPIDEM DR S, V20, P177, DOI 10.1002/pds.2082; Altamura AC, 2011, INT CLIN PSYCHOPHARM, V26, P201, DOI 10.1097/YIC.0b013e3283457d73; [Anonymous], 14 ANN M AM ASS GER; Atmaca M, 2002, INT CLIN PSYCHOPHARM, V17, P115, DOI 10.1097/00004850-200205000-00004; Ballard C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003476.pub2; Ballard C, 2005, BMJ-BRIT MED J, V330, P874, DOI 10.1136/bmj.38369.459988.8F; Ballard CG, 2004, J CLIN PSYCHIAT, V65, P114; Bandelow B, 2010, INT J NEUROPSYCHOPH, V13, P305, DOI 10.1017/S1461145709990423; Brawman-Mintzer O, 2005, J CLIN PSYCHIAT, V66, P1321, DOI 10.4088/JCP.v66n1016; Brodaty H, 2005, INT J GERIATR PSYCH, V20, P1153, DOI 10.1002/gps.1409; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; Bystritsky A, 2004, J CLIN PSYCHIAT, V65, P565; Carey PD, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-5; Cavedini P, 2004, J CLIN PSYCHOPHARM, V24, P628, DOI 10.1097/01.jcp.0000144889.51072.03; Cohen J., 2013, STAT POWER ANAL BEHA; CUMMINGS JL, NEUROPSYCHIATRIC INV; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; De Deyn PP, 2005, CLIN NEUROL NEUROSUR, V107, P497, DOI 10.1016/j.clineuro.2005.03.013; De Deyn PP, 2004, INT J GERIATR PSYCH, V19, P115, DOI 10.1002/gps.1032; Deberdt WG, 2005, AM J GERIAT PSYCHIAT, V13, P722, DOI 10.1176/appi.ajgp.13.8.722; DEDEYN PPJ, 2003, 16 ANN M AM ASS GER; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Denys D, 2004, J CLIN PSYCHIAT, V65, P1040; Denys D, 2006, NEUROPSYCHOPHARMACOL, V31, pS104; Depping AM, 2010, COCHRANE DB SYST REV, V12; Diniz JB, 2010, J PSYCHOPHARMACOL, V24, P297, DOI 10.1177/0269881108099423; Erzegovesi S, 2005, EUR NEUROPSYCHOPHARM, V15, P69, DOI 10.1016/j.euroneuro.2004.04.004; Fineberg NA, 2005, INT CLIN PSYCHOPHARM, V20, P223, DOI 10.1097/00004850-200507000-00005; Gareri P, 2004, ARCH GERONTOL GERIAT, P207; Gill SS, 2007, ANN INTERN MED, V146, P775, DOI 10.7326/0003-4819-146-11-200706050-00006; Herz LR, 2002, J CLIN PSYCHIAT, V63, P1065; Hirschfeld RMA, 2006, J CLIN PSYCHIAT, V67, P355, DOI 10.4088/JCP.v67n0304; Hollander E, 2003, INT J NEUROPSYCHOPH, V6, P397, DOI 10.1017/S1461145703003730; Holmes C, 2007, INT J GERIATR PSYCH, V22, P380, DOI 10.1002/gps.1667; Huybrechts KF, 2011, CAN MED ASSOC J, V183, pE411, DOI 10.1503/cmaj.101406; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOYCE M, 2008, 161 ANN M AM PSYCH A; Kales HC, 2007, AM J PSYCHIAT, V164, P1568, DOI 10.1176/appi.ajp.2007.06101710; Kales HC, 2011, ARCH GEN PSYCHIAT, V68, P190, DOI 10.1001/archgenpsychiatry.2010.200; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Katzman MA, 2011, INT CLIN PSYCHOPHARM, V26, P11, DOI 10.1097/YIC.0b013e32833e34d9; Kennedy J, 2005, INT J GERIATR PSYCH, V20, P1020, DOI 10.1002/gps.1397; Khan A, 2009, 49 ANN NEW CLIN DRUG; KINON BJL, 2005, INT C SCHIZ RES APR; Kordon A, 2008, J CLIN PSYCHOPHARM, V28, P550, DOI 10.1097/JCP.0b013e318185e735; Krystal JH, 2011, JAMA-J AM MED ASSOC, V306, P493, DOI 10.1001/jama.2011.1080; Liperoti R, 2009, J CLIN PSYCHIAT, V70, P1340, DOI 10.4088/JCP.08m04597yel; Lohoff FW, 2010, J CLIN PSYCHOPHARM, V30, P185, DOI 10.1097/JCP.0b013e3181d21951; MAGLIONE M, EFFICACY COMP EFFECT; Maina G, 2008, EUR NEUROPSYCHOPHARM, V18, P364, DOI 10.1016/j.euroneuro.2008.01.001; Matsunaga H, 2009, J CLIN PSYCHIAT, V70, P863, DOI 10.4088/JCP.08m04369; McDougle CJ, 2000, ARCH GEN PSYCHIAT, V57, P794, DOI 10.1001/archpsyc.57.8.794; McIntyre A, 2007, DEPRESS ANXIETY, V24, P487, DOI 10.1002/da.20275; Merideth C, 2008, EUR NEUROPSYCHOPHARM, V18, pS499, DOI 10.1016/S0924-977X(08)70749-1; Mintzer J, 2006, AM J GERIAT PSYCHIAT, V14, P280, DOI 10.1097/01.JGP.0000194643.63245.8c; MINTZER J, 2004, 4 ANN M INT COLL GER; Mintzer JE, 2007, AM J GERIAT PSYCHIAT, V15, P918, DOI 10.1097/JGP.0b013e3181557b47; Moretti R, 2005, J NEUROL, V252, P1186, DOI 10.1007/s00415-005-0830-z; Mowla A, 2010, J CLIN PSYCHOPHARM, V30, P40, DOI 10.1097/JCP.0b013e3181ca0c59; Mulsant BH, 2004, J CLIN PSYCHIAT, V65, P1708, DOI 10.4088/JCP.v65n1217; Naber D, 2007, PSYCHOPHARMACOLOGY, V191, P1027, DOI 10.1007/s00213-007-0747-6; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Paleacu D, 2008, INT J GERIATR PSYCH, V23, P393, DOI 10.1002/gps.1892; Pandina GJ, 2007, PSYCHOPHARMACOL BULL, V40, P41; Parker C, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4245; Pollack MH, 2006, BIOL PSYCHIAT, V59, P211, DOI 10.1016/j.biopsych.2005.07.005; Pollock BG, 2007, AM J GERIAT PSYCHIAT, V15, P942, DOI 10.1097/JGP.0b013e3180cc1ff5; Rainer M, 2007, EUR PSYCHIAT, V22, P395, DOI 10.1016/j.eurpsy.2007.03.001; Rappaport SA, 2009, J AM MED DIR ASSOC, V10, P21, DOI 10.1016/j.jamda.2008.06.006; Ray WA, 2009, NEW ENGL J MED, V360, P225, DOI 10.1056/NEJMoa0806994; Satterlee Winston G., 1995, Psychopharmacology Bulletin, V31, P534; Savaskan E, 2006, INT J NEUROPSYCHOPH, V9, P507, DOI 10.1017/S1461145705006036; Schneeweiss S, 2007, CAN MED ASSOC J, V176, P627, DOI 10.1503/cmaj.061250; Schneider LS, 2006, NEW ENGL J MED, V355, P1525, DOI 10.1056/NEJMoa061240; Schneider LS, 2005, JAMA-J AM MED ASSOC, V294, P1934, DOI 10.1001/jama.294.15.1934; Schneider LS, 2006, AM J GERIAT PSYCHIAT, V14, P191, DOI 10.1097/01.JGP.0000200589.01396.6d; Shapira NA, 2004, BIOL PSYCHIAT, V55, P553, DOI 10.1016/j.biopsych.2003.11.010; Sheehan DV, 2009, J AFFECT DISORDERS, V115, P376, DOI 10.1016/j.jad.2008.10.005; Simon NM, 2008, PSYCHOPHARMACOLOGY, V197, P675, DOI 10.1007/s00213-008-1087-x; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Street JS, 2000, PSYCHIAT ANN, V30, P191, DOI 10.3928/0048-5713-20000301-12; STREET JS, 2000, OLANZAPINE ZYPREXA N, P416; STREIM JE, 2004, AM PSYCH ASS ANN M M; STREIM JE, 2004, ANN M AM ASS GER PSY; Streim JE, 2008, AM J GERIAT PSYCHIAT, V16, P537, DOI 10.1097/JGP.0b013e318165db77; Suh GH, 2007, INT J GERIATR PSYCH, V22, P494, DOI 10.1002/gps.1693; Sultzer DL, 2008, AM J PSYCHIAT, V165, P844, DOI 10.1176/appi.ajp.2008.07111779; Tariot PN, 2006, AM J GERIAT PSYCHIAT, V14, P767, DOI 10.1097/01.JGP.0000196628.12010.35; TARIOT PS, 2002, ANN M AM ASS GER PSY; TODD MS, 2002, 155 ANN M AM PSYCH A; van Reekum R, 2002, INT PSYCHOGERIATR, V14, P197, DOI 10.1017/S1041610202008396; Verhey FRJ, 2006, DEMENT GERIATR COGN, V21, P1, DOI 10.1159/000089136; Vigen CLP, 2011, AM J PSYCHIAT, V168, P831, DOI 10.1176/appi.ajp.2011.08121844; Vulink NCC, 2009, J CLIN PSYCHIAT, V70, P1001, DOI 10.4088/JCP.08m04269; Wells GA, NEWCASTLE OTTAWA SCA; Yury CA, 2007, PSYCHOTHER PSYCHOSOM, V76, P213, DOI 10.1159/000101499; Zhong KX, 2007, CURR ALZHEIMER RES, V4, P81, DOI 10.2174/156720507779939805; ZHONG XT, 2004, 56 I PSYCH SERV OCT	99	355	369	0	74	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	2011	306	12					1359	1369		10.1001/jama.2011.1360	http://dx.doi.org/10.1001/jama.2011.1360			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	825FQ	21954480	Bronze			2023-01-03	WOS:000295257000025
J	Kikuchi, K; Soundararajan, A; Zarzabal, LA; Weems, CR; Nelon, LD; Hampton, ST; Michalek, JE; Rubin, BP; Fields, AP; Keller, C				Kikuchi, K.; Soundararajan, A.; Zarzabal, L. A.; Weems, C. R.; Nelon, L. D.; Hampton, S. T.; Michalek, J. E.; Rubin, B. P.; Fields, A. P.; Keller, C.			Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma	ONCOGENE			English	Article						alveolar rhabdomyosarcoma; protein kinase C iota; Rac1; mitosis; aurothiomalate; vincristine	TRANSFORMED GROWTH; CELL; EXPRESSION; VINCRISTINE; ACTIVATION; PAX3-FKHR; ONCOGENE; PHARMACOKINETICS; DIFFERENTIATION; RESISTANCE	Alveolar rhabdomyosarcoma is an aggressive pediatric cancer exhibiting skeletal-muscle differentiation. New therapeutic targets are required to improve the dismal prognosis for invasive or metastatic alveolar rhabdomyosarcoma. Protein kinase C iota (PKC iota) has been shown to have an important role in tumorigenesis of many cancers, but little is known about its role in rhabdomyosarcoma. Our gene-expression studies in human tumor samples revealed overexpression of PRKCl. We confirmed overexpression of PKC iota at the mRNA and protein levels using our conditional mouse model that authentically recapitulates the progression of rhabdomyosarcoma in humans. Inhibition of Prkci by RNA interference resulted in a dramatic decrease in anchorage-independent colony formation. Interestingly, treatment of primary cell cultures using aurothiomalate (ATM), which is a gold-containing classical anti-rheumatic agent and a PKC iota-specific inhibitor, resulted in decreased interaction between PKC iota and Par6, decreased Rac1 activity and reduced cell viability at clinically relevant concentrations. Moreover, co-treatment with ATM and vincristine (VCR), a nnicrotubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combination index of 0.470-0.793 through cooperative accumulation of non-proliferative multinuclear cells in the G2/M phase, indicating that these two drugs synergize. For in vivo tumor growth inhibition studies, ATM demonstrated a trend toward enhanced VCR sensitivity. Overall, these results suggest that PKC iota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-cell proliferation and that combination therapy with ATM and microtubule inhibitors holds promise for the treatment of alveolar rhabdomyosarcoma. Oncogene (2013) 32, 286-295; doi:10.1038/onc.2012.46; published online 20 February 2012	[Kikuchi, K.; Keller, C.] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, Portland, OR 97239 USA; [Soundararajan, A.; Nelon, L. D.; Hampton, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA; [Zarzabal, L. A.; Michalek, J. E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA; [Weems, C. R.; Fields, A. P.] Mayo Clin, Ctr Comprehens Canc, Dept Canc Biol, Jacksonville, FL 32224 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Dept Mol Genet, Cleveland, OH 44106 USA; [Rubin, B. P.] Lerner Res Inst, Cleveland, OH USA	Oregon Health & Science University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Mayo Clinic; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Keller, C (corresponding author), Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Pediat Canc Biol Program, 3181 SW Sam Jackson Pk Rd,Mail Code L321, Portland, OR 97239 USA.	keller@ohsu.edu	Kikuchi, Ken/ABG-8290-2020	Kikuchi, Ken/0000-0003-3097-7480; Keller, Charles/0000-0003-2505-7487	NIH/NCI Grant [1R01CA133229-04, 1R01CA133229-05, 4R01CA081436-13]; V Foundation for Cancer Research; National Cancer Institute; NICHD; NATIONAL CANCER INSTITUTE [R01CA133229, R01CA081436] Funding Source: NIH RePORTER	NIH/NCI Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI Grant 1R01CA133229-04 and -05 awarded to CK, NIH/NCI Grant 4R01CA081436-13 and the V Foundation for Cancer Research awarded to APF. Human tissue samples were provided by the Pediatric Cooperative Human Tissue network, which is funded by the National Cancer Institute. The Developmental Studies Hybridoma Bank is developed under the auspices of the NICHD and maintained by the University of Iowa, Iowa City, IA, USA.	Ali AS, 2009, CANCER TREAT REV, V35, P1, DOI 10.1016/j.ctrv.2008.07.006; Amstutz R, 2008, CANCER RES, V68, P3767, DOI 10.1158/0008-5472.CAN-07-2447; Anderson J, 1999, GENE CHROMOSOME CANC, V26, P275, DOI 10.1002/(SICI)1098-2264(199912)26:4<275::AID-GCC1>3.0.CO;2-3; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; BLOCKA KLN, 1986, CLIN PHARMACOKINET, V11, P133, DOI 10.2165/00003088-198611020-00003; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chen LG, 1999, GYNECOL ONCOL, V72, P171, DOI 10.1006/gyno.1998.5242; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields AP, 2007, PHARMACOL RES, V55, P487, DOI 10.1016/j.phrs.2007.04.015; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; GERMANI A, 1994, BIOCHEM BIOPH RES CO, V202, P17, DOI 10.1006/bbrc.1994.1887; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; HOUGHTON JA, 1982, CANCER RES, V42, P535; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; JORDAN MA, 1991, CANCER RES, V51, P2212; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Limatola C, 1997, BIOCHEM J, V321, P497, DOI 10.1042/bj3210497; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; Maroto B, 2008, ONCOGENE, V27, P4900, DOI 10.1038/onc.2008.131; Murray NR, 2011, J CELL PHYSIOL, V226, P879, DOI 10.1002/jcp.22463; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; NELSON RL, 1982, MED PEDIATR ONCOL, V10, P115, DOI 10.1002/mpo.2950100202; Nishijo K, 2009, CANCER RES, V69, P2902, DOI 10.1158/0008-5472.CAN-08-3723; Regala RP, 2008, CANCER RES, V68, P5888, DOI 10.1158/0008-5472.CAN-08-0438; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Svensson K, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-10; TENNYSON GS, 1983, CANCER TREAT REP, V67, P1113; Thimmaiah KN, 2010, CANCER RES, V70, P2000, DOI 10.1158/0008-5472.CAN-09-3693; Thompson J, 1999, CLIN CANCER RES, V5, P3617; Wachtel M, 2010, CANCER TREAT REV, V36, P318, DOI 10.1016/j.ctrv.2010.02.007; Win HY, 2009, CELL PROLIFERAT, V42, P182, DOI 10.1111/j.1365-2184.2009.00582.x; Win HY, 2008, CANCER LETT, V270, P302, DOI 10.1016/j.canlet.2008.05.023; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Woodcock SA, 2010, CURR BIOL, V20, P669, DOI 10.1016/j.cub.2010.02.033; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	50	26	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					286	295		10.1038/onc.2012.46	http://dx.doi.org/10.1038/onc.2012.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22349825	Green Accepted			2023-01-03	WOS:000314736600003
J	Fraile, JM; Quesada, V; Rodriguez, D; Freije, JMP; Lopez-Otin, C				Fraile, J. M.; Quesada, V.; Rodriguez, D.; Freije, J. M. P.; Lopez-Otin, C.			Deubiquitinases in cancer: new functions and therapeutic options	ONCOGENE			English	Review						deubiquitinases; cancer; degradome	NF-KAPPA-B; UBIQUITIN-SPECIFIC PROTEASES; SMALL-MOLECULE INHIBITOR; TUMOR-SUPPRESSOR; IN-VIVO; SOMATIC MUTATIONS; TGF-BETA; HEPATOCELLULAR-CARCINOMA; DEUBIQUITYLATING ENZYME; CELL-PROLIFERATION	Deubiquitinases (DUBs) have fundamental roles in the ubiquitin system through their ability to specifically deconjugate ubiquitin from targeted proteins. The human genome encodes at least 98 DUBs, which can be grouped into 6 families, reflecting the need for specificity in their function. The activity of these enzymes affects the turnover rate, activation, recycling and localization of multiple proteins, which in turn is essential for cell homeostasis, protein stability and a wide range of signaling pathways. Consistent with this, altered DUB function has been related to several diseases, including cancer. Thus, multiple DUBs have been classified as oncogenes or tumor suppressors because of their regulatory functions on the activity of other proteins involved in tumor development. Therefore, recent studies have focused on pharmacological intervention on DUB activity as a rationale to search for novel anticancer drugs. This strategy may benefit from our current knowledge of the physiological regulatory mechanisms of these enzymes and the fact that growth of several tumors depends on the normal activity of certain DUBs. Further understanding of these processes may provide answers to multiple remaining questions on DUB functions and lead to the development of DUB-targeting strategies to expand the repertoire of molecular therapies against cancer. Oncogene (2012) 31, 2373-2388; doi: 10.1038/onc.2011.443; published online 26 September 2011	[Fraile, J. M.; Quesada, V.; Rodriguez, D.; Freije, J. M. P.; Lopez-Otin, C.] Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, Inst Univ Oncol, E-33006 Oviedo, Spain.	clo@uniovi.es	López-Otín, Carlos/AAB-2106-2020; Quesada, Víctor/B-6557-2014; Rodríguez, David/K-3872-2017; Freije, José M.P./A-6535-2008	López-Otín, Carlos/0000-0001-6964-1904; Quesada, Víctor/0000-0002-8398-3457; Rodríguez, David/0000-0002-7530-2770; Freije, José M.P./0000-0002-4688-8266	Ministerio de Ciencia e Innovacion-Spain; Fundacion 'M Botin'; PCTI-FICYT Asturias; European Union; Obra Social Cajastur; Accion Transversal del Cancer-RTICC	Ministerio de Ciencia e Innovacion-Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion 'M Botin'; PCTI-FICYT Asturias; European Union(European Commission); Obra Social Cajastur; Accion Transversal del Cancer-RTICC	Our study is supported by grants from Ministerio de Ciencia e Innovacion-Spain, Fundacion 'M Botin', PCTI-FICYT Asturias and European Union (FP7 MicroEnviMet). The Instituto Universitario de Oncologia is supported by Obra Social Cajastur and Accion Transversal del Cancer-RTICC.	Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Al-Hakim A, 2010, DNA REPAIR, V9, P1229, DOI 10.1016/j.dnarep.2010.09.011; Al-Hakim AK, 2008, BIOCHEM J, V411, P249, DOI 10.1042/BJ20080067; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Aressy B, 2010, CELL CYCLE, V9, P3815, DOI 10.4161/cc.9.18.13133; Atanassov BS, 2011, FEBS LETT, V585, P2016, DOI 10.1016/j.febslet.2010.10.042; Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015; Baek KH, 2006, CURR PROTEIN PEPT SC, V7, P171, DOI 10.2174/138920306776359740; Baek KH, 2004, J BIOL CHEM, V279, P2368, DOI 10.1074/jbc.M304774200; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Bremm A, 2010, NAT STRUCT MOL BIOL, V17, P939, DOI 10.1038/nsmb.1873; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Burrows JF, 2004, J BIOL CHEM, V279, P13993, DOI 10.1074/jbc.M311291200; Cao ZW, 2007, MOL CELL BIOL, V27, P2180, DOI 10.1128/MCB.01245-06; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; Clague MJ, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-202; Colland F, 2010, BIOCHEM SOC T, V38, P137, DOI 10.1042/BST0380137; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Colombo M, 2010, CHEMMEDCHEM, V5, P552, DOI 10.1002/cmdc.200900409; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7; Dammer EB, 2011, J BIOL CHEM, V286, P10457, DOI 10.1074/jbc.M110.149633; Daviet L, 2008, BIOCHIMIE, V90, P270, DOI 10.1016/j.biochi.2007.09.013; Dayal S, 2009, J BIOL CHEM, V284, P5030, DOI 10.1074/jbc.M805871200; de la Vega M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1243; Drag M, 2010, NAT REV DRUG DISCOV, V9, P690, DOI 10.1038/nrd3053; Duex JE, 2011, J BIOL CHEM, V286, P25377, DOI 10.1074/jbc.M111.222760; Duex JE, 2009, MOL BIOL CELL, V20, P1833, DOI 10.1091/mbc.E08-08-0880; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Durkop H, 2003, J PATHOL, V200, P229, DOI 10.1002/path.1351; Eletr ZM, 2011, CELL BIOCHEM BIOPHYS, V60, P3, DOI 10.1007/s12013-011-9184-6; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Enesa K, 2008, J BIOL CHEM, V283, P18582, DOI 10.1074/jbc.M801312200; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Fan YH, 2011, CELL DEATH DIFFER, V18, P1547, DOI 10.1038/cdd.2011.11; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Freije JMP, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00025; Gao JM, 2010, BLOOD, V115, P4130, DOI 10.1182/blood-2009-10-248526; Gilbert RE, 2011, KIDNEY INT, V79, P1312, DOI 10.1038/ki.2011.39; Glinsky GV, 2005, CELL CYCLE, V4, P1171, DOI 10.4161/cc.4.9.2001; Gonzalez-Navajas JM, 2010, J EXP MED, V207, P2799, DOI 10.1084/jem.20101326; Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8; GRAY DA, 1995, ONCOGENE, V10, P2179; Guedat P, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S14; Guervilly JH, 2011, HUM MOL GENET, V20, P2171, DOI 10.1093/hmg/ddr103; GUPTA K, 1994, ONCOGENE, V9, P1729; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hellerbrand C, 2007, CARCINOGENESIS, V28, P21, DOI 10.1093/carcin/bgl081; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hirayama K, 2007, BIOORGAN MED CHEM, V15, P6810, DOI 10.1016/j.bmc.2007.07.016; Honma K, 2009, BLOOD, V114, P2467, DOI 10.1182/blood-2008-12-194852; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Hu M, 2005, EMBO J, V24, P3747, DOI 10.1038/sj.emboj.7600832; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Huang XH, 2009, J MOL BIOL, V391, P691, DOI 10.1016/j.jmb.2009.06.066; Hussain S, 2010, LEUKEMIA, V24, P1641, DOI 10.1038/leu.2010.138; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Hymowitz SG, 2010, NAT REV CANCER, V10, P332, DOI 10.1038/nrc2775; Ibarrola N, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-2; Ikeda F, 2008, EMBO REP, V9, P536, DOI 10.1038/embor.2008.93; Jang MJ, 2011, CANCER LETT, V302, P128, DOI 10.1016/j.canlet.2011.01.006; Jaster R, 1999, BBA-GENE STRUCT EXPR, V1446, P308, DOI 10.1016/S0167-4781(99)00095-0; Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kapuria V, 2010, CANCER RES, V70, P9265, DOI 10.1158/0008-5472.CAN-10-1530; Kessler BM, 2011, CELL BIOCHEM BIOPHYS, V60, P21, DOI 10.1007/s12013-011-9176-6; Kim YS, 2005, BIOCHEM BIOPH RES CO, V330, P797, DOI 10.1016/j.bbrc.2005.03.051; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55; Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Kuhlbrodt K, 2011, NAT CELL BIOL, V13, P273, DOI 10.1038/ncb2200; Kuphal S, 2011, ONCOGENE, V30, P4523, DOI 10.1038/onc.2011.163; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Lee HJ, 2005, FEBS LETT, V579, P4867, DOI 10.1016/j.febslet.2005.07.048; Li LY, 2009, BBA-MOL CELL RES, V1793, P346, DOI 10.1016/j.bbamcr.2008.09.013; Li ZB, 2005, EMBO REP, V6, P373, DOI 10.1038/sj.embor.7400377; Li ZB, 2002, BIOCHEM BIOPH RES CO, V294, P700, DOI 10.1016/S0006-291X(02)00534-X; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Liu H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005544; Liu JH, 2011, EMBO J, V30, P846, DOI 10.1038/emboj.2011.11; Liu YC, 2003, CHEM BIOL, V10, P837, DOI 10.1016/j.chembiol.2003.08.010; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2008, J BIOL CHEM, V283, P30433, DOI 10.1074/jbc.R800035200; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Love KR, 2007, NAT CHEM BIOL, V3, P697, DOI 10.1038/nchembio.2007.43; Lu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015936; Lu Y, 2009, MOL CELL BIOL, V29, P547, DOI 10.1128/MCB.00329-08; Lui TTH, 2011, MOL CELL BIOL, V31, P2053, DOI 10.1128/MCB.01094-10; Luise C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015891; Luna-Vargas MPA, 2011, EMBO REP, V12, P365, DOI 10.1038/embor.2011.33; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Mao Y, 2005, P NATL ACAD SCI USA, V102, P12700, DOI 10.1073/pnas.0506344102; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Mauri PL, 2006, FEBS J, V273, P4277, DOI 10.1111/j.1742-4658.2006.05419.x; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; McFarlane C, 2010, CANCER RES, V70, P3329, DOI 10.1158/0008-5472.CAN-09-4152; Mcnally RS, 2011, J BIOL CHEM, V286, P4098, DOI 10.1074/jbc.M110.147371; Meray RK, 2007, J BIOL CHEM, V282, P10567, DOI 10.1074/jbc.M611153200; Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124; Meulmeester E, 2008, MOL CELL, V30, P610, DOI 10.1016/j.molcel.2008.03.021; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mullally JE, 2002, MOL PHARMACOL, V62, P351, DOI 10.1124/mol.62.2.351; Murai J, 2011, MOL CELL BIOL, V31, P2462, DOI 10.1128/MCB.05058-11; Nagai H, 2009, MOL CELL, V36, P805, DOI 10.1016/j.molcel.2009.10.016; Nakamura N, 2008, MOL BIOL CELL, V19, P1903, DOI 10.1091/mbc.E07-11-1103; Navon A, 2009, J BIOL CHEM, V284, P33713, DOI 10.1074/jbc.R109.018481; Nicastro G, 2005, P NATL ACAD SCI USA, V102, P10493, DOI 10.1073/pnas.0501732102; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Oh KH, 2011, CELL DEATH DIFFER, V18, P1326, DOI 10.1038/cdd.2011.3; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parsons JL, 2011, MOL CELL, V41, P609, DOI 10.1016/j.molcel.2011.02.016; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; PICKART CM, 1985, J BIOL CHEM, V260, P7903; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Priolo C, 2006, CANCER RES, V66, P8625, DOI 10.1158/0008-5472.CAN-06-1374; Puente XS, 2004, GENOME RES, V14, P609, DOI 10.1101/gr.1946304; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Quesada V, 2004, BIOCHEM BIOPH RES CO, V314, P54, DOI 10.1016/j.bbrc.2003.12.050; Quesada V, 2009, NUCLEIC ACIDS RES, V37, pD239, DOI 10.1093/nar/gkn570; Rajan N, 2011, ONCOGENE, V30, P4243, DOI 10.1038/onc.2011.133; Ramakrishna S, 2011, J BIOL CHEM, V286, P10505, DOI 10.1074/jbc.M110.162321; Ramakrishna S, 2011, CELL MOL LIFE SCI, V68, P15, DOI 10.1007/s00018-010-0504-6; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Saggar S, 2008, J MED GENET, V45, P298, DOI 10.1136/jmg.2007.056127; Sato Y, 2008, NATURE, V455, P358, DOI 10.1038/nature07254; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Schweitzer K, 2007, EMBO J, V26, P1532, DOI 10.1038/sj.emboj.7601600; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Sun HS, 2011, BLOOD, V117, P3151, DOI 10.1182/blood-2010-03-276477; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Tian XF, 2011, ASSAY DRUG DEV TECHN, V9, P165, DOI 10.1089/adt.2010.0317; Todi SV, 2009, EMBO J, V28, P372, DOI 10.1038/emboj.2008.289; Tran H, 2008, GENE DEV, V22, P528, DOI 10.1101/gad.463208; Turk B, 2006, NAT REV DRUG DISCOV, V5, P785, DOI 10.1038/nrd2092; Urbanik T, 2011, INT J ONCOL, V38, P121, DOI 10.3892/ijo_00000831; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Vendrell JA, 2007, ONCOGENE, V26, P4656, DOI 10.1038/sj.onc.1210269; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Verstrepen L, 2009, BIOCHEM PHARMACOL, V78, P105, DOI 10.1016/j.bcp.2009.02.009; Virdee S, 2010, NAT CHEM BIOL, V6, P750, DOI [10.1038/NCHEMBIO.426, 10.1038/nchembio.426]; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wicks SJ, 2005, ONCOGENE, V24, P8080, DOI 10.1038/sj.onc.1208944; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Winborn BJ, 2008, J BIOL CHEM, V283, P26436, DOI 10.1074/jbc.M803692200; Xu GF, 2010, J BIOL CHEM, V285, P969, DOI 10.1074/jbc.M109.042689; Xu ML, 2009, BIOCHEM BIOPH RES CO, V388, P366, DOI 10.1016/j.bbrc.2009.08.015; Yamaguchi T, 2007, J BIOL CHEM, V282, P33943, DOI 10.1074/jbc.M706282200; Yang YL, 2007, INT J NANOTECHNOL, V4, P4, DOI 10.1504/IJNT.2007.012313; Yao T, 2008, MOL CELL, V31, P909, DOI 10.1016/j.molcel.2008.08.027; Yoshida A, 2010, FEBS LETT, V584, P4545, DOI 10.1016/j.febslet.2010.10.039; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10; Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang C, 2011, MOL CANCER THER, V10, P1264, DOI 10.1158/1535-7163.MCT-10-1091; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang J, 2006, J CLIN INVEST, V116, P3042, DOI 10.1172/JCI28746; Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403; Zhao B, 2009, J CELL MOL MED, V13, P1886, DOI 10.1111/j.1582-4934.2009.00682.x; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024; Zhu X, 2007, PROTEINS, V69, P1, DOI 10.1002/prot.21546	207	322	349	8	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2373	2388		10.1038/onc.2011.443	http://dx.doi.org/10.1038/onc.2011.443			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996736	Green Published			2023-01-03	WOS:000303985300001
J	Cho, SY; Jeong, HW; Sohn, JH; Seo, DB; Kim, WG; Lee, SJ				Cho, Si Young; Jeong, Hyun Woo; Sohn, Jong Hee; Seo, Dae-Bang; Kim, Wan Gi; Lee, Sang-Jun			An Ethanol Extract of Artemisia iwayomogi Activates PPAR delta Leading to Activation of Fatty Acid Oxidation in Skeletal Muscle	PLOS ONE			English	Article							GLUCOSE-METABOLISM; EXPRESSION; GW501516; AGONIST; OBESITY; BETA	Although Artemisia iwayomogi (AI) has been shown to improve the lipid metabolism, its mode of action is poorly understood. In this study, a 95% ethanol extract of AI (95EEAI) was identified as a potent ligand of peroxisome proliferator-activated receptor delta (PPAR delta) using ligand binding analysis and cell-based reporter assay. In cultured primary human skeletal muscle cells, treatment of 95EEAI increased expression of two important PPAR delta-regulated genes, carnitine palmitoyl-transferase-1 (CPT1) and pyruvate dehydrogenase kinase isozyme 4 (PDK4), and several genes acting in lipid efflux and energy expenditure. Furthermore, 95EEAI stimulated fatty acid oxidation in a PPAR delta-dependent manner. High-fat diet-induced obese mice model further indicated that administration of 95EEAI attenuated diet-induced obesity through the activation of fatty acid oxidation in skeletal muscle. These results suggest that a 95% ethanol extract of AI may have a role as a new functional food material for the prevention and/or treatment of hyperlipidermia and obesity.	[Cho, Si Young; Jeong, Hyun Woo; Sohn, Jong Hee; Seo, Dae-Bang; Kim, Wan Gi; Lee, Sang-Jun] AmorePacific Corp, Ctr Res & Dev, Hlth Sci Res Inst, Yongin, South Korea		Cho, SY (corresponding author), AmorePacific Corp, Ctr Res & Dev, Hlth Sci Res Inst, Yongin, South Korea.	leesjun@amorepacific.com						ALWAILI NSD, 1986, CLIN EXP PHARMACOL P, V13, P569, DOI 10.1111/j.1440-1681.1986.tb00940.x; Brunmair B, 2006, DIABETOLOGIA, V49, P2713, DOI 10.1007/s00125-006-0357-6; Cefalu WT, 2008, AM J CLIN NUTR, V87, p481S, DOI 10.1093/ajcn/87.2.481S; Coll Teresa, 2009, Curr Mol Pharmacol, V2, P46; de Lange P, 2007, FASEB J, V21, P3431, DOI 10.1096/fj.07-8527rev; Dressel U, 2003, MOL ENDOCRINOL, V17, P2477, DOI 10.1210/me.2003-0151; Ehrenborg E, 2009, PHARMACOL REV, V61, P373, DOI 10.1124/pr.109.001560; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Hamza N, 2010, J ETHNOPHARMACOL, V128, P513, DOI 10.1016/j.jep.2010.01.004; Jung UJ, 2009, J MED FOOD, V12, P1238, DOI 10.1089/jmf.2009.0039; Kramer DK, 2007, J BIOL CHEM, V282, P19313, DOI 10.1074/jbc.M702329200; Kramer DK, 2005, DIABETES, V54, P1157, DOI 10.2337/diabetes.54.4.1157; Lee CH, 2006, P NATL ACAD SCI USA, V103, P3444, DOI 10.1073/pnas.0511253103; Lee J, 2011, ENDOCRINOLOGY, V152, P1742, DOI 10.1210/en.2011-0211; Lee J, 2008, J ETHNOPHARMACOL, V115, P263, DOI 10.1016/j.jep.2007.09.029; Nam SM, 1998, J KOR SOC FOOD SCI N, V27, P201; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; PALOU A, 1983, COMP BIOCHEM PHYS A, V75, P597, DOI 10.1016/0300-9629(83)90426-7; Schuler M, 2006, CELL METAB, V4, P407, DOI 10.1016/j.cmet.2006.10.003; Sprecher DL, 2007, ARTERIOSCL THROM VAS, V27, P359, DOI 10.1161/01.ATV.0000252790.70572.0c; Tan RX, 1998, PLANTA MED, V64, P295, DOI 10.1055/s-2006-957438; Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100; Wagner KD, 2010, PHARMACOL THERAPEUT, V125, P423, DOI 10.1016/j.pharmthera.2009.12.001; Wang YX, 2005, PLOS BIOL, V3, P177, DOI 10.1371/journal.pbio.0030061; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Wang ZQ, 2008, METABOLISM, V57, pS58, DOI 10.1016/j.metabol.2008.04.003; Wang ZQ, 2011, J NUTR BIOCHEM, V22, P71, DOI 10.1016/j.jnutbio.2009.11.015; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yamamoto N, 2011, FOOD FUNCT, V2, P45, DOI 10.1039/c0fo00129e; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	30	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 27	2012	7	3							e33815	10.1371/journal.pone.0033815	http://dx.doi.org/10.1371/journal.pone.0033815			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	940MY	22479450	Green Published, gold, Green Submitted			2023-01-03	WOS:000303894900039
J	Lim, SS; Mokdad, AH				Lim, Stephen S.; Mokdad, Ali H.			Socioeconomic inequalities and infectious disease burden	LANCET			English	Editorial Material							MORTALITY		[Lim, Stephen S.; Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle	Lim, SS (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.	stevelim@uw.edu	Mokdad, Ali H./AAD-1232-2022	Mokdad, Ali H./0000-0002-4994-3339				Baker MG, 2012, LANCET, V379, P1112, DOI 10.1016/S0140-6736(11)61780-7; Blakely T, 2008, BRIT MED J, V336, P371, DOI 10.1136/bmj.39455.596181.25; Ezzati M, 2008, PLOS MED, V5, P557, DOI 10.1371/journal.pmed.0050066; Holman CDJ, 2008, AUST HEALTH REV, V32, P766, DOI 10.1071/AH080766; Kiyota Y, 2004, AM HEART J, V148, P99, DOI 10.1016/j.ahj.2004.02.013; Murray CJL, 2006, PLOS MED, V3, P1513, DOI 10.1371/journal.pmed.0030260	6	7	7	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 24	2012	379	9821					1080	1081		10.1016/S0140-6736(12)60151-2	http://dx.doi.org/10.1016/S0140-6736(12)60151-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22353261				2023-01-03	WOS:000302131800009
J	Yang, D; Li, SY; Yeung, CM; Chang, RCC; So, KF; Wong, D; Lo, ACY				Yang, Di; Li, Suk-Yee; Yeung, Chung-Man; Chang, Raymond Chuen-Chung; So, Kwok-Fai; Wong, David; Lo, Amy C. Y.			Lycium barbarum Extracts Protect the Brain from Blood-Brain Barrier Disruption and Cerebral Edema in Experimental Stroke	PLOS ONE			English	Article							FOCAL ISCHEMIA; MATRIX-METALLOPROTEINASE; MEDICINE; INJURY; MODEL; LEADS; POLYSACCHARIDES; OVEREXPRESSION; ENDOTHELIN-1; MECHANISMS	Background and Purpose: Ischemic stroke is a destructive cerebrovascular disease and a leading cause of death. Yet, no ideal neuroprotective agents are available, leaving prevention an attractive alternative. The extracts from the fruits of Lycium barbarum (LBP), a Chinese anti-aging medicine and food supplement, showed neuroprotective function in the retina when given prophylactically. We aim to evaluate the protective effects of LBP pre-treatment in an experimental stroke model. Methods: C57BL/6N male mice were first fed with either vehicle (PBS) or LBP (1 or 10 mg/kg) daily for 7 days. Mice were then subjected to 2-hour transient middle cerebral artery occlusion (MCAO) by the intraluminal method followed by 22-hour reperfusion upon filament removal. Mice were evaluated for neurological deficits just before sacrifice. Brains were harvested for infarct size estimation, water content measurement, immunohistochemical analysis, and Western blot experiments. Evans blue (EB) extravasation was determined to assess blood-brain barrier (BBB) disruption after MCAO. Results: LBP pre-treatment significantly improved neurological deficits as well as decreased infarct size, hemispheric swelling, and water content. Fewer apoptotic cells were identified in LBP-treated brains by TUNEL assay. Reduced EB extravasation, fewer IgG-leaky vessels, and up-regulation of occludin expression were also observed in LBP-treated brains. Moreover, immunoreactivity for aquaporin-4 and glial fibrillary acidic protein were significantly decreased in LBP-treated brains. Conclusions: Seven-day oral LBP pre-treatment effectively improved neurological deficits, decreased infarct size and cerebral edema as well as protected the brain from BBB disruption, aquaporin-4 up-regulation, and glial activation. The present study suggests that LBP may be used as a prophylactic neuroprotectant in patients at high risk for ischemic stroke.	[Yang, Di; Li, Suk-Yee; Yeung, Chung-Man; Wong, David; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai; Wong, David; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Hlth Aging, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Yang, D (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Hong Kong, Hong Kong, Peoples R China.	amylo@hkucc.hku.hk	Lo, Amy C. Y./C-1195-2009; Chang, Raymond Chuen-Chung/C-1107-2009	Lo, Amy C. Y./0000-0003-4239-6851; Chang, Raymond Chuen-Chung/0000-0001-8538-7993; So, Kwok-Fai/0000-0003-4039-4246	University of Hong Kong; Azalea Endowment Fund	University of Hong Kong(University of Hong Kong); Azalea Endowment Fund	This study was supported by the University Development Fund from The University of Hong Kong to the Eye Institute and by the Azalea (1972) Endowment Fund to RCC and KFS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asahi M, 2000, J CEREBR BLOOD F MET, V20, P452, DOI 10.1097/00004647-200003000-00002; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Balami JS, 2011, LANCET NEUROL, V10, P357, DOI 10.1016/S1474-4422(10)70313-6; Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Brouns R, 2011, EUR NEUROL, V65, P23, DOI 10.1159/000321965; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Elango C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-97; Freeman WD, 2010, SEMIN NEUROL, V30, P501, DOI 10.1055/s-0030-1268863; Ho YS, 2010, J ALZHEIMERS DIS, V19, P813, DOI 10.3233/JAD-2010-1280; Hu CF, 2010, J NAT PROD, V73, P1489, DOI 10.1021/np1001847; Huang XJ, 2009, CELL MOL NEUROBIOL, V29, P1211, DOI 10.1007/s10571-009-9417-z; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Kondoh T, 2011, BRAIN RES BULL, V84, P69, DOI 10.1016/j.brainresbull.2010.11.005; Latour LL, 2004, ANN NEUROL, V56, P468, DOI 10.1002/ana.20199; Li JJ, 2011, CLIN EXP PHARMACOL P, V38, P776, DOI 10.1111/j.1440-1681.2011.05591.x; Li SY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016380; Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310; Lo ACY, 2005, J CEREBR BLOOD F MET, V25, P998, DOI 10.1038/sj.jcbfm.9600108; Lo ACY, 2007, J CEREBR BLOOD F MET, V27, P1496, DOI 10.1038/sj.jcbfm.9600452; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Potterat O, 2010, PLANTA MED, V76, P7, DOI 10.1055/s-0029-1186218; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Schmerbach K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015052; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Spatz M, 2010, ACTA NEUROCHIR SUPPL, V106, P21, DOI 10.1007/978-3-211-98811-4_3; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Yeung CM, 2010, J NEUROSCI RES, V88, P2026, DOI 10.1002/jnr.22349; Yeung PKK, 2009, J CEREBR BLOOD F MET, V29, P1891, DOI 10.1038/jcbfm.2009.175; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zhou ZY, 2010, J ETHNOPHARMACOL, V131, P154, DOI 10.1016/j.jep.2010.06.023; ZIVIN JA, 1991, ARCH NEUROL-CHICAGO, V48, P1235, DOI 10.1001/archneur.1991.00530240039014	39	45	52	4	43	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 16	2012	7	3							e33596	10.1371/journal.pone.0033596	http://dx.doi.org/10.1371/journal.pone.0033596			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	932RV	22438957	Green Published, Green Submitted, gold			2023-01-03	WOS:000303309100065
J	Landon, BE				Landon, Bruce E.			Use of Quality Indicators in Patient Care A Senior Primary Care Physician Trying to Take Good Care of His Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH INFORMATION-TECHNOLOGY; OECD COUNTRIES; MEDICAL HOME; STRUCTURAL CAPABILITIES; PERFORMANCE; IMPROVE; PAY; MANAGEMENT; MASSACHUSETTS; GUIDELINES	Dr A is a senior primary care physician who recently moved from a small private practice to a larger group-model practice. He believes he was able to provide higher-quality and more individualized care for his patients in his small practice. As Dr A has discovered, quality measurement and improvement activities in primary care have evolved from a focus on an individual patient in an examination room to a systems approach that incorporates population management. Although many frustrations remain with physicians' ability to measure and influence the quality of care received by populations of patients, quality measures and monitoring have improved and should continue to improve. However, the perspective of patients and experienced physicians like Dr A also should be incorporated into quality measurement and management systems. Dr A clearly has the welfare of his patients at heart, and his experience and perspective could help improve his organization's systems of care and identify resources to deliver the best care. JAMA. 2012;307(9):956-964 www.jama.com	[Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	Landon@hcp.med.harvard.edu						Agency for Healthcare Research and Quality, 2009, NAT HEALTHC QUAL REP; *AM AC FAM PHYS AM, 2007, JOINT PRINC PAT CTR; Anderson GF, 2008, HEALTH AFFAIR, V27, P1718, DOI 10.1377/hlthaff.27.6.1718; Anderson GF, 2007, HEALTH AFFAIR, V26, P1481, DOI 10.1377/hlthaff.26.5.1481; Anderson GF, 2000, HEALTH AFFAIR, V19, P150, DOI 10.1377/hlthaff.19.3.150; [Anonymous], 2010, MIRROR MIRROR WALL P; Audet AMJ, 2005, HEALTH AFFAIR, V24, P843, DOI 10.1377/hlthaff.24.3.843; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Berenson RA, 2010, J GEN INTERN MED, V25, P619, DOI 10.1007/s11606-010-1290-4; Blank L, 2003, ANN INTERN MED, V138, P839, DOI 10.7326/0003-4819-138-10-200305200-00012; Buntin MB, 2011, HEALTH AFFAIR, V30, P464, DOI 10.1377/hlthaff.2011.0178; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Center for Medicare & Medicaid Services, NAT HLTH EXP ACC 200; Center for Medicare & Medicaid Services, PHYS QUAL REP IN; Center for Studying Health System Change, 1997, COMM TRACK STUD PHYS; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Chernew ME, 2011, HEALTH AFFAIR, V30, P51, DOI 10.1377/hlthaff.2010.0980; Chin MH, 2004, DIABETES CARE, V27, P2, DOI 10.2337/diacare.27.1.2; Damberg CL, 2010, AM J MANAG CARE, V16, P601; Davidoff F, 2008, ANN INTERN MED, V149, P670, DOI 10.7326/0003-4819-149-9-200811040-00009; Davis K, 2007, MIRROR MIRROR WALL I; Friedberg MW, 2011, J GEN INTERN MED, V26, P498, DOI 10.1007/s11606-010-1597-1; Friedberg MW, 2009, ANN INTERN MED, V151, P456, DOI 10.7326/0003-4819-151-7-200910060-00006; Friedberg MW, 2009, J GEN INTERN MED, V24, P162, DOI 10.1007/s11606-008-0856-x; Greene RA, 2004, AM J MANAG CARE, V10, P670; Hayward RA, 2007, AM J MANAG CARE, V13, P126; Hibbard JH, 2005, HEALTH AFFAIR, V24, P1150, DOI 10.1377/hlthaff.24.4.1150; Isaac T, 2009, ARCH INTERN MED, V169, P305, DOI 10.1001/archinternmed.2008.551; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; Kupersmith J, 2007, HEALTH AFFAIR, V26, pW156, DOI 10.1377/hlthaff.26.2.w156; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Landon BE, 2008, AM J MANAG CARE, V14, P377; Landon BE, 2007, NEW ENGL J MED, V356, P921, DOI 10.1056/NEJMsa062860; Landon BE, 2010, HEALTH AFFAIR, V29, P827, DOI 10.1377/hlthaff.2010.0016; McClellan MB, 2002, TECHNOLOGICAL CHANGE; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Merritt Hawkins, 2011 SURV FIN YEAR M; National Committee for Quality Assurance, 2010, STAT HLTH CAR QUAL R; Poon EG, 2003, J BIOMED INFORM, V36, P80, DOI 10.1016/S1532-0464(03)00061-3; Poon EG, 2010, MED CARE, V48, P203, DOI 10.1097/MLR.0b013e3181c16203; Reid RJ, 2010, HEALTH AFFAIR, V29, P835, DOI 10.1377/hlthaff.2010.0158; Rittenhouse DR, 2010, MED CARE RES REV, V67, P301, DOI 10.1177/1077558709353324; Rosenthal MB, 2005, JAMA-J AM MED ASSOC, V294, P1788, DOI 10.1001/jama.294.14.1788; Rosenthal MB, 2008, NEW ENGL J MED, V359, P1197, DOI 10.1056/NEJMp0804658; Shah NR, 2006, J AM MED INFORM ASSN, V13, P5, DOI 10.1197/jamia.M1868; Shekelle PG, 2002, QUAL SAF HEALTH CARE, V11, P6, DOI 10.1136/qhc.11.1.6; Simon SR, 2005, AM J MED, V118, P521, DOI 10.1016/j.amjmed.2004.12.023; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; Topel R, 2003, MEASURING GAINS MED; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Weiss KB, 2000, CHEST, V118, p53S, DOI 10.1378/chest.118.2_suppl.53S; Werner RM, 2009, JAMA-J AM MED ASSOC, V301, P1375, DOI 10.1001/jama.2009.423	56	11	11	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					956	964		10.1001/jama.2012.119	http://dx.doi.org/10.1001/jama.2012.119			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904CU	22298564				2023-01-03	WOS:000301172100024
J	Bucknall, CE; Miller, G; Lloyd, SM; Cleland, J; McCluskey, S; Cotton, M; Stevenson, RD; Cotton, P; McConnachie, A				Bucknall, C. E.; Miller, G.; Lloyd, S. M.; Cleland, J.; McCluskey, S.; Cotton, M.; Stevenson, R. D.; Cotton, P.; McConnachie, A.			Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EXACERBATIONS; DEPRESSION; THERAPY; ANXIETY	Objective To determine whether supported self management in chronic obstructive pulmonary disease (COPD) can reduce hospital readmissions in the United Kingdom. Design Randomised controlled trial. Setting Community based intervention in the west of Scotland. Participants Patients admitted to hospital with acute exacerbation of COPD. Intervention Participants in the intervention group were trained to detect and treat exacerbations promptly, with ongoing support for 12 months. Main outcome measures The primary outcome was hospital readmissions and deaths due to COPD assessed by record linkage of Scottish Morbidity Records; health related quality of life measures were secondary outcomes. Results 464 patients were randomised, stratified by age, sex, per cent predicted forced expiratory volume in 1 second, recent pulmonary rehabilitation attendance, smoking status, deprivation category of area of residence, and previous COPD admissions. No difference was found in COPD admissions or death (111/232 (48%) v 108/232 (47%); hazard ratio 1.05, 95% confidence interval 0.80 to 1.38). Return of health related quality of life questionnaires was poor (n=265; 57%), so that no useful conclusions could be made from these data. Pre-planned subgroup analysis showed no differential benefit in the primary outcome relating to disease severity or demographic variables. In an exploratory analysis, 42% (75/150) of patients in the intervention group were classified as successful self managers at study exit, from review of use of self management therapy. Predictors of successful self management on stepwise regression were younger age (P=0.012) and living with others (P=0.010). COPD readmissions/deaths were reduced in successful self managers compared with unsuccessful self managers (20/75 (27%) v 51/105 (49%); hazard ratio 0.44, 0.25 to 0.76; P=0.003). Conclusion Supported self management had no effect on time to first readmission or death with COPD. Exploratory subgroup analysis identified a minority of participants who learnt to self manage; this group had a significantly reduced risk of COPD readmission, were younger, and were more likely to be living with others.	[Bucknall, C. E.; Miller, G.; McCluskey, S.; Cotton, M.; Stevenson, R. D.] Glasgow Royal Infirm, Dept Resp Med, Glasgow G4 0SF, Lanark, Scotland; [Lloyd, S. M.; McConnachie, A.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Cleland, J.] Univ Aberdeen, Sch Med, Div Med & Dent Educ, Aberdeen AB9 2ZD, Scotland; [Cotton, P.] Univ Glasgow, Undergrad Med Sch, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Aberdeen; University of Glasgow	Bucknall, CE (corresponding author), Glasgow Royal Infirm, Dept Resp Med, Glasgow G4 0SF, Lanark, Scotland.	christine.bucknall@ggc.scot.nhs.uk	Lloyd, Suzanne/H-7424-2013; Cleland, Jennifer/AAI-9412-2020	Cleland, Jennifer/0000-0003-1433-9323	Chief Scientist Office, Scottish Health Department [CZH/4/246]; Boehringer Ingelheim; GlaxoSmithKline; Astra Zeneca; Chief Scientist Office [CZH/4/246] Funding Source: researchfish	Chief Scientist Office, Scottish Health Department; Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Astra Zeneca(AstraZeneca); Chief Scientist Office	In addition to funding from the Chief Scientist Office, Scottish Health Department (CZH/4/246), this study was supported by educational grants from Boehringer Ingelheim, GlaxoSmithKline, and Astra Zeneca. The commercial sponsors played no part in the design, implementation, or analysis of results from this trial or in the preparation of this paper.	ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Bischoff EWMA, 2011, THORAX, V66, P26, DOI 10.1136/thx.2009.127621; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; British Thoracic Society, 2006, BURD LUNG DIS; Clark NM, 2001, HEALTH EDUC BEHAV, V28, P769, DOI 10.1177/109019810102800608; Effing T, 2009, COCHRANE LIB; GIBSON PG, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001117; Gonzalez AV, 2011, THORAX, V66, P38, DOI 10.1136/thx.2010.141978; HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Kind P, 1996, QUALITY LIFE PHARMAC; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; McLoone P., 2004, CARSTAIRS SCORES SCO; Monninkhof E, 2003, THORAX, V58, P394, DOI 10.1136/thorax.58.5.394; National Clinical Guideline Centre, 2010, CHRON HEART FAIL NAT; Purdy S., 2010, AVOIDING HOSP ADMISS; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Royal College of Physicians British Thoracic Society British Lung Foundation, 2008, REP NAT CHRON OBSTR; Silverman J., 1996, ED GEN PRACT, V7, P288; Silverman J, 1997, ED GEN PRACTICE, V8, P16; Walters JA., 2010, COCHRANE DB SYST REV, V5; WIGAL JK, 1991, CHEST, V99, P1193, DOI 10.1378/chest.99.5.1193; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC; Wong AWM, 2008, CAN RESPIR J, V15, P361, DOI 10.1155/2008/569496; Woolhouse IS, 2001, THORAX, V56, P947, DOI 10.1136/thorax.56.12.947; Xu WN, 2008, AM J RESP CRIT CARE, V178, P913, DOI 10.1164/rccm.200804-619OC; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	153	156	1	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	2012	344								e1060	10.1136/bmj.e1060	http://dx.doi.org/10.1136/bmj.e1060			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908GM	22395923	Green Accepted, Green Published, hybrid, Green Submitted			2023-01-03	WOS:000301478900001
J	Yi, CX; Heppner, KM; Kirchner, H; Tong, J; Bielohuby, M; Gaylinn, BD; Muller, TD; Bartley, E; Davis, HW; Zhao, YM; Joseph, A; Kruthaupt, T; Ottaway, N; Kabra, D; Habegger, KM; Benoit, SC; Bidlingmaier, M; Thorner, MO; Perez-Tilve, D; Tschop, MH; Pfluger, PT				Yi, Chun-Xia; Heppner, Kristy M.; Kirchner, Henriette; Tong, Jenny; Bielohuby, Maximillian; Gaylinn, Bruce D.; Mueller, Timo D.; Bartley, Erin; Davis, Harold W.; Zhao, Yongmei; Joseph, Anupama; Kruthaupt, Traci; Ottaway, Nickki; Kabra, Dhiraj; Habegger, Kirk M.; Benoit, Stephen C.; Bidlingmaier, Martin; Thorner, Michael O.; Perez-Tilve, Diego; Tschoep, Matthias H.; Pfluger, Paul T.			The GOAT-Ghrelin System Is Not Essential for Hypoglycemia Prevention during Prolonged Calorie Restriction	PLOS ONE			English	Article							HORMONE SECRETAGOGUE RECEPTOR; UNACYLATED GHRELIN; INSULIN-SECRETION; ENERGY-BALANCE; PEPTIDE; ACYLTRANSFERASE; ADIPOSITY; STOMACH; HUMANS; MICE	Objective: Ghrelin acylation by ghrelin O-acyltransferase (GOAT) has recently been reported to be essential for the prevention of hypoglycemia during prolonged negative energy balance. Using a unique set of four different genetic loss-of-function models for the GOAT/ghrelin/growth hormone secretagogue receptor (GHSR) system, we thoroughly tested the hypothesis that lack-of-ghrelin activation or signaling would lead to hypoglycemia during caloric deprivation. Methodology: Male and female knockout (KO) mice for GOAT, ghrelin, GHSR, or both ghrelin and GHSR (dKO) were subjected to prolonged calorie restriction (40% of ad libitum chow intake). Body weight, fat mass, and glucose levels were recorded daily and compared to wildtype (WT) controls. Forty-eight hour blood glucose profiles were generated for each individual mouse when 2% or less body fat mass was reached. Blood samples were obtained for analysis of circulating levels of acyl-and desacyl-ghrelin, IGF-1, and insulin. Principal Findings: Chronic calorie restriction progressively decreased body weight and body fat mass in all mice regardless of genotype. When fat mass was depleted to 2% or less of body weight for 2 consecutive days, random hypoglycemic events occurred in some mice across all genotypes. There was no increase in the incidence of hypoglycemia in any of the four loss-of-function models for ghrelin signaling including GOAT KO mice. Furthermore, no differences in insulin or IGF-1 levels were observed between genotypes. Conclusion: The endogenous GOAT-ghrelin-GHSR system is not essential for the maintenance of euglycemia during prolonged calorie restriction.	[Yi, Chun-Xia; Mueller, Timo D.; Kabra, Dhiraj; Tschoep, Matthias H.; Pfluger, Paul T.] Helmholtz Ctr Munich, Inst Diabet & Obes, Neuherberg, Germany; [Heppner, Kristy M.; Kirchner, Henriette; Tong, Jenny; Bartley, Erin; Davis, Harold W.; Zhao, Yongmei; Joseph, Anupama; Kruthaupt, Traci; Ottaway, Nickki; Habegger, Kirk M.; Benoit, Stephen C.; Perez-Tilve, Diego] Univ Cincinnati, Metab Dis Inst, Cincinnati, OH USA; [Bielohuby, Maximillian; Bidlingmaier, Martin] Univ Munich, Med Klin Innenstadt, Endocrine Res Unit, D-8000 Munich, Germany; [Gaylinn, Bruce D.; Thorner, Michael O.] Univ Virginia, Dept Med, Div Endocrinol, Charlottesville, VA USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University System of Ohio; University of Cincinnati; University of Munich; University of Virginia	Yi, CX (corresponding author), Helmholtz Ctr Munich, Inst Diabet & Obes, Neuherberg, Germany.	paul.pfluger@helmholtz-muenchen.de	Yi, Chun-Xia/J-4068-2016; Tschoep, Matthias H/I-5443-2014; Gaylinn, Bruce/AAD-4663-2020; Müller, Timo D./AAZ-4445-2020; Pfluger, Paul T/A-3770-2019	Yi, Chun-Xia/0000-0003-1184-4615; Pfluger, Paul T/0000-0002-8118-7588; Habegger, Kirk/0000-0002-0342-5480; Muller, Timo/0000-0002-0624-9339; Bidlingmaier, Martin/0000-0002-4681-6668; Perez-Tilve, Diego/0000-0002-0351-4133; Gaylinn, Bruce/0000-0003-1195-0864; Tschoep, Matthias/0000-0002-4744-371X	Hilda and Preston Davis Foundation; Davis Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076037] Funding Source: NIH RePORTER	Hilda and Preston Davis Foundation; Davis Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Hilda and Preston Davis Foundation - Davis Foundation Postdoctoral Fellowship Program in Eating Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bednarek MA, 2000, J MED CHEM, V43, P4370, DOI 10.1021/jm0001727; Broglio F, 2004, J CLIN ENDOCR METAB, V89, P3062, DOI 10.1210/jc.2003-031964; Broglio F, 2001, J CLIN ENDOCR METAB, V86, P5083, DOI 10.1210/jc.86.10.5083; Delhanty PJD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011749; Gauna C, 2006, MOL CELL ENDOCRINOL, V251, P103, DOI 10.1016/j.mce.2006.03.040; Gutierrez JA, 2008, P NATL ACAD SCI USA, V105, P6320, DOI 10.1073/pnas.0800708105; Kiewiet RM, 2009, EUR J ENDOCRINOL, V161, P567, DOI 10.1530/EJE-09-0339; Kirchner H, 2009, NAT MED, V15, P741, DOI 10.1038/nm.1997; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lin LG, 2011, AGING CELL, V10, P996, DOI 10.1111/j.1474-9726.2011.00740.x; Liu JH, 2008, J CLIN ENDOCR METAB, V93, P1980, DOI 10.1210/jc.2007-2235; Lucidi P, 2002, DIABETES, V51, P2911, DOI 10.2337/diabetes.51.10.2911; Ma XJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016391; Pfluger PT, 2008, AM J PHYSIOL-GASTR L, V294, pG610, DOI 10.1152/ajpgi.00321.2007; Reimer MK, 2003, ENDOCRINOLOGY, V144, P916, DOI 10.1210/en.2002-220819; Sun YX, 2008, ENDOCRINOLOGY, V149, P843, DOI 10.1210/en.2007-0271; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107	19	40	42	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2012	7	2							e32100	10.1371/journal.pone.0032100	http://dx.doi.org/10.1371/journal.pone.0032100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926ZM	22363801	gold, Green Submitted, Green Published			2023-01-03	WOS:000302873700142
J	Degenhardt, L; Hall, W				Degenhardt, Louisa; Hall, Wayne			Extent of illicit drug use and dependence, and their contribution to the global burden of disease	LANCET			English	Article							CANNABIS USE; HEPATITIS-C; SUBSTANCE USE; HEROIN OVERDOSE; INJECT DRUGS; RISK-FACTORS; METHAMPHETAMINE USE; HEALTH OUTCOMES; MENTAL-HEALTH; YOUNG-PEOPLE	This paper summarises data for the prevalence, correlates, and probable adverse health consequences of problem use of amphetamines, cannabis, cocaine, and opioids. We discuss findings from systematic reviews of the prevalence of illicit drug use and dependence, remission from dependence, and mortality in illicit drug users, and evidence for acute and chronic effects of illicit drug use. We outline the regional and global distribution of use and estimated health burden from illicit drugs. These distributions are likely to be underestimates because they have not included all adverse outcomes of drug use and exclude those of cannabis-the mostly widely used illicit drug. In high-income countries, illicit drug use contributes less to the burden of disease than does tobacco but a substantial proportion of that due to alcohol. The major adverse health effects of cannabis use are dependence and probably psychotic disorders and other mental disorders. The health-related harms of cannabis use differ from those of amphetamine, cocaine, and opioid use, in that cannabis contributes little to mortality. Intelligent policy responses to drug problems need better data for the prevalence of different types of illicit drug use and the harms that their use causes globally. This need is especially urgent in high-income countries with substantial rates of illicit drug use and in low-income and middle-income countries close to illicit drug production areas.	[Degenhardt, Louisa] Univ New S Wales, Fac Med, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Degenhardt, Louisa] Univ Melbourne, Sch Populat Hlth, Burnet Inst, Melbourne, Vic, Australia; [Degenhardt, Louisa] Univ Melbourne, Sch Populat Hlth, Ctr Hlth Policy Programs & Econ, Melbourne, Vic, Australia; [Hall, Wayne] Univ Queensland, Clin Res Ctr, Brisbane, Qld 4072, Australia; [Hall, Wayne] Univ Queensland, Ctr Youth Subst Abuse Res, Brisbane, Qld 4072, Australia	University of New South Wales Sydney; Burnet Institute; University of Melbourne; University of Melbourne; University of Queensland; University of Queensland	Degenhardt, L (corresponding author), Univ New S Wales, Fac Med, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	l.degenhardt@unsw.edu.au	Hall, Wayne D/A-3283-2008; Degenhardt, Louisa J/D-4515-2012	Hall, Wayne D/0000-0003-1984-0096; Degenhardt, Louisa J/0000-0002-8513-2218				Ali H, 2010, 314 NDARC U NSW; [Anonymous], 2010, LANCET, V375, P1319, DOI 10.1016/S0140-6736(10)60556-9; [Anonymous], WORLD DRUG REP 2011; [Anonymous], 2001, HLTH PSYCHOL CONSEQU; [Anonymous], 307 NDARC U NSW; [Anonymous], HEP C VIR PROJ WORK; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; APA, 2000, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890423349, DOI 10.1176/APPI.BOOKS.9780890423349]; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; Babor TF., 2010, DRUG POLICY PUBLIC G, V2nd ed., DOI [10.1093/oso/9780198818014.001.0001, DOI 10.1093/OSO/9780198818014.001.0001]; Bachman J. G, 1997, SMOKING DRINKING DRU; Baggaley RF, 2006, AIDS, V20, P805, DOI 10.1097/01.aids.0000218543.46963.6d; Ball A L, 1998, Public Health Rep, V113 Suppl 1, P170; Beautrais AL, 1999, ADDICTION, V94, P1155, DOI 10.1046/j.1360-0443.1999.94811555.x; Begg S., 2007, BURDEN DIS INJURY AU; Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0; Boot BP, 2000, LANCET, V355, P1818, DOI 10.1016/S0140-6736(00)02276-5; Borgwardt SJ, 2008, BIOL PSYCHIAT, V64, P966, DOI 10.1016/j.biopsych.2008.05.011; Bucello C, 2010, 308 NDARC U NSW; Calabria B., 2008, 293 NDARC U NSW; Calabria B, 2010, ADDICT BEHAV, V35, P741, DOI 10.1016/j.addbeh.2010.03.019; Calabria B, 2010, DRUG ALCOHOL REV, V29, P318, DOI 10.1111/j.1465-3362.2009.00149.x; Cannon DS, 1993, PSYCHOL ASSESSMENT, V5, P62; Charlson F, 2009, PHARMACOEPIDEM DR S, V18, P93, DOI 10.1002/pds.1694; COHEN DA, 1994, PEDIATRICS, V94, P368; Collins D, 2007, COSTS TOBACCO ALCOHO; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Coutinho RA, 1998, BRIT MED J, V317, P424, DOI 10.1136/bmj.317.7156.424; Daniel JZ, 2009, DRUG ALCOHOL REV, V28, P142, DOI 10.1111/j.1465-3362.2008.00042.x; Darke S, 1996, ADDICTION, V91, P1765, DOI 10.1111/j.1360-0443.1996.tb03800.x; Darke S., 2006, MORTALITY ILLICIT DR; Darke S., 2011, LIFE HEROIN USER TYP; Darke S, 2008, DRUG ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702; Darke S, 2006, ADDICTION, V101, P1771, DOI 10.1111/j.1360-0443.2006.01601.x; Darke S, 2010, DRUG ALCOHOL REV, V29, P202, DOI 10.1111/j.1465-3362.2009.00099.x; Degenhardt L, 2006, SEX TRANSM INFECT, V82, pIII56, DOI 10.1136/sti.2005.019273; Degenhardt L, 2004, COMP QUANTIFICATION, P1109; Degenhardt L, 2010, NDARC MONOGRAPH, V62; Degenhardt L, COMP DRUG SITUATION; Degenhardt L, 2010, 310 NDARC U NSW; Degenhardt L, 2006, CAN J PSYCHIAT, V51, P556, DOI 10.1177/070674370605100903; Degenhardt L, 2008, PLOS MED, V5, P1053, DOI 10.1371/journal.pmed.0050141; Degenhardt Louisa, 2010, Lancet, V376, P285, DOI 10.1016/S0140-6736(10)60742-8; Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V117, P85, DOI 10.1016/j.drugalcdep.2010.11.032; Degenhardt L, 2011, DRUG ALCOHOL DEPEN, V113, P88, DOI 10.1016/j.drugalcdep.2010.07.026; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Degenhardt L, 2010, DRUG ALCOHOL DEPEN, V108, P84, DOI 10.1016/j.drugalcdep.2009.12.001; Degenhardt L, 2010, DRUG ALCOHOL DEPEN, V107, P1, DOI 10.1016/j.drugalcdep.2009.09.009; Degenhardt L, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000133; Degenhardt L, 2009, ADDICTION, V104, P1466, DOI 10.1111/j.1360-0443.2009.02715.x; Donoghoe M, 1996, QUANTIFYING GLOBAL H; Donoghoe MC, 1998, SOC AS AIDS, P42; Dore GJ, 2002, J GASTROEN HEPATOL, V17, P423, DOI 10.1046/j.1440-1746.2002.02730.x; English D.R., 1995, QUANTIFICATION DRUG; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2004, COMP QUANTIFICATION, P983; Fergusson DM, 2008, DRUG ALCOHOL DEPEN, V96, P165, DOI 10.1016/j.drugalcdep.2008.03.003; FERGUSSON DM, 1994, J AM ACAD CHILD PSY, V33, P1122, DOI 10.1097/00004583-199410000-00008; FLEWELLING RL, 1990, J MARRIAGE FAM, V52, P171, DOI 10.2307/352848; Foster G, 2004, HEPATITIS C INJECTIN, P79; Glantz MD, 2009, PSYCHOL MED, V39, P1365, DOI 10.1017/S0033291708004510; Gossop M, 1996, BRIT MED J, V313, P402; Hagan H, 2007, INT J DRUG POLICY, V18, P341, DOI 10.1016/j.drugpo.2007.01.016; Hall W, 1999, ADDICTION, V94, P1541, DOI 10.1046/j.1360-0443.1999.9410154110.x; Hall W, 2003, CANNABIS USE DEPENDE; Hall W., 2008, INT ENCY PUBLIC HLTH, P523; Hall W, 2007, CURR OPIN PSYCHIATR, V20, P393, DOI 10.1097/YCO.0b013e32812144cc; Hall W, 2009, LANCET, V374, P1383, DOI 10.1016/S0140-6736(09)61037-0; Hall W, 2009, ADDICT BEHAV, V34, P526, DOI 10.1016/j.addbeh.2009.03.010; Hall WD, 2000, MED J AUSTRALIA, V173, P528, DOI 10.5694/j.1326-5377.2000.tb139321.x; Hall WD, 2005, DRUG ALCOHOL REV, V24, P39, DOI 10.1080/09595230500126698; Hallinan R, 2005, J GASTROEN HEPATOL, V20, P1082, DOI 10.1111/j.1440-1746.2005.03882.x; Hartnoll R, 1997, ESTIMATING PREVALENC, P247; HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64; Hickman M., 2002, B NARCOTICS, VLIV, P15, DOI DOI 10.1016/J.DRUGOPO.2005.02.05; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jurgens R, 2010, LANCET, V376, P475, DOI 10.1016/S0140-6736(10)60830-6; Kandel DB, 2006, ADDICTION, V101, P470, DOI 10.1111/j.1360-0443.2006.01426.x; KANDEL DB, 1987, INT J ADDICT, V22, P319, DOI 10.3109/10826088709027433; Karch SB, 2002, KARCHS PATHOLOGY DRU; Kaye S, 2007, ADDICTION, V102, P1204, DOI 10.1111/j.1360-0443.2007.01874.x; Kelly E, 2004, DRUG ALCOHOL REV, V23, P319, DOI 10.1080/09595230412331289482; Kessler R. C., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P511; Kuhns JB, 2009, ADDICTION, V104, P1122, DOI 10.1111/j.1360-0443.2009.02583.x; LARANCE B, 2005, RAPID ASSESSMENT PER; Large M, 2011, ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; LaScala E, 2005, PREVENTING HARMFUL SUBSTANCE USE: THE EVIDENCE BASE FOR POLICY AND PRACTICE, P67, DOI 10.1002/9780470713624.ch6; Laumon B, 2005, BRIT MED J, V331, P1371, DOI 10.1136/bmj.38648.617986.1F; Limberg W., 2004, HEPATITIS C INJECTIN, P21; LIPKUS IM, 1994, HEALTH PSYCHOL, V13, P149, DOI 10.1037/0278-6133.13.2.149; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lynskey M, 2000, ADDICTION, V95, P1621, DOI 10.1046/j.1360-0443.2000.951116213.x; LYNSKEY MT, 1995, J ABNORM CHILD PSYCH, V23, P281, DOI 10.1007/BF01447558; LYNSKEY MT, 1994, ADDICTION, V89, P1277, DOI 10.1111/j.1360-0443.1994.tb03306.x; MacCoun R., 2003, RES DRUGS CRIME LINK, P65; MacDonald M, 1996, EPIDEMIOL REV, V18, P137, DOI 10.1093/oxfordjournals.epirev.a017921; Macleod J, 2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; MADDAHIAN E, 1988, ADDICT BEHAV, V13, P191, DOI 10.1016/0306-4603(88)90011-1; Maloney E, 2007, ADDICTION, V102, P1933, DOI 10.1111/j.1360-0443.2007.01971.x; Marincovich B, 2003, SEX TRANSM INFECT, V79, P160, DOI 10.1136/sti.79.2.160; Marshall BDL, 2010, ADDICTION, V105, P991, DOI 10.1111/j.1360-0443.2010.02932.x; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; Mathers BM, 2010, LANCET, V375, P1014, DOI 10.1016/S0140-6736(10)60232-2; McAllister William B., 2000, DRUG DIPLOMACY 20 CE; McKetin R, 2006, DRUG ALCOHOL DEPEN, V85, P198, DOI 10.1016/j.drugalcdep.2006.04.007; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; MOORE MH, 1990, CRIME JUSTICE, V13, P109, DOI 10.1086/449174; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Murray CJL, 2007, LANCET, V370, P109, DOI 10.1016/S0140-6736(07)61064-2; Murray CJ, 1996, GLOBAL BURDEN DIS CO; Murray Y.M., 2008, GETTY MUSEUM REPRESE; NEEDLE RH, 1990, J MARRIAGE FAM, V52, P157, DOI 10.2307/352847; NELSON P, 2010, 309 NDARC U NSW; Nelson PK, 2011, LANCET, V378, P571, DOI 10.1016/S0140-6736(11)61097-0; Pedraza MA, 1999, J ACQ IMMUN DEF SYND, V21, P120; PERLMAN DC, 1995, CLIN INFECT DIS, V21, P1253, DOI 10.1093/clinids/21.5.1253; Randall D, 2011, AUST NZ J PUBL HEAL, V35, P220, DOI 10.1111/j.1753-6405.2011.00682.x; Rehm J, 2004, COMP QUANTIFICATION, P959; Rehm J, 2007, J STUD ALCOHOL DRUGS, V68, P886, DOI 10.15288/jsad.2007.68.886; Reuter P., 2009, REPORT GLOBAL ILLICI; Reuter Peter, 1983, DISORGANIZED CRIME E; Rossow I, 1999, ADDICTION, V94, P209, DOI 10.1046/j.1360-0443.1999.9422095.x; SATEL SL, 1991, AM J PSYCHIAT, V148, P495; Singleton J, 2009, DRUG ALCOHOL DEPEN, V105, P1, DOI 10.1016/j.drugalcdep.2009.05.028; Strang J, 2012, LANCET, V379, P71, DOI 10.1016/S0140-6736(11)61674-7; Strathdee SA, 2010, LANCET, V376, P268, DOI 10.1016/S0140-6736(10)60743-X; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Toumbourou JW, 2007, LANCET, V369, P1391, DOI 10.1016/S0140-6736(07)60369-9; Townsend L, 2007, CLIN CHILD FAM PSYCH, V10, P295, DOI 10.1007/s10567-007-0023-7; Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070; *UN OFF DRUGS CRIM, 2009, WORLD DRUG REP 2009; UNODC, 2008, WORLD DRUG REP, V2008, P173, DOI [10.18356/4713aa6f-en, DOI 10.18356/4713AA6F-EN]; Vandenbroucke JP., 2007, EXPLAN ELAB, V4, P1628; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; Volkow ND, 2004, MOL PSYCHIATR, V9, P557, DOI 10.1038/sj.mp.4001507; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; WHO, 2004, GLOB STAT REP ALC; Wolfe D, 2010, LANCET, V376, P355, DOI 10.1016/S0140-6736(10)60832-X; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization, 2010, IMAGE SUBSTANCE; World Health Organization, 1993, ICD 10 CLASS MENT BE	143	791	801	5	182	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 7	2012	379	9810					55	70		10.1016/S0140-6736(11)61138-0	http://dx.doi.org/10.1016/S0140-6736(11)61138-0			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	873WC	22225671				2023-01-03	WOS:000298913000038
J	Marimuthu, G; Kumari, S; Kandasamy, M; Raghunathan, S; Saberwal, G				Marimuthu, Ganesan; Kumari, Sangita; Kandasamy, Muthukrishnakumar; Raghunathan, Srivatsan; Saberwal, Gayatri			Maintaining patents protecting biologics or small-molecule drugs	NATURE BIOTECHNOLOGY			English	Editorial Material									[Marimuthu, Ganesan; Kumari, Sangita; Kandasamy, Muthukrishnakumar; Raghunathan, Srivatsan; Saberwal, Gayatri] Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India		Marimuthu, G (corresponding author), Inst Bioinformat & Appl Biotechnol, Bangalore, Karnataka, India.	gayatri@ibab.ac.in						Cukier KN, 2006, NAT BIOTECHNOL, V24, P249, DOI 10.1038/nbt0306-249; Johnson L.A., 2011, ASS PRESS       0725; Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399; Lemley MA, 2001, NORTHWEST U LAW REV, V95, P1495; Ouellette Lisa Larrimore, 2010, MICH TELECOMM TECH L, V17, P300; Parida DK, 2008, NAT BIOTECHNOL, V26, P763, DOI 10.1038/nbt0708-763; Putnam J., 1996, 5741 NBER; Quinn G., 2011, IP WATCHDOG     0128; Walsh G, 2006, NAT BIOTECHNOL, V24, P769, DOI 10.1038/nbt0706-769	9	1	1	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2012	30	1					50	53		10.1038/nbt.2082	http://dx.doi.org/10.1038/nbt.2082			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	876MC	22231094				2023-01-03	WOS:000299110600017
J	Schneider, A; Thiel, C; Rindermann, J; DeRossi, C; Popovici, D; Hoffmann, GF; Grone, HJ; Korner, C				Schneider, Anette; Thiel, Christian; Rindermann, Jan; DeRossi, Charles; Popovici, Diana; Hoffmann, Georg F.; Groene, Hermann-Josef; Koerner, Christian			Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice	NATURE MEDICINE			English	Article							SYNDROME TYPE 1A; SUPPLEMENTATION; DISEASE; PMM2; GENE	Congenital disorder of glycosylation-Ia (CDG-Ia, also known as PMM2-CDG) is caused by mutations in the gene that encodes phosphomannomutase 2 (PMM2, EC 5.4.2.8) leading to a multisystemic disease with severe psychomotor and mental retardation. In a hypomorphic Pmm2 mouse model, we were able to overcome embryonic lethality by feeding mannose to pregnant dams. The results underline the essential role of glycosylation in embryonic development and may open new treatment options for this disease.	[Schneider, Anette; Thiel, Christian; DeRossi, Charles; Popovici, Diana; Hoffmann, Georg F.; Koerner, Christian] Ctr Child & Adolescent Med, Heidelberg, Germany; [Schneider, Anette; Thiel, Christian; DeRossi, Charles; Popovici, Diana; Hoffmann, Georg F.; Koerner, Christian] Ctr Metab Dis Heidelberg, Dept Kinderheilkunde 1, Heidelberg, Germany; [Rindermann, Jan] Inst Biochem II, Gottingen, Germany; [Groene, Hermann-Josef] German Canc Res Ctr Heidelberg, Div Cellular & Mol Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Korner, C (corresponding author), Ctr Child & Adolescent Med, Heidelberg, Germany.	christian.koerner@med.uni-heidelberg.de		Thiel, Christian/0000-0001-6419-8747	Deutsche Forschungsgemeinschaft [KO 2152/3-2, TH1461/2-1]; Fritz Thyssen Stiftung; US National Institutes of Health [R21 HD062914]; Rocket Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD062914] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Fritz Thyssen Stiftung; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rocket Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	The work of C.K. and C.T. was supported by grants of the Deutsche Forschungsgemeinschaft (KO 2152/3-2 and TH1461/2-1) and the Fritz Thyssen Stiftung. The work of C.D. was supported by a US National Institutes of Health grant (R21 HD062914) and The Rocket Fund.	Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Grunewald S, 2009, BBA-MOL BASIS DIS, V1792, P827, DOI 10.1016/j.bbadis.2009.01.003; Kjaergaard S, 1998, ACTA PAEDIATR, V87, P884, DOI 10.1080/080352598750013680; Kjaergaard S, 1999, EUR J HUM GENET, V7, P884, DOI 10.1038/sj.ejhg.5200398; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; Matthijs G, 1998, AM J HUM GENET, V62, P542, DOI 10.1086/301763; Matthijs G, 1997, NAT GENET, V16, P88, DOI 10.1038/ng0597-88; Mayatepek E, 1998, EUR J PEDIATR, V157, P605, DOI 10.1007/s004310050889; Mayatepek E, 1997, ACTA PAEDIATR, V86, P1138, DOI 10.1111/j.1651-2227.1997.tb14825.x; Panneerselvam K, 1996, J CLIN INVEST, V97, P1478, DOI 10.1172/JCI118570; Silvaggi NR, 2006, J BIOL CHEM, V281, P14918, DOI 10.1074/jbc.M601505200; Thiel C, 2006, MOL CELL BIOL, V26, P5615, DOI 10.1128/MCB.02391-05	12	56	60	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2012	18	1					71	73		10.1038/nm.2548	http://dx.doi.org/10.1038/nm.2548			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	875GO	22157680				2023-01-03	WOS:000299018600031
J	Bowden-Jones, H; George, S				Bowden-Jones, Henrietta; George, Sanju			A PATIENT'S JOURNEY Gambling addiction	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bowden-Jones, Henrietta] Cent NW London NHS Fdn Trust, Addict Directorate, London NW1 2PL, England; [Bowden-Jones, Henrietta] Univ London Imperial Coll Sci Technol & Med, Dept Med, London SW7 2AZ, England; [Bowden-Jones, Henrietta] Natl Problem Gambling Clin, London W1D 3HZ, England; [George, Sanju] Birmingham & Solihull Mental Hlth NHS Fdn Trust, Birmingham B37 7UR, W Midlands, England	Imperial College London	Bowden-Jones, H (corresponding author), Cent NW London NHS Fdn Trust, Addict Directorate, London NW1 2PL, England.	h.bowden-jones02@imperial.ac.uk							0	4	4	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 30	2011	343								d7789	10.1136/bmj.d7789	http://dx.doi.org/10.1136/bmj.d7789			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874TQ	22209819	Bronze			2023-01-03	WOS:000298981400001
J	Carson, JL; Terrin, ML; Noveck, H; Sanders, DW; Chaitman, BR; Rhoads, GG; Nemo, G; Dragert, K; Beaupre, L; Hildebrand, K; Macaulay, W; Lewis, C; Cook, DR; Dobbin, G; Zakriya, KJ; Apple, FS; Horney, RA; Magaziner, J				Carson, Jeffrey L.; Terrin, Michael L.; Noveck, Helaine; Sanders, David W.; Chaitman, Bernard R.; Rhoads, George G.; Nemo, George; Dragert, Karen; Beaupre, Lauren; Hildebrand, Kevin; Macaulay, William; Lewis, Courtland; Cook, Donald Richard; Dobbin, Gwendolyn; Zakriya, Khwaja J.; Apple, Fred S.; Horney, Rebecca A.; Magaziner, Jay		FOCUS Investigators	Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL; TRIAL	BACKGROUND The hemoglobin threshold at which postoperative red-cell transfusion is warranted is controversial. We conducted a randomized trial to determine whether a higher threshold for blood transfusion would improve recovery in patients who had undergone surgery for hip fracture. METHODS We enrolled 2016 patients who were 50 years of age or older, who had either a history of or risk factors for cardiovascular disease, and whose hemoglobin level was below 10 g per deciliter after hip-fracture surgery. We randomly assigned patients to a liberal transfusion strategy (a hemoglobin threshold of 10 g per deciliter) or a restrictive transfusion strategy (symptoms of anemia or at physician discretion for a hemoglobin level of <8 g per deciliter). The primary outcome was death or an inability to walk across a room without human assistance on 60-day follow-up. RESULTS A median of 2 units of red cells were transfused in the liberal-strategy group and none in the restrictive-strategy group. The rates of the primary outcome were 35.2% in the liberal-strategy group and 34.7% in the restrictive-strategy group (odds ratio in the liberal-strategy group, 1.01; 95% confidence interval [CI], 0.84 to 1.22), for an absolute risk difference of 0.5 percentage points (95% CI, -3.7 to 4.7). The rates of in-hospital acute coronary syndrome or death were 4.3% and 5.2%, respectively (absolute risk difference, -0.9%; 99% CI, -3.3 to 1.6), and rates of death on 60-day follow-up were 7.6% and 6.6%, respectively (absolute risk difference, 1.0%; 99% CI, -1.9 to 4.0). The rates of other complications were similar in the two groups. CONCLUSIONS A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk. (Funded by the National Heart, Lung, and Blood Institute; FOCUS ClinicalTrials.gov number, NCT00071032.)	[Carson, Jeffrey L.; Noveck, Helaine; Dragert, Karen] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, New Brunswick, NJ 08903 USA; [Terrin, Michael L.; Magaziner, Jay] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Zakriya, Khwaja J.] Johns Hopkins Bayview Med Ctr, Baltimore, MD USA; [Sanders, David W.] Univ Western Ontario, Div Orthopaed Surg, London, ON, Canada; [Beaupre, Lauren] Univ Alberta, Dept Phys Therapy & Surg, Edmonton, AB, Canada; [Beaupre, Lauren] Univ Alberta, Div Orthopaed Surg, Edmonton, AB, Canada; [Hildebrand, Kevin] Univ Calgary, Div Orthoped Surg, Calgary, AB, Canada; [Cook, Donald Richard] Univ Calgary, Dept Med, Calgary, AB, Canada; [Dobbin, Gwendolyn] QEII Hlth Sci Ctr, Dept Orthoped Surg, Halifax, NS, Canada; [Chaitman, Bernard R.] St Louis Univ, Sch Med, Dept Med, St Louis, MO 63103 USA; [Rhoads, George G.] Univ Med & Dent New Jersey, Sch Publ Hlth, Dept Epidemiol, Piscataway, NJ 08854 USA; [Nemo, George] NHLBI, Transfus Med & Cellular Therapeut Branch, Div Blood Dis & Resources, Bethesda, MD 20892 USA; [Horney, Rebecca A.] Vet Affairs Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA; [Macaulay, William] Columbia Univ, Dept Orthoped Surg, New York Presbyterian Hosp, New York, NY USA; [Lewis, Courtland] Hartford Hosp, Hartford, CT 06115 USA; [Apple, Fred S.] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; [Apple, Fred S.] Minneapolis Med Res Fdn Inc, Hennepin Cty Med Ctr, Minneapolis, MN USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine; Western University (University of Western Ontario); University of Alberta; University of Alberta; University of Calgary; University of Calgary; Queen Elizabeth II Health Sciences Centre; Saint Louis University; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Columbia University; NewYork-Presbyterian Hospital; Hartford Hospital; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; Minneapolis Medical Research Foundation	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu	Hug, Balthasar L./G-1568-2010; Naudie, Douglas D.R./B-5779-2015; Hildebrand, Kevin/N-8394-2015	Hildebrand, Kevin/0000-0001-8786-9021; /0000-0001-6570-3290; Macaulay, William/0000-0003-2684-0676; Coles, Chad/0000-0003-0454-3507	National Heart, Lung, and Blood Institute [U01 HL073958, U01 HL074815]; Amgen; Orthopaedic Associates of Hartford; Abbott Diagnostics; Ortho Clinical Diagnostics; Instrumentation Laboratories; Siemens; Roche Diagnostics; BioRad; Response Biomedical; Radiometer; BRAHMS; Alere; Eli Lily; Sanofi-Aventis; Novartis; Merck; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL073958, U01HL074815] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028747] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Amgen(Amgen); Orthopaedic Associates of Hartford; Abbott Diagnostics(Abbott Laboratories); Ortho Clinical Diagnostics; Instrumentation Laboratories; Siemens(Siemens AG); Roche Diagnostics; BioRad; Response Biomedical; Radiometer; BRAHMS; Alere; Eli Lily; Sanofi-Aventis(Sanofi-Aventis); Novartis(Novartis); Merck(Merck & Company); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported in part by grants from the National Heart, Lung, and Blood Institute (U01 HL073958 and U01 HL074815).; Dr. Carson reports receiving grant support to his institution from Amgen; Dr. Lewis, receiving a salary from the Orthopaedic Associates of Hartford, receiving a stipend for serving as president of the Hartford County Medical Association, and providing expert testimony representing the American Academy of Orthopaedic Surgery on the Medicare Evidence Development and Coverage Advisory Committee; Dr. Apple, serving as a scientific advisory board member for Abbott Laboratories, Alere, Beckman Coulter, Ortho Clinical Diagnostics, and Instrumentation Laboratories, receiving consulting fees from Abbott Diagnostics, Ortho Clinical Diagnostics, and Instrumentation Laboratories, receiving grant support to his institution from Abbott Diagnostics, Siemens, Ortho Clinical Diagnostics, Roche Diagnostics, BioRad, Response Biomedical, Radiometer, and BRAHMS, and receiving lecture fees and travel expenses from Abbott Diagnostics and Alere; Dr. Magazine, serving as a board member for Amgen, Novartis, and GlaxoSmithKline and receiving consulting fees from Eli Lily, Sanofi-Aventis, and Amgen, grant support to his institution from Novartis, Merck, and Eli Lilly, and lecture fees from Novartis. No other potential conflict of interest relevant to this article was reported.	Alpert JS, 2001, J AM COLL CARDIOL, V37, P973; Anderson SA, 2007, TRANSFUSION, V47, P582, DOI 10.1111/j.1537-2995.2007.01159.x; [Anonymous], 2011, REP DEP HLTH HUM SER; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Carson JL, 2006, TRANSFUSION, V46, P2192, DOI 10.1111/j.1537-2995.2006.01056.x; Cobain TJ, 2007, COCHRANE DB SYST REV, V17, P1; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011	14	875	908	0	51	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2011	365	26					2453	2462		10.1056/NEJMoa1012452	http://dx.doi.org/10.1056/NEJMoa1012452			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868SD	22168590	Green Accepted			2023-01-03	WOS:000298544600006
J	Cambien, B; Richard-Fiardo, P; Karimdjee, BF; Martini, V; Ferrua, B; Pitard, B; Schmid-Antomarchi, H; Schmid-Alliana, A				Cambien, Beatrice; Richard-Fiardo, Peggy; Karimdjee, Babou F.; Martini, Violette; Ferrua, Bernard; Pitard, Bruno; Schmid-Antomarchi, Heidy; Schmid-Alliana, Annie			CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFR beta in Colorectal Carcinoma	PLOS ONE			English	Article							FACTOR RECEPTOR; TUMOR STROMA; TYROSINE KINASES; CCR5 ANTAGONIST; GASTRIC-CANCER; RANTES LEVELS; EXPRESSION; BREAST; COLON; CELLS	Increased CCL5 levels are markers of an unfavourable outcome in patients with melanoma, breast, cervical, prostate, gastric or pancreatic cancer. Here, we have assessed the role played by CCL5/CCR5 interactions in the development of colon cancer. To do so, we have examined a number of human colorectal carcinoma clinical specimens and found CCL5 and its receptors over-expressed within primary as well as liver and pulmonary metastases of patients compared to healthy tissues. In vitro, CCL5 increased the growth and migratory responses of colon cancer cells from both human and mouse origins. In addition, systemic treatment of mice with CCL5-directed antibodies reduced the extent of development of subcutaneous colon tumors, of liver metastases and of peritoneal carcinosis. Consistently, we found increased numbers of CD45-immunoreactive cells within the stroma of the remaining lesions as well as at the interface with the healthy tissue. In contrast, selective targeting of CCR5 through administration of TAK-779, a CCR5 antagonist, only partially compromised colon cancer progression. Furthermore, CCL5 neutralization rendered the tumors more sensitive to a PDGFR beta-directed strategy in mice, this combination regimen offering the greatest protection against liver metastases and suppressing macroscopic peritoneal carcinosis. Collectively, our data demonstrate the involvement of CCL5 in the pathogenesis of colorectal carcinoma and point to its potential value as a therapeutic target.	[Cambien, Beatrice; Richard-Fiardo, Peggy; Karimdjee, Babou F.; Martini, Violette; Schmid-Antomarchi, Heidy; Schmid-Alliana, Annie] Univ Nice Sophia Antipolis, UFR Med, Nice, France; [Cambien, Beatrice; Richard-Fiardo, Peggy; Karimdjee, Babou F.; Martini, Violette; Schmid-Antomarchi, Heidy; Schmid-Alliana, Annie] Fac Med Nice, INSERM, UMR 576, F-06034 Nice, France; [Karimdjee, Babou F.] Clin St Jean, Cagnes Sur Mer, France; [Ferrua, Bernard] Fac Med Nice, INSERM, U895, F-06034 Nice, France; [Pitard, Bruno] INSERM, U915, Nantes, France; [Pitard, Bruno] In Cell Art, Nantes, France	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cambien, B (corresponding author), Univ Nice Sophia Antipolis, UFR Med, Nice, France.	cambien@unice.fr	Cambien, Béatrice/AAD-8973-2021; Pitard, Bruno F/K-9270-2015; SCHMID-ALLIANA, Annie/P-4366-2016	Cambien, Béatrice/0000-0002-6914-0525; SCHMID-ALLIANA, Annie/0000-0003-2321-7408	Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer [3707]	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	This work was supported in part by the Institut National de la Sante et de la Recherche Medicale and by the Association pour la Recherche sur le Cancer (Grant 3707). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bailey C, 2007, CLIN EXP METASTAS, V24, P121, DOI 10.1007/s10585-007-9060-3; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bhardwaj B, 1996, CLIN CANCER RES, V2, P773; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cambien B, 2009, BRIT J CANCER, V100, P1755, DOI 10.1038/sj.bjc.6605078; Cany J, 2011, J HEPATOL, V54, P115, DOI 10.1016/j.jhep.2010.06.027; COLTRERA MD, 1995, CANCER RES, V55, P2703; De Jong KP, 1998, HEPATOLOGY, V28, P971, DOI 10.1002/hep.510280411; Duell EJ, 2006, CANCER EPIDEM BIOMAR, V15, P726, DOI 10.1158/1055-9965.EPI-05-0797; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Erreni M, 2009, METHOD ENZYMOL, V460, P105, DOI 10.1016/S0076-6879(09)05205-7; Grimminger F, 2010, NAT REV DRUG DISCOV, V9, P956, DOI 10.1038/nrd3297; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; HEMMING AW, 1992, J SURG ONCOL, V51, P147, DOI 10.1002/jso.2930510304; Horst D, 2009, CANCER-AM CANCER SOC, V115, P4946, DOI 10.1002/cncr.24564; ITO M, 1990, VIRCHOWS ARCH B, V59, P173, DOI 10.1007/BF02899402; Kaplan CD, 2006, VACCINE, V24, P6994, DOI 10.1016/j.vaccine.2006.04.071; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kawai T, 1997, LAB INVEST, V77, P431; Kim HK, 2003, EUR J CANCER, V39, P184, DOI 10.1016/S0959-8049(02)00596-8; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1800, DOI 10.1002/cncr.20973; Kitadai Y, 2006, AM J PATHOL, V169, P2054, DOI 10.2353/ajpath.2006.060653; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Kuwai T, 2008, CLIN EXP METASTAS, V25, P477, DOI 10.1007/s10585-008-9153-7; Luboshits G, 1999, CANCER RES, V59, P4681; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; McIlroy D, 2009, MOL THER, V17, P1473, DOI 10.1038/mt.2009.84; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Niwa Y, 2001, CLIN CANCER RES, V7, P285; Ostman A, 2004, CYTOKINE GROWTH F R, V15, P275, DOI 10.1016/j.cytogfr.2004.03.002; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Pradelli E, 2009, INT J CANCER, V125, P2586, DOI 10.1002/ijc.24665; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; Singer CF, 2004, ENDOCR-RELAT CANCER, V11, P861, DOI 10.1677/erc.1.00801; Sugasawa H, 2008, INT J CANCER, V122, P2535, DOI 10.1002/ijc.23401; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tanaka T, 2005, CANCER SCI, V96, P317, DOI 10.1111/j.1349-7006.2005.00059.x; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Tsukishiro S, 2006, GYNECOL ONCOL, V102, P542, DOI 10.1016/j.ygyno.2006.01.029; Vaday GG, 2006, PROSTATE, V66, P124, DOI 10.1002/pros.20306; Vitale S, 2007, GUT, V56, P365, DOI 10.1136/gut.2005.088989; Wehler TC, 2008, ONCOL REP, V19, P697; Yaal-Hahoshen N, 2006, CLIN CANCER RES, V12, P4474, DOI 10.1158/1078-0432.CCR-06-0074; Zhang XP, 2010, BIOORG MED CHEM LETT, V20, P4627, DOI 10.1016/j.bmcl.2010.06.003	48	87	93	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2011	6	12							e28842	10.1371/journal.pone.0028842	http://dx.doi.org/10.1371/journal.pone.0028842			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	870JU	22205974	Green Published, gold, Green Submitted			2023-01-03	WOS:000298666200012
J	Chavada, R; Kok, J; van Hal, S; Chen, SCA				Chavada, Ruchir; Kok, Jen; van Hal, Sebastiaan; Chen, Sharon C-A.			Seeking Clarity within Cloudy Effluents: Differentiating Fungal from Bacterial Peritonitis in Peritoneal Dialysis Patients	PLOS ONE			English	Article							PROPHYLAXIS; EXPERIENCE; RISK	Background: Fungal peritonitis is a serious complication of peritoneal dialysis (PD) therapy with the majority of patients ceasing PD permanently. The aims of this study were to identify risk factors and clinical associations that may discriminate between fungal from bacterial peritonitis. Methods: We retrospectively identified episodes of fungal peritonitis from 2001-2010 in PD patients at Liverpool and Westmead Hospitals (Australia). Fungal peritonitis cases were matched in a 1: 2 ratio with patients with bacterial peritonitis from each institution's dialysis registry, occurring closest in time to the fungal episode. Patient demographic, clinical and outcome data were obtained from the medical records. Results: Thirty-nine episodes of fungal peritonitis (rate of 0.02 episodes per patient-year of dialysis) were matched with 78 episodes of bacterial peritonitis. Candida species were the commonest pathogens (35/39; 90% episodes) with Candida albicans (37%), Candida parapsilosis (32%) and Candida glabrata (13%) the most frequently isolated species. Compared to bacterial peritonitis, fungal peritonitis patients had received PD for significantly longer (1133 vs. 775 catheter-days; p = 0.016), were more likely to have had previous episodes of bacterial peritonitis (51% vs. 10%; p = 0.01), and to have received prior antibacterial therapy (51% vs. 10%; p = 0.01). Patients with fungal peritonitis were less likely to have fever and abdominal pain on presentation, but had higher rates of PD catheter removal (79% vs. 22%; p < 0.005), and permanent transfer to haemodialysis (87% vs. 24%; p < 0.005). Hospital length of stay was significantly longer in patients with fungal peritonitis (26.1 days vs. 12.6 days; p = 0.017), but the all-cause 30-day mortality rate was similar in both groups. Fluconazole was a suitable empiric antifungal agent; with no Candida resistance detected. Conclusion: Prompt recognition of clinical risk factors, initiation of antifungal therapy and removal of PD catheters are key considerations in optimising outcomes.	[Chavada, Ruchir; van Hal, Sebastiaan] Liverpool Hosp, Sydney SW Pathol Serv, Dept Microbiol & Infect Dis, Liverpool, Merseyside, England; [Kok, Jen; Chen, Sharon C-A.] Westmead Hosp, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol Lab Serv, Westmead, NSW 2145, Australia	University of Sydney	Chavada, R (corresponding author), Liverpool Hosp, Sydney SW Pathol Serv, Dept Microbiol & Infect Dis, Liverpool, Merseyside, England.	sharon.chen@swahs.health.nsw.gov.au		van Hal, Sebastiaan/0000-0001-5852-4155				[Anonymous], 2010, 33 AUSTR NZ DIAL TRA; Bren A, 1998, EUR J CLIN MICROBIOL, V17, P839, DOI 10.1007/s100960050203; Chang TI, 2011, PERITON DIALYSIS INT, V31, P60, DOI 10.3747/pdi.2009.00057; Chen Chih-Ming, 2004, Journal of Microbiology Immunology and Infection, V37, P115; CLSI, 2010, M27A3 CLSI; Gandhi B. V., 2005, Journal of Postgraduate Medicine, V51, P30; Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Matuszkiewicz-Rowinska J, 2009, PERITON DIALYSIS INT, V29, pS161; Miles R, 2009, KIDNEY INT, V76, P622, DOI 10.1038/ki.2009.202; Mohanram A, 2004, KIDNEY INT, V66, P1131, DOI 10.1111/j.1523-1755.2004.00863.x; Mujais S, 2006, KIDNEY INT, V70, pS55, DOI 10.1038/sj.ki.5001916; Oygar DD, 2009, RENAL FAILURE, V31, P25, DOI 10.1080/08860220802546446; Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06; Prasad N, 2005, PERITON DIALYSIS INT, V25, P207; Ram R, 2008, NEPHRON CLIN PRACT, V110, pC207, DOI 10.1159/000167867; Restrepo C, 2010, PERITON DIALYSIS INT, V30, P619, DOI 10.3747/pdi.2008.00189; Troidle L, 2003, SEMIN DIALYSIS, V16, P428, DOI 10.1046/j.1525-139X.2003.16095.x; US Renal Data System, 2010, USRDS 2010 ANN DAT R; Wang AYM, 2000, AM J KIDNEY DIS, V36, P1183, DOI 10.1053/ajkd.2000.19833; Wong PN, 2008, PERITON DIALYSIS INT, V28, P155; Wong PN, 2007, PERITON DIALYSIS INT, V27, P531	22	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2011	6	12							e28247	10.1371/journal.pone.0028247	http://dx.doi.org/10.1371/journal.pone.0028247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863MQ	22145033	Green Published, Green Submitted, gold			2023-01-03	WOS:000298168900016
J	Spence, D				Spence, Des			FROM THE FRONTLINE The painful truth: deaths and misuse of prescribed drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Aggarwal VR, 2010, PAIN, V149, P354, DOI 10.1016/j.pain.2010.02.040; Aggarwal VR, 2006, INT J EPIDEMIOL, V35, P468, DOI 10.1093/ije/dyi265; [Anonymous], 2011, POL IMP PRESCR PAINK; CAVE D, 2008, NY TIMES        0614; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; OSPINA M, 2002, PREVALENCE CHRONIC P; SZALAVITZ M, 2011, TIME HEALTHLAND 0629	7	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 16	2011	343								d7403	10.1136/bmj.d7403	http://dx.doi.org/10.1136/bmj.d7403			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	854LV	22088400				2023-01-03	WOS:000297497100007
J	Gopel, W; Kribs, A; Ziegler, A; Laux, R; Hoehn, T; Wieg, C; Siegel, J; Avenarius, S; von der Wense, A; Vochem, M; Groneck, P; Weller, U; Moller, J; Haertel, C; Haller, S; Roth, B; Herting, E				Goepel, Wolfgang; Kribs, Angela; Ziegler, Andreas; Laux, Reinhard; Hoehn, Thomas; Wieg, Christian; Siegel, Jens; Avenarius, Stefan; von der Wense, Axel; Vochem, Matthias; Groneck, Peter; Weller, Ursula; Moeller, Jens; Haertel, Christoph; Haller, Sebastian; Roth, Bernhard; Herting, Egbert		German Neonatal Network	Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial	LANCET			English	Article							RESPIRATORY-DISTRESS-SYNDROME; POSITIVE AIRWAY PRESSURE; LARYNGEAL MASK AIRWAY; BIRTH-WEIGHT INFANTS; BRONCHOPULMONARY DYSPLASIA; ENDOTRACHEAL INTUBATION; NASAL CPAP; THERAPY; MULTICENTER; FAILURE	Background Surfactant is usually given to mechanically ventilated preterm infants via an endotracheal tube to treat respiratory distress syndrome. We tested a new method of surfactant application to spontaneously breathing preterm infants to avoid mechanical ventilation. Method In a parallel-group, randomised controlled trial, 220 preterm infants with a gestational age between 26 and 28 weeks and a birthweight less than 1.5 kg were enrolled in 12 German neonatal intensive care units. Infants were independently randomised in a 1:1 ratio with variable block sizes, to standard treatment or intervention, and randomisation was stratified according to centre and multiple birth status. Masking was not possible. Infants were stabilised with continuous positive airway pressure and received rescue intubation if necessary. In the intervention group, infants received surfactant treatment during spontaneous breathing via a thin catheter inserted into the trachea by laryngoscopy if they needed a fraction of inspired oxygen more than 0.30. The primary endpoint was need for any mechanical ventilation, or being not ventilated but having a partial pressure of carbon dioxide more than 65 mm Hg (8.6 kPa) or a fraction of inspired oxygen more than 0.60, or both, for more than 2 h between 25 h and 72 h of age. Analysis was by intention to treat. This study is registered, number ISRCTN05025922. Findings 108 infants were assigned to the intervention group and 112 infants to the standard treatment group. All infants were analysed. On day 2 or 3 after birth, 30 (28%) infants in the intervention group were mechanically ventilated versus 51 (46%) in the standard treatment group (number needed to treat 6, 95% CI 3-20, absolute risk reduction 0.18, 95% CI 0.30-0.05, p=0.008). 36 (33%) infants in the intervention group were mechanically ventilated during their stay in the hospital compared with 82 (73%) in the standard treatment group (number needed to treat: 3, 95% CI 2-4, p<0.0001). The intervention group had significantly fewer median days on mechanical ventilation, (0 days. IQR 0-3 vs 2 days, 0-5) and a lower need for oxygen therapy at 28 days (30 infants [30%] vs 49 infants [45%], p=0.032) compared with the standard treatment group. We recorded no differences between groups for mortality (seven deaths in the intervention group vs five in the standard treatment group) and serious adverse events (21 vs 28). Interpretation The application of surfactant via a thin catheter to spontaneously breathing preterm infants receiving continuous positive airway pressure reduces the need for mechanical ventilation.	[Goepel, Wolfgang; Ziegler, Andreas; Haertel, Christoph; Haller, Sebastian; Herting, Egbert] Univ Lubeck, D-23538 Lubeck, Germany; [Kribs, Angela; Roth, Bernhard] Univ Cologne, Cologne, Germany; [Laux, Reinhard] Asklepios Klin Barmbek, Hamburg, Germany; [Hoehn, Thomas] Univ Dusseldorf, Dusseldorf, Germany; [Wieg, Christian] Klin Kinder & Jugendmed, Aschaffenburg, Germany; [Siegel, Jens] Kinderkrankenhaus Bult, Hannover, Germany; [Avenarius, Stefan] Univ Magdeburg, D-39106 Magdeburg, Germany; [von der Wense, Axel] Altonaer Kinderkrankenhaus, Hamburg, Germany; [Vochem, Matthias] Olga Hosp, Stuttgart, Germany; [Groneck, Peter] Klin Kinder & Jugendliche, Leverkusen, Germany; [Weller, Ursula] Evangel Krankenhaus, Bielefeld, Germany; [Moeller, Jens] Klin Kinder & Jugendmed, Saarbrucken, Germany	University of Lubeck; University of Cologne; Heinrich Heine University Dusseldorf; Otto von Guericke University; University of Hamburg; University Medical Center Hamburg-Eppendorf; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart	Herting, E (corresponding author), Univ Lubeck, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	herting@paedia.ukl.mu-luebeck.de	Möller, Jens/H-1204-2017; Ziegler, Andreas/G-4246-2012; Haller, Sebastian/P-1634-2014	Möller, Jens/0000-0003-1767-5859; Ziegler, Andreas/0000-0002-8386-5397; Haller, Sebastian/0000-0001-8242-711X	German Ministry of Research and Technology [01ER0805]; Lubeck University; Chiesi Pharmaceuticals; Abbot; Chiesi; Nycomed; Boehringer; Altana; Byk Gulden	German Ministry of Research and Technology; Lubeck University; Chiesi Pharmaceuticals(Chiesi Pharmaceuticals Inc); Abbot; Chiesi(Chiesi Pharmaceuticals Inc); Nycomed; Boehringer(Boehringer Ingelheim); Altana; Byk Gulden	EH has received speaking fees and travel grants from the surfactant-producing companies Abbot, Chiesi, Nycomed, Boehringer, and Altana. EH has participated in clinical trials sponsored by Abbott, Boehringer, Chiesi, Byk Gulden, Altana, and Nycomed. EH has worked on advisory boards for Chiesi, Nycomed, and Draeger Medical, a company working in the field of neonatal ventilation, monitoring, and thermal care. EH received no money personally for this study, the support was institutional to cover insurance and other regulatory costs of the trial.; The trial was supported by grants from Chiesi Pharmaceuticals, Lubeck University, and the German Ministry of Research and Technology (grant number 01ER0805, The German Neonatal Network). Chiesi Pharmaceuticals is a manufacturer of surfactant. We thank all the staff in participating hospitals and especially the parents and infants who participated in the trial.	Ammari A, 2005, J PEDIATR-US, V147, P341, DOI 10.1016/j.jpeds.2005.04.062; Berggren E, 2000, ACTA PAEDIATR, V89, P460, DOI 10.1080/080352500750028195; Dahmen G, 2004, BIOMETRICAL J, V46, P214, DOI 10.1002/bimj.200310018; Dani C, 2004, PEDIATRICS, V113, pE560, DOI 10.1542/peds.113.6.e560; Dargaville PA, 2011, ARCH DIS CHILD-FETAL, V96, pF243, DOI 10.1136/adc.2010.192518; Escobedo MB, 2004, J PEDIATR-US, V144, P804, DOI 10.1016/j.jpeds.2004.03.024; Finer NN, 2010, NEW ENGL J MED, V362, P1970, DOI 10.1056/NEJMoa0911783; Gandini D, 2003, PAEDIATR ANAESTH, V13, P181, DOI 10.1046/j.1460-9592.2003.01019_4.x; Halliday HL, 2008, J PERINATOL, V28, pS47, DOI 10.1038/jp.2008.50; Jung SH, 2001, STAT MED, V20, P2149, DOI 10.1002/sim.857; Kattwinkel John, 2004, J Perinatol, V24, P360, DOI 10.1038/sj.jp.7211103; Kribs A, 2010, KLIN PADIATR, V222, P13, DOI 10.1055/s-0029-1241867; Kribs A, 2008, ACTA PAEDIATR, V97, P293, DOI 10.1111/j.1651-2227.2007.00617.x; Kribs A, 2007, PEDIATR ANESTH, V17, P364, DOI 10.1111/j.1460-9592.2006.02126.x; Lindner W, 1999, PEDIATRICS, V103, P961, DOI 10.1542/peds.103.5.961; Mercier JC, 2010, LANCET, V376, P346, DOI 10.1016/S0140-6736(10)60664-2; Morley CJ, 2008, NEW ENGL J MED, V358, P700, DOI 10.1056/NEJMoa072788; Nava S, 2009, LANCET, V374, P250, DOI 10.1016/S0140-6736(09)60496-7; O'Donnell CPF, 2006, PEDIATRICS, V117, pE16, DOI 10.1542/peds.2005-0901; Reininger Ann, 2005, J Perinatol, V25, P703, DOI 10.1038/sj.jp.7211381; Rojas MA, 2009, PEDIATRICS, V123, P137, DOI 10.1542/peds.2007-3501; Sandri F, 2010, PEDIATRICS, V125, pE1402, DOI 10.1542/peds.2009-2131; Seger N, 2009, COCHRANE DB SYST REV, V2; Soll Roger F, 2009, Neonatology, V95, P368, DOI 10.1159/000209303; Stevens TP, 2007, COCHRANE DB SYST REV, V4; Trevisanuto D, 2005, BIOL NEONATE, V87, P217, DOI 10.1159/000083370; van den Berg E, 2010, ARCH DIS CHILD-FETAL, V95, pF53, DOI 10.1136/adc.2008.156414; VERDER H, 1994, NEW ENGL J MED, V331, P1051, DOI 10.1056/NEJM199410203311603; Verder H, 1992, Ugeskr Laeger, V154, P2136; Walsh MC, 2004, PEDIATRICS, V114, P1305, DOI 10.1542/peds.2004-0204; Welzing L, 2010, PEDIATR ANESTH, V20, P605, DOI 10.1111/j.1460-9592.2010.03330.x	31	282	301	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2011	378	9803					1627	1634		10.1016/S0140-6736(11)60986-0	http://dx.doi.org/10.1016/S0140-6736(11)60986-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844ST	21963186				2023-01-03	WOS:000296768300027
J	Patou, G				Patou, Gary			In vogue with venture	NATURE BIOTECHNOLOGY			English	Editorial Material									MPM Capital, San Francisco, CA 94080 USA		Patou, G (corresponding author), MPM Capital, San Francisco, CA 94080 USA.	gpatou@mpmcapital.com							0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2011	29	11					967	969						3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	845CT	22175076				2023-01-03	WOS:000296801300010
J	Chen, J; Normand, SLT; Wang, Y; Krumholz, HM				Chen, Jersey; Normand, Sharon-Lise T.; Wang, Yun; Krumholz, Harlan M.			National and Regional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998-2008	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; LONG-TERM TRENDS; RISK-FACTORS; 1ST HOSPITALIZATION; ELDERLY-PATIENTS; OLDER-ADULTS; OUTCOMES; POPULATION; SURVIVAL; EPIDEMIOLOGY	Context It is not known whether recent declines in ischemic heart disease and its risk factors have been accompanied by declines in heart failure (HF) hospitalization and mortality. Objective To examine changes in HF hospitalization rate and 1-year mortality rate in the United States, nationally and by state or territory. Design, Setting, and Participants From acute care hospitals in the United States and Puerto Rico, 55 097 390 fee-for-service Medicare beneficiaries hospitalized between 1998 and 2008 with a principal discharge diagnosis code for HF. Main Outcome Measures Changes in patient demographics and comorbidities, HF hospitalization rates, and 1-year mortality rates. Results The HF hospitalization rate adjusted for age, sex, and race declined from 2845 per 100 000 person-years in 1998 to 2007 per 100 000 person-years in 2008 (P < .001), a relative decline of 29.5%. Age-adjusted HF hospitalization rates declined over the study period for all race-sex categories. Black men had the lowest rate of decline (4142 to 3201 per 100 000 person-years) among all race-sex categories, which persisted after adjusting for age (incidence rate ratio, 0.81; 95% CI, 0.79-0.84). Heart failure hospitalization rates declined significantly faster than the national mean in 16 states and significantly slower in 3 states. Risk-adjusted 1-year mortality decreased from 31.7% in 1999 to 29.6% in 2008 (P < .001), a relative decline of 6.6%. One-year mortality rates declined significantly in 4 states but increased in 5 states. Conclusions The overall HF hospitalization rate declined substantially from 1998 to 2008 but at a lower rate for black men. The overall 1-year mortality rate declined slightly over the past decade but remains high. Changes in HF hospitalization and 1-year mortality rates were uneven across states. JAMA. 2011;306(15):1669-1678	[Chen, Jersey; Wang, Yun; Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06520 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06520 USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Normand, Sharon-Lise T.; Wang, Yun] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Wang, Yun; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Yale University	Chen, J (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, 333 Cedar St, New Haven, CT 06520 USA.	jersey.chen@yale.edu	, Harlan/AAI-2875-2020	Normand, Sharon-Lise/0000-0001-7027-4769	Centers for Medicare & Medicaid Services; Yale University; Medtronic Inc through Yale University; Agency for Healthcare Research and Quality (AHRQ) [1K08HS018781-01]; National Heart, Lung, Blood Institute (NHLBI) [U01HL105270-01]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018781] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL105270] Funding Source: NIH RePORTER	Centers for Medicare & Medicaid Services; Yale University; Medtronic Inc through Yale University(Medtronic); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Chen, Normand, Wang, and Krumholz reported that they develop and maintain performance measures under contract with the Centers for Medicare & Medicaid Services. Dr Normand reported receiving consulting fees from Yale University. Dr Krumholz reported that he chairs a cardiac scientific advisory board for United Healthcare and is the recipient of a research grant from Medtronic Inc through Yale University.; This work was supported by an Agency for Healthcare Research and Quality (AHRQ) Career Development Award (1K08HS018781-01) for Dr Chen and a National Heart, Lung, Blood Institute (NHLBI) Cardiovascular Outcomes Center Award (U01HL105270-01) for Drs Chen, Normand, Wang, and Krumholz.	Bernheim SM, 2010, 2010 MEASURES MAINTE; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Chen J, 2010, CIRCULATION, V121, P1322, DOI 10.1161/CIRCULATIONAHA.109.862094; Curtis LH, 2008, ARCH INTERN MED, V168, P418, DOI 10.1001/archinternmed.2007.80; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Eicheldinger C, 2008, HEALTH CARE FINANC R, V29, P27; Ezekowitz JA, 2011, EUR J HEART FAIL, V13, P142, DOI 10.1093/eurjhf/hfq185; Ezekowitz JA, 2010, HEART FAIL REV, V15, P407, DOI 10.1007/s10741-010-9162-x; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Fonarow GC, 2007, AM HEART J, V153, P1021, DOI [10.1016/j.ahj.2007.03.012, 10.1016/j.ahj.2007.07.043]; Fonarow GC, 2010, CIRCULATION, V122, P585, DOI 10.1161/CIRCULATIONAHA.109.934471; Grosso LM, 2009 MEASURES MAINTE; Hajjar I, 2006, ANNU REV PUBL HEALTH, V27, P465, DOI 10.1146/annurev.publhealth.27.021405.102132; He J, 2001, ARCH INTERN MED, V161, P996, DOI 10.1001/archinte.161.7.996; Hellermann JP, 2003, AM J EPIDEMIOL, V157, P1101, DOI 10.1093/aje/kwg078; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jhund PS, 2009, CIRCULATION, V119, P515, DOI 10.1161/CIRCULATIONAHA.108.812172; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lee DS, 2004, AM J MED, V116, P581, DOI 10.1016/j.amjmed.2003.11.025; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; McAlister FA, 2007, JAMA-J AM MED ASSOC, V297, P2502, DOI 10.1001/jama.297.22.2502; Medicare Payment Advisory Commission, 2008, REP C MED PAYM POL M; Mehta PA, 2009, HEART, V95, P1851, DOI 10.1136/hrt.2008.156034; Morgan RO, 1997, NEW ENGL J MED, V337, P169, DOI 10.1056/NEJM199707173370306; Roger VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344; Schaufelberger M, 2004, EUR HEART J, V25, P300, DOI 10.1016/j.ehj.2003.12.012; Shafazand M, 2011, EUR J HEART FAIL, V13, P135, DOI 10.1093/eurjhf/hfq205; Shah RU, 2011, CIRC-HEART FAIL, V4, P301, DOI 10.1161/CIRCHEARTFAILURE.110.959114; Smith NL, 2004, AM HEART J, V148, P710, DOI 10.1016/j.ahj.2004.04.002; Teng THK, 2010, CIRC-HEART FAIL, V3, P236, DOI 10.1161/CIRCHEARTFAILURE.109.879239; Titler MG, 2008, HEALTH SERV RES, V43, P635, DOI 10.1111/j.1475-6773.2007.00789.x; Wang TJ, 2005, CIRCULATION, V112, P1651, DOI 10.1161/CIRCULATIONAHA.104.490599; Wasywich CA, 2010, EUR J HEART FAIL, V12, P462, DOI 10.1093/eurjhf/hfq027; Wier LM, HCUP FACTS FIGURES S; Wong CY, 2011, AM J MED, V124, P136, DOI 10.1016/j.amjmed.2010.08.017; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	43	515	571	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2011	306	15					1669	1678		10.1001/jama.2011.1474	http://dx.doi.org/10.1001/jama.2011.1474			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834MA	22009099	Green Accepted, Bronze			2023-01-03	WOS:000295963200026
J	Kiaii, M; Djurdjev, O; Farah, M; Levin, A; Jung, B; MacRae, J				Kiaii, Mercedeh; Djurdjev, Ognjenka; Farah, Myriam; Levin, Adeera; Jung, Beverly; MacRae, Jennifer			Use of Electron-Beam Sterilized Hemodialysis Membranes and Risk of Thrombocytopenia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIALYSIS MEMBRANES; THROMBUS FORMATION; PLATELET; ACTIVATION	Context Thrombocytopenia is not widely recognized as a potential dialyzer-related complication. Following the observation of significant thrombocytopenia among 20 patients undergoing hemodialysis in a single dialysis unit after the introduction of dialyzers sterilized by electron beam (e-beam), a larger investigation was undertaken. Objective To determine the prevalence and etiology of thrombocytopenia in hemodialysis populations of 2 Canadian provinces (British Columbia and Alberta). Design, Setting, and Participants A cohort study of patients undergoing hemodialysis in British Columbia (n = 1706) and southern Alberta (n = 425) between April 1, 2009, and November 30, 2010. Retrospective analyses of historical patient, laboratory, and dialyzer data predating conversion to e-beam dialyzers were undertaken, with prospective collection of predialysis and postdialysis platelet counts before and after the change from e-beam to non-e-beam sterilized dialyzers in September 2009. Main Outcome Measure Significant thrombocytopenia, defined a priori as postdialysis treatment platelet count of less than 100 x 10(3)/mu L and a postdialysis decrease in platelet count of more than 15%. Results Among 1706 patients undergoing hemodialysis in British Columbia, 1411 (83%) were undergoing hemodialysis with e-beam sterilized dialyzers. Of 1706 patients, 194 (11.4%; 95% CI, 9.9%-12.9%) had postdialysis platelet counts of less than 100 x 10(3)/mu L; 400 (23.4%; 95% CI, 21.5%-25.5%) had postdialysis decreases in platelet counts of more than 15%; and 123 (7.2%; 95% CI, 6.0%-8.6%) met both criteria. Among 425 patients in Alberta undergoing dialysis with polysulfone, e-beam sterilized dialyzers made by a different manufacturer, 46 (10.8%; 95% CI, 8.1%-14.3%) had platelet counts of less than 100 x 10(3)/mu L; 156 (32.0%; 95% CI, 27.6%-36.7%) had decreases in platelet counts of more than 15%; and 31 (7.3%; 95% CI, 5.1%-10.3%) met both criteria. In multivariable analysis adjusting for patient and dialysis history characteristics, a significant association was observed between using an e-beam sterilized dialyzer and risk of significant thrombocytopenia (odds ratio [OR], 2.52; 95% CI, 1.20-5.29; P =. 02). Compared with use of e-beam sterilized dialyzers, following the change to use of non-e-beam sterilized dialyzers, among 1784 patients, significant reductions were observed in postdialysis thrombocytopenia (120 patients [6.7%; 95% CI, 5.6%-8.0%; P < .001] had platelet counts of <100 x 10(3)/mu L; 167 patients [9.4%; 95% CI, 8.1%-10.8%; P < .001] had decreases in platelet counts of >15%; and 38 patients [2.1%; 95% CI, 1.5%-2.9%; P < .001] met both criteria). Using generalized estimating equation modeling for repeated data with binary outcome, after adjusting for patient characteristics, the odds of significant thrombocytopenia were higher during the use of e-beam sterilized dialyzers than with use of non-e-beam sterilized dialyzers (OR, 3.57; 95% CI, 2.54-5.04; P < .001). Conclusion In this cohort of patients undergoing hemodialysis in 2 Canadian provinces in 2009-2010, the use of e-beam sterilized dialyzers was associated with significant thrombocytopenia following dialysis. JAMA. 2011;306(15):1679-1687	[Kiaii, Mercedeh; Farah, Myriam; Levin, Adeera; Jung, Beverly] Univ British Columbia, Div Nephrol, Vancouver, BC V6Z 2E8, Canada; [Djurdjev, Ognjenka; Levin, Adeera] British Columbia Prov Renal Agcy, Vancouver, BC, Canada; [MacRae, Jennifer] Univ Calgary, Div Nephrol, Calgary, AB, Canada	University of British Columbia; University of Calgary	Kiaii, M (corresponding author), Univ British Columbia, Div Nephrol, 602-1160 Burrard St, Vancouver, BC V6Z 2E8, Canada.	mkiaii@providencehealth.bc.ca	MacRae, Jennifer/AAV-9827-2020	MacRae, Jennifer/0000-0002-4711-1440				Clark WR, 2002, SEMIN DIALYSIS, V15, P191, DOI 10.1046/j.1525-139X.2002.00019.x; Daugirdas J T, 1988, Kidney Int Suppl, V24, pS37; Gavioli G, 2002, HEMODIALYSIS TECHNOL, P80; GAWAZ MP, 1994, KIDNEY INT, V46, P489, DOI 10.1038/ki.1994.299; Gritters-van den Oever Mareille, 2009, Blood Purif, V28, P253, DOI 10.1159/000232933; HAKIM RM, 1993, CARDIOVASC PATHOL, V2, pS187; HAKIM RM, 1985, AM J MED, V78, P575, DOI 10.1016/0002-9343(85)90398-5; LINDSAY RM, 1973, BRIT J HAEMATOL, V24, P377, DOI 10.1111/j.1365-2141.1973.tb01661.x; LINDSAY RM, 1972, BRIT MED J, V4, P454, DOI 10.1136/bmj.4.5838.454; LINDSAY RM, 1973, T AM SOC ART INT ORG, V19, P487; LOTNER GZ, 1980, J IMMUNOL, V124, P676; Milburn JA, 2011, INT J ARTIF ORGANS, V34, P280, DOI 10.5301/IJAO.2011.6469; Olafiranye F, 2011, CASE REP MED, V2011, DOI 10.1155/2011/134295; Posadas MA, 2011, HEMODIAL INT, V15, P416, DOI 10.1111/j.1542-4758.2011.00561.x; Post JB, 2010, AM J KIDNEY DIS, V55, pE25, DOI 10.1053/j.ajkd.2009.10.059; SHINTANI H, 1991, J BIOMED MATER RES, V25, P1275, DOI 10.1002/jbm.820251008; Uhlenbusch-Korwer I., 2004, UNDERSTANDING MEMBRA, P265	17	39	40	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	2011	306	15					1679	1687		10.1001/jama.2011.1499	http://dx.doi.org/10.1001/jama.2011.1499			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834MA	22009100	Bronze			2023-01-03	WOS:000295963200027
J	Rydstrom, A; Deshayes, S; Konate, K; Crombez, L; Padari, K; Boukhaddaoui, H; Aldrian, G; Pooga, M; Divita, G				Rydstroem, Anna; Deshayes, Sebastien; Konate, Karidia; Crombez, Laurence; Padari, Kaert; Boukhaddaoui, Hassan; Aldrian, Gudrun; Pooga, Margus; Divita, Gilles			Direct Translocation as Major Cellular Uptake for CADY Self-Assembling Peptide-Based Nanoparticles	PLOS ONE			English	Article							PENETRATING PEPTIDES; MOLECULAR-MECHANISMS; SIRNA DELIVERY; INTERNALIZATION; PATHWAYS; INSIGHT; STRATEGIES; PROTEINS; CARRIER; REPAIR	Cell penetrating peptides constitute a potent approach to overcome the limitations of in vivo siRNA delivery. We recently proposed a peptide-based nanoparticle system, CADY, for efficient delivery of siRNA into numerous cell lines. CADY is a secondary amphipathic peptide that forms stable complexes with siRNA thereby improving both their cellular uptake and biological response. With the aim of understanding the cellular uptake mechanism of CADY: siRNA complexes, we have combined biochemical, confocal and electron microscopy approaches. In the present work, we provide evidence that the major route for CADY: siRNA cellular uptake involves direct translocation through the membrane but not the endosomal pathway. We have demonstrated that CADY: siRNA complexes do not colocalize with most endosomal markers and remain fully active in the presence of inhibitors of the endosomal pathway. Moreover, neither electrostatic interactions with cell surface heparan sulphates nor membrane potential are essential for CADY: siRNA cell entry. In contrast, we have shown that CADY: siRNA complexes clearly induce a transient cell membrane permeabilization, which is rapidly restored by cell membrane fluidity. Therefore, we propose that direct translocation is the major gate for cell entry of CADY: siRNA complexes. Membrane perturbation and uptake are driven mainly by the ability of CADY to interact with phospholipids within the cell membrane, followed by rapid localization of the complex in the cytoplasm, without affecting cell integrity or viability.	[Rydstroem, Anna; Deshayes, Sebastien; Konate, Karidia; Crombez, Laurence; Aldrian, Gudrun; Divita, Gilles] Univ Montpellier, Ctr Rech Biochim Macromol, Dept Mol Biophys & Therapeut, UMR 5237,UM1 UM2,CRBM,CNRS, F-34059 Montpellier, France; [Padari, Kaert; Pooga, Margus] Univ Tartu, Dept Dev Biol, Inst Mol & Cell Biol, EE-50090 Tartu, Estonia; [Boukhaddaoui, Hassan] Inst Neurosci Montpellier, INSERM, U1051, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Tartu; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Rydstrom, A (corresponding author), Univ Montpellier, Ctr Rech Biochim Macromol, Dept Mol Biophys & Therapeut, UMR 5237,UM1 UM2,CRBM,CNRS, F-34059 Montpellier, France.	gilles.divita@crbm.cnrs.fr	Deshayes, Sebastien/J-9228-2018; DIVITA, GILLES/AAV-9214-2021; Pooga, Margus/A-8575-2011	Deshayes, Sebastien/0000-0002-4684-9152; Pooga, Margus/0000-0003-4532-4087; Aldrian, Gudrun/0000-0002-7899-0572; Rydstrom, Anna/0000-0002-3404-7195; BOUKHADDAOUI, HASSAN/0000-0003-1808-7901	Centre National de la Recherche Scientifique; Agence Nationale de la Recherche [ANR- ANR-06-BLAN-0071]; Estonian Science Foundation [ESF8705]; Estonian Ministry of Education and Research [180019s11]	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Estonian Science Foundation; Estonian Ministry of Education and Research(Ministry of Education and Research, Estonia)	This work was supported by the Centre National de la Recherche Scientifique and grants from the Agence Nationale de la Recherche (ANR- ANR-06-BLAN-0071), the Estonian Science Foundation (ESF8705) and the Estonian Ministry of Education and Research (180019s11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves ID, 2010, BBA-BIOMEMBRANES, V1798, P2231, DOI 10.1016/j.bbamem.2010.02.009; Andaloussi SEL, 2011, NUCLEIC ACIDS RES, V39, P3972, DOI 10.1093/nar/gkq1299; Brasseur R, 2010, BBA-BIOMEMBRANES, V1798, P2177, DOI 10.1016/j.bbamem.2010.09.001; Broeck DV, 2007, ACTA BIOCHIM POL, V54, P757, DOI 10.18388/abp.2007_3154; Castanotto D, 2009, NATURE, V457, P426, DOI 10.1038/nature07758; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Crombez L, 2009, NUCLEIC ACIDS RES, V37, P4559, DOI 10.1093/nar/gkp451; Crombez L, 2009, MOL THER, V17, P95, DOI 10.1038/mt.2008.215; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; de Toledo M, 2003, MOL BIOL CELL, V14, P4846, DOI 10.1091/mbc.E03-04-0254; Deshayes S, 2004, BIOCHEMISTRY-US, V43, P1449, DOI 10.1021/bi035682s; Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010; Deshayes S, 2010, BBA-BIOMEMBRANES, V1798, P2304, DOI 10.1016/j.bbamem.2010.06.005; Dorsett Y, 2004, NAT REV DRUG DISCOV, V3, P318, DOI 10.1038/nrd1345; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Eguchi A, 2009, TRENDS PHARMACOL SCI, V30, P341, DOI 10.1016/j.tips.2009.04.009; Eguchi A, 2009, NAT BIOTECHNOL, V27, P567, DOI 10.1038/nbt.1541; Eiriksdottir E, 2010, BBA-BIOMEMBRANES, V1798, P1119, DOI 10.1016/j.bbamem.2010.03.005; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044; Gao K, 2009, MOL PHARMACEUT, V6, P651, DOI 10.1021/mp800134q; Gerbal-Chaloin S, 2007, BIOL CELL, V99, P223, DOI 10.1042/BC20060123; Gump JM, 2010, J BIOL CHEM, V285, P1500, DOI 10.1074/jbc.M109.021964; Hassane FS, 2010, CELL MOL LIFE SCI, V67, P715, DOI 10.1007/s00018-009-0186-0; Heitz F, 2009, BRIT J PHARMACOL, V157, P195, DOI 10.1111/j.1476-5381.2009.00057.x; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Henriques ST, 2006, BIOCHEM J, V399, P1, DOI 10.1042/BJ20061100; Jarver P, 2010, TRENDS PHARMACOL SCI, V31, P528, DOI 10.1016/j.tips.2010.07.006; Juliano R, 2008, NUCLEIC ACIDS RES, V36, P4158, DOI 10.1093/nar/gkn342; Konate K, 2010, BIOCHEMISTRY-US, V49, P3393, DOI 10.1021/bi901791x; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Morris MC, 2008, BIOL CELL, V100, P201, DOI 10.1042/BC20070116; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z; Palm-Apergi C, 2009, FASEB J, V23, P214, DOI 10.1096/fj.08-110254; Raagel H, 2010, BBA-BIOMEMBRANES, V1798, P2240, DOI 10.1016/j.bbamem.2010.02.013; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; Sibley CR, 2010, MOL THER, V18, P466, DOI 10.1038/mt.2009.306; Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385; Torgersen ML, 2001, J CELL SCI, V114, P3737; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Vercauteren D, 2010, MOL THER, V18, P561, DOI 10.1038/mt.2009.281; Via LE, 1998, J CELL SCI, V111, P897; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Watkins CL, 2009, BIOCHEM J, V420, P179, DOI 10.1042/BJ20090042; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742	49	85	90	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2011	6	10							e25924	10.1371/journal.pone.0025924	http://dx.doi.org/10.1371/journal.pone.0025924			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834NA	21998722	Green Published, gold, Green Submitted			2023-01-03	WOS:000295966900074
J	Wang, Y; Lu, JJ; He, L; Yu, Q				Wang, Ying; Lu, Jin-jian; He, Li; Yu, Qiang			Triptolide (TPL) Inhibits Global Transcription by Inducing Proteasome-Dependent Degradation of RNA Polymerase II (Pol II)	PLOS ONE			English	Article							CARBOXYL-TERMINAL DOMAIN; KAPPA-B ACTIVATION; COUPLED DNA-REPAIR; CELL-DEATH; INDUCED UBIQUITINATION; LARGE SUBUNIT; COMET ASSAY; IN-VITRO; PHOSPHORYLATION; ELONGATION	Triptolide (TPL), a key biologically active component of the Chinese medicinal herb Tripterygium wilfordii Hook. f., has potent anti-inflammation and anti-cancer activities. Its anti-proliferative and pro-apoptotic effects have been reported to be related to the inhibition of Nuclear Factor kappa B (NF-kappa B) and Nuclear Factor of Activated T-cells (NFAT) mediated transcription and suppression of HSP70 expression. The direct targets and precise mechanisms that are responsible for the gene expression inhibition, however, remain unknown. Here, we report that TPL inhibits global gene transcription by inducing proteasome-dependent degradation of the largest subunit of RNA polymerase II (Rpb1) in cancer cells. In the presence of proteosome inhibitor MG132, TPL treatment causes hyperphosphorylation of Rpb1 by activation of upstream protein kinases such as Positive Transcription Elongation Factor b (P-TEFb) in a time and dose dependent manner. Also, we observe that short time incubation of TPL with cancer cells induces DNA damage. In conclusion, we propose a new mechanism of how TPL works in killing cancer. TPL inhibits global transcription in cancer cells by induction of phosphorylation and subsequent proteasome dependent degradation of Rpb1 resulting in global gene transcription, which may explain the high potency of TPL in killing cancer.	[Wang, Ying; Lu, Jin-jian; He, Li; Yu, Qiang] Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol, Shanghai 200031, Peoples R China; [Lu, Jin-jian] Zhejiang Chinese Med Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Zhejiang Chinese Medical University	Wang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol, Shanghai 200031, Peoples R China.	qyu@sibs.ac.cn	Lu, Jinjian/R-6207-2019; Lu, Jinjian/X-2083-2019	Lu, Jinjian/0000-0001-6703-3120	China National Natural Science Foundation [31129004, 31000619]; National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" China [2009ZX09301-001, 2009ZX09103-064]; Shanghai Science and Technology Research grants [08DZ1971403, 09JC1416700]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" China; Shanghai Science and Technology Research grants	This work was supported by the China National Natural Science Foundation, grant 31129004 and 31000619; the National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program" China (numbers 2009ZX09301-001 and 2009ZX09103-064); and the Shanghai Science and Technology Research grants 08DZ1971403 and 09JC1416700. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao XF, 2007, J MOL MED, V85, P85, DOI 10.1007/s00109-006-0113-x; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898; Choi YJ, 2003, BIOCHEM PHARMACOL, V66, P273, DOI 10.1016/S0006-2952(03)00282-X; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Efferth T, 2007, TRENDS MOL MED, V13, P353, DOI 10.1016/j.molmed.2007.07.001; Fidler JM, 2003, MOL CANCER THER, V2, P855; Hartley JA, 1999, BRIT J CANCER, V79, P264, DOI 10.1038/sj.bjc.6690043; Huang M, 2007, CLIN CANCER RES, V13, P1298, DOI 10.1158/1078-0432.CCR-06-1277; Inukai N, 2004, J BIOL CHEM, V279, P8190, DOI 10.1074/jbc.M311412200; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; Jung Y, 2006, J BIOL CHEM, V281, P1361, DOI 10.1074/jbc.M509688200; KANG ME, 1993, J BIOL CHEM, V268, P25033; Kiviharju TM, 2002, CLIN CANCER RES, V8, P2666; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Leuenroth SJ, 2005, CHEM BIOL, V12, P1259, DOI 10.1016/j.chembiol.2005.09.009; Leuenroth SJ, 2008, CANCER RES, V68, P5257, DOI 10.1158/0008-5472.CAN-07-6207; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Matsui Y, 2008, ONCOGENE, V27, P4603, DOI 10.1038/onc.2008.89; McCallum C, 2007, IMMUNOBIOLOGY, V212, P549, DOI 10.1016/j.imbio.2007.02.002; Mitsui A, 1999, P NATL ACAD SCI USA, V96, P6054, DOI 10.1073/pnas.96.11.6054; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Peng J, 1998, COLD SPRING HARB SYM, V63, P365, DOI 10.1101/sqb.1998.63.365; Phillips PA, 2007, CANCER RES, V67, P9407, DOI 10.1158/0008-5472.CAN-07-1077; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Ratner JN, 1998, J BIOL CHEM, V273, P5184, DOI 10.1074/jbc.273.9.5184; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Vispe S, 2009, MOL CANCER THER, V8, P2780, DOI 10.1158/1535-7163.MCT-09-0549; Wang Y, 2009, CANCER RES, V69, P7302, DOI 10.1158/0008-5472.CAN-09-0462; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Wu YY, 2006, INT J MOL MED, V17, P141; Yang SM, 2003, MOL CANCER THER, V2, P65	40	45	49	4	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 13	2011	6	9							e23993	10.1371/journal.pone.0023993	http://dx.doi.org/10.1371/journal.pone.0023993			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825ZV	21931633	Green Submitted, Green Published, gold			2023-01-03	WOS:000295321800011
J	Von Korff, M; Kolodny, A; Deyo, RA; Chou, R				Von Korff, Michael; Kolodny, Andrew; Deyo, Richard A.; Chou, Roger			Long-Term Opioid Therapy Reconsidered	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC NONCANCER PAIN; OLDER-ADULTS; RECEIVING OPIOIDS; UNITED-STATES; ASSOCIATION; MORTALITY; OVERDOSE; HEALTH; MISUSE	In the past 20 years, primary care physicians have greatly increased prescribing of long-term opioid therapy. However, the rise in opioid prescribing has outpaced the evidence regarding this practice. Increased opioid availability has been accompanied by an epidemic of opioid abuse and overdose. The rate of opioid addiction among patients receiving long-term opioid therapy remains unclear, but research suggests that opioid misuse is not rare. Recent studies report increased risks for serious adverse events, including fractures, cardiovascular events, and bowel obstruction, although further research on medical risks is needed. New data indicate that opioid-related risks may increase with dose. From a societal perspective, higher-dose regimens account for the majority of opioids dispensed, so cautious dosing may reduce both diversion potential and patient risks for adverse effects. Limiting long-term opioid therapy to patients for whom it provides decisive benefits could also reduce risks. Given the warning signs and knowledge gaps, greater caution and selectivity are needed in prescribing long-term opioid therapy. Until stronger evidence becomes available, clinicians should err on the side of caution when considering this treatment.	[Von Korff, Michael] Grp Hlth Res Inst, Seattle, WA 98101 USA; Maimonides Hosp, Brooklyn, NY 11219 USA; Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA	Maimonides Medical Center; Oregon Health & Science University; Kaiser Permanente	Von Korff, M (corresponding author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	vonkorff.m@ghc.org		Chou, Roger/0000-0001-9889-8610; VonKorff, Michael/0000-0001-5386-8477	Group Health Foundation; National Institute of Drug Abuse [R01 DA022557]; National Institute of Aging, National Institutes of Health [R01AG034181]; NATIONAL INSTITUTE ON AGING [R01AG034181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA022557] Funding Source: NIH RePORTER	Group Health Foundation; National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institute of Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Grant Support: By the Group Health Foundation and by the National Institute of Drug Abuse (R01 DA022557) and National Institute of Aging (R01AG034181), National Institutes of Health.	Banta-Green CJ, 2009, DRUG ALCOHOL DEPEN, V104, P34, DOI 10.1016/j.drugalcdep.2009.03.021; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boscarino JA, 2010, ADDICTION, V105, P1776, DOI 10.1111/j.1360-0443.2010.03052.x; Butler SF, 2009, J ADDICT MED, V3, P66, DOI 10.1097/ADM.0b013e31818e41da; Carman WJ, 2011, PHARMACOEPIDEMIOL DR; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Croft P BF, 2010, CHRONIC PAIN EPIDEMI, P9, DOI DOI 10.1093/ACPROF:OSO/9780199235766.001.0001; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Fleming MF, 2007, J PAIN, V8, P573, DOI 10.1016/j.jpain.2007.02.432; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Haddox JD, 1997, CLIN J PAIN, V13, P6; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; Moore TM, 2009, PAIN MED, V10, P1426, DOI 10.1111/j.1526-4637.2009.00743.x; Naliboff BD, 2011, J PAIN, V12, P288, DOI 10.1016/j.jpain.2010.09.003; Office of National Drug Control Policy, EP RESP AM PRESCR DR; Papaleontiou M, 2010, J AM GERIATR SOC, V58, P1353, DOI 10.1111/j.1532-5415.2010.02920.x; Paulozzi LJ, 2008, PHARMACOEPIDEM DR S, V17, P997, DOI 10.1002/pds.1626; Physicians for Responsible Opioid Prescribing, CAUT EV BAS OP PRESC; Reid MC, 2010, PAIN MED, V11, P1063, DOI 10.1111/j.1526-4637.2010.00883.x; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391; Starrels JL, 2010, ANN INTERN MED, V152, P712, DOI 10.7326/0003-4819-152-11-201006010-00004; Sullivan MD, 2010, PAIN, V149, P345, DOI 10.1016/j.pain.2010.02.037; Sung HE, 2005, J ADOLESCENT HEALTH, V37, P44, DOI 10.1016/j.jadohealth.2005.02.013; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009	26	166	165	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2011	155	5					325	328		10.7326/0003-4819-155-5-201109060-00011	http://dx.doi.org/10.7326/0003-4819-155-5-201109060-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	815PX	21893626	Green Accepted			2023-01-03	WOS:000294538900007
J	Bell, CM; Brener, SS; Gunraj, N; Huo, C; Bierman, AS; Scales, DC; Bajcar, J; Zwarenstein, M; Urbach, DR				Bell, Chaim M.; Brener, Stacey S.; Gunraj, Nadia; Huo, Cindy; Bierman, Arlene S.; Scales, Damon C.; Bajcar, Jana; Zwarenstein, Merrick; Urbach, David R.			Association of ICU or Hospital Admission With Unintentional Discontinuation of Medications for Chronic Diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; LONG-TERM MEDICATION; INTENSIVE-CARE-UNIT; ELDERLY-PATIENTS; ANTIHYPERTENSIVE THERAPY; ATRIAL-FIBRILLATION; STATIN THERAPY; PATIENT SAFETY; CANADIANS USE; HEALTH-CARE	Context Patients discharged from acute care hospitals may be at risk for unintentional discontinuation of medications prescribed for chronic diseases. The intensive care unit (ICU) may pose an even greater risk because of the focus on acute events and the presence of multiple transitions in care. Objective To evaluate rates of potentially unintentional discontinuation of medications following hospital or ICU admission. Design, Setting, and Patients A population-based cohort study using administrative records from 1997 to 2009 of all hospitalizations and outpatient prescriptions in Ontario, Canada; it included 396 380 patients aged 66 years or older with continuous use of at least 1 of 5 evidence-based medication groups prescribed for long-term use: (1) statins, (2) antiplatelet/anticoagulant agents, (3) levothyroxine, (4) respiratory inhalers, and (5) gastric acid-suppressing drugs. Rates of medication discontinuation were compared across 3 groups: patients admitted to the ICU, patients hospitalized without ICU admission, and nonhospitalized patients (controls). Odds ratios (ORs) were calculated and adjusted for patient demographics, clinical factors, and health services use. Main Outcome Measures The primary outcome was failure to renew the prescription within 90 days after hospital discharge. Results Patients admitted to the hospital (n=187 912) were more likely to experience potentially unintentional discontinuation of medications than controls (n=208 468) across all medication groups examined. The adjusted ORs (AORs) ranged from 1.18 (95% CI, 1.14-1.23) for discontinuing levothyroxine in 12.3% of hospitalized patients (n=6831) vs 11.0% of controls (n=7114) to an AOR of 1.86 (95% CI, 1.771.97) for discontinuing antiplatelet/anticoagulant agents in 19.4% of hospitalized patients (n=5564) vs 11.8% of controls (n=2535). With ICU exposure, the AORs ranged from 1.48 (95% CI, 1.39-1.57) for discontinuing statins in 14.6% of ICU patients (n=1484) to an AOR of 2.31 (95% CI, 2.07-2.57) for discontinuing antiplatelet/anticoagulant agents in 22.8% of ICU patients (n=522) vs the control group. Admission to an ICU was associated with an additional risk of medication discontinuation in 4 of 5 medication groups vs hospitalizations without an ICU admission. One-year follow-up of patients who discontinued medications showed an elevated AOR for the secondary composite outcome of death, emergency department visit, or emergent hospitalization of 1.07 (95% CI, 1.03-1.11) in the statins group and of 1.10 (95% CI, 1.03-1.16) in the antiplatelet/anticoagulant agents group. Conclusions Patients prescribed medications for chronic diseases were at risk for potentially unintentional discontinuation after hospital admission. Admission to the ICU was generally associated with an even higher risk of medication discontinuation. JAMA. 2011;306(8):840-847 www.jama.com	[Bell, Chaim M.; Brener, Stacey S.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.; Brener, Stacey S.; Bierman, Arlene S.; Zwarenstein, Merrick; Urbach, David R.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.; Brener, Stacey S.; Bierman, Arlene S.] Univ Toronto, Dept Med, Toronto, ON M5B 1W8, Canada; [Urbach, David R.] Univ Toronto, Dept Surg, Toronto, ON M5B 1W8, Canada; [Scales, Damon C.] Univ Toronto, Interdept Div Critical Care, Toronto, ON M5B 1W8, Canada; [Bierman, Arlene S.] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON M5B 1W8, Canada; [Bajcar, Jana] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.] Univ Toronto, Ctr Patient Safety, Toronto, ON M5B 1W8, Canada; [Urbach, David R.] Univ Toronto, Univ Hlth Network, Toronto, ON M5B 1W8, Canada; [Bell, Chaim M.; Gunraj, Nadia; Huo, Cindy; Bierman, Arlene S.; Scales, Damon C.; Zwarenstein, Merrick; Urbach, David R.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Scales, Damon C.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Bajcar, Jana] Sunnybrook Hlth Sci Ctr, Dept Pharm, Toronto, ON M4N 3M5, Canada	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Bell, CM (corresponding author), Univ Toronto, St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bellc@smh.toronto.on.ca	Greiver, Michelle/N-8764-2015; Zwarenstein, Merrick F/P-5210-2014; Bell, Chaim/C-4611-2015	Greiver, Michelle/0000-0001-8957-0285; Zwarenstein, Merrick F/0000-0003-0162-7027; Bell, Chaim/0000-0002-3778-9469	sanofi-aventis; AstraZeneca; Centre for Medical Technology Policy; Canadian Institutes of Health Research [67113]; Ontario Ministry of Health and Long-Term Care; Canadian Institutes of Health Research	sanofi-aventis(Sanofi-Aventis); AstraZeneca(AstraZeneca); Centre for Medical Technology Policy; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Bajcar reported that she has been a consultant to Merck Frosst Canada and AstraZeneca; has received payment from sanofi-aventis for lectures; and has received payment from AstraZeneca for manuscript preparation. Dr Zwarenstein reported that he has been consultant on trial design for Johnson & Johnson; and has received financial support from the Centre for Medical Technology Policy for teaching pragmatic trial design. No other disclosures were reported.; The study was funded by operating grant 67113 from the Canadian Institutes of Health Research. This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. Drs Bell and Scales received funding as Canadian Institutes of Health Research New Investigators. Dr Bell now holds a Canadian Institutes of Health Research/Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care.	Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Bajcar Jana M, 2005, Res Social Adm Pharm, V1, P408; Bajcar JM, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-75; Ball C, 2003, BRIT MED J, V327, P1014, DOI 10.1136/bmj.327.7422.1014; Bauer TT, 2001, INTENS CARE MED, V27, P3, DOI 10.1007/PL00020870; Bell CM, 2006, J GEN INTERN MED, V21, P937, DOI 10.1007/BF02743141; Bell CM, 2006, ARCH INTERN MED, V166, P2525, DOI 10.1001/archinte.166.22.2525; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Brown JC, RAPID RESPONSE TEAMS; Calkins DR, 1997, ARCH INTERN MED, V157, P1026, DOI 10.1001/archinte.157.9.1026; COCHRANE RA, 1992, BRIT MED J, V305, P694, DOI 10.1136/bmj.305.6855.694; Coffey Maitreya, 2009, Healthc Q, V12 Spec No Patient, P102; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cornish PL, 2005, ARCH INTERN MED, V165, P424, DOI 10.1001/archinte.165.4.424; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; Etchells E, 2004, CAN MED ASSOC J, V170, P333; Fodor JG, 2000, CAN MED ASSOC J, V162, P1441; Ganz DA, 2000, J GEN INTERN MED, V15, P776, DOI 10.1046/j.1525-1497.2000.91022.x; Gillen D, 1999, GUT, V44, P468, DOI 10.1136/gut.44.4.468; Gleason KM, 2010, J GEN INTERN MED, V25, P441, DOI 10.1007/s11606-010-1256-6; Graves T, 1997, ARCH INTERN MED, V157, P2205, DOI 10.1001/archinte.157.19.2205; Green CJ, 1997, CAN J CARDIOL, V13, P811; GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Harrington RA, 2004, CHEST, V126, p513S, DOI 10.1378/chest.126.3_suppl.513S; Hart RG, 2003, ANN INTERN MED, V138, P831, DOI 10.7326/0003-4819-138-10-200305200-00011; Himmel W, 1996, EUR J CLIN PHARMACOL, V50, P253, DOI 10.1007/s002280050103; Institute for Health Improvement, HOW TO GUID PREV ADV; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Juurlink D, 2006, CANADIAN I HLTH INFO; Katz SJ, 2002, HEALTH AFFAIR, V21, P19, DOI 10.1377/hlthaff.21.3.19; Katz SJ, 1998, HEALTH AFFAIR, V17, P225, DOI 10.1377/hlthaff.17.1.225; Kaushal R, 2001, ARCH PEDIAT ADOL MED, V155, P1002, DOI 10.1001/archpedi.155.9.1002; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Landefeld CS, 2003, ANN INTERN MED, V139, P421, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00008; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; MacLean DR, 1999, CAN J CARDIOL, V15, P434; Maslove DM, 2009, J GEN INTERN MED, V24, P995, DOI 10.1007/s11606-009-1053-2; MONANE M, 1994, ARCH INTERN MED, V154, P433, DOI 10.1001/archinte.154.4.433; Monane M, 1997, AM J HYPERTENS, V10, P697, DOI 10.1016/S0895-7061(97)00056-3; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; O'Donnell Denis E, 2003, Can Respir J, V10 Suppl A, p11A; Perkins GD, 2006, AM J RESP CRIT CARE, V173, P281, DOI 10.1164/rccm.200508-1302OC; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Racz M, 2005, J AM GERIATR SOC, V53, pS245, DOI 10.1111/j.1532-5415.2005.53350.x; Rudd P, 1998, AM J MANAG CARE, V4, P957; Schneeweiss S, 2002, J CLIN EPIDEMIOL, V55, P833, DOI 10.1016/S0895-4356(02)00437-7; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Schnipper JL, 2009, ARCH INTERN MED, V169, P771, DOI 10.1001/archinternmed.2009.51; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; SCHWARTZ D, 1962, AM J PUBLIC HEALTH N, V52, P2018, DOI 10.2105/AJPH.52.12.2018; Sibon I, 2004, NEUROLOGY, V62, P1187, DOI 10.1212/01.WNL.0000118288.04483.02; Tam VC, 2005, CAN MED ASSOC J, V173, P510, DOI 10.1503/cmaj.045311; Waldum HL, 1996, GUT, V39, P649, DOI 10.1136/gut.39.5.649	57	181	185	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	2011	306	8					840	847		10.1001/jama.2011.1206	http://dx.doi.org/10.1001/jama.2011.1206			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	810VY	21862745				2023-01-03	WOS:000294157300021
J	Kox, M; Vaneker, M; van der Hoeven, JG; Scheffer, GJ; Hoedemaekers, CW; Pickkers, P				Kox, Matthijs; Vaneker, Michiel; van der Hoeven, Johannes G.; Scheffer, Gert-Jan; Hoedemaekers, Cornelia W.; Pickkers, Peter			Effects of Vagus Nerve Stimulation and Vagotomy on Systemic and Pulmonary Inflammation in a Two-Hit Model in Rats	PLOS ONE			English	Article							INDUCED LUNG INJURY; CHOLINERGIC ANTIINFLAMMATORY PATHWAY; VENTILATOR-INDUCED INJURY; MECHANICAL VENTILATION; IMPROVES SURVIVAL; HEALTHY MICE; IN-VIVO; SEPSIS; ENDOTOXEMIA; SUSCEPTIBILITY	Pulmonary inflammation contributes to ventilator-induced lung injury. Sepsis-induced pulmonary inflammation (first hit) may be potentiated by mechanical ventilation (MV, second hit). Electrical stimulation of the vagus nerve has been shown to attenuate inflammation in various animal models through the cholinergic anti-inflammatory pathway. We determined the effects of vagotomy (VGX) and vagus nerve stimulation (VNS) on systemic and pulmonary inflammation in a two-hit model. Male Sprague-Dawley rats were i.v. administered lipopolysaccharide (LPS) and subsequently underwent VGX, VNS or a sham operation. 1 hour following LPS, MV with low (8 mL/kg) or moderate (15 mL/kg) tidal volumes was initiated, or animals were left breathing spontaneously (SP). After 4 hours of MV or SP, rats were sacrificed. Cytokine and blood gas analysis was performed. MV with 15, but not 8 mL/kg, potentiated the LPS-induced pulmonary pro-inflammatory cytokine response (TNF-alpha, IL-6, KC: p<0.05 compared to LPS-SP), but did not affect systemic inflammation or impair oxygenation. VGX enhanced the LPS-induced pulmonary, but not systemic pro-inflammatory cytokine response in spontaneously breathing, but not in MV animals (TNF-alpha, IL-6, KC: p<0.05 compared to SHAM), and resulted in decreased pO(2) (p<0.05 compared to sham-operated animals). VNS did not affect any of the studied parameters in both SP and MV animals. In conclusion, MV with moderate tidal volumes potentiates the pulmonary inflammatory response elicited by systemic LPS administration. No beneficial effects of vagus nerve stimulation performed following LPS administration were found. These results questions the clinical applicability of stimulation of the cholinergic anti-inflammatory pathway in systemically inflamed patients admitted to the ICU where MV is initiated.	[Kox, Matthijs; van der Hoeven, Johannes G.; Hoedemaekers, Cornelia W.; Pickkers, Peter] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6525 ED Nijmegen, Netherlands; [Kox, Matthijs; Vaneker, Michiel; Scheffer, Gert-Jan] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol, NL-6525 ED Nijmegen, Netherlands; [Kox, Matthijs; van der Hoeven, Johannes G.; Pickkers, Peter] Nijmegen Inst Infect Inflammat & Immun N4i, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Kox, M (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6525 ED Nijmegen, Netherlands.	m.kox@ic.umcn.nl	Scheffer, G.J./H-8086-2014; van der Hoeven, J.G./H-8048-2014; Hoedemaekers, C.W.E./L-4375-2015; Vaneker, M./L-4702-2015; Pickkers, P./H-8080-2014; Kox, Matthijs/L-4454-2015	Pickkers, P./0000-0002-1104-4303; 				Altemeier WA, 2004, AM J PHYSIOL-LUNG C, V287, pL533, DOI 10.1152/ajplung.00004.2004; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084/jem.20011714; Boland C, 2011, INFLAMMATION, V34, P29, DOI 10.1007/s10753-010-9204-5; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bregeon F, 2005, ANESTHESIOLOGY, V102, P331; Bregeon F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022386; Crimi E, 2006, AM J RESP CRIT CARE, V174, P178, DOI 10.1164/rccm.200507-1178OC; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038/ni1229; dos Santos CC, 2005, CRIT CARE, V9, P280, DOI 10.1186/cc3022; dos Santos CC, 2011, AM J RESP CRIT CARE, V183, P471, DOI 10.1164/rccm.201002-0314OC; Gattinoni L, 2010, CRIT CARE MED, V38, pS539, DOI 10.1097/CCM.0b013e3181f1fcf7; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Hofer S, 2008, CRIT CARE MED, V36, P404, DOI 10.1097/01.CCM.0B013E31816208B3; Hudson LD, 1999, JAMA-J AM MED ASSOC, V282, P77, DOI 10.1001/jama.282.1.77; Huston JM, 2007, CRIT CARE MED, V35, P2762, DOI 10.1097/01.CCM.0000288102.15975.BA; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Imai Y, 1999, J APPL PHYSIOL, V87, P510, DOI 10.1152/jappl.1999.87.2.510; Jerng JS, 2007, THORAX, V62, P527, DOI 10.1136/thx.2006.061945; Jiang JS, 2010, RESPIRATION, V80, P246, DOI 10.1159/000279438; Karzai W, 2005, ANESTHESIOLOGY, V103, P996, DOI 10.1097/00000542-200511000-00014; Kox M, 2011, BR J ANAESTH; Lang JD, 2005, CLIN EXP IMMUNOL, V141, P211, DOI 10.1111/j.1365-2249.2005.02853.x; Lin SM, 2007, SHOCK, V28, P453, DOI 10.1097/shk.0b013e3180487fb5; Liu YY, 2008, CRIT CARE, V12, DOI 10.1186/cc6982; Niederbichler AD, 2009, BURNS, V35, P783, DOI 10.1016/j.burns.2008.08.023; Opal SM, 2010, INT J ANTIMICROB AG, V36, pS70, DOI 10.1016/j.ijantimicag.2010.11.008; Plotz FB, 2004, INTENS CARE MED, V30, P1865, DOI 10.1007/s00134-004-2363-9; Rieger-Fackeldey E, 2008, RESP PHYSIOL NEUROBI, V160, P341, DOI 10.1016/j.resp.2007.10.017; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Schreiber T, 2006, ANESTHESIOLOGY, V104, P133, DOI 10.1097/00000542-200601000-00019; Sevransky Jonathan E, 2004, Crit Care Med, V32, pS548, DOI 10.1097/01.CCM.0000145947.19077.25; Terragni PP, 2009, ANESTHESIOLOGY, V111, P826, DOI 10.1097/ALN.0b013e3181b764d2; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Tremblay LN, 1998, P ASSOC AM PHYSICIAN, V110, P482; Vaneker M, 2007, ANESTHESIOLOGY, V107, P419, DOI 10.1097/01.anes.0000278908.22686.01; Wang H, 2003, NATURE, V421, P384, DOI 10.1038/nature01339; Wolthuis EK, 2009, CRIT CARE, V13, DOI 10.1186/cc7688; Wosten-van Asperen RM, 2010, AM J PATHOL, V176, P2219, DOI 10.2353/ajpath.2010.090565	38	34	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2012	7	4							e34431	10.1371/journal.pone.0034431	http://dx.doi.org/10.1371/journal.pone.0034431			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	955JA	22493690	Green Published, gold			2023-01-03	WOS:000305012700032
J	Pink, DBS; Schulte, W; Parseghian, MH; Zijlstra, A; Lewis, JD				Pink, Desmond B. S.; Schulte, Wendy; Parseghian, Missag H.; Zijlstra, Andries; Lewis, John D.			Real-Time Visualization and Quantitation of Vascular Permeability In Vivo: Implications for Drug Delivery	PLOS ONE			English	Article							CHICK CHORIOALLANTOIC MEMBRANE; TRANSCAPILLARY PRESSURE-GRADIENT; ENDOTHELIAL BARRIER FUNCTION; MICROVASCULAR PERMEABILITY; INTERSTITIAL HYPERTENSION; PHYSIOLOGICAL BARRIERS; TUMOR MICROENVIRONMENT; MICROVESSEL LEAKINESS; SOLID TUMORS; ANGIOGENESIS	The leaky, heterogeneous vasculature of human tumors prevents the even distribution of systemic drugs within cancer tissues. However, techniques for studying vascular delivery systems in vivo often require complex mammalian models and time-consuming, surgical protocols. The developing chicken embryo is a well-established model for human cancer that is easily accessible for tumor imaging. To assess this model for the in vivo analysis of tumor permeability, human tumors were grown on the chorioallantoic membrane (CAM), a thin vascular membrane which overlays the growing chick embryo. The real-time movement of small fluorescent dextrans through the tumor vasculature and surrounding tissues were used to measure vascular leak within tumor xenografts. Dextran extravasation within tumor sites was selectively enhanced an interleukin-2 (IL-2) peptide fragment or vascular endothelial growth factor (VEGF). VEGF treatment increased vascular leak in the tumor core relative to surrounding normal tissue and increased doxorubicin uptake in human tumor xenografts. This new system easily visualizes vascular permeability changes in vivo and suggests that vascular permeability may be manipulated to improve chemotherapeutic targeting to tumors.	[Pink, Desmond B. S.; Schulte, Wendy; Zijlstra, Andries; Lewis, John D.] Innovascreen Inc, Halifax, NS, Canada; [Parseghian, Missag H.] Stonsa Biopharm Inc, Carlsbad, CA USA; [Zijlstra, Andries] Vanderbilt Univ, Dept Pathol, Nashville, TN USA; [Lewis, John D.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada	Vanderbilt University; University of Alberta	Pink, DBS (corresponding author), Innovascreen Inc, Halifax, NS, Canada.	jdlewis@ualberta.ca	zijlstra, andries/G-4564-2013	zijlstra, andries/0000-0001-8460-8803; Parseghian, Missag/0000-0001-6712-6925	Canadian Cancer Society Research Institute [700537]; National Institutes of Health/National Cancer Institute [CA120711-01A1]; National Research Council [636054]; NATIONAL CANCER INSTITUTE [K01CA120711] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Research Council; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by Canadian Cancer Society Research Institute grant # 700537 to Dr. Lewis and National Institutes of Health/National Cancer Institute grant # CA120711-01A1 to Dr. Zijlstra. Dr. Pink was supported by National Research Council-Industrial Research Assistance Program # 636054. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AUSPRUNK DH, 1974, DEV BIOL, V38, P237, DOI 10.1016/0012-1606(74)90004-9; Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124; Cairns R, 2006, MOL CANCER RES, V4, P61, DOI 10.1158/1541-7786.MCR-06-0002; Campbell Robert B., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P503, DOI 10.2174/187152006778699077; CHAMBERS A F, 1990, In Vivo (Attiki), V4, P215; Cho CF, 2011, JOVE-J VIS EXP, DOI 10.3791/2808; Cruz A, 2000, MICROVASC RES, V59, P195, DOI 10.1006/mvre.1999.2226; Cruz A, 1997, TISSUE CELL, V29, P277, DOI 10.1016/S0040-8166(97)80003-1; Czabanka M, 2011, EUR J CANCER, V47, P1276, DOI 10.1016/j.ejca.2011.02.001; Czabanka M, 2009, INT J CANCER, V124, P1293, DOI 10.1002/ijc.24019; DeFouw LM, 2000, MICROVASC RES, V60, P212, DOI 10.1006/mvre.2000.2276; DeFouw LM, 2000, TISSUE CELL, V32, P238, DOI 10.1054/tice.2000.0111; Delmonte A, 2009, EXPERT OPIN INV DRUG, V18, P1541, DOI 10.1517/13543780903213697; Dickson PV, 2007, MOL CANCER RES, V5, P531, DOI 10.1158/1541-7786.MCR-06-0259; Dreher MR, 2006, JNCI-J NATL CANCER I, V98, P335, DOI 10.1093/jnci/djj070; Dvorak HF, 2011, J SURG ONCOL, V103, P468, DOI 10.1002/jso.21709; Eikenes L, 2005, BRIT J CANCER, V93, P81, DOI 10.1038/sj.bjc.6602626; Eikenes L, 2004, CANCER RES, V64, P4768, DOI 10.1158/0008-5472.CAN-03-1472; Epstein AL, 2003, J NATL CANCER I, V95, P741, DOI 10.1093/jnci/95.10.741; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Jain RK, 2007, CANCER RES, V67, P2729, DOI 10.1158/0008-5472.CAN-06-4102; JAIN RK, 1989, JNCI-J NATL CANCER I, V81, P570, DOI 10.1093/jnci/81.8.570; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jang SH, 2003, PHARM RES-DORDR, V20, P1337, DOI 10.1023/A:1025785505977; Khawli L, 2005, CLIN CANCER RES, V11, P3084, DOI 10.1158/1078-0432.CCR-04-2310; Kim TJ, 2007, CANCER RES, V67, P9337, DOI 10.1158/0008-5472.CAN-06-4018; LEESON TS, 1963, J ANAT, V97, P585; Leong HS, 2010, NAT PROTOC, V5, P1406, DOI 10.1038/nprot.2010.103; Lewis JD, 2006, NAT MED, V12, P354, DOI 10.1038/nm1368; Machado MJC, 2011, J PHYSIOL-LONDON, V589, P4681, DOI 10.1113/jphysiol.2011.208355; Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0; Mikhail AS, 2009, J CONTROL RELEASE, V138, P214, DOI 10.1016/j.jconrel.2009.04.010; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Palmer TD, 2011, JOVE-J VIS EXP, DOI 10.3791/2815; Pietras K, 2004, SEMIN ONCOL, V31, P18, DOI 10.1053/j.seminoncol.2004.03.036; Pietras K, 2001, CANCER RES, V61, P2929; Presta LG, 1997, CANCER RES, V57, P4593; Qayum N, 2011, CLIN CANC RES; Qayum N, 2009, CANCER RES, V69, P6347, DOI 10.1158/0008-5472.CAN-09-0657; Reyes-Aldasoro CC, 2008, MICROCIRCULATION, V15, P65, DOI 10.1080/10739680701436350; Ribatti D, 2008, INT REV CEL MOL BIO, V270, P181, DOI 10.1016/S1937-6448(08)01405-6; RIZZO V, 1993, MICROVASC RES, V46, P320, DOI 10.1006/mvre.1993.1056; RIZZO V, 1995, MICROVASC RES, V49, P49, DOI 10.1006/mvre.1995.1005; Rizzo V, 1997, INT J MICROCIRC, V17, P75, DOI 10.1159/000179210; Saw CLL, 2008, DRUG DEV IND PHARM, V34, P1168, DOI [10.1080/03639040801974295, 10.1080/03639040801974295 ]; Seandel M, 2001, BLOOD, V97, P2323, DOI 10.1182/blood.V97.8.2323; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Staton CA, 2009, INT J EXP PATHOL, V90, P195, DOI 10.1111/j.1365-2613.2008.00633.x; Stohrer M, 2000, CANCER RES, V60, P4251; Strieth S, 2008, CLIN CANCER RES, V14, P4603, DOI 10.1158/1078-0432.CCR-07-4738; Strojnik T, 2010, ANTICANCER RES, V30, P4851; Tailor TD, 2010, MOL CANCER THER, V9, P1798, DOI 10.1158/1535-7163.MCT-09-0856; Tartis MS, 2006, ULTRASOUND MED BIOL, V32, P1771, DOI 10.1016/j.ultrasmedbio.2006.03.017; Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074; Valdes TI, 2003, J BIOMED MATER RES A, V67A, P215, DOI 10.1002/jbm.a.10055; Valdes TI, 2002, J BIOMED MATER RES, V62, P273, DOI 10.1002/jbm.10152; Vargas A, 2007, ADV DRUG DELIVER REV, V59, P1162, DOI 10.1016/j.addr.2007.04.019; WU NZ, 1993, CANCER RES, V53, P3765; YUAN F, 1995, CANCER RES, V55, P3752; Zijlstra A, 2002, CANCER RES, V62, P7083; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	64	37	37	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2012	7	3							e33760	10.1371/journal.pone.0033760	http://dx.doi.org/10.1371/journal.pone.0033760			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SR	22479438	Green Published, gold			2023-01-03	WOS:000304523400033
J	Das, M; Sahoo, SK				Das, Manasi; Sahoo, Sanjeeb K.			Folate Decorated Dual Drug Loaded Nanoparticle: Role of Curcumin in Enhancing Therapeutic Potential of Nutlin-3a by Reversing Multidrug Resistance	PLOS ONE			English	Article							P-GLYCOPROTEIN ABCB1; CELL-CYCLE ARREST; CANCER-THERAPY; RETINOBLASTOMA CELLS; IN-VIVO; ANTAGONIST NUTLIN-3; PROTEIN-1 ABCC1; TURMERIC POWDER; P53 PATHWAY; APOPTOSIS	Retinoblastoma is the most common intraocular tumor in children. Malfunctioning of many signaling pathways regulating cell survival or apoptosis, make the disease more vulnerable. Notably, resistance to chemotherapy mediated by MRP-1, lung-resistance protein (LRP) is the most challenging aspect to treat this disease. Presently, much attention has been given to the recently developed anticancer drug nutlin-3a because of its non-genotoxic nature and potency to activate tumor suppressor protein p53. However, being a substrate of multidrug resistance protein MRP1 and Pgp its application has become limited. Currently, research has step towards reversing Multi drug resistance (MDR) by using curcumin, however its clinical relevance is restricted by plasma instability and poor bioavailability. In the present investigation we tried to encapsulate nutlin-3a and curcumin in PLGA nanoparticle (NPs) surface functionalized with folate to enhance therapeutic potential of nutlin-3a by modulating MDR. We document that curcumin can inhibit the expression of MRP-1 and LRP gene/protein in a concentration dependent manner in Y79 cells. In vitro cellular cytotoxicity, cell cycle analysis and apoptosis studies were done to compare the effectiveness of native drugs (single or combined) and single or dual drug loaded nanoparticles (unconjugated/folate conjugated). The result demonstrated an augmented therapeutic efficacy of targeted dual drug loaded NPs (Fol-Nut-Cur-NPs) over other formulation. Enhanced expression or down regulation of proapoptotic/antiapoptotic proteins respectively and down-regulation of bcl2 and NF kappa B gene/protein by Fol-Nut-Cur-NPs substantiate the above findings. This is the first investigation exploring the role of curcumin as MDR modulator to enhance the therapeutic potentiality of nutlin-3a, which may opens new direction for targeting cancer with multidrug resistance phenotype.	[Das, Manasi; Sahoo, Sanjeeb K.] Inst Life Sci, Bhubaneswar, Orissa, India	Department of Biotechnology (DBT) India; Institute of Life Sciences India (ILS)	Das, M (corresponding author), Inst Life Sci, Bhubaneswar, Orissa, India.	sanjeebsahoo2005@gmail.com	Sanjeeb, Sahoo/ABF-3419-2020					Acharya S, 2009, BIOMATERIALS, V30, P5737, DOI 10.1016/j.biomaterials.2009.07.008; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Anand P, 2010, BIOCHEM PHARMACOL, V79, P330, DOI 10.1016/j.bcp.2009.09.003; Anuchapreeda S, 2002, BIOCHEM PHARMACOL, V64, P573, DOI 10.1016/S0006-2952(02)01224-8; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Chearwae W, 2006, CANCER CHEMOTH PHARM, V57, P376, DOI 10.1007/s00280-005-0052-1; Chearwae W, 2004, BIOCHEM PHARMACOL, V68, P2043, DOI 10.1016/j.bcp.2004.07.009; Chearwae W, 2006, MOL CANCER THER, V5, P1995, DOI 10.1158/1535-7163.MCT-06-0087; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Das M, 2011, ACTA BIOMATER, V7, P355, DOI 10.1016/j.actbio.2010.08.010; Das M, 2009, EXPERT OPIN DRUG DEL, V6, P285, DOI 10.1517/17425240902780166; Dilnawaz F, 2010, BIOMATERIALS, V31, P3694, DOI 10.1016/j.biomaterials.2010.01.057; Drago-Ferrante R, 2008, INT J ONCOL, V33, P677, DOI 10.3892/ijo_00000053; Elison JR, 2006, ARCH OPHTHALMOL-CHIC, V124, P1269, DOI 10.1001/archopht.124.9.1269; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j; Greco F, 2009, ADV DRUG DELIVER REV, V61, P1203, DOI 10.1016/j.addr.2009.05.006; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu L, 2008, LEUKEMIA, V22, P730, DOI 10.1038/leu.2008.11; HARPER JW, 1993, CELL, V75, P805; Hendig D, 2009, MOL CELL BIOCHEM, V328, P85, DOI 10.1007/s11010-009-0077-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jain TK, 2008, BIOMATERIALS, V29, P4012, DOI 10.1016/j.biomaterials.2008.07.004; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Kim BS, 2008, ARCH PHARM RES, V31, P1050, DOI 10.1007/s12272-001-1267-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kocbek P, 2007, J CONTROL RELEASE, V120, P18, DOI 10.1016/j.jconrel.2007.03.012; Krishnakumar S, 2004, BRIT J OPHTHALMOL, V88, P1521, DOI 10.1136/bjo.2004.047928; Lee DS, 2009, ANTICANCER RES, V29, P5039; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lim KJ, 2011, CANC BIOL THER, P11; Limtrakul P, 2007, MOL CELL BIOCHEM, V296, P85, DOI 10.1007/s11010-006-9302-8; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Misra R, 2010, EUR J PHARM SCI, V39, P152, DOI 10.1016/j.ejps.2009.11.010; Miyachi M, 2009, CLIN CANCER RES, V15, P4077, DOI 10.1158/1078-0432.CCR-08-2955; Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062; Mohanty C, 2010, NANOMEDICINE-UK, V5, P433, DOI [10.2217/nnm.10.9, 10.2217/NNM.10.9]; Park JS, 2006, J CONTROL RELEASE, V115, P37, DOI 10.1016/j.jconrel.2006.07.011; Parveen S, 2008, J DRUG TARGET, V16, P108, DOI [10.1080/10611860701794353, 10.1080/10611860701794353 ]; Parveen Suphiya, 2010, Cancer Nanotechnol, V1, P47, DOI 10.1007/s12645-010-0006-0; Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021; Reddy MK, 2008, CIRC-CARDIOVASC INTE, V1, P209, DOI 10.1161/CIRCINTERVENTIONS.108.830018; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Rodriguez-Galindo C, 2008, PEDIATRICS, V122, pE763, DOI 10.1542/peds.2008-0518; Roy Madhumita, 2002, Asian Pac J Cancer Prev, V3, P61; Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z; Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405; Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9; Sareen D, 2006, INVEST OPHTH VIS SCI, V47, P3708, DOI 10.1167/iovs.06-0119; Thiyagarajan S, 2009, CURR EYE RES, V34, P845, DOI 10.3109/02713680903125329; Tseng CL, 2007, BIOMATERIALS, V28, P3996, DOI 10.1016/j.biomaterials.2007.05.006; Vandana M, 2010, BIOMATERIALS, V31, P9340, DOI 10.1016/j.biomaterials.2010.08.010; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wang YZ, 2007, INT J PHARM, V337, P63, DOI 10.1016/j.ijpharm.2006.12.033; Zhang ZP, 2007, BIOMATERIALS, V28, P1889, DOI 10.1016/j.biomaterials.2006.12.018; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	57	66	67	1	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2012	7	3							e32920	10.1371/journal.pone.0032920	http://dx.doi.org/10.1371/journal.pone.0032920			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	939YN	22470431	Green Submitted, Green Published, gold			2023-01-03	WOS:000303857100009
J	Prabakar, I; Webb, A				Prabakar, I.; Webb, A.			Emergency contraception	BRITISH MEDICAL JOURNAL			English	Editorial Material							ULIPRISTAL ACETATE; LEVONORGESTREL; PREGNANCY; OVULATION; TRIALS; MG		[Prabakar, I.; Webb, A.] Liverpool Community Hlth, Abacus Serv Sexual & Reprod Healthcare, Liverpool L2 5SF, Merseyside, England		Prabakar, I (corresponding author), Liverpool Community Hlth, Abacus Serv Sexual & Reprod Healthcare, Liverpool L2 5SF, Merseyside, England.	iprabakar@nhs.net						[Anonymous], 2004, SEL PRACT REC CONTR; Brache V, 2010, HUM REPROD, V25, P2256, DOI 10.1093/humrep/deq157; Cheng L, 2008, COCHRANE DB SYST REV, V2; Creinin MD, 2006, OBSTET GYNECOL, V108, P1089, DOI 10.1097/01.AOG.0000239440.02284.45; Croxatto HB, 2004, CONTRACEPTION, V70, P442, DOI 10.1016/j.contraception.2004.05.007; Espinos JJ, 1999, CONTRACEPTION, V60, P243, DOI 10.1016/S0010-7824(99)00090-6; *FAC SEX REPR HEAL, 2010, QUICK START CONTR; Faculty of Sexual and Reproductive Healthcare, 2007, FSRH CLIN GUID INTR; Faculty of Sexual and Reproductive Healthcare, 2011, CLIN GUID; Glasier A, 2011, CONTRACEPTION, V84, P363, DOI 10.1016/j.contraception.2011.02.009; Glasier AF, 2010, LANCET, V375, P555, DOI 10.1016/S0140-6736(10)60101-8; HRA Pharma UK, 2011, ELLAONE SUMM PROD CH; Lader D., 2008, REPORT RES USING NAT; Noe G, 2010, CONTRACEPTION, V81, P414, DOI 10.1016/j.contraception.2009.12.015; Piaggio G, 2011, CONTRACEPTION, V84, P35, DOI 10.1016/j.contraception.2010.11.010; Raymond EG, 2007, OBSTET GYNECOL, V109, P181, DOI 10.1097/01.AOG.0000250904.06923.4a; Stirling A, 2002, CONTRACEPTION, V66, P19, DOI 10.1016/S0010-7824(02)00310-4; Thomas CM, 2010, J FAM PLAN REPROD H, V36, P197, DOI 10.1783/147118910793048656; Trussell J, 2012, EMERGENCY CONTRACEPTION: THE STORY OF A GLOBAL REPRODUCTIVE HEALTH TECHNOLOGY, P19; WILCOX AJ, 1995, NEW ENGL J MED, V333, P1517, DOI 10.1056/NEJM199512073332301; World Health Organization, 2015, MED EL CRIT CONTR US, V5th	21	4	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 19	2012	344								e1492	10.1136/bmj.e1492	http://dx.doi.org/10.1136/bmj.e1492			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913CG	22431662				2023-01-03	WOS:000301848400008
J	Miller, MA; Stabenow, JM; Parvathareddy, J; Wodowski, AJ; Fabrizio, TP; Bina, XWR; Zalduondo, L; Bina, JE				Miller, Mark A.; Stabenow, Jennifer M.; Parvathareddy, Jyothi; Wodowski, Andrew J.; Fabrizio, Thomas P.; Bina, Xiaowen R.; Zalduondo, Lillian; Bina, James E.			Visualization of Murine Intranasal Dosing Efficiency Using Luminescent Francisella tularensis: Effect of Instillation Volume and Form of Anesthesia	PLOS ONE			English	Article							ENDOTRACHEAL INTUBATION; PSEUDOMONAS-AERUGINOSA; TISSUE DISTRIBUTION; TULAREMIA VACCINE; INFECTION; MICE; MOUSE; DELIVERY; MODEL; LIVE	Intranasal instillation is a widely used procedure for pneumonic delivery of drugs, vaccine candidates, or infectious agents into the respiratory tract of research mice. However, there is a paucity of published literature describing the efficiency of this delivery technique. In this report we have used the murine model of tularemia, with Francisella tularensis live vaccine strain (FTLVS) infection, to evaluate the efficiency of pneumonic delivery via intranasal dosing performed either with differing instillation volumes or different types of anesthesia. FTLVS was rendered luminescent via transformation with a reporter plasmid that constitutively expressed the Photorhabdus luminescens lux operon from a Francisella promoter. We then used an IVIS Spectrum whole animal imaging system to visualize FT dissemination at various time points following intranasal instillation. We found that instillation of FT in a dose volume of 10 mu l routinely resulted in infection of the upper airways but failed to initiate infection of the pulmonary compartment. Efficient delivery of FT into the lungs via intranasal instillation required a dose volume of 50 mu l or more. These studies also demonstrated that intranasal instillation was significantly more efficient for pneumonic delivery of FTLVS in mice that had been anesthetized with inhaled (isoflurane) vs. parenteral (ketamine/xylazine) anesthesia. The collective results underscore the need for researchers to consider both the dose volume and the anesthesia type when either performing pneumonic delivery via intranasal instillation, or when comparing studies that employed this technique.	[Miller, Mark A.; Stabenow, Jennifer M.; Parvathareddy, Jyothi; Wodowski, Andrew J.; Fabrizio, Thomas P.; Bina, Xiaowen R.; Zalduondo, Lillian; Bina, James E.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA; [Fabrizio, Thomas P.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	Miller, MA (corresponding author), Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA.	mamiller@uthsc.edu	Bina, Xiaowen/AAE-9100-2022; Fabrizio, Thomas/J-9935-2013	Fabrizio, Thomas/0000-0002-8960-0728	National Institutes of Health (NIH) from the Southeastern Regional Center of Excellence for Emerging Infections and Biodefense [U54 AI057157]; NIH [AI074582, AI079482, AI061260]; Department of Defense Army [W81XHW-05-1-0227]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI074582, R21AI079482, U54AI057157] Funding Source: NIH RePORTER	National Institutes of Health (NIH) from the Southeastern Regional Center of Excellence for Emerging Infections and Biodefense(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Army(United States Department of Defense); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was supported by National Institutes of Health (NIH) grant #U54 AI057157 from the Southeastern Regional Center of Excellence for Emerging Infections and Biodefense (www.serceb.org/), by NIH (www.niaid.nih.gov/) grants AI074582 and AI079482 (to JEB) and AI061260 (to MAM), and by Department of Defense Army grant W81XHW-05-1-0227 (usacehr.amedd.army.mil/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN SD, 1994, J ANTIMICROB CHEMOTH, V34, P1001, DOI 10.1093/jac/34.6.1001; Asensio CJA, 2011, VACCINE, V29, P1649, DOI 10.1016/j.vaccine.2010.12.068; Ayala VI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019016; Balogh EP, 2011, INT J MED MICROBIOL, V301, P252, DOI 10.1016/j.ijmm.2010.08.020; Bina XR, 2010, PLASMID, V64, P156, DOI 10.1016/j.plasmid.2010.07.001; Chapoval SP, 1999, J CLIN INVEST, V103, P1707, DOI 10.1172/JCI6175; Cheng CM, 2011, VACCINE, V29, P2437, DOI 10.1016/j.vaccine.2011.01.031; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Easton A, 2011, J INFECT DIS, V204, P636, DOI 10.1093/infdis/jir301; Ebino K, 1999, INHAL TOXICOL, V11, P171, DOI 10.1080/089583799197131; EIGELSBACH H, 1961, J IMMUNOL, V87, P415; Elkins KL, 2003, MICROBES INFECT, V5, P135, DOI 10.1016/S1286-4579(02)00084-9; Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929; Ezoe H, 2011, VACCINE, V29, P1754, DOI 10.1016/j.vaccine.2010.12.117; Flecknell PA., 2009, LAB ANIMAL ANESTHESI, V3rd edition; Fox J, 2007, MOUSE BIOMEDICAL RES, DOI DOI 10.1016/B978-012369454-6/50094-7; Gabryszewski SJ, 2011, J IMMUNOL, V186, P1151, DOI 10.4049/jimmunol.1001751; Gonzalez A, 2011, MICROB PATHOGENESIS, V51, P161, DOI 10.1016/j.micpath.2011.03.013; Hamacher J, 2008, LAB ANIM-UK, V42, P222, DOI 10.1258/la.2007.006068; He XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020846; Hilliard JJ, 2011, ANTIMICROB AGENTS CH, V55, P836, DOI 10.1128/AAC.00670-10; Hoogendijk AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018519; Hrvacic B, 2006, PHARM RES-DORDR, V23, P1765, DOI 10.1007/s11095-006-9029-y; Kadioglu A, 2011, J IMMUNOL, V186, P5907, DOI 10.4049/jimmunol.1001533; Kamei A, 2011, INFECT IMMUN, V79, P1289, DOI 10.1128/IAI.01139-10; KuoLee R, 2011, MICROBES INFECT, V13, P447, DOI 10.1016/j.micinf.2011.01.010; Lange M, 2011, BIOCHEM BIOPH RES CO, V404, P877, DOI 10.1016/j.bbrc.2010.12.078; Lee LN, 2011, INFECT IMMUN, V79, P3328, DOI 10.1128/IAI.01133-10; MacDonald KD, 2009, J APPL PHYSIOL, V106, P984, DOI 10.1152/japplphysiol.91376.2008; Mares CA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014088; Margolis DA, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-71; Matsuo K, 2000, VACCINE, V18, P1344, DOI 10.1016/S0264-410X(99)00401-6; McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191; Mendez MP, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-12; Mijares LA, 2011, J IMMUNOL, V186, P7080, DOI 10.4049/jimmunol.1003687; Onischuk AA, 2009, J AEROSOL MED PULM D, V22, P245, DOI 10.1089/jamp.2008.0721; Pore D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022663; Rivera B, 2005, CONTEMP TOP LAB ANIM, V44, P52; Rouf R, 2011, MICROBIOL-SGM, V157, P2133, DOI 10.1099/mic.0.048157-0; SASLAW S, 1961, ARCH INTERN MED, V107, P702, DOI 10.1001/archinte.1961.03620050068007; SASLAW S, 1961, ARCH INTERN MED, V107, P689, DOI 10.1001/archinte.1961.03620050055006; SCHOOK LB, 1977, CAN J MICROBIOL, V23, P823, DOI 10.1139/m77-120; Smee DF, 2008, INT J ANTIMICROB AG, V31, P352, DOI 10.1016/j.ijantimicag.2007.11.013; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Spoelstra EN, 2007, LAB ANIM-UK, V41, P128, DOI 10.1258/002367707779399400; Stabenow J, 2010, J VIROL, V84, P3909, DOI 10.1128/JVI.02012-09; Su X, 2004, EXP LUNG RES, V30, P479, DOI 10.1080/01902140490476382; Surendran N, 2011, VACCINE, V29, P2749, DOI 10.1016/j.vaccine.2011.01.090; Thomas RJ, 2008, APPL ENVIRON MICROB, V74, P6437, DOI 10.1128/AEM.01194-08; Twine S, 2005, INFECT IMMUN, V73, P8345, DOI 10.1128/IAI.73.12.8345-8352.2005; van den Boogaard FE, 2011, J THROMB HAEMOST, V9, P122, DOI 10.1111/j.1538-7836.2010.04089.x; Vergari A, 2003, LAB ANIM-UK, V37, P204, DOI 10.1258/002367703766453047; Visweswaraiah A, 2002, VACCINE, V20, P3209, DOI 10.1016/S0264-410X(02)00247-5; Weber SE, 2011, J IMMUNOL, V186, P432, DOI 10.4049/jimmunol.1001963; Zhao L, 2011, INT IMMUNOPHARMACOL, V11, P1378, DOI 10.1016/j.intimp.2011.03.024	55	50	51	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2012	7	2							e31359	10.1371/journal.pone.0031359	http://dx.doi.org/10.1371/journal.pone.0031359			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927OG	22384012	Green Published, gold, Green Submitted			2023-01-03	WOS:000302916800013
J	Gnant, M; Steger, GG				Gnant, Michael; Steger, Guenther G.			Dual inhibition of HER2 in breast cancer treatment	LANCET			English	Editorial Material							TRASTUZUMAB; CHEMOTHERAPY		[Gnant, Michael] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, A-1090 Vienna, Austria; Med Univ Vienna, Dept Med Oncol, Ctr Comprehens Canc, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna	Gnant, M (corresponding author), Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, A-1090 Vienna, Austria.	michael.gnant@meduniwien.ac.at	Gnant, Michael/AAN-7054-2020	Gnant, Michael/0000-0003-1002-2118				Alba E, 2011, CANCER RES, V71, DOI 10.1158/0008-5472.SABCS11-P007-04; Baselga J, 2012, LANCET, V379, P633, DOI 10.1016/S0140-6736(11)61847-3; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Bozovic I, 2011, BREAST INT GROUP DEC; Garnock-Jones KP, 2010, DRUGS, V70, P215, DOI 10.2165/11203700-000000000-00000; Gianni L, 2011, CANCER RES, V71, DOI 10.1158/0008-5472.SABCS11-55-1; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Gnant M, 2009, LANCET, V374, P2029, DOI 10.1016/S0140-6736(09)62097-3; Guarneri V, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.507; Hall PS, 2011, PHARMACOECONOMICS, V29, P415, DOI 10.2165/11588340-000000000-00000; Holmes FA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.506; Joensuu H, 2009, J CLIN ONCOL, V27, P5685, DOI 10.1200/JCO.2008.21.4577; Steger GG, 2007, J CLIN ONCOL, V25, P2012, DOI 10.1200/JCO.2006.09.1777; Untch M, 2012, LANCET ONCOL, V13, P135, DOI 10.1016/S1470-2045(11)70397-7	15	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 18	2012	379	9816					596	598		10.1016/S0140-6736(12)60068-3	http://dx.doi.org/10.1016/S0140-6736(12)60068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	897ES	22257672				2023-01-03	WOS:000300629000008
J	Lee, SS; Lam, ANS; Lee, CK; Wong, NS				Lee, Shui-Shan; Lam, Agnes N. S.; Lee, Chi-Kei; Wong, Ngai-Sze			Virtual versus Physical Channel for Sex Networking in Men Having Sex with Men of Sauna Customers in the City of Hong Kong	PLOS ONE			English	Article							HIV PREVENTION; RISK BEHAVIORS; INTERNET; INFECTION; PREVALENCE; EPIDEMIC; SYPHILIS; TRANSMISSION; PARTNERS; INCREASE	Background: Advances in communication technology may affect networking pattern, thereby influencing the dynamics of sex partnership. The aim of the study is to explore the impacts of partner sourcing through internet and related channels on exposure risk to sexually transmitted infections (STI) including HIV. Methods: Using venue-based sampling, a cross-sectional questionnaire survey was conducted at saunas frequented by men having sex with men (MSM) in Hong Kong. Comparison was made between MSM sourcing partners through physical venues alone versus concomitant users of physical and virtual channels, the latter referring to internet and smart-phone applications, using bivariate logistic regression. Results: Over a 7-week study period, 299 MSM were recruited from 9 saunas. Three main types of sex partners were distinguished: steady (46.8%), regular (26.4%) and casual (96.0%) partners. Users of sauna (n = 78) were compared with concomitant users of saunas and virtual channels (n = 179) for partner sourcing. Sauna-visiting virtual channel users were younger and inclined to use selected physical venues for sourcing partners. Smart-phone users ( n = 90) were not different from other internet-users in terms of age, education level and single/mixed self-identified body appearance. Classifying respondents into high risk and low risk MSM by their frequency of condom use, concomitant use of both sauna and virtual channels accounted for a higher proportion in the high risk category (71.6% vs. 58.2%, OR = 1.81, p<0.05). In virtual channel users, partner sourcing through smart-phone was not associated with a higher practice of unprotected sex. Conclusion: MSM sauna customers commonly use virtual channels for sex partner sourcing. Unprotected sex is more prevalent in sauna customers who use virtual channel for sex partner sourcing. While the popularity of smart-phone is rising, its use is not associated with increased behavioural risk for HIV/STI transmission.	[Lee, Shui-Shan; Lam, Agnes N. S.; Lee, Chi-Kei; Wong, Ngai-Sze] Chinese Univ Hong Kong, Prince Wales Hosp, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Lee, SS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China.	sslee@cuhk.edu.hk	Lee, Shui Shan/B-9374-2008; Wong, Ngai Sze/A-3145-2012	Lee, Shui Shan/0000-0003-1448-765X; Wong, Ngai Sze/0000-0003-3788-8114	Council for the AIDS Trust Fund, Hong Kong [MSS172R]	Council for the AIDS Trust Fund, Hong Kong	The study was supported by the Council for the AIDS Trust Fund, Hong Kong (http://www.atf.gov.hk), grant number MSS172R. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, ECONOMIST; Benotsch EG, 2002, ARCH SEX BEHAV, V31, P177, DOI 10.1023/A:1014739203657; Bremer V, 2006, Euro Surveill, V11, P152; CHIN J, 1988, AIDS, V2, pS247, DOI 10.1097/00002030-198800001-00038; Jenness SM, 2010, AIDS BEHAV, V14, P1353, DOI 10.1007/s10461-010-9769-x; Lau JTF, 2003, AIDS EDUC PREV, V15, P516, DOI 10.1521/aeap.15.7.516.24046; Lee SS, 2011, PUBLIC HEALTH, V125, P433, DOI 10.1016/j.puhe.2011.03.010; Lee Shui Shan, 2009, J Infect Public Health, V2, P177, DOI 10.1016/j.jiph.2009.09.002; Liau A, 2006, SEX TRANSM DIS, V33, P576, DOI 10.1097/01.olq.0000204710.35332.c5; Likatavicius G, 2008, SEX TRANSM INFECT, V84, P499, DOI 10.1136/sti.2008.031419; Marcus U, 2005, SEX TRANSM INFECT, V81, P456, DOI 10.1136/sti.2005.014555; Quan VM, 2002, JAIDS-J ACQ IMM DEF, V31, P188, DOI 10.1097/00126334-200210010-00010; Raymond HF, 2009, AIDS BEHAV, V13, P630, DOI 10.1007/s10461-009-9574-6; Rosser BRS, 2011, AIDS BEHAV, V15, pS91, DOI 10.1007/s10461-011-9910-5; Rosser BRS, 2009, AIDS BEHAV, V13, P746, DOI 10.1007/s10461-008-9399-8; Simms I, 2005, SEX TRANSM DIS, V32, P220, DOI 10.1097/01.olq.0000149848.03733.c1; Spielmann N, 2010, SEX TRANSM INFECT, V86, P331, DOI 10.1136/sti.2009.040857; Swendeman D, 2010, CURR OPIN PSYCHIATR, V23, P139, DOI 10.1097/YCO.0b013e328336656a; Tsui HY, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-232; van de Laar TJW, 2007, J INFECT DIS, V196, P230, DOI 10.1086/518796; van de Laar TJW, 2010, AIDS, V24, P1799, DOI 10.1097/QAD.0b013e32833c11a5; van Griensven F, 2010, AIDS, V24, pS30, DOI 10.1097/01.aids.0000390087.22565.b4; Wilson DP, 2009, JAIDS-J ACQ IMM DEF, V51, P356; Wolitski RJ, 2001, AM J PUBLIC HEALTH, V91, P883, DOI 10.2105/AJPH.91.6.883; Youm Y, 2010, SEX TRANSM INFECT, V86, P24, DOI 10.1136/sti.2010.044008; Zhang M, 2011, AIDS RES HUM RE 0506	26	23	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2012	7	2							e31072	10.1371/journal.pone.0031072	http://dx.doi.org/10.1371/journal.pone.0031072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924ZX	22348038	Green Submitted, gold, Green Published			2023-01-03	WOS:000302730900018
J	Chen, V; Staub, RE; Fong, S; Tagliaferri, M; Cohen, I; Shtivelman, E				Chen, Vivian; Staub, Richard E.; Fong, Sylvia; Tagliaferri, Mary; Cohen, Isaac; Shtivelman, Emma			Bezielle Selectively Targets Mitochondria of Cancer Cells to Inhibit Glycolysis and OXPHOS	PLOS ONE			English	Article							SCUTELLARIA-BARBATA; BREAST-CANCER; ANTICANCER ACTIVITY; ROS RELEASE; DEATH; EXTRACT; APOPTOSIS; BZL101; POLY(ADP-RIBOSE); MECHANISMS	Bezielle (BZL101) is a candidate oral drug that has shown promising efficacy and excellent safety in the early phase clinical trials for advanced breast cancer. Bezielle is an aqueous extract from the herb Scutellaria barbata. We have reported previously that Bezielle was selectively cytotoxic to cancer cells while sparing non-transformed cells. In tumor, but not in non-transformed cells, Bezielle induced generation of ROS and severe DNA damage followed by hyperactivation of PARP, depletion of the cellular ATP and NAD, and inhibition of glycolysis. We show here that tumor cells' mitochondria are the primary source of reactive oxygen species induced by Bezielle. Treatment with Bezielle induces progressively higher levels of mitochondrial superoxide as well as peroxide-type ROS. Inhibition of mitochondrial respiration prevents generation of both types of ROS and protects cells from Bezielle-induced death. In addition to glycolysis, Bezielle inhibits oxidative phosphorylation in tumor cells and depletes mitochondrial reserve capacity depriving cells of the ability to produce ATP. Tumor cells lacking functional mitochondria maintain glycolytic activity in presence of Bezielle thus supporting the hypothesis that mitochondria are the primary target of Bezielle. The metabolic effects of Bezielle towards normal cells are not significant, in agreement with the low levels of oxidative damage that Bezielle inflicts on them. Bezielle is therefore a drug that selectively targets cancer cell mitochondria, and is distinguished from other such drugs by its ability to induce not only inhibition of OXPHOS but also of glycolysis. This study provides a better understanding of the mechanism of Bezielle's cytotoxicity, and the basis of its selectivity towards cancer cells.	[Chen, Vivian; Staub, Richard E.; Fong, Sylvia; Tagliaferri, Mary; Cohen, Isaac; Shtivelman, Emma] BioNovo Inc, Emeryville, CA USA		Chen, V (corresponding author), BioNovo Inc, Emeryville, CA USA.	emmas@bionovo.com		Fong, Sylvia/0000-0002-3818-4146	BioNovo, Inc.; BioNovo. Bezielle [BZL101]	BioNovo, Inc.; BioNovo. Bezielle	This research was supported entirely by BioNovo, Inc. No external funding was received for this study. The funder played a role in the decision to research Bezielle as an anti-cancer agent, but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors acknowledge that they are paid employees and stock holders of BioNovo, Inc, and that this study, in its entirety, was supported by funds from BioNovo. Bezielle (BZL101) is Bionovo's proprietary botanical drug candidate (FDA-IND: 59,521) for the treatment of metastatic breast cancer. Bionovo's United States Patent No. 7,700,136 covers a method of treating breast cancer using an extract of Scutellaria Barbata. This patent also covers the use of Bionovo's proprietary BezielleR formulation as a monotherapy for the treatment of breast cancer. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Batandier C, 2002, J CELL MOL MED, V6, P175, DOI 10.1111/j.1582-4934.2002.tb00185.x; Cha YY, 2004, CLIN CHIM ACTA, V348, P41, DOI 10.1016/j.cccn.2004.04.013; Chen G, 2010, MITOCHONDRION, V10, P614, DOI 10.1016/j.mito.2010.08.001; Choi SW, 2009, J NEUROCHEM, V109, P1179, DOI 10.1111/j.1471-4159.2009.06055.x; Chui CH, 2005, INT J MOL MED, V16, P337; Dai Zhi-jun, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P1835; Desouki MM, 2005, CANCER BIOL THER, V4, P1367, DOI 10.4161/cbt.4.12.2233; Dranka BP, 2010, FREE RADICAL BIO MED, V48, P905, DOI 10.1016/j.freeradbiomed.2010.01.015; Fong S, 2008, CANCER BIOL THER, V7, P577, DOI 10.4161/cbt.7.4.5535; Goh D, 2005, J AGR FOOD CHEM, V53, P8197, DOI 10.1021/jf051506+; Graham KA, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.3.12207; Hegedus C, 2008, FEBS LETT, V582, P1672, DOI 10.1016/j.febslet.2008.04.023; Kim EK, 2007, INT J MOL MED, V20, P123; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Klawitter J, 2011, INT J CANCER, V129, P2945, DOI 10.1002/ijc.25965; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee SB, 2006, J BIOL CHEM, V281, P36228, DOI 10.1074/jbc.M606702200; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Marconett CN, 2010, CANCER BIOL THER, V10, P397, DOI 10.4161/cbt.10.4.12424; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124/mol.106.030122; Parajuli P, 2009, PLANTA MED, V75, P41, DOI 10.1055/s-0028-1088364; Parajuli P, 2011, J NEURO-ONCOL, V101, P15, DOI 10.1007/s11060-010-0221-x; Perez AT, 2010, BREAST CANCER RES TR, V120, P111, DOI 10.1007/s10549-009-0678-5; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Rugo H, 2007, BREAST CANCER RES TR, V105, P17, DOI 10.1007/s10549-006-9430-6; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Shoemaker M, 2005, PHYTOTHER RES, V19, P649, DOI 10.1002/ptr.1702; Sun XG, 2006, CELL CYCLE, V5, P2029, DOI 10.4161/cc.5.17.3312; von Kleist-Retzow JC, 2007, EXP CELL RES, V313, P3076, DOI 10.1016/j.yexcr.2007.04.015; Wong BYY, 2009, EUR J CANCER PREV, V18, P331, DOI 10.1097/CEJ.0b013e32832c3859; Wong BYY, 1996, CANCER BIOTHER RADIO, V11, P51, DOI 10.1089/cbr.1996.11.51; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Yin XL, 2004, LIFE SCI, V75, P2233, DOI 10.1016/j.lfs.2004.05.015; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	39	34	38	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2012	7	2							e30300	10.1371/journal.pone.0030300	http://dx.doi.org/10.1371/journal.pone.0030300			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917LO	22319564	Green Published, Green Submitted, gold			2023-01-03	WOS:000302178400006
J	Santos-Silva, R; Castro, LS; Taddei, JA; Tufik, S; Bittencourt, LRA				Santos-Silva, Rogerio; Castro, Laura Siqueira; Taddei, Jose Augusto; Tufik, Sergio; Azeredo Bittencourt, Lia Rita			Sleep Disorders and Demand for Medical Services: Evidence from a Population-Based Longitudinal Study	PLOS ONE			English	Article							HEALTH-CARE; RISK-FACTOR; INSOMNIA; APNEA; COMPLAINTS; BURDEN; COSTS; DEATH	Background: The aim of this study was to investigate whether insomnia and obstructive sleep apnea (OSA) were predictors of hospitalizations or emergency department visits during two years following the Sao Paulo Epidemiologic Sleep Study (EPISONO) sample. Methods and Findings: All participants (n = 1,101) who underwent a baseline evaluation between July and December 2007 were contacted in December 2009 and asked to fill out a questionnaire about body weight changes, number of hospitalizations and visits to the emergency department. Participants lost during the follow-up period represented 3.2% (n = 35) and 7 subjects had died. Hospitalizations were reported by 116 volunteers (10.5%) and emergency department visits were reported by 136 participants (12.4%). The average body mass index (BMI) did not vary significantly between the first and the second assessment [26.7(95% CI: 26.3-27.1) vs. 26.9(26.5-27.4) kg/m(2)]. After adjusting for confounders, a multiple logistic regression model revealed that female gender [1.4(1.0-1.9)], age >= 40 years, insomnia diagnosed according to the DSM-IV criteria [1.6(1.0-2.6)], and apnea-hypopnea index >= 15 [1.5(1.0-2.2)] were predictors of hospitalizations and/or demand for emergency services. Conclusion: Our study of a probabilistic sample of the Sao Paulo inhabitants shows that over a period of two years, insomnia and OSA were both associated with health impairment. Considering the high prevalence and public health burden of sleep disorders, the consequences of untreated disease for both the individual and society are undeniable and should be addressed.	[Santos-Silva, Rogerio; Castro, Laura Siqueira; Tufik, Sergio; Azeredo Bittencourt, Lia Rita] Univ Fed Sao Paulo UNIFESP, Dept Psicobiol, Disciplina Med & Biol Sono, Sao Paulo, Brazil; [Taddei, Jose Augusto] Univ Fed Sao Paulo UNIFESP, Dept Pediat, Disciplina Nutr & Metab, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	Santos-Silva, R (corresponding author), Univ Fed Sao Paulo UNIFESP, Dept Psicobiol, Disciplina Med & Biol Sono, Sao Paulo, Brazil.	lia@psicobio.epm.br	TADDEI, JOSE AUGUSTO A C/D-8216-2015; Tufik, Sergio/D-7606-2012; Bittencourt, Lia/C-6551-2012; Santos-Silva, Rogerio/E-4630-2013; Castro, Laura/ABB-1293-2021; Sono, Cepid/I-5371-2013	TADDEI, JOSE AUGUSTO A C/0000-0003-3833-392X; Bittencourt, Lia/0000-0001-7738-0927; Castro, Laura/0000-0002-0852-8235; 	Associacao Fundo de Incentivo a Pesquisa (AFIP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [07/50525-1]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CEPID) [98/14303-3]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico	Associacao Fundo de Incentivo a Pesquisa (AFIP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CEPID)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This study was supported by the Associacao Fundo de Incentivo a Pesquisa (AFIP) and Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (#07/50525-1 to RS-S, CEPID # 98/14303-3 to ST). LSC, JAT, ST and LRAB are recipients of fellowships from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; American Psychiatric Association, 1994, TASK FORC D 1 DSM 4; Ban HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018455; Banno K, 2009, SLEEP, V32, P247, DOI 10.1093/sleep/32.2.247; Budhiraja R, 2010, RESP CARE, V55, P1322; Chien KL, 2010, SLEEP, V33, P177, DOI 10.1093/sleep/33.2.177; Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003; Daley M, 2009, SLEEP, V32, P55; Gami AS, 2005, NEW ENGL J MED, V352, P1206, DOI 10.1056/NEJMoa041832; Holty JC, 2011, SLEEP, V34, pA334; Kapur V, 1999, SLEEP, V22, P749, DOI 10.1093/sleep/22.6.749; Kapur Vishesh, 2002, Sleep Breath, V6, P49, DOI 10.1007/s11325-002-0049-5; Kapur VK, 2002, SLEEP, V25, P289; Kish L., 1965, SURVEY SAMPLING; Korn EL., 1999, ANAL HLTH SURVEYS; Leger D, 2010, SLEEP MED, V11, P999, DOI 10.1016/j.sleep.2010.04.018; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marshall NS, 2009, J CLIN SLEEP MED, V5, P15; Morrell MJ, 2010, THORAX, V65, P908, DOI 10.1136/thx.2009.126730; Ohayon MM, 1996, CAN J PSYCHIAT, V41, P457, DOI 10.1177/070674379604100711; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Santos-Silva R, 2009, SLEEP MED, V10, P679, DOI 10.1016/j.sleep.2008.11.001; Sassani A, 2004, SLEEP, V27, P453, DOI 10.1093/sleep/27.3.453; Simon GE, 1997, AM J PSYCHIAT, V154, P1417; Tufik S, 2010, SLEEP MED, V11, P441, DOI 10.1016/j.sleep.2009.10.005; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Young T, 2008, SLEEP, V31, P1071	27	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2012	7	2							e30085	10.1371/journal.pone.0030085	http://dx.doi.org/10.1371/journal.pone.0030085			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914UG	22312420	Green Published, gold, Green Submitted			2023-01-03	WOS:000301977500003
J	Dewan, M; Kumar, A; Saxena, A; De, A; Mozumdar, S				Dewan, Manika; Kumar, Ajeet; Saxena, Amit; De, Arnab; Mozumdar, Subho			Using Hydrophilic Ionic Liquid, [bmim]BF4 - Ethylene Glycol System as a Novel Media for the Rapid Synthesis of Copper Nanoparticles	PLOS ONE			English	Article							EFFICIENT CATALYST; NI-NANOPARTICLES; TEMPERATURE; CHLORIDE; SOLVENTS	In this work, we present a novel method for the synthesis of copper nanoparticles. We utilize the charge compensatory effect of ionic liquid [bmim]BF4 in conjunction with ethylene glycol for providing electro-steric stabilization to copper nanoparticles prepared from copper sulphate using hydrazine hydrate as a reducing agent. The formed copper nanoparticles showed extended stability over a period of one year. Copper nanoparticles thus prepared were characterized by powder X-ray diffraction measurements (pXRD), transmission electron microscopy (TEM) and quasi elastic light scattering (QELS) techniques. Powder X-ray diffraction (pXRD) analysis revealed relevant Bragg's reflection for crystal structure of copper. Powder X-ray diffraction plots also revealed no oxidized material of copper nanoparticles. TEM showed nearly uniform distribution of the particles in methanol and confirmed by QELS. Typical applications of copper nanoparticles include uses in conductive films, lubrication and nanofluids. Currently efforts are under way in our laboratory for using these nanoparticles as catalysts for a variety of organic reactions.	[Dewan, Manika; Kumar, Ajeet; Saxena, Amit; Mozumdar, Subho] Univ Delhi, Dept Chem, Delhi 110007, India; [De, Arnab] Columbia Univ, Med Ctr, Dept Microbiol & Immunol, New York, NY USA	University of Delhi; Columbia University	Dewan, M (corresponding author), Univ Delhi, Dept Chem, Delhi 110007, India.	subhoscom@yahoo.co.in						Antonietti M, 2004, ANGEW CHEM INT EDIT, V43, P4988, DOI 10.1002/anie.200460091; Dewan M, 2010, TETRAHEDRON LETT, V51, P6108, DOI 10.1016/j.tetlet.2010.09.052; Dhas NA, 1998, CHEM MATER, V10, P1446, DOI 10.1021/cm9708269; Earle MJ, 2000, PURE APPL CHEM, V72, P1391, DOI 10.1351/pac200072071391; Germani R, 2007, TETRAHEDRON LETT, V48, P1767, DOI 10.1016/j.tetlet.2007.01.038; Ha SH, 2010, KOREAN J CHEM ENG, V27, P1360, DOI 10.1007/s11814-010-0386-1; He YF, 2008, J PHOTOCH PHOTOBIO A, V197, P253, DOI 10.1016/j.jphotochem.2008.01.001; Holomb R, 2008, J RAMAN SPECTROSC, V39, P793, DOI 10.1002/jrs.1912; Jin K, 2002, CHEM COMMUN, P2872, DOI 10.1039/b209937n; Kachoosangi RT, 2009, ANAL CHEM, V81, P435, DOI 10.1021/ac801853r; Kamavaram V, 2008, INT J THERM SCI, V47, P773, DOI 10.1016/j.ijthermalsci.2007.06.012; Khanna PK, 2007, MATER LETT, V61, P4711, DOI 10.1016/j.matlet.2007.03.014; Kim KS, 2005, KOREAN J CHEM ENG, V22, P717, DOI 10.1007/BF02705788; Kumar A, 2008, CATAL COMMUN, V10, P17, DOI 10.1016/j.catcom.2008.07.030; Kumar A, 2008, CATAL COMMUN, V9, P778, DOI 10.1016/j.catcom.2007.08.021; Kumar A, 2008, CATAL LETT, V122, P98, DOI 10.1007/s10562-007-9349-5; Kumar A, 2011, TETRAHEDRON LETT, V52, P4835, DOI 10.1016/j.tetlet.2011.07.016; Kumar A, 2010, CATAL COMMUN, V11, P679, DOI 10.1016/j.catcom.2010.01.017; Liu X, 2006, TRIBOL LETT, V23, P191, DOI 10.1007/s11249-006-9050-7; Paczal A, 2007, MONATSH CHEM, V138, P1115, DOI 10.1007/s00706-007-0759-2; Redel E, 2008, CHEM COMMUN, P1789, DOI 10.1039/b718055a; Salavati-Niasari M, 2009, MATER LETT, V63, P441, DOI 10.1016/j.matlet.2008.11.023; Seddon KR, 2000, PURE APPL CHEM, V72, P2275, DOI 10.1351/pac200072122275; Trohalaki S, 2005, QSAR COMB SCI, V24, P485, DOI 10.1002/qsar.200430927; Wang L, 2007, SCI CHINA SER B, V50, P63, DOI 10.1007/s11426-007-0016-x; Zhang JD, 2010, J MATER CHEM, V20, P9798, DOI 10.1039/c0jm01970d; Zhang M, 2008, J DISPER SCI TECHNOL, V29, P508, DOI 10.1080/01932690701728734; Zhou Y, 2005, CURR NANOSCI, V1, P35, DOI 10.2174/1573413052953174; Zhu HT, 2005, NANOTECHNOLOGY, V16, P3079, DOI 10.1088/0957-4484/16/12/059; Zhu JM, 2007, J PHYS CHEM C, V111, P7629, DOI 10.1021/jp0711850	30	26	27	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2012	7	1							e29131	10.1371/journal.pone.0029131	http://dx.doi.org/10.1371/journal.pone.0029131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904IR	22238589	gold, Green Published, Green Submitted			2023-01-03	WOS:000301188800005
J	Druce, HC; Mackey, RL; Slotow, R				Druce, Heleen C.; Mackey, Robin L.; Slotow, Rob			How Immunocontraception Can Contribute to Elephant Management in Small, Enclosed Reserves: Munyawana Population as a Case Study	PLOS ONE			English	Article							LONG-TERM CONSERVATION; KRUGER-NATIONAL-PARK; PRIVATE GAME RESERVE; SOUTH-AFRICA; LOXODONTA-AFRICANA; MAKALALI CONSERVANCY; UNGULATE POPULATIONS; WILDLIFE MANAGEMENT; DENSITY; HORSES	Immunocontraception has been widely used as a management tool to reduce population growth in captive as well as wild populations of various fauna. We model the use of an individual-based rotational immunocontraception plan on a wild elephant, Loxodonta africana, population and quantify the social and reproductive advantages of this method of implementation using adaptive management. The use of immunocontraception on an individual, rotational basis stretches the inter-calving interval for each individual female elephant to a management-determined interval, preventing exposing females to unlimited long-term immunocontraception use (which may have as yet undocumented negative effects). Such rotational immunocontraception can effectively lower population growth rates, age the population, and alter the age structure. Furthermore, such structured intervention can simulate natural process such as predation or episodic catastrophic events (e. g., drought), which regulates calf recruitment within an abnormally structured population. A rotational immunocontraception plan is a feasible and useful elephant population management tool, especially in a small, enclosed conservation area. Such approaches should be considered for other long-lived, social species in enclosed areas where the long-term consequences of consistent contraception may be unknown.	[Druce, Heleen C.; Mackey, Robin L.; Slotow, Rob] Univ KwaZulu Natal, Amarula Elephant Res Programme, Sch Biol & Conservat Sci, Durban, South Africa	University of Kwazulu Natal	Druce, HC (corresponding author), Univ KwaZulu Natal, Amarula Elephant Res Programme, Sch Biol & Conservat Sci, Westville Campus, Durban, South Africa.	slotow@ukzn.ac.za	Slotow, Rob/AAM-9053-2020	Slotow, Rob/0000-0001-9469-1508	Distell (Pty) Ltd; University of KwaZulu-Natal; National Research Foundation; Wildlands Conservation Trust	Distell (Pty) Ltd; University of KwaZulu-Natal; National Research Foundation; Wildlands Conservation Trust	Funding received from Distell (Pty) Ltd to the Amarula Elephant Research Programme, University of KwaZulu-Natal, National Research Foundation and by the Conservation Internship Programme of the Wildlands Conservation Trust. The authors are grateful to &Beyond Africa, Phinda Private Game Reserve for providing accommodation and logistical support. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balme GA, 2009, BIOL CONSERV, V142, P2681, DOI 10.1016/j.biocon.2009.06.020; Bertschinger Henk, 2008, P257; BERTSCHINGER HJ, 2005, ROLE IMMUNOCONTRACEP, P13; BERTSCHINGER HJ, 2011, IMMUNOCONTRACEPTION; Biggs Harry C., 2008, P537; Bradshaw GA, 2005, NATURE, V433, P807, DOI 10.1038/433807a; CAUGHLEY G, 1976, E AFR WILDL J, V14, P265; CAUGHLEY G, 1970, ECOLOGY, V51, P53, DOI 10.2307/1933599; Cooper DW, 2001, REPROD FERT DEVELOP, V13, P451, DOI 10.1071/RD01072; Cumming DHM, 1997, S AFR J SCI, V93, P231; DELSINK A, 2005, ROLE IMMUNOCONTRACEP, P69; Delsink AK, 2007, J S AFR VET ASSOC, V78, P25; Delsink AK, 2006, S AFR J SCI, V102, P403; Druce Heleen, 2006, Koedoe, V49, P77; Druce HC, 2008, BIOL CONSERV, V141, P3127, DOI 10.1016/j.biocon.2008.09.024; Estes RD, 1991, BEHAV GUIDE AFRICAN; Fayrer-Hosken RA, 1999, THERIOGENOLOGY, V52, P835, DOI 10.1016/S0093-691X(99)00176-4; Fayrer-Hosken RA, 2000, NATURE, V407, P149, DOI 10.1038/35025136; Foley C, 2008, BIOL LETTERS, V4, P541, DOI 10.1098/rsbl.2008.0370; Garai Marion E., 2004, Pachyderm, V37, P28; Gobush KS, 2008, CONSERV BIOL, V22, P1590, DOI 10.1111/j.1523-1739.2008.01035.x; Gough KF, 2006, ORYX, V40, P434, DOI 10.1017/S0030605306001189; Hayward MW, 2010, ACTA THERIOL, V55, P289, DOI 10.4098/j.at.0001-7051.076.2009; Hayward MW, 2009, BIODIVERS CONSERV, V18, P887, DOI 10.1007/s10531-008-9452-y; Hunter LTB, 2007, ORYX, V41, P196, DOI 10.1017/S003060530700172X; Kerley GIH, 2007, S AFR J SCI, V103, P181; Kerley Graham I.H., 2008, P146; Kettles R, 2009, S AFR J WILDL RES, V39, P23, DOI 10.3957/056.039.0103; KIRKPATRICK JF, 1995, ZOO BIOL, V14, P403, DOI 10.1002/zoo.1430140503; KIRKPATRICK JF, 1992, J REPROD FERTIL, V94, P437, DOI 10.1530/jrf.0.0940437; KIRKPATRICK JF, 2005, ROLE IMMUNOCONTRACEP, P43; KREBS E, 2006, VASECTOMY BIRTH CONT; Laws RM., 1975, ELEPHANT THEIR HABIT; LEE PC, 1987, ANIM BEHAV, V35, P278, DOI 10.1016/S0003-3472(87)80234-8; Lombard AT, 2001, BIOL CONSERV, V102, P191, DOI 10.1016/S0006-3207(01)00056-8; Low AB, 1996, VEGETATION S AFRICA; Mackey RL, 2006, S AFR J WILDL RES, V36, P33; Mackey RL, 2009, AFR J ECOL, V47, P747, DOI 10.1111/j.1365-2028.2009.01075.x; McShea WJ, 1997, J WILDLIFE MANAGE, V61, P560, DOI 10.2307/3802615; Merrill JA, 2003, J WILDLIFE MANAGE, V67, P267, DOI 10.2307/3802768; Moss C. J., 1988, ELEPHANT MEMORIES 13; Moss CJ, 2001, J ZOOL, V255, P145, DOI 10.1017/S0952836901001212; MOSS CJ, 2000, ELEPHANTS MAJESTIC C, P106; Naugle RE, 2002, REPRODUCTION, P143; Owen-Smith N, 2006, S AFR J SCI, V102, P389; Owen-Smith N, 2005, J ANIM ECOL, V74, P774, DOI 10.1111/j.1365-2656.2005.00974.x; Owen-Smith R.N., 1988, MEGAHERBIVORES INFLU, DOI [10.1017/CBO9780511565441, DOI 10.1017/CBO9780511565441]; Perdok AA, 2007, PACHYDERM, P97; Poole JH, 1993, PACHYDERM, V16, P62; Poole Joyce H., 1994, P331; Powell D. M., 2001, Journal of Applied Animal Welfare Science, V4, P271, DOI 10.1207/S15327604JAWS0404_04; RIJKSEN HD, 1981, BEHAVIOUR, V78, P138, DOI 10.1163/156853981X00293; Shi DZ, 2002, J APPL ECOL, V39, P337, DOI 10.1046/j.1365-2664.2002.00716.x; Shideler SE, 2000, US FOR SERV RMRS-P, V3, P137; Sikes S. K., 1971, NATURAL HIST AFRICAN; Singh M, 2005, CURR SCI INDIA, V89, P1230; Slotow R, 2000, NATURE, V408, P425, DOI 10.1038/35044191; Slotow R, 2005, S AFR J WILDL RES, V35, P23; Slotow Rob, 2004, CCA Ecological Journal, V6, P56; STOUT TAE, 2005, ROLE IMMUNOCONTRACEP, P7; Trinkel M, 2010, ANIM CONSERV, V13, P374, DOI 10.1111/j.1469-1795.2009.00344.x; Turner A, 2002, REPRODUCTION, P187; Turner JW, 2007, J WILDLIFE MANAGE, V71, P662, DOI 10.2193/2005-779; Walker B, 1998, WILDLIFE RES, V25, P1, DOI 10.1071/WR97030; Whitehouse AM, 2002, ORYX, V36, P243, DOI 10.1017/S0030605302000455; Whyte I, 1998, ANIM CONSERV, V1, P77, DOI 10.1111/j.1469-1795.1998.tb00014.x; Whyte Ian J., 1998, Pachyderm, V25, P45; Wiseman R, 2004, S AFR J WILDL RES, V34, P25; Wittemyer G, 2007, ECOGRAPHY, V30, P42, DOI 10.1111/j.2006.0906-7590.04900.x; Woolley LA, 2008, ORYX, V42, P49, DOI 10.1017/S0030605308000495; Woolley LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003233	71	21	22	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e27952	10.1371/journal.pone.0027952	http://dx.doi.org/10.1371/journal.pone.0027952			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866FK	22174758	Green Published, Green Submitted, gold			2023-01-03	WOS:000298365700011
J	Mitsunaga, M; Ogawa, M; Kosaka, N; Rosenblum, LT; Choyke, PL; Kobayashi, H				Mitsunaga, Makoto; Ogawa, Mikako; Kosaka, Nobuyuki; Rosenblum, Lauren T.; Choyke, Peter L.; Kobayashi, Hisataka			Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules	NATURE MEDICINE			English	Article							MONOCLONAL-ANTIBODY; PHOTODYNAMIC THERAPY; SINGLET OXYGEN; OVARIAN-CANCER; TUMOR; PHOTOSENSITIZERS; HEMATOPORPHYRIN	Three major modes of cancer therapy (surgery, radiation and chemotherapy) are the mainstay of modern oncologic therapy. To minimize the side effects of these therapies, molecular-targeted cancer therapies, including armed antibody therapy, have been developed with limited success. In this study, we have developed a new type of molecular-targeted cancer therapy, photoimmunotherapy (PIT), that uses a target-specific photosensitizer based on a near-infrared (NIR) phthalocyanine dye, IR700, conjugated to monoclonal antibodies (mAbs) targeting epidermal growth factor receptors. Cell death was induced immediately after irradiating mAbIR-700-bound target cells with NIR light. We observed in vivo tumor shrinkage after irradiation with NIR light in target cells expressing the epidermal growth factor receptor. The mAb-IR700 conjugates were most effective when bound to the cell membrane and produced no phototoxicity when not bound, suggesting a different mechanism for PIT as compared to conventional photodynamic therapies. Target-selective PIT enables treatment of cancer based on mAb binding to the cell membrane.	[Mitsunaga, Makoto; Ogawa, Mikako; Kosaka, Nobuyuki; Rosenblum, Lauren T.; Choyke, Peter L.; Kobayashi, Hisataka] NCI, Mol Imaging Program, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kobayashi, H (corresponding author), NCI, Mol Imaging Program, Ctr Canc Res, US Natl Inst Hlth, Bethesda, MD 20892 USA.	kobayash@mail.nih.gov			US National Institutes of Health, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010656] Funding Source: NIH RePORTER	US National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the US National Institutes of Health, National Cancer Institute, Center for Cancer Research. We would like to thank C. Regino, T. Hirano and C. Paik for their technical support.	Carcenac M, 2001, BRIT J CANCER, V85, P1787, DOI 10.1054/bjoc.2001.2170; Detty MR, 2004, J MED CHEM, V47, P3897, DOI 10.1021/jm040074b; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471; Hamblin MR, 1996, CANCER RES, V56, P5205; Kosaka N, 2010, PROC SPIE, V7576, DOI 10.1117/12.842090; Kosaka N, 2010, CANCER SCI, V101, P820, DOI 10.1111/j.1349-7006.2009.01423.x; Mandler R, 2004, CANCER RES, V64, P1460, DOI 10.1158/0008-5472.CAN-03-2485; MEW D, 1985, CANCER RES, V45, P4380; MEW D, 1983, J IMMUNOL, V130, P1473; Nanus DM, 2003, J UROLOGY, V170, pS84, DOI 10.1097/01.ju.0000095151.97404.7c; Ogawa M, 2009, BIOCONJUGATE CHEM, V20, P2177, DOI 10.1021/bc900362k; Ogawa M, 2009, MOL CANCER THER, V8, P232, DOI 10.1158/1535-7163.MCT-08-0862; Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891; PATTERSON MS, 1990, J PHOTOCH PHOTOBIO B, V5, P69, DOI 10.1016/1011-1344(90)85006-I; POOLER JP, 1979, PHOTOCHEM PHOTOBIOL, V30, P581, DOI 10.1111/j.1751-1097.1979.tb07183.x; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Sobolev AS, 2000, PROG BIOPHYS MOL BIO, V73, P51, DOI 10.1016/S0079-6107(00)00002-X; THORPE WP, 1995, BIOPHYS J, V68, P2198, DOI 10.1016/S0006-3495(95)80402-9; van Dongen GAMS, 2004, ADV DRUG DELIVER REV, V56, P31, DOI 10.1016/j.addr.2003.09.003; Vrouenraets MB, 1999, CANCER RES, V59, P1505; Vrouenraets MB, 2001, CANCER RES, V61, P1970; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; Wilson BC, 1990, PHOTODYNAMIC THERAPY, V1, P129; Yang XD, 1999, CANCER RES, V59, P1236; Zhong W, 2009, BRIT J CANCER, V101, P2015, DOI 10.1038/sj.bjc.6605436	28	676	706	15	334	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2011	17	12					1685	U210		10.1038/nm.2554	http://dx.doi.org/10.1038/nm.2554			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	860WC	22057348	Green Accepted			2023-01-03	WOS:000297978000044
J	Kim, SN; Doo, AR; Park, JY; Bae, H; Chae, Y; Shim, I; Lee, H; Moon, W; Lee, H; Park, HJ				Kim, Seung-Nam; Doo, Ah-Reum; Park, Ji-Yeun; Bae, Hyungjin; Chae, Younbyoung; Shim, Insop; Lee, Hyangsook; Moon, Woongjoon; Lee, Hyejung; Park, Hi-Joon			Acupuncture Enhances the Synaptic Dopamine Availability to Improve Motor Function in a Mouse Model of Parkinson's Disease	PLOS ONE			English	Article							INDUCED ROTATIONAL BEHAVIOR; ELECTROACUPUNCTURE STIMULATION; MESSENGER-RNA; EXERCISE; DEFICITS	Parkinson's disease (PD) is caused by the selective loss of dopaminergic neurons in the substantia nigra (SN) and the depletion of striatal dopamine (DA). Acupuncture, as an alternative therapy for PD, has beneficial effects in both PD patients and PD animal models, although the underlying mechanisms therein remain uncertain. The present study investigated whether acupuncture treatment affected dopamine neurotransmission in a PD mouse model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We found that acupuncture treatment at acupoint GB34 improved motor function with accompanying dopaminergic neuron protection against MPTP but did not restore striatal dopamine depletion. Instead, acupuncture treatment increased dopamine release that in turn, may lead to the enhancement of dopamine availability in the synaptic cleft. Moreover, acupuncture treatment mitigated MPTP-induced abnormal postsynaptic changes, suggesting that acupuncture treatment may increase postsynaptic dopamine neurotransmission and facilitate the normalization of basal ganglia activity. These results suggest that the acupuncture-induced enhancement of synaptic dopamine availability may play a critical role in motor function improvement against MPTP.	[Kim, Seung-Nam; Doo, Ah-Reum; Park, Ji-Yeun; Bae, Hyungjin; Chae, Younbyoung; Shim, Insop; Lee, Hyangsook; Moon, Woongjoon; Lee, Hyejung; Park, Hi-Joon] Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea; [Kim, Seung-Nam] Kyung Hee Univ, Dept Oriental Med Sci, Seoul, South Korea	Kyung Hee University; Kyung Hee University	Kim, SN (corresponding author), Kyung Hee Univ, Acupuncture & Meridian Sci Res Ctr, Seoul, South Korea.	wm9306@naver.com; acufind@khu.ac.kr	Chae, Younbyoung/AAM-1243-2020; Park, Hi-Joon/AAG-1196-2021; LEE, HYANGSOOK/D-2070-2017	LEE, HYANGSOOK/0000-0002-1107-9389; Park, Hi-Joon/0000-0002-0538-2664; Shim, Insop/0000-0002-8014-9782; Chae, Younbyoung/0000-0001-6787-2215	National Research Foundation of Korea (NRF); Korea government (MEST) [2010-0008834, 2005-0049404]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government)	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) [2010-0008834 and 2005-0049404]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson M, 1999, NEUROBIOL DIS, V6, P461, DOI 10.1006/nbdi.1999.0259; Antonini A, 2009, LANCET NEUROL, V8, P929, DOI 10.1016/S1474-4422(09)70225-X; CHERAMY A, 1981, NATURE, V289, P537, DOI 10.1038/289537a0; Crocker SJ, 2003, J NEUROSCI, V23, P4081; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; Hirsch EC, 1998, MOVEMENT DISORD, V13, P39; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Jeon S, 2008, PROTEOMICS, V8, P4822, DOI 10.1002/pmic.200700955; Jeun SS, 2005, AM J CHINESE MED, V33, P573, DOI 10.1142/S0192415X0500317X; Jia J, 2010, BEHAV NEUROSCI, V124, P305, DOI 10.1037/a0018931; Jia J, 2009, BEHAV BRAIN RES, V205, P214, DOI 10.1016/j.bbr.2009.06.024; Kang JM, 2007, BRAIN RES, V1131, P211, DOI 10.1016/j.brainres.2006.10.089; Keith B.J., 2008, MOUSE BRAIN STEREOTA; Kim ST, 2010, J PHYSIOL SCI, V60, P27, DOI 10.1007/s12576-009-0061-7; KIM SN, 2011, INT J NEURO IN PRESS; Liang XB, 2003, NEUROREPORT, V14, P1177, DOI 10.1097/00001756-200306110-00015; LIANGYUE D, 2004, CHINESE ACUPUNCTURE; Mount MP, 2007, J NEUROSCI, V27, P3328, DOI 10.1523/JNEUROSCI.5321-06.2007; MOURADIAN MM, 1987, CLIN NEUROPHARMACOL, V10, P351, DOI 10.1097/00002826-198708000-00005; Na BJ, 2009, NEUROSCI LETT, V464, P1, DOI 10.1016/j.neulet.2009.08.009; Nishi A, 2008, J NEUROSCI, V28, P10460, DOI 10.1523/JNEUROSCI.2518-08.2008; Park HJ, 2003, EXP NEUROL, V180, P92, DOI 10.1016/S0014-4886(02)00031-6; Petzinger GM, 2007, J NEUROSCI, V27, P5291, DOI 10.1523/JNEUROSCI.1069-07.2007; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; ROBERTSON GS, 1989, J NEUROSCI, V9, P3326; Rozas G, 1997, BRAIN RES PROTOC, V2, P75, DOI 10.1016/S1385-299X(97)00034-2; Rozas G, 1998, J NEUROSCI METH, V83, P165, DOI 10.1016/S0165-0270(98)00078-8; Santini E, 2008, FEBS J, V275, P1392, DOI 10.1111/j.1742-4658.2008.06296.x; Smith PD, 2003, P NATL ACAD SCI USA, V100, P13650, DOI 10.1073/pnas.2232515100; Tseng JL, 1997, J NEUROSCI, V17, P325, DOI 10.1523/JNEUROSCI.17-01-00325.1997; Vuckovic MG, 2008, NEUROBIOL DIS, V32, P319, DOI 10.1016/j.nbd.2008.07.015; World Health Organization. (WHO) Regional Office for the Western Pacific, 2008, WHO STAND AC POINT L; Yin CS, 2008, RES VET SCI, V84, P159, DOI 10.1016/j.rvsc.2007.04.004; Yu YP, 2010, BRAIN RES, V1336, P58, DOI 10.1016/j.brainres.2010.04.020	36	60	63	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 22	2011	6	11							e27566	10.1371/journal.pone.0027566	http://dx.doi.org/10.1371/journal.pone.0027566			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858JH	22132113	gold, Green Submitted, Green Published			2023-01-03	WOS:000297792400009
J	Ferreira, JP; Anderson, KL; Correa, MT; Lyman, R; Ruffin, F; Reller, LB; Fowler, VG				Ferreira, Jorge Pinto; Anderson, Kevin L.; Correa, Maria T.; Lyman, Roberta; Ruffin, Felicia; Reller, L. Barth; Fowler, Vance G., Jr.			Transmission of MRSA between Companion Animals and Infected Human Patients Presenting to Outpatient Medical Care Facilities	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; SOFT-TISSUE INFECTIONS; PET ANIMALS; DOG; PSEUDINTERMEDIUS; COLONIZATION; PREVALENCE; HOUSEHOLD; CARRIAGE; SKIN	Methicillin-resistant Staphylococcus aureus (MRSA) is a significant pathogen in both human and veterinary medicine. The importance of companion animals as reservoirs of human infections is currently unknown. The companion animals of 49 MRSA-infected outpatients (cases) were screened for MRSA carriage, and their bacterial isolates were compared with those of the infected patients using Pulsed-Field Gel Electrophoresis (PFGE). Rates of MRSA among the companion animals of MRSA-infected patients were compared to rates of MRSA among companion animals of pet guardians attending a "veterinary wellness clinic'' (controls). MRSA was isolated from at least one companion animal in 4/49 (8.2%) households of MRSA-infected outpatients vs. none of the pets of the 50 uninfected human controls. Using PFGE, patient-pets MRSA isolates were identical for three pairs and discordant for one pair (suggested MRSA inter-specie transmission p-value = 0.1175). These results suggest that companion animals of MRSA-infected patients can be culture-positive for MRSA, representing a potential source of infection or re-infection for humans. Further studies are required to better understand the epidemiology of MRSA human-animal inter-specie transmission.	[Ferreira, Jorge Pinto; Anderson, Kevin L.; Correa, Maria T.; Lyman, Roberta] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol PHP, Raleigh, NC 27607 USA; [Ferreira, Jorge Pinto; Ruffin, Felicia; Reller, L. Barth; Fowler, Vance G., Jr.] Duke Univ, Sch Med, Dept Infect Dis, Durham, NC USA	University of North Carolina; North Carolina State University; Duke University	Ferreira, JP (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol PHP, Raleigh, NC 27607 USA.	jmferrei@ncsu.edu	Fowler, Vance/AAW-2017-2021		National Institutes of Health (NIH) [K24AI093969-01, R01 AI068804]; Fulbright program; NIH; Astellas; Cubist; Inhibitex; Merck; Theravance; Cerexa; Pfizer; Novartis; Advanced Liquid Logic; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI093969, R01AI068804] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fulbright program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Astellas(Astellas Pharmaceuticals); Cubist; Inhibitex; Merck(Merck & Company); Theravance; Cerexa; Pfizer(Pfizer); Novartis(Novartis); Advanced Liquid Logic; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by the National Institutes of Health (NIH) K24AI093969-01 and R01 AI068804. Dr. Ferreira's stipend was partially supported by Fulbright program, a not-for-profit organization. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Dr. Vance G. Fowler has received or has pending grants from NIH, Astellas, Cubist, Inhibitex, Merck, Theravance, Cerexa, Pfizer, Novartis, Advanced Liquid Logic; has received royalties from UpToDate; has been paid for development of educational presentations by Astellas, Merck, Pfizer, Targanta, Theravance, Wyeth, Novartis, Vertex, Medimmune; has served as a consultant for Astellas, Cubist, Inhibitex, Johnson & Johnson, Shire, Leo Pharmaceuticals, Merck, NovaDigm, Medicines Company, Baxter, Biosynexus, Inimex, Galderma; has received honoraria from Arpida, Astellas, Cubist, Inhibitex, Merck, Pfizer, Targanta, Theravance, Wyeth, Ortho-McNeil, Novartis & Vertex Pharmaceuticals; and has served on an advisory committee and on a speaker's bureau for Cubist. There are no patents, products in development or marketed products related to this study to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Baptiste KE, 2005, EMERG INFECT DIS, V11, P1942, DOI 10.3201/eid1112.050241; Blanc DS, 2007, J CLIN MICROBIOL, V45, P3729, DOI 10.1128/JCM.00511-07; Boost MV, 2008, EPIDEMIOL INFECT, V136, P953, DOI 10.1017/S0950268807009326; CEFAI C, 1994, LANCET, V344, P539, DOI 10.1016/S0140-6736(94)91926-7; Chuang CY, 2010, J CLIN MICROBIOL, V48, P1497, DOI 10.1128/JCM.02033-09; Daum RS, 2007, NEW ENGL J MED, V357, P380, DOI 10.1056/NEJMcp070747; *DEP HLTH HUM SERV, 2001, OX RES STAPH AUR PUL; Devriese LA, 2005, INT J SYST EVOL MICR, V55, P1569, DOI 10.1099/ijs.0.63413-0; Faires MC, 2009, JAVMA-J AM VET MED A, V235, P540, DOI 10.2460/javma.235.5.540; Frank LA, 2009, VET DERMATOL, V20, P496, DOI 10.1111/j.1365-3164.2009.00826.x; Guardabassi L, 2004, J ANTIMICROB CHEMOTH, V54, P321, DOI 10.1093/jac/dkh332; Hanselman BA, 2006, EMERG INFECT DIS, V12, P1933; Karchmer AW, 2008, CLIN INFECT DIS, V46, pS342, DOI 10.1086/533589; King MD, 2006, ANN INTERN MED, V144, P309, DOI 10.7326/0003-4819-144-5-200603070-00005; Lee JH, 2006, VET MICROBIOL, V114, P155, DOI 10.1016/j.vetmic.2005.10.024; Leonard FC, 2008, VET J, V175, P27, DOI 10.1016/j.tvjl.2006.11.008; Lilenbaum W, 1998, LETT APPL MICROBIOL, V27, P224, DOI 10.1046/j.1472-765X.1998.00406.x; Lloyd DH, 2007, CLIN INFECT DIS, V45, pS148, DOI 10.1086/519254; Loeffler A, 2005, J ANTIMICROB CHEMOTH, V56, P692, DOI 10.1093/jac/dki312; LOEFFLER A, 2010, EPIDEMIOL INFECT, V14, P1; Manian FA, 2003, CLIN INFECT DIS, V36, pE26, DOI 10.1086/344772; Mathema Barun, 2008, V431, P285; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Oehler RL, 2009, LANCET INFECT DIS, V9, P439, DOI 10.1016/S1473-3099(09)70110-0; Sanders R C Jr, 2011, J Ark Med Soc, V107, P288; Sasaki T, 2010, J CLIN MICROBIOL, V48, P765, DOI 10.1128/JCM.01232-09; SCOTT GM, 1988, J HOSP INFECT, V12, P29, DOI 10.1016/0195-6701(88)90119-3; Silbergeld EK, 2008, MED CLIN N AM, V92, P1391, DOI 10.1016/j.mcna.2008.07.003; Smith TC, 2011, VECTOR-BORNE ZOONOT, V11, P327, DOI 10.1089/vbz.2010.0072; van Duijkeren E, 2008, VET MICROBIOL, V128, P213, DOI 10.1016/j.vetmic.2007.11.016; van Duijkeren E, 2005, J CLIN MICROBIOL, V43, P6209, DOI 10.1128/JCM.43.12.6209-6211.2005; van Duijkeren E, 2011, VET MICROBIOL, V150, P338, DOI 10.1016/j.vetmic.2011.02.012; van Duijkeren E, 2004, EMERG INFECT DIS, V10, P2235, DOI 10.3201/eid1012.040387; Van Hoovels L, 2006, J CLIN MICROBIOL, V44, P4609, DOI 10.1128/JCM.01308-06; van Loo I, 2007, EMERG INFECT DIS, V13, P1834, DOI 10.3201/eid1312.070384; Wayne P. A., 2008, PERFORMANCE STANDA S; Weese JS, 2006, VET MICROBIOL, V115, P148, DOI 10.1016/j.vetmic.2006.01.004	37	52	52	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2011	6	11							e26978	10.1371/journal.pone.0026978	http://dx.doi.org/10.1371/journal.pone.0026978			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HQ	22102871	Green Submitted, Green Published, gold			2023-01-03	WOS:000297348800014
J	Steinsbekk, A; Rise, MB; Bishop, F; Lewith, G				Steinsbekk, Aslak; Rise, Marit By; Bishop, Felicity; Lewith, George			Predictors for Adolescent Visits to Practitioners of Complementary and Alternative Medicine in a Total Population (the Young-HUNT Studies)	PLOS ONE			English	Article							CHILDREN; CAM; PREVALENCE; PROVIDERS; CARE	Aim: To investigate the factors predicting adolescent visits to practitioners of complementary and alternative medicine (CAM). Methods: A longitudinal cohort study conducted in an adolescent total population in Central Norway (The Nord-Trondelag Health Studies (HUNT)). In Young-HUNT 1, all inhabitants aged 13 to 19 years (N = 8944, 89% response rate) were invited to participate, and the youngest group (13 to 15 year olds) was surveyed again 4 years later (Young-HUNT 2, N = 2429, 82% response rate). The participants completed a comprehensive questionnaire on health and life style which included a question regarding visits to a CAM practitioner in the last 12 months. Results: One in eleven (8.7%, 95% CI 7.6-9.8%) had visited a CAM practitioner, an increase of 26% in 4 years (1.8% points). The final multivariable analysis predicted increased odds of an adolescent becoming a CAM visitor four years later (p<0.05) if she or he had previously visited a CAM practitioner (adjOR 3.4), had musculoskeletal pain (adjOR 1.5), had migraine (adjOR 2.3), used asthma medicines (adjOR 1.8) or suffered from another disease lasting more than three months (adjOR 2.1). Being male predicted reduced odds of visiting a CAM practitioner in the future (adjOR 0.6). Conclusion: We can conclude from this study that future visits to a CAM practitioner are predicted by both predisposing factors (being female, having visited a CAM practitioner previously) and medical need factors (having had musculoskeletal pain, migraine, used asthma medicines or experienced another disease lasting more than three months). None of the specific variables associated with CAM visits were predictive for CAM visits four years later.	[Steinsbekk, Aslak; Rise, Marit By] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7034 Trondheim, Norway; [Bishop, Felicity; Lewith, George] Univ Southampton, Complementary & Integrated Med Res Unit, Southampton, Hants, England	Norwegian University of Science & Technology (NTNU); University of Southampton	Steinsbekk, A (corresponding author), Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7034 Trondheim, Norway.	aslak.steinsbekk@ntnu.no	Steinsbekk, Aslak/E-9223-2012	Steinsbekk, Aslak/0000-0001-9090-0739; Lewith, George/0000-0002-2364-3960; Bishop, Felicity/0000-0002-8737-6662				ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; April KT, 2009, COMPLEMENT THER MED, V17, P208, DOI 10.1016/j.ctim.2009.03.003; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Birdee GS, 2010, PEDIATRICS, V125, P249, DOI 10.1542/peds.2009-1406; Bishop Felicity L, 2009, Complement Ther Clin Pract, V15, P8, DOI 10.1016/j.ctcp.2008.09.005; Bishop FL, 2010, PEDIATRICS, V125, P768, DOI 10.1542/peds.2009-1775; Braun C A, 2000, J Holist Nurs, V18, P176, DOI 10.1177/089801010001800208; Breuner CC, 1998, ARCH PEDIAT ADOL MED, V152, P1071; FOULADBAKHSH JM, 2007, J COMPLEMENTARY INTE, V4, P1, DOI DOI 10.2202/1553-3840.1035; Gross-Tsur V, 2003, PEDIATR NEUROL, V29, P53, DOI 10.1016/s0887-8994(03)00027-4; Harris P, 2000, COMPLEMENT THER MED, V8, P88, DOI 10.1054/ctim.2000.0353; Heuschkel R, 2002, AM J GASTROENTEROL, V97, P382, DOI 10.1111/j.1572-0241.2002.05474.x; Holmen J., 2003, NORSK EPIDEMIOLOGI, V13, P19, DOI DOI 10.1093/eurheartj/eht019; Hughes SC, 2006, AMBUL PEDIATR, V6, P293, DOI 10.1016/j.ambp.2005.11.007; Little P, 2001, BRIT J GEN PRACT, V51, P977; Lorenc A, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-9; Quandt SA, 2009, J ALTERN COMPLEM MED, V15, P331, DOI 10.1089/acm.2008.0521; Steinsbekk A, 2008, FORSCH KOMPLEMENTMED, V15, P146, DOI 10.1159/000134904; Steinsbekk A, 2006, FORSCH KOMP KLAS NAT, V13, P88, DOI 10.1159/000092004; Yussman SM, 2004, AMBUL PEDIATR, V4, P429, DOI 10.1367/A03-091R1.1; Zwaanswijk M, 2003, EUR CHILD ADOLES PSY, V12, P153, DOI 10.1007/S00787-003-0322-6	22	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2011	6	10							e25719	10.1371/journal.pone.0025719	http://dx.doi.org/10.1371/journal.pone.0025719			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834OC	22003404	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000295970300025
J	Ratner, ES; Keane, FK; Lindner, R; Tassi, RA; Paranjape, T; Glasgow, M; Nallur, S; Deng, Y; Lu, L; Steele, L; Sand, S; Muller, RU; Bignotti, E; Bellone, S; Boeke, M; Yao, X; Pecorelli, S; Ravaggi, A; Katsaros, D; Zelterman, D; Cristea, MC; Yu, H; Rutherford, TJ; Weitzel, JN; Neuhausen, SL; Schwartz, PE; Slack, FJ; Santin, AD; Weidhaas, JB				Ratner, E. S.; Keane, F. K.; Lindner, R.; Tassi, R. A.; Paranjape, T.; Glasgow, M.; Nallur, S.; Deng, Y.; Lu, L.; Steele, L.; Sand, S.; Muller, R-U; Bignotti, E.; Bellone, S.; Boeke, M.; Yao, X.; Pecorelli, S.; Ravaggi, A.; Katsaros, D.; Zelterman, D.; Cristea, M. C.; Yu, H.; Rutherford, T. J.; Weitzel, J. N.; Neuhausen, S. L.; Schwartz, P. E.; Slack, F. J.; Santin, A. D.; Weidhaas, J. B.			A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer	ONCOGENE			English	Article						platinum resistance; KRAS variant; ovarian cancer; outcome	LET-7 MICRORNA-BINDING; 3'-UNTRANSLATED REGION; EXPRESSION; CARBOPLATIN; PACLITAXEL; SURVIVAL; MODELS; MARKER; SITE	Germline variants in the 30 untranslated region (3'UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3'UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS variant-positive EOC patients. As this variant seems to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival. EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n = 536), response to neoadjuvant chemotherapy (n = 25) and platinum resistance (n = 306). Outcome was separately analyzed for women with known BRCA mutations (n = 79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were used to confirm altered sensitivity to chemotherapy associated with the KRAS variant. Finally, the KRAS variant was directly targeted through small-interfering RNA/miRNA oligonucleotides in cell lines and survival was measured. Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio 1.67, 95% confidence interval: 1.09-2.57, P = 0.019, n = 279). Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio 3.18, confidence interval: 1.31-7.72, P = 0.0106, n = 291). In addition, direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this study supports the hypothesis that these tumors have continued dependence on such 3'UTR lesions, and that direct targeting may be a viable future treatment approach.	[Weidhaas, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; [Ratner, E. S.; Bellone, S.; Rutherford, T. J.; Schwartz, P. E.; Santin, A. D.] Yale Univ, Dept Gynecol Oncol, New Haven, CT 06520 USA; [Lindner, R.] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Heidelberg, Germany; [Tassi, R. A.; Bignotti, E.; Pecorelli, S.; Ravaggi, A.] Univ Brescia, Div Gynecol Oncol, Angelo Nocivelli Inst Mol Med, Brescia, Italy; [Deng, Y.; Lu, L.; Yao, X.; Zelterman, D.; Yu, H.] Yale Univ, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Steele, L.; Neuhausen, S. L.] Beckman Res Inst City Hope, Dept Populat Sci, Duarte, CA USA; [Sand, S.; Weitzel, J. N.] City Hope Natl Med Ctr, Div Clin Canc Genet, Duarte, CA USA; [Muller, R-U] Univ Cologne, Dept Med, Div Renal, D-50931 Cologne, Germany; [Muller, R-U] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany; [Katsaros, D.] Univ Turin, Dept Gynecol Oncol, Turin, Italy; [Cristea, M. C.] City Hope Natl Med Ctr, Dept Med Oncol, Duarte, CA USA; [Slack, F. J.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University; Ruprecht Karls University Heidelberg; University of Brescia; Yale University; City of Hope; Beckman Research Institute of City of Hope; City of Hope; University of Cologne; University of Cologne; University of Turin; City of Hope; Yale University	Weidhaas, JB (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.	joanne.weidhaas@yale.edu	Müller, Roman-Ulrich/AAK-3493-2021; Ravaggi, Antonella/K-5585-2016	Müller, Roman-Ulrich/0000-0001-6910-0745; Ravaggi, Antonella/0000-0003-4661-9979; Slack, Frank/0000-0001-8263-0409; Sand, Sharon/0000-0002-9390-5583; Weidhaas, Joanne/0000-0002-5096-3281; Bellone, Stefania/0000-0001-5909-5292; Zelterman, Daniel/0000-0003-0711-8688; Weitzel, Jeffrey/0000-0001-6714-092X	Women's Reproductive Health Research (WRHR) Career Development Program grant [5K12HD047018-08]; Mary Kay Foundation; NCI [CA131301-01A1, RC4CA153828]; K08 grant [CA124484]; Morris and Horowitz Families Endowed Professorship; NIH [R01CA74415]; Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health;  [R01CA122728]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD047018] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K08CA124484, R01CA122728, R01CA157749, RC4CA153828, R01CA131301, R01CA074415] Funding Source: NIH RePORTER	Women's Reproductive Health Research (WRHR) Career Development Program grant; Mary Kay Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); K08 grant; Morris and Horowitz Families Endowed Professorship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Markel Foundation; Shannon Family Foundation; Segesta family; Office of the Director, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank JL and his group for supplying the cell line-associated chemosensitivity data. We appreciate Greg Wilhoite for performing the TaqMan assay and Josef Herzog for processing samples for the City of Hope. We also appreciate Discovery to Cure at Yale University for samples and Jeff Boyd for supplying the BG1 cell line for targeting studies. ER was supported by a Women's Reproductive Health Research (WRHR) Career Development Program grant (5K12HD047018-08). FS and JW were supported by a Mary Kay Foundation Grant, and an R01 from the NCI (CA131301-01A1). JW also was supported by a K08 grant (CA124484). AS was supported by R01CA122728. SLN is partially supported by the Morris and Horowitz Families Endowed Professorship and NIH R01CA74415. JNW and SS are supported by RC4CA153828 from the National Cancer Institute and the Office of the Director, National Institutes of Health, and also by funding from the Markel Foundation. We also appreciate support from the Shannon Family Foundation, the Segesta family and donations made in memory of Jennifer Casey.	ACS, 2010, CANC FACTS FIG 2010, P1; Chen KX, 2008, CARCINOGENESIS, V29, P1306, DOI 10.1093/carcin/bgn116; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Christensen BC, 2009, CARCINOGENESIS, V30, P1003, DOI 10.1093/carcin/bgp099; Cox D.R., 1989, CONCISE ENCY STAT; COX DR, 1972, J R STAT SOC B, V34, P187; Eitan R, 2009, GYNECOL ONCOL, V114, P253, DOI 10.1016/j.ygyno.2009.04.024; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Graziano F, 2010, PHARMACOGENOMICS J, V10, P458, DOI 10.1038/tpj.2010.9; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Herzog TJ, 2006, NAT CLIN PRACT ONCOL, V3, P604, DOI 10.1038/ncponc0637; Hollestelle A, 2011, BREAST CANCER RES TR, V128, P79, DOI 10.1007/s10549-010-1080-z; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Lu L, 2011, GYNECOL ONCOL, V122, P366, DOI 10.1016/j.ygyno.2011.04.033; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mezzanzanica D, 2010, INT J BIOCHEM CELL B, V42, P1262, DOI 10.1016/j.biocel.2009.12.017; Paranjape T, 2011, LANCET ONCOL, V12, P377, DOI 10.1016/S1470-2045(11)70044-4; Parmar MKB, 2003, LANCET, V361, P2099; Peters D, 2005, MOL CANCER THER, V4, P1605, DOI 10.1158/1535-7163.MCT-04-0311; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pharoah PDP, 2011, CLIN CANCER RES, V17, P3742, DOI 10.1158/1078-0432.CCR-10-3405; Ratner E, 2010, CANCER RES, V70, P6509, DOI 10.1158/0008-5472.CAN-10-0689; Salzman DW, 2011, NAT MED, V17, P934, DOI 10.1038/nm0811-934; Sasaki H, 2011, J THORAC ONCOL, V6, P15, DOI 10.1097/JTO.0b013e31820594f0; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; van Jaarsveld MTM, 2010, INT J BIOCHEM CELL B, V42, P1282, DOI 10.1016/j.biocel.2010.01.014; Youn CK, 2004, CANCER RES, V64, P4849, DOI 10.1158/0008-5472.CAN-04-0348; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105	33	55	56	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	42					4559	4566		10.1038/onc.2011.539	http://dx.doi.org/10.1038/onc.2011.539			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22139083	Green Submitted, Green Accepted			2023-01-03	WOS:000309982100007
J	Yoo, JO; Lim, YC; Kim, YM; Ha, KS				Yoo, Je-Ok; Lim, Young-Cheol; Kim, Young-Myeong; Ha, Kwon-Soo			Transglutaminase 2 Promotes Both Caspase-dependent and Caspase-independent Apoptotic Cell Death via the Calpain/Bax Protein Signaling Pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED PHOTODYNAMIC THERAPY; EPIDERMAL-GROWTH-FACTOR; TISSUE TRANSGLUTAMINASE; CANCER CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR CA2+; ACTIVATION; STRESS; MECHANISMS; INDUCTION	Transglutaminase 2(TG2) is a versatile protein that is implicated in significant biological processes, including cell death and degenerative diseases. A possible role of TG2 in the apoptotic death of cancer cells induced by photodynamic therapy (PDT) was suggested recently; however, the mechanism by which TG2 regulates apoptotic responses to PDT remains to be elucidated. In this study, we investigated the key signaling pathways stimulated during apoptotic cell death following PDT and whether inhibition of TG2 activation using pharmacological approaches and siRNAs affects the signaling pathways. PDT caused the release of both cytochrome c and apoptosis-inducing factor (AIF) by damaging mitochondria, which resulted in caspase-dependent and caspase-independent apoptotic cell death, respectively. Released AIF translocated to the nucleus and, synergistically with the caspase-dependent pathway, led to apoptotic cell death. Both the caspase cascade and the activation of AIF following PDT were mediated by TG2 activation. In addition, PDT-activated calpain was responsible for the sequential events of Bax translocation, the collapse of Delta Psi(m), caspase-3 activation, and AIF translocation, all of which were provoked by TG2 activation. Together, these results demonstrate that PDT with a chlorin-based photosensitizer targets TG2 by activating calpain-linduced Bax translocation, which induces apoptotic cell death through both caspase-dependent and AIF-mediated pathways. Moreover, these results indicate that TG2 may be a possible therapeutic target for PDT treatment of cancer.	[Ha, Kwon-Soo] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon 200701, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Inst Med Sci, Chunchon 200701, Kangwon Do, South Korea	Kangwon National University; Kangwon National University	Ha, KS (corresponding author), Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Kangwondaehak Gil 1, Chunchon 200701, Kangwon Do, South Korea.	ksha@kangwon.ac.kr	Ha, Kwon-Soo/AAU-4417-2020	Ha, Kwon-Soo/0000-0002-4219-1787	Korea Research Foundation [2008-05943]; Ministry of Health and Welfare [1020420]; Korean Ministry of Education, Science, and Technology (Medical & Bio-Materials Research Center)	Korea Research Foundation(National Research Foundation of Korea); Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Korean Ministry of Education, Science, and Technology (Medical & Bio-Materials Research Center)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported in part by Basic Research Program Grant 2008-05943 from the Korea Research Foundation, National R&D Program for Cancer Control Grant 1020420 from the Ministry of Health and Welfare, and the Korean Ministry of Education, Science, and Technology (Regional Core Research Program/Medical & Bio-Materials Research Center).	Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Antonyak MA, 2009, J BIOL CHEM, V284, P17914, DOI 10.1074/jbc.M109.013037; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Caccamo D, 2010, AMINO ACIDS, V38, P653, DOI 10.1007/s00726-009-0428-3; Chung PS, 2009, CANCER BIOL THER, V8, P1343, DOI 10.4161/cbt.8.14.8693; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Filiano AJ, 2010, NEUROBIOL DIS, V39, P334, DOI 10.1016/j.nbd.2010.04.018; Fok JY, 2007, APOPTOSIS, V12, P1455, DOI 10.1007/s10495-007-0079-3; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Furre IE, 2006, APOPTOSIS, V11, P2031, DOI 10.1007/s10495-006-0190-x; Haggie PM, 2002, J BIOL CHEM, V277, P40782, DOI 10.1074/jbc.M207456200; Iismaa SE, 2009, PHYSIOL REV, V89, P991, DOI 10.1152/physrev.00044.2008; Isaeva EV, 2005, J PHYSIOL-LONDON, V565, P855, DOI 10.1113/jphysiol.2005.086280; Kao SH, 2010, J CELL BIOCHEM, V110, P660, DOI 10.1002/jcb.22577; Lee MJ, 2009, TOXICOLOGY, V264, P205, DOI 10.1016/j.tox.2009.08.012; Lee ZW, 2003, BIOCHEM BIOPH RES CO, V305, P633, DOI 10.1016/S0006-291X(03)00835-0; Lee ZW, 2000, CELL SIGNAL, V12, P91, DOI 10.1016/S0898-6568(99)00069-8; Lindfors K, 2010, AUTOIMMUN REV, V9, P744, DOI 10.1016/j.autrev.2010.06.003; Lorenzo HK, 2007, DRUG RESIST UPDATE, V10, P235, DOI 10.1016/j.drup.2007.11.001; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Mehta K, 2010, BIOCHEM PHARMACOL, V80, P1921, DOI 10.1016/j.bcp.2010.06.029; Nadalutti C, 2011, CELL PROLIFERAT, V44, P49, DOI 10.1111/j.1365-2184.2010.00716.x; Ortel B, 2009, FRONT BIOSCI-LANDMRK, V14, P4157, DOI 10.2741/3520; Park D, 2010, AMINO ACIDS, V39, P619, DOI 10.1007/s00726-010-0500-z; Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001; Robitaille K, 2008, CELL DEATH DIFFER, V15, P1522, DOI 10.1038/cdd.2008.77; Ruan QM, 2007, J NEUROCHEM, V102, P25, DOI 10.1111/j.1471-4159.2007.04491.x; Sanges D, 2006, APOPTOSIS, V11, P1629, DOI 10.1007/s10495-006-9006-2; Sarang Z, 2007, CELL DEATH DIFFER, V14, P1842, DOI 10.1038/sj.cdd.4402193; Shin DM, 2008, FASEB J, V22, P2498, DOI 10.1096/fj.07-095455; Song H, 2011, J RECEPT SIG TRANSD, V31, P66, DOI 10.3109/10799893.2010.529577; Sanchez-Gomez MV, 2011, J NEUROSCI, V31, P2996, DOI 10.1523/JNEUROSCI.5578-10.2011; Vittar NBR, 2010, INT J BIOCHEM CELL B, V42, P1123, DOI 10.1016/j.biocel.2010.03.019; Yi SJ, 2004, BIOCHEM BIOPH RES CO, V325, P819, DOI 10.1016/j.bbrc.2004.10.122; Yoo JO, 2011, J CELL BIOCHEM, V112, P3061, DOI 10.1002/jcb.23231; Yoo JO, 2005, BIOCHEM BIOPH RES CO, V337, P655, DOI 10.1016/j.bbrc.2005.09.108; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	38	32	37	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2012	287	18					14377	14388		10.1074/jbc.M111.326074	http://dx.doi.org/10.1074/jbc.M111.326074			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	941XU	22418443	hybrid, Green Published			2023-01-03	WOS:000304003200006
J	Wu, B; Dong, BJ; Xu, YJ; Zhang, Q; Shen, JF; Chen, HF; Xue, W				Wu, Bin; Dong, Baijun; Xu, Yuejuan; Zhang, Qiang; Shen, Jinfang; Chen, Huafeng; Xue, Wei			Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource-Limited Setting	PLOS ONE			English	Article							INTERFERON-ALPHA; SUNITINIB; BEVACIZUMAB; TEMSIROLIMUS; GUIDELINES; MANAGEMENT; SYSTEM	Background: To estimate, from the perspective of the Chinese healthcare system, the economic outcomes of five different first-line strategies among patients with metastatic renal cell carcinoma (mRCC). Methods and Findings: A decision-analytic model was developed to simulate the lifetime disease course associated with renal cell carcinoma. The health and economic outcomes of five first-line strategies (interferon-alfa, interleukin-2, interleukin-2 plus interferon-alfa, sunitinib and bevacizumab plus interferon-alfa) were estimated and assessed by indirect comparison. The clinical and utility data were taken from published studies. The cost data were estimated from local charge data and current Chinese practices. Sensitivity analyses were used to explore the impact of uncertainty regarding the results. The impact of the sunitinib patient assistant program (SPAP) was evaluated via scenario analysis. The base-case analysis showed that the sunitinib strategy yielded the maximum health benefits: 2.71 life years and 1.40 quality-adjusted life-years (QALY). The marginal cost-effectiveness (cost per additional QALY) gained via the sunitinib strategy compared with the conventional strategy was $220,384 (without SPAP, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated) and $16,993 (with SPAP, interferon-alfa, interleukin-2 plus interferon-alfa and bevacizumab plus interferon-alfa were dominated). In general, the results were sensitive to the hazard ratio of progression-free survival. The probabilistic sensitivity analysis demonstrated that the sunitinib strategy with SPAP was the most cost-effective approach when the willingness-to-pay threshold was over $16,000. Conclusions: Our analysis suggests that traditional cytokine therapy is the cost-effective option in the Chinese healthcare setting. In some relatively developed regions, sunitinib with SPAP may be a favorable cost-effective alternative for mRCC.	[Wu, Bin; Shen, Jinfang; Chen, Huafeng] Shanghai Jiao Tong Univ, Clin Outcomes & Econ Grp, Dept Pharm, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China; [Dong, Baijun; Xue, Wei] Shanghai Jiao Tong Univ, Dept Urol, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China; [Xu, Yuejuan] South E Univ, Dept Oncol, Hosp Nanjing 2, Sch Med, Nanjing, Jiangsu, Peoples R China; [Zhang, Qiang] Shanghai Univ Tradit Chinese Med, Dept Oncol, Shanghai Putuo Hosp, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine	Wu, B (corresponding author), Shanghai Jiao Tong Univ, Clin Outcomes & Econ Grp, Dept Pharm, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China.	xwurosjtu@yeah.net			Shanghai government [08411951500]	Shanghai government	This work was supported by a grant from Shanghai government (no. 08411951500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbui C, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000322; Benedict A, 2011, BJU INT; Chabot I, 2010, VALUE HEALTH, V13, P837, DOI 10.1111/j.1524-4733.2010.00738.x; Coon JT, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14020; COON JT, 2010, HEALTH TECHNOL ASSES, V14, pR3; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; Curti BD, 2004, JAMA-J AM MED ASSOC, V292, P97, DOI 10.1001/jama.292.1.97; de Reijke TM, 2009, EUR J CANCER, V45, P765, DOI 10.1016/j.ejca.2008.12.010; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Gore ME, 2008, BJU INT, V101, P1063, DOI 10.1111/j.1464-410X.2008.07435.x; Gore ME, 2010, LANCET, V375, P641, DOI 10.1016/S0140-6736(09)61921-8; Hougaard JL, 2011, APPL HEALTH ECON HEA, V9, P1, DOI 10.2165/11531800-000000000-00000; Hoyle M, 2010, VALUE HEALTH, V13, P61, DOI 10.1111/j.1524-4733.2009.00617.x; Hutson Thomas E, 2005, Clin Genitourin Cancer, V4, P181, DOI 10.3816/CGC.2005.n.030; Kielhorn A, 2008, CURR MED RES OPIN, V24, P2639, DOI [10.1185/03007990802321683, 10.1185/03007990802321683 ]; Lam JS, 2008, NAT CLIN PRACT UROL, V5, P308, DOI 10.1038/ncpuro1121; Mickisch G, 2010, BRIT J CANCER, V102, P80, DOI 10.1038/sj.bjc.6605417; Molina AM, 2011, ONCOLOGIST, V16, P45, DOI 10.1634/theoncologist.2011-S2-45; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Ravasio R, 2011, CLIN DRUG INVEST, V31, P507, DOI 10.2165/11590230-000000000-00000; Remak E, 2008, J CLIN ONCOL, V26, P3995, DOI 10.1200/JCO.2007.13.2662; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Sengupta S, 2005, UROLOGY, V66, P36, DOI 10.1016/j.urology.2005.06.004; Sun M, 2010, NAT REV UROL, V7, P327, DOI 10.1038/nrurol.2010.57; Vickers MM, 2010, UROLOGY, V76, P430, DOI 10.1016/j.urology.2009.12.031; Wagstaff A, 2009, HEALTH ECON, V18, pS7, DOI 10.1002/hec.1518; Wu B, 2011, CLIN THER, V33, P1446, DOI 10.1016/j.clinthera.2011.09.016	32	57	62	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2012	7	3							e32530	10.1371/journal.pone.0032530	http://dx.doi.org/10.1371/journal.pone.0032530			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KT	22412884	Green Published, Green Submitted, gold			2023-01-03	WOS:000303062000013
J	Ludwig, DS				Ludwig, David S.			Weight Loss Strategies for Adolescents A 14-Year-Old Struggling to Lose Weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; CHILDHOOD OBESITY; METABOLIC SYNDROME; US CHILDREN; OVERWEIGHT ADOLESCENTS; CARDIOVASCULAR-DISEASE; PEDIATRIC OBESITY	With prevalence approaching 20% in the United States, adolescent obesity has become a common problem for patients, parents, and clinicians. Obese adolescents may experience physical and psychosocial complications, as illustrated by the case of Ms K, a 14-year-old girl with a body mass index of 40. Unfortunately, the effectiveness of pediatric obesity treatment is modest in younger children and declines in older children and adolescents, and few interventions involving adolescents have produced significant long-term weightloss. Nevertheless, novel strategies to alter energy balance have shown preliminary evidence of benefit in clinical trials, including a diet focused on food quality rather than fat restriction and a lifestyle approach to encourage enjoyable physical activity throughout the day rather than intermittent exercise. Parents can have an important influence on weight-related behaviors in adolescents despite typically complicated emotional dynamics at this age, especially through the use of noncoercive methods. A key parenting practice applicable to children of all ages is to create a protective environment in the home, substituting nutritious foods for un-healthful ones and facilitating physical activities instead of sedentary pursuits. Other behaviors that may promote successful long-term weight management include good sleep hygiene, stress reduction, and mindfulness. Ultimately, the obesity epidemic can be attributed to changes in the social environment that hinder healthful lifestyle habits, and prevention will require a comprehensive public health strategy. JAMA. 2012;307(5):498-508	[Ludwig, David S.] Childrens Hosp Boston, Div Endocrinol, Optimal Weight Life OWL Program, Boston, MA 02115 USA; [Ludwig, David S.] Childrens Hosp Boston, New Balance Fdn, Obes Prevent Ctr, Boston, MA 02115 USA; [Ludwig, David S.] Harvard Univ, Sch Med, Boston, MA USA; [Ludwig, David S.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Ludwig, DS (corresponding author), Childrens Hosp Boston, Div Endocrinol, Optimal Weight Life OWL Program, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Ludwig, David/0000-0003-3307-8544	National Institutes of Health; Children's Hospital Boston; National Institute of Diabetes and Digestive and Kidney Diseases [K24DK082730]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK082730] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Hospital Boston; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ludwig reports receiving grants from the National Institutes of Health and foundations for obesity-related research, mentoring, and patient care and royalties from a book about childhood obesity.; Dr Ludwig is supported in part by an endowment from Children's Hospital Boston and career award K24DK082730 from the National Institute of Diabetes and Digestive and Kidney Diseases.	Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603; American Medical Association, 2004, NAT SUMM OB BUILD PL; Atlantis E, 2006, INT J OBESITY, V30, P1027, DOI 10.1038/sj.ijo.0803286; Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515; Bauer KW, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-25; Berntsen S, 2010, INT J PEDIATR OBES, V5, P64, DOI 10.3109/17477160902957166; Binkin N, 2013, NUTR METAB CARDIOVAS, V23, P410, DOI 10.1016/j.numecd.2011.09.006; Birch LL, 2003, AM J CLIN NUTR, V78, P215, DOI 10.1093/ajcn/78.2.215; Black MM, 2010, PEDIATRICS, V126, P280, DOI 10.1542/peds.2009-1832; Bornstein M. H., 2002, HDB PARENTING CHILDR; Catoira N, 2010, EXPERT OPIN PHARMACO, V11, P2973, DOI 10.1517/14656566.2010.512005; Chanoine JP, 2005, JAMA-J AM MED ASSOC, V293, P2873, DOI 10.1001/jama.293.23.2873; Craigie AM, 2011, MATURITAS, V70, P266, DOI 10.1016/j.maturitas.2011.08.005; Dabelea D, 2007, JAMA-J AM MED ASSOC, V297, P2716; Daley AJ, 2006, PEDIATRICS, V118, P2126, DOI 10.1542/peds.2006-1285; De Vriendt T, 2009, NUTR METAB CARDIOVAS, V19, P511, DOI 10.1016/j.numecd.2009.02.009; Dietz WH, 2005, NEW ENGL J MED, V352, P2100, DOI 10.1056/NEJMcp043052; Din-Dzietham R, 2007, CIRCULATION, V116, P1488, DOI 10.1161/CIRCULATIONAHA.106.683243; Ebbeling CB, 2008, JAMA-J AM MED ASSOC, V299, P2442, DOI 10.1001/jama.299.20.2442; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Ebbeling CB, 2004, JAMA-J AM MED ASSOC, V291, P2828, DOI 10.1001/jama.291.23.2828; Ebbeling CB, 2003, ARCH PEDIAT ADOL MED, V157, P773, DOI 10.1001/archpedi.157.8.773; Epstein L H, 2001, Exerc Sport Sci Rev, V29, P103, DOI 10.1097/00003677-200107000-00003; Epstein LH, 2008, ARCH PEDIAT ADOL MED, V162, P239, DOI 10.1001/archpediatrics.2007.45; EPSTEIN LH, 1994, ADDICT BEHAV, V19, P135, DOI 10.1016/0306-4603(94)90038-8; Epstein LH, 1996, INT J OBESITY, V20, pS14; Epstein LH, 2001, PEDIATR CLIN N AM, V48, P981, DOI 10.1016/S0031-3955(05)70352-7; Epstein LH, 1998, PEDIATRICS, V101, P554; Flynn JT, 2008, AM J HYPERTENS, V21, P605, DOI 10.1038/ajh.2008.159; Galloway AT, 2006, APPETITE, V46, P318, DOI 10.1016/j.appet.2006.01.019; George Mary G, 2011, Ann Neurol, V70, P713, DOI 10.1002/ana.22539; Goldfield GS, 2006, PEDIATRICS, V118, pE157, DOI 10.1542/peds.2005-3052; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; Grey M, 2004, J SCHOOL HEALTH, V74, P10, DOI 10.1111/j.1746-1561.2004.tb06595.x; Griffiths LJ, 2010, INT J PEDIATR OBES, V5, P282, DOI 10.3109/17477160903473697; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hahn TN, 2010, SAVOR MINDFUL EATING; Hall KD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007940; Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317; Hart CN, 2011, PEDIATR CLIN N AM, V58, P715, DOI 10.1016/j.pcl.2011.03.007; Hart CN, 2010, EAT BEHAV, V11, P217, DOI 10.1016/j.eatbeh.2010.05.001; Hebebrand J, 2009, CHILD ADOL PSYCH CL, V18, P49, DOI 10.1016/j.chc.2008.08.002; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hofker M, 2009, NAT GENET, V41, P139, DOI 10.1038/ng0209-139; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Inge TH, 2004, PEDIATRICS, V114, P217, DOI 10.1542/peds.114.1.217; Jelalian E, 2006, INT J OBESITY, V30, P31, DOI 10.1038/sj.ijo.0803069; Johnston CA, 2007, PEDIATRICS, V120, pE1450, DOI 10.1542/peds.2006-3321; Johnston CA, 2007, INT J PEDIATR OBES, V2, P144, DOI 10.1080/17477160701305864; Kamath CC, 2008, J CLIN ENDOCR METAB, V93, P4606, DOI 10.1210/jc.2006-2411; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Kelley GA, 2007, ATHEROSCLEROSIS, V191, P447, DOI 10.1016/j.atherosclerosis.2006.04.019; Kimm SYS, 2002, NEW ENGL J MED, V347, P709, DOI 10.1056/NEJMoa003277; Krebs NF, 2007, PEDIATRICS, V120, pS193, DOI 10.1542/peds.2007-2329D; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Latner JD, 2003, OBES RES, V11, P452, DOI 10.1038/oby.2003.61; Lavizzo-Mourey R, 2007, JAMA-J AM MED ASSOC, V298, P920, DOI 10.1001/jama.298.8.920; Lawlor DA, 2007, AM J EPIDEMIOL, V165, P418, DOI 10.1093/aje/kwk030; Lee H, 2009, POPUL RES POLICY REV, V28, P505, DOI 10.1007/s11113-008-9115-4; Levin BE, 1998, AM J PHYSIOL-REG I, V275, pR1374, DOI 10.1152/ajpregu.1998.275.4.R1374; Li W, 2009, OBES REV, V10, P87, DOI 10.1111/j.1467-789X.2008.00528.x; Ludwig DS, 2008, JAMA-J AM MED ASSOC, V300, P1350, DOI 10.1001/jama.300.11.1350; Ludwig DS, 2011, JAMA-J AM MED ASSOC, V305, P1352, DOI 10.1001/jama.2011.380; Ludwig DS, 2010, LANCET, V376, P984, DOI 10.1016/S0140-6736(10)60751-9; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 1999, JAMA-J AM MED ASSOC, V282, P1539, DOI 10.1001/jama.282.16.1539; Luttikhuis HO, 2009, SAO PAULO MED J, V127, P321, DOI 10.1590/S1516-31802009000500015; McGovern L, 2008, J CLIN ENDOCR METAB, V93, P4600, DOI 10.1210/jc.2006-2409; Monteiro CA, 2011, PUBLIC HEALTH NUTR, V14, P5, DOI 10.1017/S1368980010003241; Mozaffarian D, 2011, NEW ENGL J MED, V364, P2392, DOI 10.1056/NEJMoa1014296; Murtagh L, 2011, JAMA-J AM MED ASSOC, V306, P206, DOI 10.1001/jama.2011.903; NEEL JV, 1962, AM J HUM GENET, V14, P353; O'Brien PE, 2010, JAMA-J AM MED ASSOC, V303, P519, DOI 10.1001/jama.2010.81; Ogden CL, 2012, JAMA-J AM MED ASSOC, V307, P483, DOI 10.1001/jama.2012.40; Oken E, 2003, OBES RES, V11, P496, DOI 10.1038/oby.2003.69; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; Papadaki A, 2010, PEDIATRICS, V126, pE1143, DOI 10.1542/peds.2009-3633; Pereira MA, 2005, LANCET, V365, P36, DOI 10.1016/S0140-6736(04)17663-0; Pereira MA, 2001, PEDIATR CLIN N AM, V48, P969, DOI 10.1016/S0031-3955(05)70351-5; Prins JB, 1997, CLIN SCI, V92, P3, DOI 10.1042/cs0920003; Puder JJ, 2010, INT J OBESITY, V34, pS37, DOI 10.1038/ijo.2010.238; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Roden M, 2006, NAT CLIN PRACT ENDOC, V2, P335, DOI 10.1038/ncpendmet0190; Rolls BJ, 2009, PHYSIOL BEHAV, V97, P609, DOI 10.1016/j.physbeh.2009.03.011; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Saelens BE, 2002, OBES RES, V10, P22, DOI 10.1038/oby.2002.4; Savoye M, 2007, JAMA-J AM MED ASSOC, V297, P2697, DOI 10.1001/jama.297.24.2697; Schwimmer JB, 2003, JAMA-J AM MED ASSOC, V289, P1813, DOI 10.1001/jama.289.14.1813; Schwimmer JB, 2006, PEDIATRICS, V118, P1388, DOI 10.1542/peds.2006-1212; Schwimmer JB, 2008, CIRCULATION, V118, P277, DOI 10.1161/CIRCULATIONAHA.107.739920; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Shils ME, 2006, MODERN NUTR HLTH DIS, P982; Skelton JA, 2009, ACAD PEDIATR, V9, P322, DOI 10.1016/j.acap.2009.04.005; Steinberger J, 2009, CIRCULATION, V119, P628, DOI 10.1161/CIRCULATIONAHA.108.191394; Stevelos J, BULLYING BULLYCIDE C; Story M, 2008, ANNU REV PUBL HEALTH, V29, P253, DOI 10.1146/annurev.publhealth.29.020907.090926; Strauss RS, 2001, ARCH PEDIAT ADOL MED, V155, P897, DOI 10.1001/archpedi.155.8.897; Summerbell CD, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001871.pub4, 10.1002/14651858.CD001871.pub2]; Szajewska H, 2010, CRIT REV FOOD SCI, V50, P113, DOI 10.1080/10408390903467514; Treadwell JR, 2008, ANN SURG, V248, P763, DOI 10.1097/SLA.0b013e31818702f4; Treasure J., 2004, ADV PSYCHIAT TREATME, V10, P331, DOI [DOI 10.1192/APT.10.5.331, 10.1192/apt.10.5.331]; UnitedHealth Group, 2010, US DIAB CHALL OPP DE; Wang YC, 2006, PEDIATRICS, V118, pE1721, DOI 10.1542/peds.2006-0682; Wang YC, 2009, ARCH PEDIAT ADOL MED, V163, P336, DOI 10.1001/archpediatrics.2009.23; Williamson DA, 2006, OBESITY, V14, P1231, DOI 10.1038/oby.2006.140; Wilson DK, 2005, J PEDIATR PSYCHOL, V30, P293, DOI 10.1093/jpepsy/jsi039	107	25	26	1	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 1	2012	307	5					498	508		10.1001/jama.2011.2011	http://dx.doi.org/10.1001/jama.2011.2011			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	884SH	22215761				2023-01-03	WOS:000299728000031
J	Mak, HC				Mak, H. Craig			Drug pipeline: Q411	NATURE BIOTECHNOLOGY			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2012	30	1					15	15		10.1038/nbt.2090	http://dx.doi.org/10.1038/nbt.2090			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	876MC	22231084				2023-01-03	WOS:000299110600007
J	DiPersio, JF				DiPersio, John F.			Diabetic Stem-Cell "Mobilopathy"	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Washington Univ, Sch Med, Div Oncol, St Louis, MO 63130 USA	Washington University (WUSTL)	DiPersio, JF (corresponding author), Washington Univ, Sch Med, Div Oncol, St Louis, MO 63130 USA.							DiPersio JF, 2009, J CLIN ONCOL, V27, P4767, DOI 10.1200/JCO.2008.20.7209; Ferraro F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002191; Mendez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262; Pusic I, 2008, BIOL BLOOD MARROW TR, V14, P1045, DOI 10.1016/j.bbmt.2008.07.004; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016	5	69	71	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2011	365	26					2536	2538		10.1056/NEJMcibr1112347	http://dx.doi.org/10.1056/NEJMcibr1112347			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868SD	22204729	Green Published			2023-01-03	WOS:000298544600016
J	Cheung, F				Cheung, Felix			TCM Made in China	NATURE			English	Editorial Material																			0	295	301	5	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S82	S83		10.1038/480S82a	http://dx.doi.org/10.1038/480S82a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190085	Bronze			2023-01-03	WOS:000298318000001
J	Singarapu, KK; Tonelli, M; Chow, DC; Frederick, RO; Westler, WM; Markley, JL				Singarapu, Kiran K.; Tonelli, Marco; Chow, Darius C.; Frederick, Ronnie O.; Westler, William M.; Markley, John L.			Structural Characterization of Hsp12, the Heat Shock Protein from Saccharomyces cerevisiae, in Aqueous Solution Where It Is Intrinsically Disordered and in Detergent Micelles Where It Is Locally alpha-Helical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEA-LIKE PROTEIN; TREHALOSE; GENE; SPECTROSCOPY; DESICCATION; TOLERANCE; PROGRAM; STRESS; CELLS	Hsp12 (heat shock protein 12) belongs to the small heat shock protein family, partially characterized as a stress response, stationary phase entry, late embryonic abundant-like protein located at the plasma membrane to protect membrane from desiccation. Here, we report the structural characterization of Hsp12 by NMR and biophysical techniques. The protein was labeled uniformly with nitrogen-15 and carbon-13 so that its conformation could be determined in detail both in aqueous solution and in two membrane-mimetic environments, SDS and dodecylphosphocholine (DPC) micelles. Secondary structural elements determined from assigned chemical shifts indicated that Hsp12 is dynamically disordered in aqueous solution, whereas it gains four helical stretches in the presence of SDS micelles and a single helix in presence of DPC. These conclusions were reinforced by circular dichroism spectra of the protein in all three environments. The lack of long range interactions in NOESY spectra indicated that the helices present in SDS micelles do not pack together. R-1 and R-2, relaxation and heteronuclear NOE measurements showed that the protein is disordered in aqueous solution but becomes more ordered in presence of detergent micelles. NMR spectra collected in presence of paramagnetic spin relaxation agents (5DSA, 16DSA, and Gd(DTPA-BMA)) indicated that the amphipathic alpha-helices of Hsp12 in SDS micelles lie on the membrane surface. These observations are in agreement with studies suggesting that Hsp12 functions to protect the membrane from desiccation.	[Singarapu, Kiran K.; Tonelli, Marco; Westler, William M.; Markley, John L.] Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53705 USA; [Chow, Darius C.; Frederick, Ronnie O.; Markley, John L.] Univ Wisconsin, Ctr Eukaryot Struct Gen, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Markley, JL (corresponding author), 433 Babcock Dr, Madison, WI 53706 USA.	markley@nmrfam.wisc.edu	Singarapu, Kiran/AAU-3435-2020		National Institutes of Health [P41 RR02301, P41 GM66326, 1U54 GM074901]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074901, P41GM066326] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants P41 RR02301, P41 GM66326, and 1U54 GM074901 (to J. L. M.).	Bahrami A, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000307; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bhattacharya A, 2007, PROTEINS, V66, P778, DOI 10.1002/prot.21165; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W. L., 2010, PYMOL MOL GRAPHICS S; FARROW NA, 1995, BIOCHEMISTRY-US, V34, P868, DOI 10.1021/bi00003a021; Guntert Peter, 2004, Methods Mol Biol, V278, P353; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hilty C, 2004, CHEMBIOCHEM, V5, P467, DOI 10.1002/cbic.200300815; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Martin J, 1997, CURR OPIN STRUC BIOL, V7, P41, DOI 10.1016/S0959-440X(97)80006-1; Motshwene P, 2004, BIOCHEM J, V377, P769, DOI 10.1042/bj20031301; Mtwisha L, 1998, PLANT MOL BIOL, V37, P513, DOI 10.1023/A:1005904219201; Pacheco A, 2009, MICROBIOL-SGM, V155, P2021, DOI 10.1099/mic.0.025981-0; Park JI, 1997, APPL ENVIRON MICROB, V63, P3818, DOI 10.1128/AEM.63.10.3818-3824.1997; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Sales K, 2000, BBA-BIOMEMBRANES, V1463, P267, DOI 10.1016/S0005-2736(99)00215-1; Sano F, 1999, CRYOBIOLOGY, V39, P80, DOI 10.1006/cryo.1999.2188; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schade B, 2004, MOL BIOL CELL, V15, P5492, DOI 10.1091/mbc.E04-03-0167; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; Shamrock VJ, 2008, CAN J MICROBIOL, V54, P559, DOI [10.1139/W08-044, 10.1139/w08-044]; Sharma SC, 1997, FEMS MICROBIOL LETT, V152, P11, DOI 10.1111/j.1574-6968.1997.tb10402.x; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; STONE RL, 1990, GENE, V96, P171, DOI 10.1016/0378-1119(90)90249-Q; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; Tyler RC, 2005, PROTEIN EXPRES PURIF, V40, P268, DOI 10.1016/j.pep.2004.12.024; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Welker S, 2010, MOL CELL, V39, P507, DOI 10.1016/j.molcel.2010.08.001; Zara S, 2002, YEAST, V19, P269, DOI 10.1002/yea.831	35	23	23	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 16	2011	286	50					43447	43453		10.1074/jbc.M111.306464	http://dx.doi.org/10.1074/jbc.M111.306464			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	866AF	21998307	Green Published, hybrid			2023-01-03	WOS:000298351300064
J	Saberi, P; Johnson, MO				Saberi, Parya; Johnson, Mallory O.			Technology-Based Self-Care Methods of Improving Antiretroviral Adherence: A Systematic Review	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; DRUG-RESISTANCE; MEDICATION ADHERENCE; REPORTED ADHERENCE; THERAPY ADHERENCE; PATIENT ADHERENCE; INFECTED PERSONS; HAART ADHERENCE; SOUTH-AFRICA	Background: As HIV infection has shifted to a chronic condition, self-care practices have emerged as an important topic for HIV-positive individuals in maintaining an optimal level of health. Self-care refers to activities that patients undertake to maintain and improve health, such as strategies to achieve and maintain high levels of antiretroviral adherence. Methodology/Principal Findings: Technology-based methods are increasingly used to enhance antiretroviral adherence; therefore, we systematically reviewed the literature to examine technology-based self-care methods that HIV-positive individuals utilize to improve adherence. Seven electronic databases were searched from 1/1/1980 through 12/31/2010. We included quantitative and qualitative studies. Among quantitative studies, the primary outcomes included ARV adherence, viral load, and CD4+ cell count and secondary outcomes consisted of quality of life, adverse effects, and feasibility/acceptability data. For qualitative/descriptive studies, interview themes, reports of use, and perceptions of use were summarized. Thirty-six publications were included (24 quantitative and 12 qualitative/descriptive). Studies with exclusive utilization of medication reminder devices demonstrated less evidence of enhancing adherence in comparison to multicomponent methods. Conclusions/Significance: This systematic review offers support for self-care technology-based approaches that may result in improved antiretroviral adherence. There was a clear pattern of results that favored individually-tailored, multi-function technologies, which allowed for periodic communication with health care providers rather than sole reliance on electronic reminder devices.	[Saberi, Parya; Johnson, Mallory O.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Saberi, P (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	parya.saberi@ucsf.edu			National Institute of Mental Health [F32MH086323, K24MH087220]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH087220, F32MH086323] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institute of Mental Health (F32MH086323 and K24MH087220) The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anastasio C, 1995, J Assoc Nurses AIDS Care, V6, P31, DOI 10.1016/S1055-3290(95)80015-8; Andrade ASA, 2005, CLIN INFECT DIS, V41, P875, DOI 10.1086/432877; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Barroso J, 1995, Holist Nurs Pract, V10, P44; Bartlett JA, 2002, J ACQ IMMUN DEF SYND, V29, pS2, DOI 10.1097/00126334-200202011-00002; Biadgilign S, 2009, SAHARA J-J SOC ASP H, V6, P148, DOI 10.1080/17290376.2009.9724943; Blower SM, 2001, NAT MED, V7, P1016, DOI 10.1038/nm0901-1016; Chesney MA, 1999, AIDS, V13, pS271; Chou FY, 2004, J ASSOC NURSE AIDS C, V15, P58, DOI 10.1177/1055329003255592; Chou FY, 2004, NURS RES, V53, P332, DOI 10.1097/00006199-200409000-00008; Claborn KR, 2011, ELECT INTERVENTION H; Cook RF, 2010, TEST WEB BASED PROGR; Crankshaw T, 2010, AIDS PATIENT CARE ST, V24, P729, DOI 10.1089/apc.2010.0146; Curioso WH, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-24; Curioso WH, 2011, EVALUATION COMPUTER; DEAN K, 1981, SOC SCI MED-MED SOC, V15, P673, DOI 10.1016/0271-7123(81)90091-2; Dunbar PJ, 2003, J AM MED INFORM ASSN, V10, P11, DOI 10.1197/jamia.M1047; Dybul M, 2011, PANEL ANTIRETROVIRAL; Fairley CK, 2003, INT J STD AIDS, V14, P805, DOI 10.1258/095646203322556129; Garofalo R, 2010, TEXT MESSAGING INTER; Gifford AL, 2000, J ACQ IMMUN DEF SYND, V23, P386; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Grant E, 2008, AIDS CARE, V20, P1155, DOI 10.1080/09540120701854634; Grant RM, 2002, JAMA-J AM MED ASSOC, V288, P181, DOI 10.1001/jama.288.2.181; Harris LT, 2010, TELEMED J E-HEALTH, V16, P1024, DOI 10.1089/tmj.2010.0050; Harvey KM, 2008, W INDIAN MED J, V57, P293; Heckman BD, 2004, AIDS CARE, V16, P219, DOI 10.1080/09540120410001641066; Henry S B, 1999, J Assoc Nurses AIDS Care, V10, P46, DOI 10.1016/S1055-3290(06)60298-7; Holzemer W L, 2000, J Assoc Nurses AIDS Care, V11, P36, DOI 10.1016/S1055-3290(06)60420-2; Holzemer W L, 1998, J Assoc Nurses AIDS Care, V9, P22, DOI 10.1016/S1055-3290(98)80073-3; Holzemer WL, 1999, AIDS PATIENT CARE ST, V13, P185, DOI 10.1089/apc.1999.13.185; Horvath KJ, 2011, PILOT TEST ONLINE HI; Ingersoll KS, 2011, TEXT MESSAGING ADHER; Iroha E, 2010, AJAR-AFR J AIDS RES, V9, P25, DOI 10.2989/16085906.2010.484543; Kahn J, 2011, ADHERENCE IMPROVEMEN; Kalichman S C, 2001, J Assoc Nurses AIDS Care, V12, P58, DOI 10.1016/S1055-3290(06)60217-3; Kalichman SC, 2005, AIDS PATIENT CARE ST, V19, P439, DOI 10.1089/apc.2005.19.439; Kemppainen JK, 2001, AIDS PATIENT CARE ST, V15, P117, DOI 10.1089/108729101750123562; Konkle-Parker DJ, 2010, PATIENT EDUC COUNS, V78, P91, DOI 10.1016/j.pec.2009.04.010; Kumar VS, 2010, AREMIND PERSONALIZED; Lefebvre C, 2011, COCHRANE HDB SYSTEMA; Levin L S, 1979, J Am Coll Health Assoc, V28, P117; Levin L. S., 1979, SELF CARE LAY INITIA; LEVIN LS, 1983, ANNU REV PUBL HEALTH, V4, P181, DOI 10.1146/annurev.pu.04.050183.001145; Levy RW, 2004, AIDS PATIENT CARE ST, V18, P728, DOI 10.1089/apc.2004.18.728; Lewis MP, 2006, AIDS CARE, V18, P140, DOI 10.1080/09540120500161835; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Lyon ME, 2003, AIDS PATIENT CARE ST, V17, P299, DOI 10.1089/108729103322108175; Mannheimer S, 2002, CLIN INFECT DIS, V34, P1115, DOI 10.1086/339074; Mannheimer SB, 2006, JAIDS-J ACQ IMM DEF, V43, pS41, DOI 10.1097/01.qai.0000245887.58886.ac; Martin-Fernandez J, 2001, ARCH INTERN MED, V161, P2739, DOI 10.1001/archinte.161.22.2739; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Moatti JP, 2000, AIDS, V14, P151, DOI 10.1097/00002030-200001280-00010; Moore DJ, 2011, PERSONALIZED TEXT ME; Murphy DA, 2000, AIDS PATIENT CARE ST, V14, P47, DOI 10.1089/108729100318127; Murphy Debra A, 2002, J Assoc Nurses AIDS Care, V13, P57, DOI 10.1177/1055329002238026; Murphy Debra A, 2007, J Int Assoc Physicians AIDS Care (Chic), V6, P113, DOI 10.1177/1545109707301243; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Ostrop NJ, 2000, AIDS PATIENT CARE ST, V14, P351, DOI 10.1089/108729100413220; Ostrop NJ, 2000, ANN PHARMACOTHER, V34, P703, DOI 10.1345/aph.19201; Ownby RL, 2011, AUTOMATED TAILORED I; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Poppa A, 2004, HIV MED, V5, P46, DOI 10.1111/j.1468-1293.2004.00215.x; Powell-Cope GM, 2003, AIDS CARE, V15, P239, DOI 10.1080/0954012031000068380; Riegel B, 2008, J CARDIOVASC NURS, V23, P190, DOI 10.1097/01.JCN.0000305091.35259.85; Safren SA, 2003, AIDS CARE, V15, P787, DOI 10.1080/09540120310001618630; Samet JH, 2005, ANTIVIR THER, V10, P83; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; Shet A, 2010, AIDS BEHAV, V14, P716, DOI 10.1007/s10461-009-9658-3; Simon V, 2002, AIDS, V16, P1511, DOI 10.1097/00002030-200207260-00008; Simoni JM, 2006, JAIDS-J ACQ IMM DEF, V43, pS23, DOI 10.1097/01.qai.0000248342.05438.52; Simoni JM, 2009, JAIDS-J ACQ IMM DEF, V52, P465, DOI 10.1097/QAI.0b013e3181b9300c; Simoni JM, 2010, AIDS BEHAV; Smith SR, 2005, J AM PHARM ASSOC, V45, P625, DOI 10.1331/1544345055001292; Sowell R L, 1997, Holist Nurs Pract, V11, P18; Starks H, 2008, AIDS CARE, V20, P607, DOI 10.1080/09540120701660379; UNAIDS, 2009, WHAT COUNTR NEED INV; United Nations Children's Fund World Health Organization UNA-IDS, 2009, UN ACC SCAL PRIOR HI; WH Organization, 2003, ADH LONG TERM THER E; Wise J, 2008, AIDS PATIENT CARE ST, V22, P495, DOI 10.1089/apc.2007.0180; Wong IY, 2006, JAIDS-J ACQ IMM DEF, V43, pS142, DOI 10.1097/01.qai.0000248345.02760.03; Wu AW, 2006, AIDS PATIENT CARE ST, V20, P773, DOI 10.1089/apc.2006.20.773	82	46	46	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2011	6	11							e27533	10.1371/journal.pone.0027533	http://dx.doi.org/10.1371/journal.pone.0027533			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	863MI	22140446	Green Submitted, Green Published, gold			2023-01-03	WOS:000298168100011
J	van der Meer, V; van den Hout, WB; Bakker, MJ; Rabe, KF; Sterk, PJ; Assendelft, WJJ; Kievit, J; Sont, JK				van der Meer, Victor; van den Hout, Wilbert B.; Bakker, Moira J.; Rabe, Klaus F.; Sterk, Peter J.; Assendelft, Willem J. J.; Kievit, Job; Sont, Jacob K.		SMASHING Self-Management Asthma	Cost-Effectiveness of Internet-Based Self-Management Compared with Usual Care in Asthma	PLOS ONE			English	Article							ECONOMIC-EVALUATION; DECISION-MAKING; LONG-TERM; EDUCATION; INSTRUMENTS; OUTCOMES; UTILITY	Background: Effectiveness of Internet-based self-management in patients with asthma has been shown, but its cost-effectiveness is unknown. We conducted a cost-effectiveness analysis of Internet-based asthma self-management compared with usual care. Methodology and Principal Findings: Cost-effectiveness analysis alongside a randomized controlled trial, with 12 months follow-up. Patients were aged 18 to 50 year and had physician diagnosed asthma. The Internet-based self-management program involved weekly on-line monitoring of asthma control with self-treatment advice, remote Web communications, and Internet-based information. We determined quality adjusted life years (QALYs) as measured by the EuroQol-5D and costs for health care use and absenteeism. We performed a detailed cost price analysis for the primary intervention. QALYs did not statistically significantly differ between the Internet group and usual care: difference 0.024 (95% CI, -0.016 to 0.065). Costs of the Internet-based intervention were $254 (95% CI, $243 to $265) during the period of 1 year. From a societal perspective, the cost difference was $641 (95% CI, $21957 to $3240). From a health care perspective, the cost difference was $37 (95% CI, $2874 to $950). At a willingness-to-pay of $50000 per QALY, the probability that Internet-based self-management was cost-effective compared to usual care was 62% and 82% from a societal and health care perspective, respectively. Conclusions: Internet-based self-management of asthma can be as effective as current asthma care and costs are similar.	[van der Meer, Victor; van den Hout, Wilbert B.; Bakker, Moira J.; Kievit, Job; Sont, Jacob K.] Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands; [van der Meer, Victor; Assendelft, Willem J. J.] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands; [Rabe, Klaus F.; Sont, Jacob K.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands; [Sterk, Peter J.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1105 AZ Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam	van der Meer, V (corresponding author), Leiden Univ, Med Ctr, Dept Med Decis Making, Leiden, Netherlands.	v.van_der_meer@lumc.nl	Sterk, P.J./AAK-8175-2020; Sont, Jacob K/J-8071-2015; Assendelft, W.J.J./H-8008-2014; Rabe, Klaus F./AAW-6296-2021; assendelft, willem/AAW-1854-2021; Toussaint, Pieter/O-9523-2016	Sont, Jacob K/0000-0002-5840-0651; Assendelft, W.J.J./0000-0002-2966-3778; Rabe, Klaus F./0000-0002-7020-1401; assendelft, willem/0000-0002-2966-3778; Toussaint, Pieter/0000-0001-7340-7213; van den Hout, Wilbert B./0000-0002-6425-0135	governmental Netherlands Organization for Health Research and Development [945-04-061, 920-03-354]; Netherlands Asthma Foundation [3.4.03.45]	governmental Netherlands Organization for Health Research and Development; Netherlands Asthma Foundation	This study was supported by grants from the governmental Netherlands Organization for Health Research and Development (www.zonmw.nl grantnrs 945-04-061 and 920-03-354) and Netherlands Asthma Foundation (www.astmafonds.nl grantnr 3.4.03.45). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bray GA, 1999, DIABETES CARE, V22, P623; Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Contopoulos-Ioannidis DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3006; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; *DUTCH HLTH INS EX, 2007, PHARM COMP; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Gallefoss F, 2001, EUR RESPIR J, V17, P206, DOI 10.1183/09031936.01.17202060; Ghosh CS, 1998, SOC SCI MED, V46, P1087, DOI 10.1016/S0277-9536(97)10047-8; GIBSON PG, 2003, COCHRANE LIB; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Jones A, 2000, BMJ-BRIT MED J, V321, P1507, DOI 10.1136/bmj.321.7275.1507; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kauppinen R, 2001, RESP MED, V95, P56, DOI 10.1053/rmed.2000.0971; Lahdensuo A, 1998, BRIT MED J, V316, P1138, DOI 10.1136/bmj.316.7138.1138; Lamberts H., 1987, ICPC INT CLASSIFICAT; McTaggart-Cowan HM, 2008, QUAL LIFE RES, V17, P453, DOI 10.1007/s11136-008-9309-6; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; *OECD, 2008, PURCH POW PAR PPPS O; OOSTENBRINK JB, 2004, MANUAL COST ANAL MET; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; RUTTENVANMOLKEN MPMH, 1995, EUR RESPIR J, V8, P888; Schermer TR, 2002, AM J RESP CRIT CARE, V166, P1062, DOI 10.1164/rccm.2105116; Statistic Netherlands, 2008, CONS PRIC IND; Stiggelbout AM, 1996, INT J TECHNOL ASSESS, V12, P291, DOI 10.1017/S0266462300009648; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; Szende A, 2004, PHARMACOECONOMICS, V22, P537; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; van der Meer V, 2009, ANN INTERN MED, V151, P110, DOI 10.7326/0003-4819-151-2-200907210-00008; Willems DCM, 2006, INT J TECHNOL ASSESS, V22, P436, DOI 10.1017/S026646230605135X; Willems Danielle C M, 2007, Cost Eff Resour Alloc, V5, P10; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	37	31	31	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2011	6	11							e27108	10.1371/journal.pone.0027108	http://dx.doi.org/10.1371/journal.pone.0027108			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	855HG	22096523	Green Published, gold			2023-01-03	WOS:000297553900021
J	Kangovi, S; Grande, D				Kangovi, Shreya; Grande, David			Hospital Readmissions-Not Just a Measure of Quality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INSURANCE STATUS; FOLLOW-UP; CARE; ACCESS; IMPACT		[Kangovi, Shreya] Univ Penn, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA; [Grande, David] Univ Penn, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; [Kangovi, Shreya; Grande, David] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Kangovi, Shreya] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Kangovi, S (corresponding author), Univ Penn, Robert Wood Johnson Clin Scholars Program, 423 Guardian Dr,13th Floor,Blockley Hall, Philadelphia, PA 19104 USA.	kangovi@mail.med.upenn.edu	Grande, David/AAJ-8191-2021	Grande, David/0000-0002-6717-6735				ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; Ashton CM, 1996, SOC SCI MED, V43, P1533, DOI 10.1016/S0277-9536(96)00049-4; Asplin BR, 2005, JAMA-J AM MED ASSOC, V294, P1248, DOI 10.1001/jama.294.10.1248; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; McWilliams JM, 2003, JAMA-J AM MED ASSOC, V290, P757, DOI 10.1001/jama.290.6.757; Misky GJ, 2010, J HOSP MED, V5, P392, DOI 10.1002/jhm.666; Sox CM, 1998, AM J MED, V105, P506, DOI 10.1016/S0002-9343(98)00324-6; Strunin L, 2007, J HOSP MED, V2, P297, DOI 10.1002/jhm.206; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WEISSMAN JS, 1994, INQUIRY-J HEALTH CAR, V31, P163	10	115	115	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2011	306	16					1796	1797		10.1001/jama.2011.1562	http://dx.doi.org/10.1001/jama.2011.1562			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837HH	22028356				2023-01-03	WOS:000296181600025
J	Liu, XY; Liu, ZC; Sun, YG; Ross, M; Kim, S; Tsai, FF; Li, QF; Jeffry, J; Kim, JY; Loh, HH; Chen, ZF				Liu, Xian-Yu; Liu, Zhong-Chun; Sun, Yan-Gang; Ross, Michael; Kim, Seungil; Tsai, Feng-Fang; Li, Qi-Fang; Jeffry, Joseph; Kim, Ji-Young; Loh, Horace H.; Chen, Zhou-Feng			Unidirectional Cross-Activation of GRPR by MOR1D Uncouples Itch and Analgesia Induced by Opioids	CELL			English	Article							DORSAL-HORN NEURONS; MAMMALIAN BOMBESIN RECEPTORS; MORPHINE-INDUCED ANALGESIA; GASTROINTESTINAL TRANSIT; MOLECULAR-MECHANISMS; SPLICE VARIANTS; KNOCKOUT MICE; SPINAL-CORD; MU; PRURITUS	Spinal opioid-induced itch, a prevalent side effect of pain management, has been proposed to result from pain inhibition. We now report that the m-opioid receptor (MOR) isoform MOR1D is essential for morphine-induced scratching (MIS), whereas the isoform MOR1 is required only for morphine-induced analgesia (MIA). MOR1D heterodimerizes with gastrin-releasing peptide receptor (GRPR) in the spinal cord, relaying itch information. We show that morphine triggers internalization of both GRPR and MOR1D, whereas GRP specifically triggers GRPR internalization and morphine-independent scratching. Providing potential insight into opioid-induced itch prevention, we demonstrate that molecular and pharmacologic inhibition of PLC beta 3 and IP3R3, downstream effectors of GRPR, specifically block MIS but not MIA. In addition, blocking MOR1D-GRPR association attenuates MIS but not MIA. Together, these data suggest that opioid-induced itch is an active process concomitant with but independent of opioid analgesia, occurring via the unidirectional cross-activation of GRPR signaling by MOR1D heterodimerization.	[Liu, Xian-Yu; Liu, Zhong-Chun; Sun, Yan-Gang; Ross, Michael; Kim, Seungil; Tsai, Feng-Fang; Li, Qi-Fang; Jeffry, Joseph; Chen, Zhou-Feng] Washington Univ, Sch Med, Pain Ctr, Ctr Study Itch, St Louis, MO 63110 USA; [Liu, Xian-Yu; Liu, Zhong-Chun; Kim, Seungil; Li, Qi-Fang; Jeffry, Joseph; Kim, Ji-Young; Chen, Zhou-Feng] Washington Univ, Sch Med, Pain Ctr, Dept Anesthesiol, St Louis, MO 63110 USA; [Liu, Xian-Yu; Liu, Zhong-Chun; Kim, Seungil; Li, Qi-Fang; Jeffry, Joseph; Kim, Ji-Young; Chen, Zhou-Feng] Washington Univ, Sch Med, Pain Ctr, Dept Psychiat, St Louis, MO 63110 USA; [Liu, Xian-Yu; Liu, Zhong-Chun; Kim, Seungil; Li, Qi-Fang; Jeffry, Joseph; Kim, Ji-Young; Chen, Zhou-Feng] Washington Univ, Sch Med, Pain Ctr, Dept Dev Biol, St Louis, MO 63110 USA; [Loh, Horace H.] Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Minnesota System; University of Minnesota Twin Cities	Chen, ZF (corresponding author), Washington Univ, Sch Med, Pain Ctr, Ctr Study Itch, St Louis, MO 63110 USA.	chenz@wustl.edu	LIU, XIANYU/B-8111-2014	, qifang/0000-0002-5593-720X; Tsai, Feng-Fang/0000-0003-2390-3248; Ross, Michael/0000-0002-5136-650X; Liu, Xianyu/0000-0001-6089-8826	NIDA; NIAMS; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056318] Funding Source: NIH RePORTER	NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank J. Yin, S. Weng, Y.C. Pan, and Z.Q. Zhao for technical help and comments, C.J. Coscia, Y.X. Pan, and G.W. Pasternak for MOR1 and MOR1D plasmids, E. Wada and J. Battey for GRPR antibodies, P. Sternweis for PLC beta 3 antibody, E. Liman for IP3R3 antibody, D. Coy for a GRPR antagonist, B.W. Li for qRT-PCR help, and W. Huh for LCM. We also thank M. Bruchas for comments. J.J. has been supported by a NIDA training grant. The work was supported by a NIAMS grant to Z.-F.C.	Abbadie C, 2000, NEUROSCIENCE, V100, P141, DOI 10.1016/S0306-4522(00)00248-7; Agnati LF, 2003, PHARMACOL REV, V55, P509, DOI 10.1124/pr.55.3.2; Alvarez VA, 2002, J NEUROSCI, V22, P5769; Andoh T, 2008, J PHARMACOL SCI, V106, P667, DOI 10.1254/jphs.08004SC; BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; Bergasa NV, 2005, J HEPATOL, V43, P1078, DOI 10.1016/j.jhep.2005.09.004; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carstens E, 1997, J NEUROPHYSIOL, V77, P2499, DOI 10.1152/jn.1997.77.5.2499; Carstens EE, 2010, NEUROREPORT, V21, P303, DOI 10.1097/WNR.0b013e328337310a; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Davidson S, 2007, J NEUROSCI, V27, P10007, DOI 10.1523/JNEUROSCI.2862-07.2007; Davidson S, 2010, TRENDS NEUROSCI, V33, P550, DOI 10.1016/j.tins.2010.09.002; Fairbanks CA, 1999, J PHARMACOL EXP THER, V288, P1107; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; HALES P, 1980, LANCET, V2, P204; Hampton LL, 1998, P NATL ACAD SCI USA, V95, P3188, DOI 10.1073/pnas.95.6.3188; Han SK, 2006, NEURON, V52, P691, DOI 10.1016/j.neuron.2006.09.036; Hipser C, 2010, MT SINAI J MED, V77, P374, DOI 10.1002/msj.20199; Ikoma A, 2006, NAT REV NEUROSCI, V7, P535, DOI 10.1038/nrn1950; Jensen RT, 2008, PHARMACOL REV, V60, P1, DOI 10.1124/pr.107.07108; JONES EA, 1990, HEPATOLOGY, V11, P884, DOI 10.1002/hep.1840110526; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Ko MCH, 2000, ANESTHESIOLOGY, V92, P795, DOI 10.1097/00000542-200003000-00023; Ko MCH, 2004, J PHARMACOL EXP THER, V310, P169, DOI 10.1124/jpet.103.061101; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Kuraishi Y, 2000, J BIOMED SCI, V7, P248, DOI 10.1159/000025455; Lagerstrom MC, 2010, NEURON, V68, P529, DOI 10.1016/j.neuron.2010.09.016; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; LING GSF, 1989, LIFE SCI, V45, P1627, DOI 10.1016/0024-3205(89)90272-5; Liu Y, 2010, NEURON, V68, P543, DOI 10.1016/j.neuron.2010.09.008; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Lopez A, 2009, CELL MOL LIFE SCI, V66, P2093, DOI 10.1007/s00018-009-0008-4; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MCMAHON SB, 1992, TRENDS NEUROSCI, V15, P497, DOI 10.1016/0166-2236(92)90102-E; Metze D, 1999, J AM ACAD DERMATOL, V41, P533, DOI 10.1016/S0190-9622(99)80048-6; Milligan G, 2009, BRIT J PHARMACOL, V158, P5, DOI 10.1111/j.1476-5381.2009.00169.x; Nichols ML, 1999, SCIENCE, V286, P1558, DOI 10.1126/science.286.5444.1558; Pan YX, 2005, DNA CELL BIOL, V24, P736, DOI 10.1089/dna.2005.24.736; Pasternak GW, 2010, CLIN J PAIN, V26, pS3, DOI 10.1097/AJP.0b013e3181c49d2e; Pasternak GW, 2004, NEUROPHARMACOLOGY, V47, P312, DOI 10.1016/j.neuropharm.2004.07.004; Patel KN, 2010, NEURON, V68, P334, DOI 10.1016/j.neuron.2010.10.018; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Ravindranathan A, 2009, P NATL ACAD SCI USA, V106, P10811, DOI 10.1073/pnas.0904509106; Ross SE, 2010, NEURON, V65, P886, DOI 10.1016/j.neuron.2010.02.025; Samways DSK, 2006, CELL SIGNAL, V18, P151, DOI 10.1016/j.cellsig.2005.08.005; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Sun YG, 2009, SCIENCE, V325, P1531, DOI 10.1126/science.1174868; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Trafton JA, 2000, J NEUROSCI, V20, P8578; van Baarlen P, 2009, P NATL ACAD SCI USA, V106, P2371, DOI 10.1073/pnas.0809919106; Waldhoer M, 2005, P NATL ACAD SCI USA, V102, P9050, DOI 10.1073/pnas.0501112102; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Zhao ZQ, 2007, P NATL ACAD SCI USA, V104, P14519, DOI 10.1073/pnas.0705740104	62	199	211	3	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 14	2011	147	2					447	458		10.1016/j.cell.2011.08.043	http://dx.doi.org/10.1016/j.cell.2011.08.043			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837KD	22000021	Green Accepted, Bronze			2023-01-03	WOS:000296199300021
J	Leffler, D				Leffler, Daniel			Celiac Disease Diagnosis and Management A 46-Year-Old Woman With Anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUTEN-FREE DIET; IRRITABLE-BOWEL-SYNDROME; POPULATION-BASED COHORT; COST-EFFECTIVENESS ANALYSIS; ANTITISSUE TRANSGLUTAMINASE ANTIBODIES; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; UNITED-STATES; PEDIATRIC-GASTROENTEROLOGY; GASTROINTESTINAL SYMPTOMS	Celiac disease is one of the most prevalent autoimmune gastrointestinal disorders, but as the case of Ms J illustrates, diagnosis is often delayed or missed. Based on serologic studies, the prevalence of celiac disease in many populations is estimated to be approximately 1% and has been increasing steadily over the last 50 years. Evaluation for celiac disease is generally straightforward and uses commonly available serologic tests; however, the signs and symptoms of celiac disease are nonspecific and highly heterogeneous, making diagnosis difficult. Although celiac disease is often considered a mild disorder treatable with simple dietary changes, in reality celiac disease imparts considerable risks, including reduced bone mineral density, impaired quality of life, and increased overall mortality. In addition, a gluten-free diet is highly burdensome and can profoundly affect patients and their families. For these reasons, care of individuals with celiac disease requires prompt diagnosis and ongoing multidisciplinary management. JAMA. 2011;306(14):1582-1592	[Leffler, Daniel] Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA; [Leffler, Daniel] Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Leffler, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.	dleffler@caregroup.harvard.edu			National Institutes of Health [DK082619]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK095937, K23DK082619] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Leffler reports that he receives support from National Institutes of Health K23 Career Development Award DK082619 and has served as a consultant for Alba Pharmaceuticals, Alvine Pharmaceuticals, Prometheus Laboratories, and Shire Pharmaceuticals.	Abdulkarim AS, 2002, AM J GASTROENTEROL, V97, P2016; Abenavoli L, 2009, EXPERT REV CLIN IMMU, V5, P789, DOI 10.1586/ECI.09.46; Accomando S, 2004, DIGEST LIVER DIS, V36, P492, DOI 10.1016/j.dld.2004.01.026; Akobeng AK, 2008, ALIMENT PHARM THER, V27, P1044, DOI 10.1111/j.1365-2036.2008.03669.x; American Dietetic Association, CEL DIS EV BAS NUTR; [Anonymous], 2004, NIH Consens State Sci Statements, V21, P1; Bernstein CN, 2003, GASTROENTEROLOGY, V124, P795, DOI 10.1053/gast.2003.50106; Biesiekierski JR, 2011, AM J GASTROENTEROL, V106, P508, DOI 10.1038/ajg.2010.487; Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Catassi C, 2004, CURR OPIN PEDIATR, V16, P445, DOI 10.1097/01.mop.0000133637.64414.20; Catassi C, 2007, AM J CLIN NUTR, V85, P160, DOI 10.1093/ajcn/85.1.160; Catassi C, 2007, AM J GASTROENTEROL, V102, P1454, DOI 10.1111/j.1572-0241.2007.01173.x; Catassi C, 2010, AM J MED, V123, P691, DOI 10.1016/j.amjmed.2010.02.019; Cheng JF, 2010, J CLIN GASTROENTEROL, V44, P191, DOI 10.1097/MCG.0b013e3181ac9942; Collin P, 2003, AM J CLIN DERMATOL, V4, P13, DOI 10.2165/00128071-200304010-00002; Corazza GR, 1999, AM J GASTROENTEROL, V94, P391; Cosnes J, 2008, CLIN GASTROENTEROL H, V6, P753, DOI 10.1016/j.cgh.2007.12.022; Cranney A, 2007, DIGEST DIS SCI, V52, P1087, DOI 10.1007/s10620-006-9258-2; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Dipper CR, 2009, ALIMENT PHARM THER, V30, P236, DOI 10.1111/j.1365-2036.2009.04039.x; DISANTAGNESE PA, 1953, PEDIATRICS, V11, P224; Dube C, 2005, GASTROENTEROLOGY, V128, pS57, DOI 10.1053/j.gastro.2005.02.014; Evans KE, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3674; Fasano A, 2008, J PEDIATR GASTR NUTR, V47, P214, DOI 10.1097/MPG.0b013e318181afed; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2009, BRIT MED J, V339, pb3592; Ferrara F, 2010, CLIN EXP IMMUNOL, V159, P217, DOI 10.1111/j.1365-2249.2009.04054.x; Ford AC, 2009, ARCH INTERN MED, V169, P651, DOI 10.1001/archinternmed.2009.22; Garud S, 2009, ALIMENT PHARM THER, V29, P898, DOI 10.1111/j.1365-2036.2009.03942.x; Giordano L, 2009, PEDIATR NEUROL, V41, P34, DOI 10.1016/j.pediatrneurol.2009.02.009; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Green PHR, 2009, CLIN GASTROENTEROL H, V7, P1210, DOI 10.1016/j.cgh.2009.07.011; Green PHR, 2001, AM J GASTROENTEROL, V96, P126, DOI 10.1111/j.1572-0241.2001.03462.x; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hadjivassiliou M, 2003, BRAIN, V126, P685, DOI 10.1093/brain/awg050; Hadjivassiliou M, 2006, J NEUROL NEUROSUR PS, V77, P1262, DOI 10.1136/jnnp.2006.093534; Hadjivassiliou M, 2010, LANCET NEUROL, V9, P318, DOI 10.1016/S1474-4422(09)70290-X; Hall NJ, 2009, ALIMENT PHARM THER, V30, P315, DOI 10.1111/j.1365-2036.2009.04053.x; Hernandez Lincoln, 2006, Curr Gastroenterol Rep, V8, P383, DOI 10.1007/s11894-006-0023-7; Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001; Howard MR, 2002, J CLIN PATHOL, V55, P754, DOI 10.1136/jcp.55.10.754; Hu WT, 2006, ARCH NEUROL-CHICAGO, V63, P1440, DOI 10.1001/archneur.63.10.1440; Johnston SD, 2004, EUR J GASTROEN HEPAT, V16, P1281, DOI 10.1097/00042737-200412000-00008; Kinsey L, 2008, EUR J CLIN NUTR, V62, P1333, DOI 10.1038/sj.ejcn.1602856; Lanzini A, 2009, ALIMENT PHARM THER, V29, P1299, DOI 10.1111/j.1365-2036.2009.03992.x; Lee AR, 2007, J HUM NUTR DIET, V20, P423, DOI 10.1111/j.1365-277X.2007.00763.x; Leffler DA, 2007, ALIMENT PHARM THER, V26, P1227, DOI 10.1111/j.1365-2036.2007.03501.x; Leffler DA, 2009, CLIN GASTROENTEROL H, V7, pe1; Leffler DA, 2007, CLIN GASTROENTEROL H, V5, P445, DOI 10.1016/j.cgh.2006.12.006; Leffler DA, 2010, AM J GASTROENTEROL, V105, P2520, DOI 10.1038/ajg.2010.276; Leffler DA, 2009, CLIN GASTROENTEROL H, V7, P530, DOI 10.1016/j.cgh.2008.12.032; Lionetti E, 2010, DEV MED CHILD NEUROL, V52, P700, DOI 10.1111/j.1469-8749.2010.03647.x; Lohi S, 2009, GUT, V58, P643, DOI 10.1136/gut.2007.140970; Ludvigsson JF, 2008, GUT, V57, P1074, DOI 10.1136/gut.2007.133868; Ludvigsson JF, 2005, GASTROENTEROLOGY, V129, P454, DOI 10.1053/j.gastro.2005.05.065; Ludvigsson JF, 2007, CLIN GASTROENTEROL H, V5, P1347, DOI 10.1016/j.cgh.2007.06.002; Ludvigsson JF, 2007, J AFFECT DISORDERS, V99, P117, DOI 10.1016/j.jad.2006.08.032; Ludvigsson JF, 2009, JAMA-J AM MED ASSOC, V302, P1171, DOI 10.1001/jama.2009.1320; Maglio M, 2010, J PEDIATR GASTR NUTR, V50, P43, DOI 10.1097/MPG.0b013e3181b99c8f; Mein SM, 2004, ALIMENT PHARM THER, V19, P1199, DOI 10.1111/j.1365-2036.2004.01958.x; Moccia M, 2010, MOVEMENT DISORD, V25, P877, DOI 10.1002/mds.22903; Murray JA, 2004, AM J CLIN NUTR, V79, P669; Mustalahti Kirsi, 2002, Eff Clin Pract, V5, P105; Nachman F, 2011, CLIN GASTROENTEROL H, V9, P214, DOI 10.1016/j.cgh.2010.06.017; National Institute for Health and Clinical Excellence, COEL DIS REC ASS COE; Neuhausen SL, 2008, J AUTOIMMUN, V31, P160, DOI 10.1016/j.jaut.2008.06.001; Olsson C, 2008, J HUM NUTR DIET, V21, P359, DOI 10.1111/j.1365-277X.2008.00867.x; Peracchi M, 2002, AM J GASTROENTEROL, V97, P2850; Primary Care Society for Gastroenterology, 2006, MAN AD COEL DIS PRIM; Ransford RAJ, 2002, J CLIN GASTROENTEROL, V35, P228, DOI 10.1097/00004836-200209000-00006; Robert ME, 2005, SEMIN DIAGN PATHOL, V22, P284, DOI 10.1053/j.semdp.2006.04.004; Rostami K, 2000, EUR J GASTROEN HEPAT, V12, P51, DOI 10.1097/00042737-200012010-00010; Rostom A, 2006, GASTROENTEROLOGY, V131, P1981, DOI 10.1053/j.gastro.2006.10.004; Rubio-Tapia A, 2007, HEPATOLOGY, V46, P1650, DOI 10.1002/hep.21949; Rubio-Tapia A, 2010, AM J GASTROENTEROL, V105, P1412, DOI 10.1038/ajg.2010.10; Rubio-Tapia A, 2010, GUT, V59, P547, DOI 10.1136/gut.2009.195131; Rubio-Tapia A, 2009, GASTROENTEROLOGY, V137, P88, DOI 10.1053/j.gastro.2009.03.059; Sabel'nikova E A, 2004, Eksp Klin Gastroenterol, P31; Sanders DS, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c5161; Sanders DS, 2005, DIGEST DIS SCI, V50, P587, DOI 10.1007/s10620-005-2479-y; Schuppan Detlef, 2005, Nutr Clin Care, V8, P54; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Shah S, 2010, WOMENS HEALTH, V6, P753, DOI 10.2217/WHE.10.57; Shamir R, 2006, MED DECIS MAKING, V26, P282, DOI 10.1177/0272989X06289012; Siniscalchi M, 2005, ALIMENT PHARM THER, V22, P489, DOI 10.1111/j.1365-2036.2005.02619.x; Sivash ES, 2004, EKSP KLIN GASTROENTE, V31, P102; Solaymani-Dodaran M, 2007, AM J GASTROENTEROL, V102, P864, DOI 10.1111/j.1572-0241.2007.01111.x; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Soni S, 2010, J REPROD MED, V55, P3; Spiegel BMR, 2004, GASTROENTEROLOGY, V126, P1721, DOI 10.1053/j.gastro.2004.03.012; Strong K, 2005, J MED SCREEN, V12, P12, DOI 10.1258/0969141053279086; Tata LJ, 2005, GASTROENTEROLOGY, V128, P849, DOI 10.1053/j.gastro.2005.02.017; Thompson T, 2005, J HUM NUTR DIET, V18, P163, DOI 10.1111/j.1365-277X.2005.00607.x; Thompson T, 2010, J AM DIET ASSOC, V110, P937, DOI 10.1016/j.jada.2010.03.014; Tursi A, 2008, DIGEST DIS SCI, V53, P2925, DOI 10.1007/s10620-008-0242-x; van der Windt DAWM, 2010, JAMA-J AM MED ASSOC, V303, P1738, DOI 10.1001/jama.2010.549; van Koppen EJ, 2009, PEDIATRICS, V123, pE582, DOI 10.1542/peds.2008-2221; Verdu EF, 2011, AM J GASTROENTEROL, V106, P516, DOI 10.1038/ajg.2010.490; Villalta D, 2005, CLIN CHIM ACTA, V356, P102, DOI 10.1016/j.cccn.2005.01.015; Virta LJ, 2009, SCAND J GASTROENTERO, V44, P933, DOI 10.1080/00365520903030795; Volta U, 2010, EXPERT REV GASTROENT, V4, P31, DOI 10.1586/EGH.09.66; Wahnschaffe U, 2007, CLIN GASTROENTEROL H, V5, P844, DOI 10.1016/j.cgh.2007.03.021; West J, 2004, BRIT MED J, V329, P716, DOI 10.1136/bmj.38169.486701.7C; Whitaker JKH, 2009, ALIMENT PHARM THER, V29, P1131, DOI 10.1111/j.1365-2036.2009.03983.x; World Gastroenterology Organisation, WORLD GASTR ORG PRAC; Zarkadas M, 2006, J HUM NUTR DIET, V19, P41, DOI 10.1111/j.1365-277X.2006.00659.x; Zelnik N, 2004, PEDIATRICS, V113, P1672, DOI 10.1542/peds.113.6.1672; Zipser RD, 2003, DIGEST DIS SCI, V48, P761, DOI 10.1023/A:1022897028030; Zone JJ, 2005, GASTROENTEROLOGY, V128, pS87, DOI 10.1053/j.gastro.2005.02.026	110	18	18	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2011	306	14					1582	1592		10.1001/jama.2011.1312	http://dx.doi.org/10.1001/jama.2011.1312			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831FS	21990301	Green Accepted			2023-01-03	WOS:000295714700024
J	Chan, PA; Mermel, LA; Andrea, SB; McCulloh, R; Mills, JP; Echenique, I; Leveen, E; Rybak, N; Cunha, C; Machan, JT; Healey, TT; Chapin, KC				Chan, Philip A.; Mermel, Leonard A.; Andrea, Sarah B.; McCulloh, Russell; Mills, John P.; Echenique, Ignacio; Leveen, Emily; Rybak, Natasha; Cunha, Cheston; Machan, Jason T.; Healey, Terrance T.; Chapin, Kimberle C.			Distinguishing Characteristics between Pandemic 2009-2010 Influenza A (H1N1) and Other Viruses in Patients Hospitalized with Respiratory Illness	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; CLINICAL-FEATURES; A(H1N1) INFECTION; UNITED-STATES; PNEUMONIA; OUTBREAK; DIAGNOSIS; HUMANS	Background: Differences in clinical presentation and outcomes among patients infected with pandemic 2009 influenza A H1N1 (pH1N1) compared to other respiratory viruses have not been fully elucidated. Methodology/Principal Findings: A retrospective study was performed of all hospitalized patients at the peak of the pH1N1 season in whom a single respiratory virus was detected by a molecular assay targeting 18 viruses/subtypes (RVP, Luminex xTAG). Fifty-two percent (615/1192) of patients from October, 2009 to December, 2009 had a single respiratory virus (291 pH1N1; 207 rhinovirus; 45 RSV A/B; 37 parainfluenza; 27 adenovirus; 6 coronavirus; and 2 metapneumovirus). No seasonal influenza A or B was detected. Individuals with pH1N1, compared to other viruses, were more likely to present with fever (92% & 70%), cough (92% & 86%), sore throat (32% & 16%), nausea (31% & 8%), vomiting (39% & 30%), abdominal pain (14% & 7%), and a lower white blood count (8,500/L & 13,600/L, all p-values<0.05). In patients with cough and gastrointestinal complaints, the presence of subjective fever/chills independently raised the likelihood of pH1N1 (OR 10). Fifty-five percent (336/615) of our cohort received antibacterial agents, 63% (385/615) received oseltamivir, and 41% (252/615) received steroids. The mortality rate of our cohort was 1% (7/615) and was higher in individuals with pH1N1 compared to other viruses (2.1% & 0.3%, respectively; p = 0.04). Conclusions/Significance: During the peak pandemic 2009-2010 influenza season in Rhode Island, nearly half of patients admitted with influenza-like symptoms had respiratory viruses other than influenza A. A high proportion of patients were treated with antibiotics and pH1N1 infection had higher mortality compared to other respiratory viruses.	[Chan, Philip A.; Mermel, Leonard A.] Rhode Isl Hosp, Div Infect Dis, Providence, RI 02903 USA; [Chan, Philip A.; Mermel, Leonard A.; Mills, John P.; Echenique, Ignacio; Leveen, Emily; Rybak, Natasha; Cunha, Cheston; Chapin, Kimberle C.] Brown Univ, Dept Med, Alpert Med Sch, Providence, RI 02912 USA; [Andrea, Sarah B.; Chapin, Kimberle C.] Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA; [McCulloh, Russell] Rhode Isl Hosp, Div Pediat Infect Dis, Providence, RI 02902 USA; [McCulloh, Russell] Brown Univ, Dept Pediat, Alpert Med Sch, Providence, RI 02912 USA; [Machan, Jason T.] Rhode Isl Hosp, Dept Orthoped & Surg, Providence, RI USA; [Healey, Terrance T.] Rhode Isl Hosp, Dept Radiol, Providence, RI USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Lifespan Health Rhode Island; Rhode Island Hospital	Chan, PA (corresponding author), Rhode Isl Hosp, Div Infect Dis, Providence, RI 02903 USA.	kchapin@lifespan.org	Cunha, Cheston/Z-2779-2019; Mermel, Leonard/Z-1475-2019; McCulloh, Russell/GVU-6139-2022; McCulloh, Russell/W-6128-2019; Machan, Jason/D-3897-2013	Cunha, Cheston/0000-0003-4149-9146; McCulloh, Russell/0000-0002-0403-6639; Machan, Jason/0000-0003-2048-4914; Mills, John/0000-0001-6529-2911; Echenique, Ignacio A./0000-0002-6301-0121; Chan, Philip/0000-0003-0964-5895				Babcock HM, 2008, INFECT CONT HOSP EP, V29, P921, DOI 10.1086/590663; Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Belongia EA, 2010, JAMA-J AM MED ASSOC, V304, P1091, DOI 10.1001/jama.2010.1277; Boggild AK, 2010, CRIT CARE MED, V38, pE38, DOI 10.1097/CCM.0b013e3181cd7bb2; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Bryant PA, 2010, PEDIATR INFECT DIS J, V29, P694, DOI 10.1097/INF.0b013e3181de4b9c; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Carcione D, 2010, EMERG INFECT DIS, V16, P1388, DOI 10.3201/eid1609.100076; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433; Crum-Cianflone NF, 2009, CLIN INFECT DIS, V49, P1801, DOI 10.1086/648508; Cunha BA, 2010, HEART LUNG, V39, P461, DOI 10.1016/j.hrtlng.2010.01.005; Cunha BA, 2010, INFECT DIS CLIN N AM, V24, P203, DOI 10.1016/j.idc.2009.10.001; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; Fox JD, 2007, J CLIN VIROL, V40, pS15, DOI 10.1016/S1386-6532(07)70005-7; Ganzenmueller T, 2010, J MED MICROBIOL, V59, P713, DOI 10.1099/jmm.0.017244-0; Ginocchio CC, 2009, J CLIN VIROL, V45, P191, DOI 10.1016/j.jcv.2009.06.005; Gootz TD, 2010, CRIT REV IMMUNOL, V30, P79, DOI 10.1615/CritRevImmunol.v30.i1.60; Gordon A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010364; Greenberg S B, 1991, Infect Dis Clin North Am, V5, P603; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jennings LC, 2008, THORAX, V63, P42, DOI 10.1136/thx.2006.075077; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Landry ML, 2011, CURR OPIN PEDIATR, V23, P91, DOI 10.1097/MOP.0b013e328341ebd9; Lee EH, 2010, CLIN INFECT DIS, V50, P1498, DOI 10.1086/652446; Leonardi GP, 2010, J CLIN MICROBIOL, V48, P1189, DOI 10.1128/JCM.01657-09; Lessler J, 2009, NEW ENGL J MED, V361, P2628, DOI 10.1056/NEJMoa0906089; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583; Medina RA, 2011, J CLIN MICROBIOL, V49, P335, DOI 10.1128/JCM.01142-10; Park S. Y., 2010, Morbidity and Mortality Weekly Report, V58, P1440; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Shinde V, 2009, NEW ENGL J MED, V360, P2616, DOI 10.1056/NEJMoa0903812; Thompson WW, 2009, AM J PUBLIC HEALTH, V99, pS225, DOI 10.2105/AJPH.2008.151944; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; Welch DF, 2010, J CLIN MICROBIOL, V48, P22, DOI 10.1128/JCM.02268-09; Wigton RS, 2008, J GEN INTERN MED, V23, P1615, DOI 10.1007/s11606-008-0707-9	40	23	23	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2011	6	9							e24734	10.1371/journal.pone.0024734	http://dx.doi.org/10.1371/journal.pone.0024734			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	824BI	21949746	Green Submitted, Green Published, gold			2023-01-03	WOS:000295173800035
J	Stoll, M; Kollan, C; Bergmann, F; Bogner, J; Faetkenheuer, G; Fritzsche, C; Hoeper, K; Horst, HA; van Lunzen, J; Plettenberg, A; Reuter, S; Rockstroh, J; Stellbrink, HJ; Hamouda, O; Bartmeyer, B				Stoll, Matthias; Kollan, Christian; Bergmann, Frank; Bogner, Johannes; Faetkenheuer, Gerd; Fritzsche, Carlos; Hoeper, Kirsten; Horst, Heinz-August; van Lunzen, Jan; Plettenberg, Andreas; Reuter, Stefan; Rockstroh, Juergen; Stellbrink, Hans-Juergen; Hamouda, Osamah; Bartmeyer, Barbara		ClinSurv Study Grp	Calculation of Direct Antiretroviral Treatment Costs and Potential Cost Savings by Using Generics in the German HIV ClinSurv Cohort	PLOS ONE			English	Article							THERAPY; DRUGS; EMTRICITABINE; INDIVIDUALS; STRATEGIES; INFECTION; REDUCE; PRICE; LIFE	Background/Aim of the Study: The study aimed to determine the cost impacts of antiretroviral drugs by analysing a long-term follow-up of direct costs for combined antiretroviral therapy,cART,-regimens in the nationwide long-term observational multi-centre German HIV ClinSurv Cohort. The second aim was to develop potential cost saving strategies by modelling different treatment scenarios. Methods: Antiretroviral regimens (ART) from 10,190 HIV-infected patients from 11 participating ClinSurv study centres have been investigated since 1996. Biannual data cART,-initiation, cART-changes, surrogate markers, clinical events and the Centre of Disease Control-(CDC)-stage of HIV disease are reported. Treatment duration was calculated on a daily basis via the documented dates for the beginning and end of each antiretroviral drug treatment. Prices were calculated for each individual regimen based on actual office sales prices of the branded pharmaceuticals distributed by the license holder including German taxes. Results: During the 13-year follow-up period, 21,387,427 treatment days were covered. Cumulative direct costs for antiretroviral drugs of (sic)812,877,356 were determined according to an average of (sic)42.08 per day (sic)7.52 to (sic)217.70). Since cART is widely used in Germany, the costs for an entire regimen increased by 13.5%. Regimens are more expensive in the advanced stages of HIV disease. The potential for cost savings was calculated using non-nucleotide-reverse-transcriptase-inhibitor, NNRTI, more frequently instead of ritonavir-boosted protease inhibitor, PI/r, in first line therapy. This calculation revealed cumulative savings of 10.9% to 19.8% of daily treatment costs (50% and 90% substitution of PI/r, respectively). Substituting certain branded drugs by generic drugs showed potential cost savings of between 1.6% and 31.8%. Conclusions: Analysis of the data of this nationwide study reflects disease-specific health services research and will give insights into the cost impacts of antiretroviral therapy, and might allow a more rational allocation of resources within the German health care system.	[Stoll, Matthias; Hoeper, Kirsten] Med Univ, Infect Dis Unit, Hannover, Germany; [Kollan, Christian; Hamouda, Osamah; Bartmeyer, Barbara] Robert Koch Inst, D-1000 Berlin, Germany; [Bergmann, Frank] Charite, D-13353 Berlin, Germany; [Bogner, Johannes] Univ Munich, Univ Hosp, Munich, Germany; [Faetkenheuer, Gerd] Univ Hosp Cologne, Cologne, Germany; [Fritzsche, Carlos] Univ Hosp, Rostock, Germany; [Horst, Heinz-August] Univ Schleswig Holstein, Kiel, Germany; [van Lunzen, Jan] Univ Hosp Eppendorf, Hamburg, Germany; [Plettenberg, Andreas] Ifi Inst Interdisciplinary Med, Hamburg, Germany; [Reuter, Stefan] Univ Hosp, Dusseldorf, Germany; [Rockstroh, Juergen] Univ Hosp, Bonn, Germany; [Stellbrink, Hans-Juergen] ICH Studyctr, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Robert Koch Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Cologne; University of Rostock; University of Kiel; Schleswig Holstein University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn	Stoll, M (corresponding author), Med Univ, Infect Dis Unit, Hannover, Germany.	Stoll.Matthias@mh-hannover.de	Reuter, Stefan/F-5895-2011		Robert Koch Institute, Germany; Boehringer-Ingelheim; Glaxo-Smith-Kline; Roche; Tibotec	Robert Koch Institute, Germany; Boehringer-Ingelheim(Boehringer Ingelheim); Glaxo-Smith-Kline(GlaxoSmithKline); Roche(Roche Holding); Tibotec	The ClinSurv Study was funded by the Robert Koch Institute which is the competent Body for Public health in Germany. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.; The first author Matthias Stoll received honoraria as a lecturer by Abbott, Bristol-Myers-Squibb, Boehringer, Ingelheim, Glaxo-Smith-Kline, Roche, Gilead, Tibotec, Pfizer, Merck, Sharp & Dohme, and ViiV. He had served as a scientific advisor for Glaxo-Smith-Kline, Gilead, DuPont, Merck, Sharp & Dohme, Abbott, Roche, Solvay, Tibotec and ViiV. He received funding for scientific projects by Boehringer-Ingelheim, Glaxo-Smith-Kline, Roche, and Tibotec This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Augurzky B, 2009, HEALTH ECON, V18, P421, DOI 10.1002/hec.1376; BARTMEYER B, 2010, INT AIDS C 2010 VIEN; Borroto-Esoda Katyna, 2007, Antiviral Chemistry & Chemotherapy, V18, P297; Borroto-Esoda K, 2006, ANTIVIR THER, V11, P377; Chowers M, 2010, EUR J CLIN MICROBIOL, V29, P779, DOI 10.1007/s10096-010-0926-y; *DAIG, 2010, GERM AUSTR TREATM GU; Davidson I, 2010, ANTIVIR RES, V86, P227, DOI 10.1016/j.antiviral.2010.03.001; DHHS, 2011, GUID US ANT AG HIV 1; European AIDS Clinical Society (EACS), 2009, GUID CLIN MAN TREATM; FEIGENBAUM JB, 2010, COH PROF GERM CLIN S; Green CJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008654; HELLSTRO MJ, 2004, EUR J HEALTH ECON, V5, P203; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Kingham R, 2009, FOOD DRUG LAW J, V64, P101; Ledergerber B, 2011, HIV MED, V12, P279, DOI 10.1111/j.1468-1293.2010.00880.x; Levy AR, 2006, LANCET INFECT DIS, V6, P171, DOI 10.1016/S1473-3099(06)70413-3; Mannheimer SB, 2005, AIDS CARE, V17, P10, DOI 10.1080/09540120412331305098; McKinnon JE, 2009, ANTIVIR THER, V14, P1; Metzner KJ, 2010, J INFECT DIS, V201, P1063, DOI 10.1086/651136; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Rizzo JA, 2009, INT J HEALTH CARE FI, V9, P291, DOI 10.1007/s10754-008-9052-0; Roebuck MC, 2009, HEALTH SERV RES, V44, P988, DOI 10.1111/j.1475-6773.2008.00943.x; Shimatani T, 2009, DIGEST DIS SCI, V54, P2385, DOI 10.1007/s10620-008-0634-y; Stargardt T, 2007, HEALTH POLICY, V84, P30, DOI 10.1016/j.healthpol.2007.04.006; TOMECZKOWSKI JGH, 2010, ESTIMATION PATIENTS; von der Schulenburg J-Matthias Graf, 2005, Eur J Health Econ, V6, P183; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Waning B, 2009, B WORLD HEALTH ORGAN, V87, P520, DOI 10.2471/BLT.08.058925	28	32	32	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2011	6	9							e23946	10.1371/journal.pone.0023946	http://dx.doi.org/10.1371/journal.pone.0023946			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	819CN	21931626	Green Published, gold, Green Submitted			2023-01-03	WOS:000294803100007
J	Lee, JS; Ward, WO; Liu, J; Ren, HZ; Vallanat, B; Delker, D; Corton, JC				Lee, Janice S.; Ward, William O.; Liu, Jie; Ren, Hongzu; Vallanat, Beena; Delker, Don; Corton, J. Christopher			Hepatic Xenobiotic Metabolizing Enzyme and Transporter Gene Expression through the Life Stages of the Mouse	PLOS ONE			English	Article							DRUG-METABOLISM; LYMPHOID NEOGENESIS; MICROARRAY ANALYSIS; MAMMALIAN LIVER; RAT-LIVER; PHASE-II; MICE; AGE; PROFILES; ONTOGENY	Background: Differences in responses to environmental chemicals and drugs between life stages are likely due in part to differences in the expression of xenobiotic metabolizing enzymes and transporters (XMETs). No comprehensive analysis of the mRNA expression of XMETs has been carried out through life stages in any species. Results: Using full-genome arrays, the mRNA expression of all XMETs and their regulatory proteins was examined during fetal (gestation day (GD) 19), neonatal (postnatal day (PND) 7), prepubescent (PND32), middle age (12 months), and old age (18 and 24 months) in the C57BL/6J (C57) mouse liver and compared to adults. Fetal and neonatal life stages exhibited dramatic differences in XMET mRNA expression compared to the relatively minor effects of old age. The total number of XMET probe sets that differed from adults was 636, 500, 84, 5, 43, and 102 for GD19, PND7, PND32, 12 months, 18 months and 24 months, respectively. At all life stages except PND32, under-expressed genes outnumbered over-expressed genes. The altered XMETs included those in all of the major metabolic and transport phases including introduction of reactive or polar groups (Phase I), conjugation (Phase II) and excretion (Phase III). In the fetus and neonate, parallel increases in expression were noted in the dioxin receptor, Nrf2 components and their regulated genes while nuclear receptors and regulated genes were generally down-regulated. Suppression of male-specific XMETs was observed at early (GD19, PND7) and to a lesser extent, later life stages (18 and 24 months). A number of female-specific XMETs exhibited a spike in expression centered at PND7. Conclusions: The analysis revealed dramatic differences in the expression of the XMETs, especially in the fetus and neonate that are partially dependent on gender-dependent factors. XMET expression can be used to predict life stage-specific responses to environmental chemicals and drugs.	[Lee, Janice S.; Ward, William O.; Ren, Hongzu; Vallanat, Beena; Delker, Don; Corton, J. Christopher] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Liu, Jie] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA	United States Environmental Protection Agency; University of Kansas; University of Kansas Medical Center	Lee, JS (corresponding author), US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA.	lee.janices@epa.gov		Lee, Janice/0000-0002-4331-8452	United States Environmental Protection Agency	United States Environmental Protection Agency(United States Environmental Protection Agency)	Work funded by the United States Environmental Protection Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlborn GJ, 2009, TOXICOLOGY, V262, P106, DOI 10.1016/j.tox.2009.05.003; Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Amador-Noguez D, 2005, BIOCHEM BIOPH RES CO, V332, P1086, DOI 10.1016/j.bbrc.2005.05.063; [Anonymous], 2005, GUID CARC RISK ASS; Barski OA, 2008, DRUG METAB REV, V40, P553, DOI [10.1080/03602530802431439, 10.1080/03602530802431439 ]; Bleasby K, 2006, XENOBIOTICA, V36, P963, DOI 10.1080/00498250600861751; BORLAKOGLU JT, 1993, BIOCHEM PHARMACOL, V46, P29, DOI 10.1016/0006-2952(93)90344-V; Broccardo C, 2001, CYTOGENET CELL GENET, V92, P264, DOI 10.1159/000056914; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Clodfelter KH, 2007, PHYSIOL GENOMICS, V31, P63, DOI 10.1152/physiolgenomics.00055.2007; Clodfelter KH, 2006, MOL ENDOCRINOL, V20, P1333, DOI 10.1210/me.2005-0489; Czekaj P, 2005, ARCH TOXICOL, V79, P13, DOI 10.1007/s00204-004-0607-7; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endo S, 2006, BIOL PHARM BULL, V29, P2488, DOI 10.1248/bpb.29.2488; Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528; Fujimori K, 2010, J BIOL CHEM, V285, P8880, DOI 10.1074/jbc.M109.077164; FUJITA S, 1990, J PHARMACOL EXP THER, V253, P369; Guo Minglei, 2009, Adv Stud Biol, V1, P61; Hakkola J, 1998, CRIT REV TOXICOL, V28, P35, DOI 10.1080/10408449891344173; He XJ, 2007, EXP MOL PATHOL, V83, P428, DOI 10.1016/j.yexmp.2006.05.002; Hines RN, 2008, PHARMACOL THERAPEUT, V118, P250, DOI 10.1016/j.pharmthera.2008.02.005; Hjelmstrom P, 2001, J LEUKOCYTE BIOL, V69, P331; Huang HZ, 2005, CHEM RES TOXICOL, V18, P1371, DOI 10.1021/tx050072+; IMAOKA S, 1991, BIOCHIM BIOPHYS ACTA, V1097, P187, DOI 10.1016/0925-4439(91)90034-7; Karanth S, 2000, TOXICOL SCI, V58, P282, DOI 10.1093/toxsci/58.2.282; Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231; Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009; Lee JS, 2008, TOXICOL SCI, V106, P263, DOI 10.1093/toxsci/kfn144; McGlynn KA, 2003, CANCER RES, V63, P4594; McGrath K, 2008, CURR TOP DEV BIOL, V82, P1, DOI 10.1016/S0070-2153(07)00001-4; Mickley L, 2001, MAMM GENOME, V12, P86, DOI 10.1007/s003350010237; Mori K, 2007, TOXICOL PATHOL, V35, P242, DOI 10.1080/01926230601156286; Nakata K, 2006, DRUG METAB PHARMACOK, V21, P437, DOI 10.2133/dmpk.21.437; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Rich KJ, 1997, MICROSC RES TECHNIQ, V39, P424, DOI 10.1002/(SICI)1097-0029(19971201)39:5<424::AID-JEMT5>3.0.CO;2-G; Schmucker DL, 2005, EXP GERONTOL, V40, P650, DOI 10.1016/j.exger.2005.06.009; Schroder O, 2005, CELL MOL LIFE SCI, V62, P87, DOI 10.1007/s00018-004-4366-7; Singh P, 2008, HEPATOLOGY, V47, P1680, DOI 10.1002/hep.22224; Slatter JG, 2006, XENOBIOTICA, V36, P902, DOI 10.1080/00498250600861694; Spear BT, 2006, CELL MOL LIFE SCI, V63, P2922, DOI 10.1007/s00018-006-6258-5; U.S. EPA, 2005, SUPPL GUID ASS CANC; Wang T, 2010, J BIOL CHEM, V285, P7670, DOI 10.1074/jbc.M109.090175; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	45	146	147	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2011	6	9							e24381	10.1371/journal.pone.0024381	http://dx.doi.org/10.1371/journal.pone.0024381			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CK	21931700	Green Published, Green Submitted, gold			2023-01-03	WOS:000294802800046
J	Needham, DM; Colantuoni, E; Mendez-Tellez, PA; Dinglas, VD; Sevransky, JE; Himmelfarb, CRD; Desai, SV; Shanholtz, C; Brower, RG; Pronovost, PJ				Needham, Dale M.; Colantuoni, Elizabeth; Mendez-Tellez, Pedro A.; Dinglas, Victor D.; Sevransky, Jonathan E.; Himmelfarb, Cheryl R. Dennison; Desai, Sanjay V.; Shanholtz, Carl; Brower, Roy G.; Pronovost, Peter J.			Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE-UNIT; TIDAL VOLUME VENTILATION; LONG-TERM SURVIVAL; ORGAN FAILURE; OUTCOMES; MORTALITY; SYSTEM; RELIABILITY; VALIDATION	Objective To evaluate the association of volume limited and pressure limited (lung protective) mechanical ventilation with two year survival in patients with acute lung injury. Design Prospective cohort study. Setting 13 intensive care units at four hospitals in Baltimore, Maryland, USA. Participants 485 consecutive mechanically ventilated patients with acute lung injury. Main outcome measure Two year survival after onset of acute lung injury. Results 485 patients contributed data for 6240 eligible ventilator settings, as measured twice daily (median of eight eligible ventilator settings per patient; 41% of which adhered to lung protective ventilation). Of these patients, 311 (64%) died within two years. After adjusting for the total duration of ventilation and other relevant covariates, each additional ventilator setting adherent to lung protective ventilation was associated with a 3% decrease in the risk of mortality over two years (hazard ratio 0.97, 95% confidence interval 0.95 to 0.99, P=0.002). Compared with no adherence, the estimated absolute risk reduction in two year mortality for a prototypical patient with 50% adherence to lung protective ventilation was 4.0% (0.8% to 7.2%, P=0.012) and with 100% adherence was 7.8% (1.6% to 14.0%, P=0.011). Conclusions Lung protective mechanical ventilation was associated with a substantial long term survival benefit for patients with acute lung injury. Greater use of lung protective ventilation in routine clinical practice could reduce long term mortality in patients with acute lung injury.	[Needham, Dale M.; Dinglas, Victor D.; Sevransky, Jonathan E.; Desai, Sanjay V.; Brower, Roy G.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Outcomes Crit Illness & Surg Grp, Baltimore, MD 21205 USA; [Needham, Dale M.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA; [Colantuoni, Elizabeth] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; [Mendez-Tellez, Pedro A.; Pronovost, Peter J.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Himmelfarb, Cheryl R. Dennison; Pronovost, Peter J.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA; [Shanholtz, Carl] Univ Maryland, Div Pulm & Crit Care Med, Baltimore, MD 21201 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	Needham, DM (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Outcomes Crit Illness & Surg Grp, Baltimore, MD 21205 USA.	Dale.Needham@jhmi.edu	Shanholtz, Carl/P-1190-2019; Himmelfarb, Cheryl Dennison/V-5660-2019	Shanholtz, Carl/0000-0003-3938-178X; Himmelfarb, Cheryl Dennison/0000-0003-1918-4316	National Institutes of Health (Acute Lung Injury Specialized Centers of Clinically Oriented Research) [P050 HL 73994]; Canadian Institutes of Health Research; National Institutes of Health [NIGMS K-23 GMO7-1399]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073994] Funding Source: NIH RePORTER	National Institutes of Health (Acute Lung Injury Specialized Centers of Clinically Oriented Research); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This research was supported by the National Institutes of Health (Acute Lung Injury Specialized Centers of Clinically Oriented Research grant No P050 HL 73994). DNM received support from a clinician-scientist award from the Canadian Institutes of Health Research. JES received support from the National Institutes of Health (NIGMS K-23 GMO7-1399). All researchers are independent of the funding bodies. The funding bodies had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication.	Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Angus DC, 2004, CRIT CARE MED, V32, P2199, DOI 10.1097/01.CCM.0000145228.62451.F6; [Anonymous], 2006, GOODMAN GILMANS PHAR; [Anonymous], 2011, SOCIAL SECURITY DEAT; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cooke CR, 2008, CRIT CARE MED, V36, P1412, DOI 10.1097/CCM.0b013e318170a375; Cuthbertson BH, 2010, CRIT CARE, V14, DOI 10.1186/cc8848; Dennison CR, 2007, CRIT CARE MED, V35, P2747, DOI 10.1097/01.CCM.0000287591.09487.70; Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Fan E, 2005, JAMA-J AM MED ASSOC, V294, P2889, DOI 10.1001/jama.294.22.2889; Fan E, 2008, CRIT CARE MED, V36, P94, DOI 10.1097/01.CCM.0000295308.29870.4F; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kosuke A, 2004, J AM STAT ASSOC, V99, P865; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Needham DM, 2007, J CRIT CARE, V22, P275, DOI 10.1016/j.jcrc.2007.02.001; Needham DM, 2010, RESP CARE, V55, P922; Needham DM, 2005, CRIT CARE MED, V33, P574, DOI [10.1097/01.CCM.0000155992.21174.31, 10.1097/01.ccm.0000155992.21174.31]; Needham DM, 2004, CRIT CARE MED, V32, P1504, DOI 10.1097/01.CCM.0000129972.31533.37; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Petrucci N, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub3; Pronovost PJ, 2010, AM J RESP CRIT CARE, V182, P1463, DOI 10.1164/rccm.201008-1255ED; Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011; Rubenfeld G, 2001, AM J RESP CRIT CARE, V163, pA295; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2004, CRIT CARE MED, V32, P1289, DOI 10.1097/01.CCM.0000127266.39560.96; Rubenfeld GD, 2009, CRIT CARE MED, V37, pS112, DOI 10.1097/CCM.0b013e3181922bb7; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Seeley E, 2008, THORAX, V63, P994, DOI 10.1136/thx.2007.093658; Seeley EJ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-52; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Umoh NJ, 2008, CRIT CARE MED, V36, P1463, DOI 10.1097/CCM.0b013e31816fc3d0; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang WW, 2011, J R STAT SOC C-APPL, V60, P475, DOI 10.1111/j.1467-9876.2010.00757.x; Weinert CR, 2003, AM J RESP CRIT CARE, V167, P1304, DOI 10.1164/rccm.200205-478OC; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Young MP, 2004, CRIT CARE MED, V32, P1260, DOI 10.1097/01.CCM.0000127784.54727.56	43	226	234	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2012	344								e2124	10.1136/bmj.e2124	http://dx.doi.org/10.1136/bmj.e2124			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923HF	22491953	Green Published, hybrid			2023-01-03	WOS:000302609700003
J	Gale, C; Santhakumaran, S; Nagarajan, S; Statnikov, Y; Modi, N				Gale, C.; Santhakumaran, S.; Nagarajan, S.; Statnikov, Y.; Modi, N.		Neonatal Data Anal Unit; Med Neonates Investigator Grp	Impact of managed clinical networks on NHS specialist neonatal services in England: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; PRETERM INFANTS; MORTALITY; CARE; LEVEL; TRANSPORT; RISK	Objective To assess the impact of reorganisation of neonatal specialist care services in England after a UK Department of Health report in 2003. Design A population-wide observational comparison of outcomes over two epochs, before and after the establishment of managed clinical neonatal networks. Setting Epoch one: 294 maternity and neonatal units in England, Wales, and Northern Ireland, 1 September 1998 to 31 August 2000, as reported by the Confidential Enquiry into Stillbirths and Sudden Deaths in Infancy Project 27/28. Epoch two: 146 neonatal units in England contributing data to the National Neonatal Research Database at the Neonatal Data Analysis Unit, 1 January 2009 to 31 December 2010. Participants Babies born at a gestational age of 27(+0)-28(+6) (weeks+days): 3522 live births in epoch one; 2919 babies admitted to a neonatal unit within 28 days of birth in epoch two. Intervention The national reorganisation of neonatal services into managed clinical networks. Main outcome measures The proportion of babies born at hospitals providing the highest volume of neonatal specialist care (>= 2000 neonatal intensive care days annually), having an acute transfer (within the first 24 hours after birth) and/or a late transfer (between 24 hours and 28 days after birth) to another hospital, assessed by change in distribution of transfer category ("none," "acute," "late"), and babies from multiple births separated by transfer. For acute transfers in epoch two, the level of specialist neonatal care provided at the destination hospital (British Association of Perinatal Medicine criteria). Results After reorganisation, there were increases in the proportions of babies born at 27-28 weeks' gestation in hospitals providing the highest volume of neonatal specialist care (18% (631/3495) v 49% (1325/2724); odds ratio 4.30, 95% confidence interval 3.83 to 4.82; P < 0.001) and in acute and late postnatal transfers (7% (235) v 12% (360) and 18% (579) v 22% (640), respectively; P < 0.001). There was no significant change in the proportion of babies from multiple births separated by transfer (33% (39) v 29% (38); 0.86, 0.50 to 1.46; P = 0.57). In epoch two, 32% of acute transfers were to a neonatal unit providing either an equivalent (n = 87) or lower (n = 26) level of specialist care. Conclusions There is evidence of some improvement in the delivery of neonatal specialist care after reorganisation. The increase in acute transfers in epoch two, in conjunction with the high proportion transferred to a neonatal unit providing an equivalent or lower level of specialist care, and the continued separation of babies from multiple births, are indicative of poor coordination between maternity and neonatal services to facilitate in utero transfer before delivery, and continuing inadequacies in capacity of intensive care cots. Historical data representing epoch one are available only in aggregate form, preventing examination of temporal trends or confounding factors. This limits the extent to which differences between epochs can be attributed to reorganisation and highlights the importance of routine, prospective data collection for evaluation of future health service reorganisations.	[Gale, C.; Santhakumaran, S.; Nagarajan, S.; Statnikov, Y.; Modi, N.; Neonatal Data Anal Unit; Med Neonates Investigator Grp] Univ London Imperial Coll Sci Technol & Med, Sect Neonatal Med, Dept Med, London SW10 9NH, England	Imperial College London	Modi, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Neonatal Med, Dept Med, Chelsea & Westminster Campus, London SW10 9NH, England.	n.modi@imperial.ac.uk	Gale, Chris/F-1833-2010	Gale, Chris/0000-0003-0707-876X; Greenough, Anne/0000-0002-8672-5349; Majeed, Azeem/0000-0002-2357-9858	National Institute of Health Research (NIHR) [RP-PG-0707-10010]; Department of Health; Danone; Abbott International; Royal College of Paediatrics and Child Health (RCPCH); Child Growth Foundation (CGF); Westminster Medical School Research Trust; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [RP-PG-0707-10010] Funding Source: researchfish	National Institute of Health Research (NIHR)(National Institute for Health Research (NIHR)); Department of Health; Danone(Danone Nutricia); Abbott International(Abbott Laboratories); Royal College of Paediatrics and Child Health (RCPCH); Child Growth Foundation (CGF); Westminster Medical School Research Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The Neonatal Data Analysis Unit is supported by a Programme Grant for Applied Research (RP-PG-0707-10010) from the National Institute of Health Research (NIHR) and unrestricted funding from the Department of Health, Danone, and Abbott International. The study funders had no role in study design, collection, analysis, and interpretation of data, writing of the report, or in the decision to submit the article for publication; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare financial support for the submitted work from the National Institute for Health Research (NIHR) through a Programme Grant for Applied Research (RP-PG-0707-10010). SN receives part funding from the Royal College of Paediatrics and Child Health (RCPCH) National Neonatal Audit Programme. CG receives part funding though an unrelated award to NM from the Child Growth Foundation (CGF) and support from the Westminster Medical School Research Trust. SS and YS are funded by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the RCPCH, CGF, Westminster Medical School Research Trust, NHS, NIHR, or Department of Health.	[Anonymous], 2007, PROVISION NEONATAL S; Binder S, 2011, PEDIATRICS, V127, P487, DOI 10.1542/peds.2010-1064; British Association of Perinatal Medicine (BAPM), 2001, STAND HOSP PROV NEON STAND HOSP PROV NEON, V2nd; Chien LY, 2001, OBSTET GYNECOL, V98, P247, DOI 10.1016/S0029-7844(01)01438-7; Chung JH, 2011, J PERINATOL, V31, P770, DOI 10.1038/jp.2011.29; COOKE RWI, 1992, ARCH DIS CHILD-FETAL, V67, P868; Crump C, 2011, JAMA-J AM MED ASSOC, V306, P1233, DOI 10.1001/jama.2011.1331; Goodwin N, 2004, MANAGING DIVERSE NET; Greene A, 2009, QUAL SAF HEALTH CARE, V18, P456, DOI 10.1136/qshc.2007.023119; Guthrie BG, 2010, DELIVERING HLTH CARE; Honest H, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13430; Kirrane H, 2010, CHANCE LIFETIME BLIS; KOLLEE LAA, 1992, OBSTET GYNECOL, V80, P635; Langhoff-Roos J, 2006, BMJ-BRIT MED J, V332, P937, DOI 10.1136/bmj.38751.524132.2F; Lasswell SM, 2010, JAMA-J AM MED ASSOC, V304, P992, DOI 10.1001/jama.2010.1226; Lui K, 2006, PEDIATRICS, V118, P2076, DOI 10.1542/peds.2006-1540; March of Dimes, 2012, PERISTATS; Marlow N, 2007, ARCH DIS CHILD-FETAL, V92, pF137, DOI 10.1136/adc.2005.086413; Mohamed MA, 2010, ARCH DIS CHILD-FETAL, V95, pF403, DOI 10.1136/adc.2010.183236; National Audit Office, 2007, CAR VULN BAB REORG N; National Institute for Health and Clinical Excellence, 2011, SPEC NEON CAR QUAL S; National Neonatal Audit Programme (NNAP), 2009, ANN REP NNAP; Norman JE, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000153; Phibbs CS, 2007, NEW ENGL J MED, V356, P2165, DOI 10.1056/NEJMsa065029; Provan KG, 2007, J MANAGE, V33, P479, DOI 10.1177/0149206307302554; Roberts C, 2005, CLIN TRIALS, V2, P152, DOI 10.1191/1740774505cn076oa; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Santhakumaran S, 2010, NEONATAL SPECIALIST; Scottish Executive, 1999, INTR MAN CLIN NETW N; Shlossman PA, 1997, AM J PERINAT, V14, P449, DOI 10.1055/s-2007-994178; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Thomas EL, 2011, PEDIATR RES, V70, P507, DOI 10.1203/PDR.0b013e31822d7860; Towers CV, 2000, OBSTET GYNECOL, V95, P291, DOI 10.1016/S0029-7844(99)00528-1; Zeitlin J, 2010, ARCH DIS CHILD-FETAL, V95, pF188, DOI 10.1136/adc.2008.156745	34	44	44	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2012	344								e2105	10.1136/bmj.e2105	http://dx.doi.org/10.1136/bmj.e2105			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923GM	22490978	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000302607700001
J	You, JHS; Chan, ESK; Leung, MYK; Ip, M; Lee, NLS				You, Joyce H. S.; Chan, Eva S. K.; Leung, Maggie Y. K.; Ip, Margaret; Lee, Nelson L. S.			A Cost-Effectiveness Analysis of "Test'' versus "Treat'' Patients Hospitalized with Suspected Influenza in Hong Kong	PLOS ONE			English	Article							RESPIRATORY SYNCYTIAL VIRUSES; REVERSE TRANSCRIPTION-PCR; A H1N1; VIRAL CULTURE; RAPID DIAGNOSIS; UNITED-STATES; B VIRUSES; FLU-A; INFECTION; ADULTS	Background: Seasonal and 2009 H1N1 influenza viruses may cause severe diseases and result in excess hospitalization and mortality in the older and younger adults, respectively. Early antiviral treatment may improve clinical outcomes. We examined potential outcomes and costs of test-guided versus empirical treatment in patients hospitalized for suspected influenza in Hong Kong. Methods: We designed a decision tree to simulate potential outcomes of four management strategies in adults hospitalized for severe respiratory infection suspected of influenza: "immunofluorescence-assay'' (IFA) or "polymerase-chain-reaction'' (PCR)-guided oseltamivir treatment, " empirical treatment plus PCR'' and "empirical treatment alone''. Model inputs were derived from literature. The average prevalence (11%) of influenza in 2010-2011 (58% being 2009 H1N1) among cases of respiratory infections was used in the base-case analysis. Primary outcome simulated was cost per quality-adjusted life-year (QALY) expected (ICER) from the Hong Kong healthcare providers' perspective. Results: In base-case analysis, "empirical treatment alone'' was shown to be the most cost-effective strategy and dominated the other three options. Sensitivity analyses showed that "PCR-guided treatment'' would dominate "empirical treatment alone'' when the daily cost of oseltamivir exceeded USD18, or when influenza prevalence was <2.5% and the predominant circulating viruses were not 2009 H1N1. Using USD50,000 as the threshold of willingness-to-pay, "empirical treatment alone'' and "PCR-guided treatment'' were cost-effective 97% and 3% of time, respectively, in 10,000 Monte-Carlo simulations. Conclusions: During influenza epidemics, empirical antiviral treatment appears to be a cost-effective strategy in managing patients hospitalized with severe respiratory infection suspected of influenza, from the perspective of healthcare providers in Hong Kong.	[You, Joyce H. S.; Chan, Eva S. K.; Leung, Maggie Y. K.] Chinese Univ Hong Kong, Fac Med, Sch Pharm, Ctr Pharmacoecon Res, Shatin, Hong Kong, Peoples R China; [Ip, Margaret] Chinese Univ Hong Kong, Dept Microbiol, Fac Med, Shatin, Hong Kong, Peoples R China; [Lee, Nelson L. S.] Chinese Univ Hong Kong, Dept Med & Therapeut, Fac Med, Div Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	You, JHS (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Pharm, Ctr Pharmacoecon Res, Shatin, Hong Kong, Peoples R China.	leelsn@cuhk.edu.hk	Ip, Margaret/K-1096-2013; Lee, Nelson/B-6418-2008; You, Joyce H. S./C-2984-2008	Ip, Margaret/0000-0003-1291-6537; Lee, Nelson/0000-0002-0783-6607; You, Joyce H. S./0000-0002-5763-7403	F. Hoffmann-La Roche Ltd.	F. Hoffmann-La Roche Ltd.(Hoffmann-La Roche)	Dr. Lee has previously received grant support from F. Hoffmann-La Roche Ltd. on principal-investigator initiated clinical influenza research, paid to the Chinese University of Hong Kong, unrelated to the study of cost-effectiveness of oseltamivir treatment. F. Hoffmann- La Roche Ltd. has no role in the initiation, original conception, design and execution of this study, nor has any influence on the results. All other authors: no conflict of interest declared. This does not affect the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449; Boivin G, 2004, J CLIN MICROBIOL, V42, P45, DOI 10.1128/JCM.42.1.45-51.2004; Campbell CN, 2010, EPIDEMIOL INFECT, V26, P1, DOI DOI 10.1017/S0950268810002657; Cheng PKC, 2010, J CLIN VIROL, V47, P182, DOI 10.1016/j.jcv.2009.11.022; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Falsey AR, 2007, ARCH INTERN MED, V167, P354, DOI 10.1001/archinte.167.4.ioi60207; Ginocchio CC, 2009, J CLIN VIROL, V45, P191, DOI 10.1016/j.jcv.2009.06.005; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Hanshaoworakul W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006051; Hui DS, 2010, CHEST, V137, P916, DOI 10.1378/chest.09-2344; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Kaufman MA, 2009, MED J AUSTRALIA, V191, P154, DOI 10.5694/j.1326-5377.2009.tb02726.x; Lavelle TA, 2012, J PEDIATR-US, V160, P67, DOI 10.1016/j.jpeds.2011.07.001; Lee BY, 2011, AM J MANAG CARE, V17, P693; Lee EH, 2010, CLIN INFECT DIS, V50, P1498, DOI 10.1086/652446; Lee N, 2010, THORAX, V65, P510, DOI 10.1136/thx.2009.130799; Lee N, ANTIVIRAL T IN PRESS; Lee N, 2007, ANTIVIR THER, V12, P501; Lee N, 2011, J INFECT DIS, V203, P1739, DOI 10.1093/infdis/jir187; LeGoff J, 2008, J CLIN MICROBIOL, V46, P789, DOI 10.1128/JCM.00959-07; Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152; McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584; McGeer AJ, 2009, CLIN INFECT DIS, V48, pS14, DOI 10.1086/591852; Mehlmann M, 2007, J CLIN MICROBIOL, V45, P1234, DOI 10.1128/JCM.02202-06; Okomo-Adhiambo M, 2010, VIRUSES-BASEL, V2, P2269, DOI 10.3390/v2102269; Rahman M, 2008, DIAGN MICR INFEC DIS, V62, P162, DOI 10.1016/j.diagmicrobio.2007.10.012; Shiley KT, 2010, INFECT CONT HOSP EP, V31, P676, DOI 10.1086/653204; Smit M, 2007, DIAGN MICR INFEC DIS, V57, P67, DOI 10.1016/j.diagmicrobio.2006.11.003; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; van den Hoeven AM, 2007, INFECTION, V35, P65, DOI 10.1007/s15010-007-6112-1; Venkata C, 2010, MAYO CLIN PROC, V85, P798, DOI 10.4065/mcp.2010.0166; Viasus D, 2011, CLIN MICROBIOL INFEC, V17, P738, DOI 10.1111/j.1469-0691.2010.03362.x; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; You JHS, 2009, J EPIDEMIOL COMMUN H, V63, P906, DOI 10.1136/jech.2008.081885; [No title captured]	35	41	41	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2012	7	3							e33123	10.1371/journal.pone.0033123	http://dx.doi.org/10.1371/journal.pone.0033123			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948SR	22479363	gold, Green Published, Green Submitted			2023-01-03	WOS:000304523400012
J	Wilkinson, TA; Fahey, N; Suther, E; Cabral, HJ; Silverstein, M				Wilkinson, Tracey A.; Fahey, Nisha; Suther, Emily; Cabral, Howard J.; Silverstein, Michael			Access to Emergency Contraception for Adolescents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Wilkinson, Tracey A.; Suther, Emily; Silverstein, Michael] Boston Med Ctr, Boston, MA USA; [Cabral, Howard J.] Boston Univ, Sch Publ Hlth, Boston, MA USA	Boston Medical Center; Boston University	Wilkinson, TA (corresponding author), Boston Med Ctr, Boston, MA USA.	tracey.wilkinson@bmc.org		Fahey, Nisha/0000-0001-9059-1470; Silverstein, Michael/0000-0002-9474-7548; Cabral, Howard/0000-0002-1185-8331				Agency for Healthcare Research and Quality, 2010, NAT HEALTHC DISP REP; GeoLytics Inc, OFF CENS 2010 DAT; Hastings Julia, 2005, J Health Soc Policy, V21, P33, DOI 10.1300/J045v21n01_02; Kost K., 2010, US TEENAGE PREGNANCI; KowaleskiJones L, 2006, FRAGILE FAMILIES AND THE MARRIAGE AGENDA, P1; Miller BC, 2001, DEV REV, V21, P1, DOI 10.1006/drev.2000.0513	6	28	28	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 25	2012	307	4					362	363		10.1001/jama.2011.1949	http://dx.doi.org/10.1001/jama.2011.1949			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	881EP	22182591				2023-01-03	WOS:000299464000015
J	Pizzo, PA; Clark, NM				Pizzo, Philip A.; Clark, Noreen M.			Alleviating Suffering 101-Pain Relief in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pizzo, Philip A.] Stanford Univ, Off Dean, Sch Med, Stanford, CA 94305 USA; [Clark, Noreen M.] Univ Michigan, Ctr Managing Chron Dis, Ann Arbor, MI 48109 USA	Stanford University; University of Michigan System; University of Michigan	Pizzo, PA (corresponding author), Stanford Univ, Off Dean, Sch Med, Stanford, CA 94305 USA.							Institute of Medicine, 2011, REL PAIN AM BLU TRAN	1	142	144	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					197	199		10.1056/NEJMp1109084	http://dx.doi.org/10.1056/NEJMp1109084			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877RZ	22256802				2023-01-03	WOS:000299201400002
J	Gill, TM; Gahbauer, EA; Murphy, TE; Han, L; Allore, HG				Gill, Thomas M.; Gahbauer, Evelyne A.; Murphy, Terrence E.; Han, Ling; Allore, Heather G.			Risk Factors and Precipitants of Long-Term Disability in Community Mobility A Cohort Study of Older Persons	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-STYLE INTERVENTIONS; LOWER-EXTREMITY FUNCTION; BODY-MASS INDEX; SUBSEQUENT DISABILITY; PHYSICAL PERFORMANCE; MAINTAINING MOBILITY; RESTRICTED ACTIVITY; BATHING DISABILITY; DRIVING CESSATION; RANDOMIZED-TRIAL	Background: Relatively little is known about why older persons develop long-term disability in community mobility. Objective: To identify the risk factors and precipitants for long-term disability in walking a quarter mile and driving a car. Design: Prospective cohort study from March 1998 to December 2009. Setting: Greater New Haven, Connecticut. Participants: 641 persons, aged 70 years or older, who were active drivers or nondisabled in walking a quarter mile. Persons who were physically frail were oversampled. Measurements: Candidate risk factors were assessed every 18 months. Disability in community mobility and exposure to potential precipitants, including illnesses or injuries leading to hospitalization or restricted activity, were assessed every month. Disability that lasted 6 or more consecutive months was considered long-term. Results: 318 (56.0%) and 269 (53.1%) participants developed long-term disability in walking and driving, respectively. Seven risk factors were independently associated with walking disability and 8 were associated with driving disability; the strongest associations for each outcome were found for older age and lower score on the Short Physical Performance Battery. The precipitants had a large effect on long-term disability, with multivariate hazard ratios for each outcome greater than 6.2 for hospitalization and greater than 2.4 for restricted activity. The largest differences in absolute risk were generally observed in participants with a specific risk factor who were subsequently hospitalized. Limitations: The observed associations may not be causal. The severity of precipitants was not assessed. The effect of the precipitants may have been underestimated because their exposure after the initial onset of disability was not evaluated. Conclusion: Long-term disability in community mobility is common among older persons. Multiple risk factors, together with subsequent precipitants, greatly increase the likelihood of long-term mobility disability.	[Gill, Thomas M.] Yale Univ, Sch Med, Adler Geriatr Assessment Ctr, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Adler Geriatr Assessment Ctr, 20 York St, New Haven, CT 06504 USA.	thomas.gill@yale.edu; heather.allore@yale.edu	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	National Institute on Aging [R37AG17560, K24AG021507]; National Institutes of Health [P30AG21342]; National Institute on Aging, National Institutes of Health; NATIONAL INSTITUTE ON AGING [R37AG017560, P30AG021342, K24AG021507] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By grant R37AG17560 from the National Institute on Aging and Midcareer Investigator Award in Patient-Oriented Research K24AG021507 from the National Institute on Aging (Dr. Gill). The study was conducted at the Yale Claude D. Pepper Older Americans Independence Center (funded by National Institutes of Health grant P30AG21342).; National Institute on Aging, National Institutes of Health.	[Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x; BENICHOU J, 1990, BIOMETRICS, V46, P813, DOI 10.2307/2532098; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Brown CJ, 2009, ANN INTERN MED, V150, P372, DOI 10.7326/0003-4819-150-6-200903170-00005; Bruce ML, 2001, AM J GERIAT PSYCHIAT, V9, P102, DOI 10.1176/appi.ajgp.9.2.102; Chaves PHM, 2000, ARCH INTERN MED, V160, P2525, DOI 10.1001/archinte.160.16.2525; Clark DO, 1998, J AGING HEALTH, V10, P422, DOI 10.1177/089826439801000402; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; Daniels R, 2010, EUR J AGEING, V7, P37, DOI 10.1007/s10433-010-0141-9; Daviglus ML, 2010, ANN INTERN MED, V153, P176, DOI 10.7326/0003-4819-153-3-201008030-00260; Edwards JD, 2008, J GERONTOL B-PSYCHOL, V63, pP6, DOI 10.1093/geronb/63.1.P6; Edwards JD, 2009, J GERONTOL A-BIOL, V64, P1290, DOI 10.1093/gerona/glp114; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fragoso CAV, 2008, J AM GERIATR SOC, V56, P1014, DOI 10.1111/j.1532-5415.2008.01687.x; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Gill TM, 2008, J AM GERIATR SOC, V56, P436, DOI 10.1111/j.1532-5415.2007.01603.x; Gill TM, 2007, J AM GERIATR SOC, V55, P534, DOI 10.1111/j.1532-5415.2007.01099.x; Gill TM, 2006, J GERONTOL A-BIOL, V61, P821, DOI 10.1093/gerona/61.8.821; Gill TM, 2011, J GERONTOL A-BIOL, V66, P1238, DOI 10.1093/gerona/glr142; Gill TM, 2009, J AM GERIATR SOC, V57, P1850, DOI 10.1111/j.1532-5415.2009.02443.x; Gill TM, 2006, J AM GERIATR SOC, V54, P248, DOI 10.1111/j.1532-5415.2005.00586.x; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Gill TM, 2006, ARCH INTERN MED, V166, P418, DOI 10.1001/.418; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1993, AM J EPIDEMIOL, V137, P845, DOI 10.1093/oxfordjournals.aje.a116746; Guralnik JM, 2001, J AM GERIATR SOC, V49, P1463, DOI 10.1046/j.1532-5415.2001.4911238.x; Hardy SE, 2005, ARCH INTERN MED, V165, P106, DOI 10.1001/archinte.165.1.106; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Hardy SE, 2011, J GEN INTERN MED, V26, P130, DOI 10.1007/s11606-010-1543-2; Harrell FEJr, 2001, REGRESSION MODELING, DOI DOI 10.1007/978-1-4757-3462-1; Ho SC, 1997, J GERONTOL A-BIOL, V52, pM356, DOI 10.1093/gerona/52A.6.M356; Hosmer DW, 1999, APPL SURVIVAL ANAL; Iezzoni LI, 2003, WALKING FAILS MOBILI; Katula JA, 2007, J AM GERIATR SOC, V55, P674, DOI 10.1111/j.1532-5415.2007.01136.x; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; LICHTENSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V259, P2875, DOI 10.1001/jama.259.19.2875; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Marottoli RA, 1999, PRINCIPLES GERIATRIC, P267; Newman AB, 2006, JAMA-J AM MED ASSOC, V295, P2018, DOI 10.1001/jama.295.17.2018; Pahor M, 2006, J GERONTOL A-BIOL, V61, P1157; Rantanen T, 2001, J AM GERIATR SOC, V49, P21, DOI 10.1046/j.1532-5415.2001.49005.x; Reid MC, 2003, J AM GERIATR SOC, V51, P1092, DOI 10.1046/j.1532-5415.2003.51357.x; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; Shumway-Cook A, 2003, J AM GERIATR SOC, V51, P393, DOI 10.1046/j.1532-5415.2003.51114.x; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; U.S. Census Bureau, 2011, AM FACTFINDER; Wang ML, 2006, BIOMETRICAL J, V48, P302, DOI 10.1002/bimj.200510188; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9; Webber SC, 2010, GERONTOLOGIST, V50, P443, DOI 10.1093/geront/gnq013	64	114	115	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 17	2012	156	2					131	W25		10.7326/0003-4819-156-2-201201170-00009	http://dx.doi.org/10.7326/0003-4819-156-2-201201170-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	894IW	22250144	Green Accepted			2023-01-03	WOS:000300421400004
J	McMichael, L				McMichael, Louise			PRACTICE POINTER Skin camouflage	BRITISH MEDICAL JOURNAL			English	Editorial Material									British Assoc Skin Camouflage, Stourbridge DY9 9QA, England		McMichael, L (corresponding author), British Assoc Skin Camouflage, Stourbridge DY9 9QA, England.	louise.mcmichael@tiscali.co.uk						*ALL PART PARL GRO, 2003, REP ENQ IMP SKIN DIS; [Anonymous], 2005, EUR J DERMATOL, V15, P284; British Association of Skin Camouflage, 2010, COV PRINC ART PAR SK; Gawkrodger D. J., 2002, DERMATOLOGY ILLUSTRA; Holme SA, 2002, BRIT J DERMATOL, V147, P956; Schofield J., 2009, SKIN CONDITIONS UK H; Sreedhar K, 2009, OPEN DERMATOL J, V3, P54	7	10	10	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 5	2012	344								d7921	10.1136/bmj.d7921	http://dx.doi.org/10.1136/bmj.d7921			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874UH	22223831				2023-01-03	WOS:000298983100006
J	Ghafouri, N; Ghafouri, B; Larsson, B; Turkina, MV; Karlsson, L; Fowler, CJ; Gerdle, B				Ghafouri, Nazdar; Ghafouri, Bijar; Larsson, Britt; Turkina, Maria V.; Karlsson, Linn; Fowler, Christopher J.; Gerdle, Bjorn			High Levels of N-Palmitoylethanolamide and N-Stearoylethanolamide in Microdialysate Samples from Myalgic Trapezius Muscle in Women	PLOS ONE			English	Article							WHIPLASH-ASSOCIATED DISORDERS; ACTIVATED-RECEPTOR-ALPHA; FATTY-ACID AMIDE; PAIN; HYPERALGESIA; TRPV1; WORK; ACYLETHANOLAMINE; QUANTIFICATION; FIBROMYALGIA	Background: N-acylethanolamines (NAEs) are endogenous compounds that regulate inflammation and pain. These include the cannabinoid ligand anandamide (AEA) and the peroxisome proliferator-activated receptor-a ligand palmitoylethanolamide (PEA). Little is known as to the levels of NAEs in pain states in human, particularly in the skeletal muscle. The aim of this study was to investigate the levels of these lipid mediators in muscle dialysate from women with chronic neck-/shoulder pain compared to healthy controls. Methods: Eleven women with chronic neck-/shoulder pain and eleven healthy women participated in this study. All participants went through microdialysis procedures in the trapezius muscle. Muscle dialysate samples were collected during four hours and analysed by nano liquid chromatography tandem mass spectrometry (nLC-MS/MS). Results: We were able to detect AEA, PEA, N-stearoylethanolamine (SEA) and 2-arachidonoylglycerol (2-AG) in a single chromatographic run. Of the NAEs studied, PEA and SEA were clearly detectable in the muscle microdialysate samples. The muscle dialysate levels of PEA and SEA were significantly higher in myalgic subjects compared to healthy controls. Conclusion: This study demonstrates that microdialysis in combination with mass spectrometry can be used for analysing NAE's in human muscle tissue regularly over time. Furthermore the significant group differences in the concentration of PEA and SEA in this study might fill an important gap in our knowledge of mechanisms in chronic myalgia in humans. In the long run this expanded understanding of nociceptive and anitinociceptive processes in the muscle may provide a base for ameliorating treatment and rehabilitation of pain.	[Ghafouri, Nazdar; Ghafouri, Bijar; Larsson, Britt; Turkina, Maria V.; Karlsson, Linn; Gerdle, Bjorn] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden; [Ghafouri, Nazdar; Ghafouri, Bijar; Larsson, Britt; Turkina, Maria V.; Karlsson, Linn; Gerdle, Bjorn] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden; [Ghafouri, Nazdar; Fowler, Christopher J.] Cty Council Ostergotland, Pain & Rehabil Ctr, Linkoping, Sweden; [Ghafouri, Bijar] Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden; [Ghafouri, Bijar] Linkoping Univ, Dept Clin & Expt Med, Fac Hlth Sci, Linkoping, Sweden; [Ghafouri, Bijar] Cty Council Ostergotland, Dept Occupat & Environm Med, Linkoping, Sweden	Linkoping University; Linkoping University; City Council Ostergotland; Umea University; Linkoping University; City Council Ostergotland	Ghafouri, N (corresponding author), Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden.	bjorn.gerdle@liu.se	Ghafouri, Bijar/H-8257-2014; Fowler, Christopher J./M-6313-2019	Fowler, Christopher J./0000-0002-6658-7874; Gerdle, Bjorn/0000-0002-4316-1264	Swedish Council for Working Life and Social Research [2010-0683, 2007-0760]; Swedish Research Council [2010-2893]; IngaBritt and Arne Lundberg foundation	Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Swedish Research Council(Swedish Research CouncilEuropean Commission); IngaBritt and Arne Lundberg foundation	This study was supported by the Swedish Council for Working Life and Social Research (2010-0683, 2007-0760), the Swedish Research Council (2010-2893) and IngaBritt and Arne Lundberg foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Borsbo B, 2008, J REHABIL MED, V40, P562, DOI 10.2340/16501977-0207; Buczynski MW, 2010, BRIT J PHARMACOL, V160, P423, DOI 10.1111/j.1476-5381.2010.00787.x; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carbonare MD, 2008, J NEUROENDOCRINOL, V20, P26, DOI 10.1111/j.1365-2826.2008.01689.x; Costa B, 2008, PAIN, V139, P541, DOI 10.1016/j.pain.2008.06.003; Coutaux A, 2005, JOINT BONE SPINE, V72, P359, DOI 10.1016/j.jbspin.2004.01.010; D'Agostino G, 2009, EUR J PHARMACOL, V613, P54, DOI 10.1016/j.ejphar.2009.04.022; Dersh J, 2001, Spine J, V1, P88, DOI 10.1016/S1529-9430(01)00017-1; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Ernberg M, 1999, LIFE SCI, V65, P313, DOI 10.1016/S0024-3205(99)00250-7; Farquhar-Smith WP, 2002, PAIN, V97, P11, DOI 10.1016/S0304-3959(01)00419-5; Flodgren GM, 2005, EUR J PAIN, V9, P511, DOI 10.1016/j.ejpain.2004.11.004; Fowler CJ, 2009, BRIT J PHARMACOL, V156, P412, DOI 10.1111/j.1476-5381.2008.00029.x; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Gatchel RJ, 2007, PSYCHOL BULL, V133, P581, DOI 10.1037/0033-2909.133.4.581; Gerdle B, 2008, PAIN, V139, P578, DOI 10.1016/j.pain.2008.06.012; Gerdle B, 2008, EUR J PAIN, V12, P82, DOI 10.1016/j.ejpain.2007.03.009; Gerdle B, 2010, J REHABIL MED, V42, P679, DOI 10.2340/16501977-0581; Gibson W, 2006, PAIN, V120, P113, DOI 10.1016/j.pain.2005.10.023; GravenNielsen T, 1997, PAIN, V69, P111, DOI 10.1016/S0304-3959(96)03243-5; Hula N M, 2009, Ukr Biokhim Zh (1999), V81, P107; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; KUORINKA I, 1987, APPL ERGON, V18, P233, DOI 10.1016/0003-6870(87)90010-X; Langley CK, 2008, NEUROIMAGE, V42, P467, DOI 10.1016/j.neuroimage.2008.05.030; Larsson B, 2008, PAIN, V140, P479, DOI 10.1016/j.pain.2008.10.001; Lidgren L, 2008, SPINE, V33, pS1, DOI 10.1097/BRS.0b013e3181643f14; Lo Verme J, 2005, MOL PHARMACOL, V67, P15, DOI 10.1124/mol.104.006353; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; MEANSCHRISTENSE.AJ, 2008, ANXIETY, V25, P593; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Ocanez KLS, 2010, DEPRESS ANXIETY, V27, P760, DOI 10.1002/da.20681; OHLSSON K, 1994, ERGONOMICS, V37, P891, DOI 10.1080/00140139408963698; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Plock N, 2005, EUR J PHARM SCI, V25, P1, DOI 10.1016/j.ejps.2005.01.017; Rosendal L, 2005, PAIN, V119, P201, DOI 10.1016/j.pain.2005.09.026; Rosendal L, 2004, PAIN, V112, P324, DOI 10.1016/j.pain.2004.09.017; SCHELLER D, 1991, J NEUROSCI METH, V40, P31, DOI 10.1016/0165-0270(91)90114-F; Schneider GM, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-29; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Sjogaard G, 2010, EUR J APPL PHYSIOL, V108, P657, DOI 10.1007/s00421-009-1268-2; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Staud R, 2009, PAIN, V145, P96, DOI 10.1016/j.pain.2009.05.020; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0	44	32	33	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2011	6	11							e27257	10.1371/journal.pone.0027257	http://dx.doi.org/10.1371/journal.pone.0027257			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858IH	22125609	Green Published, Green Submitted, gold			2023-01-03	WOS:000297789200009
J	Newman, JD; Muntner, P; Shimbo, D; Davidson, KW; Shaffer, JA; Edmondson, D				Newman, Jonathan D.; Muntner, Paul; Shimbo, Daichi; Davidson, Karina W.; Shaffer, Jonathan A.; Edmondson, Donald			Post-Traumatic Stress Disorder (PTSD) Symptoms Predict Delay to Hospital in Patients with Acute Coronary Syndrome	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PREHOSPITAL DELAY; HEART-DISEASE; COPING STRATEGIES; SEEK TREATMENT; CARE; TIME; DEPRESSION; MANAGEMENT; CARDIOLOGY	Background: Increased delay to hospital presentation with acute coronary syndrome (ACS) is associated with poor outcomes. While demographic factors associated with this delay have been well described, scarce data are available on the role of modifiable factors, such as psychosocial disorders, on pre-hospital delay. Patients with symptoms of post-traumatic stress disorder (PTSD) often avoid stressful situations and may delay presenting for care when they experience cardiac symptoms. It is unknown, however, whether PTSD symptoms negatively impact the time to presentation during an ACS. Methods: We assessed the relationship between PTSD symptoms and pre-hospital delay in 241 adults with an ACS in the ongoing Prescription Use, Lifestyle, Stress Evaluation (PULSE) study. Results: Overall, 66% of patients were male; 40% were Hispanic or Latino. The mean age was 61.9 +/- 11.6 years old. PTSD symptoms were present in 17.8% of patients. Pre-hospital delay was longer for patients with PTSD symptoms compared to those without [geometric mean: 25.8 hours (95% CI 13.8 - 44.8) vs. 10.7 hours (95% CI 8.3 - 13.8)]; P = 0.005. After multivariable adjustment for age, sex, ethnicity, depression, left ventricular ejection fraction and history of myocardial infarction, the mean pre-hospital delay was 173% (95% CI: 36% -450%) longer for patients with versus without PTSD symptoms. Conclusion: Among patients presenting with an ACS, PTSD symptoms were independently associated with longer pre-hospital delays. Future studies of pre-hospital delay should examine the mechanisms underlying this association.	[Newman, Jonathan D.; Shimbo, Daichi; Davidson, Karina W.; Shaffer, Jonathan A.; Edmondson, Donald] Columbia Univ, Dept Med, Med Ctr, New York, NY 10027 USA; [Muntner, Paul] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA	Columbia University; University of Alabama System; University of Alabama Birmingham	Newman, JD (corresponding author), Columbia Univ, Dept Med, Med Ctr, New York, NY 10027 USA.	kd2124@columbia.edu	Edmondson, Donald/G-7486-2016; Davidson, Karina/GWC-0996-2022; Davidson, Karina/AAG-2388-2019; Shaffer, Jonathan A/B-2783-2013	Davidson, Karina/0000-0002-9162-477X; Davidson, Karina/0000-0002-9162-477X; Edmondson, Donald/0000-0002-4518-8196; Newman, Jonathan/0000-0001-6855-7305	National Heart, Lung, and Blood Institute [HL-088117, HL-091099, HL-076857, HL-47540, HL-101663, HL-098037, HL-083056, HL-084438, HL-84034, T32 HL007854-15]; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1 RR024156]; NIH Roadmap for Medical Research; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024156] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL076857, P01HL047540, P01HL088117, T32HL007854, R01HL083056, RC2HL101663, R01HL091099, R01HL114924, R01HL084438, K24HL084034, R01HL098037] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by grants HL-088117, HL-091099, HL-076857, HL-47540, HL-101663, HL-098037, HL-083056, HL-084438, HL-84034 and T32 HL007854-15 from the National Heart, Lung, and Blood Institute. The project described was also supported by Grant Number UL1 RR024156 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	AHMADI N, 2011, AM J CARDIO IN PRESS; Amir M, 1997, PERS INDIV DIFFER, V23, P399, DOI 10.1016/S0191-8869(97)80005-0; Beck A. T., 1979, COGNITIVE THERAPY DE; Bedi US, 2007, J NATL MED ASSOC, V99, P642; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Bunde J, 2006, PSYCHOSOM MED, V68, P51, DOI 10.1097/01.psy.0000195724.58085.f0; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Chang CM, 2003, J NERV MENT DIS, V191, P391, DOI 10.1097/01.NMD.0000071588.73571.3D; De Luca G, 2004, CIRCULATION, V109, P1223, DOI 10.1161/01.CIR.0000121424.76486.20; Dracup K, 1997, HEART LUNG, V26, P253, DOI 10.1016/S0147-9563(97)90082-0; Dracup K, 2009, CIRC-CARDIOVASC QUAL, V2, P144, DOI 10.1161/CIRCOUTCOMES.109.855635; Dracup K, 2009, CIRC-CARDIOVASC QUAL, V2, P524, DOI 10.1161/CIRCOUTCOMES.109.852608; Elhai JD, 2008, DEPRESS ANXIETY, V25, P737, DOI 10.1002/da.20318; Figueredo VM, 2009, AM J MED, V122, P704, DOI 10.1016/j.amjmed.2009.05.001; First M, 2016, STRUCTURED CLIN INTE; Franklin CL, 2002, PSYCHOL ASSESSMENT, V14, P467, DOI 10.1037//1040-3590.14.4.467; Goldberg RJ, 2002, AM J CARDIOL, V89, P791, DOI 10.1016/S0002-9149(02)02186-0; King KB, 2007, HEART LUNG, V36, P235, DOI 10.1016/j.hrtlng.2006.08.008; Kubzansky LD, 2007, ARCH GEN PSYCHIAT, V64, P109, DOI 10.1001/archpsyc.64.1.109; Lichtman JH, 2008, CIRCULATION, V118, P1768, DOI 10.1161/CIRCULATIONAHA.108.190769; Luepker RV, 2000, JAMA-J AM MED ASSOC, V284, P60, DOI 10.1001/jama.284.1.60; Nguyen HL, 2010, CIRC-CARDIOVASC QUAL, V3, P82, DOI 10.1161/CIRCOUTCOMES.109.884361; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Shemesh E, 2004, PSYCHOSOM MED, V66, P521, DOI 10.1097/01.psy.0000126199.05189.86; Smolderen KG, 2010, JAMA-J AM MED ASSOC, V303, P1392, DOI 10.1001/jama.2010.409; Strik JJMH, 2003, J AM COLL CARDIOL, V42, P1801, DOI 10.1016/j.jacc.2003.07.007; Sullivan MD, 2009, CIRC-CARDIOVASC QUAL, V2, P148, DOI 10.1161/CIRCOUTCOMES.108.825471; Ting HH, 2008, ARCH INTERN MED, V168, P959, DOI 10.1001/archinte.168.9.959; Ting HH, 2010, ARCH INTERN MED, V170, P1834, DOI 10.1001/archinternmed.2010.385; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; Walczewska J, 2011, EUR HEART J, V32, P730, DOI 10.1093/eurheartj/ehq354; Walsh JC, 2004, J PSYCHOSOM RES, V56, P67, DOI 10.1016/S0022-3999(03)00082-5	33	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2011	6	11							e27640	10.1371/journal.pone.0027640	http://dx.doi.org/10.1371/journal.pone.0027640			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HG	22096608	Green Published, Green Submitted, gold			2023-01-03	WOS:000297553900067
J	Debarnot, U; Clerget, E; Olivier, E				Debarnot, Ursula; Clerget, Emeline; Olivier, Etienne			Role of the Primary Motor Cortex in the Early Boost in Performance Following Mental Imagery Training	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST STIMULATION; MEMORY CONSOLIDATION; TIME-COURSE; SLEEP; PLASTICITY; INTERFERENCE; IMAGINATION; MECHANISMS; EXECUTION	Recently, it has been suggested that the primary motor cortex (M1) plays a critical role in implementing the fast and transient post-training phase of motor skill consolidation, known to yield an early boost in performance. Whether a comparable early boost in performance occurs following motor imagery (MIM) training is still unknown. To address this issue, two groups of subjects learned a finger tapping sequence either by MIM or physical practice (PP). In both groups, performance increased significantly in the post-training phase when compared with the pre-training phase and further increased after a 30 min resting period, indicating that both MIM and PP trainings were equally efficient and induced an early boost in motor performance. This conclusion was corroborated by the results of an additional control group. In a second experiment, we then investigated the causal role of M1 in implementing the early boost process resulting from MIM training. To do so, we inhibited M1 by applying a continuous theta-burst stimulation (cTBS) in healthy volunteers just after they learnt, by MIM, the same finger-tapping task as in Experiment #1. As a control, cTBS was applied over the vertex of subjects who underwent the same experiment. We found that cTBS applied over M1 selectively abolished the early boost process subsequent to MIM training. Altogether, the present study provides evidence that MIM practice induces an early boost in performance and demonstrates that M1 is causally involved in this process. These findings further divulge some degree of behavioral and neuronal similitude between MIM and PP.	[Debarnot, Ursula; Clerget, Emeline; Olivier, Etienne] Catholic Univ Louvain, Inst Neurosci, B-1200 Brussels, Belgium	Universite Catholique Louvain	Debarnot, U (corresponding author), Catholic Univ Louvain, Inst Neurosci, B-1200 Brussels, Belgium.	etienne.olivier@uclouvain.be			ARC from the Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain [07/12-007]	ARC from the Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain	This work was supported by grants from the ARC (grant 07/12-007, Communaute Francaise de Belgique, Actions de Recherche Concertees), from the Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain. This work was performed at the Institute of Neuroscience of the Universite Catholique de Louvain (Brussels, Belgium). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albouy G, 2008, NEURON, V58, P261, DOI 10.1016/j.neuron.2008.02.008; Albouy G, 2006, BRAIN RES, V1090, P163, DOI 10.1016/j.brainres.2006.03.076; Allami N, 2008, EXP BRAIN RES, V184, P105, DOI 10.1007/s00221-007-1086-x; Carrillo-de-la-Pena MT, 2008, BRAIN RES, V1226, P134, DOI 10.1016/j.brainres.2008.05.089; Cash CD, 2009, J RES MUSIC EDUC, V57, P252, DOI 10.1177/0022429409343470; Censor N, 2011, J PHYSIOL-LONDON, V589, P21, DOI 10.1113/jphysiol.2010.198077; Censor N, 2010, CURR BIOL, V20, P1545, DOI 10.1016/j.cub.2010.07.047; Clerget E, J COGN NEUR IN PRESS; Clerget E, 2009, NEUROREPORT, V20, P1496, DOI 10.1097/WNR.0b013e3283329be8; Debarnot U, 2010, BRAIN COGNITION, V74, P52, DOI 10.1016/j.bandc.2010.06.004; Debarnot U, 2009, SLEEP, V32, P1559, DOI 10.1093/sleep/32.12.1559; Debarnot U, 2009, BRAIN COGNITION, V69, P398, DOI 10.1016/j.bandc.2008.08.029; Decety J, 1996, COGNITIVE BRAIN RES, V3, P87, DOI 10.1016/0926-6410(95)00033-X; Doyon J, 2005, CURR OPIN NEUROBIOL, V15, P161, DOI 10.1016/j.conb.2005.03.004; Doyon J, 2002, P NATL ACAD SCI USA, V99, P1017, DOI 10.1073/pnas.022615199; Doyon J, 2003, NEUROPSYCHOLOGIA, V41, P252, DOI 10.1016/S0028-3932(02)00158-6; Gentili R, 2006, NEUROSCIENCE, V137, P761, DOI 10.1016/j.neuroscience.2005.10.013; Geyer S, 1996, NATURE, V382, P805, DOI 10.1038/382805a0; Guillot A., 2008, INT REV SPORT EXER P, V1, P31, DOI [10.1080/17509840701823139, DOI 10.1080/17509840701823139]; Guillot A, 2008, NEUROIMAGE, V41, P1471, DOI 10.1016/j.neuroimage.2008.03.042; Hall C. R., 1997, J MENTAL IMAG, V21, P143, DOI DOI 10.1037/T07979-000; Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0; HODDES E, 1972, PSYCHOPHYSIOLOGY, V9, P150; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; Holmes PS, 2001, J APPL SPORT PSYCHOL, V13, P60, DOI 10.1080/10413200109339004; Hotermans C, 2008, EUR J NEUROSCI, V28, P1216, DOI 10.1111/j.1460-9568.2008.06421.x; Hotermans C, 2006, LEARN MEMORY, V13, P580, DOI 10.1101/lm.239406; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Iezzi E, 2010, EUR J NEUROSCI, V31, P585, DOI 10.1111/j.1460-9568.2010.07090.x; JEANNEROD M, 1995, NEUROPSYCHOLOGIA, V33, P1419, DOI 10.1016/0028-3932(95)00073-C; KARNI A, 1995, LANCET, V345, P395, DOI 10.1016/S0140-6736(95)90386-0; KARNI A, 1995, NATURE, V377, P155; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Korman M, 2007, NAT NEUROSCI, V10, P1206, DOI 10.1038/nn1959; Kuhtz-Buschbeck JP, 2003, EUR J NEUROSCI, V18, P3375, DOI 10.1111/j.1460-9568.2003.03066.x; Lacourse MG, 2004, J REHABIL RES DEV, V41, P505, DOI 10.1682/JRRD.2004.04.0505; Lafleur MF, 2002, NEUROIMAGE, V16, P142, DOI 10.1006/nimg.2001.1048; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Munzert J, 2009, BRAIN RES REV, V60, P306, DOI 10.1016/j.brainresrev.2008.12.024; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; Nyberg L, 2006, NEUROPSYCHOLOGIA, V44, P711, DOI 10.1016/j.neuropsychologia.2005.08.006; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Page SJ, 2007, STROKE, V38, P1293, DOI 10.1161/01.STR.0000260205.67348.2b; Pelgrims B, 2011, HUM BRAIN MAPP, V32, P1471, DOI 10.1002/hbm.21121; Rathelot JA, 2009, P NATL ACAD SCI USA, V106, P918, DOI 10.1073/pnas.0808362106; Robertson EM, 2005, J NEUROSCI, V25, P6372, DOI 10.1523/JNEUROSCI.1851-05.2005; Sandrini M, 2011, NEUROSCI BIOBEHAV R, V35, P516, DOI 10.1016/j.neubiorev.2010.06.005; Schmitz Remy, 2009, BMC Res Notes, V2, P170, DOI 10.1186/1756-0500-2-170; Shadmehr R, 1997, SCIENCE, V277, P821, DOI 10.1126/science.277.5327.821; Sharma N, 2008, NEUROIMAGE, V41, P92, DOI 10.1016/j.neuroimage.2008.02.009; Sharma N, 2006, STROKE, V37, P1941, DOI 10.1161/01.STR.0000226902.43357.fc; Stickgold R, 2007, SLEEP MED, V8, P331, DOI 10.1016/j.sleep.2007.03.011; Tononi G, 2003, BRAIN RES BULL, V62, P143, DOI 10.1016/j.brainresbull.2003.09.004; Walker MP, 2005, CLIN SPORT MED, V24, P301, DOI 10.1016/j.csm.2004.11.002; Wohldmann EL, 2008, J EXP PSYCHOL LEARN, V34, P823, DOI 10.1037/0278-7393.34.4.823; Wohldmann EL, 2007, J EXP PSYCHOL LEARN, V33, P254, DOI 10.1037/0278-7393.33.1.254; Zafar N, 2008, CLIN NEUROPHYSIOL, V119, P1393, DOI 10.1016/j.clinph.2008.02.006; Zenon A, 2010, J COGNITIVE NEUROSCI, V22, P918, DOI 10.1162/jocn.2009.21233; Zhang X, 2011, J NEUROSCI, V31, P11515, DOI 10.1523/JNEUROSCI.6759-10.2011	59	26	26	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2011	6	10							e26717	10.1371/journal.pone.0026717	http://dx.doi.org/10.1371/journal.pone.0026717			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841NR	22046337	gold, Green Published, Green Submitted			2023-01-03	WOS:000296519600047
J	Vladeck, BC				Vladeck, Bruce C.			The Continuing Paradoxes of Nursing Home Policy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Nexera Inc, New York, NY 10019 USA		Vladeck, BC (corresponding author), Nexera Inc, 555 W 57th St,15th Floor, New York, NY 10019 USA.	bvladeck@nexeraconsulting.com						*ADAPT, ADAPTS DEF OUR FREED; *HJ KAIS FAM FDN K, 2011, POL BRIEF PROP MOD I; *HJ KAIS FAM FDN K, 2011, ISS PAP MED HOM COMM; *MED PAY ADV COMM, REP C MED PAYM POL, pCH7; Mor V, 2007, HEALTH AFFAIR, V26, P1762, DOI 10.1377/hlthaff.26.6.1762; Vladeck BC, 2003, HEALTH AFFAIR, V22, P90, DOI 10.1377/hlthaff.22.1.90; Zweig SC, 2011, JAMA-J AM MED ASSOC, V306, P1468, DOI 10.1001/jama.2011.1420; LONG TERM CARE	8	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2011	306	16					1802	1803		10.1001/jama.2011.1527	http://dx.doi.org/10.1001/jama.2011.1527			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837HH	21972271				2023-01-03	WOS:000296181600028
J	Price, CF; Tyssen, D; Sonza, S; Davie, A; Evans, S; Lewis, GR; Xia, S; Spelman, T; Hodsman, P; Moench, TR; Humberstone, A; Paull, JRA; Tachedjian, G				Price, Clare F.; Tyssen, David; Sonza, Secondo; Davie, Ashley; Evans, Sonya; Lewis, Gareth R.; Xia, Shirley; Spelman, Tim; Hodsman, Peter; Moench, Thomas R.; Humberstone, Andrew; Paull, Jeremy R. A.; Tachedjian, Gilda			SPL7013 Gel (VivaGel (R)) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans	PLOS ONE			English	Article							SIMPLEX-VIRUS INFECTION; CANDIDATE TOPICAL MICROBICIDES; CERVICOVAGINAL SECRETIONS; CONTROLLED-TRIAL; EXPLANT CULTURE; SEMINAL PLASMA; DOUBLE-BLIND; IN-VITRO; LOW PH; PREVENTION	SPL7013 Gel (VivaGel (R)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants received 5 single doses of product with >= 5 days between doses. A cervicovaginal fluid (CVF) sample was collected using a SoftCup (TM) pre-dose, and immediately, or 1, 3, 12 or 24 h post-dose. HIV-1 and HSV-2 antiviral activities of CVF samples were determined in cell culture assays. Antiviral activity in the presence of seminal plasma was also tested. Mass and concentration of SPL7013 in CVF samples was determined. Safety was assessed by reporting of adverse events. Statistical analysis was performed using the Wilcoxon signed-rank test with Bonferroni adjustment; p <= 0.003 was significant. Eleven participants completed the study. Inhibition of HIV-1 and HSV-2 by pre-dose CVF samples was negligible. CVF samples obtained immediately after dosing almost completely inhibited (median, interquartile range) HIV-1 [96% (95,97)] and HSV-2 [86% (85,94)], and activity was maintained in all women at 3 h (HIV-1 [ 96% (95,98), p = 0.9]; HSV-2 [94% (91,97), p = 0.005]). At 24 h, >90% of initial HIV-1 and HSV-2 inhibition was maintained in 6/11 women. SPL7013 was recovered in CVF samples obtained at baseline (46% of 105 mg dose). At 3 and 24 h, 22 mg and 4 mg SPL7013, respectively, were recovered. More than 70% inhibition of HIV-1 and HSV-2 was observed if there was >0.5 mg SPL7013 in CVF samples. High levels of antiviral activity were retained in the presence of seminal plasma. VivaGel was well tolerated with no signs or symptoms of vaginal, vulvar or cervical irritation reported. Potent antiviral activity was observed against HIV-1 and HSV-2 immediately following vaginal administration of VivaGel, with activity maintained for at least 3 h post-dose. The data provide evidence of antiviral activity in a clinical setting, and suggest VivaGel could be administered up to 3 h before coitus.	[Price, Clare F.; Davie, Ashley; Evans, Sonya; Lewis, Gareth R.; Xia, Shirley; Paull, Jeremy R. A.] Starpharma Pty Ltd, Melbourne, Vic, Australia; [Tyssen, David; Sonza, Secondo; Tachedjian, Gilda] Burnet Inst, Ctr Virol, Melbourne, Vic, Australia; [Sonza, Secondo; Tachedjian, Gilda] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; [Spelman, Tim] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic, Australia; [Hodsman, Peter; Humberstone, Andrew] Nucleus Network, Melbourne, Vic, Australia; [Moench, Thomas R.] ReProtect Inc, Baltimore, MD USA; [Tachedjian, Gilda] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia	Burnet Institute; Monash University; Burnet Institute; Monash University	Price, CF (corresponding author), Starpharma Pty Ltd, Melbourne, Vic, Australia.	clare.price@starpharma.com; gildat@burnet.edu.au	Tachedjian, Gilda/AAF-1327-2020	Tachedjian, Gilda/0000-0002-7733-7037; Paull, Jeremy/0000-0002-9981-421X	Starpharma Pty Ltd; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN266200500042C]; Burnet Institute	Starpharma Pty Ltd; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Burnet Institute	The study was sponsored by Starpharma Pty Ltd. The study was funded in whole with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200500042C (http://www.niaid.nih.gov/). Representaives of NIAID, NIH, were directly involved with study design and interpretation of data, and the study protocol was reviewed by NIAID's Prevention Sciences Review Committee. Starpharma Pty Ltd was responsible for study design, data collection and analysis, decision to publish, and preparation of the manuscript.; CFP, JRAP, SE, AD, GRL, and SX are either past or present employees of Starpharma Pty Ltd, which sponsored the study. At the time of the study PH and AH were employees of Nucleus Network, which was contracted by Starpharma Pty Ltd to conduct the study. GT and TRM were paid consultancy fees under contract to Starpharma Pty Ltd, and the Burnet Institute was contracted to perform the antiviral assays. TRM is the President and COO of ReProtect, Inc. "VivaGel" is Starpharma's lead product (http://www.starpharma.com/vivagel). These affiliations do not alter any authors' adherence to all PLoS ONE polices on sharing data and materials. The remaining authors declare that they have no conflicts of interest.	Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424; Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5; Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003; Boskey ER, 2003, SEX TRANSM DIS, V30, P107, DOI 10.1097/00007435-200302000-00002; Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000; Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6; Connor RI, 2006, JAIDS-J ACQ IMM DEF, V43, P499, DOI 10.1097/01.qai.0000243048.50451.18; Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06; *DAIDS RSC, SAF PHARM; Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Ghosh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011366; Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004; Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207; John M, 2005, J INFECT DIS, V192, P1731, DOI 10.1086/497168; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Karim SSA, 2011, AIDS, V25, P957, DOI 10.1097/QAD.0b013e32834541d9; Kashuba AD, 2010, 18 INT AIDS C VIENN; Keller MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008781; Keller MJ, 2006, J INFECT DIS, V193, P27, DOI 10.1086/498533; Lacey CJN, 2006, AIDS, V20, P1027, DOI 10.1097/01.aids.0000222075.83490.ca; Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q; McCormack S, 2010, LANCET, V376, P1329, DOI 10.1016/S0140-6736(10)61086-0; Neurath AR, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-150; O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac; OCONNOR TJ, 1995, INT J STD AIDS, V6, P267, DOI 10.1177/095646249500600409; Olmsted SS, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-79; Patel S, 2007, J INFECT DIS, V196, P1394, DOI 10.1086/522606; Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006; Rupp R, 2007, INT J NANOMED, V2, P561; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Sonza S, 2009, ANTIMICROB AGENTS CH, V53, P3565, DOI 10.1128/AAC.00102-09; Tyssen D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012309; UNAIDS, 2008, REP GLOB AIDS EP	36	113	117	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24095	10.1371/journal.pone.0024095	http://dx.doi.org/10.1371/journal.pone.0024095			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822JR	21935377	gold, Green Published			2023-01-03	WOS:000295041700012
J	Choi, M; Kim, H; Qian, H; Palepu, A				Choi, Mark; Kim, Haerin; Qian, Hong; Palepu, Anita			Readmission Rates of Patients Discharged against Medical Advice: A Matched Cohort Study	PLOS ONE			English	Article							LEAVE; HOSPITALS	Objective: We compared the readmission rates and the pattern of readmission among patients discharged against medical advice (AMA) to control patients discharged with approval over a one-year follow-up period. Methods: A retrospective matched-cohort study of 656 patients(328 were discharged AMA) who were followed for one year after their initial hospitalization at an urban university-affiliated teaching hospital in Vancouver, Canada that serves a population with high prevalence of addiction and psychiatric disorders. Multivariate conditional logistic regression was used to examine the independent association of discharge AMA on 14-day related diagnosis hospital readmission. We fit a multivariate conditional negative binomial regression model to examine the readmission frequency ratio between the AMA and non-AMA group. Principal Findings: AMA patients were more likely to be homeless (32.3% vs. 11%) and have co-morbid conditions such as psychiatric illnesses, injection drug use, HIV, hepatitis C and previous gastrointestinal bleeding. Patients discharged AMA were more likely to be readmitted: 25.6% vs. 3.4%, p<0.001 by day 14. The AMA group were more likely to be readmitted within 14 days with a related diagnosis than the non-AMA group (Adjusted Odds Ratio 12.0; 95% Confidence Interval [CI]: 3.7-38.9). Patients who left AMA were more likely to be readmitted multiple times at one year compared to the non-AMA group (adjusted frequency ratio 1.6; 95% CI: 1.3-2.0). There was also higher all-cause in-hospital mortality during the 12-month follow-up in the AMA group compared to non-AMA group (6.7% vs. 2.4%, p = 0.01). Conclusions: Patients discharged AMA were more likely to be homeless and have multiple co-morbid conditions. At one year follow-up, the AMA group had higher readmission rates, were predisposed to multiple readmissions and had a higher in-hospital mortality. Interventions to reduce discharges AMA in high-risk groups need to be developed and tested.	[Choi, Mark; Kim, Haerin; Palepu, Anita] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Qian, Hong; Palepu, Anita] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada	University of British Columbia; St. Paul's Hospital; University of Saskatchewan	Choi, M (corresponding author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.	anita@hivnet.ubc.ca		Palepu, Anita/0000-0002-7881-4800				Alfandre DJ, 2009, MAYO CLIN PROC, V84, P255, DOI 10.1016/S0025-6196(11)61143-9; Aliyu Z, 2002, INT J CLIN PRACT, V56, P325; Anis AH, 2002, CAN MED ASSOC J, V167, P633; [Anonymous], 2010, J GEN INTERN MED, V26, P926; Baptist AP, 2007, J ALLERGY CLIN IMMUN, V119, P924, DOI 10.1016/j.jaci.2006.11.695; Brook M, 2006, PSYCHIAT SERV, V57, P1192, DOI 10.1176/appi.ps.57.8.1192; Chan ACH, 2004, JAIDS-J ACQ IMM DEF, V35, P56, DOI 10.1097/00126334-200401010-00008; COOK CAL, 1994, J SUBST ABUSE TREAT, V11, P239; DUBOW D, 1992, Journal of Emergency Medicine, V10, P513, DOI 10.1016/0736-4679(92)90289-6; Hwang SW, 2003, CAN MED ASSOC J, V168, P417; Ibrahim SA, 2007, AM J PUBLIC HEALTH, V97, P2204, DOI 10.2105/AJPH.2006.100164; JEREMIAH J, 1995, J GEN INTERN MED, V10, P403, DOI 10.1007/BF02599843; Kuo CJ, 2010, J CLIN PSYCHIAT, V71, P808, DOI 10.4088/JCP.09l05404blu; Maas B, 2007, HEALTH PLACE, V13, P432, DOI 10.1016/j.healthplace.2006.05.005; *NAT CTR HLTH STAT, 2001, HLTH US; Onukwugha E, 2010, QUAL SAF HEALTH CARE, V19, P420, DOI 10.1136/qshc.2009.036269; Pages KP, 1998, PSYCHIATR SERV, V49, P1187, DOI 10.1176/ps.49.9.1187; Perry S, 2009, ST HEAL T, V143, P496, DOI 10.3233/978-1-58603-979-0-496; Reinke DA, 2009, CLIN PEDIATR, V48, P263, DOI 10.1177/0009922808323109; Saitz R, 1999, AM J MED, V107, P507, DOI 10.1016/S0002-9343(99)00262-4; Saitz R, 2000, J GEN INTERN MED, V15, P103, DOI 10.1046/j.1525-1497.2000.12068.x; Sclar David A, 2010, Prim Care Companion J Clin Psychiatry, V12, DOI 10.4088/PCC.09m00827yel; Seaborn Moyse Heidi, 2004, Can J Rural Med, V9, P148; Shepperd S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub3; SMITH DB, 1991, AM J PUBLIC HEALTH, V81, P210, DOI 10.2105/AJPH.81.2.212; Valevski A, 2012, EUR PSYCHIAT, V27, P496, DOI 10.1016/j.eurpsy.2011.04.009; Weingart SN, 1998, J GEN INTERN MED, V13, P568, DOI 10.1046/j.1525-1497.1998.00169.x; Windish DM, 2008, J GEN INTERN MED, V23, P1698, DOI 10.1007/s11606-008-0728-4	28	87	88	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2011	6	9							e24459	10.1371/journal.pone.0024459	http://dx.doi.org/10.1371/journal.pone.0024459			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	819CK	21931723	gold, Green Published, Green Submitted			2023-01-03	WOS:000294802800054
J	Wagner, L; Marschall, V; Karl, S; Cristofanon, S; Zobel, K; Deshayes, K; Vucic, D; Debatin, KM; Fulda, S				Wagner, L.; Marschall, V.; Karl, S.; Cristofanon, S.; Zobel, K.; Deshayes, K.; Vucic, D.; Debatin, K-M; Fulda, S.			Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1-and NF-kappa B-dependent manner	ONCOGENE			English	Article						Smac; apoptosis; glioblastoma; temozolomide; RIP1	IRRADIATION-INDUCED APOPTOSIS; MALIGNANT GLIOMA; BETULINIC ACID; ACTIVATION; GAMMA; DEATH; RESISTANCE; CASPASE-8; CIAP1; IAPS	Inhibitor of apoptosis (IAP) proteins are expressed at high levels in many cancers and therefore represent attractive targets for therapeutic intervention. Here, we report for the first time that the second mitochondria-derived activator of caspases (Smac) mimetic BV6 sensitizes glioblastoma cells toward Temozolomide (TMZ), the first-line chemotherapeutic agent in the treatment of glioblastoma. BV6 and TMZ synergistically reduce cell viability and trigger apoptosis in glioblastoma cells (combination index <0.4-0.8), which is accompanied by increased loss of mitochondrial-membrane potential, cytochrome c release, caspase activation and caspase-dependent apoptosis. Analysis of the molecular mechanisms reveals that BV6 causes rapid degradation of clAP1, leading to stabilization of NF-kappa B-inducing kinase and NF-kappa B activation. BV6-stimulated NF-kappa B activation is critically required for sensitization toward TMZ, as inhibition of NF-kappa B by overexpression of the mutant l kappa B alpha super-repressor profoundly reduces loss of mitochondrial membrane potential, cytochrome c release, caspase activation and apoptosis. Of note, BV6-mediated sensitization to TMZ is not associated with increased tumor necrosis factor alpha (TNF alpha) production. Also, TNF alpha, CD95 or TRAIL-blocking antibodies or knockdown of TNFR1 have no or little effect on combination treatment-induced apoptosis. Interestingly, BV6 and TMZ cooperate to trigger the formation of a RIP1 (receptor activating protein 1)/caspase-8/FADD complex. Knockdown of RIP1 by small interfering RNA significantly reduces BV6- and TMZ-induced caspase-8 activation and apoptosis, showing that RIP1 is necessary for apoptosis induction. By demonstrating that BV6 primes glioblastoma cells for TMZ in a NF-kappa B- and RIP1-dependent manner, these findings build the rationale for further (pre)clinical development of Smac mimetics in combination with TMZ. Oncogene (2013) 32, 988-997; doi:10.1038/onc.2012.108; published online 2 April 2012	[Wagner, L.; Karl, S.; Debatin, K-M; Fulda, S.] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany; [Marschall, V.; Cristofanon, S.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Hesse, Germany; [Zobel, K.; Deshayes, K.; Vucic, D.] Genentech Inc, San Francisco, CA USA	Ulm University; Goethe University Frankfurt; Roche Holding; Genentech	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3A, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de	Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; European Community (ApopTrain, APO-SYS); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Community (ApopTrain, APO-SYS)(European CommissionEuropean Commission Joint Research Centre); IAP6/18; International Graduate School in Molecular Medicine Ulm, Ulm University	We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, European Community (ApopTrain, APO-SYS) and IAP6/18 (to SF) and by a scholarship from the International Graduate School in Molecular Medicine Ulm, Ulm University (to LW). Kerry Zobel, Kurt Deshayes, and Domagoj Vucic are employees of Genentech, Inc.	Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001; Berger R, 2011, MOL CANCER THER, V10, P1867, DOI 10.1158/1535-7163.MCT-11-0218; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064; Giagkousiklidis S, 2005, CANCER RES, V65, P10502, DOI 10.1158/0008-5472.CAN-05-0866; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Hacker S, 2009, ONCOGENE, V28, P3097, DOI 10.1038/onc.2009.161; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Opel D, 2008, CANCER RES, V68, P6271, DOI 10.1158/0008-5472.CAN-07-6769; Probst BL, 2010, CELL DEATH DIFFER, V17, P1645, DOI 10.1038/cdd.2010.44; Shirley S., 2010, CANC LETT; Straub CS, 2011, CURR TOP MED CHEM, V11, P291; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vellanki S, 2009, NEOPLASIA, V11, P743, DOI 10.1593/neo.09436; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036	29	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					988	997		10.1038/onc.2012.108	http://dx.doi.org/10.1038/onc.2012.108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22469979				2023-01-03	WOS:000316523200006
J	Nunns, D; Murphy, R				Nunns, David; Murphy, Ruth			Assessment and management of vulval pain	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELECTROMYOGRAPHIC BIOFEEDBACK; DIAGNOSTIC-CRITERIA; VULVODYNIA; VESTIBULITIS; VESTIBULECTOMY; GUIDELINES; THERAPY		[Nunns, David; Murphy, Ruth] Univ Nottingham Hosp, Nottingham NG5 1PB, England	University of Nottingham	Nunns, D (corresponding author), Univ Nottingham Hosp, Nottingham NG5 1PB, England.	david.nunns@nuh.nhs.uk						Bergeron S, 2001, PAIN, V91, P297, DOI 10.1016/S0304-3959(00)00449-8; Bergeron S, 2001, OBSTET GYNECOL, V98, P45, DOI 10.1016/S0029-7844(01)01389-8; Bornstein J, 1999, OBSTET GYNECOL, V93, P876, DOI 10.1016/S0029-7844(98)00535-3; Bowen AR, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.03.004; Eanes A, 2011, INT J GYNECOL OBSTET, V113, P225, DOI 10.1016/j.ijgo.2010.12.018; Farmer K., 2010, EFFECT VOLUNATARY EX; Foster DC, 2010, OBSTET GYNECOL, V116, P583, DOI 10.1097/AOG.0b013e3181e9e0ab; Harlow Bernard L, 2003, J Am Med Womens Assoc (1972), V58, P82; Harris G, 2007, J REPROD MED, V52, P103; JADRESIC D, 1993, INT J STD AIDS, V4, P237, DOI 10.1177/095646249300400413; Kehoe S, 1996, ACTA OBSTET GYN SCAN, V75, P676, DOI 10.3109/00016349609054697; Labat JJ, 2008, NEUROUROL URODYNAM, V27, P306, DOI 10.1002/nau.20505; Lehman JS, 2009, INT J DERMATOL, V48, P682, DOI 10.1111/j.1365-4632.2009.04062.x; Lewis FM, 1997, J REPROD MED, V42, P169; Mandal D, 2010, BRIT J DERMATOL, V162, P1180, DOI 10.1111/j.1365-2133.2010.09684.x; McKay E, 2001, J REPROD MED, V46, P337; Moyal-Barracco M, 2004, J REPROD MED, V49, P772; Munday P E, 2001, J Obstet Gynaecol, V21, P610; Munday P, 2007, J REPROD MED, V52, P19; Murphy R, 2008, J REPROD MED, V53, P124; Neill SM, 2010, BRIT J DERMATOL, V163, P672, DOI 10.1111/j.1365-2133.2010.09997.x; Nunns D, 1997, CONTACT DERMATITIS, V37, P87, DOI 10.1111/j.1600-0536.1997.tb00045.x; Reed Barbara D, 2006, J Low Genit Tract Dis, V10, P245, DOI 10.1097/01.lgt.0000225899.75207.0a; Royal College of Obstetricians & Gynecologists, 2011, MAN VULV SKIN DIS; SCHOVER LR, 1992, AM J OBSTET GYNECOL, V167, P630, DOI 10.1016/S0002-9378(11)91562-2; Schultz WCMW, 1996, J PSYCHOSOM OBST GYN, V17, P143, DOI 10.3109/01674829609025675; Sobel JD, 2004, NEW ENGL J MED, V351, P876, DOI 10.1056/NEJMoa033114; STEWART DE, 1994, OBSTET GYNECOL, V84, P587; Ventolini G, 2009, J OBSTET GYNAECOL, V29, P648, DOI 10.1080/01443610903095882; Wylie K, 2004, J PSYCHOSOM OBST GYN, V25, P257, DOI 10.1080/01674820400024463	30	10	10	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2012	344								e1723	10.1136/bmj.e1723	http://dx.doi.org/10.1136/bmj.e1723			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923FF	22457438				2023-01-03	WOS:000302604100007
J	Remuzzi, G				Remuzzi, Giuseppe			Ethical disputes still beset Italian medicine 150 years after Count Cavour's death	LANCET			English	Editorial Material							ASSISTED REPRODUCTION; LAW		Mario Negri Inst Pharmacol Res, Negri Bergamo Labs, I-24126 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Negri Bergamo Labs, I-24126 Bergamo, Italy.	giuseppe.remuzzi@marionegri.it	Remuzzi, Giuseppe/V-9766-2017	Remuzzi, Giuseppe/0000-0002-6194-3446				Abbott A, 2009, NATURE, V460, P19, DOI 10.1038/460019a; [Anonymous], 1861, BOSTON MED SURG J, V64, P495; [Anonymous], 1861, LANCET, V77, P593; [Anonymous], 2010, TIMES HIGHER ED; Bianchi N, 1874, CARLO MATTEUCCI ITAL; Boggio A, 2005, HUM REPROD, V20, P1153, DOI 10.1093/humrep/deh871; Brown J., 1784, ELEMENTA MED EDITIO; Cattaneo E, 2010, NATURE, V463, P729, DOI 10.1038/463729c; Cazzaniga A., 1951, GRANDE CRISI MED ITA; Cosmacini G., 1987, STORIA MED SANITA IT; De Feo I, 2011, CAVOUR UOMO OPERA; European Commission CORDIS, 2006, IT WITHDR ETH DECL E; Fineschi V, 2005, J MED ETHICS, V31, P536, DOI 10.1136/jme.2004.010231; Levi-Montalcini R, 2010, ELOGIO IMPERFEZIONE; Luchetti M, 2010, J MED ETHICS, V36, P333, DOI 10.1136/jme.2009.034835; Nature Cell Biology, 2008, NATURE CELL BIOL, V10, P1373; Paterlini M, 2011, EMBO REP, V12, P23, DOI 10.1038/embor.2010.194; Paterlini M, 2009, LANCET, V373, P1413, DOI 10.1016/S0140-6736(09)60803-5; Poggi R., 2009, MORTE CAVOUR; Pontificia Accdemia per la Vita, 2000, DICH PROD SULL SCI T; Rasori G., 1795, COMPENDIO NUOVA DOTT; Robertson JA, 2004, HUM REPROD, V19, P1693, DOI 10.1093/humrep/deh326; Romeo Rosario, 2004, VITA CAVOUR; Ruini C., 2005, PROL CARD CAM RUIN 5; Times Higher Education, 2008, TIMES HIGHER ED 0417; Wollaston R., 1861, BRIT MED J, V2, P48; World Health Organization, 2000, WORLD HLTH REP 2000	28	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 17	2012	379	9820					1068	1073		10.1016/S0140-6736(11)61382-2	http://dx.doi.org/10.1016/S0140-6736(11)61382-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JE	22000154				2023-01-03	WOS:000301712300035
J	Levison, JH; Orrell, C; Gallien, S; Kuritzkes, DR; Fu, N; Losina, E; Freedberg, KA; Wood, R				Levison, Julie H.; Orrell, Catherine; Gallien, Sebastien; Kuritzkes, Daniel R.; Fu, Naishin; Losina, Elena; Freedberg, Kenneth A.; Wood, Robin			Virologic Failure of Protease Inhibitor-Based Second-Line Antiretroviral Therapy without Resistance in a Large HIV Treatment Program in South Africa	PLOS ONE			English	Article							DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; LOPINAVIR-RITONAVIR; EARLY MORTALITY; PATIENTS LOST; FOLLOW-UP; CLADE-C; OUTCOMES; MUTATIONS; ADULTS	Background: We investigated the prevalence of wild-type virus (no major drug resistance) and drug resistance mutations at second-line antiretroviral treatment (ART) failure in a large HIV treatment program in South Africa. Methodology/ Principal Findings: HIV-infected patients >= 15 years of age who had failed protease inhibitor (PI)-based second-line ART (2 consecutive HIV RNA tests >1000 copies/ml on lopinavir/ritonavir, didanosine, and zidovudine) were identified retrospectively. Patients with virologic failure were continued on second-line ART. Genotypic testing for drug resistance was performed on frozen plasma samples obtained closest to and after the date of laboratory confirmed second-line ART failure. Of 322 HIV-infected patients on second-line ART, 43 were adults with confirmed virologic failure, and 33 had available plasma for viral sequencing. HIV-1 RNA subtype C predominated (n = 32, 97%). Mean duration on ART (SD) prior to initiation of second-line ART was 23 (17) months, and time from second-line ART initiation to failure was 10 (9) months. Plasma samples were obtained 7(9) months from confirmed failure. At second-line failure, 22 patients (67%) had wild-type virus. There was no major resistance to PIs found. Eleven of 33 patients had a second plasma sample taken 8 (5.5) months after the first. Median HIV-1 RNA and the genotypic resistance profile were unchanged. Conclusions/ Significance: Most patients who failed second-line ART had wild-type virus. We did not observe evolution of resistance despite continuation of PI-based ART after failure. Interventions that successfully improve adherence could allow patients to continue to benefit from second-line ART therapy even after initial failure.	[Levison, Julie H.; Fu, Naishin; Losina, Elena; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; [Levison, Julie H.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Orrell, Catherine; Wood, Robin] Univ Cape Town, Dept Med, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa; [Levison, Julie H.; Gallien, Sebastien; Kuritzkes, Daniel R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA; [Losina, Elena; Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Losina, Elena; Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Gallien, Sebastien; Kuritzkes, Daniel R.; Losina, Elena; Freedberg, Kenneth A.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Cape Town; Harvard University; Brigham & Women's Hospital; Boston University; Boston University; Harvard University	Levison, JH (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.	jlevison@partners.org	Orrell, Catherine/AAF-3405-2019; Gallien, Sébastien/F-9930-2015	Orrell, Catherine/0000-0003-1134-7475; Gallien, Sébastien/0000-0002-8033-0936; Losina, ELENA/0000-0002-3424-0892	United States National Institute of Allergy and Infectious Diseases [NIAID T32 AI007433, R01AI058736, K24 A1062476]; National Center for Research Resources [K24 RR016482]; Harvard University Center for AIDS Research [P30-AI060354]; Virology Specialty Laboratory from AIDS Clinical Trials Group [U01 AI068636]; "Agence Nationale de Recherche sur le SIDA" (French National Agency for Research on AIDS), France; Abbott; Boehringer Ingelheim; Gilead; GlaxoSmithKline; Merck; ViiV; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR016482] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI062476, U01AI068636, R01AI058736, P30AI060354, T32AI007433] Funding Source: NIH RePORTER	United States National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Harvard University Center for AIDS Research; Virology Specialty Laboratory from AIDS Clinical Trials Group; "Agence Nationale de Recherche sur le SIDA" (French National Agency for Research on AIDS), France; Abbott(Abbott Laboratories); Boehringer Ingelheim(Boehringer Ingelheim); Gilead(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); ViiV; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was supported by the United States National Institute of Allergy and Infectious Diseases (NIAID T32 AI007433, R01AI058736, K24 A1062476), the National Center for Research Resources (K24 RR016482), Harvard University Center for AIDS Research (P30-AI060354), Virology Specialty Laboratory subcontract from the AIDS Clinical Trials Group (U01 AI068636). SG was a recipient of the "Agence Nationale de Recherche sur le SIDA" (French National Agency for Research on AIDS) Fellowship Grant for Post-Graduate Studies, France. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following competing interest: DRK is a consultant to and has received honoraria or research support from Abbott, Boehringer Ingelheim, Gilead, GlaxoSmithKline, Merck and ViiV. This does not alter the authors' adherence to all the PloS ONE policies on sharing data and materials. All other authors have declared that no competing interests exist.	Barreiro P, 2004, AIDS PATIENT CARE ST, V18, P329, DOI 10.1089/1087291041444087; Bekker LG, 2006, SAMJ S AFR MED J, V96, P315; Bellocchi MC, 2005, J MED VIROL, V76, P452, DOI 10.1002/jmv.20382; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Decloedt EH, 2011, ANTIMICROB AGENTS CH, V55, P3195, DOI 10.1128/AAC.01598-10; El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b; FOX M, 2009, J ACQ IMMUN DEF SYND, V53, P500; Frater AJ, 2001, AIDS, V15, P1493, DOI 10.1097/00002030-200108170-00006; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Grossman Z, 2001, AIDS, V15, P1453, DOI 10.1097/00002030-200108170-00001; Gupta R, 2008, CLIN INFECT DIS, V47, P712, DOI 10.1086/590943; Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93; Hosseinipour MC, 2010, HIV MED, V11, P510, DOI 10.1111/j.1468-1293.2010.00825.x; Johnson Victoria A, 2010, Top HIV Med, V18, P156; Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112; Kunches LM, 2001, J ACQ IMMUN DEF SYND, V28, P150, DOI 10.1097/00126334-200110010-00006; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Levison JH, 2011, ANTIVIR THER, V16, P853, DOI 10.3851/IMP1819; Li JF, 2011, J INFECT DIS, V203, P798, DOI 10.1093/infdis/jiq126; Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375; Long L, 2010, AIDS, V24, P915, DOI 10.1097/QAD.0b013e3283360976; Marconi VC, 2008, CLIN INFECT DIS, V46, P1589, DOI 10.1086/587109; Miller CM, 2010, TROP MED INT HEALTH, V15, P48, DOI 10.1111/j.1365-3156.2010.02514.x; Mo HM, 2005, J VIROL, V79, P3329, DOI 10.1128/JVI.79.6.3329-3338.2005; Murphy RA, 2010, AIDS, V24, P1007, DOI 10.1097/QAD.0b013e3283333639; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; National Department of Health South Africa, 2010, CLIN GUID MAN HIV AI; Orrell C, 2007, ANTIVIR THER, V12, P83; Orrell C, 2009, ANTIVIR THER, V14, P523; Pasquet A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013414; Ross LL, 2010, J ANTIMICROB CHEMOTH, V65, P307, DOI 10.1093/jac/dkp419; UNAIDS Joint United Nations Programme on HIV/AIDS, 2010, COUNTR FACT SHEETS S; Velazquez-Campoy A, 2001, P NATL ACAD SCI USA, V98, P6062, DOI 10.1073/pnas.111152698; Vergne L, 2000, J CLIN MICROBIOL, V38, P3919, DOI 10.1128/JCM.38.11.3919-3925.2000; Wallis CL, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/769627; Wallis CL, 2010, J VIROL METHODS, V163, P505, DOI 10.1016/j.jviromet.2009.11.011; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Walmsley Sharon, 2002, J Int Assoc Physicians AIDS Care (Chic), V1, P95, DOI 10.1177/154510970200100304; World Health Organisation, 2007, PRIOR 2 LIN ANT DRUG; World Health Organization, 2010, UN ACC SCAL PRIOR HI	40	50	51	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2012	7	3							e32144	10.1371/journal.pone.0032144	http://dx.doi.org/10.1371/journal.pone.0032144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	930IA	22427821	Green Published, gold, Green Submitted			2023-01-03	WOS:000303129700006
J	Talbot, E; Munseri, P; Teixeira, P; Matee, M; Bakari, M; Lahey, T; von Reyn, F				Talbot, Elizabeth; Munseri, Patricia; Teixeira, Pedro; Matee, Mecky; Bakari, Muhammad; Lahey, Timothy; von Reyn, Fordham			Test Characteristics of Urinary Lipoarabinomannan and Predictors of Mortality among Hospitalized HIV-Infected Tuberculosis Suspects in Tanzania	PLOS ONE			English	Article							DIAGNOSTIC-ACCURACY; ENVELOPE	Background: Tuberculosis is the most common cause of death among patients with HIV infection living in tuberculosis endemic countries, but many cases are not diagnosed pre-mortem. We assessed the test characteristics of urinary lipoarabinomannan (LAM) and predictors of mortality among HIV-associated tuberculosis suspects in Tanzania. Methods: We prospectively enrolled hospitalized HIV-infected patients in Dar es Salaam, with >= 2 weeks of cough or fever, or weight loss. Subjects gave 2 mLs of urine to test for LAM using a commercially available ELISA, >= 2 sputum specimens for concentrated AFB smear and solid media culture, and 40 mLs of blood for culture. Results: Among 212 evaluable subjects, 143 (68%) were female; mean age was 36 years; and the median CD4 count 86 cells/mm 3.69 subjects (33%) had culture confirmation of tuberculosis and 65 (31%) were LAM positive. For 69 cases of sputum or blood culture-confirmed tuberculosis, LAM sensitivity was 65% and specificity 86% compared to 36% and 98% for sputum smear. LAM test characteristics were not different in patients with bacteremia but showed higher sensitivity and lower specificity with decreasing CD4 cell count. Two month mortality was 64 (53%) of 121 with outcomes available. In multivariate analysis there was significant association of mortality with absence of anti-retroviral therapy (p = 0.004) and a trend toward association with a positive urine LAM (p = 0.16). Among culture-negative patients mortality was 9 (75%) of 12 in LAM positive patients and 27 (38%) of 71 in LAM negative patients (p = 0.02). Conclusions: Urine LAM is more sensitive than sputum smear and has utility for the rapid diagnosis of culture-confirmed tuberculosis in this high-risk population. Mortality data raise the possibility that urine LAM may also be a marker for culture-negative tuberculosis.	[Talbot, Elizabeth; Teixeira, Pedro; Lahey, Timothy; von Reyn, Fordham] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; [Talbot, Elizabeth] Fdn Innovat New Diagnost, Geneva, Switzerland; [Munseri, Patricia; Matee, Mecky; Bakari, Muhammad] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania; [Munseri, Patricia] Karolinska Inst, Stockholm, Sweden	Dartmouth College; Foundation For Innovative New Diagnostics; Muhimbili University of Health & Allied Sciences; Karolinska Institutet	Talbot, E (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.	Elizabeth.talbot@dartmouth.edu		Teixeira, J. Pedro/0000-0002-2466-9644	National Institutes of Health [D43TW006807]; Dartmouth Hitchcock Medical Center Department of Medicine; Foundation for Innovative New Diagnostics, Geneva, Switzerland; FOGARTY INTERNATIONAL CENTER [D43TW006807] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dartmouth Hitchcock Medical Center Department of Medicine; Foundation for Innovative New Diagnostics, Geneva, Switzerland; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by National Institutes of Health-Fogarty Training Grant D43TW006807 (PJM and FvR), the Dartmouth Hitchcock Medical Center Department of Medicine, and the Foundation for Innovative New Diagnostics, Geneva, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Corbett EL, 2006, LANCET, V367, P926, DOI 10.1016/S0140-6736(06)68383-9; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dye C, 2010, SCIENCE, V328, P856, DOI 10.1126/science.1185449; Eng J, 2006, ROC ANAL WEB BASED C; Gounder CR, 2011, JAIDS-J ACQ IMM DEF, V58, P219, DOI 10.1097/QAI.0b013e31822b75d4; KRASNOW I, 1969, APPL MICROBIOL, V18, P915, DOI 10.1128/AEM.18.5.915-917.1969; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; Lockman S, 2003, INT J TUBERC LUNG D, V7, P714; Minion J, 2011, EUR RESPIR J, V38, P1398, DOI 10.1183/09031936.00025711; Munseri PJ, 2011, SCAND J INFECT DIS, V43, P696, DOI 10.3109/00365548.2011.577802; Peter J, 2010, CURR OPIN PULM MED, V16, P262, DOI 10.1097/MCP.0b013e328337f23a; Shah M, 2009, JAIDS-J ACQ IMM DEF, V52, P145, DOI 10.1097/QAI.0b013e3181b98430; von Reyn CF, 2011, J INFECT DIS, V204, P817, DOI 10.1093/infdis/jir418; von Reyn CF, 1999, AIDS, V13, P2193, DOI 10.1097/00002030-199911120-00001; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; WHO, 1997, TREATM TUB GUID NAT, V2	17	36	36	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2012	7	3							e32876	10.1371/journal.pone.0032876	http://dx.doi.org/10.1371/journal.pone.0032876			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KT	22412939	Green Published, Green Submitted, gold			2023-01-03	WOS:000303062000018
J	Richer, MJ; Lavallee, DJ; Shanina, I; Horwitz, MS				Richer, Martin J.; Lavallee, Danielle J.; Shanina, Iryna; Horwitz, Marc S.			Immunomodulation of Antigen Presenting Cells Promotes Natural Regulatory T Cells That Prevent Autoimmune Diabetes in NOD Mice	PLOS ONE			English	Article							TGF-BETA; CUTTING EDGE; COXSACKIEVIRUS INFECTION; VIRAL-INFECTIONS; INDUCTION; HOMEOSTASIS; VIRUS; FOXP3; COSTIMULATION; ACCELERATION	Progression towards type 1 diabetes (T1D) in susceptible patients is linked to a progressive decline in the capacity of regulatory T cells (Treg) to maintain tolerance. As such, therapies aimed at redressing the failing Treg compartment have been the subject of intense investigation. Treg dysfunction in T1D has recently been linked to a reduced capacity of antigen presenting cells (APCs) to maintain Treg function rather than Treg intrinsic defects. This suggests that therapies aimed simply at addressing the failing Treg compartment are unlikely to provide long-term protection. Here, we demonstrate that modulation of the inflammatory status of CD11b+CD11c- APCs favors the upregulation of protective Tregs in a mouse model of T1D. We further demonstrate that reduced expression of the costimulatory molecule CD40 plays a role in this increased immunoregulatory capacity. Strikingly, Treg upregulation resulted exclusively from an increase in natural Tregs rather than the peripheral conversion of conventional T cells. This suggests that modulation of CD11b+CD11c- APCs inflammatory properties favors the establishment of natural Treg responses that, unlike adaptive Treg responses, are likely to maintain tolerance to a broad range of antigens. As such, modulation of this APC subset represents a potential therapeutic avenue to reestablish peripheral tolerance and protect from autoimmune diseases such as T1D.	[Richer, Martin J.; Lavallee, Danielle J.; Shanina, Iryna; Horwitz, Marc S.] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Richer, MJ (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	mhorwitz@mail.ubc.ca			Canadian Institutes of Health Research; Canadian Diabetes Association	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Diabetes Association	This work was supported by grants from the Canadian Institutes of Health Research and the Canadian Diabetes Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alard P, 2006, DIABETES, V55, P2098, DOI 10.2337/db05-0810; Anderson AC, 2008, J IMMUNOL, V181, P7449, DOI 10.4049/jimmunol.181.11.7449; Anderson MS, 2005, ANNU REV IMMUNOL, V23, P447, DOI 10.1146/annurev.immunol.23.021704.115643; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bour-Jordan H, 2009, IMMUNOL REV, V229, P41, DOI 10.1111/j.1600-065X.2009.00775.x; Bradshaw EM, 2009, J IMMUNOL, V183, P4432, DOI 10.4049/jimmunol.0900576; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen ZB, 2005, J EXP MED, V202, P1387, DOI 10.1084/jem.20051409; Cui GL, 2009, CELL RES, V19, P574, DOI 10.1038/cr.2009.12; D'Alise AM, 2008, P NATL ACAD SCI USA, V105, P19857, DOI 10.1073/pnas.0810713105; Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Feuerer M, 2009, IMMUNITY, V31, P654, DOI 10.1016/j.immuni.2009.08.023; Filippi CM, 2009, J CLIN INVEST, V119, P1515, DOI 10.1172/JCI38503; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Ford ML, 2009, IMMUNOL REV, V229, P294, DOI 10.1111/j.1600-065X.2009.00776.x; Gaddy DF, 2010, DIABETES, V59, P3108, DOI 10.2337/db09-1886; Gregg RK, 2004, J IMMUNOL, V173, P7308, DOI 10.4049/jimmunol.173.12.7308; Gregori S, 2003, J IMMUNOL, V171, P4040, DOI 10.4049/jimmunol.171.8.4040; Guiducci C, 2005, EUR J IMMUNOL, V35, P557, DOI 10.1002/eji.200425810; Herman AE, 2004, J EXP MED, V199, P1479, DOI 10.1084/jem.20040179; Horwitz MS, 2006, VIRAL IMMUNOL, V19, P722, DOI 10.1089/vim.2006.19.722; Horwitz MS, 2004, CLIN IMMUNOL, V110, P134, DOI 10.1016/j.clim.2003.09.014; Horwitz MS, 2002, J CLIN INVEST, V109, P79, DOI 10.1172/JCI11198; Horwitz MS, 1998, NAT MED, V4, P781, DOI 10.1038/nm0798-781; Jahromi MM, 2006, ANN NY ACAD SCI, V1079, P289, DOI 10.1196/annals.1375.044; Jin Y, 2009, CLIN IMMUNOL, V130, P272, DOI 10.1016/j.clim.2008.10.005; Jun HS, 2003, DIABETES-METAB RES, V19, P8, DOI 10.1002/dmrr.337; King C, 1998, IMMUNITY, V8, P601, DOI 10.1016/S1074-7613(00)80565-8; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kumanogoh A, 2001, J IMMUNOL, V166, P353, DOI 10.4049/jimmunol.166.1.353; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Manirarora JN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003739; OLDSTONE MBA, 1988, SCIENCE, V239, P500, DOI 10.1126/science.3277269; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pop SM, 2005, J EXP MED, V201, P1333, DOI 10.1084/jem.20042398; Richer MJ, 2008, DIABETES, V57, P1302, DOI 10.2337/db07-1460; Richer MJ, 2006, CLIN IMMUNOL, V121, P339, DOI 10.1016/j.clim.2006.07.009; Richer MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004127; Richer MJ, 2008, FRONT BIOSCI-LANDMRK, V13, P4241, DOI 10.2741/3002; Riedel MJ, 2010, GENE THER, V17, P171, DOI 10.1038/gt.2009.143; Salama AD, 2003, J EXP MED, V198, P71, DOI 10.1084/jem.20022119; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Serreze DV, 2005, J VIROL, V79, P1045, DOI 10.1128/JVI.79.2.1045-1052.2005; Serreze DV, 2000, DIABETES, V49, P708, DOI 10.2337/diabetes.49.5.708; Tang QZ, 2003, J IMMUNOL, V171, P3348, DOI 10.4049/jimmunol.171.7.3348; Thornton AM, 2010, J IMMUNOL, V184, P3433, DOI 10.4049/jimmunol.0904028; Walker LSK, 2008, EXPERT OPIN BIOL TH, V8, P1691, DOI 10.1517/14712598.8.11.1691 ; WEBB SR, 1976, J EXP MED, V143, P1239, DOI 10.1084/jem.143.5.1239; Weber MS, 2007, NAT MED, V13, P935, DOI 10.1038/nm1620; You S, 2005, DIABETES, V54, P1415, DOI 10.2337/diabetes.54.5.1415; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	53	10	12	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 15	2012	7	2							e31153	10.1371/journal.pone.0031153	http://dx.doi.org/10.1371/journal.pone.0031153			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925DP	22355341	Green Submitted, Green Published, gold			2023-01-03	WOS:000302741300041
J	Metges, CC; Lang, IS; Hennig, U; Brussow, KP; Kanitz, E; Tuchscherer, M; Schneider, F; Weitzel, JM; Steinhoff-Ooster, A; Sauerwein, H; Bellmann, O; Nurnberg, G; Rehfeldt, C; Otten, W				Metges, Cornelia C.; Lang, Iris S.; Hennig, Ulf; Bruessow, Klaus-Peter; Kanitz, Ellen; Tuchscherer, Margret; Schneider, Falk; Weitzel, Joachim M.; Steinhoff-Ooster, Anika; Sauerwein, Helga; Bellmann, Olaf; Nuernberg, Gerd; Rehfeldt, Charlotte; Otten, Winfried			Intrauterine Growth Retarded Progeny of Pregnant Sows Fed High Protein:Low Carbohydrate Diet Is Related to Metabolic Energy Deficit	PLOS ONE			English	Article							WEIGHT-LOSS; LIPOPROTEIN CHOLESTEROL; COMPOSITIONAL TRAITS; STEROL-METABOLISM; BODY-COMPOSITION; GENE-EXPRESSION; EARLY GESTATION; CORTISOL; TRYPTOPHAN; PLASMA	High and low protein diets fed to pregnant adolescent sows led to intrauterine growth retardation (IUGR). To explore underlying mechanisms, sow plasma metabolite and hormone concentrations were analyzed during different pregnancy stages and correlated with litter weight (LW) at birth, sow body weight and back fat thickness. Sows were fed diets with low (6.5%, LP), adequate (12.1%, AP), and high (30%, HP) protein levels, made isoenergetic by adjusted carbohydrate content. At -5, 24, 66, and 108 days post coitum (dpc) fasted blood was collected. At 92 dpc, diurnal metabolic profiles were determined. Fasted serum urea and plasma glucagon were higher due to the HP diet. High density lipoprotein cholesterol (HDLC), %HDLC and cortisol were reduced in HP compared with AP sows. Lowest concentrations were observed for serum urea and protein, plasma insulin-like growth factor-I, low density lipoprotein cholesterol, and progesterone in LP compared with AP and HP sows. Fasted plasma glucose, insulin and leptin concentrations were unchanged. Diurnal metabolic profiles showed lower glucose in HP sows whereas non-esterified fatty acids (NEFA) concentrations were higher in HP compared with AP and LP sows. In HP and LP sows, urea concentrations were 300% and 60% of AP sows, respectively. Plasma total cholesterol was higher in LP than in AP and HP sows. In AP sows, LW correlated positively with insulin and insulin/glucose and negatively with glucagon/insulin at 66 dpc, whereas in HP sows LW associated positively with NEFA. In conclusion, IUGR in sows fed high protein:low carbohydrate diet was probably due to glucose and energy deficit whereas in sows with low protein:high carbohydrate diet it was possibly a response to a deficit of indispensable amino acids which impaired lipoprotein metabolism and favored maternal lipid disposal.	[Metges, Cornelia C.; Lang, Iris S.; Hennig, Ulf] Leibniz Inst Farm Anim Biol FBN, Res Unit Nutr Physiol Oskar Kellner, Dummerstorf, Germany; [Bruessow, Klaus-Peter; Schneider, Falk; Weitzel, Joachim M.] Leibniz Inst Farm Anim Biol FBN, Res Unit Reprod Biol, Dummerstorf, Germany; [Kanitz, Ellen; Tuchscherer, Margret; Otten, Winfried] Leibniz Inst Farm Anim Biol FBN, Res Unit Behav Physiol, Dummerstorf, Germany; [Steinhoff-Ooster, Anika; Sauerwein, Helga] Univ Bonn, Inst Anim Sci, Physiol & Hyg Unit, Bonn, Germany; [Nuernberg, Gerd] Leibniz Inst Farm Anim Biol FBN, Res Unit Genet & Biometry, Dummerstorf, Germany; [Rehfeldt, Charlotte] Leibniz Inst Farm Anim Biol FBN, Res Unit Muscle Biol & Growth, Dummerstorf, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); University of Bonn; Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN)	Metges, CC (corresponding author), Leibniz Inst Farm Anim Biol FBN, Res Unit Nutr Physiol Oskar Kellner, Dummerstorf, Germany.	otten@fbn-dummerstorf.de	Sauerwein, Helga/R-8242-2019; Otten, Winfried/V-8376-2019	Otten, Winfried/0000-0002-5613-5356; Weitzel, Joachim/0000-0002-4073-6691	Deutsche Forschungsgemeinschaft [ME 1420/8-1, OT137/3-1, PAK 24]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Supported by the Deutsche Forschungsgemeinschaft (www.dfg.de; grant numbers: ME 1420/8-1;OT137/3-1; PAK 24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brown KR, 2007, J ANIM SCI, V85, P1687, DOI 10.2527/jas.2006-569; Christian P, 2009, NESTLE NUTR WORKS SE, V63, P59, DOI 10.1159/000209973; Divino JC, 1999, AM J PHYSIOL-ENDOC M, V277, pE693, DOI 10.1152/ajpendo.1999.277.4.E693; El Khattabi I, 2003, AM J PHYSIOL-ENDOC M, V285, pE991, DOI 10.1152/ajpendo.00037.2003; Fernandez-Twinn DS, 2003, BRIT J NUTR, V90, P815, DOI 10.1079/BJN2003967; Firk C, 2009, CLIN NUTR, V28, P266, DOI 10.1016/j.clnu.2009.03.002; Gardner D. K., 2004, Reproduction Fertility and Development, V16, P190, DOI 10.1071/RDv16n1Ab136; GfE (Gesellschaft fur Erna hrungsphysiologie), 2006, EMPF EN NAHRST SCHW; Govoni N, 2007, REPROD DOMEST ANIM, V42, P39, DOI 10.1111/j.1439-0531.2006.00722.x; GRUMMER RR, 1988, J ANIM SCI, V66, P3160; Guzik AC, 2006, J ANIM SCI, V84, P2251, DOI 10.2527/jas.2005-292; Halton TL, 2004, J AM COLL NUTR, V23, P373, DOI 10.1080/07315724.2004.10719381; Henson MC, 2006, BIOL REPROD, V74, P218, DOI 10.1095/biolreprod.105.045120; Jackson AA, 2001, AM J PHYSIOL-GASTR L, V281, pG1179, DOI 10.1152/ajpgi.2001.281.5.G1179; Jahoor F, 1996, J NUTR, V126, P1489, DOI 10.1093/jn/126.5.1489; Jia Y, 2010, J NUTR, V140, P1646, DOI 10.3945/jn.110.123034; Jindal R, 1997, J ANIM SCI, V75, P1063; Kalhan S C, 1999, Curr Opin Clin Nutr Metab Care, V2, P359, DOI 10.1097/00075197-199909000-00001; Kanitz E, 2009, PHYSIOL BEHAV, V98, P176, DOI 10.1016/j.physbeh.2009.05.007; Koopmans SJ, 2006, J ANIM SCI, V84, P963, DOI 10.2527/2006.844963x; Koopmans SJ, 2005, PHYSIOL BEHAV, V85, P469, DOI 10.1016/j.physbeh.2005.05.010; Kucia M, 2011, ANIMAL, V5, P268, DOI 10.1017/S1751731110001734; Lacroix M, 2004, AM J PHYSIOL-REG I, V287, pR934, DOI 10.1152/ajpregu.00100.2004; Lane M, 2003, BIOL REPROD, V69, P1109, DOI 10.1095/biolreprod.103.018093; Langley-Evans SC, 2001, P NUTR SOC, V60, P505, DOI 10.1079/PNS2001111; Markus CR, 2000, AM J CLIN NUTR, V71, P1536; Martens MJI, 2010, PHYSIOL BEHAV, V101, P563, DOI 10.1016/j.physbeh.2010.09.007; McConihay JA, 2000, J LIPID RES, V41, P424; McConihay JA, 2001, J LIPID RES, V42, P1111; McPherson RL, 2004, J ANIM SCI, V82, P2534; Meza-Herrera CA, 2010, REPROD DOMEST ANIM, V45, P723, DOI 10.1111/j.1439-0531.2009.01341.x; Mooradian AD, 2006, ENDOCR REV, V27, P2, DOI 10.1210/er.2005-0013; Musser RE, 2004, J ANIM SCI, V82, P3154; Nissen PM, 2005, ANIM SCI, V80, P299, DOI 10.1079/ASC40700299; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Okereke NC, 2004, AM J PHYSIOL-ENDOC M, V287, pE472, DOI 10.1152/ajpendo.00589.2003; Peters JC, 2008, J ANIM SCI, V86, P2247, DOI 10.2527/jas.2007-0431; Rehfeldt C, 2011, J ANIM SCI, V89, P329, DOI 10.2527/jas.2010-2970; Rehfeldt C, 2001, J ANIM SCI, V79, P1789; Rehfeldt C, 2012, EUR J NUTR, V51, P151, DOI 10.1007/s00394-011-0201-8; REMESY C, 1988, J NUTR, V118, P569, DOI 10.1093/jn/118.5.569; ROBERTSON HA, 1974, J REPROD FERTIL, V40, P133, DOI 10.1530/jrf.0.0400133; RODRIGUEZ H, 1983, ACTA VET SCAND, V24, P318; Sauerwein H, 2004, LIVEST PROD SCI, V87, P189, DOI 10.1016/j.livprodsci.2003.08.001; Schneider F, 2006, REPROD FERT DEVELOP, V18, P857, DOI 10.1071/RD06027; SCHOLL TO, 1994, AM J CLIN NUTR, V60, P183, DOI 10.1093/ajcn/60.2.183; Sferruzzi-Perri AN, 2011, J PHYSIOL-LONDON, V589, P7, DOI 10.1113/jphysiol.2010.198622; Spurlock ME, 2008, J NUTR, V138, P397, DOI 10.1093/jn/138.2.397; Stepien M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014664; Stepien M, 2010, J NUTR, V140, P939, DOI 10.3945/jn.109.120139; Toscano MJ, 2007, J ANIM SCI, V85, P441, DOI 10.2527/jas.2006-316; Wallace J, 2001, REPRODUCTION, V122, P347, DOI 10.1530/rep.0.1220347; Wallace JM, 2006, PLACENTA, V27, pS61, DOI 10.1016/j.placenta.2005.12.002; Wallace JM, 2010, BIOL REPROD, V82, P320, DOI 10.1095/biolreprod.109.080069; Wiseman TG, 2007, J ANIM SCI, V85, P1816, DOI 10.2527/jas.2006-406	56	35	37	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 6	2012	7	2							e31390	10.1371/journal.pone.0031390	http://dx.doi.org/10.1371/journal.pone.0031390			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917LV	22328932	gold, Green Published, Green Submitted			2023-01-03	WOS:000302179300018
J	Zhang, G; Guo, BS; Wu, H; Tang, T; Zhang, BT; Zheng, LZ; He, YX; Yang, ZJ; Pan, XH; Chow, H; To, K; Li, YP; Li, DH; Wang, XL; Wang, YX; Lee, K; Hou, ZB; Dong, N; Li, G; Leung, K; Hung, L; He, FC; Zhang, LQ; Qin, L				Zhang, Ge; Guo, Baosheng; Wu, Heng; Tang, Tao; Zhang, Bao-Ting; Zheng, Lizhen; He, Yixin; Yang, Zhijun; Pan, Xiaohua; Chow, Heelum; To, Kinwah; Li, Yaping; Li, Dahu; Wang, Xinluan; Wang, Yixiang; Lee, Kwongman; Hou, Zhibo; Dong, Nan; Li, Gang; Leung, Kwoksui; Hung, Leungkim; He, Fuchu; Zhang, Lingqiang; Qin, Ling			A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy	NATURE MEDICINE			English	Article							PARATHYROID-HORMONE; POSTMENOPAUSAL WOMEN; COMBINATION; ALENDRONATE; DEPOSITION; FRACTURES; DOMAINS	Metabolic skeletal disorders associated with impaired bone formation are a major clinical challenge. One approach to treat these defects is to silence bone-formation-inhibitory genes by small interference RNAs (siRNAs) in osteogenic-lineage cells that occupy the niche surrounding the bone-formation surfaces. We developed a targeting system involving dioleoyl trimethylammonium propane (DOTAP)-based cationic liposomes attached to six repetitive sequences of aspartate, serine, serine ((AspSerSer)(6)) for delivering siRNAs specifically to bone-formation surfaces. Using this system, we encapsulated an osteogenic siRNA that targets casein kinase-2 interacting protein-1 (encoded by Plekho1, also known as Plekho1). In vivo systemic delivery of Plekho1 siRNA in rats using our system resulted in the selective enrichment of the siRNAs in osteogenic cells and the subsequent depletion of Plekho1. A bioimaging analysis further showed that this approach markedly promoted bone formation, enhanced the bone micro-architecture and increased the bone mass in both healthy and osteoporotic rats. These results indicate (AspSerSer)(6)-liposome as a promising targeted delivery system for RNA interference- based bone anabolic therapy.	[Zhang, Ge; Guo, Baosheng; Wu, Heng; Tang, Tao; Zhang, Bao-Ting; Zheng, Lizhen; He, Yixin; Wang, Xinluan; Li, Gang; Leung, Kwoksui; Hung, Leungkim; Qin, Ling] Chinese Univ Hong Kong, Musculoskeletal Res Lab, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Bao-Ting] Chinese Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Yang, Zhijun] Hong Kong Baptist Univ, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Pan, Xiaohua] Ji Nan Univ, Dept Orthoped, Hosp Med Coll 2, Shenzhen Peoples Hosp, Shenzhen, Peoples R China; [Chow, Heelum; To, Kinwah] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Hong Kong, Peoples R China; [Li, Yaping] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Delivery Syst, Shanghai 200031, Peoples R China; [Li, Dahu; He, Fuchu; Zhang, Lingqiang] Beijing Inst Radiat Med, State Key Lab Prote, Beijing Proteome Res Ctr, Beijing, Peoples R China; [Wang, Yixiang] Chinese Univ Hong Kong, Dept Imaging & Intervent Radiol, Hong Kong, Hong Kong, Peoples R China; [Lee, Kwongman] Chinese Univ Hong Kong, Lee Hysan Clin Res Lab, Hong Kong, Hong Kong, Peoples R China; [Hou, Zhibo] Jinan Univ, Biomed Res & Dev Ctr, Guangdong Prov Key Lab Bioengn Med, Natl Engn Res Ctr Genet Med, Guangzhou, Guangdong, Peoples R China; [Dong, Nan] Nankai Univ, Inst Mol Biol, Tianjin, Peoples R China; [Qin, Ling] Shenzhen Inst Adv Technol, Translat Med Res & Dev Ctr, Inst Biomed & Hlth Engn, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Baptist University; Jinan University; Chinese University of Hong Kong; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Academy of Military Medical Sciences - China; Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Nankai University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Qin, L (corresponding author), Chinese Univ Hong Kong, Musculoskeletal Res Lab, Dept Orthopaed & Traumatol, Hong Kong, Hong Kong, Peoples R China.	zhangge@ort.cuhk.edu.hk; zhanglq@nic.bmi.ac.cn; lingqin@cuhk.edu.hk	Zhang, Baoting/B-6273-2015; GUO, Baosheng/M-6023-2013; Li, Gang/J-7830-2018; Zheng, Lizhen/C-6550-2014; Wang, Yi Xiang/I-5952-2016; To, Kenneth K W/M-4500-2013; Zhang, Ge/K-9118-2019; Guo, Baosheng/ABD-4800-2021; Qin, Ling/J-9047-2018; Zhang, Ge/N-4150-2013	Li, Gang/0000-0002-3981-2239; Wang, Yi Xiang/0000-0001-5697-0717; To, Kenneth K W/0000-0003-2755-0283; Zhang, Ge/0000-0002-7807-7695; Guo, Baosheng/0000-0002-4510-5418; Qin, Ling/0000-0001-6173-6167; Zhang, Ge/0000-0002-7807-7695; Zhang, Bao-Ting/0000-0003-1421-0212; Yang, Zhijun/0000-0002-6094-0438; Zhang, Lingqiang/0000-0002-9795-2141	Chinese National Basic Research Programs [2011CB910602]; Hong Kong Competitive Earmarked Research Grant [CUHK479111, 473011]; Faculty of Medicine of the Chinese University of Hong Kong [2041478, 2041525]; Hong Kong Baptist University [31-08-089]; Chinese National Natural Science Foundation [30830029]; National Key Technologies Research and Development Program for New Drugs [2009ZX09503-002]	Chinese National Basic Research Programs(National Basic Research Program of China); Hong Kong Competitive Earmarked Research Grant; Faculty of Medicine of the Chinese University of Hong Kong; Hong Kong Baptist University; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Key Technologies Research and Development Program for New Drugs	We thank X.-H. Yang for technical support with the confocal imaging, H. Yang for technical support with the flow cytometry and F.C. Chun-Wan for assistance with the bone histomorphometry. This study was supported by the Chinese National Basic Research Programs (2011CB910602), the Hong Kong Competitive Earmarked Research Grant (CUHK479111 and 473011), the Direct Grant of Faculty of Medicine of the Chinese University of Hong Kong (2041478 and 2041525), the Faculty Research Grant of Hong Kong Baptist University (31-08-089), the Chinese National Natural Science Foundation Project (30830029) and the National Key Technologies Research and Development Program for New Drugs (2009ZX09503-002).	Aubin J., 2002, PEDIAT BONE, P43; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157; CULLIS P R, 1989, Advanced Drug Delivery Reviews, V3, P267, DOI 10.1016/0169-409X(89)90024-0; Federman N, 2010, PEDIATR RES, V67, P514, DOI 10.1203/PDR.0b013e3181d601c5; Gronthos S, 1999, J BONE MINER RES, V14, P47, DOI 10.1359/jbmr.1999.14.1.47; Hoang QQ, 2003, NATURE, V425, P977, DOI 10.1038/nature02079; Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004-0006; Ishikawa S, 2004, INT IMMUNOL, V16, P1019, DOI 10.1093/intimm/dxh103; Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Lopez-Fraga M, 2009, BIODRUGS, V23, P305, DOI 10.2165/11318190-000000000-00000; Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760; Midura RJ, 2004, J BIOL CHEM, V279, P25464, DOI 10.1074/jbc.M312409200; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; POSNER AS, 1975, ACCOUNTS CHEM RES, V8, P273, DOI 10.1021/ar50092a003; Steitz SA, 2002, AM J PATHOL, V161, P2035, DOI 10.1016/S0002-9440(10)64482-3; STUART AJ, 1992, AVIAN DIS, V36, P447, DOI 10.2307/1591527; Takahashi-Nishioka Tatsuo, 2008, Curr Drug Discov Technol, V5, P39; Vegni FE, 2004, NEW ENGL J MED, V350, P189; Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011; Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j; Wang D, 2007, BIOCONJUGATE CHEM, V18, P1375, DOI 10.1021/bc7002132; Wang GL, 2010, J DRUG TARGET, V18, P611, DOI 10.3109/10611861003622560; Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223-009-9312-0; Zhang LQ, 2007, CELL SIGNAL, V19, P932, DOI 10.1016/j.cellsig.2006.11.002	28	285	302	7	200	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2012	18	2					307	314		10.1038/nm.2617	http://dx.doi.org/10.1038/nm.2617			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	890JG	22286306				2023-01-03	WOS:000300140300048
J	Rando, TA; Chang, HY				Rando, Thomas A.; Chang, Howard Y.			Aging, Rejuvenation, and Epigenetic Reprogramming: Resetting the Aging Clock	CELL			English	Review							EXTENDS LIFE-SPAN; STEM-CELLS; GENE-EXPRESSION; CALORIE RESTRICTION; GENOMIC INSTABILITY; HEMATOPOIETIC STEM; DNA METHYLATION; NONCODING RNA; SOMATIC-CELLS; PLURIPOTENCY	The underlying cause of aging remains one of the central mysteries of biology. Recent studies in several different systems suggest that not only may the rate of aging be modified by environmental and genetic factors, but also that the aging clock can be reversed, restoring characteristics of youthfulness to aged cells and tissues. This Review focuses on the emerging biology of rejuvenation through the lens of epigenetic reprogramming. By defining youthfulness and senescence as epigenetic states, a framework for asking new questions about the aging process emerges.	[Rando, Thomas A.; Chang, Howard Y.] Stanford Univ, Sch Med, Glenn Labs Biol Aging, Stanford, CA 94305 USA; [Rando, Thomas A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Chang, Howard Y.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Chang, Howard Y.] Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; [Rando, Thomas A.] VA Palo Alto Hlth Care Syst, RR&D Ctr Excellence, Palo Alto, CA 94304 USA; [Rando, Thomas A.] VA Palo Alto Hlth Care Syst, Neurol Serv, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Rando, TA (corresponding author), Stanford Univ, Sch Med, Glenn Labs Biol Aging, Stanford, CA 94305 USA.	rando@stanford.edu; howchang@stanford.edu		Rando, Thomas/0000-0001-5843-8564	Glenn Foundation for Medical Research; NIH [P01 AG036695, R37 AG23806]; Ellison Medical Foundation; NATIONAL INSTITUTE ON AGING [R01AG023806, R37AG023806, P01AG036695] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000392] Funding Source: NIH RePORTER	Glenn Foundation for Medical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the Glenn Foundation for Medical Research and from the NIH (P01 AG036695, R37 AG23806, and an NIH Director's Pioneer Award) to T.A.R. and by a grant to H.Y.C. from the Ellison Medical Foundation. H.Y.C. is an Early Career Scientist of the Howard Hughes Medical Institute. The authors would like to thank Dr. Ami Okada and Jamie Brett for useful comments on the manuscript.	Adler AS, 2007, GENE DEV, V21, P3244, DOI 10.1101/gad.1588507; Agarwal S, 2010, NATURE, V464, P292, DOI 10.1038/nature08792; Agger K., 2009, GENE DEV, V23, P1171; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Barradas M., 2009, GENE DEV, V23, P1177; Batista LFZ, 2011, NATURE, V474, P399, DOI 10.1038/nature10084; Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; BRIGGS R, 1952, P NATL ACAD SCI USA, V38, P455, DOI 10.1073/pnas.38.5.455; Bunster E, 1933, ANAT REC, V57, P339, DOI 10.1002/ar.1090570404; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; Campisi J, 2009, J GERONTOL A-BIOL, V64, P175, DOI 10.1093/gerona/gln065; CANO RJ, 1995, SCIENCE, V268, P1060, DOI 10.1126/science.7538699; Carlson ME, 2008, NATURE, V454, P528, DOI 10.1038/nature07034; Charville GW, 2011, PHILOS T R SOC B, V366, P85, DOI 10.1098/rstb.2010.0279; Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085; De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019; Dhawan S, 2009, GENE DEV, V23, P906, DOI 10.1101/gad.1742609; Dodd IB, 2007, CELL, V129, P813, DOI 10.1016/j.cell.2007.02.053; Donohoe ME, 2009, NATURE, V460, P128, DOI 10.1038/nature08098; Douglas PM, 2010, J CELL BIOL, V190, P719, DOI 10.1083/jcb.201005144; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; Fielenbach N, 2008, GENE DEV, V22, P2149, DOI 10.1101/gad.1701508; FINERTY JC, 1952, PHYSIOL REV, V32, P277, DOI 10.1152/physrev.1952.32.3.277; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Garinis GA, 2008, NAT CELL BIOL, V10, P1241, DOI 10.1038/ncb1108-1241; Girton JR, 2008, ADV GENET, V61, P1, DOI 10.1016/S0065-2660(07)00001-6; Greer EL, 2011, NATURE, V479, P365, DOI 10.1038/nature10572; Greer EL, 2010, NATURE, V466, P383, DOI 10.1038/nature09195; Guarente L, 2007, COLD SPRING HARB SYM, V72, P483, DOI 10.1101/sqb.2007.72.024; GURDON JB, 1962, DEV BIOL, V4, P256, DOI 10.1016/0012-1606(62)90043-X; Haigis MC, 2010, MOL CELL, V40, P333, DOI 10.1016/j.molcel.2010.10.002; Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hayflick L, 2007, ANN NY ACAD SCI, V1100, P1, DOI 10.1196/annals.1395.001; Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235; Hung T, 2010, RNA BIOL, V7, P582, DOI 10.4161/rna.7.5.13216; Ieda M, 2010, CELL, V142, P375, DOI 10.1016/j.cell.2010.07.002; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; Jones DL, 2011, NAT CELL BIOL, V13, P506, DOI 10.1038/ncb0511-506; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kauffman AL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000372; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; Kirkwood TBL, 2010, ANN NY ACAD SCI, V1204, P21, DOI 10.1111/j.1749-6632.2010.05520.x; Koga H, 2011, AGEING RES REV, V10, P205, DOI 10.1016/j.arr.2010.02.001; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krizhanovsky V, 2009, NATURE, V460, P1085, DOI 10.1038/4601085a; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee JH, 2009, HUM MOL GENET, V18, P2567, DOI 10.1093/hmg/ddp188; Lee JH, 2009, HUM MOL GENET, V18, P835, DOI 10.1093/hmg/ddn409; Lee N, 2005, NATURE, V438, P234, DOI 10.1038/nature04120; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu L, 2011, J CELL BIOL, V193, P257, DOI 10.1083/jcb.201010131; Loh KM, 2010, CELL STEM CELL, V7, P137, DOI 10.1016/j.stem.2010.07.005; Luo SJ, 2010, CELL, V143, P299, DOI 10.1016/j.cell.2010.09.013; Maegawa S, 2010, GENOME RES, V20, P332, DOI 10.1101/gr.096826.109; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Marion RM, 2010, CURR OPIN GENET DEV, V20, P190, DOI 10.1016/j.gde.2010.01.005; Martin GM, 2009, AGING CELL, V8, P761, DOI 10.1111/j.1474-9726.2009.00515.x; MCCAY CM, 1957, GERONTOLOGY, V1, P7, DOI 10.1159/000210677; Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Mikkelsen TS, 2008, NATURE, V454, P49, DOI 10.1038/nature07056; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Murgatroyd C, 2010, AGING-US, V2, P107; Navarro P, 2008, SCIENCE, V321, P1693, DOI 10.1126/science.1160952; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oberdoerffer P, 2007, NAT REV MOL CELL BIO, V8, P692, DOI 10.1038/nrm2238; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Ouyang ZQ, 2010, CELL STEM CELL, V7, P649, DOI 10.1016/j.stem.2010.11.018; Piccolo FM, 2011, PHILOS T R SOC B, V366, P2260, DOI 10.1098/rstb.2011.0004; Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692; Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023; Rando OJ, 2009, ANNU REV BIOCHEM, V78, P245, DOI 10.1146/annurev.biochem.78.071107.134639; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rossant J, 2001, STEM CELLS, V19, P477, DOI 10.1634/stemcells.19-6-477; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Sallon S, 2008, SCIENCE, V320, P1464, DOI 10.1126/science.1153600; Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683; Seviour EG, 2010, AGING-US, V2, P900, DOI 10.18632/aging.100248; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Stadtfeld M, 2010, GENE DEV, V24, P2239, DOI 10.1101/gad.1963910; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAUCHI H, 1977, MECH AGEING DEV, V6, P333, DOI 10.1016/0047-6374(77)90034-3; Tennen RI, 2011, TRENDS BIOCHEM SCI, V36, P39, DOI 10.1016/j.tibs.2010.07.009; Terranova R, 2006, J CELL SCI, V119, P2065, DOI 10.1242/jcs.02945; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016; Vaquero A, 2009, GENE DEV, V23, P1849, DOI 10.1101/gad.1807009; Vastenhouw NL, 2010, NATURE, V464, P922, DOI 10.1038/nature08866; Vijg J, 2005, ANN NY ACAD SCI, V1055, P35, DOI 10.1196/annals.1323.007; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vreeland RH, 2000, NATURE, V407, P897, DOI 10.1038/35038060; Wang MC, 2008, SCIENCE, V322, P957, DOI 10.1126/science.1162011; Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154; Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032; Zeng XM, 2007, STEM CELL REV, V3, P270, DOI 10.1007/s12015-007-9005-x	113	338	360	1	124	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 20	2012	148	1-2					46	57		10.1016/j.cell.2012.01.003	http://dx.doi.org/10.1016/j.cell.2012.01.003			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	882DC	22265401	Green Accepted, Bronze			2023-01-03	WOS:000299540700013
J	Bronfort, G; Evans, R; Anderson, AV; Svendsen, KH; Bracha, Y; Grimm, RH				Bronfort, Gert; Evans, Roni; Anderson, Alfred V.; Svendsen, Kenneth H.; Bracha, Yiscah; Grimm, Richard H.			Spinal Manipulation, Medication, or Home Exercise With Advice for Acute and Subacute Neck Pain A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; 2000-2010 TASK-FORCE; WHIPLASH-ASSOCIATED DISORDERS; CLINICAL-TRIAL; MANUAL THERAPY; PHYSICAL-THERAPY; GENERAL-PRACTITIONER; COVARIATE ADJUSTMENT; CHIROPRACTIC CARE; DISABILITY INDEX	Background: Mechanical neck pain is a common condition that affects an estimated 70% of persons at some point in their lives. Little research exists to guide the choice of therapy for acute and subacute neck pain. Objective: To determine the relative efficacy of spinal manipulation therapy (SMT), medication, and home exercise with advice (HEA) for acute and subacute neck pain in both the short and long term. Design: Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00029770) Setting: 1 university research center and 1 pain management clinic in Minnesota. Participants: 272 persons aged 18 to 65 years who had nonspecific neck pain for 2 to 12 weeks. Intervention: 12 weeks of SMT, medication, or HEA. Measurements: The primary outcome was participant-rated pain, measured at 2, 4, 8, 12, 26, and 52 weeks after randomization. Secondary measures were self-reported disability, global improvement, medication use, satisfaction, general health status (Short Form-36 Health Survey physical and mental health scales), and adverse events. Blinded evaluation of neck motion was performed at 4 and 12 weeks. Results: For pain, SMT had a statistically significant advantage over medication after 8, 12, 26, and 52 weeks (P <= 0.010), and HEA was superior to medication at 26 weeks (P = 0.02). No important differences in pain were found between SMT and HEA at any time point. Results for most of the secondary outcomes were similar to those of the primary outcome. Limitations: Participants and providers could not be blinded. No specific criteria for defining clinically important group differences were prespecified or available from the literature. Conclusion: For participants with acute and subacute neck pain, SMT was more effective than medication in both the short and long term. However, a few instructional sessions of HEA resulted in similar outcomes at most time points.	NW Hlth Sci Univ, Pain Management & Rehabil Ctr, Minneapolis, MN USA; Minneapolis Med Res Fdn Inc, Berman Ctr Outcomes & Clin Res, Minneapolis, MN 55404 USA	Minneapolis Medical Research Foundation	Bronfort, G (corresponding author), NW Hlth Sci Univ, Wolfe Harris Ctr Clin Studies, 2501 W 84th St, Bloomington, MN 55431 USA.	gbronfort@nwhealth.edu			National Institutes of Health's National Center for Complementary and Alternative Medicine [R01 AT000707]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000707] Funding Source: NIH RePORTER	National Institutes of Health's National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	By the National Institutes of Health's National Center for Complementary and Alternative Medicine (grant R01 AT000707).	Barnes PM, 2004, ADV DATA, P1; Bendtsen L, 2010, CEPHALALGIA, V30, P1, DOI 10.1111/j.1468-2982.2009.01948.x; Bergmann TF, 2011, CHIROPRACTIC TECHNIQ, V3rd; Bronfort G, 1996, J Manipulative Physiol Ther, V19, P570; Bronfort G, 2001, SPINE, V26, P788, DOI 10.1097/00007632-200104010-00020; Brown H., 1999, APPL MIXED MODELS ME; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; Cleland JA, 2007, PHYS THER, V87, P431, DOI 10.2522/ptj.20060217; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Cote P, 2008, SPINE, V33, pS60, DOI 10.1097/BRS.0b013e3181643ee4; Cote P, 2008, SPINE, V33, pS192, DOI 10.1097/BRS.0b013e3181644616; Coulter ID, 2002, SPINE, V27, P291, DOI 10.1097/00007632-200202010-00018; Daffner SD, 2003, SPINE, V28, P2030, DOI 10.1097/01.BRS.0000083325.27357.39; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DVORAK J, 1992, SPINE, V17, pS393, DOI 10.1097/00007632-199210001-00009; Dworkin RH, 2009, PAIN, V146, P238, DOI 10.1016/j.pain.2009.08.019; Evans R, 2003, J MANIP PHYSIOL THER, V26, P403, DOI 10.1016/S0161-4754(03)00093-9; Evans R, 2002, SPINE, V27, P2383, DOI 10.1097/00007632-200211010-00013; Fejer R, 2006, EUR SPINE J, V15, P834, DOI 10.1007/s00586-004-0864-4; Fritz JM, 2009, SPINE, V34, P2803, DOI 10.1097/BRS.0b013e3181ae2bd4; Gross A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004249.pub3; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Guzman J, 2008, SPINE, V33, pS14, DOI 10.1097/BRS.0b013e3181643efb; Guzman J, 2008, SPINE, V33, pS199, DOI 10.1097/BRS.0b013e3181644641; Haines T.A., 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD004249.PUB2; HANSEN FR, 1993, SPINE, V18, P98, DOI 10.1097/00007632-199301000-00015; Hill J, 2004, SPINE, V29, P1648, DOI 10.1097/01.BRS.0000132307.06321.3C; Hogg-Johnson S, 2008, SPINE, V33, pS39, DOI 10.1097/BRS.0b013e31816454c8; Hoving JL, 2006, CLIN J PAIN, V22, P370, DOI 10.1097/01.ajp.0000180185.79382.3f; Hoving JL, 2002, ANN INTERN MED, V136, P713, DOI 10.7326/0003-4819-136-10-200205210-00006; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JAESCHKE R, 1990, CONTROL CLIN TRIALS, V11, P43, DOI 10.1016/0197-2456(90)90031-V; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kay TM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004250.pub3; KOES BW, 1992, J MANIP PHYSIOL THER, V15, P16; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Linton SJ, 1998, SPINE, V23, P1457, DOI 10.1097/00007632-199807010-00006; Littell R.C., 1996, SAS SYSTEMS MIXED MO; Little R. J., 2019, STAT ANAL MISSING DA, V793; Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656; McKenzie R, 2002, TREAT YOUR OWN NECK; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Peloso P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000319.pub4; Petersen CM, 2000, MANUAL THER, V5, P82, DOI 10.1054/math.2000.0232; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Pocock SJ, 1986, CLIN TRIALS PRACTICA; Pool JJM, 2007, SPINE, V32, P3047, DOI 10.1097/BRS.0b013e31815cf75b; Pool JJM, 2006, MANUAL THER, V11, P297, DOI 10.1016/j.math.2005.07.006; Riddle DL, 2007, SPINE, V32, P132, DOI 10.1097/01.brs.0000250999.69978.24; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Scholten-Peeters GGM, 2002, SPINE, V27, P412, DOI 10.1097/00007632-200202150-00018; Seffinger MA, 2004, SPINE, V29, pE413, DOI 10.1097/01.brs.0000141178.98157.8e; Sherman KJ, 2009, CLIN J PAIN, V25, P233, DOI 10.1097/AJP.0b013e31818b7912; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; SPITZER WO, 1995, SPINE, V20, pS1; Tierney LM, 1997, CURRENT MED DIAGNOSI; Verbeke G, 1997, LINEAR MIXED MODELS; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Yu LM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-59	61	109	114	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 3	2012	156	1	1				1	U47		10.7326/0003-4819-156-1-201201030-00002	http://dx.doi.org/10.7326/0003-4819-156-1-201201030-00002			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872VK	22213489				2023-01-03	WOS:000298837600001
J	Graves, JA; Curtis, R; Gruber, J				Graves, John A.; Curtis, Rick; Gruber, Jonathan			Balancing Coverage Affordability and Continuity under a Basic Health Program Option	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Graves, John A.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Curtis, Rick] Inst Hlth Policy Solut, Washington, DC USA; [Gruber, Jonathan] MIT, Cambridge, MA 02139 USA	Vanderbilt University; Massachusetts Institute of Technology (MIT)	Graves, JA (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.							Short PF, 2011, REALIZING HLTH REFOR; Sommers BD, 2011, HEALTH AFFAIR, V30, P228, DOI 10.1377/hlthaff.2010.1000	2	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					E44	U107		10.1056/NEJMp1111863	http://dx.doi.org/10.1056/NEJMp1111863			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	861PN	22129219				2023-01-03	WOS:000298031800005
J	Daniel, SB; Lovegrove, MC; Shehab, N; Richards, CL				Budnitz, Daniel S.; Lovegrove, Maribeth C.; Shehab, Nadine; Richards, Chesley L.			Emergency Hospitalizations for Adverse Drug Events in Older Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPARTMENT VISITS; MEDICATION USE; ADMISSIONS; SURVEILLANCE; SAFETY	BACKGROUND Adverse drug events are important preventable causes of hospitalization in older adults. However, nationally representative data on adverse drug events that result in hospitalization in this population have been limited. METHODS We used adverse-event data from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project (2007 through 2009) to estimate the frequency and rates of hospitalization after emergency department visits for adverse drug events in older adults and to assess the contribution of specific medications, including those identified as high-risk or potentially inappropriate by national quality measures. RESULTS On the basis of 5077 cases identified in our sample, there were an estimated 99,628 emergency hospitalizations (95% confidence interval [CI], 55,531 to 143,724) for adverse drug events in U. S. adults 65 years of age or older each year from 2007 through 2009. Nearly half of these hospitalizations were among adults 80 years of age or older (48.1%; 95% CI, 44.6 to 51.6). Nearly two thirds of hospitalizations were due to unintentional overdoses (65.7%; 95% CI, 60.1 to 71.3). Four medications or medication classes were implicated alone or in combination in 67.0% (95% CI, 60.0 to 74.1) of hospitalizations: warfarin (33.3%), insulins (13.9%), oral antiplatelet agents (13.3%), and oral hypoglycemic agents (10.7%). High-risk medications were implicated in only 1.2% (95% CI, 0.7 to 1.7) of hospitalizations. CONCLUSIONS Most emergency hospitalizations for recognized adverse drug events in older adults resulted from a few commonly used medications, and relatively few resulted from medications typically designated as high-risk or inappropriate. Improved management of antithrombotic and antidiabetic drugs has the potential to reduce hospitalizations for adverse drug events in older adults.	[Budnitz, Daniel S.; Lovegrove, Maribeth C.; Shehab, Nadine] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA; [Richards, Chesley L.] Ctr Dis Control & Prevent, Off Prevent Healthcare, Atlanta, GA 30333 USA; [Richards, Chesley L.] Emory Univ, Sch Med, Div Geriatr & Gerontol, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	Daniel, SB (corresponding author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-24, Atlanta, GA 30333 USA.	dbudnitz@cdc.gov	Hug, Balthasar L./G-1568-2010	Shehab, Nadine/0000-0001-8700-8539; Budnitz, Daniel/0000-0002-0136-2623				Agency for Healthcare Research and Quality, HCUPNET HEALTHC COST; [Anonymous], HEALTHC EFF DAT INF; [Anonymous], PATT MED US US 2006; [Anonymous], 2002, NAT EL INJ SURV SYST; Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Budnitz DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; Buie VC, 2010, VITAL HLTH STAT, V13, P168; Burt CW, 2002, HEALTH AFFAIR, V21, P206, DOI 10.1377/hlthaff.21.4.206; Centers for Disease Control and Prevention, BRIDG RAC POP EST US; Centers for Disease Control and Prevention, AMB HLTH CAR DAT; Curtiss FR, 2011, J MANAGE CARE PHARM, V17, P60, DOI 10.18553/jmcp.2011.17.1.60; ElDesoky Ehab S, 2007, Am J Ther, V14, P488, DOI 10.1097/01.mjt.0000183719.84390.4d; Fick, 2004, ARCH INTERN MED, V164, P298; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Gage BF, 2009, NEW ENGL J MED, V361, P1200, DOI 10.1056/NEJMe0906886; Goulding MR, 2004, ARCH INTERN MED, V164, P305, DOI 10.1001/archinte.164.3.305; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; HealthCare. gov, PARTN PAT BETT CAR L; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Jha AK, 2001, PHARMACOEPIDEM DR S, V10, P113, DOI 10.1002/pds.568; Jhung MA, 2007, MED CARE, V45, pS96, DOI 10.1097/MLR.0b013e318041f737; Kim MM, 2010, PHARMACOEPIDEM DR S, V19, P731, DOI 10.1002/pds.1953; Kish L, 1995, SCI 1995; Kocher R, 2010, ANN INTERN MED, V153, P536, DOI 10.7326/0003-4819-153-8-201010190-00274; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; McLean AJ, 2004, PHARMACOL REV, V56, P163, DOI 10.1124/pr.56.2.4; National Quality Forum, NQF END STAND; Onder G, 2002, J AM GERIATR SOC, V50, P1962, DOI 10.1046/j.1532-5415.2002.50607.x; Page Robert L 2nd, 2006, Am J Geriatr Pharmacother, V4, P297; Pogach L, 2010, JAMA-J AM MED ASSOC, V303, P2076, DOI 10.1001/jama.2010.655; Shehab N, 2010, ARCH INTERN MED, V170, P1926, DOI 10.1001/archinternmed.2010.407; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Spinler SA, 2009, PHARMACOTHERAPY, V29, P812, DOI 10.1592/phco.29.7.812; Steinman MA, 2011, J AM GERIATR SOC, V59, P1513, DOI 10.1111/j.1532-5415.2011.03500.x; Streiff MB, 2010, ANN PHARMACOTHER, V44, P733, DOI 10.1345/aph.1M666; Wachter RM, 2010, HEALTH AFFAIR, V29, P165, DOI 10.1377/hlthaff.2009.0785; Wears RL, 2010, ANN EMERG MED, V55, P511, DOI 10.1016/j.annemergmed.2010.01.018; Wu WK, 2003, AM J HEALTH-SYST PH, V60, P253, DOI 10.1093/ajhp/60.3.253; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	41	1085	1114	1	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2011	365	21					2002	2012		10.1056/NEJMsa1103053	http://dx.doi.org/10.1056/NEJMsa1103053			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	851PF	22111719	Bronze			2023-01-03	WOS:000297282600010
J	Tanner, M				Tanner, Michael			Review: Pregabalin and other drugs reduce pain in patients with painful diabetic neuropathy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NYU Med Ctr, Bellevue Hosp, New York, NY 10016 USA	Bellevue Hospital Center; New York University	Tanner, M (corresponding author), NYU Med Ctr, Bellevue Hosp, New York, NY 10016 USA.			Tanner, Michael/0000-0002-3012-8641				SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401	1	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-8	10.7326/0003-4819-155-10-201111150-02008	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084355				2023-01-03	WOS:000208885300007
J	Feng, B; Jiao, P; Nie, YH; Kim, T; Jun, DL; van Rooijen, N; Yang, ZQ; Xu, HY				Feng, Bin; Jiao, Ping; Nie, Yaohui; Kim, Thomas; Jun, Dale; van Rooijen, Nico; Yang, Zaiqing; Xu, Haiyan			Clodronate Liposomes Improve Metabolic Profile and Reduce Visceral Adipose Macrophage Content in Diet-Induced Obese Mice	PLOS ONE			English	Article							INSULIN-RESISTANCE ATHEROSCLEROSIS; NECROSIS-FACTOR-ALPHA; FATTY LIVER; ADIPONECTIN EXPRESSION; HEPATIC STEATOSIS; 3T3-L1 ADIPOCYTES; IMMUNE-RESPONSE; PROTEIN-KINASE; TNF-ALPHA; T-CELLS	Background: Obesity-related adipose inflammation has been thought to be a causal factor for the development of insulin resistance and type 2 diabetes. Infiltrated macrophages in adipose tissue of obese animals and humans are an important source for inflammatory cytokines. Clodronate liposomes can ablate macrophages by inducing apoptosis. In this study, we aim to determine whether peritoneal injection of clodronate liposomes has any beneficial effect on systemic glucose homeostasis/insulin sensitivity and whether macrophage content in visceral adipose tissue will be reduced in diet-induced obese (DIO) mice. Methodology/Principal Findings: Clodronate liposomes were used to deplete macrophages in lean and DIO mice. Macrophage content in visceral adipose tissue, metabolic parameters, glucose and insulin tolerance, adipose and liver histology, adipokine and cytokine production were examined. Hyperinsulinemic-euglycemic clamp study was also performed to assess systemic insulin sensitivity. Peritoneal injection of clodronate liposomes significantly reduced blood glucose and insulin levels in DIO mice. Systemic glucose tolerance and insulin sensitivity were mildly improved in both lean and DIO mice treated with clodronate liposomes by intraperitoneal (ip) injection. Hepatosteatosis was dramatically alleviated and suppression of hepatic glucose output was markedly increased in DIO mice treated with clodronate liposomes. Macrophage content in visceral adipose tissue of DIO mice was effectively decreased without affecting subcutaneous adipose tissue. Interestingly, levels of insulin sensitizing hormone adiponectin, including the high molecular weight form, were significantly elevated in circulation. Conclusions/Significance: Intraperitoneal injection of clodronate liposomes reduces visceral adipose tissue macrophages, improves systemic glucose homeostasis and insulin sensitivity in DIO mice, which can be partially attributable to increased adiponectin levels.	[Feng, Bin; Yang, Zaiqing] Huazhong Agr Univ, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Coll Life Sci & Technol, Wuhan, Peoples R China; [van Rooijen, Nico] Vrije Univ Amsterdam, Dept Mol Cell Biol, Fac Med, Amsterdam, Netherlands; [Feng, Bin; Jiao, Ping; Nie, Yaohui; Kim, Thomas; Jun, Dale; Xu, Haiyan] Brown Univ, Alpert Med Sch, Hallett Ctr Diabet & Endocrinol, Providence, RI 02912 USA	Huazhong Agricultural University; Vrije Universiteit Amsterdam; Brown University	Feng, B (corresponding author), Huazhong Agr Univ, Key Lab Agr Anim Genet Breeding & Reprod, Minist Educ, Coll Life Sci & Technol, Wuhan, Peoples R China.	HXu@Lifespan.org	Van Rooijen, Nico/Z-1578-2019		American Heart Association; China Scholarship Council	American Heart Association(American Heart Association); China Scholarship Council(China Scholarship Council)	Dr. Xu received a scientist development grant from the American Heart Association. Dr. Feng received a scholarship from China Scholarship Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asano T, 2009, J GASTROEN HEPATOL, V24, P1669, DOI 10.1111/j.1440-1746.2009.06039.x; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Clementi AH, 2009, BBA-MOL BASIS DIS, V1792, P1062, DOI 10.1016/j.bbadis.2009.08.007; Elgazar-Carmon V, 2008, J LIPID RES, V49, P1894, DOI 10.1194/jlr.M800132-JLR200; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Ghanim H, 2004, CIRCULATION, V110, P1564, DOI 10.1161/01.CIR.0000142055.53122.FA; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; Hajri T, 2011, AM J PHYSIOL-ENDOC M, V300, pE350, DOI 10.1152/ajpendo.00307.2010; Hirasaka K, 2007, DIABETES, V56, P2511, DOI 10.2337/db06-1768; Hotamisligil GS, 2008, NAT REV IMMUNOL, V8, P923, DOI 10.1038/nri2449; Kamei N, 2006, J BIOL CHEM, V281, P26602, DOI 10.1074/jbc.M601284200; Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498; Kim K, 2005, BIOCHEM BIOPH RES CO, V327, P460, DOI 10.1016/j.bbrc.2004.12.026; Komai Norio, 2007, Mod Rheumatol, V17, P385; Kosteli A, 2010, J CLIN INVEST, V120, P3466, DOI 10.1172/JCI42845; Lanthier N, 2010, AM J PHYSIOL-GASTR L, V298, pG107, DOI 10.1152/ajpgi.00391.2009; Lim JY, 2008, FEBS LETT, V582, P3473, DOI 10.1016/j.febslet.2008.09.012; Liu J, 2009, NAT MED, V15, P940, DOI 10.1038/nm.1994; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Nara N, 2007, J BIOL CHEM, V282, P30794, DOI 10.1074/jbc.M700412200; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Nomiyama T, 2007, J CLIN INVEST, V117, P2877, DOI 10.1172/JCI31986; Patsouris D, 2008, CELL METAB, V8, P301, DOI 10.1016/j.cmet.2008.08.015; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Polyzos SA, 2010, DIABETES OBES METAB, V12, P365, DOI 10.1111/j.1463-1326.2009.01176.x; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Schenk S, 2008, J CLIN INVEST, V118, P2992, DOI 10.1172/JCI34260; Shen Z, 2010, AM J PHYSIOL-GASTR L, V298, pG364, DOI 10.1152/ajpgi.00456.2009; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Stofkova A, 2009, Endocr Regul, V43, P157; SU D, 1989, IMMUNOLOGY, V66, P466; van Rooijen N, 2003, METHOD ENZYMOL, V373, P3; VanRooijen N, 1996, HEPATOLOGY, V23, P1239; Vozarova B, 2002, DIABETES, V51, P455, DOI 10.2337/diabetes.51.2.455; Wang Y, 2009, ARQ BRAS ENDOCRINOL, V53, P201, DOI 10.1590/S0004-27302009000200012; Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Zhang HR, 2010, ARTERIOSCL THROM VAS, V30, P2156, DOI 10.1161/ATVBAHA.110.214700	44	85	87	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 12	2011	6	9							e24358	10.1371/journal.pone.0024358	http://dx.doi.org/10.1371/journal.pone.0024358			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CO	21931688	Green Published, Green Submitted, gold			2023-01-03	WOS:000294803200015
J	Schnipper, JL; Rothschild, JM				Schnipper, Jeffrey L.; Rothschild, Jeffrey M.			Improving medication safety	LANCET			English	Editorial Material							INFORMATION-TECHNOLOGY; EVENTS; CARE; HOME		[Schnipper, Jeffrey L.; Rothschild, Jeffrey M.] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital	Rothschild, JM (corresponding author), Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA.	jrothschild@partners.org						Avery AJ, 2012, LANCET, V379, P1310, DOI 10.1016/S0140-6736(11)61817-5; Bates DW, 2010, HEALTH AFFAIR, V29, P614, DOI 10.1377/hlthaff.2010.0007; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Berwick DM, 2011, NEW ENGL J MED, V365, P1753, DOI 10.1056/NEJMp1111671; Blumenthal D, 2010, NEW ENGL J MED, V362, P382, DOI 10.1056/NEJMp0912825; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Institute of Medicine, 2011, HLTH IT PAT SAF BUIL; Kaboli PJ, 2006, ARCH INTERN MED, V166, P955, DOI 10.1001/archinte.166.9.955; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Schnipper JL, 2011, ARCH INTERN MED, V171, P1019, DOI 10.1001/archinternmed.2011.220; Schnipper JL, 2010, AM J MANAG CARE, V16, pSP72; Simon SR, 2009, J AM MED INFORM ASSN, V16, P465, DOI 10.1197/jamia.M3081; Thomsen LA, 2007, ANN PHARMACOTHER, V41, P1411, DOI 10.1345/aph.1H658	13	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 7	2012	379	9823					1278	1280		10.1016/S0140-6736(12)60078-6	http://dx.doi.org/10.1016/S0140-6736(12)60078-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	922FB	22357107				2023-01-03	WOS:000302531100006
J	Stukel, TA; Fisher, ES; Alter, DA; Guttmann, A; Ko, DT; Fung, K; Wodchis, WP; Baxter, NN; Earle, CC; Lee, DS				Stukel, Therese A.; Fisher, Elliott S.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Fung, Kinwah; Wodchis, Walter P.; Baxter, Nancy N.; Earle, Craig C.; Lee, Douglas S.			Association of Hospital Spending Intensity With Mortality and Readmission Rates in Ontario Hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; QUALITY-OF-CARE; SURGICAL OUTCOMES; 30-DAY MORTALITY; HIP FRACTURE; REGIONAL-VARIATIONS; CARDIAC MANAGEMENT; HEALTH OUTCOMES; UNITED-STATES	Context The extent to which better spending produces higher-quality care and better patient outcomes in a universal health care system with selective access to medical technology is unknown. Objective To assess whether acute care patients admitted to higher-spending hospitals have lower mortality and readmissions. Design, Setting, and Patients The study population comprised adults (>18 years) in Ontario, Canada, with a first admission for acute myocardial infarction (AMI) (n=179 139), congestive heart failure (CHF) (n=92 377), hip fracture (n=90 046), or colon cancer (n=26 195) during 1998-2008, with follow-up to 1 year. The exposure measure was the index hospital's end-of-life expenditure index for hospital, physician, and emergency department services. Main Outcome Measures The primary outcomes were 30-day and 1-year mortality and readmissions and major cardiac events (readmissions for AMI, angina, CHF, or death) for AMI and CHF. Results Patients' baseline health status was similar across hospital expenditure groups. Patients admitted to hospitals in the highest-vs lowest-spending intensity terciles had lower rates of all adverse outcomes. In the highest-vs lowest-spending hospitals, respectively, the age-and sex-adjusted 30-day mortality rate was 12.7% vs 12.8% for AMI, 10.2% vs 12.4% for CHF, 7.7% vs 9.7% for hip fracture, and 3.3% vs 3.9% for CHF; fully adjusted relative 30-day mortality rates were 0.93 (95% CI, 0.89-0.98) for AMI, 0.81 (95% CI, 0.76-0.86) for CHF, 0.74 (95% CI, 0.68-0.80) for hip fracture, and 0.78 (95% CI, 0.66-0.91) for colon cancer. Results for 1-year mortality, readmissions, and major cardiac events were similar. Higher-spending hospitals had higher nursing staff ratios, and their patients received more inpatient medical specialist visits, interventional (AMI cohort) and medical (AMI and CHF cohorts) cardiac therapies, preoperative specialty care (colon cancer cohort), and postdischarge collaborative care with a cardiologist and primary care physician (AMI and CHF cohorts). Conclusion Among Ontario hospitals, higher spending intensity was associated with lower mortality, readmissions, and cardiac event rates. JAMA. 2012;307(10):1037-1045 www.jama.com	[Stukel, Therese A.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Fung, Kinwah; Wodchis, Walter P.; Baxter, Nancy N.; Earle, Craig C.; Lee, Douglas S.] Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; [Stukel, Therese A.; Alter, David A.; Guttmann, Astrid; Ko, Dennis T.; Wodchis, Walter P.; Baxter, Nancy N.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Stukel, Therese A.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Clin Epidemiol Unit, Toronto, ON, Canada; [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada; [Ko, Dennis T.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Schulich Heart Ctr, Div Cardiol, Toronto, ON, Canada; [Stukel, Therese A.; Fisher, Elliott S.] Dartmouth Inst Hlth Policy & Clin Practice, Ctr Populat Hlth, Lebanon, NH USA; [Stukel, Therese A.; Fisher, Elliott S.] Dartmouth Med Sch, Lebanon, NH USA; [Alter, David A.; Baxter, Nancy N.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Alter, David A.; Wodchis, Walter P.] Toronto Rehabil Inst, Toronto, ON, Canada; [Lee, Douglas S.] Toronto Gen Hosp, Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Dartmouth College; Dartmouth College; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Stukel, TA (corresponding author), Inst Clin Evaluat Sci, G106-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	stukel@ices.on.ca	Baxter, Nancy N/E-7020-2015; Greiver, Michelle/N-8764-2015	Baxter, Nancy N/0000-0003-4793-4620; Greiver, Michelle/0000-0001-8957-0285; wodchis, walter/0000-0003-2494-7031; Ko, Dennis/0000-0001-6840-8051; Lee, Douglas/0000-0001-7078-745X; Stukel, Therese/0000-0002-2951-1360	Canadian Institutes of Health Research [ETG92248]; US National Institute on Aging [1PO1-AG19783-01]; Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding was provided by an Emerging Team Grant (ETG92248) in Applied Health Services and Policy Research from the Canadian Institutes of Health Research, by a grant from the US National Institute on Aging (1PO1-AG19783-01), and by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care.	Alter DA, 2006, CIRCULATION, V113, P380, DOI 10.1161/CIRCULATIONAHA.105.560466; Austin PC, 2006, J ROY STAT SOC A STA, V169, P115, DOI 10.1111/j.1467-985X.2005.00380.x; Ayanian JZ, 2006, CIRCULATION, V113, P333, DOI 10.1161/CIRCULATIONAHA.105.598789; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; Bach PB, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp0909947; Barnato AE, 2010, MED CARE, V48, P125, DOI 10.1097/MLR.0b013e3181c161e4; Birkmeyer NJO, 2005, CANCER-AM CANCER SOC, V103, P435, DOI 10.1002/cncr.20785; Chen LM, 2010, ARCH INTERN MED, V170, P340, DOI 10.1001/archinternmed.2009.511; Fisher E, 2010, HLTH SERV RES 2, V45, P1908; Fisher E, 2010, HEALTH SERV RES, V45, P1893, DOI 10.1111/j.1475-6773.2010.01186.x; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Ghaferi AA, 2009, NEW ENGL J MED, V361, P1368, DOI 10.1056/NEJMsa0903048; Goodman DC, 2002, NEW ENGL J MED, V346, P1538, DOI 10.1056/NEJMoa011921; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Juurlink D, 2006, CANADIAN I HLTH INFO; Krumholz HM, 2008, CIRCULATION, V118, P2596, DOI 10.1161/CIRCULATIONAHA.108.191099; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Landrum MB, 2008, HEALTH AFFAIR, V27, P159, DOI 10.1377/hlthaff.27.1.159; Lee DS, 2010, CIRCULATION, V122, P1806, DOI 10.1161/CIRCULATIONAHA.110.940262; Lee DS, 2003, CAN J CARDIOL, V19, P357; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; Lucas FL, 2006, CIRCULATION, V113, P374, DOI 10.1161/CIRCULATIONAHA.105.560433; Martin S, 2008, J HEALTH ECON, V27, P826, DOI 10.1016/j.jhealeco.2007.12.002; Meyerhardt JA, 2003, ANN INTERN MED, V139, P649, DOI 10.7326/0003-4819-139-8-200310210-00008; Morrison RS, 1998, ANN INTERN MED, V128, P1010, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00010; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Needleman J, 2011, NEW ENGL J MED, V364, P1037, DOI 10.1056/NEJMsa1001025; Neuman MD, 2009, J AM GERIATR SOC, V57, P2046, DOI 10.1111/j.1532-5415.2009.02492.x; OECD, 2011, OECD HLTH DAT 2011; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Richards J, 2012, DATA QUALITY STUDY C; Romley JA, 2011, ANN INTERN MED, V154, P160, DOI 10.7326/0003-4819-154-3-201102010-00005; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Rothberg MB, 2010, HEALTH AFFAIR, V29, P1523, DOI 10.1377/hlthaff.2009.0287; Shortell SM, 2008, JAMA-J AM MED ASSOC, V300, P95, DOI 10.1001/jama.300.1.95; Silber JH, 2010, HEALTH SERV RES, V45, P1872, DOI 10.1111/j.1475-6773.2010.01180.x; Skinner J., 2012, HDB HLTH EC, V2, P45; Skinner J, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp1000448; Skinner JS, 2006, HEALTH AFFAIR, V25, pW34, DOI 10.1377/hlthaff.25.w34; StataCorp, 2009, STAT STAT SOFTW SE R; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Stukel TA, 2010, MED CARE, V48, P157, DOI 10.1097/MLR.0b013e3181bd4da7; Tourangeau AE, 2007, J ADV NURS, V57, P32, DOI 10.1111/j.1365-2648.2006.04084.x; Tu JV, 2008, CAN MED ASSOC J, V179, P909, DOI 10.1503/cmaj.080749; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Tu JV, 2001, JAMA-J AM MED ASSOC, V285, P3116, DOI 10.1001/jama.285.24.3116; Weinstein MC, 2010, NEW ENGL J MED, V362, P460, DOI 10.1056/NEJMsb0911104; Weller I, 2005, J BONE JOINT SURG BR, V87B, P361, DOI 10.1302/0301-620X.87B3.15300; World Health Organization, COUNTR; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566	52	104	105	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 14	2012	307	10					1037	1045		10.1001/jama.2012.265	http://dx.doi.org/10.1001/jama.2012.265			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GU	22416099	Green Accepted			2023-01-03	WOS:000301479700024
J	Silbergleit, R; Durkalski, V; Lowenstein, D; Conwit, R; Pancioli, A; Palesch, Y; Barsan, W				Silbergleit, Robert; Durkalski, Valerie; Lowenstein, Daniel; Conwit, Robin; Pancioli, Arthur; Palesch, Yuko; Barsan, William		NETT Investigators	Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAZEPAM; MIDAZOLAM; SEIZURES	BACKGROUND Early termination of prolonged seizures with intravenous administration of benzodiazepines improves outcomes. For faster and more reliable administration, paramedics increasingly use an intramuscular route. METHODS This double-blind, randomized, noninferiority trial compared the efficacy of intramuscular midazolam with that of intravenous lorazepam for children and adults in status epilepticus treated by paramedics. Subjects whose convulsions had persisted for more than 5 minutes and who were still convulsing after paramedics arrived were given the study medication by either intramuscular autoinjector or intravenous infusion. The primary outcome was absence of seizures at the time of arrival in the emergency department without the need for rescue therapy. Secondary outcomes included endotracheal intubation, recurrent seizures, and timing of treatment relative to the cessation of convulsive seizures. This trial tested the hypothesis that intramuscular midazolam was noninferior to intravenous lorazepam by a margin of 10 percentage points. RESULTS At the time of arrival in the emergency department, seizures were absent without rescue therapy in 329 of 448 subjects (73.4%) in the intramuscular-midazolam group and in 282 of 445 (63.4%) in the intravenous-lorazepam group (absolute difference, 10 percentage points; 95% confidence interval, 4.0 to 16.1; P<0.001 for both noninferiority and superiority). The two treatment groups were similar with respect to need for endotracheal intubation (14.1% of subjects with intramuscular midazolam and 14.4% with intravenous lorazepam) and recurrence of seizures (11.4% and 10.6%, respectively). Among subjects whose seizures ceased before arrival in the emergency department, the median times to active treatment were 1.2 minutes in the intramuscularmidazolam group and 4.8 minutes in the intravenous-lorazepam group, with corresponding median times from active treatment to cessation of convulsions of 3.3 minutes and 1.6 minutes. Adverse-event rates were similar in the two groups. CONCLUSIONS For subjects in status epilepticus, intramuscular midazolam is at least as safe and effective as intravenous lorazepam for prehospital seizure cessation. (Funded by the National Institute of Neurological Disorders and Stroke and others; ClinicalTrials. gov number, NCT00809146.)	[Silbergleit, Robert; Barsan, William] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48105 USA; [Durkalski, Valerie; Palesch, Yuko] Med Univ S Carolina, Dept Med, Div Biostat & Epidemiol, Charleston, SC USA; [Lowenstein, Daniel] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Conwit, Robin] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA; [Pancioli, Arthur] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH USA	University of Michigan System; University of Michigan; Medical University of South Carolina; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University System of Ohio; University of Cincinnati	Silbergleit, R (corresponding author), Univ Michigan, Dept Emergency Med, Suite 3100,24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105 USA.	robert.silbergleit@umich.edu	Milling, Truman J/N-6601-2017; Beltran, Gerald W/O-2584-2013	Milling, Truman J/0000-0002-5588-0426; Beltran, Gerald W/0000-0001-8670-4786; Ortega-Gutierrez, Santiago/0000-0002-3408-1297; Vibbert, Matthew/0000-0001-6699-6646; McMullan, Jason/0000-0002-7656-7447; Quinn, James/0000-0002-3694-2118	National Institute of Neurological Disorders and Stroke (NINDS) [U01NS056975, U01NS059041]; National Institutes of Health Office; Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U10NS058982, U10NS058940, U10NS059012, U01NS056975, U10NS058931, U10NS058927, U01NS059041] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health Office; Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by awards from the National Institute of Neurological Disorders and Stroke (NINDS) (U01NS056975 and U01NS059041); the National Institutes of Health Office of the Director CounterACT Program; and the Biomedical Advanced Research and Development Authority of the Assistant Secretary for Preparedness and Response.	Aldredge BK, 2001, NEW ENGL J MED, V345, P1860; Alldredge BK, 2001, NEW ENGL J MED, V345, P631, DOI 10.1056/NEJMoa002141; [Anonymous], 2010, GUID IND NO IN PRESS; Chamberlain JM, 1997, PEDIATR EMERG CARE, V13, P92, DOI 10.1097/00006565-199704000-00002; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; Gottwald MD, 1999, AM J EMERG MED, V17, P333, DOI 10.1016/S0735-6757(99)90079-7; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Lowenstein DH, 2001, CONTROL CLIN TRIALS, V22, P290, DOI 10.1016/S0197-2456(01)00120-9; McMullan J, 2010, ACAD EMERG MED, V17, P575, DOI 10.1111/j.1553-2712.2010.00751.x; Millikan D, 2009, EMERG MED CLIN N AM, V27, P101, DOI 10.1016/j.emc.2008.12.001; Warden CR, 2006, PREHOSP EMERG CARE, V10, P463, DOI 10.1080/10903120600885126	11	404	413	3	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2012	366	7					591	600		10.1056/NEJMoa1107494	http://dx.doi.org/10.1056/NEJMoa1107494			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	892IL	22335736	Green Accepted			2023-01-03	WOS:000300279800004
J	Norian, LA; Kresowik, TP; Rosevear, HM; James, BR; Rosean, TR; Lightfoot, AJ; Kucaba, TA; Schwarz, C; Weydert, CJ; Henry, MD; Griffith, TS				Norian, Lyse A.; Kresowik, Timothy P.; Rosevear, Henry M.; James, Britnie R.; Rosean, Timothy R.; Lightfoot, Andrew J.; Kucaba, Tamara A.; Schwarz, Christopher; Weydert, Christine J.; Henry, Michael D.; Griffith, Thomas S.			Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy	PLOS ONE			English	Article							CD8(+) T-CELLS; IN-VIVO; IMMUNE SUPPRESSION; KIDNEY CANCER; PRIMARY TUMOR; GENE-THERAPY; GROWTH; MICE; INTERLEUKIN-2; COMBINATION	Despite evidence that antitumor immunity can be protective against renal cell carcinoma (RCC), few patients respond objectively to immunotherapy and the disease is fatal once metastases develop. We asked to what extent combinatorial immunotherapy with Adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) plus CpG oligonucleotide, given at the primary tumor site, would prove efficacious against metastatic murine RCC. To quantitate primary renal and metastatic tumor growth in mice, we developed a luciferase-expressing Renca cell line, and monitored tumor burdens via bioluminescent imaging. Orthotopic tumor challenge gave rise to aggressive primary tumors and lung metastases that were detectable by day 7. Intra-renal administration of Ad5mTRAIL+CpG on day 7 led to an influx of effector phenotype CD4 and CD8 T cells into the kidney by day 12 and regression of established primary renal tumors. Intra-renal immunotherapy also led to systemic immune responses characterized by splenomegaly, elevated serum IgG levels, increased CD4 and CD8 T cell infiltration into the lungs, and elimination of metastatic lung tumors. Tumor regression was primarily dependent upon CD8 T cells and resulted in prolonged survival of treated mice. Thus, local administration of Ad5mTRAIL+CpG at the primary tumor site can initiate CD8-dependent systemic immunity that is sufficient to cause regression of metastatic lung tumors. A similar approach may prove beneficial for patients with metastatic RCC.	[Norian, Lyse A.; Kresowik, Timothy P.; Rosevear, Henry M.; Lightfoot, Andrew J.; Schwarz, Christopher] Univ Iowa, Carver Coll Med, Dept Urol, Iowa City, IA 52242 USA; [James, Britnie R.; Griffith, Thomas S.] Univ Minnesota, Microbiol Immunol & Canc Biol Program, Minneapolis, MN USA; [Rosean, Timothy R.] Univ Iowa, Carver Coll Med, Interdisciplinary Grad Program Immunol, Iowa City, IA USA; [Kucaba, Tamara A.; Griffith, Thomas S.] Univ Minnesota, Dept Urol, Minneapolis, MN USA; [Weydert, Christine J.; Henry, Michael D.] Univ Iowa, Carver Coll Med, Dept Physiol, Iowa City, IA USA	University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; University of Iowa	Norian, LA (corresponding author), Univ Iowa, Carver Coll Med, Dept Urol, Iowa City, IA 52242 USA.	tgriffit@umn.edu	Griffith, Thomas/ABF-8225-2020	Norian, Lyse/0000-0003-1016-313X; Henry, Michael/0000-0002-7871-245X	National Institutes of Health (NIH) [CA109446]; NATIONAL CANCER INSTITUTE [R01CA109446] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a National Institutes of Health (NIH) grant # CA109446, grants.nih.gov. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Ather MH, 2010, UROL J, V7, P1; Atzpodien J, 2004, J CLIN ONCOL, V22, P1188, DOI 10.1200/JCO.2004.06.155; Cao QH, 2008, DNA CELL BIOL, V27, P91, DOI 10.1089/dna.2007.0633; Clausen BE, 2010, IMMUNOL CELL BIOL, V88, P351, DOI 10.1038/icb.2010.40; Rocha FGD, 2010, CANCER IMMUNOL IMMUN, V59, P1357, DOI 10.1007/s00262-010-0865-6; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Elliott MR, 2010, J CELL BIOL, V189, P1059, DOI 10.1083/jcb.201004096; Elzey BD, 2003, IMMUNITY, V19, P9, DOI 10.1016/S1074-7613(03)00177-8; Flanigan Robert C, 2003, Curr Treat Options Oncol, V4, P385, DOI 10.1007/s11864-003-0039-2; Frankenberger B, 2007, SEMIN CANCER BIOL, V17, P330, DOI 10.1016/j.semcancer.2007.06.004; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; Godley PA, 2001, CURR OPIN ONCOL, V13, P199, DOI 10.1097/00001622-200105000-00012; Griffith TS, 2009, CURR GENE THER, V9, P9, DOI 10.2174/156652309787354612; Gruys ME, 2001, CANCER RES, V61, P6255; Hofmann MA, 2008, J IMMUNOTHER, V31, P520, DOI 10.1097/CJI.0b013e318174a4df; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Kemp TJ, 2003, APOPTOSIS, V8, P587, DOI 10.1023/A:1026286108366; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Kobayashi H, 2010, ANTICANCER RES, V30, P575; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2007, J CLIN INVEST, V117, P1184, DOI 10.1172/JCI31414; Kusmartsev S, 2008, J IMMUNOL, V181, P346, DOI 10.4049/jimmunol.181.1.346; Lv S, 2005, IMMUNOL LETT, V99, P217, DOI 10.1016/j.imlet.2005.03.019; Matin SF, 2010, J UROLOGY, V183, P333, DOI 10.1016/j.juro.2009.08.110; McDermott DF, 2009, CANCER-AM CANCER SOC, V115, P2298, DOI 10.1002/cncr.24236; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Patil S, 2010, CANCER-AM CANCER SOC, V116, P347, DOI 10.1002/cncr.24713; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Quezada SA, 2010, J EXP MED, V207, P637, DOI 10.1084/jem.20091918; Rini BI, 2010, CLIN CANCER RES, V16, P1348, DOI 10.1158/1078-0432.CCR-09-2273; SALUP RR, 1986, CANCER RES, V46, P3358; SAYERS TJ, 1990, CANCER RES, V50, P5414; Seki N, 2003, CANCER RES, V63, P207; Seki N, 2002, J IMMUNOL, V168, P3484, DOI 10.4049/jimmunol.168.7.3484; Shablak A, 2009, CLIN CANCER RES, V15, P6503, DOI 10.1158/1078-0432.CCR-09-1605; Shanker A, 2008, JNCI-J NATL CANCER I, V100, P649, DOI 10.1093/jnci/djn113; Shanker A, 2009, CANCER RES, V69, P6615, DOI 10.1158/0008-5472.CAN-09-0685; Shvarts O, 2006, UROLOGY, V68, P1132, DOI 10.1016/j.urology.2006.08.1073; SPARANO JA, 1993, J CLIN ONCOL, V11, P1969, DOI 10.1200/JCO.1993.11.10.1969; Svensson RU, 2007, CANCER RES, V67, P10445, DOI 10.1158/0008-5472.CAN-07-1955; Teng MWL, 2010, CANCER RES, V70, P2665, DOI 10.1158/0008-5472.CAN-09-1574; VanOosten RL, 2007, CANCER RES, V67, P11980, DOI 10.1158/0008-5472.CAN-07-1526; Wang LX, 2010, CLIN CANCER RES, V16, P164, DOI 10.1158/1078-0432.CCR-09-1758; Webster WS, 2006, CANCER-AM CANCER SOC, V107, P46, DOI 10.1002/cncr.21951; Westwood JA, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-42; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wysocki PJ, 2010, CANCER GENE THER, V17, P465, DOI 10.1038/cgt.2010.2; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Yockman JW, 2007, GENE THER, V14, P1399, DOI 10.1038/sj.gt.3302999; Yu P, 2007, J IMMUNOL, V179, P1960, DOI 10.4049/jimmunol.179.3.1960; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505	53	43	44	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 1	2012	7	2							e31085	10.1371/journal.pone.0031085	http://dx.doi.org/10.1371/journal.pone.0031085			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914UG	22312440	gold, Green Published, Green Submitted			2023-01-03	WOS:000301977500028
J	Sharma, SK; Agrawal, S; Damodaran, D; Sreenivas, V; Kadhiravan, T; Lakshmy, R; Jagia, P; Kumar, A				Sharma, Surendra K.; Agrawal, Swastik; Damodaran, Deepak; Sreenivas, Vishnubhatla; Kadhiravan, Tamilarasu; Lakshmy, Ramakrishnan; Jagia, Priya; Kumar, Atin			RETRACTED: CPAP for the Metabolic Syndrome in Patients with Obstructive Sleep Apnea (Retracted article. See vol. 369, pg. 1770, 2013)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Retracted Publication							POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; HYPERTENSION; PREVALENCE; ABNORMALITIES; OBESITY; LEPTIN	BACKGROUND Obstructive sleep apnea is associated with an increased prevalence of the metabolic syndrome and its components. It is unclear whether treatment of obstructive sleep apnea syndrome with continuous positive airway pressure (CPAP) would modify these outcomes. METHODS In our double-blind, placebo-controlled trial, we randomly assigned patients with obstructive sleep apnea syndrome to undergo 3 months of therapeutic CPAP followed by 3 months of sham CPAP, or vice versa, with a washout period of 1 month in between. Before and after each intervention, we obtained measurements of anthropometric variables, blood pressure, fasting blood glucose levels, insulin resistance (with the use of homeostasis model assessment), fasting blood lipid profile, glycated hemoglobin levels, carotid intima-media thickness, and visceral fat. The metabolic syndrome was defined according to National Cholesterol Education Program Adult Treatment Panel III criteria, with Asian cutoff values for abdominal obesity. RESULTS A total of 86 patients completed the study, 75 (87%) of whom had the metabolic syndrome. CPAP treatment (vs. sham CPAP) was associated with significant mean decreases in systolic blood pressure (3.9 mm Hg; 95% confidence interval [CI], 1.4 to 6.4; P=0.001), diastolic blood pressure (2.5 mm Hg; 95% CI, 0.9 to 4.1; P < 0.001), serum total cholesterol (13.3 mg per deciliter; 95% CI, 5.3 to 21.3; P=0.005), non-high-density lipoprotein cholesterol (13.3 mg per deciliter; 95% CI, 4.8 to 21.8; P=0.009), low-density lipoprotein cholesterol (9.6 mg per deciliter; 95% CI, 2.5 to 16.7; P=0.008), triglycerides (18.7 mg per deciliter; 95% CI, 4.3 to 41.6; P=0.02), and glycated hemoglobin (0.2%; 95% CI, 0.1 to 0.4; P=0.003). The frequency of the metabolic syndrome was reduced after CPAP therapy (reversal found in 11 of 86 patients [13%] undergoing CPAP therapy vs. 1 of 86 [1%] undergoing sham CPAP). Accelerated hypertension developed 1 patient receiving CPAP therapy first, intolerance to CPAP developed in 2 others, and another patient declined to continue sham CPAP. CONCLUSIONS In patients with moderate-to-severe obstructive sleep apnea syndrome, 3 months of CPAP therapy lowers blood pressure and partially reverses metabolic abnormalities. (Funded by Pfizer; ClinicalTrials.gov number, NCT00694616.)	[Sharma, Surendra K.; Agrawal, Swastik; Damodaran, Deepak] All India Inst Med Sci, Dept Med, New Delhi 110029, India; [Sreenivas, Vishnubhatla] All India Inst Med Sci, Dept Biostat, New Delhi 110029, India; [Lakshmy, Ramakrishnan] All India Inst Med Sci, Dept Cardiac Biochem, New Delhi 110029, India; [Jagia, Priya] All India Inst Med Sci, Dept Cardiac Radiol, New Delhi 110029, India; [Kumar, Atin] All India Inst Med Sci, Dept Radiodiag, New Delhi 110029, India; [Kadhiravan, Tamilarasu] Jawaharlal Inst Postgrad Med Educ & Res, Dept Med, Pondicherry, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Jawaharlal Institute of Postgraduate Medical Education & Research	Sharma, SK (corresponding author), All India Inst Med Sci, Dept Med, New Delhi 110029, India.	sksharma.aiims@gmail.com		Agrawal, Swastik/0000-0002-5671-5174	Pfizer	Pfizer(Pfizer)	Supported by Pfizer through an investigator-initiated research grant.	Baigent C, 2008, LANCET, V371, P2084; Bairaktari E, 2000, CLIN BIOCHEM, V33, P549, DOI 10.1016/S0009-9120(00)00162-4; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Basta M, 2007, SLEEP MED, V8, P5, DOI 10.1016/j.sleep.2006.10.001; Borgel J, 2006, EUR RESPIR J, V27, P121, DOI 10.1183/09031936.06.00131304; Campos-Rodriguez F, 2006, CHEST, V129, P1459, DOI 10.1378/chest.129.6.1459; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Coughlin SR, 2007, EUR RESPIR J, V29, P720, DOI 10.1183/09031936.00043306; Coughlin SR, 2004, EUR HEART J, V25, P735, DOI 10.1016/j.ehj.2004.02.021; Cuhadaroglu C, 2009, LUNG, V187, P75, DOI 10.1007/s00408-008-9131-5; DAVIES RJO, 1990, EUR RESPIR J, V3, P509; Dorkova Z, 2008, CHEST, V134, P686, DOI 10.1378/chest.08-0556; Drager LF, 2007, AM J RESP CRIT CARE, V176, P706, DOI 10.1164/rccm.200703-500OC; Duran-Cantolla J, 2010, BMJ-BRIT MED J, V341, pc5991; Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263; Harsch IA, 2004, AM J RESP CRIT CARE, V169, P156, DOI 10.1164/rccm.200302-206OC; Harsch IA, 2003, EUR RESPIR J, V22, P251, DOI 10.1183/09031936.03.00010103; Ip MSM, 2002, AM J RESP CRIT CARE, V165, P670, DOI 10.1164/ajrccm.165.5.2103001; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Lozano L, 2010, J HYPERTENS, V28, P2161, DOI 10.1097/HJH.0b013e32833b9c63; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mota PC, 2010, SLEEP BREATH    0924; Nieto F. Javier, 2002, JAMA (Journal of the American Medical Association), V288, P1985; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Robinson GV, 2006, EUR RESPIR J, V27, P1229, DOI 10.1183/09031936.06.00062805; Robinson GV, 2004, THORAX, V59, P777, DOI 10.1136/thx.2003.018739; SALONEN JT, 1993, CIRCULATION, V87, P56; Sharma SK, 2007, SLEEP MED, V8, P12, DOI 10.1016/j.sleep.2006.06.014; Sharma SK, 2004, SLEEP MED, V5, P351, DOI 10.1016/j.sleep.2004.03.004; Sharma SK, 2010, SLEEP MED, V11, P562, DOI 10.1016/j.sleep.2010.02.008; Sharma SK, 2006, CHEST, V130, P149, DOI 10.1378/chest.130.1.149; Steiropoulos P, 2007, CHEST, V132, P843, DOI 10.1378/chest.07-0074; Tatsumi K, 2005, CHEST, V127, P716, DOI 10.1378/chest.127.3.716; Yoshizumi T, 1999, RADIOLOGY, V211, P283, DOI 10.1148/radiology.211.1.r99ap15283; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	36	239	250	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	2011	365	24					2277	2286		10.1056/NEJMoa1103944	http://dx.doi.org/10.1056/NEJMoa1103944			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	861PN	22168642				2023-01-03	WOS:000298031800008
J	Saunier, EF; Vivar, OI; Rubenstein, A; Zhao, XY; Olshansky, M; Baggett, S; Staub, RE; Tagliaferri, M; Cohen, I; Speed, TP; Baxter, JD; Leitman, DC				Saunier, Elise F.; Vivar, Omar I.; Rubenstein, Andrea; Zhao, Xiaoyue; Olshansky, Moshe; Baggett, Scott; Staub, Richard E.; Tagliaferri, Mary; Cohen, Isaac; Speed, Terence P.; Baxter, John D.; Leitman, Dale C.			Estrogenic Plant Extracts Reverse Weight Gain and Fat Accumulation without Causing Mammary Gland or Uterine Proliferation	PLOS ONE			English	Article							POSTMENOPAUSAL HORMONE-THERAPY; RECEPTOR-BETA; BODY-WEIGHT; REPLACEMENT THERAPY; GLUCOSE-HOMEOSTASIS; INSULIN SENSITIVITY; PLUS PROGESTIN; BREAST-CANCER; OB/OB MICE; ALPHA	Long-term estrogen deficiency increases the risk of obesity, diabetes and metabolic syndrome in postmenopausal women. Menopausal hormone therapy containing estrogens might prevent these conditions, but its prolonged use increases the risk of breast cancer, as wells as endometrial cancer if used without progestins. Animal studies indicate that beneficial effects of estrogens in adipose tissue and adverse effects on mammary gland and uterus are mediated by estrogen receptor alpha (ER alpha). One strategy to improve the safety of estrogens to prevent/treat obesity, diabetes and metabolic syndrome is to develop estrogens that act as agonists in adipose tissue, but not in mammary gland and uterus. We considered plant extracts, which have been the source of many pharmaceuticals, as a source of tissue selective estrogens. Extracts from two plants, Glycyrrhiza uralensis (RG) and Pueraria montana var. lobata (RP) bound to ER alpha, activated ER alpha responsive reporters, and reversed weight gain and fat accumulation comparable to estradiol in ovariectomized obese mice maintained on a high fat diet. Unlike estradiol, RG and RP did not induce proliferative effects on mammary gland and uterus. Gene expression profiling demonstrated that RG and RP induced estradiol-like regulation of genes in abdominal fat, but not in mammary gland and uterus. The compounds in extracts from RG and RP might constitute a new class of tissue selective estrogens to reverse weight gain, fat accumulation and metabolic syndrome in postmenopausal women.	[Saunier, Elise F.; Rubenstein, Andrea; Zhao, Xiaoyue; Baggett, Scott; Staub, Richard E.; Tagliaferri, Mary; Cohen, Isaac] Bionovo Inc, Emeryville, CA 94608 USA; [Vivar, Omar I.; Leitman, Dale C.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; [Olshansky, Moshe; Speed, Terence P.] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Bioinformat, Parkville, Vic 3050, Australia; [Speed, Terence P.] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; [Baxter, John D.] Methodist Hosp, Diabet Ctr & Canc Res Unit, Res Inst, Houston, TX 77030 USA	University of California System; University of California Berkeley; Royal Melbourne Hospital; Walter & Eliza Hall Institute; University of California System; University of California Berkeley; The Methodist Hospital System; The Methodist Hospital - Houston	Saunier, EF (corresponding author), Bionovo Inc, Emeryville, CA 94608 USA.	dale@leitmanlab.com		Olshansky, Moshe/0000-0003-2085-9851	National Institutes of Health/National Center for Complementary and Alternative Medicine [1R41AT005575]; Bionovo, Inc.; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R41AT005575] Funding Source: NIH RePORTER	National Institutes of Health/National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)NIH National Center for Complementary & Alternative Medicine); Bionovo, Inc.; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This work was supported by a grant (1R41AT005575) from the National Institutes of Health/National Center for Complementary and Alternative Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; OIV and MO have nothing to declare. EFS, AR, SB, RES, MT and IC are employees of Bionovo, Inc. and are stock owners. JDB is a Director and owner of options of Bionovo. JDB and TPS are on the Scientific Advisory Board of Bionovo, Inc. JDB has stock ownership in Karo Bio, A.B., which has commercial interests in this area of research. DCL has received financial support for research from Bionovo, Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; BAILEY CJ, 1980, DIABETOLOGIA, V19, P475, DOI 10.1007/BF00281829; Barros RPA, 2011, CELL METAB, V14, P289, DOI 10.1016/j.cmet.2011.08.005; Bonds DE, 2006, DIABETOLOGIA, V49, P459, DOI 10.1007/s00125-005-0096-0; Bryzgalova G, 2006, DIABETOLOGIA, V49, P588, DOI 10.1007/s00125-005-0105-3; Bryzgalova G, 2008, AM J PHYSIOL-ENDOC M, V295, pE904, DOI 10.1152/ajpendo.90248.2008; Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Cvoro A, 2007, ENDOCRINOLOGY, V148, P538, DOI 10.1210/en.2006-0803; Dahlman-Wright K, 2006, PHARMACOL REV, V58, P773, DOI 10.1124/pr.58.4.8; Espeland MA, 1997, J CLIN ENDOCR METAB, V82, P1549, DOI 10.1210/jc.82.5.1549; Ettinger B, 2003, OBSTET GYNECOL, V102, P1225, DOI 10.1016/j.obstetgynecol.2003.08.007; Forster C, 2002, P NATL ACAD SCI USA, V99, P15578, DOI 10.1073/pnas.192561299; Gao H, 2006, MOL ENDOCRINOL, V20, P1287, DOI 10.1210/me.2006-0012; Gower BA, 2006, OBESITY, V14, P1046, DOI 10.1038/oby.2006.120; Grady D, 2009, MENOPAUSE, V16, P458, DOI 10.1097/gme.0b013e31818e64dd; Harris HA, 2003, ENDOCRINOLOGY, V144, P4241, DOI 10.1210/en.2003-0550; Hartman J, 2009, CANCER RES, V69, P6100, DOI 10.1158/0008-5472.CAN-09-0506; Heine PA, 2000, P NATL ACAD SCI USA, V97, P12729, DOI 10.1073/pnas.97.23.12729; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Jensen L, 2003, J BONE MINER RES, V18, P333, DOI 10.1359/jbmr.2003.18.2.333; Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886; Kanaya AM, 2003, ANN INTERN MED, V138, P1, DOI 10.7326/0003-4819-138-1-200301070-00005; KIAN TM, 2004, MOL BIOL CELL, V15, P1262; Leitman DC, 2010, CURR OPIN PHARMACOL, V10, P629, DOI 10.1016/j.coph.2010.09.009; Levy N, 2007, ENDOCRINOLOGY, V148, P3449, DOI 10.1210/en.2006-1632; Louet Jean-Francois, 2004, Curr Atheroscler Rep, V6, P180, DOI 10.1007/s11883-004-0030-9; Lundholm L, 2008, J ENDOCRINOL, V199, P275, DOI [10.1677/JOE-08-0192, 10.1530/JOE-08-0192e]; Mahady GB, 2003, MENOPAUSE, V10, P65, DOI 10.1097/01.GME.0000029028.95924.F9; Margolis KL, 2004, DIABETOLOGIA, V47, P1175, DOI 10.1007/s00125-004-1448-x; Mattiasson I, 2002, HORM METAB RES, V34, P583, DOI 10.1055/s-2002-35420; Mersereau JE, 2008, MOL CELL ENDOCRINOL, V283, P49, DOI 10.1016/j.mce.2007.11.020; Meyers MJ, 2001, J MED CHEM, V44, P4230, DOI 10.1021/jm010254a; Minutolo F, 2011, MED RES REV, V31, P364, DOI 10.1002/med.20186; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Mo B, 2006, BIOL REPROD, V75, P387, DOI 10.1095/biolreprod.106.051870; Molenda HA, 2003, BIOL REPROD, V69, P1449, DOI 10.1095/biolreprod.103.019364; Mostafaie N, 2009, MOL CARCINOGEN, V48, P642, DOI 10.1002/mc.20510; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; PARUTHIYIL S, 2011, BREAST CANC RES TREA, V186, P4354; Paruthiyil S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006271; Roesch DM, 2006, PHYSIOL BEHAV, V87, P39, DOI 10.1016/j.physbeh.2005.08.035; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Saunier E, 2003, ENDOCRINOLOGY, V144, P2669, DOI 10.1210/en.2002-221038; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; Stauffer SR, 2000, J MED CHEM, V43, P4934, DOI 10.1021/jm000170m; Vivar OI, 2010, J BIOL CHEM, V285, P22059, DOI 10.1074/jbc.M110.114116; YI ST, 2008, CLIN PRACTICE CHINES, V2; Zhou YJ, 2009, J BIOL CHEM, V284, P11152, DOI 10.1074/jbc.M900754200	52	8	12	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2011	6	12							e28333	10.1371/journal.pone.0028333	http://dx.doi.org/10.1371/journal.pone.0028333			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KK	22163294	Green Published, gold			2023-01-03	WOS:000298161900029
J	Nunes, MC; von Gottberg, A; de Gouveia, L; Cohen, C; Kuwanda, L; Karstaedt, AS; Klugman, KP; Madhi, SA				Nunes, Marta C.; von Gottberg, Anne; de Gouveia, Linda; Cohen, Cheryl; Kuwanda, Locadiah; Karstaedt, Alan S.; Klugman, Keith P.; Madhi, Shabir A.			Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected Adults in the Era of an Antiretroviral Treatment Program	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; STREPTOCOCCUS-PNEUMONIAE; TRIMETHOPRIM-SULFAMETHOXAZOLE; POLYSACCHARIDE VACCINE; HAEMOPHILUS-INFLUENZAE; CONTROLLED-TRIAL; UGANDAN ADULTS; UNITED-STATES; COTE-DIVOIRE; THERAPY	Background: Highly active antiretroviral treatment (HAART) programs have been associated with declines in the burden of invasive pneumococcal disease (IPD) in industrialized countries. The aim of this study was to evaluate trends in IPD hospitalizations in HIV-infected adults in Soweto, South Africa, associated with up-scaling of the HAART program from 2003 to 2008. Methods: Laboratory-confirmed IPD cases were identified from 2003 through 2008 through an existing surveillance program. The period 2003-04 was designated as the early-HAART era, 2005-06 as the intermediate-HAART era and 2007-08 as the established-HAART era. The incidence of IPD was compared between the early-HAART and established-HAART eras in HIV-infected and-uninfected individuals. Results: A total of 2,567 IPD cases among individuals older than 18 years were reported from 2003 through 2008. Overall incidence of IPD (per 100,000) did not change during the study period in HIV-infected adults (207.4 cases in the early-HAART and 214.0 cases in the established-HAART era; p = 0.55). IPD incidence, actually increased 1.16-fold (95% CI: 1.01; 1.62) in HIV-infected females between the early-and established-HAART eras (212.1 cases and 246.2 cases, respectively; p = 0.03). The incidence of IPD remained unchanged in HIV-uninfected adults across the three time periods. Conclusion: Despite a stable prevalence of HIV and the increased roll-out of HAART for treatment of AIDS patients in our setting, the burden of IPD has not decreased among HIV-infected adults. The study indicates a need for ongoing monitoring of disease and HAART program effectiveness to reduce opportunistic infections in African adults with HIV/AIDS, as well as the need to consider alternate strategies including pneumococcal conjugate vaccine immunization for the prevention of IPD in HIV-infected adults.	[Nunes, Marta C.; Kuwanda, Locadiah; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Fac Hlth Sci, Johannesburg, South Africa; [von Gottberg, Anne; de Gouveia, Linda; Klugman, Keith P.; Madhi, Shabir A.] Natl Inst Communicable Dis, Resp & Meningeal Pathogens Reference Unit, Johannesburg, South Africa; [Cohen, Cheryl] Natl Inst Communicable Dis, Epidemiol & Surveillance Unit, Johannesburg, South Africa; [Karstaedt, Alan S.] Univ Witwatersrand, Dept Med, ZA-2001 Johannesburg, South Africa; [Karstaedt, Alan S.] Chris Hani Baragwanath Acad Hosp, Johannesburg, South Africa; [Nunes, Marta C.; Kuwanda, Locadiah; Madhi, Shabir A.] Univ Witwatersrand, Med Res Council Resp & Meningeal Pathogens Res Un, Fac Hlth Sci, Johannesburg, South Africa; [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA; [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA	National Research Foundation - South Africa; University of Witwatersrand; National Institute for Communicable Diseases (NICD); National Institute for Communicable Diseases (NICD); University of Witwatersrand; University of Witwatersrand; Emory University; Rollins School Public Health; Emory University	Nunes, MC (corresponding author), Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn Vaccine Preventable Dis, Fac Hlth Sci, Johannesburg, South Africa.	shabirm@nicd.ac.za		de Gouveia, Linda/0000-0002-1418-8468; von Gottberg, Anne/0000-0002-0243-7455; Nunes, Marta/0000-0003-3788-878X; Cohen, Cheryl/0000-0003-0376-2302	University of the Witwatersrand; United States Agency for International Development's Antimicrobial Resistance Initiative from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia [U60/CCU022088]; CDC; National Center for HIV/AIDS; Viral Hepatitis, STD, and TB Prevention (NCHHSTP) [U62/PSO022901]; Pfizer; GSK	University of the Witwatersrand; United States Agency for International Development's Antimicrobial Resistance Initiative from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia(United States Agency for International Development (USAID)); CDC(Centre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for HIV/AIDS; Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Pfizer(Pfizer); GSK(GlaxoSmithKline)	MCN had financial support from the University of the Witwatersrand. This study was funded in part in 2003-2006 by the United States Agency for International Development's Antimicrobial Resistance Initiative, transferred via a cooperative agreement (number U60/CCU022088) from the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia. In 2005-2007, the study was also supported by the CDC, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) Cooperative Agreement U62/PSO022901. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts: Receipt of research funding (SAM, AvG, KPK) and consultancy from Pfizer (SAM, KPK). Receipt of research funding (SAM, AvG, KPK), consultancies and honoraria from GSK (SAM, KPK). Consultancy for Merck (KPK). This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Adam MA, 2009, SAMJ S AFR MED J, V99, P661; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; ASSA2003, FULL PROV AIDS DEM M; Barry PM, 2006, AIDS, V20, P437, DOI 10.1097/01.aids.0000206507.54901.84; Bliss SJ, 2008, LANCET INFECT DIS, V8, P67, DOI 10.1016/S1473-3099(07)70242-6; *CDCP, 2005, MMWR-MORBID MORTAL W, V54, P893; Cohen AL, 2010, AIDS, V24, P2253, DOI 10.1097/QAD.0b013e32833d46fd; Everett DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017765; FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742; Feldman C, 1999, CHEST, V116, P107, DOI 10.1378/chest.116.1.107; French N, 2000, LANCET, V355, P2106, DOI 10.1016/S0140-6736(00)02377-1; French N, 2010, NEW ENGL J MED, V362, P812, DOI 10.1056/NEJMoa0903029; Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668; Grau I, 2005, ARCH INTERN MED, V165, P1533, DOI 10.1001/archinte.165.13.1533; Heffernan RT, 2005, J INFECT DIS, V191, P2038, DOI 10.1086/430356; Huebner RE, 1999, S AFR MED J, V89, P924; Jones N, 1998, AIDS, V12, P2177, DOI 10.1097/00002030-199816000-00013; Jordano Q, 2004, CLIN INFECT DIS, V38, P1623, DOI 10.1086/420933; Karstaedt AS, 2001, CLIN INFECT DIS, V33, P610, DOI 10.1086/322589; Kourtis AP, 2010, JAIDS-J ACQ IMM DEF, V55, P128, DOI 10.1097/QAI.0b013e3181e8ed15; Mayanja BN, 2010, TROP MED INT HEALTH, V15, P697, DOI 10.1111/j.1365-3156.2010.02528.x; McEllistrem MC, 2002, J INFECT DIS, V185, P1364, DOI 10.1086/339882; Morrison KE, 2000, J CLIN MICROBIOL, V38, P434; National Department of Health, 2003, OP PLAN COMPR HIV AI; Nunes MC, 2011, AIDS, V25, P453, DOI 10.1097/QAD.0b013e328341b7f1; Nuorti JP, 2000, ANN INTERN MED, V132, P182, DOI 10.7326/0003-4819-132-3-200002010-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pemba L, 2008, J INFECTION, V56, P171, DOI 10.1016/j.jinf.2007.12.003; RADSTROM P, 1994, J CLIN MICROBIOL, V32, P2738; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; SHISANA O, 2005, S AFRICAN NATL HIV P; SHISANA O, 2010, S AFRICAN NATL HIV P; STATSSA, MID POP EST 2003 200; Teshale EH, 2008, VACCINE, V26, P5830, DOI 10.1016/j.vaccine.2008.08.032; Watera C, 2004, AIDS, V18, P1210, DOI 10.1097/00002030-200405210-00018; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Winn W, 2006, INTRO MICROBIOLOGY 2, P68; World Health Organization/UNAIDS, 2001, AFR HEALTH SCI, V1, P30	38	42	43	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2011	6	11							e27929	10.1371/journal.pone.0027929	http://dx.doi.org/10.1371/journal.pone.0027929			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KW	22140487	Green Submitted, gold, Green Published			2023-01-03	WOS:000298163400024
J	Jani, IV; Sitoe, NE; Alfai, ER; Chongo, PL; Quevedo, JI; Rocha, BM; Lehe, JD; Peter, TF				Jani, Ilesh V.; Sitoe, Nadia E.; Alfai, Eunice R.; Chongo, Patrina L.; Quevedo, Jorge I.; Rocha, Beatriz M.; Lehe, Jonathan D.; Peter, Trevor F.			Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study	LANCET			English	Article							RESOURCE-LIMITED SETTINGS; SUB-SAHARAN AFRICA; SOUTH-AFRICA; FOLLOW-UP; HIV TREATMENT; HIV-1-INFECTED PATIENTS; TREATMENT PROGRAMS; TREATMENT SERVICE; MORTALITY; DURBAN	Background Loss to follow-up of HIV-positive patients before initiation of antiretroviral therapy can exceed 50% in low-income settings and is a challenge to the scale-up of treatment. We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation. Methods In this observational cohort study, data for enrolment into HIV management and initiation of antiretroviral therapy were extracted retrospectively from patients' records at four primary health clinics providing HIV treatment and point-of-care CD4 services. Loss to follow-up and the duration of each preparatory step before treatment initiation were measured and compared with baseline data from before the introduction of point-of-care CD4 testing. Findings After the introduction of point-of-care CD4 the proportion of patients lost to follow-up before completion of CD4 staging dropped from 57% (278 of 492) to 21% (92 of 437) (adjusted odds ratio [OR] 0.2, 95% CI 0.15-0.27). Total loss to follow-up before initiation of antiretroviral treatment fell from 64% (314 of 492) to 33% (142 of 437) (OR 0.27, 95% CI 0.21-0.36) and the proportion of enrolled patients initiating antiretroviral therapy increased from 12% (57 of 492) to 22% (94 of 437) (OR 2.05, 95% CI 1.42-2.96). The median time from enrolment to antiretroviral therapy initiation reduced from 48 days to 20 days (p<0.0001), primarily because of a reduction in the median time taken to complete CD4 staging, which decreased from 32 days to 3 days (p<0.0001). Loss to follow-up between staging and antiretroviral therapy initiation did not change significantly (OR 0.84, 95% CI 0.49-1.45). Interpretation Point-of-care CD4 testing enabled clinics to stage patients rapidly on-site after enrolment, which reduced opportunities for pretreatment loss to follow-up. As a result, more patients were identified as eligible for and initiated antiretroviral treatment. Point-of-care testing might therefore be an effective intervention to reduce pretreatment loss to follow-up.	[Jani, Ilesh V.; Sitoe, Nadia E.; Alfai, Eunice R.; Chongo, Patrina L.] Inst Nacl Saude, Maputo, Mozambique; [Quevedo, Jorge I.; Rocha, Beatriz M.; Lehe, Jonathan D.; Peter, Trevor F.] Clinton Hlth Access Initiat, Maputo, Mozambique		Jani, IV (corresponding author), Inst Nacl Saude, Av Eduardo Mondlane 1008,2nd Floor, Maputo, Mozambique.	ilesh.jani@gmail.com		Jani, Ilesh/0000-0002-6880-6655; Sitoe, Nadia/0000-0001-7310-8221	Absolute Return for Kids; UNITAID	Absolute Return for Kids; UNITAID	Absolute Return for Kids and UNITAID.	Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; [Anonymous], 2009, LANCET, V373, P1352; Bassett IV, 2010, AIDS, V24, pS37, DOI 10.1097/01.aids.0000366081.91192.1c; Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2; Bekker LG, 2006, SAMJ S AFR MED J, V96, P315; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brinkhof MWG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005790; Cleary SM, 2008, AIDS, V22, pS35, DOI 10.1097/01.aids.0000327621.24232.71; Forster M, 2008, B WORLD HEALTH ORGAN, V86, P939, DOI 10.2471/BLT.07.049908; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng EH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014098; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Holmes CB, 2010, JAMA-J AM MED ASSOC, V304, P313, DOI 10.1001/jama.2010.993; Jani IV, 2011, AIDS, V25, P807, DOI 10.1097/QAD.0b013e328344f424; Kranzer K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013801; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; Maskew M, 2007, SAMJ S AFR MED J, V97, P853; Mccoy D, 2009, HEALTH POLICY PLANN, V24, P407, DOI 10.1093/heapol/czp026; Micek MA, 2009, JAIDS-J ACQ IMM DEF, V52, P397, DOI 10.1097/QAI.0b013e3181ab73e2; Mossdorf E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-98; Mulissa Z, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013268; Nash D, 2011, AIDS, V25, P1523, DOI 10.1097/QAD.0b013e32834811b2; Ravishankar N, 2009, LANCET, V373, P2113, DOI 10.1016/S0140-6736(09)60881-3; Rosen S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001056; UNAIDS, UNAIDS OUTL REP 2010; *UNAIDS, UNAIDS UPD GLOB AIDS; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Walensky RP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000382; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; World Health Organization, 2010, ANT THER HIV INF INF; Zachariah R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000121	32	220	222	0	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 29	2011	378	9802					1572	1579		10.1016/S0140-6736(11)61052-0	http://dx.doi.org/10.1016/S0140-6736(11)61052-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844SL	21951656				2023-01-03	WOS:000296767500022
J	Mourani, PM; Harris, JK; Sontag, MK; Robertson, CE; Abman, SH				Mourani, Peter M.; Harris, J. Kirk; Sontag, Marci K.; Robertson, Charles E.; Abman, Steven H.			Molecular Identification of Bacteria in Tracheal Aspirate Fluid from Mechanically Ventilated Preterm Infants	PLOS ONE			English	Article							CHRONIC LUNG-DISEASE; UREAPLASMA-UREALYTICUM COLONIZATION; BIRTH-WEIGHT INFANTS; BRONCHOPULMONARY DYSPLASIA; CHLAMYDIA-TRACHOMATIS; CHILDHOOD ASTHMA; BARCODED PRIMERS; GUT MICROBIOTA; INFLAMMATION; INFECTION	Background: Despite strong evidence linking infections to the pathogenesis of bronchopulmonary dysplasia (BPD), limitations of bacterial culture methods have precluded systematic studies of airway organisms relative to disease outcomes. Application of molecular bacterial identification strategies may provide new insight into the role of bacterial acquisition in the airways of preterm infants at risk for BPD. Methods: Serial (within 72 hours, 7, 14, and 21 days of life) tracheal aspirate samples were collected from 10 preterm infants with gestational age <= 34 weeks at birth, and birth weight of 500-1250 g who required mechanical ventilation for at least 21 days. Samples were analyzed by quantitative real time PCR assays for total bacterial load and by pyrosequencing for bacterial identification. Results: Subjects were diagnosed with mild (1), moderate (3), or severe (5) BPD. One patient died prior to determination of disease severity. 107,487 sequences were analyzed, with mean of 3,359 (range 1,724-4,915) per sample. 2 of 10 samples collected <72 hours of life contained adequate bacterial DNA for successful sequence analysis, one of which was from a subject exposed to chorioamnionitis. All other samples exhibited bacterial loads >70copies/reaction. 72 organisms were observed in total. Seven organisms represented the dominant organism (>50% of total sequences) in 31/32 samples with positive sequences. A dominant organism represented>90% of total sequences in 13 samples. Staphylococcus, Ureaplasmaparvum, and Ureaplasmaurealyticum were the most frequently identified dominant organisms, but Pseudomonas, Enterococcus, and Escherichia were also identified. Conclusions: Early bacterial colonization with diverse species occursafter the first 3 days of life in the airways of intubated preterm infants, and can be characterized by bacterial load and marked species diversity. Molecular identification of bacteria in the lower airways of preterm infants has the potential to yield further insight into the pathogenesis of BPD.	[Mourani, Peter M.; Harris, J. Kirk; Abman, Steven H.] Univ Colorado Denver, Sch Med, Dept Pediat, Pediat Heart Lung Ctr, Aurora, CO USA; [Sontag, Marci K.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA; [Robertson, Charles E.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Boulder	Mourani, PM (corresponding author), Univ Colorado Denver, Sch Med, Dept Pediat, Pediat Heart Lung Ctr, Aurora, CO USA.	Peter.Mourani@UCDenver.edu		Harris, Jonathan/0000-0002-2378-4202; ROBERTSON, CHARLES/0000-0002-4136-4121; Sontag, Marci/0000-0003-2501-652X	National Institutes of Health, National Center for Research Resources [K23 RR021021]; Colorado Clinical and Translational Sciences Institute [UL1 RR025780]; National Heart Lung Blood Institute [R01 HL085703]; Thrasher Research Fund; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780, S10RR021021] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085703] Funding Source: NIH RePORTER	National Institutes of Health, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Colorado Clinical and Translational Sciences Institute; National Heart Lung Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Thrasher Research Fund; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by National Institutes of Health, National Center for Research Resources K23 RR021021, http://www.ncrr.nih.gov/ and Colorado Clinical and Translational Sciences Institute UL1 RR025780, http://cctsi.ucdenver.edu/Pages/index.aspx; National Heart Lung Blood Institute R01 HL085703, http://www.nhlbi.nih.gov/; Thrasher Research Fund, http://www.thrasherresearch.org/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baier R John, 2003, BMC Pediatr, V3, P10, DOI 10.1186/1471-2431-3-10; Ballard HO, 2011, PEDIATR PULM, V46, P111, DOI 10.1002/ppul.21352; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bose CL, 2008, ARCH DIS CHILD-FETAL, V93, P1455, DOI 10.1136/adc.2007.121327; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cayabyab R G, 2003, J Matern Fetal Neonatal Med, V14, P205, DOI 10.1080/713606608; DaSilva O, 1997, PEDIATR INFECT DIS J, V16, P364, DOI 10.1097/00006454-199704000-00006; de La Serre CB, 2010, AM J PHYSIOL-GASTR L, V299, pG440, DOI 10.1152/ajpgi.00098.2010; DiGiulio DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003056; Dimmitt RA, 2010, J PEDIATR GASTR NUTR, V51, P262, DOI 10.1097/MPG.0b013e3181e1a114; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Frank DN, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-362; Frank DN, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-420; Frank DN, 2010, XPLORSEQ TOOL KIT TO; Garland SM, 1996, PATHOLOGY, V28, P266, DOI 10.1080/00313029600169134; GRONECK P, 1995, ARCH DIS CHILD-FETAL, V73, pF1, DOI 10.1136/fn.73.1.F1; Groneck P, 2001, PEDIATR PULM, V31, P331, DOI 10.1002/ppul.1055; Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110; Hamady M, 2008, NAT METHODS, V5, P235, DOI 10.1038/NMETH.1184; Harris JK, APPL ENV MICROBIOL, V3863-3868; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Iles R, 1996, ACTA PAEDIATR, V85, P482, DOI 10.1111/j.1651-2227.1996.tb14067.x; JONSSON B, 1994, ACTA PAEDIATR, V83, P927, DOI 10.1111/j.1651-2227.1994.tb13174.x; Jonsson B, 1997, ARCH DIS CHILD-FETAL, V77, pF198, DOI 10.1136/fn.77.3.F198; Kallopur SG, 2006, ARCH DIS CHILD-FETAL, V91, pF132, DOI 10.1136/adc.2004.068544; Kotecha S, 1996, PEDIATR RES, V40, P250, DOI 10.1203/00006450-199608000-00010; Li P, 2010, NATURE, V464, P1287, DOI 10.1038/4641287a; Lyon AJ, 1998, ARCH DIS CHILD-FETAL, V78, pF10, DOI 10.1136/fn.78.1.F10; Nadkarni MA, 2002, MICROBIOL-SGM, V148, P257, DOI 10.1099/00221287-148-1-257; Nawrocki EP, 2009, BIOINFORMATICS, V25, P1335, DOI 10.1093/bioinformatics/btp157; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Speer CP, 2006, SEMIN FETAL NEONAT M, V11, P354, DOI 10.1016/j.siny.2006.03.004; Speer Christian P, 2003, Semin Neonatol, V8, P29, DOI 10.1016/S1084-2756(02)00190-2; Speer Christian P, 2009, Neonatology, V95, P353, DOI 10.1159/000209301; Speer CP, 2010, BRONCHOPULMONARY DYS, Vxvii; Stressmann FA, 2010, J PERINAT MED, V38, P333, DOI 10.1515/jpm.2010.026; Suerbaum S, 2009, GASTROENTEROLOGY, V137, P419, DOI 10.1053/j.gastro.2009.06.017; Van Marter LJ, 2002, J PEDIATR-US, V140, P171, DOI 10.1067/mpd.2002.121381; van Vliet MJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000879; vanWaarde WM, 1997, EUR RESPIR J, V10, P886; Viscardi RM, 2009, PEDIATR RES, V65, p84R, DOI 10.1203/PDR.0b013e31819dc2f9; WAITES KB, 1994, PEDIATR INFECT DIS J, V13, P287, DOI 10.1097/00006454-199404000-00008; Walsh Michele C, 2003, J Perinatol, V23, P451, DOI 10.1038/sj.jp.7210963; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Yang LY, 2009, GASTROENTEROLOGY, V137, P588, DOI 10.1053/j.gastro.2009.04.046; Zemanick ET, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015101	48	56	57	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 10	2011	6	10							e25959	10.1371/journal.pone.0025959	http://dx.doi.org/10.1371/journal.pone.0025959			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834OO	22016793	Green Published, Green Submitted, gold			2023-01-03	WOS:000295971700030
J	Cortes, JE; Curns, AT; Tate, JE; Cortese, MM; Patel, MM; Zhou, FJ; Parashar, UD				Cortes, Jennifer E.; Curns, Aaron T.; Tate, Jacqueline E.; Cortese, Margaret M.; Patel, Manish M.; Zhou, Fangjun; Parashar, Umesh D.			Rotavirus Vaccine and Health Care Utilization for Diarrhea in US Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; GASTROENTERITIS; HOSPITALIZATIONS; EFFICACY; SAFETY	Background Routine vaccination of U. S. infants with pentavalent rotavirus vaccine (RV5) began in 2006. Methods Using MarketScan databases, we assessed RV5 coverage and diarrhea-associated health care use from July 2007 through June 2009 versus July 2001 through June 2006 in children under 5 years of age. We compared the rates of diarrhea-associated health care use in unvaccinated children in the period from January through June (when rotavirus is most prevalent) in 2008 and 2009 with the prevaccine rates to estimate indirect benefits. We estimated national reductions in the number of hospitalizations for diarrhea, and associated costs, by extrapolation. Results By December 31, 2008, at least one dose of RV5 had been administered in 73% of children under 1 year of age, 64% of children 1 year of age, and 8% of children 2 to 4 years of age. Among children under 5 years of age, rates of hospitalization for diarrhea in 2001-2006, 2007-2008, and 2008-2009 were 52, 35, and 39 cases per 10,000 person-years, respectively, for relative reductions from 2001-2006 by 33% (95% confidence interval [CI], 31 to 35) in 2007-2008 and by 25% (95% CI, 23 to 27) in 2008-2009; rates of hospitalization specifically coded for rotavirus infection were 14, 4, and 6 cases per 10,000 person-years, respectively, for relative reductions in the rate from 2001-2006 by 75% (95% CI, 72 to 77) in 2007-2008 and by 60% (95% CI, 58 to 63) in 2008-2009. In the January-June periods of 2008 and 2009, the respective relative rate reductions among vaccinated children as compared with unvaccinated children were as follows: hospitalization for diarrhea, 44% (95% CI, 33 to 53) and 58% (95% CI, 52 to 64); rotavirus-coded hospitalization, 89% (95% CI, 79 to 94) and 89% (95% CI, 84 to 93); emergency department visits for diarrhea, 37% (95% CI, 31 to 43) and 48% (95% CI, 44 to 51); and outpatient visits for diarrhea, 9% (95% CI, 6 to 11) and 12% (95% CI, 10 to 15). Indirect benefits (in unvaccinated children) were seen in 2007-2008 but not in 2008-2009. Nationally, for the 2007-2009 period, there was an estimated reduction of 64,855 hospitalizations, saving approximately $278 million in treatment costs. Conclusions Since the introduction of rotavirus vaccine, diarrhea-associated health care utilization and medical expenditures for U. S. children have decreased substantially.	[Cortes, Jennifer E.; Curns, Aaron T.; Tate, Jacqueline E.; Cortese, Margaret M.; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA; [Cortes, Jennifer E.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA; [Zhou, Fangjun] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Parashar, UD (corresponding author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd,MS A-47, Atlanta, GA 30333 USA.	uparashar@cdc.gov			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2010, MMWR RECOMM REP, V59, P1074; Atlanta: Centers for Disease Control and Prevention, 2008, MARKETSCAN; Block SL, 2007, PEDIATRICS, V119, P11, DOI 10.1542/peds.2006-2058; Boom JA, 2010, PEDIATRICS, V125, pE199, DOI 10.1542/peds.2009-1021; Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088; Clark HF, 2009, CLIN VACCINE IMMUNOL, V16, P382, DOI 10.1128/CVI.00382-08; Cortese M, 2010, ADV COMM IMM PRACT M; Cortese MM, 2010, PEDIATR INFECT DIS J, V29, P489, DOI 10.1097/INF.0b013e3181d95b53; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Parashar Umesh D., 2006, Morbidity and Mortality Weekly Report, V55, P1; Patel MM, 2011, NEW ENGL J MED, V364, P2283, DOI 10.1056/NEJMoa1012952; Patel MM, 2011, VITALSTATS, V364, P2283; Payne DC, 2010, PEDIATR INFECT DIS J, V29, P287, DOI 10.1097/INF.0b013e3181d40e76; Payne DC, 2009, PEDIATR INFECT DIS J, V28, P948, DOI 10.1097/INF.0b013e3181a6ad6e; Pitzer VE, 2009, SCIENCE, V325, P290, DOI 10.1126/science.1172330; Rothman KJ, 1998, NAT IMM SURV EST VAC; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Tate JE, 2011, PEDIATR INFECT DIS J, V30, pS30, DOI 10.1097/INF.0b013e3181ffe3eb; Tate JE, 2009, PEDIATRICS, V123, P744, DOI 10.1542/peds.2008-1200; US Department of Labor Bureau of Labor Statistics, CONS PRIC IND; Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664; Wang FT, 2010, PEDIATRICS, V125, pE208, DOI 10.1542/peds.2009-1246; Widdowson MA, 2007, PEDIATRICS, V119, P684, DOI 10.1542/peds.2006-2876; Yen C, 2011, PEDIATRICS, V127, pE9, DOI 10.1542/peds.2010-1393	25	124	127	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	2011	365	12					1108	1117		10.1056/NEJMoa1000446	http://dx.doi.org/10.1056/NEJMoa1000446			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	822WR	21992123				2023-01-03	WOS:000295081600010
J	Balachandran, VP; Cavnar, MJ; Zeng, S; Bamboat, ZM; Ocuin, LM; Obaid, H; Sorenson, EC; Popow, R; Ariyan, C; Rossi, F; Besmer, P; Guo, TH; Antonescu, CR; Taguchi, T; Yuan, JD; Wolchok, JD; Allison, JP; DeMatteo, RP				Balachandran, Vinod P.; Cavnar, Michael J.; Zeng, Shan; Bamboat, Zubin M.; Ocuin, Lee M.; Obaid, Hebroon; Sorenson, Eric C.; Popow, Rachel; Ariyan, Charlotte; Rossi, Ferdinand; Besmer, Peter; Guo, Tianhua; Antonescu, Cristina R.; Taguchi, Takahiro; Yuan, Jianda; Wolchok, Jedd D.; Allison, James P.; DeMatteo, Ronald P.			Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido	NATURE MEDICINE			English	Article							INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION; RECEPTOR TYROSINE KINASE; DENDRITIC CELLS; MOUSE MODEL; COMBINATION IMMUNOTHERAPY; TRYPTOPHAN CATABOLISM; CTLA-4 BLOCKADE; OVARIAN-CANCER; REGULATORY CELLS; C-KIT	Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and produces a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor-cell survival and proliferation. Using a mouse model of spontaneous GIST, we found that the immune system contributes substantially to the antitumor effects of imatinib. Imatinib therapy activated CD8(+) T cells and induced regulatory T cell (T-reg cell) apoptosis within the tumor by reducing tumor-cell expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (Ido). Concurrent immunotherapy augmented the efficacy of imatinib in mouse GIST. In freshly obtained human GIST specimens, the T cell profile correlated with imatinib sensitivity and IDO expression. Thus, T cells are crucial to the antitumor effects of imatinib in GIST, and concomitant immunotherapy may further improve outcomes in human cancers treated with targeted agents.	[Balachandran, Vinod P.; Cavnar, Michael J.; Zeng, Shan; Bamboat, Zubin M.; Ocuin, Lee M.; Obaid, Hebroon; Sorenson, Eric C.; Popow, Rachel; Ariyan, Charlotte; DeMatteo, Ronald P.] Mem Hosp, Dept Surg, New York, NY USA; [Rossi, Ferdinand; Besmer, Peter] Sloan Kettering Inst, Dev Biol Program, New York, NY USA; [Guo, Tianhua; Antonescu, Cristina R.] Mem Hosp, Dept Pathol, New York, NY USA; [Taguchi, Takahiro] Kochi Univ, Div Human Hlth & Med Sci, Grad Sch Kuroshio Sci, Kochi 780, Japan; [Yuan, Jianda; Wolchok, Jedd D.; Allison, James P.] Ludwig Ctr Canc Immunotherapy, New York, NY USA; [Wolchok, Jedd D.] Mem Hosp, Dept Med, New York, NY USA; [Allison, James P.] Sloan Kettering Inst, Program Immunol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Kochi University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Hosp, Dept Surg, New York, NY USA.	dematter@mskcc.org		Allison, James/0000-0001-8980-5697; Guo, Tianhua/0000-0003-0876-9837; Ariyan, Charlotte/0000-0003-0818-3895	US National Institutes of Health (NIH) [R01 CA102613]; Geoffrey Beene Cancer Research Center; Dutch GIST Foundation; GIST; Society for University; NIH [R01 CA102774, R01 HL55748, P50 CA140146, R24 CA83084, P30 CA08748]; LifeRaft Group and Starr Cancer Consortium; Cancer Center [NCI P30-CA008748]; NATIONAL CANCER INSTITUTE [T32CA009501, R01CA102613, P30CA008748, P50CA140146, R01CA102774, R24CA083084] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055748] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Geoffrey Beene Cancer Research Center; Dutch GIST Foundation; GIST; Society for University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); LifeRaft Group and Starr Cancer Consortium; Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank members of the Genomics, Tissue Procurement, Monoclonal Antibody, Molecular Cytology and Animal Imaging core facilities and the Laboratory of Comparative Pathology of Sloan-Kettering Institute. We acknowledge H.F. Gallardo, Y. Li, B. Zaidi, T. Rasalan, R. Chua, the Research Animal Resource Center, members of the laboratories of B. Singh and M. Weiser, and R. Holmes for technical assistance and logistical support, G. Rizzuto, D. Hirschhorn-Cymerman, D. Schaer, F. Avogadri and T. Merghoub for helpful discussions, and M. Gonen for statistical assistance. This work was supported by US National Institutes of Health (NIH) grant R01 CA102613, the Geoffrey Beene Cancer Research Center, Mr. J.H.L. Pit and Mrs. Pit-van Karnebeek and the Dutch GIST Foundation, GIST Cancer Research Fund and Swim Across America (R.P.D.); the Society for University Surgeons Ethicon Research Fellowship Award (V.P.B.); and NIH grants R01 CA102774, R01 HL55748 and P50 CA140146, LifeRaft Group and Starr Cancer Consortium (P.B.). Technical services provided by the Animal Imaging Core Facility were supported by the Small-Animal Imaging Research Program (SAIRP) NIH grants R24 CA83084 and P30 CA08748; the Molecular Cytology Core Facility was supported by Cancer Center Support grant NCI P30-CA008748.	Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966; Brenk M, 2009, J IMMUNOL, V183, P145, DOI 10.4049/jimmunol.0803277; Cameron S, 2008, EUR J GASTROEN HEPAT, V20, P327, DOI 10.1097/MEG.0b013e3282f3a403; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Cho HJ, 2009, NEOPLASIA, V11, P247, DOI 10.1593/neo.81360; Cohen AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010436; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Demaria S, 2005, CLIN CANCER RES, V11, P728; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hirschhorn-Cymerman D, 2009, J EXP MED, V206, P1103, DOI 10.1084/jem.20082205; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Hurwitz AA, 2000, CANCER RES, V60, P2444; Katz JB, 2008, IMMUNOL REV, V222, P206, DOI 10.1111/j.1600-065X.2008.00610.x; Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105; Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200; Klein S, 2005, NAT REV CANCER, V5, P573, DOI 10.1038/nrc1651; Koch LK, 2009, BLOOD, V114, P5062, DOI 10.1182/blood-2009-06-227587; Kroczynska B, 2009, MOL CELL BIOL, V29, P2865, DOI 10.1128/MCB.01537-08; Larmonier N, 2008, J IMMUNOL, V181, P6955, DOI 10.4049/jimmunol.181.10.6955; Lee HJ, 2007, BIOCHEM PHARMACOL, V73, P1412, DOI 10.1016/j.bcp.2006.12.018; Lee KC, 2010, LEUKEMIA, V24, P896, DOI 10.1038/leu.2010.11; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Menard C, 2009, CANCER RES, V69, P3563, DOI 10.1158/0008-5472.CAN-08-3807; Mokyr MB, 1998, CANCER RES, V58, P5301; Muller AJ, 2010, CANCER RES, V70, P1845, DOI 10.1158/0008-5472.CAN-09-3613; Munn DH, 2007, J CLIN INVEST, V117, P1147, DOI 10.1172/JCI31178; Okamoto A, 2005, CLIN CANCER RES, V11, P6030, DOI 10.1158/1078-0432.CCR-04-2671; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Pedicord VA, 2011, P NATL ACAD SCI USA, V108, P266, DOI 10.1073/pnas.1016791108; Peggs KS, 2008, IMMUNOL REV, V224, P141, DOI 10.1111/j.1600-065X.2008.00649.x; Perez D, 2008, INT J CANCER, V123, P1551, DOI 10.1002/ijc.23698; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Sharma MD, 2007, J CLIN INVEST, V117, P2570, DOI 10.1172/JCI31911; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Takao M, 2007, ONCOL REP, V17, P1333; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; van Dongen M, 2010, INT J CANCER, V127, P899, DOI 10.1002/ijc.25113; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	58	389	424	3	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2011	17	9					1094	U99		10.1038/nm.2438	http://dx.doi.org/10.1038/nm.2438			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	816MM	21873989	Green Accepted			2023-01-03	WOS:000294605100029
J	Joynt, KE; Jha, AK				Joynt, Karen E.; Jha, Ashish K.			Thirty-Day Readmissions - Truth and Consequences	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HOSPITAL READMISSIONS; CARE		[Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.							Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; van Walraven C, 2011, CAN MED ASSOC J, V183, pE1067, DOI 10.1503/cmaj.110400; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	5	372	374	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1366	1369		10.1056/NEJMp1201598	http://dx.doi.org/10.1056/NEJMp1201598			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22455752				2023-01-03	WOS:000302608600013
J	Puppala, M; Ponder, J; Suryanarayana, P; Reddy, GB; Petrash, JM; LaBarbera, DV				Puppala, Muthenna; Ponder, Jessica; Suryanarayana, Palla; Reddy, Geereddy Bhanuprakash; Petrash, J. Mark; LaBarbera, Daniel V.			The Isolation and Characterization of beta-Glucogallin as a Novel Aldose Reductase Inhibitor from Emblica officinalis	PLOS ONE			English	Article							DIABETIC-RETINOPATHY; TRANSGENIC MICE; KETO REDUCTASES; RAT RETINA; COMPLICATIONS; CATARACT; TANNINS; LENS; ACCUMULATION; DEFICIENCY	Diabetes mellitus is recognized as a leading cause of new cases of blindness. The prevalence of diabetic eye disease is expected to continue to increase worldwide as a result of the dramatic increase in the number of people with diabetes. At present, there is no medical treatment to delay or prevent the onset and progression of cataract or retinopathy, the most common causes of vision loss in diabetics. The plant Emblica officinalis (gooseberry) has been used for thousands of years as a traditional Indian Ayurvedic preparation for the treatment of diabetes in humans. Extracts from this plant have been shown to be efficacious against the progression of cataract in a diabetic rat model. Aldose reductase (ALR2) is implicated in the development of secondary complications of diabetes including cataract and, therefore, has been a major drug target for the development of therapies to treat diabetic disease. Herein, we present the bioassay-guided isolation and structure elucidation of 1-O-galloy1-beta-D-glucose (beta-glucogallin), a major component from the fruit of the gooseberry that displays selective as well as relatively potent inhibition (IC50=17 mu M) of AKR1B1 in vitro. Molecular modeling demonstrates that this inhibitor is able to favorably bind in the active site. Further, we show that beta-glucogallin effectively inhibits sorbitol accumulation by 73% at 30 mu M under hyperglycemic conditions in an ex-vivo organ culture model of lenses excised from transgenic mice overexpressing human ALR2 in the lens. This study supports the continued development of natural products such as beta-glucogallin as therapeutic leads in the development of novel therapies to treat diabetic complications such as cataract.	[Puppala, Muthenna; Suryanarayana, Palla; Reddy, Geereddy Bhanuprakash] Natl Inst Nutr, Dept Biochem, Hyderabad 500007, Andhra Pradesh, India; [Ponder, Jessica; Petrash, J. Mark; LaBarbera, Daniel V.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO USA; [Petrash, J. Mark] Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO USA	Indian Council of Medical Research (ICMR); ICMR - National Institute of Nutrition (NIN); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Puppala, M (corresponding author), Natl Inst Nutr, Dept Biochem, Hyderabad 500007, Andhra Pradesh, India.	daniel.labarbera@ucdenver.edu	Reddy, G Bhanuprakash/AAJ-3494-2020; Puppala, Muthenna/R-9629-2017	Reddy, G Bhanuprakash/0000-0003-4787-3944; Puppala, Muthenna/0000-0002-7035-749X	Department of Biotechnology; Life Sciences Research Board of Defense Research; Development Organization, Government of India (GBR); National Institutes of Health [EY005856, EY021498]; Skaggs School of Pharmacy and Pharmaceutical Sciences; University Grants Commission, India; BOYSCAST from the Department of Science and Technology, New Delhi, India; NATIONAL EYE INSTITUTE [R55EY005856, R01EY021498, R23EY005856, R01EY005856] Funding Source: NIH RePORTER	Department of Biotechnology; Life Sciences Research Board of Defense Research; Development Organization, Government of India (GBR); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Skaggs School of Pharmacy and Pharmaceutical Sciences; University Grants Commission, India(University Grants Commission, India); BOYSCAST from the Department of Science and Technology, New Delhi, India; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	This work was funded in part by grants from the Department of Biotechnology (under 7th FP of Indo-EU collaborative program on functional foods) and Life Sciences Research Board of Defense Research and Development Organization, Government of India (GBR), National Institutes of Health grants EY005856 (JMP) and EY021498 (DVL and JMP), and through Skaggs School of Pharmacy and Pharmaceutical Sciences start up funds (DVL). MP was supported by a Senior Research Fellowship from the University Grants Commission, India. PS was supported by a BOYSCAST fellowship from the Department of Science and Technology, New Delhi, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello LP, 1998, DIABETES CARE, V21, P143, DOI 10.2337/diacare.21.1.143; Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; Diabetes Control and Complications Trial, 1995, ARCH OPHTHALMOL, V113, P36; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; El-Kabbani O, 2000, PROTEINS, V41, P407, DOI 10.1002/1097-0134(20001115)41:3<407::AID-PROT120>3.0.CO;2-9; El-Remessy AB, 2003, INVEST OPHTH VIS SCI, V44, P3135, DOI 10.1167/iovs.02-1022; ENGERMAN RL, 1993, DIABETES, V42, P820, DOI 10.2337/diabetes.42.6.820; Fischer E, 1918, BER DTSCH CHEM GES, V51, P45, DOI 10.1002/cber.19180510108; Ghosal S, 1996, INDIAN J CHEM B, V35, P941; Giannoukakis N, 2008, EXPERT OPIN INV DRUG, V17, P575, DOI [10.1517/13543784.17.4.575, 10.1517/13543784.17.4.575 ]; Gross G., 1999, COMPREHENSIVE NATURA; Gross GG, 1992, PLANT POLYHENOLS SYN; Haslam E, 2007, PHYTOCHEMISTRY, V68, P2713, DOI 10.1016/j.phytochem.2007.09.009; HAYMAN S, 1965, J BIOL CHEM, V240, P877; KADOR PF, 1985, J MED CHEM, V28, P841, DOI 10.1021/jm00145a001; KASHIWADA Y, 1984, CHEM PHARM BULL, V32, P3461; Klebe G, 2004, CELL MOL LIFE SCI, V61, P783, DOI 10.1007/s00018-003-3406-z; Latte KP, 2000, PHYTOCHEMISTRY, V54, P701, DOI 10.1016/S0031-9422(00)00176-X; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Levin DS, 2007, J AM SOC MASS SPECTR, V18, P502, DOI 10.1016/j.jasms.2006.10.008; Montes M, 2007, PROTEINS, V68, P712, DOI 10.1002/prot.21405; Murata M, 2002, J DIABETES COMPLICAT, V16, P363, DOI 10.1016/S1056-8727(01)00171-4; Neuhauser W, 1997, BIOCHEM J, V326, P683, DOI 10.1042/bj3260683; Oates, 1999, Expert Opin Investig Drugs, V8, P2095, DOI 10.1517/13543784.8.12.2095; Penning TM, 2007, ARCH BIOCHEM BIOPHYS, V464, P241, DOI 10.1016/j.abb.2007.04.024; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Petrash JM, 2004, CELL MOL LIFE SCI, V61, P737, DOI 10.1007/s00018-003-3402-3; Quideau, 2009, CHEM BIOL ELLAGITANN; Quin GJ, 2007, PROTEOMICS, V7, P2636, DOI 10.1002/pmic.200600486; RAO PV, 1989, NUTR RES, V9, P1143, DOI 10.1016/S0271-5317(89)80049-1; Reddy GB, 2008, MOL VIS, V14, P593; Reddy GB, 2011, PYLLANTHUS SPECIES S, P235; ROBISON WG, 1990, EXP EYE RES, V50, P355, DOI 10.1016/0014-4835(90)90136-I; SARGES R, 1986, METABOLISM, V35, P101, DOI 10.1016/0026-0495(86)90196-4; Scartezzini P, 2000, J ETHNOPHARMACOL, V71, P23, DOI 10.1016/S0378-8741(00)00213-0; Shen Y, 2011, CHEM-BIOL INTERACT, V191, P192, DOI 10.1016/j.cbi.2011.02.004; Song ZT, 2003, MOL CELL NEUROSCI, V23, P638, DOI 10.1016/S1044-7431(03)00096-4; Suryanarayana P, 2007, MOL VIS, V13, P1291; Suryanarayana P, 2004, MOL VIS, V10, P148; Urzhumtsev A, 1997, STRUCTURE, V5, P601, DOI 10.1016/S0969-2126(97)00216-5; YAMAOKA T, 1995, DIABETOLOGIA, V38, P255, DOI 10.1007/s001250050278	44	65	68	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2012	7	4							e31399	10.1371/journal.pone.0031399	http://dx.doi.org/10.1371/journal.pone.0031399			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	952GU	22485126	Green Published, gold, Green Submitted			2023-01-03	WOS:000304780500002
J	Chen, R; Mias, GI; Li-Pook-Than, J; Jiang, LH; Lam, HYK; Chen, R; Miriami, E; Karczewski, KJ; Hariharan, M; Dewey, FE; Cheng, Y; Clark, MJ; Im, H; Habegger, L; Balasubramanian, S; O'Huallachain, M; Dudley, JT; Hillenmeyer, S; Haraksingh, R; Sharon, D; Euskirchen, G; Lacroute, P; Bettinger, K; Boyle, AP; Kasowski, M; Grubert, F; Seki, S; Garcia, M; Whirl-Carrillo, M; Gallardo, M; Blasco, MA; Greenberg, PL; Snyder, P; Klein, TE; Altman, RB; Butte, AJ; Ashley, EA; Gerstein, M; Nadeau, KC; Tang, H; Snyder, M				Chen, Rui; Mias, George I.; Li-Pook-Than, Jennifer; Jiang, Lihua; Lam, Hugo Y. K.; Chen, Rong; Miriami, Elana; Karczewski, Konrad J.; Hariharan, Manoj; Dewey, Frederick E.; Cheng, Yong; Clark, Michael J.; Im, Hogune; Habegger, Lukas; Balasubramanian, Suganthi; O'Huallachain, Maeve; Dudley, Joel T.; Hillenmeyer, Sara; Haraksingh, Rajini; Sharon, Donald; Euskirchen, Ghia; Lacroute, Phil; Bettinger, Keith; Boyle, Alan P.; Kasowski, Maya; Grubert, Fabian; Seki, Scott; Garcia, Marco; Whirl-Carrillo, Michelle; Gallardo, Mercedes; Blasco, Maria A.; Greenberg, Peter L.; Snyder, Phyllis; Klein, Teri E.; Altman, Russ B.; Butte, Atul J.; Ashley, Euan A.; Gerstein, Mark; Nadeau, Kari C.; Tang, Hua; Snyder, Michael			Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes	CELL			English	Article							TIME-SERIES ANALYSIS; PERIODICITY DETECTION; GENE ONTOLOGY; RNA; EXPRESSION; IDENTIFICATION; TRANSCRIPT; MUTATIONS; ALGORITHM; DATABASE	Personalized medicine is expected to benefit from combining genomic information with regular monitoring of physiological states by multiple high-throughput methods. Here, we present an integrative personal omics profile (iPOP), an analysis that combines genomic, transcriptomic, proteomic, metabolomic, and autoantibody profiles from a single individual over a 14 month period. Our iPOP analysis revealed various medical risks, including type 2 diabetes. It also uncovered extensive, dynamic changes in diverse molecular components and biological pathways across healthy and diseased conditions. Extremely high-coverage genomic and transcriptomic data, which provide the basis of our iPOP, revealed extensive heteroallelic changes during healthy and diseased states and an unexpected RNA editing mechanism. This study demonstrates that longitudinal iPOP can be used to interpret healthy and diseased states by connecting genomic information with additional dynamic omics activity.	[Chen, Rui; Mias, George I.; Li-Pook-Than, Jennifer; Jiang, Lihua; Lam, Hugo Y. K.; Miriami, Elana; Karczewski, Konrad J.; Hariharan, Manoj; Cheng, Yong; Clark, Michael J.; Im, Hogune; O'Huallachain, Maeve; Hillenmeyer, Sara; Haraksingh, Rajini; Sharon, Donald; Euskirchen, Ghia; Lacroute, Phil; Bettinger, Keith; Boyle, Alan P.; Kasowski, Maya; Grubert, Fabian; Whirl-Carrillo, Michelle; Snyder, Phyllis; Klein, Teri E.; Altman, Russ B.; Tang, Hua; Snyder, Michael] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; [Chen, Rong; Dudley, Joel T.; Seki, Scott; Garcia, Marco; Butte, Atul J.; Nadeau, Kari C.] Stanford Univ, Dept Pediat, Div Syst Med, Stanford, CA 94305 USA; [Chen, Rong; Dudley, Joel T.; Seki, Scott; Butte, Atul J.; Nadeau, Kari C.] Stanford Univ, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA; [Dewey, Frederick E.; Ashley, Euan A.] Stanford Univ, Sch Med, Div Cardiovasc Med, Ctr Inherited Cardiovasc Dis, Stanford, CA 94305 USA; [Greenberg, Peter L.] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA; [Altman, Russ B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Habegger, Lukas; Balasubramanian, Suganthi; Gerstein, Mark] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT 06520 USA; [Habegger, Lukas; Balasubramanian, Suganthi; Gerstein, Mark] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Gerstein, Mark] Yale Univ, Dept Comp Sci, New Haven, CT 06520 USA; [Gallardo, Mercedes; Blasco, Maria A.] Spanish Natl Canc Ctr CNIO, Mol Oncol Program, Telomeres & Telomerase Grp, E-28029 Madrid, Spain; [Gallardo, Mercedes] Life Length, E-28003 Madrid, Spain	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Yale University; Yale University; Yale University; Centro Nacional de Investigaciones Oncologicas (CNIO)	Snyder, M (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	mpsnyder@stanford.edu	Mias, George/J-1138-2019; cheng, yong/I-4270-2012; Hariharan, Manoj/N-2855-2015; Boyle, Alan/I-1848-2014; Im, Hogune/ABG-3002-2021; O'Huallachain, Maeve/AAO-4312-2020; Blasco, Maria A./M-1694-2014; Karczewski, Jakub/L-7326-2018	Mias, George/0000-0002-9083-1216; Hariharan, Manoj/0000-0002-1006-5372; Boyle, Alan/0000-0002-2081-1105; Im, Hogune/0000-0002-2812-4617; O'Huallachain, Maeve/0000-0002-0618-6032; Blasco, Maria A./0000-0002-4211-233X; Balasubramanian, Suganthi/0000-0003-2243-5948; Whirl-Carrillo, Michelle/0000-0003-2414-9312; Karczewski, Konrad/0000-0003-2878-4671; Klein, Teri/0000-0001-5527-6475; Haraksingh, Rajini/0000-0002-6644-8874; Karczewski, Jakub/0000-0001-9322-7842; Snyder, Michael/0000-0003-0784-7987	Stanford University; NIH [OD004613]; NIH/NLM [T15-LM007033]; NIH/NIGMS [R24-GM61374]; Spanish Ministry of Science and Innovation [SAF2008-05384, CSD2007-00017]; European Union [2007-A-201630, 2007-A-200950]; European Research Council [GA232854]; Korber Foundation; Fundacion Marcelino Botin; Fundacion Lilly (Espana); NIH/NHLBI [T32 HL094274, KO8 HL083914]; Breetwor Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL094274, K08HL083914] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG004558, P50HG002357, T32HG000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM061374, T32GM007205] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007033] Funding Source: NIH RePORTER	Stanford University(Stanford University); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NLM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Union(European Commission); European Research Council(European Research Council (ERC)European Commission); Korber Foundation; Fundacion Marcelino Botin; Fundacion Lilly (Espana); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Breetwor Family Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	M. S. is funded by grants from Stanford University and the NIH. M.G. is funded by grants from the NIH. G.I.M. is funded by NIH training grant. K.J.K., J.T.D., and S.H. are supported by the NIH/NLM training grant T15-LM007033. T.E.K. and R.B.A are funded by NIH/NIGMS R24-GM61374. M.A.B.'s laboratory is funded by the Spanish Ministry of Science and Innovation Projects SAF2008-05384 and CSD2007-00017, European Union FP7 Projects 2007-A-201630 (GENICA) and 2007-A-200950 (TELOMARKER), European Research Council Advanced Grant GA232854, the Korber Foundation, the Fundacion Marcelino Botin, and Fundacion Lilly (Espana). F.E.D. was supported by NIH/NHLBI training grant T32 HL094274. E.A.A. was supported by NIH/NHLBI KO8 HL083914, NIH New Investigator DP2 Award OD004613, and a grant from the Breetwor Family Foundation. We dedicate this manuscript to Dr. Tara A. Gianoulis, an enthusiastic advocate for genomic science. R.B.A., E.A.A., A.B., and M.S. serve as founders and consultants for Personalis. R.B.A. is a consultant to 23andMe. M.S. is a member of the scientific advisory board of GenapSys and a consultant for Illumina. M.A.B. acts as consultant and holds stock in Life Length.	Abyzov A, 2011, GENOME RES, V21, P974, DOI 10.1101/gr.114876.110; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Ahdesmaki M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-233; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Cox J, 2011, ANNU REV BIOCHEM, V80, P273, DOI 10.1146/annurev-biochem-061308-093216; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Dewey FE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002280; Erlich HA, 2009, GENES IMMUN, V10, pS54, DOI 10.1038/gene.2009.92; Galeano F, 2010, INT J CANCER, V127, P127, DOI 10.1002/ijc.25022; Glynn EF, 2006, BIOINFORMATICS, V22, P310, DOI 10.1093/bioinformatics/bti789; Gommans WM, 2008, RNA, V14, P2074, DOI 10.1261/rna.816908; Grayson BL, 2011, GENES IMMUN, V12, P341, DOI 10.1038/gene.2011.13; Hani EH, 1998, DIABETOLOGIA, V41, P1511, DOI 10.1007/s001250051098; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Hocke K, 2009, ATMOS CHEM PHYS, V9, P4197, DOI 10.5194/acp-9-4197-2009; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Jima DD, 2010, BLOOD, V116, pE118, DOI 10.1182/blood-2010-05-285403; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621; Kersey PJ, 2004, PROTEOMICS, V4, P1985, DOI 10.1002/pmic.200300721; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kusunoki Masataka, 2007, J Med Invest, V54, P243, DOI 10.2152/jmi.54.243; Lam HYK, 2010, NAT BIOTECHNOL, V28, P47, DOI 10.1038/nbt.1600; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Levanon EY, 2005, NUCLEIC ACIDS RES, V33, P1162, DOI 10.1093/nar/gki239; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li JB, 2009, SCIENCE, V324, P1210, DOI 10.1126/science.1170995; Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018; Li RQ, 2010, NAT BIOTECHNOL, V28, P57, DOI 10.1038/nbt.1596; LOMB NR, 1976, ASTROPHYS SPACE SCI, V39, P447, DOI 10.1007/BF00648343; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Mills RE, 2011, NATURE, V470, P59, DOI 10.1038/nature09708; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Parkhomchuk D, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp596; Pickup JC, 2004, DIABETES CARE, V27, P813, DOI 10.2337/diacare.27.3.813; Rozowsky J, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.54; SCARGLE JD, 1982, ASTROPHYS J, V263, P835, DOI 10.1086/160554; SCARGLE JD, 1989, ASTROPHYS J, V343, P874, DOI 10.1086/167757; Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675; Snyder M, 2010, GENE DEV, V24, P423, DOI 10.1101/gad.1864110; Snyder M, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.32; Stewart C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002236; Sun JC, 2010, WORLD J GASTROENTERO, V16, P4611, DOI 10.3748/wjg.v16.i36.4611; Theodoridis G, 2011, MASS SPECTROM REV, V30, P884, DOI 10.1002/mas.20306; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van der Werf N, 2007, DIABETES-METAB RES, V23, P169, DOI 10.1002/dmrr.695; van Dongen HPA, 1999, BIOL RHYTHM RES, V30, P149, DOI 10.1076/brhm.30.2.149.1424; Vaxillaire M, 2008, DIABETES, V57, P2253, DOI 10.2337/db07-1807; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wu JQ, 2010, P NATL ACAD SCI USA, V107, P5254, DOI 10.1073/pnas.0914114107; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Yang RD, 2011, BIOINFORMATICS, V27, P1023, DOI 10.1093/bioinformatics/btr041; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Zhao W., 2008, EURASIP J BIOINFORM, V2008	60	812	840	18	302	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 16	2012	148	6					1293	1307		10.1016/j.cell.2012.02.009	http://dx.doi.org/10.1016/j.cell.2012.02.009			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	913PI	22424236	Green Accepted, Bronze			2023-01-03	WOS:000301889500023
J	Arndt, W; Mitnik, C; Denzler, KL; White, S; Waters, R; Jacobs, BL; Rochon, Y; Olson, VA; Damon, IK; Langland, JO				Arndt, William; Mitnik, Chandra; Denzler, Karen L.; White, Stacy; Waters, Robert; Jacobs, Bertram L.; Rochon, Yvan; Olson, Victoria A.; Damon, Inger K.; Langland, Jeffrey O.			In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox	PLOS ONE			English	Article							VACCINIA VIRUS; TERMINAL DOMAINS; INFECTIONS; CIDOFOVIR; MICE; E3L; IDENTIFICATION; INHIBITION; GENE; RNA	In the nineteenth century, smallpox ravaged through the United States and Canada. At this time, a botanical preparation, derived from the carnivorous plant Sarracenia purpurea, was proclaimed as being a successful therapy for smallpox infections. The work described characterizes the antipoxvirus activity associated with this botanical extract against vaccinia virus, monkeypox virus and variola virus, the causative agent of smallpox. Our work demonstrates the in vitro characterization of Sarracenia purpurea as the first effective inhibitor of poxvirus replication at the level of early viral transcription. With the renewed threat of poxvirus-related infections, our results indicate Sarracenia purpurea may act as another defensive measure against Orthopoxvirus infections.	[Arndt, William; Mitnik, Chandra; Denzler, Karen L.; White, Stacy; Waters, Robert; Jacobs, Bertram L.; Langland, Jeffrey O.] Arizona State Univ, Biodesign Inst, Tempe, AZ 85069 USA; [Waters, Robert; Rochon, Yvan; Langland, Jeffrey O.] SW Coll Naturopath Med, Dept Naturopath Res, Tempe, AZ USA; [Rochon, Yvan] Herbal Vital Inc, Sedona, AZ USA; [Olson, Victoria A.; Damon, Inger K.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA	Arizona State University; Arizona State University-Tempe; Centers for Disease Control & Prevention - USA	Arndt, W (corresponding author), Arizona State Univ, Biodesign Inst, Tempe, AZ 85069 USA.	Jeffrey.Langland@asu.edu			Southwest College of Naturopathic Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI095394] Funding Source: NIH RePORTER	Southwest College of Naturopathic Medicine; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Grant support from the Southwest College of Naturopathic Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bolken TC, 2010, DRUG TODAY, V46, P109, DOI 10.1358/dot.2010.46.2.1437244; Brandt TA, 2001, J VIROL, V75, P850, DOI 10.1128/JVI.75.2.850-856.2001; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; Chen NH, 2005, VIROLOGY, V340, P46, DOI 10.1016/j.virol.2005.05.030; Ciustea M, 2008, J MED CHEM, V51, P6563, DOI 10.1021/jm800366g; Clarke JH, 1900, DICT PRACTICAL MAT; COOPER JA, 1978, VIROLOGY, V88, P149, DOI 10.1016/0042-6822(78)90118-6; Ellison AM, 2004, AM J BOT, V91, P1930, DOI 10.3732/ajb.91.11.1930; Felter HW, 1898, KINGS AM DISENSATORY; Grant WH, 1864, LANCET, V83, P161; Institute of Medicine (US), 1999, ASS FUT SCI NEEDS LI; Jesus DM, 2009, INT J ANTIMICROB AG, V33, P75, DOI 10.1016/j.ijantimicag.2008.07.015; Kern ER, 2002, ANTIMICROB AGENTS CH, V46, P991, DOI 10.1128/AAC.46.4.991-995.2002; Lalezari JP, 1997, ANN INTERN MED, V126, P257, DOI 10.7326/0003-4819-126-4-199702150-00001; Langland JO, 2004, VIROLOGY, V324, P419, DOI 10.1016/j.virol.2004.03.012; Lloyd F. E., 1942, CARNIVOROUS PLANTS; Marson JF, 1863, LANCET, V82, P6; Martin KW, 2003, ANTIVIR THER, V8, P77; MILES DH, 1974, J PHARM SCI, V63, P613, DOI 10.1002/jps.2600630427; Miles H.C., 1862, LANCET, V80, P430, DOI [10.1016/S0140-6736(02)60988-2, DOI 10.1016/S0140-6736(02)60988-2]; Miles HC, 1862, LANCET, V80, P615; Millspaugh C., 1887, AM MED PLANTS ILLUST; NEYTS J, 1993, J MED VIROL, V41, P242, DOI 10.1002/jmv.1890410312; Parker S, 2008, FUTURE VIROL, V3, P595, DOI 10.2217/17460794.3.6.595; Renshaw CJ., 1863, BMJ-BRIT MED J, V1, P127, DOI [10.1136/bmj.1.109.127, DOI 10.1136/BMJ.1.109.127]; Scudder JM, 1870, SPECIFIC MED SPECIFI; Smee DF, 2001, ANTIVIR CHEM CHEMOTH, V12, P71, DOI 10.1177/095632020101200105; Taylor J, 1863, LANCET, V82, P664; Vandaveer C, 2001, COULD CARNIVOROUS PL; Wollenberg A, 2004, CURR OPIN ALLERGY CL, V4, P271, DOI 10.1097/01.all.0000136758.66442.28; Yang G, 2005, J VIROL, V79, P13139, DOI 10.1128/JVI.79.20.13139-13149.2005	31	12	12	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2012	7	3							e32610	10.1371/journal.pone.0032610	http://dx.doi.org/10.1371/journal.pone.0032610			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KX	22427855	Green Published, gold			2023-01-03	WOS:000303062800024
J	Ovadje, P; Hamm, C; Pandey, S				Ovadje, Pamela; Hamm, Caroline; Pandey, Siyaram			Efficient Induction of Extrinsic Cell Death by Dandelion Root Extract in Human Chronic Myelomonocytic Leukemia (CMML) Cells	PLOS ONE			English	Article							HUMAN T-CELLS; APOPTOSIS PATHWAYS; OXIDATIVE STRESS; IN-VITRO; AUTOPHAGY; CANCER; ACTIVATION; CASPASE-8; DISEASE; VIVO	Background: Chronic Myelomonocytic Leukemia (CMML) is a heterogeneous disease that is not only hard to diagnose and classify, but is also highly resistant to treatment. Available forms of therapy for this disease have not shown significant effects and patients rapidly develop resistance early on in therapy. These factors lead to the very poor prognosis observed with CMML patients, with median survival duration between 12 and 24 months after diagnosis. This study is therefore centered around evaluating the selective efficacy of a natural extract from dandelion roots, in inducing programmed cell death in aggressive and resistant CMML cell lines. Methodology/Principal Findings: To confirm the induction of programmed cell death in three human CMML cell lines, nuclear condensation and externalization of the phosphatidylserine, two main characteristics of apoptosis, were detected using Hoechst staining and annexin-V binding assay. The induction of another mode of cell death, autophagy, was determined using a monodansylcadaverine (MDC) stain, to detect the formation of autophagy vacuoles. The results from this study indicate that Dandelion Root Extract (DRE) is able to efficiently and selectively induce apoptosis and autophagy in these cell lines in a dose and time dependent manner, with no significant toxicity on non-cancerous peripheral blood mononuclear cells. More importantly, we observed early activation of initiator caspase-8, which led to mitochondrial destabilization and the induction of autophagy, suggesting that DRE acts through the extrinsic pathway of apoptosis. The inability of DRE to induce apoptosis in dominant-negative FADD cells, confirms the mechanism of action of DRE in in vitro models of CMML. Conclusion: The results from this study indicate that natural products, in particular Dandelion Root Extract, have great potential, as non-toxic and effective alternatives to conventional modes of chemotherapy available today.	[Ovadje, Pamela; Pandey, Siyaram] Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; [Hamm, Caroline] Windsor Reg Canc Ctr, Windsor, ON, Canada	University of Windsor	Ovadje, P (corresponding author), Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada.	spandey@uwindsor.ca	Pandey, Siyaram/AAI-5491-2020; Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161	Seeds4Hope [810257]; Knights of columbus [850285]; Kevin Couvillion Memorial grant [810340]; Seeds4hope Windsor; Essex county Cancer Centre Foundation	Seeds4Hope; Knights of columbus; Kevin Couvillion Memorial grant; Seeds4hope Windsor; Essex county Cancer Centre Foundation	This work was supported by Seeds4Hope: Grant #: 810257, Knights of columbus: Grant #: 850285, and a Kevin Couvillion Memorial grant: 810340. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the Seeds4hope Windsor and Essex county Cancer Centre Foundation for the seeds4hope grant, the Knights of Columbus, Windsor Council 9671 and the Couvillion family, for their generous donations. We dedicate this work to the memory of Kevin Couvillion.	Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Attia RR, 2008, J BIOL CHEM, V283, P30788, DOI 10.1074/jbc.M804159200; Chatterjee SJ, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1155/2011/129045; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625; DWYER JM, 1981, CLIN EXP IMMUNOL, V46, P237; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Foucar K, 2009, AM J CLIN PATHOL, V132, P281, DOI 10.1309/AJCPJ71PTVIKGEVT; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fuss IJ, 2009, CURR PROTOC IMMUNOL, V85, DOI DOI 10.1002/0471142735.IM0701S85; Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178; Gordaliza M, 2007, CLIN TRANSL ONCOL, V9, P767, DOI 10.1007/s12094-007-0138-9; Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010; Griffin C, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Liu ZH, 2007, DEV CELL, V12, P484, DOI 10.1016/j.devcel.2007.03.016; Naderi J, 2003, APOPTOSIS, V8, P91, DOI 10.1023/A:1021657220843; Negoescu A, 1996, J HISTOCHEM CYTOCHEM, V44, P959, DOI 10.1177/44.9.8773561; Ngamwongsatit P, 2008, J MICROBIOL METH, V73, P211, DOI 10.1016/j.mimet.2008.03.002; Ovadje P, 2011, J ETHNOPHARMACOL, V133, P86, DOI 10.1016/j.jep.2010.09.005; Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4; Ramshaw HS, 2002, EXP HEMATOL, V30, P1124, DOI 10.1016/S0301-472X(02)00903-7; Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031; Schutz K, 2006, J ETHNOPHARMACOL, V107, P313, DOI 10.1016/j.jep.2006.07.021; Shakibaei M, 2010, ANTIOXID REDOX SIGN, V13, P821, DOI 10.1089/ars.2009.3036; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Somayajulu-Nitu M, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-88; Steensma DP, 2006, MAYO CLIN PROC, V81, P104, DOI 10.4065/81.1.104; Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9; Yarnell E., 2009, INTEGR MED, V8, P35; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103; Zhivotovsky B, 2010, EXP CELL RES, V316, P1374, DOI 10.1016/j.yexcr.2010.02.037; Ziegler U, 2004, NEWS PHYSIOL SCI, V19, P124, DOI 10.1152/nips.01519.2004	34	27	30	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 17	2012	7	2							e30604	10.1371/journal.pone.0030604	http://dx.doi.org/10.1371/journal.pone.0030604			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926TC	22363452	Green Published, Green Submitted, gold			2023-01-03	WOS:000302853600039
J	Chiu, PH; Hsieh, HY; Wang, SC				Chiu, Pei-Hsun; Hsieh, Hsin-Ying; Wang, Sun-Chong			Prescriptions of Traditional Chinese Medicine Are Specific to Cancer Types and Adjustable to Temperature Changes	PLOS ONE			English	Article							DIAGNOSIS; SUBTYPE	Targeted cancer therapies, with specific molecular targets, ameliorate the side effect issue of radiation and chemotherapy and also point to the development of personalized medicine. Combination of drugs targeting multiple pathways of carcinogenesis is potentially more fruitful. Traditional Chinese medicine (TCM) has been tailoring herbal mixtures for individualized healthcare for two thousand years. A systematic study of the patterns of TCM formulas and herbs prescribed to cancers is valuable. We analysed a total of 187,230 TCM prescriptions to 30 types of cancer in Taiwan in 2007, a year's worth of collection from the National Health Insurance reimbursement database (Taiwan). We found that a TCM cancer prescription consists on average of two formulas and four herbs. We show that the percentage weights of TCM formulas and herbs in a TCM prescription follow Zipf's law with an exponent around 0.6. TCM prescriptions to benign neoplasms have a larger Zipf's exponent than those to malignant cancers. Furthermore, we show that TCM prescriptions, via weighted combination of formulas and herbs, are specific to not only the malignancy of neoplasms but also the sites of origins of malignant cancers. From the effects of formulas and natures of herbs that were heavily prescribed to cancers, that cancers are a 'warm and stagnant' syndrome in TCM can be proposed, suggesting anti-inflammatory regimens for better prevention and treatment of cancers. We show that TCM incorporated relevant formulas to the prescriptions to cancer patients with a secondary morbidity. We compared TCM prescriptions made in different seasons and identified temperatures as the environmental factor that correlates with changes in TCM prescriptions in Taiwan. Lung cancer patients were among the patients whose prescriptions were adjusted when temperatures drop. The findings of our study provide insight to TCM cancer treatment, helping dialogue between modern western medicine and TCM for better cancer care.	[Chiu, Pei-Hsun; Hsieh, Hsin-Ying; Wang, Sun-Chong] Natl Cent Univ, Inst Syst Biol & Bioinformat, Chungli Taoyuan, Taiwan; [Wang, Sun-Chong] Ctr Addict & Mental Hlth, Epigenet Lab, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Chiu, PH (corresponding author), Natl Cent Univ, Inst Syst Biol & Bioinformat, Chungli Taoyuan, Taiwan.	scwang@ncu.edu.tw			National Science Council, Taiwan (Republic of China) [97-2112-M-008-003-MY3]	National Science Council, Taiwan (Republic of China)(Ministry of Science and Technology, Taiwan)	This work was funded in part by the National Science Council, Taiwan (Republic of China) grant # 97-2112-M-008-003-MY3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Adamic L, 2011, NATURE, V474, P164, DOI 10.1038/474164a; Aggarwal S, 2010, NAT REV DRUG DISCOV, V9, P427, DOI 10.1038/nrd3186; Axtell RL, 2001, SCIENCE, V293, P1818, DOI 10.1126/science.1062081; Benz RW, 2008, J CHEM INF MODEL, V48, P1138, DOI 10.1021/ci700353m; Cancho RFI, 2003, P NATL ACAD SCI USA, V100, P788, DOI 10.1073/pnas.0335980100; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; Furusawa C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.088102; Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311; Ha LQ, 2003, P 19 INT C COMP LING, P315; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris ESJ, 2011, SCI TOTAL ENVIRON, V409, P4297, DOI 10.1016/j.scitotenv.2011.07.032; Hsieh HY, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/neq050; Hsieh SC, 2008, PHARMACOEPIDEM DR S, V17, P609, DOI 10.1002/pds.1611; Jemal A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009584; Li S.Z, 1982, BEN CAO GANG MU; LI WT, 1992, IEEE T INFORM THEORY, V38, P1842, DOI 10.1109/18.165464; Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Patwardhan B, 2005, EVID-BASED COMPL ALT, V2, P465, DOI 10.1093/ecam/neh140; R Core Team, 2021, R LANG ENV STAT COMP; Sawyers CL, 2007, NATURE, V449, P993, DOI 10.1038/449993a; Sung JJY, 2004, ALIMENT PHARM THER, V20, P1205, DOI 10.1111/j.1365-2036.2004.02242.x; Unschuld PU, 2003, HUANG DI NEI JING SU WEN: NATURE, KNOWLEDGE, IMAGERY IN AN ANCIENT CHINESE MEDICAL TEXT, P1, DOI 10.1525/california/9780520233225.001.0001; Wang S-C, 2008, DNA METHYLATION MICR; Wiseman N, 2009, JIN GUI YAO LUE ESSE; Wu FM, 2001, COLLECTED EXEGESIS R; Yang S, 1998, DIVINE FARMERS MAT M; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Zhang GG, 2004, ALTERN THER HEALTH M, V10, P58; Zhang Zhogjing, 1999, SHANG HAN LUN COLD D	30	15	16	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2012	7	2							e31648	10.1371/journal.pone.0031648	http://dx.doi.org/10.1371/journal.pone.0031648			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925XS	22359613	gold, Green Published, Green Submitted			2023-01-03	WOS:000302796200082
J	Baselga, J; Campone, M; Piccart, M; Burris, HA; Rugo, HS; Sahmoud, T; Noguchi, S; Gnant, M; Pritchard, KI; Lebrun, F; Beck, JT; Ito, Y; Yardley, D; Deleu, I; Perez, A; Bachelot, T; Vittori, L; Xu, ZY; Mukhopadhyay, P; Lebwohl, D; Hortobagyi, GN				Baselga, Jose; Campone, Mario; Piccart, Martine; Burris, Howard A., III; Rugo, Hope S.; Sahmoud, Tarek; Noguchi, Shinzaburo; Gnant, Michael; Pritchard, Kathleen I.; Lebrun, Fabienne; Beck, J. Thaddeus; Ito, Yoshinori; Yardley, Denise; Deleu, Ines; Perez, Alejandra; Bachelot, Thomas; Vittori, Luc; Xu, Zhiying; Mukhopadhyay, Pabak; Lebwohl, David; Hortobagyi, Gabriel N.			Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-LINE THERAPY; AROMATASE INHIBITORS; PHASE-III; WOMEN; TAMOXIFEN; TRIAL; ANASTROZOLE; LETROZOLE; SUPERIOR; EFFICACY	Background Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. Methods In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to treat advanced disease (or both). The primary end point was progression-free survival. Secondary end points included survival, response rate, and safety. A preplanned interim analysis was performed by an independent data and safety monitoring committee after 359 progression-free survival events were observed. Results Baseline characteristics were well balanced between the two study groups. The median age was 62 years, 56% had visceral involvement, and 84% had hormone-sensitive disease. Previous therapy included letrozole or anastrozole (100%), tamoxifen (48%), fulvestrant (16%), and chemotherapy (68%). The most common grade 3 or 4 adverse events were stomatitis (8% in the everolimus-plus-exemestane group vs. 1% in the placebo-plus-exemestane group), anemia (6% vs. <1%), dyspnea (4% vs. 1%), hyperglycemia (4% vs. <1%), fatigue (4% vs. 1%), and pneumonitis (3% vs. 0%). At the interim analysis, median progression-free survival was 6.9 months with everolimus plus exemestane and 2.8 months with placebo plus exemestane, according to assessments by local investigators (hazard ratio for progression or death, 0.43; 95% confidence interval [CI], 0.35 to 0.54; P<0.001). Median progression-free survival was 10.6 months and 4.1 months, respectively, according to central assessment (hazard ratio, 0.36; 95% CI, 0.27 to 0.47; P<0.001). Conclusions Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.)	[Baselga, Jose] Harvard Univ, Div Hematol Oncol, Ctr Canc, Massachusetts Gen Hosp,Sch Med, Boston, MA 02114 USA; [Campone, Mario] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France; [Piccart, Martine; Lebrun, Fabienne] Inst Jules Bordet, B-1000 Brussels, Belgium; [Burris, Howard A., III; Yardley, Denise] Sarah Cannon Res Inst, Nashville, TN USA; [Rugo, Hope S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Sahmoud, Tarek; Xu, Zhiying] Novartis, E Hanover, NJ USA; [Noguchi, Shinzaburo] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan; [Gnant, Michael] Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria; [Pritchard, Kathleen I.] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada; [Pritchard, Kathleen I.] Univ Toronto, Toronto, ON, Canada; [Beck, J. Thaddeus] Highlands Oncol Grp, Fayetteville, AR USA; [Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan; [Deleu, Ines] AZ Nikolass, Ctr Oncol, St Niklaas, Belgium; [Perez, Alejandra] Mem Canc Inst, Hollywood, FL USA; [Bachelot, Thomas] Ctr Leon Berard, F-69373 Lyon, France; [Vittori, Luc] Novartis Pharmaceut, Basel, Switzerland; [Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Institut Jules Bordet; Sarah Cannon Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Novartis; Osaka University; Medical University of Vienna; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Japanese Foundation for Cancer Research; UNICANCER; Centre Leon Berard; Novartis; University of Texas System; UTMD Anderson Cancer Center	Baselga, J (corresponding author), Harvard Univ, Div Hematol Oncol, Ctr Canc, Massachusetts Gen Hosp,Sch Med, 55 Fruit St,Lawrence House 108, Boston, MA 02114 USA.	jbaselga@partners.org	Gnant, Michael/AAN-7054-2020; de Azevedo, Sergio Jobim/P-5115-2015	Gnant, Michael/0000-0003-1002-2118; 	Novartis; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Novartis(Novartis); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Novartis, including funding for medical editorial assistance with the manuscript.	Bachelot T, 2010, 33 ANN SAN ANT BREAS; Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Burstein HJ, 2011, SEMIN ONCOL, V38, pS17, DOI 10.1053/j.seminoncol.2011.04.002; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Chia S, 2008, J CLIN ONCOL, V26, P1664, DOI 10.1200/JCO.2007.13.5822; Chow LWC, 2006, 29 ANN SAN ANT BREAS; Di Leo A, 2011, J CLIN ONCOL, V29, P2293, DOI 10.1200/JCO.2011.36.8522; Di Leo A, 2010, J CLIN ONCOL, V28, P4594, DOI 10.1200/JCO.2010.28.8415; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Johnston SRD, 2006, CLIN CANCER RES, V12, p1061S, DOI 10.1158/1078-0432.CCR-05-2125; Johnston SRD, 2010, CLIN CANCER RES, V16, P1979, DOI 10.1158/1078-0432.CCR-09-1823; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Mauri D, 2006, JNCI-J NATL CANCER I, V98, P1285, DOI 10.1093/jnci/djj357; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Mouridsen, 2001, J CLIN ONCOL, V19, P3302; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Yamnik RL, 2010, FEBS LETT, V584, P124, DOI 10.1016/j.febslet.2009.11.041; Yamnik RL, 2009, J BIOL CHEM, V284, P6361, DOI 10.1074/jbc.M807532200	25	2015	2112	3	169	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					520	529		10.1056/NEJMoa1109653	http://dx.doi.org/10.1056/NEJMoa1109653			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22149876	Green Accepted			2023-01-03	WOS:000299991300008
J	Sun, Q; Prasad, R; Rosenthal, E; Katiyar, SK				Sun, Qian; Prasad, Ram; Rosenthal, Eben; Katiyar, Santosh K.			Grape Seed Proanthocyanidins Inhibit the Invasiveness of Human HNSCC Cells by Targeting EGFR and Reversing the Epithelial-To-Mesenchymal Transition	PLOS ONE			English	Article							NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; MOUSE SKIN; CARCINOMA; HEAD; CANCER; FLUOROURACIL; DOCETAXEL; CISPLATIN; SURVIVAL	Head and neck squamous cell carcinoma (HNSCC) is responsible for approximately 20,000 deaths per year in the United States. Most of the deaths are due to the metastases. To develop more effective strategies for the prevention of metastasis of HNSCC cells, we have determined the effect of grape seed proanthocyanidins (GSPs) on the invasive potential of HNSCC cell and the mechanisms underlying these effects using OSC19 cells as an in vitro model. Using cell invasion assays, we established that treatment of the OSC19 cells with GSPs resulted in a dose-dependent inhibition of cell invasion. EGFR is over-expressed in 90% of HNSCCs and the EGFR inhibitors, erlotinib and gefitinib, are being explored as therapies for this disease. We found that GSPs treatment reduced the levels of expression of EGFR in the OSC19 cells as well as reducing the activation of NF-kappa B/p65, a downstream target of EGFR, and the expression of NF-kappa B-responsive proteins. GSPs treatment also reduced the activity of ERK1/2, an upstream regulator of NF-kappa B and treatment of the cells with caffeic acid phenethyl ester, an inhibitor of NF-kappa B, inhibited cell invasion. Overexpression of EGFR and high NF-kappa B activity play a key role in the epithelial-to-mesenchymal transition, which is of critical importance in the processes underlying metastasis, and we found treatment with GSPs enhanced the levels of epithelial (E-cadherin, cytokeratins and desmoglein-2) and reduced the levels of mesenchymal (vimentin, fibronectin, N-cadherin and Slug) biomarkers in the OSC19 cells. These results indicate that GSPs have the ability to inhibit HNSCC cell invasion, and do so by targeting the expression of EGFR and activation of NF-kappa B as well as inhibiting the epithelial-to-mesenchymal transition.	[Sun, Qian; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA; [Rosenthal, Eben] Univ Alabama Birmingham, Dept Surg Otolaryngol, Birmingham, AL USA; [Rosenthal, Eben; Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sun, Q (corresponding author), Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA.	skatiyar@uab.edu		Rosenthal, Eben/0000-0003-0294-5203	Veterans Administration	Veterans Administration(US Department of Veterans Affairs)	This work was supported by funds from the Veterans Administration Merit Review Award (SKK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar S, 2009, CLIN CANCER RES, V15, P821, DOI 10.1158/1078-0432.CCR-08-1901; Arbes SJ, 1999, CANCER CAUSE CONTROL, V10, P513, DOI 10.1023/A:1008911300100; Casiglia Jeffrey, 2001, General Dentistry, V49, P72; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Grandis JR, 1996, CANCER-AM CANCER SOC, V78, P1284, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Holt RR, 2002, AM J CLIN NUTR, V76, P798, DOI 10.1093/ajcn/76.4.798; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Hunter KD, 2005, NAT REV CANCER, V5, P127, DOI 10.1038/nrc1549; Leeman-Neill RJ, 2011, CANCER PREV RES, V4, P230, DOI 10.1158/1940-6207.CAPR-10-0249; Leon X, 2001, Expert Rev Anticancer Ther, V1, P125, DOI 10.1586/14737140.1.1.125; Maier Harald J, 2010, Cancers (Basel), V2, P2058, DOI 10.3390/cancers2042058; Mantena SK, 2006, CARCINOGENESIS, V27, P2018, DOI 10.1093/carcin/bgl043; Meeran SM, 2009, NEOPLASIA, V11, P846, DOI 10.1593/neo.09528; Meeran SM, 2009, CARCINOGENESIS, V30, P520, DOI 10.1093/carcin/bgp019; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Sano A, 2003, BIOSCI BIOTECH BIOCH, V67, P1140, DOI 10.1271/bbb.67.1140; Singh RP, 2004, INT J CANCER, V108, P733, DOI 10.1002/ijc.11620; Singh T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025224; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vaid M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023000; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Zuo JH, 2011, J CELL BIOCHEM, V112, P2508, DOI 10.1002/jcb.23175	29	28	32	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2012	7	1							e31093	10.1371/journal.pone.0031093	http://dx.doi.org/10.1371/journal.pone.0031093			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911GB	22299051	Green Published, Green Submitted, gold			2023-01-03	WOS:000301704200059
J	Zhang, JH; Benavente, CA; McEvoy, J; Flores-Otero, J; Ding, L; Chen, X; Ulyanov, A; Wu, G; Wilson, M; Wang, JM; Brennan, R; Rusch, M; Manning, AL; Ma, J; Easton, J; Shurtleff, S; Mullighan, C; Pounds, S; Mukatira, S; Gupta, P; Neale, G; Zhao, D; Lu, C; Fulton, RS; Fulton, LL; Hong, X; Dooling, DJ; Ochoa, K; Naeve, C; Dyson, NJ; Mardis, ER; Bahrami, A; Ellison, D; Wilson, RK; Downing, JR; Dyer, MA				Zhang, Jinghui; Benavente, Claudia A.; McEvoy, Justina; Flores-Otero, Jacqueline; Ding, Li; Chen, Xiang; Ulyanov, Anatoly; Wu, Gang; Wilson, Matthew; Wang, Jianmin; Brennan, Rachel; Rusch, Michael; Manning, Amity L.; Ma, Jing; Easton, John; Shurtleff, Sheila; Mullighan, Charles; Pounds, Stanley; Mukatira, Suraj; Gupta, Pankaj; Neale, Geoff; Zhao, David; Lu, Charles; Fulton, Robert S.; Fulton, Lucinda L.; Hong, Xin; Dooling, David J.; Ochoa, Kerri; Naeve, Clayton; Dyson, Nicholas J.; Mardis, Elaine R.; Bahrami, Armita; Ellison, David; Wilson, Richard K.; Downing, James R.; Dyer, Michael A.			A novel retinoblastoma therapy from genomic and epigenetic analyses	NATURE			English	Article							TYROSINE KINASE; SYK INHIBITOR; CANCER; ANEUPLOIDY; GROWTH; CELLS; TUMOR; MCL-1; GENE	Retinoblastoma is an aggressive childhood cancer of the developing retina that is initiated by the biallelic loss of RB1. Tumours progress very quickly following RB1 inactivation but the underlying mechanism is not known. Here we show that the retinoblastoma genome is stable, but that multiple cancer pathways can be epigenetically deregulated. To identify the mutations that cooperate with RB1 loss, we performed whole-genome sequencing of retinoblastomas. The overall mutational rate was very low; RB1 was the only known cancer gene mutated. We then evaluated the role of RB1 in genome stability and considered non-genetic mechanisms of cancer pathway deregulation. For example, the proto-oncogene SYK is upregulated in retinoblastoma and is required for tumour cell survival. Targeting SYK with a small-molecule inhibitor induced retinoblastoma tumour cell death in vitro and in vivo. Thus, retinoblastomas may develop quickly as a result of the epigenetic deregulation of key cancer pathways as a direct or indirect result of RB1 loss.	[Benavente, Claudia A.; McEvoy, Justina; Flores-Otero, Jacqueline; Brennan, Rachel; Dyer, Michael A.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [Zhang, Jinghui; Chen, Xiang; Ulyanov, Anatoly; Wu, Gang; Rusch, Michael; Easton, John] St Jude Childrens Res Hosp, Dept Computat Biol & Bioinformat, Memphis, TN 38105 USA; [Ding, Li; Lu, Charles; Fulton, Robert S.; Fulton, Lucinda L.; Hong, Xin; Dooling, David J.; Ochoa, Kerri; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med St Louis, Genome Inst, St Louis, MO 63108 USA; [Ding, Li; Fulton, Robert S.; Fulton, Lucinda L.; Hong, Xin; Dooling, David J.; Ochoa, Kerri; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Sch Med St Louis, Dept Genet, St Louis, MO 63108 USA; [Wilson, Matthew; Dyer, Michael A.] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN 38163 USA; [Wilson, Matthew] St Jude Childrens Res Hosp, Dept Surg, Memphis, TN 38105 USA; [Wang, Jianmin; Mukatira, Suraj; Gupta, Pankaj; Neale, Geoff] St Jude Childrens Res Hosp, Hartwell Ctr Biotechnol & Bioinformat, Memphis, TN 38105 USA; [Manning, Amity L.; Dyson, Nicholas J.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA; [Ma, Jing; Shurtleff, Sheila; Mullighan, Charles; Bahrami, Armita; Ellison, David; Downing, James R.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Pounds, Stanley] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Zhao, David; Naeve, Clayton] St Jude Childrens Res Hosp, Dept Informat Sci, Memphis, TN 38105 USA; [Mardis, Elaine R.] Washington Univ, Sch Med St Louis, Siteman Canc Ctr, St Louis, MO 63108 USA; [Wilson, Richard K.] Washington Univ, Sch Med St Louis, Dept Med, St Louis, MO 63108 USA; [Dyer, Michael A.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Saint Louis University; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Harvard University; Massachusetts General Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Saint Louis University; Siteman Cancer Center; Washington University (WUSTL); Saint Louis University; Washington University (WUSTL); Howard Hughes Medical Institute	Dyer, MA (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	rwilson@wustl.edu; james.downing@stjude.org; michael.dyer@stjude.org	Rusch, Michael/AAG-1998-2019; Dyer, Michael/N-8134-2018; Downing, James R./N-8102-2018; Mullighan, Charles/H-3253-2011; Mardis, Elaine/W-2202-2019; Bahrami, Armita/N-3262-2018; Manning, Amity/AAC-8205-2019; Chen, Xiang/N-2524-2018; Pounds, Stanley B/N-2480-2018; Zhang, Jing/GWZ-7332-2022; Wu, Gang/M-8012-2014; Wilson, Richard K./AAF-4139-2019; wang, jian/GVS-0711-2022	Rusch, Michael/0000-0002-5363-1848; Mullighan, Charles/0000-0002-1871-1850; Bahrami, Armita/0000-0002-8515-2649; Manning, Amity/0000-0003-1332-9086; Chen, Xiang/0000-0002-2499-8261; Pounds, Stanley B/0000-0002-9167-2114; Wu, Gang/0000-0002-1678-5864; Wilson, Richard K./0000-0002-1992-1358; McEvoy, Justina/0000-0003-0382-1288; Easton, John/0000-0003-4503-6608; Benavente, Claudia/0000-0002-6875-3186	St Jude Children's Research Hospital - Washington University; St Jude Children's Research Hospital; NCI [CA21765]; NIH [EY014867, EY018599, GM81607, CA64402]; American Cancer Society; Research to Prevent Blindness Foundation; American Lebanese Syrian Associated Charities; MGH Cancer Center Saltonstall Foundation; AstraZeneca; NATIONAL CANCER INSTITUTE [R01CA064402, R01CA155202, P30CA021765] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018599, R01EY014867] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081607] Funding Source: NIH RePORTER	St Jude Children's Research Hospital - Washington University; St Jude Children's Research Hospital; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); MGH Cancer Center Saltonstall Foundation; AstraZeneca(AstraZeneca); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The WGS was supported as part of the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. We thank J. Lahti, J. Dalton and M. Valentine for help with FISH analysis, L. Holmfeldt, J. Zhang and M. Barbato for help with sample preparation, and V. Valentine for spectral karyotype analysis. We thank I. Qaddoumi, C. Rodriguez-Galindo and B. Haik for the support of the St Jude Children's Research Hospital retinoblastoma clinical research and W. Lei, D. McGoldrick, D. Alford, S. Espy, J. Obenauer and K. Johnson for assistance with data acquisition, handling and analysis. We thank A. McArthur and C. Guess for editing the manuscript, J. Temirov for help with sister chromatid analysis, J. Thurman for help with histology, F. Krafcik for help with cell culture, J. Wu and C. Billups for statistical analysis, J. Jeon for help with lentiviral preparations and C. Bradley for assistance with preclinical testing. This work was supported, in part, by Cancer Center Support (CA21765) from the NCI; grants to M. A. D. from the NIH (EY014867 and EY018599), the American Cancer Society and the Research to Prevent Blindness Foundation; and the American Lebanese Syrian Associated Charities. M. A. D. is a Howard Hughes Medical Institute Early Career Scientist. This work was also supported by an American Cancer Society Fellowship to A. L. M., the MGH Cancer Center Saltonstall Foundation Scholarship to N.J.D. and funding from AstraZeneca and NIH grants GM81607 and CA64402 to N.J.D.	Amato A, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-79; Baudot AD, 2009, ONCOGENE, V28, P3261, DOI 10.1038/onc.2009.179; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P998, DOI 10.1038/nsmb0908-998b; Bourgo RJ, 2009, MOL BIOL CELL, V20, P3192, DOI 10.1091/mbc.E08-12-1224; Brennan RC, 2011, CANCER RES, V71, P4205, DOI 10.1158/0008-5472.CAN-11-0058; Buchner M, 2010, BLOOD, V115, P4497, DOI 10.1182/blood-2009-07-233692; Chen LF, 2008, BLOOD, V111, P2230, DOI 10.1182/blood-2007-07-100115; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Feldman AL, 2008, LEUKEMIA, V22, P1139, DOI 10.1038/leu.2008.77; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gobessi S, 2009, LEUKEMIA, V23, P686, DOI 10.1038/leu.2008.346; Hahn CK, 2009, CANCER CELL, V16, P281, DOI 10.1016/j.ccr.2009.08.018; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Lu JR, 2007, P NATL ACAD SCI USA, V104, P9381, DOI 10.1073/pnas.0610279104; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; SQUIRE J, 1985, HUM GENET, V70, P291, DOI 10.1007/BF00295364; Suljagic M, 2010, BLOOD, V116, P4894, DOI 10.1182/blood-2010-03-275180; Weinblatt ME, 2010, NEW ENGL J MED, V363, P1303, DOI 10.1056/NEJMoa1000500; Wen H, 2008, GENE DEV, V22, P601, DOI 10.1101/gad.1626308; Yan Y, 2000, EUR J CANCER, V36, P221, DOI 10.1016/S0959-8049(99)00277-4; Young RM, 2009, BLOOD, V113, P2508, DOI 10.1182/blood-2008-05-158618	32	342	358	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2012	481	7381					329	334		10.1038/nature10733	http://dx.doi.org/10.1038/nature10733			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	877VK	22237022	Green Accepted, hybrid, Green Submitted			2023-01-03	WOS:000299210600035
J	Mellman, I; Coukos, G; Dranoff, G				Mellman, Ira; Coukos, George; Dranoff, Glenn			Cancer immunotherapy comes of age	NATURE			English	Review							REGULATORY T-CELLS; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; DENDRITIC CELLS; ANTITUMOR IMMUNITY; PEPTIDE VACCINE; IN-VITRO; TUMOR; TOLERANCE; ANTIBODY	Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.	[Mellman, Ira] Genentech Inc, San Francisco, CA 94080 USA; [Coukos, George] Univ Penn, Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA; [Dranoff, Glenn] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Dranoff, Glenn] Brigham & Womens Hosp, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA; [Dranoff, Glenn] Harvard Univ, Sch Med, Boston, MA 02115 USA	Roche Holding; Genentech; University of Pennsylvania; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Mellman, I (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	mellman.ira@gene.com	Mellman, Ira/ABG-5896-2020; Coukos, George/ABG-7389-2020	Coukos, George/0000-0001-8813-7367	NATIONAL CANCER INSTITUTE [P01CA155258, P50CA100707, R01CA143083, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA155258, P50 CA100707, P01 CA078378, R01 CA143083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Alagkiozidis I, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-77; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Boon T, 2006, ANNU REV IMMUNOL, V24, P175, DOI 10.1146/annurev.immunol.24.021605.090733; Bouzin C, 2007, J IMMUNOL, V178, P1505, DOI 10.4049/jimmunol.178.3.1505; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Buckanovich RJ, 2008, NAT MED, V14, P28, DOI 10.1038/nm1699; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheever MA, 2008, CLIN CANCER RES, V14, P5692, DOI 10.1158/1078-0432.CCR-08-1266; Cipponi A, 2011, CANCER IMMUNOL IMMUN, V60, P1153, DOI 10.1007/s00262-011-1026-2; Cohen AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010436; Copier J, 2010, CURR OPIN MOL THER, V12, P14; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Darrasse-Jeze G, 2009, J EXP MED, V206, P1853, DOI 10.1084/jem.20090746; Disis ML, 1997, J CLIN ONCOL, V15, P3363, DOI 10.1200/JCO.1997.15.11.3363; Dougan M, 2010, J EXP MED, V207, P2195, DOI 10.1084/jem.20101123; Dougan M, 2009, ANNU REV IMMUNOL, V27, P83, DOI 10.1146/annurev.immunol.021908.132544; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Emens LA, 2009, J CLIN ONCOL, V27, P5911, DOI 10.1200/JCO.2009.23.3494; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Ferrer IR, 2010, J IMMUNOL, V185, P2004, DOI 10.4049/jimmunol.1001176; Freedman A, 2009, J CLIN ONCOL, V27, P3036, DOI 10.1200/JCO.2008.19.8903; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gadiot J, 2011, CANCER-AM CANCER SOC, V117, P2192, DOI 10.1002/cncr.25747; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8; Gogas H, 2006, NEW ENGL J MED, V354, P709, DOI 10.1056/NEJMoa053007; Golovina TN, 2010, CANCER J, V16, P342, DOI 10.1097/PPO.0b013e3181eb336d; Hall S. S., 1997, COMMOTION BLOOD LIFE; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; Hodi FS, 2008, P NATL ACAD SCI USA, V105, P3005, DOI 10.1073/pnas.0712237105; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2010, JNCI-J NATL CANCER I, V102, P1388, DOI 10.1093/jnci/djq310; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Ito T, 2006, P NATL ACAD SCI USA, V103, P13138, DOI 10.1073/pnas.0603107103; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; June CH, 2007, J CLIN INVEST, V117, P1204, DOI 10.1172/JCI31446; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8; Kooi S, 1996, CELL IMMUNOL, V174, P116, DOI 10.1006/cimm.1996.0301; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Leffers N, 2009, INT J CANCER, V125, P2104, DOI 10.1002/ijc.24597; Machiels JPH, 2001, CANCER RES, V61, P3689; Manning EA, 2007, CLIN CANCER RES, V13, P3951, DOI 10.1158/1078-0432.CCR-07-0374; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; Munn DH, 2004, TRENDS MOL MED, V10, P15, DOI 10.1016/j.molmed.2003.11.003; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Neller MA, 2008, SEMIN IMMUNOL, V20, P286, DOI 10.1016/j.smim.2008.09.006; Nishimura H, 2001, SCIENCE, V291, P319, DOI 10.1126/science.291.5502.319; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Novellino L, 2005, CANCER IMMUNOL IMMUN, V54, P187, DOI 10.1007/s00262-004-0560-6; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Okazaki T, 2011, J EXP MED, V208, P395, DOI 10.1084/jem.20100466; Palucka K, 2010, IMMUNITY, V33, P464, DOI 10.1016/j.immuni.2010.10.007; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Rammensee HG, 2002, IMMUNOL REV, V188, P164, DOI 10.1034/j.1600-065X.2002.18815.x; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schuler G, 2010, EUR J IMMUNOL, V40, P2123, DOI 10.1002/eji.201040630; Schwartzentruber DJ, 2011, NEW ENGL J MED, V364, P2119, DOI 10.1056/NEJMoa1012863; Segal NH, 2008, CANCER RES, V68, P889, DOI 10.1158/0008-5472.CAN-07-3095; Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675; Shin JY, 2009, CELL IMMUNOL, V256, P72, DOI 10.1016/j.cellimm.2009.01.006; Shrimali RK, 2010, CANCER RES, V70, P6171, DOI 10.1158/0008-5472.CAN-10-0153; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Sylvester RJ, 2011, INT J UROL, V18, P113, DOI 10.1111/j.1442-2042.2010.02678.x; Taylor C, 2007, CLIN CANCER RES, V13, P5133, DOI 10.1158/1078-0432.CCR-07-0507; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Topp MS, 2011, J CLIN ONCOL, V29, P2493, DOI 10.1200/JCO.2010.32.7270; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Vansteenkiste J, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2006.09.7097; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Watanabe T, 2010, J VIRAL HEPATITIS, V17, P453, DOI 10.1111/j.1365-2893.2010.01313.x; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Woo SR, 2010, EUR J IMMUNOL, V40, P1768, DOI 10.1002/eji.200939874; Workman CJ, 2005, J IMMUNOL, V174, P688, DOI 10.4049/jimmunol.174.2.688; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zitvogel L, 2009, J CLIN INVEST, V119, P2127, DOI 10.1172/JCI39991	99	2389	2593	44	1344	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 22	2011	480	7378					480	489		10.1038/nature10673	http://dx.doi.org/10.1038/nature10673			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22193102	Green Accepted, Bronze			2023-01-03	WOS:000298318000052
J	Lindford, AJ; Vuola, J				Lindford, Andrew J.; Vuola, Jyrki			PICTURE QUIZ Helsinki-20 degrees C	BRITISH MEDICAL JOURNAL			English	Editorial Material							FROSTBITE INJURIES; EXTREMITIES; AMPUTATION		[Lindford, Andrew J.; Vuola, Jyrki] Toolo Hosp, Helsinki Burn Ctr, Dept Plast Surg, Helsinki Univ Hosp, FIN-00029 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital	Lindford, AJ (corresponding author), Toolo Hosp, Helsinki Burn Ctr, Dept Plast Surg, Helsinki Univ Hosp, FIN-00029 Helsinki, Finland.	andrew.lindford@hus.fi						Bruen KJ, 2007, ARCH SURG-CHICAGO, V142, P546, DOI 10.1001/archsurg.142.6.546; Cauchy E, 2000, J HAND SURG-AM, V25A, P969, DOI 10.1053/jhsu.2000.16357; Cauchy E, 2011, NEW ENGL J MED, V364, P189, DOI 10.1056/NEJMc1000538; GROECHENIG E, 1994, LANCET, V344, P1152, DOI 10.1016/S0140-6736(94)90657-2; Hallam MJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c5864; Imray C, 2009, POSTGRAD MED J, V85, P481, DOI 10.1136/pgmj.2008.068635; Juopperi Kimmo, 2002, Int J Circumpolar Health, V61, P352; Koljonen V, 2004, J TRAUMA, V57, P1315, DOI 10.1097/01.TA.0000151258.06910.83; MCCAULEY RL, 1983, J TRAUMA, V23, P143, DOI 10.1097/00005373-198302000-00013; Mohr WJ, 2009, HAND CLIN, V25, P481, DOI 10.1016/j.hcl.2009.06.004; Murphy JV, 2000, J TRAUMA, V48, P171, DOI 10.1097/00005373-200001000-00036; von Heimburg D, 2001, BURNS, V27, P404, DOI 10.1016/S0305-4179(00)00132-7	12	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 20	2011	343								d8020	10.1136/bmj.d8020	http://dx.doi.org/10.1136/bmj.d8020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874SZ	22187192				2023-01-03	WOS:000298979700002
J	Lota, AS; Manisty, CH; Sutton, R; Francis, DP				Lota, Amrit S.; Manisty, Charlotte H.; Sutton, Richard; Francis, Darrel P.			CHRISTMAS 2011: PROFESSIONAL MATTERS When is a "free" registrar in clinic not free?	BRITISH MEDICAL JOURNAL			English	Editorial Material								Objective To investigate whether using registrars (doctors undergoing higher specialist training, whose salary is reimbursed) rather than consultants in outpatient clinics saves money Design Development of a formula calculating the economic breakeven point and application to retrospective audit data from 273 outpatient consultations. Setting General cardiology outpatient clinic in a secondary and tertiary referral NHS hospital. Outcomes Difference in probability of a registrar and a consultant making a diagnostic decision that completes a clinical episode. Use of UK costings for consultant salaries and outpatient attendances to determine the economic breakeven point. Results The formula showed that if a registrar's episode completing probability is 12 percentage points lower than that of a consultant, then using a registrar costs the hospital more. Real life data showed that episode completion probabilities are 43 percentage points lower for registrars than for consultants (26% versus 69%, 95% CI 32% to 54%, P<0.0001). Conclusion It is wrong to assume that external reimbursement of registrar salaries makes them a money saving option for staffing clinics. The apparent service role of a registrar can be a disservice.	[Lota, Amrit S.; Manisty, Charlotte H.; Sutton, Richard; Francis, Darrel P.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London W2 1LA, England	Imperial College London	Lota, AS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London W2 1LA, England.	amrit.lota@doctors.org.uk	Manisty, Charlotte/AAN-3723-2021	Manisty, Charlotte/0000-0003-0245-7090	British Heart Foundation [FS/10/38/28268] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		[Anonymous], 2011, BMJ CAREERS; Department of Health, NHS PAYM RES 2010 11; KASHIWAGI DT, 2011, AM J MED QUAL   0810; Medford ARL, 2008, QUAL SAF HEALTH CARE, V17, P79, DOI 10.1136/qshc.2007.023234; ROBINSON S, 2011, NHS INNOVATIONS 0125; Virgil, AENEID, VII; WYNNE K, 2009, BMJ CAREERS	7	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 20	2011	343								d7869	10.1136/bmj.d7869	http://dx.doi.org/10.1136/bmj.d7869			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	868QK	22187189				2023-01-03	WOS:000298538200010
J	Vose, JM				Vose, Julie M.			Intensified chemotherapy for diffuse large B-cell lymphomas	LANCET			English	Editorial Material							PLUS RITUXIMAB; STANDARD CHOP		Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Vose, JM (corresponding author), Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE 68198 USA.	jmvose@unmc.edu						Advani RH, 2011, ANN ONCOL, V22, P135; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Casasnovas RO, 2011, BLOOD, V118, P37, DOI 10.1182/blood-2010-12-327767; Nowakowski GS, 2011, LEUKEMIA, V25, P1877, DOI 10.1038/leu.2011.165; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Recher C, 2011, LANCET, V378, P1858, DOI 10.1016/S0140-6736(11)61040-4; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ruan J, 2011, J CLIN ONCOL, V29, P690, DOI 10.1200/JCO.2010.31.1142; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391	11	3	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	2011	378	9806					1828	1829		10.1016/S0140-6736(11)61269-5	http://dx.doi.org/10.1016/S0140-6736(11)61269-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857DQ	22118432				2023-01-03	WOS:000297695800009
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Worst cases of patient care in the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				2011, BRIT MED J, V343, DOI DOI 10.1136/BMJ.D7237	1	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 23	2011	343								d7592	10.1136/bmj.d7592	http://dx.doi.org/10.1136/bmj.d7592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857NE	22113570				2023-01-03	WOS:000297724400009
J	Pach, D; Brinkhaus, B; Roll, S; Wegscheider, K; Icke, K; Willich, SN; Witt, CM				Pach, Daniel; Brinkhaus, Benno; Roll, Stephanie; Wegscheider, Karl; Icke, Katja; Willich, Stefan N.; Witt, Claudia M.			Efficacy of Injections with Disci/Rhus Toxicodendron Compositum for Chronic Low Back Pain - A Randomized Placebo-Controlled Trial	PLOS ONE			English	Article							STERILE WATER; UNITED-STATES; MEDICINE USE; COMPLEMENTARY; ACUPUNCTURE; THERAPY; TRENDS	Background: The effectiveness of injection therapy for low-back pain is still debatable. We compared the efficacy of local injections of the homeopathic preparation Disci/Rhus toxicodendron compositum (verum) with placebo injections and with no treatment in patients with chronic low back pain. Methodology/Principal Findings: In a randomized controlled partly double blind multicenter trial patients with chronic low back pain from 9 German outpatient clinics were enrolled and randomly allocated in a 1: 1: 1 ratio to receive subcutaneous injections (verum or placebo) into painful sites on the lower back over 12 treatment sessions within eight weeks, or no treatment (rescue pain medication with paracetamol or NSAIDs). All trial personnel and participants were masked to treatment allocation. The primary outcome measure was the average pain intensity over the last seven days on a visual analogue scale (0-100 mm, 0 = no pain, 100 = worst imaginable pain) after eight weeks. Follow-up was 26 weeks. Primary analysis was by intention to treat. Between August 2007 and June 2008, 150 patients were randomly allocated to three groups (51 verum, 48 placebo and 51 no treatment). The mean baseline-adjusted low back pain intensity at week eight was: verum group 37.0 mm (97.5% CI 25.3;48.8), no treatment group 53.0 (41.8;64.2), and placebo group 41.8 (30.1;53.6). The verum was significantly superior to no treatment (P = 0.001), but not to placebo (P = 0.350). No significant side effects were reported. Conclusions/Significance: The homeopathic preparation was not superior to placebo. Compared to no treatment injections resulted in significant and clinical relevant chronic back pain relief.	[Pach, Daniel; Brinkhaus, Benno; Roll, Stephanie; Icke, Katja; Willich, Stefan N.; Witt, Claudia M.] Charite Univ Med Ctr Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Wegscheider, Karl] Univ Med Ctr Hamburg Eppendorf, Dept Med Biometry & Epidemiol, Hamburg, Germany; [Witt, Claudia M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University System of Maryland; University of Maryland Baltimore	Pach, D (corresponding author), Charite Univ Med Ctr Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.	claudia.witt@charite.de	Brinkhaus, Benno/AAU-2428-2021; Witt, Claudia M./AAX-2370-2021	Brinkhaus, Benno/0000-0001-6290-744X; Witt, Claudia M./0000-0002-5440-7805; Pach, Daniel/0000-0002-2459-6596; Roll, Stephanie/0000-0003-1191-3289	WALA Heilmittel GmbH	WALA Heilmittel GmbH	The study was sponsored by WALA Heilmittel GmbH. The publication of this paper has no direct or indirect financial implications for the authors, their relatives, or their institution. The study was designed in collaboration with the funder. The funder had no role in data collection, data analysis, data interpretation, or writing of the report.	Bullinger M, 1998, SF 36 FRAGEBOGEN ZUM; Chenot JF, 2007, Z ALLG MED, V83, P487; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Cohen J, 1988, STAT POWER ANAL BEHA; Dillmann U, 1994, Schmerz, V8, P100, DOI 10.1007/BF02530415; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eisenberg DM, 1999, VERBREITUNG ALTERNAT, P152; Ernst E, 2000, COMPLEMENT THER MED, V8, P32, DOI 10.1016/S0965-2299(00)90833-1; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; Geissner E, 1995, Rehabilitation (Stuttg), V34, pXXXV; Geissner E, 1996, SCHMERZEMPFINDUNGSSK; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Hamre HJ, 2007, EUR J MED RES, V12, P302; Hamre HJ, 2006, BMC PSYCHIATRY, V6, DOI 10.1186/1471-244X-6-57; Hartel U, 2004, Forsch Komplementarmed Klass Naturheilkd, V11, P327; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kessler RC, 2001, ANN INTERN MED, V135, P262, DOI 10.7326/0003-4819-135-4-200108210-00011; Koes BW, 2006, BMJ-BRIT MED J, V332, P1430, DOI 10.1136/bmj.332.7555.1430; Kohlmann T, 1996, Rehabilitation (Stuttg), V35, pI; Kushtagi P, 2009, ACTA OBSTET GYN SCAN, V88, P231, DOI 10.1080/00016340802635534; LEBARS D, 1979, PAIN, V6, P305, DOI 10.1016/0304-3959(79)90050-2; LeBars D, 1991, ACUPUNCT MED, V9, P47, DOI DOI 10.1136/AIM.9.2.47; Martensson L, 2008, AUST NZ J OBSTET GYN, V48, P369, DOI 10.1111/j.1479-828X.2008.00856.x; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; Savigny P., 2009, LOND NATL COLLAB CEN; Speed C, 2004, BRIT MED J, V328, P1119, DOI 10.1136/bmj.328.7448.1119; Staal J Bart, 2008, Cochrane Database Syst Rev, pCD001824, DOI 10.1002/14651858.CD001824.pub3; Yelland MJ, 2004, SPINE, V29, P9, DOI 10.1097/01.BRS.0000105529.07222.5B	30	14	14	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 8	2011	6	11							e26166	10.1371/journal.pone.0026166	http://dx.doi.org/10.1371/journal.pone.0026166			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HZ	22087222	Green Submitted, Green Published, gold			2023-01-03	WOS:000297349700004
J	Fryer, JD; Yu, P; Kang, H; Mandel-Brehm, C; Carter, AN; Crespo-Barreto, J; Gao, Y; Flora, A; Shaw, C; Orr, HT; Zoghbi, HY				Fryer, John D.; Yu, Peng; Kang, Hyojin; Mandel-Brehm, Caleigh; Carter, Angela N.; Crespo-Barreto, Juan; Gao, Yan; Flora, Adriano; Shaw, Chad; Orr, Harry T.; Zoghbi, Huda Y.			Exercise and Genetic Rescue of SCA1 via the Transcriptional Repressor Capicua	SCIENCE			English	Article							SPINOCEREBELLAR ATAXIA TYPE-1; AMYOTROPHIC-LATERAL-SCLEROSIS; MOUSE MODEL; CAG REPEAT; EXPANSION; DISEASE	Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by expansion of a translated CAG repeat in Ataxin-1 (ATXN1). To determine the long-term effects of exercise, we implemented a mild exercise regimen in a mouse model of SCA1 and found a considerable improvement in survival accompanied by up-regulation of epidermal growth factor and consequential down-regulation of Capicua, which is an ATXN1 interactor. Offspring of Capicua mutant mice bred to SCA1 mice showed significant improvement of all disease phenotypes. Although polyglutamine-expanded Atxn1 caused some loss of Capicua function, further reduction of Capicua levels-either genetically or by exercise-mitigated the disease phenotypes by dampening the toxic gain of function. Thus, exercise might have long-term beneficial effects in other ataxias and neurodegenerative diseases.	[Fryer, John D.; Yu, Peng; Kang, Hyojin; Mandel-Brehm, Caleigh; Crespo-Barreto, Juan; Gao, Yan; Flora, Adriano; Shaw, Chad; Zoghbi, Huda Y.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Carter, Angela N.; Zoghbi, Huda Y.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Shaw, Chad] Baylor Coll Med, Stem Cells & Regenerat Med Ctr, Houston, TX 77030 USA; [Orr, Harry T.] Univ Minnesota, Inst Translat Neurosci, Minneapolis, MN 55455 USA; [Zoghbi, Huda Y.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Texas Childrens Hosp, Jan & Dan Duncan Neurol Res Inst, Houston, TX 77030 USA; [Zoghbi, Huda Y.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Minnesota System; University of Minnesota Twin Cities; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Zoghbi, HY (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	hzoghbi@bcm.edu		mandel-brehm, caleigh/0000-0001-7764-6529; Orr, Harry/0000-0001-6118-741X; Zoghbi, Huda/0000-0002-0700-3349; Shaw, Chad/0000-0001-7267-5398	NIH (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center) [NS27699, NS27699-20S1-ARRA, HD24064]; NIH [1F32NS055545, NS022920, NS045667]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS043124, R01NS045667, R01NS027699, F32NS055545, R01NS022920, R37NS022920, R37NS027699] Funding Source: NIH RePORTER	NIH (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	J.D.F. and H.Y.Z. conceived of the study and designed experiments. J.D.F., C. M. B., A.N.C., and Y.G. performed behavioral assays and provided input on analysis. J.D.F. and J.C.-B. performed molecular work and analysis. P.Y., H. K., and C. S. analyzed microarray data. J.D.F. and H.Y.Z. wrote the manuscript with input from J.C.-.B, A. F., and H.T.O. We are grateful to G. Schuster for the generation of mutant mice and the members of the H.Y.Z. laboratory for comments and discussions on the manuscript. This research was supported by NIH grants NS27699, NS27699-20S1-ARRA, and HD24064 (Baylor College of Medicine-Intellectual and Developmental Disabilities Research Center) to H.Y.Z.; 1F32NS055545 to J.D.F.; and NS022920 and NS045667 to H.T.O. H.Y.Z. is an investigator with the Howard Hughes Medical Institute, holds a patent on SCA1 diagnostic testing, and is on the scientific advisory board of Pfizer Neuroscience Program.	Astigarraga S, 2007, EMBO J, V26, P668, DOI 10.1038/sj.emboj.7601532; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Ilg W, 2009, NEUROLOGY, V73, P1823, DOI 10.1212/WNL.0b013e3181c33adf; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Lam YC, 2006, CELL, V127, P1335, DOI 10.1016/j.cell.2006.11.038; Lim J, 2008, NATURE, V452, P713, DOI 10.1038/nature06731; Mahoney DJ, 2004, MUSCLE NERVE, V29, P656, DOI 10.1002/mus.20004; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Thomas PS, 2006, HUM MOL GENET, V15, P2225, DOI 10.1093/hmg/ddl148; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Vaz DV, 2008, CLIN REHABIL, V22, P234, DOI 10.1177/0269215507081578; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Zoghbi HY, 2009, J BIOL CHEM, V284, P7425, DOI 10.1074/jbc.R800041200	15	103	106	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2011	334	6056					690	693		10.1126/science.1212673	http://dx.doi.org/10.1126/science.1212673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841EG	22053053	Green Accepted			2023-01-03	WOS:000296494700060
J	Evan, AT; Kossin, JP; Chung, C; Ramanathan, V				Evan, Amato T.; Kossin, James P.; Chung, Chul 'Eddy'; Ramanathan, V.			Arabian Sea tropical cyclones intensified by emissions of black carbon and other aerosols	NATURE			English	Article							VERTICAL WIND SHEAR; INDIAN-OCEAN; CLIMATE; IMPACTS	Throughout the year, average sea surface temperatures in the Arabian Sea are warm enough to support the development of tropical cyclones(1), but the atmospheric monsoon circulation and associated strong vertical wind shear limits cyclone development and intensification, only permitting a pre-monsoon and post-monsoon period for cyclogenesis(1-4). Thus a recent increase in the intensity of tropical cyclones over the northern Indian Ocean(5) is thought to be related to the weakening of the climatological vertical wind shear(3,4). At the same time, anthropogenic emissions of aerosols have increased sixfold since the 1930s, leading to a weakening of the southwesterly lower-level and easterly upper-level winds that define the monsoonal circulation over the Arabian Sea(6-9). In principle, this aerosol-driven circulation modification could affect tropical cyclone intensity over the Arabian Sea, but so far no such linkage has been shown. Here we report an increase in the intensity of pre-monsoon Arabian Sea tropical cyclones during the period 1979-2010, and show that this change in storm strength is a consequence of a simultaneous upward trend in anthropogenic black carbon and sulphate emissions. We use a combination of observational, reanalysis and model data to demonstrate that the anomalous circulation, which is radiatively forced by these anthropogenic aerosols, reduces the basin-wide vertical wind shear, creating an environment more favourable for tropical cyclone intensification. Because most Arabian Sea tropical cyclones make landfall(1), our results suggest an additional impact on human health from regional air pollution.	[Evan, Amato T.] Univ Virginia, Charlottesville, VA 22904 USA; [Kossin, James P.] NOAA, Natl Climat Data Ctr, Asheville, NC 28801 USA; [Kossin, James P.] NOAA, Cooperat Inst Meteorol Satellite Studies, Madison, WI 53706 USA; [Chung, Chul 'Eddy'] Gwangju Inst Sci & Technol, Kwangju 500712, South Korea; [Ramanathan, V.] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of Virginia; National Center Atmospheric Research (NCAR) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; Gwangju Institute of Science & Technology (GIST); University of California System; University of California San Diego; Scripps Institution of Oceanography	Evan, AT (corresponding author), Univ Virginia, Charlottesville, VA 22904 USA.	ate9c@virginia.edu	Kossin, James/C-2022-2016; Evan, Amato/GZL-2684-2022	Kossin, James/0000-0003-0461-9794; Evan, Amato/0000-0003-2812-3750	National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office [NA10OAR4310136]; Korea's Research Agency for Climate Science [RACS 2010-2603]; National Science Foundation [ATM-0721142]	National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office(National Oceanic Atmospheric Admin (NOAA) - USA); Korea's Research Agency for Climate Science; National Science Foundation(National Science Foundation (NSF))	Partial funding for this work was provided by National Oceanic & Atmospheric Administration (NOAA)/Climate Program Office (NA10OAR4310136), Korea's Research Agency for Climate Science (RACS 2010-2603) and the National Science Foundation (ATM-0721142). Data from National Centers for Environmental Prediction reanalyses 1 and 2 were provided by the NOAA/Office of Oceanic and Atmospheric Research/Earth System Research Laboratory Physical Sciences Division, Boulder, Colorado, USA, from their website (http://www.esrl.noaa.gov/psd/).	Chung CE, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2005JD006356; Chung CE, 2003, J CLIMATE, V16, P1791, DOI 10.1175/1520-0442(2003)016<1791:SAHFRI>2.0.CO;2; Chung CE, 2006, J CLIMATE, V19, P2036, DOI 10.1175/JCLI3820.1; Dash SK, 2009, J GEOPHYS RES-ATMOS, V114, DOI 10.1029/2008JD010572; DeMaria M, 1999, WEATHER FORECAST, V14, P326, DOI 10.1175/1520-0434(1999)014<0326:AUSHIP>2.0.CO;2; Dvorak V. F., 1984, 11 NOAA; Elsberry RL, 1996, MON WEATHER REV, V124, P1374, DOI 10.1175/1520-0493(1996)124<1374:VWSIOT>2.0.CO;2; Elsner JB, 2008, NATURE, V455, P92, DOI 10.1038/nature07234; Emanuel K, 2003, ANNU REV EARTH PL SC, V31, P75, DOI 10.1146/annurev.earth.31.100901.141259; EMANUEL KA, 1988, J ATMOS SCI, V45, P1143, DOI 10.1175/1520-0469(1988)045<1143:TMIOH>2.0.CO;2; Evan AT, 2011, J CLIMATE, V24, P140, DOI 10.1175/2010JCLI3611.1; Frank WM, 2001, MON WEATHER REV, V129, P2249, DOI 10.1175/1520-0493(2001)129<2249:EOVWSO>2.0.CO;2; GRAY WM, 1968, MON WEATHER REV, V96, P669, DOI 10.1175/1520-0493(1968)096<0669:GVOTOO>2.0.CO;2; Integrated assessment of black carbon and tropospheric ozone, 2011, UNEPGC26INF20 WORLD; Kanamitsu M, 2002, B AM METEOROL SOC, V83, P1631, DOI 10.1175/Bams-83-11-1631; Kiehl JT, 1998, J CLIMATE, V11, P1131, DOI 10.1175/1520-0442(1998)011<1131:TNCFAR>2.0.CO;2; Knapp KR, 2010, B AM METEOROL SOC, V91, P363, DOI 10.1175/2009BAMS2755.1; Kossin JP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028836; Kossin JP, 2009, CLIMATIC CHANGE, V97, P329, DOI 10.1007/s10584-009-9748-2; Krishna KM, 2009, GLOBAL PLANET CHANGE, V65, P12, DOI 10.1016/j.gloplacha.2008.10.007; Kumari BP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031133; Meehl GA, 2008, J CLIMATE, V21, P2869, DOI 10.1175/2007JCLI1777.1; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; Ramanathan V, 2005, P NATL ACAD SCI USA, V102, P5326, DOI 10.1073/pnas.0500656102; Rao VB, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2008GL034729; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Singh OP, 2001, CURR SCI INDIA, V80, P575; Wang C, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL040114	28	109	111	1	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2011	479	7371					94	U119		10.1038/nature10552	http://dx.doi.org/10.1038/nature10552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840FA	22051678				2023-01-03	WOS:000296422600038
J	Nishitani, WS; Saif, TA; Wang, YX				Nishitani, Wagner Shin; Saif, Taher A.; Wang, Yingxiao			Calcium Signaling in Live Cells on Elastic Gels under Mechanical Vibration at Subcellular Levels	PLOS ONE			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; FLUORESCENT INDICATORS; PHOSPHOLIPASE-C; SHEAR-STRESS; CA2+ ENTRY; STRETCH; CHANNEL; PROTEIN; MECHANOTRANSDUCTION; STREPTOMYCIN	A new device was designed to generate a localized mechanical vibration of flexible gels where human umbilical vein endothelial cells (HUVECs) were cultured to mechanically stimulate these cells at subcellular locations. A Fluorescence Resonance Energy Transfer (FRET)-based calcium biosensor (an improved Cameleon) was used to monitor the spatiotemporal distribution of intracellular calcium concentrations in the cells upon this mechanical stimulation. A clear increase in intracellular calcium concentrations over the whole cell body (global) can be observed in the majority of cells under mechanical stimulation. The chelation of extracellular calcium with EGTA or the blockage of stretch-activated calcium channels on the plasma membrane with streptomycin or gadolinium chloride significantly inhibited the calcium responses upon mechanical stimulation. Thapsigargin, an endoplasmic reticulum (ER) calcium pump inhibitor, or U73122, a phospholipase C (PLC) inhibitor, resulted in mainly local calcium responses occurring at regions close to the stimulation site. The disruption of actin filaments with cytochalasin D or inhibition of actomyosin contractility with ML-7 also inhibited the global calcium responses. Therefore, the global calcium response in HUVEC depends on the influx of calcium through membrane stretch-activated channels, followed by the release of inositol trisphosphate (IP3) via PLC activation to trigger the ER calcium release. Our newly developed mechanical stimulation device can also provide a powerful tool for the study of molecular mechanism by which cells perceive the mechanical cues at subcellular levels.	[Nishitani, Wagner Shin; Wang, Yingxiao] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA; [Nishitani, Wagner Shin; Wang, Yingxiao] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Saif, Taher A.] Univ Illinois, Dept Mech Sci & Engn, Urbana, IL 61801 USA; [Wang, Yingxiao] Univ Illinois, Ctr Biophys & Computat Biol, Inst Genom Biol, Urbana, IL 61801 USA; [Nishitani, Wagner Shin] Minist Educ Brazil, Capes Fdn, Brasilia, DF, Brazil	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Nishitani, WS (corresponding author), Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA.	saif@illinois.edu; yingxiao@uiuc.edu	Nishitani, Wagner/C-9229-2012	Nishitani, Wagner/0000-0003-1643-7357	National Institutes of Health (NIH) [HL098472, CA139272, NS063405]; National Science Foundation (NSF) [CBET0846429, CMMI0800870]; Wallace H. Coulter Foundation; Beckman Laser Institute, Inc.; CAPES/Fulbright [2340/05-4]; NATIONAL CANCER INSTITUTE [R21CA139272] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063405] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation (NSF)(National Science Foundation (NSF)); Wallace H. Coulter Foundation; Beckman Laser Institute, Inc.; CAPES/Fulbright(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported in part by grants from National Institutes of Health (NIH) HL098472, CA139272, NS063405, National Science Foundation (NSF) CBET0846429 (Y.W.), the Wallace H. Coulter Foundation and Beckman Laser Institute, Inc. (Y.W.), NSF CMMI0800870 (T.A.S.), and a fellowship from CAPES/Fulbright 2340/05-4 (W.S.N.) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arganda-Carreras I, 2006, LECT NOTES COMPUT SC, V4241, P85; Bae C, 2011, BIOCHEMISTRY-US, V50, P6295, DOI 10.1021/bi200770q; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Feneberg W, 2004, BIOPHYS J, V87, P1338, DOI 10.1529/biophysj.103.037044; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GANNIER F, 1994, CARDIOVASC RES, V28, P1193, DOI 10.1093/cvr/28.8.1193; GARCIA JGN, 1992, BLOOD, V79, P2056; Guo YJ, 2010, J BIOL CHEM, V285, P24999, DOI 10.1074/jbc.M110.132654; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Hayakawa K, 2008, J CELL SCI, V121, P496, DOI 10.1242/jcs.022053; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hong D, 2006, AM J PHYSIOL-HEART C, V290, pH2498, DOI 10.1152/ajpheart.00828.2005; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; Ingber DE, 2006, FASEB J, V20, P811, DOI 10.1096/fj.05-5424rev; Ito S, 2010, AM J RESP CELL MOL, V43, P26, DOI 10.1165/rcmb.2009-0073OC; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; Krishnan R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005486; Kuhlmann CRW, 2007, J NEUROCHEM, V102, P501, DOI 10.1111/j.1471-4159.2007.04506.x; Lamberts RR, 2002, AM J PHYSIOL-HEART C, V283, pH1515, DOI 10.1152/ajpheart.00113.2002; Lin YF, 2006, MOL ENDOCRINOL, V20, P2514, DOI 10.1210/me.2005-0347; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; Mergler S, 2000, J LEUKOCYTE BIOL, V68, P881; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Miyazaki T, 2007, AM J PHYSIOL-CELL PH, V293, pC1216, DOI 10.1152/ajpcell.00083.2007; Munevar S, 2004, J CELL SCI, V117, P85, DOI 10.1242/jcs.00795; Na S, 2008, P NATL ACAD SCI USA, V105, P6626, DOI 10.1073/pnas.0711704105; Palmer AE, 2006, NAT PROTOC, V1, P1057, DOI 10.1038/nprot.2006.172; Sawyer SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1038, DOI 10.1152/ajpcell.2001.281.3.C1038; Seong JH, 2009, CHEM BIOL, V16, P48, DOI 10.1016/j.chembiol.2008.11.007; Shen MR, 2003, FEBS LETT, V554, P494, DOI 10.1016/S0014-5793(03)01231-6; Sung HJ, 2007, AM J PHYSIOL-CELL PH, V293, pC87, DOI 10.1152/ajpcell.00585.2006; Tang X, 2010, BIOPHYS J, V99, P2460, DOI 10.1016/j.bpj.2010.08.034; Thompson SA, 2011, CIRCULATION, V123, P2083, DOI 10.1161/CIRCULATIONAHA.110.015057; Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577; White CR, 2005, AM J PHYSIOL-HEART C, V289, pH2350, DOI 10.1152/ajpheart.01229.2004; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275; Zhao ZQ, 2008, J CELL PHYSIOL, V214, P595, DOI 10.1002/jcp.21248	41	29	32	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 28	2011	6	10							e26181	10.1371/journal.pone.0026181	http://dx.doi.org/10.1371/journal.pone.0026181			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	876BL	22053183	Green Submitted, Green Published, gold			2023-01-03	WOS:000299081800009
J	Robles, MTS; Case, A; Chong, JL; Leone, G; Pipas, JM				Robles, Maria Teresa Saenz; Case, Ashley; Chong, Jean-Leon; Leone, Gustavo; Pipas, James M.			The Retinoblastoma Tumor Suppressor Regulates a Xenobiotic Detoxification Pathway	PLOS ONE			English	Article							DRUG-METABOLIZING-ENZYMES; LARGE T-ANTIGEN; RB/E2F PATHWAY; RB; CANCER; TUMORIGENESIS; DEFICIENT; ROLES; MOUSE; MICE	The retinoblastoma tumor suppressor (pRb) regulates cell cycle entry, progression and exit by controlling the activity of the E2F-family of transcription factors. During cell cycle exit pRb acts as a transcriptional repressor by associating with E2F proteins and thereby inhibiting their ability to stimulate the expression of genes required for S phase. Indeed, many tumors harbor mutations in the RB gene and the pRb-E2F pathway is compromised in nearly all types of cancers. In this report we show that both pRb and its interacting partners, the transcriptional factors E2F1-2-3, act as positive modulators of detoxification pathways important for metabolizing and clearing xenobiotics-such as toxins and drugs-from the body. Using a combination of conventional molecular biology techniques and microarray analysis of specific cell populations, we have analyzed the detoxification pathway in murine samples in the presence or absence of pRb and/or E2F1-2-3. In this report, we show that both pRb and E2F1-2-3 act as positive modulators of detoxification pathways in mice, challenging the conventional view of E2F1-2-3 as transcriptional repressors negatively regulated by pRb. These results suggest that mutations altering the pRb-E2F axis may have consequences beyond loss of cell cycle control by altering the ability of tissues to remove toxins and to properly metabolize anticancer drugs, and might help to understand the formation and progression rates of different types of cancer, as well as to better design appropriate therapies based on the particular genetic composition of the tumors.	[Robles, Maria Teresa Saenz; Case, Ashley; Pipas, James M.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Chong, Jean-Leon; Leone, Gustavo] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Chong, Jean-Leon; Leone, Gustavo] Ohio State Univ, Coll Biol Sci, Dept Mol Genet, Columbus, OH 43210 USA; [Chong, Jean-Leon; Leone, Gustavo] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Robles, MTS (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.	pipas@pitt.edu			NIH [CA098956]; NATIONAL CANCER INSTITUTE [R01CA098956] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by an NIH grant to J. M. P. (CA098956). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chong JL, 2009, NATURE, V462, P930, DOI 10.1038/nature08677; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DeCaprio JA, 2009, VIROLOGY, V384, P274, DOI 10.1016/j.virol.2008.12.010; Gu XS, 2010, DRUG METAB REV, V42, P482, DOI 10.3109/03602531003654915; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Markovics JA, 2005, J VIROL, V79, P7492, DOI 10.1128/JVI.79.12.7492-7502.2005; Nassar AF, 2009, DRUG METABOLISM HDB; Nelson David R., 2009, Human Genomics, V4, P59; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Reed CA, 2009, ONCOGENE, V28, P4434, DOI 10.1038/onc.2009.303; Robles MTS, 2009, SEMIN CANCER BIOL, V19, P229, DOI 10.1016/j.semcancer.2009.02.002; Saenz-Robles MT, 2007, ONCOGENE, V26, P5124, DOI 10.1038/sj.onc.1210310; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; Scripture CD, 2005, LANCET ONCOL, V6, P780, DOI 10.1016/S1470-2045(05)70388-0; Stengel KR, 2008, CELL CYCLE, V7, DOI 10.4161/cc.7.8.5737; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417	26	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2011	6	10							e26019	10.1371/journal.pone.0026019	http://dx.doi.org/10.1371/journal.pone.0026019			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834PW	22022495	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000295976000055
J	Ait-Mohamed, O; Battisti, V; Joliot, V; Fritsch, L; Pontis, J; Medjkane, S; Redeuilh, C; Lamouri, A; Fahy, C; Rholam, M; Atmani, D; Ait-Si-Ali, S				Ait-Mohamed, Ouardia; Battisti, Valentine; Joliot, Veronique; Fritsch, Lauriane; Pontis, Julien; Medjkane, Souhila; Redeuilh, Catherine; Lamouri, Aazdine; Fahy, Christine; Rholam, Mohamed; Atmani, Djebbar; Ait-Si-Ali, Slimane			Acetonic Extract of Buxus sempervirens Induces Cell Cycle Arrest, Apoptosis and Autophagy in Breast Cancer Cells	PLOS ONE			English	Article							NATURAL-PRODUCTS; DRUG DISCOVERY; TRITERPENOIDAL ALKALOIDS; STEROIDAL ALKALOIDS; THERAPEUTIC TARGET; ANTICANCER AGENTS; CARCINOMA-CELLS; P21 WAF1/CIP1; TUMOR-CELLS; DEATH	Plants are an invaluable source of potential new anti-cancer drugs. Here, we investigated the cytotoxic activity of the acetonic extract of Buxus sempervirens on five breast cancer cell lines, MCF7, MCF10CA1a and T47D, three aggressive triple positive breast cancer cell lines, and BT-20 and MDA-MB-435, which are triple negative breast cancer cell lines. As a control, MCF10A, a spontaneously immortalized but non-tumoral cell line has been used. The acetonic extract of Buxus sempervirens showed cytotoxic activity towards all the five studied breast cancer cell lines with an IC(50) ranging from 7.74 mu g/ml to 12.5 mu g/ml. Most importantly, the plant extract was less toxic towards MCF10A with an IC(50) of 19.24 mu g/ml. Fluorescence-activated cell sorting (FACS) analysis showed that the plant extract induced cell death and cell cycle arrest in G0/G1 phase in MCF7, T47D, MCF10CA1a and BT-20 cell lines, concomitant to cyclin D1 downregulation. Application of MCF7 and MCF10CA1a respective IC(50) did not show such effects on the control cell line MCF10A. Propidium iodide/Annexin V double staining revealed a pre-apoptotic cell population with extract-treated MCF10CA1a, T47D and BT-20 cells. Transmission electron microscopy analyses indicated the occurrence of autophagy in MCF7 and MCF10CA1a cell lines. Immunofluorescence and Western blot assays confirmed the processing of microtubule-associated protein LC3 in the treated cancer cells. Moreover, we have demonstrated the upregulation of Beclin-1 in these cell lines and downregulation of Survivin and p21. Also, Caspase-3 detection in treated BT-20 and T47D confirmed the occurrence of apoptosis in these cells. Our findings indicate that Buxus sempervirens extract exhibit promising anti-cancer activity by triggering both autophagic cell death and apoptosis, suggesting that this plant may contain potential anti-cancer agents for single or combinatory cancer therapy against breast cancer.	[Ait-Mohamed, Ouardia; Atmani, Djebbar] Fac Sci Nat, Lab Biochim Appl, Bejaia, Algeria; [Ait-Mohamed, Ouardia; Atmani, Djebbar] Univ Bejaia, Bejaia, Algeria; [Battisti, Valentine; Joliot, Veronique; Fritsch, Lauriane; Pontis, Julien; Medjkane, Souhila; Ait-Si-Ali, Slimane] Univ Paris Diderot Sorbonne Paris Cite, CNRS, UMR7216, Lab Epigenet & Destin Cellulaire, Paris, France; [Redeuilh, Catherine; Lamouri, Aazdine; Fahy, Christine; Rholam, Mohamed] Univ Paris Diderot Sorbonne Paris Cite, CNRS, UMR7086, Lab ITODYS, Paris, France	Universite de Bejaia; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite	Ait-Mohamed, O (corresponding author), Fac Sci Nat, Lab Biochim Appl, Bejaia, Algeria.	ouardia.ait-mohamed@univ-paris-diderot.fr; slimane.aitsiali@univ-paris-diderot.fr		Medjkane, Souhila/0000-0001-7973-7707	Agence Nationale de la Recherche (ANR); Association Francaise contre les Myopathies (AFM); Fondation Bettencourt-Schueller; Centre des Oeuvres Universitaires et Scolaires (CROUS); Centre national de la recherche scientifique (CNRS); Universite Paris Diderot; Programme franco-algerien de formation superieure en France PROFAS; Ministere de l'enseignement superieur et de la recherche	Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); Fondation Bettencourt-Schueller; Centre des Oeuvres Universitaires et Scolaires (CROUS); Centre national de la recherche scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universite Paris Diderot; Programme franco-algerien de formation superieure en France PROFAS; Ministere de l'enseignement superieur et de la recherche	This work was supported by the Agence Nationale de la Recherche (ANR); the Association Francaise contre les Myopathies (AFM); the Fondation Bettencourt-Schueller; the Programme franco-algerien de formation superieure en France (PROFAS) via the Centre des Oeuvres Universitaires et Scolaires (CROUS); the Centre national de la recherche scientifique (CNRS); and Universite Paris Diderot. Dr. Ait-Mohamed was the recipient of a fellowship from the Programme franco-algerien de formation superieure en France PROFAS managed by the CROUS. Dr. Battisti and Dr. Pontis are recipients of fellowships from the Ministere de l'enseignement superieur et de la recherche. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Ata A, 2010, PHYTOCHEMISTRY, V71, P1780, DOI 10.1016/j.phytochem.2010.06.017; Babar ZU, 2006, STEROIDS, V71, P1045, DOI 10.1016/j.steroids.2006.09.002; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038/nature03194; Cragg GM, 2009, PHYTOCHEM REV, V8, P313, DOI 10.1007/s11101-009-9123-y; Cragg GM, 2009, CHEM REV, V109, P3012, DOI 10.1021/cr900019j; DARZYNKIEWICZ Z, 2004, CYTOMETRIC METHODS D, P307; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; ELGENDY M, 2011, ONCOGENIC R IN PRESS; Fan YP, 2003, MOL CANCER THER, V2, P773; FENGZHI L, 1998, CONTROL APOPTOSIS MI; Fourneau C, 1997, TETRAHEDRON LETT, V38, P2965, DOI 10.1016/S0040-4039(97)00534-0; Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200; Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; GILLETT C, 1994, CANCER RES, V54, P1812; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gurung RL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012124; Hernandez-Enriquez B, 2010, NEUROSCIENCE, V167, P298, DOI 10.1016/j.neuroscience.2010.01.046; JOHNSTON S, NEW TARGETS THERAPY; Khalid A, 2005, BIOCHEM BIOPH RES CO, V331, P1528, DOI 10.1016/j.bbrc.2005.03.248; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu SX, 2003, DRUG RESIST UPDATE, V6, P183, DOI 10.1016/S1368-7646(03)00044-X; Loru F, 2000, PHYTOCHEMISTRY, V54, P951, DOI 10.1016/S0031-9422(00)00036-4; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723; Matochko WL, 2010, J NAT PROD, V73, P1858, DOI 10.1021/np100494u; Mesaik MA, 2010, CHEM BIOL DRUG DES, V75, P310, DOI 10.1111/j.1747-0285.2009.00906.x; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Morgan G, 2004, CLIN ONCOL-UK, V16, P549, DOI 10.1016/j.clon.2004.06.007; NAKANO T, 1964, TETRAHEDRON LETT, V5, P3679; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404; Paterson I, 2005, SCIENCE, V310, P451, DOI 10.1126/science.1116364; Pezzuto JM, 1997, BIOCHEM PHARMACOL, V53, P121, DOI 10.1016/S0006-2952(96)00654-5; Russo IH, 1998, J MAMMARY GLAND BIOL, V3, P49, DOI 10.1023/A:1018770218022; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4; Tian H, 2000, CANCER RES, V60, P679; UR RA, 1992, PHYTOCHEMISTRY, V31, P2933; Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251; Wall NR, 2003, CANCER RES, V63, P230; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yan YX, 2009, J NAT PROD, V72, P308, DOI 10.1021/np800719h; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	72	37	37	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2011	6	9							e24537	10.1371/journal.pone.0024537	http://dx.doi.org/10.1371/journal.pone.0024537			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	822JR	21935420	Green Published, gold, Green Submitted			2023-01-03	WOS:000295041700040
J	Presanis, AM; Pebody, RG; Paterson, BJ; Tom, BDM; Birrell, PJ; Charlett, A; Lipsitch, M; De Angelis, D				Presanis, A. M.; Pebody, R. G.; Paterson, B. J.; Tom, B. D. M.; Birrell, P. J.; Charlett, A.; Lipsitch, M.; De Angelis, D.			Changes in severity of 2009 pandemic A/H1N1 influenza in England: a Bayesian evidence synthesis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTION; DISEASE	Objective To assess the impact of the 2009 A/H1N1 influenza pandemic in England during the two waves of activity up to end of February 2010 by estimating the probabilities of cases leading to severe events and the proportion of the population infected. Design A Bayesian evidence synthesis of all available relevant surveillance data in England to estimate severity of the pandemic. Data sources All available surveillance systems relevant to the pandemic 2009 A/H1N1 influenza outbreak in England from June 2009 to February 2010. Pre-existing influenza surveillance systems, including estimated numbers of symptomatic cases based on consultations to the health service for influenza-like illness and cross sectional population serological surveys, as well as systems set up in response to the pandemic, including follow-up of laboratory confirmed cases up to end of June 2009 (FF100 and Fluzone databases), retrospective and prospective follow-up of confirmed hospitalised cases, and reported deaths associated with pandemic 2009 A/H1N1 influenza. Main outcome measures Age specific and wave specific probabilities of infection and symptomatic infection resulting in hospitalisation, intensive care admission, and death, as well as infection attack rates (both symptomatic and total). The probabilities of intensive care admission and death given hospitalisation over time are also estimated to evaluate potential changes in severity across waves. Results In the summer wave of A/H1N1 influenza, 0.54% (95% credible interval 0.33% to 0.82%) of the estimated 606 100 (419 300 to 886 300) symptomatic cases were hospitalised, 0.05% (0.03% to 0.08%) entered intensive care, and 0.015% (0.010% to 0.022%) died. These correspond to 3200 (2300 to 4700) hospital admissions, 310 (200 to 480) intensive care admissions, and 90 (80 to 110) deaths in the summer wave. In the second wave, 0.55% (0.28% to 0.89%) of the 1 352 000 (829 900 to 2 806 000) estimated symptomatic cases were hospitalised, 0.10% (0.05% to 0.16%) were admitted to intensive care, and 0.025% (0.013% to 0.040%) died. These correspond to 7500 (5900 to 9700) hospitalisations, 1340 (1030 to 1790) admissions to intensive care, and 240 (310 to 380) deaths. Just over a third (35% (26% to 45%)) of infections were estimated to be symptomatic. The estimated probabilities of infections resulting in severe events were therefore 0.19% (0.12% to 0.29%), 0.02% (0.01% to 0.03%), and 0.005% (0.004% to 0.008%) in the summer wave for hospitalisation, intensive care admission, and death respectively. The corresponding second wave probabilities are 0.19% (0.10% to 0.32%), 0.03% (0.02% to 0.06%), and 0.009% (0.004% to 0.014%). An estimated 30% (20% to 43%) of hospitalisations were detected in surveillance systems in the summer, compared with 20% (15% to 25%) in the second wave. Across the two waves, a mid-estimate of 11.2% (7.4% to 18.9%) of the population of England were infected, rising to 29.5% (16.9% to 64.1%) in 5-14 year olds. Sensitivity analyses to the evidence included suggest this infection attack rate could be as low as 5.9% (4.2% to 8.7%) or as high as 28.4% (26.0% to 30.8%). In terms of the probability that an infection leads to death in the second wave, these correspond, respectively, to a high estimate of 0.017% (0.011% to 0.024%) and a low estimate of 0.0027% (0.0024% to 0.0031%). Conclusions This study suggests a mild pandemic, characterised by case and infection severity ratios increasing between waves. Results suggest low ascertainment rates, highlighting the importance of systems enabling early robust estimation of severity, to inform optimal public health responses, particularly in light of the apparent resurgence of the 2009 A/H1N1 strain in the 2010-11 influenza season.	[Presanis, A. M.; Tom, B. D. M.; Birrell, P. J.; De Angelis, D.] Univ Forvie Site, Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge CB2 0SR, England; [Charlett, A.] Hlth Protect Serv, Hlth Protect Agcy, Modelling & Econ Dept, London NW9 5EQ, England; [Paterson, B. J.] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2300, Australia; [Lipsitch, M.] Harvard Univ, Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Epidemiol, Boston, MA 02115 USA; [Lipsitch, M.] Harvard Univ, Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Immunol & Infect Dis, Boston, MA 02115 USA	MRC Biostatistics Unit; University of Cambridge; Health Protection Agency; Hunter Medical Research Institute; University of Newcastle; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Presanis, AM (corresponding author), Univ Forvie Site, Inst Publ Hlth, Med Res Council Biostat Unit, Cambridge CB2 0SR, England.	anne.presanis@mrc-bsu.cam.ac.uk	Paterson, Beverley J/C-6189-2012	Paterson, Beverley J/0000-0001-5108-103X; Tom, Brian/0000-0002-3335-9322; Birrell, Paul/0000-0001-8131-4893; Pebody, Richard/0000-0002-9069-2885; Presanis, Anne/0000-0003-3078-4427; De Angelis, Daniela/0000-0001-6619-6112	UK Medical Research Council [MC_US_A030_0016.01]; UK Health Protection Agency; Models of Infectious Disease Agent Study Consortium from the National Institute of General Medical Sciences [U54GM088558];  [MC_US_A030_0022.01]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM088558] Funding Source: NIH RePORTER; Medical Research Council [MC_U105260556, MC_U105261167] Funding Source: researchfish; MRC [MC_U105261167, MC_U105260556] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Health Protection Agency; Models of Infectious Disease Agent Study Consortium from the National Institute of General Medical Sciences; ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	AMP, PJB, and DDA were funded by the UK Medical Research Council (grant MC_US_A030_0016.01). BDMT was also funded by the council (grant MC_US_A030_0022.01). DDA, RGP, BJP, and AC were funded by the UK Health Protection Agency. BJP was funded as a research fellow by the Hunter Medical Research Institute, Australia. ML was supported by the Models of Infectious Disease Agent Study Consortium from the National Institute of General Medical Sciences (award No U54GM088558). The content is the responsibility of the authors and does not necessarily represent the views of the National Institute of General Medical Sciences or the National Institutes of Health. The funders had no role in study design; the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to publish the article.	Bandaranayake D, 2010, SEROPREVALENCE 2009; Bird SM, 2010, LANCET, V376, P684, DOI 10.1016/S0140-6736(10)61333-5; Birrell PJ, 2011, BAYESIAN MODEL UNPUB; Campbell CN, 2010, EPIDEMIOL INFECT, V26, P1, DOI DOI 10.1017/S0950268810002657; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Cowling BJ, 2010, NEW ENGL J MED, V362, P2175, DOI 10.1056/NEJMoa0911530; Degail M, 2010, HLTH PROT C; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Dowell SF, 2003, EMERG INFECT DIS, V9, P573, DOI 10.3201/eid0905.020556; Evans BG, 2011, HAS ESTIMATION UNPUB; FluWatch, 2009, PAND STUD; Garske T, 2009, BMJ-BRIT MED J, V339, pb2840; Grant A, 2010, COMMUNICATION; Hadler JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011677; Hardelid P, 2010, HEALTH TECHNOL ASSES, V14, P115, DOI 10.3310/hta14550-03; Harris R, 2010, STAT ANAL PRELIMINAR; Health Protection Agency, 2010, EP REP PAND H1N1 200; Health Protection Agency Health Protection Scotland Communicable Disease Surveillance Centre Northern Ireland and National Public Health Service FOR WALES, 2009, 1 FEW 100 FF100 PROJ; Ihekweazu C, 2010, INT C EM INF DIS ATL; Influenzanet, 2009, INFL; Lipsitch M, 2009, NEW ENGL J MED, V361, P112, DOI 10.1056/NEJMp0904380; Lunn D, 2009, STAT MED, V28, P3049, DOI 10.1002/sim.3680; Miller E, 2010, LANCET, V375, P1100, DOI 10.1016/S0140-6736(09)62126-7; Miller MA, 2009, NEW ENGL J MED, V360, P2595, DOI 10.1056/NEJMp0903906; Nishiura H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006852; Pebody RG, 2010, EUROSURVEILLANCE, V15; Presanis AM, 2011, ROLE EACH ITEM UNPUB; Presanis AM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000207; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; Wallinga J, 2010, P NATL ACAD SCI USA, V107, P923, DOI 10.1073/pnas.0908491107; Welliver R, 2001, JAMA-J AM MED ASSOC, V285, P748, DOI 10.1001/jama.285.6.748; Wilson N, 2009, EUROSURVEILLANCE, V14; World Health Organization, 2010, PAND H1N1 2009 UPD 1; Wu JT, 2010, CLIN INFECT DIS, V51, P1184, DOI 10.1086/656740; [No title captured]	35	62	62	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 8	2011	343								d5408	10.1136/bmj.d5408	http://dx.doi.org/10.1136/bmj.d5408			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	819RV	21903689	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000294848300003
J	Boy, S; Sauerbruch, S; Kraemer, M; Schormann, T; Schlachetzki, F; Schuierer, G; Luerding, R; Hennemann, B; Orso, E; Dabringhaus, A; Winkler, J; Bogdahn, U				Boy, Sandra; Sauerbruch, Sophie; Kraemer, Mathias; Schormann, Thorsten; Schlachetzki, Felix; Schuierer, Gerhard; Luerding, Ralph; Hennemann, Burkhard; Orso, Evelyn; Dabringhaus, Andreas; Winkler, Juergen; Bogdahn, Ulrich		RAIS Study Grp	Mobilisation of Hematopoietic CD34(+) Precursor Cells in Patients with Acute Stroke Is Safe - Results of an Open-Labeled Non Randomized Phase I/II Trial	PLOS ONE			English	Article							COLONY-STIMULATING FACTOR; FOCAL CEREBRAL-ISCHEMIA; VOXEL-GUIDED MORPHOMETRY; FACTOR G-CSF; BONE-MARROW; FUNCTIONAL RECOVERY; PERIPHERAL-BLOOD; STEM-CELLS; WORKING-MEMORY; INFARCT VOLUME	Background: Regenerative strategies in the treatment of acute stroke may have great potential. Hematopoietic growth factors mobilize hematopoietic stem cells and may convey neuroprotective effects. We examined the safety, potential functional and structural changes, and CD34(+) cell-mobilization characteristics of G-CSF treatment in patients with acute ischemic stroke. Methods and Results: Three cohorts of patients (8, 6, and 6 patients per cohort) were treated subcutaneously with 2.5, 5, or 10 mu g/kg body weight rhG-CSF for 5 consecutive days within 12 hrs of onset of acute stroke. Standard treatment included IV thrombolysis. Safety monitoring consisted of obtaining standardized clinical assessment scores, monitoring of CD34(+) stem cells, blood chemistry, serial neuroradiology, and neuropsychology. Voxel-guided morphometry (VGM) enabled an assessment of changes in the patients' structural parenchyma. 20 patients (mean age 55 yrs) were enrolled in this study, 5 of whom received routine thrombolytic therapy with r-tPA. G-CSF treatment was discontinued in 4 patients because of unrelated adverse events. Mobilization of CD34(+) cells was observed with no concomitant changes in blood chemistry, except for an increase in the leukocyte count up to 75,500/mu l. Neuroradiological and neuropsychological follow-up studies did not disclose any specific G-CSF toxicity. VGM findings indicated substantial atrophy of related hemispheres, a substantial increase in the CSF space, and a localized increase in parenchyma within the ischemic area in 2 patients. Conclusions: We demonstrate a good safety profile for daily administration of G-CSF when begun within 12 hours after onset of ischemic stroke and, in part in combination with routine IV thrombolysis. Additional analyses using VGM and a battery of neuropsychological tests indicated a positive functional and potentially structural effect of G-CSF treatment in some of our patients.	[Boy, Sandra; Sauerbruch, Sophie; Schlachetzki, Felix; Luerding, Ralph; Winkler, Juergen; Bogdahn, Ulrich] Univ Regensburg, Bezirksklinikum Regensburg, Dept Neurol, Regensburg, Germany; [Kraemer, Mathias] Neurol Therapy Ctr, Cologne, Germany; [Kraemer, Mathias] St Marien Hosp, Cologne, Germany; [Schormann, Thorsten] Univ Med Ctr, Dept Neurol, Dusseldorf, Germany; [Schuierer, Gerhard] Univ Regensburg, Med Ctr, Dist Med Ctr Regensburg, Inst Neuroradiol, Regensburg, Germany; [Hennemann, Burkhard] Univ Regensburg, Med Ctr, Dept Hematooncol, Regensburg, Germany; [Orso, Evelyn] Univ Regensburg, Med Ctr, Dept Clin Chem, Regensburg, Germany; [Dabringhaus, Andreas] St Mauritius Therapy Clin, Meerbusch, Germany	University of Regensburg; St. Marien Hospital; University of Regensburg; University of Regensburg; University of Regensburg	Boy, S (corresponding author), Univ Regensburg, Bezirksklinikum Regensburg, Dept Neurol, Regensburg, Germany.	sandra.boy@medbo.de	Kraemer, Matthias/GLR-0951-2022	Winkler, Jurgen/0000-0003-0630-9204	AMGEN Inc. Germany	AMGEN Inc. Germany	The initiation of the study protocol was supported by an unrestricted educational grant from AMGEN Inc. Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albers GW, 2007, LANCET, V369, P249, DOI 10.1016/S0140-6736(07)60120-2; ALBERTS MJ, 1993, STROKE, V24, P1817, DOI 10.1161/01.STR.24.12.1817; American Heart Association, 2006, HEART DIS STROK STAT; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Bao WK, 2004, CARDIOVASC RES, V61, P548, DOI 10.1016/j.cardiores.2003.12.004; BEGLEY CG, 1986, BLOOD, V68, P162; Bratane BT, 2009, STROKE, V40, P3102, DOI 10.1161/STROKEAHA.109.553958; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; BRUGGER W, 1995, NEW ENGL J MED, V333, P283, DOI 10.1056/NEJM199508033330503; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Endres M, 2008, CEREBROVASC DIS, V25, P268, DOI 10.1159/000118039; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gibson CL, 2005, J CEREBR BLOOD F MET, V25, P431, DOI 10.1038/sj.jcbfm.9600033; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Haas S, 2005, CURR OPIN NEUROL, V18, P59, DOI 10.1097/00019052-200502000-00012; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hennemann B, 2008, CYTOTHERAPY, V10, P303, DOI 10.1080/14653240801949994; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hirose L, 2004, EXERC IMMUNOL REV, V10, P75; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Karl C, 2005, J NEUROCHEM, V92, P264, DOI 10.1111/j.1471-4159.2004.02879.x; Kawada H, 2006, CIRCULATION, V113, P701, DOI 10.1161/CIRCULATIONAHA.105.563668; Kleinschnitz C, 2004, MOL BRAIN RES, V131, P73, DOI 10.1016/j.molbrainres.2004.08.011; Kraemer M, 2004, J NEUROIMAGING, V14, P265, DOI 10.1177/1051228404264950; Lin Q, 2006, J BIOL CHEM, V281, P30678, DOI 10.1074/jbc.C600120200; Luerding R, 2008, BRAIN, V131, P3222, DOI 10.1093/brain/awn229; Madri JA, 2009, J PHYSIOL PHARMACOL, V60, P95; METCALF D, 1990, CANCER-AM CANCER SOC, V65, P2185, DOI 10.1002/1097-0142(19900515)65:10<2185::AID-CNCR2820651005>3.0.CO;2-4; Meuer K, 2006, J NEUROCHEM, V97, P675, DOI 10.1111/j.1471-4159.2006.03727.x; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Minnerup J, 2008, STROKE, V39, P1855, DOI 10.1161/STROKEAHA.107.506816; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Prozorovski T, 2008, NAT CELL BIOL, V10, P385, DOI 10.1038/ncb1700; Root RK, 2003, CRIT CARE MED, V31, P367, DOI 10.1097/01.CCM.0000048629.32625.5D; Savitz SI, 2007, ANN NEUROL, V61, P396, DOI 10.1002/ana.21127; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schabitz WR, 2010, STROKE, V41, P2545, DOI 10.1161/STROKEAHA.110.579508; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Schormann T, 2003, IEEE T MED IMAGING, V22, P62, DOI 10.1109/TMI.2002.806571; Shyu WC, 2006, CAN MED ASSOC J, V174, P927, DOI 10.1503/cmaj.051322; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Sprigg N, 2006, STROKE, V37, P2979, DOI 10.1161/01.STR.0000248763.49831.c3; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Suzuki K, 2003, MED SCI SPORT EXER, V35, P348, DOI 10.1249/01.MSS.0000048861.57899.04; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Taguchi A, 2004, CIRCULATION, V109, P2972, DOI 10.1161/01.CIR.0000133311.25587.DE; von Aulock S, 2003, IMMUNOBIOLOGY, V208, P413, DOI 10.1078/0171-2985-00285; Weiss M, 2001, CYTOKINE, V13, P51, DOI 10.1006/cyto.2000.0796; WELTE K, 1985, P NATL ACAD SCI USA, V82, P1526, DOI 10.1073/pnas.82.5.1526; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Zhang Y, 2004, AM J PHYSIOL-RENAL, V286, pF1193, DOI 10.1152/ajprenal.00379.2002; Ziemus B, 2007, NEUROPSYCHOLOGIA, V45, P2016, DOI 10.1016/j.neuropsychologia.2007.02.012	54	24	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2011	6	8							e23099	10.1371/journal.pone.0023099	http://dx.doi.org/10.1371/journal.pone.0023099			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812MY	21887230	Green Published, Green Submitted, gold			2023-01-03	WOS:000294298800005
J	Carlsson, MA; Bisch-Knaden, S; Schapers, A; Mozuraitis, R; Hansson, BS; Janz, N				Carlsson, Mikael A.; Bisch-Knaden, Sonja; Schaepers, Alexander; Mozuraitis, Raimondas; Hansson, Bill S.; Janz, Niklas			Odour Maps in the Brain of Butterflies with Divergent Host-Plant Preferences	PLOS ONE			English	Article							MOTH SPODOPTERA-LITTORALIS; ANTENNAL LOBE; MANDUCA-SEXTA; OLFACTORY-BULB; SPHINX MOTH; SPATIAL REPRESENTATION; GLOMERULAR ACTIVITY; LEAF VOLATILES; APIS-MELLIFERA; FLORAL SCENTS	Butterflies are believed to use mainly visual cues when searching for food and oviposition sites despite that their olfactory system is morphologically similar to their nocturnal relatives, the moths. The olfactory ability in butterflies has, however, not been thoroughly investigated. Therefore, we performed the first study of odour representation in the primary olfactory centre, the antennal lobes, of butterflies. Host plant range is highly variable within the butterfly family Nymphalidae, with extreme specialists and wide generalists found even among closely related species. Here we measured odour evoked Ca2+ activity in the antennal lobes of two nymphalid species with diverging host plant preferences, the specialist Aglais urticae and the generalist Polygonia c-album. The butterflies responded with stimulus-specific combinations of activated glomeruli to single plant-related compounds and to extracts of host and non-host plants. In general, responses were similar between the species. However, the specialist A. urticae responded more specifically to its preferred host plant, stinging nettle, than P. c-album. In addition, we found a species-specific difference both in correlation between responses to two common green leaf volatiles and the sensitivity to these compounds. Our results indicate that these butterflies have the ability to detect and to discriminate between different plant-related odorants.	[Carlsson, Mikael A.; Schaepers, Alexander; Janz, Niklas] Stockholm Univ, Dept Zool, S-10691 Stockholm, Sweden; [Bisch-Knaden, Sonja; Hansson, Bill S.] Max Planck Inst Chem Ecol, Dept Evolutionary Neuroethol, Jena, Germany; [Mozuraitis, Raimondas] Royal Inst Technol, Dept Chem, Stockholm, Sweden; [Mozuraitis, Raimondas] Nat Res Ctr, Inst Ecol, Lab Chem & Behav Ecol, Vilnius, Lithuania	Stockholm University; Max Planck Society; Royal Institute of Technology; Nature Research Center - Lithuania	Carlsson, MA (corresponding author), Stockholm Univ, Dept Zool, S-10691 Stockholm, Sweden.	mikael.carlsson@zoologi.su.se	Janz, Niklas/B-1756-2010; Hansson, Bill/G-2774-2013	Janz, Niklas/0000-0002-6379-7905; Hansson, Bill/0000-0002-4811-1223; Schapers, Alexander/0000-0002-3187-3555; /0000-0002-1719-2294	Swedish Research Council; Stockholm University Faculty of Science; Royal Swedish Academy of Science; Max Planck Society	Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm University Faculty of Science; Royal Swedish Academy of Science; Max Planck Society(Max Planck SocietyFoundation CELLEX)	The project was financed by The Swedish Research Council (NJ), the Stockholm University Faculty of Science (NJ), the Royal Swedish Academy of Science (MAC), and the Max Planck Society (BSH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACKERY PR, 1988, BIOL J LINN SOC, V33, P95, DOI 10.1111/j.1095-8312.1988.tb00446.x; Andersson S, 2003, J CHEM ECOL, V29, P2319, DOI 10.1023/A:1026278531806; Andersson S, 2003, CHEMOECOLOGY, V13, P13, DOI 10.1007/s000490300001; Angioy AM, 2003, CHEM SENSES, V28, P279, DOI 10.1093/chemse/28.4.279; Braby MF, 2006, ZOOL J LINN SOC-LOND, V147, P238; Brower AVZ, 2000, P ROY SOC B-BIOL SCI, V267, P1201, DOI 10.1098/rspb.2000.1129; Carlsson MA, 2003, CHEM SENSES, V28, P269, DOI 10.1093/chemse/28.4.269; Carlsson MA, 2002, CHEM SENSES, V27, P231, DOI 10.1093/chemse/27.3.231; Carlsson MA, 2007, CHEM SENSES, V32, P433, DOI 10.1093/chemse/bjm009; CHRISTENSEN TA, 1987, J COMP PHYSIOL A, V160, P553, DOI 10.1007/BF00611929; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; Dupuy F, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-28; Elbert G, 1993, SCHMETTERLINGE BADEN; Fishilevich E, 2005, CURR BIOL, V15, P1548, DOI 10.1016/j.cub.2005.07.066; Friedrich RW, 1997, NEURON, V18, P737, DOI 10.1016/S0896-6273(00)80314-1; Galizia CG, 1998, EUR J NEUROSCI, V10, P2964, DOI 10.1111/j.1460-9568.1998.00303.x; Galizia CG, 1999, NAT NEUROSCI, V2, P473, DOI 10.1038/8144; Gao Q, 2000, NAT NEUROSCI, V3, P780, DOI 10.1038/77680; Guerrieri F, 2005, PLOS BIOL, V3, P718, DOI 10.1371/journal.pbio.0030060; Hamback PA, 2007, P NATL ACAD SCI USA, V104, P8368, DOI 10.1073/pnas.0611462104; HANSSON BS, 1992, SCIENCE, V256, P1313, DOI 10.1126/science.1598574; Hansson BS, 2003, J COMP PHYSIOL A, V189, P301, DOI 10.1007/s00359-003-0403-5; HANSSON BS, 1995, EXPERIENTIA, V51, P1003, DOI 10.1007/BF01946910; Ikeura H, 2010, BIOCHEM SYST ECOL, V38, P1199, DOI 10.1016/j.bse.2010.12.007; Janz N, 2003, OIKOS, V100, P493, DOI 10.1034/j.1600-0706.2003.12290.x; Janz N, 1997, P ROY SOC B-BIOL SCI, V264, P701, DOI 10.1098/rspb.1997.0100; Janz N, 2001, EVOLUTION, V55, P783, DOI 10.1554/0014-3820(2001)055[0783:EDOHPS]2.0.CO;2; Joerges J, 1997, NATURE, V387, P285, DOI 10.1038/387285a0; Johnson BA, 2004, J COMP NEUROL, V480, P234, DOI 10.1002/cne.20335; Kazawa T, 2009, CELL TISSUE RES, V336, P119, DOI 10.1007/s00441-009-0756-3; Masante-Roca I, 2005, J EXP BIOL, V208, P1147, DOI 10.1242/jeb.01508; Meijerink J, 2003, J COMP NEUROL, V467, P11, DOI 10.1002/cne.10914; NYLIN S, 1988, OIKOS, V53, P381, DOI 10.2307/3565539; Nylin S, 2000, J INSECT BEHAV, V13, P469, DOI 10.1023/A:1007839200323; Omura H, 2009, CHEMOECOLOGY, V19, P227, DOI 10.1007/s00049-009-0024-8; ROSPARS JP, 1992, CELL TISSUE RES, V270, P205, DOI 10.1007/BF00328007; ROSPARS JP, 1983, J COMP NEUROL, V220, P80, DOI 10.1002/cne.902200108; Sachse S, 2003, EUR J NEUROSCI, V18, P2119, DOI 10.1046/j.1460-9568.2003.02931.x; Schoonhoven LM, 2005, INSECT PLANT BIOL, Vxvii, P421; Utz S, 2005, CELL TISSUE RES, V320, P149, DOI 10.1007/s00441-004-1059-3; Utz S, 2007, DEV NEUROBIOL, V67, P764, DOI 10.1002/dneu.20381; Valentincic T, 2005, CHEM SENSES, V30, pI312, DOI 10.1093/chemse/bjh240; Varela N, 2009, CELL TISSUE RES, V337, P513, DOI 10.1007/s00441-009-0839-1; VISSER JH, 1978, ENTOMOL EXP APPL, V24, P738, DOI 10.1007/BF02385130; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; Wachowiak M, 2001, NEURON, V32, P723, DOI 10.1016/S0896-6273(01)00506-2; Wahlberg N, 2006, SYST BIOL, V55, P703, DOI 10.1080/10635150600913235; Wahlberg N, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-92; Wang JW, 2003, CELL, V112, P271, DOI 10.1016/S0092-8674(03)00004-7; Youngentob SL, 2006, BEHAV NEUROSCI, V120, P1337, DOI 10.1037/0735-7044.120.6.1337; Zhang QH, 1999, J CHEM ECOL, V25, P1923, DOI 10.1023/A:1020994119019	51	20	24	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2011	6	8							e24025	10.1371/journal.pone.0024025	http://dx.doi.org/10.1371/journal.pone.0024025			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	812MQ	21901154	Green Published, gold			2023-01-03	WOS:000294298000039
J	Dhalla, IA; Persaud, N; Juurlink, DN				Dhalla, Irfan A.; Persaud, Navindra; Juurlink, David N.			Facing up to the prescription opioid crisis	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CHRONIC NONCANCER PAIN; PRACTICE GUIDELINE; NONMALIGNANT PAIN; MORTALITY; ANALGESICS; OXYCODONE; DEATHS; SAFETY		[Dhalla, Irfan A.; Juurlink, David N.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Dhalla, Irfan A.; Juurlink, David N.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Dhalla, Irfan A.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Persaud, Navindra] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Juurlink, David N.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Persaud, Navindra] St Michaels Hosp, Dept Family & Community Med, Toronto, ON M5B 1W8, Canada; [Persaud, Navindra] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; [Juurlink, David N.] Sunnybrook Res Inst, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Dhalla, IA (corresponding author), 30 Bond St, Toronto, ON M5B 1W8, Canada.	dhallai@smh.ca						Andersen S, 1996, BRIT J CLIN PRACT, V50, P324; [Anonymous], PHARM SALES 2010; Centers for Disease Control and Prevention, 2010, MMWR-MORBID MORTAL W, V59, P1026; Chou R, 2009, J PAIN, V10, P147, DOI 10.1016/j.jpain.2008.10.007; Dhalla IA, 2011, CAN FAM PHYSICIAN, V57, pE92; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Furlan AD, 2010, CAN MED ASSOC J, V182, P923, DOI 10.1503/cmaj.100187; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Hawton K, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b2270; Noble M, 2008, J PAIN SYMPTOM MANAG, V35, P214, DOI 10.1016/j.jpainsymman.2007.03.015; Nuesch E., 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003115.PUB3; Office for National Statistics, DEATHS REL DRUG POIS; Rintoul AC, 2011, INJURY PREV, V17, P254, DOI 10.1136/ip.2010.029611; Solomon DH, 2010, ARCH INTERN MED, V170, P1968, DOI 10.1001/archinternmed.2010.391; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Spence D., 2010, BMJ-BRIT MED J, V340, pc2659; United nations, REP INT NARC CONTR B; United States General Accounting Office, 2003, OX AB DIV EFF ADDR P; US Department of Health and Human Services, 2009, WARN LETT EMBEDA MOR; US Department of Health and Human Services, 2004, WARN LETT DUR FENT T; Warner M, 1999, INCREASE FATAL POISO; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714	22	129	129	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2011	343								d5142	10.1136/bmj.d5142	http://dx.doi.org/10.1136/bmj.d5142			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	813ZK	21862533	Green Submitted			2023-01-03	WOS:000294409600005
J	Eliyahu, E; Wolfson, T; Ge, Y; Jepsen, KJ; Schuchman, EH; Simonaro, CM				Eliyahu, Efrat; Wolfson, Theodore; Ge, Yi; Jepsen, Karl J.; Schuchman, Edward H.; Simonaro, Calogera M.			Anti-TNF-Alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI	PLOS ONE			English	Article							ARYLSULFATASE-B; JOINT DISEASE; MECHANISM; BONE; IDENTIFICATION; GENE	Background: Although enzyme replacement therapy (ERT) is available for several lysosomal storage disorders, the benefit of this treatment to the skeletal system is very limited. Our previous work has shown the importance of the Toll-like receptor 4/TNF-alpha inflammatory pathway in the skeletal pathology of the mucopolysaccharidoses (MPS), and we therefore undertook a study to examine the additive benefit of combining anti-TNF-alpha therapy with ERT in a rat model of MPS type VI. Methodology/Principal Findings: MPS VI rats were treated for 8 months with Naglazyme(R) (recombinant human N-acetyl-galactosamine-4-sulfatase), or by a combined protocol using Naglazyme(R) and the rat-specific anti-TNF-alpha drug, CNTO1081. Both protocols led to markedly reduced serum levels of TNF-alpha and RANKL, although only the combined treatment reduced TNF-alpha in the articular cartilage. Analysis of cultured articular chondrocytes showed that the combination therapy also restored collagen IIA1 expression, and reduced expression of the apoptotic marker, PARP. Motor activity and mobility were improved by ERT, and these were significantly enhanced by combination treatment. Tracheal deformities in the MPS VI animals were only improved by combination therapy, and there was a modest improvement in bone length. Ceramide levels in the trachea also were markedly reduced. MicroCT analysis did not demonstrate any significant positive effects on bone microarchitecture from either treatment, nor was there histological improvement in the bone growth plates. Conclusions/Significance: The results demonstrate that combining ERT with anti-TNF-alpha therapy improved the treatment outcome and led to significant clinical benefit. They also further validate the usefulness of TNF-alpha, RANKL and other inflammatory molecules as biomarkers for the MPS disorders. Further evaluation of this combination approach in other MPS animal models and patients is warranted.	[Eliyahu, Efrat; Ge, Yi; Schuchman, Edward H.; Simonaro, Calogera M.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA; [Wolfson, Theodore; Jepsen, Karl J.] Mt Sinai Sch Med, Dept Orthopaed, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Eliyahu, E (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.	calogera.simonaro@mssm.edu	Wolfson, Theodore/ABB-2629-2020	Wolfson, Theodore/0000-0002-2593-1755	National Institutes of Health [1R01DK087185, AR44927]; National Mucopolysaccharidosis Society; Isaac Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR044927, R01AR044927, R29AR044927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK087185] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Mucopolysaccharidosis Society; Isaac Foundation; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was funded by grants from the National Institutes of Health ((http://grants.nih.gov/grants/oer.htm) 1R01DK087185 and AR44927), The National Mucopolysaccharidosis Society (http://www.mpssociety.org/), and The Isaac Foundation (www.theisaacfoundation.com/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Auclair D, 2007, MOL GENET METAB, V91, P352, DOI 10.1016/j.ymgme.2007.04.009; Becker KA, 2010, BIOCHEM BIOPH RES CO, V403, P368, DOI 10.1016/j.bbrc.2010.11.038; Clarke Lorne A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000550; Connor V, 2011, RHEUMATOL INT, V31, P327, DOI 10.1007/s00296-009-1292-x; Coppa GV, 2010, GLYCOBIOLOGY, V20, P1259, DOI 10.1093/glycob/cwq088; Cotugno G, 2010, HUM GENE THER, V21, P555, DOI 10.1089/hum.2009.189; Cox-Brinkman J, 2010, ULTRASTRUCT PATHOL, V34, P126, DOI 10.3109/01913121003648485; Decker C, 2010, J PEDIATR REHAB MED, V3, P89, DOI 10.3233/PRM-2010-0113; GLAMUZINA E, 2011, J INHERIT METAB 0216; Herati RS, 2008, MOL GENET METAB, V95, P142, DOI 10.1016/j.ymgme.2008.07.003; Klaasen R, 2011, ARTHRITIS RHEUM-US, V63, P359, DOI 10.1002/art.30136; KUNIEDA T, 1995, GENOMICS, V29, P582, DOI 10.1006/geno.1995.9962; LU JZ, 2011, BIOTECHNOL BIOE 0223; McGill JJ, 2010, CLIN GENET, V77, P492, DOI 10.1111/j.1399-0004.2009.01324.x; Metcalf JA, 2009, MOL GENET METAB, V97, P202, DOI 10.1016/j.ymgme.2009.03.005; Miebach E, 2005, ACTA PAEDIATR, V94, P58, DOI 10.1080/08035320510028120; Neufeld EF, 2001, MUCOPOLYSACCHARIDOSE, P3421, DOI DOI 10.1036/OMMBID.165; Osborn MJ, 2011, MOL THER, V19, P450, DOI 10.1038/mt.2010.249; Rodgers M, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI [10.3310/hta15100, 10.3310/hta15suppl1/01]; RUTELLA S, 2011, AM J GASTROENTE 0301; SEMENZA GL, 1988, MEDICINE, V67, P209, DOI 10.1097/00005792-198807000-00002; Shinhar SY, 2004, ARCH OTOLARYNGOL, V130, P233, DOI 10.1001/archotol.130.2.233; Simonardo CM, 1997, TRANSPLANTATION, V63, P1386, DOI 10.1097/00007890-199705270-00003; Simonaro CM, 2008, AM J PATHOL, V172, P112, DOI 10.2353/ajpath.2008.070564; Simonaro CM, 2010, P NATL ACAD SCI USA, V107, P222, DOI 10.1073/pnas.0912937107; Simonaro CM, 2005, PEDIATR RES, V57, P701, DOI 10.1203/01.PDR.0000156510.96253.5A; Simonaro CM, 2001, LAB INVEST, V81, P1319, DOI 10.1038/labinvest.3780345; Valayannopoulos V, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-5; Weaver Arthur L, 2004, Mod Rheumatol, V14, P101; Wraith JE, 2008, EUR J PEDIATR, V167, P267, DOI 10.1007/s00431-007-0635-4; YOSHIDA M, 1993, J CLIN INVEST, V91, P1099, DOI 10.1172/JCI116268	31	56	63	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 22	2011	6	8							e22447	10.1371/journal.pone.0022447	http://dx.doi.org/10.1371/journal.pone.0022447			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	811XK	21887218	gold, Green Published, Green Submitted			2023-01-03	WOS:000294251800005
J	Camus, S; Quevedo, C; Menendez, S; Paramonov, I; Stouten, PFW; Janssen, RAJ; Rueb, S; He, S; Snaar-Jagalska, BE; Laricchia-Robbio, L; Belmonte, JCI				Camus, S.; Quevedo, C.; Menendez, S.; Paramonov, I.; Stouten, P. F. W.; Janssen, R. A. J.; Rueb, S.; He, S.; Snaar-Jagalska, B. E.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua			Identification of phosphorylase kinase as a novel therapeutic target through high-throughput screening for anti-angiogenesis compounds in zebrafish	ONCOGENE			English	Article						phosphorylase kinase; PhK; angiogenesis; zebrafish; cancer	ANTIANGIOGENIC COMPOUNDS; CLINICAL RESISTANCE; GENE AMPLIFICATION; CANCER; GROWTH; METHOTREXATE	Angiogenesis is essential for development and tumor progression. With the aim of identifying new compound inhibitors of the angiogenesis process, we used an established enhanced green fluorescent protein-transgenic zebrafish line to develop an automated assay that enables high-throughput screening of compound libraries in a whole-organism setting. Using this system, we have identified novel kinase inhibitor compounds that show anti-angiogenic properties in both zebrafish in-vivo system and in human endothelial cell in-vitro angiogenesis models. Furthermore, we have determined the kinase target of these compounds and have identified and validated a previously uncharacterized involvement of phosphorylase kinase subunit G1 (PhKG1) in angiogenesis in vivo. In addition, we have found that PhKG1 is upregulated in human tumor samples and that aberrations in gene copy number of PhK subunits are a common feature of human tumors. Our results provide a novel insight into the angiogenesis process, as well as identify new potential targets for anti-angiogenic therapies. Oncogene (2012) 31, 4333-4342; doi:10.1038/onc.2011.594; published online 19 December 2011	[Belmonte, J. C. Izpisua] Salk Inst Biol Studies, La Jolla, CA 92037 USA; [Camus, S.; Menendez, S.; Paramonov, I.; Laricchia-Robbio, L.; Belmonte, J. C. Izpisua] Ctr Regenerat Med Barcelona, Barcelona, Spain; [Quevedo, C.] Biobide SL, San Sebastian, Spain; [Stouten, P. F. W.] Galapagos NV, Mechelen, Belgium; [Janssen, R. A. J.] Galapagos BV, Leiden, Netherlands; [Rueb, S.; He, S.; Snaar-Jagalska, B. E.] Leiden Univ, Inst Biol, Leiden, Netherlands	Salk Institute; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona; Galapagos NV; Galapagos NV; Leiden University; Leiden University - Excl LUMC	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu		Stouten, Pieter/0000-0002-5203-2202; Menendez, Sergio/0000-0002-7929-8641	European Community [HEALTH-F2-2008-201439]; MICINN; Fundacion Cellex	European Community(European Commission); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Fundacion Cellex(Foundation CELLEX)	We would like to thank Cornel Catana of Galapagos for molecular modeling efforts and acknowledge the support and intellectual contribution of the Scientific Director of Biobide, Carles Callol. This project was financially supported by the European Community under the FP7 ZF-Cancer project (HEALTH-F2-2008-201439), MICINN and Fundacion Cellex.	Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; CARMAN MD, 1984, J CLIN ONCOL, V2, P16, DOI 10.1200/JCO.1984.2.1.16; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cascante M, 2010, BIOCHEM SOC T, V38, P1302, DOI 10.1042/BST0381302; Edmunds SC, 2002, INVEST OPHTH VIS SCI, V43, P2845; Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010; Faucherre A, 2008, ONCOGENE, V27, P1079, DOI 10.1038/sj.onc.1210730; FERGUSON PJ, 1991, J OTOLARYNGOL, V20, P130; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; GOKER E, 1995, BLOOD, V86, P677, DOI 10.1182/blood.V86.2.677.bloodjournal862677; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Graves D, 1999, PHARMACOL THERAPEUT, V82, P143, DOI 10.1016/S0163-7258(98)00049-7; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Isogai S, 2001, DEV BIOL, V230, P278, DOI 10.1006/dbio.2000.9995; Kidd KR, 2003, BRIT J PHARMACOL, V140, P585, DOI 10.1038/sj.bjp.0705496; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Letamendia A, PLOS ONE UNPUB; Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Marshall KE, 2010, DEV DYNAM, V239, P3000, DOI 10.1002/dvdy.22437; Parng C, 2002, ASSAY DRUG DEV TECHN, V1, P41, DOI 10.1089/154065802761001293; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tran TC, 2007, CANCER RES, V67, P11386, DOI 10.1158/0008-5472.CAN-07-3126; Vizan P, 2009, CARCINOGENESIS, V30, P946, DOI 10.1093/carcin/bgp083; Wang CY, 2010, EUR UROL, V58, P418, DOI 10.1016/j.eururo.2010.05.024	29	37	40	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4333	4342		10.1038/onc.2011.594	http://dx.doi.org/10.1038/onc.2011.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22179836				2023-01-03	WOS:000309520200007
J	Moynihan, R				Moynihan, Ray			Times like these you need some "One Four Five"	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Univ Newcastle, Callaghan, NSW 2308, Australia.	Ray.Moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					Bradt J, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006911.pub2, 10.1002/14651858.CD006911]; Gold C, 2009, CLIN PSYCHOL REV, V29, P193, DOI 10.1016/j.cpr.2009.01.001; Music In Hospitals, 2011, AB MUS HOSP; Procter S, 2011, NORD J MUSIC THER, V20, P242, DOI 10.1080/08098131.2010.489998	4	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2012	344								e2342	10.1136/bmj.e2342	http://dx.doi.org/10.1136/bmj.e2342			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923FF	22457444				2023-01-03	WOS:000302604100006
J	Planer, D; Leibowitz, D; Hadid, A; Erlich, T; Sharon, N; Paltiel, O; Jacoby, E; Lotan, C; Moran, DS				Planer, David; Leibowitz, David; Hadid, Amir; Erlich, Tomer; Sharon, Nir; Paltiel, Ora; Jacoby, Elad; Lotan, Chaim; Moran, Daniel S.			The Effect of Prolonged Physical Activity Performed during Extreme Caloric Deprivation on Cardiac Function	PLOS ONE			English	Article							BRAIN NATRIURETIC PEPTIDE; OF-ECHOCARDIOGRAPHYS GUIDELINES; TROPONIN-T RELEASE; DIASTOLIC FUNCTION; VENTRICULAR DYSFUNCTION; STANDARDS COMMITTEE; ENDURANCE EXERCISE; STRENUOUS EXERCISE; MARATHON; RESTRICTION	Background: Endurance exercise may induce transient cardiac dysfunction. Data regarding the effect of caloric restriction on cardiac function is limited. We studied the effect of physical activity performed during extreme caloric deprivation on cardiac function. Methods: Thirty-nine healthy male soldiers (mean age 20+/-0.3 years) were studied during a field training exercise lasted 85-103 hours, with negligible food intake and unlimited water supply. Anthropometric measurements, echocardiographic examinations and blood and urine tests were performed before and after the training exercise. Results: Baseline VO2 max was 59+/-5.5 ml/kg/min. Participants' mean weight reduction was 5.7+/-0.9 kg. There was an increase in plasma urea (11.6+/-2.6 to 15.8+/-3.8 mmol/L, p<0.001) and urine osmolarity (692+/-212 to 1094+/-140 mmol/kg, p<0.001) and a decrease in sodium levels (140.5+/-1.0 to 136.6+/-2.1 mmol/L, p<0.001) at the end of the study. Significant alterations in diastolic parameters included a decrease in mitral E wave (93.6 to 83.5 cm/s; p = 0.003), without change in E/A and E/E' ratios, and an increase in iso-volumic relaxation time (73.9 to 82.9 ms, p = 0.006). There was no change in left or right ventricular systolic function, or pulmonary arterial pressure. Brain natriuretic peptide (BNP) levels were significantly reduced post-training (median 9 to 0 pg/ml, p<0.001). There was no elevation in Troponin T or CRP levels. On multivariate analysis, BNP reduction correlated with sodium levels and weight reduction (R = 0.8, p<0.001). Conclusions: Exposure to prolonged physical activity performed under caloric deprivation resulted in minor alterations of left ventricular diastolic function. BNP levels were significantly reduced due to negative water and sodium balance.	[Planer, David; Leibowitz, David; Lotan, Chaim] Hadassah Hebrew Univ Med Ctr, Inst Heart, Jerusalem, Israel; [Hadid, Amir; Erlich, Tomer; Jacoby, Elad; Moran, Daniel S.] Chaim Sheba Med Ctr, Heller Inst Med Res, IL-52621 Tel Hashomer, Israel; [Sharon, Nir; Paltiel, Ora] Hadassah Hebrew Univ Med Ctr, Brown Sch Publ Hlth, Jerusalem, Israel; [Planer, David] Columbia Univ, Dept Cardiol, Med Ctr, New York, NY USA	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Columbia University	Planer, D (corresponding author), Hadassah Hebrew Univ Med Ctr, Inst Heart, Jerusalem, Israel.	davidplaner@gmail.com		ERLICH, TOMER/0000-0003-4151-0018; Jacoby, Elad/0000-0003-1411-8942				Alshaher M, 2007, ECHOCARDIOGR-J CARD, V24, P237, DOI 10.1111/j.1540-8175.2007.00380.x; Daneshrad Z, 2000, MOL CELL BIOCHEM, V210, P159, DOI 10.1023/A:1007137909171; DavilaRoman VG, 1997, J AM COLL CARDIOL, V30, P468, DOI 10.1016/S0735-1097(97)00179-4; Epstein Y, 2006, IND HEALTH, V44, P388, DOI 10.2486/indhealth.44.388; Fu F, 2009, INT J SPORTS MED, V30, P168, DOI 10.1055/s-0028-1104586; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; Hammer S, 2008, J CLIN ENDOCR METAB, V93, P497, DOI 10.1210/jc.2007-2015; Hart E, 2007, J AM SOC ECHOCARDIOG, V20, P1393, DOI 10.1016/j.echo.2007.04.032; Konig D, 2003, MED SCI SPORT EXER, V35, P1679, DOI 10.1249/01.MSS.0000089248.37173.E7; La Gerche A, 2008, HEART, V94, P860, DOI 10.1136/hrt.2006.101063; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Lucia A, 1999, MED SCI SPORT EXER, V31, P1414; Meluzin J, 2001, EUR HEART J, V22, P340, DOI 10.1053/euhj.2000.2296; Middleton N, 2008, J AM COLL CARDIOL, V52, P1813, DOI 10.1016/j.jacc.2008.03.069; Middleton N, 2007, INT J CARDIOL, V122, P87, DOI 10.1016/j.ijcard.2006.11.042; Middleton N, 2007, MED SCI SPORT EXER, V39, P83, DOI 10.1249/01.mss.0000239395.93578.60; Neilan TG, 2006, CIRCULATION, V114, P2325, DOI 10.1161/CIRCULATIONAHA.106.647461; Neumayr G, 2005, AM J CARDIOL, V96, P732, DOI 10.1016/j.amjcard.2005.04.054; Ohba H, 2001, AM HEART J, V141, P751, DOI 10.1067/mhj.2001.114371; Scharhag J, 2005, AM HEART J, V150, P1128, DOI 10.1016/j.ahj.2005.01.051; Scharhag J, 2008, MED SCI SPORT EXER, V40, P1408, DOI 10.1249/MSS.0b013e318172cf22; Scharhag J, 2008, CLIN RES CARDIOL, V97, P62, DOI 10.1007/s00392-008-0601-9; Shave RE, 2002, INT J SPORTS MED, V23, P489, DOI 10.1055/s-2002-35069; Shave R, 2007, MED SCI SPORT EXER, V39, P2099, DOI 10.1249/mss.0b013e318153ff78; SHPILBERG O, 1990, EUR J APPL PHYSIOL O, V60, P305, DOI 10.1007/BF00379401; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; Suzuki J, 2002, AM J PHYSIOL-ENDOC M, V283, pE94, DOI 10.1152/ajpendo.00017.2002; Tharion WJ, 2005, APPETITE, V44, P47, DOI 10.1016/j.appet.2003.11.010; van der Meer RW, 2007, DIABETES, V56, P2849, DOI 10.2337/db07-0768; Vidotto C, 2005, INT J SPORTS MED, V26, P645, DOI 10.1055/s-2004-830491	30	6	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2012	7	2							e31266	10.1371/journal.pone.0031266	http://dx.doi.org/10.1371/journal.pone.0031266			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927OG	22384007	Green Published, gold, Green Submitted			2023-01-03	WOS:000302916800011
J	Laparra, JM; Olivares, M; Gallina, O; Sanz, Y				Laparra, Jose Moises; Olivares, Marta; Gallina, Onofrio; Sanz, Yolanda			Bifidobacterium longum CECT 7347 Modulates Immune Responses in a Gliadin-Induced Enteropathy Animal Model	PLOS ONE			English	Article							INTESTINAL EPITHELIAL-CELLS; REAL-TIME PCR; NF-KAPPA-B; CELIAC-DISEASE; GENE-EXPRESSION; TRANSGENIC MICE; T-CELLS; GLUTEN; RATS; INFLAMMATION	Coeliac disease (CD) is an autoimmune disorder triggered by gluten proteins (gliadin) that involves innate and adaptive immunity. In this study, we hypothesise that the administration of Bifidobacterium longum CECT 7347, previously selected for reducing gliadin immunotoxic effects in vitro, could exert protective effects in an animal model of gliadin-induced enteropathy. The effects of this bacterium were evaluated in newborn rats fed gliadin alone or sensitised with interferon (IFN)-gamma and fed gliadin. Jejunal tissue sections were collected for histological, NF kappa B mRNA expression and cytokine production analyses. Leukocyte populations and T-cell subsets were analysed in peripheral blood samples. The possible translocation of the bacterium to different organs was determined by plate counting and the composition of the colonic microbiota was quantified by real-time PCR. Feeding gliadin alone reduced enterocyte height and peripheral CD4+ cells, but increased CD4+/Foxp3+ T and CD8+ cells, while the simultaneous administration of B. longum CECT 7347 exerted opposite effects. Animals sensitised with IFN-gamma and fed gliadin showed high cellular infiltration, reduced villi width and enterocyte height. Sensitised animals also exhibited increased NF kappa B mRNA expression and TNF-alpha production in tissue sections. B. longum CECT 7347 administration increased NFkB expression and IL-10, but reduced TNF-alpha, production in the enteropathy model. In sensitised gliadin-fed animals, CD4+, CD4+/Foxp3+ and CD8+ T cells increased, whereas the administration of B. longum CECT 7347 reduced CD4+ and CD4+/Foxp3+ cell populations and increased CD8+ T cell populations. The bifidobacterial strain administered represented between 75-95% of the total bifidobacteria isolated from all treated groups, and translocation to organs was not detected. These findings indicate that B. longum attenuates the production of inflammatory cytokines and the CD4+ T-cell mediated immune response in an animal model of gliadin-induced enteropathy.	[Laparra, Jose Moises; Olivares, Marta; Gallina, Onofrio; Sanz, Yolanda] Natl Res Council IATA CSIC, Inst Agrochem & Food Technol, Valencia, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Laparra, JM (corresponding author), Natl Res Council IATA CSIC, Inst Agrochem & Food Technol, Valencia, Spain.	yolsanz@iata.csic.es	Llopis, Jose Moises Laparra/M-2882-2015; Llopis, José Moisés Laparra/AAB-6151-2019; Sevilla, Marta Olivares/A-7691-2019; Sanz, Yolanda/H-5498-2012; Olivares, Marta/O-9899-2019	Llopis, Jose Moises Laparra/0000-0002-9378-2552; Llopis, José Moisés Laparra/0000-0002-9378-2552; Sanz, Yolanda/0000-0002-1615-1976; Olivares, Marta/0000-0002-7966-2781	Spanish Ministry of Science and Innovation (MICINN, Spain) [AGL2007-66126-C03-01/ALI, CEN-20091006, CSD2007-00063]; Consejo Superior de Investigaciones Cientificas (CSIC, National Research Council); MICINN, Spain [CEN-20091006]	Spanish Ministry of Science and Innovation (MICINN, Spain)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Consejo Superior de Investigaciones Cientificas (CSIC, National Research Council); MICINN, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants AGL2007-66126-C03-01/ALI, CEN-20091006 and Consolider Fun-C-Food CSD2007-00063 from the Spanish Ministry of Science and Innovation (MICINN, Spain). The scholarship to Dr. Gallina from Consejo Superior de Investigaciones Cientificas (CSIC, National Research Council) is fully acknowledged. Dr. Laparra has a postdoctoral contract within the programme "Juan de la Cierva'' (MICINN, Spain) and Dr. Olivares has a contract supported by grant CEN-20091006 (MICINN, Spain), which are also acknowledged. The funders had no role in any stage of study design, data collection, execution interpretation of the results or decision to publish and preparation of the manuscript.	AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; [Anonymous], LAB RAT, VI; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Black KE, 2002, J IMMUNOL, V169, P5595, DOI 10.4049/jimmunol.169.10.5595; Collado MC, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-232; Clemente MG, 2003, GUT, V52, P218, DOI 10.1136/gut.52.2.218; Collado MC, 2009, J CLIN PATHOL, V62, P264, DOI 10.1136/jcp.2008.061366; D'Arienzo R, 2011, SCAND J IMMUNOL, V74, P335, DOI 10.1111/j.1365-3083.2011.02582.x; D'Arienzo R, 2009, EUR J IMMUNOL, V39, P3552, DOI 10.1002/eji.200839161; De Palma G, 2010, J LEUKOCYTE BIOL, V87, P765, DOI 10.1189/jlb.0709471; Frisullo G, 2009, HUM IMMUNOL, V70, P430, DOI 10.1016/j.humimm.2009.04.006; Hoffman RA, 2000, AM J PHYSIOL-GASTR L, V278, pG886, DOI 10.1152/ajpgi.2000.278.6.G886; Izcue A, 2009, ANNU REV IMMUNOL, V27, P313, DOI 10.1146/annurev.immunol.021908.132657; Jelinkova L, 2004, FEBS LETT, V571, P81, DOI 10.1016/j.febslet.2004.06.057; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kivling A, 2008, ANN NY ACAD SCI, V1150, P273, DOI 10.1196/annals.1447.018; Kozakova H, 2000, PHYSIOL RES, V49, P665; Laparra JM, 2010, J CELL BIOCHEM, V109, P801, DOI 10.1002/jcb.22459; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maiuri MC, 2003, J MOL MED-JMM, V81, P373, DOI 10.1007/s00109-003-0440-0; Malinen E, 2003, MICROBIOL-SGM, V149, P269, DOI 10.1099/mic.0.25975-0; Matsuki T, 2002, APPL ENVIRON MICROB, V68, P5445, DOI 10.1128/AEM.68.11.5445-5451.2002; Medina M, 2008, J INFLAMM-LOND, V5, DOI 10.1186/1476-9255-5-19; Nadal I, 2007, J MED MICROBIOL, V56, P1669, DOI 10.1099/jmm.0.47410-0; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Stepankova R, 2003, J PEDIATR GASTR NUTR, V36, P96, DOI 10.1097/00005176-200301000-00018; Stepankova R, 1996, SCAND J GASTROENTERO, V31, P551, DOI 10.3109/00365529609009127; Sutas Y, 1997, J PEDIATR GASTR NUTR, V24, P162, DOI 10.1097/00005176-199702000-00009; Terrazzano G, 2007, J IMMUNOL, V179, P372, DOI 10.4049/jimmunol.179.1.372; Thomas KE, 2006, J IMMUNOL, V176, P2512, DOI 10.4049/jimmunol.176.4.2512; TlaskalovaHogenova H, 1997, ANN NY ACAD SCI, V815, P503, DOI 10.1111/j.1749-6632.1997.tb52115.x; TRONCONE R, 1991, GUT, V32, P871, DOI 10.1136/gut.32.8.871; Verdu EF, 2008, AM J PHYSIOL-GASTR L, V294, pG217, DOI 10.1152/ajpgi.00225.2007; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Westendorf AM, 2006, GASTROENTEROLOGY, V131, P510, DOI 10.1053/j.gastro.2006.05.015; Whelan JA, 2003, J IMMUNOL METHODS, V278, P261, DOI 10.1016/S0022-1759(03)00223-0; Wieser H, 2008, CEREAL CHEM, V85, P1, DOI 10.1094/CCHEM-85-1-0001; WILLIAMS JG, 1992, J LEUKOCYTE BIOL, V52, P579, DOI 10.1002/jlb.52.6.579; Yu Y, 2005, BIOTECHNOL BIOENG, V89, P670, DOI 10.1002/bit.20347	40	98	100	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2012	7	2							e30744	10.1371/journal.pone.0030744	http://dx.doi.org/10.1371/journal.pone.0030744			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924ZX	22348021	Green Published, Green Submitted, gold			2023-01-03	WOS:000302730900014
J	Watkins, AJ; Lucas, ES; Wilkins, A; Cagampang, FRA; Fleming, TP				Watkins, Adam J.; Lucas, Emma S.; Wilkins, Adrian; Cagampang, Felino R. A.; Fleming, Tom P.			Maternal Periconceptional and Gestational Low Protein Diet Affects Mouse Offspring Growth, Cardiovascular and Adipose Phenotype at 1 Year of Age	PLOS ONE			English	Article							SYSTOLIC BLOOD-PRESSURE; CATCH-UP GROWTH; BETA-CELL MASS; INSULIN-RESISTANCE; GENE-EXPRESSION; PRENATAL EXPOSURE; RESTRICTION LEADS; IN-UTERO; MALE-RAT; GLUCOSE-TOLERANCE	Human and animal studies have revealed a strong association between periconceptional environmental factors, such as poor maternal diet, and an increased propensity for cardiovascular and metabolic disease in adult offspring. Previously, we reported cardiovascular and physiological effects of maternal low protein diet (LPD) fed during discrete periods of periconceptional development on 6-month-old mouse offspring. Here, we extend the analysis in 1 year aging offspring, evaluating mechanisms regulating growth and adiposity. Isocaloric LPD (9% casein) or normal protein diet (18% casein; NPD) was fed to female MF-1 mice either exclusively during oocyte maturation (for 3.5 days prior to mating; Egg-LPD, Egg-NPD, respectively), throughout gestation (LPD, NPD) or exclusively during preimplantation development (for 3.5 days post mating; Emb-LPD). LPD and Emb-LPD female offspring were significantly lighter and heavier than NPD females respectively for up to 52 weeks. Egg-LPD, LPD and Emb-LPD offspring displayed significantly elevated systolic blood pressure at 52 weeks compared to respective controls (Egg-NPD, NPD). LPD females had significantly reduced inguinal and retroperitoneal fat pad: body weight ratios compared to NPD females. Expression of the insulin receptor (Insr) and insulin-like growth factor I receptor (Igf1r) in retroperitoneal fat was significantly elevated in Emb-LPD females (P<0.05), whilst Emb-LPD males displayed significantly decreased expression of the mitochondrial uncoupling protein 1 (Ucp1) gene compared to NPD offspring. LPD females displayed significantly increased expression of Ucp1 in interscapular brown adipose tissue when compared to NPD offspring. Our results demonstrate that aging offspring body weight, cardiovascular and adiposity homeostasis can be programmed by maternal periconceptional nutrition. These adverse outcomes further exemplify the criticality of dietary behaviour around the time of conception on long-term offspring health.	[Watkins, Adam J.; Lucas, Emma S.; Fleming, Tom P.] Univ Southampton, Southampton Gen Hosp, Sch Biol Sci, Southampton, Hants, England; [Watkins, Adam J.] Univ Nottingham, Sch Biosci, Loughborough, Leics, England; [Wilkins, Adrian; Cagampang, Felino R. A.] Univ Southampton, Fac Med, Southampton Gen Hosp, Human Dev & Hlth Unit,Inst Dev Sci, Southampton SO9 5NH, Hants, England	University of Southampton; University of Nottingham; University of Southampton	Watkins, AJ (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Biol Sci, Southampton, Hants, England.	adam.watkins@nottingham.ac.uk	Cagampang, Felino/AAG-5141-2019; Watkins, Adam J/J-4839-2013; Watkins, Adam/AAH-9401-2021; Lucas, Emma S/I-2719-2013	Cagampang, Felino/0000-0003-4404-9853; Watkins, Adam J/0000-0002-0842-1251; Watkins, Adam/0000-0002-0842-1251; Lucas, Emma S/0000-0002-8571-8921	Biotechnology and Biological Sciences Research Council [BBF007450]; National Institutes of Health, USA as part of the NICHD [U01 HD04435]; Gerald Kerkut Charitable Trust; COST Action [FA0702]; BBSRC [BB/F007450/1, BB/I001840/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I001840/1, BB/F007450/1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institutes of Health, USA as part of the NICHD; Gerald Kerkut Charitable Trust; COST Action(European Cooperation in Science and Technology (COST)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Biotechnology and Biological Sciences Research Council [grant number BBF007450], the National Institutes of Health, USA as part of the NICHD National Cooperative Program on Female Health and Egg Quality under cooperative agreement [grant number U01 HD04435] and the Gerald Kerkut Charitable Trust. In addition, we acknowledge the support of the COST Action FA0702 'GEMINI' for the opportunity to discuss and share research ideas amongst scientists within this area. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armitage JA, 2005, J PHYSIOL-LONDON, V565, P171, DOI 10.1113/jphysiol.2005.084947; Augustyniak RA, 2010, AM J PHYSIOL-REG I, V298, pR1375, DOI 10.1152/ajpregu.00848.2009; Battista MC, 2002, AM J PHYSIOL-ENDOC M, V283, pE124, DOI 10.1152/ajpendo.00004.2001; Bellinger L, 2004, BRIT J NUTR, V92, P513, DOI 10.1079/BJN20041224; Berney DM, 1997, J PATHOL, V183, P109; Bertin E, 2002, AM J PHYSIOL-REG I, V283, pR623, DOI 10.1152/ajpregu.00037.2002; Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151; Bol VV, 2009, AM J PHYSIOL-REG I, V297, pR291, DOI 10.1152/ajpregu.90497.2008; Brawley L, 2003, PEDIATR RES, V54, P83, DOI 10.1203/01.PDR.0000065731.00639.02; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Cleal JK, 2007, P NATL ACAD SCI USA, V104, P9529, DOI 10.1073/pnas.0610373104; Delahaye F, 2010, AM J PHYSIOL-REG I, V299, pR101, DOI 10.1152/ajpregu.00604.2009; Edwards LJ, 2002, AM J PHYSIOL-REG I, V283, pR669, DOI 10.1152/ajpregu.00736.2001; Elahi MM, 2008, HYPERTENSION, V51, P939, DOI 10.1161/HYPERTENSIONAHA.107.100982; Elmes MJ, 2007, BRIT J NUTR, V98, P93, DOI 10.1017/S000711450769182X; Erhuma A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1702, DOI 10.1152/ajpendo.00605.2006; Fagundes ATS, 2009, HORM METAB RES, V41, P866, DOI 10.1055/s-0029-1233457; Fernandez-Twinn DS, 2005, AM J PHYSIOL-REG I, V288, pR368, DOI 10.1152/ajpregu.00206.2004; Garofano A, 1999, DIABETOLOGIA, V42, P711, DOI 10.1007/s001250051219; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; Gorski JN, 2006, AM J PHYSIOL-REG I, V291, pR768, DOI 10.1152/ajpregu.00138.2006; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; Hanson MA, 2008, BASIC CLIN PHARMACOL, V102, P90, DOI 10.1111/j.1742-7843.2007.00186.x; Kwong WY, 2000, DEVELOPMENT, V127, P4195; LANGLEY SC, 1994, COMP BIOCHEM PHYS A, V109, P223, DOI 10.1016/0300-9629(94)90124-4; Langley-Evans SC, 1999, LIFE SCI, V64, P965, DOI 10.1016/S0024-3205(99)00022-3; LangleyEvans SC, 1996, J REPROD FERTIL, V106, P307, DOI 10.1530/jrf.0.1060307; Lucas ES, 2011, THERIOGENOLOGY, V76, P558, DOI 10.1016/j.theriogenology.2011.03.008; Maloney CA, 2011, J NUTR, V141, P95, DOI 10.3945/jn.109.119453; Mao J, 2010, P NATL ACAD SCI USA, V107, P5557, DOI 10.1073/pnas.1000440107; Mortensen ELK, 2010, INT J OBESITY, V34, P1618, DOI 10.1038/ijo.2010.91; Nivoit P, 2009, DIABETOLOGIA, V52, P1133, DOI 10.1007/s00125-009-1316-9; Ozanne SE, 2003, J ENDOCRINOL, V177, P235, DOI 10.1677/joe.0.1770235; Painter RC, 2006, AM J CLIN NUTR, V84, P322; Poulos SP, 2010, MOL CELL ENDOCRINOL, V323, P20, DOI 10.1016/j.mce.2009.12.011; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Reckelhoff JF, 1998, HYPERTENSION, V31, P435, DOI 10.1161/01.HYP.31.1.435; Robinson S, 2007, GENES NUTR, V2, P31, DOI 10.1007/s12263-007-0004-y; SAKEMI T, 1995, NEPHRON, V69, P159, DOI 10.1159/000188433; Sinclair KD, 2007, P NATL ACAD SCI USA, V104, P19351, DOI 10.1073/pnas.0707258104; Sood R, 2006, P NATL ACAD SCI USA, V103, P5478, DOI 10.1073/pnas.0508035103; Sugden MC, 2002, J ENDOCRINOL, V175, P757, DOI 10.1677/joe.0.1750757; Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854; Theys N, 2009, AM J PHYSIOL-REG I, V297, pR1516, DOI 10.1152/ajpregu.00280.2009; Todd SE, 2009, PEDIATR RES, V65, P409, DOI 10.1203/PDR.0b013e3181975efa; Torrens C, 2009, BRIT J NUTR, V101, P27, DOI 10.1017/S0007114508988760; Torrens C, 2009, EXP PHYSIOL, V94, P1024, DOI 10.1113/expphysiol.2009.047340; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vickers MH, 2001, ENDOCRINOLOGY, V142, P3964, DOI 10.1210/en.142.9.3964; Warner MJ, 2010, BIOCHEM J, V427, P333, DOI 10.1042/BJ20091861; Watkins AJ, 2010, J DEV ORIG HLTH DIS, V1, P87, DOI 10.1017/S2040174409990195; Watkins AJ, 2008, J PHYSIOL-LONDON, V586, P2231, DOI 10.1113/jphysiol.2007.149229; Watkins AJ, 2008, BIOL REPROD, V78, P299, DOI 10.1095/biolreprod.107.064220; Watkins AJ, 2007, P NATL ACAD SCI USA, V104, P5449, DOI 10.1073/pnas.0610317104; Watkins AJ, 2010, BRIT J NUTR, V103, P1762, DOI 10.1017/S0007114509993783	56	88	90	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2011	6	12							e28745	10.1371/journal.pone.0028745	http://dx.doi.org/10.1371/journal.pone.0028745			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866HE	22194901	Green Accepted, Green Published, gold			2023-01-03	WOS:000298370400018
J	Albertazzi, L; Brondi, M; Pavan, GM; Sato, SS; Signore, G; Storti, B; Ratto, GM; Beltram, F				Albertazzi, Lorenzo; Brondi, Marco; Pavan, Giovanni M.; Sato, Sebastian Sulis; Signore, Giovanni; Storti, Barbara; Ratto, Gian Michele; Beltram, Fabio			Dendrimer-Based Fluorescent Indicators: In Vitro and In Vivo Applications	PLOS ONE			English	Article							RESOLUTION; PROBES; OXYGEN; PH	Background: The development of fluorescent proteins and synthetic molecules whose fluorescence properties are controlled by the environment makes it possible to monitor physiological and pathological events in living systems with minimal perturbation. A large number of small organic dyes are available and routinely used to measure biologically relevant parameters. Unfortunately their application is hindered by a number of limitations stemming from the use of these small molecules in the biological environment. Principal Findings: We present a novel dendrimer-based architecture leading to multifunctional sensing elements that can overcome many of these problems. Applications in vitro, in living cells and in vivo are reported. In particular, we image for the first time extracellular pH in the brain in a mouse epilepsy model. Conclusion: We believe that the proposed architecture can represent a useful and novel tool in fluorescence imaging that can be widely applied in conjunction with a broad range of sensing dyes and experimental setups.	[Albertazzi, Lorenzo; Brondi, Marco; Sato, Sebastian Sulis; Storti, Barbara; Ratto, Gian Michele; Beltram, Fabio] Scuola Normale Super Pisa, Lab NEST, Pisa, Italy; [Albertazzi, Lorenzo; Brondi, Marco; Sato, Sebastian Sulis; Storti, Barbara; Ratto, Gian Michele; Beltram, Fabio] Ist Nanosci CNR, Pisa, Italy; [Albertazzi, Lorenzo; Brondi, Marco; Sato, Sebastian Sulis; Signore, Giovanni; Storti, Barbara; Beltram, Fabio] Ctr Nanotechnol Innovat, IIT NEST, Pisa, Italy; [Pavan, Giovanni M.] Univ Appl Sci So Switzerland SUPSI, Lab Appl Math & Phys LaMFI, Manno, Switzerland	Scuola Normale Superiore di Pisa; Consiglio Nazionale delle Ricerche (CNR); Istituto Nanoscienze (NANO-CNR); Istituto Italiano di Tecnologia - IIT	Albertazzi, L (corresponding author), Scuola Normale Super Pisa, Lab NEST, Pisa, Italy.	l.albertazzi@sns.it	Albertazzi, Lorenzo/E-8323-2013; Pavan, Giovanni/E-7474-2011; Ratto, Gian Michele/AAX-8514-2020; Beltram, Fabio/L-9486-2019; signore, giovanni/GOV-6118-2022; Bizzarri, Ranieri/ABH-8343-2020; Storti, Barbara/AAB-7791-2019; Signore, Giovanni/A-3526-2010; Ratto, Gian Michele/AAB-8719-2021; Beltram, Fabio/F-2920-2013; Bizzarri, Ranieri/H-1779-2011; Signore, Giovanni/J-8465-2019	Albertazzi, Lorenzo/0000-0002-6837-0812; Pavan, Giovanni/0000-0002-3473-8471; Beltram, Fabio/0000-0002-6081-436X; Storti, Barbara/0000-0002-2758-0426; Signore, Giovanni/0000-0002-0067-2240; Ratto, Gian Michele/0000-0001-9632-7769; Beltram, Fabio/0000-0002-6081-436X; Bizzarri, Ranieri/0000-0002-8222-2672; Signore, Giovanni/0000-0002-0067-2240	Italian Ministry for University and Research (MiUR) [RBLA03ER38]	Italian Ministry for University and Research (MiUR)(Ministry of Education, Universities and Research (MIUR))	This work was partially supported by the Italian Ministry for University and Research (MiUR) under the framework of FIRB project RBLA03ER38. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertazzi L, 2010, J AM CHEM SOC, V132, P18158, DOI 10.1021/ja105689u; Astruc D, 2010, CHEM REV, V110, P1857, DOI 10.1021/cr900327d; Avoli Massimo, 2006, Epilepsy Curr, V6, P203, DOI 10.1111/j.1535-7511.2006.00146.x; Buccella D, 2011, J AM CHEM SOC, V133, P4101, DOI 10.1021/ja110907m; Case D. A. V. B., 2020, AMBER 2021; Dityatev A, 2010, NAT REV NEUROSCI, V11, P735, DOI 10.1038/nrn2898; FENG ZC, 1990, AM J PHYSIOL, V258, pR205, DOI 10.1152/ajpregu.1990.258.1.R205; Giepmans BNG, 2006, SCIENCE, V312, P217, DOI 10.1126/science.1124618; Grinvald A, 2004, NAT REV NEUROSCI, V5, P874, DOI 10.1038/nrn1536; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hillman EMC, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2789693; Huppert TJ, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3210779; Karton-Lifshin N, 2011, J AM CHEM SOC, V133, P10960, DOI 10.1021/ja203145v; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]; Lecoq J, 2011, NAT MED, V17, P893, DOI 10.1038/nm.2394; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; MEUWIS K, 1995, BIOPHYS J, V68, P2469, DOI 10.1016/S0006-3495(95)80428-5; Mizukami S, 2009, CHEMBIOCHEM, V10, P1465, DOI 10.1002/cbic.200900214; Painter RG, 2006, ANAL CHEM, V78, P3133, DOI 10.1021/ac0521706; Pavan GM, 2010, J PHYS CHEM B, V114, P5686, DOI 10.1021/jp911439q; Pavan GM, 2010, BIOMACROMOLECULES, V11, P721, DOI 10.1021/bm901298t; Pavan GM, 2010, J PHYS CHEM B, V114, P2667, DOI 10.1021/jp100271w; Sakadzic S, 2010, NAT METHODS, V7, P755, DOI 10.1038/nmeth.1490; Signore G, 2010, J AM CHEM SOC, V132, P1276, DOI 10.1021/ja9050444; SILVER RA, 1992, PFLUG ARCH EUR J PHY, V420, P595, DOI 10.1007/BF00374639; Szmacinski H, 1993, ANAL CHEM, V65, P168; Wangler C, 2008, CHEM-EUR J, V14, P8116, DOI 10.1002/chem.200800328; Wang XJ, 2010, ANALYST, V135, P1585, DOI 10.1039/b922751b; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132	31	28	29	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2011	6	12							e28450	10.1371/journal.pone.0028450	http://dx.doi.org/10.1371/journal.pone.0028450			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KK	22163303	Green Published, Green Submitted, gold			2023-01-03	WOS:000298161900040
J	Rice, TW; Wheeler, AP; Thompson, BT; DeBoisblanc, BP; Steingrub, J; Rock, P				Rice, Todd W.; Wheeler, Arthur P.; Thompson, B. Taylor; DeBoisblanc, Bennett P.; Steingrub, Jay; Rock, Peter		NHLBI ARDS Clinical Trials Network	Enteral Omega-3 Fatty Acid, gamma-Linolenic Acid, and Antioxidant Supplementation in Acute Lung Injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICALLY VENTILATED PATIENTS; EICOSAPENTAENOIC ACID; FATTY-ACIDS; FISH-OIL; PLASMA; INFLAMMATION; NUTRITION; OUTCOMES; MARKERS; BENEFIT	Context The omega-3 (n-3) fatty acids docosahexaenoic acid and eicosapentaenoic acid, along with gamma-linolenic acid and antioxidants, may modulate systemic inflammatory response and improve oxygenation and outcomes in patients with acute lung injury. Objective To determine if dietary supplementation of these substances to patients with acute lung injury would increase ventilator-free days to study day 28. Design, Setting, and Participants The OMEGA study, a randomized, double-blind, placebo-controlled, multicenter trial conducted from January 2, 2008, through February 21, 2009. Participants were 272 adults within 48 hours of developing acute lung injury requiring mechanical ventilation whose physicians intended to start enteral nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. All participants had complete follow-up. Interventions Twice-daily enteral supplementation of n-3 fatty acids, gamma-linolenic acid, and antioxidants compared with an isocaloric control. Enteral nutrition, directed by a protocol, was delivered separately from the study supplement. Main Outcome Measure Ventilator-free days to study day 28. Results The study was stopped early for futility after 143 and 129 patients were enrolled in the n-3 and control groups. Despite an 8-fold increase in plasma eicosapentaenoic acid levels, patients receiving the n-3 supplement had fewer ventilator-free days (14.0 vs 17.2; P=.02) (difference, -3.2 [95% CI, -5.8 to -0.7]) and intensive care unit-free days (14.0 vs 16.7; P=.04). Patients in the n-3 group also had fewer nonpulmonary organ failure-free days (12.3 vs 15.5; P=.02). Sixty-day hospital mortality was 26.6% in the n-3 group vs 16.3% in the control group (P=.054), and adjusted 60-day mortality was 25.1% and 17.6% in the n-3 and control groups, respectively (P=.11). Use of the n-3 supplement resulted in more days with diarrhea (29% vs 21%; P=.001). Conclusions Twice-daily enteral supplementation of n-3 fatty acids, gamma-linolenic acid, and antioxidants did not improve the primary end point of ventilator-free days or other clinical outcomes in patients with acute lung injury and may be harmful.	[Rice, Todd W.] Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Vanderbilt Med Ctr, Sch Med, Nashville, TN 37232 USA; [Thompson, B. Taylor] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA; [DeBoisblanc, Bennett P.] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA; [Steingrub, Jay] Baystate Med Ctr, Springfield, MA USA; [Rock, Peter] Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA	Vanderbilt University; Harvard University; Massachusetts General Hospital; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Baystate Medical Center; University System of Maryland; University of Maryland Baltimore	Rice, TW (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care Med, Vanderbilt Med Ctr, Sch Med, T-1218 MCN, Nashville, TN 37232 USA.	todd.rice@vanderbilt.edu	Rice, Todd/X-7853-2019	Rice, Todd/0000-0002-7136-5408	National Heart, Lung, and Blood Institute (NHLBI) [HHSN268200536165C, HHSN268200536176C, HHSN268200536179C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056176, R01HL056169] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268200536165C, HHSN268200536176C, and HHSN268200536179C. Abbott Nutrition, Columbus, Ohio, provided the omega-3 fatty acid, gamma-linolenic acid, antioxidant, and control supplements used in the study.	Abraham E, 2000, AM J RESP CELL MOL, V22, P401, DOI 10.1165/ajrcmb.22.4.f184; ALSAADY NM, 1989, INTENS CARE MED, V15, P290; Barbosa VM, 2010, CRIT CARE, V14, DOI 10.1186/cc8844; Barham JB, 2000, J NUTR, V130, P1925, DOI 10.1093/jn/130.8.1925; Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Caironi P, 2005, AM J RESP CRIT CARE, V172, P334, DOI 10.1164/rccm.200501-034OC; Calder PC, 2004, LIPIDS, V39, P1147, DOI 10.1007/s11745-004-1342-z; Cao J, 2006, CLIN CHEM, V52, P2265, DOI 10.1373/clinchem.2006.072322; CHILTON FH, 1993, J CLIN INVEST, V91, P115, DOI 10.1172/JCI116159; DEMETS DL, 1982, BIOMETRIKA, V69, P661; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Friesecke S, 2008, INTENS CARE MED, V34, P1411, DOI 10.1007/s00134-008-1072-1; Gadek JE, 1999, CRIT CARE MED, V27, P1409, DOI 10.1097/00003246-199908000-00001; Gust R, 1999, AM J RESP CRIT CARE, V160, P1165, DOI 10.1164/ajrccm.160.4.9811073; Johnson MM, 1997, J NUTR, V127, P1435, DOI 10.1093/jn/127.8.1435; Kumar KV, 2000, CLIN CHIM ACTA, V298, P111, DOI 10.1016/S0009-8981(00)00264-3; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; National Heart Lung and Blood Institute (NHLBI), EARL VERS DEL ENT FE; Pacht ER, 2003, CRIT CARE MED, V31, P491, DOI 10.1097/01.CCM.0000049952.96496.3E; Parsons PE, 2005, CRIT CARE MED, V33, P1, DOI 10.1097/01.CCM.0000149854.61192.DC; Pontes-Arruda A, 2006, CRIT CARE MED, V34, P2325, DOI 10.1097/01.CCM.0000234033.65657.B6; Prescott SM, 2005, NAT MED, V11, P596, DOI 10.1038/nm0605-596; Singer P, 2006, CRIT CARE MED, V34, P1033, DOI 10.1097/01.CCM.0000206111.23629.0A; Skeaff CM, 2006, J NUTR, V136, P565, DOI 10.1093/jn/136.3.565; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	30	357	383	0	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	2011	306	14					1574	1581		10.1001/jama.2011.1435	http://dx.doi.org/10.1001/jama.2011.1435			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831FS	21976613	Green Accepted, Bronze			2023-01-03	WOS:000295714700023
J	Yusuf, S; Islam, S; Chow, CK; Rangarajan, S; Dagenais, G; Diaz, R; Gupta, R; Kelishadi, R; Iqbal, R; Avezum, A; Kruger, A; Kutty, R; Lanas, F; Liu, LS; Wei, L; Lopez-Jaramillo, P; Oguz, A; Rahman, O; Swidan, H; Yusoff, K; Zatonski, W; Rosengren, A; Teo, KK				Yusuf, Salim; Islam, Shofiqul; Chow, Clara K.; Rangarajan, Sumathy; Dagenais, Gilles; Diaz, Rafael; Gupta, Rajeev; Kelishadi, Roya; Iqbal, Romaina; Avezum, Alvaro; Kruger, Annamarie; Kutty, Raman; Lanas, Fernando; Liu Lisheng; Wei, Li; Lopez-Jaramillo, Patricio; Oguz, Aytekin; Rahman, Omar; Swidan, Hany; Yusoff, Khalid; Zatonski, Witold; Rosengren, Annika; Teo, Koon K.		PURE Study Investigators	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey	LANCET			English	Article							ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; RISK-FACTORS; HEART-FAILURE; SELF-REPORT; STROKE; AVAILABILITY; MEDICINES; VALIDITY; IMPACT	Background Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, beta blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart disease or stroke. Methods In the Prospective Urban Rural Epidemiological (PURE) study, we recruited individuals aged 35-70 years from rural and urban communities in countries at various stages of economic development. We assessed rates of previous cardiovascular disease (coronary heart disease or stroke) and use of proven effective secondary preventive drugs and blood-pressure-lowering drugs with standardised questionnaires, which were completed by telephone interviews, household visits, or on patient's presentation to clinics. We report estimates of drug use at national, community, and individual levels. Findings We enrolled 153 996 adults from 628 urban and rural communities in countries with incomes classified as high (three countries), upper-middle (seven), lower-middle (three), or low (four) between January, 2003, and December, 2009. 5650 participants had a self-reported coronary heart disease event (median 5.0 years previously [IQR 2.0-10.0]) and 2292 had stroke (4.0 years previously [2.0-8.0]). Overall, few individuals with cardiovascular disease took antiplatelet drugs (25.3%), beta blockers (17.4%), ACE inhibitors or ARBs (19.5%), or statins (14.6%). Use was highest in high-income countries (antiplatelet drugs 62.0%, beta blockers 40.0%, ACE inhibitors or ARBs 49.8%, and statins 66.5%), lowest in low-income countries (8.8%, 9.7%, 5.2%, and 3.3%, respectively), and decreased in line with reduction of country economic status (p(trend)<0.0001 for every drug type). Fewest patients received no drugs in high-income countries (11.2%), compared with 45.1% in upper middle-income countries, 69.3% in lower middle-income countries, and 80.2% in low-income countries. Drug use was higher in urban than rural areas (antiplatelet drugs 28.7% urban vs 21.3% rural, beta blockers 23.5% vs 15.6%, ACE inhibitors or ARBs 22.8% vs 15.5%, and statins 19.9% vs 11.6%; all p<0.0001), with greatest variation in poorest countries (p(interaction)<0.0001 for urban vs rural differences by country economic status). Country-level factors (eg, economic status) affected rates of drug use more than did individual-level factors (eg, age, sex, education, smoking status, body-mass index, and hypertension and diabetes statuses). Interpretation Because use of secondary prevention medications is low worldwide-especially in low-income countries and rural areas-systematic approaches are needed to improve the long-term use of basic, inexpensive, and effective drugs.	[Yusuf, Salim; Islam, Shofiqul; Chow, Clara K.; Rangarajan, Sumathy; Teo, Koon K.] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON, Canada; [Yusuf, Salim; Islam, Shofiqul; Chow, Clara K.; Rangarajan, Sumathy; Teo, Koon K.] McMaster Univ, Hamilton, ON, Canada; [Dagenais, Gilles] Hosp Laval, Quebec Heart Inst, Ste Foy, PQ, Canada; [Diaz, Rafael] Estudios Clin Latinoamer, Rosario, Argentina; [Gupta, Rajeev] Fortis Escorts Hosp, Jaipur, Rajasthan, India; [Kelishadi, Roya] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Ctr, Esfahan, Iran; [Iqbal, Romaina] Aga Khan Univ, Dept Community Hlth Sci & Med, Karachi, Pakistan; [Avezum, Alvaro] Dante Pazzanese Inst Cardiol, Sao Paulo, Brazil; [Kutty, Raman] Hlth Act People, Trivandrum, Kerala, India; [Lanas, Fernando] Univ La Frontera, Temuco, Chile; [Liu Lisheng; Wei, Li] Chinese Acad Med Sci, Cardiovasc Inst, Natl Ctr Cardiovasc Dis, Beijing 100730, Peoples R China; [Liu Lisheng; Wei, Li] Chinese Acad Med Sci, FuWai Hosp, Beijing 100730, Peoples R China; [Lopez-Jaramillo, Patricio] Fdn Oftalmol Santander FOSCAL, Floridablanca Santander, Colombia; [Oguz, Aytekin] Goztepe Training & Res Hosp, Istanbul, Turkey; [Rahman, Omar] Independent Univ, Dhaka, Bangladesh; [Swidan, Hany] Dubai Hlth Author, Dubai, U Arab Emirates; [Yusoff, Khalid] Univ Teknol MARA Sungai Buloh, Fac Med, Selangor, Malaysia; [Zatonski, Witold] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; [Zatonski, Witold] Inst Oncol, Warsaw, Poland; [Rosengren, Annika] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden	McMaster University; Population Health Research Institute; McMaster University; Laval University; Fortis Escorts Hospital; Isfahan University Medical Science; Aga Khan University; Instituto Dante Pazzanese de Cardiologia; Universidad de La Frontera; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Istanbul Goztepe Training and Research Hospital; Independent University Bangladesh (IUB); Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; University of Gothenburg	Yusuf, S (corresponding author), Hamilton Gen Hosp, DBCVSRI, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Lanas, Fernando/AAE-8842-2022; Kelishadi, Roya/E-6154-2012; Yusoff, Khalid/I-7029-2019; Rahman, Omar/E-1329-2019; Avezum, Alvaro/AAP-7687-2020; Oguz, Aytekin/AAJ-2732-2021; Ramli, Anis Safura/K-3322-2014; Nawawi, Hapizah Mohd/J-8873-2019; Nawawi, Hapizah/N-7446-2019; Ramli, Anis Safura/U-3548-2018; Nor-Ashikin, Mohamed Noor Khan/P-2055-2015; Avezum, Alvaro AA/K-6137-2016; Igumbor, Ehimario U/B-2652-2012; Qorbani, Mostafa/M-8171-2017; Gomez-Arbelaez, Diego/K-1883-2013; Corsi, Daniel J/S-4689-2018	Kelishadi, Roya/0000-0001-7455-1495; Yusoff, Khalid/0000-0001-5669-5188; Rahman, Omar/0000-0002-0606-2507; Oguz, Aytekin/0000-0002-2595-5167; Ramli, Anis Safura/0000-0002-9517-1413; Nawawi, Hapizah Mohd/0000-0003-4462-8484; Nawawi, Hapizah/0000-0003-4462-8484; Ramli, Anis Safura/0000-0002-9517-1413; Nor-Ashikin, Mohamed Noor Khan/0000-0002-1325-9236; Avezum, Alvaro AA/0000-0002-3073-6890; Igumbor, Ehimario U/0000-0002-6313-6031; Yusuf, Salim/0000-0003-4776-5601; Jerling, Johann/0000-0003-2600-3536; Teo, Koon/0000-0002-3731-0956; Gomez-Arbelaez, Diego/0000-0001-6150-0066; Iqbal, Romaina/0000-0002-5364-4366; Lopez-Jaramillo, Patricio/0000-0002-9122-8742; Levitt, Naomi/0000-0001-6480-8066; Gulec, Sadi/0000-0002-2685-2522; Lanas, Fernando/0000-0003-3595-9759; Corsi, Daniel J/0000-0001-7063-3354	Marion W Burke endowed chair of the Heart and Stroke Foundation of Ontario, ON, Canada; National Heart and Medical Research Council of Australia; National Heart Foundation of Australia; Sydney Medical School Foundation; Population Health Research Institute; Canadian Institutes of Health Research; Heart and Stroke Foundation of Ontario; AstraZeneca [Sweden]; AstraZeneca [Canada]; Sanofi-Aventis [France]; Sanofi-Aventis [Canada]; Boehringer Ingelheim [Germany]; Boehringer Ingelheim [Canada]; Servier; GlaxoSmithKline; Bangladesh Independent University; Mitra and Associates in Bangladesh; Unilever Health Institute in Brazil; Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network in Canada; Universidad de la Frontera in Chile; National Center for Cardiovascular Diseases in China; Colciencias in Colombia [6566-04-18062]; Indian Council of Medical Research in India; Ministry of Science, Technology and Innovation of Malaysia [07-05-IFN-MEB010]; Universiti Teknologi MARA, Universiti Kebangsaan Malaysia in Malaysia [UKM-Hejim-Komuniti-15-2010]; Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]; Wroclaw Medical University in Poland; North-West University; South Africa and Netherlands Programme for Alternative Development (SANPAD); National Research Foundation; Medical Research Council of South Africa; South Africa Sugar Association (SASA); Faculty of Community and Health Sciences (UWC) in South Africa; Swedish Council for Working Life and Social Research; Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning; Swedish Heart and Lung Foundation; Swedish Research Council; Swedish State; Vastra Gotaland Region (FOUU) in Sweden; Metabolic Syndrome Society; Astra Zeneca; Sanofi-Aventis in Turkey; Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences; Dubai Health Authority, Dubai, in the United Arab Emirates	Marion W Burke endowed chair of the Heart and Stroke Foundation of Ontario, ON, Canada; National Heart and Medical Research Council of Australia; National Heart Foundation of Australia(National Heart Foundation of Australia); Sydney Medical School Foundation; Population Health Research Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); AstraZeneca [Sweden](AstraZeneca); AstraZeneca [Canada](AstraZeneca); Sanofi-Aventis [France](Sanofi-Aventis); Sanofi-Aventis [Canada](Sanofi-Aventis); Boehringer Ingelheim [Germany](Boehringer Ingelheim); Boehringer Ingelheim [Canada](Boehringer Ingelheim); Servier(Servier); GlaxoSmithKline(GlaxoSmithKline); Bangladesh Independent University; Mitra and Associates in Bangladesh; Unilever Health Institute in Brazil(Unilever); Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network in Canada; Universidad de la Frontera in Chile; National Center for Cardiovascular Diseases in China; Colciencias in Colombia(Departamento Administrativo de Ciencia, Tecnologia e Innovacion Colciencias); Indian Council of Medical Research in India; Ministry of Science, Technology and Innovation of Malaysia(Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia); Universiti Teknologi MARA, Universiti Kebangsaan Malaysia in Malaysia; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); Wroclaw Medical University in Poland; North-West University; South Africa and Netherlands Programme for Alternative Development (SANPAD); National Research Foundation; Medical Research Council of South Africa(South African Medical Research Council); South Africa Sugar Association (SASA); Faculty of Community and Health Sciences (UWC) in South Africa; Swedish Council for Working Life and Social Research(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning(Swedish Research Council Formas); Swedish Heart and Lung Foundation(Swedish Heart-Lung Foundation); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish State; Vastra Gotaland Region (FOUU) in Sweden; Metabolic Syndrome Society; Astra Zeneca(AstraZeneca); Sanofi-Aventis in Turkey; Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences; Dubai Health Authority, Dubai, in the United Arab Emirates	SY is supported by the Marion W Burke endowed chair of the Heart and Stroke Foundation of Ontario, ON, Canada. CKC is supported by a fellowship co-funded by the National Heart and Medical Research Council of Australia, National Heart Foundation of Australia and Sydney Medical School Foundation. The main PURE study and its components are funded by the Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, and through unrestricted grants from several pharmaceutical companies (major contributions from AstraZeneca [Sweden and Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline), and additional contributions from Novartis and King Pharma and from various national or local organisations in participating countries. These contributions were from the Bangladesh Independent University and Mitra and Associates in Bangladesh; Unilever Health Institute in Brazil; Public Health Agency of Canada and Champlain Cardiovascular Disease Prevention Network in Canada; Universidad de la Frontera in Chile; National Center for Cardiovascular Diseases in China; Colciencias in Colombia (grant number 6566-04-18062); Indian Council of Medical Research in India; Ministry of Science, Technology and Innovation of Malaysia (grant number 07-05-IFN-MEB010) and Universiti Teknologi MARA, Universiti Kebangsaan Malaysia (UKM-Hejim-Komuniti-15-2010) in Malaysia; Polish Ministry of Science and Higher Education (grant number 290/W-PURE/2008/0) and Wroclaw Medical University in Poland; The North-West University, South Africa and Netherlands Programme for Alternative Development (SANPAD), National Research Foundation, Medical Research Council of South Africa, The South Africa Sugar Association (SASA), and Faculty of Community and Health Sciences (UWC) in South Africa; Swedish Council for Working Life and Social Research, Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, Swedish Heart and Lung Foundation, Swedish Research Council, Grant from the Swedish State under LUA (LakarUtbildningsAvtalet) agreement, and grant from the Vastra Gotaland Region (FOUU) in Sweden; Metabolic Syndrome Society, Astra Zeneca, and Sanofi-Aventis in Turkey; Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences, Dubai Health Authority, Dubai, in the United Arab Emirates.	ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; Bergmann MM, 1998, AM J EPIDEMIOL, V147, P969; Bhatt DL, 2010, JAMA-J AM MED ASSOC, V304, P1350, DOI 10.1001/jama.2010.1322; Cameron A, 2011, B WORLD HEALTH ORGAN, V89, P412, DOI 10.2471/BLT.10.084327; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Fox KAA, 2007, JAMA-J AM MED ASSOC, V297, P1892, DOI 10.1001/jama.297.17.1892; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; Heckbert SR, 2004, AM J EPIDEMIOL, V160, P1152, DOI 10.1093/aje/kwh314; John RM, 2008, SOC SCI MED, V66, P1356, DOI 10.1016/j.socscimed.2007.11.020; Joshi R, 2009, CIRCULATION, V119, P1950, DOI 10.1161/CIRCULATIONAHA.108.819201; Kotseva K, 2009, LANCET, V373, P929, DOI 10.1016/S0140-6736(09)60330-5; Lampe FC, 1999, J CLIN EPIDEMIOL, V52, P73, DOI 10.1016/S0895-4356(98)00146-2; Lonn E, 2010, CIRCULATION, V122, P2078, DOI 10.1161/CIRCULATIONAHA.109.873232; MacQueen KM, 2001, AM J PUBLIC HEALTH, V91, P1929, DOI 10.2105/AJPH.91.12.1929; Mendis S, 2005, B WORLD HEALTH ORGAN, V83, P820; Niens LM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000333; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; Okura Y, 2004, J CLIN EPIDEMIOL, V57, P1096, DOI 10.1016/j.jclinepi.2004.04.005; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Ramsey FL, 2002, STAT SLEUTH COURSE M, Vsecond; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Teo K, 2009, AM HEART J, V158, P1, DOI 10.1016/j.ahj.2009.04.019; van Mourik MSM, 2010, BMC CARDIOVASC DISOR, V10, DOI 10.1186/1471-2261-10-25; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; World Bank, WE CLASS COUNTR; Xavier D, 2008, LANCET, V371, P1435, DOI 10.1016/S0140-6736(08)60623-6; Yamagishi K, 2009, J CLIN EPIDEMIOL, V62, P667, DOI 10.1016/j.jclinepi.2008.07.016; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2009, LANCET, V373, P1341, DOI 10.1016/S0140-6736(09)60611-5; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2000, NEW ENGL J MED, V342, P145	35	652	701	2	105	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	2011	378	9798					1231	1243		10.1016/S0140-6736(11)61215-4	http://dx.doi.org/10.1016/S0140-6736(11)61215-4			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	831IO	21872920				2023-01-03	WOS:000295723600025
J	Nolan, JP; Soar, J				Nolan, Jerry P.; Soar, Jasmeet			Does the evidence support the use of mild hypothermia after cardiac arrest? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; COMATOSE SURVIVORS		[Nolan, Jerry P.] Royal United Hosp NHS Trust, Bath BA2 7AJ, Avon, England; [Soar, Jasmeet] N Bristol NHS Trust, Southmead Hosp, Bristol, Avon, England	North Bristol NHS Trust; Southmead Hospital	Nolan, JP (corresponding author), Royal United Hosp NHS Trust, Bath BA2 7AJ, Avon, England.	jerry.nolan@nhs.net	Nolan, Jerry P./ABF-2561-2020; Soar, Jasmeet/HGA-2279-2022	Soar, Jasmeet/0000-0001-5970-6073; Nolan, Jerry/0000-0003-3141-3812				Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Binks AC, 2010, ANAESTHESIA, V65, P260, DOI 10.1111/j.1365-2044.2009.06227.x; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16; Kern KB, 2010, CATHETER CARDIO INTE, V75, P616, DOI 10.1002/ccd.22192; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; Nolan JP, 2003, RESUSCITATION, V57, P231, DOI 10.1016/S0300-9572(03)00184-9; Nunnally ME, 2011, CRIT CARE MED, V39, P1113, DOI 10.1097/CCM.0b013e318206bab2; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Tomte O, 2011, RESUSCITATION, V82, P1186, DOI 10.1016/j.resuscitation.2011.05.003; van der Wal G, 2011, CRIT CARE MED, V39, P84, DOI 10.1097/CCM.0b013e3181fd6aef; Walters JH, 2011, RESUSCITATION, V82, P508, DOI 10.1016/j.resuscitation.2011.01.021	15	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 23	2011	343								d5830	10.1136/bmj.d5830	http://dx.doi.org/10.1136/bmj.d5830			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826AK	21948587				2023-01-03	WOS:000295323500001
J	Xu, X; Gupta, S; Hu, WL; McGrath, BC; Cavener, DR				Xu, Xu; Gupta, Sounak; Hu, Wenli; McGrath, Barbara C.; Cavener, Douglas R.			Hyperthermia Induces the ER Stress Pathway	PLOS ONE			English	Article							UNFOLDED PROTEIN RESPONSE; HEAT-SHOCK RESPONSE; GLUCOSE-REGULATED PROTEIN; PERK EIF2-ALPHA KINASE; ENDOPLASMIC-RETICULUM; TRANSLATION INITIATION; EXPRESSION; MICE; PHOSPHORYLATION; RECOVERY	Background: The ER chaperone GRP78/BiP is a homolog of the Hsp70 family of heat shock proteins, yet GRP78/BiP is not induced by heat shock but instead by ER stress. However, previous studies had not considered more physiologically relevant temperature elevation associated with febrile hyperthermia. In this report we examine the response of GRP78/BiP and other components of the ER stress pathway in cells exposed to 40 degrees C. Methodology: AD293 cells were exposed to 43 degrees C heat shock to confirm inhibition of the ER stress response genes. Five mammalian cell types, including AD293 cells, were then exposed to 40 degrees C hyperthermia for various time periods and induction of the ER stress pathway was assessed. Principal Findings: The inhibition of the ER stress pathway by heat shock (43 degrees C) was confirmed. In contrast cells subjected to more mild temperature elevation (40 degrees C) showed either a partial or full ER stress pathway induction as determined by downstream targets of the three arms of the ER stress pathway as well as a heat shock response. Cells deficient for Perk or Gcn2 exhibit great sensitivity to ER stress induction by hyperthermia. Conclusions: The ER stress pathway is induced partially or fully as a consequence of hyperthermia in parallel with induction of Hsp70. These findings suggest that the ER and cytoplasm of cells contain parallel pathways to coordinately regulate adaptation to febrile hyperthermia associated with disease or infection.	[Xu, Xu; Gupta, Sounak; Hu, Wenli; McGrath, Barbara C.; Cavener, Douglas R.] Penn State Univ, Dept Biol, Ctr Cellular Dynam, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Xu, X (corresponding author), Penn State Univ, Dept Biol, Ctr Cellular Dynam, University Pk, PA 16802 USA.	drc9@psu.edu			National Institutes of Health [R01-GM56957]; American Heart Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056957] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the National Institutes of Health (R01-GM56957) to D. R. C. and from the American Heart Association fellowship to S. G. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASHBURNER M, 1970, CHROMOSOMA, V31, P356, DOI 10.1007/BF00321231; Cavener DR, 2010, TRENDS ENDOCRIN MET, V21, P714, DOI 10.1016/j.tem.2010.08.005; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; Civelek M, 2009, CIRC RES, V105, P453, DOI 10.1161/CIRCRESAHA.109.203711; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gupta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008008; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Iida K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-38; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje; Li YL, 2003, ENDOCRINOLOGY, V144, P3505, DOI 10.1210/en.2003-0236; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDQUIST S, 1975, P NATL ACAD SCI USA, V72, P1117, DOI 10.1073/pnas.72.3.1117; Lipson KL, 2006, CELL METAB, V4, P245, DOI 10.1016/j.cmet.2006.07.007; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Liu Y, 2008, EMBO J, V27, P1049, DOI 10.1038/emboj.2008.42; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; Nakayama Y, 2010, J BIOCHEM, V147, P471, DOI 10.1093/jb/mvp189; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SITIA R, 2004, SCI STKE, pPE27; Wei JW, 2008, J CELL PHYSIOL, V217, P693, DOI 10.1002/jcp.21543; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cb.11.110195.002301; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002; Zhang W, 2006, CELL METAB, V4, P491, DOI 10.1016/j.cmet.2006.11.002	40	43	44	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2011	6	8							e23740	10.1371/journal.pone.0023740	http://dx.doi.org/10.1371/journal.pone.0023740			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810LN	21876766	Green Submitted, Green Published, gold			2023-01-03	WOS:000294126900038
J	van der Meersch, A; Dechartres, A; Ravaud, P				van der Meersch, Amelie; Dechartres, Agnes; Ravaud, Philippe			Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review	PLOS ONE			English	Article							EQUIVALENCE; SUBSTITUTION; ISSUES	Background: Generic drugs are used by millions of patients for economic reasons, so their evaluation must be highly transparent. Objective: To assess the quality of reporting of bioequivalence trials comparing generic to brand-name drugs. Methodology/Principal Findings: PubMed was searched for reports of bioequivalence trials comparing generic to brand-name drugs between January 2005 and December 2008. Articles were included if the aim of the study was to assess the bioequivalency of generic and brand-name drugs. We excluded case studies, pharmaco-economic evaluations, and validation dosage assays of drugs. We evaluated whether important information about funding, methodology, location of trials, and participants were reported. We also assessed whether the criteria required by the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) to conclude bioequivalence were reported and that the conclusions were in agreement with the results. We identified 134 potentially relevant articles but eliminated 55 because the brand-name or generic drug status of the reference drug was unknown. Thus, we evaluated 79 articles. The funding source and location of the trial were reported in 41% and 56% of articles, respectively. The type of statistical analysis was reported in 94% of articles, but the methods to generate the randomization sequence and to conceal allocation were reported in only 15% and 5%, respectively. In total, 65 articles of single-dose trials (89%) concluded bioequivalence. Of these, 20 (31%) did not report the 3 criteria within the limits required by the FDA and 11 (17%) did not report the 2 criteria within the limits required by the EMA. Conclusions/Significance: Important information to judge the validity and relevance of results are frequently missing in published reports of trials assessing generic drugs. The quality of reporting of such trials is in need of improvement.	[van der Meersch, Amelie; Dechartres, Agnes; Ravaud, Philippe] INSERM, U738, Paris, France; [van der Meersch, Amelie; Dechartres, Agnes; Ravaud, Philippe] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, F-75181 Paris, France; [van der Meersch, Amelie; Dechartres, Agnes; Ravaud, Philippe] Univ Paris 05, Fac Med, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	van der Meersch, A (corresponding author), INSERM, U738, Paris, France.	agnes.dechartres@htd.aphp.fr	ravaud, philippe/C-1694-2009	Ravaud, Philippe/0000-0001-8264-9206				Borgherini G, 2003, CLIN THER, V25, P1578, DOI 10.1016/S0149-2918(03)80157-1; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; Djulbegovic B, 2001, JAMA-J AM MED ASSOC, V285, P1206, DOI 10.1001/jama.285.9.1206; *EMEA CMPH US, GUID INV BIOEQ; *FDA, FDA DRUG APPR REP; *FDA GUID IND, BIOAV BIOEQ STUD OR; Frank RG, 2007, NEW ENGL J MED, V357, P1993, DOI 10.1056/NEJMp078193; Friesen MH, 1999, J PHARM PHARM SCI, V2, P15; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kesselheim AS, 2010, DRUGS, V70, P605, DOI 10.2165/10898530-000000000-00000; Le Henanff A, 2006, JAMA-J AM MED ASSOC, V295, P1147, DOI 10.1001/jama.295.10.1147; Lesser RP, 2001, NEUROLOGY, V57, P571, DOI 10.1212/WNL.57.4.571; Mastoraki E, 2008, J INFECTION, V56, P35, DOI 10.1016/j.jinf.2007.09.011; McCartney M, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1514; Sabatini S, 1999, AM J KIDNEY DIS, V33, P389, DOI 10.1016/S0272-6386(99)70318-5; Wangge G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013550; Wassef AA, 2005, AM J PSYCHIAT, V162, P330, DOI 10.1176/appi.ajp.162.2.330; *WHO, WHO AN THER CHEM CLA; Wilner AN, 2004, EPILEPSY BEHAV, V5, P995, DOI 10.1016/j.yebeh.2004.05.011; Yim DS, 2009, J KOREAN MED SCI, V24, P7, DOI 10.3346/jkms.2009.24.1.7	22	24	24	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2011	6	8							e23611	10.1371/journal.pone.0023611	http://dx.doi.org/10.1371/journal.pone.0023611			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810JJ	21858184	gold, Green Published, Green Submitted			2023-01-03	WOS:000294121300069
J	Tailler, M; Senovilla, L; Lainey, E; Thepot, S; Metivier, D; Sebert, M; Baud, V; Billot, K; Fenaux, P; Galluzzi, L; Boehrer, S; Kroemer, G; Kepp, O				Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Baud, V.; Billot, K.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kroemer, G.; Kepp, O.			Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; necrosis; myeloblasts; HL-60; HCS	CELL-DEATH; CARDIAC-GLYCOSIDES; MITOCHONDRIAL ALTERATIONS; CANCER-CELLS; DIFFERENTIATION; APOPTOSIS; ASSAYS; INHIBITION; EXPRESSION; GUIDELINES	Despite recent progress in the treatment of acute myeloid leukemia (AML), the prognosis of this rather heterogeneous disease remains poor and novel chemotherapeutics that specifically target leukemic cells must be developed. To address this need at the preclinical level, we implemented a high content imaging-based screen for the identification of small agents that induce AML cell death in vitro. Among a panel of 1040 Food and Drug Administration-approved agents, we identified pyrithione zinc (PZ) and ouabain (OUA) as potential antileukemic compounds. Both PZ and OUA efficiently induced cell death associated with apoptotic chromatin condensation and inhibition of nuclear factor-kappa B survival signaling, leading to reduced expression of antiapoptotic proteins, in several AML cell lines. PZ- and OUA-induced cell death was associated with the permeabilization of the outer mitochondrial membrane and led to the release of cytochrome c followed by caspase activation. Both PZ and OUA exerted significant anticancer effects in vivo, on human AML cells xenografts as well as ex vivo, on CD34(+) (but not CD34(-)) malignant myeloblasts from AML patients. Altogether, our results suggest that PZ and OUA may exhibit antileukemic effects by inducing the apoptotic demise of AML cells. Oncogene (2012) 31, 3536-3546; doi:10.1038/onc.2011.521; published online 21 November 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, PR1, U848, F-94805 Villejuif, Val De Marne, France; [Tailler, M.; Senovilla, L.; Lainey, E.; Thepot, S.; Metivier, D.; Sebert, M.; Fenaux, P.; Galluzzi, L.; Boehrer, S.; Kepp, O.] Univ Paris Sud, F-94275 Le Kremlin Bicetre, France; [Thepot, S.; Sebert, M.; Fenaux, P.; Boehrer, S.] Univ Paris 13, AP HP, Hop Avicenne, Serv Hematol Clin, Bobigny, France; [Baud, V.; Billot, K.] INSERM, Inst Cochin, U1016, Paris, France; [Baud, V.; Billot, K.] CNRS, UMR8104, Paris, France; [Baud, V.; Billot, K.; Kroemer, G.] Univ Paris 05, Paris, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, PR1, U848, 114 Rue Edouard Vaillant, F-94805 Villejuif, Val De Marne, France.	kroemer@orange.fr; oliver.kepp@igr.fr	KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAG-6432-2019; Senovilla, Laura/AAX-5599-2021; Baud, Veronique/F-7699-2013; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/K-2709-2012; Kepp, Oliver/GPX-8627-2022; THEPOT, Sylvain/L-3078-2015; Baud, Veronique/AAL-3950-2020; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Baud, Veronique/0000-0002-4090-718X; Galluzzi, Lorenzo/0000-0003-2257-8500; Baud, Veronique/0000-0002-4090-718X; Senovilla, Laura/0000-0001-6887-2436; thepot, sylvain/0000-0003-3492-2778	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); Canceropole Ile-de-France; Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche; Association pour la Recherche sur le Cancer; Belgian InterUniversity Attraction Pole; Universite Paris Descartes; Ligue Nationale contre le Cancer; Apo-Sys	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Fondation Bettencourt-Schueller; LabEx Onco-Immunology; Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Belgian InterUniversity Attraction Pole(Belgian Federal Science Policy Office); Universite Paris Descartes; Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Apo-Sys(European CommissionEuropean Commission Joint Research Centre)	This work is supported by grants to GK from the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Medicale (FRM), Institut National du Cancer (INCa), Canceropole Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Onco-Immunology; to VB from Agence Nationale pour la Recherche, Association pour la Recherche sur le Cancer, Belgian InterUniversity Attraction Pole and Universite Paris Descartes. MT is supported by the Ligue Nationale contre le Cancer. LG is funded by Apo-Sys; KB is supported by Agence Nationale pour la Recherche.	Bielawski K, 2006, BIOL PHARM BULL, V29, P1493, DOI 10.1248/bpb.29.1493; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Chan G, 2007, BLOOD, V110, P1079, DOI 10.1182/blood-2007-01-069856; Edwards Bruce S., 2009, V486, P151, DOI 10.1007/978-1-60327-545-3_11; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Hahn CK, 2009, CANCER CELL, V16, P281, DOI 10.1016/j.ccr.2009.08.018; Hallbook H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015718; Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237; Juncker T, 2011, BIOCHEM PHARMACOL, V81, P13, DOI 10.1016/j.bcp.2010.08.025; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Lamore SD, 2011, BIOMETALS, V24, P875, DOI 10.1007/s10534-011-9441-6; Lamore SD, 2010, CELL STRESS CHAPERON, V15, P309, DOI 10.1007/s12192-009-0145-6; Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8; Newman RA, 2006, J EXP THER ONCOL, V5, P167; Perne A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008292; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Smits ELJ, 2011, CANCER IMMUNOL IMMUN, V60, P757, DOI 10.1007/s00262-011-1022-6; Stegmaier K, 2005, BLOOD, V106, P2841, DOI 10.1182/blood-2005-02-0488; Tufi R, 2008, CELL DEATH DIFFER, V15, P274, DOI 10.1038/sj.cdd.4402275; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Vitale I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001337; Wald DN, 2008, CANCER RES, V68, P4369, DOI 10.1158/0008-5472.CAN-07-6559; Wang Z, 2009, CANCER RES, V69, P6556, DOI 10.1158/0008-5472.CAN-09-0891; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Yin W, 2009, BIOCHEM PHARMACOL, V78, P191, DOI 10.1016/j.bcp.2009.03.025; ZHANG LS, 1992, CANCER RES, V52, P4634	34	47	48	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3536	3546		10.1038/onc.2011.521	http://dx.doi.org/10.1038/onc.2011.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105358				2023-01-03	WOS:000306844100006
J	Rodger, J; Mo, C; Wilks, T; Dunlop, SA; Sherrard, RM				Rodger, Jennifer; Mo, Christina; Wilks, Tenelle; Dunlop, Sarah A.; Sherrard, Rachel M.			Transcranial pulsed magnetic field stimulation facilitates reorganization of abnormal neural circuits and corrects behavioral deficits without disrupting normal connectivity	FASEB JOURNAL			English	Article						rTMS; topography; ephrin; plasticity; BDNF; neuromodulation	THETA-BURST STIMULATION; RAT SUPERIOR COLLICULUS; PRIMARY MOTOR CORTEX; FREQUENCY ELECTROMAGNETIC-FIELDS; EXPERIENCE-DEPENDENT PLASTICITY; OPTIC-NERVE REGENERATION; SPINAL-CORD-INJURY; ENVIRONMENTAL ENRICHMENT; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY	Although the organization of neuronal circuitry is shaped by activity patterns, the capacity to modify and/or optimize the structure and function of whole projection pathways using external stimuli is poorly defined. We investigate whether neuronal activity induced by pulsed magnetic fields (PMFs) alters brain structure and function. We delivered low-intensity PMFs to the posterior cranium of awake, unrestrained mice (wild-type and ephrin-A2A5(-/-)) that have disorganized retinocollicular circuitry and associated visuomotor deficits. Control groups of each genotype received sham stimulation. Following daily stimulation for 14 d, we measured biochemical, structural (anterograde tracing), and functional (electrophysiology and behavior) changes in the retinocollicular projection. PMFs induced BDNF, GABA, and nNOS expression in the superior colliculus and retina of wild-type and ephrin-A2A5(-/-) mice. Furthermore, in ephrin-A2A5(-/-) mice, PMFs corrected abnormal neuronal responses and selectively removed inaccurate ectopic axon terminals to improve structural and functional organization of their retinocollicular projection and restore normal visual tracking behavior. In contrast, PMFs did not alter the structure or function of the normal projection in wild-type mice. Sham PMF stimulation had no effect on any mice. Thus, PMF-induced biochemical changes are congruent with its capacity to facilitate beneficial reorganization of abnormal neural circuits without disrupting normal connectivity and function.-Rodger, J., Mo, C., Wilks, T., Dunlop, S. A., Sherrard, R. M. Transcranial pulsed magnetic field stimulation facilitates reorganization of abnormal neural circuits and corrects behavioral deficits without disrupting normal connectivity. FASEB J. 26, 1593-1606 (2012). www.fasebj.org	[Rodger, Jennifer; Mo, Christina; Wilks, Tenelle; Dunlop, Sarah A.] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Sherrard, Rachel M.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia; [Sherrard, Rachel M.] Univ Paris 06, Paris, France; [Sherrard, Rachel M.] CNRS, Unite Mixte Rech 7102, Paris, France	University of Western Australia; University of Western Australia; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol M317, Crawley, WA 6009, Australia.	jennifer.rodger@uwa.edu.au	Sherrard, Rachel/Y-1355-2019; Rodger, Jennifer/H-5735-2014; Dunlop, Sarah A/G-9357-2013; Sherrard, Rachel M/D-5446-2013	Sherrard, Rachel/0000-0002-6595-3545; Rodger, Jennifer/0000-0003-3413-4229; Dunlop, Sarah/0000-0002-1306-3962; Mo, Christina/0000-0001-6725-7239	Western Australian State Government; Raine Foundation (Western Australia); National Health and Medical Research Council Australia; Ecole de Neuroscience de Paris	Western Australian State Government; Raine Foundation (Western Australia); National Health and Medical Research Council Australia(National Health and Medical Research Council (NHMRC) of Australia); Ecole de Neuroscience de Paris	The authors thank Michael Archer, Stephanie Grehl, Marissa Penrose, and Clarissa Goh for technical assistance, Prof. Lindy Fitzgerald for advice on behavioral analysis, and Dr. Robert Woodward and Prof. Don Robertson for advice on measuring magnetic fields. The authors also thank Prof. A. J. Bower for his helpful comments on the manuscript. This work was funded by the Neurotrauma Research Program (Western Australian State Government), the Raine Foundation (Western Australia), and the National Health and Medical Research Council Australia. Travel funds were provided by the Ecole de Neuroscience de Paris.	Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015; Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; Allen EA, 2007, SCIENCE, V317, P1918, DOI 10.1126/science.1146426; Arias-Carrion O, 2004, J NEUROSCI RES, V78, P16, DOI 10.1002/jnr.20235; Arias-Carrion Oscar, 2008, Int Arch Med, V1, P2, DOI 10.1186/1755-7682-1-2; Aydin-Abidin S, 2008, EXP BRAIN RES, V188, P249, DOI 10.1007/s00221-008-1356-2; Aydin-Abidin S, 2006, J PHYSIOL-LONDON, V574, P443, DOI 10.1113/jphysiol.2006.108464; Baeken C, 2008, CLIN NEUROPHYSIOL, V119, P568, DOI 10.1016/j.clinph.2007.11.044; BALKEMA GW, 1981, J NEUROSCI, V1, P1320; BARKER AT, 1985, LANCET, V1, P1106; Ben-Shachar D, 1999, BRAIN RES, V816, P78, DOI 10.1016/S0006-8993(98)01119-6; Benali A, 2011, J NEUROSCI, V31, P1193, DOI 10.1523/JNEUROSCI.1379-10.2011; Berretta N, 2008, PROG NEUROBIOL, V84, P343, DOI 10.1016/j.pneurobio.2007.12.004; Brighina F, 2009, CEREBELLUM, V8, P260, DOI 10.1007/s12311-008-0090-4; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Cao LX, 2007, CURR BIOL, V17, P911, DOI 10.1016/j.cub.2007.04.040; Capone F, 2009, J NEURAL TRANSM, V116, P257, DOI 10.1007/s00702-009-0184-2; Cheetham Ce, 2007, Adv Clin Neurosci Rehabil, V7, P8; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cline H, 2003, TRENDS NEUROSCI, V26, P655, DOI 10.1016/j.tins.2003.10.005; Cotelli M, 2008, EUR J NEUROL, V15, P1286, DOI 10.1111/j.1468-1331.2008.02202.x; Daskalakis ZJ, 2008, CAN J PSYCHIAT, V53, P555, DOI 10.1177/070674370805300902; Di Lazzaro V, 2011, J NEUROPHYSIOL, V105, P2150, DOI 10.1152/jn.00781.2010; Di Marco S, 2009, J NEUROSCI, V29, P13691, DOI 10.1523/JNEUROSCI.3854-09.2009; Dontchev VD, 2002, J NEUROSCI, V22, P6659; DRAGER UC, 1975, J NEUROPHYSIOL, V38, P690, DOI 10.1152/jn.1975.38.3.690; DRAGER UC, 1976, J NEUROPHYSIOL, V39, P91, DOI 10.1152/jn.1976.39.1.91; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Egertova M, 2003, NEUROSCIENCE, V119, P481, DOI 10.1016/S0306-4522(03)00145-3; Ernst AF, 1999, J NEUROSCI, V19, P229, DOI 10.1523/JNEUROSCI.19-01-00229.1999; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; Esteban Jose A, 2003, Mol Interv, V3, P375, DOI 10.1124/mi.3.7.375; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Fernandez EA, 2010, JARO-J ASSOC RES OTO, V11, P235, DOI 10.1007/s10162-009-0204-9; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Frost DO, 2001, PROG BRAIN RES, V134, P35; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; Gangitano M, 2002, CLIN NEUROPHYSIOL, V113, P1249, DOI 10.1016/S1388-2457(02)00109-8; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Gersner R, 2011, J NEUROSCI, V31, P7521, DOI 10.1523/JNEUROSCI.6751-10.2011; GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; HARVEY AR, 1990, J COMP NEUROL, V298, P281, DOI 10.1002/cne.902980303; Hausmann A, 2000, MOL BRAIN RES, V76, P355, DOI 10.1016/S0169-328X(00)00024-3; Haustead DJ, 2008, J NEUROSCI, V28, P7376, DOI 10.1523/JNEUROSCI.1135-08.2008; HIRAI H, 1993, BRAIN RES, V629, P23, DOI 10.1016/0006-8993(93)90476-4; Huang L, 2001, J NEUROPHYSIOL, V86, P1179, DOI 10.1152/jn.2001.86.3.1179; Huang YZ, 2009, CLIN NEUROPHYSIOL, V120, P796, DOI 10.1016/j.clinph.2009.01.003; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; Ikeda T, 2005, BIOCHEM BIOPH RES CO, V327, P218, DOI 10.1016/j.bbrc.2004.12.009; Isa T, 1998, J NEUROSCI, V18, P8496; Jiang B, 2004, EUR J NEUROSCI, V20, P709, DOI 10.1111/j.1460-9568.2004.03523.x; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Keck ME, 2000, EUR J NEUROSCI, V12, P3713, DOI 10.1046/j.1460-9568.2000.00243.x; Kerchner GA, 2008, NAT REV NEUROSCI, V9, P813, DOI 10.1038/nrn2501; Klintsova AY, 2004, BRAIN RES, V1028, P92, DOI 10.1016/j.brainres.2004.09.003; Kole MHP, 1999, BRAIN RES, V826, P309, DOI 10.1016/S0006-8993(99)01257-3; Le Roux N, 2009, NEUROSCIENCE, V163, P942, DOI 10.1016/j.neuroscience.2009.07.010; Lee MC, 2010, NEURON, V66, P859, DOI 10.1016/j.neuron.2010.05.015; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Li YX, 1998, J NEUROSCI, V18, P10231; Lien CC, 2006, NAT NEUROSCI, V9, P372, DOI 10.1038/nn1649; Lin HY, 2011, BIOELECTROMAGNETICS, V32, P552, DOI 10.1002/bem.20668; Luo LQ, 2002, ANNU REV CELL DEV BI, V18, P601, DOI 10.1146/annurev.cellbio.18.031802.150501; Maccabee P. J., 1991, MAGNETIC MOTOR STIMU, P340; Martiny K, 2010, BIOL PSYCHIAT, V68, P163, DOI 10.1016/j.biopsych.2010.02.017; McAllister SM, 2009, CLIN NEUROPHYSIOL, V120, P820, DOI 10.1016/j.clinph.2009.02.003; McBain VA, 2003, INVEST OPHTH VIS SCI, V44, P540, DOI 10.1167/iovs.02-0570; MCILWAIN JT, 1975, J NEUROPHYSIOL, V38, P219, DOI 10.1152/jn.1975.38.2.219; McLaughlin T, 2003, NEURON, V40, P1147, DOI 10.1016/S0896-6273(03)00790-6; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Morgado-Valle C, 1998, CELL TISSUE RES, V291, P217, DOI 10.1007/s004410050992; Mu Y, 2006, NEURON, V50, P115, DOI 10.1016/j.neuron.2006.03.009; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; Namiki S, 2005, J PHYSIOL-LONDON, V566, P849, DOI 10.1113/jphysiol.2005.088799; Nithianantharajah J, 2004, NEUROBIOL LEARN MEM, V81, P200, DOI 10.1016/j.nlm.2004.02.002; Nithianantharajah J, 2006, NAT REV NEUROSCI, V7, P697, DOI 10.1038/nrn1970; Nithianantharajah J, 2009, PROG NEUROBIOL, V89, P369, DOI 10.1016/j.pneurobio.2009.10.001; Noda, 2000, Pathophysiology, V7, P127, DOI 10.1016/S0928-4680(00)00039-0; Pascual-Leone A, 2006, PROG BRAIN RES, V157, P315, DOI 10.1016/S0079-6123(06)57019-0; Payne BR, 1996, P NATL ACAD SCI USA, V93, P290, DOI 10.1073/pnas.93.1.290; Peinemann A, 2004, CLIN NEUROPHYSIOL, V115, P1519, DOI 10.1016/j.clinph.2004.02.005; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; POO MM, 1981, ANNU REV BIOPHYS BIO, V10, P245, DOI 10.1146/annurev.bb.10.060181.001333; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Post A, 2001, J PSYCHIATR RES, V35, P193, DOI 10.1016/S0022-3956(01)00023-1; Quigley HA, 2000, INVEST OPHTH VIS SCI, V41, P3460; Reber M, 2004, NATURE, V431, P847, DOI 10.1038/nature02957; Rodger J, 2005, MOL CELL NEUROSCI, V30, P452, DOI 10.1016/j.mcn.2005.08.009; Rodger J, 2004, MOL CELL NEUROSCI, V25, P56, DOI 10.1016/j.mcn.2003.09.010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Sale A, 2007, NAT NEUROSCI, V10, P679, DOI 10.1038/nn1899; SCHMIDT JT, 1985, CELL MOL NEUROBIOL, V5, P65, DOI 10.1007/BF00711086; SCHNEIDER GE, 1969, SCIENCE, V163, P895, DOI 10.1126/science.163.3870.895; Sefton A.J., 2004, RAT NERVOUS SYSTEM, P1083; Sherrard RM, 2009, DEV NEUROBIOL, V69, P647, DOI 10.1002/dneu.20730; Siebner HR, 2009, CORTEX, V45, P1035, DOI 10.1016/j.cortex.2009.02.007; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Singh KK, 2008, NAT NEUROSCI, V11, P649, DOI 10.1038/nn.2114; Sivakumaran S, 2009, J NEUROSCI, V29, P2637, DOI 10.1523/JNEUROSCI.5019-08.2009; Sun P, 2011, J NEUROSCI, V31, P16464, DOI 10.1523/JNEUROSCI.1542-11.2011; Szapacs ME, 2004, J NEUROSCI METH, V140, P81, DOI 10.1016/j.jneumeth.2004.03.026; Thickbroom GW, 2007, EXP BRAIN RES, V180, P583, DOI 10.1007/s00221-007-0991-3; Thickbroom GW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-4; Trippe J, 2009, EXP BRAIN RES, V199, P411, DOI 10.1007/s00221-009-1961-8; Valero-Cabre A, 2006, EXP BRAIN RES, V172, P14, DOI 10.1007/s00221-005-0307-4; Valero-Cabre A, 2005, EXP BRAIN RES, V163, P1, DOI 10.1007/s00221-004-2140-6; Valero-Cabre A, 2005, IEEE ENG MED BIOL, V24, P29, DOI 10.1109/MEMB.2005.1384097; Valero-Cabre A, 2008, EUR J NEUROSCI, V27, P765, DOI 10.1111/j.1460-9568.2008.06045.x; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Varani K, 2002, BRIT J PHARMACOL, V136, P57, DOI 10.1038/sj.bjp.0704695; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Wang HY, 2011, J NEUROSCI, V31, P11044, DOI 10.1523/JNEUROSCI.2125-11.2011; WEISSMAN JD, 1992, ELECTROEN CLIN NEURO, V85, P215, DOI 10.1016/0168-5597(92)90135-X; Wilks TA, 2010, EUR J NEUROSCI, V31, P613, DOI 10.1111/j.1460-9568.2010.07111.x; Zabouri N, 2011, J COMP NEUROL, V519, P1258, DOI 10.1002/cne.22534; Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154	119	65	67	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2012	26	4					1593	1606		10.1096/fj.11-194878	http://dx.doi.org/10.1096/fj.11-194878			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	919VS	22223750				2023-01-03	WOS:000302359700021
J	Liu, Z; Xing, MZ				Liu, Zhi; Xing, Mingzhao			Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells	PLOS ONE			English	Article							SODIUM-IODIDE SYMPORTER; DIFFERENTIATED THYROID-CARCINOMA; HISTONE DEACETYLASE INHIBITOR; GENE-EXPRESSION; NA+/I-SYMPORTER; THERAPEUTIC IMPLICATIONS; MELANOMA-CELLS; BREAST-CANCER; ACETYLATION; PATHWAYS	Background: This study was designed to explore the therapeutic potential of suppressing MAP kinase and PI3K/Akt pathways and histone deacetylase (HDAC) to induce the expression of sodium/iodide symporter (NIS) and radioiodine uptake in non-thyroid cancer cells. Methods: We tested the effects of the MEK inhibitor RDEA119, the Akt inhibitor perifosine, and the HDAC inhibitor SAHA on NIS expression in thirteen human cancer cell lines derived from melanoma, hepatic carcinoma, gastric carcinoma, colon carcinoma, breast carcinoma, and brain cancers. We also examined radioiodine uptake and histone acetylation at the NIS promoter in selected cells. Results: Overall, the three inhibitors could induce NIS expression, to various extents, in melanoma and all the epithelial carcinoma-derived cells but not in brain cancer-derived cells. SAHA was most effective and its effect could be significantly enhanced by RDEA119 and perifosine. The expression of NIS, at both mRNA and protein levels, was most robust in the melanoma cell M14, hepatic carcinoma cell HepG2, and the gastric carcinoma cell MKN-7 cell. Radioiodine uptake was correspondingly induced, accompanied by robust increase in histone acetylation at the NIS promoter, in these cells when treated with the three inhibitors. Conclusions: This is the first demonstration that simultaneously suppressing the MAP kinase and PI3K/Akt pathways and HDAC could induce robust NIS expression and radioiodine uptake in certain non-thyroid human cancer cells, providing novel therapeutic implications for adjunct radioiodine treatment of these cancers.	[Liu, Zhi; Xing, Mingzhao] Johns Hopkins Univ, Sch Med, Lab Cellular & Mol Thyroid Res, Div Endocrinol & Metab, Baltimore, MD 21218 USA	Johns Hopkins University	Liu, Z (corresponding author), Johns Hopkins Univ, Sch Med, Lab Cellular & Mol Thyroid Res, Div Endocrinol & Metab, Baltimore, MD 21218 USA.	mxing1@jhmi.edu	Liu, Zhi/D-2759-2012		National Institute of Health [CA134225]; NATIONAL CANCER INSTITUTE [R01CA134225] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by National Institute of Health R01 grant CA134225 to Dr. Xing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arturi F, 1998, J CLIN ENDOCR METAB, V83, P2493, DOI 10.1210/jc.83.7.2493; Baker C. H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P167, DOI 10.2174/1568008043339839; BAKHEET SM, 1994, EUR J NUCL MED, V21, P604, DOI 10.1007/BF00285581; Caillou B, 1998, J CLIN ENDOCR METAB, V83, P4102, DOI 10.1210/jc.83.11.4102; Carafa V, 2011, RECENT PAT ANTI-CANC, V6, P131, DOI 10.2174/157489211793980088; Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240; Cho Je-Yoel, 2002, Current Gene Therapy, V2, P393, DOI 10.2174/1566523023347599; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Ellerhorst JA, 2006, ENDOCR-RELAT CANCER, V13, P1269, DOI 10.1677/erc.1.01239; GREENLER DP, 1989, CLIN NUCL MED, V14, P111, DOI 10.1097/00003072-198902000-00009; Hingorani M, 2010, CURR CANCER DRUG TAR, V10, P242, DOI 10.2174/156800910791054194; Hou P, 2010, J CLIN ENDOCR METAB, V95, P820, DOI 10.1210/jc.2009-1888; Hou P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006200; Jhiang S M, 2000, Rev Endocr Metab Disord, V1, P205, DOI 10.1023/A:1010083132071; Jhiang SM, 1998, ENDOCRINOLOGY, V139, P4416, DOI 10.1210/en.139.10.4416; Kang DY, 2009, PATHOL INT, V59, P73, DOI 10.1111/j.1440-1827.2008.02331.x; Kim HJ, 2011, AM J TRANSL RES, V3, P166; Kitazono M, 2001, J CLIN ENDOCR METAB, V86, P3430, DOI 10.1210/jc.86.7.3430; Kogai T, 2000, P NATL ACAD SCI USA, V97, P8519, DOI 10.1073/pnas.140217197; Li W, 2007, J CLIN ENDOCR METAB, V92, P1080, DOI 10.1210/jc.2006-2106; Liu Z, 2010, CLIN CANCER RES, V16, P6009, DOI 10.1158/1078-0432.CCR-10-1627; MacDonald VE, 2009, EPIGENETICS-US, V4, P139, DOI 10.4161/epi.4.3.8484; McCubrey JA, 2010, EXPERT OPIN EMERG DR, V15, P203, DOI 10.1517/14728210903282760; MCDOUGALL IR, 1995, CLIN NUCL MED, V20, P869, DOI 10.1097/00003072-199510000-00002; Morgenstern KE, 2005, OPHTHAL PLAST RECONS, V21, P337, DOI 10.1097/01.iop.0000179369.75569.a8; Pacini F, 2006, EUR J ENDOCRINOL, V154, P787, DOI 10.1530/eje.1.02158; Park HJ, 2000, THYROID, V10, P211, DOI 10.1089/thy.2000.10.211; Puppin C, 2005, ENDOCRINOLOGY, V146, P3967, DOI 10.1210/en.2005-0128; ROSENBAUM RC, 1988, CLIN NUCL MED, V13, P657, DOI 10.1097/00003072-198809000-00011; Slominski A, 2002, J INVEST DERMATOL, V119, P1449, DOI 10.1046/j.1523-1747.2002.19617.x; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Spitzweg C, 1999, J CLIN ENDOCR METAB, V84, P4178, DOI 10.1210/jc.84.11.4178; Spitzweg C, 2002, CLIN ENDOCRINOL, V57, P559, DOI 10.1046/j.1365-2265.2002.01640.x; Spitzweg C, 2001, KIDNEY INT, V59, P1013, DOI 10.1046/j.1523-1755.2001.00584.x; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Zarnegar R, 2002, SURGERY, V132, P984, DOI 10.1067/msy.2002.128690	37	22	22	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2012	7	2							e31729	10.1371/journal.pone.0031729	http://dx.doi.org/10.1371/journal.pone.0031729			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925XS	22359623	Green Published, Green Submitted, gold			2023-01-03	WOS:000302796200092
J	Rasigade, JP; Raulin, O; Picaud, JC; Tellini, C; Bes, M; Grando, J; Ben Said, M; Claris, O; Etienne, J; Tigaud, S; Laurent, F				Rasigade, Jean-Philippe; Raulin, Olivia; Picaud, Jean-Charles; Tellini, Charlotte; Bes, Michele; Grando, Jacqueline; Ben Said, Mohamed; Claris, Olivier; Etienne, Jerome; Tigaud, Sylvestre; Laurent, Frederic			Methicillin-Resistant Staphylococcus capitis with Reduced Vancomycin Susceptibility Causes Late-Onset Sepsis in Intensive Care Neonates	PLOS ONE			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; FIELD GEL-ELECTROPHORESIS; BIRTH-WEIGHT INFANTS; BLOOD CULTURES; RESEARCH NETWORK; UNITED-STATES; AUREUS; BACTEREMIA; IDENTIFICATION; EPIDERMIDIS	Background: Coagulase-negative staphylococci, mainly Staphylococcus epidermidis, are the most frequent cause of late-onset sepsis (LOS) in the neonatal intensive care unit (NICU) setting. However, recent reports indicate that methicillin-resistant, vancomycin-heteroresistant Staphylococcus capitis could emerge as a significant pathogen in the NICU. We investigated the prevalence, clonality and vancomycin susceptibility of S. capitis isolated from the blood of NICU infants and compared these data to adult patients. Methodology/Principal Findings: We conducted a retrospective laboratory-based survey of positive blood cultures in NICU infants >= 3 days of age (n = 527) and in adult ICU patients >= 18 years of age (n = 1473) who were hospitalized from 2004 to 2009 in two hospital centers in Lyon, France. S. capitis was the most frequent pathogen in NICU infants, ahead of S. epidermidis (39.1% vs. 23.5% of positive blood cultures, respectively). Conversely, S. capitis was rarely found in adult ICU patients (1.0%) compared to S. epidermidis (15.3%). S. capitis bloodstream isolates were more frequently resistant to methicillin when collected from NICU infants than from adult patients (95.6% vs. 53.3%, respectively). Furthermore, we collected and characterized 53 S. capitis bloodstream isolates from NICU infants and adult patients from six distant cities. All methicillin-resistant S. capitis isolates from NICU infants were clonally related as determined by pulsed-field gel electrophoresis. These isolates harbored a type V-related staphylococcal chromosomal cassette mec element, and constantly showed either vancomycin resistance (37.5%) or heteroresistance (62.5%). Conversely, the isolates that were collected outside of the NICU were genetically diverse and displayed much lower rates of vancomycin resistance and heteroresistance (7.7% and 23.1%, respectively). Conclusions/Significance: A clonal population of methicillin-resistant S. capitis strains has spread into several French NICUs. These isolates exhibit reduced susceptibility to vancomycin, which is the most widely used antimicrobial agent in the NICU setting.	[Rasigade, Jean-Philippe; Bes, Michele; Etienne, Jerome; Laurent, Frederic] Univ Lyon, Natl Reference Ctr Staphylococci, INSERM, U851, Lyon, France; [Rasigade, Jean-Philippe; Raulin, Olivia; Tellini, Charlotte; Tigaud, Sylvestre; Laurent, Frederic] Hosp Civils Lyon, No Hosp Grp, Dept Clin Microbiol, Lyon, France; [Picaud, Jean-Charles; Ben Said, Mohamed] Hosp Civils Lyon, No Hosp Grp, Dept Neonatol, Lyon, France; [Grando, Jacqueline] Hosp Civils Lyon, Edouard Herriot Hosp Ctr, Dept Hyg & Epidemiol, Lyon, France; [Claris, Olivier] Hosp Civils Lyon, Eastern Hosp Grp, Dept Neonatol, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU Lyon; CHU Lyon; CHU Lyon	Rasigade, JP (corresponding author), Univ Lyon, Natl Reference Ctr Staphylococci, INSERM, U851, Lyon, France.	jean-philippe.rasigade@chu-lyon.fr	Laurent, Frederic/M-4719-2014; Rasigade, Jean-Philippe/AAE-1667-2021; LAURENT, Frederic/AGM-0706-2022; Rasigade, Jean-Philippe/L-9320-2014; ETIENNE, Jerome/C-5471-2014	Rasigade, Jean-Philippe/0000-0002-8264-0452; ETIENNE, Jerome/0000-0002-3348-3315; laurent, frederic/0000-0003-0609-9091	French Ministry of Health	French Ministry of Health	This work was supported by the French Ministry of Health. The funder had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.	Bradford R, 2006, EUR J CLIN MICROBIOL, V25, P283, DOI 10.1007/s10096-006-0130-2; Brodie SB, 2000, PEDIATR INFECT DIS J, V19, P56, DOI 10.1097/00006454-200001000-00012; Centre de Coordination de la Lutte contre les Infections Associees aux Soins, 2011, RAPP SURV 2010 RES N; Cone LA, 2005, INT J INFECT DIS, V9, P335, DOI 10.1016/j.ijid.2004.08.004; Courcol R, 2010, REFERENTIEL MICROBIO, P367; D'mello D, 2008, J CLIN MICROBIOL, V46, P3124, DOI 10.1128/JCM.00592-08; de Silva GDI, 2002, J CLIN MICROBIOL, V40, P382, DOI 10.1128/JCM.40.02.382-388.2002; de Silva GDI, 2001, CLIN INFECT DIS, V33, P1520, DOI 10.1086/323338; European Committee on Antimicrobial Susceptibility Testing, 2010, CLIN BREAKP; European_Committee_on_Antimicrobial_Susceptibility_Testing, 2010, RAT EUCAST CLIN BREA; FREEMAN J, 1990, AM J DIS CHILD, V144, P324, DOI 10.1001/archpedi.1990.02150270074029; FREEMAN J, 1990, NEW ENGL J MED, V323, P301, DOI 10.1056/NEJM199008023230504; French Society for Microbiology, 2009, REC COM ANT SOC FRAN; Gaynes RP, 1996, PEDIATRICS, V98, P357; GEORGE CG, 1994, INT J SYST BACTERIOL, V44, P404, DOI 10.1099/00207713-44-3-404; GOERING RV, 1993, INFECT CONT HOSP EP, V14, P595; GRAY JE, 1995, PEDIATRICS, V95, P225; Grisold AJ, 2010, J INFECTION, V60, P44, DOI 10.1016/j.jinf.2009.10.045; Grundmann H, 2001, J CLIN MICROBIOL, V39, P4190, DOI 10.1128/JCM.39.11.4190-4192.2001; Guen CGL, 2007, J PERINATOL, V27, P713, DOI 10.1038/sj.jp.7211798; Hall KK, 2006, CLIN MICROBIOL REV, V19, P788, DOI 10.1128/CMR.00062-05; Herwaldt LA, 1996, CLIN INFECT DIS, V22, P14, DOI 10.1093/clinids/22.1.14; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Ito T, 2009, ANTIMICROB AGENTS CH, V53, P4961, DOI 10.1128/AAC.00579-09; JohnsonRobbins LA, 1996, BIOL NEONATE, V69, P249; Kim SD, 2000, INFECT CONT HOSP EP, V21, P213, DOI 10.1086/501747; KIRCHHOFF LV, 1985, INFECT CONT HOSP EP, V6, P479, DOI 10.1017/S0195941700063591; Klingenberg C, 2007, CLIN MICROBIOL INFEC, V13, P1100, DOI 10.1111/j.1469-0691.2007.01818.x; Klingenberg C, 2004, J ANTIMICROB CHEMOTH, V54, P889, DOI 10.1093/jac/dkh453; Kondo Y, 2007, ANTIMICROB AGENTS CH, V51, P264, DOI 10.1128/AAC.00165-06; Martineau F, 2001, J CLIN MICROBIOL, V39, P2541, DOI 10.1128/JCM.39.7.2541-2547.2001; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; Nadarajah R, 2010, AM J CLIN PATHOL, V133, P844, DOI 10.1309/AJCPMV1P0VKUAZRD; Nalmas S, 2008, HEART LUNG, V37, P380, DOI 10.1016/j.hrtlng.2007.09.005; Ng PC, 2006, PEDIATR INFECT DIS J, V25, P652, DOI 10.1097/01.inf.0000225785.32137.d3; Patel SJ, 2009, PEDIATR INFECT DIS J, V28, P1047, DOI 10.1097/INF.0b013e3181b12484; Reseau d'alerte d'investigation et de surveillance des infections nosocomiales (Raisin), 2009, ENQ NAT PREV INF NOS; Ruhe J, 2004, EUR J CLIN MICROBIOL, V23, P495, DOI 10.1007/s10096-004-1134-4; Satola SW, 2011, J CLIN MICROBIOL, V49, P177, DOI 10.1128/JCM.01128-10; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Stoll BJ, 1996, J PEDIATR-US, V129, P63, DOI 10.1016/S0022-3476(96)70191-9; Van Der Zwet WC, 2002, J CLIN MICROBIOL, V40, P2520, DOI 10.1128/JCM.40.7.2520-2525.2002; Vaudaux P, 2010, ANTIMICROB AGENTS CH, V54, P3861, DOI 10.1128/AAC.00269-10; Wang Shih-Min, 1999, Journal of Microbiology Immunology and Infection, V32, P26	44	69	71	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2012	7	2							e31548	10.1371/journal.pone.0031548	http://dx.doi.org/10.1371/journal.pone.0031548			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925CF	22348102	gold, Green Submitted, Green Published			2023-01-03	WOS:000302737400033
J	Park, SJ; Ahmad, F; Philp, A; Baar, K; Williams, T; Luo, HB; Ke, HM; Rehmann, H; Taussig, R; Brown, AL; Kim, MK; Beaven, MA; Burgin, AB; Manganiello, V; Chung, JH				Park, Sung-Jun; Ahmad, Faiyaz; Philp, Andrew; Baar, Keith; Williams, Tishan; Luo, Haibin; Ke, Hengming; Rehmann, Holger; Taussig, Ronald; Brown, Alexandra L.; Kim, Myung K.; Beaven, Michael A.; Burgin, Alex B.; Manganiello, Vincent; Chung, Jay H.			Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SMALL-MOLECULE ACTIVATORS; LIFE-SPAN; PHOSPHOLIPASE-C; CYCLIC-AMP; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL-FUNCTION; CALORIE RESTRICTION; SIGNALING PATHWAY; CARDIAC MYOCYTES	Resveratrol, a polyphenol in red wine, has been reported as a calorie restriction mimetic with potential antiaging and antidiabetogenic properties. It is widely consumed as a nutritional supplement, but its mechanism of action remains a mystery. Here, we report that the metabolic effects of resveratrol result from competitive inhibition of cAMP-degrading phosphodiesterases, leading to elevated cAMP levels. The resulting activation of Epac1, a cAMP effector protein, increases intracellular Ca2+ levels and activates the CamKK beta-AMPK pathway via phospholipase C and the ryanodine receptor Ca2+-release channel. As a consequence, resveratrol increases NAD(+) and the activity of Sirt1. Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including prevention of diet-induced obesity and an increase in mitochondrial function, physical stamina, and glucose tolerance in mice. Therefore, administration of PDE4 inhibitors may also protect against and ameliorate the symptoms of metabolic diseases associated with aging.	[Park, Sung-Jun; Brown, Alexandra L.; Kim, Myung K.; Chung, Jay H.] NHLBI, Lab Obes & Aging Res, Genet & Dev Biol Ctr, NIH, Bethesda, MD 20892 USA; [Ahmad, Faiyaz; Manganiello, Vincent] NHLBI, Cardiovasc Pulm Branch, NIH, Bethesda, MD 20892 USA; [Beaven, Michael A.] NHLBI, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA; [Philp, Andrew; Baar, Keith] Univ Calif Davis, Funct Mol Biol Lab, Davis, CA 95616 USA; [Williams, Tishan; Ke, Hengming] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; [Luo, Haibin] Sun Yat Sen Univ, Sch Pharmaceut Sci, Struct Biol Lab, Guangzhou 510006, Guangdong, Peoples R China; [Rehmann, Holger] Univ Med Ctr, Dept Mol Canc Res, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; [Rehmann, Holger] Univ Med Ctr, Canc Genom Ctr, NL-3584 CG Utrecht, Netherlands; [Taussig, Ronald] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Burgin, Alex B.] Emerald BioStruct, Bainbridge Isl, WA 98110 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Davis; University of North Carolina; University of North Carolina Chapel Hill; Sun Yat Sen University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Texas System; University of Texas Southwestern Medical Center Dallas	Chung, JH (corresponding author), NHLBI, Lab Obes & Aging Res, Genet & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.	chungj@nhlbi.nih.gov	Khan, Faiyaz Ahmad/AAW-7944-2021	Philp, Andrew/0000-0003-3860-4136; Baar, Keith/0000-0001-9337-6186	National Heart Lung and Blood Institute, National Institutes of Health; Netherlands Organization for Scientific Research (NWO); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006118, ZIAHL002540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059791] Funding Source: NIH RePORTER	National Heart Lung and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Intramural Research Program, National Heart Lung and Blood Institute, National Institutes of Health. We thank Andrew Marks for the Ryr2 phosphoantibody; Dr. Yan Tang for sharing data regarding inhibition of PDE3 by resveratrol; Marije Rensen-De Leeuw and Yan Tang for technical assistance; Shutong Yang and Dalton Saunders for animal management; and Alexandra Brown for manuscript review and comments. H.R. is supported by the Netherlands Organization for Scientific Research (NWO).	Ahmad F, 2009, BIOCHEM J, V424, P399, DOI 10.1042/BJ20090842; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Beher D, 2009, CHEM BIOL DRUG DES, V74, P619, DOI 10.1111/j.1747-0285.2009.00901.x; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Brasnyo P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316; Burgin AB, 2010, NAT BIOTECHNOL, V28, P63, DOI 10.1038/nbt.1598; Campos-Toimil M, 2007, EUR J PHARMACOL, V577, P91, DOI 10.1016/j.ejphar.2007.08.003; Canto C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006; Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Crowell JA, 2004, TOXICOL SCI, V82, P614, DOI 10.1093/toxsci/kfh263; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Donmez G, 2010, CELL, V142, P320, DOI 10.1016/j.cell.2010.06.020; El-Mowafy AM, 2003, CARCINOGENESIS, V24, P869, DOI 10.1093/carcin/bgg015; Feige JN, 2008, CELL METAB, V8, P347, DOI 10.1016/j.cmet.2008.08.017; Fulco M, 2008, DEV CELL, V14, P661, DOI 10.1016/j.devcel.2008.02.004; Gerhart-Hines Z, 2007, EMBO J, V26, P1913, DOI 10.1038/sj.emboj.7601633; Gevrey JC, 2002, J BIOL CHEM, V277, P22407, DOI 10.1074/jbc.M201624200; Gruber J, 2007, ANN NY ACAD SCI, V1100, P530, DOI 10.1196/annals.1395.059; Guarente L, 2006, NATURE, V444, P868, DOI 10.1038/nature05486; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; MANGANIELLO V, 1973, J BIOL CHEM, V248, P7164; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Oestreich EA, 2007, J BIOL CHEM, V282, P5488, DOI 10.1074/jbc.M608495200; Oestreich EA, 2009, J BIOL CHEM, V284, P1514, DOI 10.1074/jbc.M806994200; Pacholec M, 2010, J BIOL CHEM, V285, P8340, DOI 10.1074/jbc.M109.088682; Park CE, 2007, EXP MOL MED, V39, P222, DOI 10.1038/emm.2007.25; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pereira L, 2007, J PHYSIOL-LONDON, V583, P685, DOI 10.1113/jphysiol.2007.133066; Pfluger PT, 2008, P NATL ACAD SCI USA, V105, P9793, DOI 10.1073/pnas.0802917105; Pizon V, 1999, EXP CELL RES, V246, P56, DOI 10.1006/excr.1998.4284; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Sareen D, 2007, MOL PHARMACOL, V72, P1466, DOI 10.1124/mol.107.039040; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; SELAWRY H, 1973, BIOCHEM BIOPH RES CO, V51, P198, DOI 10.1016/0006-291X(73)90528-7; Signorelli P, 2005, J NUTR BIOCHEM, V16, P449, DOI 10.1016/j.jnutbio.2005.01.017; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200; Suchankova G, 2009, BIOCHEM BIOPH RES CO, V378, P836, DOI 10.1016/j.bbrc.2008.11.130; Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09-0482; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Wehrens XHT, 2004, CIRC RES, V94, pE61, DOI 10.1161/01.RES.0000125626.33738.E2; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xiao B, 2011, NATURE, V472, P230, DOI 10.1038/nature09932; Yang L, 2008, EXP NEUROL, V211, P311, DOI 10.1016/j.expneurol.2007.02.010	67	996	1053	26	345	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 3	2012	148	3					421	433		10.1016/j.cell.2012.01.017	http://dx.doi.org/10.1016/j.cell.2012.01.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	891NX	22304913	Green Accepted, Bronze, Green Published			2023-01-03	WOS:000300225000012
J	Terhune, DB; Brugger, P				Terhune, Devin Blair; Brugger, Peter			Doing Better by Getting Worse: Posthypnotic Amnesia Improves Random Number Generation	PLOS ONE			English	Article							HYPNOTIC-SUSCEPTIBILITY; HYPNOTIZABILITY; MEMORIES; HYPNOSIS; SCALE	Although forgetting is often regarded as a deficit that we need to control to optimize cognitive functioning, it can have beneficial effects in a number of contexts. We examined whether disrupting memory for previous numerical responses would attenuate repetition avoidance (the tendency to avoid repeating the same number) during random number generation and thereby improve the randomness of responses. Low suggestible and low dissociative and high dissociative highly suggestible individuals completed a random number generation task in a control condition, following a posthypnotic amnesia suggestion to forget previous numerical responses, and in a second control condition following the cancellation of the suggestion. High dissociative highly suggestible participants displayed a selective increase in repetitions during posthypnotic amnesia, with equivalent repetition frequency to a random system, whereas the other two groups exhibited repetition avoidance across conditions. Our results demonstrate that temporarily disrupting memory for previous numerical responses improves random number generation.	[Terhune, Devin Blair] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Brugger, Peter] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland; [Brugger, Peter] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland	University of Oxford; University of Zurich; University Zurich Hospital; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Terhune, DB (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	devin.terhune@psy.ox.ac.uk	Terhune, Devin B./GNM-6644-2022	Terhune, Devin/0000-0002-6792-4975; Brugger, Peter/0000-0002-5137-0314	Bial Foundation [54/06]; Cogito Foundation	Bial Foundation(Bial Foundation); Cogito Foundation	The research was supported by research grant 54/06 from the Bial Foundation and a postdoctoral fellowship from the Cogito Foundation, both to DBT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MC, 2009, CURR DIR PSYCHOL SCI, V18, P189, DOI 10.1111/j.1467-8721.2009.01634.x; Barnier AJ, 2002, PSYCHOL SCI, V13, P232, DOI 10.1111/1467-9280.00443; Bowers KS, 1998, INT J CLIN EXP HYP, V46, P250, DOI 10.1080/00207149808410006; Brugger P, 1997, PERCEPT MOTOR SKILL, V84, P627, DOI 10.2466/pms.1997.84.2.627; Bryant RA, 2001, AM J PSYCHIAT, V158, P600, DOI 10.1176/appi.ajp.158.4.600; Chiu CD, 2009, J ABNORM PSYCHOL, V118, P214, DOI 10.1037/a0014654; CRAWFORD HJ, 1993, J ABNORM PSYCHOL, V102, P534, DOI 10.1037/0021-843X.102.4.534; Falk R, 1997, PSYCHOL REV, V104, P301, DOI 10.1037/0033-295X.104.2.301; FREEMAN WB, 1990, INT J CLIN EXP HYP, V38, P10, DOI 10.1080/00207149008414494; FRISCHHOLZ EJ, 1992, AM J CLIN HYPN, V35, P29, DOI 10.1080/00029157.1992.10402980; Gazzaley A, 2005, NAT NEUROSCI, V8, P1298, DOI 10.1038/nn1543; GEISELMAN RE, 1983, J EXP PSYCHOL GEN, V112, P58, DOI 10.1037/0096-3445.112.1.58; GRAHAM C, 1977, J ABNORM PSYCHOL, V86, P631, DOI 10.1037/0021-843X.86.6.631; Heuer H, 2010, Q J EXP PSYCHOL, V63, P465, DOI 10.1080/17470210902974138; Kihlstrom JF, 1998, PSYCHOL BULL, V123, P186, DOI 10.1037/0033-2909.123.2.186; King BJ, 1998, INT J CLIN EXP HYP, V46, P295, DOI 10.1080/00207149808410009; Knoch D, 2005, CEREB CORTEX, V15, P885, DOI 10.1093/cercor/bhh196; Korlin D, 2007, NORD J PSYCHIAT, V61, P126, DOI 10.1080/08039480701226112; Mendelsohn A, 2008, NEURON, V57, P159, DOI 10.1016/j.neuron.2007.11.022; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; NADON R, 1987, J PERS SOC PSYCHOL, V53, P948; Oakley DA, 2009, TRENDS COGN SCI, V13, P264, DOI 10.1016/j.tics.2009.03.004; Terhune DB, 2011, CONSCIOUS COGN, V20, P727, DOI 10.1016/j.concog.2010.11.005; Terhune DB, 2011, COGN NEUROPSYCHIATRY, V16, P113, DOI 10.1080/13546805.2010.503048; Weitzenhoffer A. M., 1967, REVISED STANFORD PRO	25	17	17	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2011	6	12							e29206	10.1371/journal.pone.0029206	http://dx.doi.org/10.1371/journal.pone.0029206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	866HE	22195022	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000298370400038
J	Canfield, SE				Canfield, Steven E.			Adding short-term androgen-deprivation therapy to radiotherapy improved survival in localized prostate cancer	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Texas Med Sch Houston, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Canfield, SE (corresponding author), Univ Texas Med Sch Houston, Houston, TX 77030 USA.							Bannuru RR, 2011, ANN INTERN MED, V155, P171, DOI 10.7326/0003-4819-155-3-201108020-00347; Taylor LG, 2009, CANCER-AM CANCER SOC, V115, P2388, DOI 10.1002/cncr.24283	2	1	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-7	10.7326/0003-4819-155-10-201111150-02007	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02007			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084354				2023-01-03	WOS:000208885300006
J	Ouslander, JG; Berenson, RA				Ouslander, Joseph G.; Berenson, Robert A.			Reducing Unnecessary Hospitalizations of Nursing Home Residents	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Ouslander, Joseph G.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA; [Berenson, Robert A.] Urban Inst, Washington, DC 20037 USA	State University System of Florida; Florida Atlantic University; Urban Institute	Ouslander, JG (corresponding author), Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.							Grabowski DC, 2007, MILBANK Q, V85, P579, DOI 10.1111/j.1468-0009.2007.00502.x; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; Ouslander JG, 2011, J AM GERIATR SOC, V59, P745, DOI 10.1111/j.1532-5415.2011.03333.x; Ouslander JG, 2010, J AM GERIATR SOC, V58, P627, DOI 10.1111/j.1532-5415.2010.02768.x; Saliba D, 2000, J AM GERIATR SOC, V48, P154, DOI 10.1111/j.1532-5415.2000.tb03906.x	5	120	120	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2011	365	13					1165	1167		10.1056/NEJMp1105449	http://dx.doi.org/10.1056/NEJMp1105449			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825YO	21991889				2023-01-03	WOS:000295318400001
J	Prasad, M; Holmboe, ES; Lipner, RS; Hess, BJ; Christie, JD; Bellamy, SL; Rubenfeld, GD; Kahn, JM				Prasad, Meeta; Holmboe, Eric S.; Lipner, Rebecca S.; Hess, Brian J.; Christie, Jason D.; Bellamy, Scarlett L.; Rubenfeld, Gordon D.; Kahn, Jeremy M.			Clinical Protocols and Trainee Knowledge About Mechanical Ventilation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEVERE SEPSIS; CARE; GUIDELINES; ADHERENCE; OUTCOMES	Context Clinical protocols are associated with improved patient outcomes; however, they may negatively affect medical education by removing trainees from clinical decision making. Objective To study the relationship between critical care training with mechanical ventilation protocols and subsequent knowledge about ventilator management. Design, Setting, and Participants A retrospective cohort equivalence study, linking a national survey of mechanical ventilation protocol availability in accredited US pulmonary and critical care fellowship programs with knowledge about mechanical ventilation among first-time examinees of the American Board of Internal Medicine (ABIM) Critical Care Medicine Certification Examination in 2008 and 2009. Exposure to protocols was defined as high intensity if an examinee's training intensive care unit had 2 or more protocols for at least 3 years and as low intensity if 0 or 1 protocol. Main Outcome Measures Knowledge, measured by performance on examination questions specific to mechanical ventilation management, calculated as a mechanical ventilation score using item response theory. The score is standardized to a mean (SD) of 500 (100), and a clinically important difference is defined as 25. Variables included in adjusted analyses were birth country, residency training country, and overall first-attempt score on the ABIM Internal Medicine Certification Examination. Results Ninety of 129 programs (70%) responded to the survey. Seventy-seven programs (86%) had protocols for ventilation liberation, 66 (73%) for sedation management, and 54 (60%) for lung-protective ventilation at the time of the survey. Eighty-eight (98%) of these programs had trainees who completed the ABIM Critical Care Medicine Certification Examination, totaling 553 examinees. Of these 88 programs, 27 (31%) had 0 protocols, 19 (22%) had 1 protocol, 24 (27%) had 2 protocols, and 18 (20%) had 3 protocols for at least 3 years. Forty-two programs (48%) were classified as high intensity and 46 (52%) as low intensity, with 304 trainees (55%) and 249 trainees (45%), respectively. In bivariable analysis, no difference in mean scores was observed in high-intensity (497; 95% CI, 486-507) vs low-intensity programs (497; 95% CI, 485-509). Mean difference was 0 (95% CI, -16 to 16), with a positive value indicating a higher score in the high-intensity group. In multivariable analyses, no association of training was observed in a high-intensity program with mechanical ventilation score (adjusted mean difference, -5.36; 95% CI, -20.7 to 10.0). Conclusion Among first-time ABIM Critical Care Medicine Certification Examination examinees, training in a high-intensity ventilator protocol environment compared with a low-intensity environment was not associated with worse performance on examination questions about mechanical ventilation management. JAMA. 2011;306(9):935-941	[Prasad, Meeta; Christie, Jason D.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Holmboe, Eric S.; Lipner, Rebecca S.; Hess, Brian J.] Amer Board Internal Med, Philadelphia, PA USA; [Christie, Jason D.; Bellamy, Scarlett L.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Rubenfeld, Gordon D.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Program Trauma Emergency & Crit Care, Toronto, ON, Canada; [Kahn, Jeremy M.] Univ Pittsburgh, Med Ctr, Dept Crit Care, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA	University of Pennsylvania; American Board of Internal Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prasad, M (corresponding author), Univ Penn, Sch Med, Dept Med, 3600 Spruce St,8th Floor,W Gates Bldg, Philadelphia, PA 19104 USA.	prasadm@uphs.upenn.edu		Kahn, Jeremy/0000-0001-9688-5576; Bellamy, Scarlett/0000-0002-2906-4046; Christie, Jason/0000-0003-0519-218X	Leonard Davis Institute of the University of Pennsylvania, Philadelphia	Leonard Davis Institute of the University of Pennsylvania, Philadelphia	This work was funded by a grant from the Leonard Davis Institute of the University of Pennsylvania, Philadelphia (Drs Prasad and Kahn).	Berenholtz Sean M, 2004, Jt Comm J Qual Saf, V30, P195; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Chatburn RL, 2007, RESP CARE, V52, P609; Chiong W, 2007, JAMA-J AM MED ASSOC, V298, P1046, DOI 10.1001/jama.298.9.1046; Cohen J., 2013, STAT POWER ANAL BEHA; Costantini O, 1999, ACAD MED, V74, P1138, DOI 10.1097/00001888-199910000-00019; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Dunn D, 1997, MED EDUC, V31, P25, DOI 10.1111/j.1365-2923.1997.tb02583.x; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Hambleton R.K., 1991, FUNDAMENTALS ITEM RE; Holmboe ES, 2008, ARCH INTERN MED, V168, P1396, DOI 10.1001/archinte.168.13.1396; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kaplan LJ, 2011, JAMA-J AM MED ASSOC, V305, P296, DOI 10.1001/jama.2010.1997; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; McLean SE, 2006, AM J CRIT CARE, V15, P299; Morris AH, 1998, PRINCIPLES PRACTICE, P1355; Morris Alan H, 2003, Curr Opin Crit Care, V9, P236, DOI 10.1097/00075198-200306000-00012; Papadakis MA, 2008, ANN INTERN MED, V148, P869, DOI 10.7326/0003-4819-148-11-200806030-00009; Prasad M, 2010, J CRIT CARE, V25, P610, DOI 10.1016/j.jcrc.2010.02.014; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Steiger JH, 2004, PSYCHOL METHODS, V9, P164, DOI 10.1037/1082-989X.9.2.164; Stoller J K, 2000, Respir Care, V45, P945; Tobin MJ, 2004, AM J RESP CRIT CARE, V169, P661, DOI 10.1164/rccm.2401006; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	28	16	16	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	2011	306	9					935	941		10.1001/jama.2011.1226	http://dx.doi.org/10.1001/jama.2011.1226			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	815QT	21900133	Bronze			2023-01-03	WOS:000294542600011
J	Howell, JD				Howell, Joel D.			Maintaining Connections: Some Thoughts on the Value of Intensive Care Unit Rounding for General Medicine Ward Teams	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								When established ward patients are unexpectedly transferred to an intensive care unit (ICU), the ward team should continue to follow them. Although there may be reasons not to do so, the advantages outweigh the obstacles. Great pedagogic value can be gained from following patients after acute decompensation, but a more important reason is that by following patients into the ICU, the ward team can enact for both patients and their families the twin virtues of caring and continuity. Doing so also demonstrates the highest ideals of medicine-that we are focused not on defined areas of turf, but on our patient's well-being. It shows that we are not merely doing narrowly defined "shift work," but that we truly care about our patients. Rounding on established patients who have been transferred into the ICU is the sort of behavior that undergirds the fundamental bases of professionalism. It takes a few minutes from a busy day, but it can be incredibly beneficial for families, patients, and the ideals of medicine.	Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Howell, JD (corresponding author), Univ Michigan, Div Gen Med, 300 N Ingalls Bldg,Room 7C27, Ann Arbor, MI 48109 USA.	jhowell@umich.edu							0	1	1	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 6	2011	155	5					323	324		10.7326/0003-4819-155-5-201109060-00010	http://dx.doi.org/10.7326/0003-4819-155-5-201109060-00010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	815PX	21893625				2023-01-03	WOS:000294538900006
J	Evers, MM; Pepers, BA; van Deutekom, JCT; Mulders, SAM; den Dunnen, JT; Aartsma-Rus, A; van Ommen, GJB; van Roon-Mom, WMC				Evers, Melvin M.; Pepers, Barry A.; van Deutekom, Judith C. T.; Mulders, Susan A. M.; den Dunnen, Johan T.; Aartsma-Rus, Annemieke; van Ommen, Gert-Jan B.; van Roon-Mom, Willeke M. C.			Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide	PLOS ONE			English	Article							ALLELE-SELECTIVE INHIBITION; NORMAL HUNTINGTIN FUNCTION; MACHADO-JOSEPH-DISEASE; MUTANT HUNTINGTIN; NEURODEGENERATIVE DISEASE; MUSCULAR-DYSTROPHY; RNA INTERFERENCE; BINDING PROTEIN; REPEAT LENGTH; POLYGLUTAMINE	To date there are 9 known diseases caused by an expanded polyglutamine repeat, with the most prevalent being Huntington's disease. Huntington's disease is a progressive autosomal dominant neurodegenerative disorder for which currently no therapy is available. It is caused by a CAG repeat expansion in the HTT gene, which results in an expansion of a glutamine stretch at the N-terminal end of the huntingtin protein. This polyglutamine expansion plays a central role in the disease and results in the accumulation of cytoplasmic and nuclear aggregates. Here, we make use of modified 2'-O-methyl phosphorothioate (CUG)n triplet-repeat antisense oligonucleotides to effectively reduce mutant huntingtin transcript and protein levels in patient-derived Huntington's disease fibroblasts and lymphoblasts. The most effective antisense oligonucleotide, (CUG)(7), also reduced mutant ataxin-1 and ataxin-3 mRNA levels in spinocerebellar ataxia 1 and 3, respectively, and atrophin-1 in dentatorubral-pallidoluysian atrophy patient derived fibroblasts. This antisense oligonucleotide is not only a promising therapeutic tool to reduce mutant huntingtin levels in Huntington's disease but our results in spinocerebellar ataxia and dentatorubral-pallidoluysian atrophy cells suggest that this could also be applicable to other polyglutamine expansion disorders as well.	[Evers, Melvin M.; Pepers, Barry A.; den Dunnen, Johan T.; Aartsma-Rus, Annemieke; van Ommen, Gert-Jan B.; van Roon-Mom, Willeke M. C.] Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; [van Deutekom, Judith C. T.; Mulders, Susan A. M.] Prosensa Therapeut BV, Leiden, Netherlands; [den Dunnen, Johan T.] Leiden Univ, Med Ctr, Leiden Genome Technol Ctr, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; BioMarin Pharmaceutical Inc.; Prosensa; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Evers, MM (corresponding author), Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands.	w.vanroon@lumc.nl	dunnen, johan den/ABH-4228-2020; van Roon-Mom, Willeke/Y-3039-2018	dunnen, johan den/0000-0002-6304-1710; van Roon-Mom, Willeke/0000-0002-3035-0533; Evers, Melvin/0000-0003-2920-5854	Center for Biomedical Genetics (The Netherlands); Agentschap NL (The Netherlands)	Center for Biomedical Genetics (The Netherlands)(Netherlands Government); Agentschap NL (The Netherlands)(Netherlands Government)	The research in this study was financed by the Center for Biomedical Genetics (The Netherlands) and Agentschap NL (The Netherlands). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Alves S, 2010, HUM MOL GENET, V19, P2380, DOI 10.1093/hmg/ddq111; ANDREW SE, 1993, AM J HUM GENET, V53, P1118; Bauer PO, 2009, J NEUROCHEM, V110, P1737, DOI 10.1111/j.1471-4159.2009.06302.x; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; *CLINICALTRIALS, 2009, SAF TOL ACT STUD ISI; Crespo-Barreto J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001021; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; de Mezer M, 2011, NUCLEIC ACIDS RES, V39, P3852, DOI 10.1093/nar/gkq1323; Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Drouet V, 2009, ANN NEUROL, V65, P276, DOI 10.1002/ana.21569; Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106; Gagnon KT, 2010, BIOCHEMISTRY-US, V49, P10166, DOI 10.1021/bi101208k; Goemans NM, 2011, NEW ENGL J MED, V364, P1513, DOI 10.1056/NEJMoa1011367; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Hu JX, 2011, BIOL CHEM, V392, P315, DOI 10.1515/BC.2011.045; Hu JX, 2009, ANN NY ACAD SCI, V1175, P24, DOI 10.1111/j.1749-6632.2009.04975.x; Hu JX, 2009, NAT BIOTECHNOL, V27, P478, DOI 10.1038/nbt.1539; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Krol J, 2007, MOL CELL, V25, P575, DOI 10.1016/j.molcel.2007.01.031; Lombardi MS, 2009, EXP NEUROL, V217, P312, DOI 10.1016/j.expneurol.2009.03.004; Manto MU, 2005, CEREBELLUM, V4, P2, DOI 10.1080/14734220510007914; Matilla-Duenas A, 2008, CEREBELLUM, V7, P106, DOI 10.1007/s12311-008-0009-0; McBride JL, 2008, P NATL ACAD SCI USA, V105, P5868, DOI 10.1073/pnas.0801775105; McNeil SM, 1997, HUM MOL GENET, V6, P775, DOI 10.1093/hmg/6.5.775; METCALF DJ, 2010, EXP NEUROL; Molla M, 2009, P NATL ACAD SCI USA, V106, P17095, DOI 10.1073/pnas.0907112106; Muchowski PJ, 2002, P NATL ACAD SCI USA, V99, P727, DOI 10.1073/pnas.022628699; Mulders SAM, 2009, P NATL ACAD SCI USA, V106, P13915, DOI 10.1073/pnas.0905780106; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Padiath QS, 2005, AM J MED GENET B, V133B, P124, DOI 10.1002/ajmg.b.30088; Passini MA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001777; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030; RANEN NG, 1995, AM J HUM GENET, V57, P593; Rao DD, 2009, CANCER GENE THER, V16, P807, DOI 10.1038/cgt.2009.53; Riess O, 2008, CEREBELLUM, V7, P125, DOI 10.1007/s12311-008-0013-4; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Robberecht W, 2000, J NEUROL, V247, P2; ROONMOM WMC, 2002, MOL BRAIN RES, V109, P1; Ross CA, 2011, LANCET NEUROL, V10, P83, DOI 10.1016/S1474-4422(10)70245-3; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Sah DWY, 2011, J CLIN INVEST, V121, P500, DOI 10.1172/JCI45130; Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200; Schmitt I, 2007, BIOCHEM BIOPH RES CO, V362, P734, DOI 10.1016/j.bbrc.2007.08.062; Scholefield J, 2010, TRENDS GENET, V26, P29, DOI 10.1016/j.tig.2009.11.005; Schols L, 2004, LANCET NEUROL, V3, P443, DOI 10.1016/S1474-4422(04)00816-6; Seo H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000238; Shen Y, 2009, CELL MOL LIFE SCI, V66, P437, DOI 10.1007/s00018-008-8403-9; Shen YG, 2007, J BIOL CHEM, V282, P5037, DOI 10.1074/jbc.M610274200; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; van Bilsen PHJ, 2008, HUM GENE THER, V19, P710, DOI 10.1089/hum.2007.116; van Deutekom JC, 2007, NEW ENGL J MED, V357, P2677, DOI 10.1056/NEJMoa073108; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zhang S, 2009, DIS MODEL MECH, V2, P247, DOI 10.1242/dmm.000653; Zhang Y, 2009, J NEUROCHEM, V108, P82, DOI 10.1111/j.1471-4159.2008.05734.x	67	71	78	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2011	6	9							e24308	10.1371/journal.pone.0024308	http://dx.doi.org/10.1371/journal.pone.0024308			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	817OO	21909428	gold, Green Published, Green Submitted			2023-01-03	WOS:000294683900044
J	Alberts, SR; Sargent, DJ; Nair, S; Mahoney, MR; Mooney, M; Thibodeau, SN; Smyrk, TC; Sinicrope, FA; Chan, E; Gill, S; Kahlenberg, MS; Shields, AF; Quesenberry, JT; Webb, TA; Farr, GH; Pockaj, BA; Grothey, A; Goldberg, RM				Alberts, Steven R.; Sargent, Daniel J.; Nair, Suresh; Mahoney, Michelle R.; Mooney, Margaret; Thibodeau, Stephen N.; Smyrk, Thomas C.; Sinicrope, Frank A.; Chan, Emily; Gill, Sharlene; Kahlenberg, Morton S.; Shields, Anthony F.; Quesenberry, James T.; Webb, Thomas A.; Farr, Gist H., Jr.; Pockaj, Barbara A.; Grothey, Axel; Goldberg, Richard M.			Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METASTATIC COLORECTAL-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; MRC COIN TRIAL; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; PHASE-III; CHEMOTHERAPY; PANITUMUMAB; FLUOROPYRIMIDINE; IRINOTECAN	Context Leucovorin, fluorouracil, and oxaliplatin (FOLFOX) is the standard adjuvant therapy for resected stage III colon cancer. Adding cetuximab to FOLFOX benefits patients with metastatic wild-type KRAS but not mutated KRAS colon cancer. Objective To assess the potential benefit of cetuximab added to the modified sixth version of the FOLFOX regimen (mFOLFOX6) in patients with resected stage III wild-type KRAS colon cancer. Design, Setting, and Participants A randomized trial of 2686 patients aged 18 years or older at multiple institutions across North America enrolled following resection and informed consent between February 10, 2004, and November 25, 2009. The primary randomized comparison was 12 biweekly cycles of mFOLFOX6 with and without cetuximab. KRAS mutation status was centrally determined. The trial was halted after a planned interim analysis of 48% of predicted events (246/515) occurring in 1863 (of 2070 planned) patients with tumors having wild-type KRAS. A total of 717 patients with mutated KRAS and 106 with indeterminate KRAS were accrued. The 2070 patients with wild-type KRAS provided 90% power to detect a hazard ratio (HR) of 1.33 (2-sided alpha=.05), with planned interim efficacy analyses after 25%, 50%, and 75% of expected relapses. Main Outcome Measures Disease-free survival in patients with wild-type KRAS mutations. Secondary end points included overall survival and toxicity. Results Median (range) follow-up was 28 (0-68) months. The trial demonstrated no benefit when adding cetuximab. Three-year disease-free survival for mFOLFOX6 alone was 74.6% vs 71.5% with the addition of cetuximab (HR, 1.21; 95% CI, 0.98-1.49; P=.08) in patients with wild-type KRAS, and 67.1% vs 65.0% (HR, 1.12; 95% CI, 0.86-1.46; P=.38) in patients with mutated KRAS, with no significant benefit in any subgroups assessed. Among all patients, grade 3 or higher adverse events (72.5% vs 52.3%; odds ratio [OR], 2.4; 95% CI, 2.1-2.8; P<.001) and failure to complete 12 cycles (33% vs 23%; OR, 1.6; 95% CI, 1.4-1.9; P<.001) were significantly higher with cetuximab. Increased toxicity and greater detrimental differences in all outcomes were observed in patients aged 70 years or older. Conclusion Among patients with stage III resected colon cancer, the use of cetuximab with adjuvant mFOLFOX6 compared with mFOLFOX6 alone did not result in improved disease-free survival.	[Alberts, Steven R.; Sinicrope, Frank A.; Grothey, Axel] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA; [Sargent, Daniel J.; Mooney, Margaret] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Nair, Suresh] Lehigh Valley Hosp, Allentown, PA USA; [Mooney, Margaret] NCI, Clin Invest Branch, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA; [Chan, Emily] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Gill, Sharlene] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; [Kahlenberg, Morton S.] Surg Oncol Associates S Texas, San Antonio, TX USA; [Shields, Anthony F.] Karmanos Canc Inst, Detroit, MI USA; [Quesenberry, James T.] Siouxland Hematol Oncol Associates, Sioux City, IA USA; [Webb, Thomas A.] Illinois Oncol Res Assoc, Community Clin Oncol Program, Peoria, IL USA; [Farr, Gist H., Jr.] Ochsner Community Clin Oncol Program, New Orleans, LA USA; [Goldberg, Richard M.] Ohio State Univ, Columbus, OH 43210 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Lehigh Valley Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; British Columbia Cancer Agency; Barbara Ann Karmanos Cancer Institute; Ochsner Health System; University System of Ohio; Ohio State University	Alberts, SR (corresponding author), Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.		Gill, Sharlene/U-7155-2019; Goldberg, Richard/O-1871-2017; Goldberg, Richard M/M-1311-2013	Goldberg, Richard/0000-0003-3713-6895; Sargent, Daniel/0000-0002-2684-4741	National Cancer Institute, Department of Health and Human Services [CA-25224, CA-37404, CA-35103, CA-35113, CA-35272, CA-114740, CA-32102, CA-14028, CA49957, CA21115, CA31946, CA12027, CA37377]; Bristol-Myers Squibb; ImClone; sanofi-aventis; Pfizer; sanofi-aventis by the North Central Cancer Treatment Group (NCCTG); Merck Serono; Eastern Cooperative Oncology Group; National Comprehensive Cancer Network; Genentech; Southwest Oncology Group; NATIONAL CANCER INSTITUTE [U10CA021115, U10CA035272, U10CA012027, U10CA014028, U10CA035103, U24CA114740, U10CA032102, U10CA035113, U10CA049957, U10CA037377, U10CA031946, U10CA037404, U10CA180835, U10CA025224] Funding Source: NIH RePORTER	National Cancer Institute, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bristol-Myers Squibb(Bristol-Myers Squibb); ImClone; sanofi-aventis(Sanofi-Aventis); Pfizer(Pfizer); sanofi-aventis by the North Central Cancer Treatment Group (NCCTG); Merck Serono(Merck & Company); Eastern Cooperative Oncology Group; National Comprehensive Cancer Network; Genentech(Roche HoldingGenentech); Southwest Oncology Group; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Alberts reported receiving grants from Pfizer, Bristol-Myers Squibb, and sanofi-aventis by the North Central Cancer Treatment Group (NCCTG) for support of the conduct of this trial. Dr Sargent reported receiving grants from Pfizer, Bristol-Myers Squibb, and sanofi-aventis for support to NCCTG for conduct of this trial. Dr Nair reported receiving support for travel to meetings from National Cancer Institute Cooperative Group. Dr Sinicrope reported receiving consultancy fees from Merck Serono, receiving grants from the National Institutes of Health, payment for lectures including service on service bureaus from the University of Kansas, and travel meeting expenses from the American Society of Clinical Oncology. Dr Chan reported receiving a grant from the Eastern Cooperative Oncology Group; being a board member of Colorectal Cancer Index and Reviews and HCPLive.com Oncology Advisory Board; being a consultant on advisory boards of Amgen, ImClone, Bristol-Myers Squibb, Genentech, Pfizer, and Celgene; receiving grants and travel meeting expenses from National Comprehensive Cancer Network; receiving travel meeting expenses from Chemotherapy Foundation; and being an institutional investigator in numerous clinical trials involving multiple pharmaceutical companies. Dr Gill reported receiving payment for lectures including service on speakers bureaus from Bristol-Myers Squibb. Dr Kahlenberg reported receiving payment for lectures including service on speakers bureaus from Genentech. Dr Shields reported receiving grant and support for travel to meetings for the study from Southwest Oncology Group. Dr Grothey reported receiving grants and consultancy fees from sanofi-aventis. No other authors provided any financial disclosures.; This trial was conducted as a collaborative trial of the North Central Cancer Treatment Group (NCCTG), Mayo Clinic, and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-35103, CA-35113, CA-35272, CA-114740, CA-32102, CA-14028, CA49957, CA21115, CA31946, CA12027, CA37377 from the National Cancer Institute, Department of Health and Human Services. Bristol-Myers Squibb, ImClone, sanofi-aventis, and Pfizer provided unrestricted support to NCCTG for conduct of trial. Bristol-Myers Squibb provided cetuximab to NCCTG.	Adams RA, 2009, BRIT J CANCER, V100, P251, DOI 10.1038/sj.bjc.6604877; Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Cancer Therapy Evaluation Program, 2003, CANC THER EV PROGR C; COX DR, 1972, J R STAT SOC B, V34, P187; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iiizumi M, 2008, BBA-REV CANCER, V1786, P87, DOI 10.1016/j.bbcan.2008.07.002; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kruser TJ, 2010, EXP CELL RES, V316, P1083, DOI 10.1016/j.yexcr.2010.01.009; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; Natalwala A, 2008, WORLD J GASTROENTERO, V14, P3792, DOI 10.3748/wjg.14.3792; National Cancer Institute, MAN PART CLIN TRIALS; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; R DEVELOPMENT CORE TEAM, 2011, R LANG ENV STAT COMP; Riethdorf S, 2008, INT J CANCER, V123, P1991, DOI 10.1002/ijc.23825; Saltz LB, 2007, J CLIN ONCOL, V25, P3456, DOI 10.1200/JCO.2007.11.2144; Shin SY, 2010, CANCER RES, V70, P6715, DOI 10.1158/0008-5472.CAN-10-1377; Tveit K, 2010, ANN ONCOL, V21, P9; Van Cutsem E, 2009, J CLIN ONCOL, V27, P3117, DOI 10.1200/JCO.2008.21.6663; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vincenzi B, 2008, CRIT REV ONCOL HEMAT, V68, P93, DOI 10.1016/j.critrevonc.2008.07.006; Ychou M, 2009, ANN ONCOL, V20, P674, DOI 10.1093/annonc/mdn680	33	370	377	1	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2012	307	13					1383	1393		10.1001/jama.2012.385	http://dx.doi.org/10.1001/jama.2012.385			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	919AY	22474202	Green Accepted			2023-01-03	WOS:000302294200025
J	Ledwaba, L; Tavel, JA; Khabo, P; Maja, P; Qin, J; Sangweni, P; Liu, X; Follmann, D; Metcalf, JA; Orsega, S; Baseler, B; Neaton, JD; Lane, HC				Ledwaba, Lotty; Tavel, Jorge A.; Khabo, Paul; Maja, Patrick; Qin, Jing; Sangweni, Phumele; Liu, Xiao; Follmann, Dean; Metcalf, Julia A.; Orsega, Susan; Baseler, Beth; Neaton, James D.; Lane, H. Clifford		Project Phidisa Biomarkers Team	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; EARLY MORTALITY; AIDS; ADULTS; ERA; POPULATION; ACTIVATION; PROGNOSIS; SURVIVAL; TIME	Background: Levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer predict mortality in HIV patients on antiretroviral therapy (ART) with relatively preserved CD4+ T cell counts. We hypothesized that elevated pre-ART levels of these markers among patients with advanced HIV would be associated with an increased risk of death following the initiation of ART. Methods: Pre-ART plasma from patients with advanced HIV in South Africa was used to measure hsCRP, IL-6 and D-dimer. Using a nested case-control study design, the biomarkers were measured for 187 deaths and two controls matched on age, sex, clinical site, follow-up time and CD4+ cell counts. Odds ratios were estimated using conditional logistic regression. In addition, for a random sample of 100 patients, biomarkers were measured at baseline and 6 months following randomization to determine whether ART altered their levels. Results: Median baseline biomarkers levels for cases and controls, respectively, were 11.25 vs. 3.6 mg/L for hsCRP, 1.41 vs. 0.98 mg/L for D-dimer, and 9.02 vs. 4.20 pg/mL for IL-6 (all p<0.0001). Adjusted odds ratios for the highest versus lowest quartile of baseline biomarker levels were 3.5 (95% CI: 1.9-6.7) for hsCRP, 2.6 (95% CI 1.4-4.9) for D-dimer, and 3.8 (95% CI: 1.87.8) for IL-6. These associations were stronger for deaths that occurred more proximal to the biomarker measurements. Levels of D-dimer and IL-6, but not hsCRP, were significantly lower at month 6 after commencing ART compared to baseline (p<0.0001). Conclusions: Among patients with advanced HIV disease, elevated pre-ART levels of hsCRP, IL-6 and D-dimer are strongly associated with early mortality after commencing ART. Elevated levels of inflammatory and coagulation biomarkers may identify patients who may benefit from aggressive clinical monitoring after commencing ART. Further investigation of strategies to reduce biomarkers of inflammation and coagulation in patients with advanced HIV disease is warranted.	[Ledwaba, Lotty; Khabo, Paul; Maja, Patrick; Sangweni, Phumele] Project Phidisa, Pretoria, South Africa; [Tavel, Jorge A.; Qin, Jing; Liu, Xiao; Follmann, Dean; Metcalf, Julia A.; Orsega, Susan; Lane, H. Clifford] NIH, Bethesda, MD 20892 USA; [Baseler, Beth] Frederick Inc, Sci Applicat Int Corp, Frederick, MD USA; [Neaton, James D.] Univ Minnesota, Minneapolis, MN USA	National Institutes of Health (NIH) - USA; Science Applications International Corporation (SAIC); University of Minnesota System; University of Minnesota Twin Cities	Ledwaba, L (corresponding author), Project Phidisa, Pretoria, South Africa.	lledwaba@phidisa.org	Emery, Sean/J-3825-2017; Emery, Sean/O-9122-2019	Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309	South African National Defence Force; United States National Institutes of Health; United States Department of Defense; SAIC-Frederick, Inc.; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000585] Funding Source: NIH RePORTER	South African National Defence Force; United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Department of Defense(United States Department of Defense); SAIC-Frederick, Inc.; National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding for the Phidisa Project, the Phidisa I and II studies, and this substudy were provided by the South African National Defence Force, the United States National Institutes of Health and the United States Department of Defense. SAIC-Frederick, Inc. helped fund the study through the employment of Beth Basseler and Xiao Liu who contributed to the study. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Clifford DB, 1999, NEUROLOGY, V52, P623, DOI 10.1212/WNL.52.3.623; Cohen HJ, 2003, AM J MED, V114, P180, DOI 10.1016/S0002-9343(02)01484-5; Correll PK, 1998, MED J AUSTRALIA, V169, P469, DOI 10.5694/j.1326-5377.1998.tb123370.x; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; Jong E, 2010, THROMB HAEMOSTASIS, V104, P1228, DOI 10.1160/TH10-04-0233; Kuller LH, 2008, PLOS MED, V5, P1496, DOI 10.1371/journal.pmed.0050203; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lehohla PJ, 2009, MIDYEAR POPULATION E; Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217; Michaels SH, 1998, NEW ENGL J MED, V339, P405, DOI 10.1056/NEJM199808063390612; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Morcroft A, 2009, P C RETR COINF SAN F; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Neuhaus J, 2010, AIDS, V24, P697, DOI 10.1097/QAD.0b013e3283365356; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Pezzotti P, 1999, AIDS; Phillips AN, 2008, AIDS, V22, P2409, DOI 10.1097/QAD.0b013e3283174636; Ratsela A, 2010, J INFECT DIS, V202, P1529, DOI 10.1086/656718; Sendi PP, 1999, J ACQ IMMUN DEF SYND, V20, P376, DOI 10.1097/00042560-199904010-00008; Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262; Spira R, 1998, J ACQ IMMUN DEF SYND, V18, P358, DOI 10.1097/00042560-199808010-00007; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Walsh JC, 1998, AIDS, V12, P613, DOI 10.1097/00002030-199806000-00010; World Health Organization, UN ACC 2010	32	71	71	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2012	7	3							e24243	10.1371/journal.pone.0024243	http://dx.doi.org/10.1371/journal.pone.0024243			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	939YB	22448211	Green Published, Green Submitted, gold			2023-01-03	WOS:000303855700001
J	Moserova, I; Kralova, J				Moserova, Irena; Kralova, Jarmila			Role of ER Stress Response in Photodynamic Therapy: ROS Generated in Different Subcellular Compartments Trigger Diverse Cell Death Pathways	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; ACTIVATED PROTEIN-KINASE; INDUCED APOPTOSIS; GENE-EXPRESSION; MOLECULAR EFFECTORS; TERMINAL KINASE; CARCINOMA-CELLS; SINGLET OXYGEN; CANCER-CELLS; FREE CALCIUM	We have analyzed the molecular mechanisms of photoinduced cell death using porphyrins with similar structure differing only in the position of the ethylene glycol (EG) chain on the phenyl ring. Meta-and para-positioned EG chains targeted porphyrins to different subcellular compartments. After photoactivation, both types of derivatives induced death of tumor cells via reactive oxygen species (ROS). Para derivatives pTPP(EG) 4 and pTPPF(EG) 4 primarily accumulated in lysosomes activated the p38 MAP kinase cascade, which in turn induced the mitochondrial apoptotic pathway. In contrast, meta porphyrin derivative mTPP(EG) 4 localized in the endoplasmic reticulum (ER) induced dramatic changes in Ca2+ homeostasis manifested by Ca2+ rise in the cytoplasm, activation of calpains and stress caspase-12 or caspase-4. ER stress developed into unfolded protein response. Immediately after irradiation the PERK pathway was activated through phosphorylation of PERK, eIF2 alpha and induction of transcription factors ATF4 and CHOP, which regulate stress response genes. PERK knockdown and PERK deficiency protected cells against mTPP(EG) 4-mediated apoptosis, confirming the causative role of the PERK pathway.	[Moserova, Irena; Kralova, Jarmila] Acad Sci Czech Republ, Dept Mol Virol, Inst Mol Genet, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Moserova, I (corresponding author), Acad Sci Czech Republ, Dept Mol Virol, Inst Mol Genet, Prague, Czech Republic.	kralova@img.cas.cz	Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	Ministry of Education of the Czech Republic [LC06077]; Grant Agency of the Czech Republic [203/09/1311, P303/11/1291]; Grant Agency of the Academy of Sciences of the Czech Republic [AV0Z50520514]	Ministry of Education of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Grant Agency of the Academy of Sciences of the Czech Republic(Czech Academy of SciencesGrant Agency of the Czech Republic)	This work was supported by grants from the Ministry of Education of the Czech Republic (LC06077), by the Grant Agency of the Czech Republic (grant 203/09/1311, P303/11/1291) and Project AV0Z50520514 awarded by the Grant Agency of the Academy of Sciences of the Czech Republic. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida RD, 2004, CANCER LETT, V216, P183, DOI 10.1016/j.canlet.2004.07.006; Almeida RD, 2004, BBA-REV CANCER, V1704, P59, DOI 10.1016/j.bbcan.2004.05.003; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Buytaert E, 2008, ONCOGENE, V27, P1916, DOI 10.1038/sj.onc.1210825; Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001; Buytaert E, 2006, FASEB J, V20, P756, DOI 10.1096/fj.05-4305fje; Ding XM, 2004, CANCER LETT, V216, P43, DOI 10.1016/j.canlet.2004.07.005; Diwakarla S, 2009, CELL MOL LIFE SCI, V66, P156, DOI 10.1007/s00018-008-8490-7; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Gomez-Vicente V, 2005, CELL DEATH DIFFER, V12, P796, DOI 10.1038/sj.cdd.4401621; Granville DJ, 2001, CELL CALCIUM, V30, P343, DOI 10.1054/ceca.2001.0243; Grebenova D, 2003, J PHOTOCH PHOTOBIO B, V69, P71, DOI 10.1016/S1011-1344(02)00410-4; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; HERMESLIMA M, 1995, FREE RADICAL BIO MED, V19, P381, DOI 10.1016/0891-5849(95)00015-P; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hubmer A, 1996, PHOTOCHEM PHOTOBIOL, V64, P211, DOI 10.1111/j.1751-1097.1996.tb02444.x; Ichinose S, 2006, INT J ONCOL, V29, P349; Inanami O, 1999, PHOTOCHEM PHOTOBIOL, V70, P650, DOI 10.1562/0031-8655(1999)070<0650:EOBAAF>2.3.CO;2; Karmakar S, 2007, NEUROSCI LETT, V415, P242, DOI 10.1016/j.neulet.2007.01.071; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaul A, 2009, NEOPLASIA, V11, P823, DOI 10.1593/neo.09388; Kessel D, 2005, CELL DEATH DIFFER, V12, P502, DOI 10.1038/sj.cdd.4401579; Kessel D, 2005, PHOTOCHEM PHOTOBIOL, V81, P569, DOI 10.1562/2004-12-16-RA-403.1; Kessel D, 2002, PHOTOCH PHOTOBIO SCI, V1, P837, DOI 10.1039/b206046a; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; Koon HK, 2010, CELL BIOCHEM FUNCT, V28, P239, DOI 10.1002/cbf.1650; Kralova J, 2008, ONCOGENE, V27, P3010, DOI 10.1038/sj.onc.1210960; Kralova J, 2003, J MED CHEM, V46, P2049, DOI 10.1021/jm021060d; Kralova J, 2008, J MED CHEM, V51, P5964, DOI 10.1021/jm8002119; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lee SY, 2008, CELL MICROBIOL, V10, P770, DOI 10.1111/j.1462-5822.2007.01083.x; Liao PC, 2008, J CELL BIOCHEM, V104, P1509, DOI 10.1002/jcb.21730; Lien YC, 2008, HISTOL HISTOPATHOL, V23, P1299, DOI 10.14670/HH-23.1299; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003; Mak NK, 2004, BIOCHEM PHARMACOL, V68, P2387, DOI 10.1016/j.bcp.2004.08.024; Marchal S, 2007, BRIT J CANCER, V96, P944, DOI 10.1038/sj.bjc.6603631; Matsuzaki S, 2010, NEUROCHEM INT, V56, P352, DOI 10.1016/j.neuint.2009.11.007; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Norberg E, 2008, CELL DEATH DIFFER, V15, P1857, DOI 10.1038/cdd.2008.123; O'Connor AE, 2012, INT J CANCER, V130, P705, DOI 10.1002/ijc.26073; Ogata M, 2003, PHOTOCHEM PHOTOBIOL, V78, P241, DOI 10.1562/0031-8655(2003)078<0241:CACACB>2.0.CO;2; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; Price M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1177, DOI 10.1111/j.1751-1097.2009.00555.x; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SAMIS JA, 1991, BIOCHEM J, V276, P293, DOI 10.1042/bj2760293; Sanovic R, 2009, INT J ONCOL, V35, P921, DOI 10.3892/ijo_00000407; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Shahzidi S, 2011, PHOTOCH PHOTOBIO SCI, V10, P1773, DOI 10.1039/c1pp05169e; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tong ZM, 2003, J PHOTOCH PHOTOBIO B, V71, P77, DOI 10.1016/j.jphotobiol.2003.08.001; Usuda J, 2003, PHOTOCHEM PHOTOBIOL, V78, P1, DOI 10.1562/0031-8655(2003)078<0001:ABTPLO>2.0.CO;2; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vittar NBR, 2010, INT J BIOCHEM CELL B, V42, P1123, DOI 10.1016/j.biocel.2010.03.019; Weyergang A, 2008, MOL CANCER THER, V7, P1740, DOI 10.1158/1535-7163.MCT-08-0020; Wong S, 2004, LASER SURG MED, V35, P336, DOI 10.1002/lsm.20110; Wu RWK, 2011, PHOTODIAGN PHOTODYN, V8, P254, DOI 10.1016/j.pdpdt.2010.12.002; Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Yoo JO, 2011, J CELL BIOCHEM, V112, P3061, DOI 10.1002/jcb.23231; Zhivotovsky B, 2011, CELL CALCIUM, V50, P211, DOI 10.1016/j.ceca.2011.03.003; Zhou ZX, 2003, BBA-MOL CELL RES, V1593, P191, DOI 10.1016/S0167-4889(02)00386-5; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	70	72	72	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2012	7	3							e32972	10.1371/journal.pone.0032972	http://dx.doi.org/10.1371/journal.pone.0032972			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928WA	22403731	Green Published, Green Submitted, gold			2023-01-03	WOS:000303017700128
J	Cao, HJ; Li, X; Liu, JP				Cao, Huijuan; Li, Xun; Liu, Jianping			An Updated Review of the Efficacy of Cupping Therapy	PLOS ONE			English	Review							BACK	Background: Since 1950, traditional Chinese medicine (TCM) cupping therapy has been applied as a formal modality in hospitals throughout China and elsewhere in the world. Based on a previous systematic literature review of clinical studies on cupping therapy, this study presents a thorough review of randomized controlled trials (RCTs) to evaluate the therapeutic effect of cupping therapy. Method: Six databases were searched for articles published through 2010. RCTs on cupping therapy for various diseases were included. Studies on cupping therapy combined with other TCM treatments versus non-TCM therapies were excluded. Results: 135 RCTs published from 1992 through 2010 were identified. The studies were generally of low methodological quality. Diseases for which cupping therapy was commonly applied were herpes zoster, facial paralysis (Bell palsy), cough and dyspnea, acne, lumbar disc herniation, and cervical spondylosis. Wet cupping was used in most trials, followed by retained cupping, moving cupping, and flash cupping. Meta-analysis showed cupping therapy combined with other TCM treatments was significantly superior to other treatments alone in increasing the number of cured patients with herpes zoster, facial paralysis, acne, and cervical spondylosis. No serious adverse effects were reported in the trials. Conclusions: Numerous RCTs on cupping therapy have been conducted and published during the past decades. This review showed that cupping has potential effect in the treatment of herpes zoster and other specific conditions. However, further rigorously designed trials on its use for other conditions are warranted.	[Cao, Huijuan] Univ Western Sydney, Ctr Complementary Med Res, Penrith, NSW 1797, Australia; [Cao, Huijuan; Li, Xun; Liu, Jianping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China	Western Sydney University; Beijing University of Chinese Medicine	Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	Jianping_l@hotmail.com		Liu, Jianping/0000-0002-0320-061X; Li, Xun/0000-0002-3513-5904	international cooperation project [2009DFA31460]; 111 Project from China [B08006]; National Center for Complementary and Alternative Medicine (NCCAM) of the US National Institutes of Health [R24 AT001293]; National Center for Complementary & Integrative Health [R24AT001293] Funding Source: NIH RePORTER	international cooperation project; 111 Project from China(Ministry of Education, China - 111 Project); National Center for Complementary and Alternative Medicine (NCCAM) of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Huijuan Cao and Jianping Liu were supported by the grant of international cooperation project (No. 2009DFA31460) and the 111 Project (B08006) from China. Jianping Liu was in part supported by the Grant Number R24 AT001293 from the National Center for Complementary and Alternative Medicine (NCCAM) of the US National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], CHIN GEN PRACT; [Anonymous], LIAONING J TRADIT CH; [Anonymous], TIANJIN PHARM; [Anonymous], COCHRANE HDB SYSTEMA; [Anonymous], J EXTERN THER TRADIT; [Anonymous], 1999, TRADITIONAL CHINESE; [Anonymous], J CLIN ACUPUNCT MOXI, DOI DOI 10.3969/J.ISSN.1005-0779.2006.08.028; [Anonymous], 2004, PRACTICAL CUPPING TH; [Anonymous], 2007, J ACUPUNCT MOXIBUST; [Anonymous], J MED THEORY PRACT; [Anonymous], SHANXI J TRADIT CHIN; [Anonymous], SHANGHAI J ACUPUNCT; Bu Tong-wen, 2007, Zhongguo Zhen Jiu, V27, P337; Cao HJ, 2010, ALTERN THER HEALTH M, V16, P48; Cao HJ, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-70; Cao RL, 2009, SHANXI J TRADITIONAL, V30, P74; Chen J, 1993, CHINESE J DERMATOVEN, V5, P252; Chen JJ, 2009, JCAM, V25, P27; Chen LA, 2010, JIANGXI J TRADITIONA, V41, P62; Chen MX, 2000, THESIS CHENGDU U TRA; Chen YL, 2008, JIANGSU J TRADIT CHI, V40, P47; Cheng G, 2000, J CLIN ACUPUNCTURE M, V6, P33; Chi FL, 1987, CHINESE PRIMARY HLTH, V1, P24; Ci HF, 2010, MODERN MED HLTH, V26, P1550; *CONSORT GROUP, CONSORT STAT 2001 CH; Dai JY, 2006, SHANGHAI J ACUPUNCTU, V25, P13; Fang X, 2006, MODERN J INTEGRATED, V15, P734; Farhadi K, 2009, COMPLEMENT THER MED, V17, P9, DOI 10.1016/j.ctim.2008.05.003; Feng WM, 2004, CHINESE J TRADITIONA, V11, P180; Fu CA, 2004, J YANAN U MED SCI, V2, P59; Fu L, 2009, SHANGHAI J ACUPUNCTU, V28, P132; Fu Y, 2005, THESIS TIANJIN U TRA; Gao BB, 2010, CHINA J GUANG MING C, V25, P1244; Gao YJ, 2009, J EXTERNAL THERAPY T, V18, P34; Ge JJ, 2003, CHINESE J PRACTICAL, V3, P823; Guo JM, 1997, SHANDONG J TRADITION, V16, P74; Guo XL, 1992, ZHEN JIU XUE BAO, P34; Han LX, 1998, TIANJIN J TRADITIONA, V15, P122; [洪永锋 HONG Yongfeng], 2006, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V21, P340; Huang GQ, 2004, CHINESE J CURRENT CL, V2, P1680; Huang J, 2010, CHINA BIOBEAUTY, V1, P19; Huang J, 2008, J LIAONING U TRADITI, V10, P168; Huang LP, 2010, SHANXI J TRADITIONAL, V31, P473; Huang LP, 2009, SHANXI J TRADITIONAL, V30, P597; Huang Z-F, 2006, SHANGHAI J ACUPUNTUR, V25, P14; Ji J, 1992, CHINESE ACUPUNCTURE, V12, P11; Jiang H, 2006, J NURSING SCI, V21, P48; Jiang XY, 2008, J NURS SCI, V23, P37; Kang HQ, 2005, J EMERGENCY TRADITIO, V14, P51; Kim JI, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep035; Kwon Young Dal, 2007, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V21, P789; Laine C, 2007, NEW ENGL J MED, V356, P2734, DOI 10.1056/NEJMe078110; Lee MS, 2011, J ACUPUNCT MERIDIAN, V4, P1, DOI 10.1016/S2005-2901(11)60001-0; Lee MS, 2010, ACUPUNCT MED, V28, P200, DOI 10.1136/aim.2010.002329; Lee MS, 2010, CLIN EXP HYPERTENS, V32, P423, DOI 10.3109/10641961003667955; Lee MS, 2010, J NEUROL SCI, V294, P70, DOI 10.1016/j.jns.2010.03.033; Li HT, 2005, J CHINESE INTEGRATED, V3, P69; Li Huang-Tong, 2005, Zhong Xi Yi Jie He Xue Bao, V3, P69; Li JC, 2008, SHANGHAI J ACUPUNCTU, V27, P8; Li KZ, 2009, J QIQIHAR MED COLL, V30, P3091; Li P, 2010, J SHANXI COLL TRADIT, V33, P83; Li Wei-Hong, 2005, Zhongguo Zhen Jiu, V25, P765; Li X, 2006, PRACTICAL NEW MED, V7, P702; Liang SY, 2009, FUJIAN J TRADITIONAL, V40, P28; Liang YL, 2009, NURSING PRACTICE RES, V6, P79; Liao FR, 2009, SHANGHAI J ACUPUNCTU, V28, P399; Lin SZ, 2005, TRADITIONAL CHINESE, V18, P47; Liu BX, 2008, CHINESE J REHABILITA, V14, P572; Liu BX, 2010, J ZHEJIANG U TRADITI, V34, P409; Liu H., 2009, LIAONING J TRAD CHIN, V36, P1395; Liu J, 2005, CHINESE J CLIN REHAB, V9, P135; Liu L, 2003, CHINESE J PRACTICAL, V3, P1088; Liu L, 2006, J HEBEI TRADITIONAL, V21, P30; Liu YZ, 2009, CHINA FOREIGN MED TR, V2, P113; Lu HM, 2009, J PRACTICAL TRADITIO, V25, P320; Lu J, 2007, J CLIN ACUPUNCTURE M, V23, P16; Lu JC, 2010, CHINA HIGHER MED ED, V10, P136; Lu ZX, 2009, J ZHEJIANG COLL TRAD, V33, P862; Ludtke R, 2006, COMPLEMENT THER MED, V14, P247, DOI 10.1016/j.ctim.2006.07.004; Luo XX, 2010, CHINESE J INFORM TCM, V17, P75; Ma CT, 2006, THESIS BEIJING U CHI; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; Michalsen A, 2009, J PAIN, V10, P601, DOI 10.1016/j.jpain.2008.12.013; Ni ML, 2010, HEILONGJIANG MED J, V23, P453; Ou XH, 2009, J CHENGDU U TRADITIO, V32, P37; Qiu JZ, 2003, CHINA J MODERN MED, V13, P146; Ren YJ, 2006, SHANXI J TRADITIONAL, V27, P480; Rui XG, 2010, SHANGHAI J ACUPUNCTU, V29, P515; Shao M, 2003, SHANGHAI J ACUPUNCTU, V22, P20; Sun HW, 2010, CHINA J GUANG MING C, V25, P1674; Sun LJ, 2007, CHINA PRACTICAL MED, V2, P138; Sun SY, 2006, J THORAC ONCOL, V1, P109, DOI 10.1097/01243894-200602000-00002; Tang CR, 2003, SICHUAN J TRADITIONA, V21, P89; Tao Q, 2007, J CLIN ACUPUNCTURE M, V23, P46; Viergever RF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014701; Wan Xue-wen, 2005, Zhongguo Zhen Jiu, V25, P551; Wan XW, 2007, J ACUPUNCTURE TUINA, V5, P345, DOI DOI 10.1007/S11726-007-0345-5; Wang J, 2010, CHINA SCI TECHNOLOGY, V15, P176; Wang L, 2010, CHINESE GEN NURSING, V8, P2574; Wang LR, 2010, SICHUAN J TRADITIONA, V8, P110; Wang PL, 2010, CLIN J CHINESE MED, V9, P15; Wang Q., 2007, SHANGHAI J ACUPUNCT, V26, P20; Wang SP, 2009, GUIDING J TRADITIONA, V15, P56; Wang XM, 2004, SHANXI J TRADITIONAL, V25, P60; Wu FF, 2010, J QIQIHAR MED COLL, V31, P1596; Wu PX, 2010, GUIDING J TRADITIONA, V16, P79; Wu Y., 2008, J PRACTICAL TRADITIO, V22, P61; Xiao W, 2010, J ANHUI COLL TRADITI, V29, P37; Xiao W, 2009, CHINESE J TRADITIONA, V21, P420; Xin KP, 2006, JIANGXI J TRADITIONA, V37, P53; Xiong JF, 2010, J EXTERNAL THERAPY T, V19, P28; Xiong SY, 2007, J NURSES TRAINING, V22, P948; Xu M, 2009, LIAONING J TRADITION, V36, P1007; Xu MY, 2006, LIAONING J TRADITION, V33, P719; Xu SW, 2008, SHANGHAI J ACUPUNCTU, V27, P11; Xu SX, 1999, CHINESE J DERMATONEU, V21, P21; Xu Y, 2010, CLIN J CHINESE MED, V10, P70; Xue WH, 2005, LIAONING J TRADITION, V32, P826; Yang JH, 2007, GUIDING J TRADITIONA, V13, P57; Yao X, 2006, JILIN MED J, V27, P1403; Yin GZ, 2009, XINJIANG CHIN MED, V27, P13; You Y, 2006, CHINESE J REHABILITA, V12, P1037; You Y, 2006, CHINESE J CONVALESCE, V15, P14; Zeng HW, 2007, SHANGHAI J ACUPUNCTU, V26, P8; Zha BG, 2005, HUNAN J TRADITIONAL, V21, P81; Zhang DD, 2009, JILIN J TRADITIONAL, V29, P796; Zhang FY, 2006, J EXTERNAL THERAPY T, V15, P42; Zhang HB, 2010, SHANXI J TRADITIONAL, V26, P28; Zhang HX., 2009, J EMERG TRADIT CHIN, V18, P1979; Zhang JX, 2007, CHINESE MAGAZINE CLI, V13, P3444; Zhang KX, 2008, WORLD HLTH DIGEST, V5, P193; Zhang QL, 2009, ACTA CHINESE MED PHA, V37, P79; Zhang XY, 2009, J CHINESE ACUPUNCTUR, V25, P45; Zhang YB, 2010, GUANGXI J TRADITIONA, V33, P17; Zhang YC, 2004, J QILU NURSING, V10, P28; Zhang YD, 2005, J EXTERNAL THERAPY T, V14, P40; Zhao J, 2010, SHANXI J TRADITIONAL, V26, P34; Zhao NX, 2010, J GUIYANG COLL TRADI, V32, P72; [赵兴全 Zhao Xingquan], 2003, [中国针灸, Chinese Acupuncture and Moxibustion], V23, P75; Zhao YS, 2010, CHINA MODERN MED, V17, P19; Zheng L., 2008, CHINESE J TRADITIONA, V16, P27; Zheng ZH, 1999, HEBEI J TRADITIONAL, V14, P29; Zhou LW, 2007, CLIN J TRADITIONAL C, V19, P170; Zhou Y, 2010, J GUIYANG COLL TRADI, V32, P54; Zhou YM, 1994, CHINESE ACUPUNCTURE, V14, P292; Zhu F, 2009, J EMERGENCY TRADITIO, V18, P702; Zhu Y, 2010, SHANXI J TRADITIONAL, V31, P476; Zhu Y, 2009, CHINESE MED MODERN D, V7, P97; Zou LY, 2009, HENAN TRADITIONAL CH, V29, P802; Zou R, 2010, CHINESE J REHABILITA, V25, P205; 王映辉, 2009, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V15, P774	151	98	101	2	81	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2012	7	2							e31793	10.1371/journal.pone.0031793	http://dx.doi.org/10.1371/journal.pone.0031793			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928RC	22389674	Green Published, Green Submitted, gold			2023-01-03	WOS:000302999600011
J	Li, YY; Lenaghan, SC; Zhang, MJ				Li, YuanYuan; Lenaghan, Scott C.; Zhang, Mingjun			A Data-Driven Predictive Approach for Drug Delivery Using Machine Learning Techniques	PLOS ONE			English	Article							GIARDIA-LAMBLIA; IN-VITRO; RESISTANT TUBERCULOSIS; METRONIDAZOLE; BENZIMIDAZOLES; INTESTINALIS; ALBENDAZOLE; TINIDAZOLE; INVITRO	In drug delivery, there is often a trade-off between effective killing of the pathogen, and harmful side effects associated with the treatment. Due to the difficulty in testing every dosing scenario experimentally, a computational approach will be helpful to assist with the prediction of effective drug delivery methods. In this paper, we have developed a data-driven predictive system, using machine learning techniques, to determine, in silico, the effectiveness of drug dosing. The system framework is scalable, autonomous, robust, and has the ability to predict the effectiveness of the current drug treatment and the subsequent drug-pathogen dynamics. The system consists of a dynamic model incorporating both the drug concentration and pathogen population into distinct states. These states are then analyzed using a temporal model to describe the drug-cell interactions over time. The dynamic drug-cell interactions are learned in an adaptive fashion and used to make sequential predictions on the effectiveness of the dosing strategy. Incorporated into the system is the ability to adjust the sensitivity and specificity of the learned models based on a threshold level determined by the operator for the specific application. As a proof-of-concept, the system was validated experimentally using the pathogen Giardia lamblia and the drug metronidazole in vitro.	[Li, YuanYuan; Lenaghan, Scott C.; Zhang, Mingjun] Univ Tennessee, Mech Aerosp & Biomed Engn Dept, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville	Li, YY (corresponding author), Univ Tennessee, Mech Aerosp & Biomed Engn Dept, Knoxville, TN 37996 USA.	mjzhang@utk.edu		Lenaghan, Scott/0000-0002-7539-1726				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; Belhassen S, 2010, MED PHYS, V37, P1309, DOI 10.1118/1.3301610; Bezdek J, ADV APPL PATTERN REC; Blaas SH, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-60; BOREHAM PFL, 1988, T ROY SOC TROP MED H, V82, P104, DOI 10.1016/0035-9203(88)90278-7; Cedillo-Rivera R, 2002, J EUKARYOT MICROBIOL, V49, P201, DOI 10.1111/j.1550-7408.2002.tb00523.x; CEDILLORIVERA R, 1992, J MED MICROBIOL, V37, P221, DOI 10.1099/00222615-37-3-221; Citron DM, 2005, ANAEROBE, V11, P315, DOI 10.1016/j.anaerobe.2005.04.005; Craun GF, 1996, WATERBORNE OUTBREAKS; Dasenbrook EC, 2010, AM J RESP CRIT CARE, V181; Dunn J. C., 1973, Journal of Cybernetics, V3, P32, DOI 10.1080/01969727308546046; EDLIND TD, 1990, J INFECT DIS, V162, P1408, DOI 10.1093/infdis/162.6.1408; Erah PO, 1997, J ANTIMICROB CHEMOTH, V39, P5, DOI 10.1093/jac/39.1.5; Gardner TB, 2001, CLIN MICROBIOL REV, V14, P114, DOI 10.1128/CMR.14.1.114-128.2001; GARDUNOESPINOSA J, 1992, REV INVEST CLIN, V44, P235; Green CE, 2009, AM J DRUG ALCOHOL AB, V35, P95, DOI 10.1080/00952990802647503; Harari O, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000862; Ibrahim KH, 2004, PHARMACODYNAMICS PUL; KATELARIS PH, 1994, ALIMENT PHARM THERAP, V8, P187, DOI 10.1111/j.1365-2036.1994.tb00277.x; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Kempker RR, 2010, J INFECTION, V61, P372, DOI 10.1016/j.jinf.2010.09.021; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Kramer M H, 1996, MMWR CDC Surveill Summ, V45, P1; Locarnini S, 2010, J GASTROEN HEPATOL, V25, P649, DOI 10.1111/j.1440-1746.2010.06255.x; MELONI BP, 1990, T ROY SOC TROP MED H, V84, P375, DOI 10.1016/0035-9203(90)90324-8; Mohamed NA, 1999, INT CONF ACOUST SPEE, P3429, DOI 10.1109/ICASSP.1999.757579; Nelson R, 2010, AM J NURS, V110, P55, DOI 10.1097/01.NAJ.0000389678.80144.cb; Ron D, 1996, MACH LEARN, V25, P117, DOI 10.1007/BF00114008; Saritas I, 2009, J INTELL MANUF, V20, P169, DOI 10.1007/s10845-008-0226-x; Sun JK, 2010, DRUG DELIV, V17, P164, DOI 10.3109/10717541003667764; Tomasetti C, 2010, MATH BIOSCI ENG, V7, P905, DOI 10.3934/mbe.2010.7.905; UPCROFT JA, 1993, PARASITOL TODAY, V9, P187, DOI 10.1016/0169-4758(93)90144-5; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001	33	9	9	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2012	7	2							e31724	10.1371/journal.pone.0031724	http://dx.doi.org/10.1371/journal.pone.0031724			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927NZ	22384063	Green Submitted, Green Published, gold			2023-01-03	WOS:000302916100031
J	Rice, TW; Wheeler, AP; Thompson, BT; Steingrub, J; Hite, RD; Moss, M; Morris, A; Dong, N; Rock, P				Rice, Todd W.; Wheeler, Arthur P.; Thompson, B. Taylor; Steingrub, Jay; Hite, R. Duncan; Moss, Marc; Morris, Alan; Dong, Ning; Rock, Peter		National Heart Lung & Blood Inst A	ONLINE FIRST Initial Trophic vs Full Enteral Feeding in Patients With Acute Lung Injury The EDEN Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL PATIENTS; CLINICAL-PRACTICE GUIDELINES; INTENSIVE-CARE-UNIT; NUTRITION SUPPORT; PARENTERAL-NUTRITION; CALORIC-INTAKE; ADULT PATIENTS; OUTCOMES; MORTALITY	Context The amount of enteral nutrition patients with acute lung injury need is unknown. Objective To determine if initial lower-volume trophic enteral feeding would increase ventilator-free days and decrease gastrointestinal intolerances compared with initial full enteral feeding. Design, Setting, and Participants The EDEN study, a randomized, open-label, multicenter trial conducted from January 2, 2008, through April 12, 2011. Participants were 1000 adults within 48 hours of developing acute lung injury requiring mechanical ventilation whose physicians intended to start enteral nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Interventions Participants were randomized to receive either trophic or full enteral feeding for the first 6 days. After day 6, the care of all patients who were still receiving mechanical ventilation was managed according to the full feeding protocol. Main Outcome Measures Ventilator-free days to study day 28. Results Baseline characteristics were similar between the trophic-feeding (n=508) and full-feeding (n=492) groups. The full-feeding group received more enteral calories for the first 6 days, about 1300 kcal/d compared with 400 kcal/d (P<.001). Initial trophic feeding did not increase the number of ventilator-free days (14.9 [95% CI, 13.9 to 15.8] vs 15.0 [95% CI, 14.1 to 15.9]; difference, -0.1 [95% CI, -1.4 to 1.2]; P=.89) or reduce 60-day mortality (23.2% [95% CI, 19.6% to 26.9%] vs 22.2% [95% CI, 18.5% to 25.8%]; difference, 1.0% [95% CI, -4.1% to 6.3%]; P=.77) compared with full feeding. There were no differences in infectious complications between the groups. Despite receiving more prokinetic agents, the full-feeding group experienced more vomiting (2.2% vs 1.7% of patient feeding days; P=.05), elevated gastric residual volumes (4.9% vs 2.2% of feeding days; P<.001), and constipation (3.1% vs 2.1% of feeding days; P=.003). Mean plasma glucose values and average hourly insulin administration were both higher in the full-feeding group over the first 6 days. Conclusion In patients with acute lung injury, compared with full enteral feeding, a strategy of initial trophic enteral feeding for up to 6 days did not improve ventilator-free days, 60-day mortality, or infectious complications but was associated with less gastrointestinal intolerance.	[Rice, Todd W.; Wheeler, Arthur P.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Thompson, B. Taylor; Dong, Ning] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Steingrub, Jay] Baystate Med Ctr, Springfield, MA USA; [Hite, R. Duncan] Wake Forest Sch Med, Winston Salem, NC USA; [Moss, Marc] Univ Colorado, Sch Med, Denver, CO USA; [Morris, Alan] Univ Utah, Sch Med, Salt Lake City, UT USA; [Rock, Peter] Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Vanderbilt University; Harvard University; Massachusetts General Hospital; Baystate Medical Center; Wake Forest University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah; University System of Maryland; University of Maryland Baltimore	Rice, TW (corresponding author), Vanderbilt Univ Sch Med, T-1218 MCN, Nashville, TN 37232 USA.	todd.rice@vanderbilt.edu	Rice, Todd/X-7853-2019	Rice, Todd/0000-0002-7136-5408	National Heart, Lung, and Blood Institute (NHLBI) [HHSN268200536165C, HHSN268200536179C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056169, R01HL056176] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by National Heart, Lung, and Blood Institute (NHLBI) contracts HHSN268200536165C and HHSN268200536179C.	Arabi YM, 2010, JPEN-PARENTER ENTER, V34, P280, DOI 10.1177/0148607109353439; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burrin DG, 2000, AM J CLIN NUTR, V71, P1603; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Clermont G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022512; Dickerson RN, 2002, NUTRITION, V18, P241, DOI 10.1016/S0899-9007(01)00793-6; Doig GS, 2009, INTENS CARE MED, V35, P2018, DOI 10.1007/s00134-009-1664-4; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; HADFIELD RJ, 1995, AM J RESP CRIT CARE, V152, P1545, DOI 10.1164/ajrccm.152.5.7582291; Hernandez G, 1999, J CRIT CARE, V14, P73, DOI 10.1016/S0883-9441(99)90017-5; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P74, DOI 10.1177/014860710302700174; Heyland DK, 2004, CRIT CARE MED, V32, P2260, DOI 10.1097/01.CCM.0000145581.54571.32; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Krishnan JA, 2003, CHEST, V124, P297, DOI 10.1378/chest.124.1.297; Matthay MA, 2011, AM J RESP CRIT CARE, V184, P561, DOI 10.1164/rccm.201012-2090OC; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; McClure RJ, 2000, ARCH DIS CHILD-FETAL, V82, pF29, DOI 10.1136/fn.82.1.F29; Omura K, 2000, ANN SURG, V231, P112, DOI 10.1097/00000658-200001000-00016; Owens L, 2002, J NUTR, V132, P2717, DOI 10.1093/jn/132.9.2717; Rice TW, 2011, JAMA-J AM MED ASSOC, V306, P1574, DOI 10.1001/jama.2011.1435; Rice TW, 2011, CRIT CARE MED, V39, P967, DOI 10.1097/CCM.0b013e31820a905a; Rice TW, 2005, NUTRITION, V21, P786, DOI 10.1016/j.nut.2004.11.014; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	29	573	606	2	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	2012	307	8					795	803		10.1001/jama.2012.137	http://dx.doi.org/10.1001/jama.2012.137			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	896FQ	22307571	Green Accepted			2023-01-03	WOS:000300551300022
J	Turner, RM; Lloyd-Jones, M; Anumba, DOC; Smith, GCS; Spiegelhalter, DJ; Squires, H; Stevens, JW; Sweeting, MJ; Urbaniak, SJ; Webster, R; Thompson, SG				Turner, Rebecca M.; Lloyd-Jones, Myfanwy; Anumba, Dilly O. C.; Smith, Gordon C. S.; Spiegelhalter, David J.; Squires, Hazel; Stevens, John W.; Sweeting, Michael J.; Urbaniak, Stanislaw J.; Webster, Robert; Thompson, Simon G.			Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality	PLOS ONE			English	Article							RHD HEMOLYTIC-DISEASE; D IMMUNOGLOBULIN; SYSTEMATIC REVIEWS; TRIAL; ISOIMMUNIZATION; PREGNANCY; PROGRAM	Background: To estimate the effectiveness of routine antenatal anti-D prophylaxis for preventing sensitisation in pregnant Rhesus negative women, and to explore whether this depends on the treatment regimen adopted. Methods: Ten studies identified in a previous systematic literature search were included. Potential sources of bias were systematically identified using bias checklists, and their impact and uncertainty were quantified using expert opinion. Study results were adjusted for biases and combined, first in a random-effects meta-analysis and then in a random-effects meta-regression analysis. Results: In a conventional meta-analysis, the pooled odds ratio for sensitisation was estimated as 0.25 (95% CI 0.18, 0.36), comparing routine antenatal anti-D prophylaxis to control, with some heterogeneity (I-2 = 19%). However, this naive analysis ignores substantial differences in study quality and design. After adjusting for these, the pooled odds ratio for sensitisation was estimated as 0.31 (95% CI 0.17, 0.56), with no evidence of heterogeneity (I-2 = 0%). A meta-regression analysis was performed, which used the data available from the ten anti-D prophylaxis studies to inform us about the relative effectiveness of three licensed treatments. This gave an 83% probability that a dose of 1250 IU at 28 and 34 weeks is most effective and a 76% probability that a single dose of 1500 IU at 28-30 weeks is least effective. Conclusion: There is strong evidence for the effectiveness of routine antenatal anti-D prophylaxis for prevention of sensitisation, in support of the policy of offering routine prophylaxis to all non-sensitised pregnant Rhesus negative women. All three licensed dose regimens are expected to be effective.	[Turner, Rebecca M.; Spiegelhalter, David J.; Sweeting, Michael J.] MRC, Biostat Unit, Inst Publ Hlth, Cambridge CB2 2BW, England; [Anumba, Dilly O. C.] Univ Sheffield, Sch Med, Acad Unit Reprod & Dev Med, Sheffield, S Yorkshire, England; [Smith, Gordon C. S.] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England; [Spiegelhalter, David J.] Univ Cambridge, Stat Lab, Cambridge CB2 1SB, England; [Stevens, John W.] Univ Sheffield, Ctr Bayesian Stat Hlth Econ, Sheffield, S Yorkshire, England; [Urbaniak, Stanislaw J.] Univ Aberdeen, Acad Transfus Med Unit, Foresterhill, Scotland; [Webster, Robert] Natl Blood Serv Sheffield Ctr, Natl Hlth Serv Blood & Transplant, Sheffield, S Yorkshire, England; [Thompson, Simon G.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England	MRC Biostatistics Unit; University of Cambridge; University of Sheffield; University of Cambridge; University of Cambridge; University of Sheffield; University of Aberdeen; NHS Blood & Transplant (NHSBT); University of Cambridge	Turner, RM (corresponding author), MRC, Biostat Unit, Inst Publ Hlth, Cambridge CB2 2BW, England.	rebecca.turner@mrc-bsu.cam.ac.uk	Squires, Hazel/GSO-3900-2022; Sweeting, Michael John/U-3917-2019; Smith, Gordon/A-8070-2008; Professor Dilly Anumba MBBS, FWACS/A-6358-2011	Sweeting, Michael John/0000-0003-0980-8965; Smith, Gordon/0000-0003-2124-0997; Professor Dilly Anumba MBBS, FWACS/0000-0003-2502-3033; Squires, Hazel/0000-0002-2776-4014; Stevens, John/0000-0002-9867-7209; Sharples, Linda/0000-0003-0894-966X	United Kingdom Medical Research Council [U.1052.00.001, U.1052.00.011, U.1052.00.005]; National Institute on Health Research (NIHR); NIHR Cambridge Comprehensive Biomedical Research Centre; British Heart Foundation [RG/08/014/24067] Funding Source: researchfish; Medical Research Council [MC_U105260792, MC_U105232027, MC_U105285807, MC_U105260557] Funding Source: researchfish; MRC [MC_U105260792, MC_U105285807, MC_U105260557, MC_U105232027] Funding Source: UKRI	United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute on Health Research (NIHR); NIHR Cambridge Comprehensive Biomedical Research Centre; British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	RT, DS, MS and ST were supported by the United Kingdom Medical Research Council grants U.1052.00.001, U.1052.00.011 and U.1052.00.005. MLJ and HS were supported by grants awarded by the National Institute on Health Research (NIHR) Health Technology Assessment Programme. GS was supported by the NIHR Cambridge Comprehensive Biomedical Research Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bowman J M, 1987, Transfus Med Rev, V1, P101, DOI 10.1016/S0887-7963(87)70010-8; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P627; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P623; Chilcott J, 2003, HLTH TECHNOLOGY ASSE, V7; Clemen RT, 1999, RISK ANAL, V19, P187, DOI 10.1023/A:1006917509560; de Craen AJM, 2005, J CLIN EPIDEMIOL, V58, P311, DOI 10.1016/j.jclinepi.2004.07.002; Greenland S, 2005, J R STAT SOC A STAT, V168, P267, DOI 10.1111/j.1467-985X.2004.00349.x; Hermann M, 1984, Acta Obstet Gynecol Scand Suppl, V124, P1; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; LEE D, 1995, TRANSFUSION MED, V5, P15, DOI 10.1111/j.1365-3148.1995.tb00180.x; MacKenzie IZ, 1999, BRIT J OBSTET GYNAEC, V106, P492, DOI 10.1111/j.1471-0528.1999.tb08304.x; Mayne S, 1997, BRIT MED J, V315, P1588, DOI 10.1136/bmj.315.7122.1588; Moja LP, 2005, BMJ-BRIT MED J, V330, P1053, DOI 10.1136/bmj.38414.515938.8F; Pilgrim H, 2009, HLTH TECHNOLOGY ASSE, V13; Stockman JA, 2001, J PEDIAT HEMATOL ONC, V23, P385, DOI 10.1097/00043426-200108000-00017; Szczepura A, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-5; TOVEY LAD, 1983, LANCET, V2, P244; TROLLE B, 1989, ACTA OBSTET GYN SCAN, V68, P45, DOI 10.3109/00016348909087688; Turner RM, 2009, J R STAT SOC A STAT, V172, P21, DOI 10.1111/j.1467-985X.2008.00547.x; Urbaniak SJ, 2000, BLOOD REV, V14, P44, DOI 10.1054/blre.1999.0123; Whitfield CR, 1997, BRIT MED J, V315, P1504, DOI 10.1136/bmj.315.7121.1504	23	43	45	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2012	7	2							e30711	10.1371/journal.pone.0030711	http://dx.doi.org/10.1371/journal.pone.0030711			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917LO	22319580	Green Published, Green Accepted, gold			2023-01-03	WOS:000302178400012
J	Shen, L; Ciesielski, M; Ramakrishnan, S; Miles, KM; Ellis, L; Sotomayor, P; Shrikant, P; Fenstermaker, R; Pili, R				Shen, Li; Ciesielski, Michael; Ramakrishnan, Swathi; Miles, Kiersten M.; Ellis, Leigh; Sotomayor, Paula; Shrikant, Protul; Fenstermaker, Robert; Pili, Roberto			Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models	PLOS ONE			English	Article							PERIPHERAL-BLOOD; DNA-BINDING; ANTITUMOR IMMUNITY; INTERLEUKIN-2; TUMOR; ACTIVATION; ACETYLATION; EXPRESSION; MS-275; GENE	Background: Immunosuppressive factors such as regulatory T cells (Tregs) limit the efficacy of immunotherapies. Histone deacetylase (HDAC) inhibitors have been reported to have antitumor activity in different malignancies and immunomodulatory effects. Herein, we report the Tregs-targeting and immune-promoting effect of a class I specific HDAC inhibitor, entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model or a survivin-based vaccine therapy (SurVaxM) in a castration resistant prostate cancer (CR Myc-CaP) model. Methods and Results: RENCA or CR Myc-CaP tumors were implanted orthotopically or subcutaneously, respectively. Inoculated mice were randomized into four treatment groups: vehicle, entinostat, cytokine or vaccine, and combination. Tregs in the blood were assessed by FACS analysis. Real time quantitative PCR and Western blot analysis of isolated T cell subpopulations from spleen were performed to determine Foxp3 gene and protein expression. The suppressive function of Tregs was tested by T cell proliferation assay. Low dose (5 mg/kg) entinostat reduced Foxp3 levels in Tregs and this was associated with enhanced tumor growth inhibition in combination with either IL-2 or a SurVaxM vaccine. Entinostat down-regulated Foxp3 expression transcriptionally and blocked Tregs suppressive function without affecting T effector cells (Teffs). In vitro low dose entinostat (0.5 mu M) induced STAT3 acetylation and a specific inhibitor of STAT3 partially rescued entinostat-induced down-regulation of Foxp3, suggesting that STAT3 signaling is involved in Foxp3 down-regulation by entinostat. Conclusions: These results demonstrate a novel immunomodulatory effect of class I HDAC inhibition and provide a rationale for the clinical testing of entinostat to enhance cancer immunotherapy.	[Shen, Li; Ramakrishnan, Swathi; Miles, Kiersten M.; Ellis, Leigh; Sotomayor, Paula; Pili, Roberto] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; [Ciesielski, Michael; Fenstermaker, Robert] Roswell Pk Canc Inst, Dept Neurooncol, Buffalo, NY 14263 USA; [Shrikant, Protul] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute; Roswell Park Cancer Institute	Shen, L (corresponding author), Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.	Roberto.Pili@RoswellPark.org	Ramakrishnan, Swathi/O-5054-2019		National Cancer Institute [23 R21CA137649]; NATIONAL CANCER INSTITUTE [R21CA137649] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by a research grant by the National Cancer Institute-23 R21CA137649. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS JS, 1990, J NATL CANCER I, V82, P1202, DOI 10.1093/jnci/82.14.1202; Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399; Antony PA, 2002, J IMMUNOTHER, V25, P202, DOI 10.1097/00002371-200205000-00002; Barnett B, 2005, AM J REPROD IMMUNOL, V54, P369, DOI 10.1111/j.1600-0897.2005.00330.x; Brogdon JL, 2007, BLOOD, V109, P1123, DOI 10.1182/blood-2006-04-019711; Cesana GC, 2006, J CLIN ONCOL, V24, P1169, DOI 10.1200/JCO.2005.03.6830; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chen LW, 2005, MOL CANCER THER, V4, P1311, DOI 10.1158/1535-7163.MCT-04-0287; Chen X, 2005, J LEUKOCYTE BIOL, V78, P114, DOI 10.1189/jlb.0604341; Ciesielski MJ, 2010, CANCER IMMUNOL IMMUN, V59, P1211, DOI 10.1007/s00262-010-0845-x; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; de Zoeten EF, 2010, GASTROENTEROLOGY, V138, P583, DOI 10.1053/j.gastro.2009.10.037; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299; Ellis L, 2011, PROSTATE; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fong L, 2009, CANCER RES, V69, P609, DOI 10.1158/0008-5472.CAN-08-3529; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hess-Stumpp H, 2005, P AM ASSOC CANC RES, V46, P607; Huber M, 2008, INT IMMUNOL, V20, P223, DOI 10.1093/intimm/dxm139; Jabion J, 2002, CANCER RES, V62, P6108; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Kato Y, 2007, CLIN CANCER RES, V13, P4538, DOI 10.1158/1078-0432.CCR-07-0014; Kishi H, 2004, J UROLOGY, V171, P1855, DOI 10.1097/01.ju.0000120317.88372.03; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; Maeda T, 2000, BLOOD, V96, P3847, DOI 10.1182/blood.V96.12.3847.h8003847_3847_3856; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Miller AM, 2006, J IMMUNOL, V177, P7398, DOI 10.4049/jimmunol.177.10.7398; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Onizuka S, 1999, CANCER RES, V59, P3128; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Qian DZ, 2005, PROSTATE, V64, P20, DOI 10.1002/pros.20209; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Rudra D, 2009, NAT IMMUNOL, V10, P1170, DOI 10.1038/ni.1795; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Sanderson L, 2004, DRUG METAB DISPOS, V32, P1132, DOI 10.1124/dmd.104.000638; Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856; Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Wang XF, 2005, CLIN CANCER RES, V11, P3535, DOI 10.1158/1078-0432.CCR-04-1092; Yokokawa J, 2008, CLIN CANCER RES, V14, P1032, DOI 10.1158/1078-0432.CCR-07-2056; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang H, 2005, NAT MED, V11, P1238, DOI 10.1038/nm1312	51	126	133	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2012	7	1							e30815	10.1371/journal.pone.0030815	http://dx.doi.org/10.1371/journal.pone.0030815			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911GB	22303460	gold, Green Submitted, Green Published			2023-01-03	WOS:000301704200036
J	Kamerow, D				Kamerow, Douglas			YANKEE DOODLING Does nicotine replacement really help smokers quit?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				Adhikari B., 2008, Morbidity and Mortality Weekly Report, V57, P1226; Alpert HR, TOB CONTROL, DOI [10.1136/tobaccocontrol-2011-050129, DOI 10.1136/TOBACCOCONTR0L-2011-050129]; Carey B., 2012, NEW YORK TIMES  0120, pA1; Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion, 2010, TOB SMOK CAUS DIS BI; Maarcher Ann, 2011, Morbidity and Mortality Weekly Report, V60, P1513; Moore David, 2009, BMJ, V338, pb1024, DOI 10.1136/bmj.b1024; Shiffman S, 2008, AM J PREV MED, V34, P102, DOI 10.1016/j.amepre.2007.09.033	7	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 18	2012	344								e450	10.1136/bmj.e450	http://dx.doi.org/10.1136/bmj.e450			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888YZ	22257979				2023-01-03	WOS:000300041900008
J	Crow, JM				Crow, James Mitchell			MICROBIOME That healthy gut feeling	NATURE			English	Editorial Material																		Darfeuille-Michaud A, 1998, GASTROENTEROLOGY, V115, P1405, DOI 10.1016/S0016-5085(98)70019-8; Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3; Jia W, 2008, NAT REV DRUG DISCOV, V7, P123, DOI 10.1038/nrd2505; Kim YS, 2008, J MICROBIOL BIOTECHN, V18, P1109; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Zhang X, 2011, WORLD SCI TECHNOLOGY, V13, P202	6	29	33	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S88	S89		10.1038/480S88a	http://dx.doi.org/10.1038/480S88a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190088	Bronze			2023-01-03	WOS:000298318000004
J	Jena, AB; Goldman, DP; Foster, SE; Califano, JA				Jena, Anupam B.; Goldman, Dana P.; Foster, Susan E.; Califano, Joseph A., Jr.			Prescription Medication Abuse and Illegitimate Internet-Based Pharmacies	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							UNITED-STATES; DRUGS	Abuse of controlled prescription medications in the United States exceeds that of all illicit drugs combined except marijuana and has grown considerably in the past decade. Although available through traditional channels, controlled prescription medications can also be purchased on the Internet without a prescription. This issue has gained the attention of federal regulators, law enforcement, and the media, but physician awareness of the problem is scarce. This article describes the nature of the problem and its magnitude, discusses the challenges to federal and private efforts to combat illegitimate online pharmacies, and outlines strategies for physicians to recognize and minimize the unwarranted effects of the availability of these medications on the Internet.	[Jena, Anupam B.] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Wang Ambulatory Care Ctr, Boston, MA 02114 USA; Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA; RAND Corp, Santa Monica, CA USA; Columbia Univ, Natl Ctr Addict & Substance Abuse, New York, NY USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Southern California; RAND Corporation; Columbia University	Jena, AB (corresponding author), Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Wang Ambulatory Care Ctr, 15 Parkman St, Boston, MA 02114 USA.	jena.anupam@mgh.harvard.edu	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				Cai R., 2010, Morbidity and Mortality Weekly Report, V59, P705; Cicero TJ, 2008, PAIN MED, V9, P718, DOI 10.1111/j.1526-4637.2007.00323.x; Cramer RJ, 2004, GAO04892T; [Drug Enforcement Administration (DEA) Department of Justice], 2009, FED REG, V74, P15595; Fentiman LC, 2003, RUTGERS LAW REV, V56, P119; Forman RF, 2003, JAMA-J AM MED ASSOC, V290, P889, DOI 10.1001/jama.290.7.889; Gordon SM, 2006, J SUBST ABUSE TREAT, V30, P271, DOI 10.1016/j.jsat.2005.08.013; Inciardi JA, 2010, DRUG ALCOHOL DEPEN, V110, P21, DOI 10.1016/j.drugalcdep.2010.01.015; Jena AB, 2011, HEALTH AFFAIR, V30, P1192, DOI 10.1377/hlthaff.2011.0155; KAUFMAN M, 2005, WASH POST, pA03; Miller C.C., 2011, NY TIMES, pB1; National Center on Addiction and Substance Abuse, 2008, YOUV GOT DRUGS; [National Drug Intelligence Center U.S. Department of Justice], 2009, US DEP JUST PUBL; Saitz R, 1997, AM J DRUG ALCOHOL AB, V23, P343, DOI 10.3109/00952999709016881; SAMHSA, 2009, NSDUH SER; Siva N, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3457; The National Center on Addiction and Substance Abuse at Columbia University (CASA), 2005, COUNT DIV AB CONTR P; U.S. Food and Drug Administration Internet Pharmacy Task Force, 2009, WARN LETT US FOOD DR	18	20	20	1	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 20	2011	155	12					848	850		10.7326/0003-4819-155-12-201112200-00008	http://dx.doi.org/10.7326/0003-4819-155-12-201112200-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	864ZU	22184692				2023-01-03	WOS:000298280500019
J	Rochira, V; Zirilli, L; Orlando, G; Santi, D; Brigante, G; Diazzi, C; Carli, F; Carani, C; Guaraldi, G				Rochira, Vincenzo; Zirilli, Lucia; Orlando, Gabriella; Santi, Daniele; Brigante, Giulia; Diazzi, Chiara; Carli, Federica; Carani, Cesare; Guaraldi, Giovanni			Premature Decline of Serum Total Testosterone in HIV-Infected Men in the HAART-Era	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; ERECTILE DYSFUNCTION; ANDROGEN DEFICIENCY; ANTIRETROVIRAL THERAPY; INTERNATIONAL INDEX; BINDING GLOBULIN; GONADAL-FUNCTION; ELDERLY-MEN; WEIGHT-LOSS; AGING MEN	Background: Testosterone (T) deficiency remains a poorly understood issue in men with Human Immunodeficiency Virus (HIV). We investigated the gonadal status in HIV-infected men in order to characterize T deficiency and to identify predictive factors for low serum T. Methodology/Principal Findings: We performed a cross-sectional, observational study on 1325 consecutive HIV male outpatients, most of them having lipodystrophy. Serum total T<300 ng/dL was used as the threshold for biochemical T deficiency. Morning serum total T, luteinizing hormone (LH), estradiol, HIV parameters, and body composition parameters by CT-scan and Dual-Energy-X-ray-Absorptiometry were measured in each case. Sexual behavior was evaluated in a subset of 247 patients. T deficiency was found in 212 subjects, especially in the age range 40-59, but was frequent even in younger patients. T deficiency occurred mainly in association with low/normal serum LH. Adiposity was higher in subjects with T deficiency (p<0.0001) and both visceral adipose tissue and body mass index were the main negative predictors of serum total T. Osteoporosis and erectile dysfunction were present in a similar percentage in men with or without T deficiency. Conclusions/Significance: Premature decline of serum T is common (16%) among young/middle-aged HIV-infected men and is associated with inappropriately low/normal LH and increased visceral fat. T deficiency occurs at a young age and may be considered an element of the process of premature or accelerated aging known to be associated with HIV infection. The role of HIV and/or HIV infection treatments, as well as the role of the general health state on the gonadal axis, remains, in fact, to be elucidated. Due to the low specificity of signs and symptoms of hypogonadism in the context of HIV, caution is needed in the diagnosis of hypogonadism in HIV-infected men with biochemical low serum T levels.	[Rochira, Vincenzo; Zirilli, Lucia; Santi, Daniele; Brigante, Giulia; Diazzi, Chiara; Carani, Cesare] Univ Modena & Reggio Emilia, Azienda AUSL NOCSAE Baggiovara, Chair & Unit Endocrinol & Metab, Dept Med Endocrinol & Metab Geriatr, Modena, Italy; [Orlando, Gabriella; Carli, Federica; Guaraldi, Giovanni] Univ Modena & Reggio Emilia, Dept Med & Med Specialties, Metab Clin, Infect & Trop Dis Unit, Modena, Italy	Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia	Rochira, V (corresponding author), Univ Modena & Reggio Emilia, Azienda AUSL NOCSAE Baggiovara, Chair & Unit Endocrinol & Metab, Dept Med Endocrinol & Metab Geriatr, Modena, Italy.	vincenzo.rochira@unimore.it	Brigante, Giulia/J-8775-2018; Orlando, Gabriella/K-3954-2018; Santi, Daniele/J-7005-2018; Rochira, Vincenzo/F-4225-2015; Guaraldi, Giovanni/J-9467-2018; Rochira, Vincenzo/S-7340-2019; Diazzi, Chiara/J-8708-2018	Brigante, Giulia/0000-0001-8426-4502; Orlando, Gabriella/0000-0002-4590-9045; Santi, Daniele/0000-0001-6607-7105; Rochira, Vincenzo/0000-0001-8169-0696; Rochira, Vincenzo/0000-0001-8169-0696; Guaraldi, Giovanni/0000-0002-5724-3914; Diazzi, Chiara/0000-0002-6259-2481	Department of Medicine, Endocrinology & Metabolism, University of Modena	Department of Medicine, Endocrinology & Metabolism, University of Modena	The authors wish to thank Prof. Manuela Simoni, Department of Medicine, Endocrinology & Metabolism, University of Modena, and Reggio Emilia for proofreading the manuscript, careful copyediting, thoughtful assistance in the preparation of this paper, and continuous support and trust.	Araujo AB, 2004, J CLIN ENDOCR METAB, V89, P5920, DOI 10.1210/jc.2003-031719; Araujo AB, 2007, J CLIN ENDOCR METAB, V92, P4241, DOI 10.1210/jc.2007-1245; Arver S, 1999, J ANDROL, V20, P611; Bhasin S, 2010, J CLIN ENDOCR METAB, V95, P2536, DOI 10.1210/jc.2009-2354; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; Brambilla DJ, 2007, CLIN ENDOCRINOL, V67, P853, DOI 10.1111/j.1365-2265.2007.02976.x; Brambilla DJ, 2009, J CLIN ENDOCR METAB, V94, P907, DOI 10.1210/jc.2008-1902; Cappelleri JC, 1999, UROLOGY, V54, P346, DOI 10.1016/S0090-4295(99)00099-0; Collazos Julio, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P43, DOI 10.1177/1545109708330908; Cotter AG, 2011, BEST PRACT RES CL EN, V25, P501, DOI 10.1016/j.beem.2010.11.003; Crum NF, 2005, AIDS PATIENT CARE ST, V19, P655, DOI 10.1089/apc.2005.19.655; Crum-Cianflone NF, 2007, AIDS PATIENT CARE ST, V21, P9, DOI 10.1089/apc.2006.0071; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; Dobs AS, 1996, J CLIN ENDOCR METAB, V81, P4108, DOI 10.1210/jc.81.11.4108; Dube MP, 2007, CLIN INFECT DIS, V45, P120, DOI 10.1086/518620; Gorman AA, 2009, NEUROPSYCHOL REV, V19, P186, DOI 10.1007/s11065-009-9095-0; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P4051, DOI 10.1210/jc.81.11.4051; Guaraldi G, 2007, ANTIVIR THER, V12, pL58; Handelsman DJ, 2011, ASIAN J ANDROL, V13, P125, DOI 10.1038/aja.2010.154; Harman SM, 2001, J CLIN ENDOCR METAB, V86, P724, DOI 10.1210/jc.86.2.724; Kalyani Rita R, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P226, DOI 10.1097/MED.0b013e32814db856; Kalyani RR, 2007, ENDOCRIN METAB CLIN, V36, P333, DOI 10.1016/j.ecl.2007.03.014; Kaufman JM, 1997, BAILLIERE CLIN ENDOC, V11, P289, DOI 10.1016/S0950-351X(97)80302-3; Klein RS, 2005, CLIN INFECT DIS, V41, P1794, DOI 10.1086/498311; Ly LP, 2010, CLIN ENDOCRINOL, V73, P382, DOI 10.1111/j.1365-2265.2010.03804.x; Martin J, 2010, ANN INTERN MED, V153, P477, DOI 10.7326/0003-4819-153-7-201010050-00013; MARTIN ME, 1992, J ENDOCRINOL INVEST, V15, P597, DOI 10.1007/BF03344932; McLachlan RI, 2010, J CLIN ENDOCR METAB, V95, P2610, DOI 10.1210/jc.2010-0838; Moreno-Perez O, 2010, J SEX MED, V7, P2873, DOI 10.1111/j.1743-6109.2010.01886.x; Mulligan T, 2006, INT J CLIN PRACT, V60, P762, DOI 10.1111/j.1742-1241.2006.00992.x; Mylonakis E, 2001, CLIN INFECT DIS, V33, P857, DOI 10.1086/322695; Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6; Onen Nur F, 2011, Curr Aging Sci, V4, P33; Palella FJ, 2004, CLIN INFECT DIS, V38, P903, DOI 10.1086/381684; Park YW, 2002, INT J OBESITY, V26, P978, DOI 10.1038/sj.ijo.0801982; Rietschel P, 2000, CLIN INFECT DIS, V31, P1240, DOI 10.1086/317457; Rochira V, 2006, EUR J ENDOCRINOL, V155, P513, DOI 10.1530/eje.1.02254; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Rosner W, 2007, J CLIN ENDOCR METAB, V92, P405, DOI 10.1210/jc.2006-1864; Sartorius G, 2009, ANN CLIN BIOCHEM, V46, P137, DOI 10.1258/acb.2008.008171; Sartorius GA, 2010, ANDROLOGY: MALE REPRODUCTIVE HEALTH AND DYSFUNCTION, THIRD EDITION, P339, DOI 10.1007/978-3-540-78355-8_18; Schneider HJ, 2009, CLIN ENDOCRINOL, V70, P446, DOI 10.1111/j.1365-2265.2008.03370.x; Shiels MS, 2010, ANN INTERN MED, V153, P452, DOI 10.7326/0003-4819-153-7-201010050-00008; Tajar A, 2010, J CLIN ENDOCR METAB, V95, P1810, DOI 10.1210/jc.2009-1796; Travison TG, 2007, J CLIN ENDOCR METAB, V92, P549, DOI 10.1210/jc.2006-1859; Travison TG, 2006, J CLIN ENDOCR METAB, V91, P2509, DOI 10.1210/jc.2005-2508; VERMEULEN A, 1992, J CLIN ENDOCR METAB, V74, P939, DOI 10.1210/jc.74.4.939; Wasserman P, 2008, J SEX MED, V5, P241, DOI 10.1111/j.1743-6109.2007.00634.x; Wu FCW, 2010, NEW ENGL J MED, V363, P123, DOI 10.1056/NEJMoa0911101; Wunder DM, 2008, HIV MED, V9, P427, DOI 10.1111/j.1468-1293.2008.00578.x; Zirilli L, 2008, J Endocrinol Invest, V31, P33	51	87	89	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e28512	10.1371/journal.pone.0028512	http://dx.doi.org/10.1371/journal.pone.0028512			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	866FK	22174826	Green Published, gold, Green Submitted			2023-01-03	WOS:000298365700041
J	Gutierrez, C; Diaz, L; Vallejo, A; Hernandez-Novoa, B; Abad, M; Madrid, N; Dahl, V; Rubio, R; Moreno, AM; Dronda, F; Casado, JL; Navas, E; Perez-Elias, MJ; Zamora, J; Palmer, S; Munoz, E; Munoz-Fernandez, MA; Moreno, S				Gutierrez, Carolina; Diaz, Laura; Vallejo, Alejandro; Hernandez-Novoa, Beatriz; Abad, Maria; Madrid, Nadia; Dahl, Viktor; Rubio, Rafael; Moreno, Ana M.; Dronda, Fernando; Luis Casado, Jose; Navas, Enrique; Jesus Perez-Elias, Maria; Zamora, Javier; Palmer, Sarah; Munoz, Eduardo; Angeles Munoz-Fernandez, Maria; Moreno, Santiago			Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LOW-LEVEL VIREMIA; PLASMA VIREMIA; RALTEGRAVIR INTENSIFICATION; IMMUNE ACTIVATION; EXTENDED PERIODS; IN-VIVO; RESERVOIR; REPLICATION; COMBINATION	Objective: The primary objective was to assess the effect of MVC intensification on latently infected CD4(+) T cells in chronically HIV-1-infected patients receiving antiretroviral therapy. Methods: We performed an open-label pilot phase II clinical trial involving chronically HIV-1-infected patients receiving stable antiretroviral therapy whose regimen was intensified with 48 weeks of maraviroc therapy. We analyzed the latent reservoir, the residual viremia and episomal 2LTR DNA to examine the relationship between these measures and the HIV-1 latent reservoir, immune activation, lymphocyte subsets (including effector and central memory T cells), and markers associated with bacterial translocation. Results: Overall a non significant reduction in the size of the latent reservoir was found (p = 0.068). A mean reduction of 1.82 IUPM was observed in 4 patients with detectable latent reservoir at baseline after 48 weeks of intensification. No effect on plasma residual viremia was observed. Unexpectedly, all the patients had detectable 2LTR DNA circles at week 24, while none of them showed those circles at the end of the study. No changes were detected in CD4(+) or CD8(+) counts, although a significant decrease was found in the proportion of HLA-DR(+)/CD38(+) CD4(+) and CD8(+) T-cells. LPS and sCD14 levels increased. Conclusions: Intensification with MVC was associated with a trend to a decrease in the size of the latent HIV-1 reservoir in memory T cells. No impact on residual viremia was detected. Additional studies with larger samples are needed to confirm the results.	[Gutierrez, Carolina; Vallejo, Alejandro; Hernandez-Novoa, Beatriz; Abad, Maria; Madrid, Nadia; Moreno, Ana M.; Dronda, Fernando; Luis Casado, Jose; Navas, Enrique; Jesus Perez-Elias, Maria; Moreno, Santiago] Hosp Univ Ramon Y Cajal, Dept Infect Dis, Madrid, Spain; [Gutierrez, Carolina; Vallejo, Alejandro; Hernandez-Novoa, Beatriz; Abad, Maria; Madrid, Nadia; Moreno, Ana M.; Dronda, Fernando; Luis Casado, Jose; Navas, Enrique; Jesus Perez-Elias, Maria; Zamora, Javier; Moreno, Santiago] IRYCIS, Madrid, Spain; [Diaz, Laura; Angeles Munoz-Fernandez, Maria] Hosp Gen Univ Gregorio Maranon, Inmunobiol Lab, Madrid, Spain; [Dahl, Viktor; Palmer, Sarah] Karolinska Inst, Stockholm, Sweden; [Rubio, Rafael] Hosp Gen Univ Doce Octubre, Infect Dis Unit, Madrid, Spain; [Zamora, Javier] Hosp Univ Ramon Y Cajal, Dept Biostat, Madrid, Spain; [Munoz, Eduardo] Univ Cordoba, Dept Immunol, Cordoba, Spain	Hospital Universitario Ramon y Cajal; General University Gregorio Maranon Hospital; Karolinska Institutet; Hospital Universitario 12 de Octubre; Hospital Universitario Ramon y Cajal; Universidad de Cordoba	Gutierrez, C (corresponding author), Hosp Univ Ramon Y Cajal, Dept Infect Dis, Madrid, Spain.	smoreno.hrc@salud.madrid.org	Zamora, Javier/B-1722-2009; Abad, Maria/AAC-3146-2020; Elias, Maria Jesus Perez/AAD-8652-2020; Vallejo, Alejandro/I-5881-2015; Zamora, Javier/AEO-0608-2022; Munoz, Eduardo/I-5225-2012	Zamora, Javier/0000-0003-4901-588X; Vallejo, Alejandro/0000-0001-5360-878X; Zamora, Javier/0000-0003-4901-588X; Munoz, Eduardo/0000-0001-8478-5842; Rubio Garcia, Rafael/0000-0001-8132-4303; Casado, Jose Luis/0000-0002-7639-8591; Dahl, Viktor/0000-0001-9921-5172; Munoz-Fernandez/0000-0002-0813-4500; Perez Elias/0000-0001-5700-5257	Spanish AIDS Network Red Tematica Cooperativa de Investigacion en SIDA [RD06/0006]; Spanish National of Health, "Instituto de Salud Carlos III" [FIS-PI080958, CP08/00046]; Foundation of Investigation and prevention of AIDS [FIPSE-36-0844/09]	Spanish AIDS Network Red Tematica Cooperativa de Investigacion en SIDA; Spanish National of Health, "Instituto de Salud Carlos III"; Foundation of Investigation and prevention of AIDS	This work was supported in part by the Spanish AIDS Network "Red Tematica Cooperativa de Investigacion en SIDA (RD06/0006), the Spanish National of Health, "Instituto de Salud Carlos III", grants (FIS-PI080958 and CP08/00046), and by the Foundation of Investigation and prevention of AIDS (FIPSE-36-0844/09). Pfizer Inc provided the drug. The Regional Blood Transfusion Center in Madrid provided the buffy coats from healthy donors. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Anderson JA, 2011, J VIROL, V85, P5220, DOI 10.1128/JVI.00284-11; Baroncelli S, 2009, J CLIN VIROL, V46, P367, DOI 10.1016/j.jcv.2009.09.011; Brenchley JM, 2008, MUCOSAL IMMUNOL, V1, P23, DOI 10.1038/mi.2007.1; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111; Chavez HH, 2007, JAIDS-J ACQ IMM DEF, V45, P247, DOI 10.1097/QAI.0b013e3180415dc2; Chege D, 2011, AIDS, V25, P741, DOI 10.1097/QAD.0b013e328344cefb; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324; Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250; Chun TW, 2011, J INFECT DIS, V204, P135, DOI 10.1093/infdis/jir208; Chun TW, 2010, AIDS, V24, P2803, DOI 10.1097/QAD.0b013e328340a239; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Cooper DA, 2010, J INFECT DIS, V201, P803, DOI 10.1086/650697; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005; Funderburg N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013188; Gandhi RT, 2010, J INFECT DIS, V201, P293, DOI 10.1086/649569; Gandhi RT, 2010, PLOS MED, V10, P7; Garcia-Merino I, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-27; Gulick RM, 2008, NEW ENGL J MED, V359, P1429, DOI 10.1056/NEJMoa0803152; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Hunt PW, 2011, 18 C RETR OPP INF FE; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Kewenig S, 1999, GASTROENTEROLOGY, V116, P1115, DOI 10.1016/S0016-5085(99)70014-4; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Kotler DP, 1999, J INFECT DIS, V179, pS454, DOI 10.1086/314803; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Markowitz M, 2011, 18 C RETR OPP INF FE, V152LB; McMahon D, 2010, CLIN INFECT DIS, V50, P912, DOI 10.1086/650749; MYERS LE, 1994, J CLIN MICROBIOL, V32, P732, DOI 10.1128/JCM.32.3.732-739.1994; Northfield JW, 2007, J VIROL, V81, P5759, DOI 10.1128/JVI.00045-07; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Persaud D, 2004, J VIROL, V78, P968, DOI 10.1128/JVI.78.2.968-979.2004; Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Sheth PM, 2008, MUCOSAL IMMUNOL, V1, P382, DOI 10.1038/mi.2008.23; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Wiegand A, 2010, 17 C RET OPP INF OR; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wu YT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000520; Yilmaz A, 2010, J ACQ IMMUN DEF SYND, V15, P590; Yukl SA, 2010, J INFECT DIS, V202, P1553, DOI 10.1086/656722; Yukl SA, 2010, AIDS, V24, P2450, DOI 10.1097/QAD.0b013e32833ef7bb; Zazzi M, 1997, J MED VIROL, V52, P20, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;20::AID-JMV4&gt;3.0.CO;2-T	50	75	75	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2011	6	12							e27864	10.1371/journal.pone.0027864	http://dx.doi.org/10.1371/journal.pone.0027864			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KY	22174752	Green Published, gold			2023-01-03	WOS:000298163600008
J	Chen, W; Lim, CED; Kang, HJ; Liu, JP				Chen, Wei; Lim, Chi Eung Danforn; Kang, Hong-Jun; Liu, Jianping			Chinese Herbal Medicines for the Treatment of Type A H1N1 Influenza: A Systematic Review of Randomized Controlled Trials	PLOS ONE			English	Review							QUALITY; THERAPY	Background: Chinese herbs are thought to be effective for type A H1N1 influenza. Series of Chinese herbs have been authorized recommended by the Chinese government, and until now a number of clinical trials of Chinese herbs for H1N1 influenza have been conducted. However, there is no critically appraised evidence such as systematic reviews or meta-analyses on potential benefits and harms of medicinal herbs for H1N1 influenza to justify their clinical use and their recommendation. Methods and Findings: CENTRAL, MEDLINE, EMBASE, CBM, CNKI, VIP, China Important Conference Papers Database, China Dissertation Database, and online clinical trial registry websites were searched for published and unpublished randomized controlled trials (RCTs) of Chinese herbs for H1N1 influenza till 31 August, 2011. A total of 26 RCTs were identified and reviewed. Most of the RCTs were of high risk of bias with flawed study design and poor methodological quality. The combination of several Chinese herbal medicines with or without oseltamivir demonstrated positive effect on fever resolution, relief of symptoms, and global effectiveness rate compared to oseltamivir alone. However, only one herbal medicine showed positive effect on viral shedding. Most of the trials did not report adverse events, and the safety of herbal medicines is still uncertain. Conclusions: Some Chinese herbal medicines demonstrated potential positive effect for 2009 type A H1N1 influenza; however, due to the lack of placebo controlled trial and lack of repeated test of the intervention, we could not draw confirmative conclusions on the beneficial effect of Chinese herbs for H1N1 influenza. More rigorous trials are warranted to support their clinical use.	[Chen, Wei; Liu, Jianping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Lim, Chi Eung Danforn] Univ New S Wales, Fac Med, S Western Sydney Clin Sch, Sydney, NSW, Australia; [Kang, Hong-Jun] Chinese Peoples Liberat Army Gen Hosp, Intens Care Unit, Beijing, Peoples R China; [Liu, Jianping] Univ Tromso, NAFKAM, Tromso, Norway	Beijing University of Chinese Medicine; University of New South Wales Sydney; Chinese People's Liberation Army General Hospital; UiT The Arctic University of Tromso	Chen, W (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	jianping_l@hotmail.com			Specific Professional Research Grant in Traditional Chinese Medicine (TCM); State Administration of TCM of China [200907001-2A]; international collaboration project; Ministry of Science and Technology of China [2009DFA31460]	Specific Professional Research Grant in Traditional Chinese Medicine (TCM); State Administration of TCM of China; international collaboration project; Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by a 2009 Specific Professional Research Grant in Traditional Chinese Medicine (TCM) funded by the State Administration of TCM of China: Clinical Study on Traditional Chinese Medicine for Severe Cases of (H1N1) Influenza A (No. 200907001-2A), and partly supported by an international collaboration project funded by the Ministry of Science and Technology of China (No. 2009DFA31460). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Center for Desease Control and Prevention, 2010, SEAS INFL FLU 2009 2; Chai LX, 2010, CRITICAL J CHINESE M, V2, P36; Chen F, 2010, J ZHEJIANG U TRADITI, V34, P658; Chen H, 2010, SICHUAN MED J, V31, P1050; Deng WL, 1998, PHARM TRADITIONAL CH; Dou AH, 2010, MODERN J INTEGRATED, V19, P3289; GOTTIEB S, 2000, BMJ-BRIT MED J, V320, P1623; Han JT, 2011, JILIN MED J CHIN, V32, P1491; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hu J., 2011, CHINESE J PRACTICAL, V26, P388; Huang M, 2010, CHINESE J MISDIAGNOS, V10, P2079; Ishizaki T, 1996, EUR RESPIR J, V9, P2691, DOI 10.1183/09031936.96.09122691; Jin F, 2010, J SICHUAN TRADITIONA, V28, P81; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kou GX, 2011, JETCM, V20, p[872, 876]; Li BF, 2009, J MED FORUM, V30, P91; Li G, 2010, J EMERG TRADIT CHIN, V19, P1681; [李同霞 Li Tongxia], 2010, [中国现代医学杂志, China Journal of Modern Medicine], V20, P3479; Li XQ, 2010, NAT CHIN W INT MED C; Lin CZ, 2011, ACTA ACAD MED QINGDA, V47, P132; Liu DaFeng, 2011, Modern Preventive Medicine, V38, P338; Liu GW, 2001, CHINESE HERBAL MED; Liu GX, 2010, CHIN J DIFFIC COMPL, V9, P14; Liu J, 2010, CONT MED, V16, P158; Liu JP, 2009, FOCUS ALTERNATIVE CO, V14, P92; Liu YL, 2010, CLIN FOCUS, V25, P439; Ma YP, 2010, SHANXI ZHONG YI, V31, P1351; Melchart D, 1999, JAMA-J AM MED ASSOC, V282, P28, DOI 10.1001/jama.282.1.28; Ministry of Health of the People's Republic of China, 2009, GUID MAN PAND H1N1 2; Moher David, 2010, BMJ, V340, pc869, DOI [10.1016/j.jclinepi.2010.03.004, 10.1136/bmj.c869]; Moscona A, 2005, NEW ENGL J MED, V353, P2633, DOI 10.1056/NEJMp058291; Narain JP, 2009, INDIAN J MED RES, V129, P465; OuYang HX, 2010, CHINA MED HERALD, V7, P6; Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X; Qian J, 2011, JILIN MED J CHIN, V32, P266; Qin XY, 2010, MED INFORM, V23, P155; Qiu YJ, 2010, GUIDING J TRADITIONA, V16, P36; Qu JL, 2010, CHINESE MED MODERN D, V8, P196; Ru GX, 2010, INT MED HLTH GUIDANC, V16, P1897; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Song K, 2010, MED FOR ROL CHIN MED; Tan X. Y., 2010, J GUANGZHOU U TRADIT, V27, P441; Tang CB, 2010, CHINESE COMMUNITY DO, V12, P141; Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160; Tian G, 2011, CHINESE J INFORM TCM, V18, p[81, 112]; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005; Wang S, 2011, INFECT DIS INFO, V24, P46; Wei Q, 2010, GUANGMING J CHINESE, V25, P2318; Wen XM, 2010, J SICHUAN TRADITIONA, V28, P56; Weng BX, 2010, INT MED HLTH GUIDANC, V16, P979; World Health Organization, 2009, PAND H1N1 2009 UPD 8; Xia BS, 2010, PEOPLES MILIT SURG, V53, P645; Xie Y, 2010, CHINA MODERN DOCTOR, V48, P47; Xie YZ, 2010, CHINA FOREIGN MED TR, V33, P38; Yang C, 2010, J COMMUNITY MED, V8, P69; Ye YM, 2010, SICHUAN MED J, V31, P1533; Zeng YiLan, 2011, Modern Preventive Medicine, V38, P2227; Zhang WS, 2011, GANSU ZHONG YI, V24, P20; Zhang ZQ, 2010, HEBEI J TRADITIONAL, V32, P1192; Zhao WN, 2007, PRACTICAL PREVENTIVE, V14, P178; Zhao ZL, 2010, NINGXIA MED J, V32, P376; Zheng HaiPeng, 2010, China Journal of Traditional Chinese Medicine and Pharmacy, V25, P780; Zheng HJ, 2010, HEBEI J TRADITIONAL, V32, P1621; Zhu Y.H., 2010, SHANDONG J TRADIT CH, V29, P535	65	60	61	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2011	6	12							e28093	10.1371/journal.pone.0028093	http://dx.doi.org/10.1371/journal.pone.0028093			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863NO	22164232	Green Published, gold, Green Submitted			2023-01-03	WOS:000298171400033
J	Mainguy, V; Provencher, S; Maltais, F; Malenfant, S; Saey, D				Mainguy, Vincent; Provencher, Steeve; Maltais, Francois; Malenfant, Simon; Saey, Didier			Assessment of Daily Life Physical Activities in Pulmonary Arterial Hypertension	PLOS ONE			English	Article							6-MINUTE WALK TEST; QUALITY-OF-LIFE; MUSCLE DYSFUNCTION; EXERCISE; SURVIVAL; COPD	Background: In pulmonary arterial hypertension (PAH), the six-minute walk test (6MWT) is believed to be representative of patient's daily life physical activities (DLPA). Whether DLPA are decreased in PAH and whether the 6MWT is representative of patient's DLPA remain unknown. Methods: 15 patients with idiopathic PAH (IPAH) and 10 patients with PAH associated with limited systemic sclerosis (PAH-SSc) were matched with 15 healthy control subjects and 10 patients with limited systemic sclerosis without PAH. Each subject completed a 6MWT. The mean number of daily steps and the mean energy expenditure and duration of physical activities >3 METs were assessed with a physical activity monitor for seven consecutive days and used as markers of DLPA. Results: The mean number of daily steps and the mean daily energy expenditure and duration of physical activities >3 METs were all reduced in PAH patients compared to their controls (all p<0.05). The mean number of daily steps correlated with the 6MWT distance for both IPAH and PAH-SSc patients (r = 0.76, p<0.01 and r = 0.85, p<0.01), respectively. Conclusion: DLPA are decreased in PAH and correlate with the 6MWT distance. Functional exercise capacity may thus be a useful surrogate of DLPA in PAH.	[Mainguy, Vincent; Provencher, Steeve; Maltais, Francois; Malenfant, Simon; Saey, Didier] Univ Laval, Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada	Laval University	Mainguy, V (corresponding author), Univ Laval, Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada.	Didier.Saey@rea.ulaval.ca	Malenfant, Simon/AAQ-5587-2020; Saey, Didier/F-7963-2014	Malenfant, Simon/0000-0002-3911-3702	Reseau en Sante Respiratoire du Fonds de Recherche en Sante du Quebec; Groupe de Recherche en Sante Respiratoire de l'Universite Laval (GESER)	Reseau en Sante Respiratoire du Fonds de Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); Groupe de Recherche en Sante Respiratoire de l'Universite Laval (GESER)	This project was supported by the Reseau en Sante Respiratoire du Fonds de Recherche en Sante du Quebec and the Groupe de Recherche en Sante Respiratoire de l'Universite Laval (GESER). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bauer R, 2007, RESP MED, V101, P2366, DOI 10.1016/j.rmed.2007.06.014; Chemla D, 2002, EUR RESPIR J, V20, P1314, DOI 10.1183/09031936.02.00068002; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; de Man FS, 2009, EUR RESPIR J, V34, P669, DOI 10.1183/09031936.00027909; Enright PL, 1998, AM J RESP CRIT CARE, V158, P1384, DOI 10.1164/ajrccm.158.5.9710086; Galie N, 2009, EUR HEART J, V30, P394, DOI 10.1093/eurheartj/ehp022; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; Groepenhoff H, 2008, MED SCI SPORT EXER, V40, P1725, DOI 10.1249/MSS.0b013e31817c92c0; Langer D, 2009, THORAX, V64, P641, DOI 10.1136/thx.2008.112102; Langer D, 2009, J HEART LUNG TRANSPL, V28, P572, DOI 10.1016/j.healun.2009.03.007; LeRoy EC, 2001, J RHEUMATOL, V28, P1573; LIGHT RW, 1985, CHEST, V87, P35, DOI 10.1378/chest.87.1.35; Mainguy V, 2010, J CARDIOPULM REHABIL, V30, P319, DOI 10.1097/HCR.0b013e3181d6f962; Mainguy V, 2010, THORAX, V65, P113, DOI 10.1136/thx.2009.117168; McKenna S, 2006, QUAL LIFE RES, V15, P103, DOI 10.1007/s11136-005-3513-4; McLaughlin VV, 2009, J AM COLL CARDIOL, V54, pS97, DOI 10.1016/j.jacc.2009.04.007; McLaughlin VV, 2009, CIRCULATION; Mereles D, 2006, CIRCULATION, V114, P1482, DOI 10.1161/CIRCULATIONAHA.106.618397; Meyer FJ, 2005, EUR RESPIR J, V25, P125, DOI 10.1183/09031936.04.00095804; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; Patel Sanjay A, 2007, COPD, V4, P107, DOI 10.1080/15412550701246658; Pitta F, 2006, EUR RESPIR J, V27, P1040, DOI 10.1183/09031936.06.00064105; Provencher S, 2006, EUR RESPIR J, V27, P114, DOI 10.1183/09031936.06.00042705; Provencher S, 2006, EUR RESPIR J, V28, P1073, DOI 10.1183/09031936.00120506; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI [10.1016/j.jacc.2009.04.012, 10.1016/j.jacc.2013.10.029]; Sitbon O, 2002, J AM COLL CARDIOL, V40, P780, DOI 10.1016/S0735-1097(02)02012-0; St-Onge M, 2007, AM J CLIN NUTR, V85, P742, DOI 10.1093/ajcn/85.3.742; Steele BG, 2000, CHEST, V117, P1359, DOI 10.1378/chest.117.5.1359; Sun XG, 2001, CIRCULATION, V104, P429, DOI 10.1161/hc2901.093198; Tudor-Locke C, 2004, SPORTS MED, V34, P1, DOI 10.2165/00007256-200434010-00001; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Watz H, 2009, EUR RESPIR J, V33, P262, DOI 10.1183/09031936.00024608; WEAVER TE, 1992, NURS RES, V41, P286; Wensel R, 2002, CIRCULATION, V106, P319, DOI 10.1161/01.CIR.0000022687.18568.2A	34	65	65	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 16	2011	6	11							e27993	10.1371/journal.pone.0027993	http://dx.doi.org/10.1371/journal.pone.0027993			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HV	22110770	Green Published, Green Submitted, gold			2023-01-03	WOS:000297555400144
J	Liu, YN; Wang, W; Li, X; Wang, H; Luo, YX; Wu, LJ; Guo, XH				Liu, Yunning; Wang, Wei; Li, Xia; Wang, Hong; Luo, Yanxia; Wu, Lijuan; Guo, Xiuhua			Geographic Distribution and Risk Factors of the Initial Adult Hospitalized Cases of 2009 Pandemic Influenza A (H1N1) Virus Infection in Mainland China	PLOS ONE			English	Article								Background: As of 31(st) March 2010, more than 127,000 confirmed cases of 2009 pandemic influenza A (H1N1), including 800 deaths, were reported in mainland China. The distribution and characteristics of the confirmed cases in the initial phase of this pandemic in this country are largely unknown. The present study aimed to characterize the geographic distribution and patient characteristics of H1N1 infection in the 2009 pandemic as well as to identify potential risk factors associated with adverse patient outcome in China, through retrospective analyses of 885 hospitalized cases with confirmed H1N1 infection. Methodology/Principal Findings: The proportional hazards model was employed to detect risk factors for adverse outcome; the geo-statistical maps were used to characterize the distribution of all 2668 confirmed H1N1 patients throughout mainland China. The number of new cases increased slowly in May, 2009, but rapidly between June and August of the year. Confirmed cases were reported in 26 provinces; Beijing, Guangdong, Shanghai, Zhejiang and Fujian were the top five regions of the incidence of the virus infection. After being adjusted for gender, age, chronic pulmonary disease and other general symptoms, delay for more than two days before hospital admission (HR: 0.6; 95% CI: 0.5-0.7) and delayed onset of the H1N1-specific respiratory symptoms (HR: 0.3; 95% CI: 0.2-0.4) were associated with adverse patient outcome. Conclusions/Significance: The 2009 pandemic influenza A affected east and southeast coastal provinces and most populous cities more severely than other regions in mainland China due to higher risk of high level traffic-, high population density-, and high population mobility-associated H1N1 transmission. The clinical symptoms were mild in the initial phase of infection. Delayed hospital admission and delayed appearance of respiratory symptoms were among the major risk factors for poor patient outcome. These findings may have significant implications in the future pandemic preparedness and response.	[Liu, Yunning; Wang, Wei; Li, Xia; Wang, Hong; Luo, Yanxia; Wu, Lijuan; Guo, Xiuhua] Capital Med Univ, Sch Publ Hlth & Family Med, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China; [Li, Xia; Wang, Hong; Luo, Yanxia; Wu, Lijuan; Guo, Xiuhua] Beijing Municipal Key Lab Clin Epidemiol, Beijing, Peoples R China	Capital Medical University	Liu, YN (corresponding author), Capital Med Univ, Sch Publ Hlth & Family Med, Dept Epidemiol & Hlth Stat, Beijing, Peoples R China.	guoxiuh@ccmu.edu.cn	liu, li/HGC-0900-2022	wang, wei/0000-0002-1430-1360	Jurisdiction of Beijing Municipality [PHR201007112]; National ST Major Project [2010ZX09401]	Jurisdiction of Beijing Municipality; National ST Major Project	This work was supported by Funding Project for Academic Human Resources Development in Institutions of Higher Learning under the Jurisdiction of Beijing Municipality (PHR201007112); National S&T Major Project (2010ZX09401). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boulos Maged N Kamel, 2004, Int J Health Geogr, V3, P2, DOI 10.1186/1476-072X-3-2; Campbell A, 2010, CAN MED ASSOC J, V182, P349, DOI 10.1503/cmaj.091823; Chowell G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021287; Fowlkes AL, 2011, CLIN INFECT DIS, V52, pS60, DOI 10.1093/cid/ciq022; Graham AJ, 2004, ACTA TROP, V91, P219, DOI 10.1016/j.actatropica.2004.05.001; Guarner J, 2009, ARCH MED RES, V40, P655, DOI 10.1016/j.arcmed.2009.10.001; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jeong I, 2010, AM J INFECT CONTROL, V38, P482, DOI 10.1016/j.ajic.2010.02.006; Khandaker G, 2011, INFLUENZA OTHER RESP, V5, P148, DOI 10.1111/j.1750-2659.2011.00199.x; *MIN HLTH PEOPL RE, 3 VERS CLIN GUID PAN; *MIN HLTH PEOPL RE, 2010, NAT INFL H1N1 PREV C; Nolan T, 2010, JAMA-J AM MED ASSOC, V303, P37, DOI 10.1001/jama.2009.1911; Rogers DJ, 2003, NAT REV MICROBIOL, V1, P231, DOI 10.1038/nrmicro776; WENGER JD, 2011, J INFECT DIS, V203, P828; WHO, CURR WHO PHAS PAND A; *WHO, PAND H1N1 2009 UPD 9	16	6	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2011	6	10							e25934	10.1371/journal.pone.0025934	http://dx.doi.org/10.1371/journal.pone.0025934			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834PW	22022474	gold, Green Submitted, Green Published			2023-01-03	WOS:000295976000048
J	Bakker, PR; de Groot, IW; van Os, J; van Harten, PN				Bakker, P. Roberto; de Groot, Izaak W.; van Os, Jim; van Harten, Peter N.			Long-Stay Psychiatric Patients: A Prospective Study Revealing Persistent Antipsychotic-Induced Movement Disorder	PLOS ONE			English	Article							INDUCED EXTRAPYRAMIDAL SYNDROMES; RANDOMIZED CONTROLLED-TRIAL; TARDIVE-DYSKINESIA; CHRONIC-SCHIZOPHRENIA; 1ST-EPISODE SCHIZOPHRENIA; BOTULINUM TOXIN; RATING-SCALE; PREVALENCE; AKATHISIA; PARKINSONISM	Objective: The purpose of this study was to assess the frequency of persistent drug-induced movement disorders namely, tardive dyskinesia (TD), parkinsonism, akathisia and tardive dystonia in a representative sample of long-stay patients with chronic severe mental illness. Method: Naturalistic study of 209, mainly white, antipsychotic-treated patients, mostly diagnosed with psychotic disorder. Of this group, the same rater examined 194 patients at least two times over a 4-year period, with a mean follow-up time of 1.1 years, with validated scales for TD, parkinsonism, akathisia, and tardive dystonia. Results: The frequencies of persistent movement disorders in the sample were 28.4% for TD, 56.2% for parkinsonism, 4.6% for akathisia and 5.7% for tardive dystonia. Two-thirds of the participants displayed at least one type of persistent movement disorder. Conclusions: Persistent movement disorder continues to be the norm for long-stay patients with chronic mental illness and long-term antipsychotic treatment. Measures are required to remedy this situation.	[Bakker, P. Roberto; van Harten, Peter N.] Psychiat Ctr GGZ Cent, Amersfoort, Netherlands; [de Groot, Izaak W.] Ctr Mental Hlth Care, Deventer, Netherlands; [van Os, Jim; van Harten, Peter N.] Maastricht Univ, EURON, S Limburg Mental Hlth Res & Teaching Network, Dept Psychiat & Psychol, Maastricht, Netherlands; [van Os, Jim] Kings Coll London, Dept Psychosis Studies, Inst Psychiat, London WC2R 2LS, England	Maastricht University; University of London; King's College London	Bakker, PR (corresponding author), Psychiat Ctr GGZ Cent, Amersfoort, Netherlands.	robertobakker@gmail.com	Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/V-8884-2019; van Os, Jim/C-2113-2014; van Os, Jim/I-9496-2012	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586; Bakker, P. Roberto/0000-0002-9964-9939	Foundation, 'The Open Ankh', The Netherlands [SG 21.02]; Eli Lilly company; BMS company; Lundbeck company; Organon company; Janssen-Cilag company; GSK company; AstraZeneca company; Pfizer company; Servier company	Foundation, 'The Open Ankh', The Netherlands; Eli Lilly company(Eli Lilly); BMS company; Lundbeck company(Lundbeck Corporation); Organon company; Janssen-Cilag company; GSK company; AstraZeneca company(AstraZeneca); Pfizer company; Servier company	This work was supported by grant from the Foundation, 'The Open Ankh', The Netherlands [grant number SG 21.02]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts: Dr. Bakker and Dr. de Groot have declared that no competing interests exist. Dr. van Os has been an unrestricted research grant holder with, or has received financial compensation as an independent symposium speaker from Eli Lilly, BMS, Lundbeck, Organon, Janssen-Cilag, GSK, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. Dr. van Harten has received financial compensation as an independent symposium speaker from Eli Lilly, BMS, Janssen-Cilag, GSK, and AstraZeneca, companies that have an interest in the treatment of psychosis. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	American Psychiatry Association, 1992, TARD DYSK TASK FORC; Arango C, 1999, AM J PSYCHIAT, V156, P1097; Ballesteros J, 2000, J CLIN PSYCHOPHARM, V20, P188, DOI 10.1097/00004714-200004000-00011; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; BARNES TRE, 1985, ARCH GEN PSYCHIAT, V42, P874; Broekema WJ, 2007, PHARM WORLD SCI, V29, P126, DOI 10.1007/s11096-006-9063-1; BURKE RE, 1985, NEUROLOGY, V35, P73, DOI 10.1212/WNL.35.1.73; Burke RE, 1992, DRUG INDUCED MOVEMEN, P167; Casey DE, 2006, CNS SPECTRUMS, V11, P25, DOI 10.1017/S1092852900026651; Chakos MH, 1996, ARCH GEN PSYCHIAT, V53, P313; Chong SA, 2009, J CLIN PSYCHOPHARM, V29, P5, DOI 10.1097/JCP.0b013e3181929f94; Correll CU, 2008, CURR OPIN PSYCHIATR, V21, P151, DOI 10.1097/YCO.0b013e3282f53132; Correll CU, 2004, AM J PSYCHIAT, V161, P414, DOI 10.1176/appi.ajp.161.3.414; Dean CE, 2009, BRIT J PSYCHIAT, V194, P360, DOI 10.1192/bjp.bp.108.049395; EMSLEY R, 2010, EUR PSYCHIAT; Esper CD, 2008, MOVEMENT DISORD, V23, P401, DOI 10.1002/mds.21854; FACTOR SA, 2009, DRUG INDUCED MOVEMEN; Factor SA., 2005, DRUG INDUCED MOVEMEN, V2nd; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Fisher WH, 2001, PSYCHIATR SERV, V52, P1051, DOI 10.1176/appi.ps.52.8.1051; Fisher WH, 2009, HEALTH AFFAIR, V28, P676, DOI 10.1377/hlthaff.28.3.676; Friedman JH, 2004, J GERIATR PSYCH NEUR, V17, P39, DOI 10.1177/0891988703262001; Guy W, 1975, ECDEU ASSESSMENT MAN, P534; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; HALSTEAD SM, 1994, BRIT J PSYCHIAT, V164, P177, DOI 10.1192/bjp.164.2.177; HOFFMAN WF, 1994, NEUROPSYCHOPHARMAC S, V135; Janno S, 2004, AM J PSYCHIAT, V161, P160, DOI 10.1176/appi.ajp.161.1.160; Jones PB, 2006, ARCH GEN PSYCHIAT, V63, P1079, DOI 10.1001/archpsyc.63.10.1079; Kahn RS, 2008, LANCET, V371, P1085, DOI 10.1016/S0140-6736(08)60486-9; KEEPERS GA, 1983, ARCH GEN PSYCHIAT, V40, P1113; Kefalopoulou Z, 2009, ACTA NEUROL SCAND, V119, P269, DOI 10.1111/j.1600-0404.2008.01115.x; Koning JPF, 2010, SCHIZOPHRENIA BULL, V36, P723, DOI 10.1093/schbul/sbn146; Lambert M, 2004, EUR PSYCHIAT, V19, P415, DOI 10.1016/j.eurpsy.2004.06.031; Laugharne J, 2004, INT J LAW PSYCHIAT, V27, P101, DOI 10.1016/j.ijlp.2003.12.004; Lerner V, 2007, ISR J PSYCHIATR REL, V44, P20; Leucht S, 2009, PSYCHOL MED, V39, P1591, DOI 10.1017/S0033291709005455; Leucht S, 2009, LANCET, V373, P31, DOI 10.1016/S0140-6736(08)61764-X; Leung JG, 2011, ANN PHARMACOTHER, V45, P525, DOI 10.1345/aph.1P312; Lewis S, 2008, BRIT J PSYCHIAT, V192, P161, DOI 10.1192/bjp.bp.107.037218; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; MACPHERSON R, 1992, BRIT J PSYCHIAT, V160, P110, DOI 10.1192/bjp.160.1.110; Miller DD, 2008, BRIT J PSYCHIAT, V193, P279, DOI 10.1192/bjp.bp.108.050088; Mittal V, 2010, POLYM SCI TECHNOL SE, P1, DOI 10.1039/9781849732192-00001; Modestin J, 2008, SCHIZOPHR RES, V100, P97, DOI 10.1016/j.schres.2007.10.018; OWENS DC, 1999, GUIDE EXTRAPYRAMIDAL; Pappa S, 2009, PSYCHOL MED, V39, P1065, DOI 10.1017/S0033291708004716; Procyshyn RM, 2001, CAN J PSYCHIAT, V46, P334, DOI 10.1177/070674370104600404; RICHARDSON MA, 1991, AM J PSYCHIAT, V148, P1322; Richardson MA, 2003, AM J PSYCHIAT, V160, P1117, DOI 10.1176/appi.ajp.160.6.1117; Rijcken CAW, 2003, J CLIN PSYCHOPHARM, V23, P657, DOI 10.1097/01.jcp.0000096247.29231.3a; Robinson DG, 2002, SCHIZOPHR RES, V57, P209, DOI 10.1016/S0920-9964(01)00312-7; Rosenheck R, 2003, JAMA-J AM MED ASSOC, V290, P2693, DOI 10.1001/jama.290.20.2693; Sachdev PS, 2005, PSYCHIAT CLIN N AM, V28, P255, DOI 10.1016/j.psc.2004.10.004; SCHOOLER NR, 1982, ARCH GEN PSYCHIAT, V39, P486; SETHI KD, 1990, MOVEMENT DISORD, V5, P319, DOI 10.1002/mds.870050411; Slotema CW, 2008, PROG NEURO-PSYCHOPH, V32, P507, DOI 10.1016/j.pnpbp.2007.10.004; Soares-Weiser K, 2007, SEMIN NEUROL, V27, P159, DOI 10.1055/s-2007-971169; Tamminga CA, 2006, AM J PSYCHIAT, V163, P563, DOI 10.1176/appi.ajp.163.4.563; Taylor D, 2010, PSYCHIATR BULL, V34, P41, DOI 10.1192/pb.bp.109.027086; Tenback DE, 2005, J CLIN PSYCHIAT, V66, P1130, DOI 10.4088/JCP.v66n0907; Tenback DE, 2009, MOVEMENT DISORD, V24, P2309, DOI 10.1002/mds.22707; van Harten PN, 2009, PSYCHOL MED, V39, P1754, DOI 10.1017/S0033291709990456; Van Harten P. N., 1996, Schizophrenia Research, V19, P195; van Harten PN, 2006, MOVEMENT DISORD, V21, P1276, DOI 10.1002/mds.20904; van Harten PN, 1999, SCHIZOPHRENIA BULL, V25, P741, DOI 10.1093/oxfordjournals.schbul.a033415; VANHARTEN PN, 1998, MOVEMENT DISORDERS A; Weiden Peter J, 2007, J Psychiatr Pract, V13, P13, DOI 10.1097/00131746-200701000-00003; WOODS SW, 2010, J CLIN PSYCHIAT; YASSA R, 1992, SCHIZOPHRENIA BULL, V18, P701, DOI 10.1093/schbul/18.4.701	69	41	42	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2011	6	10							e25588	10.1371/journal.pone.0025588	http://dx.doi.org/10.1371/journal.pone.0025588			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834EU	22022416	gold, Green Published, Green Submitted			2023-01-03	WOS:000295943000044
J	Tao, MF; Teng, YC; Shao, HF; Wu, P; Mills, EJ				Tao, MinFang; Teng, YinCheng; Shao, HongFang; Wu, Ping; Mills, Edward J.			Knowledge, Perceptions and Information about Hormone Therapy (HT) among Menopausal Women: A Systematic Review and Meta-Synthesis	PLOS ONE			English	Article							ESTROGEN PLUS PROGESTIN; BREAST-CANCER INCIDENCE; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; OBSTETRICIAN-GYNECOLOGISTS; DECISION-MAKING; HEALTH; ATTITUDES; BARRIERS; SYMPTOMS	Background: The use of hormone therapy (HT) by menopausal women has declined since the Women's Health Initiative randomized trial (WHI) in 2002 demonstrated important harms associated with long-term use. However, how this information has influenced women's knowledge and attitudes is uncertain. We aimed to evaluate the attitudes and perceptions towards HT use, as well as specific concerns and information sources on HT since the WHI trial. Method/Results: We did a systematic review to assess the attitudes and knowledge towards HT in women, and estimate the magnitude of the issue by pooling across the studies. Using meta-synthesis methods, we reviewed qualitative studies and surveys and performed content analysis on the study reports. We pooled quantitative studies using a random-effects meta-analysis. We analyzed 11 qualitative studies (n = 566) and 27 quantitative studies (n = 39251). Positive views on HT included climacteric symptom control, prevention of osteoporosis and a perceived improvement in quality of life. Negative factors reported included concerns about potential harmful effects, particularly cancer risks. Sources of information included health providers, media, and social contact. By applying a meta-synthesis approach we demonstrate that these findings are broadly applicable across large groups of patients. Conclusions: Although there are clear hazards associated with long-term HT use, many women view HT favorably for climacteric symptom relief. Media, as a source of information, is often valued as equivalent to health providers.	[Tao, MinFang; Teng, YinCheng; Shao, HongFang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gynecol, Shanghai 200030, Peoples R China; [Wu, Ping; Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada; [Mills, Edward J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada	Shanghai Jiao Tong University; University of Ottawa; McMaster University	Tao, MF (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gynecol, Shanghai 200030, Peoples R China.	taomf@hotmail.com			Shanghai Municipal Health Bureau [2008001]; Technology Innovation of Science and Technology Commission of Shanghai [09DJ1400404]	Shanghai Municipal Health Bureau; Technology Innovation of Science and Technology Commission of Shanghai	This study was supported by the Bureau Level Research Projects of Shanghai Municipal Health Bureau (2008001), and by the 2009 Action Plan for Technology Innovation of Science and Technology Commission of Shanghai (09DJ1400404). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allemand H, 2008, B CANCER, V95, P11, DOI 10.1684/bdc.2008.0556; Ballard K, 2002, FAM PRACT, V19, P591, DOI 10.1093/fampra/19.6.591; Barber CA, 2004, J WOMENS HEALTH, V13, P975, DOI 10.1089/jwh.2004.13.975; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; Bosworth HB, 2005, J BEHAV MED, V28, P105, DOI 10.1007/s10865-005-2721-2; Canderelli R, 2007, J AM ACAD NURSE PRAC, V19, P635, DOI 10.1111/j.1745-7599.2007.00269.x; Castelo-Branco C, 2007, MATURITAS, V56, P420, DOI 10.1016/j.maturitas.2006.11.006; Chaopotong Pattama, 2005, Journal of the Medical Association of Thailand, V88, P1768; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Cifcili SY, 2008, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-2; Deeks A, 2008, MENOPAUSE, V15, P304, DOI 10.1097/gme.0b013e31812f7b65; Donati S, 2009, MATURITAS, V63, P246, DOI 10.1016/j.maturitas.2009.04.001; Ekstrom H, 2005, MATURITAS, V52, P154, DOI 10.1016/j.maturitas.2005.01.010; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; French Linda M, 2006, BMC Fam Pract, V7, P61, DOI 10.1186/1471-2296-7-61; Fugh-Berman A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000425; Genazzanii AR, 2006, GYNECOL ENDOCRINOL, V22, P369, DOI 10.1080/09513590600842463; HARLAP S, 1992, AM J OBSTET GYNECOL, V166, P1986, DOI 10.1016/0002-9378(92)91399-U; Heinemann K, 2008, J WOMENS HEALTH, V17, P1151, DOI 10.1089/jwh.2007.0584; Hepworth J, 2002, PSYCHOL HEALTH MED, V7, P469, DOI [10.1080/1354850021000015285, DOI 10.1080/1354850021000015285]; Hoffmann M, 2005, MATURITAS, V52, P11, DOI 10.1016/j.maturitas.2005.06.003; Hovi Sirpa-Liisa, 2005, BMC Med Res Methodol, V5, P12, DOI 10.1186/1471-2288-5-12; Huang KE, 2010, MATURITAS, V65, P276, DOI 10.1016/j.maturitas.2009.11.015; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUNT K, 1990, BRIT J OBSTET GYNAEC, V97, P1080, DOI 10.1111/j.1471-0528.1990.tb02494.x; Huston SA, 2009, WOMEN HEALTH ISS, V19, P144, DOI 10.1016/j.whi.2009.01.004; Hyde A, 2010, MENOPAUSE, V17, P344, DOI 10.1097/gme.0b013e3181c6b26f; Jassim GA, 2009, CLIMACTERIC, V12, P38, DOI 10.1080/13697130802447066; Kaur S, 2004, CLIMACTERIC, V7, P175, DOI 10.1080/13697130410001713779; Keelan J, 2007, JAMA-J AM MED ASSOC, V298, P2482, DOI 10.1001/jama.298.21.2482; Kolip P, 2009, QUAL HEALTH RES, V19, P207, DOI 10.1177/1049732308328053; Lam PM, 2003, MATURITAS, V45, P99, DOI 10.1016/S0378-5122(03)00090-2; Lindh-Astrand L, 2007, MENOPAUSE, V14, P1039, DOI 10.1097/gme.0b013e31803816ca; Lindh-Astrand L, 2007, MATURITAS, V56, P12, DOI 10.1016/j.maturitas.2006.05.002; Loutfy I., 2006, Eastern Mediterranean Health Journal, V12, pS93; Majumdar SR, 2004, JAMA-J AM MED ASSOC, V292, P1983, DOI 10.1001/jama.292.16.1983; Malik Humaira Saeed, 2008, J Pak Med Assoc, V58, P164; Maslove DM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-26; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mills E, 2004, AIDS, V18, P2235, DOI 10.1097/00002030-200411190-00003; Mills E, 2005, J CLIN EPIDEMIOL, V58, P1081, DOI 10.1016/j.jclinepi.2005.09.002; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Mills EJ, 2006, LANCET ONCOL, V7, P141, DOI 10.1016/S1470-2045(06)70576-9; Mills EJ, 2005, J CLIN EPIDEMIOL, V58, P1101, DOI 10.1016/j.jclinepi.2005.01.014; Nekhlyudov L, 2009, WOMEN HEALTH, V49, P280, DOI 10.1080/03630240903158446; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Obermeyer CM, 2004, MENOPAUSE, V11, P456, DOI 10.1097/01.GME.0000109318.11228.DA; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P772, DOI 10.1016/S0002-9378(12)90817-0; Pereira AS, 2005, MATURITAS, V51, P146, DOI 10.1016/j.maturitas.20045.06.018; Pines A, 2007, CLIMACTERIC, V10, P181, DOI 10.1080/13697130701361657; Power ML, 2009, MENOPAUSE, V16, P500, DOI 10.1097/gme.0b013e31818fc36e; Power ML, 2006, MENOPAUSE, V13, P434, DOI 10.1097/01.gme.0000185753.77704.65; Rigby AJ, 2007, MENOPAUSE, V14, P853, DOI 10.1097/gme.0b013e3180333a33; Rolnick SJ, 2007, MENOPAUSE, V14, P441, DOI 10.1097/GME.0b013e31802cc7bc; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rothstein HR., INTRO METAANALYSIS; Shelton AJ, 2002, J HEALTH CARE POOR U, V13, P347, DOI 10.1177/10408902013003007; Simon JA, 2009, MENOPAUSE, V16, P73, DOI 10.1097/gme.0b013e31817b614a; Society CM, 2010, CHIN J OBSTET GYNECO, V45, P635; Sveinsdottir H, 2006, J ADV NURS, V54, P572, DOI 10.1111/j.1365-2648.2006.03862.x; Thunell L, 2005, ACTA OBSTET GYN SCAN, V84, P395, DOI 10.1111/j.0001-6349.2005.00725.x; Twiss JJ, 2007, J AM ACAD NURSE PRAC, V19, P602, DOI 10.1111/j.1745-7599.2007.00260.x; Uncu Y, 2007, CLIMACTERIC, V10, P63, DOI 10.1080/13697130601037324; Vankrunkelsven P, 2009, BREAST CANCER RES TR, V118, P425, DOI 10.1007/s10549-009-0346-9; Walter FM, 2002, FAM PRACT, V19, P579, DOI 10.1093/fampra/19.6.579; Welton A, 2004, CLIMACTERIC, V7, P41, DOI 10.1080/13697130310001651463	67	36	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2011	6	9							e24661	10.1371/journal.pone.0024661	http://dx.doi.org/10.1371/journal.pone.0024661			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	824BI	21949743	Green Published, Green Submitted, gold			2023-01-03	WOS:000295173800033
J	Mechanic, RE				Mechanic, Robert E.			Opportunities and Challenges for Episode-Based Payment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02453 USA	Brandeis University	Mechanic, RE (corresponding author), Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA 02453 USA.							Casale AS, 2007, ANN SURG, V246, P613, DOI 10.1097/SLA.0b013e318155a996; de Brantes F, 2009, NEW ENGL J MED, V361, P1033, DOI 10.1056/NEJMp0906121; Hussey PS, 2009, HEALTH AFFAIR, V28, P1406, DOI 10.1377/hlthaff.28.5.1406; Mechanic RE, 2009, HEALTH AFFAIR, V28, pW262, DOI 10.1377/hlthaff.28.2.w262	4	57	57	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2011	365	9					777	779		10.1056/NEJMp1105963	http://dx.doi.org/10.1056/NEJMp1105963			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	813YC	21864162				2023-01-03	WOS:000294405200001
J	Baker, MG; Barnard, LT; Kvalsvig, A; Verrall, A; Zhang, J; Keall, M; Wilson, N; Wall, T; Howden-Chapman, P				Baker, Michael G.; Barnard, Lucy Telfar; Kvalsvig, Amanda; Verrall, Ayesha; Zhang, Jane; Keall, Michael; Wilson, Nick; Wall, Teresa; Howden-Chapman, Philippa			Increasing incidence of serious infectious diseases and inequalities in New Zealand: a national epidemiological study	LANCET			English	Article							ACUTE RHEUMATIC-FEVER; UNITED-STATES; DEVELOPED COUNTRY; TRENDS; HOSPITALIZATIONS; CAMPYLOBACTERIOSIS; DEPRIVATION; POPULATION; MORTALITY; CHILDREN	Background Although the burden of infectious diseases seems to be decreasing in developed countries, few national studies have measured the total incidence of these diseases. We aimed to develop and apply a robust systematic method for monitoring the epidemiology of serious infectious diseases. Methods We did a national epidemiological study with all hospital admissions for infectious and non-infectious diseases in New Zealand from 1989 to 2008, to investigate trends in incidence and distribution by ethnic group and socioeconomic status. We extended a recoding system based on the ninth revision of international classification of diseases (ICD-9) to the tenth revision (ICD-10), and applied this to data for hospital admissions from the New Zealand Ministry of Health, National Minimum Dataset. We filtered results to account for changes in health-care practices over time. Acute overnight admissions were the events of interest. Findings Infectious diseases made the largest contribution to hospital admissions of any cause. Their contribution increased from 20.5% of acute admissions in 1989-93, to 26.6% in 2004-08. We noted clear ethnic and social inequalities in infectious disease risk. In 2004-08, the age-standardised rate ratio was 2.15 (95% CI 2.14-2.16) for Maori (indigenous New Zealanders) and 2.35 (2.34-2.37) for Pacific peoples compared with the European and other group. The ratio was 2.81 (2.80-2.83) for the most socioeconomically deprived quintile compared with the least deprived quintile. These inequalities have increased substantially in the past 20 years, particularly for Maori and Pacific peoples in the most deprived quintile. Interpretation These findings support the need for stronger prevention efforts for infectious diseases, and reinforce the need to reduce ethnic and social inequalities and to address disparities in broad social determinants such as income levels, housing conditions, and access to health services. Our method could be adapted for infectious disease surveillance in other countries.	[Baker, Michael G.; Barnard, Lucy Telfar; Kvalsvig, Amanda; Verrall, Ayesha; Zhang, Jane; Keall, Michael; Wilson, Nick; Howden-Chapman, Philippa] Univ Otago, Dept Publ Hlth, Wellington, New Zealand; [Wall, Teresa] Minist Hlth, Maori Hlth Directorate, Wellington, New Zealand	University of Otago	Baker, MG (corresponding author), Univ Otago, Dept Publ Hlth, POB 7343, Wellington 6242, New Zealand.	michael.baker@otago.ac.nz	Verrall, Ayesha/U-7223-2019; Barnard-Brak, Lucy/K-2009-2019; Barnard-Brak, Lucy/T-6856-2018	Verrall, Ayesha/0000-0001-9672-1352; Barnard-Brak, Lucy/0000-0001-7239-0720	New Zealand Ministry of Health; New Zealand Health Research Council	New Zealand Ministry of Health; New Zealand Health Research Council(Health Research Council of New Zealand)	New Zealand Ministry of Health, New Zealand Health Research Council.	Armstrong GL, 1999, ARCH INTERN MED, V159, P2531, DOI 10.1001/archinte.159.21.2531; Baker M, 2000, PEDIATR INFECT DIS J, V19, P983, DOI 10.1097/00006454-200010000-00009; Baker M, 2008, J EPIDEMIOL COMMUN H, V62, P715, DOI 10.1136/jech.2007.063610; Baker M, 2012, DISTRIBUTION HOUSEHO; Baker MG, 2007, EPIDEMIOL INFECT, V135, P163, DOI 10.1017/S0950268806006583; Baker MG, 2009, EUROSURVEILLANCE, V14, P6; Baker MG, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-332; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Christensen KLY, 2009, CLIN INFECT DIS, V49, P1025, DOI 10.1086/605562; Ford AC, 2006, COCHRANE DB SYST REV, V19; French GL, 2010, INT J ANTIMICROB AG, V36, pS3, DOI 10.1016/S0924-8579(10)70003-0; Grant CC, 1999, NEW ZEAL MED J, V112, P345; Harris R, 2007, HAUORA MAORI STANDAR, P249; Holman RC, 2001, AM J PUBLIC HEALTH, V91, P425, DOI 10.2105/AJPH.91.3.425; Jaine R, 2008, J PAEDIATR CHILD H, V44, P564, DOI 10.1111/j.1440-1754.2008.01384.x; Jaine R, 2011, PEDIATR INFECT DIS J, V30, P315, DOI 10.1097/INF.0b013e3181fbd85b; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Langley J, 2002, INJ PREV, V8, P332, DOI 10.1136/ip.8.4.332; Mills CF, 2002, NEW ZEAL MED J, V115, P254; *MIN HLTH, 2001, INT APPR INF DIS PRI; Ministry of Health, 2004, ETHN DAT PROT HLTH D; Ministry of Health, 2008, PRES ETHN COMP PRIOR; O'Hallahan J, 2009, NEW ZEAL MED J, V122, P48; O'Sullivan CE, 2010, EPIDEMIOL INFECT, V15, P1; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; Ortiz JR, 2009, EMERG INFECT DIS, V15, P1271, DOI 10.3201/eid1508.081422; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Perry B., 2010, HOUSEHOLD INCOMES NZ; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; Salmond C, 1998, AUST NZ J PUBL HEAL, V22, P835, DOI 10.1111/j.1467-842X.1998.tb01505.x; Sears A, 2011, EMERG INFECT DIS, V17, P1007, DOI [10.3201/eid1706.101272, 10.3201/eid/1706.101272]; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; Statistics New Zealand, 2003, WHAT IS EXT CROWD NZ; Tobias M, 2008, AUST NZ J PUBL HEAL, V32, P431, DOI 10.1111/j.1753-6405.2008.00275.x	35	175	177	5	49	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 24	2012	379	9821					1112	1119		10.1016/S0140-6736(11)61780-7	http://dx.doi.org/10.1016/S0140-6736(11)61780-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916VR	22353263				2023-01-03	WOS:000302131800033
J	Achieng, L; Musangi, H; Ong'uti, S; Ombegoh, E; Bryant, L; Mwiindi, J; Smith, N; Keiser, P				Achieng, Loice; Musangi, Helen; Ong'uti, Sharon; Ombegoh, Edwin; Bryant, LeeAnn; Mwiindi, Jonathan; Smith, Nathaniel; Keiser, Philip			An Observational Cohort Comparison of Facilitators of Retention in Care and Adherence to Anti-Eetroviral Therapy at an HIV Treatment Center in Kenya	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; FOLLOW-UP; PATIENTS LOST; VIRAL LOAD; PROGRAMS; AFRICA; TRIAL; SURVIVAL; OUTCOMES	Background: Most HIV treatment programs in resource-limited settings utilize multiple facilitators of adherence and retention in care but there is little data on the efficacy of these methods. We performed an observational cohort analysis of a treatment program in Kenya to assess which program components promote adherence and retention in HIV care in East Africa. Methods: Patients initiating ART at A. I. C. Kijabe Hospital were prospectively enrolled in an observational study. Kijabe has an intensive program to promote adherence and retention in care during the first 6 months of ART that incorporates the following facilitators: home visits by community health workers, community based support groups, pharmacy counseling, and unannounced pill counts by clinicians. The primary endpoint was time to treatment failure, defined as a detectable HIV-1 viral load; discontinuation of ART; death; or loss to follow-up. Time to treatment failure for each facilitator was calculated using Kaplan-Meier analysis. The relative effects of the facilitators were determined by the Cox Proportional Hazards Model. Results: 301 patients were enrolled. Time to treatment failure was longer in patients participating in support groups (448 days vs. 337 days, P<0.001), pharmacy counseling (480 days vs. 386 days, P = 0.002), pill counts (482 days vs. 189 days, P<0.001) and home visits (485 days vs. 426 days, P = 0.024). Better adherence was seen with support groups (89% vs. 82%, P = 0.05) and pill counts (89% vs. 75%, P = 0.02). Multivariate analysis using the Cox Model found significant reductions in risk of treatment failure associated with pill counts (HR = 0.19, P<0.001) and support groups (HR = 0.43, P = 0.003). Conclusion: Unannounced pill counts by the clinician and community based support groups were associated with better long term treatment success and with better adherence.	[Achieng, Loice; Ombegoh, Edwin; Smith, Nathaniel] AIC Kijabe Hosp, Kijabe, Kenya; [Achieng, Loice; Musangi, Helen] Univ Nairobi, Nairobi, Kenya; [Ong'uti, Sharon] Johns Hopkins Univ, Baltimore, MD USA; [Ong'uti, Sharon; Bryant, LeeAnn; Mwiindi, Jonathan; Keiser, Philip] Univ Texas Med Branch, Galveston, TX USA; [Smith, Nathaniel] Arkansas Dept Hlth, Little Rock, AR 72205 USA	University of Nairobi; Johns Hopkins University; University of Texas System; University of Texas Medical Branch Galveston	Achieng, L (corresponding author), AIC Kijabe Hosp, Kijabe, Kenya.	pkeise@gmail.com			Gilead Foundation; University of Texas Medical Branch	Gilead Foundation(Gilead Sciences); University of Texas Medical Branch	This study was funded by the Gilead Foundation and by the University of Texas Medical Branch. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anglaret X, 2004, JAIDS-J ACQ IMM DEF, V35, P320, DOI 10.1097/00126334-200403010-00015; [Anonymous], 2010, 6 ANN REPORT C PEPFA; [Anonymous], 2010, JOINT WHO UNICEF UNA; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bassett IV, 2009, JAIDS-J ACQ IMM DEF, V51, P135, DOI 10.1097/QAI.0b013e3181a44ef2; Bendavid E, 2009, ANN INTERN MED, V150, P688, DOI 10.7326/0003-4819-150-10-200905190-00117; Chalker J, 2010, JAIDS-J ACQ IMM DEF, V53, P159, DOI 10.1097/QAI.0b013e3181befa12; Chang LW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010923; Chung MH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000422; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101, DOI 10.1097/QAI.0b013e31815b833a; Ekouevi DK, 2010, TROP MED INT HEALTH, V15, P34, DOI 10.1111/j.1365-3156.2010.02505.x; El-Khatib Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017518; Etienne M, 2010, TROP MED INT HEALTH, V15, P76, DOI 10.1111/j.1365-3156.2010.02513.x; Fairley CK, 2003, INT J STD AIDS, V14, P805, DOI 10.1258/095646203322556129; Ford N, 2009, LANCET, V374, P2064, DOI 10.1016/S0140-6736(09)61671-8; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Geng EH, 2010, TROP MED INT HEALTH, V15, P63, DOI 10.1111/j.1365-3156.2010.02507.x; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Haberer JE, 2010, AIDS BEHAV, V14, P1340, DOI 10.1007/s10461-010-9799-4; Jerome G, 2010, AIDS, V24, pS67, DOI 10.1097/01.aids.0000366084.75945.c9; Klausner JD, 2011, JAIDS-J ACQ IMM DEF, V56, P292, DOI 10.1097/QAI.0b013e3182067d99; Krebs DW, 2008, AIDS CARE, V20, P311, DOI 10.1080/09540120701594776; Mugusi F, 2009, TROP MED INT HEALTH, V14, P1226, DOI 10.1111/j.1365-3156.2009.02359.x; Muyingo SK, 2008, JAIDS-J ACQ IMM DEF, V48, P468, DOI 10.1097/QAI.0b013e31817dc3fd; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, pS127, DOI 10.1097/01.qai.0000248349.25630.3d; Nellen JFJB, 2009, AIDS CARE, V21, P842, DOI 10.1080/09540120802612816; Pearson CR, 2007, JAIDS-J ACQ IMM DEF, V46, P238, DOI 10.1097/QAI.0b013e318153f7ba; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Stevens G, 2005, J CLIN MICROBIOL, V43, P857, DOI 10.1128/JCM.43.2.857-861.2005	30	15	16	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2012	7	3							e32727	10.1371/journal.pone.0032727	http://dx.doi.org/10.1371/journal.pone.0032727			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	929KX	22427869	gold, Green Submitted, Green Published			2023-01-03	WOS:000303062800028
J	Schubert, C; Geser, W; Noisternig, B; Fuchs, D; Welzenbach, N; Konig, P; Schussler, G; Ocana-Peinado, FM; Lampe, A				Schubert, Christian; Geser, Willi; Noisternig, Bianca; Fuchs, Dietmar; Welzenbach, Natalie; Koenig, Paul; Schuessler, Gerhard; Ocana-Peinado, Francisco M.; Lampe, Astrid			Stress System Dynamics during "Life As It Is Lived": An Integrative Single-Case Study on a Healthy Woman	PLOS ONE			English	Article							PITUITARY-ADRENAL AXIS; DAILY PSYCHOSOCIAL STRESSORS; ACUTE MENTAL STRESS; PSYCHOLOGICAL STRESS; LUPUS-ERYTHEMATOSUS; DAILY EVENTS; CORTISOL RESPONSES; NEOPTERIN; NEUROENDOCRINE; INTERLEUKIN-6	Little is known about the dynamic characteristics of stress system activity during "life as it is lived". Using as representative a study design as possible, this investigation sought to gain insights into this area. A healthy 25-year-old woman collected her entire urine over a period of 63 days in 12-h intervals (126 measurements) to determine cortisol and neopterin (immune activation marker) levels. In addition, she filled out questionnaires on emotional state and daily routine in 12-h intervals, and was interviewed weekly to identify emotionally negative and positive everyday incidents. Adjusted cross-correlational analyses revealed that stressful incidents were associated with cyclic response patterns in both urinary cortisol and urinary neopterin concentrations. Urinary cortisol levels first decreased 12-24 h after stressful incidents occurred (lag 1: -.178; p = 0.048) and then increased a total of 72-84 h later (lag 6: +.224; p = 0.013). Urinary neopterin levels first increased 0-12 h before the occurrence of stressful incidents (-lag 1: +.185; p = 0.040) and then decreased a total of 48-60 h following such stressors (lag 4: -.181; p = 0.044). Decreases in urinary neopterin levels were also found 24-36 and 48-60 h after increases in pensiveness (lag 2: -.215; p = 0.017) and depressiveness (lag 4: -.221; p = 0.014), respectively. Findings on emotionally positive incidents sharply contrasted with those dealing with negative experiences. Positive incidents were followed first by urinary cortisol concentration increases within 12 h (lag 0: +.290; p = 0.001) and then by decreases after a total of 60-72 h (lag 5: -.186; p = 0.039). Urinary neopterin levels first decreased 12-24 h before positive incidents occurred (-lag 2: -.233; p = 0.010) and then increased a total of 12-24 h following these incidents (lag 1: +.222; p = 0.014). As with previous investigations on patients with systemic lupus erythematosus (SLE), this study showed that stress system response can be considerably longer and more complex and differentiated than findings from conventional group studies have suggested. Further integrative single-case studies will need to be conducted in order to draw firm conclusions about stress system dynamics under real-life conditions.	[Schubert, Christian; Noisternig, Bianca; Schuessler, Gerhard; Lampe, Astrid] Innsbruck Med Univ, Clin Dept Med Psychol, Innsbruck, Austria; [Geser, Willi] Univ Innsbruck, Inst Psychol, A-6020 Innsbruck, Austria; [Fuchs, Dietmar; Welzenbach, Natalie] Innsbruck Med Univ, Bioctr, Div Biol Chem, Innsbruck, Austria; [Koenig, Paul] Innsbruck Med Univ, Clin Dept Internal Med, Innsbruck, Austria; [Ocana-Peinado, Francisco M.] Univ Granada, Dept Stat & Operat Res, Granada, Spain	Medical University of Innsbruck; University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; University of Granada	Schubert, C (corresponding author), Innsbruck Med Univ, Clin Dept Med Psychol, Innsbruck, Austria.	christian.schubert@i-med.ac.at	Fuchs, Dietmar/AAL-8011-2021	Fuchs, Dietmar/0000-0003-1627-9563	University Clinics Tirol (MFF Tirol) [42]; Leopold-Franzens-Universitat Innsbruck	University Clinics Tirol (MFF Tirol); Leopold-Franzens-Universitat Innsbruck	This study was supported by a grant from the University Clinics Tirol (MFF Tirol, No. 42, http://www.mff-tirol.at/) and by a fellowship (Mag. Noisternig) from the Leopold-Franzens-Universitat Innsbruck (http://www.uibk.ac.at/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam EK, 2006, P NATL ACAD SCI USA, V103, P17058, DOI 10.1073/pnas.0605053103; Allport G.W., 1942, SOCIAL SCI RES COUNC, V49; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bartlett M. S., 1955, INTRO STOCHASTIC PRO; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Besedovsky HO., 1991, PSYCHONEUROIMMUNOLOG, pp. 589, DOI [10.1159/000452902, DOI 10.1159/000452902]; Box G.E., 2015, REV; Brockwell P, 2002, INTRO TIME SERIES FO; BROWN G. W., 1989, LIFE EVENTS ILLNESS, P3; BROWN WA, 1993, PSYCHOSOM MED, V55, P458, DOI 10.1097/00006842-199309000-00009; Brunswik E., 1956, PERCEPTION REPRESENT, V2nd; Brydon L, 2005, BRAIN BEHAV IMMUN, V19, P540, DOI 10.1016/j.bbi.2004.12.003; Buchanan TW, 1999, PSYCHONEUROENDOCRINO, V24, P227, DOI 10.1016/S0306-4530(98)00078-X; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; Dahlgren A, 2009, BIOL PSYCHOL, V82, P149, DOI 10.1016/j.biopsycho.2009.07.001; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; DUNBAR PR, 1993, AUST NZ J PSYCHIAT, V27, P495, DOI 10.3109/00048679309075808; Ehlert U, 2001, BIOL PSYCHOL, V57, P141, DOI 10.1016/S0301-0511(01)00092-8; Ellins E, 2008, BRAIN BEHAV IMMUN, V22, P941, DOI 10.1016/j.bbi.2008.01.009; Eriksen HR, 1999, PSYCHIAT RES, V85, P39, DOI 10.1016/S0165-1781(98)00141-3; Feise Ronald J, 2002, BMC Med Res Methodol, V2, P8, DOI 10.1186/1471-2288-2-8; FLESHNER M, 1995, ENDOCRINOLOGY, V136, P5336, DOI 10.1210/en.136.12.5336; FUCHS D, 1993, INT ARCH ALLERGY IMM, V101, P1, DOI 10.1159/000236491; FUCHS D, 1992, CRIT REV CL LAB SCI, V29, P307, DOI 10.3109/10408369209114604; FUTTERMAN AD, 1994, PSYCHOSOM MED, V56, P499, DOI 10.1097/00006842-199411000-00005; Gerin W, 1998, J PSYCHOSOM RES, V44, P209, DOI 10.1016/S0022-3999(97)00207-9; Gutierrez MA, 1998, LUPUS, V7, P404, DOI 10.1191/096120398678920343; Hanson EKS, 2000, ANN BEHAV MED, V22, P316, DOI 10.1007/BF02895668; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; HU YH, 1993, INT ARCH ALLERGY IMM, V102, P232, DOI 10.1159/000236531; HUBERT W, 1990, BIOL PSYCHOL, V31, P73, DOI 10.1016/0301-0511(90)90079-C; HUBERT W, 1991, INT J PSYCHOPHYSIOL, V11, P131, DOI 10.1016/0167-8760(91)90005-I; Huether G, 1999, PSYCHIAT RES, V87, P83, DOI 10.1016/S0165-1781(99)00044-X; Huppe M, 1983, UNTERSUCHUNGEN EWL 6; Ilias Ioannis, 2002, Endocr Regul, V36, P63; Jacobs N, 2007, BIOL PSYCHOL, V74, P60, DOI 10.1016/j.biopsycho.2006.07.002; Jacobs R, 2001, RHEUMATOLOGY, V40, P868, DOI 10.1093/rheumatology/40.8.868; Janke W., 1978, EIGENSCHAFTSWORTERLI; Jenkins G. M., 1969, SPECTRAL ANAL ITS AP; KAPPEL M, 1991, J APPL PHYSIOL, V70, P2530, DOI 10.1152/jappl.1991.70.6.2530; KELLERWOOD ME, 1984, ENDOCR REV, V5, P1, DOI 10.1210/edrv-5-1-1; Kirschbaum C., 2000, ENCY STRESS, V3, P379, DOI DOI 10.1159/000118611; KNAPP PH, 1992, PSYCHOSOM MED, V54, P133, DOI 10.1097/00006842-199203000-00002; Koolhaas JM, 1997, NEUROSCI BIOBEHAV R, V21, P775, DOI 10.1016/S0149-7634(96)00057-7; Lazarus R. S., 1991, EMOTION ADAPTATION; Lincoln Y.S., 1985, NATURALISTIC INQUIRY; Lipsitz Lewis A, 2004, Sci Aging Knowledge Environ, V2004, ppe16; LJUNG GM, 1978, BIOMETRIKA, V65, P297, DOI 10.2307/2335207; LUNDBERG U, 1990, PHARMACOL BIOCHEM BE, V37, P697, DOI 10.1016/0091-3057(90)90550-2; Lutkepohl H., 2005, NEW INTRO MULTIPLE T, DOI DOI 10.1007/078-3-540-27752-1; Makino S, 2002, PHARMACOL BIOCHEM BE, V73, P147, DOI 10.1016/S0091-3057(02)00791-8; MCCRAE RR, 1990, STRESS MEDICINE, V6, P237, DOI 10.1002/smi.2460060309; McQuaid JR, 2000, J ABNORM PSYCHOL, V109, P787, DOI 10.1037/0021-843X.109.4.787; Michaud K, 2008, STRESS, V11, P177, DOI 10.1080/10253890701727874; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Murphy K, 2008, JANEWAYS IMMUNOBIOLO; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; Pecoraro N, 2006, PROG NEUROBIOL, V79, P247, DOI 10.1016/j.pneurobio.2006.07.004; Porta A, 2007, IEEE T BIO-MED ENG, V54, P94, DOI 10.1109/TBME.2006.883789; Posener JA, 1998, PSYCHONEUROENDOCRINO, V23, P371, DOI 10.1016/S0306-4530(98)00006-7; Righter SD, 1996, J CLIN ENDOCR METAB, V81, P1956, DOI 10.1210/jc.81.5.1956; Rohleder N, 2006, LIFE SCI, V78, P3082, DOI 10.1016/j.lfs.2005.12.016; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Roy MP, 2004, HORM BEHAV, V46, P618, DOI 10.1016/j.yhbeh.2004.06.015; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Savitz DA, 1998, AM J EPIDEMIOL, V147, P813, DOI 10.1093/oxfordjournals.aje.a009532; SCHEDLOWSKI M, 1993, NEUROPSYCHOBIOLOGY, V28, P87, DOI 10.1159/000119006; SCHEDLOWSKI M, 1993, J CLIN IMMUNOL, V13, P119, DOI 10.1007/BF00919268; Schlotz W, 2008, PSYCHOSOM MED, V70, P787, DOI 10.1097/PSY.0b013e3181810658; Schubert C, 2002, PSYCHOTHER PSYCHOSOM, V71, P123, DOI 10.1159/000049356; Schubert C, 2003, PSYCHONEUROENDOCRINO, V28, P459, DOI 10.1016/S0306-4530(02)00034-3; Schubert C, 1999, PSYCHOSOM MED, V61, P876, DOI 10.1097/00006842-199911000-00024; Schubert C, 2006, STRESS HEALTH, V22, P215, DOI 10.1002/smi.1096; Schubert Christian, 2009, Stress, V12, P464, DOI 10.1080/10253890802603925; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; SELIGMAN MEP, 1980, BEHAV RES THER, V18, P462, DOI 10.1016/0005-7967(80)90012-1; Smyth J, 1998, PSYCHONEUROENDOCRINO, V23, P353, DOI 10.1016/S0306-4530(98)00008-0; SPSS Inc, 2005, SPSS TRENDS 14 0; Stalder T, 2010, PSYCHONEUROENDOCRINO, V35, P209, DOI 10.1016/j.psyneuen.2009.06.006; Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; STEVENS SS, 1946, SCIENCE, V103, P677, DOI 10.1126/science.103.2684.677; STONE AA, 1987, J PERS SOC PSYCHOL, V52, P988, DOI 10.1037/0022-3514.52.5.988; STONE AA, 1994, HEALTH PSYCHOL, V13, P440, DOI 10.1037/0278-6133.13.5.440; Stone AA, 1996, INT J BEHAV MED, V3, P1, DOI 10.1207/s15327558ijbm0301_1; Straub RH, 1998, J CLIN ENDOCR METAB, V83, P2012, DOI 10.1210/jcem.83.6.4876; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Turner J. Rick, 1994, Annals of Behavioral Medicine, V16, P12; Valdimarsdottir HB, 1997, CRIT REV ORAL BIOL M, V8, P461, DOI 10.1177/10454411970080040601; Van Doornen LJP, 1992, INDIVIDUAL DIFFERENC, P63; vanEck M, 1996, PSYCHOSOM MED, V58, P447, DOI 10.1097/00006842-199609000-00007; vanEck MMM, 1996, BIOL PSYCHOL, V43, P69, DOI 10.1016/0301-0511(95)05159-7; von Kanel R, 2006, BRAIN BEHAV IMMUN, V20, P40, DOI 10.1016/j.bbi.2005.03.013; Yin R. K., 2003, QUALITATIVE RES STAR; Zietz B, 2000, J RHEUMATOL, V27, P911	97	22	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2012	7	3							e29415	10.1371/journal.pone.0029415	http://dx.doi.org/10.1371/journal.pone.0029415			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	928WA	22403606	Green Published, gold, Green Submitted			2023-01-03	WOS:000303017700003
J	Spanou, C; Veskoukis, AS; Kerasioti, T; Kontou, M; Angelis, A; Aligiannis, N; Skaltsounis, AL; Kouretas, D				Spanou, Chrysoula; Veskoukis, Aristidis S.; Kerasioti, Thalia; Kontou, Maria; Angelis, Apostolos; Aligiannis, Nektarios; Skaltsounis, Alexios-Leandros; Kouretas, Dimitrios			Flavonoid Glycosides Isolated from Unique Legume Plant Extracts as Novel Inhibitors of Xanthine Oxidase	PLOS ONE			English	Article							LIVER ALDEHYDE OXIDASE; BOVINE-MILK; GUINEA-PIG; KAEMPFEROL GLYCOSIDES; SUBSTRATE-SPECIFICITY; OXIDATIVE STRESS; IN-VITRO; DEHYDROGENASE; LEAVES; ANTIOXIDANT	Legumes and the polyphenolic compounds present in them have gained a lot of interest due to their beneficial health implications. Dietary polyphenolic compounds, especially flavonoids, exert antioxidant properties and are potent inhibitors of xanthine oxidase (XO) activity. XO is the main contributor of free radicals during exercise but it is also involved in pathogenesis of several diseases such as vascular disorders, cancer and gout. In order to discover new natural, dietary XO inhibitors, some polyphenolic fractions and pure compounds isolated from two legume plant extracts were tested for their effects on XO activity. The fractions isolated from both Vicia faba and Lotus edulis plant extracts were potent inhibitors of XO with IC50 values range from 40-135 mu g/mL and 55-260 mu g/mL, respectively. All the pure polyphenolic compounds inhibited XO and their K-i values ranged from 13-767 mu M. Ten of the compounds followed the non competitive inhibitory model whereas one of them was a competitive inhibitor. These findings indicate that flavonoid isolates from legume plant extracts are novel, natural XO inhibitors. Their mode of action is under investigation in order to examine their potential in drug design for diseases related to overwhelming XO action.	[Spanou, Chrysoula; Veskoukis, Aristidis S.; Kerasioti, Thalia; Kontou, Maria; Kouretas, Dimitrios] Univ Thessaly, Dept Biochem & Biotechnol, Larisa, Greece; [Angelis, Apostolos; Aligiannis, Nektarios; Skaltsounis, Alexios-Leandros] Univ Athens, Sch Pharm, Div Pharmacognosy & Nat Prod Chem, Athens, Greece	University of Thessaly; National & Kapodistrian University of Athens	Spanou, C (corresponding author), Univ Thessaly, Dept Biochem & Biotechnol, Larisa, Greece.	dkouret@uth.gr	Angelis, Apostolis/AAR-5065-2020; KOURETAS, DEMETRIOS/ABE-8519-2020; skaltsounis, alexios leandros/AAE-9617-2019	Angelis, Apostolis/0000-0002-5100-0321; KOURETAS, DEMETRIOS/0000-0002-7469-6640; ALIGIANNIS, NEKTARIOS/0000-0002-3335-8135				Agrawal PK., 1989, CARBON 13 NMR FLAVON; BEEDHAM C, 1995, ARCH BIOCHEM BIOPHYS, V319, P481, DOI 10.1006/abbi.1995.1320; Borges F, 2002, CURR MED CHEM, V9, P195, DOI 10.2174/0929867023371229; Burust N, 1989, PHYTOCHEMISTRY, V49, P241; Campos-Vega R, 2010, FOOD RES INT, V43, P461, DOI 10.1016/j.foodres.2009.09.004; Cos P, 1998, J NAT PROD, V61, P71, DOI 10.1021/np970237h; Cotelle Nicole, 2001, Current Topics in Medicinal Chemistry, V1, P569, DOI 10.2174/1568026013394750; Dew TP, 2005, J AGR FOOD CHEM, V53, P6510, DOI 10.1021/jf050716j; Eger BT, 2000, ACTA CRYSTALLOGR D, V56, P1656, DOI 10.1107/S0907444900012890; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Gomez-Cabrera MC, 2005, J PHYSIOL-LONDON, V567, P113, DOI 10.1113/jphysiol.2004.080564; Halliwell B, 1996, HDB ANTIOXIDANTS; Hasan A, 1996, PHYTOCHEMISTRY, V43, P1115, DOI 10.1016/S0031-9422(96)00416-5; Huang S, 2007, SONN ZHONGCAOYAO, V38, P1313; KELLEY WN, 1970, SCIENCE, V169, P388, DOI 10.1126/science.169.3943.388; KRENITSKY TA, 1986, ARCH BIOCHEM BIOPHYS, V247, P108, DOI 10.1016/0003-9861(86)90539-4; Lru Q, 1994, PHYTOCHEMISTRY, V36, P229; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MULINACCI N, 1995, PHYTOCHEMISTRY, V38, P531, DOI 10.1016/0031-9422(94)00554-7; Nagao A, 1999, BIOSCI BIOTECH BIOCH, V63, P1787, DOI 10.1271/bbb.63.1787; NAKANO K, 1983, PHYTOCHEMISTRY, V22, P2831, DOI 10.1016/S0031-9422(00)97707-0; Pacher P, 2006, PHARMACOL REV, V58, P87, DOI 10.1124/pr.58.1.6; Panoutsopoulos GI, 2004, ACTA BIOCHIM POL, V51, P943; Panoutsopoulos GI, 2004, CHEM RES TOXICOL, V17, P1368, DOI 10.1021/tx030059u; PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87; Perez-Castorena AL, 1997, PHYTOCHEMISTRY, V46, P1297, DOI 10.1016/S0031-9422(97)00509-8; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; Rochfort S, 2007, J AGR FOOD CHEM, V55, P7981, DOI 10.1021/jf071704w; Shen YB, 2001, J WOOD SCI, V47, P145, DOI 10.1007/BF00780564; Spanou C, 2007, ANTICANCER RES, V27, P3403; Spanou C, 2008, J AGR FOOD CHEM, V56, P6967, DOI 10.1021/jf800842p; Spanou CI, 2011, J PHYSL BIO IN PRESS; Sweeney AP, 2001, J ETHNOPHARMACOL, V75, P273, DOI 10.1016/S0378-8741(01)00176-3; Takaya Y, 2003, J AGR FOOD CHEM, V51, P8061, DOI 10.1021/jf0346206; Takeda Y, 1997, PHYTOCHEMISTRY, V44, P1335, DOI 10.1016/S0031-9422(96)00751-0; TOMASLORENTE F, 1989, PHYTOCHEMISTRY, V28, P1993, DOI 10.1016/S0031-9422(00)97908-1; Van Hoorn DEC, 2002, EUR J PHARMACOL, V451, P111, DOI 10.1016/S0014-2999(02)02192-1; Vermeris W., 2006, PHENOLIC COMPOUND BI; Veskoukis AS, 2006, EUR J DRUG METAB PH, V31, P11, DOI 10.1007/BF03190636; Veskoukis AS, 2008, APPL PHYSIOL NUTR ME, V33, P1140, DOI 10.1139/H08-102; Wang W, 2009, CHEM PHARM BULL, V57, P636, DOI 10.1248/cpb.57.636; WOOLFOLK CA, 1977, J BACTERIOL, V130, P1175, DOI 10.1128/JB.130.3.1175-1191.1977; Yamano Y, 2005, CHEM PHARM BULL, V53, P541, DOI 10.1248/cpb.53.541; Yoshimitsu H, 2007, J NAT MED-TOKYO, V61, P334, DOI 10.1007/s11418-007-0142-y	44	48	50	3	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2012	7	3							e32214	10.1371/journal.pone.0032214	http://dx.doi.org/10.1371/journal.pone.0032214			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TC	22396752	gold, Green Published, Green Submitted			2023-01-03	WOS:000303006500012
J	Barretti, P; Moraes, TMC; Camargo, CH; Caramori, JCT; Mondelli, AL; Montelli, AC; da Cunha, MDRS				Barretti, Pasqual; Moraes, Taise M. C.; Camargo, Carlos H.; Caramori, Jacqueline C. T.; Mondelli, Alessandro L.; Montelli, Augusto C.; da Cunha, Maria de Lourdes R. S.			Peritoneal Dialysis-Related Peritonitis Due to Staphylococcus aureus: A Single-Center Experience over 15 Years	PLOS ONE			English	Article							BETA-TOXIN; INFECTIONS RECOMMENDATIONS; STRAINS; UPDATE; PREDICTORS; VIRULENCE; OUTCOMES; CELLS	Peritonitis caused by Staphylococcus aureus is a serious complication of peritoneal dialysis (PD), which is associated with poor outcome and high PD failure rates. We reviewed the records of 62 S. aureus peritonitis episodes that occurred between 1996 and 2010 in the dialysis unit of a single university hospital and evaluated the host and bacterial factors influencing peritonitis outcome. Peritonitis incidence was calculated for three subsequent 5-year periods and compared using a Poisson regression model. The production of biofilm, enzymes, and toxins was evaluated. Oxacillin resistance was evaluated based on minimum inhibitory concentration and presence of the mecA gene. Logistic regression was used for the analysis of demographic, clinical, and microbiological factors influencing peritonitis outcome. Resolution and death rates were compared with 117 contemporary coagulase-negative staphylococcus (CoNS) episodes. The incidence of S. aureus peritonitis declined significantly over time from 0.13 in 1996-2000 to 0.04 episodes/patient/year in 2006-2010 (p = 0.03). The oxacillin resistance rate was 11.3%. Toxin and enzyme production was expressive, except for enterotoxin D. Biofilm production was positive in 88.7% of strains. The presence of the mecA gene was associated with a higher frequency of fever and abdominal pain. The logistic regression model showed that diabetes mellitus (p = 0.009) and beta-hemolysin production (p = 0.006) were independent predictors of non-resolution of infection. The probability of resolution was higher among patients aged 41 to 60 years than among those >60 years (p = 0.02). A trend to higher death rate was observed for S. aureus episodes (9.7%) compared to CoNS episodes (2.5%), (p = 0.08), whereas resolution rates were similar. Despite the decline in incidence, S. aureus peritonitis remains a serious complication of PD that is associated with a high death rate. The outcome of this infection is negatively influenced by host factors such as age and diabetes mellitus. In addition, beta-hemolysin production is predictive of non-resolution of infection, suggesting a pathogenic role of this factor in PD-related S. aureus peritonitis.	[Barretti, Pasqual; Moraes, Taise M. C.; Camargo, Carlos H.; Caramori, Jacqueline C. T.; Mondelli, Alessandro L.; Montelli, Augusto C.] Univ Estadual Paulista, Dept Clin Med, Fac Med, UNESP, Botucatu, SP, Brazil; [Moraes, Taise M. C.; Camargo, Carlos H.; Montelli, Augusto C.; da Cunha, Maria de Lourdes R. S.] Univ Estadual Paulista, Dept Microbiol & Imunol, Inst Biociencias, UNESP, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista	Barretti, P (corresponding author), Univ Estadual Paulista, Dept Clin Med, Fac Med, UNESP, Botucatu, SP, Brazil.	cunhamlr@ibb.unesp.br	Barretti, Pasqual/AAK-7934-2021; de Lourdes Ribeiro de Souza da Cunha, Maria/A-6287-2008; Camargo, Carlos/E-6448-2010; Caramori, Jacqueline do Socorr C. T./G-1783-2013; Barretti, Pasqual/K-4156-2012	Barretti, Pasqual/0000-0003-4979-4836; de Lourdes Ribeiro de Souza da Cunha, Maria/0000-0001-9079-2723; Camargo, Carlos/0000-0001-6834-0085; Caramori, Jacqueline do Socorr C. T./0000-0002-0093-9515; Barretti, Pasqual/0000-0003-4979-4836; Lia Mondelli, Alessandro/0000-0002-4401-5656	Sao Paulo state funding agency Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	Sao Paulo state funding agency Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	This work was supported by a grant from the Sao Paulo state funding agency Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP). The funding agency played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript	ALEXANDER W, 1987, DIAGN MICR INFEC DIS, V8, P215, DOI 10.1016/0732-8893(87)90052-6; Barretti P, 2007, PERITON DIALYSIS INT, V27, P332; Barretti P, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-212; Bunke CM, 1997, KIDNEY INT, V52, P524, DOI 10.1038/ki.1997.363; CHRISTENSEN GD, 1982, INFECT IMMUN, V37, P318, DOI 10.1128/IAI.37.1.318-326.1982; Clinical and Laboratory Standards Institute, 2008, M100S18 CLSI; da Cunha MDRD, 2005, CLIN NEPHROL, V64, P378; Deleo FR, 2009, INFECT DIS CLIN N AM, V23, P17, DOI 10.1016/j.idc.2008.10.003; DONNELLY CB, 1967, APPL MICROBIOL, V15, P1382, DOI 10.1128/AEM.15.6.1382-1387.1967; Fontan MP, 2005, PERITON DIALYSIS INT, V25, P274; Fowler VG, 2007, J INFECT DIS, V196, P738, DOI 10.1086/520088; Gill SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018673; Govindarajulu S, 2010, PERITON DIALYSIS INT, V30, P311, DOI 10.3747/pdi.2008.00258; Han SH, 2007, NEPHROL DIAL TRANSPL, V22, P2653, DOI 10.1093/ndt/gfm242; Haslinger-Loffler B, 2006, KIDNEY INT, V70, P1089, DOI 10.1038/sj.ki.5001710; Hayashida A, 2009, AM J PATHOL, V174, P509, DOI 10.2353/ajpath.2009.080394; Huseby MJ, 2010, P NATL ACAD SCI USA, V107, P14407, DOI 10.1073/pnas.0911032107; JESSEN OVE, 1959, ACTA PATHOL ET MICROBIOL SCAND, V47, P316; Keane WF, 2000, PERITON DIALYSIS INT, V20, P396; Koneman EW, 1992, COLOR ATLAS TXB DIAG; Krishnan M, 2002, PERITON DIALYSIS INT, V22, P573; LACHICA RUF, 1971, APPL MICROBIOL, V21, P585, DOI 10.1128/AEM.21.4.585-587.1971; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Martinez-Pulgarin S, 2009, MICROBIOL-SGM, V155, P1505, DOI 10.1099/mic.0.025544-0; MATOS JES, 1995, LETT APPL MICROBIOL, V21, P334, DOI 10.1111/j.1472-765X.1995.tb01073.x; Moraes TP, 2009, PERITON DIALYSIS INT, V29, P492; MURAKAMI K, 1991, J CLIN MICROBIOL, V29, P2240, DOI 10.1128/JCM.29.10.2240-2244.1991; Ortiz A, 2006, CURR MED CHEM, V13, P2695, DOI 10.2174/092986706778201576; Peacock SJ, 2000, PERITON DIALYSIS INT, V20, P215; Pimenta-Rodrigues MV, 2011, THESIS U ESTADUAL PA; Piraino B, 2005, PERITON DIALYSIS INT, V25, P107; Szeto CC, 2007, CLIN J AM SOC NEPHRO, V2, P245, DOI 10.2215/CJN.03180906; Zhong J H, 2000, Adv Perit Dial, V16, P36	33	28	32	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2012	7	2							e31780	10.1371/journal.pone.0031780	http://dx.doi.org/10.1371/journal.pone.0031780			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926ZM	22363730	Green Published, Green Submitted, gold			2023-01-03	WOS:000302873700096
J	Li, FZ; Harmer, P; Fitzgerald, K; Eckstrom, E; Stock, R; Galver, J; Maddalozzo, G; Batya, SS				Li, Fuzhong; Harmer, Peter; Fitzgerald, Kathleen; Eckstrom, Elizabeth; Stock, Ronald; Galver, Johnny; Maddalozzo, Gianni; Batya, Sara S.			Tai Chi and Postural Stability in Patients with Parkinson's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER-ADULTS; PHYSICAL-ACTIVITY; EXERCISE; BALANCE; FALLS; MOBILITY; QUALITY; PEOPLE; PREVENTION; STRENGTH	BACKGROUND Patients with Parkinson's disease have substantially impaired balance, leading to diminished functional ability and an increased risk of falling. Although exercise is routinely encouraged by health care providers, few programs have been proven effective. METHODS We conducted a randomized, controlled trial to determine whether a tailored tai chi program could improve postural control in patients with idiopathic Parkinson's disease. We randomly assigned 195 patients with stage 1 to 4 disease on the Hoehn and Yahr staging scale (which ranges from 1 to 5, with higher stages indicating more severe disease) to one of three groups: tai chi, resistance training, or stretching. The patients participated in 60-minute exercise sessions twice weekly for 24 weeks. The primary outcomes were changes from baseline in the limits-of-stability test (maximum excursion and directional control; range, 0 to 100%). Secondary outcomes included measures of gait and strength, scores on functional-reach and timed up-and-go tests, motor scores on the Unified Parkinson's Disease Rating Scale, and number of falls. RESULTS The tai chi group performed consistently better than the resistance-training and stretching groups in maximum excursion (between-group difference in the change from baseline, 5.55 percentage points; 95% confidence interval [CI], 1.12 to 9.97; and 11.98 percentage points; 95% CI, 7.21 to 16.74, respectively) and in directional control (10.45 percentage points; 95% CI, 3.89 to 17.00; and 11.38 percentage points; 95% CI, 5.50 to 17.27, respectively). The tai chi group also performed better than the stretching group in all secondary outcomes and outperformed the resistance-training group in stride length and functional reach. Tai chi lowered the incidence of falls as compared with stretching but not as compared with resistance training. The effects of tai chi training were maintained at 3 months after the intervention. No serious adverse events were observed. CONCLUSIONS Tai chi training appears to reduce balance impairments in patients with mild-to-moderate Parkinson's disease, with additional benefits of improved functional capacity and reduced falls. (Funded by the National Institute of Neurological Disorders and Stroke; ClinicalTrials.gov number, NCT00611481.)	[Li, Fuzhong] Oregon Res Inst, Eugene, OR 97403 USA; [Fitzgerald, Kathleen] Oregon Med Grp, Eugene, OR USA; [Stock, Ronald] PeaceHlth Med Grp Oregon, Eugene, OR USA; [Harmer, Peter] Willamette Univ, Salem, OR 97301 USA; [Galver, Johnny] BPM Phys Therapy Ctr, Salem, OR USA; [Eckstrom, Elizabeth] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Maddalozzo, Gianni] Oregon State Univ, Corvallis, OR 97331 USA	Oregon Research Institute; Willamette University; Oregon Health & Science University; Oregon State University	Li, FZ (corresponding author), Oregon Res Inst, 1715 Franklin Blvd, Eugene, OR 97403 USA.	fuzhongl@ori.org	Northcote, Matthew/L-1135-2019; Northcote, Matthew/B-8209-2019	Li, Fuzhong/0000-0001-6644-4702	National Institute of Neurological Disorders and Stroke [NS047130]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047130] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by a grant (NS047130) from the National Institute of Neurological Disorders and Stroke.	Ashburn A, 2001, AGE AGEING, V30, P47, DOI 10.1093/ageing/30.1.47; Cheng EM, 2010, NEUROLOGY, V75, P2021, DOI 10.1212/WNL.0b013e3181ff96dd; Deane K, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002815, DOI 10.1002/14651858.CD002815]; Dibble LE, 2006, ARCH PHYS MED REHAB, V87, P1280, DOI 10.1016/j.apmr.2006.05.016; Dibble LE, 2009, J NEUROL PHYS THER, V33, P14, DOI 10.1097/NPT.0b013e3181990fcc; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Fahn S., 2007, PRINCIPLES PRACTICE; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GOETZ CG, 1995, MOVEMENT DISORD, V10, P263, DOI 10.1002/mds.870100305; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Greendale GA, 2000, J AM GERIATR SOC, V48, P305, DOI 10.1111/j.1532-5415.2000.tb02651.x; Hackney ME, 2008, GAIT POSTURE, V28, P456, DOI 10.1016/j.gaitpost.2008.02.005; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Li FZ, 2008, AM J PUBLIC HEALTH, V98, P1195, DOI 10.2105/AJPH.2007.120402; Li FZ, 2007, J AGING PHYS ACTIV, V15, P139, DOI 10.1123/japa.15.2.139; Li FZ, 2005, J GERONTOL A-BIOL, V60, P187, DOI 10.1093/gerona/60.2.187; Li FZ, 2004, J AM GERIATR SOC, V52, P892, DOI 10.1111/j.1532-5415.2004.52255.x; Lugassy M, 2005, PRINCIPLES TREATMENT, P313; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Nirenberg MJ, 2005, PRINCIPLES TREATMENT, P3; Paterson C, 2004, J CLIN PHARM THER, V29, P339, DOI 10.1111/j.1365-2710.2004.00570.x; Pickering RM, 2007, MOVEMENT DISORD, V22, P1892, DOI 10.1002/mds.21598; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rubenstein LZ, 2000, J GERONTOL A-BIOL, V55, pM317, DOI 10.1093/gerona/55.6.M317; Scandalis TA, 2001, AM J PHYS MED REHAB, V80, P38, DOI 10.1097/00002060-200101000-00011; Schapira AHV, 2005, PRINCIPLES TREATMENT, P119; Shaw JM, 1998, J GERONTOL A-BIOL, V53, pM53, DOI 10.1093/gerona/53A.1.M53; Voukelatos A, 2007, J AM GERIATR SOC, V55, P1185, DOI 10.1111/j.1532-5415.2007.01244.x; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	33	479	524	15	355	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					511	519		10.1056/NEJMoa1107911	http://dx.doi.org/10.1056/NEJMoa1107911			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888GH	22316445	Green Accepted			2023-01-03	WOS:000299991300007
J	Gehrett, BK				Gehrett, Barbara K.			A Prescription for Drug Shortages	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Gehrett, BK (corresponding author), 14612 SE Green Valley Rd, Auburn, WA 98092 USA.	thebkg17@gmail.com	Mendoza, Elvia/A-9361-2012					[Anonymous], NAVIGATING DRUG SHOR; [Anonymous], DRUG SHORT CURR DRUG; Assistant Secretary for Planning and Evaluation US Department of Health and Human Services, ASPE ISS BRIEF EC AN; Davenport-Ennis N, 2011, IMPROVING PATIENT CA; Fox E, 2011, DRUG SHORT WORKSH SP; Jensen V, 2010, NEW ENGL J MED, V363, P806, DOI 10.1056/NEJMp1005849; McBride A, 2011, DRUG SHORT WORKSH SP	7	11	12	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 11	2012	307	2					153	154		10.1001/jama.2011.2000	http://dx.doi.org/10.1001/jama.2011.2000			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875NP	22235084				2023-01-03	WOS:000299038300025
J	Graham-Rowe, D				Graham-Rowe, Duncan			BIODIVERSITY Endangered and in demand	NATURE			English	Editorial Material																		[Anonymous], 2011, ENV INVESTIGATION AG; Chunyu S., 2011, 41 CITES, V41; Venkataraman B., 2007, TRAFFIC SE ASIA; Wasser R. M, 2010, TRAFFIC E ASIA REPOR; Wyler L. S., 2009, C RES SERVICE	5	53	57	7	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S101	S103		10.1038/480S101a	http://dx.doi.org/10.1038/480S101a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190083	Bronze			2023-01-03	WOS:000298318000012
J	Koga, F; Yoshida, S; Tatokoro, M; Kawakami, S; Fujii, Y; Kumagai, J; Neckers, L; Kihara, K				Koga, Fumitaka; Yoshida, Soichiro; Tatokoro, Manabu; Kawakami, Satoru; Fujii, Yasuhisa; Kumagai, Jiro; Neckers, Len; Kihara, Kazunori			ErbB2 and NF kappa B Overexpression as Predictors of Chemoradiation Resistance and Putative Targets to Overcome Resistance in Muscle-Invasive Bladder Cancer	PLOS ONE			English	Article							SELECTIVE ORGAN PRESERVATION; UROTHELIAL CARCINOMA; RADIATION-THERAPY; TRANSURETHRAL RESECTION; RADICAL CYSTECTOMY; LOCAL-CONTROL; EXPRESSION; APOPTOSIS; BCL-2; P53	Radical cystectomy for muscle-invasive bladder cancer (MIBC) patients frequently impairs their quality of life (QOL) due to urinary diversion. To improve their QOL, a bladder-sparing alternative strategy using chemoradiation has been developed. In bladder-sparing protocols, complete response (CR) to induction chemoradiation is a prerequisite for bladder preservation and favorable survival. Thus predicting chemoradiation resistance and overcoming it would increase individual MIBC patients' chances of bladder preservation. The aim of this study is to investigate putative molecular targets for treatment aimed at improving chemoradiation response. Expression levels of erbB2, NF kappa B, p53, and survivin were evaluated immunohistochemically in pretreatment biopsy samples from 35 MIBC patients in whom chemoradiation sensitivity had been pathologically evaluated in cystectomy specimens, and associations of these expression levels with chemoradiation sensitivity and cancer-specific survival (CSS) were investigated. Of the 35 patients, 11 (31%) achieved pathological CR, while tumors in the remaining 24 patients (69%) were chemoradiation-resistant. Multivariate analysis identified erbB2 and NF kappa B overexpression and hydronephrosis as significant and independent risk factors for chemoradiation resistance with respective relative risks of 11.8 (P = 0.014), 15.4 (P = 0.024) and 14.3 (P = 0.038). The chemoradiation resistance rate was 88.5% for tumors overexpressing erbB2 and/or NF kappa B, but only 11.1% for those negative for both (P <0.0001). The 5-year CSS rate was 74% overall. Through multivariate analysis, overexpression of erbB2 and/or NFkB was identified as an independent risk factor for bladder cancer death with marginal significance (hazard ratio 21.5, P = 0.056) along with chemoradiation resistance (P = 0.003) and hydronephrosis (P = 0.018). The 5-year CSS rate for the 11 patients achieving pathological CR was 100%, while that for the 24 with chemoradiation-resistant disease was 61% (P = 0.018). Thus, erbB2 and NFkB overexpression are relevant to chemoradiation resistance and are putative targets aimed at overcoming chemoradiation resistance in MIBC.	[Koga, Fumitaka; Yoshida, Soichiro; Tatokoro, Manabu; Kawakami, Satoru; Fujii, Yasuhisa; Kihara, Kazunori] Tokyo Med & Dent Univ, Dept Urol, Grad Sch, Tokyo, Japan; [Kumagai, Jiro] Tokyo Med & Dent Univ, Dept Surg Pathol, Grad Sch, Tokyo, Japan; [Neckers, Len] NCI, Urol Oncol Branch, Bethesda, MD 20892 USA	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Koga, F (corresponding author), Tokyo Med & Dent Univ, Dept Urol, Grad Sch, Tokyo, Japan.	f-koga.uro@tmd.ac.jp	Koga, Fumitaka/AAO-2779-2021; KOGA, Fumitaka/AAM-8739-2021; Koga, Fumitaka/AAO-4655-2021; , Fumitaka/AAO-2957-2021	KOGA, Fumitaka/0000-0001-7888-0085; , Fumitaka/0000-0001-7888-0085; yoshida, soichiro/0000-0003-2757-8083	Ministry of Education, Culture, Sports, Science and Technology of Japan [19791102, 19791103]; NATIONAL CANCER INSTITUTE [ZIASC010074] Funding Source: NIH RePORTER	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in part, by grants-in-aids for scientific research (19791102, 19791103), from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Chakravarti A, 2005, INT J RADIAT ONCOL, V62, P309, DOI 10.1016/j.ijrobp.2004.09.047; ESRIG D, 1993, AM J PATHOL, V143, P1389; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Izzo JG, 2006, J CLIN ONCOL, V24, P748, DOI 10.1200/JCO.2005.03.8810; Izzo JG, 2006, MOL CANCER THER, V5, P2844, DOI 10.1158/1535-7163.MCT-06-0351; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kawashima A, 2011, CLIN CANCER RES, V17, P2561, DOI 10.1158/1078-0432.CCR-10-1963; Koga F, 2011, EUR UROL SUPPL, V10, P167, DOI 10.1016/S1569-9056(11)60487-9; Koga F, 2003, CLIN CANCER RES, V9, P5501; Koga F, 2011, BJU INT; Koga F, 2008, UROLOGY, V72, P384, DOI 10.1016/j.urology.2008.03.017; Koga F, 2009, BJU INT, V104, P189, DOI 10.1111/j.1464-410X.2008.08297.x; Koga F, 2009, ANTICANCER RES, V29, P797; Krause FS, 2011, ANTICANCER RES, V31, P985; Kruger S, 2002, INT J CANCER, V102, P514, DOI 10.1002/ijc.10731; Lara PC, 1999, INT J RADIAT ONCOL, V43, P1015, DOI 10.1016/S0360-3016(98)00472-6; Lara PC, 1998, RADIOTHER ONCOL, V49, P163, DOI 10.1016/S0167-8140(98)00033-4; Lee R, 2000, UROL CLIN N AM, V27, P1, DOI 10.1016/S0094-0143(05)70229-9; Levidou G, 2008, VIRCHOWS ARCH, V452, P295, DOI 10.1007/s00428-007-0560-y; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Matsumoto H, 2004, BRIT J CANCER, V91, P1025, DOI 10.1038/sj.bjc.6602073; Matsumoto H, 2004, JPN J CLIN ONCOL, V34, P124, DOI 10.1093/jjco/hyh026; Moonen L, 2001, INT J RADIAT ONCOL, V49, P1305, DOI 10.1016/S0360-3016(00)01503-0; Ong F, 2001, RADIOTHER ONCOL, V61, P169, DOI 10.1016/S0167-8140(01)00421-2; Rodel C, 2002, J CLIN ONCOL, V20, P3061, DOI 10.1200/JCO.2002.11.027; Rodel C, 2000, INT J RADIAT ONCOL, V46, P1213, DOI 10.1016/S0360-3016(99)00544-1; Rodel C, 2006, J CLIN ONCOL, V24, P5536, DOI 10.1200/JCO.2006.07.6729; Sandler HM, 2010, EXPERT REV ANTICANC, V10, P895, DOI 10.1586/ERA.10.34; Shipley WU, 2003, CANCER-AM CANCER SOC, V97, P2115, DOI 10.1002/cncr.11282; Sobin L, 2002, CLASSIFICATION MALIG; Tolcher AW, 2011, ANN ONCOL; Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887; Weiss C, 2009, INT J RADIAT ONCOL, V74, P1455, DOI 10.1016/j.ijrobp.2008.10.063; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WIJKSTROM H, 1990, J UROLOGY, V144, P646, DOI 10.1016/S0022-5347(17)39545-9	36	31	31	3	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 10	2011	6	11							e27616	10.1371/journal.pone.0027616	http://dx.doi.org/10.1371/journal.pone.0027616			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	852HQ	22102915	Green Published, gold, Green Submitted			2023-01-03	WOS:000297348800037
J	Soyiri, IN; Reidpath, DD; Sarran, C				Soyiri, Ireneous N.; Reidpath, Daniel D.; Sarran, Christophe			Asthma Length of Stay in Hospitals in London 2001-2006: Demographic, Diagnostic and Temporal Factors	PLOS ONE			English	Article							PATIENT SAFETY; ADMISSION; ATTENDANCE; MORTALITY; BURDEN; ADULTS; COST; CARE; NHS	Asthma is a condition of significant public health concern associated with morbidity, mortality and healthcare utilisation. This study identifies key determinants of length of stay (LOS) associated with asthma-related hospital admissions in London, and further explores their effects on individuals. Subjects were primarily diagnosed and admitted for asthma in London between 1(st) January 2001 and 31(st) December 2006. All repeated admissions were treated uniquely as independent cases. Negative binomial regression was used to model the effect(s) of demographic, temporal and diagnostic factors on the LOS, taking into account the cluster effect of each patient's hospital attendance in London. The median and mean asthma LOS over the period of study were 2 and 3 days respectively. Admissions increased over the years from 8,308 (2001) to 10,554 (2006), but LOS consistently declined within the same period. Younger individuals were more likely to be admitted than the elderly, but the latter significantly had higher LOS (p<0.001). Respiratory related secondary diagnoses, age, and gender of the patient as well as day of the week and year of admission were important predictors of LOS. Asthma LOS can be predicted by socio-demographic factors, temporal and clinical factors using count models on hospital admission data. The procedure can be a useful tool for planning and resource allocation in health service provision.	[Soyiri, Ireneous N.] Univ Ghana, Sch Publ Hlth, Accra, Ghana; [Soyiri, Ireneous N.; Reidpath, Daniel D.] Monash Univ, Sch Med & Hlth Sci, Clayton, Vic 3800, Australia; [Sarran, Christophe] Met Off, Exeter, Devon, England	University of Ghana; Monash University; Met Office - UK	Soyiri, IN (corresponding author), Univ Ghana, Sch Publ Hlth, Accra, Ghana.	soyiriin@yahoo.com	Soyiri, Ireneous N./H-4594-2011; Soyiri, Ireneous/AAE-7617-2019	Soyiri, Ireneous N./0000-0003-4697-5156; Soyiri, Ireneous/0000-0003-4697-5156; Reidpath, Daniel/0000-0002-8796-0420				ALT JE, 2000, POLITICAL ANAL, V0009; Arnold DH, 2011, EMERGENCY MED J; Arnold DH, 2008, AM J EMERG MED, V26, P473, DOI 10.1016/j.ajem.2007.05.026; Asthma-UK, 2010, KEY FACTS STAT ASTHM; Asthma-UK, 2007, ASTHM DIV IN EM CAR; Atienza N, 2008, STAT MED, V27, P1403, DOI 10.1002/sim.3029; Burg JG, 2001, MED VET ENTOMOL, V15, P413, DOI 10.1046/j.0269-283x.2001.00329.x; Callery P, 2010, ARCH DIS CHILD, V95, P341, DOI 10.1136/adc.2009.163261; Cameron AC, 2007, ESSENTIALS COUNT DAT, P331; DiSantostefano RL, 2011, AM J RESP CRIT CARE, V183; Gerrish K, 2000, J ADV NURS, V31, P918, DOI 10.1046/j.1365-2648.2000.01357.x; [GLA Demography-Team], 2011, MIDY POP EST; Graves N, 2007, INFECT CONT HOSP EP, V28, P280, DOI 10.1086/512642; Gray B, 2009, ENVIRON ECOL STAT, V17, P573; HES, 2008, HES US HLTH SOC CAR; Hilbe J.M., 2011, NEGATIVE BINOMIAL RE; Hodder R, 2010, CAN MED ASSOC J, V182, pE55, DOI 10.1503/cmaj.080072; Holgate ST, 1995, ASTHM OUTD AIR POLL; Kuan V, 2010, THORAX, V65, pA6, DOI 10.1136/thx.2010.150912.7; Long J. S., 2003, REGRESSION MODELS CA; Long JS, 2001, STATA J, V1, P51, DOI 10.1177/1536867X0100100103; Lyratzopoulos G, 2005, BMC EMERG MED, V5, DOI 10.1186/1471-227X-5-4; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Moloney ED, 2006, EMERG MED J, V23, P363, DOI 10.1136/emj.2005.028944; Morrison DS, 2001, THORAX, V56, P687, DOI 10.1136/thorax.56.9.687; Mulla ZD, 2007, EPIDEMIOL INFECT, V135, P868, DOI 10.1017/S0950268806007448; Paradis AR, 2009, AM J MED QUAL, V24, P53, DOI 10.1177/1062860608327610; Poulos Leanne M, 2005, Paediatr Respir Rev, V6, P20, DOI 10.1016/j.prrv.2004.11.004; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; Rowe, 2010, ADMISSIONS CANADIAN; Schenkel S, 2000, ACAD EMERG MED, V7, P1204, DOI 10.1111/j.1553-2712.2000.tb00466.x; Scott IA, 2010, AUST HEALTH REV, V34, P317, DOI 10.1071/AH09821; Singh CH, 2010, EUR J HEALTH ECON, V11, P119, DOI 10.1007/s10198-009-0153-6; Sobota A, 2010, AM J HEMATOL, V85, P24, DOI 10.1002/ajh.21565; Stewart B, 2006, EMERG MED J, V23, P911, DOI 10.1136/emj.2006.039339; Watson L, 2007, INT J CLIN PRACT, V61, P1884, DOI 10.1111/j.1742-1241.2007.01559.x; Watson L, 2007, RESP MED, V101, P1659, DOI 10.1016/j.rmed.2007.03.006; Xiao J, 1999, SOCIOECONOMIC PLANNI, V33, P39, DOI DOI 10.1016/S0038-0121(98)00006-8	38	20	21	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2011	6	11							e27184	10.1371/journal.pone.0027184	http://dx.doi.org/10.1371/journal.pone.0027184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849WB	22073282	Green Published, gold, Green Submitted			2023-01-03	WOS:000297154900086
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Off-label prescribing in macular degeneration	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				2011, BRIT MED J, V343, pD6169, DOI DOI 10.1136/BMJ.D6169; 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI DOI 10.1001/ARCHOPHTHALMOL.2010.223; 2011, NEW ENGL J MED, V364, P1897, DOI DOI 10.1056/NEJMOA1102673	3	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 19	2011	343								d6778	10.1136/bmj.d6778	http://dx.doi.org/10.1136/bmj.d6778			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837HN	22012651				2023-01-03	WOS:000296183700012
J	Virgin, HW; Todd, JA				Virgin, Herbert W.; Todd, John A.			Metagenomics and Personalized Medicine	CELL			English	Article							INFLAMMATORY-BOWEL-DISEASE; TYPE-1 DIABETES-MELLITUS; DIABETOGENIC T-CELLS; GUT MICROBIOTA; INTESTINAL MICROBIOTA; CROHNS-DISEASE; IMMUNE-SYSTEM; ENTEROVIRUS INFECTION; COMMENSAL BACTERIA; VIRAL-INFECTION	The microbiome is a complex community of Bacteria, Archaea, Eukarya, and viruses that infect humans and live in our tissues. It contributes the majority of genetic information to our metagenome and, consequently, influences our resistance and susceptibility to diseases, especially common inflammatory diseases, such as type 1 diabetes, ulcerative colitis, and Crohn's disease. Here we discuss how host-gene-microbial interactions are major determinants for the development of these multifactorial chronic disorders and, thus, for the relationship between genotype and phenotype. We also explore how genome-wide association studies (GWAS) on autoimmune and inflammatory diseases are uncovering mechanism-based subtypes for these disorders. Applying these emerging concepts will permit a more complete understanding of the etiologies of complex diseases and underpin the development of both next-generation animal models and new therapeutic strategies for targeting personalized disease phenotypes.	[Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, Dept Mol Microbiol, St Louis, MO 63110 USA; [Virgin, Herbert W.] Washington Univ, Sch Med, Midwest Reg Ctr Excellence Biodef & Emerging Infe, St Louis, MO 63110 USA; [Todd, John A.] Univ Cambridge, Addenbrookes Hosp, Juvenile Diabet Res Fdn,Cambridge Inst Med Res, Wellcome Trust Diabet & Inflammat Lab,Dept Med Ge, Cambridge CB2 0XY, England	Washington University (WUSTL); Washington University (WUSTL); Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Virgin, HW (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Dept Mol Microbiol, St Louis, MO 63110 USA.	virgin@wustl.edu; john.todd@cimr.cam.ac.uk	; Todd, John/A-3542-2010	Virgin, Herbert/0000-0001-8580-7628; Todd, John/0000-0003-2740-8148	NCI; NIAID; NCRR; Crohn's and Colitis Foundation of America; Broad Medical Foundation; NIDDK; NIHR; Wellcome Trust; Juvenile Diabetes Research Foundation International; European Union; National Institute for Health Research [NF-SI-0508-10275] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA074730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065982, R01AI084887, R01AI054483] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [R01OD011170] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Crohn's and Colitis Foundation of America; Broad Medical Foundation; NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIHR(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome TrustEuropean Commission); Juvenile Diabetes Research Foundation International(Juvenile Diabetes Research Foundation); European Union(European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors would like to acknowledge helpful conversations with Thad Stappenbeck, Ramnik Xavier, Emil Unanue, Jeff Gordon, Balfour Sartor, Adolfo Garcia-Sastre, and Dermot McGovern. We thank Tom Smith for providing the images of noroviruses used in Figure 4. H. W. V. is supported by the NCI, NIAID, NCRR, the Crohn's and Colitis Foundation of America, and the Broad Medical Foundation. J.A.T. is supported by the NIDDK, NIHR, the Wellcome Trust, the Juvenile Diabetes Research Foundation International, and the European Union.	Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Arechiga AF, 2009, J IMMUNOL, V182, P3343, DOI 10.4049/jimmunol.0713370; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JC, 2009, NAT GENET, V41, P703, DOI 10.1038/ng.381; Barton ES, 2007, NATURE, V447, P326, DOI 10.1038/nature05762; Benson A, 2009, CELL HOST MICROBE, V6, P187, DOI 10.1016/j.chom.2009.06.005; Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107; Bloom SM, 2011, CELL HOST MICROBE, V9, P390, DOI 10.1016/j.chom.2011.04.009; Bluestone JA, 2010, NATURE, V464, P1293, DOI 10.1038/nature08933; Bottini N, 2006, SEMIN IMMUNOL, V18, P207, DOI 10.1016/j.smim.2006.03.008; Brehm MA, 2010, DIABETES, V59, P2265, DOI 10.2337/db10-0323; Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Calderon B, 2011, P NATL ACAD SCI USA, V108, P1561, DOI 10.1073/pnas.1018973108; Calderon B, 2011, P NATL ACAD SCI USA, V108, P1567, DOI 10.1073/pnas.1018975108; Cardwell CR, 2008, DIABETOLOGIA, V51, P726, DOI 10.1007/s00125-008-0941-z; Cardwell CR, 2010, DIABETOLOGIA, V53, P641, DOI 10.1007/s00125-009-1648-5; Clayton DG, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000540; Cooper JD, 2011, DIABETES, V60, P1624, DOI 10.2337/db10-1656; Cotsapas C, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002254; Dendrou CA, 2009, NAT GENET, V41, P1011, DOI 10.1038/ng.434; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Ehlers S, 2010, TRENDS IMMUNOL, V31, P184, DOI 10.1016/j.it.2010.02.003; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Esplugues E, 2011, NATURE, V475, P514, DOI 10.1038/nature10228; Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197; Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011; Foxman EF, 2011, NAT REV MICROBIOL, V9, P254, DOI 10.1038/nrmicro2541; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; Garrett WS, 2007, CELL, V131, P33, DOI 10.1016/j.cell.2007.08.017; Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004; Garrett WS, 2010, CELL, V140, P859, DOI 10.1016/j.cell.2010.01.023; Gianani R, 2010, DIABETOLOGIA, V53, P690, DOI 10.1007/s00125-009-1642-y; Giongo A, 2011, ISME J, V5, P82, DOI 10.1038/ismej.2010.92; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Goodman AL, 2011, P NATL ACAD SCI USA, V108, P6252, DOI 10.1073/pnas.1102938108; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Hansen EE, 2011, P NATL ACAD SCI USA, V108, P4599, DOI 10.1073/pnas.1000071108; Hansen J, 2010, CURR OPIN GASTROEN, V26, P564, DOI 10.1097/MOG.0b013e32833f1195; Heinig M, 2010, NATURE, V467, P460, DOI 10.1038/nature09386; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Imielinski M, 2009, NAT GENET, V41, P1335, DOI 10.1038/ng.489; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326; Kang SS, 2008, PLOS MED, V5, P424, DOI 10.1371/journal.pmed.0050041; Karst SM, 2003, SCIENCE, V299, P1575, DOI 10.1126/science.1077905; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kim YG, 2011, CELL HOST MICROBE, V9, P496, DOI 10.1016/j.chom.2011.05.006; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Lee YK, 2011, P NATL ACAD SCI USA, V108, P4615, DOI 10.1073/pnas.1000082107; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Long SA, 2011, GENES IMMUN, V12, P116, DOI 10.1038/gene.2010.54; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; McCartney SA, 2011, J CLIN INVEST, V121, P1497, DOI 10.1172/JCI44005; McGovern DPB, 2010, HUM MOL GENET, V19, P3468, DOI 10.1093/hmg/ddq248; Melmed GY, 2010, NAT REV GASTRO HEPAT, V7, P110, DOI 10.1038/nrgastro.2009.218; Nejentsev S, 2009, SCIENCE, V324, P387, DOI 10.1126/science.1167728; Odze R, 2003, MODERN PATHOL, V16, P347, DOI 10.1097/01.MP.0000064746.82024.D1; Oikarinen S, 2011, DIABETES, V60, P276, DOI 10.2337/db10-0186; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Pfluger M, 2010, HORM METAB RES, V42, P143, DOI 10.1055/s-0029-1241830; Rashid ST, 2010, J CLIN INVEST, V120, P3127, DOI 10.1172/JCI43122; Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Robinson T, 2011, J IMMUNOL, V187, P1298, DOI 10.4049/jimmunol.1100857; Roesch LFW, 2009, ISME J, V3, P536, DOI 10.1038/ismej.2009.5; Rossin EJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001273; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Sczesnak A, 2011, CELL HOST MICROBE, V10, P260, DOI 10.1016/j.chom.2011.08.005; Smyth DJ, 2011, DIABETES, V60, P3081, DOI 10.2337/db11-0638; Spor A, 2011, NAT REV MICROBIOL, V9, P279, DOI 10.1038/nrmicro2540; Stappenbeck TS, 2011, AUTOPHAGY, V7, P355, DOI [10.4161/auto.7.4.13074, 10.4161/auto.7.2.13074]; Stene LC, 2010, DIABETES, V59, P3174, DOI 10.2337/db10-0866; Thackray LB, 2007, J VIROL, V81, P10460, DOI 10.1128/JVI.00783-07; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; Turley SJ, 2005, P NATL ACAD SCI USA, V102, P17729, DOI 10.1073/pnas.0509006102; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vehik K, 2011, DIABETES-METAB RES, V27, P3, DOI 10.1002/dmrr.1141; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; White DW, 2010, BLOOD, V115, P4377, DOI 10.1182/blood-2009-09-245464; Wu HJ, 2010, IMMUNITY, V32, P815, DOI 10.1016/j.immuni.2010.06.001; Yeung WCG, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d35	88	151	158	1	48	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 30	2011	147	1					44	56		10.1016/j.cell.2011.09.009	http://dx.doi.org/10.1016/j.cell.2011.09.009			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	827AJ	21962506	Green Accepted, Bronze			2023-01-03	WOS:000295396700014
J	Coleman, T; Cooper, S; Thornton, JG; Grainge, MJ; Watts, K; Britton, J; Lewis, S				Coleman, Tim; Cooper, Sue; Thornton, James G.; Grainge, Matthew J.; Watts, Kim; Britton, John; Lewis, Sarah		Smoking Nicotine Pregnancy SNAP	A Randomized Trial of Nicotine-Replacement Therapy Patches in Pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOKING-CESSATION; SMOKERS; PATTERNS; COTININE	BACKGROUND Nicotine-replacement therapy is effective for smoking cessation outside pregnancy and its use is widely recommended during pregnancy. We investigated the efficacy and safety of nicotine patches during pregnancy. METHODS We recruited participants from seven hospitals in England who were 16 to 50 years of age with pregnancies of 12 to 24 weeks' gestation and who smoked five or more cigarettes per day. Participants received behavioral cessation support and were randomly assigned to 8 weeks of treatment with active nicotine patches (15 mg per 16 hours) or matched placebo patches. The primary outcome was abstinence from the date of smoking cessation until delivery, as validated by measurement of exhaled carbon monoxide or salivary cotinine. Safety was assessed by monitoring for adverse pregnancy and birth outcomes. RESULTS Of 1050 participants, 521 were randomly assigned to nicotine-replacement therapy and 529 to placebo. There was no significant difference in the rate of abstinence from the quit date until delivery between the nicotine-replacement and placebo groups (9.4% and 7.6%, respectively; unadjusted odds ratio with nicotine-replacement therapy, 1.26; 95% confidence interval, 0.82 to 1.96), although the rate was higher at 1 month in the nicotine-replacement group than in the placebo group (21.3% vs. 11.7%). Compliance was low; only 7.2% of women assigned to nicotine-replacement therapy and 2.8% assigned to placebo used patches for more than 1 month. Rates of adverse pregnancy and birth outcomes were similar in the two groups. CONCLUSIONS Adding a nicotine patch (15 mg per 16 hours) to behavioral cessation support for women who smoked during pregnancy did not significantly increase the rate of abstinence from smoking until delivery or the risk of adverse pregnancy or birth outcomes. However, low compliance rates substantially limited the assessment of safety. (Funded by the National Institute for Health Research Health Technology Assessment Programme; Current Controlled Trials number, ISRCTN07249128.)	[Coleman, Tim; Cooper, Sue] Univ Nottingham, Div Primary Care, UK Ctr Tobacco Control Studies, Nottingham NG7 2RD, England; [Coleman, Tim; Cooper, Sue] Univ Nottingham, Sch Primary Care Res, Natl Inst Hlth Res, Nottingham NG7 2RD, England; [Thornton, James G.] Univ Nottingham, Div Obstet & Gynecol, Nottingham NG7 2RD, England; [Thornton, James G.] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham NG7 2RD, England; [Grainge, Matthew J.; Britton, John; Lewis, Sarah] Univ Nottingham, Div Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Watts, Kim] Univ Nottingham, Acad Div Midwifery, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham	Coleman, T (corresponding author), Univ Nottingham, Div Primary Care, UK Ctr Tobacco Control Studies, Nottingham NG7 2RD, England.		Britton, John R/G-9705-2011; Coughtrie, Michael/C-3855-2009; Marlow, Neil/D-2918-2009; Thornton, Jim/B-8336-2008; Cooper, Sue/A-7471-2011	Coughtrie, Michael/0000-0003-1989-1416; Marlow, Neil/0000-0001-5890-2953; Thornton, Jim/0000-0001-9764-6876; Grainge, Matthew/0000-0001-7181-4042; Coleman, Tim/0000-0002-7303-4805; Godfrey, Christine/0000-0001-6290-5532; Watts, Kim/0000-0002-6698-0692; Cooper, Sue/0000-0002-1994-6395	NIHR [06/07/01]; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish; National Institute for Health Research [06/07/01] Funding Source: researchfish	NIHR(National Institute for Health Research (NIHR)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a grant from the NIHR Health Technology Assessment Programme (06/07/01).	Balmford J, 2011, NICOTINE TOB RES, V13, P94, DOI 10.1093/ntr/ntq215; Benowitz NL, 2000, TOB CONTROL, V9, P91, DOI 10.1136/tc.9.suppl_3.iii91; Bolling K., 2006, INFANT FEEDING SURVE; Cahill K., 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CDC006103.PUB2; Cnattingius S, 2004, NICOTINE TOB RES, V6, pS125, DOI 10.1080/14622200410001669187; Coleman T, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-2; Coleman T, 2011, ADDICTION, V106, P52, DOI 10.1111/j.1360-0443.2010.03179.x; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; Health Development Agency Expert Panel, 2003, STAND TRAIN SMOK CES; HEATHERTON TF, 1989, BRIT J ADDICT, V84, P791; Hughes J, 2003, NICOTINE TOB RES, V5, P603, DOI 10.1080/1462220031000139330; Hughes JR, 2003, NICOTINE TOB RES, V5, P13, DOI 10.1080/1462220031000070552; Hughes JR, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000031.PUB3; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Munafo M, 2008, NICOTINE TOB RES, V10, P1609, DOI 10.1080/14622200802412895; Oncken C, 2008, OBSTET GYNECOL, V112, P859, DOI 10.1097/AOG.0b013e318187e1ec; Pickett KE, 2005, PAEDIATR PERINAT EP, V19, P368, DOI 10.1111/j.1365-3016.2005.00660.x; Pickett KE, 2003, OBSTET GYNECOL, V101, P140, DOI 10.1016/S0029-7844(02)02370-0; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; Pollak KI, 2007, AM J PREV MED, V33, P297, DOI 10.1016/j.amepre.2007.05.006; Rogers John M., 2008, Birth Defects Research, V84, P1, DOI 10.1002/bdrc.20119; *ROYAL COLL PHYS, 1992, SMOK YOUNG REP WORK; Society for the Study of Addiction treattobacco.net, TREATM GUID; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; Stead L. F., 2008, COCHRANE DATABASE SY, V1; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; WHO, 2008, REP GLOB TOB EP 2008; Windsor RA, 2000, AM J OBSTET GYNECOL, V182, P68, DOI 10.1016/S0002-9378(00)70492-3; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1	29	142	143	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 1	2012	366	9					808	818		10.1056/NEJMoa1109582	http://dx.doi.org/10.1056/NEJMoa1109582			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	900GI	22375972				2023-01-03	WOS:000300874300007
J	Shapiro, RL; Souda, S; Parekh, N; Binda, K; Kayembe, M; Lockman, S; Svab, P; Babitseng, O; Powis, K; Jimbo, W; Creek, T; Makhema, J; Essex, M; Roberts, DJ				Shapiro, Roger L.; Souda, Sajini; Parekh, Natasha; Binda, Kelebogile; Kayembe, Mukendi; Lockman, Shahin; Svab, Petr; Babitseng, Orphinah; Powis, Kathleen; Jimbo, William; Creek, Tracy; Makhema, Joseph; Essex, Max; Roberts, Drucilla J.			High Prevalence of Hypertension and Placental Insufficiency, but No In Utero HIV Transmission, among Women on HAART with Stillbirths in Botswana	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; GESTATIONAL HYPERTENSION; INCREASED RISK; PREGNANCY; INFECTION; OUTCOMES; PREECLAMPSIA; DELIVERY	Background: Increased stillbirth rates occur among HIV-infected women, but no studies have evaluated the pathological basis for this increase, or whether highly active antiretroviral therapy (HAART) influences the etiology of stillbirths. It is also unknown whether HIV infection of the fetus is associated with stillbirth. Methods: HIV-infected women and a comparator group of HIV-uninfected women who delivered stillbirths were enrolled at the largest referral hospital in Botswana between January and November 2010. Obstetrical records, including antiretroviral use in pregnancy, were extracted at enrollment. Verbal autopsies; maternal HIV, CD4 and HIV RNA testing; stillbirth HIV PCR testing; and placental pathology (blinded to HIV and treatment status) were performed. Results: Ninety-nine stillbirths were evaluated, including 62 from HIV-infected women (34% on HAART from conception, 8% on HAART started in pregnancy, 23% on zidovudine started in pregnancy, and 35% on no antiretrovirals) and 37 from a comparator group of HIV-uninfected women. Only 2 (3.7%) of 53 tested stillbirths from HIV-infected women were HIV PCR positive, and both were born to women not receiving HAART. Placental insufficiency associated with hypertension accounted for most stillbirths. Placental findings consistent with chronic hypertension were common among HIV-infected women who received HAART and among HIV-uninfected women (65% vs. 54%, p = 0.37), but less common among HIV-infected women not receiving HAART (28%, p = 0.003 vs. women on HAART). Conclusions: In utero HIV infection was rarely associated with stillbirths, and did not occur among women receiving HAART. Hypertension and placental insufficiency were associated with most stillbirths in this tertiary care setting.	[Shapiro, Roger L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Shapiro, Roger L.; Lockman, Shahin; Powis, Kathleen; Makhema, Joseph; Essex, Max] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Shapiro, Roger L.; Souda, Sajini; Parekh, Natasha; Binda, Kelebogile; Lockman, Shahin; Powis, Kathleen; Makhema, Joseph; Essex, Max] Botswana Harvard Sch Publ Hlth, AIDS Inst Partnership HIV Res & Educ, Boston, MA 02115 USA; [Kayembe, Mukendi] Minist Hlth, Botswana Natl Hlth Lab, Gaborone, Botswana; [Lockman, Shahin] Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02115 USA; [Svab, Petr; Babitseng, Orphinah] Princess Marina Hosp, Minist Hlth, Gaborone, Botswana; [Powis, Kathleen] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Powis, Kathleen] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Jimbo, William; Creek, Tracy] Ctr Dis Control & Prevent, Atlanta, GA USA; [Roberts, Drucilla J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Centers for Disease Control & Prevention - USA; Harvard University; Massachusetts General Hospital	Shapiro, RL (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.	rshapiro@hsph.harvard.edu	Roberts, Drucilla/AAB-6379-2022; Powis, Kathleen/AAU-5123-2021		Centers for Disease Control and Prevention [U2GPS000941]; Doris Duke Charitable Research Foundation; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) [U2GPS000941] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Doris Duke Charitable Research Foundation(Doris Duke Charitable Foundation (DDCF)); National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by a grant from the Centers for Disease Control and Prevention (U2GPS000941), and by a Research Fellowship from the Doris Duke Charitable Research Foundation (N.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abalos E, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002252.pub3; BACKE E, 1994, AM J PERINAT, V11, P326, DOI 10.1055/s-2007-994545; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Buchbinder A, 2002, AM J OBSTET GYNECOL, V186, P66, DOI 10.1067/mob.2002.120080; Cotter AM, 2006, J INFECT DIS, V193, P1195, DOI 10.1086/503045; D'costa Grace Francis, 2007, Indian J Pathol Microbiol, V50, P515; GICHANGI PB, 1993, E AFR MED J, V70, P85; Goldenberg RL, 2010, LANCET, V375, P1482, DOI 10.1016/S0140-6736(09)61712-8; Hauth JC, 2000, OBSTET GYNECOL, V95, P24, DOI 10.1016/S0029-7844(99)00462-7; Ladner J, 1998, J ACQ IMMUN DEF SYND, V18, P293, DOI 10.1097/00042560-199807010-00015; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; Leroy V, 1998, AIDS, V12, P643, DOI 10.1097/00002030-199806000-00014; Pinar H, 2010, CLIN OBSTET GYNECOL, V53, P656, DOI 10.1097/GRF.0b013e3181eb68fe; Rollins NC, 2007, JAIDS-J ACQ IMM DEF, V44, P321, DOI 10.1097/QAI.0b013e31802ea4b0; Sibai BM, 2003, OBSTET GYNECOL, V102, P181, DOI 10.1016/S0029-7844(03)00475-7; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; Suy A, 2006, AIDS, V20, P59, DOI 10.1097/01.aids.0000198090.70325.bd; TEMMERMAN M, 1990, AIDS, V4, P1087, DOI 10.1097/00002030-199011000-00006; Townsend CL, 2007, AIDS, V21, P1019, DOI 10.1097/QAD.0b013e328133884b; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; Tuomala RK, 2005, JAIDS-J ACQ IMM DEF, V38, P449, DOI 10.1097/01.qai.0000139398.38236.4d; Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379; Wimalasundera RC, 2002, LANCET, V360, P1152, DOI 10.1016/S0140-6736(02)11195-0	23	20	20	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2012	7	2							e31580	10.1371/journal.pone.0031580	http://dx.doi.org/10.1371/journal.pone.0031580			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926ZZ	22384039	Green Published, Green Submitted, gold			2023-01-03	WOS:000302875500026
J	Morales, O; Richard, A; Martin, N; Mrizak, D; Senechal, M; Miroux, C; Pancre, V; Rommelaere, J; Caillet-Fauquet, P; de Launoit, Y; Delhem, N				Morales, Olivier; Richard, Audrey; Martin, Nathalie; Mrizak, Dhafer; Senechal, Magalie; Miroux, Celine; Pancre, Veronique; Rommelaere, Jean; Caillet-Fauquet, Perrine; de Launoit, Yvan; Delhem, Nadira			Activation of a Helper and Not Regulatory Human CD4+T Cell Response by Oncolytic H-1 Parvovirus	PLOS ONE			English	Article							RESTRICTED TUMOR-ANTIGENS; CD4(+) T-CELLS; MINUTE VIRUS; ANTITUMOR IMMUNITY; REPLICATIVE FUNCTIONS; FUTURE-DIRECTIONS; IN-VIVO; MICE; CANCER; VIROTHERAPY	Background: H-1 parvovirus (H-1 PV), a rodent autonomous oncolytic parvovirus, has emerged as a novel class of promising anticancer agents, because of its ability to selectively find and destroy malignant cells. However, to probe H-1 PV multimodal antitumor potential one of the major prerequisites is to decipher H-1 PV direct interplay with human immune system, and so prevent any risk of impairment. Methodology/Principal findings: Non activated peripheral blood mononuclear cells (PBMCs) are not sensitive to H-1 PV cytotoxic effect. However, the virus impairs both activated PBMC proliferation ability and viability. This effect is related to H-1 PV infection as evidenced by Western blotting detection of H-1 PV main protein NS1. However, TCID50 experiments did not allow newly generated virions to be detected. Moreover, flow cytometry has shown that H-1 PV preferentially targets B lymphocytes. Despite seeming harmful at first sight, H-1 PV seems to affect very few NK cells and CD8+ T lymphocytes and, above all, clearly does not affect human neutrophils and one of the major CD4+ T lymphocyte subpopulation. Very interestingly, flow cytometry analysis and ELISA assays proved that it even activates human CD4+ T cells by increasing activation marker expression (CD69 and CD30) and both effective Th1 and Th2 cytokine secretion (IL-2, IFN-gamma and IL-4). In addition, H-1 PV action does not come with any sign of immunosuppressive side effect. Finally, we have shown the efficiency of H-1 PV on xenotransplanted human nasopharyngeal carcinoma, in a SCID mouse model reconstituted with human PBMC. Conclusions/Significance: Our results show for the first time that a wild-type oncolytic virus impairs some immune cell subpopulations while directly activating a Helper CD4+ T cell response. Thus, our data open numerous gripping perspectives of investigation and strongly argue for the use of H-1 PV as an anticancer treatment.	[Morales, Olivier; Richard, Audrey; Martin, Nathalie; Mrizak, Dhafer; Senechal, Magalie; Miroux, Celine; Pancre, Veronique; Caillet-Fauquet, Perrine; de Launoit, Yvan; Delhem, Nadira] Univ Lille Nord France, Inst Biol Lille, CNRS, Inst Pasteur Lille,UMR 8161, Lille, France; [Rommelaere, Jean] Deutsch Krebsforschungszentrum, Res Program Infect & Canc, D-6900 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Helmholtz Association; German Cancer Research Center (DKFZ)	Morales, O (corresponding author), Univ Lille Nord France, Inst Biol Lille, CNRS, Inst Pasteur Lille,UMR 8161, Lille, France.	nadira.delhem@ibl.fr	Pancre, Véronique/L-8206-2018; MORALES, Olivier/AAR-5337-2020	de Launoit, Yvan/0000-0003-1837-9808; MORALES, Olivier/0000-0002-2135-3265				Angelova AL, 2009, CLIN CANCER RES, V15, P511, DOI 10.1158/1078-0432.CCR-08-1088; CAILLETFAUQUET P, 1990, EMBO J, V9, P2989, DOI 10.1002/j.1460-2075.1990.tb07491.x; CORNELIS JJ, 1988, J VIROL, V62, P3438, DOI 10.1128/JVI.62.9.3438-3444.1988; Daeffler L, 2003, J VIROL, V77, P12466, DOI 10.1128/JVI.77.23.12466-12478.2003; DEBEECK AO, 1995, CELL GROWTH DIFFER, V6, P781; Deleu L, 1999, J VIROL, V73, P3877, DOI 10.1128/JVI.73.5.3877-3885.1999; Depil S, 2007, J IMMUNOTHER, V30, P215, DOI 10.1097/01.cji.0000211338.99137.4f; FAISST S, 1995, J VIROL, V69, P4538, DOI 10.1128/JVI.69.7.4538-4543.1995; Geletneky K, 2010, NEURO-ONCOLOGY, V12, P804, DOI 10.1093/neuonc/noq023; Grekova S, 2010, CANCER BIOL THER, V10, P1280, DOI 10.4161/cbt.10.12.13455; Hristov G, 2010, J VIROL, V84, P5909, DOI 10.1128/JVI.01797-09; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Lachmann S, 2003, J VIROL, V77, P8048, DOI 10.1128/JVI.77.14.8048-8060.2003; Moehler M, 2001, CANCER GENE THER, V8, P158, DOI 10.1038/sj.cgt.7700288; Moehler MH, 2005, HUM GENE THER, V16, P996, DOI 10.1089/hum.2005.16.996; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Muharram G, 2010, BREAST CANCER RES TR, V121, P23, DOI 10.1007/s10549-009-0451-9; Nishikawa H, 2010, INT J CANCER, V127, P759, DOI 10.1002/ijc.25429; Nomura T, 2005, CURR TOP MICROBIOL, V293, P287, DOI 10.1007/3-540-27702-1_13; Nuesch JPF, 2003, J VIROL, V77, P433, DOI 10.1128/JVI.77.1.433-442.2003; Ostrand-Rosenberg S, 2005, CANCER INVEST, V23, P413, DOI 10.1081/CNV-200067428; Penault-Llorca F, 2002, Cancer Radiother, V6 Suppl 1, p24s; Raykov Z, 2007, ONCOL REP, V17, P1493; Reilly R T, 2001, Curr Opin Investig Drugs, V2, P133; RHODE SL, 1985, J VIROL, V55, P886, DOI 10.1128/JVI.55.3.886-889.1985; ROMMELAERE J, 1991, J VIROL METHODS, V33, P233, DOI 10.1016/0166-0934(91)90024-T; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Thorne SH, 2004, EXPERT OPIN BIOL TH, V4, P1307, DOI 10.1517/14712598.4.8.1307; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Wan YSY, 2010, IMMUNOLOGY, V130, P166, DOI 10.1111/j.1365-2567.2010.03289.x; Wang RF, 2003, METHODS, V29, P227, DOI 10.1016/S1046-2023(02)00345-6; Wang RF, 2001, TRENDS IMMUNOL, V22, P269, DOI 10.1016/S1471-4906(01)01896-8; White CA, 2001, ANNU REV MED, V52, P125, DOI 10.1146/annurev.med.52.1.125; Wilczynski JR, 2008, FRONT BIOSCI-LANDMRK, V13, P2266, DOI 10.2741/2840; Wizla P, 2010, ARCH VIROL, V155, P771, DOI 10.1007/s00705-010-0637-9; Xie Y, 2010, J EXP MED, V207, P651, DOI 10.1084/jem.20091921; Zhang W, 2009, J IMMUNOTOXICOL; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	39	17	18	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2012	7	2							e32197	10.1371/journal.pone.0032197	http://dx.doi.org/10.1371/journal.pone.0032197			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	925XS	22359669	Green Published, Green Submitted, gold			2023-01-03	WOS:000302796200138
J	Donohue, JM; Morden, NE; Gellad, WF; Bynum, JP; Zhou, WP; Hanlon, JT; Skinner, J				Donohue, Julie M.; Morden, Nancy E.; Gellad, Walid F.; Bynum, Julie P.; Zhou, Weiping; Hanlon, Joseph T.; Skinner, Jonathan			Sources of Regional Variation in Medicare Part D Drug Spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; GEOGRAPHIC-VARIATION; POTENTIAL SAVINGS; GENERIC DRUGS; INHIBITORS; QUALITY; COST; RISK	Background Sources of regional variation in spending for prescription drugs under Medicare Part D are poorly understood, and such variation may reflect differences in health status, use of effective treatments, or selection of branded drugs over lower-cost generics. Methods We analyzed 2008 Medicare data for 4.7 million beneficiaries for prescription-drug use and expenditures overall and in three drug categories: angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs), 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Differences in per capita expenditures across hospital-referral regions (HRRs) were decomposed into annual prescription volume and cost per prescription. The ratio of prescriptions filled as branded drugs to all prescriptions filled was calculated. We adjusted all measures for demographic, socioeconomic, and health-status differences. Results Mean adjusted per capita pharmaceutical spending ranged from $2,413 in the lowest to $3,008 in the highest quintile of HRRs. Most (75.9%) of that difference was attributable to the cost per prescription ($53 vs. $63). Regional differences in cost per prescription explained 87.5% of expenditure variation for ACE inhibitors and ARBs and 56.3% for statins but only 36.1% for SSRIs and SNRIs. The ratio of branded-drug to total prescriptions, which correlated highly with cost per prescription, ranged across HRRs from 0.24 to 0.45 overall and from 0.24 to 0.55 for ACE inhibitors and ARBs, 0.29 to 0.60 for statins, and 0.15 to 0.51 for SSRIs and SNRIs. Conclusions Regional variation in Medicare Part D spending results largely from differences in the cost of drugs selected rather than prescription volume. A reduction in branded-drug use in some regions through modification of Part D plan benefits might lower costs without reducing quality of care. (Funded by the National Institute on Aging and others.)	[Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA; [Gellad, Walid F.] Univ Pittsburgh, Dept Med Gen Internal Med, Pittsburgh, PA 15261 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med Geriatr Pharm & Therapeut & Biomed Infor, Pittsburgh, PA 15261 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA 15261 USA; [Gellad, Walid F.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; [Gellad, Walid F.] RAND, Pittsburgh, PA USA; [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Morden, Nancy E.; Bynum, Julie P.; Zhou, Weiping; Skinner, Jonathan] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Morden, Nancy E.; Skinner, Jonathan] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; [Skinner, Jonathan] Dartmouth Coll, Dept Econ, Hanover, NH 03755 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; RAND Corporation; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Dartmouth College; Dartmouth College; Dartmouth College	Donohue, JM (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A613, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu		Donohue, Julie/0000-0003-2418-6017	National Institute on Aging [P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, R56AG027017]; Agency for Healthcare Research and Quality [R01HS017695, R01HS018721, K12 HS019461]; National Institute of Nursing Research [R01 NR010135]; National Institute of Mental Health [R34 MH082682]; Robert Wood Johnson Foundation [059491]; Veterans Affairs Health Services Research and Development Service [IIR-06-062, CDA 09-207]; National Institute on Aging and others; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS017695, R01HS018721, K12HS019461] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146, UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R34MH082682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG012553, R37AG007001, R01AG034056, R56AG027017, P01AG019783, P30AG024827, K23AG028947, T32AG021885, K23AG035030, K07AG033174] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs); National Institute on Aging and others; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the National Institute on Aging (P01AG019783, AG-07-001, P30AG024827, T32 AG021885, K07AG033174, K23AG028947, R01AG034056, U01 AG012553, and R56AG027017), the Agency for Healthcare Research and Quality (R01HS017695, R01HS018721, and K12 HS019461), the National Institute of Nursing Research (R01 NR010135), the National Institute of Mental Health (R34 MH082682), the Robert Wood Johnson Foundation (059491), and the Veterans Affairs Health Services Research and Development Service (IIR-06-062 and CDA 09-207).; Funded by the National Institute on Aging and others.	Agency for Healthcare Research and Quality, CREAT NEW RAC ETHN C; [Anonymous], 2009, GENERIC DRUGS REVISI; [Anonymous], 2008, FACT SHEET MED PRESC; [Anonymous], LEX DAT BAS DAT LEX; [Anonymous], CENS 2000 SUMM FIL A; [Anonymous], 2007, GEN DRUG UT MED D; Anthony DL, 2009, HEALTH AFFAIR, V28, P864, DOI 10.1377/hlthaff.28.3.864; Anthony JDL, 2009, HLTH AFF MILLWOOD, V28, P1233; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Centers for Medicare and Medicaid Services, RXHCC MOD SOFTW; Dartmouth Medical School Center for the Evaluative Clinical Sciences, 1998, DARTM ATL HLTH CAR; Donohue JM, 2008, HEALTH SERV RES, V43, P1557, DOI 10.1111/j.1475-6773.2008.00858.x; Fischer MA, 2004, PHARMACOEPIDEM DR S, V13, P207, DOI 10.1002/pds.872; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Fischer MA, 2003, HEALTH SERV RES, V38, P1051, DOI 10.1111/1475-6773.00162; Fisher ES, 2009, NEW ENGL J MED, V360, P849, DOI 10.1056/NEJMp0809794; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gellad WF, 2010, AM J MANAG CARE, V16, P741; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Kaiser Family Foundation, 2007, MED PRESCR DRUG BEN; Kaiser Family Foundation, 2010, MED PRESCR DRUG PLAN; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; MaCurdy T., 2009, GEOGRAPHIC VARIATION; Matchar DB, 2008, ANN INTERN MED, V148, P16, DOI 10.7326/0003-4819-148-1-200801010-00189; Matchar DB., COMPARATIVE EFFECTIV; Oaxaca R., 1973, INT ECON REV, V14, P693, DOI 10.2307/2525981; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Robst J, 2007, HEALTH CARE FINANC R, V28, P15; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2007, J GEN INTERN MED, V22, P1298, DOI 10.1007/s11606-007-0284-3; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Sutherland JM, 2009, NEW ENGL J MED, V361, P1227, DOI 10.1056/NEJMp0907172; Welch HG, 2011, JAMA-J AM MED ASSOC, V305, P1113, DOI 10.1001/jama.2011.307; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	39	58	58	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	2012	366	6					530	538		10.1056/NEJMsa1104816	http://dx.doi.org/10.1056/NEJMsa1104816			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	888GH	22316446	Green Accepted, Bronze			2023-01-03	WOS:000299991300009
J	Perlman, AI; Ali, A; Njike, VY; Hom, D; Davidi, A; Gould-Fogerite, S; Milak, C; Katz, DL				Perlman, Adam I.; Ali, Ather; Njike, Valentine Yanchou; Hom, David; Davidi, Anna; Gould-Fogerite, Susan; Milak, Carl; Katz, David L.			Massage Therapy for Osteoarthritis of the Knee: A Randomized Dose-Finding Trial	PLOS ONE			English	Article							ALTERNATIVE MEDICINE; MODERATE PRESSURE; VISUAL ANALOG; REDUCES PAIN; BACK-PAIN; WOMAC; COMPLEMENTARY; ANXIETY; SAFETY; NECK	Background: In a previous trial of massage for osteoarthritis (OA) of the knee, we demonstrated feasibility, safety and possible efficacy, with benefits that persisted at least 8 weeks beyond treatment termination. Methods: We performed a RCT to identify the optimal dose of massage within an 8-week treatment regimen and to further examine durability of response. Participants were 125 adults with OA of the knee, randomized to one of four 8-week regimens of a standardized Swedish massage regimen (30 or 60 min weekly or biweekly) or to a Usual Care control. Outcomes included the Western Ontario and McMaster Universities Arthritis Index (WOMAC), visual analog pain scale, range of motion, and time to walk 50 feet, assessed at baseline, 8-, 16-, and 24-weeks. Results: WOMAC Global scores improved significantly (24.0 points, 95% CI ranged from 15.3-32.7) in the 60-minute massage groups compared to Usual Care (6.3 points, 95% CI 0.1-12.8) at the primary endpoint of 8-weeks. WOMAC subscales of pain and functionality, as well as the visual analog pain scale also demonstrated significant improvements in the 60-minute doses compared to usual care. No significant differences were seen in range of motion at 8-weeks, and no significant effects were seen in any outcome measure at 24-weeks compared to usual care. A dose-response curve based on WOMAC Global scores shows increasing effect with greater total time of massage, but with a plateau at the 60-minute/week dose. Conclusion: Given the superior convenience of a once-weekly protocol, cost savings, and consistency with a typical real-world massage protocol, the 60-minute once weekly dose was determined to be optimal, establishing a standard for future trials.	[Perlman, Adam I.] Duke Univ, Sch Med, Durham, NC 27708 USA; [Ali, Ather; Njike, Valentine Yanchou; Davidi, Anna; Katz, David L.] Yale Univ, Sch Med, Prevent Res Ctr, Derby, CT USA; [Hom, David] Boston Med Ctr, Clin Trials Unit, Infect Dis Sect, Boston, MA USA; [Hom, David; Gould-Fogerite, Susan; Milak, Carl] Univ Med & Dent New Jersey, Sch Hlth Related Profess, Newark, NJ 07103 USA	Duke University; Yale University; Boston Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Perlman, AI (corresponding author), Duke Univ, Sch Med, Durham, NC 27708 USA.	adam.perlman@duke.edu		Njike, Valentine/0000-0001-5468-3175; Katz, David/0000-0001-6845-6192	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health [R01 AT004623]; National Center for Complementary & Integrative Health [R01AT004623] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This publication was made possible by grant number R01 AT004623 from the National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCCAM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahles TA, 1999, J PAIN SYMPTOM MANAG, V18, P157, DOI 10.1016/S0885-3924(99)00061-5; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Anagnostis C, 2003, SPINE, V28, P1051, DOI 10.1097/00007632-200305150-00018; Angst F, 2002, J RHEUMATOL, V29, P131; Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007; Back C, 2009, HOLIST NURS PRACT, V23, P19, DOI 10.1097/01.HNP.0000343206.71957.a9; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Bauer Brent A, 2010, Complement Ther Clin Pract, V16, P70, DOI 10.1016/j.ctcp.2009.06.012; Bellamy N, 2005, CLIN EXP RHEUMATOL, V23, pS148; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Billhult A, 2008, AUTON NEUROSCI-BASIC, V140, P88, DOI 10.1016/j.autneu.2008.03.006; Billhult A, 2009, AUTON NEUROSCI-BASIC, V150, P111, DOI 10.1016/j.autneu.2009.03.010; Billhult Annika, 2009, Complement Ther Clin Pract, V15, P96, DOI 10.1016/j.ctcp.2008.10.003; Bouchet C, 1996, J CLIN EPIDEMIOL, V49, P15, DOI 10.1016/0895-4356(95)00540-4; Bronfort Gert, 2010, Chiropr Osteopat, V18, P3, DOI 10.1186/1746-1340-18-3; Cambron JA, 2007, J ALTERN COMPLEM MED, V13, P793, DOI 10.1089/acm.2006.6401; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Corbin LW, 2009, J PALLIAT MED, V12, P7, DOI 10.1089/jpm.2008.0198; Diego MA, 2004, INT J NEUROSCI, V114, P31, DOI 10.1080/00207450490249446; Diego MA, 2001, INT J NEUROSCI, V106, P35, DOI 10.3109/00207450109149736; Diego M, 2009, INT J NEUROSCI, V119, P630, DOI 10.1080/00207450802329605; Downey L, 2009, J PALLIAT CARE, V25, P100, DOI 10.1177/082585970902500204; Ernst E, 2003, RHEUMATOLOGY, V42, P1101, DOI 10.1093/rheumatology/keg306; Ernst E, 2002, CURR OPIN RHEUMATOL, V14, P58, DOI 10.1097/00002281-200201000-00011; Escobar A, 2007, OSTEOARTHR CARTILAGE, V15, P273, DOI 10.1016/j.joca.2006.09.001; Ezzo J, 2007, SPINE, V32, P353, DOI 10.1097/01.brs.0000254099.07294.21; Felson DT, 2004, RADIOL CLIN N AM, V42, P1, DOI 10.1016/S0033-8389(03)00161-1; Field T, 2005, INT J NEUROSCI, V115, P1397, DOI 10.1080/00207450590956459; Field T, 1996, INT J NEUROSCI, V86, P197, DOI 10.3109/00207459608986710; Field T, 2008, J BODYW MOV THER, V12, P146, DOI 10.1016/j.jbmt.2007.06.003; Field T, 2010, INT J NEUROSCI, V120, P381, DOI 10.3109/00207450903579475; Fisher NM, 1997, SCAND J REHABIL MED, V29, P213; Hernandez-Reif M, 2001, INT J NEUROSCI, V106, P131, DOI 10.3109/00207450109149744; Hunter DJ, 2006, BMJ-BRIT MED J, V332, P639, DOI 10.1136/bmj.332.7542.639; Jane SW, 2009, J PAIN SYMPTOM MANAG, V37, P754, DOI 10.1016/j.jpainsymman.2008.04.021; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kato T, 2004, CURR OPIN RHEUMATOL, V16, P604, DOI 10.1097/01.bor.0000133661.52599.bf; Kirby BS, 2007, J PHYSIOL-LONDON, V583, P861, DOI 10.1113/jphysiol.2007.131250; Kotlarz H, 2009, ARTHRITIS RHEUM-US, V60, P3546, DOI 10.1002/art.24984; Kutner JS, 2008, ANN INTERN MED, V149, P369, DOI 10.7326/0003-4819-149-6-200809160-00003; Law LAF, 2008, J PAIN, V9, P714, DOI 10.1016/j.jpain.2008.03.009; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Listing M, 2009, PSYCHO-ONCOLOGY, V18, P1290, DOI 10.1002/pon.1508; Matchaba P, 2005, CLIN THER, V27, P1196, DOI 10.1016/j.clinthera.2005.07.019; McConnell S, 2001, ARTHRIT RHEUM-ARTHR, V45, P453, DOI 10.1002/1529-0131(200110)45:5<453::AID-ART365>3.0.CO;2-W; MESSIER SP, 1992, ARCH PHYS MED REHAB, V73, P29; Naesdall J, 2006, DRUG SAFETY, V29, P119; National Center for Complementary and Alternative Medicine, 2010, NCCAM BACKGR MASS TH; Nayak S, 2001, J Spinal Cord Med, V24, P54; Perlman A, 2003, COMPLEMENTARY ALTERN, P352; Perlman A, 2003, INTEGRATIVE MED, P414; Perlman A, 2006, OWN YOUR OWN HLTH BE; Perlman AI, 2006, ARCH INTERN MED, V166, P2533, DOI 10.1001/archinte.166.22.2533; Poole AR, 2004, J IMMUNOL METHODS, V294, P145, DOI 10.1016/j.jim.2004.09.005; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Rapaport MH, 2010, J ALTERN COMPLEM MED, V16, P1079, DOI 10.1089/acm.2009.0634; Richmond J, 2009, J AM ACAD ORTHOP SUR, V17, P591, DOI 10.5435/00124635-200909000-00006; Sagar Stephen M, 2007, J Soc Integr Oncol, V5, P155, DOI 10.2310/7200.2007.017; SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304-3959(93)90183-P; Schnyer RN, 2002, J ALTERN COMPLEM MED, V8, P623, DOI 10.1089/107555302320825147; Sefton JM, 2010, J ALTERN COMPLEM MED, V16, P723, DOI 10.1089/acm.2009.0441; Sherman Karen J, 2005, BMC Complement Altern Med, V5, P13, DOI 10.1186/1472-6882-5-13; Sherman KJ, 2010, DEPRESS ANXIETY, V27, P441, DOI 10.1002/da.20671; Sherman KJ, 2009, CLIN J PAIN, V25, P233, DOI 10.1097/AJP.0b013e31818b7912; Smith Marlaine, 2007, J Soc Integr Oncol, V5, P139, DOI 10.2310/7200.2007.014; Stringer J, 2008, PSYCHO-ONCOL, V17, P1024, DOI 10.1002/pon.1331; Wentworth Laura J, 2009, Prog Cardiovasc Nurs, V24, P155, DOI 10.1111/j.1751-7117.2009.00054.x	68	58	58	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2012	7	2							e30248	10.1371/journal.pone.0030248	http://dx.doi.org/10.1371/journal.pone.0030248			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924ZP	22347369	Green Published, Green Submitted, gold			2023-01-03	WOS:000302730100007
J	Kimura, T; Yeliseev, AA; Vukoti, K; Rhodes, SD; Cheng, KJ; Rice, KC; Gawrisch, K				Kimura, Tomohiro; Yeliseev, Alexei A.; Vukoti, Krishna; Rhodes, Steven D.; Cheng, Kejun; Rice, Kenner C.; Gawrisch, Klaus			Recombinant Cannabinoid Type 2 Receptor in Liposome Model Activates G Protein in Response to Anionic Lipid Constituents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL RECONSTITUTION; CRYSTAL-STRUCTURE; PHASE-TRANSITION; CB2 RECEPTORS; BINDING-SITE; ANNEXIN-V; PHOSPHATIDYLSERINE; EXPRESSION; RHODOPSIN; MEMBRANE	Human cannabinoid type 2 (CB2) receptor expressed in Escherichia coli was purified and successfully reconstituted in the functional form into lipid bilayers composed of POPC, 1-palmitoyl- 2-oleoyl-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl- sn-glycero-3-phospho-L-serine (POPS), and cholesteryl hemisuccinate (CHS). Reconstitution was performed by detergent removal from the protein/lipid/detergent mixed micelles either on an adsorbent column, or by rapid dilution to below the critical micelle concentration of detergent followed by removal of detergent monomers on a concentrator. Proteoliposomes prepared at a protein/phospholipid/CHS molar ratio of 1/620 - 650/210-220 are free of detergent as shown by H-1 NMR, have a homogeneous protein/lipid ratio shown by isopycnic gradient ultracentrifugation, and are small in size with a mean diameter of 150-200 nm as measured by dynamic light scattering. Functional integrity of the reconstituted receptor was confirmed by quantitative binding of H-2-labeled agonist CP-55,940-d(6) measured by H-2 magic angle spinning NMR, as well as by activation of G protein. The efficiency of G protein activation by agonist-bound CB2 receptor was affected by negative electric surface potentials of proteoliposomes controlled by the content of anionic CHS or POPS. The activation was highest at an anionic lipid content of about 50 mol %. There was no correlation between the efficiency of G protein activation and an increase of hydrocarbon chain order induced by CHS or cholesterol. The results suggest the importance of anionic lipids in regulating signal transduction by CB2 receptor and other class A GPCR. The successful reconstitution of milligram quantities of pure, functional CB2 receptor enables a wide variety of structural studies.	[Kimura, Tomohiro; Yeliseev, Alexei A.; Vukoti, Krishna; Rhodes, Steven D.; Gawrisch, Klaus] NIAAA, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20852 USA; [Cheng, Kejun; Rice, Kenner C.] NIDA, Chem Biol Res Branch, NIH, Bethesda, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Yeliseev, AA (corresponding author), NIAAA, Lab Membrane Biochem & Biophys, NIH, Bethesda, MD 20852 USA.	yeliseeva@mail.nih.gov; gawrisch@helix.nih.gov	Kimura, Tomohiro/AEJ-1621-2022; Yeliseev, Alexei A/B-3143-2009	Kimura, Tomohiro/0000-0002-4192-7852	National Institutes of Health from the of the NIAAA; NIDA; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000529] Funding Source: NIH RePORTER	National Institutes of Health from the of the NIAAA; NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported, in whole or in part, by a National Institutes of Health grant from the Intramural Research Programs of the NIAAA and NIDA.	Appelt U, 2005, CELL DEATH DIFFER, V12, P194, DOI 10.1038/sj.cdd.4401527; Aveyard R., 1973, INTRO PRINCIPLES SUR; Baker M, 2010, NATURE, V465, P823, DOI 10.1038/465823a; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Bari M, 2005, J NEUROSCI RES, V81, P275, DOI 10.1002/jnr.20546; Bari M, 2008, NEUROPHARMACOLOGY, V54, P45, DOI 10.1016/j.neuropharm.2007.06.030; Bari M, 2006, J IMMUNOL, V177, P4971, DOI 10.4049/jimmunol.177.8.4971; Berger C, 2010, PROTEIN EXPRES PURIF, V70, P236, DOI 10.1016/j.pep.2009.12.011; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Calandra B, 1997, BIOTECHNOL LETT, V19, P425, DOI 10.1023/A:1018383808401; Callahan MK, 2000, CELL DEATH DIFFER, V7, P645, DOI 10.1038/sj.cdd.4400690; CEVC G, 1981, BIOCHEMISTRY-US, V20, P4955, DOI 10.1021/bi00520a023; Chattopadhyay A, 1996, FEBS LETT, V391, P199, DOI 10.1016/0014-5793(96)00733-8; CHEN NR, 1985, BIOCHEM BIOPH RES CO, V127, P220, DOI 10.1016/S0006-291X(85)80147-9; Choe HW, 2011, NATURE, V471, P651, DOI 10.1038/nature09789; Choi G, 2005, BBA-BIOMEMBRANES, V1668, P1, DOI 10.1016/j.bbamem.2004.10.011; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DeGrip WJ, 1998, BIOCHEM J, V330, P667; DEGRIP WJ, 1983, BIOCHIM BIOPHYS ACTA, V734, P168, DOI 10.1016/0005-2736(83)90115-3; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Escriba PV, 1997, P NATL ACAD SCI USA, V94, P11375, DOI 10.1073/pnas.94.21.11375; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Grace CRR, 2007, J STRUCT BIOL, V159, P359, DOI 10.1016/j.jsb.2007.04.004; Granier S, 2007, J BIOL CHEM, V282, P13895, DOI 10.1074/jbc.M611904200; Hafez IM, 2000, BBA-BIOMEMBRANES, V1463, P107, DOI 10.1016/S0005-2736(99)00186-8; Heerklotz H, 2006, BIOPHYS J, V91, P600, DOI 10.1529/biophysj.106.082669; HERRMANN KW, 1962, J PHYS CHEM-US, V66, P295, DOI 10.1021/j100808a025; HOLTE LL, 1995, BIOPHYS J, V68, P2396, DOI 10.1016/S0006-3495(95)80422-4; Hurst DP, 2010, J BIOL CHEM, V285, P17954, DOI 10.1074/jbc.M109.041590; Ibrahim MM, 2005, P NATL ACAD SCI USA, V102, P3093, DOI 10.1073/pnas.0409888102; Ibrahim MM, 2003, P NATL ACAD SCI USA, V100, P10529, DOI 10.1073/pnas.1834309100; JACKSON ML, 1982, BIOCHEMISTRY-US, V21, P5601, DOI 10.1021/bi00265a033; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; Kimura T, 2006, BIOCHEMISTRY-US, V45, P15601, DOI 10.1021/bi061641v; Kimura T, 2010, BIOPHYS J, V98, p625A, DOI 10.1016/j.bpj.2009.12.3421; Kimura T, 2009, BIOPHYS J, V96, P4916, DOI 10.1016/j.bpj.2009.03.033; Koenig BW, 2005, BBA-BIOMEMBRANES, V1715, P65, DOI 10.1016/j.bbamem.2005.07.006; Kosloff M, 2008, J BIOL CHEM, V283, P31197, DOI 10.1074/jbc.M803799200; Krepkiy D, 2007, PROTEIN PEPTIDE LETT, V14, P1031, DOI 10.2174/092986607782541051; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Leitz AJ, 2006, BIOTECHNIQUES, V40, P601, DOI 10.2144/000112169; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Messerschmidt A., 2007, XRAY DIFFRACTION BIO; Miller AM, 2008, BRIT J PHARMACOL, V153, P299, DOI 10.1038/sj.bjp.0707523; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Mozsolits H, 2002, BIOCHEMISTRY-US, V41, P7830, DOI 10.1021/bi0121813; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; Nebane NM, 2008, BIOCHEMISTRY-US, V47, P13811, DOI 10.1021/bi8007802; Niu SL, 2009, BIOCHEMISTRY-US, V48, P156, DOI 10.1021/bi801835s; Nunez E, 2004, SYNAPSE, V53, P208, DOI 10.1002/syn.20050; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Petrache HI, 2004, BIOPHYS J, V86, P1574, DOI 10.1016/S0006-3495(04)74225-3; Polozov IV, 2006, BIOPHYS J, V90, P2051, DOI 10.1529/biophysj.105.070441; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Roy MT, 1998, J COLLOID INTERF SCI, V206, P512, DOI 10.1006/jcis.1998.5715; Sarnataro D, 2005, FEBS LETT, V579, P6343, DOI 10.1016/j.febslet.2005.10.016; Sarramegna V, 2006, CELL MOL LIFE SCI, V63, P1149, DOI 10.1007/s00018-005-5557-6; Scheerer P, 2008, NATURE, V455, P497, DOI 10.1038/nature07330; Schubert R, 2003, METHOD ENZYMOL, V367, P46; Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474; SILVIUS JR, 1992, ANNU REV BIOPH BIOM, V21, P323, DOI 10.1146/annurev.bb.21.060192.001543; Soubias O, 2006, BIOCHEMISTRY-US, V45, P15583, DOI 10.1021/bi061416d; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; THOMAS BF, 1990, J PHARMACOL EXP THER, V255, P624; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; WATTS A, 1979, BIOCHEMISTRY-US, V18, P5006, DOI 10.1021/bi00589a031; Whorton MR, 2007, P NATL ACAD SCI USA, V104, P7682, DOI 10.1073/pnas.0611448104; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; Xie XQ, 2005, J BIOL CHEM, V280, P3605, DOI 10.1074/jbc.M410294200; Xie XQ, 2003, PROTEINS, V53, P307, DOI 10.1002/prot.10511; Yeliseev AA, 2005, PROTEIN SCI, V14, P2638, DOI 10.1110/ps.051550305; Yeliseev A, 2007, PROTEIN EXPRES PURIF, V53, P153, DOI 10.1016/j.pep.2006.12.003; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	79	35	35	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2012	287	6					4076	4087		10.1074/jbc.M111.268425	http://dx.doi.org/10.1074/jbc.M111.268425			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	894EX	22134924	hybrid, Green Published			2023-01-03	WOS:000300410900041
J	Cheung, F				Cheung, Felix			MODERN TCM Enter the clinic	NATURE			English	Editorial Material																			0	23	23	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S94	S95		10.1038/480S94a	http://dx.doi.org/10.1038/480S94a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190091	Bronze			2023-01-03	WOS:000298318000007
J	Chabner, BA				Chabner, Bruce A.			Drug Shortages - A Critical Challenge for the Generic-Drug Market	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Chabner, BA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.		Mendoza, Elvia/A-9361-2012					[Anonymous], 2008, REUTERS         0515; Centers for Medicare and Medicaid Services, MEDICARE B; Food and Drug Adminstration, DRUG SHORT; 2011, PHARM BLOG      0613	4	70	72	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 8	2011	365	23					2147	2149		10.1056/NEJMp1112633	http://dx.doi.org/10.1056/NEJMp1112633			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	857PQ	22040167				2023-01-03	WOS:000297731400013
J	Schneider, CP; Shukla, D; Trout, BL				Schneider, Curtiss P.; Shukla, Diwakar; Trout, Bernhardt L.			Effects of Solute-Solute Interactions on Protein Stability Studied Using Various Counterions and Dendrimers	PLOS ONE			English	Article							PAMAM DENDRIMERS; ARGININE; AGGREGATION; GUANIDINIUM; SULFATE; STABILIZATION; GENERATION; HYDRATION; MECHANISM; DESIGN	Much work has been performed on understanding the effects of additives on protein thermodynamics and degradation kinetics, in particular addressing the Hofmeister series and other broad empirical phenomena. Little attention, however, has been paid to the effect of additive-additive interactions on proteins. Our group and others have recently shown that such interactions can actually govern protein events, such as aggregation. Here we use dendrimers, which have the advantage that both size and surface chemical groups can be changed and therein studied independently. Dendrimers are a relatively new and broad class of materials which have been demonstrated useful in biological and therapeutic applications, such as drug delivery, perturbing amyloid formation, etc. Guanidinium modified dendrimers pose an interesting case given that guanidinium can form multiple attractive hydrogen bonds with either a protein surface or other components in solution, such as hydrogen bond accepting counterions. Here we present a study which shows that the behavior of such macromolecule species (modified PAMAM dendrimers) is governed by intra-solvent interactions. Attractive guanidiniumanion interactions seem to cause clustering in solution, which inhibits cooperative binding to the protein surface but at the same time, significantly suppresses nonnative aggregation.	[Schneider, Curtiss P.; Shukla, Diwakar; Trout, Bernhardt L.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Schneider, CP (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	trout@mit.edu	Shukla, Diwakar/GRY-2518-2022	Shukla, Diwakar/0000-0003-4079-5381	Singapore-MIT Alliance	Singapore-MIT Alliance	The Singapore-MIT Alliance funded this research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baynes BM, 2005, BIOCHEMISTRY-US, V44, P4919, DOI 10.1021/bi047528r; Baynes BM, 2004, BIOPHYS J, V87, P1631, DOI 10.1529/biophysj.104.042473; Baynes BM, 2003, J PHYS CHEM B, V107, P14058, DOI 10.1021/jp0363996; Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CANNON WR, 1994, J PHYS CHEM-US, V98, P6225, DOI 10.1021/j100075a027; Cordes H, 2007, BIOMACROMOLECULES, V8, P3578, DOI 10.1021/bm7006168; Dempsey CE, 2007, J AM CHEM SOC, V129, P15895, DOI 10.1021/ja074719j; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Frokjaer S, 2005, NAT REV DRUG DISCOV, V4, P298, DOI 10.1038/nrd1695; Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002; Ghosh K, 2009, P NATL ACAD SCI USA, V106, P10649, DOI 10.1073/pnas.0903995106; Giehm L, 2008, BIOPOLYMERS, V89, P522, DOI 10.1002/bip.20921; Heegaard PMH, 2007, MACROMOL BIOSCI, V7, P1047, DOI 10.1002/mabi.200700051; Hofmeister F., 1888, ARCH EXPER PATHOL PH, V24, P247; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Klajnert B, 2003, BBA-PROTEINS PROTEOM, V1648, P115, DOI 10.1016/S1570-9639(03)00117-1; Kozer N, 2007, BIOPHYS J, V92, P2139, DOI 10.1529/biophysj.106.097717; Labieniec M, 2009, CENT EUR J BIOL, V4, P434, DOI 10.2478/s11535-009-0056-7; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; MacKerell AD, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P7; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; Mason PE, 2005, J PHYS CHEM B, V109, P24185, DOI 10.1021/jp052799c; Mason PE, 2003, P NATL ACAD SCI USA, V100, P4557, DOI 10.1073/pnas.0735920100; Mason PE, 2009, J PHYS CHEM B, V113, P3227, DOI 10.1021/jp8112232; Minton AP, 1997, CURR OPIN BIOTECH, V8, P65, DOI 10.1016/S0958-1669(97)80159-0; MINTON AP, 1998, ENERGETICS BIOL MA B, P127; Okuro K, 2009, J AM CHEM SOC, V131, P1626, DOI 10.1021/ja800491v; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Schneider CP, 2011, J PHYS CHEM B, V115, P7447, DOI 10.1021/jp111920y; Schneider CP, 2009, J PHYS CHEM B, V113, P2050, DOI 10.1021/jp808042w; SHUKLA D, J PHYS CHEM IN PRESS; Shukla D, 2011, J PHYS CHEM B, V115, P1243, DOI 10.1021/jp108586b; Shukla D, 2010, J PHYS CHEM B, V114, P13426, DOI 10.1021/jp108399g; Shukla D, 2009, J PHYS CHEM B, V113, P12546, DOI 10.1021/jp810949t; Timasheff SN, 2002, P NATL ACAD SCI USA, V99, P9721, DOI 10.1073/pnas.122225399	37	17	17	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 18	2011	6	11							e27665	10.1371/journal.pone.0027665	http://dx.doi.org/10.1371/journal.pone.0027665			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	858IH	22125620	Green Published, Green Submitted, gold			2023-01-03	WOS:000297789200020
J	Freedman, SB; Parkin, PC; Willan, AR; Schuh, S				Freedman, Stephen B.; Parkin, Patricia C.; Willan, Andrew R.; Schuh, Suzanne			Rapid versus standard intravenous rehydration in paediatric gastroenteritis: pragmatic blinded randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LACTATED RINGERS SOLUTION; EMERGENCY-DEPARTMENT; DEHYDRATION SCALE; ORAL ONDANSETRON; NORMAL SALINE; CHILDREN; MYOCARDITIS; VALIDATION; MANAGEMENT; HYDRATION	Objective To determine if rapid rather than standard intravenous rehydration results in improved hydration and clinical outcomes when administered to children with gastroenteritis. Design Single centre, two arm, parallel randomised pragmatic controlled trial. Blocked randomisation stratified by site. Participants, caregivers, outcome assessors, investigators, and statisticians were blinded to the treatment assignment. Setting Paediatric emergency department in a tertiary care centre in Toronto, Canada. Participants 226 children aged 3 months to 11 years; complete follow-up was obtained on 223 (99%). Eligible children were aged over 90 days, had a diagnosis of dehydration secondary to gastroenteritis, had not responded to oral rehydration, and had been prescribed intravenous rehydration. Children were excluded if they weighed less than 5 kg or more than 33 kg, required fluid restriction, had a suspected surgical condition, or had an insurmountable language barrier. Children were also excluded if they had a history of a chronic systemic disease, abdominal surgery, bilious or bloody vomit, hypotension, or hypoglycaemia or hyperglycaemia. Interventions Rapid (60 mL/kg) or standard (20 mL/kg) rehydration with 0.9% saline over an hour; subsequent fluids administered according to protocol. Main outcome measures Primary outcome: clinical rehydration, assessed with a validated scale, two hours after the start of treatment. Secondary outcomes: prolonged treatment, mean clinical dehydration scores over the four hour study period, time to discharge, repeat visits to emergency department, adequate oral intake, and physician's comfort with discharge. Data from all randomised patients were included in an intention to treat analysis. Results 114 patients were randomised to rapid rehydration and 112 to standard. One child was withdrawn because of severe hyponatraemia at baseline. There was no evidence of a difference between the rapid and standard rehydration groups in the proportions of participants who were rehydrated at two hours (41/114 (36%) v 33/112 (30%); difference 6.5% (95% confidence interval -5.7% to 18.7%; P=0.32). The results did not change after adjustment for weight, baseline dehydration score, and baseline pH (odds ratio 1.8, 0.90 to 3.5; P=0.10). The rates of prolonged treatment were similar (52% rapid v 43% standard; difference 8.9%, 21% to -5%; P=0.19). Although dehydration scores were similar throughout the study period (P=0.96), the median time to discharge was longer in the rapid group (6.3 v 5.0 hours; P=0.03). Conclusions There are no relevant clinical benefits from the administration of rapid rather than standard intravenous rehydration to haemodynamically stable children deemed to require intravenous rehydration.	[Freedman, Stephen B.; Schuh, Suzanne] Hosp Sick Children, Div Paediat Emergency Med, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.] Hosp Sick Children, Di Paediat Gastroenterol Hepatol & Nutr, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.; Parkin, Patricia C.; Willan, Andrew R.; Schuh, Suzanne] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Freedman, Stephen B.; Parkin, Patricia C.; Schuh, Suzanne] Univ Toronto, Dept Paediat, Fac Med, Toronto, ON M5S 1A1, Canada; [Parkin, Patricia C.] Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada; [Parkin, Patricia C.] Hosp Sick Children, Paediat Outcomes Res Team, Toronto, ON M5G 1X8, Canada; [Willan, Andrew R.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Freedman, SB (corresponding author), Hosp Sick Children, Div Paediat Emergency Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	stephen.freedman@sickkids.ca	Freedman, Stephen/H-9102-2012	Freedman, Stephen/0000-0003-2319-6192	The Physicians' Services Incorporated Foundation; The Hospital for Sick Children Foundation	The Physicians' Services Incorporated Foundation; The Hospital for Sick Children Foundation	This study was supported by a grant from The Physicians' Services Incorporated Foundation. The Paediatric Outcomes Research Team (PCP) is funded by The Hospital for Sick Children Foundation. The study sponsors played no role in study design or data collection, analysis, and interpretation or in the writing of the article and the decision to submit it for publication; all researcher activities were independent of the funding source; and the research team had full and unrestricted access to all the data.	Alam NH, 2009, J PEDIATR GASTR NUTR, V48, P318, DOI 10.1097/MPG.0b013e318180af27; Bailey B, 2010, ACAD EMERG MED, V17, P583, DOI 10.1111/j.1553-2712.2010.00767.x; Bender BJ, 2004, PEDIATR EMERG CARE, V20, P215, DOI 10.1097/01.pec.0000121239.99242.49; Chang YJ, 2006, PEDIATR EMERG CARE, V22, P439, DOI 10.1097/01.pec.0000221346.64991.e7; Cheng A, 2011, PAED CHILD HEALT-CAN, V16, P177, DOI 10.1093/pch/16.3.177; DeCamp LR, 2008, ARCH PEDIAT ADOL MED, V162, P858, DOI 10.1001/archpedi.162.9.858; Freedman SB, 2006, NEW ENGL J MED, V354, P1698, DOI 10.1056/NEJMoa055119; Freedman SB, 2007, PEDIATRICS, V120, P1278, DOI 10.1542/peds.2007-1073; Freedman SB, 2011, ACAD EMERG MED, V18, P38, DOI 10.1111/j.1553-2712.2010.00960.x; Friedman AL, 2005, KIDNEY INT, V67, P380, DOI 10.1111/j.1523-1755.2005.00092.x; Friedman LM, 1998, FUNDAMENTALS CLIN TR, P94; Frifdman JN, 2004, J PEDIATR-US, V145, P201, DOI 10.1016/j.jpeds.2004.05.035; Gharahbaghian L, 2008, CAN J EMERG MED, V10, P488; Goldman RD, 2008, PEDIATRICS, V122, P545, DOI 10.1542/peds.2007-3141; Gorelick M, 2002, RAPID INTRAVENOUS RE; Guarino A, 2008, J PEDIATR GASTR NUTR, V46, pS81, DOI 10.1097/MPG.0b013e31816f7b16; Holliday MA, 1999, PEDIATR NEPHROL, V13, P292, DOI 10.1007/s004670050611; Hoorn EJ, 2004, PEDIATRICS, V113, P1279, DOI 10.1542/peds.113.5.1279; Juca CA, 2005, ANN TROP PAEDIATR, V25, P253, DOI 10.1179/146532805X72395; Kanaan U, 2003, CLIN PEDIATR, V42, P421, DOI 10.1177/000992280304200506; King Caleb K, 2003, MMWR Recomm Rep, V52, P1; Levy JA, 2007, ACAD EMERG MED, V14, P324, DOI 10.1197/j.aem.2006.10.098; Maitland K, 2011, N ENGL J MED; MOINEUA G, 1990, Pediatric Emergency Care, V6, P186, DOI 10.1097/00006565-199009000-00005; Myburgh JA, 2011, N ENG J MED; Nager AL, 2002, PEDIATRICS, V109, P566, DOI 10.1542/peds.109.4.566; Nager AL, 2010, TINTINALLIS EMERGENC, P971; Nager AL, 2010, AM J EMERG MED, V28, P123, DOI 10.1016/j.ajem.2008.09.046; National Collaborating Centre for Women's and Children's Health, 2009, DIARRH VOM CAUS GAST; National Patient Safety Agency, 2007, NPSA200722; Neville KA, 2006, ARCH DIS CHILD, V91, P226, DOI 10.1136/adc.2005.084103; Parkin PC, 2010, CLIN PEDIATR, V49, P235, DOI 10.1177/0009922809336670; Pawlowicz Malgorzata, 2008, Pediatr Endocrinol Diabetes Metab, V14, P7; RAHMAN O, 1988, J PEDIATR-US, V113, P654, DOI 10.1016/S0022-3476(88)80374-3; Reeves JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e62; Reid SR, 1996, ANN EMERG MED, V28, P318, DOI 10.1016/S0196-0644(96)70032-X; Scheingraber S, 1999, ANESTHESIOLOGY, V90, P1265, DOI 10.1097/00000542-199905000-00007; Shaw KN, 2010, TXB PEDIAT EMERGENCY, P206; Spandorfer PR, 2005, PEDIATRICS, V115, P295, DOI 10.1542/peds.2004-0245; Steiner MJ, 2004, JAMA-J AM MED ASSOC, V291, P2746, DOI 10.1001/jama.291.22.2746; Sunoto, 1990, Paediatr Indones, V30, P154; Waters JH, 1999, CRIT CARE MED, V27, P2142, DOI 10.1097/00003246-199910000-00011; Waters JH, 2001, ANESTH ANALG, V93, P817, DOI 10.1097/00000539-200110000-00004; Williams EL, 1999, ANESTH ANALG, V88, P999, DOI 10.1097/00000539-199905000-00006	44	26	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 17	2011	343								d6976	10.1136/bmj.d6976	http://dx.doi.org/10.1136/bmj.d6976			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875FU	22094316	Green Published, hybrid			2023-01-03	WOS:000299016600007
J	Chang, HJ; Liang, MH				Chang, Huan J.; Liang, Matthew H.			The Quiet Epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Liang, Matthew H.] Brigham & Womens Hosp, Rheumatol Sect, Boston VA Healthcare Syst, Rehabil Serv, Boston, MA 02115 USA; [Liang, Matthew H.] Brigham & Womens Hosp, Rheumatol Sect, Boston VA Healthcare Syst, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System		tina.chang@jama-archives.org						Lansdale TF, 2008, CLEV CLIN J MED, V75, P618, DOI 10.3949/ccjm.75.9.618	1	1	4	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2011	306	17					1843	1844		10.1001/jama.2011.1587	http://dx.doi.org/10.1001/jama.2011.1587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839OD	22045757				2023-01-03	WOS:000296376200001
J	Natarajan, JV; Chattopadhyay, S; Ang, M; Darwitan, A; Foo, S; Zhen, M; Koo, M; Wong, TT; Venkatraman, SS				Natarajan, Jayaganesh V.; Chattopadhyay, Sujay; Ang, Marcus; Darwitan, Anastasia; Foo, Selin; Zhen, Ma; Koo, Magdalene; Wong, Tina T.; Venkatraman, Subbu S.			Sustained Release of an Anti-Glaucoma Drug: Demonstration of Efficacy of a Liposomal Formulation in the Rabbit Eye	PLOS ONE			English	Article							OPEN-ANGLE GLAUCOMA; DELIVERY SYSTEMS; IN-VITRO; LATANOPROST; OPHTHALMOLOGY; CHOLESTEROL; PROGRESSION; STABILITY; BEHAVIOR; BILAYERS	Topical medication remains the first line treatment of glaucoma; however, sustained ocular drug delivery via topical administration is difficult to achieve. Most drugs have poor penetration due to the multiple physiological barriers of the eye and are rapidly cleared if applied topically. Currently, daily topical administration for lowering the intra-ocular pressure (IOP), has many limitations, such as poor patient compliance and ocular allergy from repeated drug administration. Poor compliance leads to suboptimal control of IOP and disease progression with eventual blindness. The delivery of drugs in a sustained manner could provide the patient with a more attractive alternative by providing optimal therapeutic dosing, with minimal local toxicity and inconvenience. To investigate this, we incorporated latanoprost into LUVs (large unilamellar vesicles) derived from the liposome of DPPC (di-palmitoyl-phosphatidyl-choline) by the film hydration technique. Relatively high amounts of drug could be incorporated into this vesicle, and the drug resides predominantly in the bilayer. Vesicle stability monitored by size measurement and DSC (differential scanning calorimetry) analysis showed that formulations with a drug/lipid mole ratio of about 10% have good physical stability during storage and release. This formulation demonstrated sustained release of latanoprost in vitro, and then tested for efficacy in 23 rabbits. Subconjunctival injection and topical eye drop administration of the latanoprost/liposomal formulation were compared with conventional daily administration of latanoprost eye drops. The IOP lowering effect with a single subconjunctival injection was shown to be sustained for up to 50 days, and the extent of IOP lowering was comparable to daily eye drop administration. Toxicity and localized inflammation were not observed in any treatment groups. We believe that this is the first demonstration, in vivo, of sustained delivery to the anterior segment of the eye that is safe and efficacious for 50 days.	[Natarajan, Jayaganesh V.; Chattopadhyay, Sujay; Darwitan, Anastasia; Zhen, Ma; Wong, Tina T.; Venkatraman, Subbu S.] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore; [Chattopadhyay, Sujay] Doctor Babasaheb Ambedkar Technol Univ, Dept Chem Engn, Lonere, Maharashtra, India; [Ang, Marcus; Foo, Selin; Koo, Magdalene; Wong, Tina T.] Singapore Natl Eye Ctr, Singapore, Singapore; [Wong, Tina T.] Singapore Eye Res Inst, Ocular Drug Delivery Grp, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Dr. Babasaheb Ambedkar Technological University; Singapore National Eye Center; National University of Singapore; Singapore National Eye Center	Natarajan, JV (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore, Singapore.	tina.wong.t.l@snec.com.sg; assubbu@ntu.edu.sg	Venkatraman, Subramanian/A-2228-2011; CHATTOPADHYAY, SUJAY/U-8544-2019	Venkatraman, Subramanian/0000-0002-8693-1070; CHATTOPADHYAY, SUJAY/0000-0001-7837-5329	Singapore Eye Research Institute [NMRC/TCR/002-SERI/2008]	Singapore Eye Research Institute	This study was supported by the grant from Singapore Eye Research Institute (NMRC/TCR/002-SERI/2008) (http://www.seri.com.sg/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALMOG R, 1991, CHEM PHYS LIPIDS, V60, P93, DOI 10.1016/0009-3084(91)90031-6; Amano S, 2008, JPN J OPHTHALMOL, V52, P334, DOI 10.1007/s10384-008-0554-6; Baker R., 1987, CONTROLLED RELEASE B; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bito LZ, 1986, US Patent No, Patent No. [4,599, 353, 4599353]; Bolean M, 2010, BIOPHYS CHEM, V152, P74, DOI 10.1016/j.bpc.2010.08.002; Costas D, 2008, J LIPOSOME RES, V18, P159; Detoni CB, 2009, J MICROENCAPSUL, V26, P684, DOI [10.3109/02652040802661887, 10.1080/02652040802661887]; Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006; Halling KK, 2004, BBA-BIOMEMBRANES, V1664, P161, DOI 10.1016/j.bbamem.2004.05.006; Hathout RM, 2007, AAPS PHARMSCITECH, V8; HIRNLE E, 1991, J MICROENCAPSUL, V8, P391, DOI 10.3109/02652049109069566; Hironaka K, 2009, J CONTROL RELEASE, V136, P247, DOI 10.1016/j.jconrel.2009.02.020; Huq F., 2007, J PHARM TOXICOLOGY, V2, P359, DOI [10.3923/jpt.2007.359.365, DOI 10.3923/jpt.2007.359.365]; Jonescu-Cuypers CP, 2001, OPHTHALMOLOGY, V108, P254, DOI 10.1016/S0161-6420(00)00514-5; Kaur IP, 2002, DRUG DEV IND PHARM, V28, P473; LANG JC, 1995, ADV DRUG DELIVER REV, V16, P39, DOI 10.1016/0169-409X(95)00012-V; LEE VHL, 1985, SURV OPHTHALMOL, V29, P335, DOI 10.1016/0039-6257(85)90109-2; LEE VHL, 1984, CURR EYE RES, V3, P585, DOI 10.3109/02713688409003058; Lee VHL, 1990, J CONTROL RELEASE, V11, P79; Lewis T. L., 2002, OPTOMETRIC CLIN PRAC; Lin HH, 1996, J PHARM PHARMACOL, V48, P801, DOI 10.1111/j.2042-7158.1996.tb03977.x; Linden C, 1997, BRIT J OPHTHALMOL, V81, P370, DOI 10.1136/bjo.81.5.370; Liu JB, 2006, CANCER CHEMOTH PHARM, V58, P306, DOI 10.1007/s00280-005-0161-x; Mannock DA, 2010, BBA-BIOMEMBRANES, V1798, P376, DOI 10.1016/j.bbamem.2009.09.002; Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3; MEISNER D, 1995, ADV DRUG DELIVER REV, V16, P75, DOI 10.1016/0169-409X(95)00016-Z; Mohammed AR, 2004, INT J PHARMACEUT, V285, P23, DOI 10.1016/j.ijpharm.2004.07.010; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Netland PA, 2001, AM J OPHTHALMOL, V132, P472, DOI 10.1016/S0002-9394(01)01177-1; NIESMAN MR, 1992, CRIT REV THER DRUG, V9, P1; Nordmann JP, 2003, HLTH QUAL LIFE OUTCO; PEREZSOLER R, 1992, CANCER RES, V52, P6341; Quigley HA, 1996, AM J OPHTHALMOL, V122, P355, DOI 10.1016/S0002-9394(14)72062-8; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; Radhakrishnan S, 2008, GLAUCOMA MEDICATION; Ritch R, 2001, PRIMARY CARE GLAUCOM, P443; ROJANASAKUL Y, 1991, INT J PHARM, V68, P135, DOI 10.1016/0378-5173(91)90136-C; ROJANASAKUL YY, 1989, INT J PHARM, V55, P237, DOI 10.1016/0378-5173(89)90047-1; Russo A, 2008, CLIN OPHTHALMOL, V2, P897; SCHAEFFER HE, 1982, INVEST OPHTH VIS SCI, V22, P220; SHAH M, 1994, J CELL SCI, V107, P1137; Sila-On W, 2008, AAPS PHARMSCITECH, V9, P684, DOI 10.1208/s12249-008-9089-x; SMOLIN G, 1981, AM J OPHTHALMOL, V91, P220, DOI 10.1016/0002-9394(81)90177-X; Stratford Jr. RE, 1983, CURR EYE RES, V2, P377; Wells AP, 2004, J GLAUCOMA, V13, P454, DOI 10.1097/00061198-200412000-00005; Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003; Yusuke S, 2005, INT J PHARMACEUT, V305, P176	48	64	65	2	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2011	6	9							e24513	10.1371/journal.pone.0024513	http://dx.doi.org/10.1371/journal.pone.0024513			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CN	21931735	gold, Green Published, Green Submitted			2023-01-03	WOS:000294803100038
J	Marchal, J; Blanc, S; Epelbaum, J; Aujard, F; Pifferi, F				Marchal, Julia; Blanc, Stephane; Epelbaum, Jacques; Aujard, Fabienne; Pifferi, Fabien			Effects of Chronic Calorie Restriction or Dietary Resveratrol Supplementation on Insulin Sensitivity Markers in a Primate, Microcebus murinus	PLOS ONE			English	Article							HOMEOSTASIS MODEL ASSESSMENT; RESTING METABOLIC-RATE; GRAPE SEED EXTRACT; HIGH-FAT DIET; RHESUS-MONKEYS; DIABETES-MELLITUS; GLUCOSE-TOLERANCE; OXIDATIVE STRESS; NONHUMAN PRIMATE; BODY-WEIGHT	The prevalence of diabetes and hyperinsulinemia increases with age, inducing metabolic failure and limiting lifespan. Calorie restriction (CR) without malnutrition delays the aging process, but its long-term application to humans seems difficult. Resveratrol (RSV), a dietary polyphenol, appears to be a promising CR mimetic that can be easily administered in humans. In this work, we hypothesized that both CR and RSV impact insulin sensitivity in a non-human primate compared to standard-fed control (CTL) animals. Four-to five-year-old male grey mouse lemurs (Microcebus murinus) were assigned to three dietary groups: a CTL group, a CR group receiving 30% fewer calories than the CTL and a RSV group receiving the CTL diet supplemented with RSV (200 mg.day(-1).kg(-1)). Insulin sensitivity and glycemia were assessed using an oral glucose tolerance test (OGTT) and the homeostasis model assessment of insulin resistance (HOMA-IR index) evaluation after 21 or 33 months of chronic treatment. Resting metabolic rate was also measured to assess the potential relationships between this energy expenditure parameter and insulin sensitivity markers. No differences were found after a 21-month period of treatment, except for lower glucose levels 30 min after glucose loading in CR animals. After 33 months, CR and RSV decreased glycemia after the oral glucose loading without decreasing fasting blood insulin. A general effect of treatment was observed on the HOMA-IR index, with an 81% reduction in CR animals and 53% in RSV animals after 33 months of treatment compared to CTL. Chronic CR and dietary supplementation with RSV affected insulin sensitivity by improving the glucose tolerance of animals without disturbing their baseline insulin secretion. These results suggest that both CR and RSV have beneficial effects on metabolic alterations, although these effects are different in amplitude between the two anti-aging treatments and potentially rely on different metabolic changes.	[Marchal, Julia; Aujard, Fabienne; Pifferi, Fabien] Museum Natl Hist Nat, UMR Ctr Natl Rech Sci 7179, Brunoy, France; [Blanc, Stephane] Univ Strasbourg, Dept Ecol, Ethol UMR CNRS 7178, Inst Pluridisciplinaire Hubert Curien, Strasbourg, France; [Epelbaum, Jacques] Univ Paris 05, Fac Med, Ctr Psychiat & Neurosci, UMR Inserm 894, Paris, France	Museum National d'Histoire Naturelle (MNHN); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marchal, J (corresponding author), Museum Natl Hist Nat, UMR Ctr Natl Rech Sci 7179, Brunoy, France.	aujard@mnhn.fr	Epelbaum, Jacques/B-2263-2013	Pifferi, Fabien/0000-0001-9316-1935	French National Research Agency [ANR-06-PNRA-010-01]; Foundation for French Medical Research	French National Research Agency(French National Research Agency (ANR)); Foundation for French Medical Research	This study was conducted with the financial support of the French National Research Agency (project ANR-06-PNRA-010-01) and the Foundation for French Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson RM, 2010, TRENDS ENDOCRIN MET, V21, P134, DOI 10.1016/j.tem.2009.11.005; Anderson SR, 2008, METABOLISM, V57, P347, DOI 10.1016/j.metabol.2007.10.009; Aubin MC, 2008, J PHARMACOL EXP THER, V325, P961, DOI 10.1124/jpet.107.135061; Aujard F, 1998, J COMP PHYSIOL B, V168, P540, DOI 10.1007/s003600050175; Barrett K, 2006, MOL CELL BIOCHEM, V293, P9, DOI 10.1007/s11010-006-0387-x; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2010, MECH AGEING DEV, V131, P261, DOI 10.1016/j.mad.2010.02.007; Blanc SP, 2003, J CLIN ENDOCR METAB, V88, P3454, DOI 10.1210/jc.2003-030547; BODKIN NL, 1995, J GERONTOL A-BIOL, V50, pB142, DOI 10.1093/gerona/50A.3.B142; CARTEE GD, 1994, AM J PHYSIOL, V266, pR1443, DOI 10.1152/ajpregu.1994.266.5.R1443; CEFALU WT, 1995, J GERONTOL A-BIOL, V50, pB337, DOI 10.1093/gerona/50A.6.B337; Chen WP, 2007, EUR J PHARMACOL, V568, P269, DOI 10.1016/j.ejphar.2007.04.062; Chi TC, 2007, LIFE SCI, V80, P1713, DOI 10.1016/j.lfs.2007.02.002; CLORE JN, 1992, J CLIN ENDOCR METAB, V74, P660, DOI 10.1210/jc.74.3.660; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cox LS, 2009, AGING CELL, V8, P607, DOI 10.1111/j.1474-9726.2009.00509.x; Dal-Pan A, 2011, AGE, V33, P15, DOI 10.1007/s11357-010-9156-6; Dal-Pan A, 2009, COMP BIOCHEM PHYS A, V153A, pS147, DOI 10.1016/j.cbpa.2009.04.282; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; Fujimoto S, 2010, LIFE SCI, V87, P679, DOI 10.1016/j.lfs.2010.10.001; FUKUDA M, 1989, DIABETES RES CLIN PR, V7, P61, DOI 10.1016/0168-8227(89)90047-8; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P2482; HOLLENBECK C, 1987, J CLIN ENDOCR METAB, V64, P1169, DOI 10.1210/jcem-64-6-1169; Ingram DK, 2006, BIOGERONTOLOGY, V7, P143, DOI 10.1007/s10522-006-9013-2; Jacobson P, 2006, AM J CLIN NUTR, V84, P1527, DOI 10.1093/ajcn/84.6.1527; Kar P, 2009, DIABETIC MED, V26, P526, DOI 10.1111/j.1464-5491.2009.02727.x; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Keskin M, 2005, PEDIATRICS, V115, pE500, DOI 10.1542/peds.2004-1921; Kirk E, 2009, GASTROENTEROLOGY, V136, P1552, DOI 10.1053/j.gastro.2009.01.048; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941; Languille S, 2012, AGEING RES REV, V11, P150, DOI 10.1016/j.arr.2011.07.001; Llado I, 1999, J NUTR BIOCHEM, V10, P609, DOI 10.1016/S0955-2863(99)00050-9; Masoro EJ, 2000, HUM ECOL RISK ASSESS, V6, P273, DOI 10.1080/10807030009380062; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mattson MP, 2008, AGEING RES REV, V7, P43, DOI 10.1016/j.arr.2007.08.004; Motero-Conejo E, 2003, ARCH LATINOAM NUTR, V53, P39; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pi-Sunyer FX, 2007, NUTR REV, V65, P101, DOI [10.1301/nr.2007.mar.101-110, 10.1111/j.1753-4887.2007.tb00287.x]; Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.2008.06.012; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; REAVEN E, 1983, DIABETES, V32, P175, DOI 10.2337/diabetes.32.2.175; Reaven G, 2006, AM J CLIN NUTR, V84, P1252, DOI 10.1093/ajcn/84.5.1252; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; Schindler TH, 2006, J AM COLL CARDIOL, V47, P1188, DOI 10.1016/j.jacc.2005.10.062; Stuart JA, 2010, MECH AGEING DEV, V131, P591, DOI 10.1016/j.mad.2010.08.005; Suwannaphet W, 2010, FOOD CHEM TOXICOL, V48, P1853, DOI 10.1016/j.fct.2010.04.021; Szkudelski T, 2008, LIFE SCI, V82, P430, DOI 10.1016/j.lfs.2007.12.008; Szkudelski T, 2006, EUR J PHARMACOL, V552, P176, DOI 10.1016/j.ejphar.2006.09.046; Thompson WG, 2006, DIABETES RES CLIN PR, V74, P129, DOI 10.1016/j.diabres.2006.03.017; Walder K, 1998, METABOLISM, V47, P125, DOI 10.1016/S0026-0495(98)90206-2; Weatherall FRS D, 2006, USE NONHUMAN PRIMATE; Weindruch R, 2003, CLIN NEUROSCI RES, V2, P279, DOI 10.1016/S1566-2772(03)00004-5; Weiss R, 2004, DIABETES, V53, pA419; WING RR, 1994, AM J MED, V97, P354, DOI 10.1016/0002-9343(94)90302-6	57	60	60	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2012	7	3							e34289	10.1371/journal.pone.0034289	http://dx.doi.org/10.1371/journal.pone.0034289			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UC	22479589	Green Published, gold, Green Submitted			2023-01-03	WOS:000305339100144
J	Everard, A; Geurts, L; Van Roye, M; Delzenne, NM; Cani, PD				Everard, Amandine; Geurts, Lucie; Van Roye, Marie; Delzenne, Nathalie M.; Cani, Patrice D.			Tetrahydro iso-Alpha Acids from Hops Improve Glucose Homeostasis and Reduce Body Weight Gain and Metabolic Endotoxemia in High-Fat Diet-Fed Mice	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; GUT MICROBIOTA; ALKALINE-PHOSPHATASE; TIGHT JUNCTIONS; INDUCED OBESITY; INFLAMMATION; LIPOPOLYSACCHARIDE; MECHANISM; ISOHUMULONES; PERMEABILITY	Obesity and related metabolic disorders such as insulin resistance and type 2 diabetes are associated with a low-grade inflammatory state possibly through changes in gut microbiota composition and the development of higher plasma lipopolysaccharide (LPS) levels, i.e. metabolic endotoxemia. Various phytochemical compounds have been investigated as potential tools to regulate these metabolic features. Humulus lupulus L. (hops) contains several classes of compounds with anti-inflammatory potential. Recent evidence suggests that hops-derived compounds positively impact adipocyte metabolism and glucose tolerance in obese and diabetic rodents via undefined mechanisms. In this study, we found that administration of tetrahydro iso-alpha acids (termed META060) to high-fat diet (HFD)-fed obese and diabetic mice for 8 weeks reduced body weight gain, the development of fat mass, glucose intolerance, and fasted hyperinsulinemia, and normalized insulin sensitivity markers. This was associated with reduced portal plasma LPS levels, gut permeability, and higher intestinal tight junction proteins Zonula occludens-1 and occludin. Moreover, META060 treatment increased the plasma level of the anti-inflammatory cytokine interleukin-10 and decreased the plasma level of the pro-inflammatory cytokine granulocyte colony-stimulating factor. In conclusion, this research allows us to decipher a novel mechanism contributing to the positive effects of META060 treatment, and supports the need to investigate such compounds in obese and type 2 diabetic patients.	[Everard, Amandine; Geurts, Lucie; Van Roye, Marie; Delzenne, Nathalie M.; Cani, Patrice D.] Catholic Univ Louvain, Metab & Nutr Res Grp, Louvain Drug Res Inst, B-1200 Brussels, Belgium	Universite Catholique Louvain	Everard, A (corresponding author), Catholic Univ Louvain, Metab & Nutr Res Grp, Louvain Drug Res Inst, B-1200 Brussels, Belgium.	patrice.cani@uclouvain.be	Delzenne, Nathalie/AAC-4628-2019; D., Cani Patrice/M-8055-2016	Delzenne, Nathalie/0000-0003-2115-6082; D., Cani Patrice/0000-0003-2040-2448; Everard, Amandine/0000-0001-8925-8144	Societe francophone du Diabete, France; Metagenics, Inc., United States of America	Societe francophone du Diabete, France; Metagenics, Inc., United States of America	NMD and PDC are recipients of Fonds speciaux de recherches, UCL, Belgium and Fonds de la recherche scientifique medicale, Belgium grants. PDC is a recipient of grants from the Societe francophone du Diabete, France. This study was supported by Metagenics, Inc., United States of America. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Sadi R, 2011, J CELL MOL MED, V15, P970, DOI 10.1111/j.1582-4934.2010.01065.x; Al-Sadi R, 2010, AM J PATHOL, V177, P2310, DOI 10.2353/ajpath.2010.100371; Basu S, 2011, OBESITY, V19, P476, DOI 10.1038/oby.2010.215; Bates JM, 2007, CELL HOST MICROBE, V2, P371, DOI 10.1016/j.chom.2007.10.010; BESSEY OA, 1946, J BIOL CHEM, V164, P321; Brun P, 2007, AM J PHYSIOL-GASTR L, V292, pG518, DOI 10.1152/ajpgi.00024.2006; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cani PD, 2011, PHARMACOL THERAPEUT, V130, P202, DOI 10.1016/j.pharmthera.2011.01.012; de La Serre CB, 2010, AM J PHYSIOL-GASTR L, V299, pG440, DOI 10.1152/ajpgi.00098.2010; Deopurkar R, 2010, DIABETES CARE, V33, P991, DOI 10.2337/dc09-1630; Desai A, 2009, INFLAMM RES, V58, P229, DOI 10.1007/s00011-008-8162-y; Everard A, 2011, DIABETES, V60, P2775, DOI 10.2337/db11-0227; Eyles JL, 2006, NAT CLIN PRACT RHEUM, V2, P500, DOI 10.1038/ncprheum0291; Geurts L, 2012, J AGR FOOD CHEM, V60, P2063, DOI 10.1021/jf204916x; Ghanim H, 2009, DIABETES CARE, V32, P2281, DOI 10.2337/dc09-0979; Gonzalez-Mariscal L, 2008, BBA-BIOMEMBRANES, V1778, P729, DOI 10.1016/j.bbamem.2007.08.018; Hall AJ, 2008, PHYTOCHEMISTRY, V69, P1534, DOI 10.1016/j.phytochem.2008.02.001; Hall D, 2010, J BIOL CHEM, V285, P31011, DOI 10.1074/jbc.M110.127159; Hong EG, 2009, DIABETES, V58, P2525, DOI 10.2337/db08-1261; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kimura H, 1997, J CELL PHYSIOL, V171, P284, DOI 10.1002/(SICI)1097-4652(199706)171:3<284::AID-JCP6>3.0.CO;2-K; Konda VR, 2010, ARTHRITIS RHEUM-US, V62, P1683, DOI 10.1002/art.27441; Lalles JP, 2010, NUTR REV, V68, P323, DOI 10.1111/j.1753-4887.2010.00292.x; Minich DM, 2010, J NUTR METAB, V2010, DOI 10.1155/2010/467316; Moroi S, 1998, AM J PHYSIOL-CELL PH, V274, pC1708, DOI 10.1152/ajpcell.1998.274.6.C1708; Muccioli GG, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.46; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Plomgaard P, 2005, DIABETES, V54, P2939, DOI 10.2337/diabetes.54.10.2939; Pussinen PJ, 2011, DIABETES CARE, V34, P392, DOI 10.2337/dc10-1676; Sheth P, 2007, AM J PHYSIOL-GASTR L, V293, pG308, DOI 10.1152/ajpgi.00582.2006; Straczkowski M, 2005, DIABETES CARE, V28, P2036, DOI 10.2337/diacare.28.8.2036; Vaishnava S, 2007, CELL HOST MICROBE, V2, P365, DOI 10.1016/j.chom.2007.11.004; VAN CM, 2009, MOL NUTR FOOD RES, V53, P1143; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Yajima H, 2005, INT J OBESITY, V29, P991, DOI 10.1038/sj.ijo.0802965; Yajima H, 2004, J BIOL CHEM, V279, P33456, DOI 10.1074/jbc.M403456200; Zanoli P, 2008, J ETHNOPHARMACOL, V116, P383, DOI 10.1016/j.jep.2008.01.011	42	51	53	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2012	7	3							e33858	10.1371/journal.pone.0033858	http://dx.doi.org/10.1371/journal.pone.0033858			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948FM	22470484	gold, Green Published, Green Submitted			2023-01-03	WOS:000304489000040
J	Shaoul, E; Ayalon, A; Tal, Y; Lotan, T				Shaoul, Esther; Ayalon, Ari; Tal, Yossi; Lotan, Tamar			Transdermal Delivery of Scopolamine by Natural Submicron Injectors: In-Vivo Study in Pig	PLOS ONE			English	Article							DRUG-DELIVERY; POSTOPERATIVE NAUSEA; MOTION SICKNESS; PREVENTION; SKIN; PHARMACOKINETICS; MICRONEEDLES; PENETRATION; ATROPINE; SYSTEMS	Transdermal drug delivery has made a notable contribution to medical practice, but has yet to fully achieve its potential as an alternative to oral delivery and hypodermic injections. While transdermal delivery systems would appear to provide an attractive solution for local and systemic drug delivery, only a limited number of drugs can be delivered through the outer layer of the skin. The most difficult to deliver in this way are hydrophilic drugs. The aquatic phylum Cnidaria, which includes sea anemones, corals, jellyfish and hydra, is one of the most ancient multicellular phyla that possess stinging cells containing organelles (cnidocysts), comprising a sophisticated injection system. The apparatus is folded within collagenous microcapsules and upon activation injects a thin tubule that immediately penetrates the prey and delivers its contents. Here we show that this natural microscopic injection system can be adapted for systemic transdermal drug delivery once it is isolated from the cells and uploaded with the drug. Using a topically applied gel containing isolated natural sea anemone injectors and the muscarinic receptor antagonist scopolamine, we found that the formulated injectors could penetrate porcine skin and immediately deliver this hydrophilic drug. An in-vivo study in pigs demonstrated, for the first time, rapid systemic delivery of scopolamine, with T-max of 30 minutes and C-max 5 times higher than in controls treated topically with a scopolamine-containing gel without cnidocysts. The ability of the formulated natural injection system to penetrate a barrier as thick as the skin and systemically deliver an exogenous compound presents an intriguing and attractive alternative for hydrophilic transdermal drug delivery.	[Shaoul, Esther; Ayalon, Ari; Tal, Yossi] NanoCyte Israel Ltd, Caesarea, Israel; [Lotan, Tamar] Univ Haifa, Leon H Charney Sch Marine Sci, Dept Marine Biol, IL-31999 Haifa, Israel	University of Haifa	Shaoul, E (corresponding author), NanoCyte Israel Ltd, Caesarea, Israel.	lotant@univ.haifa.ac.il		Lotan, Tamar/0000-0002-1679-4904				Apfel CC, 2010, CLIN THER, V32, P1987, DOI 10.1016/j.clinthera.2010.11.014; Ayalon A, 2011, INT J PHARMACEUT, V419, P147, DOI 10.1016/j.ijpharm.2011.07.042; Baroli B, 2010, J PHARM SCI-US, V99, P21, DOI 10.1002/jps.21817; Barry BW, 2004, NAT BIOTECHNOL, V22, P165, DOI 10.1038/nbt0204-165; Brown MB, 2006, DRUG DELIV, V13, P175, DOI 10.1080/10717540500455975; Cevc G, 2010, J CONTROL RELEASE, V141, P277, DOI 10.1016/j.jconrel.2009.10.016; Ceyhan T, 2001, J PHARMACEUT BIOMED, V25, P399, DOI 10.1016/S0731-7085(00)00514-8; David CN, 2008, TRENDS GENET, V24, P431, DOI 10.1016/j.tig.2008.07.001; Donnelly RF, 2010, DRUG DELIV, V17, P187, DOI 10.3109/10717541003667798; Elsayed MMA, 2007, INT J PHARMACEUT, V332, P1, DOI 10.1016/j.ijpharm.2006.12.005; Greenwood PG, 2003, COMP BIOCHEM PHYS A, V134, P275, DOI 10.1016/S1095-6433(02)00262-3; Gupta J, 2011, BIOMATERIALS, V32, P6823, DOI 10.1016/j.biomaterials.2011.05.061; Hart EA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r168; HOLSTEIN TW, 1994, SCIENCE, V265, P402, DOI 10.1126/science.265.5170.402; Kranke P, 2002, ANESTH ANALG, V95, P133, DOI 10.1097/00000539-200207000-00024; Lau OW, 1997, J CHROMATOGR A, V766, P270, DOI 10.1016/S0021-9673(96)01019-9; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; Lotan T, 2005, PERCUTANEOUS ABSORPT, P521; Lotan T, 2008, MODIFIED RELEASE DRU, P395; LUBBOCK R, 1981, NATURE, V290, P500, DOI 10.1038/290500a0; Nachum Z, 2001, J PHARMACOL EXP THER, V296, P121; Nachum Z, 2006, CLIN PHARMACOKINET, V45, P543, DOI 10.2165/00003088-200645060-00001; Nuchter T, 2006, CURR BIOL, V16, pR316, DOI 10.1016/j.cub.2006.03.089; Oertel R, 2001, J CHROMATOGR B, V750, P121, DOI 10.1016/S0378-4347(00)00433-3; Ozbek S, 2009, TOXICON, V54, P1038, DOI 10.1016/j.toxicon.2009.03.006; Ogura M, 2008, ADV DRUG DELIVER REV, V60, P1218, DOI 10.1016/j.addr.2008.03.006; Park JH, 2010, EUR J PHARM BIOPHARM, V76, P282, DOI 10.1016/j.ejpb.2010.07.001; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Prausnitz MR, 2004, ADV DRUG DELIVER REV, V56, P581, DOI 10.1016/j.addr.2003.10.023; Renner UD, 2005, THER DRUG MONIT, V27, P655, DOI 10.1097/01.ftd.0000168293.48226.57; Sherman CR, 2002, J TRAVEL MED, V9, P251; Simon GA, 2000, SKIN PHARMACOL APPL, V13, P229, DOI 10.1159/000029928; Simon GA, 1998, SKIN PHARMACOL APPL, V11, P80, DOI 10.1159/000029812; Singh Thakur R R, 2011, Recent Pat Drug Deliv Formul, V5, P11; Sivamani RK, 2007, EXPERT OPIN DRUG DEL, V4, P19, DOI 10.1517/17425247.4.1.19; Spinks AB, 2007, COCHRANE DB SYST REV, V18; Swindle MM, 2012, VET PATHOL, V49, P344, DOI 10.1177/0300985811402846; Szczepanek S, 2002, J CELL SCI, V115, P745; TARDENT P, 1995, BIOESSAYS, V17, P351, DOI 10.1002/bies.950170411	39	10	10	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2012	7	2							e31922	10.1371/journal.pone.0031922	http://dx.doi.org/10.1371/journal.pone.0031922			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	926ZM	22363770	Green Submitted, Green Published, gold			2023-01-03	WOS:000302873700124
J	Winstock, AR; Mitcheson, L				Winstock, Adam R.; Mitcheson, Luke			New recreational drugs and the primary care approach to patients who use them	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GAMMA-HYDROXYBUTYRATE; NONMEDICAL USE; KETAMINE; MEPHEDRONE; HEALTH; CONSEQUENCES; DEPENDENCE; KID		[Winstock, Adam R.] Kings Coll London, S London & Maudsley NHS Trust, Inst Psychiat, Blackfriars Rd Community Drug & Alcohol Team, London SE1 8EL, England	South London & Maudsley NHS Trust; University of London; King's College London	Winstock, AR (corresponding author), Kings Coll London, S London & Maudsley NHS Trust, Inst Psychiat, Blackfriars Rd Community Drug & Alcohol Team, London SE1 8EL, England.	adam.winstock@slam.nhs.uk		Winstock, Adam/0000-0001-7854-8015				Aan het Rot M, 2010, BIOL PSYCHIAT, V67, P139, DOI DOI 10.1016/J.BIOPSYCH.2009.08.038; Advisory Council on the Misuse of Drugs, 2011, NOV PSYCH SUBST REP, P61; [Anonymous], 2009, AM J PHARM EDUC; Baker A, 2005, ADDICTION, V100, P367, DOI 10.1111/j.1360-0443.2005.01002.x; Bell J, 2011, ADDICTION, V106, P442, DOI 10.1111/j.1360-0443.2010.03145.x; Copeland J, 2005, INT J DRUG POLICY, V16, P122, DOI 10.1016/j.drugpo.2004.12.003; Cottrell AM, 2008, J CLIN UROL, V1, P136, DOI 10.1016/j.bjmsu.2008.08.005; Curran HV, 2000, ADDICTION, V95, P575, DOI 10.1046/j.1360-0443.2000.9545759.x; Dillon P, 2003, DRUG ALCOHOL DEPEN, V69, P23, DOI 10.1016/S0376-8716(02)00243-0; European Monitoring Centre for Drugs and Drug Addiction, 2009, STAT DRUG PROBL EUR; James D, 2011, EMERG MED J, V28, P686, DOI 10.1136/emj.2010.096636; Jansen KLR, 2000, J PSYCHOACTIVE DRUGS, V32, P419, DOI 10.1080/02791072.2000.10400244; Jansen KLR, 2001, J PSYCHOACTIVE DRUGS, V33, P151, DOI 10.1080/02791072.2001.10400480; Lingford-Hughes A, J PSYCHOPHA IN PRESS; McCambridge J, 2006, ADDICTION, V101, P1014; McDonough M, 2004, DRUG ALCOHOL DEPEN, V75, P3, DOI 10.1016/j.drugalcdep.2004.01.012; Mitcheson L, 2008, INT J DRUG POLICY, V19, P304, DOI 10.1016/j.drugpo.2007.02.002; Moore NN, 1999, PSYCHOSOMATICS, V40, P356, DOI 10.1016/S0033-3182(99)71231-4; Morgan CJA, 2012, ADDICTION, V107, P27, DOI 10.1111/j.1360-0443.2011.03576.x; Morgan CJA, 2010, ADDICTION, V105, P121, DOI 10.1111/j.1360-0443.2009.02761.x; Muetzelfeldt L, 2008, DRUG ALCOHOL DEPEN, V95, P219, DOI 10.1016/j.drugalcdep.2008.01.024; Munir VL, 2008, EMERG MED AUSTRALAS, V20, P521, DOI 10.1111/j.1742-6723.2008.01140.x; National Institute for Health and Clinical Excellence, 2007, NICE CLIN GUID 51 DR; National Institute for Health and Clinical Excellence, 2007, NICE PUBL HLTH INT G; Ng S. H., 2010, Hong Kong Medical Journal, V16, P6; Rodgers J, 2004, BRIT J PSYCHIAT, V184, P104, DOI 10.1192/bjp.184.2.104; Rollnick S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1900; UK Home Office Statistical Bulletin, 2011, UK HOM OFF STAT B; Winstock A, 2011, ADDICTION, V106, P1991, DOI 10.1111/j.1360-0443.2011.03502.x; Winstock AR, 2011, ADDICTION, V106, P154, DOI 10.1111/j.1360-0443.2010.03130.x; Winstock AR, 2010, ADDICTION, V105, P1685, DOI [10.1111/j.1360-0443.2010.02934.x, 10.1111/j.1360-0443.2010.03163.x]; Winstock AR, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1605; Winstock AR, BR J UROL I IN PRESS; Wolff K, 2006, CNS DRUGS, V20, P199, DOI 10.2165/00023210-200620030-00003	34	16	17	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 15	2012	344								e288	10.1136/bmj.e288	http://dx.doi.org/10.1136/bmj.e288			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	896IB	22337751				2023-01-03	WOS:000300557800001
J	Albain, K; Anderson, S; Arriagada, R; Barlow, W; Bergh, J; Bliss, J; Buyse, M; Cameron, D; Carrasco, E; Clarke, M; Correa, C; Coates, A; Collins, R; Costantino, J; Cutter, D; Cuzick, J; Darby, S; Davidson, N; Davies, C; Davies, K; Delmestri, A; Di Leo, A; Dowsett, M; Elphinstone, P; Evans, V; Ewertz, M; Gelber, R; Gettins, L; Geyer, C; Goldhirsch, A; Godwin, J; Gray, R; Gregory, C; Hayes, D; Hill, C; Ingle, J; Jakesz, R; James, S; Kaufmann, M; Kerr, A; MacKinnon, E; McGale, P; McHugh, T; Norton, L; Ohashi, Y; Paik, S; Pan, HC; Perez, E; Peto, R; Piccart, M; Pierce, L; Pritchard, K; Pruneri, G; Raina, V; Ravdin, P; Robertson, J; Rutgers, E; Shao, YF; Swain, S; Taylor, C; Valagussa, P; Viale, G; Whelan, T; Winer, E; Wang, Y; Wood, W				Albain, K.; Anderson, S.; Arriagada, R.; Barlow, W.; Bergh, J.; Bliss, J.; Buyse, M.; Cameron, D.; Carrasco, E.; Clarke, M.; Correa, C.; Coates, A.; Collins, R.; Costantino, J.; Cutter, D.; Cuzick, J.; Darby, S.; Davidson, N.; Davies, C.; Davies, K.; Delmestri, A.; Di Leo, A.; Dowsett, M.; Elphinstone, P.; Evans, V.; Ewertz, M.; Gelber, R.; Gettins, L.; Geyer, C.; Goldhirsch, A.; Godwin, J.; Gray, R.; Gregory, C.; Hayes, D.; Hill, C.; Ingle, J.; Jakesz, R.; James, S.; Kaufmann, M.; Kerr, A.; MacKinnon, E.; McGale, P.; McHugh, T.; Norton, L.; Ohashi, Y.; Paik, S.; Pan, H. C.; Perez, E.; Peto, R.; Piccart, M.; Pierce, L.; Pritchard, K.; Pruneri, G.; Raina, V.; Ravdin, P.; Robertson, J.; Rutgers, E.; Shao, Y. F.; Swain, S.; Taylor, C.; Valagussa, P.; Viale, G.; Whelan, T.; Winer, E.; Wang, Y.; Wood, W.		EBCTCG	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials	LANCET			English	Article							PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; POSTMENOPAUSAL PATIENTS; GENE-EXPRESSION; PREMENOPAUSAL WOMEN; TAMOXIFEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PACLITAXEL	Background Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences. Methods We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44 000); one anthracycline-based regimen versus another (n=7000) or versus cyclo phosphamide, methotrexate, and fluorouracil (CMF; n=18 000); and polychemotherapy versus no chemotherapy (n=32 000). The scheduled dosages of these three drugs and of the anthracyclines doxorubicin (A) and epirubicin (E) were used to define standard CMF, standard 4AC, and CAF and CEF. Log-rank breast cancer mortality rate ratios (RRs) are reported. Findings In trials adding four separate cycles of a taxane to a fixed anthracycline-based control regimen, extending treatment duration, breast cancer mortality was reduced (RR 0.86, SE 0.04, two-sided significance [2p]=0.0005). In trials with four such extra cycles of a taxane counterbalanced in controls by extra cycles of other cytotoxic drugs, roughly doubling non-taxane dosage, there was no significant difference (RR 0.94, SE 0.06, 2p=0.33). Trials with CMF-treated controls showed that standard 4AC and standard CMF were equivalent (RR 0.98, SE 0.05, 2p=0.67), but that anthracycline-based regimens with substantially higher cumulative dosage than standard 4AC (eg, CAF or CEF) were superior to standard CMF (RR 0.78, SE 0.06, 2p=0.0004). Trials versus no chemotherapy also suggested greater mortality reductions with CAF (RR 0.64, SE 0.09, 2p<0.0001) than with standard 4AC (RR 0.78, SE 0.09, 2p=0.01) or standard CMF (RR 0.76, SE 0.05, 2p<0.0001). In all meta-analyses involving taxane-based or anthracycline-based regimens, proportional risk reductions were little affected by age, nodal status, tumour diameter or differentiation (moderate or poor; few were well differentiated), oestrogen receptor status, or tamoxifen use. Hence, largely independently of age (up to at least 70 years) or the tumour characteristics currently available to us for the patients selected to be in these trials, some taxane-plus-anthracycline-based or higher-cumulative-dosage anthracycline-based regimens (not requiring stem cells) reduced breast cancer mortality by, on average, about one-third. 10-year overall mortality differences paralleled breast cancer mortality differences, despite taxane, anthracycline, and other toxicities. Interpretation 10-year gains from a one-third breast cancer mortality reduction depend on absolute risks without chemotherapy (which, for oestrogen-receptor-positive disease, are the risks remaining with appropriate endocrine therapy). Low absolute risk implies low absolute benefit, but information was lacking about tumour gene expression markers or quantitative immunohistochemistry that might help to predict risk, chemosensitivity, or both.	[Albain, K.; Buyse, M.; Clarke, M.; Collins, R.; Darby, S.; Davies, C.; Ewertz, M.; Peto, R.; Piccart, M.; Pritchard, K.; Winer, E.; Wood, W.] EBCTCG, CTSU, Execut Grp, Oxford OX3 7LF, England	University of Oxford	Albain, K (corresponding author), EBCTCG, CTSU, Execut Grp, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England.	bc.overview@CTSU.ox.ac.uk	Rutgers, Emiel J T/C-5934-2015; Pruneri, Giancarlo/AAC-7767-2022; Cutter, David/AAU-6599-2021; Geyer, Charles/AGY-0119-2022; Viale, Giuseppe/AAE-8921-2019; Whelan, Timothy/D-3185-2017; Evans, Diane/F-9258-2017; Di Leo, Angelo/AAM-1267-2020; Pritchard, Kathleen I/I-2184-2014	Pruneri, Giancarlo/0000-0002-7963-7172; Cutter, David/0000-0001-7307-7488; Geyer, Charles/0000-0002-2379-5702; Whelan, Timothy/0000-0001-9844-2023; Di Leo, Angelo/0000-0002-3665-9056; Pritchard, Kathleen I/0000-0003-0758-9666; Delmestri, Antonella/0000-0003-0388-3403; Adolfsson, Jan/0000-0003-2992-1869; Ewertz, Marianne/0000-0002-5965-969X; Bliss, Judith/0000-0001-7957-7424; Bergh, Jonas/0000-0001-5526-1847; Anderson, Stewart/0000-0001-8948-0650; Wang, Xiang/0000-0002-1522-9532; Arriagada, Rodrigo/0000-0002-3134-1735; Valagussa, Pinuccia/0000-0003-3590-7916; Valentini, Miriam/0000-0002-1421-6975; Swain, Sandra/0000-0002-1320-3830	Cancer Research UK; British Heart Foundation; UK Medical Research Council; BHF Centre for Research Excellence [RE/08/04]; MRC [MC_U137686850] Funding Source: UKRI; Medical Research Council [MC_U137686850] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); British Heart Foundation(British Heart Foundation); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BHF Centre for Research Excellence; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This report is dedicated to Paul Meier (1924-2011), parent of Kaplan-Meier survival curves and effective advocate of widespread randomisation in US clinical research.<SUP>38,39</SUP> The main acknowledgment is to the many participants in the trials and the many staff who treated them, undertook trials, and shared the data. EBCTCG is funded by core support to the Oxford University CTSU from Cancer Research UK, the British Heart Foundation, and the UK Medical Research Council; DC is supported by the BHF Centre for Research Excellence (RE/08/04).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albain KS, 2009, LANCET, V374, P2055, DOI 10.1016/S0140-6736(09)61523-3; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Azim HA, 2011, ANN ONCOL, V22, P1939, DOI 10.1093/annonc/mdq683; Bedgonetti D, 2011, JNCI-J NATL CANCER I, V103, P1529; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Bonneterre Jacques M, 2004, Oncology (Williston Park), V18, P56; BRINCKER H, 1987, J CLIN ONCOL, V5, P1771, DOI 10.1200/JCO.1987.5.11.1771; Cardoso F, 2007, MOL ONCOL, V1, P246, DOI 10.1016/j.molonc.2007.10.004; Cuzick J, 2011, J CLIN ONCOL, V29, P4273, DOI 10.1200/JCO.2010.31.2835; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Dowsett M, 2010, J CLIN ONCOL, V28, P1829, DOI 10.1200/JCO.2009.24.4798; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATM EARL BREAST C; ENGELSMAN E, 1991, EUR J CANCER, V27, P966, DOI 10.1016/0277-5379(91)90259-G; Goldhirsch A, 2002, JNCI-J NATL CANCER I, V94, P1054; Gonzalez-Angulo AM, 2011, P AM SOC CLIN ONCO S, V29; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hutchins LF, 2005, J CLIN ONCOL, V23, P8313, DOI 10.1200/JCO.2005.08.071; International Breast Cancer Study Group (IBCSG), 2004, ANN ONCOL, V15, P1749; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Levine MN, 1998, J CLIN ONCOL, V16, P2651, DOI 10.1200/JCO.1998.16.8.2651; Marks HM, 2004, CLIN TRIALS, V1, P131; Martin M, 2008, JNCI-J NATL CANCER I, V100, P805, DOI 10.1093/jnci/djn151; Montagna E, 2010, BREAST CANCER RES TR, V124, P689, DOI 10.1007/s10549-010-1027-4; Pagani O, 2009, BREAST CANCER RES TR, V116, P491, DOI 10.1007/s10549-008-0225-9; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Peto R, 2011, BRIT J CANCER, V104, P1057, DOI 10.1038/bjc.2011.79; Pico C, 2004, ANN ONCOL, V15, P79, DOI 10.1093/annonc/mdh016; Praga C, 2005, J CLIN ONCOL, V23, P4179, DOI 10.1200/JCO.2005.05.029; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Sparano JA, 2006, CLIN BREAST CANCER, V7, P347, DOI 10.3816/CBC.2006.n.051; Straver ME, 2010, BREAST CANCER RES TR, V119, P551, DOI 10.1007/s10549-009-0333-1; van Dalen EC, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005008.pub3; Walshe JM, 2006, J CLIN ONCOL, V24, P5769, DOI 10.1200/JCO.2006.07.2793; Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2	39	1375	1393	4	117	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					432	444		10.1016/S0140-6736(11)61625-5	http://dx.doi.org/10.1016/S0140-6736(11)61625-5			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891AF	22152853	Green Published, Green Submitted			2023-01-03	WOS:000300187800033
J	Elsharkawy, AM; McPherson, S; Masson, S; Burt, AD; Dawson, RT; Hudson, M				Elsharkawy, Ahmed M.; McPherson, Stuart; Masson, Steven; Burt, Alastair D.; Dawson, Robert T.; Hudson, Mark			LESSON OF THE WEEK Cholestasis secondary to anabolic steroid use in young men	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONSEQUENCES		[Elsharkawy, Ahmed M.; McPherson, Stuart; Masson, Steven; Hudson, Mark] Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; [McPherson, Stuart; Masson, Steven; Burt, Alastair D.; Hudson, Mark] Newcastle Univ, Fac Med Sci, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Dawson, Robert T.] Med Ctr, The Grove NE39 1PW, Rowlands Gill, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK	Elsharkawy, AM (corresponding author), Freeman Rd Hosp, Liver Unit, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	ahmede@doctors.org.uk	Burt, Alastair D/D-3634-2013	Burt, Alastair D/0000-0002-3011-7774; Elsharkawy, Ahmed Mohamed/0000-0001-5369-3734; Masson, Steven/0000-0003-1041-9844; McPherson, Stuart/0000-0002-5638-2453				ACMD, 2010, CONS AN STER; Bispo M, 2009, WORLD J GASTROENTERO, V15, P2920, DOI 10.3748/wjg.15.2920; Bolding G, 2002, ADDICTION, V97, P195, DOI 10.1046/j.1360-0443.2002.00031.x; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; Cordaro FG, 2011, SCAND J MED SCI SPOR, V21, pE247, DOI 10.1111/j.1600-0838.2010.01263.x; Dawson RT, 2001, J ENDOCRINOL, V170, P55, DOI 10.1677/joe.0.1700055; Evans-Brown M, 2008, LANCET, V372, P1544, DOI 10.1016/S0140-6736(08)61651-7; Kanayama G, 2008, DRUG ALCOHOL DEPEN, V98, P1, DOI 10.1016/j.drugalcdep.2008.05.004; Lumia AR, 2010, PHYSIOL BEHAV, V100, P199, DOI 10.1016/j.physbeh.2010.01.007; Parr MK, 2007, BIOMED CHROMATOGR, V21, P164, DOI 10.1002/bmc.728; Rosenfeld Greg A, 2011, J Med Case Rep, V5, P138, DOI 10.1186/1752-1947-5-138	11	17	17	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 2	2012	344								e468	10.1136/bmj.e468	http://dx.doi.org/10.1136/bmj.e468			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889QO	22302781				2023-01-03	WOS:000300088500003
J	Slyker, JA; Chung, MH; Lehman, DA; Kiarie, J; Kinuthia, J; Holte, S; Tapia, K; Njiri, F; Overbaugh, J; John-Stewart, G				Slyker, Jennifer A.; Chung, Michael H.; Lehman, Dara A.; Kiarie, James; Kinuthia, John; Holte, Sarah; Tapia, Kenneth; Njiri, Francis; Overbaugh, Julie; John-Stewart, Grace			Incidence and Correlates of HIV-1 RNA Detection in the Breast Milk of Women Receiving HAART for the Prevention of HIV-1 Transmission	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; VIRAL LOAD; DRUG-RESISTANCE; VIREMIA BLIPS; TYPE-1 RNA; PREGNANCY; PLASMA; DNA	Background: The incidence and correlates of breast milk HIV-1 RNA detection were determined in intensively sampled women receiving highly active antiretroviral therapy (HAART) for the prevention of mother-to-child HIV-1 transmission. Methods: Women initiated HAART at 34 weeks of pregnancy. Breast milk was collected every 2-5 days during 1 month postpartum for measurements of cell-associated HIV DNA and cell-free HIV RNA. Plasma and breast milk were also collected at 2 weeks, 1, 3 and 6 months for concurrent HIV-1 RNA and DNA measurements. Regression was used to identify cofactors for breast milk HIV-1 RNA detection. Results: Of 259 breast milk specimens from 25 women receiving HAART, 34 had detectable HIV-1 RNA (13%, incidence 1.4 episodes/100 person-days 95% CI = 0.97-1.9). Fourteen of 25 (56%) women had detectable breast milk HIV-1 RNA [mean 2.5 log(10) copies/ml (range 2.0-3.9)] at least once. HIV-1 DNA was consistently detected in breast milk cells despite HAART, and increased slowly over time, at a rate of approximately 1 copy/10(6) cells per day (p = 0.02). Baseline CD4, plasma viral load, HAART duration, and frequency of breast problems were similar in women with and without detectable breast milk HIV-1 RNA. Women with detectable breast milk HIV-1 RNA were more likely to be primiparous than women without (36% vs 0%, p = 0.05). Plasma HIV-1 RNA detection (OR = 9.0, 95% CI = 1.8-44) and plasma HIV-1 RNA levels (OR = 12, 95% CI = 2.5-56) were strongly associated with concurrent detection of breast milk HIV-1 RNA. However, no association was found between breast milk HIV-1 DNA level and concurrent breast milk HIV-1 RNA detection (OR = 0.96, 95% CI = 0.54-1.7). Conclusions: The majority of women on HAART had episodic detection of breast milk HIV-1 RNA. Breast milk HIV-1 RNA detection was associated with systemic viral burden rather than breast milk HIV-1 DNA.	[Slyker, Jennifer A.; Chung, Michael H.; Holte, Sarah; Tapia, Kenneth; John-Stewart, Grace] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Chung, Michael H.; John-Stewart, Grace] Univ Washington, Dept Med, Seattle, WA USA; [Kinuthia, John] Kenyatta Natl Hosp, Dept Obstet & Gynaecol, Nairobi, Kenya; [Lehman, Dara A.; Overbaugh, Julie] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA; [Kiarie, James; Njiri, Francis] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya; [Holte, Sarah] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Chung, Michael H.; John-Stewart, Grace] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kenyatta National Hospital; Fred Hutchinson Cancer Center; University of Nairobi; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Slyker, JA (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.	jslyker@uw.edu	John-Stewart, Grace/U-3351-2019; Slyker, Jennifer/J-5439-2018; John-Stewart, Grace/L-3650-2019	kiarie, james/0000-0003-4180-7858; John-Stewart, Grace/0000-0002-4301-1573	Elizabeth Glaser Pediatric AIDS Foundation [11-03]; National Institute of Child Health and Disease, National Institutes of Health (NIH) [K24HD054314]; National Institute of Allergy and Infectious Diseases, NIH [K01AI087369, K23AI065222]; University of Washington Center for AIDS Research (CFAR); NIH [P30 AI027757]; NIH National Institute of Allergy and Infectious Diseases; NIH National Cancer Institute; NIH National Institute of Mental Health; NIH National Institute on Drug Abuse; NIH National Institute of Child Health and Human Development (NICHD); NIH National Heart, Lung, and Blood Institute; NIH National Center for Complementary and Alternative Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD054314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, K23AI065222, K01AI087369] Funding Source: NIH RePORTER	Elizabeth Glaser Pediatric AIDS Foundation; National Institute of Child Health and Disease, National Institutes of Health (NIH); National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of Washington Center for AIDS Research (CFAR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIH National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH National Institute of Child Health and Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This publication was made possible with support from an Elizabeth Glaser Pediatric AIDS Foundation Scientist Award (#11-03) and grant K24HD054314 from the National Institute of Child Health and Disease, National Institutes of Health (NIH); PI GJ-S. JS is supported by K01AI087369 and MC is supported by K23AI065222, both from National Institute of Allergy and Infectious Diseases, NIH. This research was also supported by the University of Washington Center for AIDS Research (CFAR), an NIH funded program (P30 AI027757), which is supported by the following NIH Institutes and Centers (National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Child Health and Human Development (NICHD), National Heart, Lung, and Blood Institute, National Center for Complementary and Alternative Medicine). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NICHD. The funding sources were not involved in the analyses or interpretation of data. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benki S, 2006, J CLIN MICROBIOL, V44, P4357, DOI 10.1128/JCM.01481-06; Chama CM, 2010, J OBSTET GYNAECOL, V30, P362, DOI 10.3109/01443611003672104; Chasela CS, 2010, NEW ENGL J MED, V362, P2271, DOI 10.1056/NEJMoa0911486; Chung MH, 2008, ANTIVIR THER, V13, P799; Emery S, 2000, J CLIN MICROBIOL, V38, P2688, DOI 10.1128/JCM.38.7.2688-2695.2000; Giuliano M, 2007, JAIDS-J ACQ IMM DEF, V44, P286, DOI 10.1097/QAI.0b013e31802c5441; Gray RR, 2011, AIDS, V25, P143, DOI 10.1097/QAD.0b013e328340fdaf; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Jones LE, 2007, JAIDS-J ACQ IMM DEF, V45, P483, DOI 10.1097/QAI.0b013e3180654836; Kilewo C, 2009, JAIDS-J ACQ IMM DEF, V52, P406, DOI 10.1097/QAI.0b013e3181b323ff; Koulinska IN, 2006, JAIDS-J ACQ IMM DEF, V41, P93, DOI 10.1097/01.qai.0000179424.19413.24; Lehman DA, 2008, AIDS, V22, P1475, DOI 10.1097/QAD.0b013e328302cc11; Macias J, 2005, J INFECTION, V51, P195, DOI 10.1016/j.jinf.2004.11.010; Meda N, 2011, LANCET INFECT DIS, V11, P171, DOI 10.1016/S1473-3099(10)70288-7; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Panteleeff DD, 1999, J CLIN MICROBIOL, V37, P350, DOI 10.1128/JCM.37.2.350-353.1999; Patel D, 2007, CLIN INFECT DIS, V44, P1647, DOI 10.1086/518284; Phiri W, 2006, AIDS RES HUM RETROV, V22, P607, DOI 10.1089/aid.2006.22.607; Rousseau CM, 2003, J INFECT DIS, V187, P741, DOI 10.1086/374273; Rousseau CM, 2004, J INFECT DIS, V190, P1880, DOI 10.1086/425076; Salazar-Gonzalez JF, 2011, J VIROL, V85, P2751, DOI 10.1128/JVI.02316-10; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shapiro RL, 2010, NEW ENGL J MED, V362, P2282, DOI 10.1056/NEJMoa0907736; Shapiro RL, 2005, J INFECT DIS, V192, P713, DOI 10.1086/432489; Sklar PA, 2002, AIDS, V16, P2035, DOI 10.1097/00002030-200210180-00008; Sungkanuparph S, 2005, CLIN INFECT DIS, V41, P1326, DOI 10.1086/496985; WEINBERG A, 2009, INFECT DIS OBSTET GY; World Health Organization, 2021, ANT DRUGS TREAT PREG	28	19	19	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 11	2012	7	1							e29777	10.1371/journal.pone.0029777	http://dx.doi.org/10.1371/journal.pone.0029777			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906ON	22253778	gold, Green Published, Green Submitted			2023-01-03	WOS:000301355700050
J	Uchiyama, J; Takemura, I; Satoh, M; Kato, SI; Ujihara, T; Akechi, K; Matsuzaki, S; Daibata, M				Uchiyama, Jumpei; Takemura, Iyo; Satoh, Miho; Kato, Shin-ichiro; Ujihara, Takako; Akechi, Kazue; Matsuzaki, Shigenobu; Daibata, Masanori			Improved Adsorption of an Enterococcus faecalis Bacteriophage Phi EF24C with a Spontaneous Point Mutation	PLOS ONE			English	Article							CHRONIC BACTERIAL PROSTATITIS; PHAGE THERAPY; HOST-RANGE; T2 PHAGE; TAIL; EVOLUTION; GENOME; MICROBIOLOGY; COEVOLUTION; INFECTIONS	Some bacterial strains of the multidrug-resistant Gram-positive bacteria Enterococcus faecalis can significantly reduce the efficacy of conventional antimicrobial chemotherapy. Thus, the introduction of bacteriophage (phage) therapy is expected, where a phage is used as a bioagent to destroy bacteria. E. faecalis phage Phi EF24C is known to be a good candidate for a therapeutic phage against E. faecalis. However, this therapeutic phage still produces nonuniform antimicrobial effects with different bacterial strains of the same species and this might prove detrimental to its therapeutic effects. One solution to this problem is the preparation of mutant phages with higher activity, based on a scientific rationale. This study isolated and analyzed a spontaneous mutant phage, Phi EF24C-P2, which exhibited higher infectivity against various bacterial strains when compared with phage Phi EF24C. First, the improved bactericidal effects of phage Phi EF24C-P2 were attributable to its increased adsorption rate. Moreover, genomic sequence scanning revealed that phage Phi EF24C-P2 had a point mutation in orf31. Proteomic analysis showed that ORF31 (mw, 203 kDa) was present in structural components, and immunological analysis using rabbit-derived antibodies showed that it was a component of a long, flexible fine tail fiber extending from the tail end. Finally, phage Phi EF24C-P2 also showed higher bactericidal activity in human blood compared with phage Phi EF24C using the in vitro assay system. In conclusion, the therapeutic effects of phage Phi EF24C-P2 were improved by a point mutation in gene orf31, which encoded a tail fiber component.	[Uchiyama, Jumpei; Takemura, Iyo; Akechi, Kazue; Matsuzaki, Shigenobu; Daibata, Masanori] Kochi Univ, Dept Microbiol & Infect, Fac Med, Kochi 780, Japan; [Satoh, Miho; Kato, Shin-ichiro; Ujihara, Takako] Kochi Univ, Ctr Sci Res, Kochi 780, Japan	Kochi University; Kochi University	Uchiyama, J (corresponding author), Kochi Univ, Dept Microbiol & Infect, Fac Med, Kochi 780, Japan.	matuzaki@kochi-u.ac.jp	Uchiyama, Jumpei/GWC-4189-2022; Uchiyama, Jumpei/GNP-6661-2022	Uchiyama, Jumpei/0000-0003-0846-0100	Center of Biomembrane Functions Controlling Biological Systems, Kochi University; Kochi System Glycobiology Center, Kochi University;  [22890129]; Grants-in-Aid for Scientific Research [22890129, 23591391] Funding Source: KAKEN	Center of Biomembrane Functions Controlling Biological Systems, Kochi University; Kochi System Glycobiology Center, Kochi University; ; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This article was supported by a Grant-in-Aid for Research Activity Startup No. 22890129 (http://kaken.nii.ac.jp/ja/r/20574619); the Center of Biomembrane Functions Controlling Biological Systems, Kochi University (http://www.kochi-ms.ac.jp/similar to cbm/index.htm); the Kochi System Glycobiology Center, Kochi University (http://www.kochi-ms.ac.jp/similar to ksglycoc/index.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams M., 1959, N Y; Alemayehu D, 2009, GENE, V448, P29, DOI 10.1016/j.gene.2009.08.008; Angly F, 2009, ENVIRON MICROBIOL, V11, P2863, DOI 10.1111/j.1462-2920.2009.02021.x; Bonten M J, 2001, Lancet Infect Dis, V1, P314, DOI 10.1016/S1473-3099(01)00145-1; Bull JJ, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-35; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Carlson K, 2005, BACTERIOPHAGE: BIOLOGY AND APPLICATIONS, P437; Carlton Richard M., 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P267; Ceyssens PJ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-134; Chibani-Chennoufi S, 2004, J BACTERIOL, V186, P7069, DOI 10.1128/JB.186.21.7069-7083.2004; Deshpande LM, 2007, DIAGN MICR INFEC DIS, V58, P163, DOI 10.1016/j.diagmicrobio.2006.12.022; Desplats C, 2003, RES MICROBIOL, V154, P259, DOI 10.1016/S0923-2508(03)00069-X; Eliopoulos GM, 2009, J INFECTION, V59, pS17, DOI 10.1016/S0163-4453(09)60004-9; Fujita Naohisa, 2005, Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi, V16, P1; GORSKI A, 2009, FOLIA MICROBIOL PRAH, V54, P5; Hatfull GF, 2002, SCIENCE, V295, P2031, DOI 10.1126/science.1070586; Hsieh SE, 2011, APPL ENVIRON MICROB, V77, P756, DOI 10.1128/AEM.01848-10; Hyman P, 2010, ADV APPL MICROBIOL, V70, P217, DOI 10.1016/S0065-2164(10)70007-1; Inal JM, 2003, ARCH IMMUNOL THER EX, V51, P237; JONCZYK E, 2010, FEMS IMMUNOL MED MIC, V60, P99; Kashiwagi A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002188; Kasparek P, 2007, FOLIA MICROBIOL, V52, P331, DOI 10.1007/BF02932087; Kayser FH, 2003, INT J FOOD MICROBIOL, V88, P255, DOI 10.1016/S0168-1605(03)00188-0; Klumpp J, 2008, J BACTERIOL, V190, P5753, DOI 10.1128/JB.00461-08; Klumpp J, 2010, ARCH VIROL, V155, P1547, DOI 10.1007/s00705-010-0783-0; Kropinski Andrew M., 2009, V501, P151, DOI 10.1007/978-1-60327-164-6_15; Kwan T, 2005, P NATL ACAD SCI USA, V102, P5174, DOI 10.1073/pnas.0501140102; Leiman PG, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-355; Letkiewicz S, 2009, FOLIA MICROBIOL, V54, P457, DOI 10.1007/s12223-009-0064-z; Mahichi F, 2009, FEMS MICROBIOL LETT, V295, P211, DOI 10.1111/j.1574-6968.2009.01588.x; Marinelli LJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003957; Mazzoli S, 2010, FEMS IMMUNOL MED MIC, V59, P337, DOI 10.1111/j.1574-695X.2010.00659.x; Mesyanzhinov VV, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1190, DOI 10.1007/s10541-005-0064-9; Mizoguchi K, 2003, APPL ENVIRON MICROB, V69, P170, DOI 10.1128/AEM.69.1.170-176.2003; Ohtsubo Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-376; Paterson S, 2010, NATURE, V464, P275, DOI 10.1038/nature08798; Powers JH, 2004, CLIN MICROBIOL INFEC, V10, P23, DOI 10.1111/j.1465-0691.2004.1007.x; SANDMEIER H, 1992, J BACTERIOL, V174, P3936, DOI 10.1128/jb.174.12.3936-3944.1992; SELICK HE, 1988, J BIOL CHEM, V263, P11336; Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050-MCP200; Silhavy TJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000414; SMITH HW, 1982, J GEN MICROBIOL, V128, P307; Sood S, 2008, INDIAN J MED RES, V128, P111; Stewart CR, 2009, J MOL BIOL, V388, P48, DOI 10.1016/j.jmb.2009.03.009; Sulakvelidze A, 2005, BACTERIOPHAGE: BIOLOGY AND APPLICATIONS, P381; Suyama M, 2001, TRENDS GENET, V17, P10, DOI 10.1016/S0168-9525(00)02159-4; Switala-Jelen K, 2002, ACTA VIROL, V46, P57; Talbot GH, 2006, CLIN INFECT DIS, V42, P657, DOI 10.1086/499819; Tamames J, 2001, GENOME BIOL, V2; Uchiyama J, 2008, APPL ENVIRON MICROB, V74, P4149, DOI 10.1128/AEM.02371-07; Uchiyama J, 2008, FEMS MICROBIOL LETT, V278, P200, DOI 10.1111/j.1574-6968.2007.00996.x; Uchiyama J, 2009, MICROBIOL IMMUNOL, V53, P301, DOI 10.1111/j.1348-0421.2009.00125.x; Yoichi M, 2005, J BIOTECHNOL, V115, P101, DOI 10.1016/j.jbiotec.2004.08.003	53	41	43	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 25	2011	6	10							e26648	10.1371/journal.pone.0026648	http://dx.doi.org/10.1371/journal.pone.0026648			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841MS	22046321	Green Published, gold			2023-01-03	WOS:000296517000023
J	Jankovic, J; Yeeles, K; Katsakou, C; Amos, T; Morriss, R; Rose, D; Nichol, P; McCabe, R; Priebe, S				Jankovic, Jelena; Yeeles, Ksenija; Katsakou, Christina; Amos, Tim; Morriss, Richard; Rose, Diana; Nichol, Peter; McCabe, Rosemarie; Priebe, Stefan			Family Caregivers' Experiences of Involuntary Psychiatric Hospital Admissions of Their Relatives - a Qualitative Study	PLOS ONE			English	Article							MENTAL-HEALTH-SERVICES; CARE; BURDEN; USERS; SCHIZOPHRENIA; INFORMATION; ILLNESS; PEOPLE	Background: Family caregivers of people with mental disorders are frequently involved in involuntary hospital admissions of their relatives. Objective: To explore family caregivers' experience of involuntary admission of their relative. Method: 30 in-depth interviews were conducted with family caregivers of 29 patients who had been involuntarily admitted to 12 hospitals across England. Interviews were analysed using thematic analysis. Results: Four major themes of experiences were identified: relief and conflicting emotions in response to the relative's admission; frustration with a delay in getting help; being given the burden of care by services; and difficulties with confidentiality. Relief was a predominant emotion as a response to the relative's admission and it was accompanied by feelings of guilt and worry. Family caregivers frequently experienced difficulties in obtaining help from services prior to involuntary admission and some thought that services responded to crises rather than prevented them. Family caregivers experienced increased burden when services shifted the responsibility of caring for their mentally unwell relatives to them. Confidentiality was a delicate issue with family caregivers wanting more information and a say in decisions when they were responsible for aftercare, and being concerned about confidentiality of information they provided to services. Conclusion: Compulsory admission of a close relative can be a complex and stressful experience for family caregivers. In order for caregivers to be effective partners in care, a balance needs to be struck between valuing their involvement in providing care for a patient and not overburdening them.	[Jankovic, Jelena; Yeeles, Ksenija; Katsakou, Christina; Nichol, Peter; McCabe, Rosemarie; Priebe, Stefan] Queen Mary Univ London, Barts & London Sch Med & Dent, Unit Social & Community Psychiat, London, England; [Amos, Tim] Univ Bristol, Acad Unit Psychiat, Bristol, Avon, England; [Morriss, Richard] Univ Nottingham, Sch Community Hlth Sci, Nottingham NG7 2RD, England; [Rose, Diana] Kings Coll London, Inst Psychiat, London WC2R 2LS, England	University of London; Queen Mary University London; University of Bristol; University of Nottingham; University of London; King's College London	Jankovic, J (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Unit Social & Community Psychiat, London, England.	j.jankovic@qmul.ac.uk	Rose, Diana S/D-1387-2010; Rose, Diana/HGE-8574-2022; McCabe, Rose/A-9802-2013	Rose, Diana S/0000-0002-6393-6389; Priebe, Stefan/0000-0001-9864-3394; McCabe, Rose/0000-0003-2041-7383; Yeeles, Ksenija/0000-0002-7757-0154; Morriss, Richard/0000-0003-2910-4121	Department of Health, United Kingdom [0230072]; National Institute for Health Research (NIHR) United Kingdom Mental Health Research Network; NIHR Specialist Biomedical Research Centre; Maudsley National Health Service Foundation Trust; Institute of Psychiatry, King's College London	Department of Health, United Kingdom; National Institute for Health Research (NIHR) United Kingdom Mental Health Research Network(National Institute for Health Research (NIHR)); NIHR Specialist Biomedical Research Centre; Maudsley National Health Service Foundation Trust; Institute of Psychiatry, King's College London	The study was funded by a grant from the Policy Research Programme of the Department of Health, United Kingdom (Commission no 0230072). The views expressed in the publication are those of the authors and not necessarily those of the Department of Health. This study was supported by the National Institute for Health Research (NIHR) United Kingdom Mental Health Research Network. DR acknowledges financial support from the NIHR Specialist Biomedical Research Centre for Mental Health award to the South London and Maudsley National Health Service Foundation Trust and the Institute of Psychiatry, King's College London. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Awad AG, 2008, PHARMACOECONOMICS, V26, P149, DOI 10.2165/00019053-200826020-00005; Cormac I, 2006, ADV PSYCHIAT TREAT, V12, P162, DOI DOI 10.1192/APT.12.3.162; Department of Health, 1999, NAT SERV FRAM MENT H; Department of Health, 2008, MENT HLTH ACT 1983 C; FRANCELL CG, 1988, HOSP COMMUNITY PSYCH, V39, P1296; Henderson C, 2004, BRIT MED J, V329, P136, DOI 10.1136/bmj.38155.585046.63; HERVEY N, 2004, ADV PSYCHIAT TREATME, V10, P81; Jones IR, 2009, SOC SCI MED, V69, P632, DOI 10.1016/j.socscimed.2009.06.015; Jungbauer J, 2004, SCHIZOPHRENIA BULL, V30, P665, DOI 10.1093/oxfordjournals.schbul.a007114; Katsakou C, 2010, PSYCHIAT SERV, V61, P286, DOI 10.1176/ps.2010.61.3.286; Kersten P, 2001, HEALTH SOC CARE COMM, V9, P235, DOI 10.1046/j.1365-2524.2001.00297.x; Lakeman R, 2008, J PSYCHIATR MENT HLT, V15, P203, DOI 10.1111/j.1365-2850.2007.01213.x; Lammers J, 2003, J Psychiatr Ment Health Nurs, V10, P385, DOI 10.1046/j.1365-2850.2003.00598.x; Noble LM, 2004, CURR OPIN PSYCHIATR, V17, P289, DOI 10.1097/01.yco.0000133832.42167.76; Ohaeri JU, 2003, CURR OPIN PSYCHIATR, V16, P457, DOI 10.1097/01.yco.0000079212.36371.c0; Pescosolido BA, 2004, SOC SCI MED, V58, P1795, DOI 10.1016/S0277-9536(03)00398-8; PINFOLD V, 2003, UNDER PRESSURE IMPAC; Pinfold V, 2007, MENT HEALTH REV J, V12, P7, DOI 10.1108/13619322200700015; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Priebe S, 2009, BRIT J PSYCHIAT, V194, P49, DOI 10.1192/bjp.bp.108.052266; Simpson EL, 2002, BRIT MED J, V325, P1265, DOI 10.1136/bmj.325.7375.1265; Slade M, 2007, BRIT J PSYCHIAT, V190, P148, DOI 10.1192/bjp.bp.106.024935; Szmukler GI, 1997, BRIT J PSYCHIAT, V171, P401, DOI 10.1192/bjp.171.5.401; Zahid MA, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-71	24	54	56	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2011	6	10							e25425	10.1371/journal.pone.0025425	http://dx.doi.org/10.1371/journal.pone.0025425			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	834PW	22022393	Green Published, gold			2023-01-03	WOS:000295976000015
J	Wan, CY; Bazen, L; Baars, R; Libenson, A; Zipse, L; Zuk, J; Norton, A; Schlaug, G				Wan, Catherine Y.; Bazen, Loes; Baars, Rebecca; Libenson, Amanda; Zipse, Lauryn; Zuk, Jennifer; Norton, Andrea; Schlaug, Gottfried			Auditory-Motor Mapping Training as an Intervention to Facilitate Speech Output in Non-Verbal Children with Autism: A Proof of Concept Study	PLOS ONE			English	Article							MELODIC INTONATION THERAPY; MIRROR NEURON SYSTEM; FOLLOW-UP; SPECTRUM DISORDERS; LANGUAGE; MUSIC; REPRESENTATION; IMITATION; SPEAKING; NETWORK	Although up to 25% of children with autism are non-verbal, there are very few interventions that can reliably produce significant improvements in speech output. Recently, a novel intervention called Auditory-Motor Mapping Training (AMMT) has been developed, which aims to promote speech production directly by training he association between sounds and articulatory actions using intonation and bimanual motor activities. AMMT capitalizes on the inherent musical strengths of children with autism, and offers activities that they intrinsically enjoy. It also engages and potentially stimulates a network of brain regions that may be dysfunctional in autism. Here we report an initial efficacy study to provide 'proof of concept' for AMMT. Six non-verbal children with autism participated. Prior to treatment, the children had no intelligible words. They each received 40 individual sessions of AMMT 5 times per week, over an 8-week period. Probe assessments were conducted periodically during baseline, therapy, and follow-up sessions. After therapy, all children showed significant improvements in their ability to articulate words and phrases, with generalization to items that were not practiced during therapy sessions. Because these children had no or minimal vocal output prior to treatment, the acquisition of speech sounds and word approximations through AMMT represents a critical step in expressive language development in children with autism.	[Wan, Catherine Y.; Bazen, Loes; Baars, Rebecca; Libenson, Amanda; Zuk, Jennifer; Norton, Andrea; Schlaug, Gottfried] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Mus & Neuroimaging Lab,Dept Neurol, Boston, MA 02215 USA; [Zipse, Lauryn] MGH Inst Hlth Profess, Dept Commun Sci & Disorders, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Wan, CY (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Mus & Neuroimaging Lab,Dept Neurol, Boston, MA 02215 USA.	cwan@bidmc.harvard.edu		Zuk, Jennifer/0000-0001-9113-3973	The Nancy Lurie Marks Family Foundation; Deborah Munroe Noonan Memorial Research Fund; National Institutes of Health (NIH) [1RO1 DC008796, 3RO1DC008796-02S1, RO1DC009823-01]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC009823, R01DC008796] Funding Source: NIH RePORTER	The Nancy Lurie Marks Family Foundation; Deborah Munroe Noonan Memorial Research Fund; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was supported by The Nancy Lurie Marks Family Foundation (Dr. Schlaug) and the Deborah Munroe Noonan Memorial Research Fund (Dr. Wan). Dr. Schlaug also acknowledges additional support from the National Institutes of Health (NIH) (1RO1 DC008796, 3RO1DC008796-02S1, RO1DC009823-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERT ML, 1973, ARCH NEUROL-CHICAGO, V29, P130, DOI 10.1001/archneur.1973.00490260074018; Bangert M, 2006, NEUROIMAGE, V30, P917, DOI 10.1016/j.neuroimage.2005.10.044; Bangert M, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-26; BIJOU SW, 1989, ADV CHILD DEV BEHAV, V21, P221, DOI 10.1016/S0065-2407(08)60288-8; Francis K, 2005, DEV MED CHILD NEUROL, V47, P493, DOI 10.1017/S0012162205000952; Hadjikhani N., 2007, PROGR AUTISM RES, P151; Heaton P, 1998, MUSIC PERCEPT, V15, P291; Heaton P, 2008, COGN NEUROPSYCHOL, V25, P771, DOI 10.1080/02643290802336277; Hoelzley P., 1993, CANADIAN J MUSIC THE, V1, P54; Howlin P, 2000, J CHILD PSYCHOL PSYC, V41, P561, DOI 10.1017/S0021963099005806; Iacoboni M, 2006, NAT REV NEUROSCI, V7, P942, DOI 10.1038/nrn2024; KEITH RL, 1975, BRAIN LANG, V2, P483, DOI 10.1016/S0093-934X(75)80085-X; Koegel RL, 2009, J AUTISM DEV DISORD, V39, P1587, DOI 10.1007/s10803-009-0765-9; Koelsch S, 2005, J COGNITIVE NEUROSCI, V17, P1565, DOI 10.1162/089892905774597290; Koelsch S, 2002, NEUROIMAGE, V17, P956, DOI 10.1016/S1053-8119(02)91154-7; Lahav A, 2007, J NEUROSCI, V27, P308, DOI 10.1523/JNEUROSCI.4822-06.2007; Lord C, 2006, ARCH GEN PSYCHIAT, V63, P694, DOI 10.1001/archpsyc.63.6.694; Lord C, 2004, DEV LANGUAGE DISORDE, P1; Meister IG, 2003, NEUROPSYCHOLOGIA, V41, P401, DOI 10.1016/S0028-3932(02)00179-3; Meister IG, 2009, EUR J NEUROSCI, V29, P2074, DOI 10.1111/j.1460-9568.2009.06729.x; MILLER SB, 1979, J CLIN PSYCHIAT, V40, P201; MONSEN RB, 1976, J SPEECH HEAR RES, V19, P279, DOI 10.1044/jshr.1902.279; Mullen E.M., 1995, MULLENS SCALES EARLY; Newmeyer AJ, 2007, CLIN PEDIATR, V46, P604, DOI 10.1177/0009922807299545; Norton A, 2009, ANN NY ACAD SCI, V1169, P431, DOI 10.1111/j.1749-6632.2009.04859.x; Oberman LM, 2008, NEUROPSYCHOLOGIA, V46, P1558, DOI 10.1016/j.neuropsychologia.2008.01.010; Oberman LM, 2007, PSYCHOL BULL, V133, P310, DOI 10.1037/0033-2909.133.2.310; Ozdemir E, 2006, NEUROIMAGE, V33, P628, DOI 10.1016/j.neuroimage.2006.07.013; Patel AD, 1998, J COGNITIVE NEUROSCI, V10, P717, DOI 10.1162/089892998563121; Pickett E, 2009, COGN BEHAV NEUROL, V22, P1, DOI 10.1097/WNN.0b013e318190d185; Rogers SJ, 2006, J AUTISM DEV DISORD, V36, P1007, DOI 10.1007/s10803-006-0142-x; Schlaug G, 2008, MUSIC PERCEPT, V25, P315, DOI 10.1525/MP.2008.25.4.315; Schlosser RW, 2008, AM J SPEECH-LANG PAT, V17, P212, DOI 10.1044/1058-0360(2008/021); Schopler E, CHILDHOOD AUTISM RAT, V2nd; Sherer MR, 2005, J CONSULT CLIN PSYCH, V73, P525, DOI 10.1037/0022-006X.73.3.525; SHRIBERG LD, 1993, J SPEECH HEAR RES, V36, P105, DOI 10.1044/jshr.3601.105; Smith T, 2007, J AUTISM DEV DISORD, V37, P354, DOI 10.1007/s10803-006-0173-3; SPARKS R, 1974, Cortex, V10, P303; Turner LM, 2006, AUTISM, V10, P243, DOI 10.1177/1362361306063296; Uozumi T, 2004, NEUROLOGY, V62, P757, DOI 10.1212/01.WNL.0000113731.75479.25; VENTER A, 1992, J CHILD PSYCHOL PSYC, V33, P489, DOI 10.1111/j.1469-7610.1992.tb00887.x; Wan CY, 2010, FUTUR NEUROL, V5, P797, DOI 10.2217/FNL.10.55; Wan CY, 2010, BRAIN RES BULL, V82, P161, DOI 10.1016/j.brainresbull.2010.04.010; Wan CY, 2010, MUSIC PERCEPT, V27, P287, DOI 10.1525/MP.2010.27.4.287; Warner-Czyz AD, 2010, J SPEECH LANG HEAR R, V53, P2, DOI 10.1044/1092-4388(2009/0163); Wigram T., 2002, BRIT J MUSIC THER, V16, P11, DOI [10.1177/135945750201600104, DOI 10.1177/135945750201600104]; Williams JHG, 2001, NEUROSCI BIOBEHAV R, V25, P287, DOI 10.1016/S0149-7634(01)00014-8; Williams K. T., 2007, EVT 2 EXPRESSIVE VOC, VSecond	48	71	73	0	52	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 29	2011	6	9							e25505	10.1371/journal.pone.0025505	http://dx.doi.org/10.1371/journal.pone.0025505			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	834DM	21980480	Green Published, Green Submitted, gold			2023-01-03	WOS:000295939600032
J	Yu, CC; Hu, Y; Duan, JH; Yuan, W; Wang, C; Xu, HY; Yang, XD				Yu, Chenchen; Hu, Yan; Duan, Jinhong; Yuan, Wei; Wang, Chen; Xu, Haiyan; Yang, Xian-Da			Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In Vitro	PLOS ONE			English	Article							PLGA-PEG NANOPARTICLES; TARGETED DELIVERY; FOLATE RECEPTOR; MUC1; THERAPY; VIVO; NANOTECHNOLOGY; EXPRESSION	MUC1 protein is an attractive target for anticancer drug delivery owing to its overexpression in most adenocarcinomas. In this study, a reported MUC1 protein aptamer is exploited as the targeting agent of a nanoparticle-based drug delivery system. Paclitaxel (PTX) loaded poly (lactic-co-glycolic-acid) (PLGA) nanoparticles were formulated by an emulsion/evaporation method, and MUC1 aptamers (Apt) were conjugated to the particle surface through a DNA spacer. The aptamer conjugated nanoparticles (Apt-NPs) are about 225.3 nm in size with a stable in vitro drug release profile. Using MCF-7 breast cancer cell as a MUC1-overexpressing model, the MUC1 aptamer increased the uptake of nanoparticles into the target cells as measured by flow cytometry. Moreover, the PTX loaded Apt-NPs enhanced in vitro drug delivery and cytotoxicity to MUC1(+) cancer cells, as compared with non-targeted nanoparticles that lack the MUC1 aptamer (P<0.01). The behavior of this novel aptamer-nanoparticle bioconjugates suggests that MUC1 aptamers may have application potential in targeted drug delivery towards MUC1-overexpressing tumors.	[Yu, Chenchen; Hu, Yan; Duan, Jinhong; Xu, Haiyan; Yang, Xian-Da] Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China; [Yu, Chenchen; Hu, Yan; Duan, Jinhong; Xu, Haiyan; Yang, Xian-Da] Peking Union Med Coll, Beijing 100021, Peoples R China; [Yuan, Wei] Chinese Acad Med Sci, Peking Union Med Coll, State Key Lab Mol Oncol, Canc Inst & Hosp, Beijing 100730, Peoples R China; [Wang, Chen; Yang, Xian-Da] Natl Ctr Nanosci & Technol, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Sciences; National Center for Nanoscience & Technology - China	Yu, CC (corresponding author), Chinese Acad Med Sci, Inst Basic Med Sci, Beijing 100730, Peoples R China.	ayangmd@gmail.com	Prow, Tarl W/A-4764-2010	Prow, Tarl W/0000-0003-2892-6238	Chinese Ministry of Science and Technology [2011CB911003, 2011CB911004, 2011CB933504]; Natural Science Foundation of China [81071870]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The authors acknowledge the funding support from the Chinese Ministry of Science and Technology (2011CB911003, 2011CB911004, 2011CB933504) and the Natural Science Foundation of China (81071870). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACHARYA S, 2010, ADV DRUG DELIV REV; Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]; Brown KC, 2010, CURR PHARM DESIGN, V16, P1040, DOI 10.2174/138161210790963788; Chauhan SC, 2007, J HISTOCHEM CYTOCHEM, V55, P867, DOI 10.1369/jhc.7A7213.2007; Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047; Croce MV, 2001, BREAST CANCER RES TR, V69, P1, DOI 10.1023/A:1012220902991; Da Pieve C, 2009, NUCL MED BIOL, V36, P703, DOI 10.1016/j.nucmedbio.2009.04.004; Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105; Farokhzad OC, 2004, CANCER RES, V64, P7668, DOI 10.1158/0008-5472.CAN-04-2550; Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ferreira CSM, 2006, TUMOR BIOL, V27, P289, DOI 10.1159/000096085; Ferreira CSM, 2009, NUCLEIC ACIDS RES, V37, P866, DOI 10.1093/nar/gkn967; Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805; LEE RJ, 1994, J BIOL CHEM, V269, P3198; Levy-Nissenbaum E, 2008, TRENDS BIOTECHNOL, V26, P442, DOI 10.1016/j.tibtech.2008.04.006; Manchanda R, 2010, COLLOID SURFACE B, V75, P260, DOI 10.1016/j.colsurfb.2009.08.043; O'Connor JC, 2005, PROSTATE CANCER P D, V8, P36, DOI 10.1038/sj.pcan.4500762; Ohuchida K, 2006, INT J CANCER, V118, P405, DOI 10.1002/ijc.21317; Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0; Patil YB, 2009, BIOMATERIALS, V30, P859, DOI 10.1016/j.biomaterials.2008.09.056; Ren LF, 1997, CHEM-BIOL INTERACT, V104, P55, DOI 10.1016/S0009-2797(97)03767-8; Shi H, 2011, P NATL ACAD SCI USA, V108, P3900, DOI 10.1073/pnas.1016197108; Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169-409X(99)00062-9; Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1; Wang MD, 2007, EXPERT REV ANTICANC, V7, P833, DOI 10.1586/14737140.7.6.833; Yu B, 2010, MOL MEMBR BIOL, V27, P286, DOI 10.3109/09687688.2010.521200	28	135	140	2	101	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2011	6	9							e24077	10.1371/journal.pone.0024077	http://dx.doi.org/10.1371/journal.pone.0024077			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	817OO	21912664	Green Published, gold, Green Submitted			2023-01-03	WOS:000294683900026
J	Cahn, P; Montaner, J; Junod, P; Patterson, P; Krolewiecki, A; Andrade-Villanueva, J; Cassetti, I; Sierra-Madero, J; Casiro, AD; Bortolozzi, R; Lupo, SH; Longo, N; Rampakakis, E; Ackad, N; Sampalis, JS				Cahn, Pedro; Montaner, Julio; Junod, Patrice; Patterson, Patricia; Krolewiecki, Alejandro; Andrade-Villanueva, Jaime; Cassetti, Isabel; Sierra-Madero, Juan; Casiro, Arnaldo David; Bortolozzi, Raul; Lupo, Sergio Horacio; Longo, Nadia; Rampakakis, Emmanouil; Ackad, Nabil; Sampalis, John S.			Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1(st) PI-Based Regimen	PLOS ONE			English	Article							LOPINAVIR-RITONAVIR MONOTHERAPY; INFECTED PATIENTS; LACTIC-ACIDOSIS; LOPINAVIR/RITONAVIR MONOTHERAPY; MITOCHONDRIAL TOXICITY; ANTIRETROVIRAL THERAPY; COMBINATION THERAPY; NAIVE PATIENTS; 2 NUCLEOSIDES; FOLLOW-UP	Objectives: To compare the efficacy and safety of an individualized treatment-simplification strategy consisting of switching from a highly-active anti-retroviral treatment (HAART) with a ritonavir-boosted protease inhibitor (PI/r) and 2 nucleoside reverse-transcriptase inhibitors (NRTIs) to lopinavir/ritonavir (LPV/r) monotherapy, with intensification by 2 NRTIs if necessary, to that of continuing their HAART. Methods: This is a one-year, randomized, open-label, multi-center study in virologically-suppressed HIV-1-infected adults on their first PI/r-containing treatment, randomized to either LPV/r-monotherapy or continue their current treatment. Treatment efficacy was determined by plasma HIV-1 RNA viral load (VL), time-to-virologic rebound, patient-reported outcomes (PROs) and CD4+T-cell-count changes. Safety was assessed with the incidence of treatment-emergent adverse events (AE). Results: Forty-one patients were randomized to LPV/r and 39 to continue their HAART. No statistically-significant differences between the two study groups in demographics and baseline characteristics were observed. At day-360, 71(39: LPV/r; 32: HAART) patients completed treatment, while 9(2: LPV/r; 7: HAART) discontinued. In a Last Observation Carried Forward Intent-to-Treat analysis, 40(98%) patients on LPV/r and 37(95%) on HAART had VL, 200copies/mL (P = 0.61). Time-to-virologic rebound, changes in PROs, CD4+T-cell-count and VL from baseline, also exhibited no statistically-significant between-group differences. Most frequent AEs were diarrhea (19%), headache (18%) and influenza (16%). Four (10%) patients on LPV/r were intensified with 2 NRTIs, all regaining virologic control. Eight serious AEs were reported by 5(2: LPV/r; 3: HAART) patients. Conclusion: At day-360, virologic efficacy and safety of LPV/r appears comparable to that of a PI+2NRTIs HAART. These results suggest that our individualized, simplified maintenance strategy with LPV/r-monotherapy and protocol-mandated NRTI re-introduction upon viral rebound, in virologically-suppressed patients merits further prospective long-term evaluation.	[Montaner, Julio] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Junod, Patrice] Clin Med Quartier Latin, Montreal, PQ, Canada; [Andrade-Villanueva, Jaime] Univ Guadalajara, Antiguo Hosp Civil Guadalajara Fray Antonio Alcal, CUCS, Guadalajara 44430, Jalisco, Mexico; [Cahn, Pedro; Patterson, Patricia; Krolewiecki, Alejandro] Fdn Huesped, Buenos Aires, DF, Argentina; [Cassetti, Isabel] Helios Salud, Buenos Aires, DF, Argentina; [Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Casiro, Arnaldo David] Hosp Gen Agudos Teodoro Alvarez, Buenos Aires, DF, Argentina; [Bortolozzi, Raul] Ctr Diagnost Med Alta Complejidad SA CIBIC, Div Estudios Clin, Santa Fe, Argentina; [Lupo, Sergio Horacio] Inst CAICI, Santa Fe, Argentina; [Longo, Nadia; Rampakakis, Emmanouil; Sampalis, John S.] JSS Med Res, Westmount, PQ, Canada; [Ackad, Nabil] Abbott Labs, Montreal, PQ, Canada; [Sampalis, John S.] McGill Univ, Montreal, PQ, Canada	University of British Columbia; Universidad de Guadalajara; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; McGill University	Cahn, P (corresponding author), Fdn Huesped, Buenos Aires, DF, Argentina.	jsampalis@jssresearch.com	Krolewiecki, Alejandro/AAK-2047-2021; Sierra Madero, Juan/AAW-8825-2021; Montaner, Julio/K-7621-2012; Andrade-Villanueva, Jaime Federico/GPK-6845-2022	Krolewiecki, Alejandro/0000-0001-9054-1211; Rampakakis, Emmanouil/0000-0002-7427-8246; Andrade-Villanueva, Jaime Federico/0000-0003-1948-655X	Abbott Canada	Abbott Canada(Abbott Laboratories)	This study was supported by a grant-in-aid by Abbott Canada. The funder was involved in the conception and design of the experiment but had no role in data collection and analysis, decision to publish, or writing of the manuscript. JSS Medical Research, a CRO contracted by Abbott, analyzed the data and wrote the manuscript.	Arribas JR, 2009, JAIDS-J ACQ IMM DEF, V51, P147, DOI 10.1097/QAI.0b013e3181a56de5; Bangsberg DR, 2004, J INFECT DIS, V190, P162, DOI 10.1086/420790; Bierman WFW, 2009, AIDS, V23, P279, DOI 10.1097/QAD.0b013e32831c54e5; Braithwaite RS, 2006, J ANTIMICROB CHEMOTH, V58, P1036, DOI 10.1093/jac/dkl386; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; CAMERON DW, J INFECT DIS, V198, P234; Carr A, 2001, LANCET, V357, P1412, DOI 10.1016/S0140-6736(00)04579-7; Choi AI, 2011, AIDS, V25, P1289, DOI 10.1097/QAD.0b013e328347fa16; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Delfraissy JFO, 2008, AIDS, V22, P385, DOI 10.1097/QAD.0b013e3282f3f16d; Domingo P, 2008, J ANTIMICROB CHEMOTH, V61, P1348, DOI 10.1093/jac/dkn121; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gulick RM, 2003, AIDS, V17, P2345, DOI 10.1097/00002030-200311070-00009; Hall AM, 2011, AM J KIDNEY DIS, V57, P773, DOI 10.1053/j.ajkd.2011.01.022; Hicks C, 2004, AIDS, V18, P775, DOI 10.1097/00002030-200403260-00008; Hill A, 2007, EXPERT OPIN PHARMACO, V8, P679, DOI 10.1517/14656566.8.5.679; Kakuda TN, 1999, AIDS, V13, P2311, DOI 10.1097/00002030-199911120-00019; McKinnon JE, 2009, ANTIVIR THER, V14, P1; Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010; Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594; Murphy RL, 2008, HIV CLIN TRIALS, V9, P1, DOI 10.1310/hct0901-1; Nunes EP, 2009, HIV CLIN TRIALS, V10, P368, DOI 10.1310/hct1006-368; Panel on antiretroviral guidelines for adults and adolescents, 2009, GUID US ANT AG HIV 1, P1, DOI DOI 10.1111/J.1468-1293.2008.00636.X; Pulido F, 2008, J ANTIMICROB CHEMOTH, V61, P1359, DOI 10.1093/jac/dkn103; Pulido F, 2008, AIDS, V22, pF1, DOI 10.1097/QAD.0b013e3282f4243b; Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218, DOI 10.1128/AAC.42.12.3218; Stein D. S., 1994, AIDS Clinical Care, V6, P17; Sundar K, 1997, CRIT CARE MED, V25, P1425, DOI 10.1097/00003246-199708000-00034; *US FDA, DRUG SAF COMM US FOO; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; Woodward CLN, 2009, HIV MED, V10, P482, DOI 10.1111/j.1468-1293.2009.00716.x	31	27	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2011	6	8							e23726	10.1371/journal.pone.0023726	http://dx.doi.org/10.1371/journal.pone.0023726			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810LZ	21886816	Green Submitted, Green Published, gold			2023-01-03	WOS:000294128100028
J	van Vollenhoven, RF; Geborek, P; Forslind, K; Albertsson, K; Ernestam, S; Petersson, IF; Chatzidionysiou, K; Bratt, J				van Vollenhoven, Ronald F.; Geborek, Pierre; Forslind, Kristina; Albertsson, Kristina; Ernestam, Sofia; Petersson, Ingemar F.; Chatzidionysiou, Katerina; Bratt, Johan		Swefot Study Grp	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial	LANCET			English	Article							MODIFYING ANTIRHEUMATIC DRUGS; ANTITUMOR NECROSIS FACTOR; EULAR RECOMMENDATIONS; PLUS METHOTREXATE; JOINT DESTRUCTION; MANAGEMENT; HYDROXYCHLOROQUINE; SULFASALAZINE; ETANERCEPT; THERAPY	Background Analysis of the Swedish Farmacotherapy (Swefot) trial at 12 months showed that the addition of an anti-tumour-necrosis-factor agent gave an improved clinical outcome compared with the addition of conventional disease-modifying antirheumatic drugs in patients with methotrexate-refractory early rheumatoid arthritis. Here we report the 2 year follow-up assessment. Methods In this randomised, non-blinded, parallel-group trial, we enrolled adult patients older than 18 years with rheumatoid arthritis and a symptom duration of less than 1 year from 15 rheumatology units in Sweden between December, 2002 and December, 2006. All patients were started on methotrexate. After 3-4 months, those who failed treatment were randomly assigned (1: 1) to group A (conventional treatment; additional sulfasalazine and hydroxychloroquine) or group B (biological treatment; additional infliximab). Randomisation was done with a computer-generated sequence. We analysed clinical outcomes at months 18 and 24 by the response criteria of the American College of Rheumatology and the European League Against Rheumatism, and radiographs of patients' hands and feet at months 12 and 24 using the Van der Heijde modification of the Sharp score. Analysis was by intention to treat. This trial is registered with www.ClinicalTrials.gov, number NCT00764725. Findings Of 493 screened individuals, we enrolled 487, of whom 258 were randomly allocated to treatment. The proportion of patients in group B who received a EULAR-defined good response was non-significantly greater than it was in group A at 18 months (49 of 128 [38%] vs 38 of 130 [29%]) and at 24 months (49 of 128 [38%] vs 40 of 130 [31%]; p=0.204). After 24 months, radiological disease progression was greater in patients in group A than it was in those in group B (mean 7.23 [SD 12.72] vs 4.00 [10.0]; p=0.009). We recorded three serious adverse events: an extended generalised illness in group A, an extended febrile episode in group B, and a generalised illness in group B. Interpretation Additional biological treatment is a valid option for patients who fail initial methotrexate treatment. However, improved clinical outcomes after 12 months and better radiographical results after 24 months should be weighed against the absence of a convincing clinical difference at 24 months and substantially higher costs. Therefore, for many patients who fail initial methotrexate treatment, add-on treatment with disease-modifying antirheumatic drugs is an appropriate treatment option.	[van Vollenhoven, Ronald F.] Karolinska Univ Hosp, Inflammatory Dis ClinTRID, Unit Clin Therapy Res, Rheumatol Clin, S-17176 Stockholm, Sweden; [van Vollenhoven, Ronald F.; Chatzidionysiou, Katerina] Karolinska Inst, Unit Clin Therapy Res, Stockholm, Sweden; [Geborek, Pierre; Forslind, Kristina] Lund Univ, Dept Clin Sci Lund, Rheumatol Sect, Lund, Sweden; [Forslind, Kristina] Helsingborg Hosp, Dept Internal Med, Rheumatol Sect, Helsingborg, Sweden; [Petersson, Ingemar F.] Skane Univ Hosp, Lund, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lund University; Helsingborgs Hospital; Lund University; Skane University Hospital	van Vollenhoven, RF (corresponding author), Karolinska Univ Hosp, Inflammatory Dis ClinTRID, Unit Clin Therapy Res, Rheumatol Clin, S-17176 Stockholm, Sweden.	ronald.van.vollenhoven@ki.se	Ljung, Lotta/H-8919-2019; van Vollenhoven, Ronald/ABE-1244-2021; Chatzidionysiou, Katerina/AAB-9359-2021	Ljung, Lotta/0000-0001-8999-0925; Petersson, Ingemar/0000-0001-9139-1892; Chatzidionysiou, Katerina/0000-0002-2163-0525; Chatzidionysiou, Katerina/0000-0002-2669-1247	Swedish Rheumatism Association; Stockholm County; Schering-Plough/Merck Sharp and Dohme; Abbott; GlaxoSmithKline; Merck Sharp and Dohme; Pfizer; Roche; UCB Pharma; Schering-Plough Sweden; Swedish health-care system	Swedish Rheumatism Association; Stockholm County(Stockholm County Council); Schering-Plough/Merck Sharp and Dohme; Abbott(Abbott Laboratories); GlaxoSmithKline(GlaxoSmithKline); Merck Sharp and Dohme(Merck & Company); Pfizer(Pfizer); Roche(Roche Holding); UCB Pharma(UCB Pharma SA); Schering-Plough Sweden(Merck & CompanySchering Plough Corporation); Swedish health-care system	Swedish Rheumatism Association, Stockholm County, and Schering-Plough/Merck Sharp and Dohme.; RFvV has received research support and honoraria from Abbott, GlaxoSmithKline, Merck Sharp and Dohme, Pfizer, Roche, and UCB Pharma. All other authors declare that they have no conflicts of interest.; The study was supported in part by a grant from the Swedish Rheumatism Association. RFvV and SE were supported by clinical research funds from Stockholm County. An annual unrestricted grant was provided by Schering-Plough Sweden that was used to support the study coordinator (MW). The same company also provided support for a medical monitor (between Oct 1, 2006, and March 31, 2007), several investigator meetings, the logistics involved in the radiographical analyses, and a research assistant. For the most part, time commitments of study investigators and study nurses were subsumed under daily care of patients, meaning that the most important sponsor of this study was the Swedish health-care system. We would like to thank all participating patients and the study nurses, co-investigators, and colleagues who made this trial possible. We would also like to thank Bjorn Svensson, who founded and led the BARFOT study group, Ingiald Hafstrom who continues to lead the BARFOT study group, and all the members of this group in which the idea of the Swefot clinical trial was first proposed.	Alonso-Ruiz A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-52; Askling J, 2009, ARTHRITIS RHEUM-US, V60, P3180, DOI 10.1002/art.24941; Baecklund E, 1998, BRIT MED J, V317, P180, DOI 10.1136/bmj.317.7152.180; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Bruynesteyn K, 2002, J RHEUMATOL, V29, P2306; Clair EWS, 2004, ARTHRITIS RHEUM-US, V50, P3432, DOI 10.1002/art.20568; Emery P, 2008, RHEUMATOLOGY, V47, P392, DOI 10.1093/rheumatology/kem257; Emery P, 2008, LANCET, V372, P375, DOI 10.1016/S0140-6736(08)61000-4; Gaujoux-Viala C, 2010, ANN RHEUM DIS, V69, P1004, DOI 10.1136/ard.2009.127225; Goekoop-Ruiterman YPM, 2005, ARTHRITIS RHEUM-US, V52, P3381, DOI [10.1002/art.21405, 10.1002/art.23364]; Graudal N, 2010, ARTHRITIS RHEUM-US, V62, P2852, DOI 10.1002/art.27592; Grigor C, 2004, LANCET, V364, P263, DOI 10.1016/S0140-6736(04)16676-2; Keystone EC, 2009, J RHEUMATOL, V36, P11, DOI 10.3899/jrheum.090125; Landewe R, 2006, ARTHRITIS RHEUM-US, V54, P3119, DOI 10.1002/art.22143; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; Nam JL, 2010, ANN RHEUM DIS, V69, P976, DOI 10.1136/ard.2009.126573; O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P1164, DOI 10.1002/art.10228; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; Smolen JS, 2010, ANN RHEUM DIS, V69, P964, DOI 10.1136/ard.2009.126532; Svensson B, 2005, ARTHRITIS RHEUM-US, V52, P3360, DOI 10.1002/art.21298; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; van der Heijde D, 2005, ARTHRITIS RHEUM-US, V52, P49, DOI 10.1002/art.20775; van Vollenhoven RF, 2009, LANCET, V374, P459, DOI 10.1016/S0140-6736(09)60944-2; vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105; Verstappen SMM, 2007, ANN RHEUM DIS, V66, P1443, DOI 10.1136/ard.2007.071092; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Wessels JAM, 2007, ARTHRITIS RHEUM-US, V56, P1765, DOI 10.1002/art.22640	29	158	171	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2012	379	9827					1712	1720		10.1016/S0140-6736(12)60027-0	http://dx.doi.org/10.1016/S0140-6736(12)60027-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937KX	22464340				2023-01-03	WOS:000303658500031
J	Wilson, SE; Ouedraogo, CT; Prince, L; Ouedraogo, A; Hess, SY; Rouamba, N; Ouedraogo, JB; Vosti, SA; Brown, KH				Wilson, Shelby E.; Ouedraogo, Cesaire T.; Prince, Lea; Ouedraogo, Amadou; Hess, Sonja Y.; Rouamba, Noeel; Ouedraogo, Jean Bosco; Vosti, Stephen A.; Brown, Kenneth H.			Caregiver Recognition of Childhood Diarrhea, Care Seeking Behaviors and Home Treatment Practices in Rural Burkina Faso: A Cross-Sectional Survey	PLOS ONE			English	Article							INTEGRATED MANAGEMENT; ILLNESS	Introduction: To design effective national diarrhea control programs, including oral rehydration solution (ORS) and therapeutic zinc supplementation, information is needed on local perceptions of illness, external care seeking behaviors, and home treatment practices. Methods: A cross-sectional, community-based household survey was conducted in the Orodara Health District, Burkina Faso. Caregivers of 10,490 children <27 months were interviewed to assess child diarrhea prevalence and related care practices. Characteristics of households, caregivers, children, and reported illnesses were compared for those caregivers who did or did not recognize the presence of diarrhea, as defined according to clinical criteria (>= 3 liquid or semi-liquid stools/day). Multiple logistic regression models were used to examine factors associated with illness recognition and treatment. Results: Clinically defined diarrhea was present in 7.6% (95% CI: 7.1-8.1%) of children during the 24 hours preceding the survey but recognized by only 55% of caregivers. Over half (55%) of the caregivers of 1,067 children with a clinically defined diarrhea episode in the past 14 days sought care outside the home; 78% of those seeking care attended a public sector clinic. Care was sought and treatment provided more frequently for children with fever, vomiting, anorexia, longer illness duration, and those living closer to the health center; and care was sought more frequently for male children. 80% of children with recent diarrhea received some form of treatment; only 24% received ORS, whereas 14% received antibiotics. Zinc was not yet available in the study area. Conclusions: Caregivers frequently fail to recognize children's diarrhea, especially among younger infants and when illness signs are less severe. Treatment practices do not correspond with international recommendations in most cases, even when caregivers consult with formal health services. Child caregivers need additional assistance to recognize diarrhea correctly, and both caregivers and health care providers need updated training on current diarrhea treatment recommendations.	[Wilson, Shelby E.; Hess, Sonja Y.; Brown, Kenneth H.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; [Ouedraogo, Cesaire T.; Ouedraogo, Amadou; Rouamba, Noeel; Ouedraogo, Jean Bosco] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [Prince, Lea; Vosti, Stephen A.] Univ Calif Davis, Dept Agr & Resource Econ, Davis, CA 95616 USA; [Brown, Kenneth H.] Helen Keller Int, Dakar, Senegal	University of California System; University of California Davis; University of California System; University of California Davis	Brown, KH (corresponding author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.	khbrown@ucdavis.edu		Hess, Sonja/0000-0002-4661-277X; Ouedraogo, Jean Bosco/0000-0003-0412-8733; Ouedraogo, Cesaire/0000-0003-0634-3226	Thrasher Research Fund; Canadian International Development Agency; Orodara Health District; Helen Keller International office in Ouagadougou	Thrasher Research Fund; Canadian International Development Agency; Orodara Health District; Helen Keller International office in Ouagadougou	This study was supported in part by the Thrasher Research Fund and the Canadian International Development Agency by a grant to Helen Keller International. The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We greatly appreciate the contributions of the entire study team, including field workers, supervisors, data management and other support staff. We are grateful for the support of the staff at the Orodara Health District and the Helen Keller International office in Ouagadougou. We thank Judicael Some, Oula Ouattara, and Honore Konate of the Institut de Recherche en Sciences de la Sante in Bobo-Dioulasso for assistance with the study implementation, Janet M. Peerson (University of California Davis) for guidance on statistical analyses, and Elizabeth A. Yakes (University of California Davis) for careful review of the manuscript and helpful suggestions. Finally, we sincerely appreciate the support of the children, their parents, and local communities whose participation and support made this survey possible.	[Anonymous], 2004, CLIN MAN AC DIARRH; BLACK RE, 1991, ACTA PAEDIATR SCAND, P133; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Boschi-Pinto C, 2009, MATERNAL AND CHILD HEALTH: GLOBAL CHALLENGES, PROGRAMS AND POLICIES, P225, DOI 10.1007/b106524_13; Checkley W, 2008, INT J EPIDEMIOL, V37, P816, DOI 10.1093/ije/dyn099; COGSWELL ME, 1991, SOC SCI MED, V33, P1209, DOI 10.1016/0277-9536(91)90237-7; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Koepsell T. D, 2003, EPIDEMIOLOGIC METHOD; Lambrechts T, 1999, B WORLD HEALTH ORGAN, V77, P582; Larson CP, 2011, HLTH POLICY PLAN, P1; Niehaus MD, 2002, AM J TROP MED HYG, V66, P590, DOI 10.4269/ajtmh.2002.66.590; Podewils Laura Jean, 2004, Semin Pediatr Infect Dis, V15, P155, DOI 10.1053/j.spid.2004.05.008; Tulloch J, 1999, LANCET, V354, pS16; UNICEF and World Health Organization, 2009, DIARRH WHY CHILDR ST; Winch PJ, 2008, J HEALTH POPUL NUTR, V26, P151; Winch PJ, 2002, HEALTH POLICY PLANN, V17, P345, DOI 10.1093/heapol/17.4.345; World Health Organization, 1995, TREATM DIARRH MAN PH; World Health Organization, 2004, FAM COMM PRACT PROM	19	28	28	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 13	2012	7	3							e33273	10.1371/journal.pone.0033273	http://dx.doi.org/10.1371/journal.pone.0033273			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	930IA	22428006	gold, Green Published			2023-01-03	WOS:000303129700045
J	Tinetti, ME				Tinetti, Mary E.			The Retreat From Advanced Care Planning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							END; MEDICARE		Yale Univ, Sch Med, Dept Internal Med, Sch Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sch Epidemiol & Publ Hlth, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu						Conway PH, 2011, JAMA-J AM MED ASSOC, V306, P2256, DOI 10.1001/jama.2011.1611; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Nicholas LH, 2011, JAMA-J AM MED ASSOC, V306, P1447, DOI 10.1001/jama.2011.1410; Pear Robert, 2010, N Y TIMES; RUTENBERG J, 2009, NY TIMES        0501, pA1; Tinetti ME, 2004, NEW ENGL J MED, V351, P2870, DOI 10.1056/NEJMsb042458; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	8	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 7	2012	307	9					915	916		10.1001/jama.2012.229	http://dx.doi.org/10.1001/jama.2012.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	904CU	22396510				2023-01-03	WOS:000301172100016
J	van Ginneken, E; Groenewegen, PP; McKee, M				van Ginneken, Ewout; Groenewegen, Peter P.; McKee, Martin			Personal healthcare budgets: what can England learn from the Netherlands?	BRITISH MEDICAL JOURNAL			English	Editorial Material									[McKee, Martin] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Groenewegen, Peter P.] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands	University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Netherlands Institute for Health Services Research	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	martin.mckee@lshtm.ac.uk	Mckee, Martin/E-6673-2018; McKee, Marc D/E-2187-2011; Groenewegen, Peter/I-1574-2013	Mckee, Martin/0000-0002-0121-9683; McKee, Marc D/0000-0001-8349-965X; Groenewegen, Peter/0000-0003-2127-8442				Boer L, 2010, ACHTERGRONDEN MOTIEV; Chevreul K., 2010, HLTH SYST TRANSIT, V12, P1, DOI DOI 10.1038/KI.2015.25; Dixon J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6608; Health Foundation, 2010, PERS HLTH BUDG RES S; Irvine A., 2011, PERSONAL HLTH BUDGET; Johnstone R, 2011, PUBLIC FINANCE  1005; Lansley A, 2011, COMMUNICATION   1004; McKee M, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e399; Ministry of Health, 2011, DLZKZU3067294 MIN HL; Ministry of Health, 2011, DLZU3070332 MIN HLTH; NHS Confederation, 2011, PERS HLTH BUDG COUNT; Ramakers C, 2010, WEG NAAR SOLIDE PGB; Ramakers C., 2007, EVALUATIE PERSOONGEB; Sadiraj K., 2011, OPMARS PGB ONTWIKKEL; Social Care Institute for Excellence, 2009, SCIE RES BRIEF 20 IM; The Health Foundation, 2011, PERS TOUCH DUTCH EXP	16	22	22	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 6	2012	344								e1383	10.1136/bmj.e1383	http://dx.doi.org/10.1136/bmj.e1383			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	908GM	22396156	Green Submitted			2023-01-03	WOS:000301478900014
J	Hickey, M; Elliott, J; Davison, SL				Hickey, Martha; Elliott, Jane; Davison, Sonia Louise			THERAPEUTICS Hormone replacement therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ESTROGEN PLUS PROGESTIN; HEALTHY POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; COST-EFFECTIVENESS; RECOMMENDATIONS; TIBOLONE; CANCER; BREAST; RISK; GABAPENTIN		[Hickey, Martha] Univ Melbourne, Royal Womens Hosp, Melbourne, Vic 3052, Australia; [Hickey, Martha] Univ Melbourne, Melbourne, Vic 3052, Australia; [Elliott, Jane] Univ Adelaide, Sch Paediat & Reprod Hlth, Discipline Obstet & Gynaecol, Adelaide, SA 5005, Australia; [Davison, Sonia Louise] Monash Univ, Womens Hlth Res Program, Dept Epidemiol & Prevent Med, Alfred Ctr,Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia	University of Melbourne; University of Melbourne; University of Adelaide; Monash University	Hickey, M (corresponding author), Univ Melbourne, Royal Womens Hosp, Melbourne, Vic 3052, Australia.	Martha.hickey@thewomens.org.au		Hickey, Martha/0000-0002-3941-082X				Aguirre W, 2010, GYNECOL ENDOCRINOL, V26, P333, DOI 10.3109/09513590903511539; Archer DF, 2007, J CLIN ENDOCR METAB, V92, P911, DOI 10.1210/jc.2006-2207; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Borrelli F, 2010, MATURITAS, V66, P333, DOI 10.1016/j.maturitas.2010.05.010; Bousser MG, 2000, CEPHALALGIA, V20, P155, DOI 10.1046/j.1468-2982.2000.00035.x; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Chlebowski RT, 2010, JAMA-J AM MED ASSOC, V304, P1684, DOI 10.1001/jama.2010.1500; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Cummings SR, 2008, NEW ENGL J MED, V359, P697, DOI 10.1056/NEJMoa0800743; Egarter C, 2002, ACTA OBSTET GYN SCAN, V81, P649, DOI 10.1034/j.1600-0412.2002.810711.x; Furness S., 2009, COCHRANE DB SYST REV, V2; Gebbie AE, 2011, MENOPAUSE INT, V16, P33; Gompel A, 2008, MATURITAS, V61, P227, DOI 10.1016/j.maturitas.2008.10.009; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hammar ML, 2007, BJOG-INT J OBSTET GY, V114, P1522, DOI 10.1111/j.1471-0528.2007.01537.x; Harman SM, 2011, AM J MED, V124, P199, DOI 10.1016/j.amjmed.2010.09.021; Hunter MS, 2010, J PSYCHOSOM RES, V69, P491, DOI 10.1016/j.jpsychores.2010.04.005; Kelly CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c693; Kenemans P, 2009, LANCET ONCOL, V10, P135, DOI 10.1016/S1470-2045(08)70341-3; Lekander Ingrid, 2009, Menopause Int, V15, P19, DOI 10.1258/mi.2009.009004; Lekander I, 2009, J WOMENS HEALTH, V18, P1669, DOI 10.1089/jwh.2008.1246; Liu B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a386; Maclennan A H, 2004, Cochrane Database Syst Rev, pCD002978, DOI 10.1002/14651858.CD002978.pub2; Maki PM, 2010, MENOPAUSE, V17, P815, DOI 10.1097/gme.0b013e3181d763d2; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Politi MC, 2008, J GEN INTERN MED, V23, P1507, DOI 10.1007/s11606-008-0655-4; Rada G, 2011, COCHRANE DB SYST REV, V9; Reddy SY, 2006, OBSTET GYNECOL, V108, P41, DOI 10.1097/01.AOG.0000222383.43913.ed; Renoux C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2519; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Santen RJ, 2010, J CLIN ENDOCR METAB, V95, pS7, DOI 10.1210/jc.2009-2509; Sare GM, 2008, EUR HEART J, V29, P2031, DOI 10.1093/eurheartj/ehn299; Sturdee DW, 2011, CLIMACTERIC, V14, P302, DOI 10.3109/13697137.2011.570590; Sturdee DW, 2010, CLIMACTERIC, V13, P509, DOI 10.3109/13697137.2010.522875; Suckling J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001500.pub2; Utian WH, 2010, MENOPAUSE, V17, P242, DOI 10.1097/gme.0b013e3181d0f6b9; Welton AJ, 2008, BMJ-BRIT MED J, V337, P1190; Wu O, 2006, HEALTH TECHNOL ASSES, V10, P1	38	32	32	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 16	2012	344								e763	10.1136/bmj.e763	http://dx.doi.org/10.1136/bmj.e763			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	896IP	22344303	Green Submitted			2023-01-03	WOS:000300559200001
J	Palmieri, C; Jones, A				Palmieri, Carlo; Jones, Alison			The 2011 EBCTCG polychemotherapy overview	LANCET			English	Editorial Material							BREAST; CHEMOTHERAPY		[Palmieri, Carlo] Univ London Imperial Coll Sci Technol & Med, Div Canc, London W12 0NN, England; [Jones, Alison] Univ Coll Hosp, Dept Med Oncol, London, England	Imperial College London; University of London; University College London	Palmieri, C (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Canc, London W12 0NN, England.	c.palmieri@imperial.ac.uk						Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Albain KS, 2010, LANCET ONCOL, V11, P55, DOI 10.1016/S1470-2045(09)70314-6; Baselga J, 1998, CANCER RES, V58, P2825; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Darby S, 2005, CELEBRATING STAT; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Perez EA, 2005, 41 AM SOC CLIN ONC A; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; VONHOFF DD, 1977, AM J MED, V62, P200, DOI 10.1016/0002-9343(77)90315-1	12	32	34	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 4	2012	379	9814					390	392		10.1016/S0140-6736(11)61823-0	http://dx.doi.org/10.1016/S0140-6736(11)61823-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	891AF	22152852				2023-01-03	WOS:000300187800011
J	Al-Wadei, HAN; Al-Wadei, MH; Schuller, HM				Al-Wadei, Hussein A. N.; Al-Wadei, Mohammed H.; Schuller, Hildegard M.			Cooperative Regulation of Non-Small Cell Lung Carcinoma by Nicotinic and Beta-Adrenergic Receptors: A Novel Target for Intervention	PLOS ONE			English	Article							AIRWAY EPITHELIAL-CELLS; GAMMA-AMINOBUTYRIC-ACID; PROMOTES TUMOR-GROWTH; ACETYLCHOLINE-RECEPTORS; CANCER CELLS; ADENOCARCINOMA; MODULATION; NEUROTRANSMITTERS; NITROSAMINES; ACTIVATION	Lung cancer is the leading cause of cancer death; 80-85% of lung cancer cases are non-small cell lung cancer (NSCLC). Smoking is a documented risk factor for the development of this cancer. Although nicotine does not have the ability to initiate carcinogenic events, recent studies have implicated nicotine in growth stimulation of NSCLC. Using three NSCLC cell lines (NCI-H322, NCI-H441 and NCI-H1299), we identified the cooperation of nicotinic acetylcholine receptors (nAChRs) and beta-adrenergic receptors (beta-ARs) as principal regulators of these effects. Proliferation was measured by thymidine incorporation and MTT assays, and Western blots were used to monitor the upregulation of the nAChRs and activation of signaling molecules. Noradrenaline and GABA were measured by immunoassays. Nicotine-treated NSCLC cells showed significant induction of the alpha 7nAChR and alpha 4nAChR, along with significant inductions of p-CREB and p-ERK1/2 accompanied by increases in the stress neurotransmitter noradrenaline, which in turn led to the observed increase in DNA synthesis and cell proliferation. Effects on cell proliferation and signaling proteins were reversed by the a7nAChR antagonist alpha-BTX or the beta-blocker propranolol. Nicotine treatment also down-regulated expression of the GABA synthesizing enzyme GAD 65 and the level of endogenous GABA, while treatment of NSCLC cells with GABA inhibited cell proliferation. Interestingly, GABA acts by reducing beta-adrenergic activated cAMP signaling. Our findings suggest that nicotine-induced activation of this autocrine noradrenaline-initiated signaling cascade and concomitant deficiency in inhibitory GABA, similar to modulation of these neurotransmitters in the nicotine-addicted brain, may contribute to the development of NSCLC in smokers. Our data suggest that exposure to nicotine either by tobacco smoke or nicotine supplements facilitates growth and progression of NSCLC and that pharmacological intervention by beta blocker may lower the risk for NSCLC development among smokers and could be used to enhance the clinical outcome of standard cancer therapy.	[Al-Wadei, Hussein A. N.; Al-Wadei, Mohammed H.; Schuller, Hildegard M.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Expt Oncol Lab, Knoxville, TN 37996 USA; [Al-Wadei, Hussein A. N.] Sanaa Univ, Dept Prevent Med, Sanaa, Yemen	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Al-Wadei, HAN (corresponding author), Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Expt Oncol Lab, Knoxville, TN 37996 USA.	hmsch@utk.edu			National Lung Cancer Partnership; LUNGevity Foundation; University of Tennessee Center of Excellence in Livestock Diseases and Human Health	National Lung Cancer Partnership; LUNGevity Foundation; University of Tennessee Center of Excellence in Livestock Diseases and Human Health	This project was financially supported by a grant from the National Lung Cancer Partnership and LUNGevity Foundation and by the University of Tennessee Center of Excellence in Livestock Diseases and Human Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Wadei HA, 2011, CUUR CANC D IN PRESS; Al-Wadei HAN, 2006, INT J CANCER, V118, P1370, DOI 10.1002/ijc.21537; Al-Wadei HAN, 2010, LUNG CANCER, V69, P33, DOI 10.1016/j.lungcan.2009.09.011; Al-Wadei HAN, 2009, J PATHOL, V218, P437, DOI 10.1002/path.2542; Al-Wadei HAN, 2009, CARCINOGENESIS, V30, P506, DOI 10.1093/carcin/bgp010; Arredondo J, 2006, CANCER BIOL THER, V5, P511, DOI 10.4161/cbt.5.5.2601; Barik J, 2006, MOL PHARMACOL, V69, P618, DOI 10.1124/mol.105.018184; Bunn PA, 2008, ONCOLOGIST, V13, P1, DOI 10.1634/theoncologist.13-S1-1; Davis R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007524; Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183; Drell TL, 2003, BREAST CANCER RES TR, V80, P63, DOI 10.1023/A:1024491219366; Fu XW, 2009, AM J RESP CELL MOL, V41, P93, DOI 10.1165/rcmb.2008-0352OC; GAZDAR AF, 1988, CANCER RES, V48, P4078; Govind AP, 2009, BIOCHEM PHARMACOL, V78, P756, DOI 10.1016/j.bcp.2009.06.011; Harkness PC, 2002, J NEUROSCI, V22, P10172; Hoffmann BB, 1990, PHARMACOL BASIS THER, P187; Hu W, 2010, NEUROPSYCHOPHARMACOL, V35, P1693, DOI 10.1038/npp.2010.31; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Laag E, 2006, INT J CANCER, V119, P1547, DOI 10.1002/ijc.21987; Lam DCL, 2007, CANCER RES, V67, P4638, DOI 10.1158/0008-5472.CAN-06-4628; Lawson GM, 1998, J CLIN PHARMACOL, V38, P502, DOI 10.1002/j.1552-4604.1998.tb05787.x; Lindstrom J, 1996, PROG BRAIN RES, V109, P125; Majidi M, 2007, CANCER RES, V67, P6863, DOI 10.1158/0008-5472.CAN-07-0483; MANECKJEE R, 1990, P NATL ACAD SCI USA, V87, P3294, DOI 10.1073/pnas.87.9.3294; Markou A, 2008, PHILOS T R SOC B, V363, P3159, DOI 10.1098/rstb.2008.0095; MARKS MJ, 1992, J NEUROSCI, V12, P2765; Masur K, 2001, CANCER RES, V61, P2866; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Mozayan M, 2007, AM J PHYSIOL-HEART C, V293, pH1737, DOI 10.1152/ajpheart.00269.2007; Palm D, 2006, INT J CANCER, V118, P2744, DOI 10.1002/ijc.21723; PARK PG, 1995, CANCER RES, V55, P3504; RUFFOLO RR, 1995, J MED CHEM, V38, P3681, DOI 10.1021/jm00019a001; Schuller HM, 2008, CARCINOGENESIS, V29, P1979, DOI 10.1093/carcin/bgn041; Schuller HM, 2008, ANTI-CANCER DRUG, V19, P655, DOI 10.1097/CAD.0b013e3283025b58; Schuller HM, 2009, NAT REV CANCER, V9, P195, DOI 10.1038/nrc2590; Schuller HM, 1999, CANCER RES, V59, P4510; Schuller HM, 2000, J CANCER RES CLIN, V126, P624, DOI 10.1007/PL00008474; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Soh J, 2008, J THORAC ONCOL, V3, P340, DOI 10.1097/JTO.0b013e318168d20a; Sood AK, 2006, CLIN CANCER RES, V12, P369, DOI 10.1158/1078-0432.CCR-05-1698; Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447; Wessler I, 2008, BRIT J PHARMACOL, V154, P1558, DOI 10.1038/bjp.2008.185; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; Wong HPS, 2007, TOXICOL SCI, V97, P279, DOI 10.1093/toxsci/kfm060; Wong HPS, 2007, TOXICOL APPL PHARM, V221, P261, DOI 10.1016/j.taap.2007.04.002; Wu JCF, 2009, J CELL BIOCHEM, V108, P433, DOI 10.1002/jcb.22270	48	53	55	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2012	7	1							e29915	10.1371/journal.pone.0029915	http://dx.doi.org/10.1371/journal.pone.0029915			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906OY	22253823	Green Published, gold			2023-01-03	WOS:000301357100029
J	Godart, N; Berthoz, S; Curt, F; Perdereau, F; Rein, Z; Wallier, J; Horreard, AS; Kaganski, I; Lucet, R; Atger, F; Corcos, M; Fermanian, J; Falissard, B; Flament, M; Eisler, I; Jeammet, P				Godart, Nathalie; Berthoz, Sylvie; Curt, Florence; Perdereau, Fabienne; Rein, Zoe; Wallier, Jenny; Horreard, Anne-Sophie; Kaganski, Irene; Lucet, Rejane; Atger, Frederic; Corcos, Maurice; Fermanian, Jacques; Falissard, Bruno; Flament, Martine; Eisler, Ivan; Jeammet, Philippe			A Randomized Controlled Trial of Adjunctive Family Therapy and Treatment as Usual Following Inpatient Treatment for Anorexia Nervosa Adolescents	PLOS ONE			English	Article							BODY-MASS INDEX; INDIVIDUAL THERAPY; EATING-DISORDERS; MEDICAL COMPLICATIONS; SOCIAL-ADJUSTMENT; PREDICTORS; TERM; COMORBIDITY; HOSPITALIZATION; PREVALENCE	Research on treatments in anorexia nervosa (AN) is scarce. Although most of the therapeutic programs used in 'real world practice' in AN treatment resort to multidisciplinary approaches, they have rarely been evaluated. Objective: To compare two multidimensional post-hospitalization outpatients treatment programs for adolescents with severe AN: Treatment as Usual (TAU) versus this treatment plus family therapy (TAU+FT). Method: Sixty female AN adolescents, aged 13 to 19 years, were included in a randomized parallel controlled trial conducted from 1999 to 2002 for the recruitment, and until 2004 for the 18 months follow-up. Allocation to one of the two treatment groups (30 in each arm) was randomised. The TAU program included sessions for the patient alone as well as sessions with a psychiatrist for the patient and her parents. The TAU+FT program was identical to the usual one but also included family therapy sessions targeting intra-familial dynamics, but not eating disorder symptoms. The main Outcome Measure was the Morgan and Russell outcome category (Good or Intermediate versus Poor outcome). Secondary outcome indicators included AN symptoms or their consequences (eating symptoms, body mass index, amenorrhea, number of hospitalizations in the course of follow-up, social adjustment). The evaluators, but not participants, were blind to randomization. Results: At 18 months follow-up, we found a significant group effect for the Morgan and Russell outcome category in favor of the program with family therapy (Intention-to-treat: TAU+FT : 12/30 (40%); TAU : 5/29 (17.2%) p = 0.05; Per Protocol analysis: respectively 12/26 (46.2%); 4/27 (14.8%), p = 0.01). Similar group effects were observed in terms of achievement of a healthy weight (i.e., BMI >= 10th percentile) and menstrual status. Conclusions: Adding family therapy sessions, focusing on intra-familial dynamics rather than eating symptomatology, to a multidimensional program improves treatment effectiveness in girls with severe AN. Trial Registration: Controlled-trials.com ISRCTN71142875	[Godart, Nathalie; Berthoz, Sylvie; Curt, Florence; Perdereau, Fabienne; Rein, Zoe; Wallier, Jenny; Horreard, Anne-Sophie; Kaganski, Irene; Lucet, Rejane; Atger, Frederic; Corcos, Maurice; Jeammet, Philippe] Inst Mutualiste Montsouris, Dept Adolescents & Young Adults Psychiat, Paris, France; [Godart, Nathalie; Berthoz, Sylvie; Perdereau, Fabienne; Wallier, Jenny; Atger, Frederic; Corcos, Maurice; Falissard, Bruno; Jeammet, Philippe] Natl Inst Hlth & Med Res Inserm, Unit UMR S0669, Paris, France; [Godart, Nathalie; Berthoz, Sylvie; Curt, Florence; Perdereau, Fabienne; Rein, Zoe; Wallier, Jenny; Kaganski, Irene; Lucet, Rejane; Atger, Frederic; Corcos, Maurice; Fermanian, Jacques; Falissard, Bruno; Jeammet, Philippe] Paris Descartes Univ, Paris, France; [Godart, Nathalie; Berthoz, Sylvie; Curt, Florence; Perdereau, Fabienne; Rein, Zoe; Wallier, Jenny; Kaganski, Irene; Lucet, Rejane; Atger, Frederic; Corcos, Maurice; Fermanian, Jacques; Falissard, Bruno; Jeammet, Philippe] Univ Paris 11, Paris, France; [Wallier, Jenny; Eisler, Ivan] Kings Coll London, Inst Psychiat, London WC2R 2LS, England; [Fermanian, Jacques] Hop Necker Enfants Malad, Dept Biostat, Paris, France; [Flament, Martine] Univ Ottawa, Royal Ottawa Hosp, Mental Hlth Res Inst, Ottawa, ON, Canada	Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Ottawa	Godart, N (corresponding author), Inst Mutualiste Montsouris, Dept Adolescents & Young Adults Psychiat, Paris, France.	nathalie.godart@imm.fr	Flament, Martine/D-4550-2013; Berthoz Landron, Sylvie/M-4517-2018; Eisler, Ivan/C-8386-2009; godart, nathalie/I-9553-2014	Eisler, Ivan/0000-0002-8211-7514; godart, nathalie/0000-0002-7233-6991; Berthoz, Sylvie/0000-0002-6862-2362	Hospitalier de Recherche Clinique (CRC-PHRC) [AOM97133]; Assistance Publique des Hopitaux de Paris (AP-HP)	Hospitalier de Recherche Clinique (CRC-PHRC); Assistance Publique des Hopitaux de Paris (AP-HP)	This study was funded by the Projet Hospitalier de Recherche Clinique (CRC-PHRC, 1997, AOM97133 AP-HP French Ministry of Health); and promoted by Assistance Publique des Hopitaux de Paris (AP-HP). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	American Psychiatric Association, 2006, PRACT GUID TREATM PA; Ball Jillian, 2004, Eat Disord, V12, P303, DOI 10.1080/10640260490521389; Berkman ND, 2007, INT J EAT DISORDER, V40, P293, DOI 10.1002/eat.20369; Bulik CM, 2007, INT J EAT DISORDER, V40, P310, DOI 10.1002/eat.20367; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Criquillon-Doublet S, 1995, PSYCHOPATHOLOGIE QUA, P249; Diem K, 1971, SCI TABLES; Eisler I, 2000, J CHILD PSYCHOL PSYC, V41, P727, DOI 10.1111/1469-7610.00660; Eisler I, 1997, ARCH GEN PSYCHIAT, V54, P1025; Eisler I, 2007, J CHILD PSYCHOL PSYC, V48, P552, DOI 10.1111/j.1469-7610.2007.01726.x; Fairburn CG, 2005, INT J EAT DISORDER, V37, pS26, DOI 10.1002/eat.20112; Flament M F, 2001, Eat Weight Disord, V6, P99; Fleiss J.L., 1994, HDB RES SYNTHESIS, P245; GARNER DM, 1993, LANCET, V341, P1631, DOI 10.1016/0140-6736(93)90768-C; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; Godart N, 2006, EAT WEIGHT DISORD-ST, V11, P185, DOI 10.1007/BF03327570; Godart N, 2004, Eat Weight Disord, V9, P224; Godart N, 2005, ARCH PEDIATRIE, V12, P1544, DOI 10.1016/j.arcped.2005.02.030; Godart N, 2009, EAT WEIGHT DISORD-ST, V14, pE176, DOI 10.1007/BF03325114; Godart N, 2007, MANUEL PSYCHIAT, P424; Godart NT, 2007, J AFFECT DISORDERS, V97, P37, DOI 10.1016/j.jad.2006.06.023; Godart N T, 2004, Eat Weight Disord, V9, P249; Godart NT, 2002, INT J EAT DISORDER, V32, P253, DOI 10.1002/eat.10096; Gowers SG, 2000, BRIT J PSYCHIAT, V176, P138, DOI 10.1192/bjp.176.2.138; Gowers SG, 2007, BRIT J PSYCHIAT, V191, P427, DOI 10.1192/bjp.bp.107.036764; Halmi KA, 2005, ARCH GEN PSYCHIAT, V62, P776, DOI 10.1001/archpsyc.62.7.776; Halmi KA, 2008, AM J PSYCHIAT, V165, P1227, DOI 10.1176/appi.ajp.2008.08060957; Hebebrand J, 1996, INT J EAT DISORDER, V19, P359, DOI 10.1002/(SICI)1098-108X(199605)19:4&lt;359::AID-EAT4&gt;3.0.CO;2-K; Hoek HW, 2003, INT J EAT DISORDER, V34, P383, DOI 10.1002/eat.10222; Hudson JI, 2007, BIOL PSYCHIAT, V61, P348, DOI 10.1016/j.biopsych.2006.03.040; JEAMMET P, 1991, PSYCHIAT ENFANT, V34, P381; Kaganski I., 2005, ENFANCE PSY, V2, P45; Kaganski I., 1999, PRISME, V30, P106; Kaganski I., 2004, GUERIR SOUFFRANCES F, P477; Katzman DK, 2005, INT J EAT DISORDER, V37, pS52, DOI 10.1002/eat.20118; Keel PK, 2003, ARCH GEN PSYCHIAT, V60, P179, DOI 10.1001/archpsyc.60.2.179; Keski-Rahkonen A, 2007, AM J PSYCHIAT, V164, P1259, DOI 10.1176/appi.ajp.2007.06081388; Lay B, 2002, EUR EAT DISORD REV, V10, P22, DOI 10.1002/erv.432; Lecrubier Y, 1997, EUR PSYCHIAT, V12, P224, DOI 10.1016/S0924-9338(97)83296-8; LEGRANGE D, 1992, INT J EAT DISORDER, V12, P347, DOI 10.1002/1098-108X(199212)12:4&lt;347::AID-EAT2260120402&gt;3.0.CO;2-W; Lock J, 2005, J AM ACAD CHILD PSY, V44, P632, DOI 10.1097/01.chi.0000161647.82775.0a; Lock J, 2001, J Psychother Pract Res, V10, P253; Lock J, 2006, J AM ACAD CHILD PSY, V45, P666, DOI 10.1097/01.chi.0000215152.61400.ca; Loeb KL, 2007, J AM ACAD CHILD PSY, V46, P792, DOI 10.1097/chi.0b013e318058a98e; Mitchell JE, 2006, CURR OPIN PSYCHIATR, V19, P438, DOI 10.1097/01.yco.0000228768.79097.3e; MORGAN HG, 1988, BRIT J PSYCHIAT, V152, P367, DOI 10.1192/bjp.152.3.367; MORGAN HG, 1975, PSYCHOL MED, V5, P355, DOI 10.1017/S0033291700056981; National Institute for Clinical Excellence, 2004, NAT I CLIN EXC CLIN, V9; Pike KM, 2003, AM J PSYCHIAT, V160, P2046, DOI 10.1176/appi.ajp.160.11.2046; ROBIN AL, 1995, INT J EAT DISORDER, V17, P313, DOI 10.1002/1098-108X(199505)17:4<313::AID-EAT2260170402>3.0.CO;2-8; ROBIN AL, 1994, J DEV BEHAV PEDIATR, V15, P111; Robin AL, 1999, J AM ACAD CHILD PSY, V38, P1482, DOI 10.1097/00004583-199912000-00008; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; RUSSELL GFM, 1987, ARCH GEN PSYCHIAT, V44, P1047; Schmidt U, 2006, BRIT J CLIN PSYCHOL, V45, P343, DOI 10.1348/014466505X53902; STEINHAUSEN HC, 1993, INT J EAT DISORDER, V14, P487, DOI 10.1002/1098-108X(199312)14:4<487::AID-EAT2260140412>3.0.CO;2-7; Strober M, 1997, INT J EAT DISORDER, V22, P339, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;339::AID-EAT1&gt;3.0.CO;2-N; WAINTRAUD L, 1995, ANN MED-PSYCHOL, V153, P274; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111	59	60	63	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 4	2012	7	1							e28249	10.1371/journal.pone.0028249	http://dx.doi.org/10.1371/journal.pone.0028249			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	902VE	22238574	gold, Green Submitted, Green Published			2023-01-03	WOS:000301070200006
J	Sakurai, M				Sakurai, Masatomo			PERSPECTIVE Herbal dangers	NATURE			English	Editorial Material									Kitasato Univ, Oriental Med Res Ctr, Tokyo, Japan	Kitasato University	Sakurai, M (corresponding author), Kitasato Univ, Oriental Med Res Ctr, Tokyo, Japan.	sakuraim@insti.kitasato-u.ac.jp						Arai S, 2009, KAMPOUIGAKU, P124; Gono Y, 2010, KAMPO MED, V61, P828, DOI DOI 10.3937/KAMPOMED.61.828; Ito T, 2010, KAMPO MED, V61, P299; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2	5	11	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S97	S97		10.1038/480S97a	http://dx.doi.org/10.1038/480S97a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190093	Bronze			2023-01-03	WOS:000298318000009
J	Koerts, J; Van Beilen, M; Tucha, O; Leenders, KL; Brouwer, WH				Koerts, Janneke; Van Beilen, Marije; Tucha, Oliver; Leenders, Klaus L.; Brouwer, Wiebo H.			Executive Functioning in Daily Life in Parkinson's Disease: Initiative, Planning and Multi-Task Performance	PLOS ONE			English	Article							DUAL-TASK-PERFORMANCE; COGNITIVE DECLINE; NORMATIVE DATA; DEFICITS; MOVEMENT; ABILITY; TESTS	Impairments in executive functioning are frequently observed in Parkinson's disease (PD). However, executive functioning needed in daily life is difficult to measure. Considering this difficulty the Cognitive Effort Test (CET) was recently developed. In this multi-task test the goals are specified but participants are free in their approach. This study applies the CET in PD patients and investigates whether initiative, planning and multi-tasking are associated with aspects of executive functions and psychomotor speed. Thirty-six PD patients with a mild to moderate disease severity and thirty-four healthy participants were included in this study. PD patients planned and demonstrated more sequential task execution, which was associated with a decreased psychomotor speed. Furthermore, patients with a moderate PD planned to execute fewer tasks at the same time than patients with a mild PD. No differences were found between these groups for multi-tasking. In conclusion, PD patients planned and executed the tasks of the CET sequentially rather than in parallel presumably reflecting a compensation strategy for a decreased psychomotor speed. Furthermore, patients with moderate PD appeared to take their impairments into consideration when planning how to engage the tasks of the test. This compensation could not be detected in patients with mild PD.	[Koerts, Janneke; Tucha, Oliver; Brouwer, Wiebo H.] Univ Groningen, Fac Behav & Social Sci, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Koerts, Janneke; Van Beilen, Marije; Leenders, Klaus L.; Brouwer, Wiebo H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands	University of Groningen; University of Groningen	Koerts, J (corresponding author), Univ Groningen, Fac Behav & Social Sci, Dept Clin & Dev Neuropsychol, Groningen, Netherlands.	janneke.koerts@rug.nl	Tucha, Oliver/AAD-1403-2019; van Beilen, Marije/A-7435-2011					Aarsland D, 2004, ARCH NEUROL-CHICAGO, V61, P1906, DOI 10.1001/archneur.61.12.1906; Benton AL, 1976, MULTILINGUAL APHASIA; Bialystok E, 2008, J INT NEUROPSYCH SOC, V14, P257, DOI 10.1017/S1355617708080296; Bleom BR, 2006, J NEUROL SCI, V248, P196, DOI 10.1016/j.jns.2006.05.010; BROWN RG, 1991, BRAIN, V114, P215; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colman KSF, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/213983; Cools R, 2001, BRAIN, V124, P2503, DOI 10.1093/brain/124.12.2503; Drago V, 2009, J NEUROL SCI, V276, P179, DOI 10.1016/j.jns.2008.09.026; Dubois B, 1997, J NEUROL, V244, P2, DOI 10.1007/pl00007725; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Esselink RAJ, 2004, NEUROLOGY, V62, P201, DOI 10.1212/01.WNL.0000103235.12621.C3; Fahn S., 1987, RECENT DEV PARKINSON, V2, P153; Farina E, 2000, EUR J NEUROL, V7, P259, DOI 10.1046/j.1468-1331.2000.00066.x; FLOWERS KA, 1985, J NEUROL NEUROSUR PS, V48, P517, DOI 10.1136/jnnp.48.6.517; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Foltynie T, 2004, BRAIN, V127, P550, DOI 10.1093/brain/awh067; GEORGIOU N, 1994, J NEUROL NEUROSUR PS, V57, P368, DOI 10.1136/jnnp.57.3.368; Hammes J.G.W., 1978, DE STROOP KLEUR WOOR; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Koerts J, 2011, J NEUROL SCI, V310, P172, DOI 10.1016/j.jns.2011.07.009; Lange KW, 2003, J NEURAL TRANSM, V110, P983, DOI 10.1007/s00702-003-0011-0; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Ma HI, 2009, CLIN REHABIL, V23, P229, DOI 10.1177/0269215508098896; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Monchi O, 2004, J NEUROSCI, V24, P702, DOI 10.1523/JNEUROSCI.4860-03.2004; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Muslimovic D, 2007, J INT NEUROPSYCH SOC, V13, P920, DOI 10.1017/S1355617707071160; Muslimovic D, 2009, J INT NEUROPSYCH SOC, V15, P426, DOI 10.1017/S1355617709090614; NORMAN DA, 1986, CONCIOUSSNESS SELF R; Perfetti B, 2010, PARKINSONISM RELAT D, V16, P46, DOI 10.1016/j.parkreldis.2009.07.011; Pomati S, 1996, ITAL J NEUROL SCI, V17, P201, DOI 10.1007/BF01995684; Proud EL, 2010, ARCH PHYS MED REHAB, V91, P794, DOI 10.1016/j.apmr.2010.01.008; Rahman S, 2008, MOVEMENT DISORD, V23, P1428, DOI 10.1002/mds.21667; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Schmand B, 2008, Tijdschr Gerontol Geriatr, V39, P64; Schmand B, 2003, NORMEN STROOP KLEUR; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; Strauss E., 2006, COMPENDIUM NEUROPSYC; van Beilen M, 2005, J PSYCHIATR RES, V39, P585, DOI 10.1016/j.jpsychires.2005.02.001; van Beilen M, 2006, J NEUROL SCI, V248, P68, DOI 10.1016/j.jns.2006.05.033; Van der Elst W, 2006, J INT NEUROPSYCH SOC, V12, P80, DOI 10.1017/S1355617706060115; VANBEILEN M, 2008, PARKINSONISM RELAT D, P1353; WECHSLER, 2005, SWETS TEST PUBLISHER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Weintraub D, 2005, DEMENT GERIATR COGN, V20, P140, DOI 10.1159/000087043; Werheid K, 2007, NEUROPSYCHOLOGIA, V45, P273, DOI 10.1016/j.neuropsychologia.2006.07.007; Williams-Gray CH, 2009, BRAIN, V132, P2958, DOI 10.1093/brain/awp245; Wilson B.A., 1996, BEHAV ASSESSMENT DYS; Wu T, 2008, J NEUROL NEUROSUR PS, V79, P760, DOI 10.1136/jnnp.2007.126599	52	26	30	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2011	6	12							e29254	10.1371/journal.pone.0029254	http://dx.doi.org/10.1371/journal.pone.0029254			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	870JU	22206004	Green Published, Green Submitted, gold			2023-01-03	WOS:000298666200020
J	Webster, RJ; Carter, KW; Warrington, NM; Loh, AM; Zaloumis, S; Kuijpers, TW; Palmer, LJ; Burgner, DP				Webster, Rebecca J.; Carter, Kim W.; Warrington, Nicole M.; Loh, Angeline M.; Zaloumis, Sophie; Kuijpers, Taco W.; Palmer, Lyle J.; Burgner, David P.			Hospitalisation with Infection, Asthma and Allergy in Kawasaki Disease Patients and Their Families: Genealogical Analysis Using Linked Population Data	PLOS ONE			English	Article							MANNOSE-BINDING LECTIN; CORONARY-ARTERY LESIONS; WESTERN-AUSTRALIA; ASSOCIATION; RISK; POLYMORPHISMS; CHILDREN; ALLELES; GENE	Background: Kawasaki disease results from an abnormal immunological response to one or more infectious triggers. We hypothesised that heritable differences in immune responses in Kawasaki disease-affected children and their families would result in different epidemiological patterns of other immune-related conditions. We investigated whether hospitalisation for infection and asthma/allergy were different in Kawasaki disease-affected children and their relatives. Methods/Major Findings: We used Western Australian population-linked health data from live births (1970-2006) to compare patterns of hospital admissions in Kawasaki disease cases, age-and sex-matched controls, and their relatives. There were 295 Kawasaki disease cases and 598 age-and sex-matched controls, with 1,636 and 3,780 relatives, respectively. Compared to controls, cases were more likely to have been admitted at least once with an infection (cases, 150 admissions (50.8%) vs controls, 210 admissions (35.1%); odds ratio (OR) = 1.9, 95% confidence interval (CI) 1.4-2.6, P = 7.2 x 10(-6)), and with asthma/allergy (cases, 49 admissions (16.6%) vs controls, 42 admissions (7.0%); OR = 2.6, 95% CI 1.7-4.2, P = 1.3 x 10(-5)). Cases also had more admissions per person with infection (cases, median 2 admissions, 95% CI 1-5, vs controls, median 1 admission, 95% CI 1-4, P = 1.09 x 10(-5)). The risk of admission with infection was higher in the first degree relatives of Kawasaki disease cases compared to those of controls, but the differences were not significant. Conclusion: Differences in the immune phenotype of children who develop Kawasaki disease may influence the severity of other immune-related conditions, with some similar patterns observed in relatives. These data suggest the influence of shared heritable factors in these families.	[Webster, Rebecca J.; Loh, Angeline M.; Palmer, Lyle J.] Univ Western Australia, Ctr Genet Epidemiol & Biostat, Perth, WA 6009, Australia; [Carter, Kim W.] Univ Western Australia, UWA Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Bioinformat & Biostat, Perth, WA 6009, Australia; [Warrington, Nicole M.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA 6009, Australia; [Zaloumis, Sophie] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia; [Kuijpers, Taco W.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Hematol Immunol & Infect Dis, NL-1105 AZ Amsterdam, Netherlands; [Burgner, David P.] Univ Western Australia, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; [Burgner, David P.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Melbourne; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Western Australia; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Webster, RJ (corresponding author), Univ Western Australia, Ctr Genet Epidemiol & Biostat, Perth, WA 6009, Australia.	david.burgner@mcri.edu.au	Palmer, Lyle John/N-1948-2019; Palmer, Lyle John/K-3196-2014; Zaloumis, Sophie/AAI-4396-2020; Warrington, Nicole/P-4868-2014	Palmer, Lyle John/0000-0002-1628-3055; Palmer, Lyle John/0000-0002-1628-3055; Zaloumis, Sophie/0000-0002-8253-8896; Warrington, Nicole/0000-0003-4195-775X; Burgner, David/0000-0002-8304-4302				Anaya JM, 2006, CLIN DEV IMMUNOL, V13, P185, DOI 10.1080/17402520600876762; Baker AL, 2009, J PEDIATR-US, V154, P592, DOI 10.1016/j.jpeds.2008.10.006; Benseler SM, 2005, PEDIATRICS, V116, pE760, DOI 10.1542/peds.2005-0559; Biezeveld MH, 2006, ARTHRITIS RHEUM-US, V54, P369, DOI 10.1002/art.21529; Biezeveld MH, 2005, CLIN EXP IMMUNOL, V141, P183, DOI 10.1111/j.1365-2249.2005.02829.x; BROSIUS CL, 1988, PEDIATR INFECT DIS J, V7, P863; Burgner D, 2005, INT J INFECT DIS, V9, P185, DOI 10.1016/j.ijid.2005.03.002; Burgner D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000319; Burns JC, 2004, LANCET, V364, P533, DOI 10.1016/S0140-6736(04)16814-1; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Chahal N, 2010, J PEDIATR HEALTH CAR, V24, P250, DOI 10.1016/j.pedhc.2009.07.002; Cheung YF, 2007, ARCH DIS CHILD, V92, P43, DOI 10.1136/adc.2006.096628; Dietert RR, 2010, WORLD J PEDIATR, V6, P111, DOI 10.1007/s12519-010-0026-1; Ding K, 2009, CIRC-CARDIOVASC GENE, V2, P63, DOI 10.1161/CIRCGENETICS.108.816751; ELIXHAUSER A, 2006, CLIN CLASSIFICATIONS; FUJITA Y, 1989, PEDIATRICS, V84, P666; Gee V, 1994, VALIDATION STUDY W A; Glasson EJ, 2008, INT J EPIDEMIOL, V37, P30, DOI 10.1093/ije/dym136; GLODE MP, 1986, PEDIATR INFECT DIS J, V5, P644, DOI 10.1097/00006454-198611000-00009; Gualano RC, 2006, PULM PHARMACOL THER, V19, P18, DOI 10.1016/j.pupt.2005.02.009; Harnden A, 2009, BMJ-BRIT MED J, V338, P1133; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Holman RC, 2005, PEDIATR INFECT DIS J, V24, P429, DOI 10.1097/01.inf.0000160946.05295.91; Ihaka R, 2001, J COMPUTATIONAL GRAP, V5, P299; Kim JJ, 2011, HUM GENET, V129, P487, DOI 10.1007/s00439-010-0937-x; Kimura J, 2004, CLIN EXP IMMUNOL, V137, P444, DOI 10.1111/j.1365-2249.2004.02506.x; Kuijpers TW, 1999, J INFECT DIS, V180, P1869, DOI 10.1086/315111; Kuo HC, 2009, PEDIAT ALLERG IMM-UK, V20, P266, DOI 10.1111/j.1399-3038.2008.00779.x; Liew WK, 2011, PEDIAT ALLERGY IMMUN; Mackay IR, 2009, J AUTOIMMUN, V33, P170, DOI 10.1016/j.jaut.2009.09.006; Maier LM, 2009, IMMUNOL REV, V229, P322, DOI 10.1111/j.1600-065X.2009.00777.x; Matsubara T, 1999, CLIN EXP IMMUNOL, V116, P554; Matsuoka S, 1997, EUR J PEDIATR, V156, P30; Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182; Nielsen NM, 2011, AM J EPIDEMIOL, V173, P990, DOI 10.1093/aje/kwq492; Onouchi Y, 2008, NAT GENET, V40, P35, DOI 10.1038/ng.2007.59; Read A, 1996, P BRISB WORKSH NOV; Rowley AH, 2011, J INFECT DIS, V203, P1021, DOI 10.1093/infdis/jiq136; Royle JA, 1998, ARCH DIS CHILD, V78, P33, DOI 10.1136/adc.78.1.33; Sato S, 2009, INT J RHEUM DIS, V12, P307, DOI 10.1111/j.1756-185X.2009.01428.x; Selarnet Tierney ES, 2007, J PEDIATR-US, V151, P225, DOI 10.1016/j.jpeds.2007.05.011; SHAM PC, 1995, ANN HUM GENET, V59, P97, DOI 10.1111/j.1469-1809.1995.tb01608.x; Shikishima Y, 2003, ASIAN PAC J ALLERGY, V21, P139; STANLEY FJ, 1994, PAEDIATR PERINAT EP, V8, P433, DOI 10.1111/j.1365-3016.1994.tb00482.x; Tsai FJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016853; Uehara R, 2003, ACTA PAEDIATR, V92, P694, DOI 10.1080/08035320310002768; Worthley DL, 2005, INTERN MED J, V35, P548, DOI 10.1111/j.1445-5994.2005.00908.x	47	20	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2011	6	11							e28004	10.1371/journal.pone.0028004	http://dx.doi.org/10.1371/journal.pone.0028004			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KW	22140498	Green Published, gold			2023-01-03	WOS:000298163400028
J	Van der Veer, T; Frings-Dresen, MHW; Sluiter, JK				Van der Veer, Tjeerd; Frings-Dresen, Monique H. W.; Sluiter, Judith K.			Health Behaviors, Care Needs and Attitudes towards Self-Prescription: A Cross-Sectional Survey among Dutch Medical Students	PLOS ONE			English	Article							ALCOHOL-CONSUMPTION; PHYSICAL-ACTIVITY; PREVALENCE; SEEKING; HABITS; DOCTORS; RESIDENTS; SMOKING; OBESITY; TOBACCO	Purpose: There is a growing awareness of the potent ways in which the wellbeing of physicians impacts the health of their patients. The purpose of this study was to investigate the health behaviors, care needs and attitudes towards self-prescription of Dutch medical students, and any differences between junior preclinical and senior clinically active students. Methods: All students (n = 2695) of a major Dutch medical school were invited for an online survey. Physical activity, eating habits, alcohol consumption, smoking, Body Mass Index, substance use and amount of sleep per night were inquired, as well as their need for different forms of care and their attitude towards self-prescription. Results: Data of 902 students were used. Physical activity levels (90% sufficient) and smoking prevalence (94% non-smokers) were satisfying. Healthy eating habits (51% insufficient) and alcohol consumption (46% excessive) were worrying. Body Mass Indexes were acceptable (20% unhealthy). We found no significant differences in health behaviors between preclinical and clinically active students. Care needs were significantly lower among clinically active students. (p<0.05) Student acceptance of self-prescription was significantly higher among clinically active students. (p<0.001) Conclusions: Unhealthy behaviors are prevalent among medical students, but are no more prevalent during the clinical study phase. The need for specific forms of care appears lower with study progression. This could be worrying as the acceptance of self-care and self-prescription is higher among senior clinical students. Medical faculties need to address students' unhealthy behaviors and meet their care needs for the benefit of both the future physicians as well as their patients.	[Van der Veer, Tjeerd; Frings-Dresen, Monique H. W.; Sluiter, Judith K.] Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Van der Veer, T (corresponding author), Univ Amsterdam, Acad Med Ctr, Coronel Inst Occupat Hlth, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.sluiter@amc.nl	van der Veer, Tjeerd/N-8975-2019	van der Veer, Tjeerd/0000-0003-3085-603X				Ahmed I, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.06.003; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Angyan L., 2004, Acta Physiologica Hungarica, V91, P157, DOI 10.1556/APhysiol.91.2004.2.7; Barss P, 2008, MED TEACH, V30, pE196, DOI 10.1080/01421590802334267; Boo NY, 2010, SINGAP MED J, V51, P126; Brimstone R, 2007, MED EDUC, V41, P74, DOI 10.1111/j.1365-2929.2006.02649.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Cape G, 2006, ADDICTION, V101, P841, DOI 10.1111/j.1360-0443.2006.01476.x; Cappuccio FP, 2010, SLEEP, V33, P585, DOI 10.1093/sleep/33.5.585; *CBS, 2010, PREV UNH BEH; Chew-Graham CA, 2003, MED EDUC, V37, P873, DOI 10.1046/j.1365-2923.2003.01627.x; Chourdakis M, 2010, APPETITE, V55, P722, DOI 10.1016/j.appet.2010.08.013; Compton MT, 2008, J NERV MENT DIS, V196, P891, DOI 10.1097/NMD.0b013e3181924d03; Davidson SK, 2003, MED J AUSTRALIA, V179, P302, DOI 10.5694/j.1326-5377.2003.tb05552.x; Duperly J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-218; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; FLAHERTY JA, 1993, PSYCHIAT CLIN N AM, V16, P189; Frank E, 2004, JAMA-J AM MED ASSOC, V291, P637, DOI 10.1001/jama.291.5.637; Frank E, 2000, ARCH FAM MED, V9, P287, DOI 10.1001/archfami.9.3.287; Frank E, 2006, AM J PREV MED, V31, P499, DOI 10.1016/j.amepre.2006.08.009; Frank E, 2010, CAN J PUBLIC HEALTH, V101, P390, DOI 10.1007/BF03404859; Frank E, 2009, PREV MED, V49, P233, DOI 10.1016/j.ypmed.2009.06.020; Frank E, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2155; Gawlikowska-Sroka A, 2009, EUR J MED RES, V14, P86, DOI 10.1186/2047-783X-14-S4-86; Goebert D, 2009, ACAD MED, V84, P236, DOI 10.1097/ACM.0b013e31819391bb; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hem E, 2005, BMC MED, V3, DOI 10.1186/1741-7015-3-16; Hooper C, 2005, MED EDUC, V39, P588, DOI 10.1111/j.1365-2929.2005.02175.x; Howe Michael, 2010, Prev Cardiol, V13, P180, DOI 10.1111/j.1751-7141.2010.00079.x; Keller S, 2007, ADDICT BEHAV, V32, P505, DOI 10.1016/j.addbeh.2006.05.017; Kumar P, 2000, J Indian Med Assoc, V98, P447; Lobelo F, 2009, BRIT J SPORT MED, V43, P89, DOI 10.1136/bjsm.2008.055426; Nguyen VH, 2008, ASIA-PAC J PUBLIC HE, V20, P16, DOI 10.1177/1010539507308504; Owens J A, 2001, Curr Opin Pulm Med, V7, P411, DOI 10.1097/00063198-200111000-00009; Ozasa K, 2005, MED EDUC, V39, P971, DOI 10.1111/j.1365-2929.2005.02251.x; Payne D, 2002, LANCET, V359, P1220, DOI 10.1016/S0140-6736(02)08264-8; Price Marilyn, 2007, Med Health R I, V90, P178; Richmond R, 2009, DRUG ALCOHOL REV, V28, P463, DOI 10.1111/j.1465-3362.2009.00115.x; Roberts LW, 2000, COMPR PSYCHIAT, V41, P303, DOI 10.1053/comp.2000.0410303; Roberts LW, 2000, ACAD MED, V75, P272, DOI 10.1097/00001888-200003000-00019; Roberts LW, 2001, COMPR PSYCHIAT, V42, P1, DOI 10.1053/comp.2001.19747; Rose AE, 2011, ACAD MED, V86, P1463, DOI 10.1097/ACM.0b013e3182312471; Single EW, 1995, CAN J PUBLIC HEALTH, V86, P402; Tanaka M, 2008, NUTRITION, V24, P985, DOI 10.1016/j.nut.2008.05.003	45	25	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 21	2011	6	11							e28038	10.1371/journal.pone.0028038	http://dx.doi.org/10.1371/journal.pone.0028038			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	858IO	22132202	gold, Green Published, Green Submitted			2023-01-03	WOS:000297789900043
J	Gatesman, ML; Smith, TJ				Gatesman, Mandy L.; Smith, Thomas J.			The Shortage of Essential Chemotherapy Drugs in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gatesman, Mandy L.] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA; [Smith, Thomas J.] Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Med, Baltimore, MD USA	Virginia Commonwealth University; Johns Hopkins University; Johns Hopkins Medicine	Gatesman, ML (corresponding author), Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA.			Smith, Thomas/0000-0003-3040-6434				Food and Drug Administration, CURR DRUG SHORT; Jacobson M, 2010, HEALTH AFFAIR, V29, P1391, DOI 10.1377/hlthaff.2009.0563; Kaakeh R, 2011, AM J HEALTH-SYST PH, V68, P1811, DOI 10.2146/ajhp110210; Neubauer MA, 2010, J ONCOL PRACT, V6, P12, DOI 10.1200/JOP.091058; Twombly R, 2004, J NATL CANCER I, V96, P1268, DOI 10.1093/jnci/96.17.1268	5	85	86	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2011	365	18					1653	1655		10.1056/NEJMp1109772	http://dx.doi.org/10.1056/NEJMp1109772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	840FL	22040130				2023-01-03	WOS:000296424200001
J	Rodriguez, EE; Hernandez-Lemus, E; Itza-Ortiz, BA; Jimenez, I; Rudomin, P				Rodriguez, Erika E.; Hernandez-Lemus, Enrique; Itza-Ortiz, Benjamin A.; Jimenez, Ismael; Rudomin, Pablo			Multichannel Detrended Fluctuation Analysis Reveals Synchronized Patterns of Spontaneous Spinal Activity in Anesthetized Cats	PLOS ONE			English	Article							DORSAL-HORN NEURONS; BAND EEG ACTIVITY; GAMMA-BAND; INTERSEGMENTAL SYNCHRONIZATION; TIME-SERIES; CORD; OSCILLATIONS; AFFERENTS; NETWORKS	The analysis of the interaction and synchronization of relatively large ensembles of neurons is fundamental for the understanding of complex functions of the nervous system. It is known that the temporal synchronization of neural ensembles is involved in the generation of specific motor, sensory or cognitive processes. Also, the intersegmental coherence of spinal spontaneous activity may indicate the existence of synaptic neural pathways between different pairs of lumbar segments. In this study we present a multichannel version of the detrended fluctuation analysis method (mDFA) to analyze the correlation dynamics of spontaneous spinal activity (SSA) from time series analysis. This method together with the classical detrended fluctuation analysis (DFA) were used to find out whether the SSA recorded in one or several segments in the spinal cord of the anesthetized cat occurs either in a random or in an organized manner. Our results are consistent with a non-random organization of the sets of neurons involved in the generation of spontaneous cord dorsum potentials (CDPs) recorded either from one lumbar segment (DFA-alpha mean = 1.04 +/- 0.09) or simultaneously from several lumbar segments (mDFA-alpha mean = 1.01 +/- 0.06), where alpha=0.5 indicates randomness while alpha>0.5 indicates long-term correlations. To test the sensitivity of the mDFA method we also examined the effects of small spinal lesions aimed to partially interrupt connectivity between neighboring lumbosacral segments. We found that the synchronization and correlation between the CDPs recorded from the L5 and L6 segments in both sides of the spinal cord were reduced when a lesion comprising the left dorsal quadrant was performed between the segments L5 and L6 (mDFA-alpha=0.992 as compared to initial conditions mDFA-alpha=1.186). The synchronization and correlation were reduced even further after a similar additional right spinal lesion (mDFA-alpha=0.924). In contrast to the classical methods, such as correlation and coherence quantification that define a relation between two sets of data, the mDFA method properly reveals the synchronization of multiple groups of neurons in several segments of the spinal cord. This method is envisaged as a useful tool to characterize the structure of higher order ensembles of cord dorsum spontaneous potentials after spinal cord or peripheral nerve lesions.	[Rodriguez, Erika E.; Jimenez, Ismael; Rudomin, Pablo] Ctr Res & Adv Studies CINVESTAV, Dept Physiol Biophys & Neurosci, Mexico City, DF, Mexico; [Rodriguez, Erika E.; Itza-Ortiz, Benjamin A.] Autonomous Univ Hidalgo UAEH, Ctr Res Math, Pachuca, Mexico; [Hernandez-Lemus, Enrique] Natl Inst Genom Med, Computat Genom Dept, Mexico City, DF, Mexico; [Hernandez-Lemus, Enrique] Univ Nacl Autonoma Mexico, Ctr Complex Sci, Mexico City 04510, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Universidad Autonoma del Estado de Hidalgo; Instituto Nacional de Medicina Genomica; Universidad Nacional Autonoma de Mexico	Rodriguez, EE (corresponding author), Ctr Res & Adv Studies CINVESTAV, Dept Physiol Biophys & Neurosci, Mexico City, DF, Mexico.	ehernandez@inmegen.gob.mx; rudomin@fisio.cinvestav.mx	Torres, Erika Elizabeth Rodríguez/A-3843-2019	Torres, Erika Elizabeth Rodríguez/0000-0002-7738-1863; Itza-Ortiz, Benjamin A./0000-0002-6189-3266; Hernandez-Lemus, Enrique/0000-0002-1872-1397	NIH [NS09196]; CONACYT [50900]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009196] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work has been supported by NIH (www.nih.gov) under grant NS09196 and by CONACYT (www.conacyt.mx) under grant 50900. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernasconi C, 2000, NEUROREPORT, V11, P689, DOI 10.1097/00001756-200003200-00007; BREMER F., 1941, ARCH INTERNAT PHYSIOL, V51, P51, DOI 10.3109/13813454109145564; Chavez D, 2011, J PHYSL UNPUB; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; ERTEKIN C, 1983, ELECTROEN CLIN NEURO, V55, P13, DOI 10.1016/0013-4694(83)90142-6; FEDER J., 1988, FRACTALS; Garcia CA, 2004, NEUROSCI LETT, V361, P102, DOI 10.1016/j.neulet.2003.12.068; Gerasimenko YP, 2001, B ESP BIOL MED, V11, P575; Gifani P, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6225; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Holste D, 2005, PHYS REV E, V71; Izhikevich EM., 2007, DYNAMICAL SYSTEMS NE; Kantelhardt JW, 2002, PHYSICA A, V316, P87, DOI 10.1016/S0378-4371(02)01383-3; KASPRZAK H, 1970, BRAIN RES, V22, P207, DOI 10.1016/0006-8993(70)90005-3; KERKUT GA, 1995, PROG NEUROBIOL, V46, P1, DOI 10.1016/0301-0082(94)00055-M; Lidierth M, 1996, NEUROSCI LETT, V220, P25, DOI 10.1016/S0304-3940(96)13231-6; Manjarrez E, 2003, EXP BRAIN RES, V148, P401, DOI 10.1007/s00221-002-1303-6; Manjarrez E, 2000, J PHYSIOL-LONDON, V529, P445, DOI 10.1111/j.1469-7793.2000.00445.x; MARK VH, 1953, ELECTROEN CLIN NEURO, V5, P251, DOI 10.1016/0013-4694(53)90012-1; Miltner WHR, 1999, NATURE, V397, P434, DOI 10.1038/17126; Muller MM, 1999, CLIN NEUROPHYSIOL, V110, P1913, DOI 10.1016/S1388-2457(99)00151-0; O'Donovan MJ, 1999, CURR OPIN NEUROBIOL, V9, P94, DOI 10.1016/S0959-4388(99)80012-9; O'Donovan MJ, 1998, J NEUROBIOL, V37, P131, DOI 10.1002/(SICI)1097-4695(199810)37:1<131::AID-NEU10>3.0.CO;2-H; PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PULVERMULLER F, 1995, NEUROREPORT, V6, P2059, DOI 10.1097/00001756-199510010-00025; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; Rosas A, 2002, PHYS REV E, V66, P1; Rudomin P, 2007, EXP BRAIN RES, V176, P98, DOI 10.1007/s00221-006-0600-x; Telesca L, 2007, PHYSICA A, V377, P279, DOI 10.1016/j.physa.2006.10.092; TENCATE J, 1950, ELECTROEN CLIN NEURO, V2, P445, DOI 10.1016/0013-4694(50)90080-0; von Stein A, 2000, P NATL ACAD SCI USA, V97, P14748, DOI 10.1073/pnas.97.26.14748	33	16	17	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 27	2011	6	10							e26449	10.1371/journal.pone.0026449	http://dx.doi.org/10.1371/journal.pone.0026449			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841OJ	22046288	gold, Green Submitted, Green Published			2023-01-03	WOS:000296521400021
J	Hansen, LO; Young, RS; Hinami, K; Leung, A; Williams, MV				Hansen, Luke O.; Young, Robert S.; Hinami, Keiki; Leung, Alicia; Williams, Mark V.			Interventions to Reduce 30-Day Rehospitalization: A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							CARE TRANSITIONS INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; FOLLOW-UP; HOSPITAL DISCHARGE; HEART-FAILURE; EARLY READMISSION; CLINICAL-TRIAL; OLDER-ADULTS; HIGH-RISK; IMPACT	Background: About 1 in 5 Medicare fee-for-service patients discharged from the hospital is rehospitalized within 30 days. Beginning in 2013, hospitals with high risk-standardized readmission rates will be subject to a Medicare reimbursement penalty. Purpose: To describe interventions evaluated in studies aimed at reducing rehospitalization within 30 days of discharge. Data Sources: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched for reports published between January 1975 and January 2011. Study Selection: English-language randomized, controlled trials; cohort studies; or noncontrolled before-after studies of interventions to reduce rehospitalization that reported rehospitalization rates within 30 days. Data Extraction: 2 reviewers independently identified candidate articles from the results of the initial search on the basis of title and abstract. Two 2-physician reviewer teams reviewed the full text of candidate articles to identify interventions and assess study quality. Data Synthesis: 43 articles were identified, and a taxonomy was developed to categorize interventions into 3 domains that encompassed 12 distinct activities. Predischarge interventions included patient education, medication reconciliation, discharge planning, and scheduling of a follow-up appointment before discharge. Postdischarge interventions included follow-up telephone calls, patient-activated hotlines, timely communication with ambulatory providers, timely ambulatory provider follow-up, and postdischarge home visits. Bridging interventions included transition coaches, physician continuity across the inpatient and outpatient setting, and patient-centered discharge instruction. Limitations: Inadequate description of individual studies' interventions precluded meta-analysis of effects. Many studies identified in the review were single-institution assessments of quality improvement activities rather than those with experimental designs. Several common interventions have not been studied outside of multicomponent "discharge bundles." Conclusion: No single intervention implemented alone was regularly associated with reduced risk for 30-day rehospitalization.	[Hansen, Luke O.] Northwestern Univ, Feinberg Sch Med, Div Hosp Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Hansen, LO (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hosp Med, 211 E Ontario St,07-733, Chicago, IL 60611 USA.	l-hansen@northwestern.edu	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Hinami, Keiki/0000-0002-1927-2546; Williams, Mark V/0000-0001-6107-0457	Northwestern University Feinberg School of Medicine; John A. Hartford Foundation; Society of Hospital Medicine; Institute for Healthcare Studies at Northwestern University from the Agency for Healthcare Research and Quality [T-32 HS 000078]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000078] Funding Source: NIH RePORTER	Northwestern University Feinberg School of Medicine; John A. Hartford Foundation; Society of Hospital Medicine; Institute for Healthcare Studies at Northwestern University from the Agency for Healthcare Research and Quality; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By the Northwestern University Feinberg School of Medicine (all authors). Drs. Williams and Hansen have received financial support from the John A. Hartford Foundation and the Society of Hospital Medicine for Project BOOST (Better Outcomes for Older Adults Through Safe Transitions). Dr. Young is supported by a National Research Service Award postdoctoral fellowship grant through the Institute for Healthcare Studies at Northwestern University under institutional awards from the Agency for Healthcare Research and Quality (T-32 HS 000078).	Ahmed A, 2004, EUR J HEART FAIL, V6, P421, DOI 10.1016/j.ejheart.2003.11.011; Anderson Cheryl, 2005, Congest Heart Fail, V11, P315, DOI 10.1111/j.1527-5299.2005.04458.x; Ashton CM, 1996, SOC SCI MED, V43, P1533, DOI 10.1016/S0277-9536(96)00049-4; Azevedo A, 2002, EUR J HEART FAIL, V4, P353, DOI 10.1016/S1388-9842(02)00013-2; Balaban RB, 2008, J GEN INTERN MED, V23, P1228, DOI 10.1007/s11606-008-0618-9; Bostrom J, 1996, APPL NURS RES, V9, P47, DOI 10.1016/S0897-1897(96)80402-2; Braun E, 2009, EUR J INTERN MED, V20, P221, DOI 10.1016/j.ejim.2008.07.021; Brown A, 1997, Aust J Adv Nurs, V14, P5; Centers for Medicare & Medicaid Services, MED HOSP COMP CALC 3; Cochrane Effective Practice and Organisation of Care (EPOC), EPOC RES REV AUTH; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; Coleman EA, 2004, J AM GERIATR SOC, V52, P1817, DOI 10.1111/j.1532-5415.2004.52504.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Creason H, 2001, Lippincotts Case Manag, V6, P146, DOI 10.1097/00129234-200107000-00004; Dai YT, 2003, RES NURS HEALTH, V26, P53, DOI 10.1002/nur.10067; Dedhia P, 2009, J AM GERIATR SOC, V57, P1540, DOI 10.1111/j.1532-5415.2009.02430.x; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; DUNN RB, 1994, ARCH GERONTOL GERIAT, V18, P15, DOI 10.1016/0167-4943(94)90044-2; Einstadter D, 1996, J GEN INTERN MED, V11, P684, DOI 10.1007/BF02600160; EVANS RL, 1993, MED CARE, V31, P358, DOI 10.1097/00005650-199304000-00007; Forster AJ, 2005, AM J MED, V118, P1148, DOI 10.1016/j.amjmed.2005.04.019; Gow P, 1999, J Qual Clin Pract, V19, P107, DOI 10.1046/j.1440-1762.1999.00312.x; Grafft CA, 2010, ARCH INTERN MED, V170, P955, DOI 10.1001/archinternmed.2010.105; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Harrison PL, 2011, POPUL HEALTH MANAG, V14, P27, DOI 10.1089/pop.2009.0076; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hess DR, 2010, CHEST, V138, P1475, DOI 10.1378/chest.09-2140; Houghton A, 1996, QUAL HEALTH CARE, V5, P89, DOI 10.1136/qshc.5.2.89; Jaarsma T, 1999, EUR HEART J, V20, P673, DOI 10.1053/euhj.1998.1341; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Jencks SF, 2010, ANN INTERN MED, V153, P757, DOI 10.7326/0003-4819-153-11-201012070-00010; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Koehler BE, 2009, J HOSP MED, V4, P211, DOI 10.1002/jhm.427; Kramer JS, 2007, AM J HEALTH-SYST PH, V64, P404, DOI 10.2146/ajhp060506; Kwok T, 2004, J AM GERIATR SOC, V52, P1240, DOI 10.1111/j.1532-5415.2004.52351.x; Lucas KS, 1998, AM J HEALTH-SYST PH, V55, pS32, DOI 10.1093/ajhp/55.suppl_4.S32; McDonald K, 2001, EUR J HEART FAIL, V3, P209, DOI 10.1016/S1388-9842(00)00134-3; MCPHEE SJ, 1983, MED CARE, V21, P755, DOI 10.1097/00005650-198308000-00001; MedPAC (Medicare Payment Advisory Commission), 2007, PAYM POL INP READM; Misky GJ, 2010, J HOSP MED, V5, P392, DOI 10.1002/jhm.666; Nasir K, 2010, MED CARE, V48, P477, DOI 10.1097/MLR.0b013e3181d5fb24; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; O'Dell KM, 2005, ANN PHARMACOTHER, V39, P1423, DOI 10.1345/aph.1E640; Parker S G, 2002, Health Technol Assess, V6, P1; Parry Carla, 2009, Home Health Care Serv Q, V28, P84, DOI 10.1080/01621420903155924; Project RED, 2007, PROJ RED REENG DISCH; Rainville EC, 1999, AM J HEALTH-SYST PH, V56, P1339, DOI 10.1093/ajhp/56.13.1339; Schneider J K, 1993, Clin Nurs Res, V2, P41, DOI 10.1177/105477389300200105; Scott IA, 2010, AUST HEALTH REV, V34, P445, DOI 10.1071/AH09777; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Shekelle PG, 2011, ANN INTERN MED, V154, P693, DOI 10.7326/0003-4819-154-10-201105170-00011; SMITH CS, 1995, MED CARE, V33, P221, DOI 10.1097/00005650-199503000-00001; Sorknaes AD, 2011, CLIN RESPIR J, V5, P26, DOI 10.1111/j.1752-699X.2010.00187.x; Steeman E, 2006, INT J QUAL HEALTH C, V18, P352, DOI 10.1093/intqhc/mzl026; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x; Wong FKY, 2008, J ADV NURS, V62, P585, DOI 10.1111/j.1365-2648.2008.04631.x	56	826	836	0	136	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 18	2011	155	8					520	U94		10.7326/0003-4819-155-8-201110180-00008	http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	835WB	22007045				2023-01-03	WOS:000296066300017
J	Gozalo, P; Teno, JM; Mitchell, SL; Skinner, J; Bynum, J; Tyler, D; Mor, V				Gozalo, Pedro; Teno, Joan M.; Mitchell, Susan L.; Skinner, Jon; Bynum, Julie; Tyler, Denise; Mor, Vincent			End-of-Life Transitions among Nursing Home Residents with Cognitive Issues	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVANCED DEMENTIA; COMMON OUTCOMES; ADVERSE EVENTS; CARE; MEDICARE; HOSPITALIZATION; MDS; REHOSPITALIZATIONS; IDENTIFICATION; HISTORIES	BACKGROUND Health care transitions in the last months of life can be burdensome and potentially of limited clinical benefit for patients with advanced cognitive and functional impairment. METHODS To examine health care transitions among Medicare decedents with advanced cognitive and functional impairment who were nursing home residents 120 days before death, we linked nationwide data from the Medicare Minimum Data Set and claims files from 2000 through 2007. We defined patterns of transition as burdensome if they occurred in the last 3 days of life, if there was a lack of continuity in nursing homes after hospitalization in the last 90 days of life, or if there were multiple hospitalizations in the last 90 days of life. We also considered various factors explaining variation in these rates of burdensome transition. We examined whether there was an association between regional rates of burdensome transition and the likelihood of feeding-tube insertion, hospitalization in an intensive care unit (ICU) in the last month of life, the presence of a stage IV decubitus ulcer, and hospice enrollment in the last 3 days of life. RESULTS Among 474,829 nursing home decedents, 19.0% had at least one burdensome transition (range, 2.1% in Alaska to 37.5% in Louisiana). In adjusted analyses, blacks, Hispanics, and those without an advance directive were at increased risk. Nursing home residents in regions in the highest quintile of burdensome transitions (as compared with those in the lowest quintile) were significantly more likely to have a feeding tube (adjusted risk ratio, 3.38), have spent time in an ICU in the last month of life (adjusted risk ratio, 2.10), have a stage IV decubitus ulcer (adjusted risk ratio, 2.28), or have had a late enrollment in hospice (adjusted risk ratio, 1.17). CONCLUSIONS Burdensome transitions are common, vary according to state, and are associated with markers of poor quality in end-of-life care. (Funded by the National Institute on Aging.)	[Teno, Joan M.] Brown Univ, Warren Alpert Med Sch, Ctr Gerontol & Hlth Care Res, Program Publ Hlth,Dept Hlth Serv Policy & Practic, Providence, RI 02912 USA; [Mitchell, Susan L.] Inst Aging Res, Boston, MA USA; [Skinner, Jon; Bynum, Julie] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA	Brown University; Dartmouth College	Teno, JM (corresponding author), Brown Univ, Warren Alpert Med Sch, Ctr Gerontol & Hlth Care Res, Program Publ Hlth,Dept Hlth Serv Policy & Practic, Providence, RI 02912 USA.	joan_teno@brown.edu		Tyler, Denise/0000-0001-8555-9011	National Institute on Aging [P01AG027296, K24AG033640]; NATIONAL INSTITUTE ON AGING [K24AG033640, P01AG027296] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants (P01AG027296, to Dr. Mor, and K24AG033640, to Dr. Mitchell) from the National Institute on Aging.	Bach PB, 2004, JAMA-J AM MED ASSOC, V292, P2765, DOI 10.1001/jama.292.22.2765; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; Carter MW, 2003, J AGING HEALTH, V15, P295, DOI 10.1177/0898264303015002001; Coleman E. A., 2002, INT J INTEGR CARE, V2, pe02; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; CORRIGAN JM, 1992, HEALTH SERV RES, V27, P81; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Fisher ES, 2009, HEALTH AFFAIR, V28, pW219, DOI 10.1377/hlthaff.28.2.w219; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Givens JL, 2011, ARCH INTERN MED, V171, P217; Givens JL, 2010, ARCH INTERN MED, V170, P1102, DOI 10.1001/archinternmed.2010.181; Grabowski DC, 2010, HEALTH SERV RES, V45, P1963, DOI 10.1111/j.1475-6773.2010.01104.x; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Gruneir A, 2007, GERONTOLOGIST, V47, P447, DOI 10.1093/geront/47.4.447; Harrison A, 2002, HEALTH SERV RES, V37, P1031, DOI 10.1034/j.1600-0560.2002.64_2.x; Hirdes JP, 2003, J AM GERIATR SOC, V51, P96, DOI 10.1034/j.1601-5215.2002.51017.x; Intrator O, 2007, HEALTH SERV RES, V42, P1651, DOI 10.1111/j.1475-6773.2006.00670.x; Intrator O, 2011, HEALTH SERV RES, V46, P120, DOI 10.1111/j.1475-6773.2010.01194.x; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kane RL, 2004, GERONTOLOGIST, V44, P95, DOI 10.1093/geront/44.1.95; Kane RL, 2003, J AM GERIATR SOC, V51, P1427, DOI 10.1046/j.1532-5415.2003.51461.x; Kruse RL, 2004, MED CARE, V42, P860, DOI 10.1097/01.mlr.0000135828.95415.b1; Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; McClellan M, 2010, HEALTH AFFAIR, V29, P982, DOI 10.1377/hlthaff.2010.0194; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Richardson SS, 2007, HEALTH SERV RES, V42, P183, DOI 10.1111/j.1475-6773.2006.00608.x; Roblin DW, 1999, MED CARE, V37, P1155, DOI 10.1097/00005650-199911000-00007; Saliba D, 2000, J AM GERIATR SOC, V48, P154, DOI 10.1111/j.1532-5415.2000.tb03906.x; Teno JM, 2011, J AM GERIATR SOC, V59, P881, DOI 10.1111/j.1532-5415.2011.03385.x; Thomas DR, 2008, J AM MED DIR ASSOC, V9, P292, DOI 10.1016/j.jamda.2008.03.006; Weissman JS, 1999, MED CARE, V37, P490, DOI 10.1097/00005650-199905000-00008; Wetle T, 2004, END LIFE NURSING HOM; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	40	311	313	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2011	365	13					1212	1221		10.1056/NEJMsa1100347	http://dx.doi.org/10.1056/NEJMsa1100347			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825YO	21991894	Green Accepted			2023-01-03	WOS:000295318400009
J	Walden, AP; Nielsen, N; Wise, MP				Walden, Andrew P.; Nielsen, Niklas; Wise, Matt P.			Does the evidence support the use of mild hypothermia after cardiac arrest? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							THERAPEUTIC HYPOTHERMIA; SURVIVORS		[Wise, Matt P.] Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales; [Walden, Andrew P.] Royal Berkshire Hosp, Reading RG1 5AN, Berks, England; [Nielsen, Niklas] Helsingborg Hosp, Dept Anaesthesiol & Intens Care, Helsingborg, Sweden	Cardiff University; Royal Berkshire Hospital; Helsingborgs Hospital	Wise, MP (corresponding author), Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales.	mattwise@doctors.org.uk		Wise, Matt/0000-0002-2763-4316				Arrich J, 2009, COCHRANE DB SYST REV, V4; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Carr BG, 2009, RESUSCITATION, V80, P30, DOI 10.1016/j.resuscitation.2008.09.001; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Holzer M, 2002, NEW ENGL J MED, V346, P549; Laurent I, 2005, J AM COLL CARDIOL, V46, P432, DOI 10.1016/j.jacc.2005.04.039; Mori K, 2000, CRIT CARE MED, V28, pA168; Nielsen N, 2011, INT J CARDIOL, V151, P333, DOI 10.1016/j.ijcard.2010.06.008; Nielsen N, 2011, CRIT CARE MED, V39, P57, DOI 10.1097/CCM.0b013e3181fa4301; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; *TTM TRIAL INV, TARG TEMP MAN OUT OF	14	6	6	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 23	2011	343								d5889	10.1136/bmj.d5889	http://dx.doi.org/10.1136/bmj.d5889			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	826AK	21948589				2023-01-03	WOS:000295323500003
J	Choi, KE; Hall, CL; Sun, JM; Wei, L; Mohamad, O; Dix, TA; Yu, SP				Choi, Ko-Eun; Hall, Casey L.; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Dix, Thomas A.; Yu, Shan P.			A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice	FASEB JOURNAL			English	Article						neurotensin analog; brain protection; autophagy; sensorimotor function	MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; NEUROTENSIN ANALOG; BODY-TEMPERATURE; ARTERY INFARCTION; BRAIN TEMPERATURE; HYPOXIC-ISCHEMIA; EMERGING ROLE; ACUTE-PHASE	Compelling evidence from preclinical and clinical studies has shown that mild to moderate hypothermia is neuroprotective against ischemic stroke. Clinical applications of hypothermia therapy, however, have been hindered by current methods of physical cooling, which is generally inefficient and impractical in clinical situations. In this report, we demonstrate the potential of pharmacologically induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal ischemic model of adult mice. ABS-201 (1.5-2.5 mg/kg, i.p.) reduces body and brain temperature by 2-5 degrees C in 15-30 min in a dose-dependent manner without causing shivering or altering physiological parameters. Infarct volumes at 24 h after stroke are reduced by similar to 30-40% when PIH therapy is initiated either immediately after stroke induction or after 30-60 min delay. ABS-201 treatment increases bcl-2 expression, decreases caspase-3 activation, and TUNEL-positive cells in the peri-infarct region, and suppresses autophagic cell death compared to stroke controls. The PIH therapy using ABS-201 improves recovery of sensorimotor function as tested 21 d after stroke. These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising candidates for treatment of ischemic stroke and possibly for other ischemic or traumatic injuries. Choi, K.-E., Hall, C. L., Sun, J.-M., Wei, L., Mohamad, O., Dix, T. A., Yu, S. P. A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J. 26, 2799-2810 (2012). www.fasebj.org	[Choi, Ko-Eun; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Yu, Shan P.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Hall, Casey L.; Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.; Yu, Shan P.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut, Charleston, SC USA	Emory University; Emory University; Medical University of South Carolina	Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Cir,Woodruff Mem Res Bldg,Ste 620, Atlanta, GA 30322 USA.	spyu@emory.edu			U.S. National Institutes of Health (NIH) [NS057255, NS058710, NS062097, R41NS073378, GM079044, MH65099]; Yerkes National Primate Center/NIH [P51]; NIH from National Center for Research Resources [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM079044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R41MH065099, R44MH065099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062097, R01NS057255, R01NS058710, R41NS073378] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Yerkes National Primate Center/NIH; NIH from National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by U.S. National Institutes of Health (NIH) grants NS057255, NS058710, NS062097, R41NS073378 (S.P.Y., L. W.), GM079044 (S.P.Y., T. A. D.), and MH65099 (T. A. D.) and by a Yerkes National Primate Center/NIH P51 pilot grant. This work was also supported by NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	BABCOCK AM, 1993, BRAIN RES BULL, V32, P373, DOI 10.1016/0361-9230(93)90202-M; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Dawaliby R, 2010, MOL BIOL CELL, V21, P4173, DOI 10.1091/mbc.E09-09-0782; Den Hertog H. M., 2009, COCHRANE DB SYST REV, V21; Dubuc I, 1999, J NEUROSCI, V19, P503, DOI 10.1523/JNEUROSCI.19-01-00503.1999; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Froehler MT, 2010, EXPERT REV CARDIOVAS, V8, P593, DOI [10.1586/erc.09.129, 10.1586/ERC.09.129]; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hammer MD, 2003, NEUROLOGIST, V9, P280, DOI 10.1097/01.nrl.0000094628.29312.2b; Hughes FM, 2010, J MED CHEM, V53, P4623, DOI 10.1021/jm100092s; Humeau A, 2007, MED BIOL ENG COMPUT, V45, P421, DOI 10.1007/s11517-007-0170-5; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Katz LM, 2001, ACAD EMERG MED, V8, P1115, DOI 10.1111/j.1553-2712.2001.tb01126.x; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lampe JW, 2011, ANNU REV MED, V62, P79, DOI 10.1146/annurev-med-052009-150512; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martinet W, 2006, AUTOPHAGY, V2, P55, DOI 10.4161/auto.2217; Miyazawa T, 2003, NEUROL RES, V25, P457, DOI 10.1179/016164103101201850; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650; Smith KE, 2011, BEHAV BRAIN RES, V224, P344, DOI 10.1016/j.bbr.2011.06.014; Sun J., 2011, SOC NEUR ANN M SESS; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427; Torok E, 2009, NEUROSURGERY, V65, P352, DOI 10.1227/01.NEU.0000345632.09882.FF; Torup L, 2003, NEUROSCI LETT, V351, P173, DOI 10.1016/j.neulet.2003.08.008; Tyler-McMahon BM, 2000, EUR J PHARMACOL, V390, P107, DOI 10.1016/S0014-2999(99)00877-8; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Yanagawa Y, 2002, RESUSCITATION, V53, P93, DOI 10.1016/S0300-9572(01)00499-3; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	69	65	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2799	2810		10.1096/fj.11-201822	http://dx.doi.org/10.1096/fj.11-201822			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	22459147	Green Published			2023-01-03	WOS:000305912500009
J	Kelly, KR; Espitia, CM; Mahalingam, D; Oyajobi, BO; Coffey, M; Giles, FJ; Carew, JS; Nawrocki, ST				Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Oyajobi, B. O.; Coffey, M.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.			Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma	ONCOGENE			English	Article						bortezomib; NOXA; ER stress; Reolysin; reovirus	PROTEASOME INHIBITOR BORTEZOMIB; PANCREATIC-CANCER CELLS; ONCOLYTIC VIRUS THERAPY; ER STRESS; MELANOMA-CELLS; VIRAL THERAPY; IFN-BETA; IN-VITRO; KAPPA-B; PHASE-I	Oncolytic virotherapy with reovirus has demonstrated anti-cancer activity and minimal toxicity in clinical trials, but the mechanisms underlying these effects have not been fully elucidated. Reolysin, a proprietary formulation of reovirus for cancer therapy, stimulated selective viral replication and apoptosis in multiple myeloma (MM) cells. Reolysin-mediated apoptosis was associated with an induction of endoplasmic reticular (ER) stress-related gene expression, swelling of the endoplasmic reticulum, increases in intracellular calcium levels and a strong induction of the Bcl-2 homology 3 (BH3)-only pro-apoptotic protein NOXA. Knockdown of NOXA expression by short hairpin RNA significantly reduced the pro-apoptotic effects of Reolysin. We next showed that co-administration of Reolysin and bortezomib resulted in the dual accumulation of viral and ubiquitinated proteins, which led to enhanced ER stress, NOXA induction and apoptosis. Importantly, the combination of reovirus infection and proteasomal inhibition significantly decreased tumor burden in a xenograft and syngeneic bone disease model of MM without exhibiting adverse side effects. Our study establishes ER stress stimulation and NOXA induction as novel mediators of reovirus-induced apoptosis. Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells. Oncogene (2012) 31, 3023-3038; doi: 10.1038/onc.2011.478; published online 17 October 2011	[Kelly, K. R.; Espitia, C. M.; Mahalingam, D.; Giles, F. J.; Carew, J. S.; Nawrocki, S. T.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, San Antonio, TX 78229 USA; [Oyajobi, B. O.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA; [Coffey, M.] Oncolyt Biotech Inc, Calgary, AB, Canada	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Oncolytics Biotech	Nawrocki, ST (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, Dept Med, 7979 Wurzbach Rd, San Antonio, TX 78229 USA.	Nawrocki@uthscsa.edu		Oyajobi, Babatunde/0000-0002-1064-3072	Leukemia and Lymphoma Society of America [6319-11]; International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant [CA054174]; NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society of America(Leukemia and Lymphoma Society); International Myeloma Foundation; William and Ella Owens Foundation; National Cancer Institute P30 Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by The Leukemia and Lymphoma Society of America (6319-11), The International Myeloma Foundation, The William and Ella Owens Foundation and the National Cancer Institute P30 Cancer Center Support Grant # CA054174.	Alain T, 2007, MOL THER, V15, P1512, DOI 10.1038/sj.mt.6300207; Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x; Carew JS, 2006, BLOOD, V107, P222, DOI 10.1182/blood-2005-05-1923; Clarke P, 2004, J VIROL, V78, P13132, DOI 10.1128/JVI.78.23.13132-13138.2004; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Dallas SL, 1999, BLOOD, V93, P1697, DOI 10.1182/blood.V93.5.1697.405a17_1697_1706; Etoh T, 2003, CLIN CANCER RES, V9, P1218; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Forsyth P, 2008, MOL THER, V16, P627, DOI 10.1038/sj.mt.6300403; Fribley AM, 2006, J BIOL CHEM, V281, P31440, DOI 10.1074/jbc.M604356200; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hamamdzic D, 2001, AM J PHYSIOL-LUNG C, V280, pL18, DOI 10.1152/ajplung.2001.280.1.L18; Harrington KJ, 2010, CYTOKINE GROWTH F R, V21, P91, DOI 10.1016/j.cytogfr.2010.02.006; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Holm GH, 2007, J BIOL CHEM, V282, P21953, DOI 10.1074/jbc.M702112200; Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kelly K, 2009, EXPERT OPIN BIOL TH, V9, P817, DOI 10.1517/14712590903002039; Kottke T, 2010, J CLIN INVEST, V120, P1551, DOI 10.1172/JCI41431; Kumar SK, 2004, MAYO CLIN PROC, V79, P867, DOI 10.4065/79.7.867; Kurozumi K, 2007, JNCI-J NATL CANCER I, V99, P1768, DOI 10.1093/jnci/djm229; Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200; Libertini S, 2008, CLIN CANCER RES, V14, P6505, DOI 10.1158/1078-0432.CCR-08-0200; Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179; Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nawrocki ST, 2002, MOL CANCER THER, V1, P1243; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370; Nawrocki ST, 2008, BLOOD, V112, P2917, DOI 10.1182/blood-2007-12-130823; Nencioni A, 2006, BLOOD, V108, P551, DOI 10.1182/blood-2005-08-3494; Neubert K, 2008, NAT MED, V14, P748, DOI 10.1038/nm1763; Oyajobi BO, 2007, MOL CANCER THER, V6, P1701, DOI 10.1158/1535-7163.MCT-07-0121; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Qiao J, 2008, CLIN CANCER RES, V14, P259, DOI 10.1158/1078-0432.CCR-07-1510; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rhim JH, 2007, J NATL CANCER I, V99, P1739, DOI 10.1093/jnci/djm234; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Rudd P, 2005, J GEN VIROL, V86, P1489, DOI 10.1099/vir.0.80628-0; Sei S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-47; Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676; SIDKY YA, 1987, CANCER RES, V47, P5155; Smakman N, 2006, CANCER GENE THER, V13, P815, DOI 10.1038/sj.cgt.7700949; Steele L, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-20; Strong JE, 1998, EMBO J, V17, P3351, DOI 10.1093/emboj/17.12.3351; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Sun K, 2004, P NATL ACAD SCI USA, V101, P8120, DOI 10.1073/pnas.0401563101; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Taylor KL, 2008, J INTERF CYTOK RES, V28, P733, DOI 10.1089/jir.2008.0030; Thirukkumaran Chandini, 2009, V542, P607, DOI 10.1007/978-1-59745-561-9_31; Thirukkumaran CM, 2003, BLOOD, V102, P377, DOI 10.1182/blood-2002-08-2508; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; van Houdt WJ, 2008, CANCER GENE THER, V15, P284, DOI 10.1038/cgt.2008.2; Vidal L, 2008, CLIN CANCER RES, V14, P7127, DOI 10.1158/1078-0432.CCR-08-0524; Wang Q, 2009, P NATL ACAD SCI USA, V106, P2200, DOI 10.1073/pnas.0807611106; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	59	54	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	25					3023	3038		10.1038/onc.2011.478	http://dx.doi.org/10.1038/onc.2011.478			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964OP	22002308				2023-01-03	WOS:000305705900002
J	Berenson, RA; Paulus, RA; Kalman, NS				Berenson, Robert A.; Paulus, Ronald A.; Kalman, Noah S.			Medicare's Readmissions-Reduction Program - A Positive Alternative	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							REHOSPITALIZATIONS		[Berenson, Robert A.] Urban Inst, Washington, DC 20037 USA; [Paulus, Ronald A.] Mission Hlth Syst, Asheville, NC USA; [Kalman, Noah S.] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA	Urban Institute; Duke University	Berenson, RA (corresponding author), Urban Inst, Washington, DC 20037 USA.							Chollet D., 2011, REDUCING HOSP READMI; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Jencks SF, 2011, NEW ENGL J MED, V364, P1582; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Medicare Payment Advisory Commission, 2011, PUBL M DEC 15	6	173	174	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 12	2012	366	15					1364	1366		10.1056/NEJMp1201268	http://dx.doi.org/10.1056/NEJMp1201268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GV	22455754				2023-01-03	WOS:000302608600012
J	Forster, S; Thumser, AE; Hood, SR; Plant, N				Forster, Samantha; Thumser, Alfred E.; Hood, Steve R.; Plant, Nick			Characterization of Rhodamine-123 as a Tracer Dye for Use In In vitro Drug Transport Assays	PLOS ONE			English	Article							LASER-SCANNING MICROSCOPY; P-GLYCOPROTEIN; CACO-2 CELLS; MULTIDRUG-RESISTANCE; ABC TRANSPORTERS; RAT HEPATOCYTES; PROTEIN-BINDING; TUMOR-CELLS; EFFLUX; METABOLISM	Fluorescent tracer dyes represent an important class of sub-cellular probes and allow the examination of cellular processes in real-time with minimal impact upon these processes. Such tracer dyes are becoming increasingly used for the examination of membrane transport processes, as they are easy-to-use, cost effective probe substrates for a number of membrane protein transporters. Rhodamine 123, a member of the rhodamine family of flurone dyes, has been used to examine membrane transport by the ABCB1 gene product, MDR1. MDR1 is viewed as the archetypal drug transport protein, and is able to efflux a large number of clinically relevant drugs. In addition, ectopic activity of MDR1 has been associated with the development of multiple drug resistance phenotype, which results in a poor patient response to therapeutic intervention. It is thus important to be able to examine the potential for novel compounds to be MDR1 substrates. Given the increasing use rhodamine 123 as a tracer dye for MDR1, a full characterisation of its spectral properties in a range of in vitro assay-relevant media is warranted. Herein, we determine lambda max for excitation and emission or rhodamine 123 and its metabolite rhodamine 110 in commonly used solvents and extraction buffers, demonstrating that fluorescence is highly dependent on the chemical environment: Optimal parameters are 1% (v/v) methanol in HBSS, with lambda ex=505 nm, lambda em=525 nm. We characterise the uptake of rhodamine 123 into cells, via both passive and active processes, and demonstrate that this occurs primarily through OATP1A2-mediated facilitated transport at concentrations below 2 mu M, and via micelle-mediated passive diffusion above this. Finally, we quantify the intracellular sequestration and metabolism of rhodamine 123, demonstrating that these are both cell line-dependent factors that may influence the interpretation of transport assays.	[Forster, Samantha; Thumser, Alfred E.; Plant, Nick] Univ Surrey, Ctr Toxicol, Fac Hlth & Med Sci, Guildford GU2 5XH, Surrey, England; [Hood, Steve R.] GlaxoSmithKline, PCD DMPK, Ware, Herts, England	University of Surrey; GlaxoSmithKline	Forster, S (corresponding author), Univ Surrey, Ctr Toxicol, Fac Hlth & Med Sci, Guildford GU2 5XH, Surrey, England.	N.Plant@Surrey.ac.uk	Plant, Nick/E-4510-2011	Plant, Nick/0000-0003-4332-8308; Thumser, Alfred/0000-0003-0256-8006	UK Biotechnology; Biological Sciences Research Council (BBSRC); GlaxoSmithKline	UK Biotechnology; Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); GlaxoSmithKline(GlaxoSmithKline)	Dr. Plant and Dr. Forster received joint funding from the UK Biotechnology and Biological Sciences Research Council (BBSRC) and GlaxoSmithKline to undertake this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Ando H, 2001, ANTIMICROB AGENTS CH, V45, P3462, DOI 10.1128/AAC.45.12.3462-3467.2001; Annaert PP, 2005, DRUG METAB DISPOS, V33, P388, DOI 10.1124/dmd.104.001669; Aouabdi S, 2006, DRUG METAB DISPOS, V34, P138, DOI 10.1124/dmd.105.006064; Baker M, 2007, XENOBIOTICA, V37, P1110, DOI 10.1080/00498250701658296; Baldes C, 2006, EUR J PHARM BIOPHARM, V62, P39, DOI 10.1016/j.ejpb.2005.06.001; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; Chuang VTG, 2009, DRUG METAB PHARMACOK, V24, P358, DOI 10.2133/dmpk.24.358; Cohen AA, 2008, SCIENCE, V322, P1511, DOI 10.1126/science.1160165; Coley HM, 2008, CANCER TREAT REV, V34, P378, DOI 10.1016/j.ctrv.2008.01.007; Cosa G, 2001, PHOTOCHEM PHOTOBIOL, V73, P585, DOI 10.1562/0031-8655(2001)073<0585:PPOFDD>2.0.CO;2; Di L, 2011, J PHARM SCI-US, V100, P4974, DOI 10.1002/jps.22674; Dobson PD, 2009, CURR TOP MED CHEM, V9, P163, DOI 10.2174/156802609787521616; Donnenberg VS, 2009, METHODS MOL BIOL, V568, P261, DOI 10.1007/978-1-59745-280-9_17; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hilgendorf C, 2007, DRUG METAB DISPOS, V35, P1333, DOI 10.1124/dmd.107.014902; Hollenstein K, 2007, CURR OPIN STRUC BIOL, V17, P412, DOI 10.1016/j.sbi.2007.07.003; Howe K, 2009, DRUG METAB DISPOS, V37, P391, DOI 10.1124/dmd.108.022921; Huang M, 2007, ANN BIOMED ENG, V35, P1276, DOI 10.1007/s10439-007-9265-2; Jager W, 1997, HEPATOLOGY, V26, P1467; JANCIS EM, 1993, MOL PHARMACOL, V43, P51; Kis O, 2010, TRENDS PHARMACOL SCI, V31, P22, DOI 10.1016/j.tips.2009.10.001; Klaassen CD, 2010, PHARMACOL REV, V62, P1, DOI 10.1124/pr.109.002014; Kolodkin AN, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.102; Lebedeva IV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022429; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Liu XR, 1999, AM J PHYSIOL-GASTR L, V277, pG12, DOI 10.1152/ajpgi.1999.277.1.G12; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nies AT, 2011, HANDB EXP PHARMACOL, V201, P105, DOI 10.1007/978-3-642-14541-4_3; Parasrampuria R, 2010, J PHARM SCI-US, V99, P455, DOI 10.1002/jps.21831; Pawley J.B., 2006, HDB BIOL CONFOCAL MI, DOI [10.1007/978-0-387-45524-2_23, 10.1007/978-0-387-45524-2, DOI 10.1007/978-0-387-45524-2]; Perriere N, 2007, BRAIN RES, V1150, P1, DOI 10.1016/j.brainres.2007.02.091; Plant N, 2004, DRUG DISCOV TODAY, V9, P328, DOI 10.1016/S1359-6446(03)03019-8; Prochazkova J, 2011, FREE RADICAL RES, V45, P779, DOI 10.3109/10715762.2011.579120; Qi J, 2004, BIOCHEM BIOPH RES CO, V319, P1124, DOI 10.1016/j.bbrc.2004.05.099; Sakai M, 1997, J PHARM SCI, V86, P779, DOI 10.1021/js960529n; Stormer E, 2001, DRUG METAB DISPOS, V29, P954; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; SWEATMAN TW, 1990, CANCER CHEMOTH PHARM, V27, P205, DOI 10.1007/BF00685714; Troutman MD, 2003, PHARMACEUT RES, V20, P1192, DOI 10.1023/A:1025096930604; Wakuda H, 2011, J PHARM PHARMACOL, V63, P1015, DOI 10.1111/j.2042-7158.2011.01294.x; Wessels JT, 2010, CYTOM PART A, V77A, P667, DOI 10.1002/cyto.a.20931; Yu JY, 2010, PHARM RES-DORDR, V27, P457, DOI 10.1007/s11095-009-0034-9; Zhu SJ, 2009, EUR J PHARM SCI, V37, P573, DOI 10.1016/j.ejps.2009.05.001	48	111	111	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2012	7	3							e33253	10.1371/journal.pone.0033253	http://dx.doi.org/10.1371/journal.pone.0033253			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	948FM	22470447	Green Published, Green Submitted, gold			2023-01-03	WOS:000304489000019
J	Witt, CM; Manheimer, E; Hammerschlag, R; Ludtke, R; Lao, LX; Tunis, SR; Berman, BM				Witt, Claudia M.; Manheimer, Eric; Hammerschlag, Richard; Luedtke, Rainer; Lao, Lixing; Tunis, Sean R.; Berman, Brian M.			How Well Do Randomized Trials Inform Decision Making: Systematic Review Using Comparative Effectiveness Research Measures on Acupuncture for Back Pain	PLOS ONE			English	Review							COMPLEMENTARY THERAPIES; CLINICAL-TRIALS; USUAL CARE; CHALLENGES; MEDICINE	Background: For Comparative Effectiveness Research (CER) there is a need to develop scales for appraisal of available clinical research. Aims were to 1) test the feasibility of applying the pragmatic-explanatory continuum indicator summary tool and the six CER defining characteristics of the Institute of Medicine to RCTs of acupuncture for treatment of low back pain, and 2) evaluate the extent to which the evidence from these RCTs is relevant to clinical and health policy decision making. Methods: We searched Medline, the AcuTrials (TM) Database to February 2011 and reference lists and included full-report randomized trials in English that compared needle acupuncture with a conventional treatment in adults with non-specific acute and/or chronic low back pain and restricted to those with >= 30 patients in the acupuncture group. Papers were evaluated by 5 raters. Principal Findings: From 119 abstracts, 44 full-text publications were screened and 10 trials (4,901 patients) were evaluated. Due to missing information and initial difficulties in operationalizing the scoring items, the first scoring revealed inter-rater and inter-item variance (intraclass correlations 0.02-0.60), which improved after consensus discussions to 0.20-1.00. The 10 trials were found to cover the efficacy-effectiveness continuum; those with more flexible acupuncture and no placebo control scored closer to effectiveness. Conclusion: Both instruments proved useful, but need further development. In addition, CONSORT guidelines for reporting pragmatic trials should be expanded. Most studies in this review already reflect the movement towards CER and similar approaches can be taken to evaluate comparative effectiveness relevance of RCTs for other treatments.	[Witt, Claudia M.; Manheimer, Eric; Lao, Lixing; Berman, Brian M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA; [Witt, Claudia M.] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Hammerschlag, Richard] Oregon Coll Oriental Med, Res Dept, Portland, OR USA; [Luedtke, Rainer] Carstens Fdn, Essen, Germany; [Tunis, Sean R.] Ctr Med Technol Policy, Baltimore, MD USA	University System of Maryland; University of Maryland Baltimore; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Witt, CM (corresponding author), Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA.	claudia.witt@charite.de	Lao, Lixing/P-9107-2019; Witt, Claudia M./AAX-2370-2021; Lao, Lixing/I-7979-2013	Lao, Lixing/0000-0003-0198-9714; Witt, Claudia M./0000-0002-5440-7805; 	Institute for Integrative Health a non-profit organization, Baltimore, United States of America; National Center for Complementary & Integrative Health [R24AT001293] Funding Source: NIH RePORTER	Institute for Integrative Health a non-profit organization, Baltimore, United States of America; National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	CMW received a travel grant by the Institute for Integrative Health a non-profit organization, Baltimore, United States of America. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Barnes Patricia M, 2004, Adv Data, P1; Berman BM, 2010, NEW ENGL J MED, V363, P454, DOI 10.1056/NEJMct0806114; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Committee on Comparative Effectiveness Research Priorization, 2009, IN NAT PRIOR COMP EF, P37; Conway PH, 2009, NEW ENGL J MED, V361, P328, DOI 10.1056/NEJMp0905631; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Eisenberg DM, 2007, SPINE, V32, P151, DOI 10.1097/01.brs.0000252697.07214.65; Eisenberg DM, 2001, ANN INTERN MED, V135, P344, DOI 10.7326/0003-4819-135-5-200109040-00011; Fineberg H, 2009, INITIAL NATL PRIORIT; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Koppenaal T, 2011, J CLIN EPIDEMIOL; Last J, 2001, DICT EPIDEMIOLOGY; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Luo X, 1976, SPINE, V29, P79; MacPherson H, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000261; Mason S, 2002, BRIT MED J, V325, P832, DOI 10.1136/bmj.325.7368.832; Meng CF, 2003, RHEUMATOLOGY, V42, P1508, DOI 10.1093/rheumatology/keg405; Molsberger A, 2002, DTSCH ARZTEBLATT, V99, P1539; Oregon College of Oriental Medicine, 2011, ACUTRIALS DAT; Rubinstein SM, 2010, EUR SPINE J, V19, P1213, DOI 10.1007/s00586-010-1356-3; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strom BL, 2007, MED CARE, V45, pS13, DOI 10.1097/MLR.0b013e318041f752; Szczurko O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000919; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Thorpe KE, 2009, CAN MED ASSOC J, V180, pE47, DOI 10.1503/cmaj.090523; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Witt CM, 2011, CLIN J PAIN, V27, P550, DOI 10.1097/AJP.0b013e31820dfbf5; Witt CM, 2011, INTEGRATING E ASIAN; Yuan J, 2008, SPINE, V33, pE887, DOI 10.1097/BRS.0b013e318186b276; Zwarenstein M, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2390	37	37	42	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2012	7	2							e32399	10.1371/journal.pone.0032399	http://dx.doi.org/10.1371/journal.pone.0032399			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928RC	22389699	Green Published, Green Submitted, gold			2023-01-03	WOS:000302999600037
J	Fromme, EK; Zive, D; Schmidt, TA; Olszewski, E; Tolle, SW				Fromme, Erik K.; Zive, Dana; Schmidt, Terri A.; Olszewski, Elizabeth; Tolle, Susan W.			POLST Registry Do-Not-Resuscitate Orders and Other Patient Treatment Preferences	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Fromme, Erik K.; Tolle, Susan W.] Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, Portland, OR 97239 USA; [Zive, Dana; Schmidt, Terri A.; Olszewski, Elizabeth] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Fromme, EK (corresponding author), Oregon Hlth & Sci Univ, Ctr Eth Hlth Care, UHN 86,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	frommee@ohsu.edu			NATIONAL CANCER INSTITUTE [K07CA109511] Funding Source: NIH RePORTER; NCI NIH HHS [K07CA109511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1983, DEC FORG LIF SUST TR, P251; Beach MC, 2002, J AM GERIATR SOC, V50, P2057, DOI 10.1046/j.1532-5415.2002.50620.x; Happ MB, 2002, J AM GERIATR SOC, V50, P829, DOI 10.1046/j.1532-5415.2002.50207.x; Hickman SE, 2010, J AM GERIATR SOC, V58, P1241, DOI 10.1111/j.1532-5415.2010.02955.x; McLaughlin M, EXACT CONFIDENCE INT; OHSU Center for Ethics in Health Care, POLST PAR PROGR	6	58	58	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	2012	307	1					34	35		10.1001/jama.2011.1956	http://dx.doi.org/10.1001/jama.2011.1956			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872ET	22215159				2023-01-03	WOS:000298792300015
J	Fuyuno, I				Fuyuno, Ichiko			JAPAN Will the sun set on Kampo?	NATURE			English	Editorial Material																			0	24	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S96	S96		10.1038/480S96a	http://dx.doi.org/10.1038/480S96a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	865NQ	22190092	Bronze			2023-01-03	WOS:000298318000008
J	Lim, TP; Lee, W; Tan, TY; Sasikala, S; Teo, J; Hsu, LY; Tan, TT; Syahidah, N; Kwa, AL				Lim, Tze-Peng; Lee, Winnie; Tan, Thean-Yen; Sasikala, Suranthran; Teo, Jocelyn; Hsu, Li-Yang; Tan, Thuan-Tong; Syahidah, Nur; Kwa, Andrea L.			Effective Antibiotics in Combination against Extreme Drug-Resistant Pseudomonas aeruginosa with Decreased Susceptibility to Polymyxin B	PLOS ONE			English	Article							GRAM-NEGATIVE BACTERIA; EXTENDED-SPECTRUM VARIANT; METALLO-BETA-LACTAMASES; INFECTIONS; MECHANISMS; PNEUMONIA; PHARMACOKINETICS; HOSPITALS; SINGAPORE; COLISTIN	Objective: Extreme drug-resistant Pseudomonas aeruginosa (XDR-PA) with decreased susceptibility to polymyxin B (PB) has emerged in Singapore, causing infections in immunocompromised hosts. Combination therapy may be the only viable therapeutic option until new antibiotics become available. The objective of this study is to assess the in vitro activity of various antibiotics against local XDR-PA isolates. Methods: PA isolates from all public hospitals in Singapore were systematically collected between 2006 and 2007. MICs were determined according to CLSI guidelines. All XDR-PA isolates identified were genotyped using a PCR-based method. Time-kill studies (TKS) were performed with approximately 10(5) CFU/ml at baseline using clinically achievable unbound concentrations of amikacin (A), levofloxacin (L), meropenem (M), rifampicin (R) and PB alone and in combination. Bactericidal activity (primary endpoint) was defined as a >= 3 log(10) CFU/ml decrease in the colony count from the initial inoculum at 24 hours. Results: 22 clinical XDR-PA isolates with PB MIC 2-16 mu g/ml were collected. From clonal typing, 5 clonal groups were identified and nine isolates exhibited clonal diversity. In TKS, meropenem plus PB, amikacin plus meropenem, amikacin plus rifampicin, amikacin plus PB exhibited bactericidal activity in 8/22, 3/22, 1/22 and 6/22 isolates at 24 hours respectively. Against the remaining ten isolates where none of the dual-drug combination achieved bactericidal activity against, only the triple-antibiotic combinations of ARP and AMP achieved bactericidal activity against 7/10 and 6/10 isolates respectively. Conclusion: Bactericidal activity with sustained killing effect of >= 99.9% is critical for eradicating XDR-PA infections, especially in immunocompromised hosts. These findings underscore the difficulty of developing combination therapeutic options against XDR-PA, demonstrating that at least 3 antibiotics are required in combination and that efficacy is strain dependant.	[Lim, Tze-Peng; Lee, Winnie; Sasikala, Suranthran; Teo, Jocelyn; Syahidah, Nur; Kwa, Andrea L.] Singapore Gen Hosp, Dept Pharm, Singapore 0316, Singapore; [Tan, Thean-Yen] Changi Gen Hosp, Dept Lab Med, Singapore, Singapore; [Tan, Thuan-Tong] Singapore Gen Hosp, Dept Infect Dis, Singapore 0316, Singapore; [Lim, Tze-Peng; Hsu, Li-Yang] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Div Infect Dis, Singapore 117595, Singapore	Singapore General Hospital; Changi General Hospital; Singapore General Hospital; National University of Singapore	Lim, TP (corresponding author), Singapore Gen Hosp, Dept Pharm, Singapore 0316, Singapore.	andrea.kwa.l.h@sgh.com.sg		Hsu, Li Yang/0000-0002-0396-066X; Tan, Thean Yen/0000-0003-4358-1098; Teo, Jocelyn Qi-Min/0000-0003-2508-3941	SingHealth Foundation (Singapore); Janssen-Cilag; Pfizer.Inc; Merck Sharp & Dohme (I.A.) Corp	SingHealth Foundation (Singapore); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Pfizer.Inc(Pfizer); Merck Sharp & Dohme (I.A.) Corp(Merck & Company)	This study was supported in part by research grants from the SingHealth Foundation (Singapore). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.; T-YT and L-YH have received funding for research from, and have been an invited as speakers for Wyeth Pharmaceuticals and Pfizer. ALK, WL and T-PL have received funding for research from Janssen-Cilag, Pfizer.Inc & Merck Sharp & Dohme (I.A.) Corp. None of these companies provided any funding for this particular study. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Bergen PJ, 2011, ANTIMICROB AGENTS CH, V55, P5134, DOI 10.1128/AAC.05028-11; Bonomo RA, 2006, CLIN INFECT DIS, V43, pS49, DOI 10.1086/504477; Clinical and Laboratory Standards Institute, 2009, METH DIL ANT SUSC TE, V29; DANEL F, 1995, ANTIMICROB AGENTS CH, V39, P1881, DOI 10.1128/AAC.39.8.1881; Dawson SL, 2002, J MICROBIOL METH, V50, P9, DOI 10.1016/S0167-7012(02)00003-9; Ellington MJ, 2007, J ANTIMICROB CHEMOTH, V59, P321, DOI 10.1093/jac/dkl481; Furtado GHC, 2007, INT J ANTIMICROB AG, V30, P315, DOI 10.1016/j.ijantimicag.2007.05.017; Giamarellou H, 2010, INT J ANTIMICROB AG, V36, pS50, DOI 10.1016/j.ijantimicag.2010.11.014; Gumbo T, 2007, ANTIMICROB AGENTS CH, V51, P3781, DOI 10.1128/AAC.01533-06; Hsu LY, 2010, ANTIMICROB AGENTS CH, V54, P1173, DOI 10.1128/AAC.01076-09; Jaruratanasirikul S, 2005, ANTIMICROB AGENTS CH, V49, P1337, DOI 10.1128/AAC.49.4.1337-1339.2005; Juan C, 2005, ANTIMICROB AGENTS CH, V49, P4733, DOI 10.1128/AAC.49.11.4733-4738.2005; Koh TH, 2004, J CLIN MICROBIOL, V42, P5378, DOI 10.1128/JCM.42.11.5378-5380.2004; KUNIN CM, 1973, ANN NY ACAD SCI, V226, P214, DOI 10.1111/j.1749-6632.1973.tb20483.x; Kwa A, 2007, EXPERT REV ANTI-INFE, V5, P811, DOI 10.1586/14787210.5.5.811; Kwa AL, 2008, ANN ACAD MED SINGAP, V37, P870; Kwa ALH, 2008, DIAGN MICR INFEC DIS, V60, P163, DOI 10.1016/j.diagmicrobio.2007.08.008; LETENDRE ED, 1988, J ANTIMICROB CHEMOTH, V22, P557, DOI 10.1093/jac/22.4.557; Lister PD, 2009, CLIN MICROBIOL REV, V22, P582, DOI 10.1128/CMR.00040-09; Livermore DM, 2007, INT J ANTIMICROB AG, V29, pS1, DOI 10.1016/S0924-8579(07)00158-6; Magiorakos AP, 2011, CLIN MICROBIOL INFEC; Mesaros N, 2007, CLIN MICROBIOL INFEC, V13, P560, DOI 10.1111/j.1469-0691.2007.01681.x; Mikulska M, 2009, BIOL BLOOD MARROW TR, V15, P47, DOI 10.1016/j.bbmt.2008.10.024; Navon-Venezia S, 2005, CURR OPIN INFECT DIS, V18, P306, DOI 10.1097/01.qco.0000171920.44809.f0; Ostronoff M, 2006, INT J INFECT DIS, V10, P339, DOI 10.1016/j.ijid.2005.06.003; Ouderkirk JP, 2003, ANTIMICROB AGENTS CH, V47, P2659, DOI 10.1128/AAC.47.8.2659-2662.2003; Pereira GH, 2007, DIAGN MICR INFEC DIS, V58, P235, DOI 10.1016/j.diagmicrobio.2007.01.008; Pitout JDD, 2005, J CLIN MICROBIOL, V43, P3129, DOI 10.1128/JCM.43.7.3129-3135.2005; Poirel L, 2001, ANTIMICROB AGENTS CH, V45, P447, DOI 10.1128/AAC.45.2.447-453.2001; Sobieszczyk ME, 2004, J ANTIMICROB CHEMOTH, V54, P566, DOI 10.1093/jac/dkh369; Tan TY, 2008, ANN ACAD MED SINGAP, V37, P819; Tan TT, 2010, 20 EUR C CLIN MICR I; Tod M, 1998, ANTIMICROB AGENTS CH, V42, P849, DOI 10.1128/AAC.42.4.849; Wayne P, 2011, 9 INFORM SUPPLEMENT; Zavascki AP, 2008, CLIN INFECT DIS, V47, P1298, DOI 10.1086/592577	35	44	50	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2011	6	12							e28177	10.1371/journal.pone.0028177	http://dx.doi.org/10.1371/journal.pone.0028177			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863NX	22162759	Green Published, Green Submitted, gold			2023-01-03	WOS:000298172800018
J	Heyland, DK				Heyland, Daren K.			Late initiation of parenteral nutrition reduced length of intensive care unit stay	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Queens Univ, Kingston, ON, Canada	Queens University - Canada	Heyland, DK (corresponding author), Queens Univ, Kingston, ON, Canada.		Van den Berghe, Greet/J-6788-2018; Casaer, Michael/Y-7131-2019	Van den Berghe, Greet/0000-0002-5320-1362; Casaer, Michael/0000-0002-7087-0795				Clinical Evaluation Research Unit; Kingston General Hospital, 2000, TRIAL SUPPL PAR NUTR; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; University Hospital Geneva, 2000, IMP SPN INF RAT DUR	3	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2011	155	10							JC5-11	10.7326/0003-4819-155-10-201111150-02011	http://dx.doi.org/10.7326/0003-4819-155-10-201111150-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V31LO	22084358				2023-01-03	WOS:000208885300010
J	Tilbrook, HE; Cox, H; Hewitt, CE; Kang'ombe, AR; Chuang, LH; Jayakody, S; Aplin, JD; Semlyen, A; Trewhela, A; Watt, I; Torgerson, DJ				Tilbrook, Helen E.; Cox, Helen; Hewitt, Catherine E.; Kang'ombe, Arthur Ricky; Chuang, Ling-Hsiang; Jayakody, Shalmini; Aplin, John D.; Semlyen, Anna; Trewhela, Alison; Watt, Ian; Torgerson, David J.			Yoga for Chronic Low Back Pain	ANNALS OF INTERNAL MEDICINE			English	Article							HATHA YOGA; EXERCISE; THERAPY; DISABILITY; TRIAL	Background: Previous studies indicate that yoga may be an effective treatment for chronic or recurrent low back pain. Objective: To compare the effectiveness of yoga and usual care for chronic or recurrent low back pain. Design: Parallel-group, randomized, controlled trial using computer-generated randomization conducted from April 2007 to March 2010. Outcomes were assessed by postal questionnaire. (International Standard Randomised Controlled Trial Number Register: ISRCTN 81079604) Setting: 13 non-National Health Service premises in the United Kingdom. Patients: 313 adults with chronic or recurrent low back pain. Intervention: Yoga (n = 156) or usual care (n = 157). All participants received a back pain education booklet. The intervention group was offered a 12-class, gradually progressing yoga program delivered by 12 teachers over 3 months. Measurements: Scores on the Roland-Morris Disability Questionnaire (RMDQ) at 3 (primary outcome), 6, and 12 (secondary outcomes) months; pain, pain self-efficacy, and general health measures at 3, 6, and 12 months (secondary outcomes). Results: 93 (60%) patients offered yoga attended at least 3 of the first 6 sessions and at least 3 other sessions. The yoga group had better back function at 3, 6, and 12 months than the usual care group. The adjusted mean RMDQ score was 2.17 points (95% Cl, 1.03 to 3.31 points) lower in the yoga group at 3 months, 1.48 points (Cl, 0.33 to 2.62 points) lower at 6 months, and 1.57 points (Cl, 0.42 to 2.71 points) lower at 12 months. The yoga and usual care groups had similar back pain and general health scores at 3, 6, and 12 months, and the yoga group had higher pain self-efficacy scores at 3 and 6 months but not at 12 months. Two of the 157 usual care participants and 12 of the 156 yoga participants reported adverse events, mostly increased pain. Limitation: There were missing data for the primary outcome (yoga group, n = 21; usual care group, n = 18) and differential missing data (more in the yoga group) for secondary outcomes. Conclusion: Offering a 12-week yoga program to adults with chronic or recurrent low back pain led to greater improvements in back function than did usual care. Primary Funding Source: Arthritis Research UK.	[Tilbrook, Helen E.] Univ York, Dept Hlth Sci, York Trials Unit, York YO10 5DD, N Yorkshire, England; Univ Manchester, St Marys Hosp, Manchester M13 9WL, Lancs, England; Yoga York, York YO10 4BH, N Yorkshire, England; Walsingham Clin, SBRCP Yoga, Truro TR1 2RP, Cornwall, England	University of York - UK; University of Manchester	Tilbrook, HE (corresponding author), Univ York, Dept Hlth Sci, York Trials Unit, Lower Ground Floor,ARRC Bldg, York YO10 5DD, N Yorkshire, England.	helen.tilbrook@york.ac.uk	Torgerson, David/L-4566-2019; Aplin, John/AET-4363-2022	Torgerson, David/0000-0002-1667-4275; Hewitt, Catherine Elizabeth/0000-0002-0415-3536; Aplin, John/0000-0001-8777-9261	Arthritis Research UK	Arthritis Research UK(Versus Arthritis)	Primary Funding Source: Arthritis Research UK.	Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Burton K, 2002, BACK BOOK; Cox Helen, 2010, Complement Ther Clin Pract, V16, P76, DOI 10.1016/j.ctcp.2009.09.010; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Galantino ML, 2004, ALTERN THER HEALTH M, V10, P56; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Jacobs BP, 2004, ALTERN THER HEALTH M, V10, P80; Jenkinson C, 1997, J Health Serv Res Policy, V2, P14; Johnson RE, 2007, SPINE, V32, P1578, DOI 10.1097/BRS.0b013e318074f890; Lamb SE, 2010, LANCET, V375, P916, DOI 10.1016/S0140-6736(09)62164-4; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; Man MS, 2011, J CLIN EPIDEMIOL, V64, P1001, DOI 10.1016/j.jclinepi.2010.10.013; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; Nicholas MK, 1989, P ANN C BRIT PSYCH S; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; RUTA DA, 1994, SPINE, V19, P1887, DOI 10.1097/00007632-199409000-00004; Saper RB, 2009, ALTERN THER HEALTH M, V15, P18; Savigny P., 2009, LOND NATL COLLAB CEN; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Tekur P, 2008, J ALTERN COMPLEM MED, V14, P637, DOI 10.1089/acm.2007.0815; Torgerson D J, 1996, J Health Serv Res Policy, V1, P194; Torgerson DJ, 1998, BRIT MED J, V316, P360, DOI 10.1136/bmj.316.7128.360; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Verbeke G, 2000, LINEAR MIXED MODELS, P55; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Williams KA, 2005, PAIN, V115, P107, DOI 10.1016/j.pain.2005.02.016; Williams K, 2009, SPINE, V34, P2066, DOI 10.1097/BRS.0b013e3181b315cc	27	126	134	9	50	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2011	155	9					569	U32		10.7326/0003-4819-155-9-201111010-00003	http://dx.doi.org/10.7326/0003-4819-155-9-201111010-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842PW	22041945				2023-01-03	WOS:000296612400001
J	Hegde, P; Maddur, MS; Friboulet, A; Bayry, J; Kaveri, SV				Hegde, Pushpa; Maddur, Mohan S.; Friboulet, Alain; Bayry, Jagadeesh; Kaveri, Srini V.			Viscum album Exerts Anti-Inflammatory Effect by Selectively Inhibiting Cytokine-Induced Expression of Cyclooxygenase-2	PLOS ONE			English	Article							NF-KAPPA-B; CHRONIC HEPATITIS-C; QUALITY-OF-LIFE; EUROPEAN MISTLETOE; COX-2 EXPRESSION; CANCER-PATIENTS; NITRIC-OXIDE; IN-VIVO; THERAPEUTIC-IMPLICATIONS; ANTICANCER ACTIVITIES	Viscum album (VA) preparations are extensively used as complementary therapy in cancer and are shown to exert antitumor activities which involve the cytotoxic properties, induction of apoptosis, inhibition of angiogenesis and several other immunomodulatory mechanisms. In addition to their application in cancer therapy, VA preparations have also been successfully utilized in the treatment of several inflammatory pathologies. Owing to the intricate association of inflammation and cancer and in view of the fact that several anti-tumor phytotherapeutics also exert a potent anti-inflammatory effect, we hypothesized that VA exerts an anti-inflammatory effect that is responsible for its therapeutic benefit. Since, inflammatory cytokine-induced cyclo-oxygenase-2 (COX-2) and prostaglandin E2 (PGE2) play a critical role in the pathogenesis of inflammatory diseases, we investigated the anti-inflammatory effect of VA on regulation of cyclooxygenase expression and PGE2 biosynthesis by using human lung adenocarcinoma cells (A549 cells) as a model. A549 cells were stimulated with IL-1 beta and treated with VA preparation (VA Qu Spez) for 18 hours. PGE2 was analysed in the culture supernatants by enzyme immunoassay. Expression of COX-2 and COX-1 proteins was analyzed by immunoblotting and the expression of COX-2 mRNA was assessed by semi-quantitative RT-PCR. We found that VA Qu Spez inhibit the secretion of IL-1 beta-induced PGE2 in a dose-dependent manner. Further, we also show that this inhibitory action was associated with a reduced expression of COX-2 without modulating the COX-1 expression. Together these results demonstrate a novel anti-inflammatory mechanism of action of VA preparations wherein VA exerts an anti-inflammatory effect by inhibiting cytokine-induced PGE2 via selective inhibition of COX-2.	[Hegde, Pushpa; Maddur, Mohan S.; Bayry, Jagadeesh; Kaveri, Srini V.] Inst Natl Sante & Rech Med, Unite 872, Paris, France; [Friboulet, Alain] Univ Technol Compiegne, UMR CNRS 6022, F-60206 Compiegne, France; [Maddur, Mohan S.; Bayry, Jagadeesh; Kaveri, Srini V.] Univ Paris 06, Equipe Immunopathol & Therapeut Immunointervent 1, Ctr Rech Cordeliers, UMR S 872, Paris, France; [Maddur, Mohan S.; Bayry, Jagadeesh; Kaveri, Srini V.] Univ Paris 05, UMR S 872, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Technologie de Compiegne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Hegde, P (corresponding author), Inst Natl Sante & Rech Med, Unite 872, Paris, France.	srini.kaveri@crc.jussieu.fr	Maddur, Mohan/E-4763-2015; Bayry, Jagadeesh/A-6589-2011	Bayry, Jagadeesh/0000-0003-0498-9808; Kaveri, Srini/0000-0002-0837-4053; Maddur, Mohan/0000-0002-7085-1762; Hegde, Pushpa/0000-0002-2376-8659	Institut National de la Sante et de la Recherche Medicale (INSERM); Centre National de la Recherche Scientifique (CNRS); Universite Pierre et Marie Curie; Universite Paris Descartes; Weleda AG, Switzerland	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Universite Pierre et Marie Curie; Universite Paris Descartes; Weleda AG, Switzerland	This work is Supported by Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite Pierre et Marie Curie and Universite Paris Descartes, regional program Bio-Asie 2011 and Weleda AG, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achoui M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015105; Aimanianda V, 2009, TRENDS PHARMACOL SCI, V30, P287, DOI 10.1016/j.tips.2009.03.005; Andre S, 2009, AM J PATHOL, V174, P1575, DOI 10.2353/ajpath.2009.080987; Augustin M, 2005, ARZNEIMITTELFORSCH, V55, P38; Bayry J, 2007, DRUG DISCOV TODAY, V12, P548, DOI 10.1016/j.drudis.2007.05.002; Bayry J, 2011, NAT REV RHEUMATOL, V7, P349, DOI 10.1038/nrrheum.2011.61; Bayry J, 2010, NAT REV RHEUMATOL, V6, P67, DOI 10.1038/nrrheum.2009.263; Bayry J, 2009, NAT REV RHEUMATOL, V5, P244, DOI 10.1038/nrrheum.2009.77; Bereswill S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015099; Bock PR, 2004, ARZNEIMITTELFORSCH, V54, P456; Bussing A, 1999, ANTICANCER RES, V19, P23; Bussing A, 2005, ANTICANCER RES, V25, P4753; Carey MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011610; Cerella C, 2010, BIOCHEM PHARMACOL, V80, P1801, DOI 10.1016/j.bcp.2010.06.050; Chell S, 2006, BBA-REV CANCER, V1766, P104, DOI 10.1016/j.bbcan.2006.05.002; Christen-Clottu O, 2010, J VET INTERN MED, V24, P1483, DOI 10.1111/j.1939-1676.2010.0597.x; Chrubasik S, 2001, RHEUMATOLOGY, V40, P1388, DOI 10.1093/rheumatology/40.12.1388; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Correa-Costa M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014298; Cravotto G, 2010, J CLIN PHARM THER, V35, P11, DOI 10.1111/j.1365-2710.2009.01096.x; Elluru SR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-161; Frank U, 2003, EUR J CLIN MICROBIOL, V22, P501, DOI 10.1007/s10096-003-0964-9; FRANZ H, 1981, BIOCHEM J, V195, P481, DOI 10.1042/bj1950481; Gardin NE, 2009, PHYTOTHER RES, V23, P407, DOI 10.1002/ptr.2643; GOLDYNE ME, 1973, PROSTAG OTH LIPID M, V4, P737, DOI 10.1016/S0090-6980(73)80058-9; Habib SHM, 2008, CLINICS, V63, P807, DOI 10.1590/S1807-59322008000600017; Hamsa TP, 2011, INFLAMMATION, V34, P171, DOI 10.1007/s10753-010-9221-4; Hegeman MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015653; Heinzerling L, 2006, J CLIN IMMUNOL, V26, P347, DOI 10.1007/s10875-006-9023-5; Hong JG, 2006, CARCINOGENESIS, V27, P278, DOI 10.1093/carcin/bgi208; Hostanska K, 1995, NAT IMMUN, V14, P295; Hwang YP, 2011, FOOD CHEM TOXICOL, V49, P93, DOI 10.1016/j.fct.2010.10.002; Jin M, 2010, FOOD CHEM TOXICOL, V48, P3073, DOI 10.1016/j.fct.2010.07.048; Kaegi E, 1998, CAN MED ASSOC J, V158, P1157; Kale A, 2008, PHYTOTHER RES, V22, P567, DOI 10.1002/ptr.2283; Karagoz A, 2003, PHYTOTHER RES, V17, P560, DOI 10.1002/ptr.1163; KARMALI RA, 1983, BRIT J CANCER, V48, P689, DOI 10.1038/bjc.1983.251; Kaveri SV, 2010, NEW ENGL J MED, V363, P1080, DOI 10.1056/NEJMcibr1006936; KHWAJA TA, 1986, ONCOLOGY, V43, P42, DOI 10.1159/000226419; Kienle GS, 2010, INTEGR CANCER THER, V9, P142, DOI 10.1177/1534735410369673; Klopp R, 2005, ANTICANCER RES, V25, P601; Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593; Lavastre V, 2004, CLIN EXP IMMUNOL, V137, P272, DOI 10.1111/j.1365-2249.2004.02545.x; Libby P, 2007, NUTR REV, V65, pS140, DOI [10.1111/j.1753-4887.2007.tb00352.x, 10.1301/nr.2007.dec.S140-S146]; Maddur MS, 2010, TRENDS IMMUNOL, V31, P45, DOI 10.1016/j.it.2009.12.004; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meyer-Kirchrath J, 2000, CURR MED CHEM, V7, P1121, DOI 10.2174/0929867003374219; Min KJ, 2011, INT IMMUNOPHARMACOL, V11, P1137, DOI 10.1016/j.intimp.2011.02.029; OLSNES S, 1982, J BIOL CHEM, V257, P13263; Orhan DD, 2006, Z NATURFORSCH C, V61, P26; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; PASSWELL J, 1983, CLIN EXP IMMUNOL, V51, P61; Pozzi A, 2009, WIRES SYST BIOL MED, V1, P254, DOI 10.1002/wsbm.7; Radenkovic M, 2006, PHYTOTHER RES, V20, P374, DOI 10.1002/ptr.1865; Redondo S, 2011, DIABETOLOGIA, V54, P190, DOI 10.1007/s00125-010-1947-x; Rosenkranz HS, 2003, ONCOL RES, V13, P529, DOI 10.3727/000000003108748054; Salazar AT, 2011, INT J CLIN PHARM TH, V49, P93, DOI 10.5414/CPP49093; Sharma C, 2006, TOXICOLOGY, V228, P1, DOI 10.1016/j.tox.2006.07.027; Stein GM, 2000, ANTICANCER RES, V20, P2987; Stein GM, 2000, ANTICANCER RES, V20, P1673; Stein GM, 2002, ANTICANCER RES, V22, P4215; Tenorio FA, 2005, FITOTERAPIA, V76, P204, DOI 10.1016/j.fitote.2004.12.013; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; Tomlinson KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013136; Tusenius KJ, 2005, ARZNEIMITTELFORSCH, V55, P749; Tusenius KJ, 2001, COMPLEMENT THER MED, V9, P12, DOI 10.1054/ctim.2000.0408; Urech K, 2006, ARZNEIMITTEL-FORSCH, V56, P428; Van Huyen JPD, 2006, CANCER LETT, V243, P32, DOI 10.1016/j.canlet.2005.11.016; Van Huyen JPD, 2003, CHEMOTHERAPY, V49, P298, DOI 10.1159/000074530; Van Huyen JPD, 2002, MOL MED, V8, P600, DOI 10.1007/BF03402170; Van Huyen JPD, 2001, CHEMOTHERAPY, V47, P366, DOI 10.1159/000048545; Vane JR, 1996, SCAND J RHEUMATOL, P9; Yoon TJ, 2001, INT IMMUNOPHARMACOL, V1, P881, DOI 10.1016/S1567-5769(01)00024-8; Zhou HY, 2008, EUR J PHARMACOL, V586, P340, DOI 10.1016/j.ejphar.2008.02.044	75	38	40	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2011	6	10							e26312	10.1371/journal.pone.0026312	http://dx.doi.org/10.1371/journal.pone.0026312			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837ID	22028854	gold, Green Published, Green Submitted			2023-01-03	WOS:000296186900047
J	Bryson, D				Bryson, David			PERSONAL VIEW Care homes shouldn't profit from delays in assessing their residents for discharge from hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material									Gen Hosp Kettering, Kettering, England		Bryson, D (corresponding author), Gen Hosp Kettering, Kettering, England.	davidjbryson@hotmail.com							0	2	2	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2011	343								d6570	10.1136/bmj.d6570	http://dx.doi.org/10.1136/bmj.d6570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	835EO	21994319				2023-01-03	WOS:000296018100007
J	Yamaguchi, R; Janssen, E; Perkins, G; Ellisman, M; Kitada, S; Reed, JC				Yamaguchi, Ryuji; Janssen, Edith; Perkins, Guy; Ellisman, Mark; Kitada, Shinichi; Reed, John C.			Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy	PLOS ONE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CYTOCHROME-C RELEASE; BH3 MIMETIC ABT-737; MITOCHONDRIAL PERMEABILITY TRANSITION; PROSTATE-CANCER; ONCOGENE ADDICTION; IN-VIVO; MEMBRANE PERMEABILIZATION; CYTOGENETIC RESPONSES; GLYCOLYSIS INHIBITION	As single agents, ABT-263 and ABT-737 (ABT), molecular antagonists of the Bcl-2 family, bind tightly to Bcl-2, Bcl-xL and Bcl-w, but not to Mcl-1, and induce apoptosis only in limited cell types. The compound 2-deoxyglucose (2DG), in contrast, partially blocks glycolysis, slowing cell growth but rarely causing cell death. Injected into an animal, 2DG accumulates predominantly in tumors but does not harm other tissues. However, when cells that were highly resistant to ABT were pre-treated with 2DG for 3 hours, ABT became a potent inducer of apoptosis, rapidly releasing cytochrome c from the mitochondria and activating caspases at submicromolar concentrations in a Bak/Bax-dependent manner. Bak is normally sequestered in complexes with Mcl-1 and Bcl-xL. 2DG primes cells by interfering with Bak-Mcl-1 association, making it easier for ABT to dissociate Bak from Bcl-xL, freeing Bak to induce apoptosis. A highly active glucose transporter and Bid, as an agent of the mitochondrial apoptotic signal amplification loop, are necessary for efficient apoptosis induction in this system. This combination treatment of cancer-bearing mice was very effective against tumor xenograft from hormone-independent highly metastasized chemo-resistant human prostate cancer cells, suggesting that the combination treatment may provide a safe and effective alternative to genotoxin-based cancer therapies.	[Yamaguchi, Ryuji; Kitada, Shinichi; Reed, John C.] Sanford Burnham Med Res Inst, Program Cell Death & Apoptosis, La Jolla, CA 92037 USA; [Janssen, Edith] Cincinnati Childrens Hosp Med Ctr, Div Mol Immunol, Cincinnati, OH USA; [Perkins, Guy; Ellisman, Mark] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Yamaguchi, Ryuji] Kyushu Univ, Sch Med, Dept Mol Biol, Fukuoka 812, Japan	Sanford Burnham Prebys Medical Discovery Institute; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University of California System; University of California San Diego; Kyushu University	Yamaguchi, R (corresponding author), Sanford Burnham Med Res Inst, Program Cell Death & Apoptosis, La Jolla, CA 92037 USA.	rudy.yamaguchi@gmail.com		Yamaguchi, Ryuji/0000-0002-1706-7063; Perkins, Guy/0000-0002-1834-6646; janssen, edith/0000-0001-7881-6307	National Institutes of Health(NIH)/National Cancer Institute [CA138617]; NIH [P41RR004050]; NIH NCRR [P41RR004050];  [CA113318];  [CA055164];  [CA081534]; NATIONAL CANCER INSTITUTE [P01CA055164, P20CA081534, U19CA113318, P01CA081534, R01CA138617] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER	National Institutes of Health(NIH)/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	EJ received National Institutes of Health(NIH)/National Cancer Institute Grant CA138617, ME received NIH grant P41RR004050, and JCR received CA113318, CA055164, and CA081534. Some of the work described here was conducted using facilities at the National Center for Microscopy and Imaging Research at the University of California San Diego, supported by the NIH NCRR through grant number P41RR004050 to ME. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhavan A, 2006, NEOPLASIA, V8, P725, DOI 10.1593/neo.06388; Arnoult D, 2007, TRENDS CELL BIOL, V17, P6, DOI 10.1016/j.tcb.2006.11.001; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Berman SB, 2009, J CELL BIOL, V184, P707, DOI 10.1083/jcb.200809060; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Caraco C, 2000, J BIOL CHEM, V275, P18489, DOI 10.1074/jbc.M908096199; Caro-Maldonado A, 2010, CELL DEATH DIFFER, V17, P1335, DOI 10.1038/cdd.2010.21; CHEN TR, 1993, CYTOGENET CELL GENET, V62, P183, DOI 10.1159/000133468; Chipuk JE, 2009, CELL CYCLE, V8, P2692, DOI 10.4161/cc.8.17.9412; Dearling JLJ, 2007, CLIN CANCER RES, V13, P1903, DOI 10.1158/1078-0432.CCR-06-2094; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D R, 1998, Results Probl Cell Differ, V24, P45; GRIDLEY DS, 1985, INT J RADIAT ONCOL, V11, P567, DOI 10.1016/0360-3016(85)90189-0; Hann CL, 2008, CANCER RES, V68, P2321, DOI 10.1158/0008-5472.CAN-07-5031; Hauck P, 2009, MOL CANCER THER, V8, P883, DOI 10.1158/1535-7163.MCT-08-1118; Hochhaus A, 2008, LEUKEMIA, V22, P1200, DOI 10.1038/leu.2008.84; Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552; Hyer ML, 2008, CANCER RES, V68, P2927, DOI 10.1158/0008-5472.CAN-07-5759; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kodama T, 2011, J BIOL CHEM, V286, P13905, DOI 10.1074/jbc.M110.195370; KOHNO T, 1994, ONCOGENE, V9, P103; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; Myzak MC, 2007, EXP BIOL MED, V232, P227; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Owens TW, 2009, CELL DEATH DIFFER, V16, P1551, DOI 10.1038/cdd.2009.102; Pan Y, 2001, GENE CHROMOSOME CANC, V30, P187, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1075>3.3.CO;2-8; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Salvesen GS, 2008, ADV EXP MED BIOL, V615, P13, DOI 10.1007/978-1-4020-6554-5_2; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schafer B, 2009, MOL BIOL CELL, V20, P2276, DOI 10.1091/mbc.E08-10-1056; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srivastava SK, 2003, CARCINOGENESIS, V24, P1665, DOI 10.1093/carcin/bgg123; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; van Bokhoven A, 2001, PROSTATE, V47, P36; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Vogler M, 2008, CELL DEATH DIFFER, V15, P820, DOI 10.1038/cdd.2008.25; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wojciechowski S, 2007, J EXP MED, V204, P1665, DOI 10.1084/jem.20070618; Xiao D, 2006, CLIN CANCER RES, V12, P6836, DOI 10.1158/1078-0432.CCR-06-1273; Yamaguchi R, 2008, MOL CELL, V31, P557, DOI 10.1016/j.molcel.2008.07.010; Yamaguchi R, 2009, BBA-BIOENERGETICS, V1787, P963, DOI 10.1016/j.bbabio.2009.02.005; Zhong DS, 2008, MOL CANCER THER, V7, P809, DOI 10.1158/1535-7163.MCT-07-0559; Zhong DS, 2009, J BIOL CHEM, V284, P23225, DOI 10.1074/jbc.M109.005280	72	56	59	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 19	2011	6	9							e24102	10.1371/journal.pone.0024102	http://dx.doi.org/10.1371/journal.pone.0024102			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	825FZ	21949692	gold, Green Published, Green Submitted			2023-01-03	WOS:000295257900004
J	Kumar, AMV; Gupta, D; Rewari, BB; Bachani, D; Mohammed, S; Sharma, V; Lal, K; Reddy, HRR; Naik, B; Prasad, R; Yaqoob, M; Deepak, KG; Shastri, S; Satyanarayana, S; Harries, AD; Chauhan, LS; Dewan, P				Kumar, Ajay M. V.; Gupta, Devesh; Rewari, B. B.; Bachani, Damodar; Mohammed, Suresh; Sharma, Vartika; Lal, Kumaraswamy; Reddy, H. R. Raveendra; Naik, Balaji; Prasad, Rita; Yaqoob, Mohammed; Deepak, K. G.; Shastri, Suresh; Satyanarayana, Srinath; Harries, Anthony David; Chauhan, Lakhbir Singh; Dewan, Puneet			Will Adoption of the 2010 WHO ART Guidelines for HIV-Infected TB Patients Increase the Demand for ART Services in India?	PLOS ONE			English	Article							CD4 LYMPHOCYTE COUNTS; TUBERCULOSIS	Background: In 2010, WHO expanded previously-recommended indications for anti-retroviral treatment to include all HIV-infected TB patients irrespective of CD4 count. India, however, still limits ART to those TB patients with CD4 counts <350/mm(3) or with extrapulmonary TB manifestations. We sought to evaluate the additional number of patients that would be initiated on ART if India adopted the current 2010 WHO ART guidelines for HIV-infected TB patients. Methods: We evaluated all TB patients recorded in treatment registers of the Revised National TB Control Programme in June 2010 in the high-HIV prevalence state of Karnataka, and cross-matched HIV-infected TB patients with ART programme records. Results: Of 6182 TB patients registered, HIV status was ascertained for 5761(93%) and 710(12%) were HIV-infected. 146(21%) HIV-infected TB patients were on ART prior to TB diagnosis. Of the remaining 564, 497(88%) were assessed for ART eligibility; of these, 436(88%) were eligible for ART according to 2006 WHO ART guidelines. Altogether, 487(69%) HIV-infected TB patients received ART during TB treatment. About 80% started ART within 8 weeks of TB treatment and 95% received an efavirenz based regimen. Conclusion: In Karnataka, India, about nine out of ten HIV-infected TB patients were eligible for ART according to 2006 WHO ART guidelines. The efficiency of HIV case finding, ART evaluation, and ART initiation was relatively high, with 78% of eligible HIV-infected patients actually initiated on ART, and 80% within 8 weeks of diagnosis. ART could be extended to all HIV-infected TB patients irrespective of CD4 count with relatively little additional burden on the national ART programme.	[Kumar, Ajay M. V.; Gupta, Devesh; Satyanarayana, Srinath; Chauhan, Lakhbir Singh] Govt India, Cent TB Div, Directorate Gen Hlth Serv, Minist Hlth & Family Welf, New Delhi, India; [Kumar, Ajay M. V.; Reddy, H. R. Raveendra; Naik, Balaji; Prasad, Rita; Yaqoob, Mohammed; Deepak, K. G.; Dewan, Puneet] Off World Hlth Org Representat India, New Delhi, India; [Rewari, B. B.; Bachani, Damodar; Mohammed, Suresh; Sharma, Vartika] Govt India, Minist Hlth & Family Welf, Natl AIDS Control Org, New Delhi, India; [Lal, Kumaraswamy] Govt Karnataka, State TB Cell, Directorate Gen Hlth Serv, Minist Hlth & Family Welf, Bangalore, Karnataka, India; [Shastri, Suresh] Govt Karnataka, Karnataka State AIDS Prevent & Control Soc, Minist Hlth & Family Welf, Bangalore, Karnataka, India; [Satyanarayana, Srinath] SE Asia Reg Off, Int Union TB & Lung Dis The Union, New Delhi, India; [Harries, Anthony David] Int Union TB & Lung Dis The Union, Paris, France; [Harries, Anthony David] London Sch Hyg & Trop Med, London WC1, England	World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Kumar, AMV (corresponding author), Govt India, Cent TB Div, Directorate Gen Hlth Serv, Minist Hlth & Family Welf, New Delhi, India.	kumaramv@rntcp.org; sathyasaakshi@gmail.com		Madhugiri Venkatachalaiah, Ajay Kumar/0000-0003-1011-8531; Satyanarayana, Srinath/0000-0002-5420-2551	Centre for Operational Research, International Union Against Tuberculosis and Lung Disease; Operational Research Unit, Medecins sans Frontieres, Brussels	Centre for Operational Research, International Union Against Tuberculosis and Lung Disease; Operational Research Unit, Medecins sans Frontieres, Brussels	This research was supported through an operational research course, which was jointly developed and run by the Centre for Operational Research, International Union Against Tuberculosis and Lung Disease, and the Operational Research Unit, Medecins sans Frontieres, Brussels. The study itself was not funded. However, the publication fees is being funded by Centre for Operational Research, International Union Against Tuberculosis and Lung Disease. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACKAH AN, 1995, LANCET, V345, P607, DOI 10.1016/S0140-6736(95)90519-7; [Anonymous], 2007, ANT THER GUID HIV IN; Central TB Division, 2005, TECHN OP GUID TUB CO; Central TB Division Ministry of Health and Family Welfare, 2011, REV NAT TB CONTR PRO; *EPIDATA ASSOCIATI, EPIDATA ENTR VERS 3; Harries AD, 2010, LANCET, V375, P1906, DOI 10.1016/S0140-6736(10)60409-6; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; *NAT AIDS CONTR OR, 2010, HIV EST IND; *NAT AIDS CONTR OR, 2008, TECHN BRIEF; *NAT AIDS CONTR OR, 2010, MIN NAT TECHN WORK G; National AIDS Control Organization, 2008, OP GUID INT COUNS TE; National AIDS Control Organization and Central TB Division, 2009, NAT FRAM JOINT HIV T; *OF REG GEN CENS C, 2011, 1 OF REG GEN CENS CO; Teck R, 2005, INT J TUBERC LUNG D, V9, P258; Vijay S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007899; WHO, ANT THER HIV INF AD; World Health Organization, 2010, ROADM ROLL XPERT MTB; World Health Organization, 2006, ANT THER HIV INF AD	18	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2011	6	9							e24297	10.1371/journal.pone.0024297	http://dx.doi.org/10.1371/journal.pone.0024297			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CK	21931674	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000294802800037
J	Aufderheide, TP; Nichol, G; Rea, TD; Brown, SP; Leroux, BG; Pepe, PE; Kudenchuk, PJ; Christenson, J; Daya, MR; Dorian, P; Callaway, CW; Idris, AH; Andrusiek, D; Stephens, SW; Hostler, D; Davis, DP; Dunford, JV; Pirrallo, RG; Stiell, IG; Clement, CM; Craig, A; Van Ottingham, L; Schmidt, TA; Wang, HE; Weisfeldt, ML; Ornato, JP; Sopko, G				Aufderheide, Tom P.; Nichol, Graham; Rea, Thomas D.; Brown, Siobhan P.; Leroux, Brian G.; Pepe, Paul E.; Kudenchuk, Peter J.; Christenson, Jim; Daya, Mohamud R.; Dorian, Paul; Callaway, Clifton W.; Idris, Ahamed H.; Andrusiek, Douglas; Stephens, Shannon W.; Hostler, David; Davis, Daniel P.; Dunford, James V.; Pirrallo, Ronald G.; Stiell, Ian G.; Clement, Catherine M.; Craig, Alan; Van Ottingham, Lois; Schmidt, Terri A.; Wang, Henry E.; Weisfeldt, Myron L.; Ornato, Joseph P.; Sopko, George		ROC Investigators	A Trial of an Impedance Threshold Device in Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOPULMONARY-RESUSCITATION; PORCINE MODEL; HEMODYNAMICS; SURVIVAL	Background The impedance threshold device (ITD) is designed to enhance venous return and cardiac output during cardiopulmonary resuscitation (CPR) by increasing the degree of negative intrathoracic pressure. Previous studies have suggested that the use of an ITD during CPR may improve survival rates after cardiac arrest. Methods We compared the use of an active ITD with that of a sham ITD in patients with out-of-hospital cardiac arrest who underwent standard CPR at 10 sites in the United States and Canada. Patients, investigators, study coordinators, and all care providers were unaware of the treatment assignments. The primary outcome was survival to hospital discharge with satisfactory function (i.e., a score of <= 3 on the modified Rankin scale, which ranges from 0 to 6, with higher scores indicating greater disability). Results Of 8718 patients included in the analysis, 4345 were randomly assigned to treatment with a sham ITD and 4373 to treatment with an active device. A total of 260 patients (6.0%) in the sham-ITD group and 254 patients (5.8%) in the active-ITD group met the primary outcome (risk difference adjusted for sequential monitoring, -0.1 percentage points; 95% confidence interval, -1.1 to 0.8; P = 0.71). There were also no significant differences in the secondary outcomes, including rates of return of spontaneous circulation on arrival at the emergency department, survival to hospital admission, and survival to hospital discharge. Conclusions Use of the ITD did not significantly improve survival with satisfactory function among patients with out-of-hospital cardiac arrest receiving standard CPR. (Funded by the National Heart, Lung, and Blood Institute and others; ROC PRIMED ClinicalTrials.gov number, NCT00394706.)	[Aufderheide, Tom P.; Pirrallo, Ronald G.] Med Coll Wisconsin, Dept Emergency Med, 9200 W Wisconsin Ave,Pavil 1P, Milwaukee, WI 53226 USA; [Nichol, Graham] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA; [Rea, Thomas D.] Univ Washington, Div Gen Med, Seattle, WA 98195 USA; [Kudenchuk, Peter J.] Univ Washington, Div Cardiol, Dept Med, Seattle, WA 98195 USA; [Nichol, Graham; Brown, Siobhan P.; Leroux, Brian G.; Van Ottingham, Lois] Univ Washington, Dept Biostat, Clin Trials Ctr, Seattle, WA 98195 USA; [Pepe, Paul E.; Idris, Ahamed H.] Univ Texas SW Med Ctr Dallas, Dept Surg Emergency Med, Dallas, TX 75390 USA; [Christenson, Jim] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada; [Andrusiek, Douglas] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Christenson, Jim; Andrusiek, Douglas] British Columbia Emergency & Hlth Serv Commiss, Vancouver, BC, Canada; [Daya, Mohamud R.; Schmidt, Terri A.] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97201 USA; [Dorian, Paul] Univ Toronto, Dept Med, Toronto, ON, Canada; [Craig, Alan] Toronto Emergency Med Serv, Toronto, ON, Canada; [Callaway, Clifton W.; Hostler, David] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Davis, Daniel P.; Dunford, James V.] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; [Stiell, Ian G.; Clement, Catherine M.] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Stiell, Ian G.; Clement, Catherine M.] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Weisfeldt, Myron L.] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; [Sopko, George] NHLBI, NIH, Bethesda, MD 20892 USA; [Ornato, Joseph P.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA	Medical College of Wisconsin; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of British Columbia; University of British Columbia; Oregon Health & Science University; University of Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Diego; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Johns Hopkins University; Johns Hopkins Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Virginia Commonwealth University	Aufderheide, TP (corresponding author), Med Coll Wisconsin, Dept Emergency Med, 9200 W Wisconsin Ave,Pavil 1P, Milwaukee, WI 53226 USA.	taufderh@mcw.edu	Leroux, Brian G/H-2254-2015; Cheskes, Sheldon/I-4456-2015; Daya, Mohamud R/A-9322-2012; Nichol, Graham/Z-4996-2019	Cheskes, Sheldon/0000-0001-7835-3074; Pirrallo, Ronald/0000-0002-8321-3866; Brown, Siobhan/0000-0002-4774-3122; Hostler, David/0000-0002-7711-4001; Stiell, Ian/0000-0002-2583-6408; Idris, Ahamed/0000-0001-7113-6499; Gabriel, Erin/0000-0002-0504-8404; Callaway, Clifton/0000-0002-3309-1573; Stephens, Shannon/0000-0001-5898-5170	National Heart, Lung, and Blood Institute [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077887, HL077873, HL077865]; National Institute of Neurological Disorders and Stroke; U.S. Army Medical Research and Materiel Command; Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada; Heart and Stroke Foundation of Canada; American Heart Association; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077863, U01HL077865, U01HL077866, U01HL077887, U01HL077881, U01HL077867, U01HL077871, U01HL077873, U01HL077908, U01HL077872] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); U.S. Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); American Heart Association(American Heart Association); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by a series of cooperative agreements with 10 regional clinical centers and one data coordinating center (5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077887, HL077873, HL077865) from the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, U.S. Army Medical Research and Materiel Command, the Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.	Andreka P, 2006, CURR OPIN CRIT CARE, V12, P198, DOI 10.1097/01.ccx.0000224861.70958.59; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; [Anonymous], 2005, CIRCULATION, V2005, P112; Aufderheide TP, 2008, CRIT CARE MED, V36, pS397, DOI 10.1097/CCM.0b013e31818a7e56; Aufderheide TP, 2008, RESUSCITATION, V78, P179, DOI 10.1016/j.resuscitation.2008.01.028; Aufderheide TP, 2006, CRIT CARE MED, V34, pS466, DOI 10.1097/01.CCM.0000246013.47237.86; Aufderheide TP, 2011, LANCET, V377, P301, DOI 10.1016/S0140-6736(10)62103-4; Aufderheide TP, 2005, CRIT CARE MED, V33, P734, DOI 10.1097/01.CCM.0000155909.09061.12; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eisenberg MS, 2010, JAMA-J AM MED ASSOC, V304, P87, DOI 10.1001/jama.2010.898; Emerson S S, 1990, Oncology (Williston Park), V4, P126; Lai SM, 2001, NEUROEPIDEMIOLOGY, V20, P26, DOI 10.1159/000054754; Lurie KG, 2002, CIRCULATION, V105, P124, DOI 10.1161/hc0102.101391; Mader TJ, 2008, RESUSCITATION, V77, P387, DOI 10.1016/j.resuscitation.2008.01.007; Menegazzi JJ, 2007, PREHOSP EMERG CARE, V11, P179, DOI 10.1080/10903120701206073; Pirrallo RG, 2005, RESUSCITATION, V66, P13, DOI 10.1016/j.resuscitation.2004.12.027; Stiell IG, 2011, NEW ENGL J MED, V365, P787, DOI 10.1056/NEJMoa1010076; Thayne RC, 2005, RESUSCITATION, V67, P103, DOI 10.1016/j.resuscitation.2005.05.009; Tomlinson AE, 2007, RESUSCITATION, V72, P364, DOI 10.1016/j.resuscitation.2006.07.017; WHITEHEAD J, 1986, STAT MED, V5, P459, DOI 10.1002/sim.4780050510; Yannopoulos D, 2005, RESUSCITATION, V64, P363, DOI 10.1016/j.resuscitation.2004.10.009; Yannopoulos D, 2004, RESUSCITATION, V61, P75, DOI 10.1016/j.resuscitation.2003.12.006	24	164	169	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2011	365	9					798	806		10.1056/NEJMoa1010821	http://dx.doi.org/10.1056/NEJMoa1010821			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	813YC	21879897	Green Published, Green Accepted			2023-01-03	WOS:000294405200006
J	Stiell, IG; Nichol, G; Leroux, BG; Rea, TD; Ornato, JP; Powell, J; Christenson, J; Callaway, CW; Kudenchuk, PJ; Aufderheide, TP; Idris, AH; Daya, MR; Wang, HE; Morrison, LJ; Davis, D; Andrusiek, D; Stephens, S; Cheskes, S; Schmicker, RH; Fowler, R; Vaillancourt, C; Hostler, D; Zive, D; Pirrallo, RG; Vilke, GM; Sopko, G; Weisfeldt, M				Stiell, Ian G.; Nichol, Graham; Leroux, Brian G.; Rea, Thomas D.; Ornato, Joseph P.; Powell, Judy; Christenson, James; Callaway, Clifton W.; Kudenchuk, Peter J.; Aufderheide, Tom P.; Idris, Ahamed H.; Daya, Mohamud R.; Wang, Henry E.; Morrison, Laurie J.; Davis, Daniel; Andrusiek, Douglas; Stephens, Shannon; Cheskes, Sheldon; Schmicker, Robert H.; Fowler, Ray; Vaillancourt, Christian; Hostler, David; Zive, Dana; Pirrallo, Ronald G.; Vilke, Gary M.; Sopko, George; Weisfeldt, Myron		ROC Investigators	Early versus Later Rhythm Analysis in Patients with Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPEDANCE THRESHOLD DEVICE; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; TRIAL METHODS; LIFE-SUPPORT; SWINE MODEL; DEFIBRILLATION; OUTCOMES; METHODOLOGY; RATIONALE	Background In a departure from the previous strategy of immediate defibrillation, the 2005 resuscitation guidelines from the American Heart Association-International Liaison Committee on Resuscitation suggested that emergency medical service (EMS) personnel could provide 2 minutes of cardiopulmonary resuscitation (CPR) before the first analysis of cardiac rhythm. We compared the strategy of a brief period of CPR with early analysis of rhythm with the strategy of a longer period of CPR with delayed analysis of rhythm. Methods We conducted a cluster-randomized trial involving adults with out-of-hospital cardiac arrest at 10 Resuscitation Outcomes Consortium sites in the United States and Canada. Patients in the early-analysis group were assigned to receive 30 to 60 seconds of EMS-administered CPR and those in the later-analysis group were assigned to receive 180 seconds of CPR, before the initial electrocardiographic analysis. The primary outcome was survival to hospital discharge with satisfactory functional status (a modified Rankin scale score of <= 3, on a scale of 0 to 6, with higher scores indicating greater disability). Results We included 9933 patients, of whom 5290 were assigned to early analysis of cardiac rhythm and 4643 to later analysis. A total of 273 patients (5.9%) in the later-analysis group and 310 patients (5.9%) in the early-analysis group met the criteria for the primary outcome, with a cluster-adjusted difference of -0.2 percentage points (95% confidence interval, -1.1 to 0.7; P = 0.59). Analyses of the data with adjustment for confounding factors, as well as subgroup analyses, also showed no survival benefit for either study group. Conclusions Among patients who had an out-of-hospital cardiac arrest, we found no difference in the outcomes with a brief period, as compared with a longer period, of EMS-administered CPR before the first analysis of cardiac rhythm. (Funded by the National Heart, Lung, and Blood Institute and others; ROC PRIMED ClinicalTrials.gov number, NCT00394706.)	[Stiell, Ian G.; Vaillancourt, Christian] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Stiell, Ian G.; Vaillancourt, Christian] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Nichol, Graham; Leroux, Brian G.; Powell, Judy; Schmicker, Robert H.] Univ Washington, Clin Trials Ctr, Dept Biostat, Seattle, WA 98195 USA; [Nichol, Graham; Rea, Thomas D.; Kudenchuk, Peter J.] Univ Washington, Dept Med, Seattle, WA USA; [Nichol, Graham] Univ Washington, Harborview Ctr Prehosp Emergency Care, Seattle, WA 98195 USA; [Ornato, Joseph P.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA; [Christenson, James] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada; [Andrusiek, Douglas] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Christenson, James; Andrusiek, Douglas] British Columbia Emergency & Hlth Serv Commiss, Vancouver, BC, Canada; [Callaway, Clifton W.; Hostler, David] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Aufderheide, Tom P.; Pirrallo, Ronald G.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Idris, Ahamed H.; Fowler, Ray] Univ Texas SW Med Ctr Dallas, Dept Surg Emergency Med, Dallas, TX 75390 USA; [Daya, Mohamud R.; Zive, Dana] Oregon Hlth & Sci Univ, Dept Emergency Med, Ctr Policy & Res Emergency Med, Portland, OR 97201 USA; [Wang, Henry E.; Stephens, Shannon] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, W Midlands, England; [Morrison, Laurie J.] Univ Toronto, Dept Med, Div Emergency Med, Toronto, ON, Canada; [Cheskes, Sheldon] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; [Morrison, Laurie J.; Cheskes, Sheldon] St Michaels Hosp, Li Ka Shing Knowledge Inst, Rescu Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Davis, Daniel; Vilke, Gary M.] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; [Sopko, George] NHLBI, NIH, Bethesda, MD 20892 USA; [Weisfeldt, Myron] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; Virginia Commonwealth University; University of British Columbia; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical College of Wisconsin; University of Texas System; University of Texas Southwestern Medical Center Dallas; Oregon Health & Science University; University of Toronto; University of Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Johns Hopkins University; Johns Hopkins Medicine	Stiell, IG (corresponding author), Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada.	istiell@ohri.ca	Leroux, Brian G/H-2254-2015; Daya, Mohamud R/A-9322-2012; Hug, Balthasar L./G-1568-2010; Morrison, Laurie Jean/A-6325-2012; Nichol, Graham/Z-4996-2019; Cheskes, Sheldon/I-4456-2015	Morrison, Laurie Jean/0000-0001-8369-9774; Cheskes, Sheldon/0000-0001-7835-3074; Callaway, Clifton/0000-0002-3309-1573; Stephens, Shannon/0000-0001-5898-5170; Pirrallo, Ronald/0000-0002-8321-3866; Stiell, Ian/0000-0002-2583-6408; Hostler, David/0000-0002-7711-4001; Gabriel, Erin/0000-0002-0504-8404; Idris, Ahamed/0000-0001-7113-6499	National Heart, Lung, and Blood Institute [5U01 HL077863, HL077881, HL077871 HL077872, HL077866, HL077908, HL077867, HL077887, HL077873, HL077865]; National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health; Heart and Stroke Foundation of Canada; U.S. Army Medical Research and Material Command; Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada; American Heart Association; Laerdal Foundation for Acute Medicine; Medtronic Foundation; Sotera Wireless; Medtronic; Jolife; Philips Healthcare; ZOLL Medical; Imricor Medical Systems; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077885, U01HL077881, U01HL077866, U01HL077865, U01HL077863, U01HL077887, U01HL077871, U01HL077908, U01HL077873, U01HL077867, U01HL077872] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); U.S. Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada(Canadian Institutes of Health Research (CIHR)); American Heart Association(American Heart Association); Laerdal Foundation for Acute Medicine; Medtronic Foundation; Sotera Wireless; Medtronic(Medtronic); Jolife; Philips Healthcare; ZOLL Medical; Imricor Medical Systems; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute, the National Institute of Neurological Disorders and Stroke, the Canadian Institutes of Health Research-Institute of Circulatory and Respiratory Health, and the Heart and Stroke Foundation of Canada. The Resuscitation Outcome Consortium is supported by a series of cooperative agreements with 10 regional clinical centers and one data coordinating center (5U01 HL077863, HL077881, HL077871 HL077872, HL077866, HL077908, HL077867, HL077887, HL077873, HL077865) from the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, U.S. Army Medical Research and Material Command, the Institute of Circulatory and Respiratory Health of the Canadian Institutes of Health Research, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association.; Dr. Nichol reports receiving grant support from the Laerdal Foundation for Acute Medicine and Medtronic Foundation and travel fees from Sotera Wireless, being a board member of Medic One Foundation, and participating in research collaborations with Gambro Renal, Lifebridge Medizintechnik, and Sotera Wireless; Dr. Ornato, serving on an advisory board for ZOLL Circulation; Dr. Callaway, that he and his institution receive royalties for patents from Medtronic related to the timing of defibrillation; Dr. Aufderheide, consulting fees from Jolife and Medtronic; Dr. Daya, consulting and lecture fees from Philips Healthcare and owning stock in Amgen, Johnson & Johnson, and Roche; Dr. Morrison, grant support from the Laerdal Foundation for Acute Medicine; Dr. Pirrallo, consulting fees from ZOLL Medical; and Dr. Weisfeldt, that he and his institution receive royalties for patents from Imricor Medical Systems related to an MRI Insensitive Pacemaker. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Aufderheide TP, 2008, RESUSCITATION, V78, P179, DOI 10.1016/j.resuscitation.2008.01.028; Aufderheide TP, 2011, NEW ENGL J MED, V365, P798, DOI 10.1056/NEJMoa1010821; Baker PW, 2008, RESUSCITATION, V79, P424, DOI 10.1016/j.resuscitation.2008.07.017; Bradley SM, 2010, RESUSCITATION, V81, P155, DOI 10.1016/j.resuscitation.2009.10.026; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Efron B., 1993, INTRO BOOTSTRAP; Hastie TJ, 1992, STAT MODELS S, P249, DOI DOI 10.1201/9780203738535; Jacobs IG, 2009, EMERG MED AUSTRALAS, V21, P430, DOI 10.1111/j.1742-6723.2009.01224.x; Jacobs Ian G, 2005, Emerg Med Australas, V17, P39, DOI 10.1111/j.1742-6723.2005.00694.x; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Link, 2011, CIRCULATION, V123, pE235, DOI 10.1161/CIR.0b013e31820ff4b0; Link MS, 2010, CIRCULATION, V122, pS706, DOI 10.1161/CIRCULATIONAHA.110.970954; Meier P, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-52; Menegazzi JJ, 1993, PREHOSP DISAST MED S, V8, pS15; Newcommon NJ, 2003, STROKE, V34, P377, DOI 10.1161/01.STR.0000055766.99908.58; NICHOL G, 2008, JAMA-J AM MED ASSOC, V300, P1763; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Niemann JT, 2000, ANN EMERG MED, V36, P543, DOI 10.1067/mem.2000.109441; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Peberdy MA, 2005, RESUSCITATION, V64, P135, DOI 10.1016/j.resuscitation.2004.09.015; Rea TD, 2010, ANN EMERG MED, V55, P249, DOI 10.1016/j.annemergmed.2009.09.018; Rittenberger JC, 2008, RESUSCITATION, V79, P155, DOI 10.1016/j.resuscitation.2008.04.022; Silverman B.W, 1986, DENSITY ESTIMATION; Stiell IG, 2008, RESUSCITATION, V78, P186, DOI 10.1016/j.resuscitation.2008.01.027; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; van Alem AP, 2004, AM HEART J, V148, P416, DOI 10.1016/j.ahj.2004.01.031; Wang YL, 2009, CRIT CARE MED, V37, P2250, DOI 10.1097/CCM.0b013e31819ffc6a; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; YAKAITIS RW, 1980, CRIT CARE MED, V8, P157, DOI 10.1097/00003246-198003000-00014	34	192	196	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	2011	365	9					787	797		10.1056/NEJMoa1010076	http://dx.doi.org/10.1056/NEJMoa1010076			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	813YC	21879896	Green Accepted, Green Published			2023-01-03	WOS:000294405200005
J	Becker, C; Cameron, ID; Klenk, J; Lindemann, U; Heinrich, S; Konig, HH; Rapp, K				Becker, Clemens; Cameron, Ian D.; Klenk, Jochen; Lindemann, Ulrich; Heinrich, Sven; Koenig, Hans-Helmut; Rapp, Kilian			Reduction of Femoral Fractures in Long-Term Care Facilities: The Bavarian Fracture Prevention Study	PLOS ONE			English	Article							FALL PREVENTION; HIP FRACTURE; PEOPLE; HOMES	Background: Hip fractures are a major public health burden. In industrialized countries about 20% of all femoral fractures occur in care dependent persons living in nursing care and assisted living facilities. Preventive strategies for these groups are needed as the access to medical services differs from independent home dwelling older persons at risk of osteoporotic fractures. It was the objective of the study to evaluate the effect of a fall and fracture prevention program on the incidence of femoral fracture in nursing homes in Bavaria, Germany. Methods: In a translational intervention study a fall prevention program was introduced in 256 nursing homes with 13,653 residents. The control group consisted of 893 nursing homes with 31,668 residents. The intervention consisted of staff education on fall and fracture prevention strategies, progressive strength and balance training, and on institutional advice on environmental adaptations. Incident femoral fractures served as outcome measure. Results: In the years before the intervention risk of a femoral fracture did not differ between the intervention group (IG) and control group (CG). During the one-year intervention period femoral fracture rates were 33.6 (IG) and 41.0/1000 person years (CG), respectively. The adjusted relative risk of a femoral fracture was 0.82 (95% CI 0.72-0.93) in residents exposed to the fall and fracture prevention program compared to residents from CG. Conclusions: The state-wide dissemination of a multi-factorial fall and fracture prevention program was able to reduce femoral fractures in residents of nursing homes.	[Becker, Clemens; Klenk, Jochen; Lindemann, Ulrich; Rapp, Kilian] Robert Bosch Krankenhaus, Dept Clin Gerontol, Stuttgart, Germany; [Cameron, Ian D.] Univ Sydney, Sydney Med Sch, Rehabil Studies Unit, Ryde, Australia; [Klenk, Jochen; Rapp, Kilian] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany; [Heinrich, Sven; Koenig, Hans-Helmut] Univ Med Ctr Hamburg Eppendorf, Dept Med Sociol & Hlth Econ, Hamburg, Germany	Bosch; Robert Bosch Krankenhaus; University of Sydney; Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Becker, C (corresponding author), Robert Bosch Krankenhaus, Dept Clin Gerontol, Stuttgart, Germany.	clemens.becker@rbk.de	Rapp, Kilian/AAJ-3370-2020; Klenk, Jochen/R-3614-2019; Becker, Clemens/ABI-5405-2020; König, Hans-Helmut/P-1211-2018; Klenk, Jochen/C-2164-2012	Rapp, Kilian/0000-0003-1625-2571; Klenk, Jochen/0000-0002-5987-447X; König, Hans-Helmut/0000-0001-5711-6862; 	Robert Bosch Foundation, Stuttgart, Germany; Bundesministerium fur Bildung und Forschung (Forderkennzeichen) [01EL0702, 01EL0717, 01EL0718]; AOK	Robert Bosch Foundation, Stuttgart, Germany; Bundesministerium fur Bildung und Forschung (Forderkennzeichen)(Federal Ministry of Education & Research (BMBF)); AOK	Kilian Rapp is supported by a Forschungskolleg Geriatrie Grant from the Robert Bosch Foundation, Stuttgart, Germany. The evaluation of the study was funded by the Bundesministerium fur Bildung und Forschung (Forderkennzeichen: 01EL0702, 01EL0717, 01EL0718). The AOK funded the implementation of The Bavarian Fall and Fracture Prevention Study. The AOK had no influence on the intervention components but participated in the implementation process. The evaluation of the intervention was not funded and not influenced by the AOK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becker C, 2003, J AM GERIATR SOC, V51, P306, DOI 10.1046/j.1532-5415.2003.51103.x; Becker C, 1998, FACT RES INTERV GER, P55; Becker C, 2006, STURZPROPHYLAXE; Becker C, 2010, CLIN GERIATR MED, V26, P693, DOI 10.1016/j.cger.2010.07.004; Butler M, 1996, AGE AGEING, V25, P381, DOI 10.1093/ageing/25.5.381; Cameron ID, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005465.pub2; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cox H, 2008, AGE AGEING, V37, P167, DOI 10.1093/ageing/afm168; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Glasgow RE, 2008, ANN BEHAV MED, V35, P19, DOI 10.1007/s12160-007-9008-5; Glasgow RE, 2007, ANNU REV PUBL HEALTH, V28, P413, DOI 10.1146/annurev.publhealth.28.021406.144145; Klenk J, 2011, OSTEOPOROSIS INT, V22, P1593, DOI 10.1007/s00198-010-1366-3; Marx L, 1994, BARRIEREFREIE WOHNUN, P11; Pocock NA, 1999, MED J AUSTRALIA, V170, P486, DOI 10.5694/j.1326-5377.1999.tb127851.x; Rapp K, 2009, OSTEOPOROSIS INT, V20, P1775, DOI 10.1007/s00198-009-0852-y; Rapp K, 2010, J AM GERIATR SOC, V58, P70, DOI 10.1111/j.1532-5415.2009.02630.x; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Ward JA, 2010, MED J AUSTRALIA, V192, P319, DOI 10.5694/j.1326-5377.2010.tb03530.x; Zermansky AG, 2006, AGE AGEING, V35, P586, DOI 10.1093/ageing/afl075	19	27	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2011	6	8							e24311	10.1371/journal.pone.0024311	http://dx.doi.org/10.1371/journal.pone.0024311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	817MS	21918688	Green Published, gold, Green Submitted			2023-01-03	WOS:000294678300037
J	Shibata, K; Sugawara, T; Fujishita, K; Shinozaki, Y; Matsukawa, T; Suzuki, T; Koizumi, S				Shibata, Keisuke; Sugawara, Takeshi; Fujishita, Kayoko; Shinozaki, Youichi; Matsukawa, Takashi; Suzuki, Tsutomu; Koizumi, Schuichi			The Astrocyte-Targeted Therapy by Bushi for the Neuropathic Pain in Mice	PLOS ONE			English	Article							EXCITATORY SYNAPTIC-TRANSMISSION; NERVE INJURY; MECHANICAL ALLODYNIA; PATHOLOGICAL PAIN; SPINAL ASTROCYTES; MICROGLIA; GLIA; IMMUNE; CELLS; INTERLEUKIN-1-BETA	Background: There is accumulating evidence that the activation of spinal glial cells, especially microglia, is a key event in the pathogenesis of neuropathic pain. However, the inhibition of microglial activation is often ineffective, especially for long-lasting persistent neuropathic pain. So far, neuropathic pain remains largely intractable and a new therapeutic strategy for the pain is still required. Methods/Principal Findings: Using Seltzer model mice, we investigated the temporal aspect of two types of neuropathic pain behaviors, i.e., thermal hyperalgesia and mechanical allodynia, as well as that of morphological changes in spinal microglia and astrocytes by immunohistochemical studies. Firstly, we analyzed the pattern of progression in the pain behaviors, and found that the pain consisted of an "early induction phase'' and subsequent "late maintenance phase''. We next analyzed the temporal changes in spinal glial cells, and found that the induction and the maintenance phase of pain were associated with the activation of microglia and astrocytes, respectively. When Bushi, a Japanese herbal medicine often used for several types of persistent pain, was administered chronically, it inhibited the maintenance phase of pain without affecting the induction phase, which was in accordance with the inhibition of astrocytic activation in the spinal cord. These analgesic effects and the inhibition of astrocytic activation by Bushi were mimicked by the intrathecal injection of fluorocitrate, an inhibitor of astrocytic activation. Finally, we tested the direct effect of Bushi on astrocytic activation, and found that Bushi suppressed the IL-1b- or IL-18-evoked ERK1/2-phosphorylation in cultured astrocytes but not the ATP-evoked p38- and ERK1/2-phosphorylation in microglia in vitro. Conclusions: Our results indicated that the activation of spinal astrocytes was responsible for the late maintenance phase of neuropathic pain in the Seltzer model mice and, therefore, the inhibition of astrocytic activation by Bushi could be a useful therapeutic strategy for treating neuropathic pain.	[Shibata, Keisuke; Fujishita, Kayoko; Shinozaki, Youichi; Koizumi, Schuichi] Univ Yamanashi, Dept Neuropharmacol, Interdisciplinary Grad Sch Med & Engn, Yamanashi, Japan; [Sugawara, Takeshi] Kenyudo Clin, Yamanashi, Japan; [Sugawara, Takeshi; Matsukawa, Takashi] Univ Yamanashi, Dept Anesthesiol, Interdisciplinary Grad Sch Med & Engn, Yamanashi, Japan; [Suzuki, Tsutomu] Hoshi Univ, Dept Toxicol, Sch Pharm & Pharmaceut Sci, Tokyo 142, Japan	University of Yamanashi; University of Yamanashi; Hoshi University	Shibata, K (corresponding author), Univ Yamanashi, Dept Neuropharmacol, Interdisciplinary Grad Sch Med & Engn, Yamanashi, Japan.	skoizumi@yamanashi.ac.jp	Shinozaki, Youichi/E-8594-2010; Koizumi, Schuichi/E-8568-2010; Shinozaki, Youichi/AAC-9431-2019	Shinozaki, Youichi/0000-0002-6448-1304; Koizumi, Schuichi/0000-0001-6184-3106; Shinozaki, Youichi/0000-0002-6448-1304	Ministry of Education, Culture, Sports, Science and Technology; JSPS; University of Yamanashi; Takeda Science Foundation; Sumitomo Foundation; Uehara Memorial Foundation	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); University of Yamanashi(University of Yamanashi); Takeda Science Foundation(Takeda Science Foundation (TSF)); Sumitomo Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation)	This study was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology; a Grant-in-Aid for Scientific Research (A) from JSPS (S. K.); Grants-in-Aid for a Scientific Base-Forming program (S. K.) and for an Encouragement of Young Investigators (K. S) from University of Yamanashi; and by grants from Takeda Science Foundation, Sumitomo Foundation and Uehara Memorial Foundation (S. K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbadie C, 2009, BRAIN RES REV, V60, P125, DOI 10.1016/j.brainresrev.2008.12.002; AFTANAS LI, 2002, NIPPON SEIRIGAKU ZAS, V64, P143; Araque A, 2008, NEURON GLIA BIOL, V4, P3, DOI 10.1017/S1740925X09000064; Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725; Baron R, 2006, NAT CLIN PRACT NEURO, V2, P95, DOI 10.1038/ncpneuro0113; Benarroch EE, 2010, NEUROLOGY, V75, P273, DOI 10.1212/WNL.0b013e3181e8e984; Brunelli B, 2004, J NEUROL SCI, V218, P59, DOI 10.1016/j.jns.2003.10.013; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Clark AK, 2006, J NEUROCHEM, V99, P868, DOI 10.1111/j.1471-4159.2006.04126.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; de Leo JA, 2006, PAIN, V122, P17, DOI 10.1016/j.pain.2006.02.034; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Gao YJ, 2010, NEUROTHERAPEUTICS, V7, P482, DOI 10.1016/j.nurt.2010.05.016; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Goncharov NV, 2006, J APPL TOXICOL, V26, P148, DOI 10.1002/jat.1118; Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Inoue K, 2009, GLIA, V57, P1469, DOI 10.1002/glia.20871; Ji RR, 2006, NEURON GLIA BIOL, V2, P259, DOI 10.1017/S1740925X07000403; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Koizumi S, 2003, P NATL ACAD SCI USA, V100, P11023, DOI 10.1073/pnas.1834448100; Ledeboer A, 2005, PAIN, V115, P71, DOI 10.1016/j.pain.2005.02.009; Malmberg AB, 1997, J NEUROSCI, V17, P7462; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Miyoshi K, 2008, J NEUROSCI, V28, P12775, DOI 10.1523/JNEUROSCI.3512-08.2008; MURAYAMA M, 1991, J ETHNOPHARMACOL, V35, P159, DOI 10.1016/0378-8741(91)90068-O; Nakagawa T, 2007, NEUROSCIENCE, V147, P445, DOI 10.1016/j.neuroscience.2007.03.045; Okada-Ogawa A, 2009, J NEUROSCI, V29, P11161, DOI 10.1523/JNEUROSCI.3365-09.2009; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Proudfoot Alex T, 2006, Toxicol Rev, V25, P213, DOI 10.2165/00139709-200625040-00002; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Scholz J, 2007, NAT NEUROSCI, V10, P1361, DOI 10.1038/nn1992; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Suter MR, 2007, NEURON GLIA BIOL, V3, P255, DOI 10.1017/S1740925X08000100; Suzuki Y, 1999, JPN J PHARMACOL, V79, P169, DOI 10.1254/jjp.79.169; Svensson CI, 2010, MOL INTERV, V10, P25, DOI 10.1124/mi.10.1.6; Takasaki I, 2000, PAIN, V86, P95, DOI 10.1016/S0304-3959(00)00240-2; TAWATA M, 1994, DIABETES RES CLIN PR, V26, P121, DOI 10.1016/0168-8227(94)90149-X; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; VANDAM AM, 1995, NEUROSCIENCE, V65, P815, DOI 10.1016/0306-4522(94)00549-K; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Wegert S, 1997, PAIN, V71, P57, DOI 10.1016/S0304-3959(97)03337-X; Wei F, 2008, J NEUROSCI, V28, P10482, DOI 10.1523/JNEUROSCI.3593-08.2008; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Yamamoto Tomoya, 2009, Gan To Kagaku Ryoho, V36, P89; Yang S, 2005, BRAIN RES, V1034, P172, DOI 10.1016/j.brainres.2004.11.018; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022	54	53	54	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2011	6	8							e23510	10.1371/journal.pone.0023510	http://dx.doi.org/10.1371/journal.pone.0023510			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810LN	21876755	Green Submitted, Green Published, gold			2023-01-03	WOS:000294126900027
J	White, PD; Chalder, T				White, Peter D.; Chalder, Trudie			Chronic fatigue syndrome: treatment without a cause	LANCET			English	Editorial Material							COGNITIVE-BEHAVIOR THERAPY; TRIAL		[White, Peter D.] Queen Mary Univ London, Barts & London Sch Med & Dent, St Bartholomews Hosp, London EC1A 7BE, England; [Chalder, Trudie] Kings Coll London, Acad Dept Psychol Med, London WC2R 2LS, England	University of London; Queen Mary University London; University of London; King's College London	White, PD (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, St Bartholomews Hosp, London EC1A 7BE, England.	p.d.white@qmul.ac.uk	Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; White, Peter/0000-0002-8193-5355				Castell BD, 2011, CLIN PSYCHOL-SCI PR, V18, P311, DOI 10.1111/j.1468-2850.2011.01262.x; Chalder T, 2010, PSYCHOL MED, V40, P1269, DOI 10.1017/S003329170999153X; Cohen J, 2011, SCIENCE, V333, P1694, DOI 10.1126/science.333.6050.1694; Crawley EM, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000252; Cuijpers P, 2008, J BEHAV MED, V31, P169, DOI 10.1007/s10865-007-9144-1; Internet World Stats, US POP STAT; Nijhof SL, 2012, LANCET, V379, P1412, DOI 10.1016/S0140-6736(12)60025-7; Paprotka T, 2011, SCIENCE, V333, P97, DOI 10.1126/science.1205292; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Stulemeijer M, 2005, BMJ-BRIT MED J, V330, P14, DOI 10.1136/bmj.38301.587106.63	10	5	5	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 14	2012	379	9824					1372	1373		10.1016/S0140-6736(12)60197-4	http://dx.doi.org/10.1016/S0140-6736(12)60197-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	926BR	22385681				2023-01-03	WOS:000302806800008
J	Kitsios, GD; Kent, DM				Kitsios, Georgios D.; Kent, David M.			Personalised medicine: not just in our genes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GENOME-WIDE ASSOCIATION; PERCUTANEOUS CORONARY INTERVENTION; CLINICAL-TRIALS; INDIVIDUAL PATIENTS; RISK; PHARMACOGENOMICS; HETEROGENEITY; PREDICTION; BENEFIT		[Kent, David M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Clin & Translat Sci Program, Boston, MA 02111 USA; [Kitsios, Georgios D.; Kent, David M.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA; [Kitsios, Georgios D.] Lahey Clin Med Ctr, Dept Gen Internal Med, Burlington, MA 01803 USA	Tufts University; Tufts Medical Center; Lahey Hospital & Medical Center	Kent, DM (corresponding author), Tufts Univ, Sackler Sch Grad Biomed Sci, Clin & Translat Sci Program, Boston, MA 02111 USA.	dkent1@tuftsmedicalcenter.org		Kitsios, Georgios/0000-0002-1018-948X	NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025752] Funding Source: NIH RePORTER; NCRR NIH HHS [UL1 RR025752] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670; Aradi D, 2010, AM HEART J, V160, P543, DOI 10.1016/j.ahj.2010.06.004; Barber MJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009763; Becquement L, 2011, PHARMACOGENOMICS, V12, P113, DOI 10.2217/PGS.10.147; Combescure C, 2010, J THROMB HAEMOST, V8, P923, DOI 10.1111/j.1538-7836.2010.03809.x; Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006; Flockhart DA, 2008, GENET MED, V10, P139, DOI 10.1097/GIM.0b013e318163c35f; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Hayward RA, 2005, HEALTH AFFAIR, V24, P1571, DOI 10.1377/hlthaff.24.6.1571; Hayward Rodney A, 2006, BMC Med Res Methodol, V6, P18, DOI 10.1186/1471-2288-6-18; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Holmes DR, 2010, J AM COLL CARDIOL, V56, P321, DOI 10.1016/j.jacc.2010.05.013; Holmes MV, 2011, JAMA-J AM MED ASSOC, V306, P2704, DOI 10.1001/jama.2011.1880; Holmes MV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007960; Imai K, 2011, CLIN CHEM, V57, P518, DOI 10.1373/clinchem.2010.158220; Institute for Clinical Systems Improvement, 2010, DIAGN TREATM CHEST P; Institute for Clinical Systems Improvement, 2011, ANT THER SUPPL GUID; Ioannidis JPA, 2009, CIRC-CARDIOVASC GENE, V2, P7, DOI 10.1161/CIRCGENETICS.108.833392; Janssens A Cecile Jw, 2010, Investig Genet, V1, P10, DOI 10.1186/2041-2223-1-10; Kangelaris KN, 2009, J GEN INTERN MED, V24, P656, DOI 10.1007/s11606-009-0949-1; Kent DM, 2007, JAMA-J AM MED ASSOC, V298, P1209, DOI 10.1001/jama.298.10.1209; Kent DM, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-85; Kent DM, 2002, AM J MED, V113, P104, DOI 10.1016/S0002-9343(02)01160-9; Kravitz RL, 2004, MILBANK Q, V82, P661, DOI 10.1111/j.0887-378X.2004.00327.x; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Medical Services Commission, 2011, WARF THER MAN INV PR; Nissen SE, 2011, JAMA-J AM MED ASSOC, V306, P2727, DOI 10.1001/jama.2011.1865; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; Snoep JD, 2007, AM HEART J, V154, P221, DOI 10.1016/j.ahj.2007.04.014; Sofi F, 2010, THROMB HAEMOSTASIS, V103, P841, DOI 10.1160/TH09-06-0418; Swen JJ, 2007, PLOS MED, V4, P1317, DOI 10.1371/journal.pmed.0040209; US FDA, 2011, TABL PHARM BIOM DRUG; Veenstra DL, 2000, AAPS PHARMSCI, V2, part. no.	34	29	30	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 3	2012	344								e2161	10.1136/bmj.e2161	http://dx.doi.org/10.1136/bmj.e2161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	923GM	22491484	Green Published			2023-01-03	WOS:000302607700012
J	Karaca-Mandic, P; Jena, AB; Joyce, GF; Goldman, DP				Karaca-Mandic, Pinar; Jena, Anupam B.; Joyce, Geoffrey F.; Goldman, Dana P.			Out-of-Pocket Medication Costs and Use of Medications and Health Care Services Among Children With Asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INHALED CORTICOSTEROIDS; PHARMACY BENEFITS; INSURANCE; DRUGS; CAPS	Context Health plans have implemented policies to restrain prescription medication spending by shifting costs toward patients. It is unknown how these policies have affected children with chronic illness. Objective To analyze the association of medication cost sharing with medication and hospital services utilization among children with asthma, the most prevalent chronic disease of childhood. Design, Setting, and Patients Retrospective study of insurance claims for 8834 US children with asthma who initiated asthma control therapy between 1997 and 2007. Using variation in out-of-pocket costs for a fixed "basket" of asthma medications across 37 employers, we estimated multivariate models of asthma medication use, asthma-related hospitalization, and emergency department (ED) visits with respect to out-of-pocket costs and child and family characteristics. Main Outcome Measures Asthma medication use, asthma-related hospitalizations, and ED visits during 1-year follow-up. Results The mean annual out-of-pocket asthma medication cost was $154 (95% CI, $152-$156) among children aged 5 to 18 years and $151 (95% CI, $148-$153) among those younger than 5 years. Among 5913 children aged 5 to 18 years, filled asthma prescriptions covered a mean of 40.9% of days (95% CI, 40.2%-41.5%). During 1-year follow-up, 121 children (2.1%) had an asthma-related hospitalization and 220 (3.7%) had an ED visit. Among 2921 children younger than 5 years, mean medication use was 46.2% of days (95% CI, 45.2%-47.1%); 136 children (4.7%) had an asthma-related hospitalization and 231 (7.9%) had an ED visit. An increase in out-of-pocket medication costs from the 25th to the 75th percentile was associated with a reduction in adjusted medication use among children aged 5 to 18 years (41.7% [95% CI, 40.7%-42.7%] vs 40.3% [95% CI, 39.4%-41.3%] of days; P=.02) but no change among younger children. Adjusted rates of asthma-related hospitalization were higher for children aged 5 to 18 years in the top quartile of out-of-pocket costs (2.4 [95% CI, 1.9-2.8] hospitalizations per 100 children vs 1.7 [95% CI, 1.3-2.1] per 100 in bottom quartile; P=.004) but not for younger children. Annual adjusted rates of ED use did not vary across out-of-pocket quartiles for either age group. Conclusion Greater cost sharing for asthma medications was associated with a slight reduction in medication use and higher rates of asthma hospitalization among children aged 5 years or older. JAMA. 2012;307(12):1284-1291 www.jama.com	[Jena, Anupam B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wang Ambulatory Care Ctr,Dept Med, Boston, MA 02114 USA; [Karaca-Mandic, Pinar] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA; [Joyce, Geoffrey F.; Goldman, Dana P.] Univ So Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Southern California	Jena, AB (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wang Ambulatory Care Ctr,Dept Med, 15 Parkman St, Boston, MA 02114 USA.	jena.anupam@mgh.harvard.edu	Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396	National Institute of Child Health and Human Development [1R03HD058203-01A1]; National Institute on Aging [7R01AG02514]; Roybal Center for Health Policy Simulation [5P30AG024968]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD058203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024968] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Roybal Center for Health Policy Simulation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Support was provided by the National Institute of Child Health and Human Development (grant 1R03HD058203-01A1), the National Institute on Aging (grant 7R01AG02514), and the Roybal Center for Health Policy Simulation (grant 5P30AG024968).	Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Akinbami Lara, 2006, Adv Data, P1; [Anonymous], 2010, FED REGISTER, V75, P41726; Bethell CD, 2008, MATERN CHILD HLTH J, V12, P1, DOI 10.1007/s10995-007-0220-5; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Chandra A, 2010, AM ECON REV, V100, P193, DOI 10.1257/aer.100.1.193; Duan N., 1983, J BUSINESS EC STAT, V1, P115, DOI [DOI 10.1080/07350015.1983.10509330, DOI 10.2307/1391852]; Erickson SR, 2001, ANN PHARMACOTHER, V35, P997, DOI 10.1345/aph.10379; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562, DOI 10.1001/archpedi.156.6.562; Goldman DP, 2006, HEALTH AFFAIR, V25, P1319, DOI 10.1377/hlthaff.25.5.1319; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Goldman DP, 2006, AM J MANAG CARE, V12, P21; Halterman JS, 2000, PEDIATRICS, V105, P272; HENRY RL, 1995, J PAEDIATR CHILD H, V31, P95, DOI 10.1111/j.1440-1754.1995.tb00754.x; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Huskamp HA, 2005, ARCH GEN PSYCHIAT, V62, P435, DOI 10.1001/archpsyc.62.4.435; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; Johnson TJ, 2006, AM J PUBLIC HEALTH, V96, P709, DOI 10.2105/AJPH.2004.059758; Joyce GF, 2002, JAMA-J AM MED ASSOC, V288, P1733, DOI 10.1001/jama.288.14.1733; Karaca-Mandic P, 2010, HEALTH SERV RES, V45, P1227, DOI 10.1111/j.1475-6773.2010.01117.x; Kogan MD, 2010, NEW ENGL J MED, V363, P841, DOI 10.1056/NEJMsa0909994; Kozyrskyj AL, 2003, PEDIATR PULM, V36, P241, DOI 10.1002/ppul.10335; Kozyrskyj AL, 2001, ARCH PEDIAT ADOL MED, V155, P1219; LEIBOWITZ A, 1985, PEDIATRICS, V75, P942; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Newacheck PW, 1998, NEW ENGL J MED, V338, P513, DOI 10.1056/NEJM199802193380806; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tseng CW, 2004, JAMA-J AM MED ASSOC, V292, P952, DOI 10.1001/jama.292.8.952; Ungar WJ, 2008, ARCH PEDIAT ADOL MED, V162, P104, DOI 10.1001/archpediatrics.2007.21; Ungar WJ, 2011, ANN ALLERG ASTHMA IM, V106, P17, DOI 10.1016/j.anai.2010.10.006; US Census Bureau, 2010, CURR POP SURV ANN SO	32	81	81	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 28	2012	307	12					1284	1291		10.1001/jama.2012.340	http://dx.doi.org/10.1001/jama.2012.340			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	914UP	22453569	Bronze, Green Accepted			2023-01-03	WOS:000301978400024
J	Crawford, MJ; Killaspy, H; Barnes, TRE; Barrett, B; Byford, S; Clayton, K; Dinsmore, J; Floyd, S; Hoadley, A; Johnson, T; Kalaitzaki, E; King, M; Leurent, B; Maratos, A; O'Neill, FA; Osborn, DP; Patterson, S; Soteriou, T; Tyrer, P; Waller, D				Crawford, Mike J.; Killaspy, Helen; Barnes, Thomas R. E.; Barrett, Barbara; Byford, Sarah; Clayton, Katie; Dinsmore, John; Floyd, Siobhan; Hoadley, Angela; Johnson, Tony; Kalaitzaki, Eleftheria; King, Michael; Leurent, Baptiste; Maratos, Anna; O'Neill, Francis A.; Osborn, David P.; Patterson, Sue; Soteriou, Tony; Tyrer, Peter; Waller, Diane		MATISSE Project Team	Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PSYCHOLOGICAL THERAPY; RELIABILITY; SYMPTOMS; RELAPSE; SCALE	Objectives To evaluate the clinical effectiveness of group art therapy for people with schizophrenia and to test whether any benefits exceed those of an active control treatment. Design Three arm, rater blinded, pragmatic, randomised controlled trial. Setting Secondary care services across 15 sites in the United Kingdom. Participants 417 people aged 18 or over, who had a diagnosis of schizophrenia and provided written informed consent to take part in the study. Interventions Participants, stratified by site, were randomised to 12 months of weekly group art therapy plus standard care, 12 months of weekly activity groups plus standard care, or standard care alone. Art therapy and activity groups had up to eight members and lasted for 90 minutes. In art therapy, members were given access to a range of art materials and encouraged to use these to express themselves freely. Members of activity groups were offered various activities that did not involve use of art or craft materials and were encouraged to collectively select those they wanted to pursue. Main outcome measures The primary outcomes were global functioning, measured using the global assessment of functioning scale, and mental health symptoms, measured using the positive and negative syndrome scale, 24 months after randomisation. Main secondary outcomes were levels of group attendance, social functioning, and satisfaction with care at 12 and 24 months. Results 417 participants were assigned to either art therapy (n=140), activity groups (n=140), or standard care alone (n=137). Primary outcomes between the three study arms did not differ. The adjusted mean difference between art therapy and standard care at 24 months on the global assessment of functioning scale was -0.9 (95% confidence interval -3.8 to 2.1), and on the positive and negative syndrome scale was 0.7 (-3.1 to 4.6). Secondary outcomes did not differ between those referred to art therapy or those referred to standard care at 12 or 24 months. Conclusions Referring people with established schizophrenia to group art therapy as delivered in this trial did not improve global functioning, mental health, or other health related outcomes.	[Crawford, Mike J.; Barnes, Thomas R. E.; Patterson, Sue; Tyrer, Peter; Waller, Diane] Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Mental Hlth, Claybrook Ctr, London W6 8LN, England; [Killaspy, Helen; Hoadley, Angela; King, Michael; Osborn, David P.] UCL, Fac Brain Sci, Unit Mental Hlth Sci, London, England; [Barrett, Barbara; Byford, Sarah] Kings Coll London, Hlth Serv, Ctr Econ Mental Hlth, London WC2R 2LS, England; [Barrett, Barbara; Byford, Sarah] Kings Coll London, Populat Res Dept, London WC2R 2LS, England; [Clayton, Katie] Camden & Islington NHS Fdn Trust, London, England; [Dinsmore, John; O'Neill, Francis A.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland; [Floyd, Siobhan; Soteriou, Tony] Avon & Wiltshire Mental Hlth Partnership NHS Trus, Chippenham, Wilts, England; [Johnson, Tony] MRC Biostat Unit, Cambridge, England; [Johnson, Tony] MRC Clin Trials Unit London, London, England; [Kalaitzaki, Eleftheria; Leurent, Baptiste] MRC Gen Practice Res Framework, London, England; [Maratos, Anna] Cent & N W London NHS Fdn Trust, London, England	Imperial College London; University of London; University College London; University of London; King's College London; University of London; King's College London; Queens University Belfast; MRC Biostatistics Unit; Medical Research Council Clinical Trials Unit	Crawford, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Med, Ctr Mental Hlth, Claybrook Ctr, London W6 8LN, England.	m.crawford@imperial.ac.uk	O'Neill, Francis A/C-5582-2008; King, Michael B/D-7477-2011; Barrett, Barbara M/F-7606-2010; Byford, Sarah/D-1699-2010; Osborn PhD FRCPsych, David/B-8165-2009	O'Neill, Francis A/0000-0002-7531-7657; King, Michael B/0000-0003-4715-7171; Barrett, Barbara M/0000-0002-0270-6256; Byford, Sarah/0000-0001-7084-1495; Dinsmore, John/0000-0001-8387-3496; Leurent, Baptiste/0000-0001-6420-6567; Crawford, Mike/0000-0003-3137-5772; Killaspy, Helen/0000-0003-2481-4802; Osborn PhD FRCPsych, David/0000-0003-2519-1539	National Institute for Health Research [04/39/04]; Avon and Wiltshire Mental Health Partnership NHS Trust; Belfast Health and Social Care Trust; Camden and Islington NHS Foundation Trust; Central and North West London NHS Foundation Trust	National Institute for Health Research(National Institute for Health Research (NIHR)); Avon and Wiltshire Mental Health Partnership NHS Trust; Belfast Health and Social Care Trust; Camden and Islington NHS Foundation Trust; Central and North West London NHS Foundation Trust	The project was funded by the National Institute for Health Research Health Technology Assessment programme (project No 04/39/04) and received financial support from Avon and Wiltshire Mental Health Partnership NHS Trust, Belfast Health and Social Care Trust, Camden and Islington NHS Foundation Trust, and Central and North West London NHS Foundation Trust. The sponsors of the study played no part in the preparation of this paper. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Health Technology Assessment programme, the National Institute for Health Research, or the Department of Health.	ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANGRIST JD, 1995, J AM STAT ASSOC, V90, P431, DOI 10.2307/2291054; Atkinson C, 1994, PSYCHOL TESTING TREA, P404; British Association of Art Therapists, 2011, WHAT IS ART THER; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Crawford MJ, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-65; Crawford MJ, 2007, EVID-BASED MENT HEAL, V10, P69, DOI 10.1136/ebmh.10.3.69; George CF, 2000, BRIT J CLIN PHARMACO, V50, P166, DOI 10.1046/j.1365-2125.2000.00244.x; GREEN BL, 1987, HOSP COMMUNITY PSYCH, V38, P988; JONES SH, 1995, BRIT J PSYCHIAT, V166, P654, DOI 10.1192/bjp.166.5.654; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Killaspy H, 2000, BRIT J PSYCHIAT, V176, P160, DOI 10.1192/bjp.176.2.160; Killick K, 1997, UNINTEGRATION CONTAI; Kuyken W, 2008, J CONSULT CLIN PSYCH, V76, P966, DOI 10.1037/a0013786; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; *NAT I HLTH CLIN E, 2009, NICE CLIN GUID, V82; Norman RMG, 2000, ACTA PSYCHIAT SCAND, V102, P303, DOI 10.1034/j.1600-0447.2000.102004303.x; Patterson S, 2011, J MENT HEALTH, V20, P328, DOI 10.3109/09638237.2011.556163; Pfammatter M, 2006, SCHIZOPHRENIA BULL, V32, pS64, DOI 10.1093/schbul/sbl030; Richardson P., 2007, J MENT HEALTH, V16, P483, DOI [DOI 10.1080/09638230701483111, https://doi.org/10.1080/09638230701483111]; Robinson D, 1999, ARCH GEN PSYCHIAT, V56, P241, DOI 10.1001/archpsyc.56.3.241; Rohricht F, 2006, PSYCHOL MED, V36, P669, DOI 10.1017/S0033291706007161; Ruddy R, 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003728.PUB2; Spencer D, 2010, BRIT MED J, V341, pc6038; Talwar N, 2006, BRIT J PSYCHIAT, V189, P405, DOI 10.1192/bjp.bp.105.015073; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI [10.1503/cmaj.090523, 10.1016/j.jclinepi.2008.12.011]; Tyrer P, 2005, INT J SOC PSYCHIATR, V51, P265, DOI 10.1177/0020764005057391; Waller D, 1996, GROUP INTERACTIVE AR; Walwyn R, 2010, STAT METHODS MED RES, V19, P291, DOI 10.1177/0962280209105017; [郑日昌 Zheng Richang], 2005, [心理学报, Acta Psychologica Sinica], V37, P403	30	59	59	6	36	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	2012	344								e846	10.1136/bmj.e846	http://dx.doi.org/10.1136/bmj.e846			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	904XA	22374932	Green Submitted, Green Published, hybrid, Green Accepted			2023-01-03	WOS:000301231000001
J	Paschal, D				Paschal, Dean			Launching Complex Medical Workups From an Urgent Care Platform	ANNALS OF INTERNAL MEDICINE			English	Article								The basic parameters for medical workups have scarcely changed in the past 30 years. That is, what the internal medicine community has deemed acceptable for outpatient, inpatient, emergency department, and urgent care evaluation has remained pretty much stable or stagnant during all that time. We are failing to take advantage of the phenomenal speed and accuracy of new laboratory and imaging technologies. Due to Hurricane Katrina, which destroyed the Veterans Administration Hospital in New Orleans, those of us who work in its urgent care clinic were forced to undertake complex medical workups from an 8-to-5, walk-in platform. We have been amazed at the efficiency of this. Workups that used to take weeks can often be done in a few hours or days. What we have discovered here serendipitously may be worth deliberately duplicating elsewhere.	Tulane Univ, New Orleans, LA 70115 USA	Tulane University	Paschal, D (corresponding author), Tulane Univ, 5721 Magazine St,132, New Orleans, LA 70115 USA.	ldpaschal@bellsouth.net							0	2	2	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 7	2012	156	3					232	U95		10.7326/0003-4819-156-3-201202070-00012	http://dx.doi.org/10.7326/0003-4819-156-3-201202070-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887XD	22312142				2023-01-03	WOS:000299964200007
J	Hsu, YH; Chen, YC; Chen, TH; Sue, YM; Cheng, TH; Chen, JR; Chen, CH				Hsu, Yung-Ho; Chen, Yen-Cheng; Chen, Tso-Hsiao; Sue, Yuh-Mou; Cheng, Tzu-Hurng; Chen, Jia-Rung; Chen, Cheng-Hsien			Far-Infrared Therapy Induces the Nuclear Translocation of PLZF Which Inhibits VEGF-Induced Proliferation in Human Umbilical Vein Endothelial Cells	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; ACUTE PROMYELOCYTIC LEUKEMIA; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; ZINC-FINGER; ARTERIOVENOUS-FISTULA; BALLOON ANGIOPLASTY; OXIDATIVE STRESS; VENOUS STENOSIS; HEMODIALYSIS	Many studies suggest that far-infrared (FIR) therapy can reduce the frequency of some vascular-related diseases. The non-thermal effect of FIR was recently found to play a role in the long-term protective effect on vascular function, but its molecular mechanism is still unknown. In the present study, we evaluated the biological effect of FIR on vascular endothelial growth factor (VEGF)-induced proliferation in human umbilical vein endothelial cells (HUVECs). We found that FIR ranging 3 similar to 10 mu m significantly inhibited VEGF-induced proliferation in HUVECs. According to intensity and time course analyses, the inhibitory effect of FIR peaked at an effective intensity of 0.13 mW/cm(2) at 30 min. On the other hand, a thermal effect did not inhibit VEGF-induced proliferation in HUVECs. FIR exposure also inhibited the VEGF-induced phosphorylation of extracellular signal-regulated kinases in HUVECs. FIR exposure further induced the phosphorylation of endothelial nitric oxide (NO) synthase (eNOS) and NO generation in VEGF-treated HUVECs. Both VEGF-induced NO and reactive oxygen species generation was involved in the inhibitory effect of FIR. Nitrotyrosine formation significantly increased in HUVECs treated with VEGF and FIR together. Inhibition of phosphoinositide 3-kinase (PI3K) by wortmannin abolished the FIR-induced phosphorylation of eNOS and Akt in HUVECs. FIR exposure upregulated the expression of PI3K p85 at the transcriptional level. We further found that FIR exposure induced the nuclear translocation of promyelocytic leukemia zinc finger protein (PLZF) in HUVECs. This induction was independent of a thermal effect. The small interfering RNA transfection of PLZF blocked FIR-increased PI3K levels and the inhibitory effect of FIR. These data suggest that FIR induces the nuclear translocation of PLZF which inhibits VEGF-induced proliferation in HUVECs.	[Hsu, Yung-Ho; Chen, Jia-Rung; Chen, Cheng-Hsien] Taipei Med Univ Shuang Ho Hosp, Dept Internal Med, New Taipei City, Taiwan; [Chen, Yen-Cheng; Chen, Tso-Hsiao; Sue, Yuh-Mou; Chen, Cheng-Hsien] Taipei Med Univ Wan Fang Hosp, Dept Internal Med, Taipei, Taiwan; [Cheng, Tzu-Hurng] China Med Univ, Coll Life Sci, Dept Biol Sci & Technol, Taichung, Taiwan	Taipei Medical University; Taipei Medical University; China Medical University Taiwan	Hsu, YH (corresponding author), Taipei Med Univ Shuang Ho Hosp, Dept Internal Med, New Taipei City, Taiwan.	hippy@tmu.edu.tw			Taipei Medical University-Wan Fang Hospital [99wf-eva-07]	Taipei Medical University-Wan Fang Hospital	This work was supported by Taipei Medical University-Wan Fang Hospital (grant no.: 99wf-eva-07). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agbani E, 2011, TOXICOL IN VITRO; Akasaki Y, 2006, CIRC J, V70, P463, DOI 10.1253/circj.70.463; Bouloumie A, 1999, CARDIOVASC RES, V41, P773, DOI 10.1016/S0008-6363(98)00228-4; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng TH, 2009, ANESTHESIOLOGY; Costoya JA, 2001, CURR OPIN HEMATOL, V8, P212, DOI 10.1097/00062752-200107000-00006; Couper LL, 1997, CIRC RES, V81, P932; Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2; Guarda E, 1996, J MOL CELL CARDIOL, V28, P699, DOI 10.1006/jmcc.1996.0065; Ikeda Y, 2005, CIRC J, V69, P722, DOI 10.1253/circj.69.722; Imamura M, 2001, J AM COLL CARDIOL, V38, P1083, DOI 10.1016/S0735-1097(01)01467-X; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; Kihara T, 2004, CIRC J, V68, P1146, DOI 10.1253/circj.68.1146; Lin CC, 2007, J AM SOC NEPHROL, V18, P985, DOI 10.1681/ASN.2006050534; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Misra S, 2008, AM J PHYSIOL-HEART C, V294, pH2219, DOI 10.1152/ajpheart.00650.2007; REKHTER M, 1993, ARTERIOSCLER THROMB, V13, P609, DOI 10.1161/01.ATV.13.4.609; Rosselli M, 1998, HUM REPROD UPDATE, V4, P3, DOI 10.1093/humupd/4.1.3; Roy-Chaudhury P, 2006, J AM SOC NEPHROL, V17, P1112, DOI 10.1681/ASN.2005050615; Rubbo H, 2005, TOXICOLOGY, V208, P305, DOI 10.1016/j.tox.2004.11.019; Rubbo H, 2009, ARCH BIOCHEM BIOPHYS, V484, P167, DOI 10.1016/j.abb.2008.11.007; Rush JWE, 2005, CAN J APPL PHYSIOL, V30, P442, DOI 10.1139/h05-133; Schefe JH, 2006, CIRC RES, V99, P1355, DOI 10.1161/01.RES.0000251700.00994.0d; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Sukhatme VP, 1996, KIDNEY INT, V49, P1161, DOI 10.1038/ki.1996.167; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Wang Y, 2008, NEPHROL DIAL TRANSPL, V23, P525, DOI 10.1093/ndt/gfm547; Yu SY, 2006, PHOTODERMATOL PHOTO, V22, P78, DOI 10.1111/j.1600-0781.2006.00208.x	30	46	46	3	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2012	7	1							e30674	10.1371/journal.pone.0030674	http://dx.doi.org/10.1371/journal.pone.0030674			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909NE	22292015	gold, Green Submitted, Green Published			2023-01-03	WOS:000301570600070
J	Lipworth, W; Kerridge, I; Little, M; Day, R				Lipworth, Wendy; Kerridge, Ian; Little, Miles; Day, Richard			Evidence and desperation in off-label prescribing: recombinant factor VIIa	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ACTIVATED FACTOR-VII; HEMORRHAGE; SAFETY; RULE		[Lipworth, Wendy] Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW 2052, Australia; [Lipworth, Wendy; Kerridge, Ian; Little, Miles] Univ Sydney, Ctr Values Eth & Law Med, Sydney, NSW 2006, Australia; [Day, Richard] St Vincents Hosp, Sydney, NSW 2010, Australia	University of New South Wales Sydney; University of Sydney; St Vincents Hospital Sydney	Lipworth, W (corresponding author), Univ New S Wales, Australian Inst Hlth Innovat, Sydney, NSW 2052, Australia.	w.lipworth@unsw.edu.au	Day, Richard/D-8699-2011	Day, Richard/0000-0002-6045-6937; Lipworth, Wendy/0000-0002-0234-657X; Kerridge, Ian/0000-0001-7445-4660	National Health and Medical Research Council (NHMRC) [568612]; Sydney Medical School Foundation, University of Sydney	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Sydney Medical School Foundation, University of Sydney	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Empirical research related to this article has been funded by a National Health and Medical Research Council (NH&MRC) programme grant (568612) and by the Sydney Medical School Foundation, University of Sydney.	Avorn J, 2011, ANN INTERN MED, V154, P566, DOI 10.7326/0003-4819-154-8-201104190-00010; Bright JL, 2006, ARCH INTERN MED, V166, P2554, DOI 10.1001/archinte.166.22.2554-b; Dutton RP, 2011, J TRAUMA, V71, P12, DOI 10.1097/TA.0b013e31821a42cf; Gilovich T, 1998, PSYCHOL REV, V105, P602, DOI 10.1037/0033-295X.105.3.602; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; Jonsen A R, 1986, Law Med Health Care, V14, P172; Kalina Michael, 2011, Del Med J, V83, P109; Karkouti K, 2011, ANN INTERN MED, V155, P339, DOI 10.7326/0003-4819-155-5-201109060-00023; Kesselheim AS, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000431; Largent EA, 2009, ARCH INTERN MED, V169, P1745, DOI 10.1001/archinternmed.2009.314; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Lin YL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005011.pub3; Logan AC, 2011, ANN INTERN MED, V154, P516, DOI 10.7326/0003-4819-154-8-201104190-00002; MARKS I, 1988, AM J PSYCHIAT, V145, P1207; McKie J, 2003, SOC SCI MED, V56, P2407, DOI 10.1016/S0277-9536(02)00244-7; Ray C., 2011, WALL STREET J   0610; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Witmer CM, 2011, J PEDIAT, V158, P820; Yank V, 2011, ANN INTERN MED, V154, P529, DOI 10.7326/0003-4819-154-8-201104190-00004	19	11	11	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 16	2012	344								d7926	10.1136/bmj.d7926	http://dx.doi.org/10.1136/bmj.d7926			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	888YP	22250217	Green Submitted			2023-01-03	WOS:000300040900012
J	Morrison, EA; DeKoster, GT; Dutta, S; Vafabakhsh, R; Clarkson, MW; Bahl, A; Kern, D; Ha, T; Henzler-Wildman, KA				Morrison, Emma A.; DeKoster, Gregory T.; Dutta, Supratik; Vafabakhsh, Reza; Clarkson, Michael W.; Bahl, Arjun; Kern, Dorothee; Ha, Taekjip; Henzler-Wildman, Katherine A.			Antiparallel EmrE exports drugs by exchanging between asymmetric structures	NATURE			English	Article							MULTIDRUG TRANSPORTER EMRE; ESCHERICHIA-COLI; CONFORMATIONAL-CHANGES; MEMBRANE TOPOLOGY; SUBSTRATE-BINDING; LIGAND-BINDING; PROTON RELEASE; MODEL; STATE; MECHANISM	Small multidrug resistance transporters provide an ideal system to study the minimal requirements for active transport. EmrE is one such transporter in Escherichia coli. It exports a broad class of polyaromatic cation substrates, thus conferring resistance to drug compounds matching this chemical description. However, a great deal of controversy has surrounded the topology of the EmrE homodimer. Here we show that asymmetric antiparallel EmrE exchanges between inward-and outward-facing states that are identical except that they have opposite orientation in the membrane. We quantitatively measure the global conformational exchange between these two states for substrate-bound EmrE in bicelles using solution NMR dynamics experiments. Forster resonance energy transfer reveals that the monomers within each dimer are antiparallel, and paramagnetic relaxation enhancement NMR experiments demonstrate differential water accessibility of the two monomers within each dimer. Our experiments reveal a 'dynamic symmetry' that reconciles the asymmetric EmrE structure with the functional symmetry of residues in the active site.	[Morrison, Emma A.; DeKoster, Gregory T.; Dutta, Supratik; Bahl, Arjun; Henzler-Wildman, Katherine A.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; [Vafabakhsh, Reza; Ha, Taekjip] Univ Illinois, Dept Phys, Urbana, IL 61801 USA; [Vafabakhsh, Reza; Ha, Taekjip] Univ Illinois, Howard Hughes Med Inst, Urbana, IL 61801 USA; [Clarkson, Michael W.; Kern, Dorothee] Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; [Clarkson, Michael W.; Kern, Dorothee] Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA	Washington University (WUSTL); University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; Brandeis University; Brandeis University; Howard Hughes Medical Institute	Henzler-Wildman, KA (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.	khenzler@wustl.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258; DeKoster, Gregory/0000-0001-9928-8195; Henzler-Wildman, Katherine/0000-0002-5295-2121; Clarkson, Michael W/0000-0002-4323-3424; Morrison, Emma/0000-0001-6722-7961	National Institutes of Health [1R01GM095839]; Searle Scholars Program; US Department of Energy, Office of Basic Energy Sciences; Howard Hughes Medical Institute; NSF [DGE-1143954]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM095839] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Searle Scholars Program; US Department of Energy, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Y. Liu for assistance replicating the ITC data. We thank J. Villali for assistance growing isotopically labelled EmrE. We are grateful to Y. Li and A. Palmer for providing pulse programs and G. Chang for providing the EmrE expression plasmid. This work was supported by the National Institutes of Health (1R01GM095839) and the Searle Scholars Program (K. H. W.), the US Department of Energy, Office of Basic Energy Sciences (D. K.), the Howard Hughes Medical Institute (D. K. and T. H.), and an NSF graduate research fellowship to E. M. (DGE-1143954).	Adam Y, 2007, P NATL ACAD SCI USA, V104, P17989, DOI 10.1073/pnas.0704425104; Agarwal V, 2007, BBA-BIOMEMBRANES, V1768, P3036, DOI 10.1016/j.bbamem.2007.09.012; Amadi ST, 2010, J BIOL CHEM, V285, P26710, DOI 10.1074/jbc.M110.132621; Arkin IT, 1996, BIOCHEMISTRY-US, V35, P7233, DOI 10.1021/bi960094i; Butler PJG, 2004, J MOL BIOL, V340, P797, DOI 10.1016/j.jmb.2004.05.014; Charalambous Kalypso, 2008, BMC Biochemistry, V9, P31, DOI 10.1186/1471-2091-9-31; Chen YJ, 2007, P NATL ACAD SCI USA, V104, P18999, DOI 10.1073/pnas.0709387104; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, J BIOMOL NMR, V4, P727, DOI 10.1007/BF00404280; Glover KJ, 2001, BIOPHYS J, V81, P2163, DOI 10.1016/S0006-3495(01)75864-X; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kneller, 2003, SPARKY 3; Korkhov VM, 2008, J MOL BIOL, V377, P1094, DOI 10.1016/j.jmb.2008.01.056; Korkhov VM, 2009, ACTA CRYSTALLOGR D, V65, P186, DOI 10.1107/S0907444908036640; Lehner I, 2008, J BIOL CHEM, V283, P3281, DOI 10.1074/jbc.M707899200; Li Y, 2009, J BIOMOL NMR, V45, P357, DOI 10.1007/s10858-009-9385-0; Mchaourab HS, 2008, BIOCHEMISTRY-US, V47, P7980, DOI 10.1021/bi800628d; Miller D, 2009, J MOL BIOL, V393, P815, DOI 10.1016/j.jmb.2009.08.039; Miloushev VZ, 2008, STRUCTURE, V16, P1195, DOI 10.1016/j.str.2008.05.009; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Nara T, 2007, J BIOCHEM, V142, P621, DOI 10.1093/jb/mvm169; Nasie I, 2010, J BIOL CHEM, V285, P15234, DOI 10.1074/jbc.M110.108746; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; Rapp M, 2007, SCIENCE, V315, P1282, DOI 10.1126/science.1135406; Raschle T, 2010, CURR OPIN STRUC BIOL, V20, P471, DOI 10.1016/j.sbi.2010.05.006; Rotem D, 2004, J BIOL CHEM, V279, P48787, DOI 10.1074/jbc.M408187200; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Roy R, 2008, NAT METHODS, V5, P507, DOI 10.1038/NMETH.1208; Sanders CR, 2006, MAGN RESON CHEM, V44, pS24, DOI 10.1002/mrc.1816; Schuldiner S, 2009, BBA-PROTEINS PROTEOM, V1794, P748, DOI 10.1016/j.bbapap.2008.12.018; Seppala S, 2010, SCIENCE, V328, P1698, DOI 10.1126/science.1188950; Sharoni M, 2005, J BIOL CHEM, V280, P32849, DOI 10.1074/jbc.M504910200; Sikora CW, 2005, BIOPHYS J, V88, P475, DOI 10.1529/biophysj.104.049247; Soskine M, 2004, J BIOL CHEM, V279, P9951, DOI 10.1074/jbc.M312853200; Soskine M, 2006, J BIOL CHEM, V281, P36205, DOI 10.1074/jbc.M607186200; Steiner-Mordoch S, 2008, EMBO J, V27, P17, DOI 10.1038/sj.emboj.7601951; Tate CG, 2003, J MOL BIOL, V332, P229, DOI 10.1016/S0022-2836(03)00895-7; Ubarretxena-Belandia I, 2004, FEBS LETT, V564, P234, DOI 10.1016/S0014-5793(04)00228-5; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Weinglass AB, 2005, J BIOL CHEM, V280, P7487, DOI 10.1074/jbc.M413555200; West IC, 1997, BBA-REV BIOMEMBRANES, V1331, P213, DOI 10.1016/S0304-4157(97)00007-5; Whiles JA, 2002, BIOORG CHEM, V30, P431, DOI 10.1016/S0045-2068(02)00527-8; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200	49	153	154	1	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 5	2012	481	7379					45	U50		10.1038/nature10703	http://dx.doi.org/10.1038/nature10703			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872VD	22178925	Green Accepted			2023-01-03	WOS:000298836900025
J	Kociol, RD; Lopes, RD; Clare, R; Thomas, L; Mehta, RH; Kaul, P; Pieper, KS; Hochman, JS; Weaver, WD; Armstrong, PW; Granger, CB; Patel, MR				Kociol, Robb D.; Lopes, Renato D.; Clare, Robert; Thomas, Laine; Mehta, Rajendra H.; Kaul, Padma; Pieper, Karen S.; Hochman, Judith S.; Weaver, W. Douglas; Armstrong, Paul W.; Granger, Christopher B.; Patel, Manesh R.			International Variation in and Factors Associated With Hospital Readmission After Myocardial Infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCUTANEOUS CORONARY INTERVENTION; HEART-DISEASE MORTALITY; TEMPORAL TRENDS; EARLY DISCHARGE; FOLLOW-UP; PEXELIZUMAB; TRIAL; FAILURE; US	Context ST-segment elevation myocardial infarction (STEMI) treatment has improved outcomes and shortened hospital stay. Recently, 30-day readmission rates have been proposed as a metric for care of patients with STEMI. However, international rates and predictors of 30-day readmission after STEMI have not been studied. Objective To determine international variation in and predictors of 30-day readmission rates after STEMI and country-level care patterns. Design, Setting, and Patients Post hoc analysis of the Assessment of Pexelizumab in Acute Myocardial Infarction trial that enrolled 5745 patients with STEMI at 296 sites in the United States, Canada, Australia, New Zealand, and 13 European countries from July 13, 2004, to May 11, 2006. Multivariable logistic regression analysis was used to identify independent predictors of all-cause and non-elective 30-day postdischarge readmission. Main Outcome Measures Predictors of 30-day postdischarge all-cause and non-elective readmissions. Results Of 5571 patients with STEMI who survived to hospital discharge, 631 (11.3%) were readmitted within 30 days. Thirty-day readmission rates were higher for the United States than other countries (14.5% vs 9.9%; P<.001). Median length of stay was shortest for US patients (3 days; interquartile range, 2-4 days) and longest for Germany (8 days; interquartile range, 6-11 days). In multivariable regression, the predictors of 30-day readmission included multivessel disease (odds ratio [OR], 1.97; 95% CI, 1.65-2.35) and US location (OR, 1.68; 95% CI, 1.37-2.07). Excluding elective readmission for revascularization, US enrollment was still an independent predictor of readmission (OR, 1.53; 95% CI, 1.20-1.96). After adjustment of the models for country-level median length of stay, US location was no longer an independent predictor of 30-day all-cause or nonelective readmission. Location in the United States was not a predictor of in-hospital death (OR, 0.88; 95% CI, 0.60-1.30) or 30-day postadmission death (OR, 1.0; 95% CI, 0.72-1.39). Conclusions In this multinational study, there was variation across countries in 30-day readmission rates after STEMI, with readmission rates higher in the United States than in other countries. However, this difference was greatly attenuated after adjustment for length of stay. JAMA. 2012;307(1):66-74	[Kociol, Robb D.; Lopes, Renato D.; Clare, Robert; Thomas, Laine; Mehta, Rajendra H.; Pieper, Karen S.; Granger, Christopher B.; Patel, Manesh R.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA; [Kaul, Padma; Armstrong, Paul W.] Univ Alberta, Edmonton, AB, Canada; [Hochman, Judith S.] NYU, Sch Med, Cardiovasc Clin Res Ctr, New York, NY USA; [Weaver, W. Douglas] Henry Ford Hosp, Henry Ford Heart & Vasc Inst, Detroit, MI 48202 USA	Duke University; University of Alberta; New York University; Henry Ford Health System; Henry Ford Hospital	Patel, MR (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	manesh.patel@duke.edu	Granger, Christopher B/D-3458-2014; Patel, Manesh/AAC-5385-2019	Granger, Christopher B/0000-0002-0045-3291; Hochman, Judith/0000-0002-5889-5981; Kociol, Robb/0000-0002-8759-9997; Kaul, Padma/0000-0003-2239-3944; Armstrong, Paul/0000-0002-0460-3445	Duke Clinical Research Institute; Procter & Gamble Pharmaceuticals; Alexion Pharmaceuticals; American Heart Association-Pharmaceutical Roundtable	Duke Clinical Research Institute; Procter & Gamble Pharmaceuticals(Procter & Gamble); Alexion Pharmaceuticals; American Heart Association-Pharmaceutical Roundtable(American Heart Association)	This research was supported by unrestricted funding from the Duke Clinical Research Institute. Procter & Gamble Pharmaceuticals and Alexion Pharmaceuticals jointly funded the Assessment of Pexelizumab in Acute Myocardial Infarction trial. This work was supported by an award from the American Heart Association-Pharmaceutical Roundtable and David and Stevie Spina.	Anderson GF, 2008, MULTINATIONAL COMP H; Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43; Armstrong PW, 2005, AM HEART J, V149, P402, DOI 10.1016/j.ahj.2004.12.015; Baker DW, 2004, ARCH INTERN MED, V164, P538, DOI 10.1001/archinte.164.5.538; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Brener SJ, 2006, AM HEART J, V151, pS4, DOI 10.1016/j.ahj.2006.04.007; Capewell S, 1999, HEART, V81, P380, DOI 10.1136/hrt.81.4.380; Curtis JP, 2009, J AM COLL CARDIOL, V54, P903, DOI 10.1016/j.jacc.2009.04.076; Daugherty SL, 2008, ARCH INTERN MED, V168, P485, DOI 10.1001/archinte.168.5.485; Desai MM, 2009, CIRC-CARDIOVASC QUAL, V2, P500, DOI 10.1161/CIRCOUTCOMES.108.832949; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; Ford ES, 2007, NEW ENGL J MED, V356, P2388, DOI 10.1056/NEJMsa053935; Fox CS, 2004, CIRCULATION, V110, P522, DOI 10.1161/01.CIR.0000136993.34344.41; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; Kaul P, 2004, LANCET, V363, P511, DOI 10.1016/S0140-6736(04)15536-0; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; LAU YK, 1980, BRIT MED J, V280, P1489, DOI 10.1136/bmj.280.6230.1489; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Movahed MR, 2009, AM J CARDIOL, V104, P1030, DOI 10.1016/j.amjcard.2009.05.051; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Schroder R, 2004, CIRCULATION, V110, pE506, DOI 10.1161/01.CIR.0000147778.05979.E6; Spertus John A., 2003, Circulation, V107, P1681, DOI 10.1161/01.CIR.0000062026.90014.63; Stebbins A, 2010, CIRC-CARDIOVASC INTE, V3, P414, DOI 10.1161/CIRCINTERVENTIONS.109.925180; Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011	25	99	99	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 4	2012	307	1					66	74		10.1001/jama.2011.1926	http://dx.doi.org/10.1001/jama.2011.1926			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872ET	22215167	Bronze, Green Published			2023-01-03	WOS:000298792300023
J	Burger, RA; Brady, MF; Bookman, MA; Fleming, GF; Monk, BJ; Huang, H; Mannel, RS; Homesley, HD; Fowler, J; Greer, BE; Boente, M; Birrer, MJ; Liang, SX				Burger, Robert A.; Brady, Mark F.; Bookman, Michael A.; Fleming, Gini F.; Monk, Bradley J.; Huang, Helen; Mannel, Robert S.; Homesley, Howard D.; Fowler, Jeffrey; Greer, Benjamin E.; Boente, Matthew; Birrer, Michael J.; Liang, Sharon X.		Gynecologic Oncology Grp	Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR EXPRESSION; PROGNOSTIC-SIGNIFICANCE; ANTIANGIOGENIC THERAPY; MONOCLONAL-ANTIBODY; TUMOR ANGIOGENESIS; SOLID TUMORS; PHASE-II; CARCINOMA; ASCITES	BACKGROUND Vascular endothelial growth factor is a key promoter of angiogenesis and disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal antibody, has shown single-agent activity in women with recurrent tumors. Thus, we aimed to evaluate the addition of bevacizumab to standard front-line therapy. METHODS In our double-blind, placebo-controlled, phase 3 trial, we randomly assigned eligible patients with newly diagnosed stage III (incompletely resectable) or stage IV epithelial ovarian cancer who had undergone debulking surgery to receive one of three treatments. All three included chemotherapy consisting of intravenous paclitaxel at a dose of 175 mg per square meter of body-surface area, plus carboplatin at an area under the curve of 6, for cycles 1 through 6, plus a study treatment for cycles 2 through 22, each cycle of 3 weeks' duration. The control treatment was chemotherapy with placebo added in cycles 2 through 22; bevacizumab-initiation treatment was chemotherapy with bevacizumab (15 mg per kilogram of body weight) added in cycles 2 through 6 and placebo added in cycles 7 through 22. Bevacizumab-throughout treatment was chemotherapy with bevacizumab added in cycles 2 through 22. The primary end point was progression-free survival. RESULTS Overall, 1873 women were enrolled. The median progression-free survival was 10.3 months in the control group, 11.2 in the bevacizumab-initiation group, and 14.1 in the bevacizumab-throughout group. Relative to control treatment, the hazard ratio for progression or death was 0.908 (95% confidence interval [CI], 0.795 to 1.040; P=0.16) with bevacizumab initiation and 0.717 (95% CI, 0.625 to 0.824; P<0.001) with bevacizumab throughout. At the time of analysis, 76.3% of patients were alive, with no significant differences in overall survival among the three groups. The rate of hypertension requiring medical therapy was higher in the bevacizumab-initiation group (16.5%) and the bevacizumab-throughout group (22.9%) than in the control group (7.2%). Gastrointestinal-wall disruption requiring medical intervention occurred in 1.2%, 2.8%, and 2.6% of patients in the control group, the bevacizumab-initiation group, and the bevacizumab-throughout group, respectively. CONCLUSIONS The use of bevacizumab during and up to 10 months after carboplatin and paclitaxel chemotherapy prolongs the median progression-free survival by about 4 months in patients with advanced epithelial ovarian cancer. (Funded by the National Cancer Institute and Genentech; ClinicalTrials.gov number, NCT00262847.)	[Burger, Robert A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; [Brady, Mark F.; Huang, Helen] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA; [Bookman, Michael A.] Arizona Canc Ctr, Tucson, AZ USA; [Fleming, Gini F.] Univ Chicago, Chicago, IL 60637 USA; [Monk, Bradley J.] Creighton Univ, Sch Med, St Josephs Hosp & Med Ctr, Phoenix, AZ USA; [Mannel, Robert S.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Homesley, Howard D.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Fowler, Jeffrey] Ohio State Univ, James Canc Hosp, Hilliard, OH 43026 USA; [Greer, Benjamin E.] Seattle Canc Care Alliance, Seattle, WA USA; [Boente, Matthew] Minnesota Oncol & Hematol, Minneapolis, MN USA; [Birrer, Michael J.] Harvard Univ, Sch Med, Boston, MA USA; [Birrer, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Liang, Sharon X.] N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA	Fox Chase Cancer Center; Roswell Park Cancer Institute; Arizona Center Cancer Care; University of Chicago; Creighton University; St. Joseph's Hospital and Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Wake Forest University; Wake Forest Baptist Medical Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Seattle Cancer Care Alliance; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Northwell Health	Burger, RA (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	robert.a.burger@fccc.edu			National Cancer Institute; Genentech; NATIONAL CANCER INSTITUTE [P50CA083638] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Genentech(Roche HoldingGenentech); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funded by the National Cancer Institute and Genentech; ClinicalTrials.gov number, NCT00262847.; Supported by the National Cancer Institute and Genentech.	Aghajanian CAF, 2011, 2011 AM SOC CLIN ONC; Alvarez AA, 1999, CLIN CANCER RES, V5, P587; [Anonymous], AVASTIN BEVACIZUMAB; Bagri A, 2010, CLIN CANCER RES, V16, P3887, DOI 10.1158/1078-0432.CCR-09-3100; Basen-Engquist K, 2001, J CLIN ONCOL, V19, P1809, DOI 10.1200/JCO.2001.19.6.1809; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Belotti D, 2008, MOL CANCER RES, V6, P525, DOI 10.1158/1541-7786.MCR-07-0366; Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345; Byrne AT, 2003, CLIN CANCER RES, V9, P5721; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; Cannistra SA, 2008, J CLIN ONCOL, V26, P3665, DOI 10.1200/JCO.2008.17.2676; Cannistra SA, 2007, J CLIN ONCOL, V25, P5180, DOI 10.1200/JCO.2007.12.0782; COX DR, 1972, J R STAT SOC B, V34, P187; Duncan TJ, 2008, CLIN CANCER RES, V14, P3030, DOI 10.1158/1078-0432.CCR-07-1888; Gasparini G, 1996, INT J CANCER, V69, P205, DOI 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6; Geiger-Gritsch S, 2010, ONCOLOGIST, V15, P1373, DOI 10.1634/theoncologist.2009-0155erratum; Geiger-Gritsch S, 2010, ONCOLOGIST, V15, P1179, DOI 10.1634/theoncologist.2009-0155; Gerber HP, 2005, CANCER RES, V65, P671; Goodheart MJ, 2005, CLIN CANCER RES, V11, P3733, DOI 10.1158/1078-0432.CCR-04-0056; Han ES, 2007, GYNECOL ONCOL, V105, P3, DOI 10.1016/j.ygyno.2007.01.038; HOLLINGSWORTH HC, 1995, AM J PATHOL, V147, P33; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Manenti L, 2005, MOL CANCER THER, V4, P715, DOI 10.1158/1535-7163.MCT-04-0305; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; Perren TS, 2010, 35 ANN M EUR SOC MED; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Presta LG, 1997, CANCER RES, V57, P4593; Rustin GJS, 2001, J CLIN ONCOL, V19, P4054, DOI 10.1200/JCO.2001.19.20.4054; Shen GH, 2000, BRIT J CANCER, V83, P196; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Stuart GCE, 2011, INT J GYNECOL CANCER, V21, P750, DOI 10.1097/IGC.0b013e31821b2568; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988; Xu L, 2000, INT J ONCOL, V16, P445; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340	39	1583	1628	5	106	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 29	2011	365	26					2473	2483		10.1056/NEJMoa1104390	http://dx.doi.org/10.1056/NEJMoa1104390			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868SD	22204724				2023-01-03	WOS:000298544600008
J	Piers, RD; Azoulay, E; Ricou, B; Ganz, FD; Decruyenaere, J; Max, A; Michalsen, A; Maia, PA; Owczuk, R; Rubulotta, F; Depuydt, P; Meert, AP; Reyners, AK; Aquilina, A; Bekaert, M; Van den Noortgate, NJ; Schrauwen, WJ; Benoit, DD				Piers, Ruth D.; Azoulay, Elie; Ricou, Bara; Ganz, Freda DeKeyser; Decruyenaere, Johan; Max, Adeline; Michalsen, Andrej; Maia, Paulo Azevedo; Owczuk, Radoslaw; Rubulotta, Francesca; Depuydt, Pieter; Meert, Anne-Pascale; Reyners, Anna K.; Aquilina, Andrew; Bekaert, Maarten; Van den Noortgate, Nele J.; Schrauwen, Wim J.; Benoit, Dominique D.		ESICM	Perceptions of Appropriateness of Care Among European and Israeli Intensive Care Unit Nurses and Physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; MORAL DISTRESS; ETHICAL DILEMMAS; CRITICALLY-ILL; NURSING STAFF; FUTILE CARE; END; DECISIONS; BURNOUT; COMMUNICATION	Context Clinicians in intensive care units (ICUs) who perceive the care they provide as inappropriate experience moral distress and are at risk for burnout. This situation may jeopardize patient quality of care and increase staff turnover. Objective To determine the prevalence of perceived inappropriateness of care among ICU clinicians and to identify patient-related situations, personal characteristics, and work-related characteristics associated with perceived inappropriateness of care. Design, Setting, and Participants Cross-sectional evaluation on May 11, 2010, of 82 adult ICUs in 9 European countries and Israel. Participants were 1953 ICU nurses and physicians providing bedside care. Main Outcome Measure Perceived inappropriateness of care, defined as a specific patient-care situation in which the clinician acts in a manner contrary to his or her personal and professional beliefs, as assessed using a questionnaire designed for the study. Results Of 1651 respondents (median response rate, 93% overall; interquartile range, 82%-100% [medians 93% among nurses and 100% among physicians]), perceived inappropriateness of care in at least 1 patient was reported by 439 clinicians overall (27%; 95% CI, 24%-29%), 300 of 1218 were nurses (25%), 132 of 407 were physicians (32%), and 26 had missing answers describing job title. Of these 439 individuals, 397 reported 445 situations associated with perceived inappropriateness of care. The most common reports were perceived disproportionate care (290 situations [65%; 95% CI, 58%-73%], of which "too much care" was reported in 89% of situations, followed by "other patients would benefit more" (168 situations [38%; 95% CI, 32%-43%]). Independently associated with perceived inappropriateness of care rates both among nurses and physicians were symptom control decisions directed by physicians only (odds ratio [OR], 1.73; 95% CI, 1.17-2.56; P=.006); involvement of nurses in end-of-life decision making (OR, 0.76; 95% CI, 0.60-0.96; P=.02); good collaboration between nurses and physicians (OR, 0.72; 95% CI, 0.56-0.92; P=.009); and freedom to decide how to perform work-related tasks (OR, 0.72; 95% CI, 0.59-0.89; P=.002); while a high perceived workload was significantly associated among nurses only(OR, 1.49; 95% CI, 1.07-2.06; P=.02). Perceived inappropriateness of care was independently associated with higher intent to leave a job (OR, 1.65; 95% CI, 1.04-2.63; P=.03). In the subset of 69 ICUs for which patient data could be linked, clinicians reported received inappropriateness of care in 207 patients, representing 23% (95% CI, 20%-27%) of 883 ICU beds. Conclusion Among a group of European and Israeli ICU clinicians, perceptions of inappropriate care were frequently reported and were inversely associated with factors indicating good teamwork. JAMA. 2011;306(24):2694-2703	[Piers, Ruth D.; Decruyenaere, Johan; Depuydt, Pieter; Benoit, Dominique D.] Ghent Univ Hosp, Dept Intens Care Med, B-9000 Ghent, Belgium; [Piers, Ruth D.; Van den Noortgate, Nele J.] Ghent Univ Hosp, Dept Geriatr, B-9000 Ghent, Belgium; [Schrauwen, Wim J.] Ghent Univ Hosp, Dept Med Oncol, B-9000 Ghent, Belgium; [Azoulay, Elie; Max, Adeline] Hop St Louis, Med ICU, Paris, France; [Azoulay, Elie; Max, Adeline] Univ Paris 07, Paris, France; [Ricou, Bara] Univ Hosp Geneva, Dept Intens Care, Geneva, Switzerland; [Ricou, Bara] Univ Geneva, Geneva, Switzerland; [Ganz, Freda DeKeyser] Hadassah Hebrew Univ, Sch Nursing, Jerusalem, Israel; [Michalsen, Andrej] Tuttlingen Hosp, Dept Anaesthesiol & Crit Care Med, Tuttlingen, Germany; [Maia, Paulo Azevedo] Ctr Hosp Porto, Hosp Santo Antonio, Serv Cuidados Intens 1, Oporto, Portugal; [Owczuk, Radoslaw] Med Univ Gdansk, Dept Anaesthesiol & Intens Therapy, Gdansk, Poland; [Rubulotta, Francesca] Imperial Coll NHS Trust, Charing Cross Hosp, Ctr Perioperat Med & Crit Care Res, London, England; [Meert, Anne-Pascale] Inst Jules Bordet, Serv Soins Intensifs Medicochirurg & Oncol Thorac, B-1000 Brussels, Belgium; [Reyners, Anna K.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands; [Aquilina, Andrew] Mater Dei Hosp, Dept Anaesthesia, Msida, Malta; [Bekaert, Maarten] Univ Ghent, Dept Appl Math & Comp Sci, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Geneva; University of Geneva; Hebrew University of Jerusalem; Hadassah University Medical Center; Fahrenheit Universities; Medical University Gdansk; Imperial College London; Institut Jules Bordet; University of Groningen; Ghent University	Piers, RD (corresponding author), Ghent Univ Hosp, Dept Intens Care Med, Pintelaan 185, B-9000 Ghent, Belgium.	ruth.piers@ugent.be	Owczuk, Radoslaw/AAK-9305-2020; Piers, Ruth/GNH-2561-2022; Swinnen, Walter/GZG-2677-2022; Rubulotta, Francesca/AAE-3246-2021; Philippart, Francois/AAF-2791-2019	Swinnen, Walter/0000-0001-5387-149X; Rubulotta, Francesca/0000-0001-8644-1728; Philippart, Francois/0000-0002-7323-0742; Megarbane, Bruno/0000-0002-2522-2764	European Society of Intensive Care Medicine/European Critical Care Research Network (ESICM/ECCRN); Gilead; Pfizer; Merck, Sharp, and Dohme; Astra-Zeneca; Bayer; General Electric; Abbott Laboratories, Poland	European Society of Intensive Care Medicine/European Critical Care Research Network (ESICM/ECCRN); Gilead(Gilead Sciences); Pfizer(Pfizer); Merck, Sharp, and Dohme(Merck & Company); Astra-Zeneca(AstraZeneca); Bayer(Bayer AG); General Electric(General Electric); Abbott Laboratories, Poland	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Piers, Decruyenaere, Van Den Noortgate, and Benoit report receipt of a grant from the European Society of Intensive Care Medicine/European Critical Care Research Network (ESICM/ECCRN). Dr Azoulay reports board membership, consultancy, grants received or pending, and speakers bureau participation with Gilead, Pfizer, and Merck, Sharp, and Dohme. Dr Decruyenaere reports receipt of meeting expenses from the European Society of Clinical Microbiology and Infectious Diseases; and other research grants from Astra-Zeneca, Bayer, Pfizer, Merck, Sharp, and Dohme, and General Electric. Dr Owczuk reports receipt of consultancy fees from Abbott Laboratories, Poland. Dr Depuydt reports receipt of a grant or a pending grant from Pfizer. The remaining authors report no disclosures.	Altun I, 2002, NURS ETHICS, V9, P269, DOI 10.1191/0969733002ne509oa; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Azoulay E, 2009, AM J RESP CRIT CARE, V180, P853, DOI 10.1164/rccm.200810-1614OC; Corley MC, 2005, NURS ETHICS, V12, P381, DOI 10.1191/0969733005ne809oa; Corley MC, 2001, J ADV NURS, V33, P250, DOI 10.1046/j.1365-2648.2001.01658.x; Corley MC, 2002, NURS ETHICS, V9, P636, DOI 10.1191/0969733002ne557oa; Curtis JR, 2010, LANCET, V376, P1347, DOI 10.1016/S0140-6736(10)60143-2; Curtis JR, 2001, CRIT CARE MED, V29, pN26, DOI 10.1097/00003246-200102001-00006; Daly K, 2001, BRIT MED J, V322, P1274, DOI 10.1136/bmj.322.7297.1274; De Dreu C, 2007, PSYCHOL CONFLICT CON, P3; Embriaco N, 2007, AM J RESP CRIT CARE, V175, P686, DOI 10.1164/rccm.200608-1184OC; Epstein EG, 2009, J CLIN ETHIC, V20, P330; Fassier T, 2005, CURR OPIN CRIT CARE, V11, P616, DOI 10.1097/01.ccx.0000184299.91254.ff; Ferrand E, 2003, AM J RESP CRIT CARE, V167, P1310, DOI 10.1164/rccm.200207-752OC; Goleman D., 1995, EMOTIONAL INTELLIGEN; Gutierrez KM, 2005, DIMENS CRIT CARE NUR, V24, P229, DOI 10.1097/00003465-200509000-00011; Hamric AB, 2007, CRIT CARE MED, V35, P422, DOI 10.1097/01.CCM.0000254722.50608.2D; Ho KM, 2005, INTENS CARE MED, V31, P668, DOI 10.1007/s00134-005-2613-5; Kalvemark S, 2004, SOC SCI MED, V58, P1075, DOI 10.1016/S0277-9536(03)00279-X; Karasek R., 1990, HLTH WORK STRESS PRO; Karasek R.A., 1989, JOB CONTROL WORKER H, P129; Krasner MS, 2009, JAMA-J AM MED ASSOC, V302, P1284, DOI 10.1001/jama.2009.1384; Lilly CM, 2000, AM J MED, V109, P469, DOI 10.1016/S0002-9343(00)00524-6; Lilly CM, 2003, CRIT CARE MED, V31, pS394, DOI 10.1097/01.CCM.0000065279.77449.B4; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd; McNarry AF, 2004, INTENS CARE MED, V30, P325, DOI 10.1007/s00134-003-2072-9; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Meltzer LS, 2004, AM J CRIT CARE, V13, P202, DOI 10.4037/ajcc2004.13.3.202; Mobley Melinda J, 2007, Intensive Crit Care Nurs, V23, P256, DOI 10.1016/j.iccn.2007.03.011; Nussbaum M., 2001, UPHEAVALS THOUGHT; Oberle K, 2001, J ADV NURS, V33, P707, DOI 10.1046/j.1365-2648.2001.01710.x; Palda VA, 2005, J CRIT CARE, V20, P207, DOI 10.1016/j.jcrc.2005.05.006; Penticuff JH, 2000, NURS RES, V49, P64, DOI 10.1097/00006199-200003000-00002; Piers RD, J AM MED DIR ASS; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Puntillo KA, 2006, CRIT CARE MED, V34, pS332, DOI 10.1097/01.CCM.0000237047.31376.28; Raines M L, 2000, JONAS Healthc Law Ethics Regul, V2, P29, DOI 10.1097/00128488-200002010-00006; Rushton CH, 2006, AACN ADV CRIT CARE, V17, P161, DOI 10.1097/01256961-200604000-00011; Schluter J, 2008, NURS ETHICS, V15, P304, DOI 10.1177/0969733007088357; Schwenzer KJ, 2006, CRIT CARE MED, V34, P2967, DOI 10.1097/01.CCM.0000248879.19054.73; Seale C, 2010, J MED ETHICS, V36, P677, DOI 10.1136/jme.2010.036194; Sprung CL, 2008, INTENS CARE MED, V34, P271, DOI 10.1007/s00134-007-0927-1; Sprung CL, 1999, CRIT CARE MED, V27, P1073, DOI 10.1097/00003246-199906000-00021; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; Vanheule S, 2003, HUM RELAT, V56, P321, DOI 10.1177/0018726703056003614; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; Visser MRM, 2003, CAN MED ASSOC J, V168, P271; Weiner Joseph S, 2004, J Palliat Med, V7, P817, DOI 10.1089/jpm.2004.7.817; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	49	217	221	0	37	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 28	2011	306	24					2694	2703		10.1001/jama.2011.1888	http://dx.doi.org/10.1001/jama.2011.1888			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	867VX	22203538	Bronze, Green Published			2023-01-03	WOS:000298484000020
J	Dobler, CC; McDonald, SP; Marks, GB				Dobler, Claudia C.; McDonald, Stephen P.; Marks, Guy B.			Risk of Tuberculosis in Dialysis Patients: A Nationwide Cohort Study	PLOS ONE			English	Article							DENDRITIC CELL-FUNCTION; NOTIFICATIONS; AUSTRALIA; MONOCYTE	Background: The ability to identify individuals at increased risk of developing tuberculosis (TB) has important implications for public health policy and patient care. We conducted a general population historical cohort study in all Australian States and Territories to establish the risk of TB arising in people on chronic hemo- or peritoneal dialysis. Methodology/Principal Findings: Cases of TB disease in patients receiving chronic dialysis were identified by record linkage using the Australia & New Zealand Dialysis and Transplant Registry (ANZDATA) and State and Territory TB notification databases 2001 to 2006. Main outcome measure was the relative risk of TB in people on dialysis, adjusted for TB incidence in country of birth, sex, age and indigenous status. A total of 6,276 cases of active TB were reported among 19,855,283 people living in Australia between 2001 and 2006. Among 14,506 patients on dialysis, 37 had a notification for TB disease after commencing dialysis, of whom 28 were culture positive. The incidence of TB was 66.8/100,000/year (95% Cl 47.7 to 93.2) among people on dialysis and 5.7/100,000/year (95% Cl 5.5 to 5.8) in the general population. The adjusted relative risk (aRR) of TB in people on dialysis was 7.8 (95% Cl 3.3 to 18.7), and the aRR of culture positive TB was 8.6 (95% Cl 3.9 to 19.3). Conclusions/Significance: Patients on dialysis are at increased risk of TB. The final decision to screen for, and to treat, LTBI in individual dialysis patients will be influenced by a cumulative assessment of the risk of reactivation of TB and by assessment of risk factors for adverse effects of treatment.	[Dobler, Claudia C.; Marks, Guy B.] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; [Dobler, Claudia C.; Marks, Guy B.] Liverpool Hosp, Dept Resp Med, Sydney, NSW, Australia; [McDonald, Stephen P.] Austrailia & New Zealand Dialysis & Transplant AN, Adelaide, SA, Australia; [McDonald, Stephen P.] Univ Adelaide, Discipline Med, Adelaide, SA, Australia	University of Sydney; Woolcock Institute of Medical Research; Liverpool Hospital; University of Adelaide	Dobler, CC (corresponding author), Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia.	cdobler@med.usyd.edu.au	McDonald, Stephen/G-4010-2013; Marks, Guy B./F-5058-2013	McDonald, Stephen/0000-0001-6103-1386; Marks, Guy B./0000-0002-8976-8053; Dobler, Claudia/0000-0002-5460-0189	Sydney South West Research Foundation	Sydney South West Research Foundation	The study was funded by a grant from the Sydney South West Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed AT, 2004, INT J TUBERC LUNG D, V8, P341; [Anonymous], 1995, MMWR Recomm Rep, V44, P19; Australian Bureau of Statistics (ABS), 2012, 47130 ABS; Barry C, 2009, COMMUN DIS INTELL, V33, P304; Cain KP, 2008, JAMA-J AM MED ASSOC, V300, P405, DOI 10.1001/jama.300.4.405; Chan TYK, 2000, CALCIFIED TISSUE INT, V66, P476, DOI 10.1007/s002230010095; Chia S, 1998, INT J TUBERC LUNG D, V2, P989; Chou KJ, 2001, NEPHRON, V88, P138, DOI 10.1159/000045974; Fleiss JL., 1981, STAT METHODS RATES P, P14; GIBBONS RAS, 1990, CLIN IMMUNOL IMMUNOP, V56, P66, DOI 10.1016/0090-1229(90)90170-U; Girndt M, 1999, NEPHROL DIAL TRANSPL, V14, P2807, DOI 10.1093/ndt/14.12.2807; Hussein MM, 2003, SEMIN DIALYSIS, V16, P38, DOI 10.1046/j.1525-139X.2003.03010.x; KAY N E, 1986, Blood Purification, V4, P120, DOI 10.1159/000169435; Lim WH, 2007, KIDNEY INT, V72, P1138, DOI 10.1038/sj.ki.5002425; Lim WH, 2007, KIDNEY INT, V71, P1122, DOI 10.1038/sj.ki.5002196; Lui SL, 2001, AM J KIDNEY DIS, V38, P1055, DOI 10.1053/ajkd.2001.28599; McDonald S, 2011, ANZDATA REGISTRY REP; Menzies D, 2008, INT J TUBERC LUNG D, V12, P498; Milburn H, 2010, THORAX, V65, P559, DOI 10.1136/thx.2009.133173; *NAT CTR HIV EP CL, 2006, HIV AIDS VIR HEP SEX; PRADHAN RP, 1974, JAMA-J AM MED ASSOC, V229, P798, DOI 10.1001/jama.229.7.798; Roche PW, 2008, COMMUN DIS INTELL, V32, P1; Simon TA, 1999, INFECT CONT HOSP EP, V20, P607, DOI 10.1086/501679; Singh M., 2002, AIHW B; Stewart JH, 2004, NEPHROLOGY, V9, P247, DOI 10.1111/j.1440-1797.2004.00258.x; Tubach F, 2009, ARTHRITIS RHEUM-US, V60, P1884, DOI 10.1002/art.24632; Tzanno-Martins C, 2000, NEPHRON, V84, P224, DOI 10.1159/000045581; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; World Health Organization, 2011, GLOB TUB DAT	29	49	53	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 27	2011	6	12							e29563	10.1371/journal.pone.0029563	http://dx.doi.org/10.1371/journal.pone.0029563			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	897SB	22216316	Green Published, gold, Green Submitted			2023-01-03	WOS:000300674900043
J	Grijalva, CG; Chen, L; Delzell, E; Baddley, JW; Beukelman, T; Winthrop, KL; Griffin, MR; Herrinton, LJ; Liu, LY; Ouellet-Hellstrom, R; Patkar, NM; Solomon, DH; Lewis, JD; Xie, FL; Saag, KG; Curtis, JR				Grijalva, Carlos G.; Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Winthrop, Kevin L.; Griffin, Marie R.; Herrinton, Lisa J.; Liu, Liyan; Ouellet-Hellstrom, Rita; Patkar, Nivedita M.; Solomon, Daniel H.; Lewis, James D.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.			Initiation of Tumor Necrosis Factor-alpha Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODIFYING ANTIRHEUMATIC DRUGS; SERIOUS BACTERIAL-INFECTIONS; RHEUMATOID-ARTHRITIS; OPPORTUNISTIC INFECTIONS; BRITISH-SOCIETY; THERAPY; METAANALYSIS; SAFETY; ASSOCIATION; INFLIXIMAB	Context Although tumor necrosis factor (TNF)-alpha antagonists are increasingly used in place of nonbiologic comparator medications, their safety profile remains incomplete. Objectives To determine whether initiation of TNF-alpha antagonists compared with nonbiologic comparators is associated with an increased risk of serious infections requiring hospitalization. Design, Setting, and Patients Within a US multi-institutional collaboration, we assembled retrospective cohorts (1998-2007) of patients with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies) combining data from Kaiser Permanente Northern California, New Jersey and Pennsylvania Pharmaceutical Assistance programs, Tennessee Medicaid, and national Medicaid/Medicare. TNF-alpha antagonists and nonbiologic regimens were compared in disease-specific propensity score (PS)-matched cohorts using Cox regression models with nonbiologics as the reference. Baseline glucocorticoid use was evaluated as a separate covariate. Main Outcome Measure Infections requiring hospitalization (serious infections) during the first 12 months after initiation of TNF-alpha antagonists or nonbiologic regimens. Results Study cohorts included 10 484 RA, 2323 IBD, and 3215 psoriasis and spondyloarthropathies matched pairs using TNF-alpha antagonists and comparator medications. Overall, we identified 1172 serious infections, most of which (53%) were pneumonia and skin and soft tissue infections. Among patients with RA, serious infection hospitalization rates were 8.16 (TNF-alpha antagonists) and 7.78 (comparator regimens) per 100 person-years (adjusted hazard ratio [aHR], 1.05 [95% CI, 0.91-1.21]). Among patients with IBD, rates were 10.91 (TNF-alpha antagonists) and 9.60 (comparator) per 100 person-years (aHR, 1.10 [95% CI, 0.83-1.46]). Among patients with psoriasis and spondyloarthropathies, rates were 5.41 (TNF-alpha antagonists) and 5.37 (comparator) per 100 person-years (aHR, 1.05 [95% CI, 0.76-1.45]). Among patients with RA, infliximab was associated with a significant increase in serious infections compared with etanercept (aHR, 1.26 [95% CI, 1.07-1.47]) and adalimumab (aHR, 1.23 [95% CI, 1.02-1.48]). Baseline glucocorticoid use was associated with a dose-dependent increase in infections. Conclusion Among patients with autoimmune diseases, compared with treatment with nonbiologic regimens, initiation of TNF-alpha antagonists was not associated with an increased risk of hospitalizations for serious infections. JAMA. 2011;306(21):2331-2339 Published online November 6, 2011. doi:10.1001/jama.2011.1692	[Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, Nashville, TN 37212 USA; [Chen, Lang; Delzell, Elizabeth; Baddley, John W.; Beukelman, Timothy; Patkar, Nivedita M.; Xie, Fenglong; Saag, Kenneth G.; Curtis, Jeffrey R.] Univ Alabama Birmingham, Birmingham, AL USA; [Baddley, John W.] Birmingham VA Med Ctr, Birmingham, AL USA; [Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Herrinton, Lisa J.; Liu, Liyan] Kaiser Permanente No Calif, Oakland, CA USA; [Ouellet-Hellstrom, Rita] US FDA, Silver Spring, MD USA; [Solomon, Daniel H.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Solomon, Daniel H.] Harvard Univ, Boston, MA 02115 USA; [Lewis, James D.] Univ Penn, Dept Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Lewis, James D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	Vanderbilt University; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham; Oregon Health & Science University; Kaiser Permanente; US Food & Drug Administration (FDA); Harvard University; Brigham & Women's Hospital; Harvard University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Grijalva, CG (corresponding author), Vanderbilt Univ, Sch Med, Div Pharmacoepidemiol, Dept Prevent Med, 1500 21st Ave S,Ste 2600, Nashville, TN 37212 USA.	carlos.grijalva@vanderbilt.edu		Beukelman, Timothy/0000-0001-9463-6306; Grijalva, Carlos/0000-0002-2329-7797	Amgen; Genentech; Centocor; Procter Gamble; Abbott; Eli Lilly; Bristol-Myers Squibb; Takeda; Shire; Pfizer; Roche/Genentech; UCB biopharma; CORRONA; Crescendo; Food and Drug Administration (FDA); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality (AHRQ) [U18 HS17919, R01HS018517]; National Institutes of Health (NIH) [AR053351]; NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2 RR025776-03]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [5P60AR56116]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS018517, U18HS017919] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR056116, K23AR053351] Funding Source: NIH RePORTER	Amgen(Amgen); Genentech(Roche HoldingGenentech); Centocor; Procter Gamble(Procter & Gamble); Abbott(Abbott Laboratories); Eli Lilly(Eli Lilly); Bristol-Myers Squibb(Bristol-Myers Squibb); Takeda(Takeda Pharmaceutical Company Ltd); Shire; Pfizer(Pfizer); Roche/Genentech(Roche HoldingGenentech); UCB biopharma; CORRONA; Crescendo(European Commission); Food and Drug Administration (FDA)(United States Department of Health & Human Services); US Department of Health and Human Services (DHHS); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH via the University of Alabama at Birmingham Center for Clinical and Translational Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Delzell reported receiving research support from Amgen. Dr Baddley reported consulting for Abbott and Merck. Dr Herrinton reported receiving research support from Genentech, Centocor, and Procter & Gamble. Dr Solomon reported receiving research support from Amgen, Abbott, Eli Lilly, and Bristol-Myers Squibb. Dr Lewis reported consulting for Genentech, Abbott, CORRONA (Consortium of Rheumatology Researchers of North America Inc), Millennium Pharmaceuticals, Elan, AstraZeneca, Procter & Gamble, GlaxoSmithKline, Alios Therapeutics, Roche, and Amgen; he also reported receiving research support from Centocor, Takeda, and Shire, and consultant honoraria from Amgen and Pfizer. Dr Winthrop reported receiving consultant fees from Genentech and Abbott, research support from Pfizer, and speakers honoraria from Amgen and Pfizer. Dr Saag reported receiving research support from Amgen, Genentech, and Pfizer. Dr Curtis reported receiving consultant fees and research grants from Roche/Genentech, UCB biopharma, Centocor, CORRONA, Amgen, Pfizer, Bristol-Myers Squibb, Crescendo, and Abbott. Other authors reported no conflicts.; This work was supported by the Food and Drug Administration (FDA), US Department of Health and Human Services (DHHS), and the Agency for Healthcare Research and Quality (AHRQ) grant U18 HS17919. Dr Curtis receives support from the National Institutes of Health (NIH; AR053351) and AHRQ (R01HS018517). Dr Beukelman was supported by NIH grant 5KL2 RR025776-03 via the University of Alabama at Birmingham Center for Clinical and Translational Science. Drs Grijalva and Griffin receive support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant 5P60AR56116.	Askling J, 2007, ANN RHEUM DIS, V66, P1339, DOI 10.1136/ard.2006.062760; Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637; Bernatsky S, 2010, J RHEUMATOL, V37, P928, DOI 10.3899/jrheum.091107; Bijlsma JWJ, 2003, ANN RHEUM DIS, V62, P1033, DOI 10.1136/ard.62.11.1033; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Buttgereit F, 2002, ANN RHEUM DIS, V61, P718, DOI 10.1136/ard.61.8.718; Curtis JR, 2007, ARTHRIT RHEUM-ARTHR, V57, P343, DOI 10.1002/art.22544; Curtis JR, 2007, ARTHRITIS RHEUM, V56, P4226, DOI 10.1002/art.23050; Curtis JR, 2007, ARTHRITIS RHEUM-US, V56, P1125, DOI 10.1002/art.22504; Curtis JR, 2011, ANN RHEUM DIS, V70, P1401, DOI 10.1136/ard.2010.146365; Dixon WG, 2007, ARTHRITIS RHEUM, V56, P2896, DOI 10.1002/art.22808; Dixon WG, 2006, ARTHRITIS RHEUM-US, V54, P2368, DOI 10.1002/art.21978; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2294, DOI 10.1002/art.10529; Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524; Fouque-Aubert A, 2010, ANN RHEUM DIS, V69, P1756, DOI 10.1136/ard.2008.098822; Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002; Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242; Greenberg JD, 2010, ANN RHEUM DIS, V69, P380, DOI 10.1136/ard.2008.089276; Grijalva CG, 2008, RHEUMATOLOGY, V47, P1061, DOI 10.1093/rheumatology/ken193; Grijalva CG, 2008, PHARMACOEPIDEM DR S, V17, P890, DOI 10.1002/pds.1625; Grijalva CG, 2010, RHEUMATOLOGY, V49, P82, DOI 10.1093/rheumatology/kep325; Herrinton LJ, 2011, PHARMACOEPIDEM DR S, V20, P1199, DOI 10.1002/pds.2196; Hsieh FY, 2000, CONTROL CLIN TRIALS, V21, P552, DOI 10.1016/S0197-2456(00)00104-5; Hudson M, 2010, ARTHRIT CARE RES, V62, P805, DOI 10.1002/acr.20124; Lane MA, 2011, MEDICINE, V90, P139, DOI 10.1097/MD.0b013e318211106a; Leombruno JP, 2009, ANN RHEUM DIS, V68, P1136, DOI 10.1136/ard.2008.091025; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386; Patkar NM, 2009, J CLIN EPIDEMIOL, V62, P321, DOI 10.1016/j.jclinepi.2008.06.006; Peyrin-Biroulet L, 2008, CLIN GASTROENTEROL H, V6, P644, DOI 10.1016/j.cgh.2008.03.014; Rassen JA, 2010, MED CARE, V48, pS83, DOI 10.1097/MLR.0b013e3181d59541; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; Rigby WFC, 2007, NAT CLIN PRACT RHEUM, V3, P227, DOI 10.1038/ncprheum0438; Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721; Schmajuk G, 2011, JAMA-J AM MED ASSOC, V305, P480, DOI 10.1001/jama.2011.67; Schneeweiss S, 2009, ALIMENT PHARM THER, V30, P253, DOI 10.1111/j.1365-2036.2009.04037.x; Schneeweiss S, 2007, ARTHRITIS RHEUM-US, V56, P1754, DOI 10.1002/art.22600; Schneeweiss S, 2007, J CLIN EPIDEMIOL, V60, P397, DOI 10.1016/j.jclinepi.2006.07.011; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Solomon DH, 2008, ARTHRITIS RHEUM-US, V58, P919, DOI 10.1002/art.23396; Solomon DH, 2006, ARTHRITIS RHEUM-US, V54, P3790, DOI 10.1002/art.22255; Solomon DH, 2011, JAMA-J AM MED ASSOC, V305, P2525, DOI 10.1001/jama.2011.878; STUCK AE, 1989, REV INFECT DIS, V11, P954; Ting G, 2005, J RHEUMATOL, V32, P1679; Westhovens R, 2006, ARTHRITIS RHEUM-US, V54, P1075, DOI 10.1002/art.21734; Wolfe F, 2006, ARTHRITIS RHEUM-US, V54, P628, DOI 10.1002/art.21568; Yu O, 2011, EPIDEMIOL INFECT, V139, P1296, DOI 10.1017/S0950268810002529	49	264	274	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	2011	306	21					2331	2339		10.1001/jama.2011.1692	http://dx.doi.org/10.1001/jama.2011.1692			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856YH	22056398	Green Accepted, Bronze			2023-01-03	WOS:000297680300018
J	von Roth, P; Canny, BJ; Volk, HD; Noble, JA; Prober, CG; Perka, C; Duda, GN				von Roth, Philipp; Canny, Benedict J.; Volk, Hans-Dieter; Noble, J. Alison; Prober, Charles G.; Perka, Carsten; Duda, Georg N.			The challenges of modern interdisciplinary medical research	NATURE BIOTECHNOLOGY			English	Editorial Material							ORTHOPEDIC CLINICIAN-SCIENTIST	The increasing complexity of medical science poses significant challenges to medical education, leading to a growing gap between medical researchers and treating practitioners.	[von Roth, Philipp; Perka, Carsten; Duda, Georg N.] Charite Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany; [von Roth, Philipp; Perka, Carsten; Duda, Georg N.] Charite Univ Med Berlin, Julius Wolff Inst, Berlin, Germany; [von Roth, Philipp; Perka, Carsten; Duda, Georg N.] Charite Univ Med Berlin, Ctr Musculoskeletal Surg, Berlin, Germany; [Canny, Benedict J.] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic 3800, Australia; [Volk, Hans-Dieter] Charite Univ Med Berlin, Inst Med Immunol, Berlin, Germany; [Noble, J. Alison] Univ Oxford, Inst Biomed Engn, Oxford, England; [Noble, J. Alison] Univ Oxford, RCUK Ctr Doctoral Training Healthcare Innovat, Dept Engn Sci, Oxford, England; [Prober, Charles G.] Stanford Univ, Sch Med, Stanford, CA 94305 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Monash University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Oxford; University of Oxford; Stanford University	von Roth, P (corresponding author), Charite Univ Med Berlin, Berlin Brandenburg Sch Regenerat Therapies, Berlin Brandenburg Ctr Regenerat Therapies, Berlin, Germany.	georg.duda@charite.de	Perka, Carsten/ABG-6505-2021; volk, hans-dieter/AAV-8053-2021; Duda, Georg N/H-2085-2016	volk, hans-dieter/0000-0002-7743-6668; Duda, Georg N/0000-0001-7605-3908; Perka, Carsten/0000-0002-0993-581X; Noble, Alison/0000-0002-3060-3772				Ahn J, 2008, J BONE JOINT SURG AM, V90A, P1794, DOI 10.2106/JBJS.G.00460; Butler D, 2008, NATURE, V453, P840, DOI 10.1038/453840a; GOLDSTEIN JL, 1986, J CLIN INVEST, V78, P848, DOI 10.1172/JCI112652; Jayasundera T, 2003, CLIN EXP OPHTHALMOL, V31, P294, DOI 10.1046/j.1442-9071.2003.00678.x; McKelvie J, 2009, CLIN EXP OPHTHALMOL, V37, P247, DOI 10.1111/j.1442-9071.2009.02040.x; Moran CJ, 2010, ARTHROSCOPY, V26, P1417, DOI 10.1016/j.arthro.2010.09.002; Sherwin T, 2003, CLIN EXP OPHTHALMOL, V31, P284, DOI 10.1046/j.1442-9071.2003.00680.x	7	9	9	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2011	29	12					1145	1148		10.1038/nbt.2062	http://dx.doi.org/10.1038/nbt.2062			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	861SE	22158370				2023-01-03	WOS:000298038700026
J	Recher, C; Coiffier, B; Haioun, C; Molina, TJ; Ferme, C; Casasnovas, O; Thieblemont, C; Bosly, A; Laurent, G; Morschhauser, F; Ghesquieres, H; Jardin, F; Bologna, S; Fruchart, C; Corront, B; Gabarre, J; Bonnet, C; Janvier, M; Canioni, D; Jais, JP; Salles, G; Tilly, H				Recher, Christian; Coiffier, Bertrand; Haioun, Corinne; Molina, Thierry Jo; Ferme, Christophe; Casasnovas, Olivier; Thieblemont, Catherine; Bosly, Andre; Laurent, Guy; Morschhauser, Franck; Ghesquieres, Herve; Jardin, Fabrice; Bologna, Serge; Fruchart, Christophe; Corront, Bernadette; Gabarre, Jean; Bonnet, Christophe; Janvier, Maud; Canioni, Danielle; Jais, Jean-Philippe; Salles, Gilles; Tilly, Herve		Grp Etud Lymphomes Adulte	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial	LANCET			English	Article							NON-HODGKINS-LYMPHOMA; AGGRESSIVE LYMPHOMAS; RESPONSE CRITERIA; ELDERLY-PATIENTS; POOR-PROGNOSIS; YOUNG-PATIENTS; DES-LYMPHOMES; TRANSPLANTATION; REGIMEN; MULTICENTER	Background The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy regimens. We aimed to assess, in patients aged 18-59 years, the potential survival benefit provided by a dose-intensive immunochemotherapy regimen plus rituximab compared with standard treatment plus rituximab. Methods We did an open-label randomised trial comparing dose-intensive rituximab, doxorubicin, cyclo phosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) with subsequent consolidation versus standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). Random assignment was done with a computer-assisted randomisation-allocation sequence with a block size of four. Patients were aged 18-59 years with untreated diffuse large B-cell lymphoma and an age-adjusted international prognostic index equal to 1. Our primary endpoint was event-free survival. Our analyses of efficacy and safety were of the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00140595. Findings One patient withdrew consent before treatment and 54 did not complete treatment. After a median follow-up of 44 months, our 3-year estimate of event-free survival was 81% (95% CI 75-86) in the R-ACVBP group and 67% (59-73) in the R-CHOP group (hazard ratio [HR] 0.56, 95% CI 0.38-0.83; p=0.0035). 3-year estimates of progression-free survival (87% [95% CI, 81-91] vs 73% [66-79]; HR 0.48 [0.30-0.76]; p=0.0015) and overall survival (92% [87-95] vs 84% [77-89]; HR 0.44 [0.28-0.81]; p=0.0071) were also increased in the R-ACVBP group. 82 (42%) of 196 patients in the R-ACVBP group experienced a serious adverse event compared with 28 (15%) of 183 in the R-CHOP group. Grade 3-4 haematological toxic effects were more common in the R-ACVBP group, with a higher proportion of patients experiencing a febrile neutropenic episode (38% [75 of 196] vs 9% [16 of 183]). Interpretation Compared with standard R-CHOP, intensified immunochemotherapy with R-ACVBP significantly improves survival of patients aged 18-59 years with diffuse large B-cell lymphoma with low-intermediate risk according to the International Prognostic Index. Haematological toxic effects of the intensive regimen were raised but manageable.	[Jardin, Fabrice; Tilly, Herve] Univ Rouen, Ctr Henri Becquerel, UMR918, F-76038 Rouen, France; [Recher, Christian; Laurent, Guy] Ctr Hosp Univ Toulouse, Toulouse, France; [Coiffier, Bertrand; Salles, Gilles] Univ Lyon 1, Hosp Civils Lyon, F-69622 Villeurbanne, France; [Haioun, Corinne] Hop Henri Mondor, AP HP, F-94010 Creteil, France; [Molina, Thierry Jo] Univ Paris 05, Hotel Dieu, AP HP, Paris, France; [Ferme, Christophe] Inst Cancerol Gustave Roussy, Villejuif, France; [Casasnovas, Olivier] Ctr Hosp Univ Dijon, Dijon, France; [Thieblemont, Catherine] Hop St Louis IUH INSERM U728, Paris, France; [Bosly, Andre] Catholic Univ Louvain, Mt Godinne, Belgium; [Morschhauser, Franck] CHU Lille, F-59037 Lille, France; [Ghesquieres, Herve] Ctr Leon Berard, F-69373 Lyon, France; [Bologna, Serge] Ctr Hosp Univ Nancy, Vandoeuvre Les Nancy, France; [Fruchart, Christophe] Ctr Francois Baclesse, F-14021 Caen, France; [Corront, Bernadette] Ctr Hosp Annecy, Pringy, France; [Gabarre, Jean] Hop La Pitie Salpetriere, AP HP, Paris, France; [Bonnet, Christophe] Ctr Hosp Liege, Liege, Belgium; [Janvier, Maud] Hop Rene Huguenin, Inst Curie, St Cloud, France; [Canioni, Danielle; Jais, Jean-Philippe] Univ Paris 05, Hop Necker, AP HP, Paris, France	UNICANCER; Centre Henri Becquerel; Universite de Rouen Normandie; CHU de Toulouse; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Catholique Louvain; Universite de Lille - ISITE; CHU Lille; UNICANCER; Centre Leon Berard; CHU de Nancy; UNICANCER; Centre Francois Baclesse; Centre Hospitalier Annecy Genevois; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Liege; Rene Huguenin Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Tilly, H (corresponding author), Univ Rouen, Ctr Henri Becquerel, UMR918, Rue Amiens, F-76038 Rouen, France.	herve.tilly@rouen.fnclcc.fr	Besson, Caroline/H-4648-2018; Thieblemont, Catherine/AAZ-8423-2020; Salles, Gilles/Z-2336-2019; Molina, Thierry/ABA-5214-2020; Mounier, Nicolas/X-2964-2018; , Van Eygen Koen/AAF-7668-2020; Hug, Balthasar L./G-1568-2010; Zachee, Pierre/B-5391-2018	Besson, Caroline/0000-0003-4364-7173; Thieblemont, Catherine/0000-0002-9941-2448; Salles, Gilles/0000-0002-9541-8666; Molina, Thierry/0000-0002-3929-9754; Mounier, Nicolas/0000-0002-0707-426X; , Van Eygen Koen/0000-0001-8285-906X; Zachee, Pierre/0000-0002-2275-5143; Haioun, Corinne/0000-0003-0095-5379; Delmer, Alain/0000-0002-1430-2574; Casasnovas, Rene-Olivier/0000-0002-1156-8983	Groupe d'Etudes des Lymphomes de l'Adulte; Amgen; Celgene; Roche; Chugai	Groupe d'Etudes des Lymphomes de l'Adulte; Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Roche(Roche Holding); Chugai	Groupe d'Etudes des Lymphomes de l'Adulte and Amgen.; BCoi, CH, OC, AB, GL, FM, GS, and HT have served as consultants, on advisory boards, or both for Roche, Genentech, or both. CR, GS, and HT have served as consultants, on advisory boards, or both for Celgene. CR is an advisory board member of Genzyme and received grant support from Celgene. BCoi received grant support from Amgen and payment for lectures from Amgen, Celgene, Roche, and GlaxoSmithKline. CH is an advisory board member of Pfizer and Janssen-Cilag, received grant support from Amgen, Celgene, and Roche, and received payment for lectures from Roche. OC received grants support from Amgen, Chugai, and Roche. AB received grant support from Roche and received payment for lectures from Roche. FM received payment for lectures from Bayer, Novartis, and Roche. GS received payment for lectures from Celgene, Mundi Pharma, and Roche, and received travel support from Pfizer. HT is an advisory board member of Seattle Genetics, received grant support from Amgen and Celgene, received payment for lectures from Amgen, Celgene, Janssen-Cilag, and Pfizer, and travel support from Celgene. TJM, CFer, CT, HG, FJ, SB, CFru, BCor, JG, CB, MJ, DC, and J-PJ declare that they have no conflicts of interest.	Abramson JS, 2010, CANCER-AM CANCER SOC, V116, P4283, DOI 10.1002/cncr.25278; Andre M, 2004, BLOOD, V103, P1222, DOI 10.1182/blood-2003-04-1124; Casasnovas RO, 2011, BLOOD, V118, P37, DOI 10.1182/blood-2010-12-327767; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; COIFFIER B, 1989, J CLIN ONCOL, V7, P1018, DOI 10.1200/JCO.1989.7.8.1018; COIFFIER B, 1986, J CLIN ONCOL, V4, P147, DOI 10.1200/JCO.1986.4.2.147; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Dumontet C, 2002, BRIT J HAEMATOL, V118, P210, DOI 10.1046/j.1365-2141.2002.03565.x; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gisselbrecht C, 2010, J CLIN ONCOL, V28, P4184, DOI 10.1200/JCO.2010.28.1618; Glass B, 2010, ANN ONCOL, V21, P2255, DOI 10.1093/annonc/mdq235; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Lenz G, 2010, NEW ENGL J MED, V362, P1417, DOI 10.1056/NEJMra0807082; Morel P, 2008, ANN ONCOL, V19, P560, DOI 10.1093/annonc/mdm520; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood-2003-06-2094; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Reyes F, 2005, NEW ENGL J MED, V352, P1197, DOI 10.1056/NEJMoa042040; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Tarella C, 2007, LEUKEMIA, V21, P1802, DOI 10.1038/sj.leu.2404781; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Vitolo U, 2009, HAEMATOL-HEMATOL J, V94, P1250, DOI 10.3324/haematol.2009.007005; Weiner GJ, 2010, SEMIN HEMATOL, V47, P115, DOI 10.1053/j.seminhematol.2010.01.011; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391	29	256	268	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 26	2011	378	9806					1858	1867		10.1016/S0140-6736(11)61040-4	http://dx.doi.org/10.1016/S0140-6736(11)61040-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	857DQ	22118442	Green Submitted			2023-01-03	WOS:000297695800030
J	Kesselheim, AS; Murtagh, L; Mello, MM				Kesselheim, Aaron S.; Murtagh, Lindsey; Mello, Michelle M.			"Pay for Delay" Settlements of Disputes over Pharmaceutical Patents	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GENERIC DRUGS; COMPETITION; RIGHTS		[Kesselheim, Aaron S.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; [Kesselheim, Aaron S.] Harvard Univ, Sch Med, Boston, MA USA; [Murtagh, Lindsey; Mello, Michelle M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Kesselheim, AS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.		Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Mello, Michelle/0000-0003-2877-4270				[Anonymous], 2010, OR BOOK APPR DRUG PR; Anton JJ, 2006, INNOV POLICY ECON, V6, P1; BELIAN D, 2010, GENERIC LINE, V27, P4; BELIAN D, 2010, GENERIC LINE, V27, P1; Bernard Kent S., 2005, FED CIRCUIT BAR J, V15, P617; Berndt ER, 2007, HEALTH AFFAIR, V26, P790, DOI 10.1377/hlthaff.26.3.790; Bhaven N.Sampat, 2011, EVERGREENING PATENT; Bigelow JP., 2004, ANTITRUST B, V49, P655, DOI 10.1177/0003603X0404900306; Carrier MA, 2009, MICH LAW REV, V108, P37; CRANE DA, 2002, FLA L REV, V54, P747; DICKEY B, 2010, PRELIMINARY EC ANAL; Engelberg A., 1999, IDEA, V39, P389; *FED TRAD COMM, 2002, GEN DRUG ENTR PRIOR; Federal Trade Commission, 2010, PAY FOR DEL DRUG CO; Federal Trade Commission, 2009, AUTH GEN INT REP AUTH GEN INT REP; *FTC, 2009, PAY FOR DEL SETTL MA; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; Hemphill CS, 2009, COLUMBIA LAW REV, V109, P629; Higgins MJ, 2009, SCIENCE, V326, P370, DOI 10.1126/science.1176116; HOVENKAMP H, 2005, ANTITRUST ENTERPRISE; Kesselheim AS, 2006, HEALTH AFFAIR, V25, P1637, DOI 10.1377/hlthaff.25.6.1637; PERITZ RJR, 2011, RES PAPER SERIES NEW, V1011; Roin BN, 2009, TEX LAW REV, V87, P503; ROSCH JT, 2010, REMARKS FTC COMMISSI; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shuchman M, 2006, NEW ENGL J MED, V355, P1297, DOI 10.1056/NEJMp068193; STOLBERG SG, 2000, NY TIMES        0723; Voet Martin A., 2005, GENERIC CHALLENGE UN	28	17	17	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	2011	365	15					1439	1445		10.1056/NEJMhle1102235	http://dx.doi.org/10.1056/NEJMhle1102235			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	832DQ	21916635				2023-01-03	WOS:000295782500014
J	Slamon, D; Eiermann, W; Robert, N; Pienkowski, T; Martin, M; Press, M; Mackey, J; Glaspy, J; Chan, A; Pawlicki, M; Tamas, P; Valero, V; Liu, MC; Sauter, G; von Minckwitz, G; Visco, F; Bee, V; Buyse, M; Bendahmane, B; Tabah-Fisch, I; Lindsay, MA; Riva, A; Crown, J				Slamon, Dennis; Eiermann, Wolfgang; Robert, Nicholas; Pienkowski, Tadeusz; Martin, Miguel; Press, Michael; Mackey, John; Glaspy, John; Chan, Arlene; Pawlicki, Marek; Tamas Pinter; Valero, Vicente; Liu, Mei-Ching; Sauter, Guido; von Minckwitz, Gunter; Visco, Frances; Bee, Valerie; Buyse, Marc; Bendahmane, Belguendouz; Tabah-Fisch, Isabelle; Lindsay, Mary-Ann; Riva, Alessandro; Crown, John		Breast Canc Int Res Grp	Adjuvant Trastuzumab in HER2-Positive Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY; OVARIAN-CANCER; RANDOMIZED-TRIALS; TUMOR-CELLS; HER2 STATUS; CHEMOTHERAPY; RECEPTOR; THERAPY; DOXORUBICIN; GROWTH	BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety. RESULTS At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study. CONCLUSIONS The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.)	[Slamon, Dennis; Glaspy, John] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Press, Michael] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Eiermann, Wolfgang] Frauenklin Roten Kreuz, Munich, Germany; [Sauter, Guido] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Hamburg, Germany; [von Minckwitz, Gunter] Zentrum Frauenheilkunde, Frankfurt, Germany; [Robert, Nicholas] US Oncol Res, Houston, TX USA; [Valero, Vicente] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Pienkowski, Tadeusz] Marie Curie Sklodowska Univ, Warsaw, Poland; [Martin, Miguel] Hosp Univ San Carlos, Madrid, Spain; [Mackey, John] Univ Alberta, Dept Oncol, Edmonton, AB, Canada; [Chan, Arlene] Mt Hosp, Mt Breast Grp, Perth, WA, Australia; [Press, Michael] City Oncol Dispensary, St Petersburg, Russia; [Tamas Pinter] Petz Oktato Korhaz Onkoradiol, Budapest, Hungary; [Liu, Mei-Ching] Sun Yat Sen Canc Ctr, Taipei, Taiwan; [Visco, Frances] Natl Breast Canc Coalit, Washington, DC USA; [Bee, Valerie; Lindsay, Mary-Ann; Riva, Alessandro] Breast Canc Int Res Grp, Paris, France; [Bendahmane, Belguendouz; Tabah-Fisch, Isabelle] Sanofi Aventis, Paris, France; [Buyse, Marc] Int Inst Drug Dev, Louvain, Belgium; [Crown, John] St Vincents Univ Hosp, All Ireland Cooperat Oncol Res Grp, Dublin 4, Ireland	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of Southern California; University of Hamburg; University Medical Center Hamburg-Eppendorf; US Oncology Network; University of Texas System; UTMD Anderson Cancer Center; Maria Curie-Sklodowska University; University of Alberta; Sanofi-Aventis; International Drug Development Institute; All-Ireland Cooperative Oncology Research Group; University College Dublin; Saint Vincent's University Hospital	Slamon, D (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 10945 Le Conte Ave,Suite 3360, Los Angeles, CA 90095 USA.	dslamon@mednet.ucla.edu	Buyse, Marc/J-4658-2013; Stanculeanu, Dana Lucia/AAB-7964-2019; Wardley, Andrew/N-8135-2015; Francis, Prudence A/J-4003-2012; Schwartsmann, Gilberto/G-4256-2016; Mieszkowska, Magdalena/O-6753-2017; Crown, John/AAL-3367-2020; Romero, Jose Luis Alonso/AAC-3782-2020; Sanches, Solange/G-6255-2017; Martin, Miguel/AAJ-9242-2020; Calvo, Lourdes/M-2352-2014; Martin, Miguel/V-6589-2019; Petruzelka, Lubos/A-2750-2017; Kwong, Ava/D-8005-2013	Stanculeanu, Dana Lucia/0000-0003-3930-2543; Wardley, Andrew/0000-0002-9639-0888; Francis, Prudence A/0000-0002-7207-9286; Schwartsmann, Gilberto/0000-0002-7850-1644; Romero, Jose Luis Alonso/0000-0001-8746-2096; Martin, Miguel/0000-0001-9237-3231; Petruzelka, Lubos/0000-0002-4397-0635; , International Journal of Business and Applied Social Science/0000-0001-7850-0193; Kwong, Ava/0000-0002-6968-9489; Pienkowski, Tadeusz/0000-0002-0110-5950; VANLEMMENS, LAURENCE/0000-0001-7799-1648; Lemos Ferrari, Bruno/0000-0002-7728-1125; Adrover, Encarna/0000-0001-8676-8560; Gligorov, Joseph/0000-0002-9900-6386; Crown, John/0000-0002-3125-7613; Buyse, Marc/0000-0002-4559-0994; Breitbach, Georg-Peter/0000-0002-8257-917X	Sanofi-Aventis; Genentech; Department of Defense; Revlon/UCLA; Peter and Denise Wittich Breast Cancer Program; U.S. Army Medical Research and Development Command [DAMD-03-1-0626]; National Cancer Institute [CA 48780]; California Breast Cancer Research Program [12IB-0155, 14NB-0179]; Roche; Amgen; Eli Lilly; NATIONAL CANCER INSTITUTE [R01CA048780] Funding Source: NIH RePORTER	Sanofi-Aventis(Sanofi-Aventis); Genentech(Roche HoldingGenentech); Department of Defense(United States Department of Defense); Revlon/UCLA; Peter and Denise Wittich Breast Cancer Program; U.S. Army Medical Research and Development Command(United States Department of DefenseUnited States ArmyUnited States Army Medical Research & Development Command (USAMRDC)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); California Breast Cancer Research Program; Roche(Roche Holding); Amgen(Amgen); Eli Lilly(Eli Lilly); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Sanofi-Aventis and Genentech; a Department of Defense Breast Cancer Innovator Award and funding from the Revlon/UCLA Women's Cancer Program and the Peter and Denise Wittich Breast Cancer Program (to Dr. Slamon); and grants (to Dr. Press) from the U.S. Army Medical Research and Development Command (DAMD-03-1-0626), the National Cancer Institute (CA 48780), and the California Breast Cancer Research Program (12IB-0155 and 14NB-0179) for studies of TOP2A.; Dr. Slamon reports receiving honoraria and reimbursement for travel expenses from Genentech and Sanofi-Aventis; Dr. Eiermann, receiving honoraria, lecture fees, and reimbursement for travel expenses from Roche and Sanofi-Aventis; Dr. Robert, receiving reimbursement for travel expenses from Fairfax Northern Virginia Hematology Oncology PC and that his institution has received grant support, honoraria, and payments for the development of educational presentations from Fairfax Northern Virginia Hematology Oncology PC on his behalf; Dr. Pienkowski, serving as a board member for Sanofi-Aventis and Roche, receiving honoraria from Roche and GlaxoSmithKline, and that he and his institution have received lecture fees and reimbursement for travel expenses from Roche and Sanofi-Aventis; Dr. Press, receiving consulting fees, honoraria, lecture fees, and reimbursement for travel expenses from Genentech; Dr. Mackey, receiving honoraria from Roche; Dr. Glaspy, receiving lecture fees from Genentech, Amgen, and Eli Lilly; Dr. Chan, serving on an advisory board for and receiving consulting fees, grant support, and honoraria from Roche and -receiving reimbursement for travel expenses from Sanofi-Aventis; Dr. Pinter, receiving consulting and lecture fees from Roche; Dr. Valero, receiving honoraria and reimbursement for travel expenses from Roche; Dr. Sauter, receiving honoraria and reimbursement for travel expenses from Roche; Dr. von Minckwitz, receiving fees for expert testimony, lecture fees, and reimbursement for travel expenses from Roche and Sanofi-Aventis; Dr. Buyse, being an employee of and having an equity interest in the International Drug Development Institute; Dr. Bendahmane and Dr. Tabah-Fisch, being employees of Sanofi-Aventis; Dr. Tabah-Fisch, receiving stock options from Sanofi-Aventis; and Dr. Crown, receiving honoraria and reimbursement for travel expenses from Roche and Sanofi-Aventis and that his institution has also received grant support from Roche on his behalf. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	Abe O, 1998, LANCET, V352, P930; Arboleda MJ, 2003, CANCER RES, V63, P196; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; De Luca A, 2008, J CELL PHYSIOL, V214, P559, DOI 10.1002/jcp.21260; Doyle JJ, 2005, J CLIN ONCOL, V23, P8597, DOI 10.1200/JCO.2005.02.5841; Dressler LG, 2005, J CLIN ONCOL, V23, P4287, DOI 10.1200/JCO.2005.11.012; Feigin ME, 2009, EXP CELL RES, V315, P707, DOI 10.1016/j.yexcr.2008.10.034; Gennari A, 2008, JNCI-J NATL CANCER I, V100, P14, DOI 10.1093/jnci/djm252; HANCOCK MC, 1991, CANCER RES, V51, P4575; Hershman D, 2007, JNCI-J NATL CANCER I, V99, P196, DOI 10.1093/jnci/djk028; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028; Marcotte R, 2008, J MAMMARY GLAND BIOL, V13, P323, DOI 10.1007/s10911-008-9087-3; MUSS HB, 1994, NEW ENGL J MED, V331, P211; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; O'Malley FP, 2009, JNCI-J NATL CANCER I, V101, P644, DOI 10.1093/jnci/djp067; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; PEGRAM M, 2007, J CLIN ONCOL S2, V25, pS964; Pegram MD, 1999, SEMIN ONCOL, V26, P89; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P759, DOI 10.1093/jnci/djh133; Pegram MD, 2004, JNCI-J NATL CANCER I, V96, P739, DOI 10.1093/jnci/djh131; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinder MC, 2007, J CLIN ONCOL, V25, P3808, DOI 10.1200/JCO.2006.10.4976; Press MF, 2011, J CLIN ONCOL, V29, P859, DOI 10.1200/JCO.2009.27.5644; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Slamon DJ, 2009, JNCI-J NATL CANCER I, V101, P615, DOI 10.1093/jnci/djp092; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slamon DJ, 1996, FINAL STUDY REPORT F; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; Tripathy D, 2004, J CLIN ONCOL, V22, P1063, DOI 10.1200/JCO.2004.06.557; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	44	1754	1820	5	188	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	2011	365	14					1273	1283		10.1056/NEJMoa0910383	http://dx.doi.org/10.1056/NEJMoa0910383			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	829KL	21991949	Green Accepted			2023-01-03	WOS:000295578700004
J	Lamas, DJ; Ingelfinger, JR; Rosenbaum, LS				Lamas, Daniela J.; Ingelfinger, Julie R.; Rosenbaum, Lisa S.			Treatment of a 6-Year-Old Girl with Vesicoureteral Reflux - Polling Results	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							URINARY-TRACT-INFECTION; PROPHYLAXIS											Alon US, 2011, NEW ENGL J MED, V365, P266; Brandstrom P, 2010, J UROLOGY, V184, P286, DOI 10.1016/j.juro.2010.01.061; Craig JC, 2010, NEW ENGL J MED, V362, P1250; Craig JC, 2009, NEW ENGL J MED, V361, P1748, DOI 10.1056/NEJMoa0902295; Hoberman A, 2009, NEW ENGL J MED, V361, P1804, DOI 10.1056/NEJMe0907623; Keren R, 2008, PEDIATRICS, V122, P1409, DOI 10.1542/peds.2008-1285d	6	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2011	365	8								10.1056/NEJMclde1108637	http://dx.doi.org/10.1056/NEJMclde1108637			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811JM	21864164				2023-01-03	WOS:000294205300015
J	Emery, P; Buch, MH				Emery, Paul; Buch, Maya H.			Towards an optimum strategy in rheumatoid arthritis	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; DOUBLE-BLIND; METHOTREXATE; INFLIXIMAB; REMISSION		[Emery, Paul] Univ Leeds, Div Rheumat & Musculoskeletal Dis, Leeds Inst Mol Med, Chapel Allerton Hosp, Leeds LS7 4SA, W Yorkshire, England; Leeds Teaching Hosp NHS Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds LS7 4SA, W Yorkshire, England	Chapel Allerton Hospital; University of Leeds; Leeds Biomedical Research Centre; University of Leeds	Emery, P (corresponding author), Univ Leeds, Div Rheumat & Musculoskeletal Dis, Leeds Inst Mol Med, Chapel Allerton Hosp, Leeds LS7 4SA, W Yorkshire, England.	p.emery@leeds.ac.uk	emery, paul/B-3560-2013	Buch, Maya/0000-0002-8962-5642	Arthritis Research UK [18475] Funding Source: Medline; Versus Arthritis [18475] Funding Source: Medline; National Institute for Health Research [NF-SI-0508-10299] Funding Source: researchfish	Arthritis Research UK(Versus Arthritis); Versus Arthritis(Versus Arthritis); National Institute for Health Research(National Institute for Health Research (NIHR))		Bakker MF, 2012, ANN INTERN MED, V156, P329, DOI 10.7326/0003-4819-156-5-201203060-00004; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Buch MH, 2007, RHEUMATOLOGY, V46, P1153, DOI 10.1093/rheumatology/kem075; Clair EWS, 2004, ARTHRITIS RHEUM-US, V50, P3432, DOI 10.1002/art.20568; EMERY P, 1995, ANN RHEUM DIS, V54, P944, DOI 10.1136/ard.54.12.944; Emery P, 2011, ANN RHEUM DIS     S3, V70, P262; Emery P, 2012, ANN RHEUM DIS, V71, P989, DOI 10.1136/annrheumdis-2011-201066; Quinn MA, 2005, ARTHRITIS RHEUM-US, V52, P27, DOI 10.1002/art.20712; Saleem B, 2011, ANN RHEUM DIS, V70, P792, DOI 10.1136/ard.2010.134445; Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3; Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919; van Vollenhoven RF, 2009, LANCET, V374, P459, DOI 10.1016/S0140-6736(09)60944-2; van Vollenhoven RF, 2012, LANCET, V379, P1712, DOI 10.1016/S0140-6736(12)60027-0	13	5	5	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 5	2012	379	9827					1682	1684		10.1016/S0140-6736(12)60164-0	http://dx.doi.org/10.1016/S0140-6736(12)60164-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	937KX	22464342				2023-01-03	WOS:000303658500007
J	Bretler, DM; Hansen, PR; Sorensen, R; Lindhardsen, J; Ahlehoff, O; Andersson, C; Abildstrom, SZ; Torp-Pedersen, C; Gislason, GH				Bretler, Ditte-Marie; Hansen, Peter Riis; Sorensen, Rikke; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Abildstrom, Steen Zabell; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar			Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; POSTMENOPAUSAL WOMEN; GUIDELINES; MORTALITY; INFLAMMATION; ASSOCIATION; PREVENTION; DIAGNOSIS	Objective To assess the risk of adverse cardiovascular events in women who discontinue hormone replacement therapy after myocardial infarction compared with those who continue. Design Nationwide register based cohort study. Setting All hospitals in Denmark. Population All 3322 women aged 40 years or over who survived 30 days after a myocardial infarction and were prescribed hormone replacement therapy at the time of myocardial infarction in the period 1997 to 2008. Main outcome measures Reinfarction, cardiovascular mortality, and all cause mortality 30 to 360 days after discharge. Results A total of 282 (8.5%) women had a reinfarction, 218 (6.6%) died of cardiovascular causes, and 357 (10.7%) died of any cause during follow-up. Women who discontinued overall hormone replacement therapy in the first year after myocardial infarction did not have a significantly different risk of reinfarction (hazard ratio 0.90, 95% confidence interval 0.68 to 1.19), cardiovascular mortality (1.21, 0.90 to 1.62), or all cause mortality (1.22, 0.97 to 1.53) than women who continued use. However, discontinuation of vaginal oestrogen was associated with a lower risk of reinfarction (hazard ratio 0.54, 0.34 to 0.86). Conclusion No certain conclusions can be drawn regarding increased or decreased risk of adverse cardiovascular events with continuing hormone replacement therapy after myocardial infarction. The results rule out neither a modest benefit nor a worrisome increase in risk. These figures may be valuable when a possible cardiovascular risk of hormone replacement therapy needs to be balanced with menopausal symptoms for the individual patient.	[Bretler, Ditte-Marie; Hansen, Peter Riis; Lindhardsen, Jesper; Ahlehoff, Ole; Andersson, Charlotte; Torp-Pedersen, Christian; Gislason, Gunnar Hilmar] Copenhagen Univ Hosp Gentofte, Dept Cardiol, Copenhagen, Denmark; [Sorensen, Rikke; Abildstrom, Steen Zabell] Univ Copenhagen, Dept Cardiol, Bispebjerg Hosp, Copenhagen, Denmark; [Torp-Pedersen, Christian] Univ Copenhagen, Panum Inst, Fac Hlth Sci, DK-2200 Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Bretler, DM (corresponding author), Copenhagen Univ Hosp Gentofte, Dept Cardiol, Copenhagen, Denmark.	dimabr01@geh.regionh.dk	Hansen, Peter Riis/AAR-7659-2020; Gislason, Gunnar/B-7561-2009; Andersson, Charlotte/P-4849-2014	Gislason, Gunnar/0000-0002-0548-402X; Hansen, Peter Riis/0000-0002-9056-535X; Sorensen, Rikke/0000-0001-9238-6681	Danish Heart Foundation [08-4-R65-A1904-B844-22440F]; Lundbeck Foundation [R31-A2566]; Sanofi; Neurosearch; Cardiome; Merck	Danish Heart Foundation; Lundbeck Foundation(Lundbeckfonden); Sanofi; Neurosearch; Cardiome; Merck(Merck & Company)	D-MB was supported by the Danish Heart Foundation (grant 08-4-R65-A1904-B844-22440F) and the Lundbeck Foundation (grant R31-A2566). None of the funding sponsors were involved in the design and conduct of the study; in collection, management, analysis, and interpretation of the data; or in preparation, review, and approval of the manuscript.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: CT-P has received consultant fees from Sanofi, Neurosearch, Cardiome, and Merck. All other authors declare no support from any organisations for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.	Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Bretler DM, 2011, BRIT J CLIN PHARMACO, V71, P105, DOI 10.1111/j.1365-2125.2010.03790.x; Buch P, 2007, HEART, V93, P210, DOI 10.1136/hrt.2006.092213; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Collet JP, 2009, ARCH CARDIOVASC DIS, V102, P485, DOI 10.1016/j.acvd.2009.03.012; Fichtlscherer S, 2004, CIRCULATION, V110, P1926, DOI 10.1161/01.CIR.0000143378.58099.8C; Gaist D, 1997, DAN MED BULL, V44, P445; Gislason GH, 2006, EUR HEART J, V27, P1153, DOI 10.1093/eurheartj/ehi705; Gorodeski EZ, 2010, MENOPAUSE, V17, P443, DOI 10.1097/gme.0b013e3181d0edaa; GRADY D, 1992, ANN INTERN MED, V117, P1038; Grady Deborah, 2005, Am J Med, V118 Suppl 12B, P163, DOI 10.1016/j.amjmed.2005.09.051; Greiner DZ, 1999, AM J CARDIOL, V83, P247, DOI 10.1016/S0002-9149(98)00828-5; Haimov-Kochman R, 2006, HUM REPROD, V21, P2450, DOI 10.1093/humrep/del191; Horner E, 2006, CLIMACTERIC, V9, P459, DOI 10.1080/13697130601024629; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kalela A, 2006, EUR J OBSTET GYN R B, V125, P217, DOI 10.1016/j.ejogrb.2005.10.010; Khan MA, 2000, AM J CARDIOL, V86, P330, DOI 10.1016/S0002-9149(00)00926-7; Kumler T, 2008, EUR J HEART FAIL, V10, P658, DOI 10.1016/j.ejheart.2008.05.006; Labrie F, 2009, MENOPAUSE, V16, P30, DOI 10.1097/gme.0b013e31817b6132; Lokkegaard E, 2008, EUR HEART J, V29, P2660, DOI 10.1093/eurheartj/ehn408; Madsen M, 2003, J CLIN EPIDEMIOL, V56, P124, DOI 10.1016/S0895-4356(02)00591-7; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Mosca L, 2004, J AM COLL CARDIOL, V43, P900, DOI 10.1016/j.jacc.2004.02.001; Mosca L, 2007, J AM COLL CARDIOL, V49, P1230, DOI 10.1016/j.jacc.2007.02.020; Naftolin F, 2004, CLIMACTERIC, V7, P333, DOI 10.1080/13697130400014615; Nordic Medico-Statistical Committee (NOMESCO), 2010, NOMESCO CLASS SURG P; Olesen JB, 2011, PHARMACOEPIDEM DR S, V20, P146, DOI 10.1002/pds.2073; Pettee KK, 2007, AM J PREV MED, V32, P483, DOI 10.1016/j.amepre.2007.02.019; Raunso J, 2011, EUR HEART J; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Shlipak MG, 2001, CIRCULATION, V104, P2300, DOI 10.1161/hc4401.98414; Simpson SH, 2006, BMJ-BRIT MED J, V333, P15, DOI 10.1136/bmj.38875.675486.55; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Vehkavaara S, 2001, THROMB HAEMOSTASIS, V85, P619, DOI 10.1055/s-0037-1615643; Vehkavaara S, 2000, CIRCULATION, V102, P2687, DOI 10.1161/01.CIR.102.22.2687; Vermeulen MJ, 2007, J CLIN EPIDEMIOL, V60, P971, DOI 10.1016/j.jclinepi.2006.12.009; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Vongpatanasin W, 2003, J AM COLL CARDIOL, V41, P1358, DOI 10.1016/S0735-1097(03)00156-6; Vrablik M, 2008, METABOLISM, V57, P1088, DOI 10.1016/j.metabol.2008.03.012; Welton AJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1190; Yeboah J, 2008, MENOPAUSE, V15, P1060, DOI 10.1097/gme.0b013e31816d8171	45	7	8	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2012	344								e1802	10.1136/bmj.e1802	http://dx.doi.org/10.1136/bmj.e1802			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923EV	22453184	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000302603100001
J	Jakob, SM; Ruokonen, E; Grounds, RM; Sarapohja, T; Garratt, C; Pocock, SJ; Bratty, JR; Takala, J				Jakob, Stephan M.; Ruokonen, Esko; Grounds, R. Michael; Sarapohja, Toni; Garratt, Chris; Pocock, Stuart J.; Bratty, J. Raymond; Takala, Jukka		Dexmedetomidine Long-Term Sedation	Dexmedetomidine vs Midazolam or Propofol for Sedation During Prolonged Mechanical Ventilation Two Randomized Controlled Trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; CARE-UNIT PATIENTS; INTENSIVE-CARE; DAILY INTERRUPTION; LORAZEPAM; MULTICENTER; PROTOCOL; DELIRIUM; ICU; RELIABILITY	Context Long-term sedation with midazolam or propofol in intensive care units (ICUs) has serious adverse effects. Dexmedetomidine, an alpha(2)-agonist available for ICU sedation, may reduce the duration of mechanical ventilation and enhance patient comfort. Objective To determine the efficacy of dexmedetomidine vs midazolam or propofol (preferred usual care) in maintaining sedation; reducing duration of mechanical ventilation; and improving patients' interaction with nursing care. Design, Setting, and Patients Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010. The MIDEX trial compared midazolam with dexmedetomidine in ICUs of 44 centers in 9 European countries; the PRODEX trial compared propofol with dexmedetomidine in 31 centers in 6 European countries and 2 centers in Russia. Included were adult ICU patients receiving mechanical ventilation who needed light to moderate sedation for more than 24 hours (midazolam, n=251, vs dexmedetomidine, n=249; propofol, n=247, vs dexmedetomidine, n=251). Interventions Sedation with dexmedetomidine, midazolam, or propofol; daily sedation stops; and spontaneous breathing trials. Main Outcome Measures For each trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of time at target sedation level (measured by Richmond Agitation-Sedation Scale) and superior to control with respect to duration of mechanical ventilation. Secondary end points were patients' ability to communicate pain (measured using a visual analogue scale [VAS]) and length of ICU stay. Time at target sedation was analyzed in per-protocol population (midazolam, n=233, vs dexmedetomidine, n=227; propofol, n=214, vs dexmedetomidine, n=223). Results Dexmedetomidine/midazolam ratio in time at target sedation was 1.07 (95% CI, 0.97-1.18) and dexmedetomidine/propofol, 1.00 (95% CI, 0.92-1.08). Median duration of mechanical ventilation appeared shorter with dexmedetomidine (123 hours [IQR, 67-337]) vs midazolam (164 hours [IQR, 92-380]; P=.03) but not with dexmedetomidine (97 hours [IQR, 45-257]) vs propofol (118 hours [IQR, 48-327]; P=.24). Patients' interaction (measured using VAS) was improved with dexmedetomidine (estimated score difference vs midazolam, 19.7 [95% CI, 15.2-24.2]; P < .001; and vs propofol, 11.2 [95% CI, 6.4-15.9]; P < .001). Length of ICU and hospital stay and mortality were similar. Dexmedetomidine vs midazolam patients had more hypotension (51/247 [20.6%] vs 29/250 [11.6%]; P=.007) and bradycardia (35/247 [14.2%] vs 13/250 [5.2%]; P < .001). Conclusions Among ICU patients receiving prolonged mechanical ventilation, dexmedetomidine was not inferior to midazolam and propofol in maintaining light to moderate sedation. Dexmedetomidine reduced duration of mechanical ventilation compared with midazolam and improved patients' ability to communicate pain compared with midazolam and propofol. More adverse effects were associated with dexmedetomidine.	[Jakob, Stephan M.; Takala, Jukka] Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland; [Jakob, Stephan M.; Takala, Jukka] Univ Bern, Bern, Switzerland; [Ruokonen, Esko] Kuopio Univ Hosp, Dept Anesthesiol & Intens Care Med, SF-70210 Kuopio, Finland; [Grounds, R. Michael] St George Hosp, Adult Intens Care Unit, London, England; [Sarapohja, Toni; Garratt, Chris; Bratty, J. Raymond] Orion Pharma, Espoo, Finland; [Pocock, Stuart J.] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England	University of Bern; University Hospital of Bern; University of Bern; Kuopio University Hospital; University of Eastern Finland; St Georges University London; Orion Corporation; University of London; London School of Hygiene & Tropical Medicine	Takala, J (corresponding author), Univ Hosp Bern, Dept Intens Care Med, CH-3010 Bern, Switzerland.	jukka.takala@insel.ch	Zabolotskikh, Igor Borisovich/O-2705-2014; Grigoryev, Evgeny/A-2321-2017; Chiche, Jean-Daniel/P-5220-2017	Zabolotskikh, Igor Borisovich/0000-0002-3623-2546; Grigoryev, Evgeny/0000-0001-8370-3083; Chiche, Jean-Daniel/0000-0002-6433-6254; Vincent, Jean-Louis/0000-0001-6011-6951; Maggiorini, Marco/0000-0001-8180-2117	Orion Pharma, Espoo, Finland; Abbott Nutrition International; B. Braun Medical; CSEM; Edwards Life-sciences Services; Kenta Biotech; Maquet Critical Care; Omnicare Clinical Research; Berner Forum for Intensive Care; Fresenius Kabi; MSD; Lilly; Baxter; Astellas; AstraZeneca; B. Braun; CSL Behring; Maquet; Novartis; Covidien; Mycomed; RobaPharma; Orion Pharma; Orion	Orion Pharma, Espoo, Finland; Abbott Nutrition International; B. Braun Medical; CSEM; Edwards Life-sciences Services; Kenta Biotech; Maquet Critical Care; Omnicare Clinical Research; Berner Forum for Intensive Care; Fresenius Kabi; MSD; Lilly(Eli Lilly); Baxter; Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); B. Braun; CSL Behring; Maquet; Novartis(Novartis); Covidien; Mycomed; RobaPharma; Orion Pharma; Orion	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. This study was sponsored by Orion Pharma, Espoo, Finland, through research contracts negotiated directly with the participating hospitals. Orion Pharma, Orion Corporation, is the originator of dexmedetomidine. On behalf of Drs Jakob and Takala, a grant and consulting fees were paid to the Bern University Hospital Department of Intensive Care Medicine to cover the costs of performing the study. The department was reimbursed for the authors' travel costs to publication committee meetings. Dr Jakob served as an expert for preparing the regulatory filing of the drug; the money was also paid into a departmental fund. Additionally, the Department of Intensive Care Medicine has, or has had in the past, research contracts with Abbott Nutrition International, B. Braun Medical, CSEM, Edwards Life-sciences Services, Kenta Biotech, Maquet Critical Care, and Omnicare Clinical Research and research and development or consulting contracts with Edwards Life-sciences, Maquet Critical Care, and Nestle. The money is or was paid into a departmental fund; no author received any personal financial gain. The department has received unrestricted educational grants from the following organizations for organizing a quarterly postgraduate educational symposium, the Berner Forum for Intensive Care: Fresenius Kabi, MSD, Lilly, Baxter, Astellas, AstraZeneca, B. Braun, CSL Behring, Maquet, Novartis, Covidien, Mycomed, and RobaPharma. Dr Grounds received a consulting fee from Orion Pharma during planning and execution of the study. He and members of his clinical staff at St George's Hospital received monetary support from Orion for travel to study-related meetings to ensure compliance with the study protocol. His department received payment of a fee per patient recruited to the study, as well as drugs used in the study and support personnel to assist with data input. Dr Ruokonen's institution, Kuopio University, received a grant from Orion to carry out the study, as well as consulting fees and reimbursement of travel funds. Messrs Sarapohja, Garratt, and Bratty were full-time employees of Orion Pharma throughout the period of the project. Their routine travel expenses were reimbursed as part of their employment. Dr Pocock of the London School of Hygiene and Tropical Medicine received a consulting fee from Orion in connection with the study, and his institution received a grant. London School of Hygiene and Tropical Medicine also received a grant for independent statistical review performed by Dr Duolao Wang.	Barr J, 2001, ANESTHESIOLOGY, V95, P324, DOI 10.1097/00000542-200108000-00011; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Carson SS, 2006, CRIT CARE MED, V34, P1326, DOI 10.1097/01.CCM.0000215513.63207.7F; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Jones C, 2007, INTENS CARE MED, V33, P978, DOI 10.1007/s00134-007-0600-8; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Mehta S, 2007, J CRIT CARE, V22, P191, DOI 10.1016/j.jcrc.2006.11.006; Mirski MA, 2010, INTENS CARE MED, V36, P1505, DOI 10.1007/s00134-010-1874-9; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Roberts RJ, 2009, CRIT CARE, V13, DOI 10.1186/cc8145; Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Swart EL, 2006, EUR J CLIN PHARMACOL, V62, P185, DOI 10.1007/s00228-005-0085-8; Sydow M, 1999, INTENS CARE MED, V25, P634, DOI 10.1007/s001340050917; Tan JA, 2010, INTENS CARE MED, V36, P926, DOI 10.1007/s00134-010-1877-6; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	25	552	610	5	86	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 21	2012	307	11					1151	1160		10.1001/jama.2012.304	http://dx.doi.org/10.1001/jama.2012.304			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911HN	22436955	Bronze			2023-01-03	WOS:000301708000023
J	Chauhan, A; Zubair, S; Sherwani, A; Owais, M				Chauhan, Arun; Zubair, Swaleha; Sherwani, Asif; Owais, Mohammad			Aloe vera Induced Biomimetic Assemblage of Nucleobase into Nanosized Particles	PLOS ONE			English	Article							CELL-CYCLE; SILVER NANOPARTICLES; GOLD NANOPARTICLES; CRYSTAL-STRUCTURE; CARCINOMA-CELLS; IN-SITU; 5-FLUOROURACIL; P53; MECHANISM; APOPTOSIS	Aim: Biomimetic nano-assembly formation offers a convenient and bio friendly approach to fabricate complex structures from simple components with sub-nanometer precision. Recently, biomimetic (employing microorganism/plants) synthesis of metal and inorganic materials nano-particles has emerged as a simple and viable strategy. In the present study, we have extended biological synthesis of nano-particles to organic molecules, namely the anticancer agent 5-fluorouracil (5-FU), using Aloe vera leaf extract. Methodology: The 5-FU nano-particles synthesized by using Aloe vera leaf extract were characterized by UV, FT-IR and fluorescence spectroscopic techniques. The size and shape of the synthesized nanoparticles were determined by TEM, while crystalline nature of 5-FU particles was established by X-ray diffraction study. The cytotoxic effects of 5-FU nanoparticles were assessed against HT-29 and Caco-2 (human adenocarcinoma colorectal) cell lines. Results: Transmission electron microscopy and atomic force microscopic techniques confirmed nano-size of the synthesized particles. Importantly, the nano-assembled 5-FU retained its anticancer action against various cancerous cell lines. Conclusion: In the present study, we have explored the potential of biomimetic synthesis of nanoparticles employing organic molecules with the hope that such developments will be helpful to introduce novel nano-particle formulations that will not only be more effective but would also be devoid of nano-particle associated putative toxicity constraints.	[Chauhan, Arun; Sherwani, Asif; Owais, Mohammad] Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India; [Zubair, Swaleha] Aligarh Muslim Univ, Womens Coll, Aligarh, Uttar Pradesh, India	Aligarh Muslim University; Aligarh Muslim University	Chauhan, A (corresponding author), Aligarh Muslim Univ, Interdisciplinary Biotechnol Unit, Aligarh, Uttar Pradesh, India.	owais_lakhnawi@yahoo.com	Sherwani, Mohammad Asif/AAQ-2949-2021; Sherwani, Mohammad/AAR-6089-2021	Sherwani, Mohammad Asif/0000-0001-5317-1557; Mohammad, Owais/0000-0001-7377-7388	Department of Biotechnology, Government of India, New Delhi	Department of Biotechnology, Government of India, New Delhi(Department of Biotechnology (DBT) India)	Funding was provided by the Department of Biotechnology, Government of India, New Delhi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abecassis B, 2007, NANO LETT, V7, P1723, DOI 10.1021/nl0707149; Alkhalaf M, 2003, J ENDOCRINOL, V179, P55, DOI 10.1677/joe.0.1790055; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a; Chandran SP, 2006, BIOTECHNOL PROGR, V22, P577, DOI 10.1021/bp0501423; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; CHEN RF, 1988, ANAL BIOCHEM, V172, P61, DOI 10.1016/0003-2697(88)90412-5; Choi YH, 2001, ONCOL REP, V8, P1091; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; FALLON L, 1973, ACTA CRYSTALLOGR B, V29, P2549, DOI 10.1107/S0567740873006989; Gardea-Torresdey JL, 2002, NANO LETT, V2, P397, DOI 10.1021/nl015673+; Germain V, 2003, J PHYS CHEM B, V107, P8717, DOI 10.1021/jp0303826; Glimcher J, 1981, CHEM BIOL MINERALIZE, P617; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gustavsson T, 2006, J AM CHEM SOC, V128, P607, DOI 10.1021/ja056181s; Hamman JH, 2008, MOLECULES, V13, P1599, DOI 10.3390/molecules13081599; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hulme AT, 2005, J AM CHEM SOC, V127, P1116, DOI 10.1021/ja044336a; Imhof A, 1999, J PHYS CHEM B, V103, P1408, DOI 10.1021/jp983241q; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Ji XH, 2007, J AM CHEM SOC, V129, P13939, DOI 10.1021/ja074447k; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; Johnson KR, 1997, CLIN CANCER RES, V3, P1739; Kagawa S, 2000, CANCER RES, V60, P1157; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; Kawasaki H, 2007, J PHYS CHEM C, V111, P2683, DOI 10.1021/jp066963n; Kelly C, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/727241; Khan A, 2007, MOL MED, V13, P266, DOI 10.2119/2007-00018.Khan; Kimling J, 2006, J PHYS CHEM B, V110, P15700, DOI 10.1021/jp061667w; Kompella U. B., 2006, NANOPARTICLE TECHNOL, P1; Lee JH, 2008, CRYST GROWTH DES, V8, P2638, DOI 10.1021/cg0702075; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709; Lofton C, 2005, ADV FUNCT MATER, V15, P1197, DOI 10.1002/adfm.200400091; Elechiguerra JL, 2006, J MATER CHEM, V16, P3906, DOI 10.1039/b607128g; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mukherjee P, 2001, NANO LETT, V1, P515, DOI 10.1021/nl0155274; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Polte J, 2010, J AM CHEM SOC, V132, P1296, DOI 10.1021/ja906506j; Pong BK, 2007, J PHYS CHEM C, V111, P6281, DOI 10.1021/jp068666o; Roco MC, 2003, CURR OPIN BIOTECH, V14, P337, DOI 10.1016/S0958-1669(03)00068-5; ROZENMAN Y, 1995, INT J CARDIOL, V49, P282, DOI 10.1016/0167-5273(95)02314-M; Santoro F, 2006, J AM CHEM SOC, V128, P16312, DOI 10.1021/ja0657861; Santra S, 2001, J BIOMED OPT, V6, P160, DOI 10.1117/1.1353590; Schmidt JJ, 2002, DRUG DISCOV TODAY, V7, P500, DOI 10.1016/S1359-6446(02)02174-8; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Scorates G, INFRARED CHARACTERIS; Selvaraj V, 2007, INT J PHARMACEUT, V337, P275, DOI 10.1016/j.ijpharm.2006.12.027; Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003; Singh P, 2009, DRUG TEST ANAL, V1, P240, DOI 10.1002/dta.41; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; STEWART RF, 1967, ACTA CRYSTALLOGR, V23, P1102, DOI 10.1107/S0365110X67004360; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Verma AK, 2005, CURR PHARM BIOTECHNO, V6, P121, DOI 10.2174/1389201053642349; Wang ZL, 2000, J PHYS CHEM B, V104, P1153, DOI 10.1021/jp993593c; Wangoo N, 2008, ANAL CHIM ACTA, V610, P142, DOI 10.1016/j.aca.2008.01.033; Weiss RB, 2003, J CLIN ONCOL, V21, P1825, DOI 10.1200/JCO.2003.09.006; Wiley B, 2005, CHEM-EUR J, V11, P454, DOI 10.1002/chem.200400927; Wilkinson J M, 2003, Med Device Technol, V14, P29; Yoneda K, 1998, ORAL ONCOL, V34, P529, DOI 10.1016/S1368-8375(98)00036-0; Yoshikawa R, 2001, CANCER RES, V61, P1029; Zoli W, 2005, BREAST CANCER RES, V7, pR681, DOI 10.1186/bcr1274	67	15	15	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2012	7	3							e32049	10.1371/journal.pone.0032049	http://dx.doi.org/10.1371/journal.pone.0032049			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928WA	22403622	gold, Green Submitted, Green Published			2023-01-03	WOS:000303017700019
J	Cerqueira, FM; Brandizzi, LI; Cunha, FM; Laurindo, FRM; Kowaltowski, AJ				Cerqueira, Fernanda M.; Brandizzi, Laura I.; Cunha, Fernanda M.; Laurindo, Francisco R. M.; Kowaltowski, Alicia J.			Serum from Calorie-Restricted Rats Activates Vascular Cell eNOS through Enhanced Insulin Signaling Mediated by Adiponectin	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-B; ENDOTHELIAL-CELLS; MITOCHONDRIAL BIOGENESIS; AKT; GLUCOSE; PHOSPHORYLATION; EXPRESSION; AGE; ADIPOCYTES	eNOS activation resulting in mitochondrial biogenesis is believed to play a central role in life span extension promoted by calorie restriction (CR). We investigated the mechanism of this activation by treating vascular cells with serum from CR rats and found increased Akt and eNOS phosphorylation, in addition to enhanced nitrite release. Inhibiting Akt phosphorylation or immunoprecipitating adiponectin (found in high quantities in CR serum) completely prevented the increment in nitrite release and eNOS activation. Overall, we demonstrate that adiponectin in the serum from CR animals increases NO center dot signaling by activating the insulin pathway. These results suggest this hormone may be a determinant regulator of the beneficial effects of CR.	[Cerqueira, Fernanda M.; Cunha, Fernanda M.; Kowaltowski, Alicia J.] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; [Brandizzi, Laura I.; Laurindo, Francisco R. M.] Univ Sao Paulo, Fac Med, Inst Coracao, Sao Paulo, Brazil; [Cunha, Fernanda M.] Univ Sao Paulo, Escola Artes Ciencias & Humanidades, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo	Cerqueira, FM (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil.	alicia@iq.usp.br	da Cunha, Fernanda M/G-3575-2012; Kowaltowski, Alicia J/H-8698-2012; Laurindo, Francisco R/J-6575-2015; cerqueira, fernanda/C-8326-2014; DA CUNHA, FERNANDA MARQUES/AAY-4000-2020	da Cunha, Fernanda M/0000-0002-1583-5380; 	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (Redoxoma); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES); John Simon Guggenheim Memorial Foundation	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (Redoxoma); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); John Simon Guggenheim Memorial Foundation	This work is supported by grants from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (Redoxoma), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento do Pessoal de Nivel Superior (CAPES) and the John Simon Guggenheim Memorial Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barros MH, 2010, MECH AGEING DEV, V131, P494, DOI 10.1016/j.mad.2010.04.008; Baylis C, 1998, CURR OPIN NEPHROL HY, V7, P59, DOI 10.1097/00041552-199801000-00010; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cerqueira FM, 2011, FREE RADICAL BIO MED, V51, P1454, DOI 10.1016/j.freeradbiomed.2011.07.006; Cerqueira FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018433; Cerqueira FM, 2010, AGEING RES REV, V9, P424, DOI 10.1016/j.arr.2010.05.002; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; da Silva CCC, 2008, AGING CELL, V7, P552, DOI 10.1111/j.1474-9726.2008.00407.x; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fisslthaler B, 2003, NITRIC OXIDE-BIOL CH, V8, P253, DOI 10.1016/S1089-8603(03)00042-9; Fukuzawa K, 2004, BIOCHEMISTRY-MOSCOW+, V69, P50, DOI 10.1023/B:BIRY.0000016351.77553.74; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Gopalsamy A, 2007, J MED CHEM, V50, P5547, DOI 10.1021/jm070851i; Han SH, 2009, PROG CARDIOVASC DIS, V52, P126, DOI 10.1016/j.pcad.2009.06.004; Hartell NA, 2005, BIOCHEM PHARMACOL, V69, P781, DOI 10.1016/j.bcp.2004.11.022; Hayashi H, 2008, EXP GERONTOL, V43, P827, DOI 10.1016/j.exger.2008.05.011; Head E, 2009, EXP NEUROL, V220, P171, DOI 10.1016/j.expneurol.2009.08.014; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hepple RT, 2006, REJUV RES, V9, P219, DOI 10.1089/rej.2006.9.219; Hepple RT, 2005, FASEB J, V19, P1320, DOI 10.1096/fj.04-3535fje; Koh EH, 2010, AM J PHYSIOL-ENDOC M, V298, pE846, DOI 10.1152/ajpendo.00008.2010; Le Gouill E, 2007, DIABETES, V56, P2690, DOI 10.2337/db06-1228; Leite PF, 2003, ARTERIOSCL THROM VAS, V23, P2197, DOI 10.1161/01.ATV.0000093980.46838.41; Lev-Ran A, 1998, MECH AGEING DEV, V102, P95, DOI 10.1016/S0047-6374(98)00027-X; Li B., 2011, J AGING RES; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lopez-Lluch G, 2008, EXP GERONTOL, V43, P813, DOI 10.1016/j.exger.2008.06.014; Mahoney LB, 2006, LIPIDS HLTH DIS, V18, P5; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; McConell GK, 2010, J APPL PHYSIOL, V108, P589, DOI 10.1152/japplphysiol.00377.2009; Motoshima H, 2004, BIOCHEM BIOPH RES CO, V315, P264, DOI 10.1016/j.bbrc.2004.01.049; NECHAD M, 1983, EXP CELL RES, V149, P119, DOI 10.1016/0014-4827(83)90385-3; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Oberley TD, 2008, J HISTOCHEM CYTOCHEM, V56, P615, DOI 10.1369/jhc.2008.950873; Okado-Matsumoto A, 2000, ANTIOXID REDOX SIGN, V2, P631, DOI 10.1089/ars.2000.2.4-631; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Picard Martin, 2010, Aging Cell, V9, P1032, DOI 10.1111/j.1474-9726.2010.00628.x; Reynolds JD, 1998, J PHARMACOL TOXICOL, V39, P125, DOI 10.1016/S1056-8719(98)00007-0; Ritchie SA, 2010, BIOCHEM J, V426, P85, DOI 10.1042/BJ20091580; Rogozina OP, 2011, CANCER PREV RES, V4, P568, DOI 10.1158/1940-6207.CAPR-10-0140; Roth GS, 2004, SCIENCE, V305, P1423, DOI 10.1126/science.1102541; Sobrevia L, 1996, J PHYSIOL-LONDON, V490, P775, DOI 10.1113/jphysiol.1996.sp021185; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Symons JD, 2009, CIRC RES, V104, P1085, DOI 10.1161/CIRCRESAHA.108.189316; Tahara EB, 2007, FASEB J, V21, P274, DOI 10.1096/fj.06-6686com; Takahashi S, 2003, J BIOL CHEM, V278, P30821, DOI 10.1074/jbc.M304471200; van Diepeningen AD, 2010, EXP GERONTOL, V45, P516, DOI 10.1016/j.exger.2010.01.002; Wenz T, 2009, IUBMB LIFE, V61, P1051, DOI 10.1002/iub.261; Xi W, 2005, BIOCHEM BIOPH RES CO, V332, P200, DOI 10.1016/j.bbrc.2005.04.111; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871; Zhu M, 2007, EXP GERONTOL, V42, P733, DOI 10.1016/j.exger.2007.05.011	54	14	14	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2012	7	2							e31155	10.1371/journal.pone.0031155	http://dx.doi.org/10.1371/journal.pone.0031155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914UV	22319612	Green Published, gold, Green Submitted			2023-01-03	WOS:000301979000024
J	Senft, D; Berking, C; Graf, SA; Kammerbauer, C; Ruzicka, T; Besch, R				Senft, Daniela; Berking, Carola; Graf, Saskia A.; Kammerbauer, Claudia; Ruzicka, Thomas; Besch, Robert			Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1	PLOS ONE			English	Article							BCL-2 FAMILY-MEMBERS; HUMAN MELANOCYTES; APOPTOSIS; INHIBITION; EXPRESSION; RESISTANCE; PROTEINS	Melanoma is an often fatal form of skin cancer which is remarkably resistant against radio-and chemotherapy. Even new strategies that target RAS/RAF signaling and display unprecedented efficacy are characterized by resistance mechanisms. The targeting of survival pathways would be an attractive alternative strategy, if tumor-specific cell death can be achieved. Bcl-2 proteins play a central role in regulating survival of tumor cells. In this study, we systematically investigated the relevance of antiapoptotic Bcl-2 proteins, i.e., Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1, in melanoma cell lines and non-malignant cells using RNAi. We found that melanoma cells required the presence of specific antiapoptotic Bcl-2 proteins: Inhibition of Mcl-1 and A1 strongly induced cell death in some melanoma cell lines, whereas non-malignant cells, i.e., primary human fibroblasts or keratinocytes were not affected. This specific sensitivity of melanoma cells was further enhanced by the combined inhibition of Mcl-1 and A1 and resulted in 60% to 80% cell death in all melanoma cell lines tested. This treatment was successfully combined with chemotherapy, which killed a substantial proportion of cells that survived Mcl-1 and A1 inhibition. Together, these results identify antiapoptotic proteins on which specifically melanoma cells rely on and, thus, provide a basis for the development of new Bcl-2 protein-targeting therapies.	[Senft, Daniela; Berking, Carola; Graf, Saskia A.; Kammerbauer, Claudia; Ruzicka, Thomas; Besch, Robert] Univ Munich, Dept Dermatol & Allergol, Munich, Germany	University of Munich	Besch, R (corresponding author), Univ Munich, Dept Dermatol & Allergol, Munich, Germany.	robert.besch@med.uni-muenchen.de	Senft, Daniela/O-6265-2018; Senft, Daniela/HII-5783-2022	Senft, Daniela/0000-0002-6953-8189; 	German Cancer Aid (Deutsche Krebshilfe); Mildred Scheel Foundation [107805, 109218]; German Research Funding Organization (Deutsche Forschungsgemeinschaft) [GK 1202]; Helmut-Legerlotz Foundation; Matthias-Lackas foundation	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe); Mildred Scheel Foundation(Deutsche Krebshilfe); German Research Funding Organization (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG)); Helmut-Legerlotz Foundation; Matthias-Lackas foundation	This study was funded by the German Cancer Aid (Deutsche Krebshilfe), Dr. Mildred Scheel Foundation grant 107805 and 109218 to R. B. and C. B., by the German Research Funding Organization (Deutsche Forschungsgemeinschaft) grant GK 1202 to D. S, C. B., and R. B. and by the Helmut-Legerlotz Foundation and Matthias-Lackas foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Besch R, 2007, CELL DEATH DIFFER, V14, P818, DOI 10.1038/sj.cdd.4402065; Besch R, 2009, J CLIN INVEST, V119, P2399, DOI 10.1172/JCI37155; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Bush JA, 2003, CLIN EXP METASTAS, V20, P531, DOI 10.1023/A:1025874502181; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen SQ, 2010, CANCER RES, V70, P4318, DOI 10.1158/0008-5472.CAN-09-4428; Chetoui N, 2008, MOL CANCER RES, V6, P42, DOI 10.1158/1541-7786.MCR-07-0080; Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615; Evan GI, 2006, CANCER CELL, V10, P345, DOI 10.1016/j.ccr.2006.10.013; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hassan M, 2008, ONCOGENE, V27, P4557, DOI 10.1038/onc.2008.90; Jiang CC, 2008, CANCER RES, V68, P6708, DOI 10.1158/0008-5472.CAN-08-0349; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Lawson DH, 2004, SEMIN ONCOL, V31, P33, DOI 10.1053/j.seminoncol.2004.02.014; Lens MB, 2003, EXPERT OPIN PHARMACO, V4, P2205, DOI 10.1517/eoph.4.12.2205.22414; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Tang LR, 1998, CLIN CANCER RES, V4, P1865; Van Triest B, 2000, ANN ONCOL, V11, P385, DOI 10.1023/A:1008351221345; Weber A, 2009, TRANSL ONCOL, V2, P73, DOI 10.1593/tlo.08223; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308	30	48	51	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2012	7	1							e30821	10.1371/journal.pone.0030821	http://dx.doi.org/10.1371/journal.pone.0030821			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910LV	22292048	Green Published, Green Submitted, gold			2023-01-03	WOS:000301639600056
J	Vathsala, PG; Dende, C; Nagaraj, VA; Bhattacharya, D; Das, G; Rangarajan, PN; Padmanaban, G				Vathsala, Palakkod G.; Dende, Chaitanya; Nagaraj, Viswanathan Arun; Bhattacharya, Debapriya; Das, Gobardhan; Rangarajan, Pundi N.; Padmanaban, Govindarajan			Curcumin-Arteether Combination Therapy of Plasmodium berghei-Infected Mice Prevents Recrudescence Through Immunomodulation	PLOS ONE			English	Article							ARTEMISININ RESISTANCE; CEREBRAL MALARIA; FALCIPARUM; IMMUNITY; RESPONSES; BLOOD; DIHYDROARTEMISININ; CHILDREN; ANTIBODY; CHABAUDI	Earlier studies in this laboratory have shown the potential of artemisinin-curcumin combination therapy in experimental malaria. In a parasite recrudescence model in mice infected with Plasmodium berghei (ANKA), a single dose of alpha, beta-arteether (ART) with three oral doses of curcumin prevented recrudescence, providing almost 95% protection. The parasites were completely cleared in blood with ART-alone (AE) or ART+curcumin (AC) treatments in the short-term, although the clearance was faster in the latter case involving increased ROS generation. But, parasites in liver and spleen were not cleared in AE or AC treatments, perhaps, serving as a reservoir for recrudescence. Parasitemia in blood reached up to 60% in AE-treated mice during the recrudescence phase, leading to death of animals. A transient increase of up to 2-3% parasitemia was observed in AC-treatment, leading to protection and reversal of splenomegaly. A striking increase in spleen mRNA levels for TLR2, IL-10 and IgG-subclass antibodies but a decrease in those for INF gamma and IL-12 was observed in AC-treatment. There was a striking increase in IL-10 and IgG subclass antibody levels but a decrease in INF gamma levels in sera leading to protection against recrudescence. AC-treatment failed to protect against recrudescence in TLR2(-/-) and IL-10(-/-) animals. IL-10 injection to AE-treated wild type mice and AC-treated TLR22/2 mice was able to prolong survival. Blood from the recrudescence phase in AE-treatment, but not from AC-treatment, was able to reinfect and kill naive animals. Sera from the recrudescence phase of AC-treated animals reacted with several parasite proteins compared to that from AE-treated animals. It is proposed that activation of TLR2-mediated innate immune response leading to enhanced IL-10 production and generation of anti-parasite antibodies contribute to protective immunity in AC-treated mice. These results indicate a potential for curcumin-based combination therapy to be tested for prevention of recrudescence in falciparum and relapse in vivax malaria.	[Vathsala, Palakkod G.; Dende, Chaitanya; Nagaraj, Viswanathan Arun; Rangarajan, Pundi N.; Padmanaban, Govindarajan] Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; [Bhattacharya, Debapriya; Das, Gobardhan] Int Ctr Genet Engn & Biotechnol, New Delhi, India	Indian Institute of Science (IISC) - Bangalore; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Vathsala, PG (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	geepee@biochem.iisc.ernet.in	Dende, Chaitanya/AAC-8216-2022; Rangarajan, Pundi/A-7365-2009; Dende, Chaitanya/AAQ-1578-2021	Rangarajan, Pundi/0000-0002-6536-9891; Chaitanya, Dende/0000-0002-8135-5828	Department of Biotechnology, Government of India [BT/PR10541/Med/15/605/2008, BT/01/10/MPB/DT]; National Academy of Sciences, India-Chair	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); National Academy of Sciences, India-Chair	This study was supported by grants from the Department of Biotechnology, Government of India (BT/PR10541/Med/15/605/2008 and BT/01/10/MPB/DT). GP is supported by the National Academy of Sciences, India-Chair. VAN is a Ramanujan Fellow. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhtar F, 2011, BIOTECH ADV, V06408; Ang KKH, 2001, PARASITOL RES, V87, P715, DOI 10.1007/s004360000366; Awandare GA, 2006, J INFECT DIS, V194, P1438, DOI 10.1086/508547; Cui L, 2007, ANTIMICROB AGENTS CH, V51, P488, DOI 10.1128/AAC.01238-06; Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859; Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941; Franklin BS, 2009, P NATL ACAD SCI USA, V106, P5789, DOI 10.1073/pnas.0809742106; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; Jagetia GC, 2007, J CLIN IMMUNOL, V27, P19, DOI 10.1007/s10875-006-9066-7; Joe B, 2004, CRIT REV FOOD SCI, V44, P97, DOI 10.1080/10408690490424702; Kamya Moses R, 2007, PLoS Clin Trials, V2, pe20, DOI 10.1371/journal.pctr.0020020; Karema C, 2006, T ROY SOC TROP MED H, V100, P1105, DOI 10.1016/j.trstmh.2006.01.001; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Landau I, 1999, PARASITE, V6, P311, DOI 10.1051/parasite/1999064311; Ma SH, 2007, EXP PARASITOL, V116, P266, DOI 10.1016/j.exppara.2007.01.007; Martinelli A, 2008, EXP PARASITOL, V119, P304, DOI 10.1016/j.exppara.2008.02.011; May LA, 2005, ANAL BIOCHEM, V337, P62, DOI 10.1016/j.ab.2004.10.037; Mimche PN, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S10; Mimche PN, 2011, MALARIA J S1, V10, P1; Nandakumar DN, 2006, ANTIMICROB AGENTS CH, V50, P1859, DOI 10.1128/AAC.50.5.1859-1860.2006; Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06; Niikura M, 2010, INT J PARASITOL, V40, P101, DOI 10.1016/j.ijpara.2009.08.009; Nosten F, 2007, AM J TROP MED HYG, V77, P181, DOI 10.4269/ajtmh.2007.77.181; Nunes JK, 2009, INFECT IMMUN, V77, P414, DOI 10.1128/IAI.00982-08; Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104; Reddy RC, 2005, BIOCHEM BIOPH RES CO, V326, P472, DOI 10.1016/j.bbrc.2004.11.051; Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x; Ringman John M., 2005, Current Alzheimer Research, V2, P131, DOI 10.2174/1567205053585882; Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sarciron ME, 2000, AM J TROP MED HYG, V62, P73, DOI 10.4269/ajtmh.2000.62.73; Shibui A, 2009, PARASITOL RES, V105, P281, DOI 10.1007/s00436-009-1435-8; Song YL, 2004, J BIOL CHEM, V279, P40629, DOI 10.1074/jbc.M407308200; Su Z, 2002, J IMMUNOL, V168, P1348, DOI 10.4049/jimmunol.168.3.1348; Tripathi AK, ANAL BIOCH, V325, P85; Waknine-Grinberg JH, 2010, EXP PARASITOL, V125, P141, DOI 10.1016/j.exppara.2010.01.005; Wells TNC, 2010, TRENDS PARASITOL, V26, P145, DOI 10.1016/j.pt.2009.12.005; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; Wykes MN, 2011, P NATL ACAD SCI USA, V108, P11205, DOI 10.1073/pnas.1108579108; Yeung S, 2004, AM J TROP MED HYG, V71, P179, DOI 10.4269/ajtmh.2004.71.179	40	51	53	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2012	7	1							e29442	10.1371/journal.pone.0029442	http://dx.doi.org/10.1371/journal.pone.0029442			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909MH	22276114	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000301568100011
J	Lamas, D; Rosenbaum, L				Lamas, Daniela; Rosenbaum, Lisa			Painful Inequities - Palliative Care in Developing Countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Rajagopal MR, 2007, J PAIN SYMPTOM MANAG, V33, P615, DOI 10.1016/j.jpainsymman.2007.02.028; Statement of professor Sevil Atasoy, 2009, COMMUNICATION   0730; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	3	34	35	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 19	2012	366	3					199	201		10.1056/NEJMp1113622	http://dx.doi.org/10.1056/NEJMp1113622			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	877RZ	22256803				2023-01-03	WOS:000299201400003
J	Talaei, F; Schmidt, M; Henning, RH				Talaei, Fatemeh; Schmidt, Martina; Henning, Robert H.			Induction of VMAT-1 and TPH-1 Expression Induces Vesicular Accumulation of Serotonin and Protects Cells and Tissue from Cooling/Rewarming Injury	PLOS ONE			English	Article							HYDROGEN-SULFIDE; PRESERVATION; HYPOTHERMIA; DOPAMINE; KIDNEY	DDT1 MF-2 hamster ductus deferens cells are resistant to hypothermia due to serotonin secretion from secretory vesicles and subsequent cystathionine beta synthase (CBS) mediated formation of H2S. We investigated whether the mechanism promoting resistance to hypothermia may be translationally induced in cells vulnerable to cold storage. Thus, VMAT-1 (vesicular monoamino transferase) and TPH-1 (tryptophan hydroxylase) were co-transfected in rat aortic smooth muscle cells (SMAC) and kidney tissue to create a serotonin-vesicular phenotype (named VTSMAC and VTkidney, respectively). Effects on hypothermic damage were assessed. VTSMAC showed a vesicular phenotype and an 8-fold increase in serotonin content and 5-fold increase in its release upon cooling. Cooled VTSMAC produced up to 10 fold higher concentrations of H2S, and were protected from hypothermia, as shown by a 50% reduction of caspase 3/7 activity and 4 times higher survival compared to SMAC. Hypothermic resistance was abolished by the inhibition of CBS activity or blockade of serotonin reuptake. In VTkidney slices, expression of CBS was 3 fold increased in cold preserved kidney tissue, with two-fold increase in H2S concentration. While cooling induced substantial damage to empty vector transfected kidney as shown by caspase 3/7 activity and loss of FABP1, VTkidney was fully protected and comparable to non-cooled control. Thus, transfection of VMAT-1 and TPH-1 induced vesicular storage of serotonin which is triggered release upon cooling and has protective effects against hypothermia. The vesicular serotonergic phenotype protects against hypothermic damage through re-uptake of serotonin inducing CBS mediated H2S production both in cells and kidney slices.	[Talaei, Fatemeh; Henning, Robert H.] Univ Groningen, Dept Clin Pharmacol, Univ Med Ctr Groningen, Groningen, Netherlands; [Schmidt, Martina] Univ Groningen, Dept Mol Pharmacol, Fac Pharm, Groningen, Netherlands	University of Groningen; University of Groningen	Talaei, F (corresponding author), Univ Groningen, Dept Clin Pharmacol, Univ Med Ctr Groningen, Groningen, Netherlands.	Talaei@irimc.org	Schmidt, Martina/C-5339-2018; Henning, Robert H/AAY-5222-2020	Schmidt, Martina/0000-0003-3075-0630; Henning, Robert/0000-0002-5135-4621	GUIDE sector from university medical center Groningen	GUIDE sector from university medical center Groningen	GUIDE sector from university medical center Groningen funded the PhD research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn Duck Sun, 1994, Yonsei Medical Journal, V35, P162; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Betten A, 2001, J LEUKOCYTE BIOL, V70, P65; Bos EM, 2009, J AM SOC NEPHROL, V20, P1901, DOI 10.1681/ASN.2008121269; Boutilier RG, 2001, J EXP BIOL, V204, P3171; DSa CM, 1996, J NEUROCHEM, V67, P900; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094; Happold FC, 1934, BIOCHEM J, V28, P1171, DOI 10.1042/bj0281171; Lee DA, 1998, J MATER SCI-MATER M, V9, P47, DOI 10.1023/A:1008882628142; Maurel A, 2007, AM J PHYSIOL-RENAL, V292, pF1592, DOI 10.1152/ajprenal.00514.2006; Mita M, 2002, BIOCHEM J, V364, P431, DOI 10.1042/BJ20020191; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Rauen U, 2002, BIOL CHEM, V383, P477, DOI 10.1515/BC.2002.050; RUBIN RP, 1970, PHARMACOL REV, V22, P389; Schnuelle P, 2009, JAMA-J AM MED ASSOC, V302, P1067, DOI 10.1001/jama.2009.1310; SCHUFFWERNER P, 1995, EUR J CLIN INVEST, V25, P477, DOI 10.1111/j.1365-2362.1995.tb01733.x; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SUNDBERG R, 1991, CRYOBIOLOGY, V28, P150, DOI 10.1016/0011-2240(91)90017-I; Talaei F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022568; Talaei F, 2011, J EXP BIOL, V214, P1276, DOI 10.1242/jeb.052704; Tripatara P, 2009, EUR J PHARMACOL, V606, P205, DOI 10.1016/j.ejphar.2009.01.041; Uchida N, 2000, J BACTERIOL, V182, P6933, DOI 10.1128/JB.182.24.6933-6939.2000; Wu N, 2010, J BIOL CHEM, V285, P18225, DOI 10.1074/jbc.M110.132142; Yamamoto T, 2007, J AM SOC NEPHROL, V18, P2894, DOI 10.1681/ASN.2007010097; Yonezawa D, 2007, TOXICOLOGY, V241, P11, DOI 10.1016/j.tox.2007.07.020	26	0	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2012	7	1							e30400	10.1371/journal.pone.0030400	http://dx.doi.org/10.1371/journal.pone.0030400			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	906OY	22253933	Green Published, Green Submitted, gold			2023-01-03	WOS:000301357100055
J	Villarreal, EAG; Brattico, E; Vase, L; Ostergaard, L; Vuust, P				Villarreal, Eduardo A. Garza; Brattico, Elvira; Vase, Lene; Ostergaard, Leif; Vuust, Peter			Superior Analgesic Effect of an Active Distraction versus Pleasant Unfamiliar Sounds and Music: The Influence of Emotion and Cognitive Style	PLOS ONE			English	Article							PAIN PERCEPTION; SYSTEMATIZING QUOTIENT; MODULATION; AUTISM; ATTENTION; RESPONSES; VALENCE; ADULTS; FMRI	Listening to music has been found to reduce acute and chronic pain. The underlying mechanisms are poorly understood; however, emotion and cognitive mechanisms have been suggested to influence the analgesic effect of music. In this study we investigated the influence of familiarity, emotional and cognitive features, and cognitive style on music-induced analgesia. Forty-eight healthy participants were divided into three groups (empathizers, systemizers and balanced) and received acute pain induced by heat while listening to different sounds. Participants listened to unfamiliar Mozart music rated with high valence and low arousal, unfamiliar environmental sounds with similar valence and arousal as the music, an active distraction task (mental arithmetic) and a control, and rated the pain. Data showed that the active distraction led to significantly less pain than did the music or sounds. Both unfamiliar music and sounds reduced pain significantly when compared to the control condition; however, music was no more effective than sound to reduce pain. Furthermore, we found correlations between pain and emotion ratings. Finally, systemizers reported less pain during the mental arithmetic compared with the other two groups. These findings suggest that familiarity may be key in the influence of the cognitive and emotional mechanisms of music-induced analgesia, and that cognitive styles may influence pain perception.	[Villarreal, Eduardo A. Garza; Vase, Lene; Ostergaard, Leif; Vuust, Peter] Univ Aarhus, Ctr Functionally Integrat Neurosci, Aarhus, Denmark; [Villarreal, Eduardo A. Garza; Vuust, Peter] Royal Acad Mus, Aarhus, Denmark; [Villarreal, Eduardo A. Garza; Vuust, Peter] Royal Acad Mus, Aalborg, Denmark; [Vase, Lene] Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus, Denmark; [Vase, Lene] Univ Aarhus, Dept Psychol, Aarhus, Denmark; [Brattico, Elvira] Univ Jyvaskyla, Ctr Excellence Interdisciplinary Music Res, Jyvaskyla, Finland; [Brattico, Elvira] Univ Helsinki, Inst Behav Sci, Cognit Brain Res Unit, Jyvaskyla, Finland; [Ostergaard, Leif] Aarhus Univ Hosp, Dept Neuroradiol, DK-8000 Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; University of Jyvaskyla; University of Helsinki; Aarhus University	Villarreal, EAG (corresponding author), Univ Aarhus, Ctr Functionally Integrat Neurosci, Aarhus, Denmark.	eduardoa@cfin.dk	Ostergaard, Lars/AAA-3020-2020; Garza-Villarreal, Eduardo/A-7879-2008; Brattico, Elvira/M-1455-2019; Østergaard, Leif/A-9281-2008	Ostergaard, Lars/0000-0003-2459-0511; Garza-Villarreal, Eduardo/0000-0003-1381-8648; Østergaard, Leif/0000-0003-2930-6997; Ostergaard, Lars/0000-0002-7619-605X; Vase, Lene/0000-0002-0379-2256; Brattico, Elvira/0000-0003-0676-6464	Danish Basic Research Foundation; Ulla and Mogens Folmer Andersden Foundation; Funding for Research in Neurology; Academy of Finland [133673]; Augustinus Fonden; Grosserer L.F. Foghts Fond	Danish Basic Research Foundation; Ulla and Mogens Folmer Andersden Foundation; Funding for Research in Neurology; Academy of Finland(Academy of Finland); Augustinus Fonden; Grosserer L.F. Foghts Fond	This study was financially supported by the Danish Basic Research Foundation, Ulla and Mogens Folmer Andersden Foundation, Funding for Research in Neurology, The Academy of Finland (project number 133673), Augustinus Fonden and Grosserer L.F. Foghts Fond. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allred KD, 2010, PAIN MANAG NURS, V11, P15, DOI 10.1016/j.pmn.2008.12.002; Bally Kathy, 2003, Crit Care Nurse, V23, P50; Baron-Cohen S, 2003, PHILOS T ROY SOC B, V358, P361, DOI 10.1098/rstb.2002.1206; Baron-Cohen S, 2009, ANN NY ACAD SCI, V1156, P68, DOI 10.1111/j.1749-6632.2009.04467.x; Bernatzky G, 2011, NEUROSCI BIOBEHAV R, V35, P1989, DOI 10.1016/j.neubiorev.2011.06.005; Bingel U, 2008, PHYSIOLOGY, V23, P371, DOI 10.1152/physiol.00024.2008; Blood AJ, 2001, P NATL ACAD SCI USA, V98, P11818, DOI 10.1073/pnas.191355898; Brooks JCW, 2002, NEUROIMAGE, V15, P293, DOI 10.1006/nimg.2001.0974; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; de Tommaso M, 2008, CONSCIOUS COGN, V17, P1152, DOI 10.1016/j.concog.2008.07.002; GOLDSTEIN A, 1980, PHYSIOL PSYCHOL, V8, P126; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guetin S, 2011, CLIN J PAIN; Huang ST, 2010, INT J NURS STUD, V47, P1354, DOI 10.1016/j.ijnurstu.2010.03.008; Kenntner-Mabiala R, 2008, BIOL PSYCHOL, V78, P114, DOI 10.1016/j.biopsycho.2008.01.007; Kenntner-Mabiala R, 2007, BIOL PSYCHOL, V75, P19, DOI 10.1016/j.biopsycho.2006.10.005; Klassen JA, 2008, AMBUL PEDIATR, V8, P117, DOI 10.1016/j.ambp.2007.12.005; Koelsch S, 2005, ANN NY ACAD SCI, V1060, P412, DOI 10.1196/annals.1360.034; Kreutz G, 2008, MUSIC PERCEPT, V26, P57, DOI 10.1525/MP.2008.26.1.57; Laopaiboon M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006914.pub2; Meeuse JJ, 2010, EUR J GASTROEN HEPAT, V22, P942, DOI 10.1097/MEG.0b013e328336ec6e; Menon V, 2005, NEUROIMAGE, V28, P175, DOI 10.1016/j.neuroimage.2005.05.053; MIRON D, 1989, PAIN, V39, P345, DOI 10.1016/0304-3959(89)90048-1; Mitchell LA, 2006, EUR J PAIN, V10, P343, DOI 10.1016/j.ejpain.2005.03.005; Mitchell LA, 2004, J PAIN, V5, P233, DOI 10.1016/j.jpain.2004.03.004; Mitchell LA., 2007, PSYCHOL MUSIC, V35, P37, DOI [10.1177/0305735607068887, DOI 10.1177/0305735607068887]; Mitchell LA, 2006, J MUSIC THER, V43, P295, DOI 10.1093/jmt/43.4.295; Nilsson Ulrica, 2008, AORN J, V87, P780, DOI 10.1016/j.aorn.2007.09.013; Plailly J, 2007, CEREB CORTEX, V17, P2650, DOI 10.1093/cercor/bhl173; Podder Lily, 2007, Nurs J India, V98, P161; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Rhudy JL, 2008, PAIN, V136, P250, DOI 10.1016/j.pain.2007.06.031; Roy M, 2008, PAIN, V134, P140, DOI 10.1016/j.pain.2007.04.003; Roy M, 2009, INT J PSYCHOPHYSIOL, V71, P37, DOI 10.1016/j.ijpsycho.2008.07.010; Royet JP, 2000, J NEUROSCI, V20, P7752; Salimpoor VN, 2011, NAT NEUROSCI, V14, P257, DOI 10.1038/nn.2726; Salomons TV, 2007, J COGNITIVE NEUROSCI, V19, P993, DOI 10.1162/jocn.2007.19.6.993; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Silva-Pereira C, 2011, ROLE FAMILIARI UNPUB; Tracey I, 2002, J NEUROSCI, V22, P2748, DOI 10.1523/JNEUROSCI.22-07-02748.2002; Van der Bosch I, 2011, FAMILIARITY ME UNPUB; Villemure C, 2002, PAIN, V95, P195, DOI 10.1016/S0304-3959(02)00007-6; Villemure C, 2009, J NEUROSCI, V29, P705, DOI 10.1523/JNEUROSCI.3822-08.2009; Wakabayashi A, 2007, J AUTISM DEV DISORD, V37, P1823, DOI 10.1007/s10803-006-0316-6; Wheelwright S, 2006, BRAIN RES, V1079, P47, DOI 10.1016/j.brainres.2006.01.012; Wiech K, 2008, PAIN, V139, P467, DOI 10.1016/j.pain.2008.07.030; Wiech K, 2008, TRENDS COGN SCI, V12, P306, DOI 10.1016/j.tics.2008.05.005; Williams AE, 2009, INT J PSYCHOPHYSIOL, V71, P242, DOI 10.1016/j.ijpsycho.2008.10.004	49	38	39	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 5	2012	7	1							e29397	10.1371/journal.pone.0029397	http://dx.doi.org/10.1371/journal.pone.0029397			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	058VE	22242169	Green Published, gold, Green Accepted, Green Submitted			2023-01-03	WOS:000312662100023
J	Grayson, M				Grayson, Michelle			Traditional Asian medicine	NATURE			English	Editorial Material																			0	23	24	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					S81	S81		10.1038/480S81a	http://dx.doi.org/10.1038/480S81a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	865NQ	22190084	Bronze			2023-01-03	WOS:000298318000073
J	Wynia, MK; Classen, DC				Wynia, Matthew K.; Classen, David C.			Improving Ambulatory Patient Safety Learning From the Last Decade, Moving Ahead in the Next	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Wynia, Matthew K.] Amer Med Assoc, Ctr Patient Safety, Chicago, IL 60654 USA; [Classen, David C.] Univ Utah, Salt Lake City, UT USA	American Medical Association; Utah System of Higher Education; University of Utah	Wynia, MK (corresponding author), Amer Med Assoc, Ctr Patient Safety, 515 N State St, Chicago, IL 60654 USA.	matthew.wynia@ama-assn.org	Wynia, Matthew/T-2210-2019					Bishop TF, 2011, JAMA-J AM MED ASSOC, V305, P2427, DOI 10.1001/jama.2011.813; Department of Health and Human Services, PARTN PAT BETT CAR L; Gandhi TK, 2010, NEW ENGL J MED, V363, P1001, DOI 10.1056/NEJMp1003294; HAMMONS T, 2001, AGENDA RES AMBULATOR; Hayes H, 2011, J AM BOARD FAM MED, V24, P576, DOI 10.3122/jabfm.2011.05.110043; Kohn LT, 1999, ERR IS HUMAN BUILDIN; Lorincz CY, 2011, RES AMBULATORY PATIE; Singh H, 2010, JAMA-J AM MED ASSOC, V304, P463, DOI 10.1001/jama.2010.1035; Singh H, 2009, ARCH INTERN MED, V169, P1578, DOI 10.1001/archinternmed.2009.263; Wachter RM, 2010, HEALTH AFFAIR, V29, P165, DOI 10.1377/hlthaff.2009.0785	10	37	38	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 14	2011	306	22					2504	2505		10.1001/jama.2011.1820	http://dx.doi.org/10.1001/jama.2011.1820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	860YB	22166611				2023-01-03	WOS:000297983300026
J	Iriyama, A; Oba, M; Ishii, T; Nishiyama, N; Kataoka, K; Tamaki, Y; Yanagi, Y				Iriyama, Aya; Oba, Makoto; Ishii, Takehiko; Nishiyama, Nobuhiro; Kataoka, Kazunori; Tamaki, Yasuhiro; Yanagi, Yasuo			Gene Transfer Using Micellar Nanovectors Inhibits Choroidal Neovascularization In Vivo	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; FACTOR RECEPTOR; POLYPLEX NANOMICELLES; RANIBIZUMAB; THERAPY; PEGAPTANIB; CELLS; RATS; SUPPRESSION	Purpose: Age-related macular degeneration caused by choroidal neovascularization (CNV) remains difficult to be treated despite the recent advent of several treatment options. In this study, we investigated the in vivo angiogenic control by intravenous injection of polyion complex (PIC) micelle encapsulating plasmid DNA (pDNA) using a mice CNV model. Methods: The transfection efficiency of the PIC micelle was investigated using the laser-induced CNV in eight-week-old male C57 BJ/6 mice. Firstly, each mouse received intravenous injection of micelle encapsulating pDNA of Yellow Fluorescent Protein (pYFP) on days 1,3 and 5. The expression of YFP was analyzed using fluorescein microscopy and western blotting analysis. In the next experiments, each mouse received intravenous injection of micelle encapsulating pDNA of soluble Fms-like tyrosine kinase-1 (psFlt-1) 1,3 and 5 days after the induction of CNV and the CNV lesion was analyzed by choroidal flatmounts on day 7. Results: Fluorescein microscopy and western blotting analysis revealed that the expression of YFP was confirmed in the CNV area after injection of the PIC micelle, but the expression was not detected neither in mice that received naked pDNA nor those without CNV. Furthermore, the CNV area in the mice that received intravenous injection of the psFlt-1-encapsulated PIC micelle was significantly reduced by 65% compared to that in control mice (p<0.01). Conclusions: Transfection of sFlt-1 with the PIC micelle by intravenous injection to mice CNV models showed significant inhibition of CNV. The current results revealed the significant potential of nonviral gene therapy for regulation of CNV using the PIC micelle encapsulating pDNA.	[Iriyama, Aya] Tokyo Metropolitan Geriatr Hosp, Tokyo 173, Japan; [Iriyama, Aya; Tamaki, Yasuhiro; Yanagi, Yasuo] Univ Tokyo, Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 113, Japan; [Oba, Makoto] Univ Tokyo, Dept Clin Vasc Regenerat, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Ishii, Takehiko; Kataoka, Kazunori] Univ Tokyo, Dept Bioengn, Grad Sch Engn, Bunkyo Ku, Tokyo, Japan; [Nishiyama, Nobuhiro; Kataoka, Kazunori] Univ Tokyo, Ctr Dis Biol & Integrat Med, Grad Sch Med, Bunkyo Ku, Tokyo, Japan; [Kataoka, Kazunori] Univ Tokyo, Dept Mat Engn, Grad Sch Engn, Bunkyo Ku, Tokyo, Japan	Tokyo Metropolitan Institute of Gerontology; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Iriyama, A (corresponding author), Tokyo Metropolitan Geriatr Hosp, Tokyo 173, Japan.	akagi-tky@umin.ac.jp	Kataoka, Kazunori/K-7108-2012; Yanagi, Yasuo/AAA-5441-2022; Nishiyama, Nobuhiro/F-1867-2014; Yanagi, Yasuo/AAF-2670-2020	Kataoka, Kazunori/0000-0002-8591-413X; Nishiyama, Nobuhiro/0000-0002-6886-9357; Oba, Makoto/0000-0002-3691-3608; Yanagi, Yasuo/0000-0002-0362-7285	Ministry of Education, Science, Sports and Culture of Japan	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The work is supported in part by a grant-in-aid from the Ministry of Education, Science, Sports and Culture of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54; Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Harada-Shiba M, 2009, MOL THER, V17, P1180, DOI 10.1038/mt.2009.63; Honda M, 2000, GENE THER, V7, P978, DOI 10.1038/sj.gt.3301203; Hoshida T, 2002, PANCREAS, V25, P111, DOI 10.1097/00006676-200208000-00001; Ideta R, 2004, FEBS LETT, V557, P21, DOI 10.1016/S0014-5793(03)01315-2; Ideta R, 2005, NANO LETT, V5, P2426, DOI 10.1021/nl051679d; Iriyama AUT, 2011, CORNEA; Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200; Iriyama A, 2007, BRIT J OPHTHALMOL, V91, P1230, DOI 10.1136/bjo.2007.117309; Itaka K, 2007, MOL THER, V15, P1655, DOI 10.1038/sj.mt.6300218; Itaka K, 2010, BIOMATERIALS, V31, P3707, DOI 10.1016/j.biomaterials.2009.11.072; Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012; Kanayama N, 2006, CHEMMEDCHEM, V1, P439, DOI 10.1002/cmdc.200600008; Maclachlan TK, 2010, MOL THER; Mendrinos E, 2009, INVEST OPHTHALMOL VI; Miyata K, 2008, J AM CHEM SOC, V130, P16287, DOI 10.1021/ja804561g; Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102; Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017; Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Sacu S, 2010, INVEST OPHTHALMOL VI; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Takahashi H, 2008, INVEST OPHTH VIS SCI, V49, P2143, DOI 10.1167/iovs.07-0523; Takahashi H, 2008, CURR EYE RES, V33, P1002, DOI 10.1080/02713680802492440; Takayama K, 2000, CANCER RES, V60, P2169; Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562; Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003; Wormald R., 2000, COCHRANE DB SYST REV; Yasukawa T, 1999, INVEST OPHTH VIS SCI, V40, P2690	34	9	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 5	2011	6	12							e28560	10.1371/journal.pone.0028560	http://dx.doi.org/10.1371/journal.pone.0028560			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863NX	22162776	Green Published, Green Submitted, gold			2023-01-03	WOS:000298172800047
J	Kallert, TW; Katsakou, C; Adamowski, T; Dembinskas, A; Fiorillo, A; Kjellin, L; Mastrogianni, A; Nawka, P; Onchev, G; Raboch, J; Schutzwohl, M; Solomon, Z; Torres-Gonzalez, F; Bremner, S; Priebe, S				Kallert, Thomas W.; Katsakou, Christina; Adamowski, Tomasz; Dembinskas, Algirdas; Fiorillo, Andrea; Kjellin, Lars; Mastrogianni, Anastasia; Nawka, Petr; Onchev, Georgi; Raboch, Jiri; Schuetzwohl, Matthias; Solomon, Zahava; Torres-Gonzalez, Francisco; Bremner, Stephen; Priebe, Stefan			Coerced Hospital Admission and Symptom Change-A Prospective Observational Multi-Centre Study	PLOS ONE			English	Article							PSYCHIATRIC RATING-SCALE; PERCEIVED COERCION; EUROPEAN COUNTRIES; PATIENTS VIEWS; SATISFACTION; VOLUNTARY; SCHIZOPHRENIA; PERCEPTIONS; CARE	Introduction: Coerced admission to psychiatric hospitals, defined by legal status or patient's subjective experience, is common. Evidence on clinical outcomes however is limited. This study aimed to assess symptom change over a three month period following coerced admission and identify patient characteristics associated with outcomes. Method: At study sites in 11 European countries consecutive legally involuntary patients and patients with a legally voluntary admission who however felt coerced, were recruited and assessed by independent researchers within the first week after admission. Symptoms were assessed on the Brief Psychiatric Rating Scale. Patients were re-assessed after one and three months. Results: The total sample consisted of 2326 legally coerced patients and 764 patients with a legally voluntary admission who felt coerced. Symptom levels significantly improved over time. In a multivariable analysis, higher baseline symptoms, being unemployed, living alone, repeated hospitalisation, being legally a voluntary patient but feeling coerced, and being initially less satisfied with treatment were all associated with less symptom improvement after one month and, other than initial treatment satisfaction, also after three months. The diagnostic group was not linked with outcomes. Discussion: On average patients show significant but limited symptom improvements after coerced hospital admission, possibly reflecting the severity of the underlying illnesses. Social factors, but not the psychiatric diagnosis, appear important predictors of outcomes. Legally voluntary patients who feel coerced may have a poorer prognosis than legally involuntary patients and deserve attention in research and clinical practice.	[Kallert, Thomas W.] Klin Psychiat Psychosomat & Psychotherapie, Leipzig, Germany; [Katsakou, Christina; Bremner, Stephen; Priebe, Stefan] Univ London, Social & Community Psychiat Unit, London, England; [Adamowski, Tomasz] Wroclaw Med Univ, Dept Psychiat, Wroclaw, Poland; [Dembinskas, Algirdas] Vilnius State Univ, Vilnius Mental Hlth Ctr, Psychiat Clin, Vilnius, Lithuania; [Fiorillo, Andrea] Univ Naples Federico 2, Dept Psychiat, Naples, Italy; [Kjellin, Lars] Psychiat Res Ctr, Orebro, Sweden; [Mastrogianni, Anastasia] Hosp Psychiat, Thessaloniki, Greece; [Nawka, Petr] Hosp Psychiat, Michalovce, Slovakia; [Onchev, Georgi] Med Univ Sofia, Dept Psychiat, Sofia, Bulgaria; [Raboch, Jiri] Charles Univ Prague, Dept Psychiat, Prague, Czech Republic; [Schuetzwohl, Matthias] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Dresden, Germany; [Solomon, Zahava] Tel Aviv Univ, Sch Social Work, IL-69978 Tel Aviv, Israel; [Solomon, Zahava] Tel Aviv Univ, Geha Mental Hlth Ctr, IL-69978 Tel Aviv, Israel; [Torres-Gonzalez, Francisco] Univ Granada, Dept Legal Med & Psychiat, Fac Med, Granada, Spain	University of London; Wroclaw Medical University; Vilnius University; University of Naples Federico II; Medical University Sofia; Charles University Prague; Technische Universitat Dresden; Tel Aviv University; Tel Aviv University; University of Granada	Kallert, TW (corresponding author), Klin Psychiat Psychosomat & Psychotherapie, Leipzig, Germany.	s.priebe@qmul.ac.uk	raboch, jiri/N-7445-2017; Fiorillo, Andrea/AHH-4551-2022; Bremner, Stephen/R-4038-2016	raboch, jiri/0000-0001-6667-1497; Fiorillo, Andrea/0000-0002-6926-0762; Bremner, Stephen/0000-0003-0790-7070; Onchev, Georgi/0000-0002-5139-5917; Adamowski, Tomasz/0000-0002-2872-3644; Priebe, Stefan/0000-0001-9864-3394	European Commission [QLG4-CT-2002-01036]	European Commission(European CommissionEuropean Commission Joint Research Centre)	The multi-site research project (Acronym: EUNOMIA) "European Evaluation of Coercion in Psychiatry and Harmonisation of Best Clinical Practise" was funded by the European Commission (Quality of Life and Management of Living Resources Programme, contract no. QLG4-CT-2002-01036). The researchers were independent from the funders and the European Commission had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bindman J, 2005, SOC PSYCH PSYCH EPID, V40, P160, DOI 10.1007/s00127-005-0861-x; Chamberlin J, 2007, DECLARATION DRESDEN; Commission of the European Communities, 2005, GREEN PAP IMPR MENT; Crespo-Facorro B, 2007, J PSYCHIATR RES, V41, P659, DOI 10.1016/j.jpsychires.2006.05.002; Fiorillo A, 2010, EUR PSYCHIA IN PRESS; GARDNER W, 1993, BEHAV SCI LAW, V11, P307, DOI 10.1002/bsl.2370110308; Hoge SK, 1997, INT J LAW PSYCHIAT, V20, P167, DOI 10.1016/S0160-2527(97)00001-0; Iversen KI, 2007, INT J LAW PSYCHIAT, V30, P504, DOI 10.1016/j.ijlp.2007.09.001; Jager M, 2009, WORLD J BIOL PSYCHIA, V10, P426, DOI 10.3109/15622970701541054; Johnsen L, 2007, NORD J PSYCHIAT, V61, P213, DOI 10.1080/08039480701352579; Kallert TW, 2008, EUR ARCH PSY CLIN N, V258, P195, DOI 10.1007/s00406-007-0777-4; Kallert Thomas W, 2005, World Psychiatry, V4, P168; Kallert TW, 2006, LEGISLATION COERCIVE; Kallert TW, 2007, INT J FORENSIC MENTA, V6, P197, DOI DOI 10.1186/1471-244X-7-S1-S83; KaltialaHeino R, 1997, INT J LAW PSYCHIAT, V20, P311, DOI 10.1016/S0160-2527(97)00013-7; Katsakou C, 2006, ACTA PSYCHIAT SCAND, V114, P232, DOI 10.1111/j.1600-0447.2006.00823.x; Katsakou C, 2011, PSYCHIAT RE IN PRESS; Katsakou C, 2007, EPIDEMIOL PSICHIAT S, V16, P172, DOI 10.1017/S1121189X00004802; Katsakou C, 2010, PSYCHIAT SERV, V61, P286, DOI 10.1176/ps.2010.61.3.286; Kjellin L, 2006, SOC PSYCH PSYCH EPID, V41, P241, DOI 10.1007/s00127-005-0024-0; Kjellin L., 2011, COERCIVE TREATMENT P, P271; LIDZ CW, 1995, ARCH GEN PSYCHIAT, V52, P1034; PRIEBE S, 1995, PSYCHIAT PRAX, V22, P140; Priebe S, 2011, PSYCHIAT SE IN PRESS; Priebe S, 2010, EUR PSYCHIA IN PRESS; Priebe S, 2010, EUR ARCH PSYCHIAT CL; Priebe S, 2008, PSYCHIAT SERV, V59, P570, DOI 10.1176/ps.2008.59.5.570; Priebe S, 2010, SCHIZOPHR RES, V121, P251, DOI 10.1016/j.schres.2009.12.020; Priebe S, 2010, BRIT J PSYCHIAT, V196, P179, DOI 10.1192/bjp.bp.109.068916; Priebe S, 2009, BRIT J PSYCHIAT, V194, P49, DOI 10.1192/bjp.bp.108.052266; Richardson M, 2010, SOC PSYCHIA IN PRESS; Richardson M, 2011, PSYCHIAT RES, V188, P156, DOI 10.1016/j.psychres.2011.01.020; Salize HJ, 2004, BRIT J PSYCHIAT, V184, P163, DOI 10.1192/bjp.184.2.163; Schutzwohl M, 2003, INT J METH PSYCH RES, V12, P197, DOI 10.1002/mpr.157; Sorgaard KW, 2007, SCAND J CARING SCI, V21, P214, DOI 10.1111/j.1471-6712.2007.00458.x; UN Convention on the Rights of Persons with Disabilities, 2006, HUM RIGHTS CONV RIGH; VENTURA J, 1993, INT J METH PSYCH RES, V3, P221	37	53	53	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2011	6	11							e28191	10.1371/journal.pone.0028191	http://dx.doi.org/10.1371/journal.pone.0028191			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	863MI	22140543	Green Published, Green Submitted, gold			2023-01-03	WOS:000298168100049
J	Kranzer, K; Lewis, JJ; White, RG; Glynn, JR; Lawn, SD; Middelkoop, K; Bekker, LG; Wood, R				Kranzer, Katharina; Lewis, James J.; White, Richard G.; Glynn, Judith R.; Lawn, Stephen D.; Middelkoop, Keren; Bekker, Linda-Gail; Wood, Robin			Antiretroviral Treatment Cohort Analysis Using Time-Updated CD4 Counts: Assessment of Bias with Different Analytic Methods	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; IMMUNODEFICIENCY-VIRUS-INFECTION; RISK-FACTORS; SOUTH-AFRICA; SHORT-TERM; DISEASE PROGRESSION; HAART INITIATION; THERAPY ERA; CELL COUNT; AIDS	Background: Survival analysis using time-updated CD4+ counts during antiretroviral therapy is frequently employed to determine risk of clinical events. The time-point when the CD4+ count is assumed to change potentially biases effect estimates but methods used to estimate this are infrequently reported. Methods: This study examined the effect of three different estimation methods: assuming i) a constant CD4+ count from date of measurement until the date of next measurement, ii) a constant CD4+ count from the midpoint of the preceding interval until the midpoint of the subsequent interval and iii) a linear interpolation between consecutive CD4+ measurements to provide additional midpoint measurements. Person-time, tuberculosis rates and hazard ratios by CD4+ stratum were compared using all available CD4+ counts (measurement frequency 1-3 months) and 6 monthly measurements from a clinical cohort. Simulated data were used to compare the extent of bias introduced by these methods. Results: The midpoint method gave the closest fit to person-time spent with low CD4+ counts and for hazard ratios for outcomes both in the clinical dataset and the simulated data. Conclusion: The midpoint method presents a simple option to reduce bias in time-updated CD4+ analysis, particularly at low CD4 cell counts and rapidly increasing counts after ART initiation.	[Kranzer, Katharina; Lawn, Stephen D.] London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, London WC1, England; [Kranzer, Katharina; Lawn, Stephen D.; Middelkoop, Keren; Bekker, Linda-Gail; Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Lewis, James J.; White, Richard G.; Glynn, Judith R.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1, England; [Middelkoop, Keren; Bekker, Linda-Gail; Wood, Robin] Univ Cape Town, Dept Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Lewis, James J.] Aurum Inst Hlth Res, Johannesburg, South Africa	University of London; London School of Hygiene & Tropical Medicine; University of Cape Town; University of London; London School of Hygiene & Tropical Medicine; University of Cape Town	Kranzer, K (corresponding author), London Sch Hyg & Trop Med, Dept Clin Res, Fac Infect & Trop Dis, London WC1, England.	katharina.kranzer@lshtm.ac.uk	Lewis, James/F-6333-2013; Bekker, Linda-Gail/AAZ-8929-2020; White, Richard G/D-5407-2009; Kranzer, Katharina/O-8845-2014	White, Richard G/0000-0003-4410-6635; Kranzer, Katharina/0000-0001-5691-7270; BEKKER, LINDA-GAIL/0000-0002-0755-4386; Lewis, James/0000-0002-8603-2761; Middelkoop, Keren/0000-0001-9922-4263	Wellcome Trust, London, United Kingdom [087262/Z/08/Z, 088590/Z/09/Z]; Medical Research Council (UK) [G0802414]; Bill and Melinda Gates Foundation [19790.01]; EU [242061]; IEDEA (International epidemiologic Databases to Evaluate AIDS) [5U01AI069924-02]; CEPAC (Cost Effectiveness of Preventing AIDS Complications) [5 R01 AI058736-02]; USAID [CA 674 A 00 08 0000 700]; CIPRA (Comprehensive International Programme of Research on AIDS) [IU19AI53217-07]; National Institutes of Health (NIH) CIPRA (Comprehensive International Programme of Research on AIDS) [1U19AI53217]; Wellcome Trust, Cape Town [WT084323MA]; Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health [1U19AI53217-01]; MRC [G0802414] Funding Source: UKRI; Medical Research Council [G0802414] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069924, U19AI053217, R01AI058736] Funding Source: NIH RePORTER	Wellcome Trust, London, United Kingdom(Wellcome Trust); Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); EU(European Commission); IEDEA (International epidemiologic Databases to Evaluate AIDS); CEPAC (Cost Effectiveness of Preventing AIDS Complications); USAID(United States Agency for International Development (USAID)); CIPRA (Comprehensive International Programme of Research on AIDS); National Institutes of Health (NIH) CIPRA (Comprehensive International Programme of Research on AIDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust, Cape Town(Wellcome Trust); Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	KK (087262/Z/08/Z) and SDL (088590/Z/09/Z) are funded by the Wellcome Trust, London, United Kingdom. RGW is funded by a Medical Research Council (UK) Methodology Research Fellowship (G0802414), the Bill and Melinda Gates Foundation (19790.01), and the EU FP7 (242061). JJL is funded by the Consortium to Respond Effectively to the AIDS TB Epidemic, United States, funded by the Bill and Melinda Gates Foundation. RW is funded by IEDEA (International epidemiologic Databases to Evaluate AIDS) (5U01AI069924-02, CEPAC (Cost Effectiveness of Preventing AIDS Complications) (5 R01 AI058736-02), USAID Right to Care (CA 674 A 00 08 0000 700), CIPRA (Comprehensive International Programme of Research on AIDS) (IU19AI53217-07). LGB is funded by the National Institutes of Health (NIH) CIPRA (Comprehensive International Programme of Research on AIDS) (1U19AI53217). KM is funded by the NIH CIPRA (Comprehensive International Programme of Research on AIDS) (1U19AI53217), Wellcome Trust Strategic award CIDRI, Cape Town (WT084323MA). Funding for the CIPRA-SA trial was provided by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, through the grant number 1U19AI53217-01. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	[Anonymous], 2004, NATL ANTIRETROVIRAL; Bohlius J, 2009, ANTIVIR THER, V14, P1065, DOI 10.3851/IMP1462; Bruyand M, 2009, CLIN INFECT DIS, V49, P1109, DOI 10.1086/605594; Crum-Cianflone N, 2009, AIDS, V23, P41, DOI 10.1097/QAD.0b013e328317cc2d; Crum-Cianflone N, 2009, ARCH INTERN MED, V169, P1130, DOI 10.1001/archinternmed.2009.104; De Beaudrap P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-179; Deuffic-Burban S, 2007, EUR J EPIDEMIOL, V22, P737, DOI 10.1007/s10654-007-9175-5; Dunn D, 2008, J INFECT DIS, V197, P398, DOI 10.1086/524686; Engels EA, 2010, JAIDS-J ACQ IMM DEF, V54, P78, DOI 10.1097/01.qai.0000371677.48743.8d; Griffin JT, 2006, AM J EPIDEMIOL, V163, P676, DOI 10.1093/aje/kwj083; Guarner J, 1997, CYTOMETRY, V30, P178, DOI 10.1002/(SICI)1097-0320(19970815)30:4&lt;178::AID-CYTO3&gt;3.0.CO;2-G; Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7; Guiguet Marguerite, 2008, Open AIDS J, V2, P3, DOI 10.2174/1874613600802010003; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; Kranzer K, 2010, JAIDS-J ACQ IMM DEF, V55, pE17, DOI 10.1097/QAI.0b013e3181f275fd; Lau B, 2007, AIDS RES HUM RETROV, V23, P769, DOI 10.1089/aid.2006.0171; Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f; Lodi S, 2010, JNCI-J NATL CANCER I, V102, P784, DOI 10.1093/jnci/djq134; Mocroft A, 2007, AIDS, V21, P1867, DOI 10.1097/QAD.0b013e328270b877; Monforte AD, 2008, AIDS, V22, P2143, DOI 10.1097/QAD.0b013e3283112b77; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; Phillips AN, 2007, AIDS, V21, P1717; Podlekareva D, 2008, SCAND J INFECT DIS, V40, P908, DOI 10.1080/00365540802227094; Prosperi MCF, 2010, CLIN INFECT DIS, V50, P1316, DOI 10.1086/651688; Raboud JM, 1996, J INFECT DIS, V174, P191, DOI 10.1093/infdis/174.1.191; Reekie J, 2008, AIDS, V22, P2381, DOI 10.1097/QAD.0b013e328317a6eb; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; Seyler C, 2007, AIDS RES HUM RETROV, V23, P1338, DOI 10.1089/aid.2006.0308; Sogaard OS, 2008, CLIN INFECT DIS, V47, P1345, DOI 10.1086/592692; Van Rie A, 2011, JAIDS-J ACQ IMM DEF, V56, P349, DOI 10.1097/QAI.0b013e3181f9fb39; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8	34	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 17	2011	6	11							e27763	10.1371/journal.pone.0027763	http://dx.doi.org/10.1371/journal.pone.0027763			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	855HZ	22114687	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000297555800031
J	Ettinger, WH				Ettinger, Walter H.			Can Hospitalization-Associated Disability Be Prevented?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Ettinger, Walter H.] Univ Massachusetts, Med Ctr, Sch Med, Div Geriatr Med,Dept Med, Worcester, MA 01655 USA; [Ettinger, Walter H.] Univ Massachusetts, Med Ctr, UMass Mem Med Ctr, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ettinger, WH (corresponding author), 55 N Lake Ave, Worcester, MA 01655 USA.	walter.ettinger@umassmemorial.org						[Anonymous], FED REG; Baztan JJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b50; Covinsky KE, 2011, JAMA-J AM MED ASSOC, V306, P1782, DOI 10.1001/jama.2011.1556; Department of Health and Human Services Office of Inspector General, 2010, OEI060900090 DEP HLT; Dykes PC, 2010, JAMA-J AM MED ASSOC, V304, P1912, DOI 10.1001/jama.2010.1567; Fryback DG, 2010, MEASURING HLTH RELAT; Gill TM, 2010, JAMA-J AM MED ASSOC, V304, P1919, DOI 10.1001/jama.2010.1568; Massachusetts Hospital Association, 2011, SUMM TRENDS SEL NURS; Mehta KM, 2011, J AM GERIATR SOC, V59, P1206, DOI 10.1111/j.1532-5415.2011.03409.x	9	18	18	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2011	306	16					1800	1801		10.1001/jama.2011.1563	http://dx.doi.org/10.1001/jama.2011.1563			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837HH	22028358				2023-01-03	WOS:000296181600027
J	Zweig, SC; Popejoy, LL; Parker-Oliver, D; Meadows, SE				Zweig, Steven C.; Popejoy, Lori L.; Parker-Oliver, Debra; Meadows, Susan E.			The Physician's Role in Patients' Nursing Home Care "She's a Very Courageous and Lovely Woman. I Enjoy Caring for Her"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-INCLUSIVE CARE; LONG-TERM-CARE; PRESSURE ULCER SCALE; TRANSITIONAL CARE; OLDER AMERICANS; HOSPICE CARE; END; LIFE; RESIDENTS; SERVICES	More than 1.5 million adults live in US nursing homes, and approximately 30% of individuals in the United States will die with a nursing home as their last place of residence. Physicians play a pivotal role in the rehabilitation, complex medical care, and end-of-life care of this frail and vulnerable population. The reasons for admission are multifactorial and a comprehensive care plan based on the Minimum Data Set guides the multidisciplinary nursing home team in the care of the patient and provides assessments of the quality of care provided. Using the cases of 2 patients with different experiences, we describe the physician's role in planning for admission, participating as a team member in the ongoing assessment and care in the nursing home, and guiding care at the end of life. The increasing population of older adults has also promoted community-based and residential alternatives to traditional nursing homes. The future of longterm care will include additional challenges and rich innovations in services and options for older adults. JAMA. 2011;306(13):1468-1478 www.jama.com	[Zweig, Steven C.] Univ Missouri, Interdisciplinary Ctr Aging, Columbia, MO 65212 USA; [Zweig, Steven C.; Parker-Oliver, Debra; Meadows, Susan E.] Univ Missouri, Dept Family & Community Med, Sch Med, Columbia, MO 65212 USA; [Popejoy, Lori L.] Univ Missouri, Sinclair Sch Nursing, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Zweig, SC (corresponding author), Univ Missouri, Interdisciplinary Ctr Aging, Columbia, MO 65212 USA.	zweigs@missouri.edu	Parker-Oliver, Debra/F-7998-2010		National Institute of Nursing Research; SCAN Foundation	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); SCAN Foundation	Dr Parker-Oliver reports receipt of support from the National Institute of Nursing Research. The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	Aigner Mary J, 2004, J Am Med Dir Assoc, V5, P16, DOI 10.1016/S1525-8610(04)70039-0; American Medical Directors Association, 2005, J Am Med Dir Assoc, V6, P411; American Medical Directors Association, CLIN PRACT GUID LONG; Baer WM, 2000, J AM GERIATR SOC, V48, P879, DOI 10.1111/j.1532-5415.2000.tb06883.x; BERCOVITZ A, 2008, NATL HLTH SLAT REPOR, V9, P1; Bern-Klug Mercedes, 2003, J Am Med Dir Assoc, V4, P145, DOI 10.1097/01.JAM.0000061473.13422.CC; Biola H, 2007, J AM GERIATR SOC, V55, P846, DOI 10.1111/j.1532-5415.2007.01179.x; Black K, 2007, J SOC WORK END-LIFE, V3, P39, DOI 10.1300/J457v03n02_04; Blumenthal D, 2001, JAMA-J AM MED ASSOC, V286, P1027, DOI 10.1001/jama.286.9.1027; Boult C, 2010, JAMA-J AM MED ASSOC, V304, P1936, DOI 10.1001/jama.2010.1623; Burton LC, 2003, GERONTOLOGIST, V43, P230, DOI 10.1093/geront/43.2.230; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Castle NG, 2007, MED CARE, V45, P729, DOI 10.1097/MLR.0b013e3180618b6e; Castle NG, 2010, GERONTOLOGIST, V50, P426, DOI 10.1093/geront/gnq052; Centers for Medicare and Medicaid Services, NURS HOM DAT COMP 20; CohenMansfield J, 1997, J GERONTOL A-BIOL, V52, pM369, DOI 10.1093/gerona/52A.6.M369; Collwill JM, 2008, HEALTH AFFAIR, V27, pW232, DOI 10.1377/hlthaff.27.3.w232; COWLES CM, 2007, NURSING HOME STAT YB, P56; Cravens DD, 2000, FAM MED, V32, P34; *CTR MED MED SERV, 2000, MED MED STAT OP MAN; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; *DEP VET AFF VIREC, RES ASS INSTR MIN DA; Dimant Jacob, 2003, J Am Med Dir Assoc, V4, P231, DOI 10.1097/01.JAM.0000075915.15039.B1; Dimant Jacob, 2002, J Am Med Dir Assoc, V3, P254, DOI 10.1097/00130535-200207000-00007; Doukas DJ, 2003, J AM GERIATR SOC, V51, P1155, DOI 10.1046/j.1532-5415.2003.51383.x; El-Solh AA, 2010, CHEST, V138, P1480, DOI 10.1378/chest.10-1135; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; EMANUEL LL, ED PHYS END OF LIFE; Feldt K S, 2000, Pain Manag Nurs, V1, P13, DOI 10.1053/jpmn.2000.5831; Field MJ, 1997, APPROACHING DEATH IM; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Friedemann ML, 2004, GERONTOLOGIST, V44, P520, DOI 10.1093/geront/44.4.520; Gardner SE, 2005, J GERONTOL A-BIOL, V60, P93, DOI 10.1093/gerona/60.1.93; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; Gaugler JE, 2009, MED CARE, V47, P191, DOI 10.1097/MLR.0b013e31818457ce; Gillick M, 1999, J AM GERIATR SOC, V47, P227, DOI 10.1111/j.1532-5415.1999.tb04582.x; Grabowski DC, 2010, MED CARE, V48, P859, DOI 10.1097/MLR.0b013e3181f49ed9; Hawkins NA, 2005, GERONTOLOGIST, V45, P107, DOI 10.1093/geront/45.1.107; Hedrick SC, 2009, J AGING HEALTH, V21, P190, DOI 10.1177/0898264308328929; Herr K A, 1993, Appl Nurs Res, V6, P39; Hickman SE, 2010, J AM GERIATR SOC, V58, P1241, DOI 10.1111/j.1532-5415.2010.02955.x; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Institute of Medicine (US) Committee on Nursing Home Regulation, 1986, IMPR QUAL CAR NURS H; Jones Adrienne L, 2011, NCHS Data Brief, P1; Joseph A, 1998, J AM GERIATR SOC, V46, P1152; Kane RL, 2003, J AM GERIATR SOC, V51, P1427, DOI 10.1046/j.1532-5415.2003.51461.x; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; Kane RL, 2007, GERONTOLOGIST, V47, P100, DOI 10.1093/geront/47.Supplement_1.100; Kane RL, 2011, JAMA-J AM MED ASSOC, V305, P284, DOI 10.1001/jama.2010.2015; Kane RL, 2010, J AGING SOC POLICY, V22, P321, DOI 10.1080/08959420.2010.507509; Kane RA, 2007, J AM GERIATR SOC, V55, P832, DOI 10.1111/j.1532-5415.2007.01169.x; Kelly A, 2010, J AM GERIATR SOC, V58, P1701, DOI 10.1111/j.1532-5415.2010.03005.x; Kinosian B, 2007, GERONTOLOGIST, V47, P356, DOI 10.1093/geront/47.3.356; Kolarik Russ C, 2002, J Palliat Med, V5, P697, DOI 10.1089/109662102320880516; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; LaMantia MA, 2010, J AM GERIATR SOC, V58, P777, DOI 10.1111/j.1532-5415.2010.02776.x; Lum TY, 2008, HEALTH CARE FINANC R, V30, P35; Luppa M, 2010, AGE AGEING, V39, P31, DOI 10.1093/ageing/afp202; Luppa M, 2009, INT PSYCHOGERIATR, V21, P1015, DOI 10.1017/S1041610209990238; Mehr DR, 2001, JAMA-J AM MED ASSOC, V286, P2427, DOI 10.1001/jama.286.19.2427; Miller SC, 2002, J AM GERIATR SOC, V50, P507, DOI 10.1046/j.1532-5415.2002.50118.x; Miller SC, 2010, J AM GERIATR SOC, V58, P1481, DOI 10.1111/j.1532-5415.2010.02968.x; Mukamel DB, 2008, HEALTH SERV RES, V43, P1244, DOI 10.1111/j.1475-6773.2007.00829.x; Muramatsu N, 2008, MED CARE, V46, P829, DOI 10.1097/MLR.0b013e3181791a79; Muramatsu N, 2007, J GERONTOL B-PSYCHOL, V62, pS169, DOI 10.1093/geronb/62.3.S169; Noel-Miller C, 2010, J GERONTOL B-PSYCHOL, V65, P370, DOI 10.1093/geronb/gbq020; Oliver Debra Parker, 2005, J Am Med Dir Assoc, V6, pS21, DOI 10.1016/j.jamda.2005.03.017; OUSLANDER JG, 1994, ANN INTERN MED, V120, P584, DOI 10.7326/0003-4819-120-7-199404010-00010; OUSLANDER JG, 1997, MED CARE NURSING HOM; Pavlik VN, 2001, J AM GERIATR SOC, V49, P45, DOI 10.1046/j.1532-5415.2001.49008.x; PIERCE RP, 1996, NURSING HOME EC, V3, P20; Popejoy LL, 2008, J NURS SCHOLARSHIP, V40, P326, DOI 10.1111/j.1547-5069.2008.00246.x; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rantz MJ, 2006, J NURS MEAS, V14, P129, DOI 10.1891/jnm-v14i2a005; RANTZ MJ, 2009, FIND BEST ELDERCARE; Resnick HE, 2009, J AM MED DIR ASSOC, V10, P423, DOI 10.1016/j.jamda.2009.03.009; Reuben DB, 2009, JAMA-J AM MED ASSOC, V302, P2686, DOI 10.1001/jama.2009.1871; Reuben DB, 1999, J AM GERIATR SOC, V47, P131, DOI 10.1111/j.1532-5415.1999.tb04569.x; Romer Anna L, 2004, J Palliat Med, V7, P335, DOI 10.1089/109662104773709495; Saliba, 2008, DEV VALIDATION REVIS; Steinman MA, 2010, JAMA-J AM MED ASSOC, V304, P1592, DOI 10.1001/jama.2010.1482; Stone RI, 2007, GERONTOLOGIST, V47, P23, DOI 10.1093/geront/47.Supplement_1.23; Stotts NA, 2001, J GERONTOL A-BIOL, V56, pM795, DOI 10.1093/gerona/56.12.M795; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; Temkin-Greener H, 2002, J AM GERIATR SOC, V50, P125, DOI 10.1046/j.1532-5415.2002.50018.x; Terrell KM, 2006, J AM MED DIR ASSOC, V7, P499, DOI 10.1016/j.jamda.2006.03.004; Thomas W.H., 2003, J SOCIAL WORK LONG T, V2, P141, DOI [DOI 10.1300/J181V02N01_10, 10.1300/J181v02n01_10]; Tombaugh TN, 1996, PSYCHOL ASSESSMENT, V8, P48, DOI 10.1037/1040-3590.8.1.48; U. S. Department of Health and Human Services Centers for Medicare & Medicaid Services, MDS 3 0 NURS HOM SWI; Unwin BK, 2010, AM FAM PHYSICIAN, V81, P1219; *US DEP HHS, NURS HOM CHECKL; US Department of Health and Human Services, NURS HOM COMP; Warshaw GA, 2010, J AM GERIATR SOC, V58, P1780, DOI 10.1111/j.1532-5415.2010.03029.x; Weaver FM, 2008, J AM GERIATR SOC, V56, P345, DOI 10.1111/j.1532-5415.2007.01538.x; Wieland D, 2010, J GERONTOL A-BIOL, V65, P721, DOI 10.1093/gerona/glq040	96	6	6	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	2011	306	13					1468	1478		10.1001/jama.2011.1420	http://dx.doi.org/10.1001/jama.2011.1420			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	828MZ	21972309				2023-01-03	WOS:000295506900026
J	Tu, YY				Tu, Youyou			The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine	NATURE MEDICINE			English	Article							MICROCIRCULATORY DISTURBANCE; TNF-ALPHA; ISCHEMIA; EXTRACT; INJURY; ACID		China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS	Tu, YY (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China.	youyoutu1930cn@yahoo.com.cn						[Anonymous], 1979, CHINESE MED J-PEKING, V92, P811; Chen GQ, 1997, BLOOD, V89, P3345; Chen KJ, 2006, CHINESE MED J-PEKING, V119, P6, DOI 10.1097/00029330-200601010-00002; CHEN P, 1998, JI SHENG CHONG XUE Y, V16, P421; *COLL RES GROUP QI, 1982, J TRADIT CHIN MED, V2, P3; Collaboration Research Group for Qinghaosu, 1977, KEXUE TONGBAO, V22, P142; Collaboration research group for Qinghaosu, 1979, YAOXUE TONGBAO, V14, P49; Dong Yan-jun, 2003, Zhongguo Zhong Xi Yi Jie He Za Zhi, V23, P676; [董妍君 Dong Yanjun], 2003, [中国药理学通报, Chinese Pharmacological Bulletin], V19, P1125; Gao D, 2010, CHIN J INTEGR MED, V16, P50, DOI 10.1007/s11655-010-0050-y; Goldstein JL, 2007, NAT MED, V13, P1151, DOI 10.1038/nm1642; Gu YC, 1993, CHIN HERBAL MED, V24, P122; Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008; Huang L, 1993, Zhongguo Zhong Yao Za Zhi, V18, P44; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; Li WD, 2006, INT IMMUNOPHARMACOL, V6, P1243, DOI 10.1016/j.intimp.2006.03.004; Liao FL, 2006, TRENDS PHARMACOL SCI, V27, P287, DOI 10.1016/j.tips.2006.04.001; Liu J., 1979, ACTA CHIM SINICA, V37, P129; Sun K, 2010, J ETHNOPHARMACOL, V130, P398, DOI 10.1016/j.jep.2010.05.030; SUN XZ, 1993, ZHONGGUO ZHONG XI YI, V11, P37; Tang Xi Can, 1999, CNS Drug Reviews, V5, P281; TU Y, 1987, B CHIN MAT MED, V12, P2; Tu Y Y, 1981, Yao Xue Xue Bao, V16, P366; Tu Y.Y, 2009, QINGHAO JI QINGHAOSU; Tu Youyou, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P250; Tu YY, 1999, CHINESE MED J-PEKING, V112, P976; TU YY, 1982, PLANTA MED, V44, P143, DOI 10.1055/s-2007-971424; TU YY, 1981, REV WORLD INVENT, V4, P26; Tu YY, 1985, CHIN HERBAL MED, V16, P200; TU YY, 1985, ZONGYAO TONGBAO, V10, P419; Tu YY, 1981, B CHIN MAT MED, V6, P31; WU C, 1985, CHIN TRADIT HERBAL D, V6, P2; Wu C M, 1985, Zhong Yao Tong Bao, V10, P31; Wu CM., 1985, CHIN B BOT, V3, P34; Xiao Y Q, 1984, Yao Xue Xue Bao, V19, P909; XIAO Y-Q, 1986, Acta Botanica Sinica, V28, P307; Xie LX, 2010, CLIN HEMORHEOL MICRO, V44, P245, DOI 10.3233/CH-2010-1269; Xu L, 2002, CHIN J DERMATOVENERO, V1, P19; Xu XS, 2009, SHOCK, V32, P201, DOI [10.1097/SHK.0b013e3181996d61, 10.1097/SHK.0b013e3181971f47]; YANG L, 2006, CHIN J EXP TRADIT ME, V12, P10; YANG SX, 1992, CHIN B PHARM, V9, P61; Yin JP, 1989, CHIN TRADIT HERBAL D, V20, P149; You Y, 2011, CLIN HEMORHEOL MICRO, V47, P187, DOI 10.3233/CH-2010-1380; Zhang Dong, 2007, Yaoxue Xuebao, V42, P978; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhao N, 2010, AM J PHYSIOL-HEART C, V298, pH1166, DOI 10.1152/ajpheart.01186.2009	46	741	790	209	1420	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2011	17	10					1217	1220		10.1038/nm.2471	http://dx.doi.org/10.1038/nm.2471			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	835FW	21989013				2023-01-03	WOS:000296022100036
J	Lumbiganon, P; Festin, M; Ho, J; Mohammad, H; Henderson-Smart, D; Green, S; Crowther, C; McDonald, S; Laopaiboon, M; Murano, M; Narash, N; Poombankor, R; Laopaiboon, M; Pattanittum, P; Short, J; Turner, T; Martis, R; Buppasiri, P; Komvilaisak, P; Deesrikaew, JTS; Pattanittum, P; Ussahgij, B; Khianman, B; Suwannachat, B; Siriwachirachai, T; Swadpanich, U; Chang, A; Koh, CW; Peter, J; Sidi, ZM; Subramaniam, S; Anuar, C; Geok, TB; Hassan, N; Van Rostenberghe, H; Bautista, R; Torralba, GC; Guinto, V; Crisologo, C; Andal, ML; Anzures, C; Canceran, G; Nurdiati, D; Emilia, O; Hadiati, DR; Wibowo, T; Wandita, S; Basuki, F; Purwanti, N; Swadpanich, U; Thinkhamrop, J; Suwannachat, B; Numwanul, P; Issarawong, L; Khundom, C; Saenrian, B; Khunamas, N; Choonnapran, S; Thippawat, S; Haoboon, J; Noanbuddee, S; Chanwirat, S; Supasud, J; Oadpim, T; Hempira, A; Tharnprisan, P; Laurit, J; Phanphen, N; Nanudon, U; Prapapa, U; Doweragul, O; Tongsata, P; Khianman, B; Narash, N; Poombankor, R; Subramaniam, S; Peter, JR; Van Rostenberghe, H; Karuppiah, R; Jusoh, WPW; Ismail, NEB; Andal, ML; Pelaez-Crisologo, C; Ayapana, EM; Olivaros, R; Medina, P; Canete, L; Eugogco, E; Torralba, E; Binas, B; Binas, P; Nurdiati, D; Supiyah; Amanah, L; Sari, DL; Astuti, D				Lumbiganon, Pisake; Festin, Mario; Ho, Jacqueline; Mohammad, Hakimi; Henderson-Smart, David; Green, Sally; Crowther, Caroline; McDonald, Steve; Laopaiboon, Malinee; Murano, Melissa; Narash, Natthaleeya; Poombankor, Rabieb; Laopaiboon, Malinee; Pattanittum, Porjai; Short, Jacki; Turner, Tari; Martis, Ruth; Buppasiri, Pranom; Komvilaisak, Patcharee; Deesrikaew, Jadsada Thinkhamrop Songsri; Pattanittum, Porjai; Ussahgij, Butsakorn; Khianman, Bussarin; Suwannachat, Bunpode; Siriwachirachai, Thitiporn; Swadpanich, Ussanee; Chang, Alvin; Koh, Chun Wearn; Peter, Japaraj; Sidi, Zabidah Mat; Subramaniam, Sivasangari; Anuar, Che; Geok, Tan Beng; Hassan, Noraida; Van Rostenberghe, Hans; Bautista, Resti; Torralba, Geraldine Castillo; Guinto, Valerie; Crisologo, Cristina; Andal, Maria Lu; Anzures, Cynthia; Canceran, Gina; Nurdiati, Detty; Emilia, Ova; Hadiati, Diah Rumekti; Wibowo, Tunjung; Wandita, Setya; Basuki, Fauziah; Purwanti, Nawang; Swadpanich, Ussanee; Thinkhamrop, Jadsada; Suwannachat, Bunpode; Numwanul, Pranee; Issarawong, Laaeid; Khundom, Chaywadsan; Saenrian, Banyen; Khunamas, Nattaya; Choonnapran, Supaporn; Thippawat, Savanee; Haoboon, Julaluk; Noanbuddee, Siripan; Chanwirat, Sukulrat; Supasud, Jumrad; Oadpim, Tussanewan; Hempira, Anong; Tharnprisan, Piangjit; Laurit, Jiraporn; Phanphen, Nittaya; Nanudon, Urairat; Prapapa, Umaporn; Doweragul, Orawan; Tongsata, Phechalakorn; Khianman, Bussarin; Narash, Natthaleeya; Poombankor, Rabiab; Subramaniam, Sivasangari; Peter, Japaraj R.; Van Rostenberghe, Hans; Karuppiah, Rajaywari; Jusoh, Wan Paizah Wan; Ismail, Noor Elani Bte; Andal, Maria Lu; Pelaez-Crisologo, Cristina; Ayapana, Ella Marie; Olivaros, Rosette; Medina, Paolo; Canete, Lester; Eugogco, Elizabeth; Torralba, Ermie; Binas, Brian; Binas, Paul; Nurdiati, Detty; Supiyah; Amanah, Latifatun; Sari, Dany Lukita; Astuti, Dwi		SEA-ORCHID Study Grp	Impact of Increasing Capacity for Generating and Using Research on Maternal and Perinatal Health Practices in South East Asia (SEA-ORCHID Project)	PLOS ONE			English	Article							MAGNESIUM-SULFATE; CHILD HEALTH; TRENDS; BIRTH	Background: Maternal and neonatal mortality and morbidity remain unacceptably high in many low and middle income countries. SEA-ORCHID was a five year international collaborative project in South East Asia which aimed to determine whether health care and health outcomes for mothers and babies could be improved by developing capacity for research generation, synthesis and use. Methods: Nine hospitals in Indonesia, Malaysia, the Philippines and Thailand participated in SEA-ORCHID. These hospitals were supported by researchers from three Australian centres. Health care practices and outcomes were assessed for 1000 women at each hospital both before and after the intervention. The capacity development intervention was tailored to the needs and context of each hospital and delivered over an 18 month period. Main outcomes included adherence to forms of care likely to be beneficial and avoidance of forms of care likely to be ineffective or harmful. Results: We observed substantial variation in clinical practice change between sites. The capacity development intervention had a positive impact on some care practices across all countries, including increased family support during labour and decreased perineal shaving before birth, but in some areas there was no significant change in practice and a few beneficial practices were followed less often. Conclusion: The results of SEA-ORCHID demonstrate that investing in developing capacity for research use, synthesis and generation can lead to improvements in maternal and neonatal health practice and highlight the difficulty of implementing evidence-based practice change.	[Lumbiganon, Pisake; Laopaiboon, Malinee; Narash, Natthaleeya; Poombankor, Rabieb; Pattanittum, Porjai; Buppasiri, Pranom; Komvilaisak, Patcharee; Deesrikaew, Jadsada Thinkhamrop Songsri; Pattanittum, Porjai; Ussahgij, Butsakorn] Khon Kaen Univ, Khon Kaen, Thailand; [Festin, Mario; Canceran, Gina] Univ Philippines Manila, Manila, Philippines; [Ho, Jacqueline] Penang Med Coll, George Town, Malaysia; [Mohammad, Hakimi] Gadja Mada Univ, Jakarta, Indonesia; [Henderson-Smart, David; Murano, Melissa; Short, Jacki] Univ Sydney, Sydney, NSW 2006, Australia; [Green, Sally; McDonald, Steve; Turner, Tari] Monash Univ, Clayton, Vic 3800, Australia; [Crowther, Caroline; Martis, Ruth] Univ Adelaide, Adelaide, SA 5005, Australia; [Siriwachirachai, Thitiporn; Swadpanich, Ussanee] Khon Kaen Hosp, Khon Kaen, Thailand; [Chang, Alvin; Koh, Chun Wearn; Peter, Japaraj; Sidi, Zabidah Mat; Subramaniam, Sivasangari] Ipoh Hosp, Ipoh, Malaysia; [Anuar, Che; Geok, Tan Beng; Hassan, Noraida; Van Rostenberghe, Hans] Univ Sains Malaysia, George Town, Malaysia; [Bautista, Resti; Torralba, Geraldine Castillo; Guinto, Valerie; Crisologo, Cristina] Philippine Gen Hosp, Manila, Philippines; [Andal, Maria Lu; Anzures, Cynthia] Jose Fabella Hosp, Manila, Philippines	Khon Kaen University; University of the Philippines System; University of the Philippines Manila; Gadjah Mada University; University of Sydney; Monash University; University of Adelaide; Universiti Sains Malaysia; University of the Philippines System; University of the Philippines Manila	Lumbiganon, P (corresponding author), Khon Kaen Univ, Khon Kaen, Thailand.	pisake@kku.ac.th	McDonald, Steve/AAE-1613-2020; Festin, Mario Philip/GQQ-9749-2022; Lumbiganon, Pisake/E-8634-2010; Van Rostenberghe, Hans/AAD-8096-2019; Wibowo, Tunjung/AAC-6949-2021; Martis, Ruth/AAD-2267-2022; Pattanittum, Porjai/N-1480-2016; Van Rostenberghe, Hans/B-4989-2012; WANDITA, SETYA/GLV-5077-2022	McDonald, Steve/0000-0003-2832-5205; Lumbiganon, Pisake/0000-0001-9372-0071; Van Rostenberghe, Hans/0000-0002-7908-8994; Wibowo, Tunjung/0000-0002-2655-4306; Martis, Ruth/0000-0003-1900-0038; WANDITA, SETYA/0000-0001-7264-3767; Green, Sally Elizabeth/0000-0002-9564-9050	National Health and Medical Research Council of Australia [307703]; Wellcome Trust, United Kingdom [071672/Z/03/Z]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Wellcome Trust, United Kingdom(Wellcome Trust)	SEA-ORCHID was jointly funded by an International Collaborative Research Grant from the National Health and Medical Research Council of Australia (No. 307703) and Wellcome Trust, United Kingdom (071672/Z/03/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, MILL DEV GOALS REP; Basevi V, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001236; Carroli G, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000081.pub2; Cuervo L, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000330; Duley L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000127; Duley L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000128; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002960.pub2; Global Forum for Health Research, 2008, FOST INN GLOB HLTH F; Henderson-Smart DJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-43; Hill K, 2007, LANCET, V370, P1311, DOI 10.1016/S0140-6736(07)61572-4; Hoddnet E, 2007, COCHRANE DB SYST REV; Hofmeyr GJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000184.PUB2; Johanson RBMB., 2000, COCHRANE DB SYST REV, V2, DOI 10.1002/14651858.CD000224; Kenyon S, 2013, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001058; Kettle C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000947.pub2; Kettle C, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000006; Laopaiboon M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002646; Lee C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004790.pub2; McDonald S, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-61; NSW Health Department, 2001, FRAM BUILD CAP IMPR; PRENDIVILLE WJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000007, DOI 10.1002/14651858.CD000007]; Qian X, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-29; Razmjou H, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-66; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Sauvarin J, 2006, MATERNAL NEONATAL HL; Save the Children, 2006, STAT WORLDS NEWB REP; Shaban IA, 2011, INT J EVID-BASED HEA, V9, P25, DOI 10.1111/j.1744-1609.2010.00197.x; Short J, 2010, BMC MED EDUC, V10, DOI 10.1186/1472-6920-10-37; Smaill Fiona M, 2019, Cochrane Database Syst Rev, V2019, DOI 10.1002/14651858.CD000490.pub4; Stanton CK, 2006, STUD FAMILY PLANN, V37, P41, DOI 10.1111/j.1728-4465.2006.00082.x; Suwannachat B, 2011, BJOG; Suwannachat B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006636.pub2	32	1	1	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2011	6	9							e23994	10.1371/journal.pone.0023994	http://dx.doi.org/10.1371/journal.pone.0023994			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	819CH	21915274	Green Published, Green Submitted, gold			2023-01-03	WOS:000294802500021
J	Wang, J; Li, CH; Wang, EK; Wang, XD				Wang, Jin; Li, Chunhe; Wang, Erkang; Wang, Xidi			An FPT Approach for Predicting Protein Localization from Yeast Genomic Data	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; BAYESIAN NETWORKS; DATA INTEGRATION; GENE-EXPRESSION; CLASSIFICATION; IDENTIFICATION; GENERATION; SEQUENCES; PATTERNS; SYSTEM	Accurately predicting the localization of proteins is of paramount importance in the quest to determine their respective functions within the cellular compartment. Because of the continuous and rapid progress in the fields of genomics and proteomics, more data are available now than ever before. Coincidentally, data mining methods been developed and refined in order to handle this experimental windfall, thus allowing the scientific community to quantitatively address long-standing questions such as that of protein localization. Here, we develop a frequent pattern tree (FPT) approach to generate a minimum set of rules (mFPT) for predicting protein localization. We acquire a series of rules according to the features of yeast genomic data. The mFPT prediction accuracy is benchmarked against other commonly used methods such as Bayesian networks and logistic regression under various statistical measures. Our results show that mFPT gave better performance than other approaches in predicting protein localization. Meanwhile, setting 0.65 as the minimum hit-rate, we obtained 138 proteins that mFPT predicted differently than the simple naive bayesian method (SNB). In our analysis of these 138 proteins, we present novel predictions for the location for 17 proteins, which currently do not have any defined localization. These predictions can serve as putative annotations and should provide preliminary clues for experimentalists. We also compared our predictions against the eukaryotic subcellular localization database and related predictions by others on protein localization. Our method is quite generalized and can thus be applied to discover the underlying rules for protein-protein interactions, genomic interactions, and structure-function relationships, as well as those of other fields of research.	[Wang, Jin; Li, Chunhe; Wang, Erkang] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Elect Chem, Changchun 130022, Jilin, Peoples R China; [Wang, Jin] SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; [Wang, Jin] SUNY Stony Brook, Dept Phys, Stony Brook, NY 11794 USA; [Wang, Jin] SUNY Stony Brook, Dept Astron, Stony Brook, NY 11794 USA; [Li, Chunhe] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Wang, Xidi] Citibank NA, Sao Paulo, Brazil	Chinese Academy of Sciences; Changchun Institute of Applied Chemistry, CAS; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, J (corresponding author), Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Elect Chem, Changchun 130022, Jilin, Peoples R China.	jin.wang.1@stonybrook.edu; ekwang@ciac.jl.cn	Wang, Jiabo/B-6681-2015; xiao, xiang/GWU-6035-2022; Li, Chunhe/C-8132-2011; , 汪尔康/P-1748-2019	Li, Chunhe/0000-0002-9127-3930; 	National Science Foundation; National Natural Science Foundation of China [90713022, 20735003]; 973 project [2009CB930100, 2010CB833600]	National Science Foundation(National Science Foundation (NSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 project(National Basic Research Program of China)	JW acknowledges support from the National Science Foundation. CHL and EKW are supported by the National Natural Science Foundation of China (grants 90713022 and 20735003) and the 973 project (grants 2009CB930100 and 2010CB833600). The funder of XW from a commercial company had a role in preparation of the manuscript. Otherwise, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal RC, 2001, J PARALLEL DISTR COM, V61, P350, DOI 10.1006/jpdc.2000.1693; Agrawal R., 1994, PROC 20 INT C VERY L, V1215, P487; ALEXANDROV V, 2001, INT J QUANTUM CHEM, V4, P188; Andrade MA, 1998, J MOL BIOL, V276, P517, DOI 10.1006/jmbi.1997.1498; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Boyd D, 1998, PROTEIN SCI, V7, P201, DOI 10.1002/pro.5560070121; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Drawid A, 2000, TRENDS GENET, V16, P426, DOI 10.1016/S0168-9525(00)02108-9; Drawid A, 2000, J MOL BIOL, V301, P1059, DOI 10.1006/jmbi.2000.3968; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Friedman N, 2003, MACH LEARN, V50, P95, DOI 10.1023/A:1020249912095; Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961; Frishman D, 1998, BIOINFORMATICS, V14, P551, DOI 10.1093/bioinformatics/14.7.551; Frishman D, 1997, TRENDS GENET, V13, P415, DOI 10.1016/S0168-9525(97)01224-9; GERSTEIN M, 2000, PAC S BIOCOMP, V5, P30; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; HAN J, 2000, SIGKDD EXPLORATIONS, V2, P14; Han JW, 2004, DATA MIN KNOWL DISC, V8, P53, DOI 10.1023/B:DAMI.0000005258.31418.83; HAN JW, 2006, DATA MINING CONCEPTS, P475; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huang WL, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-80; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; KLEIN P, 1985, BIOCHIM BIOPHYS ACTA, V815, P468, DOI 10.1016/0005-2736(85)90375-X; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lin N, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-154; Lu LJ, 2005, GENOME RES, V15, P945, DOI 10.1101/gr.3610305; Mewes HW, 1998, NUCLEIC ACIDS RES, V26, P33, DOI 10.1093/nar/26.1.33; NACHMAN I, 2004, THESIS HEBREW U; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAI K, 1996, INTELL SYS MOL BIOL, V4, P109; NAKAI K, 1997, INTELL SYS MOL BIOL, V5, P147; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Paulsen IT, 1998, FEBS LETT, V430, P116, DOI 10.1016/S0014-5793(98)00629-2; Pierleoni A, 2007, NUCLEIC ACIDS RES, V35, pD208, DOI 10.1093/nar/gkl775; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Riffle M, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-263; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.0.CO;2-3; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stephenson T. A., 2000, INTRO BAYESIAN NETWO; Stryer L, 1996, BIOCHEMISTRY; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; VERHASSELT P, 1995, YEAST, V11, P961, DOI 10.1002/yea.320111007; Wang J, 2009, P NATL ACAD SCI USA, V106, P3752, DOI 10.1073/pnas.0806427106; Zhang LV, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-38	53	114	143	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2011	6	1							e14449	10.1371/journal.pone.0014449	http://dx.doi.org/10.1371/journal.pone.0014449			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710OH	21283516	gold, Green Published, Green Submitted			2023-01-03	WOS:000286520600001
J	Zhang, HY; Zhang, L; Gao, B; Fan, H; Jin, JB; Botella, MA; Jiang, LW; Lin, JX				Zhang, Haiyan; Zhang, Liang; Gao, Bin; Fan, Hai; Jin, Jingbo; Botella, Miguel A.; Jiang, Liwen; Lin, Jinxing			Golgi Apparatus-Localized Synaptotagmin 2 Is Required for Unconventional Secretion in Arabidopsis	PLOS ONE			English	Article							ADP-RIBOSYLATION FACTOR-1; HYGROMYCIN-B INHIBITION; DYNAMIN-LIKE PROTEIN; BREFELDIN-A; SELECTABLE MARKER; PLASMA-MEMBRANE; PREVACUOLAR COMPARTMENTS; ACID-PHOSPHATASE; TRAFFICKING; ENDOCYTOSIS	Background: Most secretory proteins contain signal peptides that direct their sorting to the ER and secreted via the conventional ER/Golgi transport pathway, while some signal-peptide-lacking proteins have been shown to export through ER/Golgi independent secretory pathways. Hygromycin B is an aminoglycoside antibiotic produced by Streptomyces hygroscopicus that is active against both prokaryotic and eukaryotic cells. The hygromycin phosphotransferase (HYG(R)) can phosphorylate and inactivate the hygromycin B, and has been widely used as a positive selective marker in the construction of transgenic plants. However, the localization and trafficking of HYG(R) in plant cells remain unknown. Synaptotagmins (SYTs) are involved in controlling vesicle endocytosis and exocytosis as calcium sensors in animal cells, while their functions in plant cells are largely unclear. Methodology/Principal Findings: We found Arabidopsis synaptotagmin SYT2 was localized on the Golgi apparatus by immunofluorescence and immunogold labeling. Surprisingly, co-expression of SYT2 and HYG(R) caused hypersensitivity of the transgenic Arabidopsis plants to hygromycin B. HYG(R), which lacks a signal sequence, was present in the cytoplasm as well as in the extracellular space in HYG(R)-GFP transgenic Arabidopsis plants and its secretion is not sensitive to brefeldin A treatment, suggesting it is not secreted via the conventional secretory pathway. Furthermore, we found that HYG(R)-GFP was truncated at carboxyl terminus of HYG(R) shortly after its synthesis, and the cells deficient SYT2 failed to efficiently truncate HYGR-GFP, resulting in HYG(R)-GFP accumulated in prevacuoles/vacuoles, indicating that SYT2 was involved in HYG(R)-GFP trafficking and secretion. Conclusion/Significance: These findings reveal for the first time that SYT2 is localized on the Golgi apparatus and regulates HYG(R)-GFP secretion via the unconventional protein transport from the cytosol to the extracelluar matrix in plant cells.	[Zhang, Haiyan; Zhang, Liang; Gao, Bin; Jin, Jingbo; Lin, Jinxing] Chinese Acad Sci, Inst Bot, Key Lab Photosynth & Mol Environm Physiol, Beijing, Peoples R China; [Zhang, Liang] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Gao, Bin; Fan, Hai] Shandong Normal Univ, Coll Life Sci, Jinan, Peoples R China; [Botella, Miguel A.] Univ Malaga, Dept Biol Mol Bioquim, E-29071 Malaga, Spain; [Jiang, Liwen] Chinese Univ Hong Kong, Dept Biol, Shatin, Hong Kong, Peoples R China; [Jiang, Liwen] Chinese Univ Hong Kong, Mol Biotechnol Program, Shatin, Hong Kong, Peoples R China	Chinese Academy of Sciences; Institute of Botany, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Shandong Normal University; Universidad de Malaga; Chinese University of Hong Kong; Chinese University of Hong Kong	Zhang, HY (corresponding author), Chinese Acad Sci, Inst Bot, Key Lab Photosynth & Mol Environm Physiol, Beijing, Peoples R China.	linjx@ibcas.ac.cn	Botella, Miguel Ángel/S-3676-2019; Botella, Miguel A/B-5734-2012; JIANG, Liwen/S-6046-2018; Zhang, Haitao/L-7612-2015	Botella, Miguel Ángel/0000-0002-8867-1831; Botella, Miguel A/0000-0002-8867-1831; JIANG, Liwen/0000-0002-7829-1472; Lin, Jinxing/0000-0001-9338-1356; Zhang, Haitao/0000-0003-4879-2951	National Natural Science Foundation of China [90817010, 30770123]; El Ministerio de Cienciae Innovacion [BIO2008-1709]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); El Ministerio de Cienciae Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	The National Natural Science Foundation of China, (Granted No. 90817010 and 30770123)(http://www.nsfc.gov.cn/Portal0/default124.htm), and El Ministerio de Cienciae Innovacion (Grant BIO2008-1709). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal GK, 2010, PROTEOMICS, V10, P799, DOI 10.1002/pmic.200900514; Bolte S, 2004, J MICROSC-OXFORD, V214, P159, DOI 10.1111/j.0022-2720.2004.01348.x; Borovinskaya MA, 2008, RNA, V14, P1590, DOI 10.1261/rna.1076908; Cabral M, 2010, EUKARYOT CELL, V9, P1009, DOI 10.1128/EC.00337-09; Cheng FY, 2009, PLANTA, V230, P1093, DOI 10.1007/s00425-009-1006-3; Couchy I, 2003, J EXP BOT, V54, P2053, DOI 10.1093/jxb/erg230; Craxton M, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-43; Dettmer J, 2006, PLANT CELL, V18, P715, DOI 10.1105/tpc.105.037978; Dhonukshe P, 2007, CURR BIOL, V17, P520, DOI 10.1016/j.cub.2007.01.052; Fukuda M, 2004, J BIOL CHEM, V279, P52677, DOI 10.1074/jbc.M409241200; Grebe M, 2003, CURR BIOL, V13, P1378, DOI 10.1016/S0960-9822(03)00538-4; Gustavsson N, 2008, P NATL ACAD SCI USA, V105, P3992, DOI 10.1073/pnas.0711700105; Gustavsson N, 2009, BIOSCIENCE REP, V29, P245, DOI 10.1042/BSR20090031; Harlow E., 1988, ANTIBODIES LAB MANUA, Vfirst; Hu ZT, 2008, BIOCHEM BIOPH RES CO, V371, P781, DOI 10.1016/j.bbrc.2008.04.174; Jaillais Y, 2008, PLANT J, V53, P237, DOI 10.1111/j.1365-313X.2007.03338.x; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Kaneko TS, 1996, PLANT CELL REP, V15, P409, DOI 10.1007/BF00232065; Kinseth MA, 2007, CELL, V130, P524, DOI 10.1016/j.cell.2007.06.029; Kotzer AM, 2004, J CELL SCI, V117, P6377, DOI 10.1242/jcs.01564; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lee MH, 2002, PLANT PHYSIOL, V129, P1507, DOI 10.1104/pp.003624; Lee OR, 2010, PLANT CELL, V22, P1812, DOI 10.1105/tpc.110.074211; Lu Y, 2007, J FOOD SCI, V72, pM228, DOI 10.1111/j.1750-3841.2007.00437.x; Lynch KL, 2008, MOL BIOL CELL, V19, P5093, DOI 10.1091/mbc.E08-03-0235; McGaha SM, 2007, ANTIMICROB AGENTS CH, V51, P591, DOI 10.1128/AAC.01116-06; Miki B, 2004, J BIOTECHNOL, V107, P193, DOI 10.1016/j.jbiotec.2003.10.011; Nebenfuhr A, 2002, PLANT PHYSIOL, V130, P1102, DOI 10.1104/pp.011569; Neumann U, 2003, ANN BOT-LONDON, V92, P167, DOI 10.1093/aob/mcg134; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; ORCI L, 1991, CELL, V64, P1183; Ortiz JPA, 1996, PLANT CELL REP, V15, P877, DOI 10.1007/BF00231579; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PARDO JM, 1985, J GEN MICROBIOL, V131, P1289; Park JM, 1997, PLANT PHYSIOL, V115, P763, DOI 10.1104/pp.115.2.763; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Pfeffer SR, 2010, J CELL BIOL, V188, P451, DOI 10.1083/jcb.201001121; Pfeiffer W, 1996, PHYSIOL PLANTARUM, V98, P773, DOI 10.1111/j.1399-3054.1996.tb06684.x; PITTENGER RC, 1953, ANTIBIOT CHEMOTHER, V3, P1268; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; Robinson DG, 2008, TRENDS PLANT SCI, V13, P405, DOI 10.1016/j.tplants.2008.05.010; Schapire AL, 2009, TRENDS PLANT SCI, V14, P645, DOI 10.1016/j.tplants.2009.09.004; Schapire AL, 2008, PLANT CELL, V20, P3374, DOI 10.1105/tpc.108.063859; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schotman H, 2008, DEV CELL, V14, P171, DOI 10.1016/j.devcel.2007.12.006; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Teh OK, 2007, NATURE, V448, P493, DOI 10.1038/nature06023; Tian LN, 2000, PLANT CELL REP, V19, P358, DOI 10.1007/s002990050740; Tse YC, 2004, PLANT CELL, V16, P672, DOI 10.1105/tpc.019703; Ueda T, 2001, EMBO J, V20, P4730, DOI 10.1093/emboj/20.17.4730; Wang JA, 2010, PLANT CELL, V22, P4009, DOI 10.1105/tpc.110.080697; Wang JQ, 2009, J EXP BOT, V60, P3075, DOI 10.1093/jxb/erp136; Wu FH, 2009, PLANT METHODS, V5, DOI 10.1186/1746-4811-5-16; Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449; Yamazaki T, 2008, PLANT CELL, V20, P3389, DOI 10.1105/tpc.108.062679; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199	59	47	51	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 28	2011	6	11							e26477	10.1371/journal.pone.0026477	http://dx.doi.org/10.1371/journal.pone.0026477			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	863KW	22140429	Green Submitted, Green Published, gold			2023-01-03	WOS:000298163400001
J	Gupta, A; Nagilla, P; Le, HS; Bunney, C; Zych, C; Thalamuthu, A; Bar-Joseph, Z; Mathavan, S; Ayyavoo, V				Gupta, Ankit; Nagilla, Pruthvi; Le, Hai-Son; Bunney, Coulton; Zych, Courtney; Thalamuthu, Anbupalam; Bar-Joseph, Ziv; Mathavan, Sinnakaruppan; Ayyavoo, Velpandi			Comparative Expression Profile of miRNA and mRNA in Primary Peripheral Blood Mononuclear Cells Infected with Human Immunodeficiency Virus (HIV-1)	PLOS ONE			English	Article							GENE-EXPRESSION; GENOMEWIDE ASSOCIATION; DISEASE PROGRESSION; UP-REGULATION; MICRORNA; IMMUNE; IDENTIFICATION; TRANSLATION; RESISTANCE; APOPTOSIS	Host cells respond to exogenous infectious agents such as viruses, including HIV-1. Studies have evaluated the changes associated with virus infection at the transcriptional and translational levels of the cellular genes involved in specific pathways. While this approach is useful, in our view it provides only a partial view of genome-wide changes. Recently, technological advances in the expression profiling at the microRNA (miRNA) and mRNA levels have made it possible to evaluate the changes in the components of multiple pathways. To understand the role of miRNA and its interplay with host cellular gene expression (mRNA) during HIV-1 infection, we performed a comparative global miRNA and mRNA microarray using human PBMCs infected with HIV-1. The PBMCs were derived from multiple donors and were infected with virus generated from the molecular clone pNL4-3. The results showed that HIV-1 infection led to altered regulation of 21 miRNAs and 444 mRNA more than 2-fold, with a statistical significance of p<0.05. Furthermore, the differentially regulated miRNA and mRNA were shown to be associated with host cellular pathways involved in cell cycle/proliferation, apoptosis, T-cell signaling, and immune activation. We also observed a number of inverse correlations of miRNA and mRNA expression in infected PBMCs, further confirming the interrelationship between miRNA and mRNA regulation during HIV-1 infection. These results for the first time provide evidence that the miRNA profile could be an early indicator of host cellular dysfunction induced by HIV-1.	[Gupta, Ankit; Nagilla, Pruthvi; Bunney, Coulton; Zych, Courtney; Ayyavoo, Velpandi] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA; [Le, Hai-Son; Bar-Joseph, Ziv] Carnegie Mellon Univ, Dept Machine Learning, Pittsburgh, PA 15213 USA; [Thalamuthu, Anbupalam; Mathavan, Sinnakaruppan] Genome Inst Singapore, Singapore, Singapore	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Gupta, A (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15261 USA.	velpandi@pitt.edu	Bar-Joseph, Ziv/GWN-2754-2022; Thalamuthu, Anbupalam/Z-5545-2019	Thalamuthu, Anbupalam/0000-0002-7114-1260; Gupta, Amita/0000-0001-7036-2718	NIAID/NIH; ARRA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035041] Funding Source: NIH RePORTER	NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ARRA; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by ARRA supplement to U01 U0-AI35041 by the NIAID/NIH to VA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Amariglio N, 2007, BLOOD CELL MOL DIS, V39, P151, DOI 10.1016/j.bcmd.2007.04.003; Asmuth DM, 2005, CYTOM PART A, V66A, P41, DOI 10.1002/cyto.a.20148; Backes C, 2010, NUCLEIC ACIDS RES, V38, P4476, DOI 10.1093/nar/gkq167; Ballana E, 2010, CLIN INFECT DIS, V50, P1022, DOI 10.1086/651114; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Barik S, 2005, J MOL MED, V83, P764, DOI 10.1007/s00109-005-0690-0; Barnes MR, 2007, EXPERT OPIN BIOL TH, V7, P1387, DOI 10.1517/14712598.7.9.1387; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Borjabad A, 2010, J NEUROIMMUNE PHARM, V5, P44, DOI 10.1007/s11481-009-9167-1; Brown JN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003664; BURGENER A, CURR HIV AIDS REP, V7, P53; Carissimi C, 2009, AUTOIMMUN REV, V8, P520, DOI 10.1016/j.autrev.2009.01.008; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Chan EY, 2007, J VIROL, V81, P7571, DOI 10.1128/JVI.00288-07; Chang TC, 2007, ANNU REV GENOM HUM G, V8, P215, DOI 10.1146/annurev.genom.8.080706.092351; Charurat M, 2004, J WOMENS HEALTH, V13, P719, DOI 10.1089/jwh.2004.13.719; Chua JH, 2009, CURR OPIN MOL THER, V11, P189; Ciccosanti F, 2010, ANTIVIR THER, V15, P377, DOI 10.3851/IMP1530; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Fabian MR, 2010, PROG MOL SUBCELL BIO, V50, P1, DOI 10.1007/978-3-642-03103-8_1; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fritz Jorg H, 2006, Sci STKE, V2006, ppe27; Garcia-Arriaza J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012395; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; Gomase Virendra S, 2009, Int J Bioinform Res Appl, V5, P479, DOI 10.1504/IJBRA.2009.028678; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Herbeck JT, 2010, J INFECT DIS, V201, P618, DOI 10.1086/649842; Hirbod T, 2006, JAIDS-J ACQ IMM DEF, V43, P137, DOI 10.1097/01.qai.0000229016.85192.60; Hladik F, 2005, J VIROL, V79, P11677, DOI 10.1128/JVI.79.18.11677-11684.2005; Houzet L, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-118; Huang J, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M705116200; Huang JC, 2007, J COMPUT BIOL, V14, P550, DOI 10.1089/cmb.2007.R002; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; IMIG J, 2010, NUCL ACIDS RES; Imig J, 2011, NUCLEIC ACIDS RES, V39, P1880, DOI 10.1093/nar/gkq1043; JEANNET M, 1989, J ACQ IMMUN DEF SYND, V2, P28; Kaul D, 2009, MOL CELL BIOCHEM, V323, P143, DOI 10.1007/s11010-008-9973-4; Klase Z, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-18; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lee JE, 2010, CELL PROLIFERAT, V43, P378, DOI 10.1111/j.1365-2184.2010.00687.x; Li LM, 2010, CANCER RES, V70, P9798, DOI 10.1158/0008-5472.CAN-10-1001; Li QS, 2009, J IMMUNOL, V183, P1975, DOI 10.4049/jimmunol.0803222; Li Y, 2007, VIROLOGY, V366, P137, DOI 10.1016/j.virol.2007.04.020; Limou S, 2009, J INFECT DIS, V199, P419, DOI 10.1086/596067; Liu XY, 2010, VIROLOGY, V398, P57, DOI 10.1016/j.virol.2009.11.036; Majumder B, 2005, J VIROL, V79, P7990, DOI 10.1128/JVI.79.13.7990-8003.2005; McMichael AJ, 2010, SCIENCE, V330, P1488, DOI 10.1126/science.1200035; Melendez LM, 2011, J NEUROIMMUNE PHARM, V6, P89, DOI 10.1007/s11481-010-9253-4; Mothe B, 2009, DIS MARKERS, V27, P105, DOI [10.1155/2009/360362, 10.3233/DMA-2009-0655]; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; Narayanan A, 2011, EXPERT OPIN BIOL TH, V11, P17, DOI 10.1517/14712598.2011.540564; Nieto G, 2004, J STEROID BIOCHEM, V89-90, P199, DOI 10.1016/j.jsbmb.2004.03.086; Noorbakhsh F, 2010, FASEB J, V24, P1799, DOI 10.1096/fj.09-147819; O'Brien SJ, 2004, NAT GENET, V36, P565, DOI 10.1038/ng1369; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Paxton WA, 1998, SEMIN IMMUNOL, V10, P187, DOI 10.1006/smim.1998.0132; Poropatich K, 2011, J GEN VIROL, V92, P247, DOI 10.1099/vir.0.027102-0; Ringrose J, 2008, J VIROL, V82, P4320, DOI 10.1128/JVI.01819-07; Rotger M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000781; Ryo A, 2000, AIDS RES HUM RETROV, V16, P995, DOI 10.1089/08892220050058416; Shalgi R, 2007, PLOS COMPUT BIOL, V3, P1291, DOI 10.1371/journal.pcbi.0030131; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Sundaravaradan V, 2010, VIROLOGY, V400, P32, DOI 10.1016/j.virol.2010.01.018; Sung TL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000263; Tatro ET, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010337; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vahey MT, 2002, AIDS RES HUM RETROV, V18, P179, DOI 10.1089/08892220252781239; Van den Bergh R, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-53; van't Wout AB, 2003, J VIROL, V77, P1392, DOI 10.1128/JVI.77.2.1392-1402.2003; van 't Wout AB, 2005, J VIROL, V79, P10053, DOI 10.1128/JVI.79.15.10053-10058.2005; Venkatachari NJ, 2008, VIROLOGY, V376, P140, DOI 10.1016/j.virol.2008.03.015; Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000; Weber J, 2003, J GEN VIROL, V84, P2217, DOI 10.1099/vir.0.19123-0; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Wu JQ, 2008, VIROLOGY, V380, P124, DOI 10.1016/j.virol.2008.06.039; Xing HQ, 2009, NEUROPATHOLOGY, V29, P433, DOI 10.1111/j.1440-1789.2008.00996.x; Zaunders J, 2011, CURR OPIN HIV AIDS, V6, P151, DOI 10.1097/COH.0b013e3283454d5b; Zhang CX, 2009, CURR OPIN MOL THER, V11, P641; ZHANG L, PROTEOME SCI, V8, P12; Zhao XH, 2010, NEURON, V65, P612, DOI 10.1016/j.neuron.2010.02.018	81	186	189	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2011	6	7							e22730	10.1371/journal.pone.0022730	http://dx.doi.org/10.1371/journal.pone.0022730			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KC	22220193	gold, Green Published, Green Submitted			2023-01-03	WOS:000293284600035
J	Shi, XD; Pan, Y; Wang, ML; Wang, DS; Li, WY; Jiang, T; Zhang, P; Chi, XM; Jiang, YF; Gao, YH; Zhong, J; Sun, B; Xu, DM; Jiang, J; Niu, JQ				Shi, Xiaodong; Pan, Yu; Wang, Moli; Wang, Dongsheng; Li, Wanyu; Jiang, Tao; Zhang, Peng; Chi, Xiumei; Jiang, Yanfang; Gao, Yanhang; Zhong, Jin; Sun, Bing; Xu, Damo; Jiang, Jing; Niu, Junqi			IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population	PLOS ONE			English	Article							ALPHA-2B PLUS RIBAVIRIN; VIROLOGICAL RESPONSE; IFN-LAMBDA; INFECTION; THERAPY	Background: The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations. This study was to determine whether this gene variant is also associated with spontaneous clearance of HCV infection, treatment response and IL-28B protein production in Chinese patients. Methods: We genotyped IL28B genetic variations (rs12980275, rs8103142, rs8099917 and rs12979860) by pyrosequencing DNA samples from cohorts consisting of 529 subjects with persistent HCV infection, 196 subjects who cleared the infection, 171 healthy individuals and 235 chronic HCV patients underwent IFN/RBV treatment. The expression of IL-28B were measured by ELISA and RT-PCR. Results: We found that the four IL28B variants were in complete linkage disequilibrium (r2 = 0.97-0.98). The rs12979860 CC genotype was strongly associated with spontaneously HCV clearance and successful IFN/RBV treatment compared to the CT/TT. IL-28B levels in persistent HCV patients were significantly lower than subjects who spontaneously resolved HCV and healthy controls and were also associated with high levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). IL-28B levels were also significantly lower in individuals carrying T alleles than CC homozygous. Conclusions: Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population.	[Shi, Xiaodong; Pan, Yu; Li, Wanyu; Zhang, Peng; Chi, Xiumei; Jiang, Yanfang; Gao, Yanhang; Niu, Junqi] Jilin Univ, Dept Hepatol, Hosp 1, Changchun 130023, Peoples R China; [Jiang, Jing] Jilin Univ, Dept Clin Epidemiol, Hosp 1, Changchun 130023, Peoples R China; [Zhong, Jin; Sun, Bing] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai, Peoples R China; [Wang, Dongsheng; Jiang, Tao] Hosp HepatologyBiliary Jilin Prov, Changchun, Peoples R China; [Xu, Damo] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland; [Wang, Moli] Jilin Univ, Hosp 4, Changchun 130023, Peoples R China	Jilin University; Jilin University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); University of Glasgow; Jilin University	Shi, XD (corresponding author), Jilin Univ, Dept Hepatol, Hosp 1, Changchun 130023, Peoples R China.	jiangjing19702000@yahoo.cn; junqiniu@yahoo.cn	Wang, Mengqiang/A-1215-2010; zhi, zhouzhi/J-8063-2013; Zhong, Jin/J-4613-2019; Yue, Feng/S-6565-2017; Zhong, Jin/M-6859-2018	Wang, Mengqiang/0000-0003-4702-3309; Zhong, Jin/0000-0002-3554-1275	Shanghai Pasteur Health Research Foundation [SPHRF2009001]; Eleventh 5-year National Key Programs on Infectious Disease [2008ZX10002-014]; National Natural Science Foundation of China [81001312/H1005, 81072347/H2609]; Jilin University [20101036]	Shanghai Pasteur Health Research Foundation; Eleventh 5-year National Key Programs on Infectious Disease; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin University(Jilin University)	This study was supported by grants from the Shanghai Pasteur Health Research Foundation (SPHRF2009001), the Eleventh 5-year National Key Programs on Infectious Disease (2008ZX10002-014), the National Natural Science Foundation of China under grants No 81001312/H1005 and 81072347/H2609 and the Graduate Innovation Fund of Jilin University (No. 20101036). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ank N, 2006, J VIROL, V80, P4501, DOI 10.1128/JVI.80.9.4501-4509.2006; Ank N, 2008, J IMMUNOL, V180, P2474, DOI 10.4049/jimmunol.180.4.2474; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Aparicio E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013771; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; Bruno S, 2008, ANN HEPATOL, V7, P114, DOI 10.1016/S1665-2681(19)31865-4; Davis GL, 2003, HEPATOLOGY, V38, P645, DOI 10.1053/jhep.2003.50364; Dolganiuc A, 2006, J IMMUNOL, V177, P6758, DOI 10.4049/jimmunol.177.10.6758; Doyle SE, 2006, HEPATOLOGY, V44, P896, DOI 10.1002/hep.21312; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010; Hepburn MJ, 2004, AM J MED, V117, P163, DOI 10.1016/j.amjmed.2004.02.043; Huang CF, 2010, J GASTROEN HEPATOL, V25, P758, DOI 10.1111/j.1440-1746.2009.06148.x; Hwang SJ, 2001, J MED VIROL, V65, P505, DOI 10.1002/jmv.2064; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Langhans B, 2011, J HEPATOL, V54, P859, DOI 10.1016/j.jhep.2010.08.020; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marukian S, 2008, HEPATOLOGY, V48, P1843, DOI 10.1002/hep.22550; Missiha SB, 2008, GASTROENTEROLOGY, V134, P1699, DOI 10.1053/j.gastro.2008.02.069; Rauch A, 2010, EUR J CLIN INVEST, V40, P950, DOI 10.1111/j.1365-2362.2010.02337.x; Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056; Rauch A, 2009, PHARMACOGENOMICS, V10, P1819, DOI [10.2217/pgs.09.121, 10.2217/PGS.09.121]; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sarasin-Filipowicz M, 2008, P NATL ACAD SCI USA, V105, P7034, DOI 10.1073/pnas.0707882105; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Shiina M, 2008, HEPATOLOGY, V47, P385, DOI 10.1002/hep.21996; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Spann KM, 2005, J VIROL, V79, P5353, DOI 10.1128/JVI.79.9.5353-5362.2005; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suppiah V, 2009, NAT GENET, V41, P1100, DOI 10.1038/ng.447; Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Thio CL, 2000, HEPATOLOGY, V31, P819, DOI 10.1053/he.2000.4316; Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463; Yu ML, 2009, J GASTROEN HEPATOL, V24, P336, DOI 10.1111/j.1440-1746.2009.05789.x; Zechini B, 2004, EUR J GASTROEN HEPAT, V16, P891, DOI 10.1097/00042737-200409000-00013	40	101	108	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2012	7	5							e37054	10.1371/journal.pone.0037054	http://dx.doi.org/10.1371/journal.pone.0037054			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959TH	22649509	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000305335800027
J	Li, ZF; Yang, YQ; Xie, DF; Zhu, LF; Zhang, ZG; Lin, WX				Li, Zhen-Fang; Yang, Yan-Qiu; Xie, Dong-Feng; Zhu, Lan-Fang; Zhang, Zi-Guan; Lin, Wen-Xiong			Identification of Autotoxic Compounds in Fibrous Roots of Rehmannia (Rehmannia glutinosa Libosch.)	PLOS ONE			English	Article							SEEDLING GROWTH; POPULATIONS; GERMINATION; PATHOGENS; EXTRACTS	Rehmannia is a medicinal plant in China. Autotoxicity has been reported to be one of the major problems hindering the consecutive monoculture of Rehmannia. However, potential autotoxins produced by the fibrous roots are less known. In this study, the autotoxicity of these fibrous roots was investigated. Four groups of autotoxic compounds from the aqueous extracts of the fibrous roots were isolated and characterized. The ethyl acetate extracts of these water-soluble compounds were further analyzed and separated into five fractions. Among them, the most autotoxic fraction (Fr 3) was subjected to GC/MS analysis, resulting in 32 identified compounds. Based on literature, nine compounds were selected for testing their autotoxic effects on radicle growth. Seven out of the nine compounds were phenolic, which significantly reduced radicle growth in a concentration-dependent manner. The other two were aliphatic compounds that showed a moderate inhibition effect at three concentrations. Concentration of these compounds in soil samples was determined by HPLC. Furthermore, the autotoxic compounds were also found in the top soil of the commercially cultivated Rehmannia fields. It appears that a close link exists between the autotoxic effects on the seedlings and the compounds extracted from fibrous roots of Rehmannia.	[Li, Zhen-Fang; Yang, Yan-Qiu; Xie, Dong-Feng; Zhu, Lan-Fang; Zhang, Zi-Guan; Lin, Wen-Xiong] Fujian Agr & Forestry Univ, Agroecol Inst, Fuzhou, Peoples R China	Fujian Agriculture & Forestry University	Li, ZF (corresponding author), Fujian Agr & Forestry Univ, Agroecol Inst, Fuzhou, Peoples R China.	wenxiong181@163.com			National Natural Science Foundation of China [30772729]; Provincial Natural Science Foundation of Fujian, China [2008J0051]; key discipline program of Fujian Province, China [20020F012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Provincial Natural Science Foundation of Fujian, China(Natural Science Foundation of Fujian Province); key discipline program of Fujian Province, China	This work was supported by The National Natural Science Foundation of China (No. 30772729), Provincial Natural Science Foundation of Fujian, China (No. 2008J0051), and the key discipline program of Fujian Province, China (grant No. 20020F012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bogatek R, 2006, BIOL PLANTARUM, V50, P156, DOI 10.1007/s10535-005-0094-6; Canals RM, 2005, J THEOR BIOL, V235, P402, DOI 10.1016/j.jtbi.2005.01.020; Chon SU, 2005, J AGRON CROP SCI, V191, P75, DOI 10.1111/j.1439-037X.2004.00138.x; Chon SU, 2004, AGRON J, V96, P1673, DOI 10.2134/agronj2004.1673; Chou CH, 1976, J CHEM ECOL, V2, P353, DOI 10.1007/BF00988282; Cui YY, 2000, PLANT CELL TISS ORG, V62, P219, DOI 10.1023/A:1006412321864; Du Jia-fang, 2009, Shengtaixue Zazhi, V28, P445; Einhellig FA, 1996, AGRON J, V88, P886, DOI 10.2134/agronj1996.00021962003600060007x; Gao WW, 2006, CHINA J CHINESE MAT, V31, P1665; Hao ZP, 2007, SCI HORTIC-AMSTERDAM, V112, P315, DOI 10.1016/j.scienta.2006.12.030; Kalinova J, 2007, J AGR FOOD CHEM, V55, P6453, DOI 10.1021/jf070795u; Kong CH, 1999, J CHEM ECOL, V25, P2347, DOI 10.1023/A:1020882109682; Li Jing, 2010, Zhongguo Zhong Yao Za Zhi, V35, P1679; Lin WX, 2000, ALLELOPATHY J, V7, P215; Liu HY, 2006, J N CHINA AGR, V21, P131; Manici LM, 2003, PLANT SOIL, V256, P315, DOI 10.1023/A:1026103001592; Weller DM, 2002, ANNU REV PHYTOPATHOL, V40, P309, DOI 10.1146/annurev.phyto.40.030402.110010; Wilson S, 2004, SCI HORTIC-AMSTERDAM, V102, P221, DOI 10.1016/j.scienta.2004.01.001; Wu HW, 2007, PLANT SOIL, V296, P85, DOI 10.1007/s11104-007-9292-7; [解红娥 XIE Hong'e], 2007, [山西农业科学, Journal of Shanxi Agricultural Sciences], V35, P59; Yu JQ, 2000, PLANT SOIL, V223, P149, DOI 10.1023/A:1004829512147; Zhang ZC, 2008, ARCH VIROL, V153, P595, DOI 10.1007/s00705-007-0002-9; Zhao HJ, 2007, PLANT GROWTH REGUL, V51, P255, DOI 10.1007/s10725-007-9167-1; Zhao YJ, 2005, ALLELOPATHY J, V15, P67	24	93	116	8	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 3	2012	7	1							e28806	10.1371/journal.pone.0028806	http://dx.doi.org/10.1371/journal.pone.0028806			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	903NK	22235251	Green Published, gold, Green Submitted			2023-01-03	WOS:000301123400012
J	Wang, JB; Zhao, HP; Zhao, YL; Jin, C; Liu, DJ; Kong, WJ; Fang, F; Zhang, L; Wang, HJ; Xiao, XH				Wang, Jia-bo; Zhao, Hai-ping; Zhao, Yan-ling; Jin, Cheng; Liu, Dao-jian; Kong, Wei-jun; Fang, Fang; Zhang, Lin; Wang, Hong-juan; Xiao, Xiao-he			Hepatotoxicity or Hepatoprotection? Pattern Recognition for the Paradoxical Effect of the Chinese Herb Rheum palmatum L. in Treating Rat Liver Injury	PLOS ONE			English	Article							GROWTH-FACTOR; MEDICINE; HEPATITIS; FIBROSIS; RHUBARB; EXPRESSION; EMODIN; ACID	The hepatotoxicity of some Chinese herbs has been a cause for concern in recent years. However, some herbs, such as rhubarb, have been documented as having both therapeutic and toxic effects on the liver, leading to the complex problem of distinguishing the benefits from the risks of using this herb. To comparatively analyze the dose-response relationship between rhubarb and hepatic health, we administrated total rhubarb extract(RE) to normal and carbon tetrachloride(CCl4)-treated rats for 12 weeks at 4 dosage levels(2.00, 5.40, 14.69 and 40.00 g.kg(-1), measured as the quantity of crude material), followed by biochemical and histopathological tests of the rats' livers. A composite pattern was extracted by factor analysis, using all the biochemical indices as variables, into a visual representation of two mathematically obtained factors, which could be interpreted as the fibrosis factor and the cellular injury factor, according to the values of the variable loadings. The curative effect of administering the two lowest dosages of RE to CCl4-treated rats was mainly expressed as a decrease in the extent of cellular injury. The hepatoprotective mechanism of RE might be related to its antioxidant effect, the antagonism of the free radical damage to hepatocytes caused by CCl4. By contrast, the RE-induced liver damage was mainly expressed as a significant increase in the amount of fibrosis in both normal rats at all dosage levels and CCl4-treated rats at the two highest dosage levels. Therefore, the hepatotoxic potential of RE could be attributable to the liver cell fibrosis induced by high doses of the herb. This study illustrates the bidirectional potential of rhubarb and demonstrates the feasibility of using factor analysis to study the dose-response relationships between herbal medicines and hepatotoxicity or the healing effects of these herbs by extracting the underlying interrelationships among a number of functional bio-indices in a holistic manner.	[Wang, Jia-bo; Zhao, Hai-ping; Zhao, Yan-ling; Jin, Cheng; Liu, Dao-jian; Kong, Wei-jun; Fang, Fang; Zhang, Lin; Wang, Hong-juan; Xiao, Xiao-he] 302 Mil Hosp, Integrat Med Ctr, Beijing, Peoples R China; [Zhao, Hai-ping] Jiangxi Univ Tradit Chinese Med, Minist Educ, Key Lab Modern Preparat Tradit Chinese Med, Nanchang, Peoples R China; [Kong, Wei-jun; Fang, Fang; Zhang, Lin] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China	Fifth Medical Center of Chinese PLA General Hospital; Jiangxi University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine	Wang, JB (corresponding author), 302 Mil Hosp, Integrat Med Ctr, Beijing, Peoples R China.	pharmacy302@126.com	Wang, Jiabo/B-6681-2015; xiao, xiang/GWU-6035-2022; Li, Chunhe/C-8132-2011; , 汪尔康/P-1748-2019	Li, Chunhe/0000-0002-9127-3930; 	National Key Technologies R&D Program of China [2009ZX09502-022]; National Natural Science Foundation of China [30625042, 30973947]	National Key Technologies R&D Program of China(National Key Technology R&D Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was funded by the National Key Technologies R&D Program of China (No. 2009ZX09502-022) and by the National Natural Science Foundation of China (No. 30625042 and 30973947). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2006, JAP PHARM; Arosio B, 2000, PHARMACOL TOXICOL, V87, P229, DOI 10.1034/j.1600-0773.2000.d01-79.x; Attallah AM, 2007, J IMMUNOASS IMMUNOCH, V28, P199, DOI 10.1080/15321810701454649; Battinelli L, 2004, ANN INTERN MED, V140, pE589, DOI 10.7326/0003-4819-140-7-200404060-00042-w3; Cao Z, 2001, J 4 MILITARY MED U, V22, P530; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Chitturi S, 2000, J GASTROEN HEPATOL, V15, P1093, DOI 10.1046/j.1440-1746.2000.02349.x; Ding Y, 2008, EUR J PHARMACOL, V590, P377, DOI 10.1016/j.ejphar.2008.06.044; *EUR DIR QUAL MED, 2001, EUR PHARM; Huang Z H, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P459; Iizuka A, 2004, J ETHNOPHARMACOL, V91, P89, DOI 10.1016/j.jep.2003.11.021; ITOH S, 1995, DIGEST DIS SCI, V40, P1845, DOI 10.1007/BF02212712; Jeong HG, 1999, TOXICOL LETT, V105, P215, DOI 10.1016/S0378-4274(99)00004-1; Jin HY, 2005, LIFE SCI, V76, P2805, DOI 10.1016/j.lfs.2004.09.041; Leung TF, 2005, THORAX, V60, P822, DOI 10.1136/thx.2004.039321; Luo Z. Y., 2007, CHIN ARCH TRADIT CHI, V25, P612; Mase A, 2010, J ETHNOPHARMACOL, V127, P742, DOI 10.1016/j.jep.2009.11.029; Medicines and Healthcare products Regulatory Agency, POL MULT LIV REACT; Miele L, 2009, TRANSL RES, V154, P194, DOI 10.1016/j.trsl.2009.06.007; Napoli J, 1997, HEPATOLOGY, V26, P624, DOI 10.1053/jhep.1997.v26.pm0009303492; *NAT TOX PROGR, 2001, SERIES NAT TOX PROGR, V493; Ni M., 1995, YELLOW EMPERORS CLAS; Qin Y, 2011, J ETHNOPHARMACOL, V133, P1096, DOI 10.1016/j.jep.2010.11.041; Sharma S., 1996, APPL MULTIVARIATE TE, P90; Tafeit E, 2000, COMPUT BIOMED RES, V33, P365, DOI 10.1006/cbmr.2000.1550; Thoefner MB, 2001, PREV VET MED, V48, P201, DOI 10.1016/S0167-5877(00)00193-8; TIAN Y, 2008, CHIN J HISTOCHEM CYT, V17, P303; Tong ZY, 2009, HEPATOLOGY, V50, P939, DOI 10.1002/hep.23102; Vanderperren B, 2005, ANN PHARMACOTHER, V39, P1353, DOI 10.1345/aph.1E670; WAEL ED, 1997, NMR BIOMED, V10, P99; Wan Shao-hui, 2006, Zhongguo Yaolixue Tongbao, V22, P1405; WANG GS, 1985, CHIN J INTEGR TRAD W, V5, P322; WANG GS, 1985, CHIN J INTEGR TRAD W, V5, P329; Wang JB, 2009, J ETHNOPHARMACOL, V124, P18, DOI 10.1016/j.jep.2009.04.018; World Health Organization, 1999, WHO MONOGRAPHS SELEC, P231; Wu C X, 1984, Zhong Xi Yi Jie He Za Zhi, V4, P88; XU Y, 2005, MOD J INTEGR TRADIT, V14, P600; Ye M, 2007, J AM SOC MASS SPECTR, V18, P82, DOI 10.1016/j.jasms.2006.08.009; Yuen MF, 2006, ALIMENT PHARM THER, V24, P1179, DOI 10.1111/j.1365-2036.2006.03111.x; [张陆勇 Zhang Liuyong], 2004, [中国生化药物杂志, Chinese Journal of Biochemical Pharmaceutics], V25, P206; Zhao YL, 2009, BASIC CLIN PHARMACOL, V104, P463, DOI 10.1111/j.1742-7843.2009.00389.x; 2005, PHARMACOPOEIA PEOPLE, P17	42	114	143	3	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 6	2011	6	9							e24498	10.1371/journal.pone.0024498	http://dx.doi.org/10.1371/journal.pone.0024498			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	817QP	21283516	Green Submitted, gold, Green Published			2023-01-03	WOS:000294689200050
J	Shi, XW; Zhou, Z; Wang, LL; Yue, F; Wang, MQ; Yang, CY; Song, LS				Shi, Xiaowei; Zhou, Zhi; Wang, Lingling; Yue, Feng; Wang, Mengqiang; Yang, Chuanyan; Song, Linsheng			The Immunomodulation of Acetylcholinesterase in Zhikong Scallop Chlamys farreri	PLOS ONE			English	Article							PERIPHERAL ANIONIC SITE; MOLECULAR CHARACTERIZATION; MUSCLE REGENERATION; INNATE IMMUNITY; NERVOUS-SYSTEM; RAT-BRAIN; EXPRESSION; INHIBITION; HEMOCYTES; RECEPTOR	Background: Acetycholinesterase (AChE; EC 3.1.1.7) is an essential hydrolytic enzyme in the cholinergic nervous system, which plays an important role during immunomodulation in vertebrates. Though AChEs have been identified in most invertebrates, the knowledge about immunomodulation function of AChE is still quite meagre in invertebrates. Methodology: A scallop AChE gene was identified from Chlamys farreri (designed as CfAChE), and its open reading frame encoded a polypeptide of 522 amino acids. A signal peptide, an active site triad, the choline binding site and the peripheral anionic sites (PAS) were identified in CfAChE. The recombinant mature polypeptide of CfAChE (rCfAChE) was expressed in Pichia pastoris GS115, and its activity was 71.3 +/- 1.3 U mg(-1) to catalyze the hydrolysis of acetylthiocholine iodide. The mRNA transcripts of CfAChE were detected in haemocytes, hepatopancreas, adductor muscle, mantle, gill, kidney and gonad, with the highest expression level in hepatopancreas. The relative expression level of CfAChE mRNA in haemocytes was both up-regulated after LPS (0.5 mg mL(-1)) and human TNF-alpha (50 ng mL(-1)) stimulations, and it reached the highest level at 12 h (10.4-fold, P<0.05) and 1 h (3.2-fold, P<0.05), respectively. After Dichlorvos (DDVP) (50 mg L-1) stimulation, the CfAChE activity in the supernatant of haemolymph decreased significantly from 0.16 U mg(-1) at 0 h to 0.03 U mg(-1) at 3 h, while the expression level of lysozyme in the haemocytes was up-regulated and reached the highest level at 6 h, which was 3.0-fold (P<0.05) of that in the blank group. Conclusions:The results collectively indicated that CfAChE had the acetylcholine-hydrolyzing activity, which was in line with the potential roles of AChE in the neuroimmune system of vertebrates which may help to re-balance the immune system after immune response.	[Shi, Xiaowei; Zhou, Zhi; Wang, Lingling; Yue, Feng; Wang, Mengqiang; Yang, Chuanyan; Song, Linsheng] Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao, Peoples R China; [Shi, Xiaowei; Zhou, Zhi; Yue, Feng; Wang, Mengqiang; Yang, Chuanyan] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Oceanology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Shi, XW (corresponding author), Chinese Acad Sci, Inst Oceanol, Key Lab Expt Marine Biol, Qingdao, Peoples R China.	wanglingling@ms.qdio.ac.cn; lshsong@ms.qdio.ac.cn	Wang, Mengqiang/A-1215-2010; zhi, zhouzhi/J-8063-2013; Zhong, Jin/J-4613-2019; Yue, Feng/S-6565-2017; Zhong, Jin/M-6859-2018	Wang, Mengqiang/0000-0003-4702-3309; Zhong, Jin/0000-0002-3554-1275	Chinese Ministry of Science and Technology [2010CB126404]; National Natural Science Foundation of China [30925028, 30730070, 31072192]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by National Basic Research Program of China (973 program, no. 2010CB126404) from Chinese Ministry of Science and Technology, and grants (No. 30925028 and 30730070 to LS, and 31072192 to LW) from National Natural Science Foundation of China, http://www.nsfc.gov.cn/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angelini C, 2004, EUR J HISTOCHEM, V48, P235; Anguiano GA, 2010, ENVIRON TOXICOL, V25, P327, DOI 10.1002/tox.20491; Arpagaus M, 1998, J PHYSIOLOGY-PARIS, V92, P363, DOI 10.1016/S0928-4257(99)80006-0; Askar KA, 2011, APPL BIOCH BIOTECHNO; Azevedo-Pereira HMVS, 2011, ECOTOX ENVIRON SAFE, V74, P1210, DOI 10.1016/j.ecoenv.2011.03.018; Baxter GD, 1999, INT J PARASITOL, V29, P1765, DOI 10.1016/S0020-7519(99)00136-8; BERGMANN F, 1950, BIOCHIM BIOPHYS ACTA, V6, P217, DOI 10.1016/0006-3002(50)90094-1; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Boudinot E, 2009, RESP PHYSIOL NEUROBI, V165, P40, DOI 10.1016/j.resp.2008.10.003; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branduardi D, 2005, J AM CHEM SOC, V127, P9147, DOI 10.1021/ja0512780; BULBRING E, 1953, PROC R SOC SER B-BIO, V141, P445, DOI 10.1098/rspb.1953.0053; Cao A, 2007, INT IMMUNOPHARMACOL, V7, P1395, DOI 10.1016/j.intimp.2007.07.008; Cheng T.C., 1981, INVERTEBRATE BLOOD C, V1, P223; Cheng Thomas C., 1996, P299; Costa MM, 2009, FISH SHELLFISH IMMUN, V26, P515, DOI 10.1016/j.fsi.2009.02.001; CYMBOROWSKI B, 1970, COMP BIOCHEM PHYSIOL, V32, P367, DOI 10.1016/0010-406X(70)90950-3; Das UN, 2007, MED SCI MONITOR, V13, pRA214; De Zoysa M, 2009, FISH SHELLFISH IMMUN, V26, P625, DOI 10.1016/j.fsi.2008.10.004; DEWHURST SA, 1975, COMP BIOCHEM PHYS C, V50, P53; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dvir H, 2010, CHEM-BIOL INTERACT, V187, P10, DOI 10.1016/j.cbi.2010.01.042; ELBERMANI AWI, 1978, J EMBRYOL EXP MORPH, V48, P177; HORNSTEIN EP, 1994, VISUAL NEUROSCI, V11, P989, DOI 10.1017/S0952523800003928; Johnson G, 2006, CURR PHARM DESIGN, V12, P217, DOI 10.2174/138161206775193127; Johnson JL, 2003, BIOCHEMISTRY-US, V42, P5438, DOI 10.1021/bi027065u; Jones AK, 2002, FASEB J, V16, P441, DOI 10.1096/fj.01-0683fje; Kang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019063; Karczmar AG, 2010, CHEM-BIOL INTERACT, V187, P34, DOI 10.1016/j.cbi.2010.03.009; Kawli T, 2010, DIS MODEL MECH, V3, P721, DOI 10.1242/dmm.003871; KEYHANI E, 1981, J CELL SCI, V52, P327; KUSSATHE.E, 1967, HISTOCHEMISTRY, V8, P237, DOI 10.1007/BF00306086; Leone P, 2010, CHEM-BIOL INTERACT, V187, P49, DOI 10.1016/j.cbi.2010.01.030; Lin G, 2005, J BIOCHEM MOL TOXIC, V19, P234, DOI 10.1002/jbt.20087; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo CY, 2010, BIOCHEM PHARMACOL, V80, P1427, DOI 10.1016/j.bcp.2010.07.020; MCKENNA OC, 1968, CIRC RES, V23, P645, DOI 10.1161/01.RES.23.5.645; Monnet-Tschudi F, 2000, TOXICOL APPL PHARM, V165, P175, DOI 10.1006/taap.2000.8934; Nizri E, 2006, NEUROPHARMACOLOGY, V50, P540, DOI 10.1016/j.neuropharm.2005.10.013; ORON U, 1984, CELL MOL BIOL, V30, P411; Pegan K, 2010, CHEM-BIOL INTERACT, V187, P96, DOI 10.1016/j.cbi.2010.03.034; PITZURRA L, 1989, INFECT IMMUN, V57, P2452, DOI 10.1128/IAI.57.8.2452-2456.1989; QUAN N, 1994, J NEUROIMMUNOL, V49, P125, DOI 10.1016/0165-5728(94)90188-0; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; Rand James B, 2007, WormBook, P1; Rosas-Ballina M, 2009, J INTERN MED, V265, P663, DOI 10.1111/j.1365-2796.2009.02098.x; ROSENBERRY TL, 1975, ADV ENZYMOL RAMB, V43, P103; RYBICKA K, 1967, EXP PARASITOL, V20, P263, DOI 10.1016/0014-4894(67)90048-3; Salzet M, 2001, TRENDS IMMUNOL, V22, P285, DOI 10.1016/S1471-4906(01)01895-6; SCHWARTZ JH, 1975, J GEN PHYSIOL, V65, P255, DOI 10.1085/jgp.65.3.255; SERAVIN LN, 1965, DOKL AKAD NAUK SSSR+, V160, P486; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; Talesa V, 1999, J NEUROCHEM, V72, P1250, DOI 10.1046/j.1471-4159.1999.0721250.x; THIEDEMANN KU, 1986, CELL TISSUE RES, V244, P153; Travers MA, 2008, FISH SHELLFISH IMMUN, V24, P400, DOI 10.1016/j.fsi.2007.10.001; Tyagi E, 2010, EUR J PHARMACOL, V640, P206, DOI 10.1016/j.ejphar.2010.04.041; Tyagi E, 2008, J NEUROIMMUNOL, V205, P51, DOI 10.1016/j.jneuroim.2008.08.015; van Nierop P, 2006, J BIOL CHEM, V281, P1680, DOI 10.1074/jbc.M508571200; von Wachtendonk D., 1979, Comparative Biochemistry and Physiology C Comparative Pharmacology, V63, P279, DOI 10.1016/0306-4492(79)90074-1; Wang LL, 2009, FISH SHELLFISH IMMUN, V26, P744, DOI 10.1016/j.fsi.2009.03.002; WATSON JE, 1976, PFLUG ARCH EUR J PHY, V363, P161, DOI 10.1007/BF01062285; WHITTAKER JR, 1980, J EMBRYOL EXP MORPH, V55, P343; Wootton EC, 2003, FISH SHELLFISH IMMUN, V15, P195, DOI 10.1016/S1050-4648(02)00161-4; Xuereb B, 2009, AQUAT TOXICOL, V94, P114, DOI 10.1016/j.aquatox.2009.06.010; Yang JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017089; Zaitseva O V, 2008, Morfologiia, V133, P55; Zhang HA, 2010, FISH SHELLFISH IMMUN, V29, P149, DOI 10.1016/j.fsi.2010.02.024; Zhao PC, 2010, J BIOCHEM MOL TOXIC, V24, P51, DOI 10.1002/jbt.20311; Zhou XX, 2011, PROTEIN EXPRES PURIF, V77, P62, DOI 10.1016/j.pep.2010.11.017	72	101	108	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 23	2012	7	1							e30828	10.1371/journal.pone.0030828	http://dx.doi.org/10.1371/journal.pone.0030828			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909NE	22649509	Green Submitted, Green Published, gold			2023-01-03	WOS:000301570600085
J	Brown, JC; Huedo-Medina, TB; Pescatello, LS; Ryan, SM; Pescatello, SM; Moker, E; LaCroix, JM; Ferrer, RA; Johnson, BT				Brown, Justin C.; Huedo-Medina, Tania B.; Pescatello, Linda S.; Ryan, Stacey M.; Pescatello, Shannon M.; Moker, Emily; LaCroix, Jessica M.; Ferrer, Rebecca A.; Johnson, Blair T.			The Efficacy of Exercise in Reducing Depressive Symptoms among Cancer Survivors: A Meta-Analysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; BREAST-CANCER; PHYSICAL-ACTIVITY; REHABILITATION PROGRAM; CLINICAL DEPRESSION; AEROBIC EXERCISE; META-REGRESSION; WOMEN; FATIGUE	Introduction: The purpose of this meta-analysis was to examine the efficacy of exercise to reduce depressive symptoms among cancer survivors. In addition, we examined the extent to which exercise dose and clinical characteristics of cancer survivors influence the relationship between exercise and reductions in depressive symptoms. Methods: We conducted a systematic search identifying randomized controlled trials of exercise interventions among adult cancer survivors, examining depressive symptoms as an outcome. We calculated effect sizes for each study and performed weighted multiple regression moderator analysis. Results: We identified 40 exercise interventions including 2,929 cancer survivors. Diverse groups of cancer survivors were examined in seven exercise interventions; breast cancer survivors were examined in 26; prostate cancer, leukemia, and lymphoma were examined in two; and colorectal cancer in one. Cancer survivors who completed an exercise intervention reduced depression more than controls, d(+) = 20.13 (95% CI: -0.26, -0.01). Increases in weekly volume of aerobic exercise reduced depressive symptoms in dose-response fashion (beta = -0.24, p = 0.03), a pattern evident only in higher quality trials. Exercise reduced depressive symptoms most when exercise sessions were supervised (beta = -0.26, p = 0.01) and when cancer survivors were between 47-62 yr (beta = 0.27, p = 0.01). Conclusion: Exercise training provides a small overall reduction in depressive symptoms among cancer survivors but one that increased in dose-response fashion with weekly volume of aerobic exercise in high quality trials. Depressive symptoms were reduced to the greatest degree among breast cancer survivors, among cancer survivors aged between 47-62 yr, or when exercise sessions were supervised.	[Brown, Justin C.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Brown, Justin C.] Univ Penn, Perelman Sch Med, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; [Huedo-Medina, Tania B.; Pescatello, Linda S.; Moker, Emily; LaCroix, Jessica M.; Johnson, Blair T.] Univ Connecticut, Ctr Hlth Intervent & Prevent, Storrs, CT USA; [Ryan, Stacey M.] Univ Texas MD Anderson Canc Ctr, Dept Phys Therapy, Houston, TX 77030 USA; [Pescatello, Shannon M.] Western New England Coll, Dept Psychol, Springfield, MA USA; [Ferrer, Rebecca A.] NCI, Rockville, MD USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Connecticut; University of Texas System; UTMD Anderson Cancer Center; Western New England University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Brown, JC (corresponding author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.	brownjus@mail.med.upenn.edu	Brown, Jennifer Valeska Elli/C-6947-2019	Brown, Jennifer Valeska Elli/0000-0003-0943-5177; Byrne, Thirimon Moe/0000-0002-2827-9715	University of Connecticut Research Advisory Council Foundation [433527]	University of Connecticut Research Advisory Council Foundation	Funding was provided by the University of Connecticut Research Advisory Council Foundation grant no. 433527 (PIs: Blair T. Johnson and Linda S. Pescatello). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Becker B.J., 2000, HDB APPL MULTIVARIAT, P499, DOI [DOI 10.1016/B978-012691360-6/50018-5, 10.1016/B978-012691360-6/50018-5]; BECKER BJ, 1988, BRIT J MATH STAT PSY, V41, P257, DOI 10.1111/j.2044-8317.1988.tb00901.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BERGLUND G, 1994, EUR J CANCER, V30A, P1744, DOI 10.1016/0959-8049(94)00330-8; Brosse AL, 2002, SPORTS MED, V32, P741, DOI 10.2165/00007256-200232120-00001; Brown JC, 2011, CANCER EPIDEM BIOMAR, V20, P123, DOI 10.1158/1055-9965.EPI-10-0988; Burnham TR, 2002, MED SCI SPORT EXER, V34, P1863, DOI 10.1097/00005768-200212000-00001; Cadmus LA, 2009, PSYCHO-ONCOLOGY, V18, P343, DOI 10.1002/pon.1525; Chandwani Kavita D, 2010, J Soc Integr Oncol, V8, P43; Chang PH, 2008, J PAIN SYMPTOM MANAG, V35, P524, DOI 10.1016/j.jpainsymman.2007.06.013; Clark AM, 2010, EUR J CARDIOV PREV R, V17, P261, DOI 10.1097/HJR.0b013e32833090ef; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen L, 2004, CANCER-AM CANCER SOC, V100, P2253, DOI 10.1002/cncr.20236; Conn VS, 2010, ANN BEHAV MED, V39, P128, DOI 10.1007/s12160-010-9172-x; Courneya KS, 2007, J CLIN ONCOL, V25, P4396, DOI 10.1200/JCO.2006.08.2024; Courneya KS, 2009, J CLIN ONCOL, V27, P4605, DOI 10.1200/JCO.2008.20.0634; Courneya KS, 2003, EUR J CANCER CARE, V12, P347, DOI 10.1046/j.1365-2354.2003.00437.x; Courneya KS, 2003, PSYCHO-ONCOLOGY, V12, P357, DOI 10.1002/pon.658; Coventry PA, 2007, J PSYCHOSOM RES, V63, P551, DOI 10.1016/j.jpsychores.2007.08.002; Craft L, 2011, CANC EPIDEMIOL BIOMA; Culos-Reed SN, 2006, PSYCHO-ONCOLOGY, V15, P891, DOI 10.1002/pon.1021; Culos-Reed SN, 2010, SUPPORT CARE CANCER, V18, P591, DOI 10.1007/s00520-009-0694-3; Daley AJ, 2007, J CLIN ONCOL, V25, P1713, DOI 10.1200/JCO.2006.09.5083; Danhauer SC, 2009, PSYCHO-ONCOLOGY, V18, P360, DOI 10.1002/pon.1503; Demark-Wahnefried W, 2008, CLIN BREAST CANCER, V8, P70, DOI 10.3816/CBC.2008.n.005; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; Dodd MJ, 2010, CANCER NURS, V33, P245, DOI 10.1097/NCC.0b013e3181ddc58c; Drown JS, 2005, REHABIL ONCOL, V23, P11, DOI 10.1097/01893697-200523010-00004; Duijts SFA, 2011, PSYCHO-ONCOLOGY, V20, P115, DOI 10.1002/pon.1728; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eyigor S, 2010, EUR J PHYS REHAB MED, V46, P481; Ferrer RA, 2011, ANN BEHAV MED, V41, P32, DOI 10.1007/s12160-010-9225-1; GILBAR O, 1989, J PSYCHOSOM RES, V33, P1, DOI 10.1016/0022-3999(89)90100-1; Greenwood BN, 2011, EXERC SPORT SCI REV, V39, P140, DOI 10.1097/JES.0b013e31821f7e45; Harbord RM, 2008, STATA J, V8, P493, DOI 10.1177/1536867X0800800403; Hedges L, 1985, STAT METHODS META AN, P369, DOI [10.2307/1164953, DOI 10.2307/1164953]; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holland JC, 2010, J NATL COMPR CANC NE, V8, P448, DOI 10.6004/jnccn.2010.0034; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Jarden M, 2009, J PAIN SYMPTOM MANAG, V38, P174, DOI 10.1016/j.jpainsymman.2008.09.005; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnson BT, 2011, RES SYN METHOD; Jones LW, 2010, LANCET ONCOL, V11, P914, DOI 10.1016/S1470-2045(10)70184-4; Kelly CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c693; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; Latka RN, 2009, J CANCER SURVIV, V3, P148, DOI 10.1007/s11764-009-0088-z; LEBOVITS AH, 1990, CANCER, V65, P17, DOI 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I; Lee SA, 2010, CLIN REHABIL, V24, P600, DOI 10.1177/0269215510362324; Lipsey MW, 2001, PRACTICAL METAANALYS, P247; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225; McClure MK, 2010, AM J OCCUP THER, V64, P59, DOI 10.5014/ajot.64.1.59; Mock V, 1994, Oncol Nurs Forum, V21, P899; Mock V, 1997, Oncol Nurs Forum, V24, P991; Monga U, 2007, ARCH PHYS MED REHAB, V88, P1416, DOI 10.1016/j.apmr.2007.08.110; MOR V, 1994, CANCER-AM CANCER SOC, V74, P2118, DOI 10.1002/1097-0142(19941001)74:7+<2118::AID-CNCR2820741720>3.0.CO;2-N; Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082-989X.7.1.105; Mutrie N, 2007, BMJ-BRIT MED J, V334, P517, DOI 10.1136/bmj.39094.648553.AE; Newport DJ, 1998, J PSYCHOSOM RES, V45, P215, DOI 10.1016/S0022-3999(98)00011-7; North T C, 1990, Exerc Sport Sci Rev, V18, P379; O'Brien Kelly, 2010, Cochrane Database Syst Rev, pCD001796, DOI 10.1002/14651858.CD001796.pub3; Ohira T, 2006, CANCER-AM CANCER SOC, V106, P2076, DOI 10.1002/cncr.21829; Papakostas GI, 2008, J CLIN PSYCHIAT, V69, P1287, DOI 10.4088/JCP.v69n0812; Pasquini Massimo, 2007, Clin Pract Epidemiol Ment Health, V3, P2, DOI 10.1186/1745-0179-3-2; Patel SR, 2004, THESIS; Payne JK, 2008, ONCOL NURS FORUM, V35, P635, DOI 10.1188/08.ONF.635-642; Perna FM, 2010, INT J SPORT EXERC PS, V8, P36, DOI 10.1080/1612197X.2010.9671932; Pinto BM, 2003, PSYCHO-ONCOLOGY, V12, P118, DOI 10.1002/pon.618; Raghavendra RM, 2009, INTEGR CANCER THER, V8, P37, DOI 10.1177/1534735409331456; Rausch SM, 2007, THESIS; REDDON JR, 1985, J PSYCHOPATHOL BEHAV, V7, P243, DOI 10.1007/BF00960756; Reich M, 2008, BREAST CANCER RES TR, V110, P9, DOI 10.1007/s10549-007-9706-5; Salkind M R, 1969, J R Coll Gen Pract, V18, P267; Schmitz KH, 2010, MED SCI SPORT EXER, V42, P1409, DOI 10.1249/MSS.0b013e3181e0c112; Speck RM, 2010, J CANCER SURVIV, V4, P87, DOI 10.1007/s11764-009-0110-5; Spence RR, 2011, EUR J CANCER CARE, V20, P257, DOI 10.1111/j.1365-2354.2010.01214.x; SUTHERLAND HJ, 1988, CANCER NURS, V11, P303; Targ EF, 2002, GEN HOSP PSYCHIAT, V24, P238, DOI 10.1016/S0163-8343(02)00191-3; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Thompson WR, ACSMS GUIDELINES EXE; Thorsen L, 2005, J CLIN ONCOL, V23, P2378, DOI 10.1200/JCO.2005.04.106; Velthuis MJ, 2010, CLIN ONCOL-UK, V22, P208, DOI 10.1016/j.clon.2009.12.005; Vito NL, 2007, THESIS; Watson M, 1999, LANCET, V354, P1331, DOI 10.1016/S0140-6736(98)11392-2; Whitehead S, 2009, QUAL HEALTH RES, V19, P894, DOI 10.1177/1049732309337523; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	90	216	222	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2012	7	1							e30955	10.1371/journal.pone.0030955	http://dx.doi.org/10.1371/journal.pone.0030955			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	911GB	22586491	gold, Green Published			2023-01-03	WOS:000301704200049
J	Zhang, ZJ; Ng, R; Man, SC; Li, TYJ; Wong, W; Tan, QR; Wong, HK; Chung, KF; Wong, MT; Tsang, WKA; Yip, KC; Ziea, E; Wong, VT				Zhang, Zhang-Jin; Ng, Roger; Man, Sui Cheung; Li, Tsui Yin Jade; Wong, Wendy; Tan, Qing-Rong; Wong, Hei Kiu; Chung, Ka-Fai; Wong, Man-Tak; Tsang, Wai-Kiu Alfert; Yip, Ka-chee; Ziea, Eric; Wong, Vivian Taam			Dense Cranial Electroacupuncture Stimulation for Major Depressive Disorder-A Single-Blind, Randomized, Controlled Study	PLOS ONE			English	Article							ELECTRICAL-STIMULATION; PLACEBO NEEDLE; ACUPUNCTURE; FLUOXETINE; MECHANISMS; BRAIN; TOLERABILITY; EXPRESSION; PROJECTION; EFFICACY	Background: Previous studies suggest that electroacupuncture possesses therapeutic benefits for depressive disorders. The purpose of this study was to determine whether dense cranial electroacupuncture stimulation (DCEAS) could enhance the antidepressant efficacy in the early phase of selective serotonin reuptake inhibitor (SSRI) treatment of major depressive disorder (MDD). Methods: In this single-blind, randomized, controlled study, patients with MDD were randomly assigned to 9-session DCEAS or noninvasive electroacupuncture (n-EA) control procedure in combination with fluoxetine (FLX) for 3 weeks. Clinical outcomes were measured using the 17-item Hamilton Depression Rating Scale (HAMD-17), Clinical Global Impression-severity (CGI-S), and Self-rating Depression Scale (SDS) as well as the response and remission rates. Results: Seventy-three patients were randomly assigned to n-EA (n = 35) and DCEAS (n = 38), of whom 34 in n-EA and 36 in DCEAS group were analyzed. DCEAS-treated patients displayed a significantly greater reduction from baseline in HAMD-17 scores at Day 3 through Day 21 and in SDS scores at Day 3 and Day 21 compared to patients receiving n-EA. DCEAS intervention also produced a higher rate of clinically significant response compared to n-EA procedure (19.4% (7/36) vs. 8.8% (3/34)). The incidence of adverse events was similar in the two groups. Conclusions: DCEAS is a safe and effective intervention that augments the antidepressant efficacy. It can be considered as an additional therapy in the early phase of SSRI treatment of depressed patients. Trail Registration:Controlled-Trials.com ISRCTN88008690	[Zhang, Zhang-Jin; Ng, Roger; Man, Sui Cheung; Li, Tsui Yin Jade; Wong, Wendy; Wong, Hei Kiu] Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China; [Wong, Man-Tak; Tsang, Wai-Kiu Alfert; Yip, Ka-chee] Kowloon Hosp, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Tan, Qing-Rong] Fourth Mil Med Univ, Dept Psychiat, Xian 710032, Shaanxi, Peoples R China; [Chung, Ka-Fai] Univ Hong Kong, LKS Fac Med, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Ziea, Eric; Wong, Vivian Taam] Hosp Author, Chinese Med Sect, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Air Force Military Medical University; University of Hong Kong	Zhang, ZJ (corresponding author), Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.	zhangzj@hku.hk	zhang, zheng/HCH-9684-2022; Wong, Wendy/H-3939-2016; zhang, zhang/GQZ-6804-2022	Wong, Wendy/0000-0001-8731-0498; wang, li/0000-0002-1459-3412	Food and Health Bureau of Hong Kong [06070831]	Food and Health Bureau of Hong Kong	This study was supported by Health and Health Services Research Fund (HHSRF) from Food and Health Bureau of Hong Kong (ref.No.: 06070831). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adell A, 2005, DRUG DISCOV TODAY, V10, P578, DOI 10.1016/S1359-6446(05)03398-2; Allen JJB, 2006, J CLIN PSYCHIAT, V67, P1665, DOI 10.4088/JCP.v67n1101; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andreescu C, 2011, J CLIN PSYCHIAT, V72, P1129, DOI 10.4088/JCP.10m06105; ARBAB MAR, 1988, J CEREBR BLOOD F MET, V8, P54, DOI 10.1038/jcbfm.1988.8; Arroll B, 2005, ANN FAM MED, V3, P449, DOI 10.1370/afm.349; Barnes Patricia M, 2004, Adv Data, P1; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1038/nrdp.2016.65; Benham A, 2009, ACUPUNCT MED, V27, P65, DOI 10.1136/aim.2008.000174; Blier P, 2003, EUR NEUROPSYCHOPHARM, V13, P57, DOI 10.1016/S0924-977X(02)00173-6; BLIER P, 1994, TRENDS PHARMACOL SCI, V15, P220, DOI 10.1016/0165-6147(94)90315-8; Clark L, 2009, ANNU REV NEUROSCI, V32, P57, DOI 10.1146/annurev.neuro.31.060407.125618; Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040; Enck P, 2010, AUTON NEUROSCI-BASIC, V157, P68, DOI 10.1016/j.autneu.2010.03.005; Fink M, 2001, FORSCH KOMP KLAS NAT, V8, P368, DOI 10.1159/000057254; FOOTE SL, 1983, PHYSIOL REV, V63, P844, DOI 10.1152/physrev.1983.63.3.844; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Hong CJ, 2003, J CLIN PSYCHIAT, V64, P921, DOI 10.4088/JCP.v64n0810; Huang Y, 2004, SHANGHAI ZHEN JIU ZA, V23, P5; Keller Martin B, 2002, Psychopharmacol Bull, V36 Suppl 2, P133; Kirkcaldie M, 1997, CONVULSIVE THER, V13, P83; KUBOTA K, 1988, ANAT ANZEIGER, V165, P229; Kwon YB, 2000, AM J CHINESE MED, V28, P435, DOI 10.1142/S0192415X00000519; La Marca R, 2010, CLIN SCI, V118, P537, DOI 10.1042/CS20090264; LEE HC, 1994, J GERIATR PSYCH NEUR, V7, P216, DOI 10.1177/089198879400700404; Lee HJ, 2004, AM J CHINESE MED, V32, P795, DOI 10.1142/S0192415X04002405; Li A, 2007, BRAIN RES, V1186, P171, DOI 10.1016/j.brainres.2007.10.022; Li Hong-Jie, 2011, Zhongguo Zhen Jiu, V31, P3; Simpson KL, 1997, J COMP NEUROL, V385, P135; Simpson KL, 1999, J COMP NEUROL, V411, P524, DOI 10.1002/(SICI)1096-9861(19990830)411:3<524::AID-CNE13>3.0.CO;2-X; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3; STARK P, 1985, J CLIN PSYCHIAT, V46, P53; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; Takahashi T, 2010, NEUROSCI RES, V68, P103, DOI 10.1016/j.neures.2010.06.012; Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; van Dijk KRA, 2002, REV NEUROSCIENCE, V13, P257; Wang H, 2008, J AFFECT DISORDERS, V111, P125, DOI 10.1016/j.jad.2008.04.020; Yeung WF, 2011, SLEEP, V34, P807, DOI 10.5665/SLEEP.1056; Yu YWY, 2006, EUR NEUROPSYCHOPHARM, V16, P498, DOI 10.1016/j.euroneuro.2005.12.004; Zhang WJ, 2009, J ALTERN COMPLEM MED, V15, P837, DOI 10.1089/acm.2008.0607; Zhang ZJ, 2010, J AFFECT DISORDERS, V124, P9, DOI 10.1016/j.jad.2009.07.005; Zhang ZJ, 2009, J NERV MENT DIS, V197, P619, DOI 10.1097/NMD.0b013e3181b05fd1; Zhang ZJ, 2011, ECAM IN PRESS; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; Zhou F, 2010, ACUPUNCTURE THERAPY FOR NEUROLOGICAL DISEASES: A NEUROBIOLOGICAL VIEW, P32, DOI 10.1007/978-3-642-10857-0_2	48	102	105	4	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 6	2012	7	1							e29651	10.1371/journal.pone.0029651	http://dx.doi.org/10.1371/journal.pone.0029651			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	904IR	22276212	Green Published, Green Submitted, gold			2023-01-03	WOS:000301188800023
J	Zhou, JX; Brusch, L; Huang, S				Zhou, Joseph Xu; Brusch, Lutz; Huang, Sui			Predicting Pancreas Cell Fate Decisions and Reprogramming with a Hierarchical Multi-Attractor Model	PLOS ONE			English	Article							TRANSCRIPTION FACTORS; ROBUST DEVELOPMENT; NETWORK MODELS; STEM-CELLS; DIFFERENTIATION; EXPRESSION; ALPHA; DIVERSIFICATION; PRECURSORS; PLASTICITY	Cell fate reprogramming, such as the generation of insulin-producing beta cells from other pancreas cells, can be achieved by external modulation of key transcription factors. However, the known gene regulatory interactions that form a complex network with multiple feedback loops make it increasingly difficult to design the cell reprogramming scheme because the linear regulatory pathways as schemes of causal influences upon cell lineages are inadequate for predicting the effect of transcriptional perturbation. However, sufficient information on regulatory networks is usually not available for detailed formal models. Here we demonstrate that by using the qualitatively described regulatory interactions as the basis for a coarse-grained dynamical ODE (ordinary differential equation) based model, it is possible to recapitulate the observed attractors of the exocrine and beta, delta, alpha endocrine cells and to predict which gene perturbation can result in desired lineage reprogramming. Our model indicates that the constraints imposed by the incompletely elucidated regulatory network architecture suffice to build a predictive model for making informed decisions in choosing the set of transcription factors that need to be modulated for fate reprogramming.	[Zhou, Joseph Xu; Brusch, Lutz] Tech Univ Dresden, Ctr Informat Serv & High Performance Comp, Dresden, Germany; [Zhou, Joseph Xu; Huang, Sui] Univ Calgary, Inst Biocomplex & Informat, Calgary, AB, Canada; [Zhou, Joseph Xu] Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA	Technische Universitat Dresden; University of Calgary; University of California System; University of California Santa Barbara	Zhou, JX (corresponding author), Tech Univ Dresden, Ctr Informat Serv & High Performance Comp, Dresden, Germany.	joseph.x.zhou@gmail.com	Yu, Hanry/C-1031-2013	Yu, Hanry/0000-0002-0339-3685; Mahara, Sylvia/0000-0001-7261-1423	German Ministry for Education and Research [0315259]; National Science Foundation [PHY05-51164]	German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); National Science Foundation(National Science Foundation (NSF))	This research was partially supported by the German Ministry for Education and Research through grant no. 0315259. It was also supported in part by the National Science Foundation under Grant No. PHY05-51164. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abematsu Masahiko, 2006, Curr Stem Cell Res Ther, V1, P267, DOI 10.2174/157488806776956887; Aldana M, 2003, PERSPECTIVES AND PROBLEMS IN NONLINEAR SCIENCE, P23; Aldana M, 2007, J THEOR BIOL, V245, P433, DOI 10.1016/j.jtbi.2006.10.027; Bokes P, 2009, MATH MED BIOL, V26, P117, DOI 10.1093/imammb/dqn026; Bonifer C, 2008, SEMIN IMMUNOL, V20, P257, DOI 10.1016/j.smim.2008.05.001; Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965; Chickarmane V, 2006, PLOS COMPUT BIOL, V2, P1080, DOI 10.1371/journal.pcbi.0020123; Chickarmane V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003478; Chickarmane V, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000268; Collombat P, 2003, GENE DEV, V17, P2591, DOI 10.1101/gad.269003; Collombat P, 2009, CELL, V138, P449, DOI 10.1016/j.cell.2009.05.035; Davidson EH, 2006, SCIENCE, V311, P796, DOI 10.1126/science.1113832; Enver T, 2009, CELL STEM CELL, V4, P387, DOI 10.1016/j.stem.2009.04.011; Foster DV, 2009, J THEOR BIOL, V260, P589, DOI 10.1016/j.jtbi.2009.07.005; Fukuda A, 2008, DIABETES, V57, P2421, DOI 10.2337/db07-1558; Furusawa C, 2003, J THEOR BIOL, V224, P413, DOI 10.1016/S0022-5193(03)00189-9; Gittes GK, 2009, DEV BIOL, V326, P4, DOI 10.1016/j.ydbio.2008.10.024; Graf T, 2002, BLOOD, V99, P3089, DOI 10.1182/blood.V99.9.3089; Graf T, 2009, NATURE, V462, P587, DOI 10.1038/nature08533; Guney MA, 2009, BIRTH DEFECTS RES C, V87, P232, DOI 10.1002/bdrc.20156; Habener JF, 2005, ENDOCRINOLOGY, V146, P1025, DOI 10.1210/en.2004-1576; Higham DJ, 2001, SIAM REV, V43, P525, DOI 10.1137/S0036144500378302; Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701; Huang S, 2001, PHARMACOGENOMICS, V2, P203, DOI 10.1517/14622416.2.3.203; Huang S, 2007, DEV BIOL, V305, P695, DOI 10.1016/j.ydbio.2007.02.036; Huang S, 2009, BIOESSAYS, V31, P546, DOI 10.1002/bies.200800189; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Joshi CV, 2002, CURR OPIN CELL BIOL, V14, P749, DOI 10.1016/S0955-0674(02)00392-7; Kaneko K, 1999, J THEOR BIOL, V199, P243, DOI 10.1006/jtbi.1999.0952; Kubicek S, 2004, CELL, V119, P903, DOI 10.1016/j.cell.2004.12.006; Losick R, 2008, SCIENCE, V320, P65, DOI 10.1126/science.1147888; MacArthur BD, 2009, NAT REV MOL CELL BIO, V10, P672, DOI 10.1038/nrm2766; MacArthur BD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003086; Mehta S, 2005, J HEPATO-BILIARY-PAN, V12, P208, DOI 10.1007/s00534-005-0981-4; Miyatsuka T, 2008, EXPERT OPIN THER TAR, V12, P1431, DOI [10.1517/14728222.12.11.1431, 10.1517/14728222.12.11.1431 ]; Murtaugh LC, 2007, DEVELOPMENT, V134, P427, DOI 10.1242/dev.02770; Nakajima A, 2008, J THEOR BIOL, V253, P779, DOI 10.1016/j.jtbi.2008.04.007; Offield MF, 1996, DEVELOPMENT, V122, P983; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Oliver-Krasinski JM, 2008, GENE DEV, V22, P1998, DOI 10.1101/gad.1670808; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Ralston A, 2005, CLIN GENET, V68, P106, DOI 10.1111/j.1399-0004.2005.00478.x; SAVAGEAU MA, 1995, J THEOR BIOL, V176, P115, DOI 10.1006/jtbi.1995.0181; Serra R, 2004, J THEOR BIOL, V227, P149, DOI 10.1016/j.jtbi.2003.10.018; Servitja JM, 2004, DIABETOLOGIA, V47, P597, DOI 10.1007/s00125-004-1368-9; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TINBERGEN N., 1952, QUART REV BIOL, V27, P1; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Wang J, 2010, BIOPHYS J, V99, P29, DOI 10.1016/j.bpj.2010.03.058; White P, 2008, DIABETES, V57, P654, DOI 10.2337/db07-1362; Yamanaka S, 2008, CELL PROLIFERAT, V41, P51, DOI 10.1111/j.1365-2184.2008.00493.x; Zaret KS, 2008, SCIENCE, V322, P1490, DOI 10.1126/science.1161431; Zhang C, 2005, MOL CELL BIOL, V25, P4969, DOI 10.1128/MCB.25.12.4969-4976.2005; ZHOU Q, 2008, NATURE	57	110	115	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2011	6	3							e14752	10.1371/journal.pone.0014752	http://dx.doi.org/10.1371/journal.pone.0014752			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	736RS	21589872	Green Submitted, Green Published, gold			2023-01-03	WOS:000288512400002
J	Zhang, Z; Wang, WZ; Shi, ZB; Wang, L; Zhang, JX				Zhang, Zhen; Wang, Wenzhong; Shi, Zhanbiao; Wang, Li; Zhang, Jianxin			Mental Health Problems among the Survivors in the Hard-Hit Areas of the Yushu Earthquake	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; HOPKINS SYMPTOM CHECKLIST-25; TRAUMATIC STRESS; ADULT SURVIVORS; PTSD CHECKLIST; GENDER; INSTRUMENTS; PREVALENCE; EXPOSURE; VICTIMS	Background: On April 14, 2010, an earthquake registering 7.1 on the Richter scale shook Qinghai Province in southwest China. The earthquake caused numerous casualties and much damage. The epicenter, Yushu County, suffered the most severe damage. As a part of the psychological relief work, the present study evaluated the mental health statuses of the people affected and identified the mental disorder risk factors related to earthquakes. Methods: Five hundred and five earthquake survivors living in Yushu County were investigated 3-4 months after the earthquake. Participant demographic data including gender, age, marital status, ethnicity, educational level, and religious beliefs were collected. The Earthquake-Specific Trauma Exposure Indicators assessed the intensity of exposure to trauma during the earthquake. The PTSD Checklist-Civilian version (PCL-C) and the Hopkins Symptoms Checklist-25 (HSCL-25) assessed the symptoms and prevalence rates of probable Posttraumatic Stress Disorder (PTSD) as well as anxiety and depression, respectively. The Perceived Social Support Scale (PSSS) evaluated subjective social support. Results: The prevalence rates of probable PTSD, anxiety, and depression were 33.7%, 43.8% and 38.6%, respectively. Approximately one fifth of participants suffered from all three conditions. Individuals who were female, felt initial fear during the earthquake, and had less social support were the most likely to have poor mental health. Conclusions: The present study revealed that there are serious mental problems among the hard-hit survivors of the Yushu earthquake. Survivors at high risk for mental disorders should be specifically considered. The present study provides useful information for rebuilding and relief work.	[Zhang, Zhen; Wang, Wenzhong; Shi, Zhanbiao; Wang, Li; Zhang, Jianxin] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Institute of Psychology, CAS	Zhang, JX (corresponding author), Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China.	zhangjx@psych.an.cn	zhang, zheng/HCH-9684-2022; Wong, Wendy/H-3939-2016; zhang, zhang/GQZ-6804-2022	Wong, Wendy/0000-0001-8731-0498; wang, li/0000-0002-1459-3412	Youth Foundation of the Institute of Psychology, CAS [Y0CX441S01]; Development Foundation of the Institute of Psychology, CAS [O9CX143014]	Youth Foundation of the Institute of Psychology, CAS; Development Foundation of the Institute of Psychology, CAS	The Youth Foundation of the Institute of Psychology, CAS (No. Y0CX441S01) and the Development Foundation of the Institute of Psychology, CAS (No. O9CX143014) supported this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acierno Ron, 2007, Am J Public Health, V97 Suppl 1, pS103, DOI 10.2105/AJPH.2006.087007; Altindag A, 2005, COMPR PSYCHIAT, V46, P328, DOI 10.1016/j.comppsych.2005.01.005; Armenian HK, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.102001058.x; Basoglu M, 2004, J TRAUMA STRESS, V17, P133, DOI 10.1023/B:JOTS.0000022619.31615.e8; Bland SH, 1997, J NERV MENT DIS, V185, P188, DOI 10.1097/00005053-199703000-00008; BLUMENTHAL JA, 1987, PSYCHOSOM MED, V49, P331, DOI 10.1097/00006842-198707000-00002; Bramsen I, 2000, AM J PSYCHIAT, V157, P1115, DOI 10.1176/appi.ajp.157.7.1115; BROMET E, 1995, EPIDEMIOL REV, V17, P113, DOI 10.1093/oxfordjournals.epirev.a036166; Chen CH, 2007, COMPR PSYCHIAT, V48, P269, DOI 10.1016/j.comppsych.2006.12.003; Chen YY, 2006, J RELIG HEALTH, V45, P371, DOI 10.1007/s10943-006-9040-y; Cook J.D., 1990, J TRAUMA STRESS, V3, P541, DOI [10.1002/jts.2490030406, DOI 10.1002/JTS.2490030406, 10.1007/BF02039587]; Cox BJ, 2004, BEHAV RES THER, V42, P105, DOI 10.1016/S0005-7967(03)00105-0; David D, 1996, J TRAUMA STRESS, V9, P607, DOI 10.1002/jts.2490090316; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DiGrande L, 2008, J TRAUMA STRESS, V21, P264, DOI 10.1002/jts.20345; Elhai JD, 2005, J TRAUMA STRESS, V18, P541, DOI 10.1002/jts.20062; Falsetti SA, 2003, J TRAUMA STRESS, V16, P391, DOI 10.1023/A:1024422220163; Galea S, 2005, EPIDEMIOL REV, V27, P78, DOI 10.1093/epirev/mxi003; Gavranidou M, 2003, DEPRESS ANXIETY, V17, P130, DOI 10.1002/da.10103; Grant DM, 2008, J ABNORM PSYCHOL, V117, P662, DOI 10.1037/a0012591; GREEN BL, 1992, J NERV MENT DIS, V180, P760, DOI 10.1097/00005053-199212000-00004; Huang L., 1996, CHIN MENT HLTH J, V10, P160; Kumar MS, 2007, AM J PUBLIC HEALTH, V97, P99, DOI 10.2105/AJPH.2005.071167; Kun P, 2009, PUBLIC HEALTH, V123, P703, DOI 10.1016/j.puhe.2009.09.017; Li HH, 2010, PSYCHOL REP, V107, P733, DOI 10.2466/03.15.20.PR0.107.6.733-739; Lilly MM, 2009, J ANXIETY DISORD, V23, P767, DOI 10.1016/j.janxdis.2009.02.015; Liu AZ, 2006, CAN J PSYCHIAT, V51, P350, DOI 10.1177/070674370605100603; Liu MX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014706; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Sharan P, 1996, AM J PSYCHIAT, V153, P556; Shi Qi-chang, 2005, Zhonghua Yufang Yixue Zazhi, V39, P229; Solomon Z, 2005, SOC PSYCH PSYCH EPID, V40, P947, DOI 10.1007/s00127-005-0973-3; Stratta P, 2012, J RELIG HLT IN PRESS; Tolin DF, 2006, PSYCHOL BULL, V132, P959, DOI 10.1037/0033-2909.132.6.959; Tsai KY, 2007, J PSYCHIATR RES, V41, P90, DOI 10.1016/j.jpsychires.2005.10.004; van Griensven F, 2006, JAMA-J AM MED ASSOC, V296, P537, DOI 10.1001/jama.296.5.537; Ventevogel P, 2007, SOC PSYCH PSYCH EPID, V42, P328, DOI 10.1007/s00127-007-0161-8; Wang L, 2009, J TRAUMA STRESS, V22, P444, DOI 10.1002/jts.20439; [王婷 WANG Ting], 2009, [中国老年学杂志, Chinese Journal of Gerontology], V29, P1272; Wang XD, 2000, AM J PSYCHIAT, V157, P1260, DOI 10.1176/appi.ajp.157.8.1260; [王相兰 WANG Xianglan], 2008, [中山大学学报. 医学科学版, Journal of Sun Yat-sen University. Medical Sciences], V29, P367; Weathers F., 1993, P ANN C INT SOC TRAU; Wu KK., 2008, HONG KONG J PSYCHIAT, V18, P144; Xu JJ, 2011, INT J PSYCHIAT MED, V42, P167, DOI 10.2190/PM.42.2.e; Yu S., 2011, J SICHUAN NORMAL U S, V38, P45; Zhang YQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022371; Zhang Z, 2011, PUBLIC HEALTH, V125, P293, DOI 10.1016/j.puhe.2010.12.008; Zhangs W., 1998, CHINESE J PSYCHIAT, V31, P69	50	102	105	4	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2012	7	10							e46449	10.1371/journal.pone.0046449	http://dx.doi.org/10.1371/journal.pone.0046449			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	020RP	22276212	Green Submitted, Green Published, gold			2023-01-03	WOS:000309831500041
